<!-- PAGE=? -->
Anesthesia Notes - March 2010

<!-- PAGE=? -->
A

<!-- PAGE=? -->
ABGs

<!-- PAGE=? -->
Ace Inhibitors

<!-- PAGE=? -->
Acetaminophen

<!-- PAGE=? -->
Acid-base

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
Defibrillation

<!-- PAGE=? -->
Airway management

<!-- PAGE=? -->
VF/VT arrest

<!-- PAGE=? -->
Asytole / PEA

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
Stable Tachycardia

<!-- PAGE=? -->
PACs / PVCs

<!-- PAGE=? -->
Stroke

<!-- PAGE=? -->
Acute Coronary Syndrome

<!-- PAGE=? -->
CHF and Cardiogenic Shock

<!-- PAGE=? -->
Toxicology

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Drowning

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
Electric and lightning Injuries

<!-- PAGE=? -->
Hyperkalemia

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Calcium

<!-- PAGE=? -->
Magnesium

<!-- PAGE=? -->
DKA

<!-- PAGE=? -->
Achondroplasia

<!-- PAGE=? -->
Acromegaly

<!-- PAGE=? -->
ADH

<!-- PAGE=? -->
Addiction

<!-- PAGE=? -->
Adrenergic agents

<!-- PAGE=? -->
Adrenergic receptors

<!-- PAGE=? -->
Adrenocortical Malfunction

<!-- PAGE=? -->
Physiology

<!-- PAGE=? -->
Glucocorticoid Excess

<!-- PAGE=? -->
Mineralocorticoid Excess

<!-- PAGE=? -->
Glucocorticoid Deficiency

<!-- PAGE=? -->
Mineralocorticoid Deficiency

<!-- PAGE=? -->
Adrenal Cortex Function in the Elderly

<!-- PAGE=? -->
AIDS

<!-- PAGE=? -->
Airflow

<!-- PAGE=? -->
Airway (Innervation)

<!-- PAGE=? -->
Allergic reaction

<!-- PAGE=? -->
Anaphylaxis under Anesthesia

<!-- PAGE=? -->
Anaphylactoid Reactions

<!-- PAGE=? -->
Risk factors for anaphylaxis

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
ALS

<!-- PAGE=? -->
Alveolar-arterial Gradient (A-a gradient)

<!-- PAGE=? -->
Alveolar air equation:

<!-- PAGE=? -->
Alzheimer's Dementia

<!-- PAGE=? -->
Anesthetic Machine

<!-- PAGE=? -->
B

<!-- PAGE=? -->
Low-Pressure Circuit Leak Test

<!-- PAGE=? -->
Workstation Self-Tests

<!-- PAGE=? -->
Flush Valve

<!-- PAGE=? -->
Oxygen Analyzer

<!-- PAGE=? -->
Proportioning Systems

<!-- PAGE=? -->
Scavenger Systems

<!-- PAGE=? -->
Failure of Anesthesia Equipment

<!-- PAGE=? -->
The Circle System

<!-- PAGE=? -->
Ventilators

<!-- PAGE=? -->
Ambulatory surgery

<!-- PAGE=? -->
Benefits

<!-- PAGE=? -->
Indications

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
Discharge Criteria

<!-- PAGE=? -->
Amiodarone

<!-- PAGE=? -->
Anesthetic agents

<!-- PAGE=? -->
Anticholinesterases

<!-- PAGE=? -->
Anti-Epileptic Drugs

<!-- PAGE=? -->
Antimuscarinic

<!-- PAGE=? -->
Ankle

<!-- PAGE=? -->
Ankylosing Spondylitis

<!-- PAGE=? -->
Antiarrythmic drugs

<!-- PAGE=? -->
Antithrombin III

<!-- PAGE=? -->
Aortic cross-clamp

<!-- PAGE=? -->
Spinal Cord Protection

<!-- PAGE=? -->
Aortic dissection

<!-- PAGE=? -->
APGAR

<!-- PAGE=? -->
Aprotinin

<!-- PAGE=? -->
ARDS

<!-- PAGE=? -->
Arterial Blood Pressure Monitoring

<!-- PAGE=? -->
Artery of Adamkewicz

<!-- PAGE=? -->
Aspiration Pneumonitis

<!-- PAGE=? -->
ASRA Guidelines for Neuraxial and Peripheral

<!-- PAGE=? -->
Nerve Blocks

<!-- PAGE=? -->
ASA

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
Atlantoaxial Instability

<!-- PAGE=? -->
ATLS

<!-- PAGE=? -->
Atrial Fibrillation

<!-- PAGE=? -->
Atrial Kick

<!-- PAGE=? -->
ANP

<!-- PAGE=? -->
Autologous Blood Donation

<!-- PAGE=? -->
Autonomic Hyperreflexia

<!-- PAGE=? -->
Autonomic Neuropathy

<!-- PAGE=? -->
Autonomic Nervous System

<!-- PAGE=? -->
AZT

<!-- PAGE=? -->
Back Pain

<!-- PAGE=? -->
Bradykinins

<!-- PAGE=? -->
Beach chair position

<!-- PAGE=? -->
Benzodiazepines

<!-- PAGE=? -->
Beta Blockers

<!-- PAGE=? -->
C

<!-- PAGE=? -->
Renal Failure Esmolol Bicarb BiPap BIS Blood Storage Transfusion reactions Immediate Hemolytic transfusion reaction Nonhemolytic Transfusion Reaction Leukodepletion Conservations Techniques Emergency Transfusion BMV Brachial plexus Brachial Plexus Block Brain Death Budd-Chiari Syndrome Buerger's disease (thromboangiitis obliterans) Signs and symptoms: Treatment: Management of anesthesia Burns CABG CAD detection Calcium Channel Blockers Calcium Salts Capnograph PaCO2-ETCO2 gradient Sampling errors Carbon Dioxide CO2 absorbers Carcinoid Cardiac Arrest - intraoperative Cardiac evaluation for noncardiac OR Revised cardiac risk index Cardiac herniation (post-pneumonectomy) Cardiac Physiology Pathophysiology of CAD Autoregulation Myocardial metabolism Preconditioning Post-operative Myocardial Infarction Cardiovascular Reflexes Cardiac Transplant Carotid Endarterectomy Stenting Celiac Plexus Cerebral Aneurysms Cerebral blood flow Circle of Willis Cerebral palsy Cerebral salt wasting Cervical Plexus

<!-- PAGE=? -->
Cirrhosis

<!-- PAGE=? -->
D

<!-- PAGE=? -->
Physiologic consequences of lack of insulin Dopamine versus Dobutamine

<!-- PAGE=? -->
Pathophysiology Cisatracurium Child-Pugh Score Chemoreceptors Chemoreceptor Trigger Zone Chemotherapy Chiari Malformation Cholinergic receptors Cholinesterases Closing capacity Clonidine Closed Circuit Anesthesia Coagulation Coagulopathy CPB Treatment Cocaine Coma Complex regional pain syndrome (CRPS) Continuous renal replacement therapy COPD Carbon Monoxide - CO Cryoprecipitate Cerebrospinal Fluid C-spine Cushing's Syndrome Cutaneous innervation CVL Infections CVP Cyanide Toxicity Cystic Fibrosis DDAVP Deadspace Death from anesthesia Deep Cervical Plexus Block Dehydration in Infants Dental damage Dexmedetomidine Diabetes insipidus Dialysis Complications CRRT Diastolic Dysfunction Dibucaine  Number DIC Digoxin Diuretics Diabetes Mellitus Type I Effects of Insulin: Glucagon DKA Diabetic ketoacidosis versus non-ketotic hyperglycemia

<!-- PAGE=? -->
Double-Lumen Tubes Sizes Contraindications to DLTs: (insertion is difficult or dangerous) Down's Syndrome E E cylinder ECG Monitoring ECT EEG Elderly patients Elderly lung changes Electrical shock Line Isolation monitors Epidural Epidural Abscess Epidural Opioids Epidural Cardiovascular Effects Epidural blood patch Epidural Hematoma Epiglottitis vs croup Epinephrine Esmolol Esterases Etomidate EVAR Extubation Criteria F Fat embolus syndrome Fluids Flumazanil G Gabapentin Gas Analysis Gastric Emptying Gate Control Theory Glasgow Coma Scale (GCS) Glucagon Guidelines to the Practice of Anesthesia - 2008 Healthcare Facility must ensure Anesthetic Machine Waste anesthetic gases The Pre-anesthetic Period The Anesthetic Period The Post-anesthetic Period Guidelines for Obstetric Regional Anesthesia for Labour Guidelines for Acute Pain Management using Neuraxial Analgesia Guidelines for the Practice of Anesthesia outside a Hospital H HAV HBV

<!-- PAGE=? -->
I

<!-- PAGE=? -->
HCV Hepatorenal syndrome Hereditary Angioedema Hyperosmolar Nonketotic coma (HONK) Hearing loss Heliox Hemodynamics Hemodyalisis Hepatic drug metabolism Heparin resistance Hetastarch Herbal Remedies Histamine HIT HIV (CDC - 2001) Hormones post surgery Hyperaldosteronism Physiology Signs and Symptoms Diagnosis Treatment Management of Anesthesia Hyperbaric Oxygen Therapy (HBO) Hypercarbia Hyperperfusion Syndrome Hyperthermia Hypothermia Intraoperative prevention Trauma ACLS Hypocalcemia Hypernatremia Hyponatremia Hypertrophic Cardiomyopathy Hypoxic drive Hypoxic Pulmonary Vasoconstriction (HPV) IABP (Intra-aortic balloon pump) ICP Physiologic responses to increased ICP Increased ICP Brain Herniation Syndromes Jugular venous bulbs: Immunosuppressants Cyclophosphamide Cyclosporine Methotrexate Vinca alkaloids (Vincristine, Vinblastin) Cisplatin Adriamycin (Doxorubicin) Bleomycin Indomethacin Induced Hypotension Induction Drugs Infared Spectroscopy Infective Endocarditis prophylaxis

<!-- PAGE=? -->
Anesthetic Uptake Airway BPD Croup, Post-extubation Cyanotic Heart Disease Fetal Hgb Hypovolemia Midazolam NEC Neonatal Pharmacology Neonatal Physiology Neonatal Sepsis NRP Opiods PDA Persistent Pulmonary Hypertension PONV in Children Pyloric Stenosis Regional Renal Respiratory variables Sedation Stridor TBW TEF VATER Ventilation Pentaspan Peripheral nerves Distribution Neuropathy Positioning Lateral Decubitus Potassium physiology Hyperkalemia Hypokalemia Pharmacokinetics First Order Kinetics Clearance: T1/2 Steady State Volume of Distribution Phase I and II reactions Pheochromocytoma Phenylephrine Pneumoperitoneum Pituitary Tumours Pituitary Surgery Placental Abruption Pollution (Anesthetic Gases) Porphyria Postherniorrhaphy pain Post herpetic neuralgia PONV PPV / PEEP Phosphate

<!-- PAGE=? -->
Hyperphosphatemia Hypophosphatemia Preoperative Testing: Preoperative evaluation (general) Perioperative Mortality Propofol Propofol Infusion Syndrome Prostaglandins Proteins Protamine Pseudocholinesterase Deficiency Atypical Pseudocholinesterase Pulmonary physiology Distribution of Perfusion & Ventilation Elderly FRC & Postoperative pulmonary function Pulmonary dead space Pulmonary Shunt Pulmonary Artery Catheters Interpretation errors Thermodilution CO Pulmonary assessment, pre-pneumonectomy Calculating ppoFEV1 Pulmonary contusion Pulmonary hypertension Pulse Oximetry Pulsus Paradoxus PVR

<!-- PAGE=? -->
R

<!-- PAGE=? -->
Red Blood cell replacement Renal drug excretion Renal Acid-Base Regulation Renal Failure Laboratory Findings Manifestations Causes Perioperative Renal dysfunction Renal Physiology Renal Vasa Recta Renin-angiotensin system (RAS) Respiratory quotient Resusciatation Drugs: ACLS, PALS and NRP Retrobulbar and Peribulbar Blocks Rheumatoid Arthritis

<!-- PAGE=? -->
S

<!-- PAGE=? -->
S2 Sarcoidosis SAH Cerebral Vasospasm: Rebleeding: Hydrocephalus Other Complications SBE prophylaxis Scleroderma Sella Turcica Surgery Sepsis

<!-- PAGE=? -->
T

<!-- PAGE=? -->
A

<!-- PAGE=? -->
ABGs

<!-- PAGE=? -->
PaO2 = 100 - age/3, so decreased PaO2 in geriatrics  ( lange 498)

<!-- PAGE=? -->
Normal PaO2 is 90-95 ( normal A-a grd is 5-10 mmHg)

<!-- PAGE=? -->
ABG in pregnant patient : ( Chestnut 19 table 2-3)

<!-- PAGE=? -->
Sleep : PaCO2 increases by 3 mmHg and Pa O2 decreases by about the same ( Nunn 346 )

<!-- PAGE=? -->
High altitude : lower PaO2 and PaCO2 but also lower SaO2

<!-- PAGE=? -->
Nunn 361 permanent residents: PaO2 just over 50 mmHg, PaCO2 = 32 mmHg,

<!-- PAGE=? -->
Chestnut pg 56 Figure 4.9

<!-- PAGE=? -->
Barash Table 43-1. NORMAL BLOOD GAS VALUES IN THE NEWBORN

<!-- PAGE=? -->
Compensatory responses evoked by ascent to altitude

<!-- PAGE=? -->
 Inc. alveolar ventilation

<!-- PAGE=? -->
 Inc. hemoglobin production

<!-- PAGE=? -->
 Inc. 2,3-disphosphoglycerate concentrations

<!-- PAGE=? -->
 Inc. diffusing capacity of the lungs

<!-- PAGE=? -->
 Inc. vascularity of the tissues

<!-- PAGE=? -->
 Inc. cellular use of oxygen

<!-- PAGE=? -->
Ace Inhibitors

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 highly effective in the treatment of

<!-- PAGE=? -->
o essential hypertension

<!-- PAGE=? -->
o renovascular and malignant hypertension

<!-- PAGE=? -->
 CV effects

<!-- PAGE=? -->
o decreased peripheral vascular resistance

<!-- PAGE=? -->
o CO, filling pressure, and HR remain unchanged

<!-- PAGE=? -->
 effective in the management of CHF

<!-- PAGE=? -->
 results in reductions in

<!-- PAGE=? -->
o angiotensin-aldosterone

<!-- PAGE=? -->
 Hyperkalemia

<!-- PAGE=? -->
o NE

<!-- PAGE=? -->
o plasma ADH

<!-- PAGE=? -->
 Adverse effects

<!-- PAGE=? -->
o Angioedema

<!-- PAGE=? -->
o ARF

<!-- PAGE=? -->
o Hyperkalemia

<!-- PAGE=? -->
 Avoid in 2 nd and 3 rd trimester

<!-- PAGE=? -->
Acetaminophen

<!-- PAGE=? -->
P&P, Barash

<!-- PAGE=? -->
 Analgesic and antipyretic

<!-- PAGE=? -->
o strong central inhibition of prostaglandin synthesis

<!-- PAGE=? -->
 COX-3

<!-- PAGE=? -->
 Lacks significant anti-inflammatory effect

<!-- PAGE=? -->
o weak peripheral inhibition of prostaglandin synthesis

<!-- PAGE=? -->
 Does not

<!-- PAGE=? -->
o produce gastric irritation

<!-- PAGE=? -->
o alter platelet function

<!-- PAGE=? -->
o impair bone healing

<!-- PAGE=? -->
o reduce renal function

<!-- PAGE=? -->
 nearly complete systemic absorption after oral administration

<!-- PAGE=? -->
 converted to inactive metabolites

<!-- PAGE=? -->
o conjugation and hydroxylation

<!-- PAGE=? -->
 Metabolite p-aminophenol is nephrotoxic

<!-- PAGE=? -->
 Hepatotoxicity

<!-- PAGE=? -->
o 2' to N-acetyl-p-benzoquinone

<!-- PAGE=? -->
o This metabolite is usually scavenged by glutathione

<!-- PAGE=? -->
o In OD there is exhaustion of glutathione stores with resulting accumulation of the toxic metabolite

<!-- PAGE=? -->
o Induction of the P450 (ETOH abuse) inc. the risk of toxicity

<!-- PAGE=? -->
o Clinical manifestations

<!-- PAGE=? -->
 Jaundice and coag defects ~ 2 - 6 days post ingestion

<!-- PAGE=? -->
o Acetylcysteine is an antioxidant that substitutes for glutathione as a scavenger

<!-- PAGE=? -->
 Effective if administered within the first 8 hrs post ingestion

<!-- PAGE=? -->
Acid-base

<!-- PAGE=? -->
pCO2 change of 10 = 0.08 pH unit change HCO3 change of 10 = 0.15 pH unit change Chronic  :

<!-- PAGE=? -->
 Metabolic acidosis  1.0

<!-- PAGE=? -->
 Metabolic alkalosis  0.7

<!-- PAGE=? -->
 Respiratory alkalosis  0.5 (0.2 acute)

<!-- PAGE=? -->
 Respiratory acidosis  0.3 (0.1 acute)

<!-- PAGE=? -->
pH 7.4 = [H+] 40 mmol/L assume [H+] = 40 mmol/L pH increase 0.1pH = 0.8x[H+] pH decrease 0.1pH = 1.25x[H+]

<!-- PAGE=? -->
pH change of 1 requires a [H+] of 10x

<!-- PAGE=? -->
pH = 6.1 + log {HCO3 / (0.03 PaCO2)} = Henderson-Hasselbalch [H+] = 24 x PaCO2 / [HCO3-] = Henderson Equation

<!-- PAGE=? -->
6.1 = pKa carbonic acid

<!-- PAGE=? -->
0.03 solubility of CO2 in blood

<!-- PAGE=? -->
The renal acid-base mechanism works in 3 ways:

<!-- PAGE=? -->
HCO3- is filtered from the plasma and H+ is secreted by cells throughout the tubular system (except the thin loop)

<!-- PAGE=? -->
o two types of cells secreting H+ into the tubules (epithelial cells and intercalated cells)

<!-- PAGE=? -->
o HCO3- and H+ combine in the lumen to neutralize but there is generally more H+ lost (hence the usual urine pH of 6.4)

<!-- PAGE=? -->
 when the secretion of H+ exceeds filtered HCO3- it is -mopped up‖ by the phosphate

<!-- PAGE=? -->
buffering system

<!-- PAGE=? -->
o very powerful buffer in the urine compared to its minimal effect in plasma

<!-- PAGE=? -->
o pKa is 6.8 which makes it maximally active at normal urine pH

<!-- PAGE=? -->
 if the HCO3- and phosphate buffer systems are overwhelmed the NH3/NH4+ system will pitch in

<!-- PAGE=? -->
o NH3 is produced by deamination of glutamine in epithelial cell mitochondria constantly and diffuses into the tubules (ammonia production increases in the face of acidemia)

<!-- PAGE=? -->
o in the tubules ammonia combines with H+ to form ammonium (NH4+) which is poorly reabsorbed and therefore -traps‖ the H+ in the tubules thereby getting rid of it.

<!-- PAGE=? -->
Anion Gap Metabolic Acidosis

<!-- PAGE=? -->
M: methanol

<!-- PAGE=? -->
U: uremia (100:1)

<!-- PAGE=? -->
D: DKA (1:1 with HCO3), EtOH KA, starvation KA

<!-- PAGE=? -->
P: Paraldehyde, Phenformin

<!-- PAGE=? -->
I: INH, iron

<!-- PAGE=? -->
L: lactic acidosis (↑lactate by 1 = ↓ HCO3 by 1.6)

<!-- PAGE=? -->
E: Ethylene glycol

<!-- PAGE=? -->
S: Salicylates (lactic acidosis)

<!-- PAGE=? -->
C: Cyanide

<!-- PAGE=? -->
A: Arsenic

<!-- PAGE=? -->
R: Rhabdomyolysis

<!-- PAGE=? -->
T: Toluene

<!-- PAGE=? -->
note that paraproteins can decrease the anion gap

<!-- PAGE=? -->
NON-ANION GAP METABOLIC ACIDOSIS:

<!-- PAGE=? -->
F: Fistulas

<!-- PAGE=? -->
U: Ureteroenteric conduits

<!-- PAGE=? -->
S: Saline (NS leads to dilutional hyperchloremic metabolic acidosis)

<!-- PAGE=? -->
E: Endocrine (hyperparathyroidism, hypoaldosteronism)

<!-- PAGE=? -->
D: Diarrhea

<!-- PAGE=? -->
C: Carbonic anhydrase inhibitors, Chloride (TPN)

<!-- PAGE=? -->
A: Amino acids (arginine, lysine)

<!-- PAGE=? -->
R: RTA

<!-- PAGE=? -->
S: Spironolactone

<!-- PAGE=? -->
METABOLIC ALKALOSIS

<!-- PAGE=? -->
Chloride sensitive (urine Cl < 20)  ECF volume depletion

<!-- PAGE=? -->
 Vomiting

<!-- PAGE=? -->
 NG suction

<!-- PAGE=? -->
 Diuretic use

<!-- PAGE=? -->
 Post-hypercapnea

<!-- PAGE=? -->
Chloride-resistant (urine Cl > 20)  EFC normal or high

<!-- PAGE=? -->
 Aldosterone excess (e.g. Cushing's syndrome, Conn's syndrome)

<!-- PAGE=? -->
 Bartter's syndrome

<!-- PAGE=? -->
 Potassium depletion

<!-- PAGE=? -->
 Milk-Alkali syndrome

<!-- PAGE=? -->
 Excessive HCO3- production (e.g. metabolism of citrate in blood, or metabolism of lactate in RL or metabolism of acetate in hyperalimentation solutions)

<!-- PAGE=? -->
RESPIRATORY ACIDOSIS

<!-- PAGE=? -->
 CNS depression

<!-- PAGE=? -->
 Neuromuscular disorders

<!-- PAGE=? -->
o Drugs: NMB

<!-- PAGE=? -->
o Muscular disease

<!-- PAGE=? -->
o Electrolyte disorders: hypokalemia, hypophosphatemia

<!-- PAGE=? -->
o Neuropathies

<!-- PAGE=? -->
 Respiratory disorders

<!-- PAGE=? -->
RESPIRATORY ALKALOSIS

<!-- PAGE=? -->
 Physiologic: pregnancy, high altitude

<!-- PAGE=? -->
 CNS disorders: anxiety, pain, fever

<!-- PAGE=? -->
 Drugs:  aspirin, nicotine, progesterone, cocaine

<!-- PAGE=? -->
 Pulmonary disorders: CHF, PE

<!-- PAGE=? -->
 Hepatic failure

<!-- PAGE=? -->
 Hyperthyroidism

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
 Goal in treating cardiac arrest is to increase survival to hospital discharge with normal neurologic function

<!-- PAGE=? -->
 Early CPR and defibrillation are of primary importance and drug administration is of secondary importance

<!-- PAGE=? -->
o No RCT has ever shown that any medication if given during cardiac arrest increases survival to hospital discharge

<!-- PAGE=? -->
 Early bystander CPR can double or triple the patient's chance of survival from VF

<!-- PAGE=? -->
o Early defibrillation and CPR within 3 -5 min can produce survival rates as high as 49 - 75%

<!-- PAGE=? -->
 Reduction in the interval between compression and shock by as little as 15 sec can inc. the predicted shock success

<!-- PAGE=? -->
o Immediately after shock, CPR can convert a nonperfusing rhythm to a perfusing rhythm

<!-- PAGE=? -->
 Resuscitation must continue after ROSC

<!-- PAGE=? -->
o Identification and treatment of precipitating causes

<!-- PAGE=? -->
o Management of postarrest complications

<!-- PAGE=? -->
 Sudden cardiac Death

<!-- PAGE=? -->
o CAD is the most common etiology behind SCD in all comers (75%)

<!-- PAGE=? -->
 Cardiomyopathy (15%)

<!-- PAGE=? -->
 Valvular heart disease (10%)

<!-- PAGE=? -->
o In patients under the age of 35 with structural abnormalities, HCM is the most common cause of SCD (49%)

<!-- PAGE=? -->
 LVH (17%), coronary artery anomaly (14%), CAD (10%)

<!-- PAGE=? -->
Defibrillation

<!-- PAGE=? -->
 VF is the rhythm most often associated with survival

<!-- PAGE=? -->
o Termination of VF is not equivalent to ROSC

<!-- PAGE=? -->
 Reduced time to defibrillation is critical and improves prognosis

<!-- PAGE=? -->
 Integration with CPR is crucial

<!-- PAGE=? -->
 If witnessed VF arrest precede with defibrillation as soon as possible

<!-- PAGE=? -->
 AEDs should be utilized immediately in witnessed arrests

<!-- PAGE=? -->
o CPR should be given for 2 min prior to AED in unwitnessed arrest

<!-- PAGE=? -->
 AED recommendations

<!-- PAGE=? -->
o Placed in locations where SCA is likely to occur

<!-- PAGE=? -->
o Integrated with local EMS

<!-- PAGE=? -->
o No documentd value for in-home use

<!-- PAGE=? -->
o Not effective for asystole or PEA

<!-- PAGE=? -->
 If transthoracic impedance is too high the shock will not generate enough current to achieve defibrillation, persistant VF

<!-- PAGE=? -->
o If energy is too high, asystole or AV block may result

<!-- PAGE=? -->
o Shock success is defined as termination of VF for at least 5 sec

<!-- PAGE=? -->
 Reducing transthoracic impedance

<!-- PAGE=? -->
o Press firmly

<!-- PAGE=? -->
o Use coupling material

<!-- PAGE=? -->
 Avoid ETOH based produced due to fire risk

<!-- PAGE=? -->
o Consider respiratory pause

<!-- PAGE=? -->
 Large Vt inceases impedance

<!-- PAGE=? -->
o Remove chest hair

<!-- PAGE=? -->
o Avoid breast tissue

<!-- PAGE=? -->
 Even with correct paddle placement, only 4 - 25% of the delivered current actually passes through the heart

<!-- PAGE=? -->
o Use pads whenever possible

<!-- PAGE=? -->
o Sternal pad on the patient's Rt infraclavicular area

<!-- PAGE=? -->
 May be placed on the right or left upper back, or right midacillary line

<!-- PAGE=? -->
o Apex pad on the patient's infralateral left chest, midaxillary line

<!-- PAGE=? -->
o With pacemakers or AICDs, pads should not be placed over the generators - 3 to 6 inches of space

<!-- PAGE=? -->
 AP placement is preferred

<!-- PAGE=? -->
o Poor pad placement / contact is the most common cause for failure to capture for TCP

<!-- PAGE=? -->
 AICDs

<!-- PAGE=? -->
o Magents

<!-- PAGE=? -->
 Suspend antitachycardia functions

<!-- PAGE=? -->
 Allow sensing and pacing of bradycardia

<!-- PAGE=? -->
 Suspends defibrillation

<!-- PAGE=? -->
o Device programming head has the same effect as a magnet

<!-- PAGE=? -->
o If patient in VF/VT - allow AICD 60 sec to complete treatment

<!-- PAGE=? -->
 If shocks are ineffective place magnet and treat

<!-- PAGE=? -->
o If non VF/VT - place magnet and treat

<!-- PAGE=? -->
 Defibrillation is OK when the patient is lying on snow or ice

<!-- PAGE=? -->
Airway management

<!-- PAGE=? -->
 Advanced airways may be deferred until the patient fails to repond to initial CPR and defibrillation or demonstrates ROSC

<!-- PAGE=? -->
o May require interruption of CPR

<!-- PAGE=? -->
 Uninterrupted compressions is weighed against need for advanced a/w placement

<!-- PAGE=? -->
 Normal SaO2 does not ensure adequate tissue oxygenation

<!-- PAGE=? -->
o Determined by O2 content and adequate blood flow

<!-- PAGE=? -->
 Confirmation of ETT placement requires

<!-- PAGE=? -->
o Clinical confirmation

<!-- PAGE=? -->
o A technique such as capnometry

<!-- PAGE=? -->
 CO2 colorimetric devices

<!-- PAGE=? -->
o CO2 determined after six breaths can be presumed to be from the lungs

<!-- PAGE=? -->
o Sensitive in pts > 2 kg with a perfusing rhythm

<!-- PAGE=? -->
o Purple - yellow

<!-- PAGE=? -->
o Blue - yellow

<!-- PAGE=? -->
o White - purple

<!-- PAGE=? -->
 There is little benefit in providing O2 to patients with ACS after 6 hrs

<!-- PAGE=? -->
o May result in vasoconstriction

<!-- PAGE=? -->
 O2 delivery

<!-- PAGE=? -->
o Nasal Cannula

<!-- PAGE=? -->
 1L - 21-24%

<!-- PAGE=? -->
 2L - 25-28%

<!-- PAGE=? -->
 3L - 29-32%

<!-- PAGE=? -->
 4L - 33-36%

<!-- PAGE=? -->
 5L - 37-40%

<!-- PAGE=? -->
 6L - 41-44%

<!-- PAGE=? -->
o O2 mask

<!-- PAGE=? -->
 6-10L - 35-60%

<!-- PAGE=? -->
o Nonrebreathing mask

<!-- PAGE=? -->
 6L - 60%

<!-- PAGE=? -->
 7L - 70%

<!-- PAGE=? -->
 8L - 80%

<!-- PAGE=? -->
 9L - 90%

<!-- PAGE=? -->
 10-15L - 95-100%

<!-- PAGE=? -->
o Venturi

<!-- PAGE=? -->
 4-8L - 24-40%

<!-- PAGE=? -->
 10-12L - 40-50%

<!-- PAGE=? -->
 Hyperventilation is harmful

<!-- PAGE=? -->
o Inc. intrathoracic pressure

<!-- PAGE=? -->
o Dec. venous return to the heart

<!-- PAGE=? -->
o Dec. CO

<!-- PAGE=? -->
 With an advanced a/w, provide 8-10 breaths per minute

<!-- PAGE=? -->
VF/VT arrest

<!-- PAGE=? -->
 Resume 5 cycles (2 min) of CPR after shock

<!-- PAGE=? -->
 High-dose or escalating doses of epinephrine are not recommended

<!-- PAGE=? -->
 Amiodarone is the preferred treatment for shock-refractory VF

<!-- PAGE=? -->
o Contraindications and precautions

<!-- PAGE=? -->
 Sinus node dysfunction

<!-- PAGE=? -->
 Sinus bradycardia

<!-- PAGE=? -->
 2 nd or 3 rd degree HB

<!-- PAGE=? -->
 Hypersensitivity

<!-- PAGE=? -->
 Precipitates with bivarb and heparin

<!-- PAGE=? -->
o Lidocaine is an alternative

<!-- PAGE=? -->
 1-1.5mg/kg bolus then 1-4mg/min

<!-- PAGE=? -->
 Reduce dose in CHF or hepatic failure

<!-- PAGE=? -->
 Stop if neurologic abnormalities develop

<!-- PAGE=? -->
 Consider Mg in

<!-- PAGE=? -->
o Elderly

<!-- PAGE=? -->
o ETOH abuse

<!-- PAGE=? -->
o Chronic malnutrition

<!-- PAGE=? -->
 Procainamide is NOT recommended

<!-- PAGE=? -->
 Combination therapy may be harmful

<!-- PAGE=? -->
 If VF/VT is terminated with an antiarrythmic, continue it for 6-24hrs

<!-- PAGE=? -->
o Look for precipitants

<!-- PAGE=? -->
 Ischemia

<!-- PAGE=? -->
 Lytes

<!-- PAGE=? -->
 hypoxia

<!-- PAGE=? -->
 BP is only a surrogate of cardiac function

<!-- PAGE=? -->
 Does not mean that there is adequate CO or peripheral perfusion

<!-- PAGE=? -->
 Measurable CO does not mean that tissue oxygen delivery and use are adequate

<!-- PAGE=? -->
Asytole / PEA

<!-- PAGE=? -->
 Pts with a rapidly identified and correctable cause of arrest have the best chance of survival - 2-10%

<!-- PAGE=? -->
o Witness arrest

<!-- PAGE=? -->
o Short interval to starting CPR

<!-- PAGE=? -->
o Younger age

<!-- PAGE=? -->
o Noncardiac case

<!-- PAGE=? -->
 Emphasis is on good CPR and searching for reversible causes

<!-- PAGE=? -->
 Assessment of technical problems should not interrupt CPR

<!-- PAGE=? -->
 Shock in asytole trended to worse outcomes

<!-- PAGE=? -->
 Pacing is no longer recommended for asystole

<!-- PAGE=? -->
PULSELESS Arrest

<!-- PAGE=? -->
BLS Algoritnm: Call for help; give CPR

<!-- PAGE=? -->
Glve oxygen when avallable

<!-- PAGE=? -->
Attach monitorldefibrillator when available

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
VFNT

<!-- PAGE=? -->
Asystole/PEA

<!-- PAGE=? -->
Give 1 shock

<!-- PAGE=? -->
Manual biphasic: device specitic

<!-- PAGE=? -->
10

<!-- PAGE=? -->
(typically 120 t0 200 J)

<!-- PAGE=? -->
Note: If unknown; use 200 J

<!-- PAGE=? -->
Resume CPR immediately for 5 cycles

<!-- PAGE=? -->
AED: device specific

<!-- PAGE=? -->
When IVIIO available; give vasopressor

<!-- PAGE=? -->
Monophasic: 360

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
Ropeat every 3 to 5 min

<!-- PAGE=? -->
May give

<!-- PAGE=? -->
dose of vasopressin 40 U IVIIO to

<!-- PAGE=? -->
replace first or second dose of epinephrine

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Consider atropine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
lor asystole or slow PEA rate

<!-- PAGE=? -->
Repeat every 3 to 5 min (up t0 3 doses)

<!-- PAGE=? -->
Continue CPR while defibrillator is charging

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
(same as fIrst shock or higher dose)

<!-- PAGE=? -->
Note

<!-- PAGE=? -->
unknown; use 200 J

<!-- PAGE=? -->
AED: dovice specitic

<!-- PAGE=? -->
Monophasic: 360 J

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Resume CPR Immediately alter the shock

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
When IVIIO available, give vasopressor during CPR

<!-- PAGE=? -->
(betore or after the shock)

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Repeat every 3 t0 5 min

<!-- PAGE=? -->
May give

<!-- PAGE=? -->
dose of vasopressin 40 U IVIIO t0

<!-- PAGE=? -->
12

<!-- PAGE=? -->
replace first or second dose of epinephrine

<!-- PAGE=? -->
13

<!-- PAGE=? -->
If asystole, 90 to Box 10

<!-- PAGE=? -->
Nol

<!-- PAGE=? -->
If electrical activity, check

<!-- PAGE=? -->
Go to

<!-- PAGE=? -->
Box

<!-- PAGE=? -->
Box 10

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
If pulse present, begin

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
postresuscitation care

<!-- PAGE=? -->
During CPR

<!-- PAGE=? -->
Continue CPR while defibrillator is charging

<!-- PAGE=? -->
Push hard and fast (1OO/min)

<!-- PAGE=? -->
Rotate compressors every

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Ensure full chest recoll

<!-- PAGE=? -->
2 minutes with rhythm checks

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
Search for and treat possible

<!-- PAGE=? -->
(sarne as lirst shock or higher dose)

<!-- PAGE=? -->
Minimize interruptions in chest

<!-- PAGE=? -->
contnbuting lactors:

<!-- PAGE=? -->
Note:If unknown use 200 J

<!-- PAGE=? -->
compressions

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
AED: device specific

<!-- PAGE=? -->
Hypoxla

<!-- PAGE=? -->
Monophasic: 360 J

<!-- PAGE=? -->
then 2 breaths; 5 cycles =2 min

<!-- PAGE=? -->
Hydrogen ion (acidosls)

<!-- PAGE=? -->
Resume CPR Immediately after

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Avoid hyperventilation

<!-- PAGE=? -->
Hypo-/hyperkalemia

<!-- PAGE=? -->
Consider antiarrhythmics; give during CPR

<!-- PAGE=? -->
Secure airway and conlirm placerent

<!-- PAGE=? -->
Hypoglyceria

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
amiodarone (300 mg IVIIO once; then

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
consider additional 150 mg IVIIO once) or

<!-- PAGE=? -->
After an advanced alrvay is placed,

<!-- PAGE=? -->
Tamponade, cardiac

<!-- PAGE=? -->
lidocaine (1 to 1.5 ma kg first dose, then 0.5 t0

<!-- PAGE=? -->
rescuers no longer deliver "cycles"

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
0.75 mgkg IVIIO,

<!-- PAGE=? -->
maximum 3 doses or 3 mgkg)

<!-- PAGE=? -->
of CPR. Give continous chest com-

<!-- PAGE=? -->
Thrombosis (coronary or

<!-- PAGE=? -->
Consider magnesium, loading dose

<!-- PAGE=? -->
pressions wlthout pauses for breaths

<!-- PAGE=? -->
pulmonary)

<!-- PAGE=? -->
to 2g IVIO for torsades de pointes

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Atter 5 cycles of CPR; got to Box 5 above

<!-- PAGE=? -->
rhythm every 2 minutes

<!-- PAGE=? -->
the

<!-- PAGE=? -->
 Ending the Code

<!-- PAGE=? -->
o Appropriate trial of BLS / ACLS

<!-- PAGE=? -->
o ETT

<!-- PAGE=? -->
o Effective ventilation

<!-- PAGE=? -->
o Defibrillation for VF

<!-- PAGE=? -->
o IV access with epi and atropine given

<!-- PAGE=? -->
o Ruled out reversible causes

<!-- PAGE=? -->
o Continuous asystole for 5-10 min

<!-- PAGE=? -->
o Are there atypical features

<!-- PAGE=? -->
 Young age

<!-- PAGE=? -->
 Persistent toxins / electrolyte abnormalities

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 Drug O/D

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
BRADYCARDIA

<!-- PAGE=? -->
Heart rate <60 bpm and

<!-- PAGE=? -->
inadequate for clinical condition

<!-- PAGE=? -->
Maintain patent airway; assist breathing as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor ECG (identify rhythm), blood pressure; oximetry

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
or

<!-- PAGE=? -->
symptoms of

<!-- PAGE=? -->
perfusion caused by the bradycardia?

<!-- PAGE=? -->
(eg; acute altered mental status, ongoing chest pain, hypotension or other signs of shock)

<!-- PAGE=? -->
4A

<!-- PAGE=? -->
Poor

<!-- PAGE=? -->
Perlugion

<!-- PAGE=? -->
Observe/Monitor

<!-- PAGE=? -->
Prepare for transcutaneous pacing;

<!-- PAGE=? -->
use without delay for high-degree block

<!-- PAGE=? -->
(type Il second-degree block or

<!-- PAGE=? -->
third-degree AV block)

<!-- PAGE=? -->
Consider atropine 0.5 mg IV while

<!-- PAGE=? -->
awaiting pacer. May repeat to a

<!-- PAGE=? -->
total dose of 3 mg. If ineffective;

<!-- PAGE=? -->
begin pacing

<!-- PAGE=? -->
Consider epinephrine (2 to 10 pg/min)

<!-- PAGE=? -->
Reminders

<!-- PAGE=? -->
or dopamine (2 to 10 pg/kg per minute)

<!-- PAGE=? -->
If pulseless arrest develops, g0 to Pulseless Arrest Algorithm

<!-- PAGE=? -->
infusion while awaiting pacer or if

<!-- PAGE=? -->
Search for and treat possible contributing factors:

<!-- PAGE=? -->
pacing ineffective

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Tamponade, cardiac

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
Hypo-/hyperkalemia

<!-- PAGE=? -->
Thrombosis (coronary or pulmonary)

<!-- PAGE=? -->
Prepare for transvenous pacing

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
Trauma (hypovolemia, increased ICP)

<!-- PAGE=? -->
Treat contributing causes

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
Signs

<!-- PAGE=? -->
poor

<!-- PAGE=? -->
 Theoretically atropine may increase the sinus node rate, worsening the degree of block

<!-- PAGE=? -->
 Atropine should not be used if the block is definitely infranodal (2 nd degree type II or 3 rd degree)

<!-- PAGE=? -->
o Transcutaneous pacing

<!-- PAGE=? -->
o Do not give atropine to patients with 3 rd degree block and a new wide QRS due to an AMI

<!-- PAGE=? -->
 If uncertain, atropine may be used while TCP is setup

<!-- PAGE=? -->
 Isoproterenol is no longer recommended

<!-- PAGE=? -->
o May inc. infarct size

<!-- PAGE=? -->
o Contraindicated in acetylcholinesterase induced bradycardia

<!-- PAGE=? -->
o May be of use in B-blocker overdose

<!-- PAGE=? -->
 P&P pg 767 -treatment of III' heart block is a pacemaker.  Temporary cardiac pacing may be provided with an IV infusion of isoproterenol (chemical cardiac pacemaker) or a transvenous artificial cardiac pacemaker‖

<!-- PAGE=? -->
 Glucagon

<!-- PAGE=? -->
o Used in b-bloacker or CCB O/D

<!-- PAGE=? -->
o 3mg bolus then 3mg/hr

<!-- PAGE=? -->
 AV Block etiologies

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
 B-Blockers, CCB

<!-- PAGE=? -->
o Vasovagal

<!-- PAGE=? -->
o Acute MI

<!-- PAGE=? -->
 RCA - 1 st & 2 nd degree typeI

<!-- PAGE=? -->
 LAD - 2 nd degree type II & 3 rd degree

<!-- PAGE=? -->
 Do not administer amiodarone to patient's with 3 rd degree block

<!-- PAGE=? -->
 Suicide

<!-- PAGE=? -->
 Family expressing opposition

<!-- PAGE=? -->
 Cold-water submersion

<!-- PAGE=? -->
o May result in asytole

<!-- PAGE=? -->
 Not all patients with AV dissociation have 3 rd degree block

<!-- PAGE=? -->
 Set the pacer to the lowest effective ratebased on clinical assessment

<!-- PAGE=? -->
o Reduce O2 demand

<!-- PAGE=? -->
 Complications of TCP

<!-- PAGE=? -->
o Failure to recognize underlying VF

<!-- PAGE=? -->
o Failure to capture

<!-- PAGE=? -->
o Failure to recognize failure to capture

<!-- PAGE=? -->
o Failure to recognize -electrical capture without myocardial function

<!-- PAGE=? -->
o Pacing-induced arrythmias / VF

<!-- PAGE=? -->
o Pain

<!-- PAGE=? -->
 There is no risk of electric shock to HCP during TCP

<!-- PAGE=? -->
Stable Tachycardia

<!-- PAGE=? -->
TACHYCARDIA

<!-- PAGE=? -->
Wlth Pulses

<!-- PAGE=? -->
Assess and support ABCs as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor ECG (identity rhythm) , blood pressure, oximetry

<!-- PAGE=? -->
Identify and treat reversible causes

<!-- PAGE=? -->
Perform immediate

<!-- PAGE=? -->
synchronized cardioversion

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Is patient stable?

<!-- PAGE=? -->
Establish IV access and give

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
Unstable signs include altered

<!-- PAGE=? -->
sedation if patient

<!-- PAGE=? -->
(when available)

<!-- PAGE=? -->
mental status; ongoing chest pain,

<!-- PAGE=? -->
is conscious; do not delay

<!-- PAGE=? -->
or rhythm strip

<!-- PAGE=? -->
hypotension or other signs of shock

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Is QRS narrow

<!-- PAGE=? -->
Note: rate-related symptoms

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
uncommon if heart rate <15O/min

<!-- PAGE=? -->
pulseless arrest develops.

<!-- PAGE=? -->
Narruy

<!-- PAGE=? -->
12

<!-- PAGE=? -->
WIDE ORS'

<!-- PAGE=? -->
Is Rhythm Regular?

<!-- PAGE=? -->
Is Rhythm Regular?

<!-- PAGE=? -->
Expert consultation

<!-- PAGE=? -->
advised

<!-- PAGE=? -->
Attempt vagal maneuvers

<!-- PAGE=? -->
Irregular Narrow-Complex

<!-- PAGE=? -->
Revular

<!-- PAGE=? -->
Give adenosine 6 mg

<!-- PAGE=? -->
13

<!-- PAGE=? -->
14

<!-- PAGE=? -->
IV push

<!-- PAGE=? -->
If no conversion;

<!-- PAGE=? -->
Probable atrial tibrillation or

<!-- PAGE=? -->
give 12 mg rapid IV push;

<!-- PAGE=? -->
may repeat 12 mg dose once

<!-- PAGE=? -->
(multitocal atrial tachycardia)

<!-- PAGE=? -->
aberrancy

<!-- PAGE=? -->
Consider expert consultallon

<!-- PAGE=? -->
uncertaln rhythm

<!-- PAGE=? -->
See Irregular Narrow-

<!-- PAGE=? -->
Amlodarone

<!-- PAGE=? -->
Complex Tachycardia

<!-- PAGE=? -->
A-blockers; use |-blockers with

<!-- PAGE=? -->
(Box11)

<!-- PAGE=? -->
Does rhythm

<!-- PAGE=? -->
caution in pulmonary disease

<!-- PAGE=? -->
Aepeat a5 needed

<!-- PAGE=? -->
convert?

<!-- PAGE=? -->
or CHF)

<!-- PAGE=? -->
If pre-exclted atrial

<!-- PAGE=? -->
Note: Consider

<!-- PAGE=? -->
fibrlllation (AF

<!-- PAGE=? -->
WPW)

<!-- PAGE=? -->
expert consultation

<!-- PAGE=? -->
Prepare tor elective

<!-- PAGE=? -->
Expert consullation

<!-- PAGE=? -->
synchronized

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Avoid AV nodal

<!-- PAGE=? -->
blocking agents

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Il SVT with aberrancy

<!-- PAGE=? -->
Give adenosine

<!-- PAGE=? -->
rhythm converts;

<!-- PAGE=? -->
If rhythm does NOT convert

<!-- PAGE=? -->
(go Io Box 7)

<!-- PAGE=? -->
Consider antlarrhyth -

<!-- PAGE=? -->
probable reentry SVT

<!-- PAGE=? -->
mics (09, amlodarone

<!-- PAGE=? -->
(reentry supraventricular

<!-- PAGE=? -->
tachycardla)

<!-- PAGE=? -->
Observe lor recurrenca

<!-- PAGE=? -->
Il recurrent polymor-

<!-- PAGE=? -->
p-blockers;

<!-- PAGE=? -->
A-blockers wilh

<!-- PAGE=? -->
phic VT seek expert

<!-- PAGE=? -->
consultation

<!-- PAGE=? -->
adenosine or longer-

<!-- PAGE=? -->
Gaution in pulmonary disease

<!-- PAGE=? -->
acting AV nodal blocking

<!-- PAGE=? -->
It torsades de pointes,

<!-- PAGE=? -->
Treat undarlying causa

<!-- PAGE=? -->
give magnesium

<!-- PAGE=? -->
8-blockers)

<!-- PAGE=? -->
Consider expert consultatlon

<!-- PAGE=? -->
(load wlth | 2gover

<!-- PAGE=? -->
5-60 minthen Intusion)

<!-- PAGE=? -->
During Evaluation

<!-- PAGE=? -->
Treat contributing tactors:

<!-- PAGE=? -->
Secure, verily alrway

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
'Note: If patient becomes

<!-- PAGE=? -->
and vascular access

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Tamponade, cardiac

<!-- PAGE=? -->
when possible

<!-- PAGE=? -->
Hydrogen Ion (acidosis)

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
Consider expert

<!-- PAGE=? -->
Hypo-lhyperkalemia

<!-- PAGE=? -->
Throrbosis (coronary or

<!-- PAGE=? -->
consultation

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
pulmonary)

<!-- PAGE=? -->
Prepare Ior

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Trauma (hypovolemia)

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
rapid

<!-- PAGE=? -->
 Vagal maneuvers and adenosine are the preferred intial therapeutic chaices for termination of stable reentry SVT

<!-- PAGE=? -->
o Valsalva maneuver

<!-- PAGE=? -->
o Carotid sinus massage

<!-- PAGE=? -->
 Exlude patients with bruits

<!-- PAGE=? -->
 Complications (.28-.45%)

<!-- PAGE=? -->
 Cerebral emboli

<!-- PAGE=? -->
 Stroke (embolic and occlusive)

<!-- PAGE=? -->
 Syncope

<!-- PAGE=? -->
 Sinus arrest

<!-- PAGE=? -->
 Asystole

<!-- PAGE=? -->
 AV lock

<!-- PAGE=? -->
 Most complications are transient - resolving in 24hrs

<!-- PAGE=? -->
 Synchronized cardioversion

<!-- PAGE=? -->
o Atrial fibrillation - 100-200J, 300J, 360J

<!-- PAGE=? -->
o Stable monomorphic VT - 100J, 200J, 300J, 360J

<!-- PAGE=? -->
o SVT, Atrial flutter - 50J, 100J, 200J, 300J, 360J

<!-- PAGE=? -->
o Polymorphic VT - treat as VF

<!-- PAGE=? -->
 High energy unsynchronized shock

<!-- PAGE=? -->
 Sinus tachycardia does not constitute a pathologic condition of and by itself

<!-- PAGE=? -->
 Automatic rhythms do not respond to electrical cardioversion

<!-- PAGE=? -->
o multifocal or ectopic atrial tachycardia, sinus tachycardia, junctional tachycardia

<!-- PAGE=? -->
 require treatment of the underlying disorder

<!-- PAGE=? -->
 may be responsive to calcium channel blockers of B-blockers, amiodarone

<!-- PAGE=? -->
 Etiology for SVT

<!-- PAGE=? -->
o Accessory pathways

<!-- PAGE=? -->
o CAS

<!-- PAGE=? -->
o COPD

<!-- PAGE=? -->
o CHF

<!-- PAGE=? -->
o Caffeine

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
o Cigarettes

<!-- PAGE=? -->
o Stress

<!-- PAGE=? -->
o Anxiety

<!-- PAGE=? -->
o Sleep deprivation

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 Etiology of Afib / Aflutter

<!-- PAGE=? -->
o CAD

<!-- PAGE=? -->
o CHF

<!-- PAGE=? -->
o Valvular heart disease

<!-- PAGE=? -->
 Mitral, tricuspid

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
o Hyperthyroid

<!-- PAGE=? -->
 Etiology of monomorphic VT

<!-- PAGE=? -->
o Ischemia

<!-- PAGE=? -->
o PVC with an R on T phenomenon

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
 Prolonged QT

<!-- PAGE=? -->
 Treatment of preexcited atrial fib with AV nodal blockers is contraindicated

<!-- PAGE=? -->
o Adenosine, CCB, BB, digoxin

<!-- PAGE=? -->
o May result in accelerated ventricular rate

<!-- PAGE=? -->
PACs / PVCs

<!-- PAGE=? -->
 If a PAC occurs very early in diastole, it may be blocked due to a refractory conduction system

<!-- PAGE=? -->
o Represents a failure of impulse conduction to the ventricles

<!-- PAGE=? -->
o The shorter the RP interval the longer the PR interval

<!-- PAGE=? -->
o PACs require no specific treatment

<!-- PAGE=? -->
 PVCs can never be diagnosed with 100% certainty

<!-- PAGE=? -->
o conducted retrograde into the atria causing -incomplete‖ compensatory pause

<!-- PAGE=? -->
o interpolated b/w 2 normal beats without disrupting sinus rhythm

<!-- PAGE=? -->
o supraventricular beats can masquerade as PVCs

<!-- PAGE=? -->
o 4% of PVCs have a normal QRS width

<!-- PAGE=? -->
Stroke

<!-- PAGE=? -->
Identify signs of possible stroke

<!-- PAGE=? -->
2

<!-- PAGE=? -->
Critical EMS assessments and actions

<!-- PAGE=? -->
Support ABCs; give oxygen if needed

<!-- PAGE=? -->
Perform prehospital stroke assessment (Tables

<!-- PAGE=? -->
and 2)

<!-- PAGE=? -->
Establish time when patient last known normal (Note:

<!-- PAGE=? -->
therapies may be available beyond 3 hours from onset)

<!-- PAGE=? -->
NINDS

<!-- PAGE=? -->
Transport; consider triage to a center with a stroke unit

<!-- PAGE=? -->
TIME

<!-- PAGE=? -->
if appropriate; consider bringing a witness; family

<!-- PAGE=? -->
GOALS

<!-- PAGE=? -->
member; or caregiver

<!-- PAGE=? -->
Alert hospital

<!-- PAGE=? -->
Check glucose if possible

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Immediate general assessment and stabllization

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Assess ABCs, vital signs

<!-- PAGE=? -->
Provide oxygen if hypoxemic

<!-- PAGE=? -->
Obtain IV access and blood samples

<!-- PAGE=? -->
Check glucose; treat if indicated

<!-- PAGE=? -->
Perform neurologic screening assessment

<!-- PAGE=? -->
Activate stroke team

<!-- PAGE=? -->
Order emergent CT scan of brain

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
Immediate neurologic assessment by stroke team or designee

<!-- PAGE=? -->
Review patient history

<!-- PAGE=? -->
Establish symptom onset

<!-- PAGE=? -->
Mun

<!-- PAGE=? -->
Perform neurologic examination (NIH Stroke Scale or Canadian Neurologic Scale)

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
25

<!-- PAGE=? -->
Does CT scan show any hemorrhage?

<!-- PAGE=? -->
Hemorrhage

<!-- PAGE=? -->
Probable acute ischemic stroke; consider fibrinolytic therapy

<!-- PAGE=? -->
Consult neurologist or neurosurgeon;

<!-- PAGE=? -->
Check for fibrinolytic exclusions (Table 3)

<!-- PAGE=? -->
consider transfer if not available

<!-- PAGE=? -->
Repeat neurologic exam: are deficits rapidly improving to normal?

<!-- PAGE=? -->
Patient remains candidate for

<!-- PAGE=? -->
Not

<!-- PAGE=? -->
Administer aspirin

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
fibrinolytic therapy?

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Candidate

<!-- PAGE=? -->
Review riskslbenefits with patient and family:

<!-- PAGE=? -->
Begin stroke pathway

<!-- PAGE=? -->
acceptable

<!-- PAGE=? -->
Admit to stroke unit if available

<!-- PAGE=? -->
Give tPA

<!-- PAGE=? -->
Monitor BP; treat if indicated (Table 4)

<!-- PAGE=? -->
No anticoagulants or antiplatelet treatment for

<!-- PAGE=? -->
Monitor neurologic status; emergent CT

<!-- PAGE=? -->
24 hours

<!-- PAGE=? -->
if deterioration

<!-- PAGE=? -->
Monitor blood glucose; treat if needed

<!-- PAGE=? -->
Initiate supportive therapy; treat

<!-- PAGE=? -->
comorbidities

<!-- PAGE=? -->
 7 D's of stroke care

<!-- PAGE=? -->
o Early Detection

<!-- PAGE=? -->
o Dispatch EMS

<!-- PAGE=? -->
 Associated with decreased time to MD contact, CT scan, and neurologic evaluation

<!-- PAGE=? -->
o Delivery to Hospital providing acute stroke care

<!-- PAGE=? -->
o Door - immediate assessment in ED

<!-- PAGE=? -->
o Data - CT scan, serial neurologic exams, tPA exclusions

<!-- PAGE=? -->
 Timing of symptom onset is the most important component of the patient Hx

<!-- PAGE=? -->
 Inability to establish time of symptom onset is a contraindication to tPA

<!-- PAGE=? -->
o Decisions

<!-- PAGE=? -->
 Diagnosis of stroke

<!-- PAGE=? -->
 Differentiate ischemic from hemorrhagic

<!-- PAGE=? -->
o Drug - tPA treatment within 3hrs

<!-- PAGE=? -->
 Modifiable risk factors

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
o Smoking

<!-- PAGE=? -->
o TIA

<!-- PAGE=? -->
o Heart disease

<!-- PAGE=? -->
o DM

<!-- PAGE=? -->
o Hypercoagulopathy

<!-- PAGE=? -->
o High RBC count and sickle cell anemia

<!-- PAGE=? -->
o Carotis bruit

<!-- PAGE=? -->
 SBP > 185 mmHg, DBP > 110mmHg is a contraindication to tPA

<!-- PAGE=? -->
o Treat immediately if tPA has been given

<!-- PAGE=? -->
 Normal CT - give tPA

<!-- PAGE=? -->
 Contraindications to tPA

<!-- PAGE=? -->
o Intracranial hemorrhage

<!-- PAGE=? -->
o Normal CT with Hx suggestive of SAH

<!-- PAGE=? -->
o Multilobar infaction

<!-- PAGE=? -->
o Hx of intracranial hypertension

<!-- PAGE=? -->
o Uncontrolled hypertension

<!-- PAGE=? -->
o AVM, neoplasm, aneurysm

<!-- PAGE=? -->
o Seizures with post-ictal impairment

<!-- PAGE=? -->
o Internal bleeding or acute trauma

<!-- PAGE=? -->
o Bleeding diathesis

<!-- PAGE=? -->
 Plt <100K

<!-- PAGE=? -->
 Hepatin in past 48hrs with an inc. ptt

<!-- PAGE=? -->
 Current anticoagulant use with an inc. INR

<!-- PAGE=? -->
o < 3 mon from

<!-- PAGE=? -->
 intracranial or intraspinal surgery

<!-- PAGE=? -->
 serious head injury

<!-- PAGE=? -->
 previous stroke

<!-- PAGE=? -->
o arterial puncture at a noncompressible site in the past 7 days

<!-- PAGE=? -->
 Relative contraindications

<!-- PAGE=? -->
o Minor / improving stroke symptoms

<!-- PAGE=? -->
o < 14 days from major surgery or trauma

<!-- PAGE=? -->
o < 21 days from GI/GU bleeding

<!-- PAGE=? -->
o < 3 mon from MI

<!-- PAGE=? -->
o Post MI pericarditis

<!-- PAGE=? -->
o Abnormal blood glucose

<!-- PAGE=? -->
 < 2.8 or > 22.2

<!-- PAGE=? -->
 Hold all anticoagulants and antiplatelets for 24hrs post tPA

<!-- PAGE=? -->
Acute Coronary Syndrome

<!-- PAGE=? -->
 Emergency DDx of angina is

<!-- PAGE=? -->
o ACS

<!-- PAGE=? -->
o Aortic dissection

<!-- PAGE=? -->
o Pulmonary embolism

<!-- PAGE=? -->
o Pericarial effusion with tamponade

<!-- PAGE=? -->
Chest discomfort suggestive

<!-- PAGE=? -->
of ischemia

<!-- PAGE=? -->
EMS assessment and care and hospital preparation:

<!-- PAGE=? -->
Monitor; support ABCs. Be prepared to provide CPR and defibrillation

<!-- PAGE=? -->
Administer oxygen, aspirin, nitroglycerin; and morphine if needed

<!-- PAGE=? -->
If available, obtain 12-lead ECG; if ST-elevation:

<!-- PAGE=? -->
Notity receiving hospital with transmission or interpretation

<!-- PAGE=? -->
Begin fibrinolytic checklist (Figure 2)

<!-- PAGE=? -->
Notified hospital should mobilize hospltal resources to respond to STEMI

<!-- PAGE=? -->
Immediate ED assessment (<10 min)

<!-- PAGE=? -->
Immediate ED general treatment

<!-- PAGE=? -->
Check vital signs; evaluate oxygen saturation

<!-- PAGE=? -->
Start oxygen at 4 Umin; maintain 0, sat >90%

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Aspirin 160 to 325 mg (it not given by EMS)

<!-- PAGE=? -->
Obtain /review 12-lead ECG

<!-- PAGE=? -->
Nitroglycerin sublingual, spray or IV

<!-- PAGE=? -->
Perform brief; targeted history; physical exam

<!-- PAGE=? -->
Morphine IV if pain not relieved by nitroglycerin

<!-- PAGE=? -->
Review/complete fibrinolytic checklist (Figure 2);

<!-- PAGE=? -->
check contraindications (Table 1)

<!-- PAGE=? -->
Obtain initial cardiac marker levels

<!-- PAGE=? -->
initial electrolyte and coagulation studies

<!-- PAGE=? -->
Obtain portable chest x-ray

<!-- PAGE=? -->
min)

<!-- PAGE=? -->
Review initial 12-lead ECG

<!-- PAGE=? -->
13

<!-- PAGE=? -->
ST elevation or new or

<!-- PAGE=? -->
ST depression or dynamic

<!-- PAGE=? -->
Normal or nondiagnostic changes

<!-- PAGE=? -->
presumably new LBBB;

<!-- PAGE=? -->
T-wave inversion; strongly

<!-- PAGE=? -->
in ST segment or T wave

<!-- PAGE=? -->
strongly suspicious for injury

<!-- PAGE=? -->
suspicious for ischemia

<!-- PAGE=? -->
Haa

<!-- PAGE=? -->
10

<!-- PAGE=? -->
14

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
indicated (see text tor contraindications)

<!-- PAGE=? -->
indicated (see text for contraindications)

<!-- PAGE=? -->
ate risk criteria (Tables 3, 4)

<!-- PAGE=? -->
Do not delay repertusion

<!-- PAGE=? -->
Nitroglycerin

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
B-Adrenergic receptor blockers

<!-- PAGE=? -->
B-Adrenergic receptor blockers

<!-- PAGE=? -->
troponin-positive?

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
Glycoprotein Ilblllla inhibitor

<!-- PAGE=? -->
15

<!-- PAGE=? -->
Consider admission to

<!-- PAGE=? -->
ED chest pain unit or to

<!-- PAGE=? -->
Time from onset of

<!-- PAGE=? -->
Admit to monitored bed

<!-- PAGE=? -->
monitored bed in ED

<!-- PAGE=? -->
symptoms <12 hours?

<!-- PAGE=? -->
Assess risk status (Tables 3,

<!-- PAGE=? -->
Follow:

<!-- PAGE=? -->
Serial cardiac markers

<!-- PAGE=? -->
(including troponin)

<!-- PAGE=? -->
12

<!-- PAGE=? -->
Repeat ECG/continuous

<!-- PAGE=? -->
ST segment monitoring

<!-- PAGE=? -->
High-risk patient (Tables 3, 4 for

<!-- PAGE=? -->
Consider stress test

<!-- PAGE=? -->
risk stratification):

<!-- PAGE=? -->
Reperfusion strategy:

<!-- PAGE=? -->
Retractory ischemic chest pain

<!-- PAGE=? -->
Therapy defined by patient and center

<!-- PAGE=? -->
Recurrent persistent ST deviation

<!-- PAGE=? -->
criteria (Table 2)

<!-- PAGE=? -->
Ventricular tachycardia

<!-- PAGE=? -->
16

<!-- PAGE=? -->
Be aware of reperfusion goals:

<!-- PAGE=? -->
Hemodynamic instability

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
Door-to-balloon inflation (PCI)

<!-- PAGE=? -->
Signs of pump failure

<!-- PAGE=? -->
ate risk criteria (Tables 3,

<!-- PAGE=? -->
goal of 90 min

<!-- PAGE=? -->
Early invasive strategy, including

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
Door-to-needle (fibrinolysis)

<!-- PAGE=? -->
catheterization and revascularization

<!-- PAGE=? -->
troponin-positive?

<!-- PAGE=? -->
goal of 30 min

<!-- PAGE=? -->
for shock within 48 hours of an AMI

<!-- PAGE=? -->
Continue adjunctive therapies and:

<!-- PAGE=? -->
Continue ASA, heparin; and other

<!-- PAGE=? -->
ACE inhibitorslangiotensin

<!-- PAGE=? -->
therapies as indicated .

<!-- PAGE=? -->
receptor blocker (ARB) within

<!-- PAGE=? -->
ACE inhibitor/ARB

<!-- PAGE=? -->
24 hours of symptom onset

<!-- PAGE=? -->
HMG CoA reductase inhibitor

<!-- PAGE=? -->
If no evidence of ischemia

<!-- PAGE=? -->
HMG CoA reductase inhibitor

<!-- PAGE=? -->
(statin therapy)

<!-- PAGE=? -->
or infarction,

<!-- PAGE=? -->
can

<!-- PAGE=? -->
discharge

<!-- PAGE=? -->
(statin therapy)

<!-- PAGE=? -->
Not at high risk: cardiology to risk-stratify

<!-- PAGE=? -->
with follow-up

<!-- PAGE=? -->
(<30

<!-- PAGE=? -->
o Tension pneumothorax

<!-- PAGE=? -->
 DDx of ST elevation

<!-- PAGE=? -->
o ACS

<!-- PAGE=? -->
o Pericarditis

<!-- PAGE=? -->
o Old LBBB

<!-- PAGE=? -->
o Rt ventrical pacing

<!-- PAGE=? -->
o LVH

<!-- PAGE=? -->
o Early repolarization

<!-- PAGE=? -->
 EMS should be activated if angina persists 5 mins after first NTG spray

<!-- PAGE=? -->
 Pain relief is an important early goal in ACS - sympathetic stimulation has been implicated in

<!-- PAGE=? -->
o Plaque fissuring

<!-- PAGE=? -->
o Thrombus propagation

<!-- PAGE=? -->
o Reduction in VF threshold

<!-- PAGE=? -->
 IV Nitrates for

<!-- PAGE=? -->
 Ongoing ischemic discomfort

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 CHF

<!-- PAGE=? -->
o Start infusion at 10ug/min

<!-- PAGE=? -->
 Titrate by 10ug/min every 3-5 min

<!-- PAGE=? -->
 Ceiling dose of 200ug/min

<!-- PAGE=? -->
 Keep SBP > 110 or with 25% of baseline

<!-- PAGE=? -->
o Avoid in tachycardia, bradycardia, or hypotension

<!-- PAGE=? -->
 In addition to ischemic chest pain, the ECG must meet 1 of the following criteria

<!-- PAGE=? -->
o > 1mm ST elevation in 2 contiguous leads

<!-- PAGE=? -->
o New or presumed new LBBB

<!-- PAGE=? -->
o ST depression if criteria for true posterior MI are present

<!-- PAGE=? -->
 Risk factors for cardiogenic shock in STEMI

<!-- PAGE=? -->
o Age > 70

<!-- PAGE=? -->
o SBP < 120

<!-- PAGE=? -->
o HR > 110 or < 60

<!-- PAGE=? -->
o Delayed presentation

<!-- PAGE=? -->
 B-blockade within 24 hrs of STEMI

<!-- PAGE=? -->
o No risk factors for cardiogenic shock

<!-- PAGE=? -->
o No signs of CHF

<!-- PAGE=? -->
o No evidence of low output state

<!-- PAGE=? -->
o No other contraindications

<!-- PAGE=? -->
 AV block

<!-- PAGE=? -->
 Asthma

<!-- PAGE=? -->
 Patients requiring Cardiac surgery should not receive plavix

<!-- PAGE=? -->
 Paitnets > 75 should not get plavix load

<!-- PAGE=? -->
 ACE is started in hospital after AMI but is contraindicated in the first 24 hrs

<!-- PAGE=? -->
 Unstable angina is best defined by an accelerating tempo of symptoms of a period of 24-48hrs

<!-- PAGE=? -->
o Inc. Frequency and severity

<!-- PAGE=? -->
o Occur with less and less exertion

<!-- PAGE=? -->
o Occur at rest or wake patient at night

<!-- PAGE=? -->
 Most common signs and symptoms of PE are:

<!-- PAGE=? -->
o Tachypnea (96%)

<!-- PAGE=? -->
o SOB (82%)

<!-- PAGE=? -->
o Chest pain (49%)

<!-- PAGE=? -->
o Cough (20%)

<!-- PAGE=? -->
o Hemoptysis (%)

<!-- PAGE=? -->
 Primary antifibrinolytics with tPA is approved for massive PE presenting with hypotension

<!-- PAGE=? -->
o Intracranial hemorrhage may be as high as 3%

<!-- PAGE=? -->
o Risk-benefit remains unclear

<!-- PAGE=? -->
 If dynamic TWI occurs in association with symptoms, it is strongly suggestive of ischemia

<!-- PAGE=? -->
TABLE

<!-- PAGE=? -->
Point Value

<!-- PAGE=? -->
Predictor Variable

<!-- PAGE=? -->
of Variable

<!-- PAGE=? -->
Definition

<!-- PAGE=? -->
23 rsk factols for CAD

<!-- PAGE=? -->
Risk factors

<!-- PAGE=? -->
Family

<!-- PAGE=? -->
of CAD

<!-- PAGE=? -->
Hypertersion

<!-- PAGE=? -->
Hypercholsterolemia

<!-- PAGE=? -->
Diabetes

<!-- PAGE=? -->
Current smoker

<!-- PAGE=? -->
days

<!-- PAGE=? -->
Recent, severe symptoms of angina

<!-- PAGE=? -->
22 anginal events in last 24 hours

<!-- PAGE=? -->
Bevated cardiac markers

<!-- PAGE=? -->
ST devjaüon 20.5 mm

<!-- PAGE=? -->
ST depression 20.5 mm is signifcant; bansient ST elevation >0.5 mm for

<!-- PAGE=? -->
20 minutes

<!-- PAGE=? -->
is treated as ST-sgment depression and is high risk; ST elevation

<!-- PAGE=? -->
21 mm for more than

<!-- PAGE=? -->
Prior coronar; artery stenosis 25086

<!-- PAGE=? -->
Risk of 21 Primary End

<!-- PAGE=? -->
Pcint in 214

<!-- PAGE=? -->
Risk Status

<!-- PAGE=? -->
2

<!-- PAGE=? -->
1306

<!-- PAGE=? -->
Intermediate

<!-- PAGE=? -->
2086

<!-- PAGE=? -->
5

<!-- PAGE=? -->
2696

<!-- PAGE=? -->
High

<!-- PAGE=? -->
6 or

<!-- PAGE=? -->
4196

<!-- PAGE=? -->
history

<!-- PAGE=? -->
Days

<!-- PAGE=? -->
CHF and Cardiogenic Shock

<!-- PAGE=? -->
 Definition

<!-- PAGE=? -->
o SBP < 90 for > 1 hr

<!-- PAGE=? -->
 Not fluid responsive

<!-- PAGE=? -->
 Secondary to cardiac dysfunction

<!-- PAGE=? -->
 Associatd with signs of hypoperfusion, CI < 2.2, PCWP > 18

<!-- PAGE=? -->
 Pt with small or modest MI can develop cardiogenic shock

<!-- PAGE=? -->
o Prior MI or poor LV function

<!-- PAGE=? -->
o Inc. Age with inc. Comorbidity

<!-- PAGE=? -->
o Mortality rate rival large MIs because of delayed diagnosis

<!-- PAGE=? -->
o LCx is the cause in about 1/3 of patients d/t to limited ECG findings

<!-- PAGE=? -->
 Patients at high risk of severe LV dysfunction (large anterior MI) with shock, pulmonary congestion tachycardia should be transferred to a PCI / CABG capable facility

<!-- PAGE=? -->
o Defer antifibrinolytics if door-to-baloon time is < 60 min

<!-- PAGE=? -->
 If not , give fibrinolytics and transfer

<!-- PAGE=? -->
Evaluate Patient for Hemodynamic  Stability'

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
Ischemic Chest Pain

<!-- PAGE=? -->
New Or worsening CHF

<!-- PAGE=? -->
New altered level of consciousness

<!-- PAGE=? -->
Give oxygen, ECG? , Vitals, IV access

<!-- PAGE=? -->
Bradycardia algcrithm

<!-- PAGE=? -->
too slow

<!-- PAGE=? -->
Assess Rate (HR)

<!-- PAGE=? -->
too fast

<!-- PAGE=? -->
Tachycardia algorithm

<!-- PAGE=? -->
Fluid challenges

<!-- PAGE=? -->
Blocd products

<!-- PAGE=? -->
Pulmonary Edema

<!-- PAGE=? -->
high

<!-- PAGE=? -->
Assess Volume

<!-- PAGE=? -->
low

<!-- PAGE=? -->
Cause scecific

<!-- PAGE=? -->
inte ventions

<!-- PAGE=? -->
First-Line Actions

<!-- PAGE=? -->
Nitrcg ycerin SL

<!-- PAGE=? -->
Assess Pump

<!-- PAGE=? -->
Furosemide 0.5-1.0 mg/kg

<!-- PAGE=? -->
Systolic < 70 mmHg

<!-- PAGE=? -->
Second-Line Actionss

<!-- PAGE=? -->
sign symotoms shock

<!-- PAGE=? -->
Ro sign symptoms shock

<!-- PAGE=? -->
Ntroglycerin if systolic BP (SBP)

<!-- PAGE=? -->
>100 mm Hg

<!-- PAGE=? -->
Dopamine if SBP 70-100, S+5 shock

<!-- PAGE=? -->
Sta t Norecinephrine 0.5-

<!-- PAGE=? -->
Stat Dcpamine

<!-- PAGE=? -->
Stait Dobuamine

<!-- PAGE=? -->
30 mcg min

<!-- PAGE=? -->
Further Diagnostic and Therapeutic Considerations

<!-- PAGE=? -->
Identify and treat reversible causes

<!-- PAGE=? -->
Intra-acrtic balccn pumo

<!-- PAGE=? -->
Surgical inte ventions

<!-- PAGE=? -->
Additional drug therapies and dagnostic studies

<!-- PAGE=? -->
 NTG is contraindicated in hypotensive patients with signs of shock

<!-- PAGE=? -->
Toxicology

<!-- PAGE=? -->
 GI decontamination is generally not effective after more than 1 hr

<!-- PAGE=? -->
 Common toxidromes

<!-- PAGE=? -->
o Sympathomimetic

<!-- PAGE=? -->
 If VT develops, use of epinephrine is unclear - may use at greater intervals

<!-- PAGE=? -->
o Cholinergic

<!-- PAGE=? -->
o Anticholinergic

<!-- PAGE=? -->
o Opiates

<!-- PAGE=? -->
 CNS and Respiratory depression

<!-- PAGE=? -->
 Miosis

<!-- PAGE=? -->
 Specific therapy

<!-- PAGE=? -->
 Naloxone

<!-- PAGE=? -->
o Try supported ventilation first

<!-- PAGE=? -->
o Give naloxone prior to intubation

<!-- PAGE=? -->
o May precipitate acute withdrawal in opioid dependant patients

<!-- PAGE=? -->
 Duration of naloxone is shorter than duration of most opioids - will require further care

<!-- PAGE=? -->
o Cocaine

<!-- PAGE=? -->
o Cardiac toxins

<!-- PAGE=? -->
o Salicylates

<!-- PAGE=? -->
 Flumazenil is associated with significant toxicity in patients with benzodiaxepine dependence or coingestion with proconvulsants - TCAs

<!-- PAGE=? -->
o Not recommend for routine use in coma cocktails

<!-- PAGE=? -->
 Bradycardia

<!-- PAGE=? -->
o Toxin - CCB, B-blocker

<!-- PAGE=? -->
o Inotropes are first line for CCB OD - Ca infusion is used if refractory to standard treatment

<!-- PAGE=? -->
o Consider epinephrine CaCl, glucose/insulin (may result in hypokalemia), glucagon, TCP

<!-- PAGE=? -->
o Avoid atropine - unless cholinesterase inhibitor poisoning

<!-- PAGE=? -->
o Avoid isoproterenol if hypotensive

<!-- PAGE=? -->
 Tachycardia

<!-- PAGE=? -->
o Sympathomimetics

<!-- PAGE=? -->
 BDZ, lidocaine, bicarb, NTG, nitroprusside, labetolol

<!-- PAGE=? -->
 Lidocaine and bicarb or agents of choice in cocaine induced VT/VF

<!-- PAGE=? -->
o TCA

<!-- PAGE=? -->
 Bicarb, hyperventilation, NS, Mg, lidocaine

<!-- PAGE=? -->
o Anticholinergics

<!-- PAGE=? -->
 Physostigmine

<!-- PAGE=? -->
 May produce symptoms of cholinergic crisis - secretions, Sz, bradycardia

<!-- PAGE=? -->
 Don't give in TCA OD

<!-- PAGE=? -->
o Drug induced SVT is often resistant to cardioversion and adenosine - avoid

<!-- PAGE=? -->
 Impaired conduction

<!-- PAGE=? -->
o Toxin - sodium channel antagonists (flecainide, procainamide, TCAs)

<!-- PAGE=? -->
o Treat with bicarb and or lidocaine

<!-- PAGE=? -->
o Hypertonic saline and alkalinization masy prevent or terminate VT

<!-- PAGE=? -->
 Aim for pH of 7.45-7.55

<!-- PAGE=? -->
 Respiratory alkalosis ad temporizing measure

<!-- PAGE=? -->
 Bolus 1-2mEq of NaHCO3

<!-- PAGE=? -->
 Maintain with bicarb infusion

<!-- PAGE=? -->
o Avoid amiodarone

<!-- PAGE=? -->
 HTN

<!-- PAGE=? -->
o Sympathomimetics

<!-- PAGE=? -->
 BDZ, lidocaine, bicarb, NTG, nitroprusside, labetolol, phentolamine

<!-- PAGE=? -->
 Avoid B-blockers

<!-- PAGE=? -->
o Usually short lived, may not require any treatment

<!-- PAGE=? -->
 May be followed by hypotension

<!-- PAGE=? -->
 ACS

<!-- PAGE=? -->
o BDZ, lidocaine, Bicarb, NTG, ASA, heparin, reperfusion

<!-- PAGE=? -->
o Avoid B-blockers

<!-- PAGE=? -->
o NTG and phentolamine reverse cocaine induced vasoconstriction

<!-- PAGE=? -->
 Phentolamine is second line

<!-- PAGE=? -->
 Shock

<!-- PAGE=? -->
o Due to drug induced

<!-- PAGE=? -->
 Dec intravascular volume

<!-- PAGE=? -->
 Dec. SVR

<!-- PAGE=? -->
 Dec. contractility

<!-- PAGE=? -->
o CCB or B-blocker- NS, epinephrine, norepinephrine, dopamine, CaCl, glucagon, glucose / insulin

<!-- PAGE=? -->
o Consider assist devices if refractory

<!-- PAGE=? -->
 Cholinergic

<!-- PAGE=? -->
o Give atropine and pralidoxime

<!-- PAGE=? -->
o Avoid Sux

<!-- PAGE=? -->
 Anticholinergic

<!-- PAGE=? -->
o BDZ

<!-- PAGE=? -->
o Physostigmine (not in TCA)

<!-- PAGE=? -->
o Avoid antipsychotics and other anticholinergic agents

<!-- PAGE=? -->
 Torsades de pointes

<!-- PAGE=? -->
o Correct hypoxia, hypokalemia, hypomegnesemia

<!-- PAGE=? -->
o Administer Mg - 1-2g

<!-- PAGE=? -->
o Consider lidocaine

<!-- PAGE=? -->
o Consider overdrive pacing at rates of 100-120

<!-- PAGE=? -->
o Consider pharmacologic overdrive pacing with isoproterenol

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
 Mild hypothermia - >34'C

<!-- PAGE=? -->
 Shivering

<!-- PAGE=? -->
 Poor judgement

<!-- PAGE=? -->
 Tachycardia progressing to bradycardia

<!-- PAGE=? -->
o Active external rewarming of all areas

<!-- PAGE=? -->
 Moderate hypothermia - 30-34'C

<!-- PAGE=? -->
 Mental confusion

<!-- PAGE=? -->
 Tachypnea progressing to hypopnea

<!-- PAGE=? -->
 Shivering stops

<!-- PAGE=? -->
 Severe peripheral vasoconstriction

<!-- PAGE=? -->
 Difficult to obtain BP

<!-- PAGE=? -->
 Muscle rigidity

<!-- PAGE=? -->
 May lose of consciousness

<!-- PAGE=? -->
 Risk of afib and other arrythmias

<!-- PAGE=? -->
o Active external rewarming of truncal areas

<!-- PAGE=? -->
 Severe Hypothermia - < 30'C

<!-- PAGE=? -->
 Pulse and respirations slow

<!-- PAGE=? -->
 Mydriasis

<!-- PAGE=? -->
 High risk for VF with rough movements progessing to spontaneous VF and asystole

<!-- PAGE=? -->
 O2 consumption < 50% normal

<!-- PAGE=? -->
 Unconscious

<!-- PAGE=? -->
o Active internal rewarming

<!-- PAGE=? -->
 Profound hypothermia - < 20'C

<!-- PAGE=? -->
 PEA or asystole

<!-- PAGE=? -->
 Flat EEG

<!-- PAGE=? -->
Drowning

<!-- PAGE=? -->
 100% mortality

<!-- PAGE=? -->
o Submersion > 25 min

<!-- PAGE=? -->
o Resuscitation > 25 min

<!-- PAGE=? -->
o Pulseless on arrival to ED

<!-- PAGE=? -->
o Unconscious at scene and on arrival to ED

<!-- PAGE=? -->
 Patients who have ROSC and breathin ing the field usually recover with good neurologic outcomes

<!-- PAGE=? -->
 Cause of death in hospitalized victims

<!-- PAGE=? -->
o Hypoxic brain injury

<!-- PAGE=? -->
o ARDS

<!-- PAGE=? -->
o MOD

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
 Routine use of abdominal thrusts is not recommended

<!-- PAGE=? -->
 It may be difficult to assess respiration and pulse in hypothermia

<!-- PAGE=? -->
 Every drowning patient requires transport to hospital

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
 Subq epinephrine may be administer prearrest

<!-- PAGE=? -->
o 0.01mg/kg SC divided into 3 doses at 20min intervals

<!-- PAGE=? -->
 Total dose 300-500ug

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
 Patient's taking B-blockers have an inc. severity of anaphylaxis and can develop a paradoxical response to epinephrine

<!-- PAGE=? -->
o Consider glucagon (1-2mg every 5min) as well as ipratropium

<!-- PAGE=? -->
 IM epinephrine is the preferred route unless sever with immediate lifethreatening manifestations

<!-- PAGE=? -->
 Remove stinger

<!-- PAGE=? -->
 Early intubation is recommended with any A/W signs

<!-- PAGE=? -->
Electric and lightning Injuries

<!-- PAGE=? -->
 Injuries for electric current

<!-- PAGE=? -->
o Burns and bruises

<!-- PAGE=? -->
o Arrhythmia - VF, asystole

<!-- PAGE=? -->
o Fatal pump impairment

<!-- PAGE=? -->
o Electromechanical dissociation

<!-- PAGE=? -->
 Injuries from Lightning

<!-- PAGE=? -->
o Significant cardiac injury

<!-- PAGE=? -->
o CNS injury

<!-- PAGE=? -->
o Minimal burns

<!-- PAGE=? -->
 Both types

<!-- PAGE=? -->
o Blunt trauma

<!-- PAGE=? -->
o Blunt head injury

<!-- PAGE=? -->
o Long-term neurocognitive damage and chronic pain

<!-- PAGE=? -->
 Risk factors for electrocution

<!-- PAGE=? -->
o Male

<!-- PAGE=? -->
o Adolescents

<!-- PAGE=? -->
o Utility, agricultural, and construction workers

<!-- PAGE=? -->
o Unauthorized repairs

<!-- PAGE=? -->
o ETOH

<!-- PAGE=? -->
o Overlooking overhead powerlines

<!-- PAGE=? -->
o Poor judgement

<!-- PAGE=? -->
Hyperkalemia

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
o CRF

<!-- PAGE=? -->
o Metabolic acidosis

<!-- PAGE=? -->
o Pseudohypoaldosteronism type II

<!-- PAGE=? -->
o hypoaldosteronism

<!-- PAGE=? -->
o Tumor lysis

<!-- PAGE=? -->
o Rhabdomyolysis

<!-- PAGE=? -->
o RTA

<!-- PAGE=? -->
o Hemolysis

<!-- PAGE=? -->
o Hyperkalemic periodic paralysis

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 K sparing diuretics

<!-- PAGE=? -->
 ACEi

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 Potassium

<!-- PAGE=? -->
 Penicillin derivatives

<!-- PAGE=? -->
 Sux

<!-- PAGE=? -->
 B-Blockers

<!-- PAGE=? -->
o Blood transfusion

<!-- PAGE=? -->
 Progressive ECG Changes

<!-- PAGE=? -->
o Peaked T waves

<!-- PAGE=? -->
o Inc. PR and QT

<!-- PAGE=? -->
o Flattened P waves and ST segment

<!-- PAGE=? -->
o Widening QRS

<!-- PAGE=? -->
o Deepening S waves mergind with T waves

<!-- PAGE=? -->
o Sine Wvae

<!-- PAGE=? -->
o PEA, VT/VF, asystole

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
o GI losses

<!-- PAGE=? -->
o Diuretucs

<!-- PAGE=? -->
o RTA

<!-- PAGE=? -->
o Aldosteronism

<!-- PAGE=? -->
 Primary or secondary

<!-- PAGE=? -->
o Licorice

<!-- PAGE=? -->
o Chewing tobacco

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 Aminoglycosides

<!-- PAGE=? -->
 Penicillins

<!-- PAGE=? -->
 Amph B

<!-- PAGE=? -->
 L-Dopa

<!-- PAGE=? -->
 Lithium

<!-- PAGE=? -->
 Thallium

<!-- PAGE=? -->
 Theophylline

<!-- PAGE=? -->
o Redistribution

<!-- PAGE=? -->
 Alkalosis

<!-- PAGE=? -->
 Insulin

<!-- PAGE=? -->
 Hypomagnesemia

<!-- PAGE=? -->
 B-agonists

<!-- PAGE=? -->
 Hypokalemic periodic paralysis

<!-- PAGE=? -->
 Progressive ECG Changes

<!-- PAGE=? -->
o U waves, flattened t waves, low QRS voltage, prominent P waves

<!-- PAGE=? -->
o Inc. U waves, ST segment changes

<!-- PAGE=? -->
Calcium

<!-- PAGE=? -->
 Calcium antaganizes the effectsof both hyper kalemia and hypermagnesemia

<!-- PAGE=? -->
 Hypercalcemia etiology

<!-- PAGE=? -->
o Primary hyperparathyroidism

<!-- PAGE=? -->
o Malignancy

<!-- PAGE=? -->
o Granulonatous disease

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
 Lithium

<!-- PAGE=? -->
 Thiazide diuretic

<!-- PAGE=? -->
 Estrogens

<!-- PAGE=? -->
 Hypervitaminosis A & D

<!-- PAGE=? -->
o Hyperthyroid

<!-- PAGE=? -->
o Adreanal insufficiency

<!-- PAGE=? -->
o Acromegaly

<!-- PAGE=? -->
o VIP tumors

<!-- PAGE=? -->
o Immobilizaton

<!-- PAGE=? -->
o Paget's disease

<!-- PAGE=? -->
o Milk-alkali syndrome

<!-- PAGE=? -->
o ARF - recovery phase-

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Replete intravascular volume

<!-- PAGE=? -->
o Lasix

<!-- PAGE=? -->
o Chelating agents (PO4)

<!-- PAGE=? -->
o HD if required

<!-- PAGE=? -->
 Hypocalcemia etiology

<!-- PAGE=? -->
o Insufficient parathyroid hormone

<!-- PAGE=? -->
o Insufficient Vit D

<!-- PAGE=? -->
 Malnutrition

<!-- PAGE=? -->
 Malabsorption

<!-- PAGE=? -->
 Congenital rickets

<!-- PAGE=? -->
 Liver disease

<!-- PAGE=? -->
 CRF

<!-- PAGE=? -->
 Sunlight deficiency

<!-- PAGE=? -->
 Hypo/hypermag

<!-- PAGE=? -->
 Advanced bone disease

<!-- PAGE=? -->
 Medications

<!-- PAGE=? -->
 Cimetidine

<!-- PAGE=? -->
 Phosphates

<!-- PAGE=? -->
 Dilantin

<!-- PAGE=? -->
 Gent

<!-- PAGE=? -->
 Calcitonin

<!-- PAGE=? -->
 EDTA

<!-- PAGE=? -->
 Heparin

<!-- PAGE=? -->
 Protamine

<!-- PAGE=? -->
 Theophyilline

<!-- PAGE=? -->
 Glucagon

<!-- PAGE=? -->
 Norepi

<!-- PAGE=? -->
 Lasix

<!-- PAGE=? -->
 Nitroprusside

<!-- PAGE=? -->
 Pancreatitis

<!-- PAGE=? -->
 Shock

<!-- PAGE=? -->
 Sepsis

<!-- PAGE=? -->
 Burns

<!-- PAGE=? -->
o Widened QRS, arrhythmia, PEA asystole

<!-- PAGE=? -->
 Toxic shock

<!-- PAGE=? -->
Magnesium

<!-- PAGE=? -->
 Hypermagnesemia

<!-- PAGE=? -->
o Initial treatment in CaCl

<!-- PAGE=? -->
o Once stablized - volume resuscitation with lasix

<!-- PAGE=? -->
 Hypomagnesemia

<!-- PAGE=? -->
o Etiology

<!-- PAGE=? -->
 ETOH

<!-- PAGE=? -->
 Malnutrition

<!-- PAGE=? -->
 GI losses

<!-- PAGE=? -->
 Burns

<!-- PAGE=? -->
 Lactation

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
 Diuretics

<!-- PAGE=? -->
 Gentamicin

<!-- PAGE=? -->
 Digoxin

<!-- PAGE=? -->
 Parathyroid abnormalities

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 Ketoacidosis

<!-- PAGE=? -->
 Hypo/hyperthyroid

<!-- PAGE=? -->
 Phosphate deficiency

<!-- PAGE=? -->
o Give Mg and calcium

<!-- PAGE=? -->
DKA

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Bolus 1L NS followed by 1-2L of next two hours

<!-- PAGE=? -->
o Add 20mEq KCL per litre

<!-- PAGE=? -->
o Bolus 10u IV insulin and run infusion at 0.1u/kg/hr

<!-- PAGE=? -->
 Start D5W when sugar hits 300mg/dl

<!-- PAGE=? -->
o Hyperkalemia may be present from severe shift secondary to acidosis

<!-- PAGE=? -->
o Monitor for cerebral edema

<!-- PAGE=? -->
Achondroplasia

<!-- PAGE=? -->
CoExD

<!-- PAGE=? -->
 Dwarfism can occur in two forms

<!-- PAGE=? -->
o proportionate dwarfism

<!-- PAGE=? -->
 limbs, trunk, and head are in the same relative proportions as a normal adult

<!-- PAGE=? -->
o disproportionate dwarfism

<!-- PAGE=? -->
 limbs, trunk, and head are not in the usual proportions of a normal adult

<!-- PAGE=? -->
 Achondroplasia is the most common cause of disproportionate dwarfism

<!-- PAGE=? -->
 occurs predominantly in females

<!-- PAGE=? -->
 incidence of 1.5 per 10,000 births

<!-- PAGE=? -->
 Transmission is autosomal dominant

<!-- PAGE=? -->
o although estimated 80% of cases represent spontaneous mutations

<!-- PAGE=? -->
 basic defect is a decrease in the rate of endochondral ossification

<!-- PAGE=? -->
o produces short tubular bones

<!-- PAGE=? -->
 anticipated height

<!-- PAGE=? -->
o males - 132 cm (52 inches)

<!-- PAGE=? -->
o females - 122 cm (48 inches)

<!-- PAGE=? -->
 Characteristics

<!-- PAGE=? -->
o Possible Difficult intibation not confirmed with clinical experience

<!-- PAGE=? -->
 Unstable C-spine

<!-- PAGE=? -->
 Large protruding forehead, short maxilla, large mandible, flat nose, and large tongue

<!-- PAGE=? -->
 Cervical kyphosis

<!-- PAGE=? -->
Acromegaly

<!-- PAGE=? -->
 excessive secretion of growth hormone

<!-- PAGE=? -->
o most often due to an adenoma in the anterior pituitary

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o Failure of plasma growth hormone concentrations to decrease 1 to 2 hours after ingestion of 75 to 100 g of glucose

<!-- PAGE=? -->
o growth hormone concentrations higher than 3 ng/mL

<!-- PAGE=? -->
o skull xray and CT are useful for detecting enlargement of the sella turcica

<!-- PAGE=? -->
 Manifestations - reflect parasellar extension of the anterior pituitary adenoma and peripheral effects produced by the presence of excess growth hormone

<!-- PAGE=? -->
o Parasellar

<!-- PAGE=? -->
 Enlarged sella turcica

<!-- PAGE=? -->
 Headache

<!-- PAGE=? -->
 Visual field defects

<!-- PAGE=? -->
 Rhinorrhea

<!-- PAGE=? -->
o Excess Growth Hormone

<!-- PAGE=? -->
 Airway abnormalities difficult airway management

<!-- PAGE=? -->
 Prognathism

<!-- PAGE=? -->
 Overgrowth of tongue, epiglottis, vocal cords

<!-- PAGE=? -->
o Arytenoid dysfunction

<!-- PAGE=? -->
o Smaller laryngeal aditus

<!-- PAGE=? -->
 Recurrent laryngeal nerve paralysis

<!-- PAGE=? -->
o 2' to stretch

<!-- PAGE=? -->
 Pharyngeal masses

<!-- PAGE=? -->
 Subglotic stenosis

<!-- PAGE=? -->
o Stridor, dyspnea

<!-- PAGE=? -->
 Skeletal, connective and soft-tissue overgrowth

<!-- PAGE=? -->
 Smaller airways

<!-- PAGE=? -->
 Use wt to determine ETT size

<!-- PAGE=? -->
o functional fusion of the atlanto-occipital joint with odontoid hypoplasia

<!-- PAGE=? -->
 atlantoaxial instability

<!-- PAGE=? -->
 bulging discs

<!-- PAGE=? -->
 severe cervical kyphosis

<!-- PAGE=? -->
o Obstructive Sleep apnea

<!-- PAGE=? -->
o Kyphoscoliosis and genu varum are common

<!-- PAGE=? -->
 Restrictive lung disease with pHTN and cor pulmonale

<!-- PAGE=? -->
o Foramen magnum stenosis

<!-- PAGE=? -->
 Hydrocephalus

<!-- PAGE=? -->
 Central sleep apnea

<!-- PAGE=? -->
o Mental and skeletal muscle development are normal

<!-- PAGE=? -->
o life expectancy is normal for those who survive the first year of life

<!-- PAGE=? -->
 Management of Anesthesia

<!-- PAGE=? -->
o Excess skin and subcutaneous tissue may make peripheral venous access technically difficult

<!-- PAGE=? -->
o Achondroplastic dwarfs respond normally to anesthetic drugs and neuromuscular blockers

<!-- PAGE=? -->
o C-section is necessary because a small, contracted pelvis combined with a near-normal birth weight infant

<!-- PAGE=? -->
 Regional anesthesia might be considered, but technical difficulties may occur

<!-- PAGE=? -->
 kyphoscoliosis

<!-- PAGE=? -->
 narrow epidural space and spinal canal

<!-- PAGE=? -->
 Osteophytes

<!-- PAGE=? -->
 prolapsed intervertebral discs

<!-- PAGE=? -->
 deformed vertebral bodies

<!-- PAGE=? -->
 Epidural anesthesia may be preferable to spinal anesthesia because it permits titration of the local anesthetic drug to achieve the desired level of sensory blockade

<!-- PAGE=? -->
ADH

<!-- PAGE=? -->
 Peripheral neuropathy (carpal tunnel syndrome)

<!-- PAGE=? -->
 Inadequate ulnar arterial flow

<!-- PAGE=? -->
 Caution with radial artlines

<!-- PAGE=? -->
 Visceromegaly

<!-- PAGE=? -->
 Glucose intolerance and overt DM

<!-- PAGE=? -->
 Osteoarthritis

<!-- PAGE=? -->
 Osteoporosis

<!-- PAGE=? -->
 Thick oily skin

<!-- PAGE=? -->
 hyperhydrosis

<!-- PAGE=? -->
 Skeletal muscle weakness

<!-- PAGE=? -->
 Inc. incidence of HTN and CAD

<!-- PAGE=? -->
 Inc. lung volumes with V/Q mismatch

<!-- PAGE=? -->
 There is no evidence that hemodynamic instability or alterations in pulmonary gas exchange accompany anesthesia in acromegalic patients

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Transsphenoidal surgical excision of pituitary adenomas is the preferred initial therapy

<!-- PAGE=? -->
o With extension, surgery or radiation is no longer feasible; medical treatment with suppressant drugs (bromocriptine) may be an option

<!-- PAGE=? -->
o Octreotide produces effective palliation in 50% of patients

<!-- PAGE=? -->
Specialized neurons in the supraoptic and paraventricular nuclei of the hypothalamus are very sensitive to changes in extracellular osmolality.  When ECF osmolality increases, these cells shrink and release ADH from the posterior pituitray.  ADH markedly increases water reabsorption in renal collecting tubules which tends to reduce plasma osmolality to normal again.  Conversely a decrease in ECF osmolality causes osmoreceptors to swell and suppresses the release of ADH.  Decreased ADH secretion allows a water diuresis which tends to increase osmolality to normal.  Peak diuresis occurs once circulating ADH is metabolized (90-120min).

<!-- PAGE=? -->
The carotid baroreceptors and possibly atrial stretch receptors can also stimulate ADH release following a 510% decrease in blood volume.  Other nonosmotic stimuli include pain, emotional stress and hypoxia .

<!-- PAGE=? -->
Lange p604

<!-- PAGE=? -->
Addiction

<!-- PAGE=? -->
Table 4-6. SIGNS OF SUBSTANCE ABUSE AND DEPENDENCE WHAT TO LOOK FOR OUTSIDE THE HOSPITAL

<!-- PAGE=? -->
Addiction is a disease of loneliness and isolation. Addicts quickly withdraw from family, friends, and leisure activities.

<!-- PAGE=? -->
Addicts have unusual changes in behavior, including wide mood swings, periods of depression, anger, and irritability alternating with periods of euphoria.

<!-- PAGE=? -->
Unexplained overspending, legal problems, gambling, extramarital affairs, and increased problems at work are commonly seen in addicts.

<!-- PAGE=? -->
An obvious physical sign of alcoholism is the frequent smell of alcohol on the breath.

<!-- PAGE=? -->
Domestic strife, fights, and arguments may increase in number and intensity.

<!-- PAGE=? -->
Sexual drive may significantly decrease.

<!-- PAGE=? -->
Children may develop behavioral problems.

<!-- PAGE=? -->
Some addicts frequently change jobs over a period of several years in an attempt to find a geographic cure for their disease, or to hide it from co-workers.

<!-- PAGE=? -->
Addicts need to be near their drug source. For a health care professional, this means long hours at the hospital, even when off duty. For alcoholics, it means calling in sick to work. Alcoholics may disappear without any explanation to bars or hiding places to drink secretly.

<!-- PAGE=? -->
Addicts may suddenly develop the habit of locking themselves in the bathroom or other rooms while they are using drugs.

<!-- PAGE=? -->
Addicts frequently hide pills, syringes, or alcohol bottles around the house.

<!-- PAGE=? -->
Persons who inject drugs may leave bloody swabs and syringes containing blood-tinged liquid in

<!-- PAGE=? -->
conspicuous places.

<!-- PAGE=? -->
Addicts may display evidence of withdrawal, especially diaphoresis (sweating) and tremors.

<!-- PAGE=? -->
Narcotic addicts often have pinpoint pupils.

<!-- PAGE=? -->
Weight loss and pale skin are also common signs of addiction.

<!-- PAGE=? -->
Addicts may be seen injecting drugs.

<!-- PAGE=? -->
Tragically, some addicts are found comatose or dead before any of these signs have been recognized by others.

<!-- PAGE=? -->
WHAT TO LOOK FOR INSIDE THE HOSPITAL

<!-- PAGE=? -->
Addicts sign out ever-increasing quantities of narcotics.

<!-- PAGE=? -->
Addicts frequently have unusual changes in behavior, such as wide mood swings, periods of depression, anger, and irritability alternating with periods of euphoria.

<!-- PAGE=? -->
Charting becomes increasingly sloppy and unreadable

<!-- PAGE=? -->
.

<!-- PAGE=? -->
Addicts often sign out narcotics in inappropriately high doses for the operation being performed.

<!-- PAGE=? -->
They refuse lunch and coffee relief.

<!-- PAGE=? -->
Addicts like to work alone in order to use anesthetic techniques without narcotics, falsify records, and divert drugs for personal use.

<!-- PAGE=? -->
They volunteer for extra cases , often where large amounts of narcotics are available (cardiac cases).

<!-- PAGE=? -->
They frequently relieve others .

<!-- PAGE=? -->
They're often at the hospital when off duty, staying close to their drug supply to prevent withdrawal.

<!-- PAGE=? -->
They volunteer frequently for extra call .

<!-- PAGE=? -->
They're often difficult to find between cases, taking short naps after using.

<!-- PAGE=? -->
Addicted anesthesia personnel may insist on personally administering narcotics in the recovery room .

<!-- PAGE=? -->
Addicts make frequent requests for bathroom relief . This is usually where they use drugs.

<!-- PAGE=? -->
Addicts may wear long-sleeved gowns to hide needle tracks and also to combat the subjective feeling of cold they experience when using narcotics.

<!-- PAGE=? -->
Narcotic addicts often have pinpoint pupils.

<!-- PAGE=? -->
An addict's patients may come into the recovery room complaining of pain out of proportion to the amount of narcotic charted on the anesthesia records.

<!-- PAGE=? -->
Weight loss and pale skin are also commons signs of addiction.

<!-- PAGE=? -->
Addicts may be seen injecting drugs.

<!-- PAGE=? -->
Untreated addicts are found comatose.

<!-- PAGE=? -->
Undetected addicts are found dead.

<!-- PAGE=? -->
Adrenergic agents

<!-- PAGE=? -->
Phenylalanine → Tyrosine → DOPA → Dopamine → Norepinephrine → Epinephrine

<!-- PAGE=? -->
Table 12-13. ACTIONS OF ADRENERGIC AGONISTS

<!-- PAGE=? -->
Receptors

<!-- PAGE=? -->
Sympatho-

<!-- PAGE=? -->
mimetics

<!-- PAGE=? -->
alpha1

<!-- PAGE=? -->
alpha2

<!-- PAGE=? -->
Beta1

<!-- PAGE=? -->
Beta2

<!-- PAGE=? -->
DA1

<!-- PAGE=? -->
DA2

<!-- PAGE=? -->
Dose Dependence (,

<!-- PAGE=? -->
, or DA)

<!-- PAGE=? -->
Comments

<!-- PAGE=? -->
Methoxamine

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
?*

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
Vasoconstriction only

<!-- PAGE=? -->
Phenylephrine

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
±

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
Primarily vasoconstriction

<!-- PAGE=? -->
Norepinephrine

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
Beta2 effect present but not

<!-- PAGE=? -->
seen clinically

<!-- PAGE=? -->
Metaraminol

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
Releases NE

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
Ephedrine

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ + +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
Direct and indirect

<!-- PAGE=? -->
Mephentermine

<!-- PAGE=? -->
0 to + +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+?

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
Cerebral stimulation

<!-- PAGE=? -->
Dopamine

<!-- PAGE=? -->
+ to + + +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
+

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ ++ + +

<!-- PAGE=? -->
Dobutamine

<!-- PAGE=? -->
0 to +

<!-- PAGE=? -->
?

<!-- PAGE=? -->
+ + + +

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+ +

<!-- PAGE=? -->
Inotropism greater than

<!-- PAGE=? -->
* The clinical significance of the effects of agonism and antagonism is not yet known.

<!-- PAGE=? -->
Table 12-16. COMPARISON OF RELATIVE  1 CATECHOLAMINE RESPONSES ON PERIPHERAL RESISTANCE AND CAPACITANCE VESSELS*

<!-- PAGE=? -->
* Drugs are listed in descending order of potency within each vascular region.

<!-- PAGE=? -->
† Dose-dependent;  effects of epinephrine predominate at low doses.

<!-- PAGE=? -->
‡ Dose-dependent; DA and  effects predominate at low doses.

<!-- PAGE=? -->
 Veins have more A2 receptors, arteries A1 receptors.

<!-- PAGE=? -->
 Phenylephrine has higher venous:arterial ratio (because of greater A2 effect) , but is overall a weaker constrictor than norepi??.

<!-- PAGE=? -->
 Ephedrine also has higher venous:arterial constrictive effects

<!-- PAGE=? -->
Adrenergic receptors

<!-- PAGE=? -->
Types (all are postsynaptic except some Alpha2)

<!-- PAGE=? -->
 Alpha1

<!-- PAGE=? -->
o postsynaptic adrenoceptors in smooth muscle (eye, lung, blood vessels, gut, GU)

<!-- PAGE=? -->
o increases intracellular calcium ion concentration which leads to muscle contraction

<!-- PAGE=? -->
o Vasoconstriction

<!-- PAGE=? -->
o Mydriasis

<!-- PAGE=? -->
o Relaxation of GI tract

<!-- PAGE=? -->
o Contraction of GI/GU sphincters, uterus

<!-- PAGE=? -->
o inhibits insulin secretion, stimulates glycogenolysis & gluconeogenesis

<!-- PAGE=? -->
o positive inotrope, negative chronotrope

<!-- PAGE=? -->
 Alpha2

<!-- PAGE=? -->
o PREsynaptic - inhibition of NE release (vasodilation)

<!-- PAGE=? -->
 inhibits adenylyl cyclase, decrease the entry of Ca ions into the neuronal terminal which limits subsequent exocytosis of storage vesicles containing norepi

<!-- PAGE=? -->
o POSTsynaptic - platelet aggregation, Hyperpolarization of cells in the central nervous system

<!-- PAGE=? -->
o alpha2 receptors create negative feedback loop that inhibits further norepi release from neuron

<!-- PAGE=? -->
o vasoconstriction, sedation, reduces sympathetic outflow leading to peripheral vasodilation and lower BP, bradycardia

<!-- PAGE=? -->
o spinal analgesia

<!-- PAGE=? -->
o

<!-- PAGE=? -->
 Beta1

<!-- PAGE=? -->
o Postsynaptic in the heart

<!-- PAGE=? -->
o Activates adenylyl cyclase which converts ATP to cAMP and initiates a kinase phosphorylation cascade

<!-- PAGE=? -->
o Increased contractility

<!-- PAGE=? -->
o Increased conduction velocity

<!-- PAGE=? -->
o Increased automaticity

<!-- PAGE=? -->
 Beta2

<!-- PAGE=? -->
o Postsynaptic adrenoceptors in smooth muscle & gland cells

<!-- PAGE=? -->
o Adenylyl cyclase activation

<!-- PAGE=? -->
o Vasodilation

<!-- PAGE=? -->
o Bronchodilation

<!-- PAGE=? -->
o Intracellular shift of K+

<!-- PAGE=? -->
o Relaxation of GI, bladder and uterus

<!-- PAGE=? -->
o Glycogenolysis & gluconeogenesis

<!-- PAGE=? -->
 stimulates insulin release

<!-- PAGE=? -->
 lipolysis

<!-- PAGE=? -->
Adrenocortical Malfunction

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Physiology

<!-- PAGE=? -->
 Three major classes of hormones

<!-- PAGE=? -->
o Androgens

<!-- PAGE=? -->
o Glucocorticoids

<!-- PAGE=? -->
o Mineralocorticoids

<!-- PAGE=? -->
 ~ 30% of -incidentalomas‖ are hormonally active

<!-- PAGE=? -->
o 5.3% cortisone-secreting

<!-- PAGE=? -->
o 5.1% were pheochromocytomas

<!-- PAGE=? -->
o 4.7% were adrenal carcinomas

<!-- PAGE=? -->
o 2.5% were unsuspected metastatic disease

<!-- PAGE=? -->
o 1% were aldosterone-secreting

<!-- PAGE=? -->
 Androgens - Androstenedione and dehydroepiandrosterone

<!-- PAGE=? -->
o weak androgens arising from the adrenal cortex

<!-- PAGE=? -->
o major sources of androgen in women

<!-- PAGE=? -->
o Excess secretion (female)

<!-- PAGE=? -->
 Masculinization

<!-- PAGE=? -->
 Pseudopuberty

<!-- PAGE=? -->
 female pseudohermaphroditism

<!-- PAGE=? -->
o feminization can occur in males d/t conversion of excess androgen to estrogen

<!-- PAGE=? -->
o No special anesthetic evaluation is needed for such patients

<!-- PAGE=? -->
o Most of these patients are treated with exogenous glucocorticoids and mineralocorticoids and consequently requirre supplementation of these hormones perioperatively

<!-- PAGE=? -->
 Glucocorticoids - cortisol

<!-- PAGE=? -->
o regulator of carbohydrate, protein, lipid, and nucleic acid metabolism

<!-- PAGE=? -->
o Most cortisol is bound to corticosterone-binding globulin (CBG, transcortin)

<!-- PAGE=? -->
 Dec. CBG production (inc. free cortisol)

<!-- PAGE=? -->
 liver disease

<!-- PAGE=? -->
 nephrotic syndrome

<!-- PAGE=? -->
 Inc. CBG production

<!-- PAGE=? -->
 estrogen administration

<!-- PAGE=? -->
 pregnancy

<!-- PAGE=? -->
o Total serum cortisol levels may become elevated or depressed under conditions that alter the amount of bound cortisol, and yet the unbound, active form of cortisol is present in normal amounts

<!-- PAGE=? -->
 The most accurate measure of cortisol activity is the level of urinary cortisol-that is, the amount of unbound, active cortisol filtered by the kidney

<!-- PAGE=? -->
o half-life of cortisol is 80 to 110 minutes

<!-- PAGE=? -->
 because cortisol acts through intracellular receptors, pharmacokinetic data based on serum levels are not good indicators of cortisol activity

<!-- PAGE=? -->
o supraphysiologic doses (>30 mg/day) results in mineralocorticoid receptor binding

<!-- PAGE=? -->
 salt and water retention

<!-- PAGE=? -->
 loss of potassium

<!-- PAGE=? -->
 alkalosis - loss of hydrogen ions

<!-- PAGE=? -->
o ACTH secretion has a diurnal rhythm

<!-- PAGE=? -->
 greatest during the early morning hours in men, later in women

<!-- PAGE=? -->
 regulated at least in part by light-dark cycles

<!-- PAGE=? -->
 Mineralocorticoids - Aldosterone

<!-- PAGE=? -->
o comes from the zona glomerulosa of the adrenal cortex

<!-- PAGE=? -->
o results in

<!-- PAGE=? -->
 reabsorption of sodium

<!-- PAGE=? -->
 secretion of potassium (hypokalemia)

<!-- PAGE=? -->
 secretion of hydrogen ions (alkalosis)

<!-- PAGE=? -->
o major regulator of aldosterone secretion is the renin-angiotensin system

<!-- PAGE=? -->
 Juxtaglomerular cells in the cuff of renal arterioles are sensitive to decreased renal perfusion pressure or volume

<!-- PAGE=? -->
 secrete rennin

<!-- PAGE=? -->
 Renin splits the precursor angiotensinogen (from the liver) into angiotensin I - further converted by a converting enzyme, primarily in the lung, to angiotensin II

<!-- PAGE=? -->
 Angiotensin II binds to specific receptors to increase mineralocorticoid secretion

<!-- PAGE=? -->
o also stimulated by an increased potassium concentration and, to a lesser degree, by ACTH

<!-- PAGE=? -->
Glucocorticoid Excess

<!-- PAGE=? -->
 Cushing's syndrome resulting from either endogenous oversecretion or chronic treatment with glucocorticoids

<!-- PAGE=? -->
 Clinical manifestations

<!-- PAGE=? -->
o moon-faced

<!-- PAGE=? -->
o plethoric

<!-- PAGE=? -->
o centripetal distribution of fat (truncal obesity and skinny extremities)

<!-- PAGE=? -->
o thin skin

<!-- PAGE=? -->
o easy bruising

<!-- PAGE=? -->
o striae

<!-- PAGE=? -->
o Muscle wasting

<!-- PAGE=? -->
 Proximal muscle weakness

<!-- PAGE=? -->
 heart and diaphragm are usually spared

<!-- PAGE=? -->
o osteopenia

<!-- PAGE=? -->
 decreased formation of bone matrix and impaired absorption of calcium

<!-- PAGE=? -->
o Fluid retention and hypertension

<!-- PAGE=? -->
 increases in renin substrate and vascular reactivity caused by glucocorticoid

<!-- PAGE=? -->
o hyperglycemia and DM

<!-- PAGE=? -->
 inhibition of peripheral use of glucose

<!-- PAGE=? -->
 anti-insulin action and concomitant stimulation of gluconeogenesis

<!-- PAGE=? -->
o Hirsutism

<!-- PAGE=? -->
o Acne

<!-- PAGE=? -->
o Hypokalemic alkalosis

<!-- PAGE=? -->
o Kidney stones

<!-- PAGE=? -->
o Menstrual disorders

<!-- PAGE=? -->
o Increased leukocyte count

<!-- PAGE=? -->
 The most common cause of Cushing's syndrome is the administration of glucocorticoids

<!-- PAGE=? -->
 Spontaneous Cushing's syndrome may be caused by pituitary production of ACTH

<!-- PAGE=? -->
o 65% to 75% of all spontaneous cases

<!-- PAGE=? -->
o usually associated with pituitary microadenoma

<!-- PAGE=? -->
o possible nonendocrine ectopic ACTH production

<!-- PAGE=? -->
 tumors of the lung, pancreas, or thymus

<!-- PAGE=? -->
o 10% 20% of cases are caused by an ACTH-independent process

<!-- PAGE=? -->
 adrenal adenoma or carcinoma

<!-- PAGE=? -->
 administ ration of glucocorticoids is started with the sta rt of resectioning of the tumor

<!-- PAGE=? -->
 Bilateral adrenalectomy in patients with Cushing's syndrome is associated with a high incidence of postoperative complications

<!-- PAGE=? -->
 perioperative mortality rate of 5% to 10%

<!-- PAGE=? -->
o greater th an that of even cardiac surgery

<!-- PAGE=? -->
 often results in permanent mineralocorticoid and glucocorticoid deficiency

<!-- PAGE=? -->
Mineralocorticoid Excess

<!-- PAGE=? -->
 Exc ess mineralocorticoid activity leads to Conn's syndrome (Primary hyperaldosteronism)

<!-- PAGE=? -->
 represents 0.5% to 1% of hypertensive patients

<!-- PAGE=? -->
 most often results from unilateral adenoma

<!-- PAGE=? -->
o 25% to 40% of patients have been found to have bilateral adrenal hyperplasia

<!-- PAGE=? -->
 Clinical manifestations

<!-- PAGE=? -->
o potassium depletion

<!-- PAGE=? -->
o sodium retention

<!-- PAGE=? -->
o muscle weakness

<!-- PAGE=? -->
o hypertension

<!-- PAGE=? -->
 high incidence of CAD

<!-- PAGE=? -->
o tetany

<!-- PAGE=? -->
o polyuria - inability to concentrate urine

<!-- PAGE=? -->
o hypokalemic alkalosis

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Intravascular fluid volume, electrolyte concentrations, and renal function should be restored to within normal limits preoperatively by administering the aldosterone antagonist spironolactone

<!-- PAGE=? -->
o effects of spironolactone are slow in onset and increase for 1 to 2 weeks

<!-- PAGE=? -->
o Frequently, at least 24 hours is required to restore potassium equilibrium

<!-- PAGE=? -->
 A normal serum potassium level does not necessarily imply correction of a total-body deficit of potassium

<!-- PAGE=? -->
Glucocorticoid Deficiency

<!-- PAGE=? -->
 Withdrawal of steroids or suppression of synthesis by steroid therapy is the leading cause of underproduction of corticosteroids

<!-- PAGE=? -->
o Other causes of adrenocortical insufficiency

<!-- PAGE=? -->
 defects in ACTH secretion

<!-- PAGE=? -->
 destruction of the adrenal gland

<!-- PAGE=? -->
 autoimmune disease

<!-- PAGE=? -->
 tuberculosis

<!-- PAGE=? -->
 hemorrhage

<!-- PAGE=? -->
 cancer

<!-- PAGE=? -->
 some forms of congenital adrenal hyperplasia

<!-- PAGE=? -->
 administration of cytotoxic drugs

<!-- PAGE=? -->
 Addison's disease (Primary adrenal insufficiency)

<!-- PAGE=? -->
o associated with local destruction of all zones of the adrenal cortex

<!-- PAGE=? -->
o results in both glucocorticoid and mineralocorticoid deficiency if the insufficiency is bilateral

<!-- PAGE=? -->
o Clinical Manifestations

<!-- PAGE=? -->
 Weight loss

<!-- PAGE=? -->
 Weakness, fatigue, lethargy

<!-- PAGE=? -->
 Cardiopenia

<!-- PAGE=? -->
 Chronic hypotension

<!-- PAGE=? -->
 Muscle and joint pain and back pain

<!-- PAGE=? -->
 Postural hypotension and dizziness

<!-- PAGE=? -->
 hypovolemia

<!-- PAGE=? -->
 Headache

<!-- PAGE=? -->
 Anorexia, nausea, abdominal pain, constipation, diarrhea

<!-- PAGE=? -->
 Hyperpigmentation

<!-- PAGE=? -->
 Hyperkalemia

<!-- PAGE=? -->
 Hyponatremia

<!-- PAGE=? -->
 Occasional hypoglycemia

<!-- PAGE=? -->
 Hypercalcemia

<!-- PAGE=? -->
 Prerenal azotemia

<!-- PAGE=? -->
o Autoimmune disease is the most common cause of primary (nonexogenous) bilateral ACTH deficiency in the United States

<!-- PAGE=? -->
 tuberculosis is the most common cause worldwide.

<!-- PAGE=? -->
 decreased adrenal function but large adrenal glands

<!-- PAGE=? -->
 also common in

<!-- PAGE=? -->
o sarcoidosis

<!-- PAGE=? -->
o histoplasmosis

<!-- PAGE=? -->
o amyloidosis

<!-- PAGE=? -->
o metastatic malignancy

<!-- PAGE=? -->
o adrenal hemorrhage

<!-- PAGE=? -->
 adrenal insufficiency is also associated with HIT

<!-- PAGE=? -->
o Autoimmune destruction of the adrenals may be associated with other autoimmune disorders

<!-- PAGE=? -->
 type 1 diabetes

<!-- PAGE=? -->
 Hashimoto's thyroiditis

<!-- PAGE=? -->
 Secondary adrenal insufficiency occurs when ACTH secretion is deficient

<!-- PAGE=? -->
o often because of a pituitary or hypothalamic tumor

<!-- PAGE=? -->
 acute adrenal crisis (addisonian crisis) can occur when even a minor stress is present

<!-- PAGE=? -->
o URTI

<!-- PAGE=? -->
 Anesthetic optimization must include treatment of

<!-- PAGE=? -->
o Hypovolemia

<!-- PAGE=? -->
o Hyperkalemia

<!-- PAGE=? -->
o Hyponatremia

<!-- PAGE=? -->
 Stress dose steroids should be administered

<!-- PAGE=? -->
Mineralocorticoid Deficiency

<!-- PAGE=? -->
 Hypoaldosteronism can be

<!-- PAGE=? -->
o congenital

<!-- PAGE=? -->
o occur after unilateral adrenalectomy

<!-- PAGE=? -->
o occur after prolonged administration of heparin

<!-- PAGE=? -->
o consequence of long-standing diabetes and renal failure

<!-- PAGE=? -->
o NSAIDS may also inhibit renin release and exacerbate this condition in patients with renal insufficiency

<!-- PAGE=? -->
 Most symptoms are caused by hyperkalemic acidosis rather than hypovolemia

<!-- PAGE=? -->
o some patients might be hypertensive

<!-- PAGE=? -->
 These patients can have severe

<!-- PAGE=? -->
o Hyperkalemia

<!-- PAGE=? -->
o Hyponatremia

<!-- PAGE=? -->
o myocardial conduction defects

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Administration of mineralocorticoids

<!-- PAGE=? -->
 9α-fluorocortisol - 0.05 to 0.1 mg/day preoperatively

<!-- PAGE=? -->
o Doses must be carefully titrated and monitored to avoid an increase in hypertension

<!-- PAGE=? -->
Adrenal Cortex Function in the Elderly

<!-- PAGE=? -->
 Production of androgens by the adrenal gland progressively decreases with age

<!-- PAGE=? -->
o This decrease has no known implications for anesthesia

<!-- PAGE=? -->
 Plasma levels of cortisol are unaffected by increasing age

<!-- PAGE=? -->
o Levels of CBG are also unaffected by age

<!-- PAGE=? -->
 There is progressively impaired ability of aged patients to metabolize and excrete glucocorticoids

<!-- PAGE=? -->
 quantity of 17-hydroxycorticosteroids excreted is reduced by half by the seventh decade

<!-- PAGE=? -->
o reflects the reduced renal function that occurs with aging

<!-- PAGE=? -->
 when excretion of cortisol metabolites is expressed as a function of creatinine clearance, the age difference disappears

<!-- PAGE=? -->
 Further reductions in cortisol clearance may be due to impaired hepatic metabolism of circulating cortisol

<!-- PAGE=? -->
 The rate of secretion of cortisol is 30% lower in the elderly

<!-- PAGE=? -->
o May be an appropriate compensatory mechanism for maintaining a normal cortisol level in the face of decreased hepatic and renal clearance of cortisol

<!-- PAGE=? -->
 even the very elderly (those older than 100 years) display an entirely normal adrenal response to the administration of ACTH and to stresses such as hypoglycemia

<!-- PAGE=? -->
 Both underproduction and overproduction of glucocorticoids are generally considered diseases of younger individuals

<!-- PAGE=? -->
o highest incidence of Cushing's disease of either pituitary or adrenal origin occurs during the third decade of life

<!-- PAGE=? -->
o in patients over 60 in whom Cushing's disease develops, the most likely cause is adrenal carcinoma or ectopic ACTH production from tumors usually located in the lung, pancreas, or thymus

<!-- PAGE=? -->
AIDS

<!-- PAGE=? -->
A&A 2004, Barash

<!-- PAGE=? -->
 peripheral neuropathy is most frequent neurological complication in HIV patients

<!-- PAGE=? -->
o 35% of AIDs

<!-- PAGE=? -->
 AIDS dementia has an incidence of ~25%

<!-- PAGE=? -->
 autonomic dysfunction is 15%

<!-- PAGE=? -->
 Thrombocytopaenia

<!-- PAGE=? -->
 HIV related PAIN

<!-- PAGE=? -->
o abdominal pain 26%

<!-- PAGE=? -->
o peripheral neuropathy 25%

<!-- PAGE=? -->
o throat pain 20%

<!-- PAGE=? -->
o headaches 17%

<!-- PAGE=? -->
o arthralgia 5%

<!-- PAGE=? -->
o back pain 5%

<!-- PAGE=? -->
o zoster 5%

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Airflow

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 This relationship between flow, pressure, and resistance can be expressed mathematically as a variant of Ohm's law

<!-- PAGE=? -->
 Poiseuille's law  (Airway resistance)

<!-- PAGE=? -->
8 X length X Viscosity

<!-- PAGE=? -->
Resistance

<!-- PAGE=? -->
 resistance is directly proportional to viscosity of blood and the length of the vessel and inversely proportional to the fourth power of the radius of the vessel

<!-- PAGE=? -->
 Viscosity is the only physical gas property that is relevant under conditions of laminar flow

<!-- PAGE=? -->
Pressure gradient

<!-- PAGE=? -->
Laminar flow =

<!-- PAGE=? -->
Airwayresistance

<!-- PAGE=? -->
o laminar flow is directly proportional to pressure gradient & radius4 and indirectly proportional to length & viscosity

<!-- PAGE=? -->
 Helium has a low density, but its viscosity is close to that of air

<!-- PAGE=? -->
o Helium will not improve gas flow if the flow is laminar

<!-- PAGE=? -->
o Flow is commonly turbulent when there is critical airway narrowing or abnormally high airway resistance.

<!-- PAGE=? -->
Airway (Innervation)

<!-- PAGE=? -->
Mucles that close the rima glottis:

<!-- PAGE=? -->
 Ariepiglottis

<!-- PAGE=? -->
 Oblique arythenoid

<!-- PAGE=? -->
 thyroiepiglotic

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Larynx is made up of 9 cartilages (3 paired, 3 unpaired) which house the vocal cords

<!-- PAGE=? -->
 Oropharynx

<!-- PAGE=? -->
o Innervated by branches of the vagus, trigeminal and glossopharyngeal (GPN) nerves

<!-- PAGE=? -->
o GPN supplies posterior 1/3 of tongue, the vallecula, and the anterior surface of the epiglottis (lingual branch), the walls of the pharynx (pharyngeal branch), and the tonsils (tonsillar branch)

<!-- PAGE=? -->
o Blocked by topical anesthetics or injection into the base of the palatoglossal arch

<!-- PAGE=? -->
 Hypopharynx

<!-- PAGE=? -->
o Internal branch of the Superior Laryngeal Nerve (SLN), which is a branch of the Vagus

<!-- PAGE=? -->
 Supplies underside of the epiglottis, aryepiglottic folds, and arytenoids

<!-- PAGE=? -->
o The External branch of the SLN

<!-- PAGE=? -->
 supplies motor innervation to the cricothyroid muscle

<!-- PAGE=? -->
 cricothyroid muscle has an adductor effect on the vocal cords, and thus a lesion which spares the superior laryngeal nerve will leave the cords lying nearer the midline

<!-- PAGE=? -->
o SLN blocked by topical anesthetics or injection at the ipsilateral hyoid bone

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Angle of the mandible

<!-- PAGE=? -->
 Ipsilateral hyoid cornu

<!-- PAGE=? -->
 Vocal folds and trachea

<!-- PAGE=? -->
o RLN supplies all of the intrinsic muscles of the larynx (with the exception of the cricothyroid)

<!-- PAGE=? -->
o unilateral nerve injury has preserved airway function although protection against aspiration may be compromise

<!-- PAGE=? -->
o RLN blocked by topical anesthetics or transtracheal injection

<!-- PAGE=? -->
 Summary

<!-- PAGE=? -->
o GPN from posterior 1/3 tongue to anterior epiglottis

<!-- PAGE=? -->
o Internal SLN from epiglottis to cords

<!-- PAGE=? -->
o RLN from cords to trachea

<!-- PAGE=? -->
Vz

<!-- PAGE=? -->
V3

<!-- PAGE=? -->
Ophthalmic division of trigeminal nerve

<!-- PAGE=? -->
(anterior ethmoidal nerve)

<!-- PAGE=? -->
SL

<!-- PAGE=? -->
V2 Maxillary division of trigeminal nerve

<!-- PAGE=? -->
(sphenopalatine nerves)

<!-- PAGE=? -->
V3

<!-- PAGE=? -->
Mandibular division of trigeminal nerve

<!-- PAGE=? -->
(lingual nerve)

<!-- PAGE=? -->
IX

<!-- PAGE=? -->
Glossopharyngeal nerve

<!-- PAGE=? -->
X

<!-- PAGE=? -->
X

<!-- PAGE=? -->
Vagus nerve

<!-- PAGE=? -->
SL

<!-- PAGE=? -->
Superior laryngeal branch of

<!-- PAGE=? -->
the vagus nerve

<!-- PAGE=? -->
IL

<!-- PAGE=? -->
Internal laryngeal nerve

<!-- PAGE=? -->
RL

<!-- PAGE=? -->
Recurrent laryngeal nerve

<!-- PAGE=? -->
RL

<!-- PAGE=? -->
Allergic reaction

<!-- PAGE=? -->
Types of allergic reactions

<!-- PAGE=? -->
 Type I (IgE)

<!-- PAGE=? -->
o antibody mediated (aka Immediate hypersensitivity reaction)

<!-- PAGE=? -->
o anaphylactic reaction

<!-- PAGE=? -->
o atopy,  urticaria, angioedema, extrinsic asthma , allergic rhinitis

<!-- PAGE=? -->
 Type II (IgG, IgM)

<!-- PAGE=? -->
o cytotoxic

<!-- PAGE=? -->
o hemolytic transfusion reactions

<!-- PAGE=? -->
o autoimmune hemolytic anemias

<!-- PAGE=? -->
o HIT

<!-- PAGE=? -->
 Type III (Ag-Ab & complement)

<!-- PAGE=? -->
o immune complex

<!-- PAGE=? -->
o serum sickness, protamine

<!-- PAGE=? -->
 Type IV (lymphocytes)

<!-- PAGE=? -->
o delayed, cell mediated

<!-- PAGE=? -->
o contact dermatitis (poison ivy, Tb test)

<!-- PAGE=? -->
o GVHD

<!-- PAGE=? -->
Anaphylaxis under Anesthesia

<!-- PAGE=? -->
 anaphylactic (immune mediated) or anaphylactoid reactions occurring during anesthesia has been estimated at between 1 in 1000 and 1 in 25,000 anesthetics

<!-- PAGE=? -->
o ~ 5% mortality rate

<!-- PAGE=? -->
 Neuromuscular blocking drugs are the triggering agents in over 50% of these reactions

<!-- PAGE=? -->
o Succinylcholine has been incriminated as the trigger of allergic reactions more often than any other drug used in anesthesia

<!-- PAGE=? -->
o Neuromuscular blocking drugs contain two quaternary ammonium ions, which are the epitopes commonly recognized by specific IgE

<!-- PAGE=? -->
o Cross-reactivity is seen in more than 60% of patients with a history of anaphylaxis to a neuromuscular blocking drug

<!-- PAGE=? -->
Table 1. Drugs Involved in Perioperative Anaphylaxis (5)

<!-- PAGE=? -->
Anaphylactoid Reactions

<!-- PAGE=? -->
 Resemble anaphylactic rxn, but are not IgE mediated

<!-- PAGE=? -->
 are clinically indistinguishable from anaphylactic rxns;

<!-- PAGE=? -->
 a drug can directly release histamine: opioids (morphine, meperidine), STP, Propofol, NMR (sux, atracurium), NSAIDS, preservatives (suflites, benzoates), protamine, Dextran , steroids

<!-- PAGE=? -->
o Steroidal NdMBs (e.g., rocuronium, vecuronium, pancuronium, or pipecuronium) lack significant histamine release

<!-- PAGE=? -->
Risk factors for anaphylaxis

<!-- PAGE=? -->
 Atopic - other allergies

<!-- PAGE=? -->
 previous anesthetic exposures

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 Epinephrine

<!-- PAGE=? -->
o Dosage

<!-- PAGE=? -->
 0.3 - 0.5 mls SC of 1:1000 (300 - 500 mcg)

<!-- PAGE=? -->
 3 - 5 mls via ETT of 1:10,000 (300 - 500 mcg)

<!-- PAGE=? -->
 1 - 3 mcg / kg / ml if given IV of 1:10,000

<!-- PAGE=? -->
o Action

<!-- PAGE=? -->
 Bronchodilation

<!-- PAGE=? -->
 Inhibits mediator release from mast cells

<!-- PAGE=? -->
 Reduced laryngeal edema

<!-- PAGE=? -->
 Antihistamines

<!-- PAGE=? -->
o Benadryl 25 - 50 mg IV q4-6h reg

<!-- PAGE=? -->
o Ranitidine 50 mg IV q8h reg

<!-- PAGE=? -->
 Corticosteroids

<!-- PAGE=? -->
o Hydrocortisone 100 mg IV q6h reg

<!-- PAGE=? -->
PALS

<!-- PAGE=? -->
 Epinephrine

<!-- PAGE=? -->
o 10ug/kg IM q 15min (max dose 500ug)

<!-- PAGE=? -->
o 10ug/kg IV q 3-5 min if hypotensive

<!-- PAGE=? -->
 Consider infusion of .1-1ug/kg/min

<!-- PAGE=? -->
 Diphenhydramine

<!-- PAGE=? -->
o 1-2 mg/kg IV/IO/IM q 4 hr (max 50mg/dose)

<!-- PAGE=? -->
 Steroids

<!-- PAGE=? -->
 Ranitidine

<!-- PAGE=? -->
ALS

<!-- PAGE=? -->
CoExD

<!-- PAGE=? -->
 ALS is a degenerative disease of motor ganglia in the ventral horn of the spinal cord and spinal pyramidal tracts.

<!-- PAGE=? -->
 most commonly affects men 40 - 60 yo

<!-- PAGE=? -->
 disease limited to the motor cortex is designated primary lateral sclerosis.

<!-- PAGE=? -->
 disease limited to the brainstem nuclei is known as pseudobulbar palsy

<!-- PAGE=? -->
 cause is unknown ?inherited ?viral

<!-- PAGE=? -->
 Signs & Symptoms reflect UMN and LMN dysfunction

<!-- PAGE=? -->
o skeletal muscle atrophy

<!-- PAGE=? -->
o weakness and fasciculations

<!-- PAGE=? -->
 often beginning in the intrinsic muscles of the hands

<!-- PAGE=? -->
 Eventually, atrophy and weakness involve most skeletal muscles, including the tongue, pharynx, larynx and chest.

<!-- PAGE=? -->
o early symptoms of bulbar involvement include fasciculations of the tongue and dysphagia leading to pulmonary aspiration.

<!-- PAGE=? -->
o the ocular muscles are spared

<!-- PAGE=? -->
o autonomic dysfunction manifests as orthostatic hypotension and resting tachycardia

<!-- PAGE=? -->
o CK levels are normal, distinguishing this dz from chronic polymyositis

<!-- PAGE=? -->
 There is no known treatment

<!-- PAGE=? -->
 death is likely within 6 years after onset of symptoms

<!-- PAGE=? -->
o usually due to respiratory failure

<!-- PAGE=? -->
Alveolar-arterial Gradient (A-a gradient)

<!-- PAGE=? -->
 one way to assess the integrity of the alveolar-capillary unit

<!-- PAGE=? -->
o help determine the cause of a person's hypoxemia

<!-- PAGE=? -->
 Normal A-a gradient - small gradient

<!-- PAGE=? -->
o high altitude

<!-- PAGE=? -->
o hypoventilation

<!-- PAGE=? -->
 Increased - oxygen is not effectively transferred from the alveoli to the blood

<!-- PAGE=? -->
o diffusion defects

<!-- PAGE=? -->
o ventilation-perfusion mismatch

<!-- PAGE=? -->
o right-to-left shunting

<!-- PAGE=? -->
Alveolar air equation:

<!-- PAGE=? -->
 PAO2 = (Pbarometric - PH2O) x FiO2 - PACO2/R

<!-- PAGE=? -->
 Since Pbarometric is 760mmHg and PH2O is 47 and R is usually 0.8:

<!-- PAGE=? -->
 PAO2 = 713(FiO2) - PACO2/0.8

<!-- PAGE=? -->
 At sea level, the oxygen tension of humidified air is:

<!-- PAGE=? -->
 (760-47)x0.21 = 149.7

<!-- PAGE=? -->
Alzheimer's Dementia

<!-- PAGE=? -->
Barash, CoExD

<!-- PAGE=? -->
 Most common of progressive cortical dementias

<!-- PAGE=? -->
o 70% of dementias in individuals older than 55

<!-- PAGE=? -->
 Characteristics

<!-- PAGE=? -->
o progressive memory impairment, predominantly loss of short term memory, disorientation with time and place, language impairment w/ word finding and difficult spontaneous speech, impaired performance in ADL

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o CT scan showing cortical atrophy and ventricular dilation; pathology shows presence of neurofibrilllary tangles and neuritic plaques with massive neuronal degeneration and deposition of beta amyloid.

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o therapy is aimed at increasing neurotransmitter levels, especially of acetylcholine: increasing ACh levels by acetylcholine precursor loading, cholinesterase inhibition, direct cholinergic receptor stimulation, indirect cholinergic stimulation

<!-- PAGE=? -->
 Ex. Donepazil, tacrine velnacrine, sustained release physostigmine (monitor for hepatotoxicity for tacrine and velnacrine)

<!-- PAGE=? -->
 Anesthesia Management

<!-- PAGE=? -->
o Pt may be disoriented or uncooperative but sedative drugs should NOT be administered as it will cause further mental confusion

<!-- PAGE=? -->
o Use anesthetics known to result in rapid postanesthetic recovery to permit a more rapid return to pts's preoperative state: propofol, desflurane, sevo

<!-- PAGE=? -->
o If co-existing hepatic dysfunction exist may influence choice of halogenated, volatile anesthetic

<!-- PAGE=? -->
o Do NOT use centrally acting anticholinergic as it may exacerbate the dementia

<!-- PAGE=? -->
 Glycopyrollate does not cross BBB and preferable to atropine or scopolamine

<!-- PAGE=? -->
Anesthetic Machine

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 There are essentially three circuits within the anesthetic machine:

<!-- PAGE=? -->
o High Pressure

<!-- PAGE=? -->
 O2 cylinders - 2200 pounds per square inch gauge (psig)

<!-- PAGE=? -->
 N2O cylinders - 745 psig

<!-- PAGE=? -->
o Intermediate Pressure

<!-- PAGE=? -->
 O2 and N2O pipeline source - 50 psig

<!-- PAGE=? -->
 Fail safe valve

<!-- PAGE=? -->
 Oxygen flush valve

<!-- PAGE=? -->
 separated from high pressure circuit by -pressure regulators‖ which down-regulate pressure from 2200 psig (O2) or 745 psig (N2O) - 50 psig

<!-- PAGE=? -->
o Low Pressure

<!-- PAGE=? -->
 separated from intermediate pressure circuit by flow-control valve (by adjusting the flowmeters)

<!-- PAGE=? -->
 most Datex-Ohmeda machines also have a second-stage oxygen regulator which downregulates pressure to 14 psig

<!-- PAGE=? -->
NzO Pipeline

<!-- PAGE=? -->
Supply

<!-- PAGE=? -->
Low-Pressure Circuit

<!-- PAGE=? -->
NzO Cylinder

<!-- PAGE=? -->
Supply

<!-- PAGE=? -->
Calibrated

<!-- PAGE=? -->
Flovmeters

<!-- PAGE=? -->
Vaporizers

<!-- PAGE=? -->
Check

<!-- PAGE=? -->
Pipeline

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Cylinder

<!-- PAGE=? -->
Pressure

<!-- PAGE=? -->
Pressure

<!-- PAGE=? -->
Gauge

<!-- PAGE=? -->
Gauge

<!-- PAGE=? -->
Fail-Safe"

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Pressure

<!-- PAGE=? -->
Flow-control

<!-- PAGE=? -->
Regulalor

<!-- PAGE=? -->
Valvo

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Cneck Valve

<!-- PAGE=? -->
Supply

<!-- PAGE=? -->
(or Internal

<!-- PAGE=? -->
Failure

<!-- PAGE=? -->
to Vaporizer)

<!-- PAGE=? -->
Alarm

<!-- PAGE=? -->
02

<!-- PAGE=? -->
Second Stage

<!-- PAGE=? -->
O2 Pressure

<!-- PAGE=? -->
Regulator

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Flush

<!-- PAGE=? -->
O2 Cylinder

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Supply

<!-- PAGE=? -->
Machine Outlet

<!-- PAGE=? -->
(Common Gas Outlet)

<!-- PAGE=? -->
02

<!-- PAGE=? -->
Low-Pressure Circuit Leak Test

<!-- PAGE=? -->
 checks the integrity of the anesthesia machine from the flow control valves to the common outlet

<!-- PAGE=? -->
o evaluates the portion of the machine that is downstream from all safety devices except the oxygen analyzer

<!-- PAGE=? -->
o components located within this area are precisely the ones most subject to breakage and leaks

<!-- PAGE=? -->
 Flow tubes (meters) are most delicate pneumatic component of the machine and can crack or break

<!-- PAGE=? -->
 A typical three-gas anesthesia machine has 16 O-rings in the low-pressure circuit

<!-- PAGE=? -->
 Loose filler caps on vaporizers are a common source of leaks

<!-- PAGE=? -->
o can lead to delivery of subanesthetic doses of inhaled agents

<!-- PAGE=? -->
 The presence or absence of the check valve profoundly influences which preoperative check is indicated

<!-- PAGE=? -->
o Dräger Medical workstations do not have a check valve near the common gas outlet

<!-- PAGE=? -->
 the low-pressure circuit can be tested using a positive pressure leak test

<!-- PAGE=? -->
 the operator generates positive pressure in the low-pressure circuit using flow from the anesthesia machine or from a positive pressure bulb to detect a leak

<!-- PAGE=? -->
o Datex-Ohmeda workstations do have a check valve near the common gas outlet

<!-- PAGE=? -->
 located downstream from the vaporizers and upstream from the oxygen flush valve

<!-- PAGE=? -->
 open in the absence of back pressure

<!-- PAGE=? -->
 Gas flow from the manifold moves the rubber flapper valve off its seat and allows gas to proceed freely to the common outlet

<!-- PAGE=? -->
 The valve closes when back pressure is exerted on it

<!-- PAGE=? -->
 oxygen flushing

<!-- PAGE=? -->
 peak breathing circuit pressures generated during PPV

<!-- PAGE=? -->
 use of a positive pressure leak test

<!-- PAGE=? -->
 must be tested using a negative pressure leak test

<!-- PAGE=? -->
 master switch, the flow control valves, and the vaporizers are turned off

<!-- PAGE=? -->
 suction bulb is attached to the common fresh gas outlet and is squeezed repeatedly until it is fully collapsed

<!-- PAGE=? -->
o creates a vacuum in the low-pressure circuitry

<!-- PAGE=? -->
 The machine is leak-free if the hand bulb remains collapsed for at least 10 seconds

<!-- PAGE=? -->
 The test is repeated with each vaporizer individually turned to the -on‖ position because internal vaporizer leaks can be detected only with the vaporizer turned on

<!-- PAGE=? -->
Vulnerable Area

<!-- PAGE=? -->
Leak

<!-- PAGE=? -->
Check

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
+30 cm

<!-- PAGE=? -->
Airwvay Pressure

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Gauge

<!-- PAGE=? -->
Flush

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Machine

<!-- PAGE=? -->
Outlet

<!-- PAGE=? -->
+30 cm

<!-- PAGE=? -->
Reservoir

<!-- PAGE=? -->
Bag

<!-- PAGE=? -->
Workstation Self-Tests

<!-- PAGE=? -->
 many new anesthesia workstations now incorporate technology that allows the machine to either automatically or manually walk the user through a series of self-tests to check for functionality of electronic, mechanical, and pneumatic components

<!-- PAGE=? -->
 One particularly important point of caution with self-tests should be noted on systems with manifoldmounted vaporizers (Dräger Apollo, Dräger Fabius GS, and Narkomed 6000)

<!-- PAGE=? -->
o The vaporizer does not become a part of an anesthesia workstation's gas flow stream until its concentration control dial is turned to the on position

<!-- PAGE=? -->
o to detect internal vaporizer leaks on this type of a system, the -leak test‖ portion of the selfdiagnostic must be repeated separately with each individual vaporizer turned to the on position

<!-- PAGE=? -->
o If this precaution is not taken, large leaks that could potentially result in patient awareness, such those from a loose filler cap or cracked fill indicator, could go undetected

<!-- PAGE=? -->
Flush Valve

<!-- PAGE=? -->
Figure 26-5. Inappropriate use of the oxygen flush valve to check the low-pressure circuit of an Ohmeda machine equipped with a check valve. The area within the rectangle is not checked by the inappropriate use of the oxygen flush valve. The components located within this area are precisely the ones most subject to breakage and leaks. Positive pressure within the patient circuit closes the check valve, and the value on the airway pressure gauge does not decline, despite leaks in the low-pressure circuit

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 allows direct communication between the oxygen high-pressure circuit and the low-pressure circuit

<!-- PAGE=? -->
 Flow from the oxygen flush valve enters the low-pressure circuit downstream from the vaporizers and downstream from the Ohmeda machine outlet check valve

<!-- PAGE=? -->
 The spring-loaded valve stays closed until the operator opens it by depressing the oxygen flush button

<!-- PAGE=? -->
 Actuation of the valve delivers 35 to 75 L/min to the breathing circuit.

<!-- PAGE=? -->
 Is associated with several hazard:

<!-- PAGE=? -->
o Defective or damaged valve can stick in the fully open position, causing barotrauma

<!-- PAGE=? -->
o Valve sticking in a partially open position can result in patient awareness because the oxygen flow from the incompetent valve dilutes the inhaled anesthetic

<!-- PAGE=? -->
o Overzealous intraoperative oxygen flushing can dilute inhaled anesthetics.

<!-- PAGE=? -->
o Oxygen flushing during the inspiratory phase of positive-pressure ventilation can cause barotrauma

<!-- PAGE=? -->
o Excess volume cannot be vented from the breathing circuit because the ventilator relief valve is closed and the adjustable pressure-limiting (APL) valve is either out of circuit or closed

<!-- PAGE=? -->
o If a machine is equipped with a freestanding vaporizer downstream from the common gas outlet, oxygen flushing can deliver large quantities of inhaled anesthetic to the patient

<!-- PAGE=? -->
o Inappropriate preoperative use of the oxygen flush to evaluate the low-pressure circuit for leaks can be misleading, particularly on Ohmeda machines with a check valve at the common outlet. Back pressure from the breathing circuit closes the check valve airtight, and major low-pressure circuit leaks can go undetected

<!-- PAGE=? -->
Oxygen Analyzer

<!-- PAGE=? -->
 The oxygen analyzer is the most important machine monitor because it is the only machine safety device that evaluates the integrity of the low-pressure circuit

<!-- PAGE=? -->
o Other machine safety devices, such as the fail-safe valve, the oxygen supply failure alarm, and the proportioning system are all upstream from the flow control valves

<!-- PAGE=? -->
o The only machine monitor that detects problems downstream from the flow control valves is the oxygen analyzer

<!-- PAGE=? -->
Proportioning Systems

<!-- PAGE=? -->
 Nitrous oxide and oxygen are interfaced either mechanically or pneumatically so that the minimum oxygen concentration at the common outlet is 25 percent.

<!-- PAGE=? -->
o No protection against

<!-- PAGE=? -->
 the wrong supply gas

<!-- PAGE=? -->
 The oxygen analyzer is the only machine monitor that will detect this condition  Leaks Downstream

<!-- PAGE=? -->
 A leak downstream from these devices, such as a broken oxygen flowtube, can cause delivery of a hypoxic mixture

<!-- PAGE=? -->
 Inert Gas Administration

<!-- PAGE=? -->
 Administration of a third inert gas, such as helium, nitrogen, or carbon dioxide, can cause a hypoxic mixture because contemporary proportioning systems link only nitrous oxide and oxygen

<!-- PAGE=? -->
 Use of an oxygen analyzer is mandatory if the operator uses a third inert gas

<!-- PAGE=? -->
Scavenger Systems

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
Gas Collocting

<!-- PAGE=? -->
Transler Meens

<!-- PAGE=? -->
Scavenging

<!-- PAGE=? -->
Gas Disposal

<!-- PAGE=? -->
Gas Disposal

<!-- PAGE=? -->
Assembly

<!-- PAGE=? -->
19 mm

<!-- PAGE=? -->
Intertace

<!-- PAGE=? -->
Asscmbly Tubing

<!-- PAGE=? -->
Assombly

<!-- PAGE=? -->
30 mm

<!-- PAGE=? -->
Opcn

<!-- PAGE=? -->
Active (vacuum)

<!-- PAGE=? -->
Closed

<!-- PAGE=? -->
Passlve

<!-- PAGE=? -->
APL

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Ventilator

<!-- PAGE=? -->
Relief Valve

<!-- PAGE=? -->
tubing

<!-- PAGE=? -->
 5 components:

<!-- PAGE=? -->
o Gas collecting assembly

<!-- PAGE=? -->
o Transfer means - must be 19-30 mm tubing, colour coded with yellow bands

<!-- PAGE=? -->
o Scavenging interface (open or closed) - protects from barotrauma

<!-- PAGE=? -->
o Gas disposal assembly tubing

<!-- PAGE=? -->
o Gas disposal assembly (active or passive)

<!-- PAGE=? -->
 Active assembly uses vaccum system to remove waste gases

<!-- PAGE=? -->
 passive assembly uses the pressure of waste gas itself to produces flow

<!-- PAGE=? -->
 Occulsion of transfer means is problematic because it is upstream from the pressure-buffering of the scavenging interface and can lead to patient barotraumas

<!-- PAGE=? -->
 Scavenging interface protects circuit or ventilator from excessive positive or negative pressures

<!-- PAGE=? -->
o should limit pressure immediately downstream from the gas collecting assembly to -5 to +10 cmH20 under normal working conditions

<!-- PAGE=? -->
o Positive pressure relief valve is absolutely necessary in case of obstruction downstream from scavenging interface

<!-- PAGE=? -->
o If active system, a negative pressure relief valve is also necessary

<!-- PAGE=? -->
 Reservoir bag is highly desirable with an active system so there is a place to store waste gases before the vacuum kicks in

<!-- PAGE=? -->
o Doesn't matter so much with a passive system

<!-- PAGE=? -->
 Open scavenging interfaces communicate directly with the atmosphere and have no valves

<!-- PAGE=? -->
o less risk of positive or negative pressure, but may result in spillage

<!-- PAGE=? -->
o open interfaces require active gas collecting assemblies

<!-- PAGE=? -->
 Closed scavenging systems communicate with the atmosphere via valves

<!-- PAGE=? -->
o may be used with either active or passive systems

<!-- PAGE=? -->
 If used with an active system, negative and positive pressure relief valve must be used

<!-- PAGE=? -->
 If passive system, must have positive pressure relief valve

<!-- PAGE=? -->
Failure of Anesthesia Equipment

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 that the most common failure was due to an equipment leak (61/1,000)

<!-- PAGE=? -->
o most likely underlying cause of system leaks was due to -design weakness‖ followed by poor equipment maintenance and setup

<!-- PAGE=? -->
 pulse oximetry alarm was the most common principal monitor alerting the anesthesiologist to an equipment problem

<!-- PAGE=? -->
 ASA -Closed Claims‖ related to the medical gas-delivery system were rare

<!-- PAGE=? -->
o when they did occur, they were usually severe, often resulting in death or permanent brain injury

<!-- PAGE=? -->
 The most common malfunction was

<!-- PAGE=? -->
o the breathing circuit (39%)

<!-- PAGE=? -->
o vaporizers (21%)

<!-- PAGE=? -->
o ventilators (17%)

<!-- PAGE=? -->
o gas tanks or gas lines (11%)

<!-- PAGE=? -->
o the anesthesia machine itself (7%)

<!-- PAGE=? -->
The Circle System

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 prevents rebreathing of CO2 by use of CO2 absorbents but allows partial rebreathing of other exhaled gases

<!-- PAGE=? -->
 can be semiopen, semiclosed, or closed, depending on the amount of fresh gas inflow

<!-- PAGE=? -->
o semiopen system has no rebreathing and requires a very high flow of fresh gas

<!-- PAGE=? -->
o semiclosed system is associated with some rebreathing of exhaled gases and is the most commonly used system

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Inhalation

<!-- PAGE=? -->
Fresh Gas

<!-- PAGE=? -->
Check Valve

<!-- PAGE=? -->
Inlet

<!-- PAGE=? -->
Inspiratory

<!-- PAGE=? -->
Limb

<!-- PAGE=? -->
Canister

<!-- PAGE=? -->
Y-Piece

<!-- PAGE=? -->
Expiratory

<!-- PAGE=? -->
Limb

<!-- PAGE=? -->
APL

<!-- PAGE=? -->
Exhalation

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Check Valve

<!-- PAGE=? -->
Selector Switch

<!-- PAGE=? -->
B

<!-- PAGE=? -->
closed system is one in which the inflow gas exactly matches that being taken up, or consumed,

<!-- PAGE=? -->
by the patient

<!-- PAGE=? -->
 200ml/min leak due to gas sampling needs to be replaced

<!-- PAGE=? -->
 Nitrogen build up is a problem

<!-- PAGE=? -->
 Difficult to inc. depth of anesthesia

<!-- PAGE=? -->
 consists of seven primary components

<!-- PAGE=? -->
o a fresh gas inflow source

<!-- PAGE=? -->
 from the common gad outlet

<!-- PAGE=? -->
o inspiratory and expiratory unidirectional valves

<!-- PAGE=? -->
 ensure unidirectional gas flow

<!-- PAGE=? -->
o inspiratory and expiratory corrugated tubes

<!-- PAGE=? -->
o Y-piece connector

<!-- PAGE=? -->
o overflow or pop-off valve

<!-- PAGE=? -->
o reservoir bag

<!-- PAGE=? -->
o canister containing CO2absorbent

<!-- PAGE=? -->
 to prevent rebreathing of CO2, three rules must be followed

<!-- PAGE=? -->
o a unidirectional valve must be located between the patient and the reservoir bag on both the inspiratory and expiratory limbs of the circuit

<!-- PAGE=? -->
o the fresh gas inflow cannot enter the circuit between the expiratory valve and the patient

<!-- PAGE=? -->
o the overflow (pop-off) valve cannot be located between the patient and the inspiratory valve

<!-- PAGE=? -->
 The most efficient circle system arrangement with the highest conservation of fresh gases is one in which the unidirectional valves are near the patient and the pop-off valve is located just downstream from the expiratory valve

<!-- PAGE=? -->
o minimizes dead space gas and preferentially eliminates exhaled alveolar gases

<!-- PAGE=? -->
 The main advantages of the circle system over other breathing systems include

<!-- PAGE=? -->
o maintenance of relatively stable inspired gas concentrations

<!-- PAGE=? -->
o conservation of respiratory moisture and heat

<!-- PAGE=? -->
o prevention of operating room pollution

<!-- PAGE=? -->
 The major disadvantage of the circle system stems from its complex design

<!-- PAGE=? -->
o May have ten or more different connections

<!-- PAGE=? -->
 Malfunction of the circle system's unidirectional valves can result in life-threatening problems

<!-- PAGE=? -->
o Rebreathing can occur if the valves stick in the open position

<!-- PAGE=? -->
o total occlusion of the circuit can occur if they are stuck shut

<!-- PAGE=? -->
 If the expiratory valve is stuck in the closed position, breath stacking and barotrauma or volutrauma can result

<!-- PAGE=? -->
 Causes of circle system obstruction and failure include

<!-- PAGE=? -->
o manufacturing defects

<!-- PAGE=? -->
o debris

<!-- PAGE=? -->
o patient secretions

<!-- PAGE=? -->
o particulate obstruction from other odd sources such as albuterol nebulisation

<!-- PAGE=? -->
Ventilators

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Pneumatic and electronic pressure monitors are helpful in diagnosing disconnections

<!-- PAGE=? -->
o An audible or visual alarm is actuated if the peak inspiratory pressure of the breathing circuit does not exceed the threshold pressure alarm limit

<!-- PAGE=? -->
 Factors that influence monitor effectiveness include

<!-- PAGE=? -->
o disconnection site

<!-- PAGE=? -->
o the pressure sensor location

<!-- PAGE=? -->
o the threshold pressure alarm limit

<!-- PAGE=? -->
 the pressure alarm limit should be set to within 5 cm water of the peak inspiratory pressure

<!-- PAGE=? -->
o the inspiratory flow rate

<!-- PAGE=? -->
o the resistance of the disconnected breathing circuit

<!-- PAGE=? -->
30

<!-- PAGE=? -->
25

<!-- PAGE=? -->
20

<!-- PAGE=? -->
15

<!-- PAGE=? -->
10

<!-- PAGE=? -->
1

<!-- PAGE=? -->
5

<!-- PAGE=? -->
Alarm limit set correctly 10 within

<!-- PAGE=? -->
Partlal disconnection

<!-- PAGE=? -->
30

<!-- PAGE=? -->
25

<!-- PAGE=? -->
8

<!-- PAGE=? -->
20

<!-- PAGE=? -->
1

<!-- PAGE=? -->
15

<!-- PAGE=? -->
10

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Alarm limit set incorrecily >5 cm

<!-- PAGE=? -->
H20 below peak pressure.

<!-- PAGE=? -->
 Ascending (standing) bellows ascend during the expiratory phase

<!-- PAGE=? -->
 descending (hanging) bellows descend during the expiratory phase

<!-- PAGE=? -->
 ascending bellows is safer

<!-- PAGE=? -->
o An ascending bellows will not fill if a total disconnection occurs

<!-- PAGE=? -->
o descending bellows will continue its up-and-down movement during a disconnection

<!-- PAGE=? -->
 The driving gas pushes the bellows upward during the inspiratory phase

<!-- PAGE=? -->
 During the expiratory phase, room air is entrained into the breathing system at the site of the disconnection because gravity acts on the weighted bellows

<!-- PAGE=? -->
 The disconnection pressure monitor and the volume monitor may be fooled even if a disconnection is complete.

<!-- PAGE=? -->
Ambulatory surgery

<!-- PAGE=? -->
Benefits

<!-- PAGE=? -->
 Patient preference, especially children and the elderly

<!-- PAGE=? -->
 Lack of dependence on the availability of hospital beds

<!-- PAGE=? -->
 Greater flexibility in scheduling operations

<!-- PAGE=? -->
 Low morbidity and mortality

<!-- PAGE=? -->
 Lower incidence of infection

<!-- PAGE=? -->
 Lower incidence of respiratory complications

<!-- PAGE=? -->
 Higher volume of patients (greater efficiency)

<!-- PAGE=? -->
 Shorter surgical waiting lists

<!-- PAGE=? -->
 Lower overall procedural costs

<!-- PAGE=? -->
 Less preoperative testing and postoperative medication

<!-- PAGE=? -->
Indications

<!-- PAGE=? -->
 Length of surgery is NOT a criterion for ambulatory procedures

<!-- PAGE=? -->
 Advanced age alone is NOT a reason to disallow surgery in an ambulatory setting.

<!-- PAGE=? -->
 Ambulatory surgery is no longer restricted to patients of ASA physical status I or II.

<!-- PAGE=? -->
 ASA physical status III or IV ARE appropriate candidates, providing their systemic diseases are medically stable

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
 Infants at risk

<!-- PAGE=? -->
o Premature birth and <50 weeks postconceptual age

<!-- PAGE=? -->
o Apneic episodes

<!-- PAGE=? -->
o Failure to thrive

<!-- PAGE=? -->
o Respiratory distress syndrome at birth requiring ventilatory support

<!-- PAGE=? -->
o Bronchopulmonary dysplasia

<!-- PAGE=? -->
o Family history of sudden infant death syndrome and <12 months of age

<!-- PAGE=? -->
 Susceptibility to malignant hyperthermia

<!-- PAGE=? -->
o Requires 4hour monitoring plus instructions on d/c

<!-- PAGE=? -->
 Uncontrolled seizure activity

<!-- PAGE=? -->
 Systemic diseases that are not optimally managed (e.g., brittle diabetes, unstable angina, symptomatic asthma)

<!-- PAGE=? -->
 Morbid obesity complicated by symptomatic cardiovascular (e.g., angina) or respiratory (e.g., asthma) problems

<!-- PAGE=? -->
 Multiple chronic centrally active drug therapies (e.g., use of monoamine oxidase inhibitors such as pargyline and tranylcypromine) and active cocaine abuse because of the increased risk of intraoperative cardiovascular complications, including death

<!-- PAGE=? -->
 Acute substance abuse

<!-- PAGE=? -->
 Presence of infection

<!-- PAGE=? -->
 Uncooperative and/or unreliable patient

<!-- PAGE=? -->
 No responsible adult at home

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
 Most ambulatory surgery facility have admission rates of <1%

<!-- PAGE=? -->
o Ortho (3.2%) > ENT (3.1%) = GenSx (3.1%) > Uro (2.9%)

<!-- PAGE=? -->
o Free standing units have lower admission rates than hospital based units

<!-- PAGE=? -->
 Most common reasons for unexpected admissions are

<!-- PAGE=? -->
o Pain

<!-- PAGE=? -->
o Bleeding

<!-- PAGE=? -->
o Nausea & vomiting

<!-- PAGE=? -->
 Most common anesthetic reason for delayed discharge and admission

<!-- PAGE=? -->
o surgical misadventure

<!-- PAGE=? -->
o more extensive surgery

<!-- PAGE=? -->
o urinary retention

<!-- PAGE=? -->
o lack of an escort

<!-- PAGE=? -->
 In Pediatrics

<!-- PAGE=? -->
o PONV is a leading cause of delayed discharge from the PACU or, more rarely, of unplanned admission of the day surgery patient.

<!-- PAGE=? -->
 Likelihood of an unexpected hospital admission is related more to the type of surgery that to the patient or anesthetic factors

<!-- PAGE=? -->
 3% of patients returned to the hospital

<!-- PAGE=? -->
o bleeding at the surgical site was the most common reason for ER visit - 42%

<!-- PAGE=? -->
o patients undergoing varicocelectomy and hydrocelectomy were eight times more likely to return to the hospital

<!-- PAGE=? -->
o 77% of these patients were sent home after treatment

<!-- PAGE=? -->
Discharge Criteria

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Early recovery period

<!-- PAGE=? -->
o In OR or PACU

<!-- PAGE=? -->
 emergence from anesthesia, recovery of protective reflexes and early motor activity

<!-- PAGE=? -->
 vital signs, oxygen saturation

<!-- PAGE=? -->
 pain control and antiemetics

<!-- PAGE=? -->
 Intermediate recovery period

<!-- PAGE=? -->
o usually cared for in a reclining chair, progressively begin to ambulate, drink fluids, void and prepare for d/c

<!-- PAGE=? -->
o factors that predict longer stay:

<!-- PAGE=? -->
 female

<!-- PAGE=? -->
 advanced age

<!-- PAGE=? -->
 longer operations

<!-- PAGE=? -->
 large fluid or blood loss

<!-- PAGE=? -->
 opioid use

<!-- PAGE=? -->
 nondepolarizing muscle relaxants

<!-- PAGE=? -->
 postop pain and PONV

<!-- PAGE=? -->
 spinal anesthesia

<!-- PAGE=? -->
 Late recovery period

<!-- PAGE=? -->
o resumption of normal daily activities, occurs after d/c home

<!-- PAGE=? -->
 Guidelines for safe d/c:

<!-- PAGE=? -->
o stable vital signs

<!-- PAGE=? -->
o return to baseline orientation

<!-- PAGE=? -->
o ambulation w/o dizziness

<!-- PAGE=? -->
o safe ambulation after neuraxis blockade

<!-- PAGE=? -->
 normal perianal sensation

<!-- PAGE=? -->
 ability to plantar flex foot

<!-- PAGE=? -->
 proprioception of big toe

<!-- PAGE=? -->
o minimal pain

<!-- PAGE=? -->
o minimal PONV

<!-- PAGE=? -->
o minimal bleeding at surgical site

<!-- PAGE=? -->
o escort to transport them home

<!-- PAGE=? -->
o given written post op instructions including advice on who to contact if a problem develops

<!-- PAGE=? -->
o the requirement for patients to drink and void before discharge is no longer considered mandatory

<!-- PAGE=? -->
o it is advisable after spinal and epidural anesthesia for outpatients to be able to void

<!-- PAGE=? -->
 Delays in d/c are related to:

<!-- PAGE=? -->
o persistent pain

<!-- PAGE=? -->
o PONV

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
o Dizziness

<!-- PAGE=? -->
o Unsteady gait

<!-- PAGE=? -->
o Lack of escort home

<!-- PAGE=? -->
Amiodarone

<!-- PAGE=? -->
 The most serious side effect of amiodarone is pulmonary alveolitis - pneumonitis

<!-- PAGE=? -->
o The overall incidence of pulmonary toxicity is estimated at 5% to 15% of treated patients

<!-- PAGE=? -->
o reported mortality of 5% to 10%

<!-- PAGE=? -->
o cause of this drug-induced pulmonary toxicity is not known

<!-- PAGE=? -->
 may be related to enhance production of free oxygen radicals in the lungs

<!-- PAGE=? -->
 For this reason, it may be prudent to restrict the inspired concentration of oxygen in patients receiving amiodarone

<!-- PAGE=? -->
o Risk factors

<!-- PAGE=? -->
 High cumulative dose (> 400mg/day for 2 months)

<!-- PAGE=? -->
 Inc. age

<!-- PAGE=? -->
 Preexisting pulmonary disease

<!-- PAGE=? -->
o The most common form is insidious onset of

<!-- PAGE=? -->
 progressive dyspnea

<!-- PAGE=? -->
 cough

<!-- PAGE=? -->
 weight loss

<!-- PAGE=? -->
 pulmonary infiltrates

<!-- PAGE=? -->
o the second form of pulmonary toxicity has a much more acute onset of

<!-- PAGE=? -->
 dyspnea

<!-- PAGE=? -->
 Cough

<!-- PAGE=? -->
 arterial hypoxemia

<!-- PAGE=? -->
 occasionally fever

<!-- PAGE=? -->
 may mimic an infectious pneumonia

<!-- PAGE=? -->
 Postoperative pulmonary edema attributed to amiodarone induced pulmonary toxicity reflects this acute form of onset

<!-- PAGE=? -->
 Other side effects include

<!-- PAGE=? -->
o Thyroid dysfunction

<!-- PAGE=? -->
 Large iodine content

<!-- PAGE=? -->
 either hyper and hypo function may occur

<!-- PAGE=? -->
 free T4 alone may be unreliable so TSH must also be measured

<!-- PAGE=? -->
o Eye

<!-- PAGE=? -->
 Corneal micro-deposits

<!-- PAGE=? -->
 Typically asymptomatic

<!-- PAGE=? -->
 Optic neuropathy is rare

<!-- PAGE=? -->
 Abnormal liver enzymes are common

<!-- PAGE=? -->
 Rarely

<!-- PAGE=? -->
 Jaundice, hepatomegaly, hepatitis

<!-- PAGE=? -->
o Skin

<!-- PAGE=? -->
 Ble-grey skin discoloration

<!-- PAGE=? -->
 May or may not disappear with stoppage of the drug

<!-- PAGE=? -->
 Moer sensitive to the harmeful effects of UV-A light

<!-- PAGE=? -->
 Half life is ~ 58 days

<!-- PAGE=? -->
o GI

<!-- PAGE=? -->
Anesthetic agents

<!-- PAGE=? -->
Table 10-1 -- Pharmacokinetic variables of commonly used intravenous anesthetics

<!-- PAGE=? -->
Vdss, apparent volume of distribution at steady state.

<!-- PAGE=? -->
 With the exception of etomidate, all IV induction agents have been alleged to cause some histamine release (Barash)

<!-- PAGE=? -->
Anticholinesterases

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 provoke profound vagal stimulation

<!-- PAGE=? -->
o time course of the vagal effects parallels the reversal of block

<!-- PAGE=? -->
 rapid for edrophonium

<!-- PAGE=? -->
 matched well with atropine - rapid onset of action (1 min), duration of 30-60 min, and crosses the blood-brain barrier

<!-- PAGE=? -->
 slower for neostigmine

<!-- PAGE=? -->
 matched better with glycopyrrolate (onset 2-3 min)

<!-- PAGE=? -->
o Because glycopyrrolate does not cross the blood-brain barrier, the incidence of memory deficits after anesthesia is less than that after atropine

<!-- PAGE=? -->
 produce increased salivation and bowel motility

<!-- PAGE=? -->
o atropine blocks the former, it appears to have little effect on peristalsis

<!-- PAGE=? -->
 may cause an increase in airway resistance

<!-- PAGE=? -->
o anticholinergics reduce this effect

<!-- PAGE=? -->
 Renal failure

<!-- PAGE=? -->
o renal excretion accounts for about 50% of the excretion of neostigmine and about 75% of that of pyridostigmine and edrophonium

<!-- PAGE=? -->
o Renal failure decreases the plasma clearance of neostigmine, pyridostigmine, and edrophonium as much as if not more than that of the long-acting NdMB

<!-- PAGE=? -->
 renal failure should not be associated with "recurarization."

<!-- PAGE=? -->
 Neostigmine, physostigmine and pyridostigmine produce competitive reversible covalent binding

<!-- PAGE=? -->
o Neostigmine is more efficient at reversing dense motor blockade

<!-- PAGE=? -->
 Edrophonium binds via electrostatic interactions (H-bonds)

<!-- PAGE=? -->
o Faster onset and shorter duration than neostigmine & pyridostigmine

<!-- PAGE=? -->
Anti-Epileptic Drugs

<!-- PAGE=? -->
Antimuscarinic

<!-- PAGE=? -->
Table 12-11. COMPARISON OF ANTIMUSCARINIC DRUGS  (Barash)

<!-- PAGE=? -->
* Secretions may be reduced by inspissation.

<!-- PAGE=? -->
† CNS effect often manifest as sedation before stimulation.

<!-- PAGE=? -->
‡ May decelerate initially.

<!-- PAGE=? -->
Ankle

<!-- PAGE=? -->
 medial and lateral plantar nerve = posterior tibial nerve

<!-- PAGE=? -->
 common peroneal divides into superficial and deep peroneal,

<!-- PAGE=? -->
 tibial nerve divides into the sural and the posterior tibial

<!-- PAGE=? -->
2 Superticlal Poroncal Norve

<!-- PAGE=? -->
3 Postcrior Tibial Norvc

<!-- PAGE=? -->
Sural Norvc

<!-- PAGE=? -->
5 Saphonous Norve

<!-- PAGE=? -->
13

<!-- PAGE=? -->
12

<!-- PAGE=? -->
11

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Saphenous n

<!-- PAGE=? -->
Sural n.

<!-- PAGE=? -->
Superficial peroneal

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
Plantar n

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
Saphenous n.

<!-- PAGE=? -->
Superficial peroneal

<!-- PAGE=? -->
Calcaneal n

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
Www.nysora.com

<!-- PAGE=? -->
Plantar n.

<!-- PAGE=? -->
PT

<!-- PAGE=? -->
peroneal nerve

<!-- PAGE=? -->
Sural n.

<!-- PAGE=? -->
Icaneal n.

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
[Deep

<!-- PAGE=? -->
Deep peroneal nerve

<!-- PAGE=? -->
Plantar n.

<!-- PAGE=? -->
PT

<!-- PAGE=? -->
Sural n

<!-- PAGE=? -->
Calcaneal n.

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
WWW.nysora.com

<!-- PAGE=? -->
Sural

<!-- PAGE=? -->
Saphenous n

<!-- PAGE=? -->
Superficial peroneal

<!-- PAGE=? -->
Sural n.

<!-- PAGE=? -->
Deep peroneal nerve

<!-- PAGE=? -->
Ankylosing Spondylitis

<!-- PAGE=? -->
 Inflammatory spondyloarthropathy of the axial skeleton

<!-- PAGE=? -->
 Primarily affects males (3:1)

<!-- PAGE=? -->
 Strong family incidence with ~90% having HLA-B27 genotype

<!-- PAGE=? -->
 Enthesopathy (inflammation at site of attachment of ligaments and tendons to periosteum) and arthropathy (i.e. synovial involvement)

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
o Axial Skeleton Involvement

<!-- PAGE=? -->
 Begins at SI joints and spreads cranially (although may have isolated sacroiliatis)

<!-- PAGE=? -->
 Progressive inflammation of axial spine until ankylosed (i.e. fused - the bamboo spine )

<!-- PAGE=? -->
 Can fracture easily with mild trauma

<!-- PAGE=? -->
 Atlanto-axial subluxation in up to 21%

<!-- PAGE=? -->
o Extra-articular Involvement

<!-- PAGE=? -->
 Conjunctivitis and uveitis

<!-- PAGE=? -->
 Cardiovascular Disease (29%)

<!-- PAGE=? -->
 Valvular abnormalities → most common is AI

<!-- PAGE=? -->
 Conduction abnormalities

<!-- PAGE=? -->
 Pericardial effusion

<!-- PAGE=? -->
 Pulmonary Disease

<!-- PAGE=? -->
 Restrictive lung disease due to costovertebral rigidity

<!-- PAGE=? -->
o Majority have only mild ↓ TLC / VC due to compensation by ↑ abdominal excursion

<!-- PAGE=? -->
o Gas exchange generally normal

<!-- PAGE=? -->
 Apical pulmonary fibro-bullous disease 1.5 - 15%

<!-- PAGE=? -->
o Mostly asymptomatic but can be progressive

<!-- PAGE=? -->
 Renal disease  NSAID nephropathy, ass. with IgA nephropathy and secondary amyloidosis

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Acetaminophen

<!-- PAGE=? -->
o NSAID

<!-- PAGE=? -->
o Anti-TNF alpha antagonists (Etanercept, infliximab, adalimumab)

<!-- PAGE=? -->
 Risk of infections and reactivation of TB

<!-- PAGE=? -->
 Pancytopenia and aplastic anemia

<!-- PAGE=? -->
 Heart failure

<!-- PAGE=? -->
o Sulfasalazine → leucopenia, neutropenia

<!-- PAGE=? -->
o Methotrexate → pancytopenia, immunosuppression, renal toxicity

<!-- PAGE=? -->
Antiarrythmic drugs

<!-- PAGE=? -->
Yaughan Yilliams Classification 0f Antiarrhythmic Drugs

<!-- PAGE=? -->
Class |a sloys conduction Yelocity (less than class Ic) and prolongs action potential duration (APD)

<!-- PAGE=? -->
Procainamnide

<!-- PAGE=? -->
Disopyramide

<!-- PAGE=? -->
Quinidine

<!-- PAGE=? -->
Class IB has no effect on conduction vel locity and may shorten #PD

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
Mexiletine

<!-- PAGE=? -->
Phenwtoin

<!-- PAGE=? -->
Tocainide

<!-- PAGE=? -->
Class Ic sloys conduction and may pro #PD (mild). long

<!-- PAGE=? -->
Flecainide

<!-- PAGE=? -->
Propafenone

<!-- PAGE=? -->
Moricizine

<!-- PAGE=? -->
Class II blocks beta adrenergic receptors.

<!-- PAGE=? -->
Beta blockers

<!-- PAGE=? -->
Class III prolongs

<!-- PAGE=? -->
amiodarone

<!-- PAGE=? -->
Dofetilide

<!-- PAGE=? -->
Ibutilide

<!-- PAGE=? -->
Sotalol*

<!-- PAGE=? -->
N-acetyl procainamide (NAPA)

<!-- PAGE=? -->
Azimilide &

<!-- PAGE=? -->
Class |Y calcium channel blockers

<!-- PAGE=? -->
Nondihydropyridine calcium channe blockers (verapamil and dilitiazem)

<!-- PAGE=? -->
APD action potential duration

<!-- PAGE=? -->
|-sotalol has beta blocking and class Ill activities d-sotalol is a pure class IIl agent.

<!-- PAGE=? -->
2 Azimilide blocks IKS and IKr others are Predominantly IKr blockers

<!-- PAGE=? -->
Antithrombin III

<!-- PAGE=? -->
Hoffbrand ' Essential Hematology' pg 311

<!-- PAGE=? -->
 Glycoprotein, serine protease inhibitor

<!-- PAGE=? -->
 Most important inhibitor of coagulation cascade

<!-- PAGE=? -->
 It inhibits serine proteases by combining with them to form high molecular weight complexes

<!-- PAGE=? -->
 Serine proteases inhibited by AT III: Thrombin, Factor IXa, Xa, XIa, kallicrein, plasmin, urokinase, C1-esterase, trypsin (it does not selectively inhibits coagulation proteins !)

<!-- PAGE=? -->
 Heparin potentiates the action  of At III

<!-- PAGE=? -->
Chestnut (885)

<!-- PAGE=? -->
 is a circulating protease inhibitor

<!-- PAGE=? -->
 inhibits active forms of coagulation factors (X, XI, IX, XII)

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Heparin alone has no anticoagulant effect: it works by potentiating ATIII

<!-- PAGE=? -->
 ATIII is made by the liver and there is no ability to acutely increase ATIII production

<!-- PAGE=? -->
 Liver dysfunction results in decreased production

<!-- PAGE=? -->
 Heparin therapy decreases ATIII because of the removal of ATIII-heparin complexes from the circulation

<!-- PAGE=? -->
 Thrombin generation (as occurs with hematomas) can exacerbate the decerement in ATIII with heparin therapy

<!-- PAGE=? -->
 Decreased levels with:

<!-- PAGE=? -->
o Liver disease

<!-- PAGE=? -->
o nephrotic syndrome

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o pre-eclampsia

<!-- PAGE=? -->
o fatty liver of pregnancy

<!-- PAGE=? -->
o following surgery

<!-- PAGE=? -->
o variable with OCP

<!-- PAGE=? -->
o prolonged heparin - a few doses is no problem

<!-- PAGE=? -->
o pregnancy (chestnut)

<!-- PAGE=? -->
Aortic cross-clamp

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
Cardiovascular Changes

<!-- PAGE=? -->
 Three major mechanisms involved in hemodynamic changes:

<!-- PAGE=? -->
o Blood volume redistribution → ↑ Preload

<!-- PAGE=? -->
 splanchnic circulation contains ~25% of TBV majority of which can be auto-transfused during high cross clamp

<!-- PAGE=? -->
o Increased ventricular afterload

<!-- PAGE=? -->
o Increased catacholamines which potentiate ↑ preload and ↑ afterload

<!-- PAGE=? -->
 Supraceliac

<!-- PAGE=? -->
o Increased preload (iCVP, iPCWP, iLVEDV )

<!-- PAGE=? -->
o Increased afterload ( iMAP , iSVR)

<!-- PAGE=? -->
o Decreased  CO (dEF, iLVESV , iPCWP)

<!-- PAGE=? -->
o Increased MVO2 ( iLVSWI , incidence of ischemia)

<!-- PAGE=? -->
 Infraceliac

<!-- PAGE=? -->
o Decreased preload (dCVP)

<!-- PAGE=? -->
 Low resistance in splanchnic circulation

<!-- PAGE=? -->
o Milder changes in afterload (iMAP),

<!-- PAGE=? -->
o Dec. CO (dEF)

<!-- PAGE=? -->
o Inc. MVO2

<!-- PAGE=? -->
 Infrarenal

<!-- PAGE=? -->
o Mild to no significant hemodynamic response

<!-- PAGE=? -->
 no change in HR

<!-- PAGE=? -->
 Inc. arterial pressure (7% to 10%)

<!-- PAGE=? -->
 Inc. SVR (20% to 32%)

<!-- PAGE=? -->
o Effect on CO and filling pressure is dependent on myocardial response to hemodynamic changes

<!-- PAGE=? -->
 Generally CO is dec. by 9 - 33%

<!-- PAGE=? -->
 In patients without CAD

<!-- PAGE=? -->
 May have inc. CO

<!-- PAGE=? -->
 May have dec. filling pressure

<!-- PAGE=? -->
 In patients who are unable to compensate (CAD / myocardial dysfunction)

<!-- PAGE=? -->
 Dec. CO

<!-- PAGE=? -->
 inc. CVP (35%) and PCWP (50%)

<!-- PAGE=? -->
 segmental wall motion abnormalities in 30% of patients (66% of which occurred at time of x-clamp)

<!-- PAGE=? -->
o patients with aortoiliac occlusive disease have less hemodynamic response as compared to patients with abdominal aortic aneurysmal disease

<!-- PAGE=? -->
 more extensive periaortic collateral vascularization

<!-- PAGE=? -->
Physiologic Changes with Aortic Cross-Clamping and Therapeutic Interventions

<!-- PAGE=? -->
 These changes are of greater significance with longer duration of cross-clamping and with more proximal cross-clamping

<!-- PAGE=? -->
 Hemodynamic Changes

<!-- PAGE=? -->
o ↑ Arterial blood pressure above the clamp

<!-- PAGE=? -->
o ↓ Arterial blood pressure below the clamp

<!-- PAGE=? -->
o ↑ Segmental wall motion abnormalities

<!-- PAGE=? -->
o ↑ Left ventricular wall tension

<!-- PAGE=? -->
o ↓ Ejection fraction

<!-- PAGE=? -->
o ↓ Cardiac output

<!-- PAGE=? -->
 may increase with thoracic cross-clamp

<!-- PAGE=? -->
o ↓ Renal blood flow

<!-- PAGE=? -->
o ↑ Pulmonary occlusion pressure

<!-- PAGE=? -->
o ↑ Central venous pressure

<!-- PAGE=? -->
o ↑ Coronary blood flow

<!-- PAGE=? -->
 Metabolic Changes

<!-- PAGE=? -->
o ↓ Total-body oxygen consumption

<!-- PAGE=? -->
o ↓ Total-body carbon dioxide production

<!-- PAGE=? -->
o ↑ Mixed venous oxygen saturation

<!-- PAGE=? -->
o ↓ Total-body oxygen extraction

<!-- PAGE=? -->
o ↑ Epinephrine and norepinephrine

<!-- PAGE=? -->
o Respiratory alkalosis

<!-- PAGE=? -->
 When ventilatory settings are unchanged from preclamp levels

<!-- PAGE=? -->
o Metabolic acidosis

<!-- PAGE=? -->
 Therapeutic Interventions

<!-- PAGE=? -->
o Afterload reduction

<!-- PAGE=? -->
 Sodium nitroprusside

<!-- PAGE=? -->
 Inhaled anesthetics

<!-- PAGE=? -->
 Amrinone

<!-- PAGE=? -->
 Shunts and aorta-to-femoral bypass

<!-- PAGE=? -->
o Preload reduction

<!-- PAGE=? -->
 Nitroglycerin

<!-- PAGE=? -->
 Controlled phlebotomy

<!-- PAGE=? -->
 Atrial-to-femoral bypass

<!-- PAGE=? -->
o Renal protection

<!-- PAGE=? -->
 Fluid administration

<!-- PAGE=? -->
 Distal aortic perfusion techniques

<!-- PAGE=? -->
 Selective renal artery perfusion

<!-- PAGE=? -->
 Mannitol

<!-- PAGE=? -->
 Drugs to augment renal perfusion

<!-- PAGE=? -->
o Other

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 ↓ Minute ventilation

<!-- PAGE=? -->
 Sodium bicarbonate

<!-- PAGE=? -->
 Factors That May Influence the Magnitude and Direction of Physiologic Changes Occurring with Aortic Cross-Clamping

<!-- PAGE=? -->
o Level of aortic cross-clamp

<!-- PAGE=? -->
o Species differences

<!-- PAGE=? -->
o Anesthetic agents and techniques

<!-- PAGE=? -->
o Use of vasodilator therapy

<!-- PAGE=? -->
o Use of diverting circulatory support

<!-- PAGE=? -->
o Degree of periaortic collateralization

<!-- PAGE=? -->
o Left ventricular function

<!-- PAGE=? -->
o Status of the coronary circulation

<!-- PAGE=? -->
o Volume status

<!-- PAGE=? -->
o Neuroendocrine activation

<!-- PAGE=? -->
o Duration of aortic cross-clamping

<!-- PAGE=? -->
o Body temperature

<!-- PAGE=? -->
TABLE 52-11 -- Percent change in cardiovascular variables on initiation of aortic occlusion

<!-- PAGE=? -->
From Roizen MF, Beaupre PN, Alpert RA, et al: Monitoring with two-dimensional transesophageal echocardiography. Comparison of myocardial function in patients undergoing supraceliac, suprarenal-infraceliac, or infrarenal aortic occlusion. J Vasc Surg 1:300-305, 1984.

<!-- PAGE=? -->
Spinal Cord Protection

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Limitation of cross-clamp duration

<!-- PAGE=? -->
 Distal circulatory support

<!-- PAGE=? -->
 Reattachment of critical intercostal arteries

<!-- PAGE=? -->
 CSF drainage

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
o Moderate systemic (32-34°C)

<!-- PAGE=? -->
o Epidural cooling

<!-- PAGE=? -->
o Circulatory arrest

<!-- PAGE=? -->
 Maintenance of proximal blood pressure

<!-- PAGE=? -->
o Pharmacotherapy

<!-- PAGE=? -->
 Systemic

<!-- PAGE=? -->
 Corticosteroids, barbiturates, naloxone, calcium channel antagonists, O2

<!-- PAGE=? -->
 free radical scavengers, NMDA antagonists, mannitol, magnesium, vasodilators

<!-- PAGE=? -->
o (adenosine papaverine, prostacyclin), perfluorocarbons, colchicine

<!-- PAGE=? -->
 Intrathecal

<!-- PAGE=? -->
 Papaverine, magnesium, tetracaine, perfluorocarbons

<!-- PAGE=? -->
 Avoidance of postoperative hypotension

<!-- PAGE=? -->
 Sequential aortic clamping

<!-- PAGE=? -->
 Enhanced monitoring for spinal cord ischemia

<!-- PAGE=? -->
o Somatosensory evoked potentials

<!-- PAGE=? -->
o Motor evoked potentials

<!-- PAGE=? -->
o Hydrogen-saturated saline

<!-- PAGE=? -->
o Avoidance of hyperglycemia

<!-- PAGE=? -->
Aortic dissection

<!-- PAGE=? -->
Risk Factors:

<!-- PAGE=? -->
 advanced age (5 th or 6 th decade)

<!-- PAGE=? -->
 HTN (these two are the most important)

<!-- PAGE=? -->
 Men > Women

<!-- PAGE=? -->
 CTD - Marfan's syndrome

<!-- PAGE=? -->
 Bicuspid aortic valves

<!-- PAGE=? -->
 Coarctation

<!-- PAGE=? -->
 Pregnancy

<!-- PAGE=? -->
 Blunt trauma

<!-- PAGE=? -->
 postaortomy

<!-- PAGE=? -->
Clinical Manifestations - degenerative and dissecting TAAs are symptomatic at the time of presentation in 57% and 85% of patients respectively

<!-- PAGE=? -->
 back pain and or chest pain

<!-- PAGE=? -->
 dec. BP in LE

<!-- PAGE=? -->
 Rt arn BP > Lt arm

<!-- PAGE=? -->
o weak Lt pulse

<!-- PAGE=? -->
 compression of organs or structures adjacent to the aneurysm

<!-- PAGE=? -->
o L mainstem bronchus

<!-- PAGE=? -->
o Aortic regurg with CHF

<!-- PAGE=? -->
o SVC syndrome

<!-- PAGE=? -->
o Esophageal compression

<!-- PAGE=? -->
 end organ/ branch ischemia

<!-- PAGE=? -->
o coronary ischemia

<!-- PAGE=? -->
o mesenteric ischemia

<!-- PAGE=? -->
o renal ischemia

<!-- PAGE=? -->
o spinal ischemia

<!-- PAGE=? -->
 weakness to LE

<!-- PAGE=? -->
o carotid involvement

<!-- PAGE=? -->
 syncope

<!-- PAGE=? -->
 cardiac rupture/ tamponade

<!-- PAGE=? -->
 pulse pressure variation

<!-- PAGE=? -->
Classification:

<!-- PAGE=? -->
 Stanford Type A: involve ascending aorta

<!-- PAGE=? -->
 Stanford Type B: do not involve ascending aorta

<!-- PAGE=? -->
o Traumatic Aortic injury occurs most commonly just distal to the left subclavian artery and is the result of shear forces between the mobile heart and aortic arch and the immobile descending thoracic aorta

<!-- PAGE=? -->
 Acute: < 2 weeks vs chronic > 2 wks (very high mortality in acute phase)

<!-- PAGE=? -->
 All acute dissections involving the ascending portion require urgent surgical intervention

<!-- PAGE=? -->
Morbidity and Mortality of open elective surgical repair:

<!-- PAGE=? -->
 mortality 5-14%

<!-- PAGE=? -->
 paraplegia or paraparesis: 5-40%

<!-- PAGE=? -->
 renal failure: 3-30%

<!-- PAGE=? -->
 tracheostomy: 8-14%

<!-- PAGE=? -->
Diagnosis:

<!-- PAGE=? -->
-a variety of diagnostic techniques are extremely accurate in the diagnosis of acute aortic dissection‖

<!-- PAGE=? -->
 Investigations

<!-- PAGE=? -->
o ECG, TEE, CT scan, CXR

<!-- PAGE=? -->
o MIBI scan is not useful

<!-- PAGE=? -->
o CXR findings

<!-- PAGE=? -->
 Widened mediastinum

<!-- PAGE=? -->
 Left apical cap

<!-- PAGE=? -->
 Deviation of the nasogastric tube to the Right

<!-- PAGE=? -->
 Depression of the Left main stem bronchus on CXR

<!-- PAGE=? -->
 Obliteration of the space between PA and Aorta

<!-- PAGE=? -->
o TEE: highly sensitive and specific for making the diagnosis of dissection, quantifies aortic regurg, LV function, wall motion abnormalities, pericardial effusion.  Traumatic transection generally occurs just distal to the L subclavian takeoff and is often easily and rapidly identified by TEE imaging. TEE is quick and can be done in the OR (good for emergencies)

<!-- PAGE=? -->
 Dissections in the distal ascending aorta and proximal arch are difficult to visualize because of the L main bronchus

<!-- PAGE=? -->
o ECG: LVH secondary to high incidence of hypertension; ischemic changes

<!-- PAGE=? -->
o CT and MRI: useful for aneurysm size and location, following progression.  MRI is very sensitive for locating the tear, false lumen, aortic regurg and pericardial effusion

<!-- PAGE=? -->
o Angiography: locates the site of tear, assesses aortic valve integrity, involvement of coronary arteries, location of major branch vessels (although not reliable for finding those to the spinal cord)

<!-- PAGE=? -->
APGAR

<!-- PAGE=? -->
Aprotinin

<!-- PAGE=? -->
 derived from bovine lung

<!-- PAGE=? -->
 excreted by kidneys

<!-- PAGE=? -->
 anaphylaxis in 0.5%

<!-- PAGE=? -->
 prolongs CELITE ACT - need ACT > 700; less with Kaolin ACT

<!-- PAGE=? -->
 preserves GPIb receptors on platelets which are important for aggregation (GPIb-vWF)

<!-- PAGE=? -->
ARDS

<!-- PAGE=? -->
Barash, UptoDate

<!-- PAGE=? -->
 ALI: PaO2/FiO2 ratio <300

<!-- PAGE=? -->
 ARDS: PaO2/FiO2 ratio <200

<!-- PAGE=? -->
 Criteria for the Diagnosis of ALI and ARDS

<!-- PAGE=? -->
o Identifiable cause

<!-- PAGE=? -->
o Acute onset

<!-- PAGE=? -->
o Hypoxemia

<!-- PAGE=? -->
o Diffuse, bilateral radiographic opacities

<!-- PAGE=? -->
o PaOP ≤18, or no clinical evidence of left atrial hypertension

<!-- PAGE=? -->
 Conditions associated with ARDS:

<!-- PAGE=? -->
o Shock

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Aspiration

<!-- PAGE=? -->
o Radiation to chest

<!-- PAGE=? -->
o Burns

<!-- PAGE=? -->
o Pancreatitis

<!-- PAGE=? -->
o Uremia

<!-- PAGE=? -->
o Trauma

<!-- PAGE=? -->
o Massive Transfusion

<!-- PAGE=? -->
o Fat or air embolism

<!-- PAGE=? -->
o Drug ingestion

<!-- PAGE=? -->
o Head injury

<!-- PAGE=? -->
o Drowning

<!-- PAGE=? -->
o Cardiopulmonary Bypass

<!-- PAGE=? -->
 Patients with ARDS tend to progress through three relatively discrete pathologic stages:

<!-- PAGE=? -->
o exudative stage

<!-- PAGE=? -->
o proliferative stage

<!-- PAGE=? -->
o fibrotic stage

<!-- PAGE=? -->
 Laboratory findings are nonspecific

<!-- PAGE=? -->
o leukocytosis

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
o lactic acidosis

<!-- PAGE=? -->
 ABGs

<!-- PAGE=? -->
o acute respiratory alkalosis

<!-- PAGE=? -->
o elevated alveolar-arterial oxygen gradient

<!-- PAGE=? -->
o severe hypoxemia (right to left shunt physiology)

<!-- PAGE=? -->
 CXR

<!-- PAGE=? -->
o diffuse, fluffy alveolar infiltrates with prominent air bronchograms

<!-- PAGE=? -->
 CT

<!-- PAGE=? -->
o patchy abnormalities with increased density in dependent lung zones

<!-- PAGE=? -->
 Mortality is not correlated with

<!-- PAGE=? -->
o severity of hypoxemia

<!-- PAGE=? -->
o decreased compliance

<!-- PAGE=? -->
o increased radiographic opacity

<!-- PAGE=? -->
o high PEEP

<!-- PAGE=? -->
 Mortality is increased with

<!-- PAGE=? -->
o Failure to improve clinically over the first several days

<!-- PAGE=? -->
o degree of dead space ventilation

<!-- PAGE=? -->
 the dead space fraction or (Vd/Vt) can be assessed on the basis of exhaled CO2 levels

<!-- PAGE=? -->
o increased age

<!-- PAGE=? -->
o sepsis

<!-- PAGE=? -->
o more severe illness

<!-- PAGE=? -->
o steroid treatment prior to the onset of ARDS

<!-- PAGE=? -->
o acidemia

<!-- PAGE=? -->
o transfusion of packed red cells

<!-- PAGE=? -->
 Mortality is decreased with

<!-- PAGE=? -->
o trauma patients

<!-- PAGE=? -->
 The underlying cause of the ARDS is the most common cause of death among patients who die early

<!-- PAGE=? -->
 noscomial infection and sepsis are the most common causes of death among patients who die later in their clinical course

<!-- PAGE=? -->
 Inhaled nitric oxide also variably and transiently improves oxygenation - no relevant long-term outcome benefits

<!-- PAGE=? -->
o may still be useful as -rescue‖ therapy in selected patients with severe, refractory hypoxemia

<!-- PAGE=? -->
 conservative fluid management strategy that emphasized diuresis resulted in

<!-- PAGE=? -->
o improved oxygenation

<!-- PAGE=? -->
o more ventilator-free days

<!-- PAGE=? -->
o more days not in the ICU

<!-- PAGE=? -->
o no significant difference in mortality

<!-- PAGE=? -->
 Corticosteroid administration early in the course of ARDS is of no benefit or even harmful

<!-- PAGE=? -->
o administration during the fibroproliferative phase (day 3 and beyond) has be beneficial

<!-- PAGE=? -->
ARDSnet NIH Study

<!-- PAGE=? -->
 6cc/kg vs 12cc/kg

<!-- PAGE=? -->
o Reduced mortality from 40% to 31%

<!-- PAGE=? -->
o more ventilator-free and organ failure-free days

<!-- PAGE=? -->
o lower plateau pressures

<!-- PAGE=? -->
o inc RR and with similar MV

<!-- PAGE=? -->
o inc PaCO2

<!-- PAGE=? -->
o inc PEEP and FiO2, with a lower PaO2:FiO2 ratio

<!-- PAGE=? -->
 results reversed at day 7

<!-- PAGE=? -->
o number of days without nonpulmonary organ or system failure was significantly higher in the group treated with lower tidal volumes

<!-- PAGE=? -->
 circulatory failure, coagulation failure, renal failure

<!-- PAGE=? -->
o The incidence of barotrauma was similar in the two groups

<!-- PAGE=? -->
 Ventilation Goals: (ARDSnet)

<!-- PAGE=? -->
o peak pressure should be < 30cmH20

<!-- PAGE=? -->
o PEEP can be lower than 15cmH20

<!-- PAGE=? -->
o SaO2 goal is 88-95%.

<!-- PAGE=? -->
o Permissive hypercapnea is recommended

<!-- PAGE=? -->
ARDS vs CHF, pneumonia and PE

<!-- PAGE=? -->
Arterial Blood Pressure Monitoring

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Indirect Measurement of Arterial Blood Pressure

<!-- PAGE=? -->
Manual Intermittent Techniques

<!-- PAGE=? -->
 Most indirect methods of blood pressure measurement rely on a sphygmomanometer

<!-- PAGE=? -->
 Numerous techniques

<!-- PAGE=? -->
o Palpation (SBP only)

<!-- PAGE=? -->
o return-to flow (SBP only)

<!-- PAGE=? -->
o auscultatory technique both SBP, and DBP)

<!-- PAGE=? -->
 Korotkoff sounds are a complex series of audible frequencies produced by turbulent flow, instability of

<!-- PAGE=? -->
the arterial wall, and shock wave formation as external occluding pressure on the artery is reduced

<!-- PAGE=? -->
o Phase I-V

<!-- PAGE=? -->
o phase V may never occur in certain pathophysiologic states such as aortic regurgitation

<!-- PAGE=? -->
 Common sources of error include

<!-- PAGE=? -->
o ↓ peripheral blood flow (cardiogenic shock, high-dose vasopressors - underestimation)

<!-- PAGE=? -->
o low compliance of the tissues underlying the cuff (shivering, severe calcific arteriosclerosis overestimation)

<!-- PAGE=? -->
o an inappropriate cuff size (too small - overestimation, too large - minimal effect underestimation)

<!-- PAGE=? -->
 width of the blood pressure cuff should be 20% greater than arm diameter

<!-- PAGE=? -->
 pneumatic bladder should span half the circumference of the arm

<!-- PAGE=? -->
o excessively rapid cuff deflation (missed sounds - 3mmHg/sec, 2mmHg/beat)

<!-- PAGE=? -->
Automated Intermittent Techniques

<!-- PAGE=? -->
 Most automated NIBP devices are based on oscillometry

<!-- PAGE=? -->
 variations in cuff pressure resulting from arterial pulsations during cuff deflation are sensed by the monitor and used to determine arterial blood pressure values

<!-- PAGE=? -->
 peak amplitude of arterial pulsations corresponds closely MAP

<!-- PAGE=? -->
 values for systolic and diastolic pressure are derived from proprietary formulas

<!-- PAGE=? -->
 SBP is identified as the pressure at which pulsations are increasing and are at 25% to 50% of maximum

<!-- PAGE=? -->
 DBP is the most difficult value to determine by oscillometry and is commonly recorded when the pulse

<!-- PAGE=? -->
Auscultatory

<!-- PAGE=? -->
systolic

<!-- PAGE=? -->
Auscultatory

<!-- PAGE=? -->
Korotkotf

<!-- PAGE=? -->
diastolic

<!-- PAGE=? -->
200

<!-- PAGE=? -->
sounds

<!-- PAGE=? -->
78

<!-- PAGE=? -->
200

<!-- PAGE=? -->
100

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Cutf pressure

<!-- PAGE=? -->
Cull pressure oscillations

<!-- PAGE=? -->
Oscillometric

<!-- PAGE=? -->
Oscillometric

<!-- PAGE=? -->
systolic

<!-- PAGE=? -->
diastolic

<!-- PAGE=? -->
145

<!-- PAGE=? -->
Oscillometric

<!-- PAGE=? -->
80

<!-- PAGE=? -->
mean

<!-- PAGE=? -->
106

<!-- PAGE=? -->
amplitude has declined from the peak value by 80%

<!-- PAGE=? -->
 if a patient's surgical procedure or medical condition requires that the cuff be applied to the calf, ankle, or thigh, an appropriately sized cuff must be used

<!-- PAGE=? -->
Complications of Noninvasive Blood Pressure Measurement

<!-- PAGE=? -->
 Pain

<!-- PAGE=? -->
 petechiae and ecchymoses

<!-- PAGE=? -->
 limb edema

<!-- PAGE=? -->
 venous stasis and thrombophlebitis

<!-- PAGE=? -->
 peripheral neuropathy

<!-- PAGE=? -->
 occur more often after prolonged periods of excessively frequent cuff inflation/deflation cycling

<!-- PAGE=? -->
 contributing factors include cuff misplacement across a joint or repeated attempts to determine blood pressure in the presence of an artifact-producing condition such as involuntary muscle tremors

<!-- PAGE=? -->
Automated Continuous Techniques

<!-- PAGE=? -->
 Advances in microprocessor and servomechanical control technology have enabled noninvasive techniques to provide a reasonable representation of the arterial pressure waveform

<!-- PAGE=? -->
 In view of the ongoing limitations of all these technologies, it remains unclear whether any noninvasive technique will reduce the need for direct arterial pressure monitoring

<!-- PAGE=? -->
Direct Measurement of Arterial Blood Pressure

<!-- PAGE=? -->
 Arterial cannulation with continuous pressure transduction and waveform display remains the accepted reference standard for blood pressure monitoring

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o Continuous, real-time blood pressure monitoring

<!-- PAGE=? -->
o Planned pharmacologic or mechanical cardiovascular manipulation

<!-- PAGE=? -->
o Repeated blood sampling

<!-- PAGE=? -->
o Failure of indirect arterial blood pressure measurement

<!-- PAGE=? -->
 The radial artery is the most common site for invasive blood pressure monitoring in anesthesia and critical care

<!-- PAGE=? -->
o Supplementary diagnostic information from the arterial waveform (respiratory variation)technically easy to cannulate

<!-- PAGE=? -->
o complications are uncommon

<!-- PAGE=? -->
 Allen test cannot be relied on to avoid this adverse outcome.

<!-- PAGE=? -->
 Other cannulation sites

<!-- PAGE=? -->
o ulnar artery

<!-- PAGE=? -->
 Even when previous attempts to cannulate the ipsilateral radial artery have failed, the ulnar artery may be cannulated safely (first check collateral flow from the radial artery with the Allen's test)

<!-- PAGE=? -->
o brachial artery

<!-- PAGE=? -->
 no collateral circulation present, but clinical trials have confirmed the safety of this cannulation site

<!-- PAGE=? -->
 longer catheter is preferred for the catheter to traverse the elbow joint

<!-- PAGE=? -->
o Other peripheral arteries

<!-- PAGE=? -->
 dorsalis pedis

<!-- PAGE=? -->
 posterior tibial

<!-- PAGE=? -->
 superficial temporal arteries

<!-- PAGE=? -->
 axillary artery

<!-- PAGE=? -->
 Advantages include patient comfort and mobility

<!-- PAGE=? -->
 access to a central arterial pressure waveform

<!-- PAGE=? -->
 complications appear to be infrequent

<!-- PAGE=? -->
 the risk of cerebral embolization is increased whenever more centrally located arterial catheters are used

<!-- PAGE=? -->
 femoral artery

<!-- PAGE=? -->
 waveform more closely resembles aortic pressure

<!-- PAGE=? -->
Complications of Direct Arterial Pressure Monitoring

<!-- PAGE=? -->
 extremely good safety record of this technique

<!-- PAGE=? -->
 factors that may increase the risk of complication include

<!-- PAGE=? -->
o vasospastic arterial disease

<!-- PAGE=? -->
o previous arterial injury

<!-- PAGE=? -->
o thrombocytosis

<!-- PAGE=? -->
o protracted shock

<!-- PAGE=? -->
o high-dose vasopressor

<!-- PAGE=? -->
o prolonged cannulation

<!-- PAGE=? -->
o infection

<!-- PAGE=? -->
o DM

<!-- PAGE=? -->
o Low CO

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Ischemia

<!-- PAGE=? -->
 Thrombosis, emboli, shock, high-pressure flushing, drug administration

<!-- PAGE=? -->
o Aneurysm

<!-- PAGE=? -->
o AV fistula

<!-- PAGE=? -->
o Cerebral air embolism

<!-- PAGE=? -->
o Skin necrosis

<!-- PAGE=? -->
o Infection

<!-- PAGE=? -->
Technical Aspects of Direct Blood Pressure Measurement

<!-- PAGE=? -->
 natural frequency (fn , ω)

<!-- PAGE=? -->
o quantifies how rapidly the system oscillates

<!-- PAGE=? -->
 damping coefficient (δ, Z, α, D)

<!-- PAGE=? -->
o quantifies the frictional forces that act on the system and determine how rapidly it comes to rest Natural Frequency, Damping Coefficient, and Dynamic Response of Pressure Monitoring Systems

<!-- PAGE=? -->
 The arterial blood pressure waveform is a periodic complex wave which is the sum of a series of simpler sine waves of different amplitudes and frequencies

<!-- PAGE=? -->
 The original pressure wave has a characteristic periodicity termed the fundamental frequency, which is equal to the pulse rate

<!-- PAGE=? -->
o 60 beats/min equals 1 beat/sec or 1 cycle/sec or 1 Hz

<!-- PAGE=? -->
 The sine waves that sum to produce the complex wave have frequencies that are multiples or harmonics of the fundamental frequency

<!-- PAGE=? -->
o As a general rule, 6 to 10 harmonics are required to provide distortion-free reproduction of most arterial pressure waveforms

<!-- PAGE=? -->
o accurate blood pressure measurement in a patient with a pulse rate of 120 beats/min (2 cycles/sec or 2 Hz) requires a monitoring system dynamic response of 12 to 20 Hz

<!-- PAGE=? -->
Art 166/56 (82

<!-- PAGE=? -->
NIBP 126/63 (84)

<!-- PAGE=? -->
sec

<!-- PAGE=? -->
160

<!-- PAGE=? -->
 the faster the heart rate and the steeper the systolic pressure upstroke, the greater the dynamic response demands on the monitoring system

<!-- PAGE=? -->
 If the monitoring system has a natural frequency that is too low, frequencies in the monitored pressure waveform will approach the natural frequency - the system will resonate and overshoot

<!-- PAGE=? -->
 Tachycardia and steep systolic pressure upstrokes present the greatest challenge for clinical monitoring systems because the higher-frequency content of these waveforms more likely approaches the resonant frequency of the measurement system

<!-- PAGE=? -->
 the bedside monitoring system must also have an appropriate damping coefficient

<!-- PAGE=? -->
o overdamped arterial pressure waveform show

<!-- PAGE=? -->
 slurred upstroke

<!-- PAGE=? -->
 absent dicrotic notch

<!-- PAGE=? -->
 loss of fine detail

<!-- PAGE=? -->
 falsely narrowed pulse pressure

<!-- PAGE=? -->
o MAP may remain reasonably accurate

<!-- PAGE=? -->
 the lower the natural frequency of the monitoring system, the more narrow the range of damping coefficients that can be tolerated to ensure faithful reproduction of the pressure wave or adequate dynamic response

<!-- PAGE=? -->
 a pressure monitoring system will have optimal dynamic response if its natural frequency is as high as possible - achieved by:

<!-- PAGE=? -->
o short lengths of stiff pressure tubing - ↓ compliance

<!-- PAGE=? -->
o limiting the number of stopcocks - reduced air bubbles, blood clot

<!-- PAGE=? -->
o limiting monitoring system appliances

<!-- PAGE=? -->
 the fast-flush test provides a convenient bedside method for determining the total system's natural frequency or damping coefficient - system dynamic response

<!-- PAGE=? -->
o flush artifact is examined

<!-- PAGE=? -->
 natural frequency is related to the time period or distance between two successive oscillation cycles

<!-- PAGE=? -->
 Natural frequency is then calculated: paper speed/time period (25 mm/sec / 1.7mm = 14.7Hz

<!-- PAGE=? -->
 The damping coefficient is determined by measuring the amplitudes of successive oscillation cycles

<!-- PAGE=? -->
o how quickly the measuring system comes to rest

<!-- PAGE=? -->
o a low amplitude ratio corresponds to a high damping coefficient (comes to rest quickly)

<!-- PAGE=? -->
o a high amplitude ratio corresponds to a low damping coefficient (system tends to resonate)

<!-- PAGE=? -->
 Although the technical requirements for accurate blood pressure measurement are well known, these conditions are often unmet in routine clinical practice

<!-- PAGE=? -->
o systolic arterial pressure overshoot resulting from a relatively underdamped system being the most common problem

<!-- PAGE=? -->
 Effect of small air bubbles within arterial pressure monitoring systems

<!-- PAGE=? -->
o A small 0.1-mL air bubble added to the monitoring system produces a paradoxic increase in arterial blood pressure - decreased natural frequency of the system

<!-- PAGE=? -->
o A larger 0.5-mL air bubble degrades dynamic response and produces spurious arterial hypotension

<!-- PAGE=? -->
 Despite the presence of both slow- and fast-flush systems, pressure monitoring systems appear to undergo a slow degradation in dynamic response over time, with a decrease in natural frequency and increase in damping coefficient

<!-- PAGE=? -->
Transducer Setup: Zeroing, Calibrating, and Leveling

<!-- PAGE=? -->
 The initial step in this process is to expose the transducer to atmospheric pressure by opening the adjacent stopcock to air, pressing the zero pressure button on the monitor, and thereby establishing the zero pressure reference value

<!-- PAGE=? -->
 Despite the common practice of aligning pressure transducers at the midchest level, more accurate pressure monitoring will be achieved if the transducer is aligned approximately 5 cm below the sternal border in the fourth intercostal space

<!-- PAGE=? -->
 In some circumstances, the clinician may choose to level the arterial pressure transducer at a different position on the body - the ear in neurosurgical operations, to better estimate cerebral perfusion pressure

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
0.9

<!-- PAGE=? -->
0.8

<!-- PAGE=? -->
0.7

<!-- PAGE=? -->
0.6

<!-- PAGE=? -->
0.5

<!-- PAGE=? -->
1

<!-- PAGE=? -->
0.4

<!-- PAGE=? -->
0.3

<!-- PAGE=? -->
0.2

<!-- PAGE=? -->
0.1

<!-- PAGE=? -->
0.2

<!-- PAGE=? -->
0.3

<!-- PAGE=? -->
0.4

<!-- PAGE=? -->
0.5

<!-- PAGE=? -->
0.6

<!-- PAGE=? -->
0.7

<!-- PAGE=? -->
0.8

<!-- PAGE=? -->
0.9

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
Damping coetticent

<!-- PAGE=? -->
Direct ART 120/80 120/80

<!-- PAGE=? -->
4

<!-- PAGE=? -->
NIBP 120/80

<!-- PAGE=? -->
120/80

<!-- PAGE=? -->
20 cm

<!-- PAGE=? -->
20 cm

<!-- PAGE=? -->
Direct ART 120/80 120/80

<!-- PAGE=? -->
NIBP 135/95

<!-- PAGE=? -->
105/65

<!-- PAGE=? -->
Normal Arterial Pressure Waveforms

<!-- PAGE=? -->
 Appreciation of the diagnostic clues provided by the direct arterial pressure waveform requires full understanding of normal waveform components, their relationship to the cardiac cycle, and differences in waveforms recorded from different sites in the

<!-- PAGE=? -->
body

<!-- PAGE=? -->
Systolic upstroke

<!-- PAGE=? -->
systolic peak pressure

<!-- PAGE=? -->
systolic decline

<!-- PAGE=? -->
dicrotic notch

<!-- PAGE=? -->
related to aortic valve closure centrally

<!-- PAGE=? -->
related to arterial wall properties peripherally

<!-- PAGE=? -->
diastolic runoff

<!-- PAGE=? -->
end-diastolic pressure.

<!-- PAGE=? -->
 systolic upstroke of the radial artery pressure trace does not appear for 120 to 180 milliseconds after inscription of the ECG R wave

<!-- PAGE=? -->
 The bedside monitor displays numeric values for the systolic peak and end-diastolic nadir pressures

<!-- PAGE=? -->
 MAP is equal to the area beneath the arterial pressure curve divided by the beat period

<!-- PAGE=? -->
Distal Pulse Amplification

<!-- PAGE=? -->
 Pressure waveforms from different arterial sites will have different morphologies

<!-- PAGE=? -->
 Due to physical characteristics of the vascular tree

<!-- PAGE=? -->
o Impedance

<!-- PAGE=? -->
o harmonic resonance

<!-- PAGE=? -->
 moving peripherally

<!-- PAGE=? -->
o arterial upstroke becomes steeper

<!-- PAGE=? -->
o systolic peak becomes higher

<!-- PAGE=? -->
o dicrotic notch appears later

<!-- PAGE=? -->
o diastolic wave becomes more prominent

<!-- PAGE=? -->
o end-diastolic pressure becomes lower

<!-- PAGE=? -->
 MAP in the aorta is just slightly greater than that in the radial artery

<!-- PAGE=? -->
Aortic arch

<!-- PAGE=? -->
Femoral artery

<!-- PAGE=? -->
1 sec

<!-- PAGE=? -->
120

<!-- PAGE=? -->
80

<!-- PAGE=? -->
40

<!-- PAGE=? -->
o Due to little resistance to flow in the major conducting arteries

<!-- PAGE=? -->
Arterial Blood Pressure Gradients

<!-- PAGE=? -->
 In addition to the normal physiologic phenomena that exert subtle influences on the arterial pressure waveform, a number of pathophysiologic conditions cause exaggerated arterial pressure gradients in the body

<!-- PAGE=? -->
o 21% of patients undergoing peripheral vascular surgery had a blood pressure difference between the two arms that exceeded 20 mm Hg (use higher number to better estimate true aortic pressure)

<!-- PAGE=? -->
 Other pathology includes

<!-- PAGE=? -->
o Atherosclerosis

<!-- PAGE=? -->
o arterial dissection

<!-- PAGE=? -->
o embolism

<!-- PAGE=? -->
o sepsis on pressors - difference between femoral and radial my be as high as 50mmHg

<!-- PAGE=? -->
o hypothermia (thermoregulatory vasoconstriction - radial >femoral

<!-- PAGE=? -->
o cardiopulmonary bypass (radial < femoral - persists after CPB for minutes to hours)

<!-- PAGE=? -->
 possible etiologies include

<!-- PAGE=? -->
 vasodilation and decreased resistance in the forearm and hand vasculature during rewarming on bypass

<!-- PAGE=? -->
 radial artery vasoconstriction after aortic cross-clamping

<!-- PAGE=? -->
o decreased arterial elasticity

<!-- PAGE=? -->
Abnormal Arterial Pressure Waveforms

<!-- PAGE=? -->
 Aortic stenosis produces a fixed obstruction to the LV

<!-- PAGE=? -->
o Slow upstroke ( pulsus tardus)

<!-- PAGE=? -->
o A distinct shoulder, anacrotic notch, distorts the pressure upstroke

<!-- PAGE=? -->
o the dicrotic notch may not be discernible

<!-- PAGE=? -->
o small amplitude arterial pressure (pulsus parvus ) - reduced stroke volume

<!-- PAGE=? -->
o results in an overdamped appearing arterial pressure waveform

<!-- PAGE=? -->
 Aortic regurgitation

<!-- PAGE=? -->
o sharp upstroke

<!-- PAGE=? -->
o wide pulse pressure

<!-- PAGE=? -->
o low diastolic pressure (runoff of blood into the LV and periphery during diastole)

<!-- PAGE=? -->
o may have two systolic peaks (bisferiens pulse) - due to large stroke volume

<!-- PAGE=? -->
o first resulting from left ventricular ejection

<!-- PAGE=? -->
o second arising from the periphery as a reflected wave

<!-- PAGE=? -->
 Hypertrophic Cardiomyopathy

<!-- PAGE=? -->
o peculiar bifid shape termed a "spike-and-dome"

<!-- PAGE=? -->
o initial sharp upstroke (rapid LV ejection in early systole,)

<!-- PAGE=? -->
o falls rapidly with dynamic LVOT obstruction during midsystole

<!-- PAGE=? -->
o late systolic reflected wave

<!-- PAGE=? -->
 Observation of arterial waveform patterns over consecutive heartbeats provides an additional set of diagnostic clues

<!-- PAGE=? -->
o Pulsus alternans - alternating beats of larger and smaller pulse pressures

<!-- PAGE=? -->
o sign of severe LV systolic dysfunction

<!-- PAGE=? -->
 advanced aortic stenosis

<!-- PAGE=? -->
 occasionally seen during general anesthesia - presumably secondary to underlying impairment in LV contractility

<!-- PAGE=? -->
 bigeminal rhythmmust be excluded

<!-- PAGE=? -->
o Pulsus paradoxus - exaggerated inspiratory fall in systolic arterial pressure that exceeds 10 to 12 mm Hg during quiet breathing (a small reduction is normal)

<!-- PAGE=? -->
 cardiac tamponade and pericardial constriction (pulse pressure and left ventricular stroke volume decrease during inspiration)

<!-- PAGE=? -->
o forced breathing patterns and exaggerated changes in intrathoracic pressure (pulse pressure remains relatively unchanged)

<!-- PAGE=? -->
 airway obstruction

<!-- PAGE=? -->


<!-- PAGE=? -->
 bronchospasm

<!-- PAGE=? -->
 dyspnea

<!-- PAGE=? -->
Artery of Adamkewicz

<!-- PAGE=? -->
 blood supply to the thoracolumbar cord is derived from the radicular artery of Adamkiewicz

<!-- PAGE=? -->
 This artery has variable origin along the spinal cord

<!-- PAGE=? -->
o joins the ant spinal artery at T9 and T12 in ~75%

<!-- PAGE=? -->
o joins b/w L1 and L2 in 10 - 25%

<!-- PAGE=? -->
o joins b/w T5 - T8 in few

<!-- PAGE=? -->
 Much of the blood flow in the anterior spinal artery depends on the artery of Adamkiewicz.

<!-- PAGE=? -->
Aspiration Pneumonitis

<!-- PAGE=? -->
 Prophylaxis

<!-- PAGE=? -->
o Dec.gastric volume

<!-- PAGE=? -->
 raniditine 150 PO> ranitidine 50 IV> cimetidine 300> pantoprazole 40 IV> NaCitrate 1530cc

<!-- PAGE=? -->
o Dec. gastric pH

<!-- PAGE=? -->
 raniditine PO> pantoprazole IV> cimetidine > ranitidine IV> NaCitrate

<!-- PAGE=? -->
o Metoclopramide

<!-- PAGE=? -->
 dopamine antagonist

<!-- PAGE=? -->
 reduces gastric volume by stimulating gastric emptying without altering pH

<!-- PAGE=? -->
 no clear advantage of maxeran combination with H2 receptor antagonist vs. an H2 receptor antagonist alone

<!-- PAGE=? -->
 may offer an additional protective effect as a result of its ability to increase lower esophageal sphincter tone

<!-- PAGE=? -->
o NPO Guidelines

<!-- PAGE=? -->
 residual gastric volume after 2 hours is less in patients ingesting small amounts of clear fluids than in fasted patients

<!-- PAGE=? -->
 Unless outpatients have delayed gastric emptying or receive a narcotic (opioid) premedicant, the requirement for a 10- to 16-hour fast is not justified

<!-- PAGE=? -->
 adequate hydration before induction of anesthesia is associated with a decreased incidence of postoperative side effects including

<!-- PAGE=? -->
 pain

<!-- PAGE=? -->
 dizziness

<!-- PAGE=? -->
 drowsiness

<!-- PAGE=? -->
 thirst

<!-- PAGE=? -->
 nausea

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Immediate:

<!-- PAGE=? -->
 Trendelenburg position, suction pharynx, decubitus if still vomiting

<!-- PAGE=? -->
 ETT, suction trachea and main bronchi as far as possible before restarting ventilation (with FOB if available)

<!-- PAGE=? -->
 Bronchoalveolar lavage- not advocated because it can push aspirate distally

<!-- PAGE=? -->
 May be required for particulate matter

<!-- PAGE=? -->
 sample aspirate (pH, microbio)

<!-- PAGE=? -->
 NGT to remove additional gastric contents

<!-- PAGE=? -->
Supportive:

<!-- PAGE=? -->
 CPAP/PEEP

<!-- PAGE=? -->
 low VT ventilation

<!-- PAGE=? -->
 bronchodilators

<!-- PAGE=? -->
 fluid and CV support

<!-- PAGE=? -->
 good bronchopulmonary hygiene (early but appropriate extubation to allow coughing)

<!-- PAGE=? -->
Investigations:

<!-- PAGE=? -->
o ABG, CXR, aspirate

<!-- PAGE=? -->
 CXR findings may lag behind clinical signs by 12-24 hrs

<!-- PAGE=? -->
o

<!-- PAGE=? -->
 alveolar infiltrates in dependent portions, RLL most common

<!-- PAGE=? -->
 Disposition

<!-- PAGE=? -->
o monitor at least for 2 hrs- patients who do not develop symptoms within first 2hrs have uncomplicated outcome

<!-- PAGE=? -->
 Other treatments

<!-- PAGE=? -->
o alkaline fluids to neutralize acidic aspirate- acid injury occurs rapidly, alkaline fluids may cause lung injury too

<!-- PAGE=? -->
o No empiric antibiotics- not favoured due to development of resistant microbes, some pulmonary aspirations are chemical pneumonitis without bacterial infection

<!-- PAGE=? -->
 use ABx if clinical signs of infection and base choice on microbiology results

<!-- PAGE=? -->
 possible exception: if fecal aspirate or bowel obstruction- broad spectrum antibiotics

<!-- PAGE=? -->
o No benefit from steroids- no positive impact on course of aspiration injury has been demonstrated

<!-- PAGE=? -->
 Sequelae

<!-- PAGE=? -->
o Respiratory complications

<!-- PAGE=? -->
 laryngospasm, bronchospasm, hypoxemia, pneumonitis, pneumonia, lung abscess, ARDS, Respiratory failure

<!-- PAGE=? -->
ASRA Guidelines for Neuraxial and Peripheral Nerve Blocks

<!-- PAGE=? -->
General

<!-- PAGE=? -->
 Applies to plexus and peripheral techniques, however, may be more restrictive than necessary

<!-- PAGE=? -->
 Beware of concurrent administration of drugs with anticoagulant properties

<!-- PAGE=? -->
 All continuous neuraxial techniques should use medications which allow neurologic monitoring, particularly in high risk pts/situations

<!-- PAGE=? -->
 ASA Closed Claims: The most common symptom of spinal hematoma is paralysis; back pain may or may not be present - therefore spinal hematoma must be considered in the pt presenting with what appears to be -dense motor block‖

<!-- PAGE=? -->
Thrombolytic/Fibrinolytic Therapy

<!-- PAGE=? -->
 Use of thrombolytics pre-op, or if likely intra- or post-op  avoid neuraxial at all costs

<!-- PAGE=? -->
 No consensus on time frames, but puncture of noncompressible vessels is a contraindication to thrombolytic therapy for 10 days

<!-- PAGE=? -->
 If catheter insitu and patient unexpectedly gets thrombolytics (e.g. periop STEMI/PE)

<!-- PAGE=? -->
o Use infusion with minimal sensory/motor block, post-op neuro monitoring q2h

<!-- PAGE=? -->
o Consider fibrinogen level (last to recover) to guide catheter removal

<!-- PAGE=? -->
Unfractionated Heparin (UFH)

<!-- PAGE=? -->
 Subcutaneous (mini-dose) prophylaxis

<!-- PAGE=? -->
o No contraindication to neuraxial techniques

<!-- PAGE=? -->
o Hold AM of surgery and give after placement of block

<!-- PAGE=? -->
o If receiving heparin >4 days, check platelets prior to block/catheter removal (R/O HIT)

<!-- PAGE=? -->
 Intraoperative heparin for vascular surgery

<!-- PAGE=? -->
o Avoid in patients with other coagulopathies

<!-- PAGE=? -->
o Delay heparin 1 h after needle placement

<!-- PAGE=? -->
o Remove catheter 2-4 h after last heparin dose and patient's coagulation status evaluated

<!-- PAGE=? -->
o Re-heparinize 1 h after catheter removal

<!-- PAGE=? -->
o Bloody/difficult tap may increase risk; no data to support mandatory delay, discuss with surgeon

<!-- PAGE=? -->
 Full anticoagulation of cardiac surgery

<!-- PAGE=? -->
o Insufficient data; use infusion with minimal sensory/motor block, post-op neuro monitoring

<!-- PAGE=? -->
Low Molecular Weight Heparin (LMWH)

<!-- PAGE=? -->
 Anti-Xa level not predictive of bleeding risk

<!-- PAGE=? -->
 After bloody tap, avoid LMWH x 24 hours and inform surgeon

<!-- PAGE=? -->
 Preoperative LMWH

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Prophylactic doses: delay needle >10-12 h

<!-- PAGE=? -->
o Enoxaparin 30 mg q12h

<!-- PAGE=? -->
o Dalteparin 5000U q12h

<!-- PAGE=? -->
o Treatment doses: delay needle >24 h

<!-- PAGE=? -->
o Enoxaparin 1 mg/kg q12h

<!-- PAGE=? -->
o Enoxaparin 1.5 mg/kg daily

<!-- PAGE=? -->
o Dalteparin 120 U/kg q12h

<!-- PAGE=? -->
o Dalteparin 200 U/kg daily

<!-- PAGE=? -->
o Tinzaparin 175 U/kg daily

<!-- PAGE=? -->
 Postoperative LMWH (thromboprophylaxis)

<!-- PAGE=? -->
o Once daily dosing

<!-- PAGE=? -->
 First dose 6-8h post-op, second dose >24h after first dose

<!-- PAGE=? -->
 Indwelling neuraxial catheters may be safely maintained

<!-- PAGE=? -->
 Remove catheter >10-12h after last dose of LMWH

<!-- PAGE=? -->
 Subsequent LMWH dosing >2h after catheter removal

<!-- PAGE=? -->
o Twice daily dosing

<!-- PAGE=? -->
 First dose > 24 hours postoperatively, with surgical hemostasis

<!-- PAGE=? -->
 Indwelling neuraxial catheters are NOT safely maintained: remove >2h before starting BID LMWH thromboprophylaxis

<!-- PAGE=? -->
Oral Anticoagulants

<!-- PAGE=? -->
 D/C warfarin 4-5 days prior to procedure and check INR prior to initiation of neuraxial block. INR should be normal before initiating block after chronic warfarin treatment (INR reflects mainly Factor VII, therefore after discontinuation of warfarin, an INR of 1.4 or less may not indicate adequate hemostasis because FII and FX levels may be <40%)

<!-- PAGE=? -->
 Remove epidural catheters when INR <1.5 during initiation of thromboprophylaxis

<!-- PAGE=? -->
 In pts receiving initial dose of warfarin pre-op, check INR if first dose was given > 24h earlier or if second dose has been administered

<!-- PAGE=? -->
 Low-dose warfarin (for thromboprophylaxis): if epidural catheter present, monitor INR daily, use infusion with minimal sensory/motor block, neuro monitoring until 24h post catheter removal

<!-- PAGE=? -->
Antiplatelet Agents

<!-- PAGE=? -->
 NSAIDs (ASA, COX-2) alone do not increase risk of spinal hematoma

<!-- PAGE=? -->
 Discontinue clopidogrel 7 days and ticlopidine 14 days before needle placement

<!-- PAGE=? -->
 Glycoprotein IIb/IIIa Inhibitors: contraindicated within 4 weeks of surgery

<!-- PAGE=? -->
o Eptifibatide (Integrilin) and Tirofiban (Aggrastat): needle placement 4-8 hours after administration

<!-- PAGE=? -->
o Abciximab (ReoPro): needle placement 24-48 hours after administration

<!-- PAGE=? -->
Herbal drugs (Garlic, ginkgo, ginseng)

<!-- PAGE=? -->
 Alone, no increased risk, thus no need to D/C or to withhold neuraxial techniques

<!-- PAGE=? -->
 In combination with other anticoagulants, may increase risk (no data, no accepted test of hemostasis)

<!-- PAGE=? -->
Thrombin Inhibitors (Hirudin derivatives e.g. bivalirudin, argatroban (L-arginine derivative))

<!-- PAGE=? -->
 Inhibit both free and clot-bound thrombin for 1-3h, irreversible, monitor by PTT

<!-- PAGE=? -->
 No data re: risk/safety

<!-- PAGE=? -->
Fondaparinux (Arixtra)

<!-- PAGE=? -->
 Factor Xa inhibition  produce sustained, irreversible antithrombotic effect, T1/2 = 21h Perform a single atraumatic needle pass (!) and avoid indwelling catheters

<!-- PAGE=? -->
Table 6 Neuraxial Anesthesia in the Patient Receiving Thromboprophylaxis

<!-- PAGE=? -->
Abbreviations: NSAIDs nonsteroidal anti-inflammatory drugs; GP Ilblllla, platelet glycoprotein receptor Ilblllla inhibitors; INR, international normalized ratio; LMWH, low molecular weight heparin. Data from the German Society of Anesthesiology and Intensive Care Medicine Consensus guidelines77 and the Spanish Consensus Forum. 76

<!-- PAGE=? -->
ASA

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
Managementof asthma exacerbations: emergency department and hospital-based

<!-- PAGE=? -->
care

<!-- PAGE=? -->
Initial assessment

<!-- PAGE=? -->
heart rale,

<!-- PAGE=? -->
respiratory rale} FEF

<!-- PAGE=? -->
FEVl, oxygen saturalion, and other tests a5 indicated

<!-- PAGE=? -->
FEV1 Dr PEF <50 percent

<!-- PAGE=? -->
Impending or aclual

<!-- PAGE=? -->
Inhaled betaz-agonist by merered

<!-- PAGE=? -->
(severe exacerbation)

<!-- PAGE=? -->
respiralory arrest

<!-- PAGE=? -->
Inhaled high-dose beta?-agonist and

<!-- PAGE=? -->
Intubation and mechanical

<!-- PAGE=? -->
anticholinergic by nebulization

<!-- PAGE=? -->
ventilation wilh 100

<!-- PAGE=? -->
Oxygen to achieve 02 saturation

<!-- PAGE=? -->
every 20 Minutes

<!-- PAGE=? -->
continupusly

<!-- PAGE=? -->
percent 02

<!-- PAGE=? -->
290 percent

<!-- PAGE=? -->
for

<!-- PAGE=? -->
1 hour

<!-- PAGE=? -->
Nebulized betaz-agonist and

<!-- PAGE=? -->
Oral systemic corticnsteroids if

<!-- PAGE=? -->
Oxygen to achieve 02 saturation

<!-- PAGE=? -->
anticholinergic

<!-- PAGE=? -->
290 percent

<!-- PAGE=? -->
Inlravenous corlicosleroid

<!-- PAGE=? -->
patient recently tnnk oral

<!-- PAGE=? -->
Oral systemic corticosteroid

<!-- PAGE=? -->
SYstemic corticosteroid

<!-- PAGE=? -->
Repeat assessment

<!-- PAGE=? -->
Admit to hospital

<!-- PAGE=? -->
Symptoms , physical examination, PEF; 02 saturation, other tests as needed

<!-- PAGE=? -->
intensive carc

<!-- PAGE=? -->
Moderale exacerbalion

<!-- PAGE=? -->
Severe exacerbation

<!-- PAGE=? -->
FEV1 or PEF 50-80 percent predicted/personal best

<!-- PAGE=? -->
FEVI Or PEF <50 percent Predicted personal best

<!-- PAGE=? -->
Physical exam: moderate symptoms

<!-- PAGE=? -->
Physical exam: severe symptoms at rest, accessory

<!-- PAGE=? -->
Inhaled short-acting betaz-agonist every 60

<!-- PAGE=? -->
muscle use, chest relraction

<!-- PAGE=? -->
minutes

<!-- PAGE=? -->
History

<!-- PAGE=? -->
high-risk patient

<!-- PAGE=? -->
Systemic corticosteroid

<!-- PAGE=? -->
No improvement after initial treatment

<!-- PAGE=? -->
Inhaled short-acting betaz-agonist, hcurly or

<!-- PAGE=? -->
improvement

<!-- PAGE=? -->
continuous , an0 Inhaled anticholinergic

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Systemic corticosteroid

<!-- PAGE=? -->
Good response

<!-- PAGE=? -->
Incomplele response

<!-- PAGE=? -->
Poor response

<!-- PAGE=? -->
FEV1

<!-- PAGE=? -->
or PEF 270 percent

<!-- PAGE=? -->
FEVl or PEF 250 percent bul

<!-- PAGE=? -->
Response sustained 60 minutes

<!-- PAGE=? -->
70 percent

<!-- PAGE=? -->
PCO2 242 mmHg

<!-- PAGE=? -->
after last treatment

<!-- PAGE=? -->
Mild-to-moderate symptoms

<!-- PAGE=? -->
Physical exam: symptoms

<!-- PAGE=? -->
No Oistress

<!-- PAGE=? -->
severe, drowsiness, confusior

<!-- PAGE=? -->
Physical exam: normal

<!-- PAGE=? -->
Individualized decision re: hospitalization

<!-- PAGE=? -->
Discharge home

<!-- PAGE=? -->
Admil co hospilal ward

<!-- PAGE=? -->
Admit to hospital intensive care

<!-- PAGE=? -->
Conlinue trealment

<!-- PAGE=? -->
inhalea

<!-- PAGE=? -->
Inhaled betaz-agonist and

<!-- PAGE=? -->
Inhaled belaz-agonist hourly or

<!-- PAGE=? -->
betaz-agonist

<!-- PAGE=? -->
Inhaled anticholinergic

<!-- PAGE=? -->
continuously and inhaled

<!-- PAGE=? -->
Continue course Of Oral systemic

<!-- PAGE=? -->
Systemic {oral or

<!-- PAGE=? -->
anticholinergic

<!-- PAGE=? -->
corticosleroid

<!-- PAGE=? -->
Intravenous) corticosteroid

<!-- PAGE=? -->
Intravenous corticosterold

<!-- PAGE=? -->
Fatient education

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
Review medicine use

<!-- PAGE=? -->
Monitor FEVI or PEF 02

<!-- PAGE=? -->
Possible Inlubation and

<!-- PAGE=? -->
Review initlate action plan

<!-- PAGE=? -->
saturation; pulse

<!-- PAGE=? -->
mechanical ventilation

<!-- PAGE=? -->
Recommend close medical followup

<!-- PAGE=? -->
Discharge home

<!-- PAGE=? -->
Improve

<!-- PAGE=? -->
Continue treatment with inhaled beta-2 agonist

<!-- PAGE=? -->
Continue Course of oral systemic corticosteroid

<!-- PAGE=? -->
Reviev medicine use

<!-- PAGE=? -->
Reviewinitiate action plan

<!-- PAGE=? -->
Recommend close Medical followup

<!-- PAGE=? -->
with

<!-- PAGE=? -->
The causes of wheezing and increased airway pressure include the following: · Kinked endotracheal tube · Solidified secretions or blood · Pulmonary edema · Tension pneumothorax · Aspiration pneumonitis · Pulmonary embolism · Endobronchial intubation · Persistent coughing and straining · Negative pressure expiration

<!-- PAGE=? -->
The physiologic criteria for mechanical ventilation are as follows:

<!-- PAGE=? -->
Mechanics

<!-- PAGE=? -->
 Respiratory rate of >35/min

<!-- PAGE=? -->
 Vital capacity of <15 ml/kg (1L)

<!-- PAGE=? -->
 Inspiratory force <25 cm H2O

<!-- PAGE=? -->
Oxygenation

<!-- PAGE=? -->
 PaO2 <70 mm Hg on mask oxygen

<!-- PAGE=? -->
 P (A-a) DO2 >350 mm Hg on 100% FIO2 or QS/QT 20%

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
 PaCO2 >55 mm Hg, except in patients with chronic hypercarbia

<!-- PAGE=? -->
 VD/VT >0.60

<!-- PAGE=? -->
The trend of values is of utmost importance. The numerical guidelines should not be followed to the exclusion of clinical judgment

<!-- PAGE=? -->
Aminophyline:

<!-- PAGE=? -->
 degree of bronchodilation obtained with aminophylline is not different than that produced by selective beta2-adrenergic agonists

<!-- PAGE=? -->
 recommendation that IV administration of aminophylline be considered only when beta2-adrenergic agonists and corticosteroids produce an inadequate response

<!-- PAGE=? -->
Systemic Corticosteroids

<!-- PAGE=? -->
 Systemic corticosteroids are the most effective anti-inflammatory treatment for asthma

<!-- PAGE=? -->
 onset of action is 4 to 6 hours

<!-- PAGE=? -->
 no difference between IV and PO

<!-- PAGE=? -->
Miscellaneous

<!-- PAGE=? -->
 Thiopental and Desflurane inc. airway resistance while the other volatiles dec. airway resistance

<!-- PAGE=? -->
 Histamine releasing NdMB should be avoided

<!-- PAGE=? -->
o Rocuronium, Pancuronium OK

<!-- PAGE=? -->
 Succinylcholine is well tolerated

<!-- PAGE=? -->
Atlantoaxial Instability

<!-- PAGE=? -->
Miller, COExD

<!-- PAGE=? -->
 Rheumatoid arthritis

<!-- PAGE=? -->
 Down syndrome

<!-- PAGE=? -->
 Ankylosing spondylitis

<!-- PAGE=? -->
 Mucopolysaccharidosis (morquio disease)

<!-- PAGE=? -->
o Hypoplasia of the odontoid and atlantoaxial subluxation, resulting in instability of the cervical spine, may be present

<!-- PAGE=? -->
ATLS

<!-- PAGE=? -->
Primary Survey: (simultaneous assessment and intervention) - rule out -THE PRIMARY SURVEY 6‖

<!-- PAGE=? -->
A -focused examination of airway (usual A/W exam, deformation/crepitus in the external area)

<!-- PAGE=? -->
-if intubation needed:  consider C-spine injury, head injury, possible laryngeal trauma

<!-- PAGE=? -->
B -Oxygen, assistance PRN

<!-- PAGE=? -->
-focused examination of chest to rule-out THE PRIMARY SURVEY 6

<!-- PAGE=? -->
C -vitals, monitors, 2 large-bore IVs

<!-- PAGE=? -->
-focused examination to rule-out THE PRIMARY SURVEY 6

<!-- PAGE=? -->
D -GCS and pupils

<!-- PAGE=? -->
E -expose (protect from hypothermia)

<!-- PAGE=? -->
-THE PRIMARY SURVEY 6‖: (in ABC order)

<!-- PAGE=? -->
Airway Obstruction

<!-- PAGE=? -->
Laryngeal injury or upper thoracic injury (ie: posterior dislocation of sternoclavicular joint) can cause airway obstruction - reduce above dislocation with towel clamp

<!-- PAGE=? -->
Tension Pneumothorax

<!-- PAGE=? -->
Respiratory distress, absent breath sounds, hypotension, JVD, tracheal deviation to contralateral side, hyper-resonant to percussion

<!-- PAGE=? -->
Needle thoracostomy (2nd IC space, mid-clavicular line), then insert a chest tube

<!-- PAGE=? -->
Open Pneumothorax

<!-- PAGE=? -->
Respiratory distress, absent breath sounds, tracheal deviation to ipsilateral side, hyper-resonant to percussion

<!-- PAGE=? -->
3 sided occlusive dressing and set up for chest tube insertion

<!-- PAGE=? -->
Flail Chest

<!-- PAGE=? -->
Respiratory distress, paradoxical chest wall movement with respiration, crepitus on palpation (underlying pulmonary contusion is generally of more clinical significance)

<!-- PAGE=? -->
Assist ventilation PRN / intubate if impending respiratory failure

<!-- PAGE=? -->
Massive Hemothorax

<!-- PAGE=? -->
Respiratory distress, hypotension, absent breath sounds, dullness to percussion

<!-- PAGE=? -->
IV resuscitation with blood / insert chest tube / if drainage > 1500cc initially or 200cc/h over next 2-4 hours, obtain surgical consultation emergently

<!-- PAGE=? -->
Cardiac Tamponade

<!-- PAGE=? -->
Beck's Triad (JVD, hypotension, muffled heart sounds), pulsus paradoxus > 10 mmHg, Kussmaul's sign (may also ask FAST technician to visualize pericardium in 2° survey)

<!-- PAGE=? -->
Pericardial decompression: Sub-xiphoid approach (Seldinger technique):  Aim towards Left shoulder / about 30° to bed / continuous aspiration / watch ECG for ST or T changes

<!-- PAGE=? -->
indicated in patients who do not respond to initial resuscitation efforts (with plausible mechanism of injury)

<!-- PAGE=? -->
If pericardiocentesis is positive, surgical exploration is necessary (leave drain in situ)

<!-- PAGE=? -->
-THE SECONDARY SURVEY 8‖:

<!-- PAGE=? -->
Tracheo-bronchial tree injury

<!-- PAGE=? -->
Hemoptysis, pneumothorax, SC emphysema (also requires high index of suspicion)

<!-- PAGE=? -->
Managed as a broncho-pleural fistula: chest tubes, maintenance of spontaneous ventilation and lung separation

<!-- PAGE=? -->
If combined with vascular injury, this can lead to massive air embolism

<!-- PAGE=? -->
Mediastinal traversing wounds

<!-- PAGE=? -->
Penetrating trauma with entrance and exit wounds which traverse mediastinum

<!-- PAGE=? -->
Requires surgical exploration (anything can be injured, incl. esophagus and spinal cord)

<!-- PAGE=? -->
Simple pneumothorax

<!-- PAGE=? -->
Prior to GA and IPPV, a chest-tube must be inserted to prevent a tension pneumothorax

<!-- PAGE=? -->
Pulmonary contusion

<!-- PAGE=? -->
Diagnosed with index of suspicion, external trauma, and hypoxia (SpO2<90% on R/A)

<!-- PAGE=? -->
Treated with IPPV as necessary, and judicious fluids if blood pressure is OK

<!-- PAGE=? -->
Hemothorax

<!-- PAGE=? -->
Usually diagnosed on CXR if it is not massive

<!-- PAGE=? -->
Placement of chest tube is mandatory to monitor blood loss (see above guidelines for operative intervention) and to prevent loculation or empyema

<!-- PAGE=? -->
Blunt cardiac injury (ie: myocardial contusion)

<!-- PAGE=? -->
Hypotension, dysrhythmias (PVCs, A. fib, RBBB, ST/T changes), WMAs on ECHO

<!-- PAGE=? -->
These patients must be monitored for at least 24 hours (for malignant dysrhythmias)

<!-- PAGE=? -->
Valvular rupture (torrential murmurs) or cardiac rupture (tamponade) are also possible

<!-- PAGE=? -->
If suspicious, obtain an ECHO

<!-- PAGE=? -->
Aortic disruption

<!-- PAGE=? -->
BP differs between arms, widened mediastinum, rightward deviation of trachea or NG

<!-- PAGE=? -->
All survivors have contained hematoma near ligamentum arteriosum

<!-- PAGE=? -->
Angiography usually required (high res. CT may be adequate) - needs surgical repair

<!-- PAGE=? -->
Traumatic diaphragmatic injury

<!-- PAGE=? -->
Bowel sounds in chest or diagnosed on CXR (may need UGI contrast study to diagnose)

<!-- PAGE=? -->
May lead to respiratory failure or strangulation of bowel

<!-- PAGE=? -->
Surgical repair is necessary

<!-- PAGE=? -->
Atrial Fibrillation

<!-- PAGE=? -->
Risk factors for Afib

<!-- PAGE=? -->
 Thoracic surgery

<!-- PAGE=? -->
o Pnuemonectomy highest risk

<!-- PAGE=? -->
 Inc. age > 50-60

<!-- PAGE=? -->
 HTN

<!-- PAGE=? -->
 Ischemia

<!-- PAGE=? -->
 Male

<!-- PAGE=? -->
 CHF

<!-- PAGE=? -->
 Arrythmia

<!-- PAGE=? -->
 PVD

<!-- PAGE=? -->
Risk factors for stroke include

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 rheumatic heart disease

<!-- PAGE=? -->
 diabetes

<!-- PAGE=? -->
 history of previous stroke or transient ischemic attack

<!-- PAGE=? -->
 left atrial enlargement

<!-- PAGE=? -->
 coronary artery disease

<!-- PAGE=? -->
 history of congestive heart failure

<!-- PAGE=? -->
 significant valvular heart disease

<!-- PAGE=? -->
 age greater than 65 years

<!-- PAGE=? -->
TABLE 12. Stroke Risk in Patients With Nonvalvular AF Not Treated With Anticoagulation According to the CHADSz Index

<!-- PAGE=? -->
"The adjusted stroke rate was derived from multivariate analysis assuming no aspirin usage.  Data are from van Walraven WC, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003,163.936~43415; and BF, Waterman Shannon   W, et al. Validation of   clinical   classification Fibrillation . JAMA 2001,285.2864-70.42 Gage AD,

<!-- PAGE=? -->
ischemic attack

<!-- PAGE=? -->
TABLE 11. Risk Factors for Ischemic Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation

<!-- PAGE=? -->
primary   prevention   trials.47 As group;   patients with nonvalvular atrial fibrillation   (AF) about 6-fold   increased risk   of   thromboembolism compared with patients in sinus rhythm. Relative risk refers to comparison of patients with AF to patients without these risk factors: carry

<!-- PAGE=? -->
TIA indicates transient ischemic attack

<!-- PAGE=? -->
TABLE 13. Antithrombotic Therapy for Patients With Atrial Fibrillation

<!-- PAGE=? -->
"If mechanical valve; target international normalized ratio (INR) greater than 2.5. INR indicates international normalized ratio; LV, left ventricular; and TIA   transient ischemic attack

<!-- PAGE=? -->
TABLE 14. Risk-Based Approach to Antithrombotic Therapy in Patients With Atrial Fibrillation

<!-- PAGE=? -->
"Risk factors for thromboembolism include heart failure (HF) , left ventricular (LV) ejection fraction less than 35%, and history of hypertension.

<!-- PAGE=? -->
TEE;   transesophageal echocardiography . ratio; and

<!-- PAGE=? -->
Atrial Kick

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Passive blood flow accounts for approximately 75% of total ventricular filling

<!-- PAGE=? -->
o The atrial kick is responsible for the remainder - 25%

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Atrial contraction establishes final ventricular stroke volume at end-diastole and normally contributes between 15 and 20% of this volume

<!-- PAGE=? -->
Kaplan

<!-- PAGE=? -->
 Normally, greater than 75% of flow occurs during passive portion of diastole

<!-- PAGE=? -->
o Atrial contraction or -atrial kick‖ occurs at the end of diastole just prior to closing of the MV

<!-- PAGE=? -->
ANP

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 ANP is secreated by atrial myocytes in response to local stretching of the atrial wall in cases of hypervolemia (CHF, RF)

<!-- PAGE=? -->
 Direct peripheral vasodilator

<!-- PAGE=? -->
 Suppression of ADH release

<!-- PAGE=? -->
 Inhibition of aldosterone release

<!-- PAGE=? -->
 Renal effects

<!-- PAGE=? -->
increased GFR

<!-- PAGE=? -->
ANP increases the glomerular filtration rate (GFR) without raising renal blood flow, suggesting that it causes both afferent dilatation and efferent constriction natriuresis diuresis

<!-- PAGE=? -->
 No direct inotropic or chronotropic effects

<!-- PAGE=? -->
Autologous Blood Donation

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Advantages

<!-- PAGE=? -->
 Prevents transfusion-transmitted disease

<!-- PAGE=? -->
 Prevents alloimmunization

<!-- PAGE=? -->
o RBC, WBC, Plts, proteins

<!-- PAGE=? -->
 Supplements the blood supply

<!-- PAGE=? -->
Disadvantages

<!-- PAGE=? -->
 Does not affect risk of bacterial contamination

<!-- PAGE=? -->
 Does not affect risk of ABO incompatibility error

<!-- PAGE=? -->
 Is more costly than allogeneic blood

<!-- PAGE=? -->
 Results in wastage of blood not transfused

<!-- PAGE=? -->
 Provides compatible blood for patients with alloantibodies

<!-- PAGE=? -->
 Increased incidence of adverse reactions to autologous donation

<!-- PAGE=? -->
 Prevents some adverse transfusion reactions o Febrile, allergic, GVHD

<!-- PAGE=? -->
 Provides reassurance to patients concerned about blood risks

<!-- PAGE=? -->
 patients who underwent PAD were much less likely than controls to receive allogeneic blood (odds ratio 0.17) but were more likely to undergo any transfusion with autologous and/or allogeneic blood (odds ratio 3.0)

<!-- PAGE=? -->
o due both to a lower hematocrit in patients undergoing PAD and a more liberal transfusion policy with autologous blood

<!-- PAGE=? -->
 the transfusion of autologous blood does NOT eliminate the chance of human error during blood collection, processing, and reinfusion nor the risk of bacterial contamination

<!-- PAGE=? -->
 Effective in reducing exposure to homologous blood

<!-- PAGE=? -->
 Relative Contrainfications

<!-- PAGE=? -->
o Severe aortic stenosis

<!-- PAGE=? -->
o significant CAD or myocardial dysfunction

<!-- PAGE=? -->
o low initial hematocrit

<!-- PAGE=? -->
o low blood volume (weight less than ~110 pounds)

<!-- PAGE=? -->
 Donated at weekly intervals prior to surgery x a max of 4 weeks

<!-- PAGE=? -->
 supplemental Fe and EPO

<!-- PAGE=? -->
Complications associated with autologous blood transfusions include the following:

<!-- PAGE=? -->
 Anemia

<!-- PAGE=? -->
 Preoperative myocardial ischemia from anemia

<!-- PAGE=? -->
 Administration of the wrong unit (1:100,000)

<!-- PAGE=? -->
 Need for more frequent blood transfusions???

<!-- PAGE=? -->
 increased cost

<!-- PAGE=? -->
 Subjects patient to perioperative anemia and increased likelihood of transfusion

<!-- PAGE=? -->
Autonomic Hyperreflexia

<!-- PAGE=? -->
Barash, CoExD, Miller

<!-- PAGE=? -->
 occurs w/ lesions above T4-7

<!-- PAGE=? -->
 develops 2-3wks post injury

<!-- PAGE=? -->
o After recovering from spinal shock

<!-- PAGE=? -->
 Spinal shock lasts 48-72hours (possibly several days)

<!-- PAGE=? -->
 incidence depends on the level of transaction

<!-- PAGE=? -->
o Above T6 85%

<!-- PAGE=? -->
 Dysfunctional splanchnic nerve outflow

<!-- PAGE=? -->
o Uncommon with injury below T10

<!-- PAGE=? -->
o stimulation below level of injury initiates afferents

<!-- PAGE=? -->
 spinal reflex w/ loss of descending inhibitory fibers from brain

<!-- PAGE=? -->
o excessive sympathetic discharge below level of injury

<!-- PAGE=? -->
o relex bradycardia (carotid sinus) and vasodilatation (nasal stuffiness) above the lesion

<!-- PAGE=? -->
 triggers:  hot/cold stimuli; surgery; manipulation/ distention of hollow viscus; labour

<!-- PAGE=? -->
o vasoconstriction + pallor below level of injury

<!-- PAGE=? -->
o vasodilation, flushing, sweating, goose bumps, nasal congestion, bradycardia, hypertension above level of injury

<!-- PAGE=? -->
o also muscle spasm; H/A (incr ICP d/t dilation, risk of hemorrhagic CVA, sz, vision changes, decr LOC); ischemic ECG changes/ arrhythmias; pulm edema/ CVS collapse

<!-- PAGE=? -->
 magnitude of response proportional to magnitude of stimulus

<!-- PAGE=? -->
 magnitude of response increases w/ increased distance from level of injury

<!-- PAGE=? -->
 physiologic changes

<!-- PAGE=? -->
o piloerection above the lesion (alpha 1 - NE)

<!-- PAGE=? -->
o Sweating above the lesion - ? secondary to vagal response

<!-- PAGE=? -->
o Intense vasoconstriction below the lesion with reflex vasodilatation above the lesion

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Stop stimulus

<!-- PAGE=? -->
o Deepend anesthetic

<!-- PAGE=? -->
o Epidural for pain in obs or spinal (better at preventing sacral sparing)

<!-- PAGE=? -->
o NTG or NTP

<!-- PAGE=? -->
Autonomic Neuropathy

<!-- PAGE=? -->
COExD

<!-- PAGE=? -->
 orthostatic hypotension

<!-- PAGE=? -->
 resting tachycardia

<!-- PAGE=? -->
 absent variation in HR with deep breathing

<!-- PAGE=? -->
 gastroparesis , vomiting, diarrhea, abdo distension

<!-- PAGE=? -->
 bladder atony

<!-- PAGE=? -->
 impotence

<!-- PAGE=? -->
 cardiac dysrrythmia

<!-- PAGE=? -->
 altered regulation of breathing

<!-- PAGE=? -->
 asyptomatic hypoglycemia

<!-- PAGE=? -->
 sudden death syndrome

<!-- PAGE=? -->
Miller - Chpt 12

<!-- PAGE=? -->
 autonomic dysfunction occurs with aging and diabetes

<!-- PAGE=? -->
o inc. operative risk

<!-- PAGE=? -->
o five tests of cardiovascular function has been developed to evaluate autonomic function in diabetic patients

<!-- PAGE=? -->
 The tests involving changes in heart rate measure injury to the parasympathetic system

<!-- PAGE=? -->
o precedes changes in the measures of blood pressure that reflect sympathetic injury

<!-- PAGE=? -->
 Early autonomic dysfunction I - a single abnormal or two borderline-abnormal HR tests

<!-- PAGE=? -->
 Definite involvement - two abnormal HR tests

<!-- PAGE=? -->
 Severe dysfunction - abnormalities in blood pressure assessments

<!-- PAGE=? -->
Autonomic Nervous System

<!-- PAGE=? -->
Parasymnpalhetic

<!-- PAGE=? -->
Sympathetic

<!-- PAGE=? -->
Innervatiua

<!-- PAGE=? -->
Pons

<!-- PAGE=? -->
Radial muscles ,

<!-- PAGE=? -->
iris

<!-- PAGE=? -->
Circular mnuscles

<!-- PAGE=? -->
Superior

<!-- PAGE=? -->
Salivary glands

<!-- PAGE=? -->
cerical

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Blcod vessels,

<!-- PAGE=? -->
head and neck

<!-- PAGE=? -->
Salivary glanas

<!-- PAGE=? -->
1

<!-- PAGE=? -->
cervical

<!-- PAGE=? -->
Head

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Stellate

<!-- PAGE=? -->
Cardicaccelerator

<!-- PAGE=? -->
nerve

<!-- PAGE=? -->
Hear

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Aespiralory

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
Iract

<!-- PAGE=? -->
trunk

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Sweat glands

<!-- PAGE=? -->
Stornacn

<!-- PAGE=? -->
Splanchnic

<!-- PAGE=? -->
nerve

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Spleen

<!-- PAGE=? -->
Proximal

<!-- PAGE=? -->
colon

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Celiac

<!-- PAGE=? -->
ganglicn

<!-- PAGE=? -->
Colon

<!-- PAGE=? -->
Kioneys

<!-- PAGE=? -->
Aeclumn

<!-- PAGE=? -->
Ureters

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Bladder

<!-- PAGE=? -->
Distal colon

<!-- PAGE=? -->
Inlerior

<!-- PAGE=? -->
Bladder

<!-- PAGE=? -->
mesenterkc

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Genitals

<!-- PAGE=? -->
Genitals

<!-- PAGE=? -->
Hypogastnic

<!-- PAGE=? -->
Blcod vessel3

<!-- PAGE=? -->
Pclvk

<!-- PAGE=? -->
nere

<!-- PAGE=? -->
lower

<!-- PAGE=? -->
Spinal coru

<!-- PAGE=? -->
AZT

<!-- PAGE=? -->
A&A 2004

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o anemia

<!-- PAGE=? -->
o neutropenia

<!-- PAGE=? -->
o pancytopenia

<!-- PAGE=? -->
o headache

<!-- PAGE=? -->
o neuropathy

<!-- PAGE=? -->
o myopathy

<!-- PAGE=? -->
B

<!-- PAGE=? -->
Back Pain

<!-- PAGE=? -->
 Classification

<!-- PAGE=? -->
o Acute - few days to weeks

<!-- PAGE=? -->
o Subacute - weeks to < 3 months

<!-- PAGE=? -->
o Chronic - more than 3 months

<!-- PAGE=? -->
 85% of patients with isolated low back pain cannot be given a precise pathoanatomical diagnosis

<!-- PAGE=? -->
 pathophysiologic causes/mechanisms of low back pain

<!-- PAGE=? -->
o Mechanical - 97%

<!-- PAGE=? -->
 Strain/sprain - 70%

<!-- PAGE=? -->
 Degenerative process - 10%

<!-- PAGE=? -->
 Herniated disc - 4%

<!-- PAGE=? -->
 Spinal stenosis - 3%

<!-- PAGE=? -->
 Osteoporotic compression # - 4%

<!-- PAGE=? -->
 Traumatic # - <1%

<!-- PAGE=? -->
 Congenital disease - <1%

<!-- PAGE=? -->
 Spondylolysis

<!-- PAGE=? -->
o Non-Mechanical - 1%

<!-- PAGE=? -->
 Neoplasm - 0.7%

<!-- PAGE=? -->
 Infection - 0.01%

<!-- PAGE=? -->
 Inflammatory arthritis - 0.3%

<!-- PAGE=? -->
 Paget's disease

<!-- PAGE=? -->
o Visceral - 2%

<!-- PAGE=? -->
 Pelvic pain

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
 Aortic aneurysm

<!-- PAGE=? -->
 GI - pancreas, gallbladder, ulcer

<!-- PAGE=? -->
 Treatments - Exercise programs that combine aerobic conditioning with specific strengthening of the back and legs seems to be the single best intervention for preventing low back pain

<!-- PAGE=? -->
o nonspecific low back pain

<!-- PAGE=? -->
 Medications

<!-- PAGE=? -->
 NSAIDs - symptom relief

<!-- PAGE=? -->
 Muscle relaxants

<!-- PAGE=? -->
 Physical therapy

<!-- PAGE=? -->
 Spinal manipulation

<!-- PAGE=? -->
 Massage therapy

<!-- PAGE=? -->
 acupuncture

<!-- PAGE=? -->
 Return to normal activities - not rest or increase exercise

<!-- PAGE=? -->
 Not Effective (RCTs): bed rest, back exercises (in acute phase), traction, facet-joint injections, TENS, surgery (unless sciatica or spondylolisthesis)

<!-- PAGE=? -->
o Herniated Intervertebral Disks

<!-- PAGE=? -->
 Non-surgical for at least 1 month (see above), unless neurological compromise

<!-- PAGE=? -->
 Epidural steroid injections - temporary symptomatic relief

<!-- PAGE=? -->
 Improved sensory and flexability at 3 weeks

<!-- PAGE=? -->
 No benefit at 6 months

<!-- PAGE=? -->
 Discectomy - better pain relief over 4y, ? benefit over 10y

<!-- PAGE=? -->
o Spinal Stenosis

<!-- PAGE=? -->
 Exercise programs including cycling and walking

<!-- PAGE=? -->
 Symptoms improve when leaning forward

<!-- PAGE=? -->
 Physical therapy

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 Epidural steroid injections

<!-- PAGE=? -->
 Decompressive laminectomy +/- spinal fusion

<!-- PAGE=? -->
 Symptoms often return after surgery

<!-- PAGE=? -->
o Chronic Low Back Pain

<!-- PAGE=? -->
 Exercise

<!-- PAGE=? -->
 Antidepressants - tricyclic

<!-- PAGE=? -->
 Opioids?

<!-- PAGE=? -->
 Multidisciplinary pain centre referral

<!-- PAGE=? -->
Bradykinins

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 Plasma kinins are the most potent known endogenous vasodilators

<!-- PAGE=? -->
o ten times more potent than histamine in causing vasodilation

<!-- PAGE=? -->
 increase capillary permeability

<!-- PAGE=? -->
 produce edema

<!-- PAGE=? -->
 may increase airway resistance in patients with reactive airway disease, such as bronchial asthma

<!-- PAGE=? -->
 evoke intense burning pain by acting on nerve endings

<!-- PAGE=? -->
 IV injection produces

<!-- PAGE=? -->
o flushing in the blush area

<!-- PAGE=? -->
o dilation in renal, coronary, and cerebral arterioles

<!-- PAGE=? -->
 results in marked decreases in systolic and diastolic blood pressure

<!-- PAGE=? -->
o tend to constrict large veins , leading to increased venous return

<!-- PAGE=? -->
 results in increased cardiac output and heart rate

<!-- PAGE=? -->
 intradermal injections of plasma kinins produce a -wheal and flare‖ response

<!-- PAGE=? -->
Beach chair position

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Position for Shoulder Surgery

<!-- PAGE=? -->
 semirecumbent position is increasing in popularity in parallel with surgical procedures on the shoulder

<!-- PAGE=? -->
o provides anterior and posterior access to the shoulder, with the upper extremity freely mobile.

<!-- PAGE=? -->
 Extreme rotation of the head away from the operative side can result in stretching of the brachial plexus during surgical manipulation

<!-- PAGE=? -->
 Venous air embolism is a risk

<!-- PAGE=? -->
o PFO is contraindication

<!-- PAGE=? -->
 rapid, progressive, and complete airway obstruction , caused by extravasation of the fluid out of the capsule and into the tissues of the neck can occur during arthroscopy

<!-- PAGE=? -->
 reduced CPP related to head-up positioning

<!-- PAGE=? -->
o maintain higher MAP

<!-- PAGE=? -->
 Postion realated hypotension related to venous pooling

<!-- PAGE=? -->
o B-blockers are a risk - sympathectomy

<!-- PAGE=? -->
 Position related traction on neck / non-surgical arm

<!-- PAGE=? -->
Benzodiazepines

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 five principal pharmacologic effects

<!-- PAGE=? -->
o sedation

<!-- PAGE=? -->
o anxio-lysis

<!-- PAGE=? -->
o anticonvulsant actions

<!-- PAGE=? -->
o spinal cord-mediated skeletal muscle relaxation

<!-- PAGE=? -->
o anterograde amnesia

<!-- PAGE=? -->
TABLE 5-1. Comparative pharmacology of benzodiazepines

<!-- PAGE=? -->
 midazolam

<!-- PAGE=? -->
o two to three times as potent as diazepam

<!-- PAGE=? -->
o imidazole ring is open in acidic (stored) pH - water soluble

<!-- PAGE=? -->
 closes at physiologic pH - lipid soluble

<!-- PAGE=? -->
o undergoes extensive hydroxylation by hepatic cytochrome (P-4503A)

<!-- PAGE=? -->
 water-soluble metabolites are excreted in urine as glucuronide conjugates

<!-- PAGE=? -->
 Very little unchanged midazolam is excreted by the kidneys

<!-- PAGE=? -->
o Elimination half-time may be doubled in elderly patients

<!-- PAGE=? -->
 Reflects age-related decreases in hepatic blood flow and enzyme activity

<!-- PAGE=? -->
o No change in elimination in reanl failure

<!-- PAGE=? -->
o produces dose-dependent decreases in ventilation

<!-- PAGE=? -->
 similar to diazepam

<!-- PAGE=? -->
 resp depression is enhanced with opioids

<!-- PAGE=? -->
Beta Blockers

<!-- PAGE=? -->
JAMA 2002

<!-- PAGE=? -->
 RCT's demonstrated that β-blockers reduce cardiac morbidity and mortality associated with silent myocardial ischemia, CHF, and acute MI after noncardiac surgery

<!-- PAGE=? -->
 the prevention of catecholamine-induced arrhythmia, coronary plaque disruption, and other effects of sympathetic stimulation likely play a significant role

<!-- PAGE=? -->
B1 specific: BEAAM, bis, esmo, aceb, atenol, meto

<!-- PAGE=? -->
Renal Failure

<!-- PAGE=? -->
 N ephrons A lter A borption of S ome B eta-blockers = Nadolol, Atenolol, Acetabutalol, Sotolol, Bisoprolol

<!-- PAGE=? -->
Esmolol

<!-- PAGE=? -->
Typical dose of 0.5 mg/kg IV over 60 seconds reaches full therapeutic effect within 5 min

<!-- PAGE=? -->
 Useful for blunting response to intubation (give ~2 min prior)

<!-- PAGE=? -->
 Lidocaine and fentanyl blunt SBP response but NOT heart rate response

<!-- PAGE=? -->
 Infusion 500 mcg/kg/min IV in ECT blunts HR increase but decreaes seizure duration

<!-- PAGE=? -->
 Other situations where it might be useful:

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o PIH

<!-- PAGE=? -->
o Epinephrine or cocaine induced cardiovascular toxicity

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o HOCM

<!-- PAGE=? -->
o TOF

<!-- PAGE=? -->
 Action ceases 10-30 min after administration

<!-- PAGE=? -->
 Half life is 9 min

<!-- PAGE=? -->
 primarily beta-1 selective

<!-- PAGE=? -->
 acidotic solution (pain on injection)

<!-- PAGE=? -->
 lacks intrinsic sympathomimetic activity. [Barash 310, Table 12-23]

<!-- PAGE=? -->
 rapidly degraded by RBC esterases. [Barash 312] to INACTIVE acid metabolite

<!-- PAGE=? -->
 no membrane stabilizing activity

<!-- PAGE=? -->
 Poor lipid solubility limits transfer of esmolol into the CNS or across the placenta (in ewes)

<!-- PAGE=? -->
FIG. 14-6. Maximum percent increases in heart rate (HR) and systolic blood pressure (SBP) after induction of anesthesia and direct laryngoscopy with tracheal intubation in patients pretreated with saline, lidocaine, fentanyl, or esmolol. All three drugs blunt the increase in SBP, but only esmolol is also effective in attenuating the increase in HR.

<!-- PAGE=? -->
Bicarb

<!-- PAGE=? -->
Faust

<!-- PAGE=? -->
 Administration of sodium bicarbonate is not necessary unless the acidosis is severe enough to overcome the compensatory mechanisms

<!-- PAGE=? -->
o pH < 7.1 or 7.2 or plasma bicarbonate concentration of 8mEq/L or less

<!-- PAGE=? -->
 bicarbonate dose is based on the calculated deficit determined from ABG measurements, as well as on the patient's age, weight and clinical condition

<!-- PAGE=? -->
o NaHCO3 (mEq) = 0.3 x wt (kg) x base deficit (mEq/L)

<!-- PAGE=? -->
o NaHCO3 is available for injection in an 8.4% solution (1mEq/mL)

<!-- PAGE=? -->
o Only ½ of the calculated deficit should be replaced at one time

<!-- PAGE=? -->
o Fractional doses may be repeated as necessary

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o chemical cellulitis

<!-- PAGE=? -->
 extravasation of NaHCO3

<!-- PAGE=? -->
o metabolic alkalosis

<!-- PAGE=? -->
 L shift of the oxyhemoglobin dissociation curve and subsequent impairment of oxygen release

<!-- PAGE=? -->
 hyperirritability or tetany

<!-- PAGE=? -->
 bicarbonate induced increase in pH increases the binding of free Ca to albumin

<!-- PAGE=? -->
 decreased free Ca++ concentration

<!-- PAGE=? -->
 Hypokalemia

<!-- PAGE=? -->
 exchange of K+ for H+ in the tissues in an attempt to offset the metabolic alkalosis

<!-- PAGE=? -->
 treatment

<!-- PAGE=? -->
 IV Ca gluconate and/or an acidifying agent such as ammonium chloride

<!-- PAGE=? -->
o during cardiac arres

<!-- PAGE=? -->
 sodium bicarbonate may exacerbate acidosis

<!-- PAGE=? -->
 hypertonic solution may cause a decrease in coronary perfusion pressure

<!-- PAGE=? -->
o HCO3 and H+ do not readily cross the BBB

<!-- PAGE=? -->
 [HCO3] is similar in blood and CSF

<!-- PAGE=? -->
 arterial pH (7.4) is normally higher than CSF pH (7.32)

<!-- PAGE=? -->
 PCO2 is higher in the CSF than in arterial blood (48mmHg versus 40mmHg)

<!-- PAGE=? -->
 Because CO2 crosses the BBB, an increase in PCO2 may result in a paradoxical CSF and tissue acidosis

<!-- PAGE=? -->
o sodium and water retention with edema

<!-- PAGE=? -->
 sodium load

<!-- PAGE=? -->
 hypertonic (1800mOsm/L)

<!-- PAGE=? -->
o Hypovolemia

<!-- PAGE=? -->
 Related to paradoxical acidosis

<!-- PAGE=? -->
 Inc. CO2 production without inc. MV

<!-- PAGE=? -->
BiPap

<!-- PAGE=? -->
Miller, NEJM

<!-- PAGE=? -->
 continuous high-flow positive airway pressure that cycles between a high positive pressure and a lower positive pressure

<!-- PAGE=? -->
 reliably senses patient's breathing efforts even if there are air leaks in the patient's circuit

<!-- PAGE=? -->
 expiratory pressure is equivalent to PEEP and inspiratory pressure is the sum of PEEP and the PS level (eg BIPAP of 12/5 is equiv to PSV of 7 with PEEP of 5)

<!-- PAGE=? -->
 BIPHASIC PAP

<!-- PAGE=? -->
o alternates at fixed intervals between two pressures and allows unrestricted breathing at both pressures

<!-- PAGE=? -->
 An impressive series of studies have demonstrated the efficacy of mechanical ventilation noninvasively applied to patient's mouth or nose to restore respiratory function minimizing the side effects associated with invasive ventilation

<!-- PAGE=? -->
 Potential advantages of avoiding endotracheal intubation include

<!-- PAGE=? -->
o less patient discomfort

<!-- PAGE=? -->
o reduced need for sedation

<!-- PAGE=? -->
o a lower incidence of ventilator-associated pneumonia and sepsis

<!-- PAGE=? -->
 success depends on the correct patient selection

<!-- PAGE=? -->
o patients intubated after failing NIV experience a longer duration of invasive mechanical ventilation and a longer intensive care stay

<!-- PAGE=? -->
 indications

<!-- PAGE=? -->
o acute COPD exacerbation

<!-- PAGE=? -->
o acute cardiogenic pulmonary edema

<!-- PAGE=? -->
o postoperative respiratory failure

<!-- PAGE=? -->
o respiratory failure in immunocompromised patients (e.g., solid organ transplant recipients and bone marrow transplant patients)

<!-- PAGE=? -->
 Relative indications

<!-- PAGE=? -->
o community acquired pneumonia

<!-- PAGE=? -->
 Lower intubation rates and shorter hospital lengths of stay have been reported

<!-- PAGE=? -->
o ARDS

<!-- PAGE=? -->
 In experienced centers 54% of cases avoided intubation

<!-- PAGE=? -->
 CPAP was not associated with better survival nor with a decreased length of hospital stay

<!-- PAGE=? -->
o Weaning

<!-- PAGE=? -->
 inconclusive clinical investigations evidence

<!-- PAGE=? -->
o palliative therapy in patients who are not candidates for invasive ventilation

<!-- PAGE=? -->
 NIV does not prevent reintubation in patients developing acute respiratory failure after extubation

<!-- PAGE=? -->
 No evidence for

<!-- PAGE=? -->
o acute asthma

<!-- PAGE=? -->
o upper airway obstruction

<!-- PAGE=? -->
o trauma

<!-- PAGE=? -->
 Predictors of successful NIV

<!-- PAGE=? -->
o younger age

<!-- PAGE=? -->
o lower APACHE II

<!-- PAGE=? -->
o ability of the patient to cooperate

<!-- PAGE=? -->
o intact dentition

<!-- PAGE=? -->
o technical ability to minimize air leaks

<!-- PAGE=? -->
o moderate hypercapnia (i.e., between 45 and 90 mm Hg)

<!-- PAGE=? -->
o moderate acidosis (i.e., pH between 7.35 and 7.10).

<!-- PAGE=? -->
 should see inmprovement in 30-60min

<!-- PAGE=? -->
o trend toward slower respiratory rates and decrease in Paco2

<!-- PAGE=? -->
 side effects of an oronasal mask

<!-- PAGE=? -->
o air leaks in 80% to 100%

<!-- PAGE=? -->
o facial skin reddening in 20% to 34%

<!-- PAGE=? -->
o mask intolerance in 8% to 32%

<!-- PAGE=? -->
o nasal-mouth dryness

<!-- PAGE=? -->
o nasal congestion in 10% to 20%

<!-- PAGE=? -->
o nasal bridge ulceration in 2% to 31%

<!-- PAGE=? -->
o eye irritation in 16%

<!-- PAGE=? -->
o gastric distention in 8%

<!-- PAGE=? -->
o aspiration in 6%

<!-- PAGE=? -->
BIS

<!-- PAGE=? -->
 When hypnotic drugs such as propofol or isoflurane are used as the primary anesthetic, changes in the BIS index correlate with the probability of a movement response to skin incision.

<!-- PAGE=? -->
 When opioid analgesics are used at higher doses, the correlation to patient movement became much less significant.

<!-- PAGE=? -->
 The dissociative anesthetic ketamine can create excitatory effects on the EEG.

<!-- PAGE=? -->
Blood

<!-- PAGE=? -->
Storage

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 When Stored, a series of biochemical reactions occur that alter the biochemical makeup of blood

<!-- PAGE=? -->
o RBCs metabolize glucose to lactate

<!-- PAGE=? -->
 hydrogen ions accumulate and plasma pH decreases

<!-- PAGE=? -->
o Alteration in the sodium-potassium pump function

<!-- PAGE=? -->
 RBCs lose potassium and gain sodium

<!-- PAGE=? -->
o The osmotic fragility of RBCs increases

<!-- PAGE=? -->
 some cells undergo lysis, resulting in elevated plasma hemoglobin levels

<!-- PAGE=? -->
o progressive decreases in RBC concentrations of ATP and 2,3-diphosphoglycerate (2,3-DPG) .

<!-- PAGE=? -->
Table 47-4. Properties of whole blood and packed red cell concentrates stored in CPDA-1

<!-- PAGE=? -->
Transfusion reactions

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Antibodies associated with acute reactions:

<!-- PAGE=? -->
o Anti-A

<!-- PAGE=? -->
o Anti-B

<!-- PAGE=? -->
o Anti-Kell

<!-- PAGE=? -->
o Anti-Kidd

<!-- PAGE=? -->
o Anti-Duffy

<!-- PAGE=? -->
o Anti-Lewis

<!-- PAGE=? -->
 Type and screen:

<!-- PAGE=? -->
o Typing involves determining the ABO (mixing patient's cells with known sera) and RH status

<!-- PAGE=? -->
o Screening detects antibodies in the patient's sera by using commercially supplied RBCs.

<!-- PAGE=? -->
o Type and screen gives a probability that the transfusion will be compatible of 99.94%

<!-- PAGE=? -->
 Cross matching

<!-- PAGE=? -->
o The likelihood of a compatibility increases only to 99.95%

<!-- PAGE=? -->
o Donor RBC are mixed with the recipient serum

<!-- PAGE=? -->
o The test takes 45 min.

<!-- PAGE=? -->
o 3 phases:

<!-- PAGE=? -->
 immediate phase - Patient's serum + donor's RBC = centrifugation, look for agglutination (detects ABO incompatibilities, and incompatibilities due to Ab's in MN, P and Lewis systems)

<!-- PAGE=? -->
 incubation phase take 30-45 min, detects Ab's in the Rh system and aids in the detection of incomplete Ab's (Ab's that attach to a specific Ag but do not produce

<!-- PAGE=? -->
o BIS index may not have clinical utility when used with ketamine alone or ketamine + other anesthetic drugs.

<!-- PAGE=? -->
agglutination)

<!-- PAGE=? -->
 antiglobulin phase antiglobulin sera is added to the previously incubated tubes from phase 2.  IT identifies the most incomplete Ab's

<!-- PAGE=? -->
 O recipient and A donor is worst ABO incompatibility

<!-- PAGE=? -->
o O recipient and B donor

<!-- PAGE=? -->
o A recipient and AB donor

<!-- PAGE=? -->
o B recipient and AB donor

<!-- PAGE=? -->
 Acute reactions

<!-- PAGE=? -->
o Immune (5):

<!-- PAGE=? -->
 Febrile (WBC)

<!-- PAGE=? -->
 Hemoyltic - intravascular ( ABO )

<!-- PAGE=? -->
 Allergic (mild)

<!-- PAGE=? -->
 Anaphylactic (IgE, IgA deficient)

<!-- PAGE=? -->
 TRALI (donor Ab)

<!-- PAGE=? -->
o Infectious (1):

<!-- PAGE=? -->
 Bacterial (platelets)

<!-- PAGE=? -->
o Other (6):

<!-- PAGE=? -->
 Coagulopathy (dilutional, consumptive)

<!-- PAGE=? -->
 Potassium (hypo & hyper, depending on pH)

<!-- PAGE=? -->
 Hypocalcemia (citrate)

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 Overload

<!-- PAGE=? -->
 Air embolism (rapid transfusion)

<!-- PAGE=? -->
 Delayed reactions:

<!-- PAGE=? -->
o Immune (4):

<!-- PAGE=? -->
Hemolytic - extravascular (alloantigen)

<!-- PAGE=? -->
TA GVHD (immunodeficient, direct donor)

<!-- PAGE=? -->
Immunomodulation

<!-- PAGE=? -->
Post-transfusion purpura

<!-- PAGE=? -->
o Infectious (3):

<!-- PAGE=? -->
Viral infection (CMV>HBV > HCV > HIV, nvCJD, WNV, HTLV1)

<!-- PAGE=? -->
 CMV = <1:100

<!-- PAGE=? -->
 HBV = 1:63,000

<!-- PAGE=? -->
 HCV = 1:103,000

<!-- PAGE=? -->
 HIV =  1: 493,000

<!-- PAGE=? -->
 HTLV-1&II = 1:641,000

<!-- PAGE=? -->
 HAV = no carrier state, infectious period in 2 weeks

<!-- PAGE=? -->
Bacterial

<!-- PAGE=? -->
 Bacterial from platelets = 1: 2 500 - 12 000

<!-- PAGE=? -->
 Bacterial from rBC <1: 1M

<!-- PAGE=? -->
Parasitic (malaria)

<!-- PAGE=? -->
o Other (1):

<!-- PAGE=? -->
Iron overload (thalasemics, telangectasia).

<!-- PAGE=? -->
Immediate Hemolytic transfusion reaction

<!-- PAGE=? -->
 The incidence 1 per 6000-7000 units transfused

<!-- PAGE=? -->
 Physician errors responsible for 20%

<!-- PAGE=? -->
 mortality ranging from 20-60%.

<!-- PAGE=? -->
 The antibodies that fix complement and commonly produce immediate intravascular hemolysis include anti-A, anti-B, anti-Kell, anti-Kidd, anti-Lewis, and anti-Duffy

<!-- PAGE=? -->
 Signs and Symptoms

<!-- PAGE=? -->
o Fever

<!-- PAGE=? -->
o Chills

<!-- PAGE=? -->
o nausea and vomiting

<!-- PAGE=? -->
o diarrhea

<!-- PAGE=? -->
o rigors

<!-- PAGE=? -->
o chest and back pain

<!-- PAGE=? -->
 2nd to intravascular occlusion by agglutinated RBC

<!-- PAGE=? -->
o hemoghobinuria

<!-- PAGE=? -->
o Hypotension and tachycardia is caused by bradykinin

<!-- PAGE=? -->
o Dyspnea and flushing is caused by histamine

<!-- PAGE=? -->
o DIC in 30-50%

<!-- PAGE=? -->
 Under Anesthesia, hypotension, DIC, hemoglobinuria may be the only clues

<!-- PAGE=? -->
 direct antiglobulin (coombs) test is the definitive test for an acute hemolytic transfusion reaction

<!-- PAGE=? -->
o shows that there is antibody attached to transfused donor red blood cells

<!-- PAGE=? -->
Nonhemolytic Transfusion Reaction

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 due to WBC Ag

<!-- PAGE=? -->
 febrile reaction (common = 1-3%)

<!-- PAGE=? -->
o reduced with leukodepleted PRBC

<!-- PAGE=? -->
o due to donor leukocyte antigens

<!-- PAGE=? -->
o use of 40  m filter reduces WBCs infused

<!-- PAGE=? -->
o Rx with Tylenol

<!-- PAGE=? -->
 TRALI

<!-- PAGE=? -->
o Rare (1:10,000)

<!-- PAGE=? -->
o noncardiogenic pulmonary edema

<!-- PAGE=? -->
o donor antileukocyte Ab react with recipient's leukocytes and cause aggregation in pulmonary circulation with endothelial damage

<!-- PAGE=? -->
o treatment is same as ARDS; resolves in 12-48 hours

<!-- PAGE=? -->
 GVHD

<!-- PAGE=? -->
o often in immunocompromised patients (organ tx recepients, nn with one blood exchange tx)

<!-- PAGE=? -->
o mediated through donor lymphocytes

<!-- PAGE=? -->
o WBC filters does not prevent it

<!-- PAGE=? -->
o irradiation of units inactivates lymphocytes

<!-- PAGE=? -->
o presentation: 7-10 days post transfusion

<!-- PAGE=? -->
 fever

<!-- PAGE=? -->
 maculopapular rash

<!-- PAGE=? -->
 epidermolysis bullosa

<!-- PAGE=? -->
 N/V

<!-- PAGE=? -->
 bloody diarrhea

<!-- PAGE=? -->
 liver dysfunction

<!-- PAGE=? -->
o 90% fatal

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
 stop transfusion

<!-- PAGE=? -->
 check identity of patient and labelling on blood bags

<!-- PAGE=? -->
 goals of management:

<!-- PAGE=? -->
 maintenance of BP with fluids

<!-- PAGE=? -->
 prevent RF (fluids, lasix, mannitol)

<!-- PAGE=? -->
 Prevent DIC (?)

<!-- PAGE=? -->
 Labs

<!-- PAGE=? -->
o repeat Cross-match

<!-- PAGE=? -->
o direct antiglobulin  (Coombs) test) - indicative of acute hemolytic reaction

<!-- PAGE=? -->
o plasma, urine Hgb, plasma haptoglobin, bilirubin, - indicative of hemolysis

<!-- PAGE=? -->
o baseline coags(apt, INR, TT, fibrinogen, FDP

<!-- PAGE=? -->
o quick screening test: centrifuge blood in EDTA tube, pink plasma indicates plasma Hbg= hemolysis

<!-- PAGE=? -->
Leukodepletion

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 confirmed benefits of :

<!-- PAGE=? -->
o Reduced CMV transmission

<!-- PAGE=? -->
o Decreased alloimmunization/platelet refractoriness in multiply transfused leukemics

<!-- PAGE=? -->
o Prevention of febrile reactions to RBC transfusions

<!-- PAGE=? -->
o Decreased postoperative infections

<!-- PAGE=? -->
o Shortened hospitalization

<!-- PAGE=? -->
 Unconfirmed Benefits

<!-- PAGE=? -->
o Prevention of transfusion-related HIV acceleration

<!-- PAGE=? -->
o Prevention of transfusion-related increase in tumor recurrence

<!-- PAGE=? -->
Conservations Techniques

<!-- PAGE=? -->
 Preoperative iron supplementation

<!-- PAGE=? -->
 Preoperative EPO

<!-- PAGE=? -->
 Autologous blood donation

<!-- PAGE=? -->
 Cell saver

<!-- PAGE=? -->
 Acute normovolemic hemodilution

<!-- PAGE=? -->
 Antifibrinolytic therapy (eg. TXA)

<!-- PAGE=? -->
 Surgical technique

<!-- PAGE=? -->
o Electrocautery

<!-- PAGE=? -->
o Bone Wax

<!-- PAGE=? -->
Emergency Transfusion

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 first choice is to transfuse type-specific partially crossmatched blood or type-specific uncrossmatched blood

<!-- PAGE=? -->
 if required, and Rh type is unknown, group O RBCs should be administered until there is time to complete ABO and Rh testing

<!-- PAGE=? -->
o Rh-negative blood is preferable, particularly if the patient is a woman of child-bearing age

<!-- PAGE=? -->
 If a non-group O patient receives a large volume of group O red cells, the combined amount of anti-A and/or anti-B present in small amounts in the residual plasma of each PRBC unit may react with the patient's own A, B, or AB red cells and cause some hemolysis

<!-- PAGE=? -->
 A non-group O patient who has received 10-12 units (one blood volume) of group O red cells should not be switched back to his or her own ABO group until testing has been performed to confirm that significant titres of anti-A or anti-B antibodies are not present

<!-- PAGE=? -->
o If whole blood is used, the switch should not be done after 3 or more units

<!-- PAGE=? -->
 Inc. plasma and antibodies

<!-- PAGE=? -->
 When FFP or TP (see later discussion) are administered prior to ABO typing, type AB plasma is preferable, although sometimes not feasible because of limited supply

<!-- PAGE=? -->
BMV

<!-- PAGE=? -->
Predictors of difficult BMV

<!-- PAGE=? -->
 inc. BMI

<!-- PAGE=? -->
o > 26

<!-- PAGE=? -->
 Beard

<!-- PAGE=? -->
 Mallampati III or IV

<!-- PAGE=? -->
 Age > 55

<!-- PAGE=? -->
 Limited jaw protrusion

<!-- PAGE=? -->
 Snoring

<!-- PAGE=? -->
 Lack of Teeth

<!-- PAGE=? -->
Brachial plexus

<!-- PAGE=? -->
Anatomy of the brachial plexus

<!-- PAGE=? -->
Dorsal scapular

<!-- PAGE=? -->
nerve

<!-- PAGE=? -->
rhomboids

<!-- PAGE=? -->
C5

<!-- PAGE=? -->
Suprascapular nerve

<!-- PAGE=? -->
C5 [o

<!-- PAGE=? -->
supraspinatus {abduclion) and

<!-- PAGE=? -->
infaspinatus {ext. rotalion)

<!-- PAGE=? -->
Laleral anterior

<!-- PAGE=? -->
Musculocutaneous

<!-- PAGE=? -->
thoracic nerve

<!-- PAGE=? -->
nerve

<!-- PAGE=? -->
to biceps,

<!-- PAGE=? -->
pecloralis major

<!-- PAGE=? -->
brachialis and

<!-- PAGE=? -->
C7

<!-- PAGE=? -->
coracobrachialis

<!-- PAGE=? -->
(elbow, flexlon;

<!-- PAGE=? -->
C5 {C6 contribullon

<!-- PAGE=? -->
variable)

<!-- PAGE=? -->
Median nerve

<!-- PAGE=? -->
C6

<!-- PAGE=? -->
Long thoracic

<!-- PAGE=? -->
forearm

<!-- PAGE=? -->
nerve Lo

<!-- PAGE=? -->
serralus

<!-- PAGE=? -->
long finger

<!-- PAGE=? -->
Medial anterior

<!-- PAGE=? -->
anterior

<!-- PAGE=? -->
nexors. (1.2)

<!-- PAGE=? -->
(abduction of

<!-- PAGE=? -->
pectoralis major

<!-- PAGE=? -->
scapula)

<!-- PAGE=? -->
muscles (see

<!-- PAGE=? -->
and minor

<!-- PAGE=? -->
mainly C5

<!-- PAGE=? -->
laler;

<!-- PAGE=? -->
shoulder

<!-- PAGE=? -->
abduction

<!-- PAGE=? -->
Thoraco

<!-- PAGE=? -->
dorsal

<!-- PAGE=? -->
Axilary nerve

<!-- PAGE=? -->
nerye

<!-- PAGE=? -->
delloid and [eres

<!-- PAGE=? -->
dorsi

<!-- PAGE=? -->
{shoulder

<!-- PAGE=? -->
minor (shoulder

<!-- PAGE=? -->
abduction)

<!-- PAGE=? -->
abduction}

<!-- PAGE=? -->
Ulnar nerve:

<!-- PAGE=? -->
Cb

<!-- PAGE=? -->
subscapular nerves (2}

<!-- PAGE=? -->
Radial nerve:

<!-- PAGE=? -->
flexionlong finger

<!-- PAGE=? -->
subscapularis and

<!-- PAGE=? -->
C6

<!-- PAGE=? -->
supinators

<!-- PAGE=? -->
fexors (3.4}

<!-- PAGE=? -->
teres Major {shoulder

<!-- PAGE=? -->
(brachiordialis, supinator)

<!-- PAGE=? -->
ulnar

<!-- PAGE=? -->
inversion)

<!-- PAGE=? -->
C5

<!-- PAGE=? -->
Innervaled snall

<!-- PAGE=? -->
and wrist exlensors

<!-- PAGE=? -->
hand muscle (see

<!-- PAGE=? -->
CB

<!-- PAGE=? -->
long finger extensors

<!-- PAGE=? -->
laler;

<!-- PAGE=? -->
upper

<!-- PAGE=? -->
trunk

<!-- PAGE=? -->
trunk

<!-- PAGE=? -->
trunk

<!-- PAGE=? -->
Reproduced with permission from Patten, J. Neurological Differential Diagnosis; 2nd edSpringer-Verlag; Inc. New York 1996.

<!-- PAGE=? -->
Roots Trunks Divisions

<!-- PAGE=? -->
Cords

<!-- PAGE=? -->
Branches

<!-- PAGE=? -->
Frsm C4

<!-- PAGE=? -->
C6

<!-- PAGE=? -->
Sufrascapuar N (C5,6)

<!-- PAGE=? -->
C7

<!-- PAGE=? -->
T

<!-- PAGE=? -->
Arllary N, (C5,6)

<!-- PAGE=? -->
Long Thprazic N

<!-- PAGE=? -->
(C56,7)

<!-- PAGE=? -->
(CBTI)

<!-- PAGE=? -->
2cms

<!-- PAGE=? -->
Biceps

<!-- PAGE=? -->
Brachial

<!-- PAGE=? -->
Artery

<!-- PAGE=? -->
Pectoral m.

<!-- PAGE=? -->
greater

<!-- PAGE=? -->
Median

<!-- PAGE=? -->
Coracobrachial m.

<!-- PAGE=? -->
Norve

<!-- PAGE=? -->
Biceps m

<!-- PAGE=? -->
Musculocutaneous n

<!-- PAGE=? -->
Radial Nerve

<!-- PAGE=? -->
Biceps

<!-- PAGE=? -->
Tendon

<!-- PAGE=? -->
Intercondylar

<!-- PAGE=? -->
Line

<!-- PAGE=? -->
Axillary a.

<!-- PAGE=? -->
Medlan n.

<!-- PAGE=? -->
Ulnar n.

<!-- PAGE=? -->
Radial n.

<!-- PAGE=? -->
Superior

<!-- PAGE=? -->
Lateral

<!-- PAGE=? -->
Poslerior

<!-- PAGE=? -->
Medai

<!-- PAGE=? -->
Brachial Plexus Block

<!-- PAGE=? -->
Miller, P&P

<!-- PAGE=? -->
 local anesthetic solutions diffuse from the outer surface (mantle) toward the center (core) of the nerve

<!-- PAGE=? -->
o mantle of the mixed nerve are anesthetized first

<!-- PAGE=? -->
 mantle fibers usually are distributed to more proximal anatomical structures

<!-- PAGE=? -->
o distal structures innervated by nerve fibers near the core of the nerve

<!-- PAGE=? -->
 this results in the initial development of anesthesia proximally, with subsequent distal spread as local anesthetic solution diffuses to reach more central core nerve fibers

<!-- PAGE=? -->
 Conversely, recovery of sensation occurs in a reverse direction

<!-- PAGE=? -->
o sensation returns initially to the proximal and last to the distal parts of the limb

<!-- PAGE=? -->
Axillary block

<!-- PAGE=? -->
 The neurovascular bundle is multicompartmental

<!-- PAGE=? -->
 The median nerve is found superior to the artery

<!-- PAGE=? -->
 the ulnar nerve is inferior

<!-- PAGE=? -->
 the radial nerve is posterior and somewhat lateral.

<!-- PAGE=? -->
 the musculocutaneous nerve has already left the sheath and lies in the substance of the coracobrachialis muscle.

<!-- PAGE=? -->
 (Cousins) Radial nerve is lateral to biceps tendon at elbow.

<!-- PAGE=? -->
Brain Death

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 irreversible cessation of all functions of the entire brain, including the brainstem

<!-- PAGE=? -->
Transverse

<!-- PAGE=? -->
Unarnerve

<!-- PAGE=? -->
AV

<!-- PAGE=? -->
H

<!-- PAGE=? -->
Nenerves

<!-- PAGE=? -->
AA

<!-- PAGE=? -->
Reglonal

<!-- PAGE=? -->
Anesthesia

<!-- PAGE=? -->
Vlew

<!-- PAGE=? -->
o no treatment may be reasonably expected to change the condition

<!-- PAGE=? -->
o responsible disorder may be thought of as structural

<!-- PAGE=? -->
 does not result from functional and potentially reversible causes

<!-- PAGE=? -->
 drug intoxication

<!-- PAGE=? -->
 hypothermia

<!-- PAGE=? -->
 metabolic or endocrine disturbance

<!-- PAGE=? -->
 practically determined by

<!-- PAGE=? -->
o loss of consciousness

<!-- PAGE=? -->
o loss of brainstem responses

<!-- PAGE=? -->
o apnea

<!-- PAGE=? -->
o confirmatory tests include

<!-- PAGE=? -->
 lack of electroencephalographic activity

<!-- PAGE=? -->
 traditional or isotope angiography

<!-- PAGE=? -->
 Brainstem Responses

<!-- PAGE=? -->
o light reflex

<!-- PAGE=? -->
o oculocephalic reflex

<!-- PAGE=? -->
o caloric (vestibular) test

<!-- PAGE=? -->
o corneal reflex

<!-- PAGE=? -->
o jaw reflex

<!-- PAGE=? -->
o pharyngeal reflex

<!-- PAGE=? -->
o cough reflex

<!-- PAGE=? -->
 Preservation of the cough reflex indicates preservation of the brainstem respiratory center

<!-- PAGE=? -->
 None of the brainstem reflexes (except those of the respiratory centers) need to be present for the organism to be said to be alive, but they are tested to confirm preservation of brainstem functions

<!-- PAGE=? -->
 motor responses of the limbs or facial muscles to painful supraorbital pressure should be absent

<!-- PAGE=? -->
o Motor responses (ie the Lazarus sign) may occur spontaneously during apnea testing and are considered to have a spinal origin

<!-- PAGE=? -->
 often observed during hypoxic or hypotensive episodes

<!-- PAGE=? -->
o Other spontaneous movements from spinal origin are observed

<!-- PAGE=? -->
 The CNS structures essential to the definition of brain death do not include the spinal cord

<!-- PAGE=? -->
o Histologic studies have shown that the spinal cord is the best preserved part of the CNS in cases of brain death

<!-- PAGE=? -->
o Spontaneous and reflex movements are found in brain-dead patients

<!-- PAGE=? -->
 observed during the apnea test, while the body is being prepared for transport, at the time of a skin incision for the retrieval of organs, or in synchrony with the respirations produced by the mechanical ventilation

<!-- PAGE=? -->
 a patient may move in response to noxious stimulation and that full curarization is required for surgical procedures involving brain death

<!-- PAGE=? -->
 brain death is associated with MOF

<!-- PAGE=? -->
o Cardiovascular

<!-- PAGE=? -->
 Physiology (Sequence of brain death hemodynamics)

<!-- PAGE=? -->
Ischemic cerebrum → vagal activation (slow HR, low MAP, CO)

<!-- PAGE=? -->
Progression to midbrain → vagal and sympathetic activation (Cushing phenomenon - slow HR, HTN)

<!-- PAGE=? -->
Entire brainstem ischemic → no more vagal outflow, unopposed sympathetic → called autonomic storm → tachycardia, HTN (which may cause end organ ischemia), transient ususall , tx with esmolol

<!-- PAGE=? -->
 Adrenergic surges can cause ischemia and ischemia-reperfusion injury

<!-- PAGE=? -->
 May get Herniation of brain stem → sudden cessation of autonomic outflow with profound hypotension

<!-- PAGE=? -->
o After a few days of disconnection from supraspinal structures, spinal cord automaticity returns BP to normal (cardioaccelorator and  vasomotor neurons still intact)

<!-- PAGE=? -->
o Development of heightened spinal cord reflexes → HTN with bladder distension and surgical stimulation (similar to autonomic hyperreflexia)

<!-- PAGE=? -->
 The initial period of intense autonomic activity is followed by loss of sympathetic tone and a massive reduction in SVR exacerbated by hemorrhage, massive diuresis from DI, or dehydration therapy for increased ICP

<!-- PAGE=? -->
 ECG abnormalities are common with brain stem death or secondary to increased ICP

<!-- PAGE=? -->
 ST segment and T wave changes

<!-- PAGE=? -->
 Atrial and ventricular arrhythmias

<!-- PAGE=? -->
 Conduction abnormalities

<!-- PAGE=? -->
 Bradycardia: resistant to atropine but responds to direct acting chronotropic agents (isoproterenol, dopamine)

<!-- PAGE=? -->
 Treatment:

<!-- PAGE=? -->
 Maintain multi-end organ perfusion while protecting heart

<!-- PAGE=? -->
 Esmolol for sympathetic over activity as it is usually short lived

<!-- PAGE=? -->
 Invasive cardiovascular monitoring

<!-- PAGE=? -->
o MAP of 60 mmHg with CVP of 5 to 10 mmHg

<!-- PAGE=? -->
 Restoration of intravascular volume with colloid and crystalloid

<!-- PAGE=? -->
 Vasopressin for DI and to maintain afterload, reduces inotrope requirements

<!-- PAGE=? -->
 Can also consider dopamine over phenylephrine for preserved splanchnic perfusion

<!-- PAGE=? -->
o Pulmonary

<!-- PAGE=? -->
 Pulmonary dysfunction is common after brain stem death

<!-- PAGE=? -->
 Pneumonia (VAP), aspiration, neurogenic pulmonary edema , and pulmonary trauma, and secondary to over-zealous fluid resuscitation

<!-- PAGE=? -->
 Elevation of left atrial pressure, systemic hypertension, and pulmonary vasoconstriction cause increased pressure in the pulmonary capillary bed and endothelial damage

<!-- PAGE=? -->
 After brain stem death, high FiO2 and PEEP are often required to maintain adequate oxygenation

<!-- PAGE=? -->
 Maintain oxygenation against risks of oxygen toxicity and pulmonary barotrauma in potentially transplantable lungs

<!-- PAGE=? -->
 Management:

<!-- PAGE=? -->
 Use of Lung protective ventilation strategies :

<!-- PAGE=? -->
o Tidal volumes of 6 to 8 mL/kg

<!-- PAGE=? -->
o Optimize PEEP (limit to 10 cmH2O if lungs are to be harvested)

<!-- PAGE=? -->
o If the lungs are to be considered for transplantation, FiO2 should be as low as necessary to achieve a PaO2 > 60 mmHg

<!-- PAGE=? -->
o PAP<30mmhg

<!-- PAGE=? -->
o HOB 45 degrees

<!-- PAGE=? -->
o Endocrine

<!-- PAGE=? -->
 After brain stem death comes hypothalamic and  anterior and posterior pituitary failure

<!-- PAGE=? -->
 Early depletion of ADH and development of DI in almost 80% of brain stem dead organ donors

<!-- PAGE=? -->
 A rapid decline in free tri-iodothyronine (T3) is seen after brain stem death as a result of impaired TSH secretion and peripheral conversion of tetra-iodothyronine (T4)

<!-- PAGE=? -->
 Decreased insulin → anaerobic metabolism, acidosis, and hyperglycemia

<!-- PAGE=? -->
 The decrease in plasma cortisol may be associated with a decrease in the release of its stimulating factor adrenocorticotropic hormone ( ACTH ) from the anterior lobe of the pituitary gland

<!-- PAGE=? -->
 Temperature: after brain death the patient becomes poikilothermic (unable to alter temperature) and body temperature tends to be hypothermic

<!-- PAGE=? -->
 Management:

<!-- PAGE=? -->
 Vasopressi n (1 U bolus followed by 2.4 U/h)

<!-- PAGE=? -->
o Vasopressin infusion (< 2.5 U/h) may be useful as it counteracts volume loss from DI and has been shown to reduce inotrope requirements

<!-- PAGE=? -->
o Excessive rates of infusion may lead to heart and kidney problems

<!-- PAGE=? -->
 Methylprednisolone IV (15 mg/kg q24h)

<!-- PAGE=? -->
 Tetra -iodothyronine / T4 (20 mcg bolus followed by infusion of 10 mcg/hour)

<!-- PAGE=? -->
o Tri-iodothyronine / T3 used as well

<!-- PAGE=? -->
 Insulin

<!-- PAGE=? -->
 In severe cases of DI, intermittent treatment with the synthetic analog 1-D-amino8-D-arginine vasopressin (DDAVP) may also be required

<!-- PAGE=? -->
 Warming blanket

<!-- PAGE=? -->
o Hematological

<!-- PAGE=? -->
 Ischemic or necrotic brain releases tissue thromboplastin that activates coagulation pathways in association with the disruption of endothelial surfaces

<!-- PAGE=? -->
 DIC o ccurs in up to 28% of brain stem dead organ donors

<!-- PAGE=? -->
o After Harvest

<!-- PAGE=? -->
 Solid organ preservation is achieved using a wide variety of preservation fluids (EuroCollins, University of Wisconsin / Belzer's) depending on the centre and the type of organ

<!-- PAGE=? -->
 Most are stored at 4°C without continuous perfusion after the initial flush

<!-- PAGE=? -->
 Cold preservation time varies between organ types → kidney can be kept for 1-2 days, heart only hours

<!-- PAGE=? -->
 Damage to organs may occur during one of three distinct periods:

<!-- PAGE=? -->
 During ex vivo cold storage and transport

<!-- PAGE=? -->
 During implantation and rewarming

<!-- PAGE=? -->
 After reperfusion and reintroduction of oxygen

<!-- PAGE=? -->
Diagnostic criteria for the clinical diagnosis of brain death

<!-- PAGE=? -->
 Prerequisites.  Brain death is the absence of clinical brain function when the proximate cause is known and demonstrably irreversible.

<!-- PAGE=? -->
clinical or neuroimaging evidence of an acute CNS catastrophe that is compatible with the clinical diagnosis of brain death

<!-- PAGE=? -->
exclusion of complicating medical conditions that may confound clinical assessment (no severe electrolyte, acid-base or endocrine disturbance)

<!-- PAGE=? -->
no drug intoxication or poisoning

<!-- PAGE=? -->
core temp > or = 32 deg C

<!-- PAGE=? -->
 the three cardinal findings in brain death are coma or unresponsiveness, absence of brainstem reflexes and apnea

<!-- PAGE=? -->
coma or unresponsiveness - no cerebral motor response to pain in all extremities (nail bed pressure and supraorbital pressure)

<!-- PAGE=? -->
absence of brainstem reflexes

<!-- PAGE=? -->
 pupils

<!-- PAGE=? -->
no response to bright light

<!-- PAGE=? -->
size: midposition (4 mm) to dilated (9mm)

<!-- PAGE=? -->
 Ocular movement

<!-- PAGE=? -->
No oculocephalic reflex (testing only when no fracture or instability f the C spine is apparent)

<!-- PAGE=? -->
No deviation of eyes to irrigation in each ear with 50 ml of cold water (allow 1 minute after injection and at least 5 min between testing on each side)

<!-- PAGE=? -->
 Facial sensation and facial motor response

<!-- PAGE=? -->
No corneal reflex to touch with a throat swab

<!-- PAGE=? -->
No jaw reflex

<!-- PAGE=? -->
No grimacing to deep pressure on nail bed, supraorbital ridge or temporomandibular joint

<!-- PAGE=? -->
 Pharyngeal and tracheal reflexes

<!-- PAGE=? -->
No response after stimulation of the posterior pharynx with tongue blade

<!-- PAGE=? -->
No cough response to bronchial suctioning

<!-- PAGE=? -->
apnea testing performed as follows:

<!-- PAGE=? -->
 prereqs

<!-- PAGE=? -->
core temp > = 36.5 deg C

<!-- PAGE=? -->
SPB > or = 90

<!-- PAGE=? -->
Euvolemia (or positive fluid balance in the previous 6 hrs)

<!-- PAGE=? -->
Normal PaCO2 or arterial PCO2 > or = 40 mmHg

<!-- PAGE=? -->
Normal PaO2 or preoxygenate to obtain PaO2 > = 200 mmHg

<!-- PAGE=? -->
 connect a pulse oximeter and disconnect the ventilator

<!-- PAGE=? -->
 deliver 100% O2 6 L/min into the trachea.  Option, place a cannula at the level of the carina

<!-- PAGE=? -->
 look closely for respiratory movements (abdominal or chest excursions that produce adequate tidal volumes)

<!-- PAGE=? -->
 measure arterial PaO2, PCO2 and pH after 8 min and reconnect the ventilator

<!-- PAGE=? -->
 if resp movements are absent and arterial PCO2 > or = 60 mm Hg or 20 mmHg increase over baseline, the apnea test supports the dx of brain death

<!-- PAGE=? -->
 if resp movements are observed, the test should be repeated

<!-- PAGE=? -->
 connect the ventilator if, during testing, the SBP becomes < or = 90 mmHg or the pulse ox indicates significant oxygen destauration and cardiac arrhythmias are present.  Draw an arterial blood sample.  If PCO2 is > or = 60 mmHg or increase of more than or = 20 mmHg from baseline, the apnea test is positive (supports diagnosis of brain death).  If not, the result is indeterminate and an additional confirmatory test can be considered

<!-- PAGE=? -->
 Criteria For Brain Death (Canadian Critical Care 2003 conference)

<!-- PAGE=? -->
o Minimum of 2 physicians, not involved in transplant

<!-- PAGE=? -->
o Time of death is time of initial declaration of brain death

<!-- PAGE=? -->
o Children > 1 yr

<!-- PAGE=? -->
 NDD as per standards with a second physician performing the NDD

<!-- PAGE=? -->
o Infants <1 yr

<!-- PAGE=? -->
 Minimum clinical criteria include the oculocephalic reflex, as this test may be more reliable that the vestibulo-ocular reflex in infants due to the unique anatomy of the external auditory canal

<!-- PAGE=? -->
 Repeat exam at different time by another qualified physician, regardless of brain injury

<!-- PAGE=? -->
o Term Neonate <30 days

<!-- PAGE=? -->
 NDD is a clinical diagnosis, i.e., clinical criteria have primacy

<!-- PAGE=? -->
 Minimum clinical criteria include absence of oculocephalic reflex and suck reflex

<!-- PAGE=? -->
 Minimum temperature must be a core temperature 36°C

<!-- PAGE=? -->
 Minimum time from birth to first determination is 48 h

<!-- PAGE=? -->
 Two determinations are required, with a minimum interval of 24 h between examinations

<!-- PAGE=? -->
 Ancillary testing, as defined by demonstration of the absence of intracerebral blood flow, should be performed when any of the minimum clinical criteria cannot be established or confounding factors remain unresolved

<!-- PAGE=? -->
Recommendation AI: Minimum Clinical Criteria for NDD

<!-- PAGE=? -->
We recommend the use of the following minimun clinical criteria as a Canadian medical standard for neurological determination of death:

<!-- PAGE=? -->
Established etiology capable of causing neurological death in the absence of reversible conditions capable of mimicking neurological death

<!-- PAGE=? -->
b Deep unresponsive coma

<!-- PAGE=? -->
Absent brainstem reflexes as defined by absent gag and cough reflexes and the bilateralabsence of

<!-- PAGE=? -->
motor responses, excluding spinal reflexes

<!-- PAGE=? -->
corneal responses

<!-- PAGE=? -->
pupillary responses to light with pupils at mid-size or greater and

<!-- PAGE=? -->
vestibulo-ocular responses

<!-- PAGE=? -->
d Absent respiratory effort based on the apnea test

<!-- PAGE=? -->
Absent confounding factors.

<!-- PAGE=? -->
Recommendation A2:   Confounding Factors

<!-- PAGE=? -->
We recommend that; at the time of assessment for NDD; the following confounding factors preclude the clinical diagnosis:

<!-- PAGE=? -->
Unresuscitated shock

<!-- PAGE=? -->
Hypothermia (core temperature degrees Celsius) <34

<!-- PAGE=? -->
Severe metabolic disorders of causing a potentially reversible coma Severe metabolic abnormalities including gucose, electrolytes (including phosphate; calcium and magnesium), inborn errors of metabolism; liver or renal dysfunction may play 1 role in the patients clinical presentation If the primary etiology does not explain the clinical picture; and if in the treating physician's judgment the metabolic abnormality may play a role; it should be corrected. capable fully

<!-- PAGE=? -->
Peripheral muscle   dysfunction Or neuromuscular   blockade  potentially accounting for unresponsiveness

<!-- PAGE=? -->
Clinically significant intoxications alcohol, barbiturates; sedatives, notics); therapeutic levels and /or therapeutic dosing of anticonvulsants, sedatives and analgesics do not preclude the diagnosis. drug (e.g hsP -

<!-- PAGE=? -->
Recommendation A3: Minimum Temperature

<!-- PAGE=? -->
Tle recommended minimum temperature that should be to the minimun clinical criteria for NDD (Recommendation A1) is 34 degrees Celsius defined by core temperature. applied

<!-- PAGE=? -->
Recommendation A4:  Apnea Testing

<!-- PAGE=? -->
We recommend that the thresholds at the completion of the apnea test should be 7=60 These thresholds must be documented by arterial blood gas measurement. PaCOz 7.28.

<!-- PAGE=? -->
Io correctly interpret an apnea test, the certifying physician must continuously observe the patient for respiratory effort throughout the performance of the test.

<!-- PAGE=? -->
Recommendation A5: Examination Interval

<!-- PAGE=? -->
We recommend that when a second determination is performed, there should be no fixed examination interval, regardless of the primary mechanism of the brain injury

<!-- PAGE=? -->
Recommendation A6:  Ancillary Tests

<!-- PAGE=? -->
We recommend that an ancillary test be performed when it is impossible to complete the minimum clinical criteria as defined in Recommendation A1. At 1 minimun; twvo particular clinical criteria must be met prior to performing any ancillary tests:

<!-- PAGE=? -->
An established etiology capable of causing neurological death in the absence of reversible conditions capable of mimicking neurological death and

<!-- PAGE=? -->
b

<!-- PAGE=? -->
We recommend that demonstration of the global absence of intracranial blood flow be considered as the standard for determination of neurological death by ancillary testing

<!-- PAGE=? -->
Recommendation A7: Concept

<!-- PAGE=? -->
We recommend that neurologically determined death be defined as the irreversible loss of the capacity for consciousness conbined with the irreversible loss of all brainstemn functions (as defined in Recommendation A1), including the capacity to breathe.

<!-- PAGE=? -->
Recommendation A8: Physicians Declaring Neurological Death

<!-- PAGE=? -->
We recommend that the minimun level of physician qualification required to perform NDD is:

<!-- PAGE=? -->
Full and current licensure for independent medical practice in the relevant Canadian jurisdiction and

<!-- PAGE=? -->
Slill and knowledge in the management of patients with severe brain injury and in the NDD).

<!-- PAGE=? -->
Recommendation A9: Age-Related Criteria

<!-- PAGE=? -->
We recommend that the Forum Recommendations (A1 to A8) for NDI should be to infants, children and adolescents with the following qualifications: applied

<!-- PAGE=? -->
NDL Recommendations Specific to Children and Adolescents:

<!-- PAGE=? -->
1 All children age>=1 year (corrected for gestational age) should have NDD as per stan dards established at the Foru. Asecond physician performing the NDDis required by law for the purposes of post-mortem transplantation; with no fixed interval of time required, regardless of the primary mechanism of the brain injuy. (Recommendation 45)

<!-- PAGE=? -->
Ihe minimum level of physician qualifications should be understood as specialists with skill and knowledge in the management of children and/or adolescents with severe brain injury and NDD. (Recommendation 48)

<!-- PAGE=? -->
NDD Recommendations Specific to Infants:

<!-- PAGE=? -->
Infants >= 30 and <1 year (corrected for gestational age) days

<!-- PAGE=? -->
more reliable than the vestibulo-ocular reflex in infants due to the anatomy of the external auditory canal. (Recommendation A1) unique

<!-- PAGE=? -->
b Given less widespread   experience with NDD for this age range, repeat exanination at a different in time is recommended to ensure independent confirmation by another qualified physician, regardless of the primary mechanism of the brain injury. It is prudent to have an independent examination because of the lack of collective experience and research on brain death in this age group. Ihere is no recommended minimun time interval between determinations. Should uncertainty or confounding issues arise that cannot be resolved; the time interval may be extended according to physician judgment; Or an ancillary test demonstrating absence of intracranial blood flow may be used. point

<!-- PAGE=? -->
Ihe minimum level of physician qualifications should be understood as specialists with skill and knowledge in the management of infants with severe brain injuy and NDI). (Recommendation 48)

<!-- PAGE=? -->
Budd-Chiari Syndrome

<!-- PAGE=? -->
Occlusion of hepatic vein or inferior vena cava resulting in rapidly progressive liver failure secondary to congestion.

<!-- PAGE=? -->
Classic triad

<!-- PAGE=? -->
abdominal pain

<!-- PAGE=? -->
hepatomegally

<!-- PAGE=? -->
ascites

<!-- PAGE=? -->
LIVER BLOOD FLOW

<!-- PAGE=? -->
INFERIOR

<!-- PAGE=? -->
AORTA

<!-- PAGE=? -->
HEART

<!-- PAGE=? -->
HEPA TIC

<!-- PAGE=? -->
HEPAIIC

<!-- PAGE=? -->
ARIERY

<!-- PAGE=? -->
LIVER

<!-- PAGE=? -->
FORTAL

<!-- PAGE=? -->
DIGESIIVE IRACT

<!-- PAGE=? -->
SMALL

<!-- PAGE=? -->
Buerger's disease (thromboangiitis obliterans)

<!-- PAGE=? -->
Coexisting 4 th , pg 163

<!-- PAGE=? -->
 An inflammatory vasculitis leading to occlusion of small and middle-sized arteries and veins in the extremities

<!-- PAGE=? -->
 Most prevalent in men from asia, eastern Europe and Israel

<!-- PAGE=? -->
 Onset typically < 45 yo

<!-- PAGE=? -->
 Tobacco use predisposes

<!-- PAGE=? -->
 Diagnosis made by biopsy

<!-- PAGE=? -->
Signs and symptoms:

<!-- PAGE=? -->
 forearm, calf or foot claudication

<!-- PAGE=? -->
 rest pain in hands and feet

<!-- PAGE=? -->
 ulcerations

<!-- PAGE=? -->
 skin nerosis

<!-- PAGE=? -->
 Raynaud's phenomenon

<!-- PAGE=? -->
 Cold exacerbates the disease process

<!-- PAGE=? -->
 Vasospasm, digital artery obstruction

<!-- PAGE=? -->
 Migratory superficial vein thrombosis develops in about 40%

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
 smoking cessation

<!-- PAGE=? -->
 surgical revascularization usually not an option

<!-- PAGE=? -->
 no proven effective pharmacologic thereapy including anticoagulants, steroids and vasodilators

<!-- PAGE=? -->
Management of anesthesia

<!-- PAGE=? -->
 avoid exacerbating:

<!-- PAGE=? -->
o careful positioning

<!-- PAGE=? -->
o keep patient warm

<!-- PAGE=? -->
o theoretical concern to palce a catheter in an artery

<!-- PAGE=? -->
 considerations of smoking

<!-- PAGE=? -->
Burns

<!-- PAGE=? -->
Parkland Formula

<!-- PAGE=? -->
 4ml/kg x %burn

<!-- PAGE=? -->
 ½ over fist 8 hrs, remainder over 16hrs

<!-- PAGE=? -->
Phases of Recovery:

<!-- PAGE=? -->
Resucitative (24 - 48 H)

<!-- PAGE=? -->
 Hyperadrenergic (iSVR, iHR, poor response to catecholamines)

<!-- PAGE=? -->
o CO 2x normal

<!-- PAGE=? -->
o Contractility may dec. due to circulating mediators

<!-- PAGE=? -->
 Hypermetabolic (inc. VO2, inc. PaCO2)

<!-- PAGE=? -->
 Hypovolemic (capillary leak)

<!-- PAGE=? -->
 dGFR (increased after volume replacement)

<!-- PAGE=? -->
 Poor temperature control (hypo & hyperthermia)

<!-- PAGE=? -->
 High opiod requirements

<!-- PAGE=? -->
 Succinylcholine has been safely used within the first 24 hours (Miller)

<!-- PAGE=? -->
Convalescent (few weeks)

<!-- PAGE=? -->
 Altered pharmacokinetics (Stoelting CoED)

<!-- PAGE=? -->
o Dec. albumin (inc. free fraction of drugs which bind to it - BDZ, anticonvulsants)

<!-- PAGE=? -->
o Inc. alpha1-acid glycoprotein (dec. free fraction of drugs which bind to it: NMR, TCA)

<!-- PAGE=? -->
o STP requirements are increased in children for more than one year after burn injury

<!-- PAGE=? -->
o Resistance to NdMR (up to 3x increase in dose requirement) begins at 1 wk, peaks at 5-6 wks, declines after 60 days

<!-- PAGE=? -->
 possible role of inc. number of extrajunctional Ach receptors

<!-- PAGE=? -->
 Usually seen with >25% total BSA burns

<!-- PAGE=? -->
o Hyperkalemia to sux

<!-- PAGE=? -->
 Unrelated to extent of burn

<!-- PAGE=? -->
o Resistance to chatechoamines

<!-- PAGE=? -->
 Supportive care (ventilation, nutrition, infection, ulcer)

<!-- PAGE=? -->
 Redistribution of fluid (edema, ARDS)

<!-- PAGE=? -->
 Inc. p50 and DPG - remains elevated for weeks

<!-- PAGE=? -->
o Shift to the Right

<!-- PAGE=? -->
Reconstructive (up to 6 months):

<!-- PAGE=? -->
 Resistance to IV anesthetic

<!-- PAGE=? -->
 Resistance to NdMB (especially with BSA > 30 %)

<!-- PAGE=? -->
 Hyperkalemia to sux

<!-- PAGE=? -->
 Opioid tolerance

<!-- PAGE=? -->
Barash, CoExD

<!-- PAGE=? -->
 Difficult monitoring

<!-- PAGE=? -->
 Hyperthermia and hypothermia

<!-- PAGE=? -->
 OR between 28° and 32°C to minimize exposure and evaporative fluid losses

<!-- PAGE=? -->
 Blood loss can be minimized by

<!-- PAGE=? -->
o restricting the escharotomy to 15-20% of TBSA

<!-- PAGE=? -->
o use of extremity tourniquets

<!-- PAGE=? -->
o applying dilute epinephrine solution

<!-- PAGE=? -->
 topically (1:10,000)

<!-- PAGE=? -->
 by injection (0.5 mg per 1000 ml)

<!-- PAGE=? -->
o using compression bandages

<!-- PAGE=? -->
 Multiple blood transfusions inc. risk of complications of transfusion

<!-- PAGE=? -->
 Ketamine is a commonly used anesthetic for serial wound debridements during the convalescent phase

<!-- PAGE=? -->
o spontaneous ventilation at a surgical plane of anesthesia

<!-- PAGE=? -->
o stable hemodynamics

<!-- PAGE=? -->
o excellent analgesia

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
 inflammatory mediations contribute to local inflammation and edema

<!-- PAGE=? -->
 with major burns, systemic response occurs

<!-- PAGE=? -->
o hypermetabolism

<!-- PAGE=? -->
o immunosuppression

<!-- PAGE=? -->
o SIRS

<!-- PAGE=? -->
 Cardiac:

<!-- PAGE=? -->
o Dramatic decreased cardiac output in postburn period

<!-- PAGE=? -->
o Occurs before volume loss ? negative inotropes circulating

<!-- PAGE=? -->
o Third space fluid shifts further depress CO

<!-- PAGE=? -->
o CO remains depressed after resuscitation until the second post burn day

<!-- PAGE=? -->
o Intense vasoconstriction, increased metabolic demands and hemolysis strain the heart

<!-- PAGE=? -->
o CA can occur with anesthetic

<!-- PAGE=? -->
o After the first 24 hrs generally hyperdynamic state that lasts for a long time

<!-- PAGE=? -->
 Increased BP and HR

<!-- PAGE=? -->
 CO 2x normal

<!-- PAGE=? -->
o Pulmonary edema is common during the first postburn week as edema fluid is resorbed

<!-- PAGE=? -->
o Systemic hypertension

<!-- PAGE=? -->
 Occurs in 30% of children

<!-- PAGE=? -->
 Onset usually during first 2 wks and may persist for several weeks

<!-- PAGE=? -->
 Can results in encephalopathy: irritability, HA, sz

<!-- PAGE=? -->
 Hydralazine, nitroprusside

<!-- PAGE=? -->
 volume resus

<!-- PAGE=? -->
o hypovolemic shock develops in burns > 10-15% of BSA

<!-- PAGE=? -->
o increased permeability of vascular compartment results in leakage and severe hypoproteinemia

<!-- PAGE=? -->
o pulmonary capillary permeability does not increase unless smoke inhalation occurs

<!-- PAGE=? -->
o loss on first post burn day is 4 ml/kg/% BSA burned

<!-- PAGE=? -->
o give 2/3 of this fluid in the first 8 hrs post burn

<!-- PAGE=? -->
 airway

<!-- PAGE=? -->
o direct burn injuries to the airway are above the level of the cords (except for steam inhalation) because low thermal capacity of air

<!-- PAGE=? -->
 upper airway: edema and secretions = obstruction, hoarseness, stridor, tachypnea

<!-- PAGE=? -->
 lower airway: decreased surfactant and mucociliary function, mucosal necrosis and ulceration, edema, tissue sloughing, and secretions

<!-- PAGE=? -->
 bronchial obstruction, air trapping, and bronchopneumonia

<!-- PAGE=? -->
 development usually takes 1-5 days and presents with ARDS

<!-- PAGE=? -->
 pneumonia and PE usually occur > 5 days post burn

<!-- PAGE=? -->
o indicators of possible airway injury:

<!-- PAGE=? -->
 singed facial hair

<!-- PAGE=? -->
 facial burns

<!-- PAGE=? -->
C

<!-- PAGE=? -->
CABG

<!-- PAGE=? -->
H ensley CD Ch. 9

<!-- PAGE=? -->
Factors contributing to adverse cardiovascular outcome in the postbypass period

<!-- PAGE=? -->
Age . Patients older than 70 years suffer greater cardiac morbidity and mortality. Explanations for this observation include more extensive atherosclerosis, impairment of right ventricular (RV) or left ventricular (LV) function, and greater likelihood of coexistent medical illnesses, such as diabetes, chronic obstructive pulmonary disease, and peripheral vascular disease [1].

<!-- PAGE=? -->
Female gender . Women represent a high-risk group, particularly in those procedures involving myocardial revascularization. The reason for this is uncertain; however, it has been noted that women are older at the time of presentation for surgery, are less likely to be revascularized, have smaller coronary vessels, and more frequently are diabetic and hypertensive.

<!-- PAGE=? -->
Congestive heart failure . Preoperative ventricular dysfunction represents a significant risk factor and is associated with a higher mortality. Patients with the following conditions are likely to undergo a surgical procedure in congestive heart failure (CHF): (a) acute valvular dysfunction with hemodynamic deterioration, (b) recent myocardial infarction with ongoing ischemia despite optimal medical therapy, and (c) CHF secondary to significant impairment of LV/RV function.

<!-- PAGE=? -->
 dysphonia or hoarseness

<!-- PAGE=? -->
 cough

<!-- PAGE=? -->
 soot in mouth or nose

<!-- PAGE=? -->
 swallowing difficulties

<!-- PAGE=? -->
o Fiberoptic laryngoscopy should be done if the presence of edema is questioned

<!-- PAGE=? -->
 Patients may not have respiratory distress at presentation

<!-- PAGE=? -->
 Q3-4 hours for the first 12 after injury in non-intubated patients

<!-- PAGE=? -->
o Secure airway early

<!-- PAGE=? -->
 Airway obstruction in upper airway injury develops because of upper airway, glottic and periglottic edema and copious thick secretions

<!-- PAGE=? -->
 Airway obstruction may be exacerbated by fluid resuscitation even in the absences of significant inhalational injury

<!-- PAGE=? -->
o Give 100% O2 by face mask

<!-- PAGE=? -->
o Intubate: massive burns, stridor, resp distress, hypoxemia, hypercarbia, LOC, altered mentation

<!-- PAGE=? -->
 Safest approach: awake FOI with topical anesthesia

<!-- PAGE=? -->
 Described techniques: airtraq, glidescope, intubating LMA, retrograde intubation

<!-- PAGE=? -->
 Peds: spontaneously breathing induction (inhalational or TIVA) and then intubation

<!-- PAGE=? -->
 Reserve trach for those that require surgical airway access because other techniques are likely to fail

<!-- PAGE=? -->
o May need intubation for several days

<!-- PAGE=? -->
o Ventilation: PEEP, airway humidification, bronchial toilet and bronchodilators

<!-- PAGE=? -->
o Trach for pulmonary complications that will result in prolonged ventilatory support

<!-- PAGE=? -->
 Significant risk of sepsis, later upper airway sequelae, death in burned patients

<!-- PAGE=? -->
o Perform CXR, ABG and PFTs (for baseline.  Usually normal immediately post burn)

<!-- PAGE=? -->
o Note: Chest radiography at presentation is a poor predictor of inhalation injury because of its low sensitivity; most patients with inhalation injury have a normal chest x-ray

<!-- PAGE=? -->
Emergency operation . Patients requiring emergent myocardial revascularization due to ongoing ischemia or hemodynamic deterioration after thrombolytic therapy, or unsuccessful angioplasty or stent placement also represent a high-risk group for multiple reasons. Some patients will be at greater risk for both prebypass and postbypass bleeding due to recent thrombolytic therapy, heparin administration, or recent use of platelet inhibitors including IIb/IIIa receptor antagonists and clopidogrel bisulfate (Plavix).

<!-- PAGE=? -->
Prior heart surgery

<!-- PAGE=? -->
Percentage of left main stenosis

<!-- PAGE=? -->
Kaplan 1167

<!-- PAGE=? -->
predictors of inotrope use post CABG

<!-- PAGE=? -->
 inc. Age

<!-- PAGE=? -->
 female sex

<!-- PAGE=? -->
 dec. LVEF

<!-- PAGE=? -->
 inc. pump time

<!-- PAGE=? -->
Kaplan - 692 risk factors of mortality post cardiac surgery

<!-- PAGE=? -->
 emergency

<!-- PAGE=? -->
 CHF

<!-- PAGE=? -->
 prior operation

<!-- PAGE=? -->
 gender

<!-- PAGE=? -->
 age

<!-- PAGE=? -->
 vavlular disease

<!-- PAGE=? -->
 renal dysfunction

<!-- PAGE=? -->
 obesity

<!-- PAGE=? -->
Hensley pg 504

<!-- PAGE=? -->
Abnormalities acquired during cardiac surgery

<!-- PAGE=? -->
Endothelial dysfunction

<!-- PAGE=? -->
Persistent heparin effect

<!-- PAGE=? -->
Platelet abnormalities

<!-- PAGE=? -->
Dilutional thrombocytopenia

<!-- PAGE=? -->
Platelet dysfunction: most prevalent yet elusive cause of hemostatic

<!-- PAGE=? -->
abnormalities after CPB

<!-- PAGE=? -->
Coagulopathy: hemodilution and consumption

<!-- PAGE=? -->
Fibrinolysis

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
CAD detection

<!-- PAGE=? -->
i.e. it appears that dipyridamole-thallium (or MIBI) scanning more sensitive whereas dobutamine stress echo is more specific.

<!-- PAGE=? -->
DSE does not add risk discrimination for patients with no clinical markers according to the criteria of Eagle et al,   because morbid events are rare in this subgroup.  DSE does stratify patients with one or two clinical markers, and perioperative cardiac events are unlikely to occur in patients with a negative result on stress echocardiogram in this subgroup. A meta-analysis found DSE to be the best predictor of cardiac morbidity (relative risk [rr] =6.2), followed by DTI (rr=4.6), radionuclide ventriculography (rr =3.7), and AECG (rr =2.7

<!-- PAGE=? -->
Old Barash table 18-14, pg. 454

<!-- PAGE=? -->
 dipyradamol thalium is 90% sens and 90% spec

<!-- PAGE=? -->
 stress thallium (planar) is 90% and 85%

<!-- PAGE=? -->
 stress echo is 80% and 85%

<!-- PAGE=? -->
 holter is 70% and 85%

<!-- PAGE=? -->
 stress ECG is 65% and 80% (the worst)

<!-- PAGE=? -->
Calcium Channel Blockers

<!-- PAGE=? -->
P&P, Barash

<!-- PAGE=? -->
 The pharmacologic effects of calcium channels blockers may be predicted by considering the normal role of calcium ions in the production of action potentials

<!-- PAGE=? -->
o decreased myocardial contractility

<!-- PAGE=? -->
o decreased heart rate

<!-- PAGE=? -->
o decreased activity of the sinoatrial node

<!-- PAGE=? -->
o decreased rate of conduction through the AVnode

<!-- PAGE=? -->
o decreases in SBP d/t vascular smooth muscle relaxation with vasodilation

<!-- PAGE=? -->
 Interaction with other drugs

<!-- PAGE=? -->
o Verapamil has potent local anesthetic activity

<!-- PAGE=? -->
 may increase the risk of local anesthetic toxicity

<!-- PAGE=? -->
 Diltiazem known as most cardiac friendly ito ionotropism (ACLS)

<!-- PAGE=? -->
Calcium Salts

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Important in the genesis of the cardiac action potential

<!-- PAGE=? -->
 Not recommended during cardiac arrest except when hyperkalemia, hypocalcemia, or calcium-channel blocker toxicity is present

<!-- PAGE=? -->
 often given at the termination of cardiopulmonary bypass to offset the myocardial depression associated with hypothermic potassium cardioplegia

<!-- PAGE=? -->
o may induce spasm of the coronaries

<!-- PAGE=? -->
o may cause hypercontracture of the heart cells with increased risk for MI

<!-- PAGE=? -->
 clearly indicated during rapid or massive transfusions of citrated blood

<!-- PAGE=? -->
o Citrate binds calcium

<!-- PAGE=? -->
 Calcium chloride produces only transient increases in CO and blood pressure

<!-- PAGE=? -->
o rapid administration can produce bradycardia and must be used cautiously

<!-- PAGE=? -->
 may produce toxic effects in digitalized pt

<!-- PAGE=? -->
Capnograph

<!-- PAGE=? -->
Changes to waveform

<!-- PAGE=? -->
o       Elevated baseline:

<!-- PAGE=? -->
     CO2 absorber exhaustion

<!-- PAGE=? -->
     Incompetent expiratory valve

<!-- PAGE=? -->
     Calibration problem

<!-- PAGE=? -->
o       Slow upstroke and plateau:

<!-- PAGE=? -->
     Partial obstruction (ETT, tube)

<!-- PAGE=? -->
     Bronchospasm

<!-- PAGE=? -->
     Sidestream analyzer too slow

<!-- PAGE=? -->
o       Slow downstroke

<!-- PAGE=? -->
     Incompetent inspiratory valve

<!-- PAGE=? -->
     Partial CO2 rebreathing

<!-- PAGE=? -->
     Slow gas sampling

<!-- PAGE=? -->
     Slow ventilation

<!-- PAGE=? -->
A

<!-- PAGE=? -->
B

<!-- PAGE=? -->
D

<!-- PAGE=? -->
E

<!-- PAGE=? -->
G

<!-- PAGE=? -->
J

<!-- PAGE=? -->
K

<!-- PAGE=? -->
40

<!-- PAGE=? -->
M

<!-- PAGE=? -->
N

<!-- PAGE=? -->
[

<!-- PAGE=? -->
Miller Figure 36-18 Examples of capnograph waves.

<!-- PAGE=? -->
A, Normal spontaneous breathing.

<!-- PAGE=? -->
B, Normal mechanical ventilation.

<!-- PAGE=? -->
C, Prolonged exhalation during spontaneous breathing. As CO2 diffuses from the mixed venous blood into the alveoli, its concentration progressively rises

<!-- PAGE=? -->
D, Increased slope of phase III in a mechanically ventilated patient with emphysema

<!-- PAGE=? -->
E, Added dead space during spontaneous ventilation.

<!-- PAGE=? -->
F, Dual plateau (i.e. tails-up pattern) caused by a leak in the sample line . The alveolar plateau is artifactually low because of dilution of exhaled gas with air leaking inward. During each mechanical breath, the leak is reduced because of higher pressure within the airway and tubing, explaining the rise in the CO2 concentration at the end of the alveolar plateau. This pattern is not seen during spontaneous ventilation because the required increase in airway pressure is absent.

<!-- PAGE=? -->
G, Exhausted CO2 absorbent produces an inhaled CO2 concentration greater than zero.

<!-- PAGE=? -->
H, Double peak for a patient with a single lung transplant. The first peak represents CO2 from the transplanted (normal) lung. CO2 exhalation from the remaining (obstructed) lung is delayed, producing the second peak.

<!-- PAGE=? -->
I, Inspiratory valve stuck open during spontaneous breathing. Some backflow into the inspired limb of the circuit causes a rise in the level of inspired CO2

<!-- PAGE=? -->
J, Inspiratory valve stuck open during mechanical ventilation. The "slurred" downslope during inspiration represents a small amount of inspired CO2 in the inspired limb of the circuit.

<!-- PAGE=? -->
K and L, Expiratory valve stuck open during spontaneous breathing or mechanical ventilation. Inhalation of exhaled gas causes an increase in inspired CO2.

<!-- PAGE=? -->
M, Cardiogenic oscillations, when seen, usually occur with sidestream capnographs for spontaneously breathing patients at the end of each exhalation. Cardiac action causes to-and-fro movement of the interface between exhaled and fresh gas. The CO2 concentration in gas entering the sampling line therefore alternates between high and low values.

<!-- PAGE=? -->
N, Electrical noise resulting from a malfunctioning component. The seemingly random nature of the signal perturbations (about three per second) implies a nonbiologic cause.

<!-- PAGE=? -->
PaCO2-ETCO2 gradient

<!-- PAGE=? -->
Barash, Lange

<!-- PAGE=? -->
 PaCO2 - ETCO2 is normally less than 5 mmHg and represents dilution of the alveolar gas with the CO2-free gas form nonperfused alveoli (alveolar dead space)

<!-- PAGE=? -->
 conditions resulting in an increase of dead space ventilation lower the ETCO2 measurement and increase the PaCO2-ETCO2 gradient

<!-- PAGE=? -->
o nonperfused alveoli have a PaCO2 of zero

<!-- PAGE=? -->
o The ventilation-weighted average of the perfused and nonperfused alveoli determines the ETCO2

<!-- PAGE=? -->
o conditions resulting in an increase of dead space ventilation lower the ETCO2 measurement and increase the PaCO2-ETCO2 gradient

<!-- PAGE=? -->
 The common clinical causes associated with a widened PaCO2-ETCO2 gradient include

<!-- PAGE=? -->
o embolic phenomena (thrombus, fat, air, amniotic fluid)

<!-- PAGE=? -->
o hypoperfusion states with reduced pulmonary blood flow

<!-- PAGE=? -->
o COPD

<!-- PAGE=? -->
 conditions that increase pulmonary shunt (perfusion in the absence of ventilation) result in minimal changes in the PaCO2-ETCO2 gradient

<!-- PAGE=? -->
o > 30% venous admixture results in a relatively small gradient (2-3 mm Hg)

<!-- PAGE=? -->
Decrease ETCO2

<!-- PAGE=? -->
Increase ETCO2

<!-- PAGE=? -->
 A sudden drop in ETCO2 to near zero followed by the absence of a CO2 waveform is a potentially lifethreatening problem that could indicate:

<!-- PAGE=? -->
o malposition of an endotracheal tube into the pharynx or esophagus,

<!-- PAGE=? -->
o sudden severe hypotension

<!-- PAGE=? -->
 pulmonary embolism - usually not to zero

<!-- PAGE=? -->
o cardiac arrest

<!-- PAGE=? -->
o artifact resulting from disruption of sampling lines.

<!-- PAGE=? -->
 ET CO2 is occasionally higher than arterial CO2

<!-- PAGE=? -->
o Causes include errors in calibration, rebreathing, and inadvertent addition of CO2 to the inspired gas

<!-- PAGE=? -->
Sampling errors

<!-- PAGE=? -->
Lange, Barash, Miller

<!-- PAGE=? -->
 High aspiration rates (up to 250 mL/min) and low-dead-space sampling tubing usually increase sensitivity and decrease lag time

<!-- PAGE=? -->
o If tidal volumes are small (e.g. pediatric patients), however, a high rate of aspiration may entrain fresh gas from the circuit and dilute ETCO2 measurement (underestimation).

<!-- PAGE=? -->
 Low aspiration rates (less than 50 mL/min) can retard ETCO2 measurement and underestimate it during rapid respiratory ventilation

<!-- PAGE=? -->
 Sampling errors resulting from loose connections or system leaks also may dilute the expiratory sample and reduce the estimate of ETCO2

<!-- PAGE=? -->
 Aspiration units are prone to water precipitation in the aspiration tube and sampling cell that can cause obstruction of the sampling line and erroneous readings

<!-- PAGE=? -->
o Water vapor may condense on the window of the sensor cell and absorb IR light, thereby produce falsely high CO2 readings

<!-- PAGE=? -->
Carbon Dioxide

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 With apnea, PaCO2 rises approximately 6 mm Hg in the first minute because of the wash in of venous blood into the arterial compartment (venous blood has a carbon dioxide tension 6 mm Hg higher than that of arterial blood) and then 3 to 4 mm Hg each minute thereafter because of normal carbon dioxide production

<!-- PAGE=? -->
CO2 absorbers

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
The Reaction in the container:

<!-- PAGE=? -->
 Needs lots of water for the reaction to take place, but also creates a lot as well!

<!-- PAGE=? -->
 Forms carbonic acid in first reaction step

<!-- PAGE=? -->
 can absorb up to 26L of CO2 per 100 g of absorbent

<!-- PAGE=? -->
o normally ends up being 18 - 20 L in dual chambered canister and 10 - 15L in single chambered canister

<!-- PAGE=? -->
 contain ethyl violet which changes to mauve as carbonic acid accumulates

<!-- PAGE=? -->
 Increased compound A production

<!-- PAGE=? -->
o Low fresh gas flow

<!-- PAGE=? -->
o High temperatures

<!-- PAGE=? -->
o High concentrations of sevoflurane

<!-- PAGE=? -->
o Baralyme > soda lime

<!-- PAGE=? -->
 Related to inc temperature

<!-- PAGE=? -->
o Dry absorbents (barash)

<!-- PAGE=? -->
 dehydration of Baralyme increases the concentration of compound

<!-- PAGE=? -->
o Fresh absorbents (Miller)

<!-- PAGE=? -->
 Dec. Compound A production

<!-- PAGE=? -->
o dehydration of soda lime decreases the concentration of compound A

<!-- PAGE=? -->
 inc. moister inc. compound A production for soda lime

<!-- PAGE=? -->
 Increased CO production

<!-- PAGE=? -->
o Type of volatile

<!-- PAGE=? -->
 desflurane ≥ enflurane > isoflurane > halothane = sevoflurane

<!-- PAGE=? -->
 Sevo and halothane do NOT produce CO

<!-- PAGE=? -->
o High anesthetic concentration

<!-- PAGE=? -->
o absorbent dessication

<!-- PAGE=? -->
 completely dry absorbent produces more carbon monoxide than hydrated absorbent

<!-- PAGE=? -->
o type of absorbent

<!-- PAGE=? -->
 Baralyme > soda lime

<!-- PAGE=? -->
o Low fresh gas flow rates

<!-- PAGE=? -->
o High temperature

<!-- PAGE=? -->
o Reduced animal size per 100 g of absorbent (i.e. ?? children vs. adults ??)

<!-- PAGE=? -->
Carcinoid

<!-- PAGE=? -->
CoExD, Miller, Barash

<!-- PAGE=? -->
 Incidence = 1-2/100,000 (higher at autopsy)

<!-- PAGE=? -->
 Presents in 5-7 th decade of life

<!-- PAGE=? -->
 Some are nonfunctional

<!-- PAGE=? -->
 Carcinoid tumors are neuroendocrine tumors which can secrete proteins and monoamines

<!-- PAGE=? -->
o Serotonin is the most common mediator

<!-- PAGE=? -->
o Others : histamine, bradykinin, kalikrein, substance P, prostaglandins, gastrin, corticotropin, neuron-specific enolase

<!-- PAGE=? -->
 May arise anywhere in GI tract and bronchi

<!-- PAGE=? -->
o 70-90% found in the GI tract

<!-- PAGE=? -->
 Bronchial and thymus tumours

<!-- PAGE=? -->
o <2% may secrete ACTH and may result in cushings syndrome

<!-- PAGE=? -->
 Mets almost always go to the liver (rarer to lungs)

<!-- PAGE=? -->
 Tryptophan (essential amino acid) stores are depleted in the production of serotonin, so proteins and niacin synthesis is impaired

<!-- PAGE=? -->
o hypoproteinemia (hypoalbuminemia)

<!-- PAGE=? -->
o pellagra (dermatitis, diarrhea, dementia from niacin deficiency)

<!-- PAGE=? -->
 10-20% patients have coexisting malignancy

<!-- PAGE=? -->
 10% associated with MEN-1

<!-- PAGE=? -->
o parathyroid, pancreatic, pituitary

<!-- PAGE=? -->
 Common reasons OR

<!-- PAGE=? -->
o tumor de-bulking

<!-- PAGE=? -->
o relief of intestinal obstruction

<!-- PAGE=? -->
o -appendicitis‖

<!-- PAGE=? -->
o liver resection or transplant

<!-- PAGE=? -->
o heart valve replacement

<!-- PAGE=? -->
o thoracic surgery for lung or bronchial carcinoid resection

<!-- PAGE=? -->
Carcinoid syndrome

<!-- PAGE=? -->
 seen in 2-5% patients with carcinoid tumor (some sources say up to 18%)

<!-- PAGE=? -->
 clinical spectrum includes

<!-- PAGE=? -->
o cutaneous flushing

<!-- PAGE=? -->
o hypotension or hypertension

<!-- PAGE=? -->
o bronchoconstiction

<!-- PAGE=? -->
o diarrhea

<!-- PAGE=? -->
o carcinoid heart disease

<!-- PAGE=? -->
o Venous telangiectasia

<!-- PAGE=? -->
o Chr abdo pain and diarrhea

<!-- PAGE=? -->
o Hepatomegaly

<!-- PAGE=? -->
o Hyperglycemia

<!-- PAGE=? -->
 Carcinoid Triad

<!-- PAGE=? -->
o Flushing

<!-- PAGE=? -->
o Diarrhea

<!-- PAGE=? -->
o Heart Disease

<!-- PAGE=? -->
 Higher incidence seen with lung or liver mets (extra-GI tumors)

<!-- PAGE=? -->
o GI tumours release vasoactive mediators into the portal venous circulation and they are metabolized by the liver before they reach systemic circulation

<!-- PAGE=? -->
 >20 substances secreted including serotonin, histamine, bradykinin, tachykinin, motilin, sub P, kallikrein, PG, catecholamines

<!-- PAGE=? -->
 Serotonin can cause

<!-- PAGE=? -->
o hypertension (commonly)

<!-- PAGE=? -->
o hypotension (less common)

<!-- PAGE=? -->
o diarrhea

<!-- PAGE=? -->
o hyperglc

<!-- PAGE=? -->
o hypoproteinemia

<!-- PAGE=? -->
 Bradykinin/histamine produce cutaneous flushing, hypotension and bronchospasm

<!-- PAGE=? -->
o These features may be severe and resistant to usual periop tx

<!-- PAGE=? -->
Carcinoid heart disease

<!-- PAGE=? -->
 45-60% of pts with carcinoid sx

<!-- PAGE=? -->
 high levels of circulating serotonin causes myocardial fibrosis which affects the right side of the heart

<!-- PAGE=? -->
o TR most common (valve fibrosis and retraction  regurge)

<!-- PAGE=? -->
o PS

<!-- PAGE=? -->
o plaques in

<!-- PAGE=? -->
 vena cava

<!-- PAGE=? -->
 coronary sinus

<!-- PAGE=? -->
 PA

<!-- PAGE=? -->
o may result in RV failure

<!-- PAGE=? -->
 may see contrictive pericarditis or myocardial mets even in pts without the syndrome

<!-- PAGE=? -->
o Vasoactive mediators are inactivated by metabolism in the lungs so left-sided involvement is rare (<10%)

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 Tumors are treated with surgery (limited response to chemo but may reduce bulk and attenuate substance release, resistant to radiation)

<!-- PAGE=? -->
 Hepatic tumours may be treated with hepatic artery embolization in the radiology suite

<!-- PAGE=? -->
o same anesthetic considerations and management as if they were an open resection plus:

<!-- PAGE=? -->
 abdominal pain, fever, N / V +/- liver dysfunction post-procedure

<!-- PAGE=? -->
o Can get massive mediator release during and after embolization

<!-- PAGE=? -->
 Patients at highest risk of perioperative complications are those with carcinoid heart disease and high urine levels of 5-hydroxyindoleacetic acid (serotonin metabolite)

<!-- PAGE=? -->
o These complications are greatly reduced with octreotide

<!-- PAGE=? -->
o Octreotide acetate = long-acting somatostatin analogue

<!-- PAGE=? -->
 Binds to somatostatin 2 receptors on the tumour

<!-- PAGE=? -->
 inhibits serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin and pancreatic polypeptide release

<!-- PAGE=? -->
 Acute administration has no significant side effects

<!-- PAGE=? -->
 It can be given IV, SC or IM

<!-- PAGE=? -->
 Anesthesia management:

<!-- PAGE=? -->
o Preop octreotide blocks ectopic hormone release

<!-- PAGE=? -->
 Octreotide 50 mcg iv and sc prior to manipulation of the tumor

<!-- PAGE=? -->
o Avoid hypotension - stimulate release of vasoactive substances

<!-- PAGE=? -->
 Preop hydration to prevent hypotension is important

<!-- PAGE=? -->
o Avoid SNS

<!-- PAGE=? -->
 Light anesthesia, pain, anxiey, Ketaine

<!-- PAGE=? -->
o Avoid Histamine-releasing drugs (morphine)

<!-- PAGE=? -->
o Disposition

<!-- PAGE=? -->
 Monitor for minimum of 24 hrs post-op resection

<!-- PAGE=? -->
 Wean ocreotide over ~ 1 week

<!-- PAGE=? -->
 Intraop events:

<!-- PAGE=? -->
o Bronchospasm:

<!-- PAGE=? -->
 Treated with bolus octreotide - 200ug IV, nebulized atrovent

<!-- PAGE=? -->
 prophylactic use of H1 and H2 blockers and steroids

<!-- PAGE=? -->
o Hypertension:

<!-- PAGE=? -->
 Increase depth of anesthesia, octreotide

<!-- PAGE=? -->
 Methotrimeprazine

<!-- PAGE=? -->
 conventional vasodilating agents  - SNP, NTG

<!-- PAGE=? -->
 ketanserin (antiserotonin )

<!-- PAGE=? -->
o Hypotension (most serious complication of crisis)

<!-- PAGE=? -->
 treat with fluid and octreotide

<!-- PAGE=? -->
 sympathomimetics are contraindicated and aggravate symptoms

<!-- PAGE=? -->
 If severe hypotension occurs that is not treatable with somatostatin give vasopressin

<!-- PAGE=? -->
Cardiac Arrest - intraoperative

<!-- PAGE=? -->
 Incidence of ~ 2 per 10,000 cases - 0.02%

<!-- PAGE=? -->
o 1 per 10,000 cases died - 0.01%

<!-- PAGE=? -->
 Pediatric patients have a threefold higher risk of arrest than adults

<!-- PAGE=? -->
 Emergency cases have a sixfold greater risk

<!-- PAGE=? -->
 Inc. risk with inc. comorbidity and inc. ASA classification

<!-- PAGE=? -->
 Specific errors in anesthesia management could be identified in 75% of cases

<!-- PAGE=? -->
o inadequate ventilation (most common)

<!-- PAGE=? -->
 absolute overdose of an inhaled anesthetic

<!-- PAGE=? -->
o asystole post succynlcholine

<!-- PAGE=? -->
o postinduction hypotension

<!-- PAGE=? -->
 No effect from the time of day

<!-- PAGE=? -->
 progressive bradycardia was commly identified preceding arrest

<!-- PAGE=? -->
Cardiac evaluation for noncardiac OR

<!-- PAGE=? -->
1: Emergency Surgery

<!-- PAGE=? -->
medical ris < reducbon ard

<!-- PAGE=? -->
perioperative surverlance

<!-- PAGE=? -->
2: Active Cardiac Conditions

<!-- PAGE=? -->
Decompensated HF (new onset NYHA class IV)

<!-- PAGE=? -->
Postpone surgery until

<!-- PAGE=? -->
Step 3; Low-Rlsk Surgery (rIsk

<!-- PAGE=? -->
196)

<!-- PAGE=? -->
Calaract or breast

<!-- PAGE=? -->
Proceed to surgery

<!-- PAGE=? -->
Ambulalory

<!-- PAGE=? -->
Stop 4; Functional Capacily

<!-- PAGE=? -->
flight

<!-- PAGE=? -->
Proceed to surgery

<!-- PAGE=? -->
Step 5: Clinical Predictors

<!-- PAGE=? -->
Vascular surgery

<!-- PAGE=? -->
Prcceed to surgery with

<!-- PAGE=? -->
1-? cllnical prec cic s

<!-- PAGE=? -->
Dabeles mnenilus

<!-- PAGE=? -->
Renal insuficiency

<!-- PAGE=? -->
will change management

<!-- PAGE=? -->
23 clinical predictors

<!-- PAGE=? -->
Vascular surgery

<!-- PAGE=? -->
change managemen:

<!-- PAGE=? -->
Step

<!-- PAGE=? -->
Step

<!-- PAGE=? -->
Table 3.

<!-- PAGE=? -->
Can you

<!-- PAGE=? -->
Can you

<!-- PAGE=? -->
MET

<!-- PAGE=? -->
METs

<!-- PAGE=? -->
Climb a flight of stairs or walk

<!-- PAGE=? -->
up a hill?

<!-- PAGE=? -->
Walk on level ground at 4 mph

<!-- PAGE=? -->
(6,4 kph)?

<!-- PAGE=? -->
Run a short distance?

<!-- PAGE=? -->
house?

<!-- PAGE=? -->
Do heavy work around the house

<!-- PAGE=? -->
like scrubbing floors or lifting or

<!-- PAGE=? -->
to 4.8 kph)?

<!-- PAGE=? -->
moving heavy furniture?

<!-- PAGE=? -->
METs

<!-- PAGE=? -->
Participate in moderate

<!-- PAGE=? -->
recreational activities like golf;

<!-- PAGE=? -->
washing dishes?

<!-- PAGE=? -->
bowling, dancing, doubles tennis;

<!-- PAGE=? -->
throwing a baseball or

<!-- PAGE=? -->
football?

<!-- PAGE=? -->
Greater

<!-- PAGE=? -->
Participate in strenuous sports

<!-- PAGE=? -->
than 10

<!-- PAGE=? -->
like swimming; singles tennis,

<!-- PAGE=? -->
METs

<!-- PAGE=? -->
football , basketball, or skiing?

<!-- PAGE=? -->
'Modified from Hlatky et al (11), copyright 1989, with permission from Elsevier, and adapted from

<!-- PAGE=? -->
Revised cardiac risk index

<!-- PAGE=? -->
High Risk Surgery: 1 Point

<!-- PAGE=? -->
Coronary Artery Disease: 1 Point

<!-- PAGE=? -->
Congestive Heart Failure: 1 Point

<!-- PAGE=? -->
Cerebrovascular Disease: 1 Point

<!-- PAGE=? -->
Diabetes Mellitus (Insulin): 1 Point

<!-- PAGE=? -->
Serum Creatinine (>170mmol/L): 1 Point

<!-- PAGE=? -->
Points 0: Class I Very Low (0.4% complications)

<!-- PAGE=? -->
Points 1: Class II Low (0.9% complications)

<!-- PAGE=? -->
Points 2: Class III Moderate (6.6% complications)

<!-- PAGE=? -->
Points 3: Class IV High (>11% complications)

<!-- PAGE=? -->
 If no active cardiac conditions and if low risk surgery or METs >4 proceed with surgery

<!-- PAGE=? -->
 if poor or unknown METs, use clinical risk factors

<!-- PAGE=? -->
o CAD

<!-- PAGE=? -->
o Compensated or prior heart failure

<!-- PAGE=? -->
o Cerebrovascular disease

<!-- PAGE=? -->
o Diabetes mellitus (on insulin)

<!-- PAGE=? -->
o Renal insufficiency (Cr >170 mmol/L)

<!-- PAGE=? -->
 METS

<!-- PAGE=? -->
1 Eating, working at a computer, dressing

<!-- PAGE=? -->
2 Walking down stairs or in your house, cooking

<!-- PAGE=? -->
3 Walking 1-2 blocks

<!-- PAGE=? -->
4 Raking leaves, gardening

<!-- PAGE=? -->
5 Climbing 1 flight of stairs, dancing, bicycling

<!-- PAGE=? -->
6 Playing golf, carrying clubs

<!-- PAGE=? -->
7 Playing singles tennis

<!-- PAGE=? -->
8 Rapidly climbing stairs, jogging slowly

<!-- PAGE=? -->
9 Jumping rope slowly, moderate cycling

<!-- PAGE=? -->
10 Swimming quickly, running or jogging briskly

<!-- PAGE=? -->
11 Skiing cross country, playing full-court basketball

<!-- PAGE=? -->
12 Running rapidly for moderate to long distances

<!-- PAGE=? -->
Table 2 Active Cardiac Conditions for Which the Patient Should Undergo Evaluation and Treatment Before Noncardiac Surgery (Class |, Level of Evidence: B)

<!-- PAGE=? -->
CCS indicates Canadian Cardiovascular Society; HF , heart failure; HR, heart rate; MI, myocardial infarction; NYHA, New York Heart Association .

<!-- PAGE=? -->
tMay include "stable" angina in patients who are unusually sedentary .

<!-- PAGE=? -->
"According to Campeau (10).

<!-- PAGE=? -->
recent MI as more than 7 days but less than or equal to month (within 30 days).

<!-- PAGE=? -->
Cardiac herniation (post-pneumonectomy)

<!-- PAGE=? -->
     Treatment:

<!-- PAGE=? -->
     Surgical (empty) side up.

<!-- PAGE=? -->
     No PEEP (reduce Paw, VT)

<!-- PAGE=? -->
     No suction to affected CT

<!-- PAGE=? -->
     Air (1 - 2 L) into affected CT

<!-- PAGE=? -->
     Hemodynamic support PRN

<!-- PAGE=? -->
Miller chapter 48

<!-- PAGE=? -->
-heart herniates through pericardial defect into empty hemithorax, can cause any combination of SVC, IVC, PA, and tracheal  torsion

<!-- PAGE=? -->
-CVS collapse, +/- SVC syndrome, +/- airway obstruction

<!-- PAGE=? -->
-CXR: apex points to lateral wall + shift mediatinum

<!-- PAGE=? -->
-surgical exploration indicated; temporizing measures include removal of PEEP, decrease tidal vol., avoid suction to empty hemithorax (can inject 1-2 L of air into CT), and place empty hemithorax up

<!-- PAGE=? -->
Cardiac Physiology

<!-- PAGE=? -->
Hensley, Lange, Barash

<!-- PAGE=? -->
Pathophysiology of CAD

<!-- PAGE=? -->
 Ischemia results from:

<!-- PAGE=? -->
o increased myocardial metabolic demand

<!-- PAGE=? -->
o decreased myocardial oxygen delivery

<!-- PAGE=? -->
 Determinants of O2 demand:

<!-- PAGE=? -->
o Heart rate

<!-- PAGE=? -->
 Increased HR causes an increase in contractility → increased O2 demand

<!-- PAGE=? -->
o Contractility

<!-- PAGE=? -->
 Rate of rise of LV pressure = dP/dt (depends on preload and afterload)

<!-- PAGE=? -->
 dP/dt is a measure of contractility

<!-- PAGE=? -->
 Pressure-volume curves

<!-- PAGE=? -->
 Brisk rise in arterial tracing (confounding factors)

<!-- PAGE=? -->
 Predicted from HR, BP, CO

<!-- PAGE=? -->
o Wall stress (Laplace's Law)

<!-- PAGE=? -->
 Wall stress (T) = pressure x Radius/ 2 (wall thickness)

<!-- PAGE=? -->
 O2 demand increases linearly with chamber pressure reflected by BP. MAP (not peak SBP) correlates with O2 demand.

<!-- PAGE=? -->
 Increased chamber size leads to more modest increase in O2 demand. Preload determined the chamber size.  The goal is to keep preload low .  Beneficial effect of NTG via venodilation

<!-- PAGE=? -->
 A thicker wall serves to decrease the wall stress. However hypertrophy leads to increased O2 due to the additional tissue O2 requirements

<!-- PAGE=? -->
 Determinants of O2 delivery:

<!-- PAGE=? -->
o Arterial O2 content :

<!-- PAGE=? -->
 CaO2 (ml/L) = (Hgb x %SaO2 x 1.34 ml O2/gmHgb) + (0.003 x PaO2)

<!-- PAGE=? -->
 Depends on Hgb, SaO2, PaO2

<!-- PAGE=? -->
o Coronary blood flow

<!-- PAGE=? -->
 Directly proportional to CPP (coronary perfusion pressure)

<!-- PAGE=? -->
 CPP = DBP- LVEDP

<!-- PAGE=? -->
 To optimize CPP aim at high DPB, low LVEDP

<!-- PAGE=? -->
 Diastolic perfusion index = CPP x diastolic time ( Faust pg 44)

<!-- PAGE=? -->
 low HR - inc. CBF (CBF to LV occurs in diastole)

<!-- PAGE=? -->
 Inversely proportional to CVR ; factors that affect CVR include:

<!-- PAGE=? -->
Vasoconstriction

<!-- PAGE=? -->
Vasodilation

<!-- PAGE=? -->
 Metabolic

<!-- PAGE=? -->
↑ O2, ↓ CO2, ↓H+

<!-- PAGE=? -->
↓O2,↑CO2,↑H+

<!-- PAGE=? -->
Lactate, adenosine

<!-- PAGE=? -->
 ANS

<!-- PAGE=? -->
↑α-adrenergic tone

<!-- PAGE=? -->
↑β- adrenergic tone

<!-- PAGE=? -->
↑ cholinergic tone

<!-- PAGE=? -->
Ach ? via NO

<!-- PAGE=? -->
 Hormonal

<!-- PAGE=? -->
↑ADH, ↑angiotensin

<!-- PAGE=? -->
↑PC, ↑PGE-1, ↑H2

<!-- PAGE=? -->
↑TX, ↑PGE-2, ↑H1

<!-- PAGE=? -->
 Other :

<!-- PAGE=? -->
Blood viscosity,

<!-- PAGE=? -->
 HR and LVEDV are the two factors most likely to produce ischemia if either or both are increased

<!-- PAGE=? -->
 Wall motion abnormalities on TEE is the earliest indicator of intraoperative ischemia

<!-- PAGE=? -->
o Occurs before ECG changes

<!-- PAGE=? -->
 Postoperative MI

<!-- PAGE=? -->
o Mortality is 17%

<!-- PAGE=? -->
o Peak incidence 0-3 days

<!-- PAGE=? -->
o Postoperative myocardial ischemia is the best predictor of long term cardiac morbidity

<!-- PAGE=? -->
o Most are NSTEMI

<!-- PAGE=? -->
 Inc duration of ST depression is associated with adverse outcome

<!-- PAGE=? -->
o Tachycardia is a possible predictor of perioperative ischemia

<!-- PAGE=? -->
Autoregulation

<!-- PAGE=? -->
 constant Coronary Blood Flow (CBF) over CPP = 50-120

<!-- PAGE=? -->
 refers strictly to pressure-dependent changes in coronary resistance, unrelated to changes in myocardial metabolism.

<!-- PAGE=? -->
 CBF ceases at CPP of 20

<!-- PAGE=? -->
o critical flow pressure (critical closure)

<!-- PAGE=? -->
 Main site of action is in the coronary arterioles (<150 mcm)

<!-- PAGE=? -->
 Can be altered by changes in myocardial O2 demand

<!-- PAGE=? -->
 A low myocardial PO2 (49mmHg) increases CBF (mediated by adenosine)

<!-- PAGE=? -->
 The threshold O2 tension for autoregulation is 32 mmHg

<!-- PAGE=? -->
 Coronary blood flow = 5% of CO (250 ml/min) Q = (DBP-LVEDP)/ R

<!-- PAGE=? -->
Myocardial metabolism

<!-- PAGE=? -->
 Normal oxygen extraction by the heart is 60-70%

<!-- PAGE=? -->
o changes very little with increased cardiac work because coronary vascular resistance decreases

<!-- PAGE=? -->
o Coronary venous blood saturation = 30% (PmvO2 = 18-20% )

<!-- PAGE=? -->
 extraction can be increased to more than 90%, if the coronary vascular resistance response is limited

<!-- PAGE=? -->
 myocardial O2 consumption is divided as follows

<!-- PAGE=? -->
o 64% pressure work

<!-- PAGE=? -->
o 20% basal requirements

<!-- PAGE=? -->
o 15 % volume work

<!-- PAGE=? -->
o 1% electrical activity

<!-- PAGE=? -->
Preconditioning

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 brief intermittent periods of myocardial ischemia may confer protection against a subsequent larger ischemic insult

<!-- PAGE=? -->
o limited infarct size

<!-- PAGE=? -->
 two windows of protection

<!-- PAGE=? -->
o first window occurs within 2 to 3 hours

<!-- PAGE=? -->
o second (late preconditioning) occurs between 24 and 96 hours

<!-- PAGE=? -->
 benefits of preconditioning may include

<!-- PAGE=? -->
o limitation of infarct size

<!-- PAGE=? -->
o dysrhythmia prevention

<!-- PAGE=? -->
 Anesthetics may interact with the mechanisms underlying preconditioning

<!-- PAGE=? -->
o specific anesthetics in common use (e.g., sevoflurane and isoflurane) have the capacity to profoundly modulate the preconditioning phenomenon when the process itself has been provoked by other triggers

<!-- PAGE=? -->
o Because of the influence of many changing variables, it may be difficult in the clinical setting to determine the impact of specific anesthetics on end points

<!-- PAGE=? -->
o Dec. Troponin leak has been associated with sevoflurane

<!-- PAGE=? -->
Post-operative Myocardial Infarction

<!-- PAGE=? -->
Miller pg 2065

<!-- PAGE=? -->
 The peak incidence of ischemia occurs during the early (day 0-3) versus late (days 4-7) postoperative period.

<!-- PAGE=? -->
 67% of ischemic events started within 2 hours from the end of surgery and emergence from anesthesia.

<!-- PAGE=? -->
 The vast majority (more than 90%) of postoperative episodes of myocardial ischaemia are silent.

<!-- PAGE=? -->
 Postoperative ST segment changes are almost exclusively episodes of ST segment depression rather than elevation.

<!-- PAGE=? -->
 The vast majority of perioperative myocardial infarctions are preceded by episodes of ST-segment depression. Long-duration (single duration >20±30 min or cumulative\ duration >1±2 h) ST-segment change, rather than merely the presence of postoperative ST-segment depression, seems to be the important factor associated with adverse cardiac outcome.

<!-- PAGE=? -->
 Short ischaemic episodes (<10 min) did not correlate with postoperative myocardial infarction and cardiac complications.

<!-- PAGE=? -->
 When multiple studies are pooled, the overall prevalence of perioperative MI and death is 5.0 percent and 1.6 percent, respectively. When outcomes are assessed over the long-term postoperative period (3-4 years), the prevalence of MI and death is 8.9 percent and 9.1 percent, respectively.

<!-- PAGE=? -->
Barash 4th Ed Ch 33:

<!-- PAGE=? -->
 Landesberg et al found that patients experienced twice as much ischemia after vascular surgery than before or during.

<!-- PAGE=? -->
 Ischemia that lasted >2 hr was associated with a 32-fold increase in the risk of postoperative morbid cardiac events.

<!-- PAGE=? -->
 In this study, postoperative MI was usually preceded by long periods of severe ST-segment depression. Aggressive efforts at prevention or treatment of ischemia during these periods may improve patient outcome.

<!-- PAGE=? -->
 We refer patients with documented severe postoperative myocardial ischemia (>2 hr; 2 mm ST-segment depression) to a cardiologist because 70% of all adverse cardiac outcomes in a two-year follow-up program were preceded by in-hospital postoperative ischemia.

<!-- PAGE=? -->
 Badner et al; 18 of 323 patients with known CAD undergoing major surgery (5.6%) had a PMI, of which 3 (17%) were fatal. Only 3 of 18 patients had chest pain, whereas 10 of 18 patients (56%) had other clinical findings. The PMIs occurred on the day of operation in nearly half of the cases.

<!-- PAGE=? -->
Cardiovascular Reflexes

<!-- PAGE=? -->
(Miller, chp18)

<!-- PAGE=? -->
Cardiac Reflexes

<!-- PAGE=? -->
 reflex loops between the heart and the central nervous system (CNS) that contribute to the regulation of cardiac function and maintenance of physiologic homeostasis

<!-- PAGE=? -->
 Cardiac receptors in the atria, ventricles, pericardium, and coronary arteries, are linked to the CNS by myelinated or unmyelinated afferent fibers that travel along the vagus nerve

<!-- PAGE=? -->
 Extracardiac receptors are located in the great vessels and the carotid artery

<!-- PAGE=? -->
Baroreceptor Reflex (Carotid Sinus Reflex)

<!-- PAGE=? -->
 responsible for the maintenance of blood pressure

<!-- PAGE=? -->
 blood pressure is monitored by circumferential and longitudinal stretch receptors located in the carotid sinus and aortic arch

<!-- PAGE=? -->
 afferents via the glossopharyngeal (nerve of Hering)

<!-- PAGE=? -->
 the nucleus solitarius located in the cardiovascular center of the medulla consists of two functionally different areas

<!-- PAGE=? -->
o laterally and rostrally → responsible for increasing blood pressure

<!-- PAGE=? -->
o centrally and caudally → responsible for lowering blood pressure and  integrating impulses from the hypothalamus and the limbic system

<!-- PAGE=? -->
 activation occurs with SBP > 170 mm Hg

<!-- PAGE=? -->
o decreased sympathetic activity leading to a decrease in cardiac contractility, heart rate, and vascular tone

<!-- PAGE=? -->
o activation of the parasympathetic system further decreases the heart rate and myocardial contractility

<!-- PAGE=? -->
 Reverse effects are elicited with the onset of hypotension

<!-- PAGE=? -->
 the reflex arch loses its functional capacity at a blood pressure less than 50 mm Hg

<!-- PAGE=? -->
 volatile anesthetics (in particular, halothane) inhibit the heart rate component of this reflex

<!-- PAGE=? -->
 calcium channel blockers, angiotensin-converting enzyme inhibitors, or phosphodiesterase inhibitors will lessen the cardiovascular response of raising blood pressure through the baroreceptor reflex

<!-- PAGE=? -->
o direct effects on the peripheral vasculature

<!-- PAGE=? -->
o interference with CNS signaling pathways (calcium, angiotensin)

<!-- PAGE=? -->
 chronic HTN often results in perioperative circulatory instability as a result of a decrease in baroreceptor reflex response

<!-- PAGE=? -->
Chemoreceptor Reflex

<!-- PAGE=? -->
 Chemosensitive cells are located in the carotid bodies and the aortic body

<!-- PAGE=? -->
 respond to changes in pH status and blood oxygen tension (<50mmHg)

<!-- PAGE=? -->
 afferents via the sinus nerve of Hering (a branch of the glossopharyngeal nerve ) and the vagus nerve to the chemosensitive area of the medulla resulting in stimulation of the respiratory centers → increasing the ventilatory drive

<!-- PAGE=? -->
 parasympathetic system activation leads to a reduction in heart rate and myocardial contractility

<!-- PAGE=? -->
 With persistent hypoxia, the CNS will be directly stimulated, with a resultant increase in sympathetic activity.

<!-- PAGE=? -->
Bainbridge Reflex

<!-- PAGE=? -->
 elicited by stretch receptors located in the right atrial wall and the cavoatrial junction

<!-- PAGE=? -->
 ↑ right-sided filling pressure → vagal afferent signals to the cardiovascular center in the medulla → inhibit parasympathetic activity → increased heart rate

<!-- PAGE=? -->
 Acceleration of the heart rate also results from a direct effect on the SA node by stretching the atrium

<!-- PAGE=? -->
 The changes in heart rate are dependent on the underlying heart rate before stimulation

<!-- PAGE=? -->
 Stretching of the atria evokes reflex vasodilation and decreases the systemic blood pressure back toward the normal level

<!-- PAGE=? -->
Bradycardiac with Spinal The -reverse Bainbridge‖ relates to slowing of the heart seen with spinal anesthetics

<!-- PAGE=? -->
 Blockade of the SNS levels of T1-T4 ablates the efferent limb of the cardiac accelerator nerves unopposed vagus

<!-- PAGE=? -->
 bradycardia during spinal anesthesia is more closely related to the development of arterial hypotension than to the height of the block

<!-- PAGE=? -->
 The primary defect in the development of spinal hypotension is a decrease in venous return

<!-- PAGE=? -->
o arterial hypotension should reflexly produce a tachycardia through the arterial baroreceptors, but bradycardia is more common

<!-- PAGE=? -->
 Greene suggests that in the unmedicated person, the venous baroreceptors are dominant over the arterial. A reduced venous pressure, therefore, slows HR. In contrast, humorally mediated tachycardia is the usual response to hypotension or acidosis from other causes…Unlike the arterial baroreceptors, venous sensors are not thought to alter vascular tone; however, venoconstriction is postulated to occur when atrial pressures decline

<!-- PAGE=? -->
Bezold-Jarisch Reflex

<!-- PAGE=? -->
 responds to noxious ventricular stimuli sensed by chemoreceptors and mechanoreceptors within the LV wall with the triad of

<!-- PAGE=? -->
o hypotension

<!-- PAGE=? -->
o bradycardia

<!-- PAGE=? -->
o coronary artery dilatation

<!-- PAGE=? -->
 afferents are via unmyelinated vagal type C fibers → increased parasympathetic tone

<!-- PAGE=? -->
 thought of as a cardioprotective reflex

<!-- PAGE=? -->
 implicated in the physiologic response to

<!-- PAGE=? -->
o myocardial ischemia or infarction

<!-- PAGE=? -->
o thrombolysis

<!-- PAGE=? -->
o revascularization

<!-- PAGE=? -->
o syncope

<!-- PAGE=? -->
 Natriuretic peptide receptors stimulated by endogenous ANP or BNP may modulate the Bezold-Jarisch reflex, blunting it in patients with cardiac hypertrophy or atrial fibrillation

<!-- PAGE=? -->
Valsalva Maneuver

<!-- PAGE=? -->
 Forced expiration against a closed glottis produces

<!-- PAGE=? -->
o ↑ intrathoracic pressure

<!-- PAGE=? -->
o ↑ central venous pressure

<!-- PAGE=? -->
o ↓ venous return

<!-- PAGE=? -->
 → ↓ CO, and BP → sensed by baroreceptors → ↑ in heart rate and myocardial contractility (sympathetic stimulation) → glottis opens → ↑ venous return, vigorous contraction and an ↑ in blood pressure → sensed by baroreceptors → parasympathetic efferent pathways to the heart → bradycardia

<!-- PAGE=? -->
Cushing's Reflex - result of cerebral ischemia caused by ↑ ICP

<!-- PAGE=? -->
 ischemia at the medullary vasomotor center → activation of the sympathetic nervous system → increased heart rate, blood pressure, and myocardial contractility in an effort to improve cerebral perfusion → reflex bradycardia mediated by baroreceptors will ensue.

<!-- PAGE=? -->
Oculocardiac Reflex - provoked by pressure applied to the globe of the eye or traction on the surrounding structures

<!-- PAGE=? -->
 Stretch receptors are located in the extraocular muscles → afferent signals through the short and long ciliary nerves → merge with the ophthalmic division of the trigeminal nerve (V) at the ciliary ganglion → gasserian ganglion → increased parasympathetic tone and subsequent bradycardia

<!-- PAGE=? -->
 incidence of this reflex during ophthalmic surgery ranges from 30% to 90%

<!-- PAGE=? -->
Cardiac Transplant

<!-- PAGE=? -->
Cardiac function after transplantation

<!-- PAGE=? -->
Mvocardial metabolism normal

<!-- PAGE=? -->
Contractilc rescrve nornal

<!-- PAGE=? -->
Ventricular function slightly rcduccd

<!-- PAGE=? -->
Frank-Starling mechanisn intact

<!-- PAGE=? -->
Lcft-ventricular nass /end-diastolic thickness nornal wall

<!-- PAGE=? -->
Diastolic rclaxation abnornal

<!-- PAGE=? -->
Freload dependence for ventricular output

<!-- PAGE=? -->
Cardiac output increase due to increase venous rcturn

<!-- PAGE=? -->
Exercisc responses include

<!-- PAGE=? -->
Heart ratc incrcascs due to catecholaminc increasc

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 drugs that act indirectly on the heart fail to produce their typical effects after denervation

<!-- PAGE=? -->
o atropine or pancuronium does not elevate heart rate although neostigmine can cause bradycardia in this population

<!-- PAGE=? -->
 Neostigmine produced bradycardia cannot be countered by atropine or glycopyrrolate

<!-- PAGE=? -->
 indirectly acting cardiac drugs lose their vagolytic effects after denervation

<!-- PAGE=? -->
 Agents that directly on myocardium or cardiac conduction tissues manifest their usual effects

<!-- PAGE=? -->
o isoproterenol increases contractility and heart rate

<!-- PAGE=? -->
o propranolol decreases HR

<!-- PAGE=? -->
 Digoxin, which has mixed direct-indirect actions , acts only directly after transplantation

<!-- PAGE=? -->
o fails to alter either the functional or effective refractory periods of the atrioventricular node

<!-- PAGE=? -->
o suggests that digoxin's acute, chronotropic effects are vagotonic, dependent on intact autonomic innervations

<!-- PAGE=? -->
o inotropic response from a direct effect remains and is independent of autonomic innervations

<!-- PAGE=? -->
 Norepinephrine has somewhat atypical effects

<!-- PAGE=? -->
o Infusions at conventional doses may be accompanied by more pronounced chronotropic effects than usual, through a direct b-adrenergic receptor-mediated effect on the sinus node that is normally masked by vagal reflexes

<!-- PAGE=? -->
 moderate supersensitivity to adenosine after transplantation

<!-- PAGE=? -->
 In the absence of rejection or significant pulmonary hypertension, the resting stroke volume and indices of myocardial contractility are often normal  or only subtly reduced

<!-- PAGE=? -->
o the response of the denervated heart to the demands for increased cardiac output are demonstrably different

<!-- PAGE=? -->
 In the normally innervated heart, immediate increases in cardiac output are mediated by elevation in heart rate with little change in stroke volume

<!-- PAGE=? -->
o the denervated heart responds to such demands by increases in stroke volume rather than in heart rate

<!-- PAGE=? -->
 Cardiac recipients are preload dependent and must have adequate central volume to meet the demands of stress or anesthetic techniques that redistribute vascular volume to the periphery

<!-- PAGE=? -->
 The absence of cardiac vagal tone will result in a baseline heart rate of 90 to 100 beats/min in most patients

<!-- PAGE=? -->
 Autonomic denervation limits the normal tachycardic and inotropic reflex response to hypovolemia or hypotension (i.e., that caused by neuraxial and general anesthetic drugs)

<!-- PAGE=? -->
 reflex-mediated vasoconstriction of capacitance vessels may still serve to recruit additional stroke volume by intact Frank-Starling mechanisms

<!-- PAGE=? -->
 When assessed at 5 years, coronary artery vasculopathy (CAV) has developed in about 33% of heart transplant recipients

<!-- PAGE=? -->
 Drugs with direct effects at cardiac autonomic receptors… should be selected for inotropic or chronotropic therapy

<!-- PAGE=? -->
Carotid Endarterectomy

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 overall risk for stroke and death was 3.4% for asymptomatic stenosis

<!-- PAGE=? -->
o 5.2% for symptomatic stenosis

<!-- PAGE=? -->
 incidence of perioperative stroke

<!-- PAGE=? -->
o previous stroke > TIAs > asymptomatic

<!-- PAGE=? -->
 Indications for carotid endarterectomy include:

<!-- PAGE=? -->
o TIAs associated with > 70% stenosis (10% risk of stroke per year)

<!-- PAGE=? -->
 NASCET trial: >70%, ipsilateral stroke 9% CEA vs. 26% medical

<!-- PAGE=? -->
o Severe ipsilateral stenosis in a patient with an incomplete stroke

<!-- PAGE=? -->
 following recent neurologic event, CEA probably has greatest benefit if performed within two weeks despite theoretical increased risk of ICH

<!-- PAGE=? -->
o Asymptomatic with stenosis > 60% (controversial)

<!-- PAGE=? -->
 ACAS trial: >60%, risk of stroke or death 5% with CEA vs 11%

<!-- PAGE=? -->
o Soft, ulcerated plaques (carry a risk of 7 - 8%/year)

<!-- PAGE=? -->
 Risk factors for neurologic deficits

<!-- PAGE=? -->
o preoperative hypertension

<!-- PAGE=? -->
o postoperative hypertension or hypotension

<!-- PAGE=? -->
 hypertension is more common

<!-- PAGE=? -->
 may precipitate MI, CHF, cerebral edema, cerebral hemorrhage

<!-- PAGE=? -->
 incidence of perioperative MI ranges from 0% to 4%

<!-- PAGE=? -->
o incidence of myocardial ischemia is high in the first few hours after carotid endarterectomy, even in patients who have been -awake‖ during carotid endarterectomy

<!-- PAGE=? -->
o MI is the leading cause of perioperative and late mortality

<!-- PAGE=? -->
 Post-op hypertension is significantly associated with adverse events stroke or death

<!-- PAGE=? -->
o postoperative hypotension and bradycardia do not correlate with primary or secondary outcomes

<!-- PAGE=? -->
 hypertensive episode has its peak 2-3 hr after surgery, but in individual cases it may persist for 24 hr

<!-- PAGE=? -->
 Postoperative respiratory distress may occur as the result of

<!-- PAGE=? -->
o Wound hematoma

<!-- PAGE=? -->
o Laryngeal edema

<!-- PAGE=? -->
o Residual neuromuscular blockade

<!-- PAGE=? -->
o Opiods

<!-- PAGE=? -->
Stenting

<!-- PAGE=? -->
 Generally reserved for patients at high operative risk for CEA

<!-- PAGE=? -->
 SAPPHIRE trial: noninferiority of stenting vs CEA in patients with CAD associated with one or more major risk factors for peri-operative morbidity

<!-- PAGE=? -->
o Composite of death/stroke/MI within 30 days: ARR 8%.

<!-- PAGE=? -->
o Lower death or ipsilateral stroke between 31 days and 1 year.

<!-- PAGE=? -->
o Reduction in MI, CN palsy, LOS

<!-- PAGE=? -->
o This study used -umbrella‖ devices to retrieve atheromatous debris; previous series without such protection had higher rates of distal embolization

<!-- PAGE=? -->
 Gurm HS et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008 Apr 10;358(15):1572-9.

<!-- PAGE=? -->
o no significant difference could be shown in long-term outcomes between patients who underwent carotid artery stenting with an emboli-protection device and those who underwent endarterectomy

<!-- PAGE=? -->
Celiac Plexus

<!-- PAGE=? -->
 The celiac plexus contributes to the innervation of all the intra-abdominal viscera derived from embryonic foregut

<!-- PAGE=? -->
o distal esophagus, stomach, duodenum, small bowel, ascending and proximal transverse colon), pancreas, adrenal glands, spleen, liver, and biliary system

<!-- PAGE=? -->
 kidney is innervated by the aorticorenal ganglion (Netter)

<!-- PAGE=? -->
 spares the left side of the colon and the pelvic viscera

<!-- PAGE=? -->
 T5 - T12 = celiac plexus: ( GI tract (distal esopahus to mid-transverse colon), liver, adrenals, ureters, vessels of abdomen, parenchymatous organs)

<!-- PAGE=? -->
o Preganglionic fibers

<!-- PAGE=? -->
 T5 - T10 great splachnic nerve

<!-- PAGE=? -->
 T10 - T11 lesser splanchnic nerve

<!-- PAGE=? -->
 T11-T12 least splanchnic nerve

<!-- PAGE=? -->
o Synapse in paired celiac ganglion

<!-- PAGE=? -->
 generally clustered at the body of L1

<!-- PAGE=? -->
 kidneys are lateral

<!-- PAGE=? -->
 medial to the IVC on the right

<!-- PAGE=? -->
 lateral to the aorta on the left

<!-- PAGE=? -->
 posterior to the pancreas

<!-- PAGE=? -->
o often blocked bilaterally, but if you were to only do one side, it would be the left

<!-- PAGE=? -->
 L1-L3 lumbar ganglion  (urogenital organs, colon ,rectum, skin, vessels of lower limb)

<!-- PAGE=? -->
 celiac plexus is located

<!-- PAGE=? -->
o anterior to the crura of the diaphragm

<!-- PAGE=? -->
o surrounds the abdominal aorita and the celiac and superior mesenteric arteries

<!-- PAGE=? -->
 celiac block has potential utility for treating pain emanating from a variety of intra-abdominal structures, although its most important indication is pain due to pancreatic cancer .

<!-- PAGE=? -->
o Diffuse abdominal pain due to disseminated peritoneal implants is unlikely to be relieved after celiac block

<!-- PAGE=? -->
o Painful hepatic metastases may respond to celiac block, unless referred right shoulder pain is prominent.

<!-- PAGE=? -->
o Short- and long-term outcomes for pain of non-neoplastic origin are often disappointing

<!-- PAGE=? -->
o It does not result in good, prolonged pain relief in pts with chronic pancreatitis or other chronic abdo pain sx

<!-- PAGE=? -->
 Most effective in tx CA pain, better with fewer s/e to high dose opiods

<!-- PAGE=? -->
 Can be of therapeutic value in relieving spasm of acute pancreatitis - LA and methyprednisolone

<!-- PAGE=? -->
 The celiac plexus is the largest of the great plexuses of the sympathetic nervous system

<!-- PAGE=? -->
o cardiac plexus innervates primarily thoracic structures

<!-- PAGE=? -->
o celiac plexus innervates abdominal organs

<!-- PAGE=? -->
o hypogastric plexus supplies pelvic organs

<!-- PAGE=? -->
 All three contain visceral afferent and efferent fiber of the sympathetic nervous system

<!-- PAGE=? -->
 They also contain parasympathetic fibers that pass through these ganglia after originating in cranial or sacral areas of the nervous system

<!-- PAGE=? -->
 They contain no somatic fibers but do innervate most of the abdominal viscera

<!-- PAGE=? -->
Three Splanchnic Nerves

<!-- PAGE=? -->
(Cell Bodies in Spinal Cord)

<!-- PAGE=? -->
Celiac Ganglia

<!-- PAGE=? -->
Right and

<!-- PAGE=? -->
Celiac Plexus

<!-- PAGE=? -->
Lell

<!-- PAGE=? -->
Vagal Trunks

<!-- PAGE=? -->
Vaqus Io Abdominal

<!-- PAGE=? -->
Viscera Except

<!-- PAGE=? -->
Sympathetic to al/

<!-- PAGE=? -->
Hindqut Gonad and

<!-- PAGE=? -->
Abdominal Viscera

<!-- PAGE=? -->
Adrenal

<!-- PAGE=? -->
(Including Gonads)

<!-- PAGE=? -->
Vagal Relay in

<!-- PAGE=? -->
Wall of Viscus

<!-- PAGE=? -->
 Fibers from this ganglion send postganglionic innervation to carry pain sensation from many of the intraperitoneal organs such as the pancreas and liver

<!-- PAGE=? -->
 blockade produces supplementary intra-abdominal anesthesia when used in conjunction with intercostal blockade or general anesthesia

<!-- PAGE=? -->
 It is more commonly applied as a neurolytic sympathetic blockade for the relief of pain from malignancy of the pancreas, liver, or other upper abdominal organs

<!-- PAGE=? -->
o EtOH is used due to the risk of high volumes of Phenol

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
 The most common complication is postural hypotension, which is largely due to blockade of the lumbar sympathetic chain

<!-- PAGE=? -->
 Other causes of hypotension include retroperitoneal hematoma secondary to bleeding from aorta or vena cava

<!-- PAGE=? -->
o Inadvertent injection

<!-- PAGE=? -->
 Subarachnoid

<!-- PAGE=? -->
 Epidural

<!-- PAGE=? -->
 Intraosseous

<!-- PAGE=? -->
 Intrapsoas

<!-- PAGE=? -->
 Intravascular

<!-- PAGE=? -->
o puncture of viscera (most often kidney)

<!-- PAGE=? -->
 lymphatic duct

<!-- PAGE=? -->
o abscesses or cysts

<!-- PAGE=? -->
o after neurolytic blocks (spread of solution to contaminate lumbar plexus and central neuroaxis)

<!-- PAGE=? -->
 paralysis

<!-- PAGE=? -->
 lower extremity dysesthesias

<!-- PAGE=? -->
 sexual dysfunction

<!-- PAGE=? -->
 incidence of 0.15%

<!-- PAGE=? -->
 orthostatic hypotension

<!-- PAGE=? -->
 interscapular back pain

<!-- PAGE=? -->
 reactive pleurisy

<!-- PAGE=? -->
 hiccups

<!-- PAGE=? -->
 hematuria

<!-- PAGE=? -->
 transient diarrhea

<!-- PAGE=? -->
 Aortic dissection

<!-- PAGE=? -->
Cerebral Aneurysms

<!-- PAGE=? -->
 Post SAH -- 2-4% rebleed within 24hrs, 15-20% rebleed within 2wks

<!-- PAGE=? -->
 50% of SAH have a prior sentinal bleed

<!-- PAGE=? -->
 HTN and smoking are risk factors

<!-- PAGE=? -->
Kidnc

<!-- PAGE=? -->
Kidacy

<!-- PAGE=? -->
Pancreas

<!-- PAGE=? -->
 Risk factors for rupture include

<!-- PAGE=? -->
 HTN, smoking, cocaine abuse, female, OCP

<!-- PAGE=? -->
 Most aneurysms involve the anterior circulation (ACA=30%, MCA=25%)

<!-- PAGE=? -->
 Posterior circulation aneurysms have the highest rates of rupture

<!-- PAGE=? -->
Cerebral blood flow

<!-- PAGE=? -->
250

<!-- PAGE=? -->
200

<!-- PAGE=? -->
150

<!-- PAGE=? -->
PP

<!-- PAGE=? -->
Normol

<!-- PAGE=? -->
100

<!-- PAGE=? -->
PP

<!-- PAGE=? -->
50

<!-- PAGE=? -->
0

<!-- PAGE=? -->
PP

<!-- PAGE=? -->
100

<!-- PAGE=? -->
150-

<!-- PAGE=? -->
200

<!-- PAGE=? -->
250

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
40

<!-- PAGE=? -->
60

<!-- PAGE=? -->
80

<!-- PAGE=? -->
100

<!-- PAGE=? -->
50

<!-- PAGE=? -->
150

<!-- PAGE=? -->
200-

<!-- PAGE=? -->
Pocoz

<!-- PAGE=? -->
Pooz

<!-- PAGE=? -->
Pocoz

<!-- PAGE=? -->
Pocoz

<!-- PAGE=? -->
Poo2

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 CBF changes 1 to 2 mL/100 g/min (2-4%) for each 1-mm Hg change in PaCO2 around normal PaCO2 values

<!-- PAGE=? -->
o CBF is linear between PaCO2 20 - 80

<!-- PAGE=? -->
 Over range of PaCO2 20-80mmHg, CBF quadruples

<!-- PAGE=? -->
 As PaCO2 increases from 40-80mmHg, CBF doubles

<!-- PAGE=? -->
 As PaCO2 decreases from 40-20mmHg, CBF decreases to one half normal

<!-- PAGE=? -->
 Changes in PaO2 from 60 to over 300 mm Hg have little influence on CBF

<!-- PAGE=? -->
o mechanisms mediating the cerebral vasodilation during hypoxia are not fully understood but may include neurogenic effects initiated by peripheral or neuraxial chemoreceptors, as well as local humoral influences

<!-- PAGE=? -->
 Autoregulation refers to the capacity of the cerebral circulation to adjust its resistance so that it can maintain CBF constant over a wide range of mean arterial pressure (MAP) values.

<!-- PAGE=? -->
o normal human subjects, the limits of autoregulation occur at MAP values of approximately 60 and 160 mm Hg (CPP of 50 - 150)

<!-- PAGE=? -->
 maintain CPP at minimum of 60mmHg

<!-- PAGE=? -->
o The lower limit of autoregulation (LLA) has been widely quoted as an MAP of 50 mm Hg. Although this number may be correct for some animal species, the available data argue that the LLA is considerably higher in humans

<!-- PAGE=? -->
 CMR ( not CBF) decreases by 6% to 7%/°C of temperature reduction

<!-- PAGE=? -->
o hypothermia can also cause complete suppression of the EEG (at about 18°C to 20°C).

<!-- PAGE=? -->
o Hyperthermia has an opposite influence on cerebral physiology. Between 37°C and 42°C, CBF and CMR increase

<!-- PAGE=? -->
o in contrast to anesthetics, temperature reduction beyond that at which EEG suppression first occurs does produce a further decrease in CMR

<!-- PAGE=? -->
Barash 4 th Ch 33:

<!-- PAGE=? -->
 EEG deterioration begins usually below a cerebral blood flow rate of about 15 mL/min/100g brain tissue

<!-- PAGE=? -->
 cellular metabolic failure does not seem to occur until blood flow falls below 10-12 mL/min/100g brain tissue.

<!-- PAGE=? -->
20

<!-- PAGE=? -->
20

<!-- PAGE=? -->
40

<!-- PAGE=? -->
60

<!-- PAGE=? -->
00

<!-- PAGE=? -->
Thiopenlal

<!-- PAGE=? -->
10 . 55 mgkg

<!-- PAGE=? -->
Propolol

<!-- PAGE=? -->
Elomidale

<!-- PAGE=? -->
0.2 mgkg + infusion

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
1

<!-- PAGE=? -->
CBF

<!-- PAGE=? -->
Fenlanyl

<!-- PAGE=? -->
Sulentanil

<!-- PAGE=? -->
10 pgkg

<!-- PAGE=? -->
Diazepam

<!-- PAGE=? -->
0.2 mgkg

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
0,15 mgkg

<!-- PAGE=? -->
n.5.

<!-- PAGE=? -->
Ketamlne 3 mgkg

<!-- PAGE=? -->
~RO

<!-- PAGE=? -->
40

<!-- PAGE=? -->
20

<!-- PAGE=? -->
60

<!-- PAGE=? -->
80

<!-- PAGE=? -->
Percent change in CBF and CMRO?

<!-- PAGE=? -->
Table 28-5. EFFECTS OF ANESTHETICS ON CBF/CMRO2

<!-- PAGE=? -->
CBF

<!-- PAGE=? -->
CMRO2

<!-- PAGE=? -->
Direct Cerebral

<!-- PAGE=? -->
Vasodilation

<!-- PAGE=? -->
Halothane

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Enflurane

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Isoflurane

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Desflurane

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Sevoflurane

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
N2O alone

<!-- PAGE=? -->
-

<!-- PAGE=? -->
N2O with volatile anesthetics

<!-- PAGE=? -->
-

<!-- PAGE=? -->
Circle of Willis

<!-- PAGE=? -->
Pnterior

<!-- PAGE=? -->
communicating

<!-- PAGE=? -->
Anterior

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
cerebra]

<!-- PAGE=? -->
cerebral

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Ophthalmic

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Internal

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
thoroidal

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
communic

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
'cerebral

<!-- PAGE=? -->
Superior

<!-- PAGE=? -->
Pontine

<!-- PAGE=? -->
Cerebellar

<!-- PAGE=? -->
ateries

<!-- PAGE=? -->
'Basilar

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Anterior

<!-- PAGE=? -->
inferior

<!-- PAGE=? -->
cerebella

<!-- PAGE=? -->
Vertebral

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
Anterior

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
spina]

<!-- PAGE=? -->
inferior

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
cerebellar

<!-- PAGE=? -->
atery

<!-- PAGE=? -->
ating

<!-- PAGE=? -->
artery

<!-- PAGE=? -->
Cerebral palsy

<!-- PAGE=? -->
Stoelting 702-703

<!-- PAGE=? -->
 symptom complex of motor impairment

<!-- PAGE=? -->
 High freq of epilepsy and cognitive disorders

<!-- PAGE=? -->
 1-2/1000 live births

<!-- PAGE=? -->
 Symptoms

<!-- PAGE=? -->
o skeletal muscle spasticity

<!-- PAGE=? -->
o mental retardation and speech deficits

<!-- PAGE=? -->
o seizures

<!-- PAGE=? -->
o GERD is common

<!-- PAGE=? -->
o Poor laryngeal and pharyngeal reflexes

<!-- PAGE=? -->
 Sux ok

<!-- PAGE=? -->
 Susceptible to hypothermia

<!-- PAGE=? -->
 Slow emergence

<!-- PAGE=? -->
 High incidence postop complications

<!-- PAGE=? -->
Cerebral salt wasting

<!-- PAGE=? -->
 Cerebral salt-wasting syndrome is characterized by the triad of hyponatremia, volume contraction, and high urine sodium concentrations (>50 mmol/L)

<!-- PAGE=? -->
 Cerebral salt-wasting syndrome appears to be mediated by brain natriuretic peptide

<!-- PAGE=? -->
 SIADH is characterized by normovolemia or mild hypervolemia

<!-- PAGE=? -->
 SIADH and cerebral salt-wasting syndrome can best be differentiated by determination of total-body water by clinical measurements, including skin turgor, body weight, central venous pressure (CVP), and overall vital signs

<!-- PAGE=? -->
Cervical Plexus

<!-- PAGE=? -->
Anatomy:

<!-- PAGE=? -->
Cervical Plexus Branches include:

<!-- PAGE=? -->
 Lesser occipital

<!-- PAGE=? -->
 Greater auricular

<!-- PAGE=? -->
 Supraclavicular nerve

<!-- PAGE=? -->
 Transverse cervical (anterior cutaneous, anterior cervical)

<!-- PAGE=? -->
The spinal accessory nerve receives branches from the cervical plexus and is commonly blocked by the superficial cervical plexus block.

<!-- PAGE=? -->
Lesser

<!-- PAGE=? -->
Occional Nerve

<!-- PAGE=? -->
Antcrior Corvical

<!-- PAGE=? -->
Greal Auricular Nerve

<!-- PAGE=? -->
Nerve

<!-- PAGE=? -->
Accessory Nerve

<!-- PAGE=? -->
Supraclavicular Nerve

<!-- PAGE=? -->
Sternonastoid Nuscle

<!-- PAGE=? -->
Trapezus Muscle

<!-- PAGE=? -->
Sternomastoid Muscle

<!-- PAGE=? -->
Superficial Infiltration

<!-- PAGE=? -->
Superficial cervical plexus:

<!-- PAGE=? -->
 four distinct nerves from the posterior border of the sternomastoid muscle (midpoint), just below the emergence of the accessory nerve.

<!-- PAGE=? -->
o lesser occipital nerve radiates upward and backwards, supplies part of the posterior surface of the upper part of the ear and skin behind the ear

<!-- PAGE=? -->
o great auricular nerve - runs upward and forward, supplies skin over the posterior surface of the ear and the anterior lower third of the ear, as well as over the angle of the mandible

<!-- PAGE=? -->
o anterior cutaneous nerve of the neck -supplies skin from the chin to the suprasternal notch

<!-- PAGE=? -->
o supraclavicular nerves - inferior aspect of the neck, clavicle and chest

<!-- PAGE=? -->
 All four nerves can be blocked by infiltration at the midpoint of the posterior border of the sternomastoid - at the point where the external jugular crosses - 10 cc 1% lidocaine

<!-- PAGE=? -->
 Phrenic nerve is only blocked in deep cervical plexus block not superficial

<!-- PAGE=? -->
 Accessory nerve only blocked by superficial cervical nerve block

<!-- PAGE=? -->
Indication Superficial

<!-- PAGE=? -->
 Carotid endartrectomy

<!-- PAGE=? -->
o Advantages include

<!-- PAGE=? -->
 Reduced hospital/monitoring costs

<!-- PAGE=? -->
 Less hemodynamic lability (not related to baroreceptor block)

<!-- PAGE=? -->
 Decreased use of shunt.

<!-- PAGE=? -->
 Avoidance of ETT

<!-- PAGE=? -->
 +/- reduced CVA/MI (weak evidence)

<!-- PAGE=? -->
Deep Indications

<!-- PAGE=? -->
 Thyroidectomy

<!-- PAGE=? -->
 tracheostomy

<!-- PAGE=? -->
 CEA

<!-- PAGE=? -->
 Removal of cervical lymphnodes

<!-- PAGE=? -->
Technique

<!-- PAGE=? -->
Accessory

<!-- PAGE=? -->
Nerve

<!-- PAGE=? -->
Fascia

<!-- PAGE=? -->
Skin

<!-- PAGE=? -->
Sternomastoid Muscle

<!-- PAGE=? -->
Transverse Section 0f Neck

<!-- PAGE=? -->
Sternomaslold Muscle

<!-- PAGE=? -->
Single Injection

<!-- PAGE=? -->
 paravertebral block of the C2 to C4 spinal nerves as they emerge from their foramina in the cervical vertebrae

<!-- PAGE=? -->
o three separate injections at C2, C3, and C4

<!-- PAGE=? -->
 supine with the neck slightly extended and the head turned away

<!-- PAGE=? -->
 A line is drawn connecting the tip of the mastoid process and the Chassaignac tubercle (i.e., transverse process of C6)

<!-- PAGE=? -->
o second line is drawn 1 cm posterior to this first line

<!-- PAGE=? -->
 C2 transverse process lies 1 to 2 cm caudad to the mastoid process

<!-- PAGE=? -->
o C3 and C4 transverse processes lie at 1.5-cm intervals along the second line

<!-- PAGE=? -->
 needles are advanced perpendicular to the skin entry site with a slight caudad angulation

<!-- PAGE=? -->
o The transverse process is contacted at a depth of 1.5 to 3 cm

<!-- PAGE=? -->
 the needle is walked along the transverse process in the anteroposterior plane until a paresthesia is obtained

<!-- PAGE=? -->
Complications of Deep cervical plexus block

<!-- PAGE=? -->
 direct vertebral artery injection

<!-- PAGE=? -->
o results in profound and very rapid toxic side-effects

<!-- PAGE=? -->
 convulsions

<!-- PAGE=? -->
 unconsciousness

<!-- PAGE=? -->
 blindness

<!-- PAGE=? -->
o best avoided with aspiration tests

<!-- PAGE=? -->
 Epidural or subdural extension (via dural sleeves of leakage through the interverebral foramen)

<!-- PAGE=? -->
 bilateral phrenic nerve block

<!-- PAGE=? -->
 Horner's syndrome and block of the RLN

<!-- PAGE=? -->
o the deep cervical plexus lies deep to the deep cervical fascia, spread to the cervical sympathetic chain should not occur. If, however, infiltration has spread anterior to the prevertebral fascia, the cervical sympathetic chain will be involved, with resultant Horner's syndrome and also spread to the recurrent laryngeal nerve, resulting in hoarseness. Both of these complications in a failed block will indicate that, in fact, the anesthetic has been injected at a site superficial to the deep cervical fascia

<!-- PAGE=? -->
Cirrhosis

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 hyperdynamic circulation with

<!-- PAGE=? -->
o high CO

<!-- PAGE=? -->
o low PVR (unless portopulmonary hypertension exists)

<!-- PAGE=? -->
 secondary to mediators normally cleared by the liver

<!-- PAGE=? -->
o low/Normal  BP

<!-- PAGE=? -->
o Normal/inc SV

<!-- PAGE=? -->
o Normal filling Pressure

<!-- PAGE=? -->
o mild inc HR

<!-- PAGE=? -->
 increased total blood volume

<!-- PAGE=? -->
o Maldistribution with

<!-- PAGE=? -->
 Central hypovolemia

<!-- PAGE=? -->
 Hypervolemic splanchnic bed

<!-- PAGE=? -->
 ++ A-V collateralization in tissue

<!-- PAGE=? -->
o inc O2 tension and saturation of peripheral and mixed venous blood

<!-- PAGE=? -->
 blood flow exceeds metabolic demands

<!-- PAGE=? -->
o decreased in A-V CaO2

<!-- PAGE=? -->
 Glucagon dec vascular responsiveness to infused catecholamines/vasopressors.

<!-- PAGE=? -->
 Decreased hepatic blood flow

<!-- PAGE=? -->
o Normal arterial flow

<!-- PAGE=? -->
o Dec. portal venous flow d/t inc. resistance

<!-- PAGE=? -->
Table 39-4. CARDIOVASCULAR FUNCTION IN HEPATIC CIRRHOSIS

<!-- PAGE=? -->
Decreased vascular resistance (peripheral vasodilation, increased arteriovenous shunting)

<!-- PAGE=? -->
Increased cardiac output

<!-- PAGE=? -->
Maintained arterial blood pressure, filling pressures, and heart rate (deterioration is late)

<!-- PAGE=? -->
Blood volume maintained or increased, but redistributed (splanchnic hypervolemia, central hypovolemia).

<!-- PAGE=? -->
Possible cardiomyopathy

<!-- PAGE=? -->
Increased O2 content in mixed venous blood; decreased difference in the O2 contents of arterial and venous blood

<!-- PAGE=? -->
Diminished responsiveness to catecholamines

<!-- PAGE=? -->
Increased blood flow in splanchnic (extrahepatic), pulmonary, muscular, and cutaneous tissues

<!-- PAGE=? -->
Decreased total hepatic blood flow:

<!-- PAGE=? -->
Maintained hepatic arterial blood flow

<!-- PAGE=? -->
 Decreased portal venous blood flow

<!-- PAGE=? -->
Maintained or decreased renal blood flow

<!-- PAGE=? -->
Cisatracurium

<!-- PAGE=? -->
 Potent isomer of atracurium

<!-- PAGE=? -->
 Histamine release with cardiovascular effects only occurs at >0.4 mg/kg but ED95 much lower at 0.05mg/kg so not a problem in clinical practice

<!-- PAGE=? -->
 Metabolism via Hoffman degredation and ester hydrolysis (independent of hepatic and renal systems)

<!-- PAGE=? -->
 Onset time 4 min at 0.1 mg/kg, duration 30-45 min

<!-- PAGE=? -->
 Recommended intubating dose 0.15 mg/kg (in order to speed onset) duration 45-60 min

<!-- PAGE=? -->
 Because the doses are lower than atracurium, less laudanosine and acrylate byproducts are produced (less potential for toxic side effects)

<!-- PAGE=? -->
 No need to adjust dose for elderly, children, infants

<!-- PAGE=? -->
 Dose on IBW in obese

<!-- PAGE=? -->
Child-Pugh Score

<!-- PAGE=? -->
Predictor of perioperative risk with cirrhosis

<!-- PAGE=? -->
Classes

<!-- PAGE=? -->
Class A

<!-- PAGE=? -->
 5-6 points

<!-- PAGE=? -->
 80% 2 yr survival

<!-- PAGE=? -->
 ~ 10% perioperative morbidity & mortality

<!-- PAGE=? -->
Class B

<!-- PAGE=? -->
 7-9 points

<!-- PAGE=? -->
 60% 2 yr survival

<!-- PAGE=? -->
 ~ 30% perioperative morbidity & mortality

<!-- PAGE=? -->
Class C

<!-- PAGE=? -->
 10-15 points

<!-- PAGE=? -->
 35% 2 yr survival

<!-- PAGE=? -->
 ~ 80% perioperative morbidity & mortality

<!-- PAGE=? -->
Chemoreceptors

<!-- PAGE=? -->
 peripheral chemoreceptors

<!-- PAGE=? -->
o primarily respond to lack of oxygen

<!-- PAGE=? -->
 decreased PaO2 (60-65mmHg), but not by decreased SaO2 or CaO2

<!-- PAGE=? -->
 Respiratory response is inc. Mv

<!-- PAGE=? -->
 Hemodynamic response is bradycardia, hypertension, increased bronchiolar tone, and increases in adrenal secretion

<!-- PAGE=? -->
o composed of the  carotid and aortic bodies

<!-- PAGE=? -->
o carotid bodies are located at the bifurcation of the common carotid artery, have predominantly ventilatory effects

<!-- PAGE=? -->
 neural output reaches the central respiratory centers via the afferent glossopharyngeal nerves

<!-- PAGE=? -->
o The aortic bodies , which are scattered about the aortic arch and its branches, have predominantly circulatory effects

<!-- PAGE=? -->
 Output travels to the medullary centers via the vagus nerve

<!-- PAGE=? -->
 Central chemoreceptors (CNS)

<!-- PAGE=? -->
o primarily respond to changes in PCO2, pH, and acid-base disturbances

<!-- PAGE=? -->
 The peripheral receptor's response to hypoxemia is relatively resistant to the influences of anesthesia and tissue hypoxia that may depress central responses

<!-- PAGE=? -->
 However, the peripheral receptor's response is not sufficiently robust to reliably increase ventilatory rate or minute ventilation to herald the onset of arterial hypoxemia during general anesthesia or recovery from anesthesia

<!-- PAGE=? -->
Chemoreceptor Trigger Zone

<!-- PAGE=? -->
 The CTZ is rich in opioid, dopamine (D2), serotonin (5-HT3), histamine, and (muscarinic) acetylcholine receptors, and also receives input from the vestibular portion of the eighth cranial nerve.

<!-- PAGE=? -->
 Morphine and related opioids induce nausea by direct stimulation of the CTZ, and can also produce increased vestibular sensitivity

<!-- PAGE=? -->
Histamine (H,?)

<!-- PAGE=? -->
Acetylcholine (Muscarinic)

<!-- PAGE=? -->
Antagonists

<!-- PAGE=? -->
Antagonists

<!-- PAGE=? -->
Antagonists

<!-- PAGE=? -->
Antagonists

<!-- PAGE=? -->
Inhibit

<!-- PAGE=? -->
CTZ

<!-- PAGE=? -->
Stimulaic

<!-- PAGE=? -->
Vestibular Poruon

<!-- PAGE=? -->
CN VIII

<!-- PAGE=? -->
?Inhibit

<!-- PAGE=? -->
Benzodiazepines

<!-- PAGE=? -->
Propofol

<!-- PAGE=? -->
Stimulate (dosc-dependent)

<!-- PAGE=? -->
Stimulate

<!-- PAGE=? -->
OPIOIDS

<!-- PAGE=? -->
Inhibit (high doscs)

<!-- PAGE=? -->
Vomiting

<!-- PAGE=? -->
GI distension

<!-- PAGE=? -->
Center

<!-- PAGE=? -->
Pharynx

<!-- PAGE=? -->
(via

<!-- PAGE=? -->
Higher Centers

<!-- PAGE=? -->
Medastinum

<!-- PAGE=? -->
Vagus

<!-- PAGE=? -->
Table 1  Gradesof hepaticencephalopathy

<!-- PAGE=? -->
Chemotherapy

<!-- PAGE=? -->
Adriamycin (Doxorubicin)

<!-- PAGE=? -->
 used for leukemias, lymphomas, solid tumors (breast )

<!-- PAGE=? -->
 acute, reversible nonspecific ST-T changes in 33% cases

<!-- PAGE=? -->
 depressed QRS voltage of >30% is irreversible and predictive of subsequent cardiomyopathy

<!-- PAGE=? -->
 Cardiomyopathy - days to years after cessation, incidence 2-32%, mortality 61%, risk factor = total dose > 550 mg/m2, irradiation. Angiography = best noninvasive dx test , endomyocardial bx = gold standard

<!-- PAGE=? -->
Bleomycin

<!-- PAGE=? -->
 used for lymphomas, testicular tumors, squamous cell carcinoma

<!-- PAGE=? -->
 causes pulmonary toxicity, risk is dose related

<!-- PAGE=? -->
 causes all four major categories of pulmonary toxicity:

<!-- PAGE=? -->
o pulmonary fibrosis (most common, in 2-40%. 10% mortality),

<!-- PAGE=? -->
o PHTN,

<!-- PAGE=? -->
o acute hypersensitivity rxn,

<!-- PAGE=? -->
o non-cardiogenic pulmonary edema.

<!-- PAGE=? -->
 risk increased with radiation, concurrent cyclophosphaminde, increased age.

<!-- PAGE=? -->
 high FiO2 has been implicated as a risk factor but not clearly proven; it is prudent to keep low FiO2 in patients with hx of Bleomycin.

<!-- PAGE=? -->
Mytomycin

<!-- PAGE=? -->
 plm fibrosis in 3-12% patients

<!-- PAGE=? -->
 risk increased with radiation and oxygen therapy

<!-- PAGE=? -->
Methotrexate

<!-- PAGE=? -->
 pulmonary complications in 8%:

<!-- PAGE=? -->
 fulminant noncardiogenic plm edema,

<!-- PAGE=? -->
 interstitial infiltrates and plm effusions

<!-- PAGE=? -->
 low mortality from plm complications

<!-- PAGE=? -->
 symptoms respond to corticostroids

<!-- PAGE=? -->
 neurologic

<!-- PAGE=? -->
 IT administration causes meningeal irritation in 61%; transient/permanent paraplegia is more rare.

<!-- PAGE=? -->
 Encephalopathic syndrome after iv/IT administration

<!-- PAGE=? -->
 renal

<!-- PAGE=? -->
 incidence = 10%

<!-- PAGE=? -->
 renal insufficiency can be prevented by hydration and urinary alkalinization

<!-- PAGE=? -->
 hepatic

<!-- PAGE=? -->
 short-term therapy leads to elevated LFT

<!-- PAGE=? -->
 longer tx lead to fibrosis and cirrhosis

<!-- PAGE=? -->
 recent MXT - do LFT preop

<!-- PAGE=? -->
Chiari Malformation

<!-- PAGE=? -->
Cottrell 4 th

<!-- PAGE=? -->
 Chiari type I (most common)= descent of cerebellar tonsils into the upper cervical spinal canal

<!-- PAGE=? -->
o Less commonly associated with hydrocephalus

<!-- PAGE=? -->
o presents with symptoms in late childhood or young adulthood

<!-- PAGE=? -->
 elevated ICP

<!-- PAGE=? -->
 a classic downbeat nystagmus

<!-- PAGE=? -->
 cerebellar ataxia

<!-- PAGE=? -->
 bulbar dysfunction

<!-- PAGE=? -->
 symptoms of syringomyelia

<!-- PAGE=? -->
 capelike sensory loss extending to the face, to the back of the head, and onto the trunk

<!-- PAGE=? -->
 long-tract signs

<!-- PAGE=? -->
 upper extremity atrophy

<!-- PAGE=? -->
 Chiari type II (-classic‖) = herniation of inferior vermis through the foramen magnum

<!-- PAGE=? -->
o associated additional anomalies

<!-- PAGE=? -->
 -beaking‖ of the quadrigeminal plate

<!-- PAGE=? -->
 elongation of the fourth ventricle

<!-- PAGE=? -->
 kinking of the medulla

<!-- PAGE=? -->
o nearly always associated with spina bifida aperta

<!-- PAGE=? -->
o Hydrocephalus is nearly always present

<!-- PAGE=? -->
o Syringomyelia (or hydromyelia)

<!-- PAGE=? -->
o may manifest itself in the neonate

<!-- PAGE=? -->
 progressive hydrocephalus and lower cranial nerve problems (stridor and dysphagia) in addition to their spina bifida

<!-- PAGE=? -->
o Inc. risk of anaphylactic latex reactions

<!-- PAGE=? -->
o Possible AA instability

<!-- PAGE=? -->
 Chiari type III is essentially a hindbrain hernia into an occipital enphalocele.

<!-- PAGE=? -->
Surgical therapy is indicated when brainstem of longtract signs are present or when the patient suffers from intractable headaches

<!-- PAGE=? -->
Cholinergic receptors

<!-- PAGE=? -->
   Cholinergic crisis:

<!-- PAGE=? -->
o       Muscarinic effects

<!-- PAGE=? -->
     Confusion (ataxia, seizure)

<!-- PAGE=? -->
     Miosis

<!-- PAGE=? -->
     Bradycardia

<!-- PAGE=? -->
     Bronchoconstriction & bronchorhea

<!-- PAGE=? -->
     Salivation

<!-- PAGE=? -->
     Bowel and bladder incontinence

<!-- PAGE=? -->
     Abdominal cramping

<!-- PAGE=? -->
o       Nicotinic effects

<!-- PAGE=? -->
     Weakness

<!-- PAGE=? -->
     Respiratory depression

<!-- PAGE=? -->
    Types (4):

<!-- PAGE=? -->
o       Nicotinic (N1) - all ANS ganglia (SNS & PNS)

<!-- PAGE=? -->
o       Nicotinic (N2) - NMJ (motor end plate)

<!-- PAGE=? -->
o       Muscarinic (M1) - POSTganglionic PNS (effector site)

<!-- PAGE=? -->
o       Mucsarinic (M2) - PREsynaptic cardiac SNS (inhibits NE release)

<!-- PAGE=? -->
Cholinesterases

<!-- PAGE=? -->
 Plasma cholinesterase, pseudocholinesterase, or nonspecific cholinesterase is an enzyme with a molecular weight of 320,000 and a tetrahedral structure. It is found in plasma and most tissue but not in red blood cells

<!-- PAGE=? -->
 Cholinesterase is manufactured in the liver

<!-- PAGE=? -->
 succinylcholine, mivacurium, and (in some cases) ester-linked local anesthetics, as well as the toxicity of cocaine

<!-- PAGE=? -->
 , it is only when there is a >75% decrease in the levels of the normal pseudocholinesterase that there is clinically evident prolongation of succinylcholine activity

<!-- PAGE=? -->
 When there is a question of succinylcholine sensitivity, the absolute activity of pseudocholinesterase should be determined as well as the < dibucaine and fluoride numbers

<!-- PAGE=? -->
 The more common situations in which homozygote normals and heterozygotes are at risk are as follows : patients who have been receiving echothiophate eyedrops (up to 2 weeks after therapy is discontinued), patients who are undergoing plasmapheresis,262 patients with severe liver disease, and patients (particularly heterozygotes) who have received succinylcholine after reversal of nondepolarizing blockade with neostigmine

<!-- PAGE=? -->
Treatment of Succinylcholine Apnea

<!-- PAGE=? -->
The safest course of treatment after the patient fails to breathe within 10-15 minutes after succinylcholine administration is to continue mechanical ventilation until adequate muscle tone has returned. Two units of blood may contain adequate amounts of pseudocholinesterase to hydrolyze the succinylcholine ,265 although blood transfusion is not recommended for routine treatment of succinylcholine-induced apnea.

<!-- PAGE=? -->
abnormal pseudocholinesterase=plasma cholinesterases decr metabolism of ester LA, mivacurium and succinylcholine

<!-- PAGE=? -->
Plasma cholinesterase activity is decreased in parturients, neonates, the elderly, and patients with severe underlying hepatic disease.

<!-- PAGE=? -->
Pancuronium/cyclophopphamide inhibits

<!-- PAGE=? -->
Children >6mo have incr cholinesterase activity, as do morbidly obese not remifentanil nonspecific tissue esterase or esmolol Plasma esterases responsible for the hydrolysis of < esmolol > are distinct from plasma cholinesterase, and the duration of action of succinylcholine is not predictably prolonged in patients treated with < esmolol

<!-- PAGE=? -->
Closing capacity

<!-- PAGE=? -->
 small airways which lack cartilaginous support relay on radial traction by elastic recoil of surrounding tissue to stent them open

<!-- PAGE=? -->
 elastic tissue helps keep the airways open

<!-- PAGE=? -->
 volume at which these airways begin to close in dependent parts of the lung is called closing capacity dynamic airway closure

<!-- PAGE=? -->
 CC = CV + residual volume

<!-- PAGE=? -->
 Closing volume is the lung volume at which the terminal airways begin to collapse

<!-- PAGE=? -->
 closing volume is small in late adolescents and relatively large in the elderly and the very young

<!-- PAGE=? -->
 Anything that decreases FRC relative to

<!-- PAGE=? -->
Total lung

<!-- PAGE=? -->
Airway closure begins

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Functional

<!-- PAGE=? -->
Closing

<!-- PAGE=? -->
volume

<!-- PAGE=? -->
residual

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Closing capacity

<!-- PAGE=? -->
Residual volume

<!-- PAGE=? -->
Zero lung volume

<!-- PAGE=? -->
CC or increases CC relative to FRC will convert normal areas to low V/Q and atelectatic areas, which causes hypoxemia

<!-- PAGE=? -->
o Increased by (4)

<!-- PAGE=? -->
 Age (increased in the elderly and very young)

<!-- PAGE=? -->
 Smoking

<!-- PAGE=? -->
 Obesity

<!-- PAGE=? -->
 Supine position

<!-- PAGE=? -->
 Relationship between CC and FRC

<!-- PAGE=? -->
o shunting and thus hypoxemia, will occur if CC > FRC (either due to  CC or  FRC or both)

<!-- PAGE=? -->
o normally CC < FRC until

<!-- PAGE=? -->
 Age 44 in supine position

<!-- PAGE=? -->
 Age 66 in upright position

<!-- PAGE=? -->
o under anesthesia,  FRC which leads to shunting

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Closing

<!-- PAGE=? -->
Capacity

<!-- PAGE=? -->
ISpontaneous

<!-- PAGE=? -->
IPPB

<!-- PAGE=? -->
IPPB

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
PEEP

<!-- PAGE=? -->
o also note that in children < 5 CC > FRC, thus they are prone to desaturation

<!-- PAGE=? -->
Clonidine

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 a2  > a1 agonist - 220:1

<!-- PAGE=? -->
o highest density of receptors is in the locus ceruleus

<!-- PAGE=? -->
 sedation is associated with inhibition of this nucleus

<!-- PAGE=? -->
 inhibits central NE release

<!-- PAGE=? -->
 Dosage

<!-- PAGE=? -->
o Oral - 3-5 mg/kg

<!-- PAGE=? -->
o IM - 2 mg/kg

<!-- PAGE=? -->
o IV - 1-3 mg/kg

<!-- PAGE=? -->
o transdermal - 0.1-0.3 mg released per day

<!-- PAGE=? -->
o intrathecal  - 75-150 mg

<!-- PAGE=? -->
o epidural - 1-2 mg/kg

<!-- PAGE=? -->
 Peak plasma level in 60-90 min

<!-- PAGE=? -->
 Elimination half-live is 9-12 hrs

<!-- PAGE=? -->
 50% metabolized by the liver, 50% excreted unchanged in the urine

<!-- PAGE=? -->
 Effects

<!-- PAGE=? -->
o enhances intraoperative circulatory stability

<!-- PAGE=? -->
 reduced catecholamine levels

<!-- PAGE=? -->
 inc. response to ephedrine

<!-- PAGE=? -->
o inc. duration of neuroaxial and peripheral nerve block

<!-- PAGE=? -->
 Direct effects on the spinal cord may be mediated by a2-postsynaptic receptors within the dorsal horn

<!-- PAGE=? -->
 Does not produce pruritus, N&V, dec. respiration, or delayed gastric emptying

<!-- PAGE=? -->
 Urinary retention is uncommon

<!-- PAGE=? -->
o Other possible benefits include

<!-- PAGE=? -->
 dec. postoperative shivering

<!-- PAGE=? -->
 inhibition of opioid-induced muscle rigidity

<!-- PAGE=? -->
 attenuation of opioid withdrawal symptoms

<!-- PAGE=? -->
o Analgesia

<!-- PAGE=? -->
 Modulate pain pathways in the spinal cord

<!-- PAGE=? -->
 treatment of some chronic pain syndromes

<!-- PAGE=? -->
 Side effects:

<!-- PAGE=? -->
o NO dec. respiratory efects

<!-- PAGE=? -->
o Bradycardia (dSNS)

<!-- PAGE=? -->
o Hypotension (dSVR)

<!-- PAGE=? -->
o Sedation (central)

<!-- PAGE=? -->
o Dry mouth

<!-- PAGE=? -->
o Na and water retention

<!-- PAGE=? -->
Time

<!-- PAGE=? -->
o Rebound hypertension

<!-- PAGE=? -->
 Within 8-36 hrs

<!-- PAGE=? -->
 Baroreceptor response is intact - minimal othostatic hypotension

<!-- PAGE=? -->
o Mediated by peripheral NE release

<!-- PAGE=? -->
Closed Circuit Anesthesia

<!-- PAGE=? -->
 a form of low-flow anesthesia in which the fresh gas flow equal uptake of anesthetic gases and oxygen by the patient and system. There is complete rebreathing of exhaled gases after absorption of carbon dioxide and no gas in vented through the APL valve.

<!-- PAGE=? -->
o Low flow anesthesia is defined as FGF less than half the minute volume

<!-- PAGE=? -->
o Closed circuit: delivery of gases in amounts sufficient to replace O2 and anesthetic gas removed by patient uptake

<!-- PAGE=? -->
 Cannot easily change depth of anesthesia

<!-- PAGE=? -->
 Nitrogen buildup can be a problem - may need to periodically vent circuit

<!-- PAGE=? -->
 Need to compensate for a 200 ml/min leak via the gas sampling line (although it is possible to somehow return these gases to the circuit)

<!-- PAGE=? -->
 Advantages (FGF < ½ MV)

<!-- PAGE=? -->
o Lower cost

<!-- PAGE=? -->
o Increased humidification

<!-- PAGE=? -->
o Reduced heat loss

<!-- PAGE=? -->
o Decreased release of anesthetic gas to the environment

<!-- PAGE=? -->
o Better capacity to assess physiologic variables (eg ventilation)

<!-- PAGE=? -->
 Disadvantages:

<!-- PAGE=? -->
o Oxygen level may fall: nitrous, nitrogenation from patient stores

<!-- PAGE=? -->
 As well this will dilute anesthetic gases and may lead to awareness

<!-- PAGE=? -->
o Increasing concentrations of carbon monoxide

<!-- PAGE=? -->
o Rebreathing of toxic breakdown products from volatiles

<!-- PAGE=? -->
 CO2 absorber degrades halothane and sevo to toxic compounds

<!-- PAGE=? -->
 Compound A (used to be a warning regarding Sevo that has been removed in US and Europe but not Canada)

<!-- PAGE=? -->
o -lack of control‖

<!-- PAGE=? -->
Coagulation

<!-- PAGE=? -->
The intrinsic pathway

<!-- PAGE=? -->
 activated when blood comes into contact with sub-endothelial connective tissues

<!-- PAGE=? -->
o Quantitatively it is the most important of the two pathways

<!-- PAGE=? -->
o slower to produce fibrin than the extrinsic pathway

<!-- PAGE=? -->
 Activation involves

<!-- PAGE=? -->
o factor XII (Hageman factor)

<!-- PAGE=? -->
o factor XI

<!-- PAGE=? -->
o prekallikrein

<!-- PAGE=? -->
o high molecular weight kininogen (HMWK)

<!-- PAGE=? -->
 factor XII binds to a sub-endothelial surface exposed by an injury

<!-- PAGE=? -->
o A complex of prekallikrein and HMWK also interacts with the exposed surface in close proximity to the bound factor XII, which becomes activated

<!-- PAGE=? -->
 the pathway is self-amplifying

<!-- PAGE=? -->
 Activated factor XII, activates

<!-- PAGE=? -->
o prekallikrein

<!-- PAGE=? -->
 kallikrein can then also cleave factor XII, and further amplify the reaction

<!-- PAGE=? -->
o factor XI

<!-- PAGE=? -->
 process requires calcium

<!-- PAGE=? -->
 The intrinsic pathway ultimately activates factor X by

<!-- PAGE=? -->
o activated factor IX

<!-- PAGE=? -->
o factor VIII

<!-- PAGE=? -->
o calcium

<!-- PAGE=? -->
o phospholipids (provided by the platelet surface)

<!-- PAGE=? -->
The extrinsic pathway

<!-- PAGE=? -->
 provides a very rapid response to tissue injury

<!-- PAGE=? -->
o activated factor X is generated almost instantaneously

<!-- PAGE=? -->
 main function of the extrinsic pathway is to augment the activity of the intrinsic pathway

<!-- PAGE=? -->
 tissue factor (factor III)

<!-- PAGE=? -->
o present in most human cells

<!-- PAGE=? -->
o Once activated, tissue factor binds rapidly to factor VII

<!-- PAGE=? -->
 complex of tissue factor, activated factor VII, calcium and a phospholipid rapidly activates factor X

<!-- PAGE=? -->
Clot formation

<!-- PAGE=? -->
 The end result of the clotting pathway is the production of thrombin  which converts fibrinogen to fibrin

<!-- PAGE=? -->
 The polymerised fibrin, held together by non-covalent and electrostatic forces, is stabilised by factor XIIIa

<!-- PAGE=? -->
 insoluble fibrin aggregates, together with aggregated platelets, block the damaged blood vessel and prevent further bleeding

<!-- PAGE=? -->
INTRINSIC PATHWAY

<!-- PAGE=? -->
Damaged Surface

<!-- PAGE=? -->
Kininogen

<!-- PAGE=? -->
Kallikrein

<!-- PAGE=? -->
EXTRINSIC PATHWAY

<!-- PAGE=? -->
XII

<!-- PAGE=? -->
Xlla

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
XI

<!-- PAGE=? -->
Xla

<!-- PAGE=? -->
IX

<!-- PAGE=? -->
IXa

<!-- PAGE=? -->
VIla

<!-- PAGE=? -->
VII

<!-- PAGE=? -->
Tissue

<!-- PAGE=? -->
factor

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
X

<!-- PAGE=? -->
Xa

<!-- PAGE=? -->
Va

<!-- PAGE=? -->
Prothrombin

<!-- PAGE=? -->
Thrombin

<!-- PAGE=? -->
(Ila)

<!-- PAGE=? -->
Fibrinogen

<!-- PAGE=? -->
Flbrin

<!-- PAGE=? -->
FINAL COMMON PATHWAY

<!-- PAGE=? -->
(la)

<!-- PAGE=? -->
Cross-linked

<!-- PAGE=? -->
fibrin clot

<!-- PAGE=? -->
Fibrinolysis

<!-- PAGE=? -->
 Plasmin is formed by activation of plasminogen by either plasma or tissue activators

<!-- PAGE=? -->
o Tissue plasminogen activators are found in most tissues, except the liver and the placenta

<!-- PAGE=? -->
 Can be synthesized by endothelial cells and macrophages

<!-- PAGE=? -->
o level of tissue activator in the plasma is normally low, but can be increased by exercise and stress

<!-- PAGE=? -->
 Triggering of fibrinolysis occurs when the plasminogen activator, plasminogen, and fibrin are all in close proximity

<!-- PAGE=? -->
 Both plasminogen and its activator bind avidly to fibrin as the clot forms

<!-- PAGE=? -->
 Plasmin inhibitors (antiplasmins) which can control plasmin activity include

<!-- PAGE=? -->
o alpha-1 antitrypsin

<!-- PAGE=? -->
o alpha-2 antiplasmin

<!-- PAGE=? -->
o C1 inhibitor

<!-- PAGE=? -->
o antithrombin III

<!-- PAGE=? -->
 Plasmin attacks fibrin at least 50 different sites, reducing its size such that it no longer has haemostatic activity

<!-- PAGE=? -->
 Normally, the clotting mechanism is balanced by opposing reactions

<!-- PAGE=? -->
o preventing coagulation

<!-- PAGE=? -->
 anti-thrombin III which inhibits active factors II,IX, X, XI and XII

<!-- PAGE=? -->
 Prostacyclin secreted by vascular endothelium inhibits platelet aggregation

<!-- PAGE=? -->
Coagulopathy

<!-- PAGE=? -->
 Uremia results in a prolonged bleeding time and defective platelet adhesion, aggregation, and procoagulant activity

<!-- PAGE=? -->
 Acquired bleeding disorders with prolonged bleeding times but normal PT and aPTT usually arise from inhibitors to von Willebrand factor or result from uremia

<!-- PAGE=? -->
 prolonged ACT signifies impaired ability of the blood sample to generate clot, non-specific

<!-- PAGE=? -->
o ACT is relatively resistant to platelet dysfunction

<!-- PAGE=? -->
o affected by only severe thrombocytopenia and platelet inhibitors such as prostacyclin or monoclonal antibodies directed against GPIIb/IIIa surface receptors

<!-- PAGE=? -->
PTT:

<!-- PAGE=? -->
 Measures the intrinsic pathway

<!-- PAGE=? -->
 Normal value = 40 -100 sec

<!-- PAGE=? -->
 -partial thromboplastin‖ (rabbit brain tissue phospholipid) is added to the test tube to sustitute for PF3 (PTT deon not evaluate platelets function or number)

<!-- PAGE=? -->
 unique to PTT is VIII, IX, XI, XII

<!-- PAGE=? -->
aPTT (activated PTT)

<!-- PAGE=? -->
 insensitive to deficiencies of XII and XI

<!-- PAGE=? -->
 Factor VII is not involved in the intrinsic pathway

<!-- PAGE=? -->
 aPTT is prolonged when:

<!-- PAGE=? -->
o deficiency, abN , inhibition of IX, VIII, X, V, II

<!-- PAGE=? -->
o VIII< 25% activity, all others <30%

<!-- PAGE=? -->
o fibrinogen < 100 mg/dl (Normal fibrinogen = 160-300 mg/dl)

<!-- PAGE=? -->
INR

<!-- PAGE=? -->
 measures the extrinsic pathway

<!-- PAGE=? -->
 normal PT= 10-12 sec, INR = 1

<!-- PAGE=? -->
 prolonged when deficiency, inhibition or abn of VII, X, V, II, I

<!-- PAGE=? -->
 factor activity has to be < 30%

<!-- PAGE=? -->
 fibrinogen <100 mg/dl

<!-- PAGE=? -->
 unique to INR is VII, and TF (III)

<!-- PAGE=? -->
Table 16-15 Interpretation of Coagulation Tests

<!-- PAGE=? -->
factors aaPTT prolongation is more likely to occur with LMWHs with lower Xa/IIa effect ratios, for example, tinzaparin, than with greater ratios, for example, enoxaparin.

<!-- PAGE=? -->
bBleeding time may also be prolonged in association with a marked aPTT increase.

<!-- PAGE=? -->
cDIC may be distinguished by the presence of D-dimers.

<!-- PAGE=? -->
CPB

<!-- PAGE=? -->
 The most prevalent yet elusive cause of hemostatic abnormalities after CPB is platelet dysfunction

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Barash, Bloody Easy, National Advisory Committee on Blood and Blood Products

<!-- PAGE=? -->
Frozen Plasma

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o Rapid reversal of inc. INR/pTT

<!-- PAGE=? -->
 Must be infused via a 170-260 micron filter

<!-- PAGE=? -->
 Compatible with only NS

<!-- PAGE=? -->
 Each unit contains 400-900mg fibrinogen

<!-- PAGE=? -->
 Dose

<!-- PAGE=? -->
o 10-15cc/kg

<!-- PAGE=? -->
 Half-life of each factor is different

<!-- PAGE=? -->
o Factor VII - 3-6hrs

<!-- PAGE=? -->
o Factor VIII - 8-12hrs

<!-- PAGE=? -->
o Factor II, IX - 2-3 days

<!-- PAGE=? -->
Cryoprecipitate

<!-- PAGE=? -->
 Does NOT contain all the factors

<!-- PAGE=? -->
o NOT a substitute for FP

<!-- PAGE=? -->
 Contains

<!-- PAGE=? -->
o Factor VIII

<!-- PAGE=? -->
o Fibrinogen

<!-- PAGE=? -->
 150mg / unit

<!-- PAGE=? -->
o Von Willebrand's factor

<!-- PAGE=? -->
 Must be infused via a 170-260 micron filter

<!-- PAGE=? -->
 Compatible with only NS

<!-- PAGE=? -->
 Dose

<!-- PAGE=? -->
o 1 unit/10kg

<!-- PAGE=? -->
 Usual dose 8-12 units

<!-- PAGE=? -->
Recombinant Factor VIIa

<!-- PAGE=? -->
 Developed for the treatment of patients with hemophilia A or B and inhibitors to exogenous FVIII or FIX preparations

<!-- PAGE=? -->
o only current -on-label‖ indications for rFVIIa in the United States are those two conditions plus congenital FVII deficiency

<!-- PAGE=? -->
 Its use has been reported in

<!-- PAGE=? -->
o Trauma

<!-- PAGE=? -->
o hepatic failure

<!-- PAGE=? -->
o gastrointestinal bleeding

<!-- PAGE=? -->
o obstetric hemorrhage

<!-- PAGE=? -->
o acute intracerebral hemorrhage

<!-- PAGE=? -->
o cardiac, prostatic, hepatic, spinal, neurologic, and hepatic transplantation surgery

<!-- PAGE=? -->
 It has been used to reverse the anticoagulant effect of

<!-- PAGE=? -->
o Warfarin

<!-- PAGE=? -->
o LMWHs

<!-- PAGE=? -->
o selective Xa inhibitors

<!-- PAGE=? -->
 It has been administered to patients with

<!-- PAGE=? -->
o vWD

<!-- PAGE=? -->
o FXI deficiency

<!-- PAGE=? -->
o Thrombocytopenia

<!-- PAGE=? -->
o both congenital and acquired platelet abnormalities

<!-- PAGE=? -->
 most of these uses are supported by only anecdotal reports, among which there may be significant publication bias; that is, apparent success is reported more often than obvious failure

<!-- PAGE=? -->
 Mechanism of action

<!-- PAGE=? -->
o more than an augmentation of the native functions of FVII

<!-- PAGE=? -->
o It seems probable that rFVIIa directly activates FX on platelet surfaces and thereby effects, without the participation of factors VIII, IX, and XI, the generation of the large amounts of thrombin necessary to produce a firm fibrin clot

<!-- PAGE=? -->
 The serum concentrations achieved by typical rFVIIa dosing are several hundred times those that occur physiologically and are probably sufficient to activate FX on the platelet surface

<!-- PAGE=? -->
 In trauma patients, acidosis (pH <7.20) appeared to decrease the efficacy of rFVIIa but moderate hypothermia did not

<!-- PAGE=? -->
 Several reports speak to the efficacy of rFVIIa in reversing the effects of warfarin, LMWH, and fondaparinux

<!-- PAGE=? -->
o production of the fibrin burst in response to rFVIIa requires the availability of some FX

<!-- PAGE=? -->
o Warfarin, LMWH, and fondaparinux, all either inhibit the synthesis or the activity of FX

<!-- PAGE=? -->
o It seems reasonable to expect that in severe overdoses, rFVIIa may not be effective

<!-- PAGE=? -->
 Dose

<!-- PAGE=? -->
o Little information is available for the effective dose

<!-- PAGE=? -->
o ~60ug/kg rounded to the nearest 1200ug (1 vial)

<!-- PAGE=? -->
 half-life is approximately 2 hours

<!-- PAGE=? -->
o repeat dosing at that interval may be required

<!-- PAGE=? -->
 thrombosis in locations remote from sites of vessel disruption has been infrequent

<!-- PAGE=? -->
o rVIIa is an active procoagulant only when it is in contact with TF or activated platelets

<!-- PAGE=? -->
o However, thrombotic complications, have been reported

<!-- PAGE=? -->
 The effectiveness of available laboratory tests in monitoring the clinical effect of rFVIIa is uncertain

<!-- PAGE=? -->
Vitamin K

<!-- PAGE=? -->
 Hepatic synthesis of clotting factors II, VII, IX, and X as well as protein C and protein S requires the presence of vitamin K

<!-- PAGE=? -->
 With vitamin K deficiency, these factors are depleted in an order determined by their half-lives

<!-- PAGE=? -->
o Factor VII has the shortest half-life and is the first to be depleted followed by FIX, FX, and finally FII

<!-- PAGE=? -->
 deficiency occurs frequently in hospitalized patients

<!-- PAGE=? -->
o dietary insufficiency

<!-- PAGE=? -->
o gut sterilization

<!-- PAGE=? -->
o malabsorption

<!-- PAGE=? -->
 Vitamin K1 (phylloquinone) is found in leafy green vegetables

<!-- PAGE=? -->
 Vitamin K2 (menaquinone) is synthesized by the normal intestinal flora

<!-- PAGE=? -->
 the body has no appreciable stores of vitamin K

<!-- PAGE=? -->
o deficiencies can develop in as little as 7 days

<!-- PAGE=? -->
 Newborns, who have a sterile gut at birth, have been noted to develop vitamin K deficiency

<!-- PAGE=? -->
 Vitamin K is fat-soluble and therefore requires bile salts for absorption from the jejunum.

<!-- PAGE=? -->
o Biliary obstruction, malabsorption syndromes, gastrointestinal obstruction, or rapid gastrointestinal transit can result in vitamin K deficiency because of inadequate absorption

<!-- PAGE=? -->
 Will cause prolongation of the PT

<!-- PAGE=? -->
o FVII-sensitive assay

<!-- PAGE=? -->
 With more prolonged deficiency, aPTT (a very FIX-sensitive assay) will also increase

<!-- PAGE=? -->
 Dosage

<!-- PAGE=? -->
o 1-10 mg PO/IM/IV

<!-- PAGE=? -->
 Depending on urgency

<!-- PAGE=? -->
 Onset of reversal within 6-24 hrs

<!-- PAGE=? -->
 Dose may be repeated every 12 hrs

<!-- PAGE=? -->
 Rapid administration may cause hypotension

<!-- PAGE=? -->
 Even if other agents are used, Vit K should be administered to maintain reversal

<!-- PAGE=? -->
Octaplex

<!-- PAGE=? -->
 Prothrombin complex concentrate

<!-- PAGE=? -->
 Human plasm derivative

<!-- PAGE=? -->
o Viral inactivated

<!-- PAGE=? -->
 Indicated for rapid reversal of warfarin or Vit K deficiency

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Previous history of HIT

<!-- PAGE=? -->
 NOT recommended for

<!-- PAGE=? -->
o Inc. INR without bleeding or need for emergency surgery

<!-- PAGE=? -->
o Massive transfusion

<!-- PAGE=? -->
o Coagulopathy of liver disease

<!-- PAGE=? -->
o Patient Hx of

<!-- PAGE=? -->
 Thrombosis

<!-- PAGE=? -->
 MI

<!-- PAGE=? -->
 Ischemic stroke

<!-- PAGE=? -->
 DIC

<!-- PAGE=? -->
o Pregnancy or lactation

<!-- PAGE=? -->
 Insufficient evidence

<!-- PAGE=? -->
 inc. risk of thrombosis

<!-- PAGE=? -->
o Pediatrics

<!-- PAGE=? -->
 Insufficient evidence

<!-- PAGE=? -->
o Congenital factor II or X deficient patients

<!-- PAGE=? -->
 Max infusion rate of 2-3mls/min

<!-- PAGE=? -->
o No filter is required

<!-- PAGE=? -->
 Product composition - one 20ml vial

<!-- PAGE=? -->
o Factor II - 220-760 IU

<!-- PAGE=? -->
o Factor VII - 180-480 IU

<!-- PAGE=? -->
o Factor IX - 400-620 IU

<!-- PAGE=? -->
o Factor X - 360-600 IU

<!-- PAGE=? -->
o Protein C - 140-620 IU

<!-- PAGE=? -->
o Protein S - 140-640 IU

<!-- PAGE=? -->
o Heaprin - 80-310 IU

<!-- PAGE=? -->
o Sodiu Citrate - 17-27 mmol/L

<!-- PAGE=? -->
 Dosage

<!-- PAGE=? -->
o Based on Factor IX activity

<!-- PAGE=? -->
 15 IU/kg if INR < 5

<!-- PAGE=? -->
 30 IU/kg if INR > 5

<!-- PAGE=? -->
o Generally 40 mls (1000IU)

<!-- PAGE=? -->
o A second and higher dose may be required

<!-- PAGE=? -->
 Extreme inc. INR

<!-- PAGE=? -->
 Inc. body weight

<!-- PAGE=? -->
o Max dosage of 120 mls

<!-- PAGE=? -->
 Therapeutic response can be assessed by INR 15 min after administration

<!-- PAGE=? -->
 Duration of action

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o H/A

<!-- PAGE=? -->
 Rare

<!-- PAGE=? -->
 If severe, stop infusion

<!-- PAGE=? -->
o Allergic reaction (hives, pruritus)

<!-- PAGE=? -->
 Rare

<!-- PAGE=? -->
 Continue administration with abservation

<!-- PAGE=? -->
o Anaphylactic reactions

<!-- PAGE=? -->
 Rare

<!-- PAGE=? -->
 Stop infusion

<!-- PAGE=? -->
o Fevers

<!-- PAGE=? -->
 Rare

<!-- PAGE=? -->
 Stop infusion

<!-- PAGE=? -->
 Blood cultures

<!-- PAGE=? -->
o Thromboembolic complications

<!-- PAGE=? -->
 Very rare

<!-- PAGE=? -->
 Stop infusion

<!-- PAGE=? -->
 Must be infused within two hours of reconstitution

<!-- PAGE=? -->
o Maintain at room temperature

<!-- PAGE=? -->
Cocaine

<!-- PAGE=? -->
P&P, Barash

<!-- PAGE=? -->
 SNS stimulation by blocking the presynaptic uptake of norepinephrine and dopamine, thus increasing their postsynaptic concentrations

<!-- PAGE=? -->
 acute cocaine intoxication resembles pheochromocytoma

<!-- PAGE=? -->
o patients need both vasodilators and beta blockers

<!-- PAGE=? -->
o beta blocker alone may allow unopposed alpha-adrenergic stimulation and a huge increase in systemic vascular resistance

<!-- PAGE=? -->
 Patients with chronic cocaine intoxication are less of a problem, but they are still at risk for dysrhythmias

<!-- PAGE=? -->
o avoid halothane, pancuronium, atropine, and sympathomimetics

<!-- PAGE=? -->
 Intranasal

<!-- PAGE=? -->
o maximum effects in 15 to 40 minutes

<!-- PAGE=? -->
o last 60 minutes after peak effects

<!-- PAGE=? -->
 IV and smoked

<!-- PAGE=? -->
o peak plasma effect in 5 minutes

<!-- PAGE=? -->
o duration is 30 to 45 minutes

<!-- PAGE=? -->
 elimination half-time of cocaine is 60 to 90 minutes

<!-- PAGE=? -->
 metabolism is by plasma and liver cholinesterases

<!-- PAGE=? -->
o Miller states that cocaine is metabolized predominantly by hepatic carboxylesterase not in plasma by cholinesterase enzymes

<!-- PAGE=? -->
 metabolites may be present in the urine for 24-36 hrs

<!-- PAGE=? -->
 Maximum dose ~ 150 - 200mg - 1.5-3mg/kg

<!-- PAGE=? -->
 Even remote cocaine use can result in myocardial ischemia and hypotension for as long as 6 weeks

<!-- PAGE=? -->
after discontinuing cocaine use

<!-- PAGE=? -->
o due to cocaine-induced coronary artery vasospasm

<!-- PAGE=? -->
o sensitizes the LAD to catecholamines, even in the absence of circulating cocaine

<!-- PAGE=? -->
 cocaine is contraindicated in

<!-- PAGE=? -->
o chronic or acute HTN

<!-- PAGE=? -->
o tricyclic antidepressants

<!-- PAGE=? -->
o MAOIs

<!-- PAGE=? -->
 sympathomimetics such as epinephrine or phenylephrine should not be given with cocaine

<!-- PAGE=? -->
Myocardial Ischemia

<!-- PAGE=? -->
ACLS 2005

<!-- PAGE=? -->
 Mechanisms

<!-- PAGE=? -->
o Coronary artery vasospasm

<!-- PAGE=? -->
o Inc. O2 demand

<!-- PAGE=? -->
o Coronary artery thrombosis

<!-- PAGE=? -->
 Medications:

<!-- PAGE=? -->
o Mainstay of treatment are NTG, BDZ

<!-- PAGE=? -->
o Phentolamine is second line

<!-- PAGE=? -->
 NTG and phentolamine have been shown to reduce vasospasm

<!-- PAGE=? -->
 Propranolol makes it worse

<!-- PAGE=? -->
o Morphine, oxygen, ASA

<!-- PAGE=? -->
o Beta-blockers are contra-indicated

<!-- PAGE=? -->
o Labetalol has been used safely despite alpha-blockade > beta-blockade

<!-- PAGE=? -->
o For rate control, consider Calcium Channel Blockers

<!-- PAGE=? -->
 Verapamil 2.5 - 10 mg IV

<!-- PAGE=? -->
o ?Mg

<!-- PAGE=? -->
 Refer to cardiology for possible catheterization

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
o treat with lidocaine, bicarb

<!-- PAGE=? -->
 HTN

<!-- PAGE=? -->
o NTG , labetalol, alpha-blockers ( phentolamine )

<!-- PAGE=? -->
 Seizures - benzodiazepines

<!-- PAGE=? -->
 Heparin, GP IIb/IIIa, PCI, thrombolysis for persistent chest pain and symptoms

<!-- PAGE=? -->
Coma

<!-- PAGE=? -->
Oculocephalic reflex:

<!-- PAGE=? -->
 Brainstem intact:  both eyes deviate away from direction head is turned (doll's eyes)

<!-- PAGE=? -->
 Global brainstem injury:  eyes follow direction head is turned

<!-- PAGE=? -->
 Focal brainstem injury:  disconjugate eye movements

<!-- PAGE=? -->
Metabolic coma:  spontaneous nystagmus

<!-- PAGE=? -->
Oculovestibular reflex (Cold Caloric):  a stronger stimulus than oculocephalic reflex

<!-- PAGE=? -->
 Brainstem intact / coma:  eyes tonically look towards cold side

<!-- PAGE=? -->
 Global brainstem injury:  no eye movement

<!-- PAGE=? -->
 Normal (no coma):  nystagmus (fast beat away from cold), vertigo, N/V

<!-- PAGE=? -->
Focal Brainstem lesion:  disconjugate eye movements

<!-- PAGE=? -->
Table 2 - Pupil Abnormalities in Coma

<!-- PAGE=? -->
Unilateral fixed wide (6-9 mm)

<!-- PAGE=? -->
Acute intracranial mass

<!-- PAGE=? -->
Local anticholinergics

<!-- PAGE=? -->
Bilateral fixed wide (6-9 mm)

<!-- PAGE=? -->
Brain death

<!-- PAGE=? -->
End-stage diencephalic herniations

<!-- PAGE=? -->
Intoxication with scopolamine, atropine,

<!-- PAGE=? -->
methyl alcohol, or glutethimide

<!-- PAGE=? -->
Bilateral pinpoint (< 2mm)

<!-- PAGE=? -->
Acute pontine lesion

<!-- PAGE=? -->
Narcotic agents

<!-- PAGE=? -->
Nonketotic hyperglycemia

<!-- PAGE=? -->
Hypercapnia

<!-- PAGE=? -->
Pupil anisocoria (difference 2-3 mm)

<!-- PAGE=? -->
Horner's syndrome

<!-- PAGE=? -->
Brain stem lesion

<!-- PAGE=? -->
Carotid artery dissection

<!-- PAGE=? -->
Complex regional pain syndrome (CRPS)

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 two types

<!-- PAGE=? -->
o CRPS type I (reflex sympathetic dystrophy)

<!-- PAGE=? -->
 No preceding nerve injury

<!-- PAGE=? -->
 Distal aspect of extremity involvement

<!-- PAGE=? -->
 Pain, allodynia or hyperalgesia

<!-- PAGE=? -->
 Pain disproportionate to injury

<!-- PAGE=? -->
 Pain not limited to single nerve

<!-- PAGE=? -->
 Associated edema, changes in skin blood flow or abnormal sudomotor activity

<!-- PAGE=? -->
o CRPS type II (causalgia)

<!-- PAGE=? -->
 Preceding nerve injury

<!-- PAGE=? -->
 Buring pain

<!-- PAGE=? -->
 Allodynia

<!-- PAGE=? -->
 Huperpathia

<!-- PAGE=? -->
 Hand and foot involvement

<!-- PAGE=? -->
 Sequela of injury to major nerve or branch

<!-- PAGE=? -->
 More discrete localization than type i

<!-- PAGE=? -->
 Most commonly involves: median, sciateic, tibial, ulnar

<!-- PAGE=? -->
o What is NOT CRPS type I

<!-- PAGE=? -->
 Pain in an area of decreased sensation

<!-- PAGE=? -->
 No cutaneous hyperalgesia or allodynia

<!-- PAGE=? -->
 Pain only in a specific nerve distribution

<!-- PAGE=? -->
 Proximal symptoms only

<!-- PAGE=? -->
 risk factors include

<!-- PAGE=? -->
o previous trauma

<!-- PAGE=? -->
o nerve injury (type II)

<!-- PAGE=? -->
o previous surgery

<!-- PAGE=? -->
o work-related injuries

<!-- PAGE=? -->
o female sex

<!-- PAGE=? -->
 signs and symptoms include

<!-- PAGE=? -->
o spontaneous pain

<!-- PAGE=? -->
o hyperalgesia

<!-- PAGE=? -->
o allodynia

<!-- PAGE=? -->
o trophic, sudomotor, vasomotor abnormalities in skin, hair, nails

<!-- PAGE=? -->
 smooth and glossy

<!-- PAGE=? -->
 bone demineralization

<!-- PAGE=? -->
o active and passive movement disorders

<!-- PAGE=? -->
o joints

<!-- PAGE=? -->
 synovial edema, hyperplasia, fibrosis, inflammation

<!-- PAGE=? -->
o autonimic dysfunction

<!-- PAGE=? -->
 skin temp changes

<!-- PAGE=? -->
 alterations of sweat glands resulting in hyperhidrosis

<!-- PAGE=? -->
 cyaonsis

<!-- PAGE=? -->
 edema

<!-- PAGE=? -->
 typically a discrepancy between the severity of the symptoms and intensity of the inciting injury

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o at least 1 feature from each of the following general categories

<!-- PAGE=? -->
 sensory - hyperesthesia-increased sensitivity to a sensory stimulation

<!-- PAGE=? -->
 vasomotor - temperature abnormalities or skin color changes

<!-- PAGE=? -->
 sudomotor (fluid balance) - sweating abnormalities or edema

<!-- PAGE=? -->
 motor - decreased range of movement, weakness, tremor, or neglect

<!-- PAGE=? -->
o at least one sign within two or more of the following categories

<!-- PAGE=? -->
 sensory - allodynia or hyperalgesia

<!-- PAGE=? -->
 vasomotor - objective temperature abnormalities or skin color changes

<!-- PAGE=? -->
 sudomotor (fluid balance) - sweating abnormalities or objective edema

<!-- PAGE=? -->
 motor - objective decreased range of motion, weakness, tremor or neglect

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o sympathetic blocks

<!-- PAGE=? -->
o physical therapy

<!-- PAGE=? -->
 may need regional block (lumbar plexus) to allow physio to occur

<!-- PAGE=? -->
o Pharmacologic

<!-- PAGE=? -->
 alpha blockers (prazosin)

<!-- PAGE=? -->
 clonidine

<!-- PAGE=? -->
 phenoxybenzamine

<!-- PAGE=? -->
 phentolamine

<!-- PAGE=? -->
 TCAs

<!-- PAGE=? -->
 CCB Gabapentin

<!-- PAGE=? -->
 Memantine (NMDA-blocker)

<!-- PAGE=? -->
 High dose course of systemic steroids

<!-- PAGE=? -->
o IVRA - bretylium, lidocaine or ketorolac, steroids

<!-- PAGE=? -->
o spinal cord stimulation

<!-- PAGE=? -->
o TENS

<!-- PAGE=? -->
o Surgical or neurolytic sympathectomy

<!-- PAGE=? -->
Complex Regional Pain Syndrome

<!-- PAGE=? -->
Formerly known by a variety of names (Reflex Sympathetic Dystropy, Causalgia), CRPS refers to a variety of post-traumatic neuropathic conditions characterized by pain, sensory-motor abnormalities, and autonomic symptoms; divided into CRPS I and II (with the latter being distinguished by a identifiable peripheral nerve injury).

<!-- PAGE=? -->
Anesthetic Considerations

<!-- PAGE=? -->
 Need for primarily a clinical diagnosis, with diagnostic tests used to rule out other causes

<!-- PAGE=? -->
 Sequelae of chronic pain

<!-- PAGE=? -->
o Possible narcotic tolerance/dependence

<!-- PAGE=? -->
o Cognitive, behavioural, and affective changes related to chronicity/severity of pain

<!-- PAGE=? -->
 Need for an early multi-modal and multi-disciplinary approach to treatment

<!-- PAGE=? -->
o Requirement for medications not commonly used by anesthesiologists (TCA's, alpha-blockers, anticonvulsants)

<!-- PAGE=? -->
 Potential need for sympathetic blockade or other specialized neuromodulatory appproaches

<!-- PAGE=? -->
Primary Goals

<!-- PAGE=? -->
 Early, aggressive, coordinated, multi-modal (pharmacological, interventional, psychological) approach

<!-- PAGE=? -->
 Pain goals

<!-- PAGE=? -->
o Decreased pain, and pain behaviours

<!-- PAGE=? -->
o Decreased appropriate (and inappropriate) use of health services

<!-- PAGE=? -->
o Increased quality of life, functional capacity, and self-esteem

<!-- PAGE=? -->
o Increased social function, improved relationships

<!-- PAGE=? -->
Assessment (Hx and PE)

<!-- PAGE=? -->
 History

<!-- PAGE=? -->
o Initiating event (although not essential for diagnosis); may precede onset of symptoms by months

<!-- PAGE=? -->
 Trauma (contusion, crush, laceration), surgery (carpal tunnel release, palmar fasciotomy, arthroplasties), sprain, fracture , dislocation

<!-- PAGE=? -->
o Characteristics, severity, duration of symptoms

<!-- PAGE=? -->
 -Burning, electrical-like shooting pains ‖

<!-- PAGE=? -->
 Allodynia - perception of pain from non-noxious stimuli

<!-- PAGE=? -->
 Hyperalgesia - exaggerated response to noxious stimuli

<!-- PAGE=? -->
 Autonomic changes -edema , hot/cold skin , abnormal sweat gland function

<!-- PAGE=? -->
o Exacerbation with increases in sympathetic tone (fear, anxiety, light, noise)

<!-- PAGE=? -->
o Response (if any) to previous treatments

<!-- PAGE=? -->
o Functional capacity; particularly ability to complete ADL's or recreational activities

<!-- PAGE=? -->
 Useful to establish baseline (pain scales, distance able to walk, ability to bend over) so that effectiveness of treatment can be gauged

<!-- PAGE=? -->
o Cognitive , behavioral , mood-related sequelae of the pain syndrome

<!-- PAGE=? -->
o Comorbid disease, to rule out these as potential etiologies (i.e. peripheral vascular disease, compartment syndrome, nerve entrapment)

<!-- PAGE=? -->
 Physical Exam

<!-- PAGE=? -->
o Vitals +/- MSE (for depression, etc…)

<!-- PAGE=? -->
o Abnormal response to pain

<!-- PAGE=? -->
 Allodynia, hyperalgesia, hypo/hyperesthesia

<!-- PAGE=? -->
o Guarding or touch intolerance, avoidance of using the involved extremity (which perpetuates pain cycle)

<!-- PAGE=? -->
o Autonomic changes

<!-- PAGE=? -->
 Areas of altered skin colour (pallor, cyanosis), temperature , sweat gland activity (hypo/hyperhidrosis), edema

<!-- PAGE=? -->
 Rule out compartment syndrome by doing peripheral pulses

<!-- PAGE=? -->
o Dystrophic changes

<!-- PAGE=? -->
 Atrophy of skin, hair, nails

<!-- PAGE=? -->
 Dry skin +/- shedding

<!-- PAGE=? -->
 Muscle wasting

<!-- PAGE=? -->
 Joint stiffness , contractures

<!-- PAGE=? -->
o Motor changes

<!-- PAGE=? -->
 Weakness , tremor, dystonia

<!-- PAGE=? -->
o Demonstratable neurological deficits

<!-- PAGE=? -->
 Sensory/motor/reflex abnormalities consistent with a discrete peripheral nerve injury

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
 Labs

<!-- PAGE=? -->
o CBC, lytes, BUN, Cr

<!-- PAGE=? -->
o INR/PTT if considering invasive interventional procedures

<!-- PAGE=? -->
 Misc X-rays, bone scan

<!-- PAGE=? -->
o May demonstrate demineralization consistent with osteopenia /osteoporosis

<!-- PAGE=? -->
 MRI/CT

<!-- PAGE=? -->
o Demonstratable peripheral nerve lesion

<!-- PAGE=? -->
 Special tests

<!-- PAGE=? -->
o EMG

<!-- PAGE=? -->
o Sweat testing

<!-- PAGE=? -->
 QSART (cutaneous Doppler -Quantitative Sudomotor Axon Reflex Test‖) stimulates skin and measures sweat gland response, suggestive of autonomic function

<!-- PAGE=? -->
o Thermography

<!-- PAGE=? -->
 Determines variation of heat emitted by body

<!-- PAGE=? -->
 Altered blood supply to painful areas (warmer or cooler; 1 degree C may be significant)

<!-- PAGE=? -->
 Diagnostic sympathetic blocks

<!-- PAGE=? -->
Optimization

<!-- PAGE=? -->
 Consult multi-disciplinary pain clinic (early)

<!-- PAGE=? -->
o Physiotherapy and increased joint mobility are essential , and it may be necessary to carry out these treatments under partial anesthesia (peripheral nerve block, or epidural block)

<!-- PAGE=? -->
o Mood, cognitive, and behavioral aspects must be addressed by the appropriate health care profesional

<!-- PAGE=? -->
 Medications (unsure of the effectiveness of some of these)

<!-- PAGE=? -->
o Opioids

<!-- PAGE=? -->
o Tylenol/NSAIDs

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
o Topical Clonidine

<!-- PAGE=? -->
o Gabapentin/Pregabalin

<!-- PAGE=? -->
o IV Bretylium

<!-- PAGE=? -->
o IV Lidocaine

<!-- PAGE=? -->
o Bisphosphonates (decreased pain/swelling, increase ROM)

<!-- PAGE=? -->
o Anti-depressants ( TCA's )

<!-- PAGE=? -->
o Anti-convulsants

<!-- PAGE=? -->
o Anxiolysis

<!-- PAGE=? -->
o NMDA antagonists ( Ketamine )

<!-- PAGE=? -->
 Sympathetic blockade

<!-- PAGE=? -->
o Up to 3/week during acute phase (to be tapered off)

<!-- PAGE=? -->
o Stellate ganglion block

<!-- PAGE=? -->
o Celiac plexus block

<!-- PAGE=? -->
o Lumbar sympathetic plexus block

<!-- PAGE=? -->
o IV regional block with Guanethidine

<!-- PAGE=? -->
 Neuraxial blockade

<!-- PAGE=? -->
o Intrathecal narcotics

<!-- PAGE=? -->
o Baclofen pump (if dystonias)

<!-- PAGE=? -->
 Surgery

<!-- PAGE=? -->
o Sympathectomy (neuroablation - primarily for those with vascular insufficiency; not really a -permanent‖ solution because the ganglia grow back to some extent)

<!-- PAGE=? -->
o Amputation

<!-- PAGE=? -->
o Spinal cord stimulation (neuromodulation)

<!-- PAGE=? -->
 Other

<!-- PAGE=? -->
o TENS

<!-- PAGE=? -->
o Warm packs

<!-- PAGE=? -->
o Vitamin C (reduces prevalence of CRPS after wrist fractures)

<!-- PAGE=? -->
 Jill Osborn's Treatment approach

<!-- PAGE=? -->
Physiotherapy +/- creams (containing Lidocaine, Bupivicaine, Ketamine, Doxazosin)

<!-- PAGE=? -->
Oral medications

<!-- PAGE=? -->
 Gabapentin/Pregabalin

<!-- PAGE=? -->
 TCA's (Amitriptyline, Nortriptyline)

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 Opioids

<!-- PAGE=? -->
Blocks

<!-- PAGE=? -->
 Sympathetic blocks (Stellate, celiac, lumbar)

<!-- PAGE=? -->
 IV regional blocks (Guanethidine, Bretylium)

<!-- PAGE=? -->
Infusions

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 Amytal (sodium barbitol)

<!-- PAGE=? -->
 More extreme measures

<!-- PAGE=? -->
 Intrathecal pumps (clonidine, local anesthetic)

<!-- PAGE=? -->
 Neuromodulation

<!-- PAGE=? -->
Setup and Monitors

<!-- PAGE=? -->
 Standard CAS monitors

<!-- PAGE=? -->
 +/- 5 lead ECG

<!-- PAGE=? -->
 Usual emergency drugs

<!-- PAGE=? -->
 Remainder of drugs/monitors as dictated by the clinical situation

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
 Goals

<!-- PAGE=? -->
o Pain relief

<!-- PAGE=? -->
o Functional improvement

<!-- PAGE=? -->
o Physio & Occupational therapy is key to treatment; medications and therapies allow PT/OT to proceed

<!-- PAGE=? -->
 Therapies requiring anesthetic

<!-- PAGE=? -->
o Sympathetic blocks (stellate/celiac/lumbar)

<!-- PAGE=? -->
o IV regional sympathetic block

<!-- PAGE=? -->
o Surgical intervention

<!-- PAGE=? -->
 If CRPS is suspected clinically, sympathetic blockade to the affected limb is carried out for diagnostic purposes

<!-- PAGE=? -->
o If the syndrome has been longstanding (i.e. > 2 yrs) the results are uniformly poor, but good progress can be made if treatment started early (within 3 months)

<!-- PAGE=? -->
o If sympathetic block reduces pain, further options include:

<!-- PAGE=? -->
 Repeat sympathetic blocks

<!-- PAGE=? -->
 IV regional sympathetic blockade

<!-- PAGE=? -->
 Sympathetically active drugs (Clonidine, Prazosin)

<!-- PAGE=? -->
 Neuroablactive sympathectomy

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Poor movement/ambulation resulting in DVT/PE

<!-- PAGE=? -->
o Sequelae of any comorbid disease

<!-- PAGE=? -->
IV Regional Sympathetic Block

<!-- PAGE=? -->
 Indication - prolonged sympathetic blockade of an extremity in CRPS (diagnosis or treatment), particularly in vascular disease

<!-- PAGE=? -->
 Agents must apparently be special ordered , which decreases their -real-world‖ utility

<!-- PAGE=? -->
 Can be done in anticoagulated patient

<!-- PAGE=? -->
 Guanethidine depletes norepinphrine , and inhibits reuptake at presynaptic nerve terminals

<!-- PAGE=? -->
 If Guanethidine unavailable, can use Reserpine (1-1.5 mg) or Bretylium (5 mg/kg)

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
o Usual resuscitative equipment

<!-- PAGE=? -->
o Bier block using Guanethidine

<!-- PAGE=? -->
 20 mg in 20 cc NS for upper extremity

<!-- PAGE=? -->
 40 mg in 40 cc NS for lower extremity

<!-- PAGE=? -->
 +/- 10 cc 0.5% Lidocaine to prevent burning

<!-- PAGE=? -->
o Tourniquet up for approx 20 minutes

<!-- PAGE=? -->
 Results

<!-- PAGE=? -->
o Can produce prolonged sympathetic block ( 3-7 days , compared with 10 hrs for the standard cervicothoracic sympathetic block with Bupivicaine)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Premature deflation of tourniquet - hypotension, bradycardia, edema, diarrhea, nausea

<!-- PAGE=? -->
o Postural hypotension of up to 48 hrs, from systemic effect of Guanethidine

<!-- PAGE=? -->
Background Pathophysiology

<!-- PAGE=? -->
 IASP definitions of CRPS

<!-- PAGE=? -->
 CRPS Type I (formerly known as reflex sympathetic dystrophy )

<!-- PAGE=? -->
o The presence of an initiating noxious event or a cause of immobilization

<!-- PAGE=? -->
o Continuing pain , allodynia (perception of pain from a non-painful stimulus), or hyperalgesia disproportionate to the inciting event

<!-- PAGE=? -->
o Evidence at some time of edema , changes in skin blood flow , or abnormal sudomotor (sweat gland) activity in the area of pain

<!-- PAGE=? -->
o The diagnosis is excluded by the existence of any condition that would otherwise account for the degree of pain and dysfunction

<!-- PAGE=? -->
o Note that CRPS type I can be subdivided into three stages:

<!-- PAGE=? -->
 Stage 1 ( acute ): may be hypothermic or hyperthermic (2-3 months)

<!-- PAGE=? -->
 Stage 2 ( dystrophic ): vasomotor instability for several months

<!-- PAGE=? -->
 Stage 3 ( atrophic ): cold extremity with atrophic changes

<!-- PAGE=? -->
 CRPS Type II (formerly known as causalgia )

<!-- PAGE=? -->
o Same criteria as Type I, except occurring secondary to a definable nerve injury

<!-- PAGE=? -->
o Pain, allodynia, hyperalgesia not necessarily limited to distribution of the injured nerve

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
o Trauma (majority)

<!-- PAGE=? -->
 Trauma (contusion, crush, laceration), surgery (carpal tunnel release, palmar fasciotomy, arthroplasties), sprain, fracture, dislocation

<!-- PAGE=? -->
o Neurological insults

<!-- PAGE=? -->
 CVA, tumours, syrinx, peripheral nerve injury (2-5% incidence of CRPS Type II)

<!-- PAGE=? -->
o Herpes Zoster

<!-- PAGE=? -->
o MI

<!-- PAGE=? -->
o Malignancy

<!-- PAGE=? -->
o Idiopathic

<!-- PAGE=? -->
 Epidemiology

<!-- PAGE=? -->
o CRPS I occurs in 1-2% of fractures

<!-- PAGE=? -->
o CRPS II occurs in 2-5 % of peripheral nerve injuries

<!-- PAGE=? -->
o Female:male 3:1

<!-- PAGE=? -->
o Mean age at diagnosis = 42, but diagnosed in children/adolescents as well

<!-- PAGE=? -->
 Pathophysiology Robert's Hypothesis (from Annika's seminar) to explain post-traumatic pain

<!-- PAGE=? -->
o (Pain, 24; 297; 1986; diagram from Cousins 3rd Ed p839)

<!-- PAGE=? -->
o An initiating injury provides a conditioning stimulus via nociceptive C fibers which sensitizes the wide dynamic range (WDR) cells in the dorsal horn

<!-- PAGE=? -->
o WDR cells, which transmit to the brain, now fire in response to innocuous stimuli conveyed via low threshold A-mechanoreceptor afferents ( physiological wind-up, and CNS sensitization )

<!-- PAGE=? -->
o Spontaneous pain is produced by sympathetic efferent actions on A-mechanoreceptor afferents

<!-- PAGE=? -->
 Sympathetically mediated pain - pain that is either initiated or maintained by activity in the sympathetic nervous system, either efferent sympathetic nerve activity, or circulating catecholamines

<!-- PAGE=? -->
 CRPS prophylaxis during orthopedic surgery

<!-- PAGE=? -->
o Care with peripheral nerves

<!-- PAGE=? -->
o Minimize immoblization time

<!-- PAGE=? -->
o Good post-op analgesia

<!-- PAGE=? -->
o Early recognition an treatment (Physio, meds, avoiding cold, early referral)

<!-- PAGE=? -->
References

<!-- PAGE=? -->
 Previous seminars (particularly Annika's)

<!-- PAGE=? -->
 Miller, Barash

<!-- PAGE=? -->
 Cousins - Neural blockade

<!-- PAGE=? -->
 Faust - Anesthesiology Review

<!-- PAGE=? -->
 Raja and Grabow, 2002. CRPS - Anesthesiology 92:1254-60.

<!-- PAGE=? -->
Continuous renal replacement therapy

<!-- PAGE=? -->
Vs IHD is

<!-- PAGE=? -->
 more hemodynamically stable

<!-- PAGE=? -->
 more tolerable if LV dysfunction

<!-- PAGE=? -->
 filtrates more fluid

<!-- PAGE=? -->
No form of dialysis decreases mortality from renal failure

<!-- PAGE=? -->
Anesth Analg 2002;94:1288-97, Continuous Renal Replacement Therapy:Anesthetic Implications, Kenneth and Cohen

<!-- PAGE=? -->
 Definition: CRRT refers to any continuous mode of extracorporeal solute or fluid removal. A variety of renal replacement therapies are encompassed within the term CRRT.

<!-- PAGE=? -->
 Common to all forms of CRRT is an extracorporeal circuit connected to the patient via an arterial or venous access catheter, or both.

<!-- PAGE=? -->
 All CRRT circuits include a hemofilter with a semipermeable membrane. By connecting the hemofilter to the patient's circulation, fluid can be removed from the patient on the basis of the hydrostatic pressure gradient across the filter.

<!-- PAGE=? -->
 The rate of fluid removal is affected by either the patient's arterial blood pressure (when an arterial cannula is used) or by the pressure generated with an extracorporeal pump (for venous cannulation techniques).

<!-- PAGE=? -->
 The ultrafiltrate is composed of water as well as compounds with a molecular weight of up to approximately 20,000 Da (14).

<!-- PAGE=? -->
 Large volumes of ultrafiltrate can be removed with CRRT.

<!-- PAGE=? -->
 To prevent volume depletion, fluid is replaced through the system to optimize intravascular volume and normalize electrolytes. The infusion rate and composition of the replacement fluid are variable and are dictated by the rate of ultrafiltrate formation, the rate of all other IV fluids administered to the patient, and the need for a positive or negative hourly fluid balance.

<!-- PAGE=? -->
 bicarbonate is lost in the ultrafiltrate and by the neutralization of exogenous acids. Therefore, the replacement fluid is usually an isotonic, buffered electrolyte solution. The buffer used in the replacement fluid may be acetate, citrate, lactate, or bicarbonate.

<!-- PAGE=? -->
 The use of citrate is becoming more commonplace because it may be used as both a buffer and an anticoagulant

<!-- PAGE=? -->
 In addition to allowing careful control over fluid balance with hemofiltration, CRRT can also be used as a form of dialytic therapy for patients with renal insufficiency.

<!-- PAGE=? -->
 When dialysis is required, the volume of ultrafiltrate can be controlled as necessary to provide adequate uremic control.

<!-- PAGE=? -->
 Alternatively, a dialysate can be run through the hemofilter in a countercurrent direction. The dialysate creates a concentration gradient across the hemofilter membrane, resulting in solute clearance by diffusion.

<!-- PAGE=? -->
Indications for CRRT

<!-- PAGE=? -->
 ARF. CRRT can also be used to facilitate fluid clearance, correct electrolyte abnormalities, and manage metabolic acidosis (Table 2).

<!-- PAGE=? -->
o CRRT provides a more stable hemodynamic profile than CIHD and minimizes the risks of infection associated with PD.

<!-- PAGE=? -->
o Because CRRT is a slow, continuous form of therapy, treatment of renal failure and fluid and electrolyte abnormalities is possible without hemodynamic compromise.

<!-- PAGE=? -->
 van Bommel et al. (10) Despite being sicker and having more organ dysfunction, patients treated with CAVHDF had more hemodynamic stability and better control of fluid balance

<!-- PAGE=? -->
 occaisionally used to facilitate fluid removal in patients without renal failure but for whom diuresis is unsuccessful or is contraindicated

<!-- PAGE=? -->
 to facilitate nutritional replacement for malnourished or catabolic patients (esp those with ARF or fluid overload)

<!-- PAGE=? -->
Hemodynamic changes associated with IHD:

<!-- PAGE=? -->
 decreases in mean arterial pressure, PCWP

<!-- PAGE=? -->
 decreased cardiac index

<!-- PAGE=? -->
 decreased O2 consumption

<!-- PAGE=? -->
patients undergoing CAVHDF had no significant hemodynamic changes.

<!-- PAGE=? -->
Although CRRT has potential advantages and is safe when used to manage critically ill patients with ARF, it is still important to note that no prospective, randomized study has shown CRRT to improve patient survival when compared with CIHD. The two prospective, randomized studies comparing CRRT with IHD that have been performed showed no difference in hospital outcome. These studies have not been reported in peer-reviewed journals; they have been criticized for their poor methodology and design

<!-- PAGE=? -->
COPD

<!-- PAGE=? -->
 More sensitive to CNS depressants and opioids

<!-- PAGE=? -->
 Only if FEV1<40% do COPD retain CO2

<!-- PAGE=? -->
 The reasons for inc. pCO2 in COPD patients given supplemental O2 is:

<!-- PAGE=? -->
o Inc. Vd/Vt primarily d/t loss of HPV - 48%

<!-- PAGE=? -->
o Dec. Ve (minor) - 22%

<!-- PAGE=? -->
o Haldane effect

<!-- PAGE=? -->
 decrease affinity of HgB for CO2 in presence of inc. O2 (rightward shift of Hb - CO2 dissociation curve) - 30%

<!-- PAGE=? -->
 CO2 is differentially bound to Hgb based on O2 content - less O2 - more CO2 binding

<!-- PAGE=? -->
 With increased FiO2 - CO2 is displaced from Hgb - inc. CO2 in blood

<!-- PAGE=? -->
 Acute exacerbations of COPD

<!-- PAGE=? -->
o NPPV provides benefit in selected patients with hypercapnic COPD exacerbations

<!-- PAGE=? -->
o Significant benefits included:

<!-- PAGE=? -->
 Decrease in the rate of intubation by 30 to 60 percent in the NPPV patients when compared to controls receiving conventional care

<!-- PAGE=? -->
 Decrease in mortality of 10 to 20 percent

<!-- PAGE=? -->
 Decrease in ICU length of stay (13 versus 32 days)

<!-- PAGE=? -->
 Decrease in hospital length of stay (23 versus 35 days)

<!-- PAGE=? -->
Carbon Monoxide - CO

<!-- PAGE=? -->
 a colorless, odorless, tasteless, nonirritating gas produced by the incomplete combustion of carbonaceous material

<!-- PAGE=? -->
 causes tissue hypoxia functional anemia

<!-- PAGE=? -->
o reduced O2 content

<!-- PAGE=? -->
o PaO2 is not changed

<!-- PAGE=? -->
 binds hemoglobin with an affinity of 200 times that of O2

<!-- PAGE=? -->
 of the Hgb that does bind O2 shifts O2Hgb curve to the left (decreased release of O2 to tissues)

<!-- PAGE=? -->
 Symptoms

<!-- PAGE=? -->
o depend on the amount of carboxyhemoglobin present and the patient's activity level, tissue oxygen demands, and hemoglobin concentration.

<!-- PAGE=? -->
o low concentrations of CO

<!-- PAGE=? -->
 irritability, altered visual and motor skills, headache, nausea, vomiting, cardiac ischemia, dysrrhythmia

<!-- PAGE=? -->
o Severe poisoning

<!-- PAGE=? -->
 seizures, coma, respiratory failure, and death

<!-- PAGE=? -->
o classic cherry red color of the skin and mucous membranes of patients with CO poisoning results from the bright red cast of carboxyhemoglobin

<!-- PAGE=? -->
 in severe poisoning, cyanosis may predominate over the cherry red color

<!-- PAGE=? -->
o No tachypnea because carotid bodies are sensitive to PaO2, not O2 content

<!-- PAGE=? -->
o Can get Rhabdo, and lactic acidosis in severe disease

<!-- PAGE=? -->
o Delayed neuropschy disorders

<!-- PAGE=? -->
 Diagnosis:

<!-- PAGE=? -->
o Cooxymetry (4 wavelength)

<!-- PAGE=? -->
o CO > 20%

<!-- PAGE=? -->
 Levels do not correlate with severity, esp if concurrent anemia

<!-- PAGE=? -->
 may be misleadingly low - decr amount of HB available for transport

<!-- PAGE=? -->
o Falsely elevated SpO2

<!-- PAGE=? -->
 Treatment:

<!-- PAGE=? -->
o remove the offending agent and provide a high oxygen-enriched environment.

<!-- PAGE=? -->
o The half-time of CO elimination can be shortened from 4 hr to 40 min by hyperventilation of the lungs with 100% oxygen

<!-- PAGE=? -->
 Ventilation may require mechanical support.

<!-- PAGE=? -->
o Parturients require 5X longer treatment due to delayed elimination from fetus

<!-- PAGE=? -->
 Can cause limb and cranial abnormalities

<!-- PAGE=? -->
o Other treatment modalities

<!-- PAGE=? -->
 hyperbaric oxygen

<!-- PAGE=? -->
 2.5 atm shortens half-time elimination to 20min

<!-- PAGE=? -->
 Consider if

<!-- PAGE=? -->
o COHb > 25% (> 15% in pregnancy)

<!-- PAGE=? -->
o Neurologic impairment

<!-- PAGE=? -->
o Cardiac abnormalities

<!-- PAGE=? -->
 transfusion therapy

<!-- PAGE=? -->
 diuretics and steroids

<!-- PAGE=? -->
 treatment of complicating cerebral edema

<!-- PAGE=? -->
Cryoprecipitate

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 concentrated source of Factor VIII , Factor XIII , vWF , fibronectin and fibrinogen

<!-- PAGE=? -->
 stored at -20°C and thawed immediately prior to use

<!-- PAGE=? -->
 Indications:

<!-- PAGE=? -->
o hypofibrinogenemia (<100 mg·dl -1 )

<!-- PAGE=? -->
o hemophilia A (if a virus-inactivated Factor VIII concentrate is not available)

<!-- PAGE=? -->
o von Willebrand's disease

<!-- PAGE=? -->
o Factor XIII deficiency

<!-- PAGE=? -->
o preparation of fibrin -glue,‖

<!-- PAGE=? -->
o uremia with active bleeding

<!-- PAGE=? -->
 ABO compatibility is not essential b/c low concentration of  antibodies

<!-- PAGE=? -->
 The current indications for Cryo in the Canadian Blood Services Circular (1999) is for fibrinogen and factor XIII.  In both cases inactivated concertates of Fibrinogen and F XIII are preferred but are not licensed in Canada (can be obtained through the Special Access Program of Health Canada)

<!-- PAGE=? -->
 1 u cryo - 10-15 ml plasma

<!-- PAGE=? -->
 dose: 1 u increases fibrinogen by 5-10 mg/dL (hemostatic level is > 100 mg/dL)

<!-- PAGE=? -->
 should be administered through a filter and as rapidly as possible

<!-- PAGE=? -->
o rate of administration should be at least 200 mL/h, and infusion should be completed within 6 hours of thawing.

<!-- PAGE=? -->
Cerebrospinal Fluid

<!-- PAGE=? -->
 CSF contains an array of molecules

<!-- PAGE=? -->
o electrolytes, proteins, glucose, neurotransmitters, neurotransmitter metabolites, cyclic nucleotides, amino acids, among many others

<!-- PAGE=? -->
 produced by ultrafiltration of plasma in the choroid plexus and the cerebral/spinal capillaries and by oxidation of glucose

<!-- PAGE=? -->
 CSF volume is approximately 100 to 160 mL in the adult

<!-- PAGE=? -->
o produced at the rate of 20 to 25 mL/hr

<!-- PAGE=? -->
o the entire volume is replaced roughly every 6 hours

<!-- PAGE=? -->
 removed by arachnoid villi present in the superior sagittal sinus and along many spinal nerve roots

<!-- PAGE=? -->
 CSF does not -flow‖ or -circulate‖ through the subarachnoid space, it oscillates in the cephalocaudal axis with a frequency equal to the heart rate

<!-- PAGE=? -->
o cerebral expansion during systole displaces CSF caudally into the spinal canal and cerebral contraction during diastole causes the CSF displaced into the spinal canal to retreat back into the cranial vault

<!-- PAGE=? -->
o Net CSF movement is estimated at 0.04% per oscillation

<!-- PAGE=? -->
o Consequently, CSF cannot be relied on to distribute drugs in the subarachnoid space

<!-- PAGE=? -->
 i n single-shot spinal the kinetic energy of the injection and the baricity of the solution serve to distribute drug

<!-- PAGE=? -->
 very slow infusions used for chronic intrathecal analgesia result in very l i mited drug distribution

<!-- PAGE=? -->
 Composition vs. serum:

<!-- PAGE=? -->
o Serum > CSF

<!-- PAGE=? -->
 K, Ca, glucose, protein, pH

<!-- PAGE=? -->
o Equal

<!-- PAGE=? -->
 osmolarity, HCO3, Na

<!-- PAGE=? -->
o CSF > serum

<!-- PAGE=? -->
 Cl, Mg

<!-- PAGE=? -->
C-spine

<!-- PAGE=? -->
Barash, ASA refresher, CoExD

<!-- PAGE=? -->
COMPOSITION OF CEREBROSPINAL FLUID AND SERUM

<!-- PAGE=? -->
CSF

<!-- PAGE=? -->
Serum

<!-- PAGE=? -->
Sodium (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
141

<!-- PAGE=? -->
140

<!-- PAGE=? -->
Potassium (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
2.9

<!-- PAGE=? -->
4.6

<!-- PAGE=? -->
Calcium (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
2.5

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
Magnesium (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
2.4

<!-- PAGE=? -->
1.7

<!-- PAGE=? -->
Chloride (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
124

<!-- PAGE=? -->
101

<!-- PAGE=? -->
Bicarbonate (mEq

<!-- PAGE=? -->


<!-- PAGE=? -->
l

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
21

<!-- PAGE=? -->
23

<!-- PAGE=? -->
Glucose (mg

<!-- PAGE=? -->


<!-- PAGE=? -->
100 ml

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
61

<!-- PAGE=? -->
92

<!-- PAGE=? -->
Protein (mg

<!-- PAGE=? -->


<!-- PAGE=? -->
100 ml

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
)

<!-- PAGE=? -->
28

<!-- PAGE=? -->
7000

<!-- PAGE=? -->
pH

<!-- PAGE=? -->
7.31

<!-- PAGE=? -->
7.41

<!-- PAGE=? -->
Osmolality (mOsm

<!-- PAGE=? -->


<!-- PAGE=? -->
kg

<!-- PAGE=? -->
-1

<!-- PAGE=? -->
H2O)

<!-- PAGE=? -->
289

<!-- PAGE=? -->
289

<!-- PAGE=? -->
 Vertebral alignment is determined on the lateral cervical radiograph by evaluating four longitudinal curves

<!-- PAGE=? -->
o anterior and posterior borders of the vertebral bodies

<!-- PAGE=? -->
o the posterior border of the spinal canal

<!-- PAGE=? -->
o the tips of the spinous processes

<!-- PAGE=? -->
 Vertebral dislocation should be suspected if there is >3 mm of malalignment in any of these curves

<!-- PAGE=? -->
 The prevertebral space measures 10 mm at the level of the anterior arch of the atlas, 4 mm between C2 and C4, and 15 mm below C4

<!-- PAGE=? -->
 Current guidelines consider absence of neck pain or paresthesia and a negative physical exam (lack of tenderness with palpation and during voluntary flexion/extension of the neck) in a neurologically intact, conscious pt as adequate for ruling out C-spine injury w/o further radiological studies.

<!-- PAGE=? -->
o Alcohol intoxication and distracting associated injuries do NOT seem to alter these guidelines as long as the pt is alert, conscious and able to concentrate

<!-- PAGE=? -->
 Despite cervical pain and tenderness, cervical spine radiographs may at times be normal

<!-- PAGE=? -->
o A high index of suspicion of an unstable injury should appropriately lead to obtaining a flexionextension series, which may demonstrate a fracture or dislocation that has been missed by the standard views.

<!-- PAGE=? -->
 Predental space or atlas-dens interval (distance between posterior aspect of anterior arch of C1 and anterior aspect of odontoid process normally 2-2.5 mm in adults and 4-4.5 mm in children …

<!-- PAGE=? -->
 Retropharyngeal space (space between posterior pharyngeal wall and anterior border of vertebrae). Normally < 7 mm in children and adults at C2 . < 1/2 width of the vertebral body at C3&4

<!-- PAGE=? -->
 Retrotracheal space (space between posterior tracheal wall and anterior inferior body C6 normally no more than 22 mm in adults and 14 mm in children <15 yrs

<!-- PAGE=? -->
 ATLS Manual chapter review questions >3mm dislocation

<!-- PAGE=? -->
o 5mm in children (Down Syndrome)

<!-- PAGE=? -->
 30 % of patients with severe RA will have some instability of C1-C2 although surgical correction is needed in relatively few

<!-- PAGE=? -->
 The radiologist is looking for anterior atlantodental interval (AADI)increasing with flexion

<!-- PAGE=? -->
o Anterior subluxation is the most common ( transverse ligament dysfunction), is worse in flexion, > 5mm preodontoid space ( > 3 mm in children), plan for intubation with neck stabilization of AFOI

<!-- PAGE=? -->
Figure 1. The Canadian C-Spine Rule.

<!-- PAGE=? -->
high-risk factor that mandates

<!-- PAGE=? -->
radiography?

<!-- PAGE=? -->
Age 265yr o

<!-- PAGE=? -->
dangerous mechanism

<!-- PAGE=? -->
or

<!-- PAGE=? -->
paresthesias in extremities

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
low-risk factor that allows safe

<!-- PAGE=? -->
assessment of range of motion?

<!-- PAGE=? -->
Simple rear-end motor vehicle

<!-- PAGE=? -->
collision or sitting position in the

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Radiography

<!-- PAGE=? -->
emergency department or ambulatory

<!-- PAGE=? -->
at any time or delayed (not immediate)

<!-- PAGE=? -->
onset of neck pain or absence of

<!-- PAGE=? -->
midline cervical-spine tenderness

<!-- PAGE=? -->
Unable

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Able to rotate neck actively?

<!-- PAGE=? -->
45" left and right

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No radiography

<!-- PAGE=? -->
Any

<!-- PAGE=? -->
Any

<!-- PAGE=? -->
For patients with trauma who are alert (as indicated by a score of 15 on the Glasgow Coma Scale) and in stable condition and in whom cervical-spine injury is a concern; the determination of risk factors guides the use ofcervicalspine radiography A dangerous mechanism is considered to be a fall from an diving); a motor vehicle collision at high speed (>100 km/hr) or with rollover or ejection; a collision involving a motorized recreationalvehicle; or a bicycle collision. A simple rear-end motor vehicle collision excludes pushed into oncoming traffic, being hit by a bus or a being hit by a high-speed vebeing

<!-- PAGE=? -->
Table 1. The NEXUS Low-Risk Criteria.

<!-- PAGE=? -->
Cervical-spine radiography is indicated for patients with trauma unless meet all ofthe following criteria: they

<!-- PAGE=? -->
No posterior midline cervical-spine tenderness;í

<!-- PAGE=? -->
No evidence of intoxication;$

<!-- PAGE=? -->
A normal level of alertness; $

<!-- PAGE=? -->
No focal neurologic deficit; and

<!-- PAGE=? -->
No painful distracting injuries |

<!-- PAGE=? -->
Cushing's Syndrome

<!-- PAGE=? -->
 signs and symptoms follow from the known actions of glucocorticoids

<!-- PAGE=? -->
o Truncal obesity and thin extremities

<!-- PAGE=? -->
 redistribution of fat in facial, cervical, and truncal areas

<!-- PAGE=? -->
o osteopenia

<!-- PAGE=? -->
 Impaired calcium absorption and a decrease in bone formation

<!-- PAGE=? -->
o Hyperglycemia

<!-- PAGE=? -->
 overt diabetes mellitus occurs in less than 20%

<!-- PAGE=? -->
o Hypertension and fluid retention

<!-- PAGE=? -->
o emotional changes ranging from emotional lability to frank psychosis

<!-- PAGE=? -->
o inc. susceptibility to infection reflects the immunosuppressive effects of corticosteroids

<!-- PAGE=? -->
o Hypokalemic alkalosis

<!-- PAGE=? -->
 common when adrenal hyperplasia is caused by ectopic ACTH production from a nonendocrine tumor

<!-- PAGE=? -->
 Plasma renin activity is usually normal, as is aldosterone, indicating that the most likely explanation for the development of K+ depletion is increased fluid delivery to the distal nephron

<!-- PAGE=? -->
Cutaneous innervation

<!-- PAGE=? -->
LUMBAR PLEXUS Cutaneous innervation

<!-- PAGE=? -->
Genitofemoral nerve

<!-- PAGE=? -->
Lateral

<!-- PAGE=? -->
Ilioinguinal nerve

<!-- PAGE=? -->
Femoral

<!-- PAGE=? -->
Cutaneous nerve

<!-- PAGE=? -->
Obturator nerve

<!-- PAGE=? -->
Anterior Femoral

<!-- PAGE=? -->
Cutaneous nerve

<!-- PAGE=? -->
Lateral Sural

<!-- PAGE=? -->
Cutaneous nerve

<!-- PAGE=? -->
Saphenous nerve

<!-- PAGE=? -->
Superficial

<!-- PAGE=? -->
Peroneal nerve

<!-- PAGE=? -->
Sural nerve

<!-- PAGE=? -->
peroneal nerve

<!-- PAGE=? -->
Deep

<!-- PAGE=? -->
ANTERIOR

<!-- PAGE=? -->
CVL Infections

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Prevention

<!-- PAGE=? -->
o Wash hands prior to procedure

<!-- PAGE=? -->
o Mask, cap, gown, sterile gloves

<!-- PAGE=? -->
o 2% chlohexidine likely beter than proviodine

<!-- PAGE=? -->
o Large sterile drapes

<!-- PAGE=? -->
o Antimicrobial impregnated catheters

<!-- PAGE=? -->
 No current support for routine catheter site changes

<!-- PAGE=? -->
 Multilumen catheters have been associated with an inc. risk of infection

<!-- PAGE=? -->
CVP

<!-- PAGE=? -->
Basic waves

<!-- PAGE=? -->
 a wave: atrial contraction

<!-- PAGE=? -->
 c wave: tricuspid closure

<!-- PAGE=? -->
 v wave: systolic filling of RA

<!-- PAGE=? -->
 x descent: early systolic pull of RV (atrial relaxation)

<!-- PAGE=? -->
 y descent: emptying of RA after tricuspid opening (ventricle relaxation)

<!-- PAGE=? -->
R

<!-- PAGE=? -->
T

<!-- PAGE=? -->
ECG

<!-- PAGE=? -->
SYSTOLE

<!-- PAGE=? -->
'DIASTOLE

<!-- PAGE=? -->
CVP

<!-- PAGE=? -->
 two diastolic components

<!-- PAGE=? -->
o a wave, y descent

<!-- PAGE=? -->
 three systolic components

<!-- PAGE=? -->
o c wave, x descent, v wave

<!-- PAGE=? -->
 v and a waves merge with tachycardia

<!-- PAGE=? -->
o reduced length of diastole and the duration of the y descent

<!-- PAGE=? -->
 Large v waves - decreased LV compliance (MI, tamponade, constrictive percarditis)

<!-- PAGE=? -->
 Atrial fibrillation

<!-- PAGE=? -->
o obliterates the a wave

<!-- PAGE=? -->
o inc. the c wave

<!-- PAGE=? -->
o preserves the v wave and y descent

<!-- PAGE=? -->
 Atrioventricular dissociation .

<!-- PAGE=? -->
o early systolic cannon a wave - atrial contraction on closed valve

<!-- PAGE=? -->
 Ventricular pacing

<!-- PAGE=? -->
o Systolic cannon waves are evident in the CVP trace during ventricular pacing

<!-- PAGE=? -->
 Pericardial constriction

<!-- PAGE=? -->
o tall a and v waves with steep x and y descents and a mid-diastolic plateau or h wave

<!-- PAGE=? -->
 Cardiac tamponade

<!-- PAGE=? -->
o increased mean pressure (16 mm Hg)

<!-- PAGE=? -->
o attenuation of the y descent

<!-- PAGE=? -->
 Tricuspid regurgitation

<!-- PAGE=? -->
o broad, tall systolic c-v wave

<!-- PAGE=? -->
o overestimated RVEDP

<!-- PAGE=? -->
 estimated best by measuring the CVP value at the time of the ECG R wave , prior to the regurgitant systolic wave

<!-- PAGE=? -->
 tricuspid stenosis

<!-- PAGE=? -->
o Mean CVP is elevated, and a pressure gradient exists throughout diastole

<!-- PAGE=? -->
o a wave is unusually prominent and the y descent is slurred,

<!-- PAGE=? -->
 Other conditions that reduce right ventricular compliance, such as right ventricular ischemia, pulmonary hypertension, or pulmonic valve stenosis, may produce a prominent end-diastolic a wave in the CVP trace but do not attenuate the early diastolic y descent

<!-- PAGE=? -->
Cyanide Toxicity

<!-- PAGE=? -->
Barash hydrogen cyanide exposure

<!-- PAGE=? -->
 impairs cytochrome oxidase and aerobic metabolism at the level of the mitochondria

<!-- PAGE=? -->
 Oxygen can get to the tissue, but the uncoupled oxidative phosphorylation prevents effective usage of oxygen by the mitochondria

<!-- PAGE=? -->
Initial symptoms:

<!-- PAGE=? -->
 restless

<!-- PAGE=? -->
 tachypneic

<!-- PAGE=? -->
 headaches

<!-- PAGE=? -->
 palpitations

<!-- PAGE=? -->
 dyspnea

<!-- PAGE=? -->
Progressive symptoms

<!-- PAGE=? -->
 nausea, vomiting

<!-- PAGE=? -->
 convulsions leading to coma

<!-- PAGE=? -->
 respiratory failure

<!-- PAGE=? -->
 cardiac arrest

<!-- PAGE=? -->
Cyanide is produced when SNP is metabolized

<!-- PAGE=? -->
 1 mg of SNP contains 0.44 mg of cyanide

<!-- PAGE=? -->
 Toxic blood levels (>100 mg/dL)

<!-- PAGE=? -->
o >1 mg/kg SNP is administered within 2 hours or

<!-- PAGE=? -->
o >0.5 mg/kg/hr is administered within 24 hours

<!-- PAGE=? -->
 presenting signs of cyanide toxicity

<!-- PAGE=? -->
o elevated mixed venous O2 (PVO2)

<!-- PAGE=? -->
o increasing SNP requirements (tachyphylaxis)

<!-- PAGE=? -->
o metabolic acidosis

<!-- PAGE=? -->
 SNP can cause inhibition of platelet aggregation; however, this complication is reversible and transitory

<!-- PAGE=? -->
 SNP deteriorates in the presence of light

<!-- PAGE=? -->
Greater risk of cyanide toxicity exists in patients who are nutritionally deficient in cobalamine (vitamin B12 compounds)

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 discontinuing infusion

<!-- PAGE=? -->
 100% O2

<!-- PAGE=? -->
 administer

<!-- PAGE=? -->
o amyl nitrate (inhaler)

<!-- PAGE=? -->
o sodium thiosulfate - 150mg/kg over 15 min

<!-- PAGE=? -->
 Cyanide ions are normally metabolized by the rhodanese enzyme in the liver, which is a sulfur-requiring step that leads to the bioformation of methemoglobin

<!-- PAGE=? -->
 avoid in renal failure

<!-- PAGE=? -->
 Thiocyanate is cleared slowly by the kidneys (T ½ = 4-7 d)

<!-- PAGE=? -->
 Toxicity is rare, 100x less toxic then cyanide

<!-- PAGE=? -->
o In patients with CRF who are not undergoing dialysis, 3-6 days of SNP are required

<!-- PAGE=? -->
 Nonspecific symptoms:

<!-- PAGE=? -->
o Fatigue, tinnitus, nausea, vomiting

<!-- PAGE=? -->
o Skeletal muscle weakness, hypereflexia, confusion, pshychosis, miosis

<!-- PAGE=? -->
o Seizures, coma

<!-- PAGE=? -->
o Clinical hypothyroidism

<!-- PAGE=? -->
 thiocyanate can inhibit uptake and binding of iodine in the thyroid

<!-- PAGE=? -->
 Thiocyanate clearance can be facilitated by dialysis

<!-- PAGE=? -->
 hydroxocobalamin is recommended for cyanide toxicity in renal failure

<!-- PAGE=? -->
o IV sodium nitrite - 5mg/kg IV over 5 min

<!-- PAGE=? -->
 supportive care

<!-- PAGE=? -->
o intubation, ventilation, 100% oxygen

<!-- PAGE=? -->
o cardiac support with inotropes and vasopressors

<!-- PAGE=? -->
Cystic Fibrosis

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 inherited multisystem disorder characterized by abnormalities in exocrine gland function

<!-- PAGE=? -->
 Pulmonary dysfunction is the most common cause of morbidity and mortality

<!-- PAGE=? -->
o severe obstructive disease with bronchiectasis, emphysema , and ultimately, terminal respiratory failure

<!-- PAGE=? -->
 Pancreatic dysfunction, hepatobiliary and genitourinary disease is also a common accompaniment

<!-- PAGE=? -->
 median survival is about 20 years

<!-- PAGE=? -->
 All levels of the respiratory tract can be involved

<!-- PAGE=? -->
o Nasal polyposis

<!-- PAGE=? -->
o Sinusitis

<!-- PAGE=? -->
o lower respiratory tract disease

<!-- PAGE=? -->
 The common denominator is the alteration in mucus secretion

<!-- PAGE=? -->
 Pancreatic insufficiency leads to protein and fat malabsorption and recurrent pancreatitis

<!-- PAGE=? -->
 Hepatobiliary disease is common in older patients with chronic cholestasis, inflammation, fibrosis, and even cirrhosis

<!-- PAGE=? -->
 Extrahepatic disease of the biliary system and abnormalities of the genitourinary tract are also common

<!-- PAGE=? -->
 Sweat test is the most reliable diagnostic test for cystic fibrosis

<!-- PAGE=? -->
 elevations of sodium, potassium, and chloride levels

<!-- PAGE=? -->
 Treatment is primarily directed at the respiratory system

<!-- PAGE=? -->
o control of airway infection

<!-- PAGE=? -->
 Antibiotics

<!-- PAGE=? -->
 Pseudomonas aeruginosa is likely

<!-- PAGE=? -->
o secretion mobilization

<!-- PAGE=? -->
 mechanical drainage (chest physio)

<!-- PAGE=? -->
D

<!-- PAGE=? -->
DDAVP

<!-- PAGE=? -->
 vWD

<!-- PAGE=? -->
o iv in a dose of 0.3 ug/kg

<!-- PAGE=? -->
 effect is almost immediate

<!-- PAGE=? -->
 Peak levels of Factor VIII:C and vWF are achieved within 30-60 min

<!-- PAGE=? -->
 effect lasts for several hours - may be repeated after 8-12 hours

<!-- PAGE=? -->
 clinically significant water retention is relatively uncommon in adults

<!-- PAGE=? -->
 Increased release of von Willebrand (promotes platelet adhesiveness to the vascular endothelium)  factor accounts for the hemostatic activity in patients with

<!-- PAGE=? -->
o Uremia

<!-- PAGE=? -->
o chronic liver disease

<!-- PAGE=? -->
o certain types of hemophilia

<!-- PAGE=? -->
 has also been reported to minimize intraoperative blood loss in patients undergoing cardiac surgery

<!-- PAGE=? -->
o there is no evidence for this

<!-- PAGE=? -->
o treatment of choice for DI due to inadequate production of ADH by the posterior pituitary

<!-- PAGE=? -->
o intranasally twice daily

<!-- PAGE=? -->
o not effective in the treatment of nephrogenic diabetes insipidus

<!-- PAGE=? -->
Deadspace

<!-- PAGE=? -->
Physiologic dead space = anatomic + alveolar dead space

<!-- PAGE=? -->
Anatomic deadspace = volume of conducting airways

<!-- PAGE=? -->
 essentially equal to physiologic deadspace in supine individual

<!-- PAGE=? -->
Alveolar deadspace = volume of gas that ventilates underperfused areas of the lung

<!-- PAGE=? -->
 increases with PE or decrease in CO

<!-- PAGE=? -->
 60-80 mls in the upright position because upper alveoli are no longer perfused (West zone I), negligible in the supine

<!-- PAGE=? -->
Miller 6th, ch 17

<!-- PAGE=? -->
 The PaCO2 will be greater than or equal to end-tidal PaCO2 (PETCO2) unless the patient inspires carbon dioxide. The difference between PETCO2 and PaCO2 is due to dead space ventilation.

<!-- PAGE=? -->
 Some clinicians use the divergence of PETCO2 from PaCO2 as a reflection of pulmonary blood flow for other applications. During intentional pharmacologic or surgical manipulation of pulmonary blood flow, the difference between PaCO2 and PETCO2 serves as a useful physiologic monitor of the effectiveness of these interventions

<!-- PAGE=? -->
 physiologic dead space = anatomic dead space (nonrespiratory airways) + alveolar dead space

<!-- PAGE=? -->
 Normal Vd = 150 ml ( 2 ml/kg, or weight in pounds)

<!-- PAGE=? -->
 Bohr equation is Vd/Vt = (PACO2 - PETCO2)/ PACO2, can be used to determine Vd (Pet CO2 is the average measured over several minutes).  Can be used to calculate physiologic dead space

<!-- PAGE=? -->
 DI

<!-- PAGE=? -->
 Bronchodilators

<!-- PAGE=? -->
 Nebulized racemic epinephrine promotes α- and β-adrenergic receptors

<!-- PAGE=? -->
o reduction of airway inflammation

<!-- PAGE=? -->
o Aerosolized recombinant human DNase decreases the viscosity of tracheobronchial secretions

<!-- PAGE=? -->
o inhaled N-acetylcysteine, decreases the viscosity of pulmonary secretions by disrupting protein disulfide bonds

<!-- PAGE=? -->
 may provoke bronchospasm

<!-- PAGE=? -->
 Factors that decrease Vd include: supine position, neck flexion, artificial airways

<!-- PAGE=? -->
 Factors that increase Vd include: upright position, neck extension, age, PPV, anticholinergics, decreased perfusion (pulmonary emboli, hTN), emphysema

<!-- PAGE=? -->
Death from anesthesia

<!-- PAGE=? -->
 Death within 24 hours attributable solely to anesthesia= 25% Miller pg 899

<!-- PAGE=? -->
 Death within 48 hrs = 4 % Miller pg 902 Lagasse study

<!-- PAGE=? -->
 Risk of death solely d/t anesthesia ~ 1 in 13,000

<!-- PAGE=? -->
Deep Cervical Plexus Block

<!-- PAGE=? -->
 From Cousins

<!-- PAGE=? -->
 Paravertebral nerve block of C2-C4

<!-- PAGE=? -->
 Indications:

<!-- PAGE=? -->
o Awake carotid endarterectomy

<!-- PAGE=? -->
o Thyroid surgery

<!-- PAGE=? -->
o Awake tracheostomy

<!-- PAGE=? -->
o Cervical lymph nodes

<!-- PAGE=? -->
 Contraindications:

<!-- PAGE=? -->
 Anatomy:

<!-- PAGE=? -->
o Nerves are blocked as the emerge from the cervical foramina

<!-- PAGE=? -->
o Each nerve lies in the sulcus in the transverse process of each vertebra

<!-- PAGE=? -->
o In vicinity of vertebral arteries, foramen and dural sleeves of cervical nerves

<!-- PAGE=? -->
 Technique:

<!-- PAGE=? -->
o Patient lies supine with neck slightly extended and head turned away from side being blocked

<!-- PAGE=? -->
o Line drawn joining mastoid process with Chassaignac's tubercle (C6)

<!-- PAGE=? -->
o C2 is located one fingerbreadth caudad to mastoid process on this line

<!-- PAGE=? -->
o C3 and C4 are similar intervals caudally on the same line

<!-- PAGE=? -->
o Alternatively, a horizontal line through the lower border of the ramus of the mandible intersects this line at C4

<!-- PAGE=? -->
o 5cm, 22g needles are directed medially and caudally (to avoid peridural or spinal block!)

<!-- PAGE=? -->
o End point is bony landmark of transverse process, and paresthesias are obtained

<!-- PAGE=? -->
o Injection of 3-4 cc of 1% lidocain or equivalent on each nerve is usually adequate for anesthesia

<!-- PAGE=? -->
o Fortunately, the paraverterbral space communicates freely in the cervical region, and the anesthetic solution can spread easily to adjacent levels - deep cervical plexus block can be obtained with injections at just one level with larger volume (6-8cc)

<!-- PAGE=? -->
o In fact, if digital pressure is maintained distally in the inter-scalene groove and patient is placed in a horizontal or even head-down posture, cervical plexus block can be predictalbly produced using same needle insertion technique as IS brachial plexus block

<!-- PAGE=? -->
 Complications:

<!-- PAGE=? -->
o Major complication is intravertebral injection - which can cause rapid convulsions, unconsciousness, and blindness

<!-- PAGE=? -->
o Extentsion in to epidural or subdural spaces by either dural sleeves or leakage through intervertebral foramen

<!-- PAGE=? -->
o Phrenic nerve block and resultant diaphragm paralysis (serious if bilateral DCP blocks)

<!-- PAGE=? -->
o The deep cervical plexus lies deep to the deep cervical fascia, therefore spread to cervical sympathetic chain should not occur; if there is anterior spread, complications of cervical sympathetic blockade could develop:

<!-- PAGE=? -->
 Horner's syndrome

<!-- PAGE=? -->
 Recurrent laryngeal nerve block (hoarseness)

<!-- PAGE=? -->
Dehydration in Infants

<!-- PAGE=? -->
Dental damage

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Incidence of dental injury 1:1,000 cases where ETT was used; 75% at intubation, 25% at extubation/in PAR

<!-- PAGE=? -->
 Most common injury during anesthesia (40% of claims)

<!-- PAGE=? -->
o dislodge teeth  (47%)

<!-- PAGE=? -->
o chip or fracture teeth (39%)

<!-- PAGE=? -->
o damage to dental prosthesis (12%)

<!-- PAGE=? -->
 RF dental injury

<!-- PAGE=? -->
o GA

<!-- PAGE=? -->
o tracheal intubation

<!-- PAGE=? -->
o preexisting poor dentition

<!-- PAGE=? -->
o inc. difficulty of intubation

<!-- PAGE=? -->
 previous difficult intubation

<!-- PAGE=? -->
o preexisting craniofacial abnormalities,

<!-- PAGE=? -->
o limited cervical range of motion

<!-- PAGE=? -->
 Difficult/ER intubations accounted for > 50% of all incidents

<!-- PAGE=? -->
 Upper L central incisor = most often affected

<!-- PAGE=? -->
 the tooth should be carefully handled without touching the root

<!-- PAGE=? -->
o the tooth can be placed in saline or milk until dental expertise can be obtained

<!-- PAGE=? -->
Dexmedetomidine

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 alpha2-agonist

<!-- PAGE=? -->
o 1620:1 alpha2:alpha1

<!-- PAGE=? -->
 Shorter acting than clonidine

<!-- PAGE=? -->
o Half-time of 2-3 hrs

<!-- PAGE=? -->
 Highly protein bound

<!-- PAGE=? -->
 Extensive hepatic metabolism

<!-- PAGE=? -->
 Effects

<!-- PAGE=? -->
o Attenuates hemodynamic response to intubation

<!-- PAGE=? -->
o Dec. plasma catecholamine levels

<!-- PAGE=? -->
o Dec. opioid requirements

<!-- PAGE=? -->
o Dec. MAC

<!-- PAGE=? -->
o Minimal resp depression

<!-- PAGE=? -->
o Total IV anesthesia without resp depression with high doses

<!-- PAGE=? -->
 1ug/kg bolus with 5-10ug/kg/hr infusion

<!-- PAGE=? -->
Diabetes insipidus

<!-- PAGE=? -->
 Diagnosis (central DI post-op):

<!-- PAGE=? -->
o Hypernatremia (> 150 mEq/L)

<!-- PAGE=? -->
o Increased serum osmolality (> 300 mosm/kg)

<!-- PAGE=? -->
o Decreased urine osmolality (< 200 mosm/kg)

<!-- PAGE=? -->
o Urine output (> 2 L/day)

<!-- PAGE=? -->
 Results in hypovolemic hypernatremia

<!-- PAGE=? -->
 Usually occurs after destruction of the pituitary gland - stored in posterior pituitary

<!-- PAGE=? -->
o Trauma, tumor, Surgery

<!-- PAGE=? -->
 Central DI: Dx

<!-- PAGE=? -->
o CNS infection

<!-- PAGE=? -->
o CNS neoplasia

<!-- PAGE=? -->
o CNS vascular

<!-- PAGE=? -->
o Head trauma

<!-- PAGE=? -->
o Systemic disease (sarcoidosis, Wegener's)

<!-- PAGE=? -->
 Nephrogenic DI

<!-- PAGE=? -->
o congenital

<!-- PAGE=? -->
o Drugs (Amphotericin B, vinblastin, Lithium, Methoxyflurane (fluoride toxicity), Prostaglandin

<!-- PAGE=? -->
o Primary renal (Chronic interstitial disease, PKD, Chronic obstructive uropathy

<!-- PAGE=? -->
o Systemic disease (amyloidosis, hypercalcemia, hypoK, multiple myeloma, sarcoidosis, sickle cell)

<!-- PAGE=? -->
 80-85% of vasopressin-secreting neurons must be destroyed for sx to occur

<!-- PAGE=? -->
 Postop diabetes insipidus develops in 20-30% of pts undergoing pituitary surgery

<!-- PAGE=? -->
 DI postop or post head trauma may be transient, permanent, or follow a triphasic course

<!-- PAGE=? -->
o Transient: most common , abrupt onset w/in first 12-24 hrs & resolves within 2-4 days (some say several days to weeks)

<!-- PAGE=? -->
o Permanent: abrupt onset w/in first 24 hrs, but does not resolve

<!-- PAGE=? -->
o Triphasic: initial period of vasopressin deficiency lasting 2-4 days d/t axonal injury; followed by 57d period of inappropriate vasopressin release d/t leakage from degenerating neurons; finally, permanent diabetes insipidus

<!-- PAGE=? -->
 Signs and symptoms

<!-- PAGE=? -->
o polyuria/polydipsia; pts asymptomatic until urine volume > 3-4 L/d when develop nocturia

<!-- PAGE=? -->
o pts with DI who are unable to respond to thirst can develop life-threatening hypernatremia

<!-- PAGE=? -->
 muscular weakness, fasciculations, lethargy, coma

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Stop offending drugs / treat reversible renal pathology

<!-- PAGE=? -->
o Vasopressin

<!-- PAGE=? -->
 100-200 mU/hr by infusion

<!-- PAGE=? -->
 Inc. SVR

<!-- PAGE=? -->
o DDAVP

<!-- PAGE=? -->
 s/c q4h

<!-- PAGE=? -->
 Antidiuretic activity lasts 12-24 hrs

<!-- PAGE=? -->
 No change in SVR

<!-- PAGE=? -->
o Incomplete DI may be treated with

<!-- PAGE=? -->
 chlorpropamide 200-500 mg/day

<!-- PAGE=? -->
Dialysis

<!-- PAGE=? -->
Lange, Miller

<!-- PAGE=? -->
 indications for dialysis include

<!-- PAGE=? -->
o Anuria-oliguria (diuresis ≤ 200 mL in 12 hr)

<!-- PAGE=? -->
o Severe metabolic acidosis (pH < 7.10)

<!-- PAGE=? -->
o Hyperazotemia (BUN ≥ 80 mg/dL) or creatinine > 4 mg/dL

<!-- PAGE=? -->
o Hyperkalemia (K+≥ 6.5 mEq/L)

<!-- PAGE=? -->
o Clinical signs of uremic toxicity

<!-- PAGE=? -->
o Severe dysnatremia (Na+≤ 115 or ≥ 160 mEq/L)

<!-- PAGE=? -->
o Hyperthermia (temperature > 40°C without response to medical therapy)

<!-- PAGE=? -->
o Anasarca or severe fluid overload

<!-- PAGE=? -->
o Multiple organ failure with renal dysfunction and/or systemic inflammatory response syndrome, sepsis, or septic shock with renal dysfunction

<!-- PAGE=? -->
 Dialysis improves platelets function

<!-- PAGE=? -->
 Hypoxemia is a complication of dialysis

<!-- PAGE=? -->
o Neutrophils can interact with cellophane derived dialysis membranes leading to neutropena and leukocyte-mediated pulmonary dysfunction

<!-- PAGE=? -->
o Neutrophils sequester temporarily in the lungs causing hypoxemia

<!-- PAGE=? -->
 hypopnea has been found to occur during and after dialysis when the dialysate contained acetate

<!-- PAGE=? -->
 disequilibrium syndrome

<!-- PAGE=? -->
o caused by brain edema 2' to rapid reduction in serum osmolality

<!-- PAGE=? -->
 largely because of urea removal

<!-- PAGE=? -->
o HA, nausea, restlessness, cramps, seizures, coma

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
Lange

<!-- PAGE=? -->
 Neurological

<!-- PAGE=? -->
o Disequilibrium syndrome

<!-- PAGE=? -->
o Dementia

<!-- PAGE=? -->
 Cardiovascular

<!-- PAGE=? -->
o Intravascular volume depletion

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
o Arrhythmia

<!-- PAGE=? -->
 Pulmonary

<!-- PAGE=? -->
o Hypoxemia

<!-- PAGE=? -->
 Gastrointestinal

<!-- PAGE=? -->
o Ascites

<!-- PAGE=? -->
 Stimulates the release of ADH and sensitizes the renal tubules

<!-- PAGE=? -->
 Hypogycemia is a side effect

<!-- PAGE=? -->
 Clofibrate may also be used

<!-- PAGE=? -->
 HCTZ

<!-- PAGE=? -->
 Potentates renal effect of ADH

<!-- PAGE=? -->
o None of these treatments work in nephrogenic DI

<!-- PAGE=? -->
o Volume status

<!-- PAGE=? -->
 if hypovolemic: titrate NS boluses to euvolemia

<!-- PAGE=? -->
 Hourly maintenance fluid + 2/3 of the previous hour's urine output, usually D5-½NS

<!-- PAGE=? -->
 If hourly fluids > 350 - 400 mL, add DDAVP

<!-- PAGE=? -->
o Hypernatremia

<!-- PAGE=? -->
 hypervolemia- loop diuretics, hypotonic crystalloid to replace water deficit

<!-- PAGE=? -->
 euvolemia- hypotonic fluids or oral water hydration

<!-- PAGE=? -->
 avoid rapid correction- replace water deficit over 24-48 hrs, not more than 1-2mEq/L/hr

<!-- PAGE=? -->
 Hematological

<!-- PAGE=? -->
o Anemia

<!-- PAGE=? -->
o Transient neutropenia

<!-- PAGE=? -->
o Residual anticoagulation

<!-- PAGE=? -->
o Hypocomplementemia

<!-- PAGE=? -->
 Metabolic

<!-- PAGE=? -->
o Hypokalemia

<!-- PAGE=? -->
o Large protein losses

<!-- PAGE=? -->
 Skeletal

<!-- PAGE=? -->
o Osteomalacia

<!-- PAGE=? -->
o Arthropathy

<!-- PAGE=? -->
o Myopathy

<!-- PAGE=? -->
 Infectious

<!-- PAGE=? -->
o Peritonitis

<!-- PAGE=? -->
o Transfusion-related hepatitis

<!-- PAGE=? -->
CRRT

<!-- PAGE=? -->
A&A 2002

<!-- PAGE=? -->
 Benefit as compared to intermittent HD

<!-- PAGE=? -->
o More hemodynamically stable

<!-- PAGE=? -->
o Better tolerated in patients with LV dysfunction

<!-- PAGE=? -->
o More volume is removed

<!-- PAGE=? -->
 No dec. in mortality as compared with intermittent HD

<!-- PAGE=? -->
Diastolic Dysfunction

<!-- PAGE=? -->
NEJM 2003

<!-- PAGE=? -->
 Diastolic dysfunction refers to an abnormality of diastolic distensibility, filling, or relaxation of the left ventricle

<!-- PAGE=? -->
 Diastolic heart failure is characterized by effort intolerance and dyspnea in combination with venous congestion and pulmonary edema in the presence of normal systolic function

<!-- PAGE=? -->
 20-50% of patients with heart failure have preserved systolic function or a normal left ventricular ejection fraction

<!-- PAGE=? -->
 diastolic heart failure is highest in patients over the age of 75 years

<!-- PAGE=? -->
Dibucaine  Number

<!-- PAGE=? -->
Table 13-2 -- Relationship between dibucaine number and duration of succinylcholine or mivacurium neuromuscular blockade

<!-- PAGE=? -->
* The dibucaine number indicates the percentage of enzyme inhibited.

<!-- PAGE=? -->
DIC

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 end result of systemic activation of coagulation and is secondary to another disorder or disease process (OB, sepsis, trauma)

<!-- PAGE=? -->
 triggered by the appearance of tissue factor (thromboplastin) in the circulation resulting in SIRS-like cytokine response that overwhelms the mechanisms that restrain and localize clot formation

<!-- PAGE=? -->
 The accelerated process of clot formation causes both tissue ischemia and, ultimately, critical depletion of platelets and factors leading to bleeding

<!-- PAGE=? -->
 Contrary to the common feeling DIC is most commonly associated with thrombosis and NOT bleeding o The only exception is probably in OB

<!-- PAGE=? -->
 In OB, amiotic fluid itself activates the coagulation cascade and in placental abruption the degree of separation directly correlates with the extent of DIC

<!-- PAGE=? -->
 Bleeding is caused by the consumption and exhaustion of coagulation factors and platelets

<!-- PAGE=? -->
 It is felt to be modulated by Factor VIIa

<!-- PAGE=? -->
 Anti-thrombin cannot adequately regulate thrombin (degraded and its synthesis is impaired

<!-- PAGE=? -->
 Protein C is decreased

<!-- PAGE=? -->
 In sepsis and trauma DIC is an independent predictor of mortality

<!-- PAGE=? -->
 Etiologies

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Malignancies

<!-- PAGE=? -->
o Obstetric conditions

<!-- PAGE=? -->
 Amniotic fluid embolus

<!-- PAGE=? -->
 Fetal death in utero

<!-- PAGE=? -->
 Including saline abortion

<!-- PAGE=? -->
 Abruptio placentae

<!-- PAGE=? -->
 Pre-eclampsia

<!-- PAGE=? -->
o Metabolic derangement

<!-- PAGE=? -->
 Acidosis

<!-- PAGE=? -->
 Shock

<!-- PAGE=? -->
 hyoxia

<!-- PAGE=? -->
o Extensive tissue damage

<!-- PAGE=? -->
 Burns

<!-- PAGE=? -->
 Trauma

<!-- PAGE=? -->
 Liver failure

<!-- PAGE=? -->
o Extensive cerebral injury

<!-- PAGE=? -->
 Head injury

<!-- PAGE=? -->
 Stroke

<!-- PAGE=? -->
o Extensive vascular endothelial damage

<!-- PAGE=? -->
 Vasculitis

<!-- PAGE=? -->
 Pre-eclampsia

<!-- PAGE=? -->
o Hemolytic transfusion reactions

<!-- PAGE=? -->
o Snake venoms

<!-- PAGE=? -->
Digoxin

<!-- PAGE=? -->
 The electrophysiologic effects of therapeutic levels are

<!-- PAGE=? -->
o prolonged PR interval  - delayed AV node conduction

<!-- PAGE=? -->
o shortened Q-T interval - more rapid ventricular repolarization

<!-- PAGE=? -->
o ST-T segment depression (scaphoid or scooped-out) - dec. slope of phase 3 repolarization

<!-- PAGE=? -->
o Diminished T wave amplitude or inversion

<!-- PAGE=? -->
 TOXICITY

<!-- PAGE=? -->
o Worsened by hypokalemia and hypomagnesemia

<!-- PAGE=? -->
o Prolongation of PR interval

<!-- PAGE=? -->
 May progress to second-degree atrioventricular (AV) block

<!-- PAGE=? -->
 Profound sinus bradycardia

<!-- PAGE=? -->
 sinoatrial block

<!-- PAGE=? -->
o Supraventricular arrhythmias

<!-- PAGE=? -->
Diuretics

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 Acetazolamide

<!-- PAGE=? -->
o carbonic anhydrase inhibitor

<!-- PAGE=? -->
 noncompetitive

<!-- PAGE=? -->
o sulfonamide

<!-- PAGE=? -->
o acts on proximal convoluted tubule

<!-- PAGE=? -->
o dec. H ion excretion with inc loss of HCO

<!-- PAGE=? -->
o Cl is retained to offset the loss of HCO

<!-- PAGE=? -->
o Dec. H in the distal renal tubules results in excretion of potassium in exchange for sodium

<!-- PAGE=? -->
o Produces alkaline urine with a hypercholremic metabolic acidosis

<!-- PAGE=? -->
o Therapeutics

<!-- PAGE=? -->
 Dec. IOP

<!-- PAGE=? -->
 Inhibits Sz activity (metabolic acidosis)

<!-- PAGE=? -->
 Familial periodic paralysis

<!-- PAGE=? -->
 Metabolic acidosis results in inc. potassium in skeletal muscles

<!-- PAGE=? -->
 May stimulate ventilation in patients hypoventilating from metabolic alkalosis

<!-- PAGE=? -->
 May exacerbate hypercarbia in COPD

<!-- PAGE=? -->
 Dec. HCO to buffer CO2

<!-- PAGE=? -->
 Furosemide

<!-- PAGE=? -->
o loop diuretic

<!-- PAGE=? -->
o acts on medullary ascending loop

<!-- PAGE=? -->
 inhibits reabsortion of sodium and chloride

<!-- PAGE=? -->
o extensively protein-bound

<!-- PAGE=? -->
o Elimination time is <1 hour

<!-- PAGE=? -->
o Side effects

<!-- PAGE=? -->
 Hypokalemia

<!-- PAGE=? -->
 Hypochloremia

<!-- PAGE=? -->
 Hyperuricemia

<!-- PAGE=? -->
 hyperglycemia (less than with thiazides)

<!-- PAGE=? -->
 increases nephrotoxicity of aminoglycosides and cephalosporins

<!-- PAGE=? -->
 association with allergic interstitial nephritis

<!-- PAGE=? -->
 potential cross-sensitivity in patients allergic to other sulfanomides

<!-- PAGE=? -->
 decreased renal clearance of lithium

<!-- PAGE=? -->
o in symptomatic hypercalcemia, furosemide may lower plasma concetration of calcium by stimulation urine output

<!-- PAGE=? -->
o High doses of furosemide can result in accumulation of reactive intermediary metabolites which cause hepatic necrosis in animals (theoretical, but could be of concern if given in large doses to patients with renal failure)

<!-- PAGE=? -->
o Development of deafnes is rare

<!-- PAGE=? -->
 Mannitol

<!-- PAGE=? -->
o osmotic diuretic

<!-- PAGE=? -->
o acts on the medullary ascending loop

<!-- PAGE=? -->
o Freely filterable at glomerulus

<!-- PAGE=? -->
 limited reabsorption from renal tubules

<!-- PAGE=? -->
 atrial or nodal ectopic beats and tachycardias (particularly if accompanied by AV block)

<!-- PAGE=? -->
 more common than ventricular arrhythmias in children

<!-- PAGE=? -->
o Ventricular arrhythmias

<!-- PAGE=? -->
 ventricular bigeminy and trigeminy

<!-- PAGE=? -->
 extremely rare in children, although they are common in adults

<!-- PAGE=? -->
 isolated premature ventricular contractions in childred - rarely normal or benign

<!-- PAGE=? -->
o Ventricular fibrillation is the most frequent cause of death from digitalis toxicity

<!-- PAGE=? -->
 Thiazides

<!-- PAGE=? -->
o act on the cortical ascending loop

<!-- PAGE=? -->
 Inhibit reabsorption of sodium and chloride ions

<!-- PAGE=? -->
o delivery of higher concentrations of sodium to distal renal tubules results in enhancement of secretion of potassium into the renal tubules (hypokalemia)

<!-- PAGE=? -->
o Initial antihypertensive effect is due to decrease in extracellular fluid volume, often with a decrease in cardiac output

<!-- PAGE=? -->
 sustained antihypertensive effect is due to peripheral vasodilation, which requires several weeks to develop

<!-- PAGE=? -->
o Side effects

<!-- PAGE=? -->
 Hypokalemic

<!-- PAGE=? -->
 skeletal muscle weakness

<!-- PAGE=? -->
 GI ileus

<!-- PAGE=? -->
 Nephropathy

<!-- PAGE=? -->
 increased risk of digoxin toxicity

<!-- PAGE=? -->
 potentiation of NDMR

<!-- PAGE=? -->
 hypochloremic metabolic alkalosis

<!-- PAGE=? -->
 hypomagnesemia

<!-- PAGE=? -->
 cardiac arrhythmias

<!-- PAGE=? -->
 orthostatic hypotension

<!-- PAGE=? -->
 May cause hyperglycemia and aggrevate DM

<!-- PAGE=? -->
 Hyperuricemia

<!-- PAGE=? -->
 Borderline renal or hepatic function may deteriorate

<!-- PAGE=? -->
 Maculopapular rash in 1% or more of patients

<!-- PAGE=? -->
 K sparing diuretics (triampterene)

<!-- PAGE=? -->
o act directly on renal tubular transport mechanisms in the distal convoluted tubule independent of aldosterone to produce dieresis

<!-- PAGE=? -->
 increases urinary excretion of sodium, chloride, and bicarbonate ions

<!-- PAGE=? -->
 increases urine pH

<!-- PAGE=? -->
o Diuresis is accompanied by no increase or decrease in potassium excretion in the urine

<!-- PAGE=? -->
o Used in combination with HCTZ

<!-- PAGE=? -->
o Side effects

<!-- PAGE=? -->
 Hyperkalemia

<!-- PAGE=? -->
 do not produce hyperuricemia

<!-- PAGE=? -->
 Spironolactone

<!-- PAGE=? -->
o aldosterone antagonist

<!-- PAGE=? -->
 competitive antagonist

<!-- PAGE=? -->
 only effective when aldosterone is present

<!-- PAGE=? -->
o acts at collecting duct

<!-- PAGE=? -->
o blocks renal tubular effects of aldosterone

<!-- PAGE=? -->
 inhibition of reabsorption of sodium and chloride

<!-- PAGE=? -->
 resist metabolism

<!-- PAGE=? -->
 pharmacologically inert

<!-- PAGE=? -->
o Clinical uses

<!-- PAGE=? -->
 prophylaxis against acute renal failure

<!-- PAGE=? -->
 treatment of increases in ICP

<!-- PAGE=? -->
 decreasing intraocular pressure

<!-- PAGE=? -->
o Side effects

<!-- PAGE=? -->
 pulmonary edema (especially if evidence of LV dysfunction)

<!-- PAGE=? -->
 hypovolemia

<!-- PAGE=? -->
 electrolyte disturbances

<!-- PAGE=? -->
 plasma hyperosmolarity due to excessive excretion of water and sodium

<!-- PAGE=? -->
o also acts as an antiandrogen by altering steroidogenesis in adrenal tissue and by affecting target organ responses to circulating androgens

<!-- PAGE=? -->
o Side effects

<!-- PAGE=? -->
 hyperkalemia especially in presence of renal dysfunction

<!-- PAGE=? -->
Figure 15-1. Tubule transport systems and sites of action of diuretics.

<!-- PAGE=? -->
NaHCO;

<!-- PAGE=? -->
NaCI

<!-- PAGE=? -->
NaCI

<!-- PAGE=? -->
Distal convoluted

<!-- PAGE=? -->
Proximal

<!-- PAGE=? -->
(+PTH)

<!-- PAGE=? -->
tubule

<!-- PAGE=? -->
tubule

<!-- PAGE=? -->
Proximal

<!-- PAGE=? -->
straight tubule

<!-- PAGE=? -->
K+

<!-- PAGE=? -->
K+

<!-- PAGE=? -->
H+

<!-- PAGE=? -->
Ca2+

<!-- PAGE=? -->
Na+

<!-- PAGE=? -->
Collecting

<!-- PAGE=? -->
Glomerulus

<!-- PAGE=? -->
tubule

<!-- PAGE=? -->
K'

<!-- PAGE=? -->
Cortex

<!-- PAGE=? -->
2CI-

<!-- PAGE=? -->
NaCI

<!-- PAGE=? -->
(+aldosterone)

<!-- PAGE=? -->
Outer medulla

<!-- PAGE=? -->
Na'

<!-- PAGE=? -->
K'

<!-- PAGE=? -->
2CI

<!-- PAGE=? -->
Diuretics

<!-- PAGE=? -->
Thick

<!-- PAGE=? -->
Acetazolamide

<!-- PAGE=? -->
ascending

<!-- PAGE=? -->
limb

<!-- PAGE=? -->
Osmotic agents (mannitol)

<!-- PAGE=? -->
Thin

<!-- PAGE=? -->
(+ADH)

<!-- PAGE=? -->
Loop agents

<!-- PAGE=? -->
furosemide)

<!-- PAGE=? -->
descending

<!-- PAGE=? -->
limb

<!-- PAGE=? -->
Collecting

<!-- PAGE=? -->
Thiazides

<!-- PAGE=? -->
duct

<!-- PAGE=? -->
Aldoslerone antagonists

<!-- PAGE=? -->
Thin

<!-- PAGE=? -->
ADH antagonists

<!-- PAGE=? -->
ascending

<!-- PAGE=? -->
limb

<!-- PAGE=? -->
Loop of

<!-- PAGE=? -->
Henle

<!-- PAGE=? -->
Inner medulla

<!-- PAGE=? -->
convoluted

<!-- PAGE=? -->
(eg

<!-- PAGE=? -->
TABLE 25-2. Sites of action of diuretics

<!-- PAGE=? -->
+, minor site of action; +++, major site of action.

<!-- PAGE=? -->
TABLE 25-1. Classification of diuretics

<!-- PAGE=? -->
Thiazide diuretics

<!-- PAGE=? -->
Chlorothiazide

<!-- PAGE=? -->
Hydrochlorothiazide

<!-- PAGE=? -->
Benzthiazide

<!-- PAGE=? -->
Cyclothiazide

<!-- PAGE=? -->
Loop diuretics

<!-- PAGE=? -->
Ethacrynic Acid

<!-- PAGE=? -->
Furosemide

<!-- PAGE=? -->
Osmotic diuretics

<!-- PAGE=? -->
Mannitol

<!-- PAGE=? -->
Urea

<!-- PAGE=? -->
Potassium-sparing diuretics

<!-- PAGE=? -->
Triamterene Amiloride

<!-- PAGE=? -->
Aldosterone antagonists

<!-- PAGE=? -->
Spironolactone

<!-- PAGE=? -->
Carbonic anhydrase inhibitors

<!-- PAGE=? -->
Acetazolamide

<!-- PAGE=? -->
Diabetes Mellitus Type I

<!-- PAGE=? -->
 5-10% of all cases of diabetics

<!-- PAGE=? -->
 second peak in older patients (generally severe and brittle)

<!-- PAGE=? -->
Physiologic consequences of lack of insulin

<!-- PAGE=? -->
 insulin stimulates glycogen formation: without insulin there is less glycogen

<!-- PAGE=? -->
 increased lipolysis (ketogenic)

<!-- PAGE=? -->
 increased gluconeogenesis

<!-- PAGE=? -->
 increased protein catabolism (barash 5 th 1134: negative nitrogen balance)

<!-- PAGE=? -->
 the brain and liver are two organs where glucose transport does NOT depend on insulin

<!-- PAGE=? -->
Effects of Insulin:

<!-- PAGE=? -->
 insulin is prodeuce by beta cells of the islets of langerhans in pancreas

<!-- PAGE=? -->
 basal rate is about 1 unit/ hour which increases 5-10x with food ingestion

<!-- PAGE=? -->
 normal production 40-50 units  / day

<!-- PAGE=? -->
 insulin is metabolized in the liver and kidney

<!-- PAGE=? -->
o hepatic dysfunction: loss of gluconeogenesis and prolongation of insulin effect = hypoglycemia

<!-- PAGE=? -->
o renal disease: prolonged action of insulin

<!-- PAGE=? -->
 release stimulated by

<!-- PAGE=? -->
o glucose and amino acids via GIT hormones,

<!-- PAGE=? -->
o vagal stimulation

<!-- PAGE=? -->
o beta adrenergic agents

<!-- PAGE=? -->
o alpha blockade

<!-- PAGE=? -->
 release decreased by:

<!-- PAGE=? -->
o potassium depletion

<!-- PAGE=? -->
 actions:

<!-- PAGE=? -->
o stimulates cellular upteake of glucose in skeletal muscle, adipose tissue and cadiac cells

<!-- PAGE=? -->
barash 6 th 1295

<!-- PAGE=? -->
DKA:

<!-- PAGE=? -->
 most serious acute metabolic complication of DM

<!-- PAGE=? -->
 most often in Type 1 (the small amt of insulin action in Type II may not be enough to prevent hyperglycemia, but is enough to pevent Ketosis)

<!-- PAGE=? -->
 ppt by poor compliance w/ insulin, or abrupt increases in insulin resistance (stress, sepsis, infections, MI, beta agonist tocolytics)

<!-- PAGE=? -->
 Signs and symps of dehydration, osmotic diuresis, acidosis

<!-- PAGE=? -->
o N/V

<!-- PAGE=? -->
o Dehydration (hypotension, tachycardia)..can often present w/ intravasc fluid deficit of 5-8L

<!-- PAGE=? -->
o Kussmalul's resps (to increases excretion volatile acid)

<!-- PAGE=? -->
o Abdo pain/Ileus

<!-- PAGE=? -->
o Somnolence or coma

<!-- PAGE=? -->
 Lab reveals:

<!-- PAGE=? -->
o Hyperglycemia

<!-- PAGE=? -->
o Metabolic acidosis (pH,7.3, Bicarb < 15mEq/L)

<!-- PAGE=? -->
o Ketone sin urine and blood

<!-- PAGE=? -->
o Hypersomolarity

<!-- PAGE=? -->
o Hypokalemia

<!-- PAGE=? -->
o Incr Bun/Cr

<!-- PAGE=? -->
 Treatment:

<!-- PAGE=? -->
 Intubation if CNS depression

<!-- PAGE=? -->
 Admin IV regular insulin 10U, then 5-10U/hr

<!-- PAGE=? -->
 Restore intravasc volume (NS 5-10cc/kg/hr. Ad D5 when BG <14

<!-- PAGE=? -->
 Restore total body K (initial labs may show hyperK, but volume repletion reveals total body K deficit): 0305mEq/kg/hr IV

<!-- PAGE=? -->
 Monitor BG, Serum K, pH, ketones

<!-- PAGE=? -->
 Identify and treat cause (sepsis, MI, compliance)

<!-- PAGE=? -->
o brain, liver and immune cells are exceptions (do not need insulin for glucose uptake)

<!-- PAGE=? -->
o potassium enters cells with the glucose

<!-- PAGE=? -->
o stimulation of glycogen formation

<!-- PAGE=? -->
o suppression of gluconeogenesis and lipolysis

<!-- PAGE=? -->
Glucagon

<!-- PAGE=? -->
 released from alpha dcells of pancreas and opposes insulin

<!-- PAGE=? -->
 increases circulating glucse levels

<!-- PAGE=? -->
 release timulated by hypoglycemia, epinephrine, cortisol

<!-- PAGE=? -->
DKA

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 The most important electrolyte disturbance in diabetic ketoacidosis is depletion of total-body potassium

<!-- PAGE=? -->
o Serum potassium levels decline rapidly and reach a nadir within 2 to 4 hours after the start of intravenous insulin administration

<!-- PAGE=? -->
o Aggressive replacement therapy is required

<!-- PAGE=? -->
o The potassium administered moves into the intracellular space with insulin as the acidosis is corrected

<!-- PAGE=? -->
o Potassium is also excreted in urine because of the increased delivery of sodium to the distal renal tubules that accompanies volume expansion.

<!-- PAGE=? -->
HONK

<!-- PAGE=? -->
 Hypersomolar, hyperglycemic nonketotic coma

<!-- PAGE=? -->
 Sever hyperclycemia (ie >30), but not associated w/ ketoacidosis

<!-- PAGE=? -->
 Hypersomolarity (>350mOsm/L)

<!-- PAGE=? -->
 Normal pH

<!-- PAGE=? -->
 Osmotic diuresis (hypokalemia)

<!-- PAGE=? -->
 Hypovolemia (hemoconcetration)

<!-- PAGE=? -->
 CNS depression

<!-- PAGE=? -->
 Severe volume deficit (ie avg 25%TBW)

<!-- PAGE=? -->
 PPt factors: advanced age, sepsis, hyperalimnetation w/ carbs, corticosteroids

<!-- PAGE=? -->
 Hyperglycemia stims osmotic diuresis, dehydration and eventually coma

<!-- PAGE=? -->
 Trx:

<!-- PAGE=? -->
 correct hypovolemia, trv hypersomolarity w/ admin hypotonic saline,

<!-- PAGE=? -->
 low dose IV insulin infusion to decr BG to <15, but after that usually do not need exogenous insulin

<!-- PAGE=? -->
 Higher mortality than DKA

<!-- PAGE=? -->
BRITISH COLUMBIA'S CHILDREN'S HOSPITAL

<!-- PAGE=? -->
DIABETIC KETOACIDOSIS PROTOCOL

<!-- PAGE=? -->
CHILDRENS

<!-- PAGE=? -->
HOSPITAL

<!-- PAGE=? -->
0 Confirm DKA: plasma glucose (PG) 211 mmolL, ketones, capillary pH 7.3, HCO;- 215 mmolL:

<!-- PAGE=? -->
Rationale & Notes:

<!-- PAGE=? -->
1 Measure body weight (BW) in kilograms kg

<!-- PAGE=? -->
'Please note that this protocol is designed as an algorithm for treating the majority of cases of DKA in infants, children and adolescents . It cannot replace careful clinical observation and judgment in treating this potentially very serious condition. If you have questions or problems related to the management of DKA Or diabetes BCCH Pediatric Endocrinologist on call.

<!-- PAGE=? -->
2 Establish extent of dehydration ( BP , tears, skin turgor, capillary refill; hematocrit) in cclkg: infants: children:

<!-- PAGE=? -->
mild:

<!-- PAGE=? -->
3% = 30 ccíkg

<!-- PAGE=? -->
moderate:

<!-- PAGE=? -->
10% 100 cclkg

<!-- PAGE=? -->
6%

<!-- PAGE=? -->
severe:

<!-- PAGE=? -->
15% = 150 cckg

<!-- PAGE=? -->
9% = 90 cckg cclkg

<!-- PAGE=? -->
3 Calculate total fluid deficit: multiply (1) x (2) Cc

<!-- PAGE=? -->
4 Give normal saline (NS) resuscitation bolus only if patient is orthostatic or shocky:"

<!-- PAGE=? -->
Mild hyperglycemia, even with ketones and mild acidosis, can often be managed without IV fluids or IV insulin; particularly in the older child or known diabetic who is not vomiting or seriously dehydrated

<!-- PAGE=? -->
recommended amount: 5-10 cckg BW over 1-2 hours, max <30 cc/kg (2)

<!-- PAGE=? -->
Calculate remainder of fluid deficit after fluid bolus: subtract (4) from (3) (5)

<!-- PAGE=? -->
Calculate maintenance fluid requirements for the next 48 hours: €

<!-- PAGE=? -->
CRapid, deep mouth-breathing (Kussmaul respiration) often dries out the oral mucosa making the child appear more dehydrated than shhe really is. The hematocrit and other clinical signs noted are more accurate

<!-- PAGE=? -->
9 200 cclkg for the first 10 kg BW

<!-- PAGE=? -->
100 cclkg for the next 10 kg BW

<!-- PAGE=? -->
40 cc/kg for the rest of BW cc/48 h

<!-- PAGE=? -->
7 Calculate total amount of fluid still to be given over 48 hours: add (5) and (6) cc/48 h

<!-- PAGE=? -->
fluid boluses are potentially dangerous and should be administered slowly and with caution, unless the patient is truly shocky- Only very rarely will larger (220 cclkg BW ) fluid bolus will be required to maintain perfusion.

<!-- PAGE=? -->
8 Calculate hourly rate of fluid replacement: divide (7) by 48 cchh

<!-- PAGE=? -->
9 Use normal saline (NS) as initial replacement fluid, at rate determined in (8). Add KCI 20-40 mEqL only if hypokalemic and patient has adequate urine output. Continue this for 1-2 hours.

<!-- PAGE=? -->
ESince most patients develop DKA over slow metabolic repair is safest. Over; hydration may contribute to cerebral edema Nonetheless, DKA in children often resolves in than 48 h days ,

<!-- PAGE=? -->
 After 1-2 hours, make up and start a piggyback insulin drip at 0.1 unitkg BWIh:

<!-- PAGE=? -->
50 units Regular insulin (Humulin@ Ror Novolin@ Toronto) in 500 cc NS or DIOINS

<!-- PAGE=? -->
run at 1 cckg BWIh

<!-- PAGE=? -->
(10)

<!-- PAGE=? -->
cchh

<!-- PAGE=? -->
11 Begin "2-bag method" to replace NS with 40 mEqL KCI. Decrease replacement fluid rate to adjust for insulin drip rate: subtract (10) from (8) cchh

<!-- PAGE=? -->
indicated Insulin given in the first 1-2h of DKA repair is thought to increase mortality This insulin rate fully inhibits ketogenesis and gluconeogenesis and should be maintained if possible. If unable to keep PG >10 mmollL drop the insulin rate by 25-50%_

<!-- PAGE=? -->
8

<!-- PAGE=? -->
12 Aim to keep PG ~10-15 mmollL by titrating the rates of these two solutions, keeping the combined rate at (11)

<!-- PAGE=? -->
SEPTEMBER 21,2008

<!-- PAGE=? -->
HTTP:IlENDODIAB. BCCHILDRENS CAIFORPROFESSIONALSIDKAPROTOCOL HTM

<!-- PAGE=? -->
PAGE 1 OF 2

<!-- PAGE=? -->
1

<!-- PAGE=? -->
13 Re-evaluate appropriateness of replacement fluid type frequently; anticipating the need to add or increase Na' K' , dextrose, etc

<!-- PAGE=? -->
dextrose

<!-- PAGE=? -->
aim to keep the PG ~10-15 mmolL range

<!-- PAGE=? -->
sodium'

<!-- PAGE=? -->
potassium

<!-- PAGE=? -->
bicarbonate  : NaHCO; is not generally recommended

<!-- PAGE=? -->
corrected Na' <140 mmolL or falling: continue NS

<!-- PAGE=? -->
corrected Nat >150, stable: switch to VNS after 10-12h corrected Na' 140-150, stable: switch to V2NS after 4-6 h

<!-- PAGE=? -->
patient urinating: continue KCI 20-40 mmoVL may give 50% of K' as acetate or phosphate

<!-- PAGE=? -->
Close neurological observation and frequent rousing of the child with finger pokes to detect any changes consistent with cerebral edema_ Follow Glasgow Coma Scale. Severe headache; change in sensorium or BP , dilated pupils, bradycardia, irregular breathing; posturing and incontinence are signs of impending deterioration. Rapid intervention is imperative:

<!-- PAGE=? -->
elevate head of bed

<!-- PAGE=? -->
airway / breathing / circulation

<!-- PAGE=? -->
decrease fluid rate by one-third

<!-- PAGE=? -->
consider intubation and mild hyperventilation (keep pCO2 >22 mg Hg) for impending respiratory failure

<!-- PAGE=? -->
mannitol (0.5-1 g/kg IV over 20 min) or 3% NaCI (5-10 mLkg IV over 30 min) -

<!-- PAGE=? -->
arrange CT when stable

<!-- PAGE=? -->
15 Follow laboratory parameters (use of a flowsheet is highly recommended):

<!-- PAGE=? -->
follow Na' anion gap; capillary pH every 2-4 hours

<!-- PAGE=? -->
follow PG by meter every 30-60 min $: does child respond to the poke?

<!-- PAGE=? -->
follow Ca?- , Mg?+ and Pi every 2-4 hours if giving phosphate

<!-- PAGE=? -->
follow urine ketones with each void or whole-blood B-hydroxybutyrate (ketones) every 2-4 hours

<!-- PAGE=? -->
Re-evaluate appropriateness of replacement fluid type frequently, anticipating the need to increase or decrease Na K' , dextrose, etc.

<!-- PAGE=? -->
Accompanying documents on our website (see below):

<!-- PAGE=? -->
DKA_Sample Physician_Order_Sheet

<!-- PAGE=? -->
DKA_Elowsheet

<!-- PAGE=? -->
Recipes for Making DKA Solutions

<!-- PAGE=? -->
BRITISH COLUMBIA'S CHILDREN'S HOSPITAL ENDOCRINOLOGY & DIABETES UNIT

<!-- PAGE=? -->
DIABETES CLINIC: 604-875-2868

<!-- PAGE=? -->
DIABETES CLINIC FAX: 604-875-3231

<!-- PAGE=? -->
TOLL-FREE PHONE: 1-888-300-3088

<!-- PAGE=? -->
24-H PAGER: 604-875-2161

<!-- PAGE=? -->
SEPTEMBER 21,2008

<!-- PAGE=? -->
HTTP:IlENDODIAB BCCHILDRENS.CAIFORPROFESSIONALSIDKAPROTOCOL HTM

<!-- PAGE=? -->
PAGE 2 OF 2

<!-- PAGE=? -->
Diabetic ketoacidosis versus non-ketotic hyperglycemia

<!-- PAGE=? -->
CKeeping the PG in the ~10-15 mmoliL range allows for a buffer against hypoglycemia and a too-rapid fall in plasma osmolality-_ The "two-bag method (see our DKA Nursing_Protocol) is a handy way to adjust the glucose without altering the Na or K delivery- It also allows for faster response to PG changes, and it decreases and costs and time nursing

<!-- PAGE=? -->
ISerum K' levels are usually normal at diagnosis and fall precipitously An IV fluid containing 20-40 is usually required to keep the serum K" >3.0 mmolL. Begin K and insulin together. Oralinasogastric KCI boluses (0.5-1 mmollkg BW may also be administered .

<!-- PAGE=? -->
pharmacy introduction of hypotonic fluids must be considered carefully . The corrected Na` should be calculated and followed closely: corrected Na' [measured Na' + 0.36x(PG-5.6)] If corrected Na- falls or fails to rise as the PG falls, this could indicate excess free-water administration It is also helpful to monitor the active osmolality [PG 2x(Na which should not fall >0.5 mOsmkglh. If the corrected sodium is 140 150 mmolL and stable and the active osmolality has been dropping slowly, switching t0 VNS can be considered after 4-6 h An elevated measured Na in the face of hyperglycemia indicates severe dehydration and an element of the hyperglycemic hyperosmolar state Such patients should be rehydrated with extreme caution; using fluids with higher osmolar content (e.9.NS) for longer time periods (10-12 h)

<!-- PAGE=? -->
'While there is no proven benefit to potassium phosphate or acetate; it does have the theoretical advantage of repleting the severe phosphate deficit of DKA andlor ameliora the hyperchloremia which inevitably occurs during DKA treatment If phosphate is given; serum calcium, magnesium and phosphate levels should be monitored closely using

<!-- PAGE=? -->
LSubclinical brain swelling is common in children with DKA. Cerebral edema (CE) accounts for more than half of the ~1-5% mortality rate of DKA in children. At highest risk are newly diagnosed patients those aged <5 years, and those with initial pH <7.1or pCOz <18. The of CE remains unclear, but aggressive hydration has been implicatedin several studies . Resuscitation is successful in only 50% of cases. Most expers suggest fluids to <4 Um - body surface area, or to <2.5x maintenance fluid rate,in the first 24 h, andto <50 mL/kg in the first 4 h etiology limiting

<!-- PAGE=? -->
The acidosis of DKA is due to both ketoacids and lactic acid, and these resolve with fluid and insulin replacement.There is no evidence that NaHCO? is either necessary or safe in DKA but it does have number of deleterious effects: paradoxical CNS acidosis, hypokalemia, hyperosmolality, delayed clearance of ketones and cerebral edema NaHCOzin DKA should only be considered if pH <6.9 or cardiac failure:

<!-- PAGE=? -->
Dopamine versus Dobutamine

<!-- PAGE=? -->
Stolting chapter 12, p260 (steve):

<!-- PAGE=? -->
 HR increase is the same

<!-- PAGE=? -->
 Dobutamine causes NO CHANGE in peripheral vascular resistance

<!-- PAGE=? -->
 both cause a (mild) increase in blood pressure according to stoleting

<!-- PAGE=? -->
 dobutamine lowers pulmonary vascular resistance

<!-- PAGE=? -->
 increase in CI is about the same

<!-- PAGE=? -->
Double-Lumen Tubes

<!-- PAGE=? -->
Sizes

<!-- PAGE=? -->
 height correlates much better than weight with tracheal size

<!-- PAGE=? -->
o Short patients (4'6" to 5'5") - 35 to 37 French

<!-- PAGE=? -->
o medium-height patients (5'5" to 5'10"), a 37-39 French

<!-- PAGE=? -->
o tall patients (5'11" to 6'4"), a 39 to 41 French left

<!-- PAGE=? -->
 the airways tend to be larger than would be predicted by height alone in

<!-- PAGE=? -->
o chronic smokers

<!-- PAGE=? -->
o bronchiectasis

<!-- PAGE=? -->
o chronic pulmonary infections

<!-- PAGE=? -->
 Young teenagers (13 to 14 years old) can frequently use an adult-sized 35 French DLT

<!-- PAGE=? -->
 In pediatrics

<!-- PAGE=? -->
o 32 - 12 yr old

<!-- PAGE=? -->
o 28 - 10 yr old (only lt)

<!-- PAGE=? -->
o 26  - 8 yr old  (only lt)

<!-- PAGE=? -->
 For smaller children, bronchial blockers and main stem intubation are typically used for lung isolation

<!-- PAGE=? -->
 Sizing

<!-- PAGE=? -->
Internal diameter

<!-- PAGE=? -->
41F 6.5

<!-- PAGE=? -->
39

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
37 5.5

<!-- PAGE=? -->
35

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
28

<!-- PAGE=? -->
4.5

<!-- PAGE=? -->
Contraindications to DLTs: (insertion is difficult or dangerous)

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Any

<!-- PAGE=? -->
o Difficult Airway

<!-- PAGE=? -->
o full stomach

<!-- PAGE=? -->
o airway stricture

<!-- PAGE=? -->
o endoluminal tumor

<!-- PAGE=? -->
o critically ill patients who would not tolerate being taken off mechanical ventilation and PEEP for even a short time

<!-- PAGE=? -->
 Contraindications to LDLT

<!-- PAGE=? -->
o carinal and proximal left main stem bronchial lesions

<!-- PAGE=? -->
o strictures, endoluminal tumors, tracheobronchial disruptions, compression of the airway by an external mass, and tenting of the left main stem bronchus so that the angle of the takeoff from the trachea is approximately 90 degrees

<!-- PAGE=? -->
Complications of DLT:

<!-- PAGE=? -->
 Traumatic laryngitis

<!-- PAGE=? -->
 disruption of tracheobronchial tree

<!-- PAGE=? -->
 suturing of pulmonary vessel to DLT

<!-- PAGE=? -->
Table 49-12 -- Endobronchial cuff considerations to minimize tracheobronchial wall damage (disruption)

<!-- PAGE=? -->
* Most important considerations.

<!-- PAGE=? -->
 Except for independent unilateral intermittent positive-pressure ventilation and suctioning, all selective differential lung functions possible with a DLT are possible with a Univent bronchial blocker tube.

<!-- PAGE=? -->
 The ease of placement of Univent tube is equivalent to that of a standard single-lumen tube

<!-- PAGE=? -->
o May be an easier and quicker means (than with a DLT) of obtaining lung isolation

<!-- PAGE=? -->
 it is possible to apply CPAP to the nonventilated operative lung through the lumen of the Univent bronchial blocker

<!-- PAGE=? -->
 the Univent bronchial blocker behaves as a high-pressure cuff when the intracuff volume is larger than 2 mL

<!-- PAGE=? -->
o inflate the bronchial blocker cuff with a just-seal volume of air

<!-- PAGE=? -->
 order of bronchial cuff pressures

<!-- PAGE=? -->
o left PVC DLT < right PVC DLT < Univent bronchial blocker cuff < red rubber double-lumen tube

<!-- PAGE=? -->
Table 49-13 -- Advantages of the Univent bronchial blocker tube (relative to a double-lumen tube and other bronchial blockers)

<!-- PAGE=? -->
Easier to insert and properly position

<!-- PAGE=? -->
Can be properly positioned during continuous ventilation and in the lateral decubitus position

<!-- PAGE=? -->
No need to change the tube for postoperative mechanical ventilation

<!-- PAGE=? -->
No need to change the tube intraoperatively when turning from the supine to the prone position

<!-- PAGE=? -->
Selective blockade of some lobes of each lung

<!-- PAGE=? -->
Possible to apply nonventilated operative lung CPAP

<!-- PAGE=? -->
Table 49-14 -- Limitations to use of the Univent bronchial blocker

<!-- PAGE=? -->
Down's Syndrome

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Airway Abnormalities

<!-- PAGE=? -->
o potential for atlanto-occiptal dislocation (15% instability)

<!-- PAGE=? -->
 recommended that all patients be treated as if they have instability

<!-- PAGE=? -->
o macroglossia

<!-- PAGE=? -->
o hypoplastic maxilla

<!-- PAGE=? -->
o palatal abnormalities

<!-- PAGE=? -->
o mandibular protrusion

<!-- PAGE=? -->
o small mouth

<!-- PAGE=? -->
o large adenoids and tonsils

<!-- PAGE=? -->
o Subglottic Stenosis

<!-- PAGE=? -->
 Cardiac Abnormilities

<!-- PAGE=? -->
o associated CHD in 40%

<!-- PAGE=? -->
 endocardial cushion defects (~45%)

<!-- PAGE=? -->
 VSD (35%)

<!-- PAGE=? -->
 secundum ASD (8%)

<!-- PAGE=? -->
 PDA (7%)

<!-- PAGE=? -->
 tetralogy of fallot(4%)

<!-- PAGE=? -->
 Respiratory Abnormalities

<!-- PAGE=? -->
o upper respiratory infections

<!-- PAGE=? -->
 Other

<!-- PAGE=? -->
o Hypothyroid

<!-- PAGE=? -->
E

<!-- PAGE=? -->
E cylinder

<!-- PAGE=? -->
 Gas in E tanks is 2200 psig

<!-- PAGE=? -->
 N2O E cylinders hold 1600 L of gas because it is a liquid form

<!-- PAGE=? -->
o pressure of gas remains constant independent of how much liquid remains in the cyclinder

<!-- PAGE=? -->
o Only when the liquid has evaporated does the pressure start to fall.

<!-- PAGE=? -->
 O2 and Air E cylinders hold only about 660L

<!-- PAGE=? -->
 Regulator of O2 cylinder reduces from 2200 psig to 45 psig

<!-- PAGE=? -->
ECG

<!-- PAGE=? -->
Rule of L's (number indicates number of -L‖s)

<!-- PAGE=? -->
I = RA  LA

<!-- PAGE=? -->
II = RA  LL

<!-- PAGE=? -->
III = LA  LL

<!-- PAGE=? -->
-ve to +ve, dictated by who has the most L's

<!-- PAGE=? -->
aVR, aVL, aVF = averaged (perpendicular to line and pointing to direction)

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
Lead

<!-- PAGE=? -->
L

<!-- PAGE=? -->
aVR -

<!-- PAGE=? -->
Leg

<!-- PAGE=? -->
V1: right 4 th intercostal space V2: left 4 th intercostal space V3: halfway between V2 and V4 V4: left 5 th intercostal space, mid-clavicular line V5: horizontal to V4, anterior axillary line

<!-- PAGE=? -->
V6: horizontal to V5, mid-axillary line

<!-- PAGE=? -->
Coronary Artery Distribution (Barash p.808)

<!-- PAGE=? -->
Left Coronary

<!-- PAGE=? -->
Anterior descending branch Right bundle branch Anterior and posterior facicle LBB Anterior and posterior papillary muscles Anterolateral LV

<!-- PAGE=? -->
Circumflex

<!-- PAGE=? -->
Lateral LV

<!-- PAGE=? -->
Right Coronary

<!-- PAGE=? -->
SA and AV nodes RA and RV Posterior interventricular septum Posterior facicle LBB Interatrial septum

<!-- PAGE=? -->
ECG placement of CVP

<!-- PAGE=? -->
Ao

<!-- PAGE=? -->
PA

<!-- PAGE=? -->
2

<!-- PAGE=? -->
2

<!-- PAGE=? -->
~VV

<!-- PAGE=? -->
3

<!-- PAGE=? -->
5

<!-- PAGE=? -->
 ECG  from multiorifice catheter comes from proximal hole 2cm from tip therefore should be in SVC (#2)

<!-- PAGE=? -->
o Single orifice #4 is what you want

<!-- PAGE=? -->
Monitoring

<!-- PAGE=? -->
All ECG monitors use filters to narrow the bandwidth in an attempt to reduce environmental artifacts.

<!-- PAGE=? -->
 The high-frequency filters reduce distortions from muscle movement , 60-Hz electrical current, and electromagnetic interference from other electrical equipment.

<!-- PAGE=? -->
 The low-frequency filters ensure a more stable baseline by reducing respiratory and body movement artifacts, as well as those resulting from poor electrode contact .

<!-- PAGE=? -->
 The AHA recommends that a flat frequency response be obtained at a bandwidth of 0.05 to 100 Hz . The 100-Hz high-frequency limit ensures that tracings are of sufficient fidelity to assess QRS morphology and to evaluate rapid rhythms such as atrial flutter accurately. The low-frequency limit of 0.05 Hz allows accurate representation of slower events such as P-wave and T-wave morphology and ST-segment excursion. Most modern ECG monitors allow the operator a choice among several bandwidths.

<!-- PAGE=? -->
 The actual filter frequencies tend to vary among manufacturers. One manufacturer (Hewlett Packard, Andover, Mass) allows a choice among ;

<!-- PAGE=? -->
o -diagnostic mode ‖ with a bandwidth of 0.05 to 130 Hz for adults and 0.5 to 130 Hz for neonates, a

<!-- PAGE=? -->
o -monitoring mode ‖ with a bandwidth of 0.5 to 40 Hz for adults and 0.5 to 60 Hz for neonates, and a

<!-- PAGE=? -->
o -filter mode ‖ with a bandwidth of 0.5 to 20 Hz .

<!-- PAGE=? -->
sensitive for intraop ischemia detection

<!-- PAGE=? -->
 V4 and V5 =90%

<!-- PAGE=? -->
 V5=75%

<!-- PAGE=? -->
 V4=61%

<!-- PAGE=? -->
 V5 and II=80%

<!-- PAGE=? -->
 II,V4 and V5=96%

<!-- PAGE=? -->
 Miller

<!-- PAGE=? -->
o Lead V4 rather than V5 detects ischemia earlier, is more sensitive, and shows a greater STsegment deviation

<!-- PAGE=? -->
Significant ST Changes

<!-- PAGE=? -->
1mm horizontal or downward sloping ST segment depression

<!-- PAGE=? -->
60 to 80 milliseconds after the J point

<!-- PAGE=? -->
duration of at least 1 minute

<!-- PAGE=? -->
separation from other discrete episodes by at least 1 minute of normal baseline

<!-- PAGE=? -->
2mm upsloping ST segment depression

<!-- PAGE=? -->
80msec after the J point

<!-- PAGE=? -->
ST-segment elevation with peaked T waves

<!-- PAGE=? -->
T-wave inversion

<!-- PAGE=? -->
ECG changes consistent with ischemia are difficult to detect in

<!-- PAGE=? -->
 RBBB

<!-- PAGE=? -->
LVH with a strain pattern

<!-- PAGE=? -->
atrial fibrillation

<!-- PAGE=? -->
hypokalemia

<!-- PAGE=? -->
digitalis

<!-- PAGE=? -->
 WPW

<!-- PAGE=? -->
Acute pericarditis

<!-- PAGE=? -->
Ischemia monitoring by ECG is not possible in patients with

<!-- PAGE=? -->
 LBBB

<!-- PAGE=? -->
pacemaker dependency

<!-- PAGE=? -->
5 lead system allows monitoring of bipolar and unipolar leads plus one precordial (usually V5)

<!-- PAGE=? -->
R sided precordial lead may be of benefit in pts with occlusive disease of RCA

<!-- PAGE=? -->
3 lead system =monitoring of bipolar leads only, can be modified to incr sensitivity for ant MI or arrythmias

<!-- PAGE=? -->
hemiblocks -  normal QRS duration

<!-- PAGE=? -->
LAFB - LAD, I qR, aVF Rs; LPFB  - RAD, I Rs, aVF qR

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Three types of conduction system blocks

<!-- PAGE=? -->
o sinoatrial block

<!-- PAGE=? -->
 block occurs at the sinus node

<!-- PAGE=? -->
 no P waves

<!-- PAGE=? -->
 next beat can be a normal sinus beat, a nodal escape beat, or a ventricular escape beat

<!-- PAGE=? -->
o atrioventricular heart block

<!-- PAGE=? -->
 first- and second-degree atrioventricular blocks are incomplete

<!-- PAGE=? -->
 type two 2 nd degree AV block has a serious prognosis, because it frequently progresses to complete heart block

<!-- PAGE=? -->
 third degree AV block is complete

<!-- PAGE=? -->
o intraventricular conduction block

<!-- PAGE=? -->
 LBBB

<!-- PAGE=? -->
 most serious of these conduction

<!-- PAGE=? -->
 LBBB pattern is always associated with significant cardiac disease

<!-- PAGE=? -->
 RBBB

<!-- PAGE=? -->
 May be of no clinical significance

<!-- PAGE=? -->
 Associated with chronic lung disease, ASDs

<!-- PAGE=? -->
 Hemiblocks

<!-- PAGE=? -->
 when one of two divisions of the left bundle is blocked

<!-- PAGE=? -->
 QRS complex is not prolonged

<!-- PAGE=? -->
 LAHB

<!-- PAGE=? -->
o left axis deviation (usually -60 degrees)

<!-- PAGE=? -->
o small Q in leads I and aVL and small R in leads II, III, and aVF;

<!-- PAGE=? -->
o a normal QRS duration

<!-- PAGE=? -->
o a late intrinsicoid deflection in lead aVL (0.045 s); and

<!-- PAGE=? -->
o an increased QRS voltage in limb leads

<!-- PAGE=? -->
 LPHB

<!-- PAGE=? -->
o right axis deviation (usually +120 degrees)

<!-- PAGE=? -->
o small R in leads I and aVL and small Q in leads II, III, and aVF;

<!-- PAGE=? -->
o a normal QRS duration;

<!-- PAGE=? -->
o a late intrinsicoid deflection in lead aVF (>0.045 second);

<!-- PAGE=? -->
o an increased QRS voltage in limb leads; and

<!-- PAGE=? -->
o no evidence of right ventricular hypertrophy

<!-- PAGE=? -->
 are often associated with an RBBB to form a bilateral bundle branch block

<!-- PAGE=? -->
o Only 10% of patients with an RBBB and a left anterior hemiblock progress to complete heart block

<!-- PAGE=? -->
o RBBB and a left posterior hemiblock often do proceed to complete heart block

<!-- PAGE=? -->
 Trifascicular blocks

<!-- PAGE=? -->
 one of the foregoing bilateral bundle branch blocks (i.e., RBBB plus a left fascicular block) in addition to a prolonged PR interval

<!-- PAGE=? -->
ECT

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Absolute contraindications

<!-- PAGE=? -->
o pheochromocytoma

<!-- PAGE=? -->
 Relative contraindications:

<!-- PAGE=? -->
o increased ICP

<!-- PAGE=? -->
RBBB with LAD - LAFB, RBBB with RAD - LPFB RBBB alone usually has normal axis

<!-- PAGE=? -->
o recent CVA or MI

<!-- PAGE=? -->
o cardiovascular conduction defects

<!-- PAGE=? -->
o high risk pregnancy

<!-- PAGE=? -->
o aneurysms: aortic or cerebral

<!-- PAGE=? -->
o long bone fractures

<!-- PAGE=? -->
o thrombophlebitis

<!-- PAGE=? -->
o acute or severe pulmonary disease

<!-- PAGE=? -->
o retinal detachment

<!-- PAGE=? -->
Physiologic effects:

<!-- PAGE=? -->
 Cardiovascular

<!-- PAGE=? -->
o initial phase - parasympathetic

<!-- PAGE=? -->
 Bradycardia

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
o later phase - sympathetic ( older patients have more profound response (A&A 2002)

<!-- PAGE=? -->
 peaks ~2-5 min

<!-- PAGE=? -->
 Tachycardia

<!-- PAGE=? -->
 Dysrhythmia

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 Increased systemic and MVO2

<!-- PAGE=? -->
 Cerebral Effects

<!-- PAGE=? -->
o Increased cerebral blood flow

<!-- PAGE=? -->
o Elevated intracranial pressure

<!-- PAGE=? -->
o Increased oxygen consumption

<!-- PAGE=? -->
 Other Effects

<!-- PAGE=? -->
o Elevated intraocular pressure

<!-- PAGE=? -->
o Elevated intragastric pressure

<!-- PAGE=? -->
ANESTH ANALC

<!-- PAGE=? -->
REYIEW ARTICLE DINC ANDWHITE ANESTHESIA FOR ELECTROCONVULSIVE THERAPY

<!-- PAGE=? -->
1353

<!-- PAGE=? -->
Table 1. Comnmon Fhysiologic Responses and Side Effects Associated with Electroconvulsive Therapy

<!-- PAGE=? -->
Table 2 Effects of IV Anesthetic and Cardiovascular on the Duration of ECT-Induced Seizure Activity (relative to methohexital or saline; respectively) Drugs

<!-- PAGE=? -->
Inc. Seizure Activity

<!-- PAGE=? -->
 Cisatracurioum

<!-- PAGE=? -->
 Atracurium

<!-- PAGE=? -->
 Enflurane

<!-- PAGE=? -->
 Alfentanil

<!-- PAGE=? -->
 Remifentanil

<!-- PAGE=? -->
o Dose sparing effect

<!-- PAGE=? -->
 Merperdine

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
o Conflicting reports on affect on duration

<!-- PAGE=? -->
o Undesirable hemodynamic effects

<!-- PAGE=? -->
 Etomidate

<!-- PAGE=? -->
o Inc. duration

<!-- PAGE=? -->
 hypocarbia

<!-- PAGE=? -->
Derc. Seizure Activity

<!-- PAGE=? -->
 propofol

<!-- PAGE=? -->
o no difference in outcomes compared to methohexital

<!-- PAGE=? -->
 benzo

<!-- PAGE=? -->
 STP

<!-- PAGE=? -->
 Hypercarbia

<!-- PAGE=? -->
 Esmolol

<!-- PAGE=? -->
o May dec. duration of Sz activity

<!-- PAGE=? -->
EEG

<!-- PAGE=? -->
Normal CBF = 50cc/100g Critical CBF = 30 cc/100g EEG changes = 20 cc/100g Irreversible change = 10cc/100g

<!-- PAGE=? -->
Elderly patients

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Cardiovascular changes (3):

<!-- PAGE=? -->
o Diastolic dysfunction (LVH)

<!-- PAGE=? -->
o Decreased adrenergic response (α & β):

<!-- PAGE=? -->
 Decreased maximal HR and resting (more vagal)

<!-- PAGE=? -->
 Decreased CO with exercise (preload dependent)

<!-- PAGE=? -->
 Decreased baroreceptor response (orthostatic HoTN)

<!-- PAGE=? -->
o Increased afterload (SBP, LV dilation)

<!-- PAGE=? -->
 Respiratory changes:

<!-- PAGE=? -->
o Increases:

<!-- PAGE=? -->
 CC (reduced elastic recoil)

<!-- PAGE=? -->
 RV (reduced elastic recoil, reduced expiratory force?)

<!-- PAGE=? -->
 FRC (reduced elastic recoil, decreased CW compliance)

<!-- PAGE=? -->
o Decreases:

<!-- PAGE=? -->
 VC (increased RV)

<!-- PAGE=? -->
 TLC (slightly, reduced CW compliance)

<!-- PAGE=? -->
o loss of lung elastin  increased compliance

<!-- PAGE=? -->
o nonuniform loss of elasin  V/Q mismatch

<!-- PAGE=? -->
o breakdown of alveolar septa  increase alveolar dead space

<!-- PAGE=? -->
o calcification of thorax  decreased thoracic compliance and  increased work of breathing

<!-- PAGE=? -->
 Pharmacology, altered determinants

<!-- PAGE=? -->
o Protein binding (minor effect)

<!-- PAGE=? -->
o Body composition

<!-- PAGE=? -->
 Dec. central compartment if deconditioned and HTN (usually well maintained if normotensive)

<!-- PAGE=? -->
 Dec. Vd for water soluble drugs

<!-- PAGE=? -->
o NdMB

<!-- PAGE=? -->
 Inc. fat concentration

<!-- PAGE=? -->
 Inc. Vd for lipid soluble drugs

<!-- PAGE=? -->
o Propofol, benzodiazepines, barbiturates

<!-- PAGE=? -->
 May delay recovery

<!-- PAGE=? -->
o Metabolism

<!-- PAGE=? -->
 Reduced hepatic clearance d/t dec. hepatic perfusion

<!-- PAGE=? -->
o Pharmacodynamics

<!-- PAGE=? -->
 Neuronal loss is a possible mechanism for inc. drug sensitivity

<!-- PAGE=? -->
Table 62-4 -- Clinical pharmacology of anesthetic agents in the elderly

<!-- PAGE=? -->
Elderly lung changes

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 The patency of small airways, normally maintained by elastic recoil, may be compromised, moving closing capacity (CC) above functional residual capacity (FRC)

<!-- PAGE=? -->
 FRC has a minor increase

<!-- PAGE=? -->
 vital capacity (VC) is significantly and progressively compromised as residual volume increases at the expense of inspiratory and expiratory reserve volumes

<!-- PAGE=? -->
 Total lung capacity, the sum of vital capacity (VC) and residual volume (RV), is reduced only modestly in older adults

<!-- PAGE=? -->
VOLUME (L)

<!-- PAGE=? -->
7.0

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
VC

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
CC

<!-- PAGE=? -->
3.0

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
3.0

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
2.0

<!-- PAGE=? -->
20

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
20

<!-- PAGE=? -->
30

<!-- PAGE=? -->
40

<!-- PAGE=? -->
50

<!-- PAGE=? -->
60

<!-- PAGE=? -->
70

<!-- PAGE=? -->
80

<!-- PAGE=? -->
AGE (YEARS)

<!-- PAGE=? -->
Electrical shock

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Skin resistance can vary from a few thousand to 1 million ohms

<!-- PAGE=? -->
 Ohm's Law   V=I/R

<!-- PAGE=? -->
 Rearrange to solve for current

<!-- PAGE=? -->
o I = V/R

<!-- PAGE=? -->
o Ex.  120V/1000 Ohms = 120mA current

<!-- PAGE=? -->
 40% of electrical accidents in hospitals occurred in the operating room

<!-- PAGE=? -->
 To provide an extra measure of safety from gross electrical shock (macroshock), the power supplied to most operating rooms is ungrounded

<!-- PAGE=? -->
o the current is isolated from ground potential

<!-- PAGE=? -->
 no circuit exists between the ground and either of the isolated power lines

<!-- PAGE=? -->
o neither wire is hot or neutral with reference to ground

<!-- PAGE=? -->
 If the wires of the isolated power system are connected, the short circuit will trip the circuit breaker

<!-- PAGE=? -->
Isolation

<!-- PAGE=? -->
Hot

<!-- PAGE=? -->
Transformer

<!-- PAGE=? -->
Line 1

<!-- PAGE=? -->
Electrical

<!-- PAGE=? -->
Fuse

<!-- PAGE=? -->
Power

<!-- PAGE=? -->
Box

<!-- PAGE=? -->
Company

<!-- PAGE=? -->
Line 2

<!-- PAGE=? -->
Ground

<!-- PAGE=? -->
8

<!-- PAGE=? -->
4

<!-- PAGE=? -->
 An individual contacting one side of the isolated power system (point A ) and standing on the ground (point B ) will not receive a shock

<!-- PAGE=? -->
o the individual is not contacting the circuit at two points and thus is not completing the circuit

<!-- PAGE=? -->
o Point A is part of the isolated power system

<!-- PAGE=? -->
o Point B is part of the primary or grounded side of the circuit

<!-- PAGE=? -->
 if the person contacts both lines of the isolated power system (an unlikely event), he or she would receive a shock

<!-- PAGE=? -->
Line Isolation monitors

<!-- PAGE=? -->
 Monitors the integrity of an isolated power system

<!-- PAGE=? -->
 The LIM continuously monitors the isolated power to ensure that it is indeed isolated from ground

<!-- PAGE=? -->
o The LIM alerts the personnel that the power is no longer ungrounded

<!-- PAGE=? -->
 If a faulty piece of equipment is connected to the isolated power system, the system will revert back to a conventional grounded system, and the faulty piece of equipment will continue to function normally

<!-- PAGE=? -->
o Continuing to use this faulty equipment would create the potential for a serious electrical shock

<!-- PAGE=? -->
 The displayed number is a measure of the potential for current flow from the isolated system to the ground

<!-- PAGE=? -->
 LIM alarms when a single fault exists

<!-- PAGE=? -->
o Single contact to either line 1 or 2

<!-- PAGE=? -->
o Usually set to alarm with a 2-5 mA leak

<!-- PAGE=? -->
o Double fault is required for a shock to occur

<!-- PAGE=? -->
 LIM does not detect current leak from equipment with faulty ground wire

<!-- PAGE=? -->
 If the LIM alarm is triggered

<!-- PAGE=? -->
o Check the gauge to determine if it is a true fault.  (DDx: too much electrical equipment plugged in)

<!-- PAGE=? -->
o Identify the faulty equipment. - Unplug each piece of equipment until alarm ceases

<!-- PAGE=? -->
o If the faulty equipment is not of a life-support nature, it should be removed from the OR.

<!-- PAGE=? -->
Epidural

<!-- PAGE=? -->
Epidural Space

<!-- PAGE=? -->
 Boundaries

<!-- PAGE=? -->
o foramen magnum - fused to the base of the skull

<!-- PAGE=? -->
o the sacral hiatus - covered by the sacrococcygeal ligament

<!-- PAGE=? -->
o anteriorly by the posterior longitudinal ligament

<!-- PAGE=? -->
o laterally by the pedicles and the intervertebral foramina

<!-- PAGE=? -->
o posteriorly by the ligamentum flavum and the anterior surface of the lamina

<!-- PAGE=? -->
 width varies with the vertebral level, ranging from 1 to 1.5 mm at C5 to 2.5 to 3 mm at T6 to its widest point 5 to 6 mm at the level of L2.

<!-- PAGE=? -->
 the contents of the epidural space are

<!-- PAGE=? -->
o nerve roots

<!-- PAGE=? -->
o fat

<!-- PAGE=? -->
o areolar tissue

<!-- PAGE=? -->
o lymphatics

<!-- PAGE=? -->
o arteries

<!-- PAGE=? -->
o extensive internal vertebral venous plexus of Batson

<!-- PAGE=? -->
Epidural Abscess

<!-- PAGE=? -->
Symptoms & Signs

<!-- PAGE=? -->
 Back pain (moderate to severe) +/- radicular

<!-- PAGE=? -->
 Fever

<!-- PAGE=? -->
 Leukocytosis

<!-- PAGE=? -->
 Abnormal myelogram

<!-- PAGE=? -->
Epidural Opioids

<!-- PAGE=? -->
Side effects

<!-- PAGE=? -->
 Pruritus

<!-- PAGE=? -->
 Nausea and vomiting

<!-- PAGE=? -->
 Urinary retention

<!-- PAGE=? -->
 Sedation

<!-- PAGE=? -->
 Depression of ventilation (early = 2H, late = 6-12H, <24H)

<!-- PAGE=? -->
 Central nervous system excitation

<!-- PAGE=? -->
 Viral reactivation (HSV)

<!-- PAGE=? -->
 Neonatal morbidity (depression of ventilation)

<!-- PAGE=? -->
 Sexual dysfunction

<!-- PAGE=? -->
 Ocular dysfunction (miosis, nystagmus, vertigo)

<!-- PAGE=? -->
 Gastrointestinal dysfunction (delayed emptying)

<!-- PAGE=? -->
 Thermoregulatory dysfunction (decreased shivering)

<!-- PAGE=? -->
 Water retention (increased ADH)

<!-- PAGE=? -->
Risk factors for delayed respiratory depression

<!-- PAGE=? -->
 hydrophilic opioid (morphine)

<!-- PAGE=? -->
 large doses

<!-- PAGE=? -->
 concomitant administration by other routes of opioids or other CNS-depressant drugs

<!-- PAGE=? -->
 Thoracic epidural

<!-- PAGE=? -->
 marked changes in thoracoabdominal pressure, including artificial ventilation

<!-- PAGE=? -->
 Respiratory disease (lung, OSA)

<!-- PAGE=? -->
 lack of tolerance to opioids

<!-- PAGE=? -->
 Extensive surgery (?)

<!-- PAGE=? -->
Epidural Cardiovascular Effects

<!-- PAGE=? -->
Epidural blood patch

<!-- PAGE=? -->
 Patients who are unable or unwilling to await spontaneous resolution of PDPH should be offered epidural blood patch

<!-- PAGE=? -->
o Likely forms a clot over the meningeal hole

<!-- PAGE=? -->
 Symptoms are relieved within 1 to 24 hours in 85 to 95% of patients

<!-- PAGE=? -->
o 90% of patients who fail an initial blood patch will respond to a second patch

<!-- PAGE=? -->
 The most common side effects of blood patch are backache and radicular pain

<!-- PAGE=? -->
 transient bradycardia and cranial nerve palsies have also been reported

<!-- PAGE=? -->
 The timing of epidural blood patch is controversial

<!-- PAGE=? -->
o prophylactic blood patch may or may not be effective

<!-- PAGE=? -->
 worth considering in high-risk outpatients for whom a return trip to the hospital for epidural blood patch would be difficult

<!-- PAGE=? -->
 Epidurally administered fibrin glue has been shown to be an effective alternative to blood administration

<!-- PAGE=? -->
Epidural Hematoma

<!-- PAGE=? -->
 Severe back pain or pressure is classically the earliest symptom

<!-- PAGE=? -->
o often develops a radicular component

<!-- PAGE=? -->
o may develop focal neurologic findings from injury to the spinal cord or nerve root

<!-- PAGE=? -->
 In one study motor weakness was the most common initial presenting symptom (46%), followed by back pain

<!-- PAGE=? -->
(38%), sensory deficit (14%), and urinary retention

<!-- PAGE=? -->
o Paraplegia subsequently developed over an average of 14.5 hours

<!-- PAGE=? -->
 Both CT and MRI are acceptable imaging modalities

<!-- PAGE=? -->
 Time is of the essence for if the spinal cord compression persists for longer than 6-12 h, catastrophic paralysis may result

<!-- PAGE=? -->
o early surgical intervention (less than 8 hours from onset of symptoms) may result in improved neurologic outcome.

<!-- PAGE=? -->
 The risk of spinal hematoma during removal of an epidural catheter is nearly as great as with placement of the catheter

<!-- PAGE=? -->
 Epidural puncture should be avoided if the platelet count falls below 100,000/ mm3

<!-- PAGE=? -->
Epiglottitis vs croup

<!-- PAGE=? -->
CROUP (laryngotrachoebronchitis )

<!-- PAGE=? -->
EPIGLOTTITIS

<!-- PAGE=? -->
Age

<!-- PAGE=? -->
6 mo -6 y/o (peak 1-2 y/o)

<!-- PAGE=? -->
2-6 y/o (usually older)

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
parainfluenza, influenza, RSV, adenoviruses

<!-- PAGE=? -->
H. influenzae

<!-- PAGE=? -->
Onset

<!-- PAGE=? -->
insidious

<!-- PAGE=? -->
sudden

<!-- PAGE=? -->
Clinical Manifestations

<!-- PAGE=? -->
low-grade fever nontoxic Barking cough Stridor (biphasic with severe croup) Hoarse voice (more common in older children)

<!-- PAGE=? -->
high fever toxic nonbarking cough if present is inspiratory muffeled voice (subglittic structures not affected Drooling Dysphagia Sitting, leaning forward

<!-- PAGE=? -->
Endoscopic findings

<!-- PAGE=? -->
subglottic swelling,

<!-- PAGE=? -->
cherry-red epiglottis

<!-- PAGE=? -->
Deep red mucosa

<!-- PAGE=? -->
aryepiglottic swelling

<!-- PAGE=? -->
Labs

<!-- PAGE=? -->
mild leukocytosis steeple sign (subglottic stenosis)

<!-- PAGE=? -->
marked leukocytosis thumb print (large epiglottis)

<!-- PAGE=? -->
X-ray

<!-- PAGE=? -->
Therapy

<!-- PAGE=? -->
mist Calm Epinephrine 1:1000 0.25 cc for <6mo. 0.5 cc for > 6 mo to max of 5 cc Decadron 0.6- 1 mg/kg po/im/iv

<!-- PAGE=? -->
intubation

<!-- PAGE=? -->
antibiotics

<!-- PAGE=? -->
References:

<!-- PAGE=? -->
Badgwell  283,

<!-- PAGE=? -->
PALS 114

<!-- PAGE=? -->
Anesthesiology Clinics of NA Vol 19 No2, June 2001 Pediatric Emergencies

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Epinephrine is the drug of choice when resuscitating pts during anaphylactic shock

<!-- PAGE=? -->
 α-adrenergic effects vasoconstrict to reverse hypotension

<!-- PAGE=? -->
 β2-receptor stimulation bronchodilates and inhibits mediator release by increasing cAMP in mast cells and basophils

<!-- PAGE=? -->
 in hypotensive pts

<!-- PAGE=? -->
o 5-10mcg boluses of epinephrine should be administered IV and incrementally titrated to restore BP

<!-- PAGE=? -->
o with CV collapse, full CPR doses of epinephrine 0.1-1.0 mg should be administered and repeated until hemodynamic stability resumes

<!-- PAGE=? -->
 pts with laryngeal edema without hypotension should receive SC epinephrine (epinephrine should NOT be administered IV to pts with normal BP

<!-- PAGE=? -->
Esmolol

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 Rapid onset, short-acting selective B1 agonist

<!-- PAGE=? -->
 Initial dose 0.5mg/kg IV

<!-- PAGE=? -->
 Full effect: 5min

<!-- PAGE=? -->
 Duration 10 - 30 min

<!-- PAGE=? -->
 Action - Decr HR and BP

<!-- PAGE=? -->
 T ½ = 9min

<!-- PAGE=? -->
 Rapid hydrolysis by plasma esterases (distinct from plasma cholinesterase)

<!-- PAGE=? -->
o independent of liver, renal, and hepatic function

<!-- PAGE=? -->
 <1% excreted unchanged in urine

<!-- PAGE=? -->
 Clinically insignificant amts of methanol from esmolol metabolism

<!-- PAGE=? -->
 Poor lipid solubility limits transfer of esmolol into CNS or across placenta

<!-- PAGE=? -->
 membrane stabilization in the heart is detectable only at plasma concentrations far higher than needed to produce clinically adequate B-blockade

<!-- PAGE=? -->
o not a membrane stabilizer

<!-- PAGE=? -->
Esterases

<!-- PAGE=? -->
 red cell esterases = non specific plasma and tissue esterases = Remi, esmolol

<!-- PAGE=? -->
 plasma cholin esterases (pseudo) = cocaine, Sux, Miv, ester LA (exist in plasma or liver)  decreased in liver failure

<!-- PAGE=? -->
Etomidate

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 a carboxylated imidazole-containing compound that is chemically unrelated to any other drug used for the IV induction of anesthesia

<!-- PAGE=? -->
o imidazole nucleus renders etomidate, like midazolam, water soluble at an acidic pH and lipid soluble at physiologic pH

<!-- PAGE=? -->
 dextro-isomer of etomidate is pharmacologically active

<!-- PAGE=? -->
 It is presumed that etomidate, like barbiturates, propofol, and benzodiazepines, produces CNS depression via an ability to enhance the effects of the CNS inhibitory neurotransmitter GABA

<!-- PAGE=? -->
o Analogous to the barbiturates, etomidate decreases CMRO2, CBF, and ICP, as well as CPP

<!-- PAGE=? -->
 Involuntary myoclonic movements are common during the induction period as a result of subcortical disinhibition, and are unrelated to cortical seizure activity

<!-- PAGE=? -->
o Attenuated by opioids, benzos, or small doses of etomidate

<!-- PAGE=? -->
 can induce convulsion-like EEG potentials in epileptic patients without the appearance of myoclonic or convulsant-like motor activity

<!-- PAGE=? -->
 Etomidate causes minimal cardiorespiratory depression even in the presence of cardiovascular and pulmonary disease

<!-- PAGE=? -->
 does not induce histamine release

<!-- PAGE=? -->
 does not effectively blunt the sympathetic response to laryngoscopy and intubation unless combined with a potent opioid analgesic

<!-- PAGE=? -->
 inc. mortality in critically ill patients sedated with an etomidate infusion has been attributed to its inhibitory effect on cortisol synthesis

<!-- PAGE=? -->


<!-- PAGE=? -->
o inhibits the activity of 11-β-hydroxylase, an enzyme necessary for the synthesis of cortisol, aldosterone, 17-hydroxyprogesterone, and corticosterone

<!-- PAGE=? -->
o after a single induction dose of etomidate, adrenal suppression persists for 5 to 8 hours reported to inhibit platelet function

<!-- PAGE=? -->
 high clearance rate of etomidate is a result of extensive ester hydrolysis in the liver (forming inactive water-soluble metabolites)

<!-- PAGE=? -->
o Severe hepatic disease causes a prolongation of the elimination half-life secondary to an increased volume of distribution and a decreased plasma clearance rate

<!-- PAGE=? -->
 produces a significant increase of the amplitude of somatosensory evoked potentials while only minimally increasing their latency

<!-- PAGE=? -->
EVAR

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o 50-60 % patients with infra-renal AAA have suitable anatomy

<!-- PAGE=? -->
o DREAM/EVAR-1 = better short-term outcomes vs open AAA

<!-- PAGE=? -->
 less 30 day operative mortality ( 1.6% vs 4.6%)

<!-- PAGE=? -->
 shorter hospital stay

<!-- PAGE=? -->
 less peri-operative systemic complications

<!-- PAGE=? -->
 After a follow-up of 4 years, all-cause mortality did not differ between groups (26% for EVAR versus 29% for open)

<!-- PAGE=? -->
o More secondary interventions required with EVAR due to migration, kinding, thrombosis and endoleak

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Endoleak

<!-- PAGE=? -->
 Inability to obtain/maintain complete exclusion of aneurysm sac from arterial blood flow.

<!-- PAGE=? -->
 any pressurization of the aneurysm sac (i.e., endotension) can lead to aneurysm enlargement and rupture.

<!-- PAGE=? -->
 Type I

<!-- PAGE=? -->
 inadequate seal between the stent-graft and the aortic wall at the proximal or distal attachment sites

<!-- PAGE=? -->
 Type II

<!-- PAGE=? -->
 retrograde filling of the aneurysm sac from patent intercostal, lumbar, inferior mesenteric, or testicular arteries

<!-- PAGE=? -->
 Type III

<!-- PAGE=? -->
 structural failure of the stent-graft that allows blood to flow directly into the aneurysm sac.

<!-- PAGE=? -->
 Type IV

<!-- PAGE=? -->
 directly to the porosity of the graft material

<!-- PAGE=? -->
o Type I and III endoleaks are associated with an increased risk of rupture

<!-- PAGE=? -->
 GA vs. locoregional

<!-- PAGE=? -->
o Sadat et al. Vascular. 2008 Nov-Dec;16(6):340-5

<!-- PAGE=? -->
o there is no level 1 evidence for or against locoregional anesthesia in EVAR

<!-- PAGE=? -->
o This review suggests that locoregional anesthesia can improve postoperative outcomes following EVAR by reducing hospital stay, ICU stay, mortality, and morbidity.

<!-- PAGE=? -->
Extubation Criteria

<!-- PAGE=? -->
 Subjective

<!-- PAGE=? -->
o Following commands

<!-- PAGE=? -->
o Clear oropharynx

<!-- PAGE=? -->
o Sustained head lift > 5 sec

<!-- PAGE=? -->
o Sustained hand grips

<!-- PAGE=? -->
o Adequate pain control

<!-- PAGE=? -->
F

<!-- PAGE=? -->
Fat embolus syndrome

<!-- PAGE=? -->
Barashm, CoExD, Miller

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o long bone #, major trauma:

<!-- PAGE=? -->
o Intramedullary instrumentation

<!-- PAGE=? -->
o THA using using cement

<!-- PAGE=? -->
o Bilateral TKR

<!-- PAGE=? -->
o Male sex

<!-- PAGE=? -->
o Age 20-30 years

<!-- PAGE=? -->
o Hypovolemic shock

<!-- PAGE=? -->
o Rheumatoid arthritis

<!-- PAGE=? -->
 Clinically significant FES seen in 10-15% of pts with long bone #

<!-- PAGE=? -->
o Usually presents in 12-72h

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
o capillary endothelieal breakdown causeing hemorrhagic exudates

<!-- PAGE=? -->
 Diagnostic criteria:

<!-- PAGE=? -->
o Requires 1 major and 4 minor criteria

<!-- PAGE=? -->
o Major signs (4):

<!-- PAGE=? -->
 Petechiae (subconjunctival, axillary)

<!-- PAGE=? -->
 Change in LOC

<!-- PAGE=? -->
 Significant hypoxemia

<!-- PAGE=? -->
 Pulmonary edema

<!-- PAGE=? -->
o Minor signs (6):

<!-- PAGE=? -->
 Tachycardia

<!-- PAGE=? -->
 Hyperthermia

<!-- PAGE=? -->
 Elevated ESR

<!-- PAGE=? -->
 Decreased Hct or platelets

<!-- PAGE=? -->
 Fat emboli in retina

<!-- PAGE=? -->
 Fat globules in urine or sputum

<!-- PAGE=? -->
 May have hemoptysis secondary to pulmonary edema and/or DIC

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o early recognition

<!-- PAGE=? -->
o oxygen

<!-- PAGE=? -->
o judicious fluids

<!-- PAGE=? -->
o ? steroids

<!-- PAGE=? -->
o Lung protective ventilation

<!-- PAGE=? -->
 ARDS

<!-- PAGE=? -->
 Objective

<!-- PAGE=? -->
o Tidal Volume > 6 cc/kg

<!-- PAGE=? -->
o Vital Capacity > 10 cc/kg

<!-- PAGE=? -->
o Peak negative inspiratory pressure > 20 cm H2O

<!-- PAGE=? -->
o Sustained tetanic contraction (5 sec)

<!-- PAGE=? -->
o T1/T4 ratio > 0.7

<!-- PAGE=? -->
o A-a PO2 (on FIO2 of 1.0) < 350 mm Hg

<!-- PAGE=? -->
o Vd/Vt < 0.6 (Vd=2-3cc/kg)

<!-- PAGE=? -->
Fluids

<!-- PAGE=? -->
TABLE 45-15. Composition of Replacement Fluids

<!-- PAGE=? -->
NA mEq/L

<!-- PAGE=? -->
K mEq/L

<!-- PAGE=? -->
DEXTROSE g/L

<!-- PAGE=? -->
Osm

<!-- PAGE=? -->
pH

<!-- PAGE=? -->
OTHER

<!-- PAGE=? -->
Whole blood in CPD

<!-- PAGE=? -->
a

<!-- PAGE=? -->
168-156

<!-- PAGE=? -->
3.9-21.0

<!-- PAGE=? -->
7.20-6.84

<!-- PAGE=? -->
Hct = 35-40

<!-- PAGE=? -->
PRBC, † AS-1

<!-- PAGE=? -->
117

<!-- PAGE=? -->
?-49

<!-- PAGE=? -->
552

<!-- PAGE=? -->
6.6

<!-- PAGE=? -->
Hct = 59

<!-- PAGE=? -->
PRBC, † CPD

<!-- PAGE=? -->
?-95

<!-- PAGE=? -->
6.6

<!-- PAGE=? -->
Hct = 77

<!-- PAGE=? -->
PRBC, † CPDA-1

<!-- PAGE=? -->
169-111

<!-- PAGE=? -->
5.1-78.5

<!-- PAGE=? -->
7.55-6.71

<!-- PAGE=? -->
Hct = 65-80

<!-- PAGE=? -->
FFP

<!-- PAGE=? -->
15.4

<!-- PAGE=? -->
5% albumin

<!-- PAGE=? -->
145 ± 15

<!-- PAGE=? -->
<2.5

<!-- PAGE=? -->
0

<!-- PAGE=? -->
330

<!-- PAGE=? -->
7.4

<!-- PAGE=? -->
COP = 32-35 mm Hg

<!-- PAGE=? -->
2.5% albumin

<!-- PAGE=? -->
145 ± 15

<!-- PAGE=? -->
<2.0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
330

<!-- PAGE=? -->
Plasmanate

<!-- PAGE=? -->
145 ± 15

<!-- PAGE=? -->
<2.0

<!-- PAGE=? -->
7.4

<!-- PAGE=? -->
COP = 20 mm Hg

<!-- PAGE=? -->
10% Dextran 40

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
50

<!-- PAGE=? -->
255

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
Hetastarch

<!-- PAGE=? -->
154

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
310

<!-- PAGE=? -->
5.9

<!-- PAGE=? -->
0.9% NaCl

<!-- PAGE=? -->
154

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
308

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
3% NaCl

<!-- PAGE=? -->
513

<!-- PAGE=? -->
1025

<!-- PAGE=? -->
Ringer lactate

<!-- PAGE=? -->
130

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
273

<!-- PAGE=? -->
6.5

<!-- PAGE=? -->
Lactate = 28

<!-- PAGE=? -->
5% Dextrose

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
50

<!-- PAGE=? -->
252

<!-- PAGE=? -->
4.5

<!-- PAGE=? -->
D5LR

<!-- PAGE=? -->
130

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
50

<!-- PAGE=? -->
525

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
D50.45%

<!-- PAGE=? -->
77

<!-- PAGE=? -->
0

<!-- PAGE=? -->
50

<!-- PAGE=? -->
406

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
Normosol (plasmalyte)

<!-- PAGE=? -->
140

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
100

<!-- PAGE=? -->
555

<!-- PAGE=? -->
7.4

<!-- PAGE=? -->
Mg = 3, acetate = 27 gluconate = 23

<!-- PAGE=? -->
Normosol M

<!-- PAGE=? -->
40

<!-- PAGE=? -->
13

<!-- PAGE=? -->
50

<!-- PAGE=? -->
363

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
Mg = 3, acetate = 16

<!-- PAGE=? -->
Normosol R

<!-- PAGE=? -->
140

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
294

<!-- PAGE=? -->
6.6

<!-- PAGE=? -->
Mg = 3, acetate = 27 gluconate = 23

<!-- PAGE=? -->
D5Normosol R

<!-- PAGE=? -->
140

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
547

<!-- PAGE=? -->
5.2

<!-- PAGE=? -->
Mg = 3, acetate = 27 gluconate = 23

<!-- PAGE=? -->
Normosol R pH 7.4

<!-- PAGE=? -->
140

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
295

<!-- PAGE=? -->
7.4

<!-- PAGE=? -->
Mg = 3, acetate = 27 gluconate = 23

<!-- PAGE=? -->
a

<!-- PAGE=? -->
The range of values refers to concentrations on day 1 and day 21 (CPD), 35 (CPDA-1), or 42 (AS-1) of storage.

<!-- PAGE=? -->
b

<!-- PAGE=? -->
Fructose substituted for dextrose

<!-- PAGE=? -->
Hct, hematocrit; PRBC, packed red blood cells; D5LR, 5% dextrose in Ringer lactate; FFP, fresh frozen plasma; D50.45% NaCl, 5% dextrose in 0.45% NaCl

<!-- PAGE=? -->
 .3-.5 gm/kg/hr of glucose in neonates

<!-- PAGE=? -->
 HCO - (base excess x wt x .3) = mls of 8.4% HCO

<!-- PAGE=? -->
 Free water deficit = TBW x ([Na]/140-1)

<!-- PAGE=? -->
o 42 (150/140 - 1)

<!-- PAGE=? -->
o 42 (0.714) = 3L

<!-- PAGE=? -->
 Na deficit = TBW (140- [Na])

<!-- PAGE=? -->
 Na correction - per liter of fluid

<!-- PAGE=? -->
o Inc in  Serum Na = (infusate [Na] - serum Na) / (TBW+1)

<!-- PAGE=? -->
o Inc in Serum Na = (154 - 120) / 43

<!-- PAGE=? -->
o Inc in Serum Na = 0.7 mmol/L

<!-- PAGE=? -->
 ~1mmol / L NS

<!-- PAGE=? -->
Flumazanil

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 benzodiazepine receptor ligand with

<!-- PAGE=? -->
o high affinity

<!-- PAGE=? -->
 will replace a relatively weak agonist such as diazepam as long as it is given in sufficient dose

<!-- PAGE=? -->
o great specificity

<!-- PAGE=? -->
o minimal intrinsic effect

<!-- PAGE=? -->
 very weak agonist activity

<!-- PAGE=? -->
 Rapid onset, with peak effect occurring in 1 to 3 minutes

<!-- PAGE=? -->
 Low protein binding

<!-- PAGE=? -->
 Duration is determined by

<!-- PAGE=? -->
o Dose

<!-- PAGE=? -->
o Dose of BZD

<!-- PAGE=? -->
o Specific BZD used

<!-- PAGE=? -->
 competitive antagonist at the benzodiazepine receptor

<!-- PAGE=? -->
o its antagonism is reversible and surmountable

<!-- PAGE=? -->
 cleared relatively rapidly with potential for resedation

<!-- PAGE=? -->
o less likely to occur when flumazenil is used to reverse midazolam

<!-- PAGE=? -->
 rapidly cleared compared to lorazepam or diazepam

<!-- PAGE=? -->
 may precipitate withdrawal symptoms in physically dependent patients

<!-- PAGE=? -->
 flumazenil produces rapid and dependable reversal of

<!-- PAGE=? -->
o unconsciousness

<!-- PAGE=? -->
o respiratory depression

<!-- PAGE=? -->
o +/- sedation

<!-- PAGE=? -->
o Amnesia

<!-- PAGE=? -->
o psychomotor dysfunction

<!-- PAGE=? -->
 Flumazenil has successfully reversed the effects of midazolam, diazepam, lorazepam, and flunitrazepam

<!-- PAGE=? -->
 NO significant effect on cardiovascular variables in patients with CAD

<!-- PAGE=? -->
 devoid of the respiratory and cardiovascular depressant effects of benzodiazepine receptor agonists

<!-- PAGE=? -->
G

<!-- PAGE=? -->
Gabapentin

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o postherpetic neuralgia

<!-- PAGE=? -->
o diabetic neuropathy

<!-- PAGE=? -->
o multiple sclerosis

<!-- PAGE=? -->
o neuropathic pain

<!-- PAGE=? -->
 including cancer-related

<!-- PAGE=? -->
o CRPS

<!-- PAGE=? -->
 Therapeutic response includes reduced

<!-- PAGE=? -->
o paroxysmal burning

<!-- PAGE=? -->
o lancinating pain

<!-- PAGE=? -->
o allodynia to cold and light touch

<!-- PAGE=? -->
 Side effects include

<!-- PAGE=? -->
o Dizziness - 24%

<!-- PAGE=? -->
o Sedation - 23-27%

<!-- PAGE=? -->
o Confusion - 8%

<!-- PAGE=? -->
o Ataxia - 7%

<!-- PAGE=? -->
o Vertigo

<!-- PAGE=? -->
o GI upset

<!-- PAGE=? -->
 Mechanism of Action

<!-- PAGE=? -->
o Remains unclear

<!-- PAGE=? -->
o Likely acts centrally

<!-- PAGE=? -->
o structural analog of GABA

<!-- PAGE=? -->
 may enhance the actions of GABA but does NOT interact with GABA receptors

<!-- PAGE=? -->
 may interact with the GABAB receptor

<!-- PAGE=? -->
o binds to specific receptors in the brain

<!-- PAGE=? -->
o inhibits voltage-gated N-type Ca channels

<!-- PAGE=? -->
o anti-inflammatory effects

<!-- PAGE=? -->
 decreases central sensitization

<!-- PAGE=? -->
 acts within the spinal cord or brain to reduce sensitization of dorsal horn neurons

<!-- PAGE=? -->
 appears to reduce abnormal hypersensitivity induced by inflammatory responses or nerve injury

<!-- PAGE=? -->
 does not affect nociceptive thresholds

<!-- PAGE=? -->
Gas Analysis

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Infrared Absorption Spectrophotometry can detect

<!-- PAGE=? -->
o CO2

<!-- PAGE=? -->
o N2O

<!-- PAGE=? -->
o Volatiless

<!-- PAGE=? -->
 Designed to measure the unique energy absorbed by each gas when placed in the path of an infrared beam

<!-- PAGE=? -->
 O2 is measured by

<!-- PAGE=? -->
o Polarographic cells

<!-- PAGE=? -->
 electrochemical system

<!-- PAGE=? -->
o Galvanic cells

<!-- PAGE=? -->
 measure current produced when O2 diffuses across a membrane

<!-- PAGE=? -->
o Paramagnetic cells

<!-- PAGE=? -->
 detect changes in pressure when O2 enters magnetic field

<!-- PAGE=? -->
Gastric Emptying

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
SOME FACTORS INFLUENCING GASTRIC EMPTYING RATE

<!-- PAGE=? -->
Gate Control Theory

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 theory proposes that neural mechanisms in the dorsal horns of the spinal cord act as a gate that can increase or decrease the flow of nerve impulses from peripheral fibers to the spinal cord cells that project to the brain.

<!-- PAGE=? -->
 Somatic input is therefore subjected to the modulating influence of the gate before it evokes pain perception and response.

<!-- PAGE=? -->
 large-fiber inputs tend to close the gate whereas small-fiber inputs generally open it, and that the gate is also profoundly influenced by descending influences from the brain.

<!-- PAGE=? -->
 Pain occurs when the number of nerve impulses that arrives at these areas exceeds a critical level.

<!-- PAGE=? -->
CONIROL

<!-- PAGE=? -->
DESCENDING

<!-- PAGE=? -->
CONIROL

<!-- PAGE=? -->
SG

<!-- PAGE=? -->
SYSTEM

<!-- PAGE=? -->
GAIE

<!-- PAGE=? -->
CONIROL

<!-- PAGE=? -->
SYSIEM

<!-- PAGE=? -->
excitatory (white circle) and inhibitory (black circle) links from the substantia gelatinosa (SG) to the transmission (T) cells, as well as descending inhibitory control from brain-stem systems. The round knob at the end of the inhibitory link implies that its action may be presynaptic, postsynaptic, or both. All connections are excitatory, except the inhibitory link from SG to T cell.

<!-- PAGE=? -->
 These six points of the gate control theory emphasize that sensory input is subject to modulation by afferent, intrinsic (interneuronal), and descending (bulbospinal) activity

<!-- PAGE=? -->
 Modulation can be either excitatory or inhibitory .

<!-- PAGE=? -->
 All primary afferents, large and small, were activated by noxious stimulation of the skin.

<!-- PAGE=? -->
 Both large and small fibers activate the nociceptive neurons deeper in the dorsal horn, which they named transmission neurons.

<!-- PAGE=? -->
 Large fibers activated, but small fibers inhibited, the neurons of the substantia gelatinosa.

<!-- PAGE=? -->
 Substantia gelatinosa neurons, when active, inhibited the input onto transmission neurons from both large and small primary afferents by a presynaptic mechanism (-close the gate‖).

<!-- PAGE=? -->
 Higher brain centers could also activate this inhibitory system to close the gate.

<!-- PAGE=? -->
 Pain perception, thus, was influenced by the net effect of large primary afferents, small primary afferents, and higher brain function, via their pattern of activity on substantia gelatinosa neurons.

<!-- PAGE=? -->
Glasgow Coma Scale (GCS)

<!-- PAGE=? -->
 Eye-opening (4)

<!-- PAGE=? -->
o Spontaneous, already open and blinking - 4

<!-- PAGE=? -->
o To speech - 3

<!-- PAGE=? -->
o To pain - 2

<!-- PAGE=? -->
o None - 1

<!-- PAGE=? -->
 Verbal response(5)

<!-- PAGE=? -->
o Oriented - 5

<!-- PAGE=? -->
o Answers but confused - 4

<!-- PAGE=? -->
o Inappropriate but recognizable words - 3

<!-- PAGE=? -->
o Incomprehensible sounds - 2

<!-- PAGE=? -->
o None - 1

<!-- PAGE=? -->
 Best motor response (6)

<!-- PAGE=? -->
o Obeys verbal commands - 6

<!-- PAGE=? -->
o Localizes painful stimulus - 5

<!-- PAGE=? -->
o Withdraws from painful stimulus - 4

<!-- PAGE=? -->
o Decorticate posturing (upper extremity flexion) - 3

<!-- PAGE=? -->
o Decerebrate posturing (upper extremity extension) - 2

<!-- PAGE=? -->
o No movement - 1

<!-- PAGE=? -->
 GCS 8 = deep coma, severe head trauma, poor outcome

<!-- PAGE=? -->
 GCS 9-12 = concious patient with moderate injury

<!-- PAGE=? -->
 GCS >12 = mild injury.

<!-- PAGE=? -->
 LEVEL 1. AVPU SYSTEM A = Alert V = Responds to verbal stimuli P = Responds to painful stimuli U = Unresponsive < LEVEL 2.

<!-- PAGE=? -->
Glucagon

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o low CO syndrome following CPB

<!-- PAGE=? -->
o low CO syndrome with MI

<!-- PAGE=? -->
o chronic CHF

<!-- PAGE=? -->
o excessive beta-blockade

<!-- PAGE=? -->
 Actions

<!-- PAGE=? -->
o Inhibits gastric motility

<!-- PAGE=? -->
o Enhanced urinary excretion of inorganic electrolytes

<!-- PAGE=? -->
o Increased insulin secretion,

<!-- PAGE=? -->
o Hepatic glycogenolysis & gluconeogenesis,

<!-- PAGE=? -->
o Anorexia

<!-- PAGE=? -->
o Inotropic & chronotropic cardiac effects

<!-- PAGE=? -->
 Action not blocked by B-blockade or catecholamine depeletion

<!-- PAGE=? -->
 Rarely causes dysrhythmias

<!-- PAGE=? -->
 Enhances AV nodal conduction

<!-- PAGE=? -->
o Relaxation of smooth muscle

<!-- PAGE=? -->
 Dose 1 - 5 mg

<!-- PAGE=? -->
 Duration ~ 30 min

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o N&V

<!-- PAGE=? -->
o Hypokalemia

<!-- PAGE=? -->
o Hypoglycemia & hyperglycemia

<!-- PAGE=? -->
Guidelines to the Practice of Anesthesia - 2008

<!-- PAGE=? -->
Healthcare Facility must ensure

<!-- PAGE=? -->
 Equipment, supplies and assistance necessary for the safe performance of invasive procedures are available

<!-- PAGE=? -->
 Diagnostic equipment such as nerve stimulators, ultrasound, fluoroscopy, and X-ray should be available

<!-- PAGE=? -->
 Resuscitator, a defibrillator with synchronized electrocardiograph and drugs and equipment to manage emergencies

<!-- PAGE=? -->
 Specialized pediatric equipment as required

<!-- PAGE=? -->
 Separate area for newborn assessment and resuscitation, including designated oxygen, suction apparatus, electrical outlets and source of radiant heat, and equipment for neonatal airway management and resuscitation

<!-- PAGE=? -->
 that all anesthetic and ancillary equipment undergoes regular inspection and maintenance by qualified personnel

<!-- PAGE=? -->
Anesthetic Machine

<!-- PAGE=? -->
 equipped with

<!-- PAGE=? -->
O2 analyzer

<!-- PAGE=? -->
keyed vaporizers

<!-- PAGE=? -->
vent with low-pressure alarm

<!-- PAGE=? -->
dedicated exhaust scavenger

<!-- PAGE=? -->
tracheal suction

<!-- PAGE=? -->
Waste anesthetic gases

<!-- PAGE=? -->
 OR ventilation at the rate of 20 changes/hour

<!-- PAGE=? -->
 Recirculation of air shall not be permitted during the hours when operations may be in progress and is not recommended at any other time

<!-- PAGE=? -->
 A scavenger shall be provided to capture anesthetic gases

<!-- PAGE=? -->
 A maintenance program to detect and repair leakage

<!-- PAGE=? -->
 Conduct regular monitoring of exposure to waste anesthetic gases

<!-- PAGE=? -->
N2O monitoring is a suitable representation for the assessment of adequacy of scavenging

<!-- PAGE=? -->
The Pre-anesthetic Period

<!-- PAGE=? -->
Primary goal of pre-anesthetic assessment is to obtain the information required to plan anesthetic management

<!-- PAGE=? -->
 medical and surgical history

<!-- PAGE=? -->
AMPLE, ASA class, Fhx of anesthetic complications

<!-- PAGE=? -->
 physical examination

<!-- PAGE=? -->
 laboratory investigations

<!-- PAGE=? -->
ordered only when indicated by the patient's medical status, drug therapy or the nature of the proposed procedure

<!-- PAGE=? -->
 documented by a physician who is knowledgeable about anesthetic management for the proposed procedure

<!-- PAGE=? -->
Before elective procedures, the minimum duration of fasting should be

<!-- PAGE=? -->
 8 hours after a meal that includes meat, fried or fatty foods

<!-- PAGE=? -->
 6 hours after a light meal (such as toast and a clear fluid), or after ingestion of infant formula or nonhuman milk

<!-- PAGE=? -->
 4 hours after ingestion of breast milk

<!-- PAGE=? -->
 2 hours after clear fluids

<!-- PAGE=? -->
The Anesthetic Period

<!-- PAGE=? -->
Before beginning the anesthesiologist must ensure that

<!-- PAGE=? -->
An explanation of the planned anesthetic procedure has been provided

<!-- PAGE=? -->
An adequate review of the patient's condition has been performed

<!-- PAGE=? -->
All equipment that is expected to be required is available and in working order

<!-- PAGE=? -->
A reserve source of oxygen under pressure is available

<!-- PAGE=? -->
Suggested indications for specific tests

<!-- PAGE=? -->
Tes

<!-- PAGE=? -->
Indicnions

<!-- PAGE=? -->
rnor

<!-- PAGE=? -->
Intematlonal

<!-- PAGE=? -->
Ble-ding diachesis

<!-- PAGE=? -->
thonbo-

<!-- PAGE=? -->
Diaberes

<!-- PAGE=? -->
Digorin

<!-- PAGE=? -->
diwretic thrapy

<!-- PAGE=? -->
cher

<!-- PAGE=? -->
Prgnancy

<!-- PAGE=? -->
El-coo-

<!-- PAGE=? -->
{mavirlud:

<!-- PAGE=? -->
myelo

<!-- PAGE=? -->
Partia]

<!-- PAGE=? -->
drug

<!-- PAGE=? -->
All drugs and agents that are expected to be required arecorrectly identified

<!-- PAGE=? -->
Until a specific connection system is devised for neuraxial use, both sides of all Luer connections are labeled

<!-- PAGE=? -->
The manufacturers' recommendations concerning the use, handling and disposal of anesthetic equipment and supplies have been considered

<!-- PAGE=? -->
The anesthesiologist or an anesthesia assistant supervised by the anesthesiologist shall remain with the patient at all times throughout the conduct of all general, major regional and monitored intravenous anesthetics until the patient has been transferred to the care of personnel in the PACU or ICU

<!-- PAGE=? -->
 When the attending anesthesiologist delegates care to a resident in anesthesia or an anesthesia assistant, the attending anesthesiologist remains responsible, and immediately available for the anesthetic management of the patient

<!-- PAGE=? -->
 Before delegating care of the patient to an anesthesia assistant, the anesthesiologist must ensure that the anesthesia assistant is familiar with the operative procedure, the operating room environment and equipment, and that the patient's condition is stable

<!-- PAGE=? -->
 Only under the most exceptional circumstances, for example to provide life-saving emergency care to another patient, may an anesthesiologist briefly delegate routine care of a stable patient to a competent person who is not an anesthesia assistant

<!-- PAGE=? -->
 Simultaneous administration of anesthesia by one anesthesiologist on more than one patient is unacceptable (local only is OK)

<!-- PAGE=? -->
it is acceptable to supervise more than one patient receiving regional analgesia for labour

<!-- PAGE=? -->
 When an anesthesiologist is providing anesthetic care for an obstetric delivery, a second appropriately trained person should be available to provide neonatal resuscitation

<!-- PAGE=? -->
Records

<!-- PAGE=? -->
All monitored physiologic variables should be charted at intervals appropriate to the clinical circumstances

<!-- PAGE=? -->
 Heart rate and blood pressure should be recorded at least every 5 min

<!-- PAGE=? -->
 Oxygen saturation should be continuously monitored and recorded at frequent intervals

<!-- PAGE=? -->
 if the trachea is intubated, end-tidal carbon dioxide concentration should be monitored continuously

<!-- PAGE=? -->


<!-- PAGE=? -->
Reasons for deviation from these charting guidelines should be documented in the anesthetic record

<!-- PAGE=? -->
 Monitors, equipment and techniques, as well as time, dose and route of all drugs and fluids should be recorded

<!-- PAGE=? -->
 Initial LOC, HR, BP, SaO2, and RR in PACU should be documented

<!-- PAGE=? -->
Patient Monitoring

<!-- PAGE=? -->
The only indispensable monitor is the presence, at all times, of a physician or an anesthesia assistant, under the immediate supervision of an anesthesiologist, with appropriate training and experience

<!-- PAGE=? -->
 Mechanical and electronic monitors are, at best, aids to vigilance

<!-- PAGE=? -->
 A pre-anesthetic checklist (Appendix 3 or equivalent) shall be completed prior to initiation of anesthesia

<!-- PAGE=? -->
Required Monitors - must be in continuous use throughout the administration of all anesthetics

<!-- PAGE=? -->
 Pulse oximeter

<!-- PAGE=? -->
 Apparatus to measure blood pressure

<!-- PAGE=? -->
 Electrocardiography

<!-- PAGE=? -->
 Capnography (with ETT or LMA)

<!-- PAGE=? -->
 Agent-specific anesthetic gas monitor (with inhalation anesthetic agents)

<!-- PAGE=? -->
Exclusively available for each patient - must be available at each anesthetic work station, applied without any delay

<!-- PAGE=? -->
 Apparatus to measure temperature

<!-- PAGE=? -->
 Peripheral nerve stimulator (with NMB)

<!-- PAGE=? -->
 Stethoscope (precordial, esophageal or paratracheal)

<!-- PAGE=? -->
 Appropriate lighting to visualize an exposed portion of the patient

<!-- PAGE=? -->
Immediately available - must be available so that they can be applied without undue delay

<!-- PAGE=? -->
 Spirometer for measurement of tidal volume

<!-- PAGE=? -->
Audible and visual alarms for oximetry and capnography should not be indefinitely disabled during the conduct of an anesthetic

<!-- PAGE=? -->
 The variable pitch pulse tone and the low-threshold alarm of the pulse oximeter and the capnograph apnea alarm must give an audible and visual alarms

<!-- PAGE=? -->
The Post-anesthetic Period

<!-- PAGE=? -->
Recovery Facility

<!-- PAGE=? -->
 The department of anesthesia should have overall medical administrative responsibility for the PACU

<!-- PAGE=? -->
The anesthesiologist should accompany the patient to the PACU, communicate necessary information

<!-- PAGE=? -->
 and write appropriate orders

<!-- PAGE=? -->
Care should not be delegated to the PACU nurse until the anesthesiologist is assured that the patient may be safely observed and cared for by the nursing staff

<!-- PAGE=? -->
The anesthesiologist or designated alternate is responsible for providing anesthetic-related care in the PACU

<!-- PAGE=? -->
Discharge from the PACU is the responsibility of the anesthesiologist

<!-- PAGE=? -->
 Emergency equipment for resuscitation and life support must be available in the PACU

<!-- PAGE=? -->
 The use of pulse oximetry in the initial phase of recovery is required

<!-- PAGE=? -->
 An accurate record of the immediate recovery period shall be maintained

<!-- PAGE=? -->
Discharge of Patients after Day Surgery

<!-- PAGE=? -->
Specific written instructions should include

<!-- PAGE=? -->
 management of

<!-- PAGE=? -->
pain

<!-- PAGE=? -->
postoperative complications

<!-- PAGE=? -->
routine and emergency follow-up

<!-- PAGE=? -->
 the additive effects of alcohol and other sedative drugs

<!-- PAGE=? -->
 the danger of driving or the operation of other hazardous machinery in the postoperative period (24 hrs)

<!-- PAGE=? -->
 necessity for attention by a competent adult for the postoperative period (24 hrs)

<!-- PAGE=? -->
Guidelines for Obstetric Regional Anesthesia for Labour

<!-- PAGE=? -->
 Hospitals should have appropriate monitoring protocols in place

<!-- PAGE=? -->
outline the types of monitoring required and the frequency of monitoring

<!-- PAGE=? -->
they should clearly state how to manage common problems and emergencies and indicate who to contact if assistance is required

<!-- PAGE=? -->
Initiation of Regional Anesthesia during Labour

<!-- PAGE=? -->
 Regional analgesia should only be initiated and maintained in locations in which appropriate resuscitation equipment and drugs are immediately available

<!-- PAGE=? -->
 Informed consent should be obtained and documented

<!-- PAGE=? -->
 IV access must be established before initiating regional analgesia

<!-- PAGE=? -->
The intravenous access should be maintained as long as regional analgesia is administered

<!-- PAGE=? -->
 The anesthesiologist should be immediately available until analgesia is established and the patient's vital signs are stable

<!-- PAGE=? -->
Maintenance of Regional Analgesia during Labour

<!-- PAGE=? -->
 Due to the very low incidence of significant complications with low-dose (diluted) epidural local anesthetics (continuous and PECA), it is not necessary for an anesthesiologist to remain present or immediately available during maintenance of continuous epidural infusion analgesia provided that

<!-- PAGE=? -->
There are appropriate protocols for management of patients receiving epidural analgesia

<!-- PAGE=? -->
The anesthesiologist can be contacted for the purpose of obtaining advice and direction

<!-- PAGE=? -->
 when a bolus dose of local anesthetic is injected through the epidural catheter (except PCEA), an anesthesiologist must be -available to intervene appropriately‖

<!-- PAGE=? -->
Oral Intake during Labour

<!-- PAGE=? -->
 parturients should not eat solid foods once they are in established labour

<!-- PAGE=? -->
clear liquids are are permitted

<!-- PAGE=? -->
Guidelines for Acute Pain Management using Neuraxial Analgesia

<!-- PAGE=? -->
When neuraxial analgesia is managed by anesthesiologists, the incidence of side effects is no higher than when alternative techniques of pain management are used

<!-- PAGE=? -->
 The department of anesthesia should establish an acute pain service that is responsible for

<!-- PAGE=? -->
Developing policies and procedures for neuraxial analgesia

<!-- PAGE=? -->
Liaison with the surgical departments

<!-- PAGE=? -->
Education and certification of nurses

<!-- PAGE=? -->
The risk of respiratory depression

<!-- PAGE=? -->
Assessment and management of respiratory depression

<!-- PAGE=? -->
Assessment of motor and sensory blockade

<!-- PAGE=? -->
Assessment and management of hypotension in patients receiving neuraxial analgesia

<!-- PAGE=? -->
Signs and symptoms of the rare, but catastrophic, complications of epidural hematoma or abscess

<!-- PAGE=? -->
Policies for Drug Administration

<!-- PAGE=? -->
 limit the number of standard solutions

<!-- PAGE=? -->
 Preprinted order sheets listing the standard solutions are strongly recommended

<!-- PAGE=? -->
 Before dispensing any solution that is not standard in the hospital, the anesthesiologist should verify the order with nursing and pharmacy personnel

<!-- PAGE=? -->
 PCEA pumps must be tamper-proof and should be distinct from the pumps used for intravenous fluid or drug administration

<!-- PAGE=? -->
tubing between neuraxial analgesia infusion pumps and catheters should not have any ports

<!-- PAGE=? -->
 When possible, the catheter should be no lower than the dermatome innervating the middle of the incision

<!-- PAGE=? -->
Patient Monitoring and Management of Adverse Events

<!-- PAGE=? -->
 Patients receiving neuraxial analgesia should be in a room equipped with oxygen and suction

<!-- PAGE=? -->
 Resuscitation drugs and equipment must be immediately available

<!-- PAGE=? -->
 IV access must be secured before initiation of neuraxial analgesia and maintained for the expected duration of drug effects after discontinuing neuraxial analgesia

<!-- PAGE=? -->
 Epidural catheter dressings should permit examination for catheter movement and daily inspection of the catheter entry site for any signs of infection

<!-- PAGE=? -->
 The parameters to be assessed, frequency of assessments, documentation and procedures for management of complications should be specified

<!-- PAGE=? -->
Monitoring should continue after discontinuation of neuraxial analgesia until its effects have dissipated

<!-- PAGE=? -->
 An anesthesiologist must be readily available to advise nursing personnel on such issues as dose titration and management of adverse effects

<!-- PAGE=? -->
other physicians should not order sedatives or analgesics for any patient receiving neuraxial analgesia

<!-- PAGE=? -->
Guidelines for the Practice of Anesthesia outside a Hospital

<!-- PAGE=? -->
Patient Selection

<!-- PAGE=? -->
 Usually, only ASA I and II patients should be considered for an anesthetic outside a hospital

<!-- PAGE=? -->
 ASA III patients may be accepted under certain circumstances

<!-- PAGE=? -->
Preoperative Considerations

<!-- PAGE=? -->
 recent, recorded history, physical examination and appropriate laboratory investigations

<!-- PAGE=? -->
 The duration of fasting before anesthesia should conform to the previously stated guidelines

<!-- PAGE=? -->
 The patient should be given an information sheet with instructions for pre- and postanesthetic periods

<!-- PAGE=? -->
Conduct of Anesthesia

<!-- PAGE=? -->
 The anesthetic and recovery facilities shall conform to hospital standards published by the CSA as defined in other sections

<!-- PAGE=? -->
 The standards of care and monitoring shall be the same in all anesthetizing locations.

<!-- PAGE=? -->
Appendix 3: Pre-anesthetic Checklist

<!-- PAGE=? -->
Gas pipelines

<!-- PAGE=? -->
E Scavenging system

<!-- PAGE=? -->
Secure  connections  between   terminal units   (outlets) and anesthetic machine

<!-- PAGE=? -->
0 Correctly connected to patient circuit and functioning

<!-- PAGE=? -->
Routine equipment

<!-- PAGE=? -->
Anesthetic machine

<!-- PAGE=? -->
Airway Management:

<!-- PAGE=? -->
0Turn on machine master switch and all other necessary electrical equipment

<!-- PAGE=? -->
7Functioning laryngoscope (back-up available)

<!-- PAGE=? -->
0Line oxygen (49-60 psi or 275-415 KPa)

<!-- PAGE=? -->
of cu#

<!-- PAGE=? -->
or 275-415 KPa) Fsi

<!-- PAGE=? -->
Appropriate oropharyngeal airways

<!-- PAGE=? -->
DAdequate reserve cylinder oxygen pressure

<!-- PAGE=? -->
Stvlet

<!-- PAGE=? -->
DAdequate reserve cylinder nitrous oxide content

<!-- PAGE=? -->
Magill forceps

<!-- PAGE=? -->
Intravenous supplies

<!-- PAGE=? -->
0Flow meter function of oxygen and nitrous oxide over the working range

<!-- PAGE=? -->
Blood pressure cuff of appropriate size

<!-- PAGE=? -->
Stethoscope

<!-- PAGE=? -->
OVaporizer filled

<!-- PAGE=? -->
DECG monitor

<!-- PAGE=? -->
porcs pin-indexed and closed Filling

<!-- PAGE=? -->
0 Pulse oximeter

<!-- PAGE=? -->
Capnograph

<!-- PAGE=? -->
0Functioning oxygen bspass (flush)

<!-- PAGE=? -->
Temperature monitor

<!-- PAGE=? -->
Functioning oxygen fail-safe device

<!-- PAGE=? -->
0Functioning low- and high-pressure alarm

<!-- PAGE=? -->
on functioning mixer (where avilble)

<!-- PAGE=? -->
DAttempt to create hypoxic OyN:O mixture and verif; correct changes in flow andor alarm

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
Adequate supply of frequently  used and intravenous solutions drugs

<!-- PAGE=? -->
0 Functioning common fresh gas outlet

<!-- PAGE=? -->
0Ventilator tunction veritied

<!-- PAGE=? -->
0Appropriate doses of in labeled ssringes drugs

<!-- PAGE=? -->
Backup vencilation equipment available and functioning

<!-- PAGE=? -->
If an anesthesiologist uses  the same machine in successive cases deparrmental policy may permic performing an abbreviated checklist

<!-- PAGE=? -->
Location of special equipment in each anesthetising location

<!-- PAGE=? -->
0Detibrillacor

<!-- PAGE=? -->
0 Emergency drugs

<!-- PAGE=? -->
Breathing circuit

<!-- PAGE=? -->
0Difticult intubation kit

<!-- PAGE=? -->
0 assembly ofcircuit to be used Correct

<!-- PAGE=? -->
0Patient circuit connected to common fresh gas outlet

<!-- PAGE=? -->
Oxygen flow meter tumned on

<!-- PAGE=? -->
0Pressurize Check for   leaks, and   integrity of  circuit (eg,Pethick test for co-axal)

<!-- PAGE=? -->
0Functioning high-pressure relief valve

<!-- PAGE=? -->
0Unidirectional valves and soda lime

<!-- PAGE=? -->
Functioning adjustable pressure Telief valve

<!-- PAGE=? -->
Vacuum system

<!-- PAGE=? -->
0 Suction adequate

<!-- PAGE=? -->
H

<!-- PAGE=? -->
HAV

<!-- PAGE=? -->
 Incubation time is 7-10 days (or 3-4 weeks)

<!-- PAGE=? -->
 first viral marker is Hep A Ag in stool

<!-- PAGE=? -->
o Antibody to HAV is next to appear

<!-- PAGE=? -->
 Duration of elevated AST and ALT is 1-3wks, may see cholestasis (rare with other viral hepatitis)

<!-- PAGE=? -->
 Rarely transmitted by transfusion due to short viremic phase and lack of carrier state.  Usually fecal-oral route of transmission.

<!-- PAGE=? -->
 Self-limited disease, no chronic liver disease.

<!-- PAGE=? -->
 Anti-HVA IgM = test for recent infection (short-term immunity)

<!-- PAGE=? -->
 Anti-HVA IgG = test for long immunity

<!-- PAGE=? -->
HBV

<!-- PAGE=? -->
 Acute hepatitis B infection resolves without significant hepatic damage in about 90% of cases

<!-- PAGE=? -->
o Less than 1% develop fulminant hepatitis

<!-- PAGE=? -->
o 10% become chronic carriers of HBV

<!-- PAGE=? -->
 serologic evidence demonstrated for more than 6 months

<!-- PAGE=? -->
 within 2 yrs half the chronic carriers resolve their infection without sig hepatic impairment

<!-- PAGE=? -->
 Hepatitis B surface antigen (HBsAg) is detectable in the serum within 3-4 weeks after infection (7-14days)

<!-- PAGE=? -->
o patient is asymptomatic but is capable of infecting others

<!-- PAGE=? -->
o Presence of HbsAg indicates active replication

<!-- PAGE=? -->
 Symptoms of hepatitis and jaundice occur within 8-12 weeks of infection

<!-- PAGE=? -->
o LFTs are elevated

<!-- PAGE=? -->
 HBsAg disappears from the serum with resolution of acute hepatitis

<!-- PAGE=? -->
o antibody to the surface antigen (anti-HBs) appears

<!-- PAGE=? -->
o Anti-HBs confers lasting immunity against subsequent HBV infection s

<!-- PAGE=? -->
o During the -window‖ period in which HBsAg has declined to undetectable levels and anti-HBs is not measurable, antibody to the core antigen (anti-HBc) is detectable

<!-- PAGE=? -->
 after many years one of these antibodies may no longer be detectable in the serum .

<!-- PAGE=? -->
 Chronic HBV carriers are likely to have HBsAg and anti-HBc present in serum samples

<!-- PAGE=? -->
 Percutaneous exposure may result in infection in up to 30% of occurrences

<!-- PAGE=? -->
o postexposure prophylaxis with HBV hyperimmune globulin and initiation of HBV vaccine series is recommended

<!-- PAGE=? -->
o HBV hyperimmune globulin is prepared from human plasma that contains a high anti-HBs titer and provides temporary, passive immunity

<!-- PAGE=? -->
 may be infectious for at least  week when there is contact with dried blood on environmental surfaces

<!-- PAGE=? -->
 vaccine confers immunity in 90% of recipients

<!-- PAGE=? -->
o contain HB sAg

<!-- PAGE=? -->
o may need booster 7years

<!-- PAGE=? -->
o anti-Hbs begin to decline and in 5 yrs 20-30% of people lack protective Ab levles

<!-- PAGE=? -->
HCV

<!-- PAGE=? -->
Barash, Kelly

<!-- PAGE=? -->
 small enveloped, single-stranded , positive sense RNA virus in the family Flaviviridae

<!-- PAGE=? -->
 Most acute and chronic HCV infections are clinically asymptomatic

<!-- PAGE=? -->
o Viral load does NOT indicate severity of disease

<!-- PAGE=? -->
 Up to 60% of HCV-infected patients will have chronic hepatitis with many progressing to cirrhosis

<!-- PAGE=? -->
o commonest cause of chronic liver disease in U.S

<!-- PAGE=? -->
 no effective vaccine or postexposure prophylaxis

<!-- PAGE=? -->
 Hep C is transmitted through percutaneous and permucosal routes

<!-- PAGE=? -->
o Risk of transmission = 3%

<!-- PAGE=? -->
o Postexposure prophylaxis with immunoglobulin is not effective in blocking HCV infection and is not recommended

<!-- PAGE=? -->
 initial test for anti-HCV (IgG) but significant false positives so then confirmed with second generation immunoblot test then look for viral RNA

<!-- PAGE=? -->
o the presence of Anti-HCV does not correlate with resolution of the infection or progression of the hepatitis

<!-- PAGE=? -->
o Immunity against HCV infection is not conferred by anti-HCV

<!-- PAGE=? -->
o HCV rna can be still be detected in most pts after resolution of hep C

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Interferon-alph monotherapy and the combination of interferon-alph and ribavirin are two regimens approved for the treatment of HCV

<!-- PAGE=? -->
o most patients relapse on discontinuation of the therapy.

<!-- PAGE=? -->
 HCC associated with any chronic liver disease , including HBC, HVC, and EtOH cirrhosis

<!-- PAGE=? -->
Hepatorenal syndrome

<!-- PAGE=? -->
 functional prerenal failure that occurs in up to 10% pts with advanced cirrhosis and ascites

<!-- PAGE=? -->
 the outcome is generally fatal

<!-- PAGE=? -->
 Typical patients are

<!-- PAGE=? -->
o chronic cirrhotic with portal hypertension

<!-- PAGE=? -->
o jaundiced

<!-- PAGE=? -->
o moribund

<!-- PAGE=? -->
o moderate to severe ascites

<!-- PAGE=? -->
o hypoalbuminemia

<!-- PAGE=? -->
o hypoprothrombinemia

<!-- PAGE=? -->
 2 types of HRS based on intensity and presentation

<!-- PAGE=? -->
o type 1 HRS

<!-- PAGE=? -->
 progressive oliguria and rapid rise in serum creatinine

<!-- PAGE=? -->
 onset is precipitated in

<!-- PAGE=? -->
 upper GI bleed (5% of patients)

<!-- PAGE=? -->
 spontaneous bacterial peritonitis (30%)

<!-- PAGE=? -->
 ascites undergoing paracentesis (10%)

<!-- PAGE=? -->
 severe acute EtOH hepatitis (25%)

<!-- PAGE=? -->
 Poor prognosis - median survival of <1 month w/o intervention

<!-- PAGE=? -->
o Type 2 HRS

<!-- PAGE=? -->
 assoc'd with refractory ascites

<!-- PAGE=? -->
 characterized by moderate and more stable impairment of renal function

<!-- PAGE=? -->
 Pathogenesis is unclear but HRS is characterized by

<!-- PAGE=? -->
o intense vasoconstriction of the renal circulation - likely 2' to dec. effective circulating volume and reflex activation of the RAS and SNS stimulation

<!-- PAGE=? -->
o low GFR

<!-- PAGE=? -->
o preserved renal tubular function

<!-- PAGE=? -->
o normal renal histology

<!-- PAGE=? -->
 a circulating toxin may be responsible for extreme renal vasoconstriction and acute renal failure

<!-- PAGE=? -->
o hemodialysis has not been reliable for eliminating suspected hepatic toxins

<!-- PAGE=? -->
 Treatment is directed at intravascular fluid volume replacement

<!-- PAGE=? -->
o saline and albumin may aggravate ascites

<!-- PAGE=? -->
o whole blood or packed RBCs may be a more appropriate form of volume replacement

<!-- PAGE=? -->
o peritoneal to venous shunt for the treatment of ascites may also be associated with improved renal function

<!-- PAGE=? -->
 Reversible with liver transplant

<!-- PAGE=? -->
Hereditary Angioedema

<!-- PAGE=? -->
 autosomal dominant

<!-- PAGE=? -->
 disorder of the complement system

<!-- PAGE=? -->
o decreased activity of the C1 esterase inhibitor

<!-- PAGE=? -->
o initiation of complement activation is not regulated

<!-- PAGE=? -->
 release of vasoactive mediators with minimal stimulation

<!-- PAGE=? -->
 hypotension and increase vascular permeability

<!-- PAGE=? -->
 may occur spontaneously or as the result of trauma

<!-- PAGE=? -->
 emotional stress alone is responsible for 30-40%

<!-- PAGE=? -->
 different subtypes

<!-- PAGE=? -->
o most common having 30% normal levels of a functional C1 inhibitor

<!-- PAGE=? -->
o others have normal levels of non-functional C1

<!-- PAGE=? -->
 Attacks may present with painless edema

<!-- PAGE=? -->
o airway edema is the most serious

<!-- PAGE=? -->
o normally last 24-72 hour

<!-- PAGE=? -->
o treatment

<!-- PAGE=? -->
 C1 esterase inhibitor 25 units/kg

<!-- PAGE=? -->
 FFP

<!-- PAGE=? -->
 Steroids, antihistamines, catecholamines, antifibrinolytics don't work

<!-- PAGE=? -->
 Long term treatment

<!-- PAGE=? -->
o anabolic steroids (testosterone)- increase hepatic synthesis of C1 esterase inhibitor

<!-- PAGE=? -->
o antifibrinolytics - decreases plasmin activation

<!-- PAGE=? -->
 Preop optimization includes

<!-- PAGE=? -->
o 5-7 day course of anabolic steroid if mild

<!-- PAGE=? -->
o C1 esterase inhibitor concentrate

<!-- PAGE=? -->
o FFP

<!-- PAGE=? -->
 2-4 units of FFP 24 hours preop usually sufficient to prevent airway swelling in perioperative period

<!-- PAGE=? -->
Hyperosmolar Nonketotic coma (HONK)

<!-- PAGE=? -->
 usually precipitated by any acute illness

<!-- PAGE=? -->
o infection

<!-- PAGE=? -->
o myocardial infarction

<!-- PAGE=? -->
o stroke

<!-- PAGE=? -->
 A relative insulin deficiency leads to hyperglycemia and consequently inc. serum osmolarity

<!-- PAGE=? -->
 polyuria (an osmotic diuresis) leads to volume depletion and hemoconcentration with further increases in blood glucose level

<!-- PAGE=? -->
 Ketosis is absent because the presence of some insulin inhibits lipolysis

<!-- PAGE=? -->
o an anion gap metabolic acidosis may be present because of dehydration (lactic acidosis)

<!-- PAGE=? -->
 Diagnostic criteria for nonketotic hyperosmolar hyperglycemic coma

<!-- PAGE=? -->
o Hyperglycemia

<!-- PAGE=? -->
o Glucosuria

<!-- PAGE=? -->
o absence of ketosis

<!-- PAGE=? -->
o plasma osmolality greater than 330 mOsm/kg

<!-- PAGE=? -->
o dehydration

<!-- PAGE=? -->
o CNS dysfunction

<!-- PAGE=? -->
 Hypovolemia and hypertonicity are the immediate threats to life

<!-- PAGE=? -->
o Serum sodium may be high, normal, or low, depending on the state of hydration

<!-- PAGE=? -->
o Serum potassium may be normal/high (shift d/t insulin deficiency)

<!-- PAGE=? -->
 Total body potassium stores are low

<!-- PAGE=? -->
 Drugs that increase serum glucose, inhibit insulin, or cause dehydration can cause HHNC:

<!-- PAGE=? -->
o diuretics

<!-- PAGE=? -->
o B-blockers

<!-- PAGE=? -->
 Inhibit insulin

<!-- PAGE=? -->
o H2 blockers

<!-- PAGE=? -->
o Dialysis, TPN, and fluids that contain dextrose

<!-- PAGE=? -->
 Many factors in neurosurgical patients predispose to nonketotic hyperosmolar hyperglycemic coma

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
o prolonged mannitol therapy

<!-- PAGE=? -->
o hyperosmolar tube feedings

<!-- PAGE=? -->
o phenytoin

<!-- PAGE=? -->
o limited water replacement

<!-- PAGE=? -->
 Management with hydration, potassium repletion, and insulin infusion (0.1u/kg/hr)

<!-- PAGE=? -->
Hearing loss

<!-- PAGE=? -->
Spinal 40% , lasting 1-3d, >10dB

<!-- PAGE=? -->
Female 3:1 Prilocaine >BPV

<!-- PAGE=? -->
Heliox

<!-- PAGE=? -->
 most resistance in the lung is due to the large airways

<!-- PAGE=? -->
 Flow is primarily turbulent from the trachea to the start of the bronchioles, particularly when the flow rate is high

<!-- PAGE=? -->
 Turbulent flow occurs at high flow rates

<!-- PAGE=? -->
o gas density is a major determinant of trubulent flow

<!-- PAGE=? -->
 laminar flow occurs at lower flow rates

<!-- PAGE=? -->
o gas viscosity is the major determinant of laminar flow

<!-- PAGE=? -->
 The tendency for flow to be laminar or turbulent within a given region can be quantified by the Reynolds number (Re)

<!-- PAGE=? -->
o a dimensionless ratio of inertial (turbulent) to viscous (laminar) forces:

<!-- PAGE=? -->
velocity of fluid x density of fluid x diameter of pipe

<!-- PAGE=? -->
Reynolds number

<!-- PAGE=? -->
viscosity of fluid

<!-- PAGE=? -->
Re

<!-- PAGE=? -->
2000

<!-- PAGE=? -->
 Density/viscosity

<!-- PAGE=? -->
o laminar flow predominates when Re is <2000. When Re is >4000, flow is mainly turbulent

<!-- PAGE=? -->
 Turbulence may be created with

<!-- PAGE=? -->
High flow rates

<!-- PAGE=? -->
Changes in

<!-- PAGE=? -->
diameter

<!-- PAGE=? -->
angles

<!-- PAGE=? -->
Sharp

<!-- PAGE=? -->
Branches

<!-- PAGE=? -->
(iv)

<!-- PAGE=? -->
 the benefits of heliox in patients with high airway resistance are due to decreasing Re and facilitating laminar flow, resulting in improved ventilation and a decreased work of breathing.

<!-- PAGE=? -->
 Therapeutic use of heliox capitalizes on the physical effect of lowering gas density to improve air flow

<!-- PAGE=? -->
 The effects of heliox are typically seen within the first several minutes

<!-- PAGE=? -->
 a therapeutic trial may be reasonable in the following clinical situations

<!-- PAGE=? -->
o Mechanical upper airway obstruction

<!-- PAGE=? -->
o Postoperative stridor

<!-- PAGE=? -->
o Severe exacerbations of COPD, particularly in conjunction with noninvasive ventilation

<!-- PAGE=? -->
o Asthma complicated by impending respiratory failure and refractory to standard therapy

<!-- PAGE=? -->
Hemodynamics

<!-- PAGE=? -->
CVP = mean central venous pressure; BSA = body surface area; CO = cardiac output; PAP = mean pulmonary artery pressure; PWP = pulmonary wedge pressure; MAP = mean arterial blood pressure.

<!-- PAGE=? -->
Hemodyalisis

<!-- PAGE=? -->
         Complications:

<!-- PAGE=? -->
Hypoventilation (secondary to removal of CO2)

<!-- PAGE=? -->
Increased VO2

<!-- PAGE=? -->
Increased temperature

<!-- PAGE=? -->
Thrombocytopenia (uremic platelet dysfunction may improve).

<!-- PAGE=? -->
Thrombotic (patients are anti-coagulatied)

<!-- PAGE=? -->
Osmotic dysequilibrium (weakness, nausea, vomiting, and occasionally, convulsions and coma 2ary to cerebral edema )

<!-- PAGE=? -->
CV changes (HoTN, MI, arrhythmia)

<!-- PAGE=? -->
Anaphylaxis (ACEI & certain membranes)

<!-- PAGE=? -->
     Long term

<!-- PAGE=? -->
 Arthropathy (crystal deposition)

<!-- PAGE=? -->
 Dialysis dementia (long-term accumulation of aluminum)

<!-- PAGE=? -->
         Indications (5)

<!-- PAGE=? -->
     A:        acidosis

<!-- PAGE=? -->
     E:         electrolytes (K+)

<!-- PAGE=? -->
     I:          intoxication

<!-- PAGE=? -->
     O:        overload, volume

<!-- PAGE=? -->
     U:        uremic syndrome (pericarditis, encephalopathy

<!-- PAGE=? -->
Hepatic drug metabolism

<!-- PAGE=? -->
Heparin resistance

<!-- PAGE=? -->
 is primarily due to ATIII deficiency in pediatric patients

<!-- PAGE=? -->
 is multifactorial in adult cardiac surgery patients

<!-- PAGE=? -->
 the critical ACT value necessary in patients who demonstrate acquired heparin resistance is not yet determined

<!-- PAGE=? -->
 heparin resistance can also be a sign of heparin induced thrombocytopenia

<!-- PAGE=? -->
Table 18-1 disease states associated with heparin resistance:

<!-- PAGE=? -->
Sepsis is mentioned in the text but is not part of the table resistance to heparin is due to ATIII deficiency ATIII is decreased by:

<!-- PAGE=? -->
 genetics

<!-- PAGE=? -->
 pregnancy (note: disagrees with Kaplan)

<!-- PAGE=? -->
 cirrhosis/ liver dysfunction

<!-- PAGE=? -->
 DIC (Coexisting pg 495)

<!-- PAGE=? -->
Hetastarch

<!-- PAGE=? -->
 Volume expansion is equal to volume infused

<!-- PAGE=? -->
 Incidence of anaphylaxis or anaphylactoid reactions: (Miller)

<!-- PAGE=? -->
o Albumen 0.011

<!-- PAGE=? -->
o HES

<!-- PAGE=? -->
0.085

<!-- PAGE=? -->
o Pentaspan 0.002

<!-- PAGE=? -->
 decreases VIII:C levels by 50% with 1L with ↑PTT

<!-- PAGE=? -->
o also interferes with clot formation by direct movement into the fibrin clot of the hetastarch molecules

<!-- PAGE=? -->
 primarily eliminated by the kidneys

<!-- PAGE=? -->
 duration of volume expansion is ~ 24 hrs

<!-- PAGE=? -->
Herbal Remedies

<!-- PAGE=? -->
Table 15-2 -- Clinically important effects, perioperative concerns, and recommendations for perioperative discontinuation of nine commonly used herbal medicines

<!-- PAGE=? -->
Histamine

<!-- PAGE=? -->
 Table 12-5  Drugs capable of nonimmunologic histamine release:

<!-- PAGE=? -->
o Antibiotics (Vancomycin, pentamidine)

<!-- PAGE=? -->
o Basic compounds

<!-- PAGE=? -->
o Hyperosmotic agents

<!-- PAGE=? -->
o Muscle relaxants (d-tubocurarine, metocurine, atracurium, mivacurium, doxacurium)

<!-- PAGE=? -->
o Opioids (morphine, meperidine, codeine)

<!-- PAGE=? -->
o Thiobarbiturates

<!-- PAGE=? -->
 Non immumologic histamine release may involve mast cell activation (basophils aren't activated)

<!-- PAGE=? -->
 Fentanyl and sufentanil don't cause histamine release in human skin

<!-- PAGE=? -->
Barash 6th

<!-- PAGE=? -->
Barash chapter 18

<!-- PAGE=? -->
 With the exception of etomidate, all IV induction agents have been alleged to cause some histamine release

<!-- PAGE=? -->
 the incidence of severe anaphylactic reactions is extremely low with the currently available IV induction agents

<!-- PAGE=? -->
 profound hypotension attributed to nonimmunologically mediated histamine release has been reported with thiopental use

<!-- PAGE=? -->
 Although anaphylactic reactions to etomidate have been reported, it does not appear to release histamine and is considered to be the most -immunologically safe‖ IV anesthetic

<!-- PAGE=? -->
 Etomidate causes minimal cardiorespiratory depression even in the presence of cardiovascular and pulmonary disease.55  The drug does not induce histamine release and can be safely used in patients with reactive airway disease

<!-- PAGE=? -->
Miller chapter 26

<!-- PAGE=? -->
 propofol

<!-- PAGE=? -->
o Anaphylactoid reactions to the present formulation of propofol have been reported. In at least some patients, the immune response was entirely due to propofol and not to the lipid emulsion. A high percentage of the patients developing the anaphylactoid response to propofol had a previous history of allergic responses. In patients with multiple drug allergies, propofol should be used with caution.

<!-- PAGE=? -->
o Propofol alone in intralipid does not trigger histamine release.

<!-- PAGE=? -->
 Etomidate:

<!-- PAGE=? -->
o It (etomidate) does not induce histamine release either in healthy patients or in patients with reactive airway disease

<!-- PAGE=? -->
o The lipid formulation of etomidate also is associated with a much lower incidence of pain on injection, thrombophlebitis, and histamine release on injection

<!-- PAGE=? -->
HIT

<!-- PAGE=? -->
P&P, Hensley

<!-- PAGE=? -->
 Associated with IGg

<!-- PAGE=? -->
 Usually occurs 3-15 days after exposure

<!-- PAGE=? -->
o HIT I - 2-5 days

<!-- PAGE=? -->
o HIT II - >5 days

<!-- PAGE=? -->
 Associated with heparin resistance

<!-- PAGE=? -->
 Heparin should be immediately stopped

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Alternative anticoagulant

<!-- PAGE=? -->
Distinguishing Characteristics of the Tvo Types of

<!-- PAGE=? -->
Heparin-Induced Thrombocytopeniat

<!-- PAGE=? -->
Type

<!-- PAGE=? -->
Type 2

<!-- PAGE=? -->
Frequency

<!-- PAGE=? -->
10 to 20 percent

<!-- PAGE=? -->
to 3 percent

<!-- PAGE=? -->
Timing of onset

<!-- PAGE=? -->
to 4

<!-- PAGE=? -->
5 to 10

<!-- PAGE=? -->
Nadir platelet count

<!-- PAGE=? -->
Antibody mediated

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Thromboembolic sequelae

<!-- PAGE=? -->
None

<!-- PAGE=? -->
30 to 80 percent

<!-- PAGE=? -->
Hemorrhagic sequelae

<!-- PAGE=? -->
None

<!-- PAGE=? -->
Rarely

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Observe

<!-- PAGE=? -->
Cessation of heparin,

<!-- PAGE=? -->
alternative anticoagulation

<!-- PAGE=? -->
additional therapy

<!-- PAGE=? -->
Adapted from Brieger

<!-- PAGE=? -->
DB_

<!-- PAGE=? -->
Mak

<!-- PAGE=? -->
KH , Kohke-Marchant,K,et al. J Am Coll Cardiol

<!-- PAGE=? -->
1998

<!-- PAGE=? -->
days

<!-- PAGE=? -->
days

<!-- PAGE=? -->
HIV (CDC - 2001)

<!-- PAGE=? -->
Precautions apply to blood, all body fluids, secretions, and excretions except sweat

<!-- PAGE=? -->
TABLE5. Recommended HIV postexposure prophylaxis for mucous membrane exposures andnonintact skin* exposures

<!-- PAGE=? -->
HIv-Positive, Class concern, Obtain exper consulationbecause expert and follow-UP care tor all exposures

<!-- PAGE=? -->
ina

<!-- PAGE=? -->
The designation; 'consider PEP indicates that FEP is optional and should be based Dn an individualized decision betwveen the

<!-- PAGE=? -->
a few drcps}

<!-- PAGE=? -->
HIv-Positive, Class known high viral load. If because expert be available to provide imrediare evaluation drug

<!-- PAGE=? -->
solid reedle and suparficial irjury)

<!-- PAGE=? -->
The designation consider PEP exposed person and the treating clinician.

<!-- PAGE=? -->
severe More (e.9

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 rate of seroconversion in health care workers sustaining a percutaneous exposure ( needle stick injury ) to HIV-infected blood was 0.3%

<!-- PAGE=? -->
o after mucous membrane exposure is estimated to be 0.09%

<!-- PAGE=? -->
 risk factors for seroconversion include

<!-- PAGE=? -->
o deep injury

<!-- PAGE=? -->
o visible blood on the device producing the injury

<!-- PAGE=? -->
o source needle was placed in an artery or vein

<!-- PAGE=? -->
o Large gauge

<!-- PAGE=? -->
o Hollow bore

<!-- PAGE=? -->
o terminal illness (death from AIDS within 2 months) in the source patient

<!-- PAGE=? -->
 exposed worker and the source individual may be tested for serologic evidence of HIV (.3%), HCV (3%) and HBV (30%) infection

<!-- PAGE=? -->
 If the source patient is found to be HIV-positive , the employee should be retested periodically for HIV antibodies for a minimum of 6 months

<!-- PAGE=? -->
o During this period, the exposed employee should follow CDC recommendations for preventing transmission of HIV to family members and patients

<!-- PAGE=? -->
 universal precautions should be applied to

<!-- PAGE=? -->
o Blood

<!-- PAGE=? -->
o Semen

<!-- PAGE=? -->
o vaginal secretions

<!-- PAGE=? -->
o human tissues

<!-- PAGE=? -->
o Other body fluids

<!-- PAGE=? -->
 Cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic

<!-- PAGE=? -->
 Standard Precautions recommends use of gloves when a health care worker contacts mucous membranes and oral fluids

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Prophylaxis should begin as soon as possible

<!-- PAGE=? -->
o less effective if begun more than 24 to 36 hours after exposure

<!-- PAGE=? -->
o U.S. Public Health Service advises beginning prophylaxis up to 1 week after exposure

<!-- PAGE=? -->
 Four weeks of treatment is recommended if tolerated

<!-- PAGE=? -->
 follow-up should include counseling and HIV antibody testing at 6 and 12 weeks, as well as 6 months after exposure

<!-- PAGE=? -->
 Precautions apply to blood, all body fluids, secretions, and excretions

<!-- PAGE=? -->
o Sweat is the exception

<!-- PAGE=? -->
Hormones post surgery

<!-- PAGE=? -->
 Increase in catecholamines, cortisol, angiotensin II, ADH (catabolic hormones)

<!-- PAGE=? -->
 increase in ACTH, GH, and glucagon

<!-- PAGE=? -->
 decrease in testosterone and insulin (anabolic hormones)

<!-- PAGE=? -->
 Epinephrine, cortisol, and glucagon produce hyperglycemia by promoting insulin resistance and increases in gluconeogenesis. They induce protein catabolism and lipolysis to provide substrates for gluconeogenesis

<!-- PAGE=? -->
Hyperaldosteronism

<!-- PAGE=? -->
CoExD

<!-- PAGE=? -->
 Primary hyperaldosteronism is present when there is excess secretion of aldosterone from a functional tumor (aldosteronoma) independent of a physiologic stimulus

<!-- PAGE=? -->
o Conn's Syndrome

<!-- PAGE=? -->
 prevalence of primary aldosteronism in patients with essential hypertension appears to be less than 1%

<!-- PAGE=? -->
 Aldosteronomas occur more often in women

<!-- PAGE=? -->
 May be associated with

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o primary hyperparathyroidism

<!-- PAGE=? -->
o acromegaly

<!-- PAGE=? -->
 Secondary hyperaldosteronism is present when increased circulating serum concentrations of renin, as associated with renovascular hypertension, stimulate the release of aldosterone. Aldosteronism associated with Bartter syndrome is not accompanied by systemic hypertension. The

<!-- PAGE=? -->
Physiology

<!-- PAGE=? -->
 Aldosterone promotes renal excretion of potassium resulting in hypokalemic metabolic alkalosis

<!-- PAGE=? -->
 Increased urinary excretion of potassium (more than 30 mEq/day) in the presence of hypokalemia suggests primary aldosteronism

<!-- PAGE=? -->
o Hypokalemic nephropathy can result in polyuria and an inability to concentrate urine optimally

<!-- PAGE=? -->
Signs and Symptoms

<!-- PAGE=? -->
 nonspecific, and may be asymptomatic

<!-- PAGE=? -->
o systemic hypertension (headache)

<!-- PAGE=? -->
 aldosterone-induced sodium retention

<!-- PAGE=? -->
o hypokalemia

<!-- PAGE=? -->
 polyuria

<!-- PAGE=? -->
 nocturia

<!-- PAGE=? -->
 skeletal muscle cramps

<!-- PAGE=? -->
 skeletal muscle weakness

<!-- PAGE=? -->
o Hypomagnesemia and abnormal glucose tolerance may be present

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
 Spontaneous hypokalemia in patients with systemic hypertension is highly suggestive of aldosteronism

<!-- PAGE=? -->
 Plasma renin activity is suppressed in almost all patients with untreated primary aldosteronism and in many with essential hypertension

<!-- PAGE=? -->
o Plasma rennin activity is high in patients with secondary aldosteronism

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 supplemental potassium and administration of a competitive aldosterone antagonist, such as spironolactone

<!-- PAGE=? -->
 antihypertensive drugs

<!-- PAGE=? -->
o potassium-sparing diuretic such as triamterene may be useful to decrease drug induced potassium loss

<!-- PAGE=? -->
 Definitive treatment for an aldosterone-secreting tumor is surgical excision

<!-- PAGE=? -->
Management of Anesthesia

<!-- PAGE=? -->
 preoperative correction of hypokalemia and treatment of systemic hypertension

<!-- PAGE=? -->
o hypokalemia may modify responses to NdMB

<!-- PAGE=? -->
 orthostatic hypotension detected during the preoperative evaluation is a clue to the presence of unexpected hypovolemia

<!-- PAGE=? -->
 Acid base status and plasma electrolyte concentrations should be measured frequently

<!-- PAGE=? -->
 Supplementation with exogenous cortisol is probably unnecessary for surgical excision of a solitary adenoma in the adrenal cortex

<!-- PAGE=? -->
o Bilateral mobilization of the adrenal glands to excise multiple functional tumors, however, may introduce the need for exogenous administration of cortisol

<!-- PAGE=? -->
Hyperbaric Oxygen Therapy (HBO)

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Indications for hyperbaric oxygen therapy

<!-- PAGE=? -->
Decompression sickness Air embolism Carbon monoxide poisoning Clostridial gangrene Refractory osteomyelitis Radiation necrosis

<!-- PAGE=? -->
Profound anemia

<!-- PAGE=? -->
 elimination half-time of carboxyhemoglobin

<!-- PAGE=? -->
o 320 minutes with room air

<!-- PAGE=? -->
o 80 minutes with 100% oxygen

<!-- PAGE=? -->
o 23 minutes with 100% oxygen at 3 atm

<!-- PAGE=? -->
 Most hyperbaric oxygen treatments are performed at 2 to 3 atm

<!-- PAGE=? -->
 In treatment of decompression sickness and air embolism treatments are often initiated at 6 atm

<!-- PAGE=? -->
o mechanical reduction in bubble size by an increase in ambient pressure is crucial to the therapeutic effect

<!-- PAGE=? -->
o at 6 atm, a bubble is reduced to 20% of its original volume and 60% of its original diameter

<!-- PAGE=? -->
Complications of hyperbaric oxygen therapy

<!-- PAGE=? -->
Tympanic membrane rupture Nasal sinus trauma Pneumothorax Air embolism Oxygen toxicity

<!-- PAGE=? -->
 Central nervous system toxicity

<!-- PAGE=? -->
o Seizures

<!-- PAGE=? -->
 Pulmonary toxicity

<!-- PAGE=? -->
o cough

<!-- PAGE=? -->
o chest pain

<!-- PAGE=? -->
o reduced VC

<!-- PAGE=? -->
o ARDS

<!-- PAGE=? -->
o pulmonary fibrosis

<!-- PAGE=? -->
Eye toxicity

<!-- PAGE=? -->
Hypercarbia

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
TABLE 17-7 -- Cardiovascular responses to hypercapnia (PaCO2 = 60 to 83 mm Hg) during various types of anesthesia (1 MAC equivalent except for nitrous oxide) *

<!-- PAGE=? -->
+, <10% increase; ++, 10% to 25% increase; +++, >25% increase; 0, no change; -, <10% decrease; -- 10% to 25% decrease; ---, >25% decrease; MAC, minimum alveolar concentration for adequate anesthesia in 50% of subjects.

<!-- PAGE=? -->
 Hypercapnia appears to cause direct depression of both cardiac muscle and vascular smooth muscle

<!-- PAGE=? -->
 Reflex SNS stimulation over compensates for direct depressant effects

<!-- PAGE=? -->
o Enfluarne and halothane inhibit SNS stimulation

<!-- PAGE=? -->
Hyperperfusion Syndrome

<!-- PAGE=? -->
 thought to result from blood flow to the brain that is greatly in excess of its metabolic needs

<!-- PAGE=? -->
o usually following carotid endarterectomy

<!-- PAGE=? -->
 often does not occur until several days after surgery

<!-- PAGE=? -->
 patients present with severe ipsilateral headache

<!-- PAGE=? -->
o can progress to signs of increased cerebral excitability or frank seizures

<!-- PAGE=? -->
 symptomatic patients may be started on phenytoin for seizure prophylaxis

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
 Excessive heat production:

<!-- PAGE=? -->
o MH

<!-- PAGE=? -->
o Transfusion reaction

<!-- PAGE=? -->
o NMS

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o Delirium tremens

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o Salicylate intoxication

<!-- PAGE=? -->
o Cocaine & amphetamine

<!-- PAGE=? -->
o Status epilepticus

<!-- PAGE=? -->
o Exertional heat stroke

<!-- PAGE=? -->
 Decreased heat loss:

<!-- PAGE=? -->
o Autonomic dysfunction (impaired sweating)

<!-- PAGE=? -->
o Anticholinergics

<!-- PAGE=? -->
o Dehydration

<!-- PAGE=? -->
o Occlusive dressings

<!-- PAGE=? -->
 Hypothalamic dysfunction:

<!-- PAGE=? -->
o CHI

<!-- PAGE=? -->
o CVA

<!-- PAGE=? -->
o Encephalitis

<!-- PAGE=? -->
o Hypoxic encephalopathy

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Humans actively regulate body temperature once it falls below the thermoregulatory threshold temperature,

<!-- PAGE=? -->
o thermoregulatory threshold temperature is decreased by approximately 2.5°C during general anesthesia

<!-- PAGE=? -->
 Rate of heat loss is approximately the same during general or regional anesthetics, but patients rewarm more slowly after regional anesthetics because residual vasodilation and paralysis impede heat generation and retention

<!-- PAGE=? -->
 CV changes:

<!-- PAGE=? -->
o Inc SNS

<!-- PAGE=? -->
 Inc. SVR

<!-- PAGE=? -->
 Inc. PVR

<!-- PAGE=? -->
 Dec. venous capacitance

<!-- PAGE=? -->
o Reduced CO (inc. with shivering)

<!-- PAGE=? -->
o interferes with cardiac rhythm generation and impulse conduction

<!-- PAGE=? -->
 lengthens PR, QRS, or QT intervals, and generates J waves on the ECG

<!-- PAGE=? -->
 Spontaneous VF occurs at temperatures <28°C

<!-- PAGE=? -->
o Inc risk of MI

<!-- PAGE=? -->
 Respiratory changes:

<!-- PAGE=? -->
o Inhibits HPV

<!-- PAGE=? -->
o Respiratory muscle weakness

<!-- PAGE=? -->
o Inc anesthetic solubility

<!-- PAGE=? -->
o Inc. A-a gradient

<!-- PAGE=? -->
 End organ dysfunction:

<!-- PAGE=? -->
o Renal failure (cold diuresis)

<!-- PAGE=? -->
o Dec. LOC (decreased CBF)

<!-- PAGE=? -->
o Hepatic failure

<!-- PAGE=? -->
 reduced drug metabolism

<!-- PAGE=? -->
 Metabolic changes:

<!-- PAGE=? -->
o Inc. glucose

<!-- PAGE=? -->
o Coagulopathy

<!-- PAGE=? -->
 Platelet sequestration

<!-- PAGE=? -->
 decreased platelet function

<!-- PAGE=? -->
 reduced clotting factor activity

<!-- PAGE=? -->
o Electrolyte abnormalities (K+, Ca++)

<!-- PAGE=? -->
o Metabolic acidosis

<!-- PAGE=? -->
 shift of Hgb-O2 to the Lt

<!-- PAGE=? -->
 hypoperfusion

<!-- PAGE=? -->
o compromised cellular immune responses with inc. postoperative infection rates

<!-- PAGE=? -->
 dec. MAC of inhalation anesthetics of 5-7% per 1°C reduction in core temperature

<!-- PAGE=? -->
o accentuates sedation from residual inhalation anesthetics

<!-- PAGE=? -->
 potentiation and prolongation of neuromuscular relaxants and sedatives

<!-- PAGE=? -->
o core hypothermia decreases twitch strength 10 to 15 percent, even without muscle relaxants

<!-- PAGE=? -->
o Reduced perfusion and impaired biotransformation

<!-- PAGE=? -->
o The efficacy of neostigmine as an antagonist of vecuronium-induced neuromuscular blockade is not altered by mild hypothermia, although onset time is about 20% longer

<!-- PAGE=? -->
 Dec. accuracy of monitoring

<!-- PAGE=? -->
o pulse oximetry

<!-- PAGE=? -->
o intra-arterial pressure monitoring

<!-- PAGE=? -->
o peripheral nerve stimulation

<!-- PAGE=? -->
 Inc. duration of PACU stay

<!-- PAGE=? -->
o averages 90 minutes longer

<!-- PAGE=? -->
o 40 minutes longer if rewarming is not used as a discharge criteria

<!-- PAGE=? -->
 Shivering increases the risk of

<!-- PAGE=? -->
o incidental trauma or disruption of medical devices

<!-- PAGE=? -->
o interferes with accuracy of ECG and pulse oximetry monitoring

<!-- PAGE=? -->
o makes bedside interventions more difficult

<!-- PAGE=? -->
o inc. oxygen consumption and CO2 production

<!-- PAGE=? -->
 ~800%

<!-- PAGE=? -->
 increases in minute ventilation and cardiac output can precipitate ventilatory failure in patients with limited reserve, or myocardial ischemia in patients with coronary artery disease

<!-- PAGE=? -->
o Many medications have been shown to suppress shivering, including meperidine, morphine, sufentanil, droperidol, physostigmine (0.04mg/kg), clonidine (75u IV), propofol, nalbuphine, chlorpromazine, magnesium (30mg/kg), dexmedetomidate

<!-- PAGE=? -->
 Meperidine may be more effective then other opioids d/t action on central alpha receptors

<!-- PAGE=? -->
 Withholding reversal of relaxants in ventilated, sedated patients attenuates shivering but increases rewarming time

<!-- PAGE=? -->
Intraoperative prevention

<!-- PAGE=? -->
P&P, Miller

<!-- PAGE=? -->
 Operating room temperature is the most critical factor influencing heat loss

<!-- PAGE=? -->
o room temperature must exceed 23°C are to maintain normothermia (infants my require > 26°C

<!-- PAGE=? -->
o Such temperatures are sufficiently high to impair the performance of operating room personnel and decrease their vigilance

<!-- PAGE=? -->
 The easiest method of decreasing cutaneous heat loss is to apply passive insulation

<!-- PAGE=? -->
o A single layer reduces heat loss approximately 30%, with no clinically important differences noted among the insulation types

<!-- PAGE=? -->
o adding additional layers of insulation further reduces heat loss only slightly

<!-- PAGE=? -->
 Cutaneous heat loss is roughly proportional to surface area throughout the body

<!-- PAGE=? -->
o The popular perception that a large fraction of metabolic heat is lost from the head is false in adults

<!-- PAGE=? -->
o Passive insulation alone is rarely sufficient to maintain normothermia

<!-- PAGE=? -->
 Cutaneous warming will transfer sufficient heat to prevent hypothermia

<!-- PAGE=? -->
o about 90% of metabolic heat is lost through the skin surface

<!-- PAGE=? -->
o circulating-water mattresses are nearly ineffective

<!-- PAGE=? -->
o Forced air usually maintains normothermia even during the largest operations

<!-- PAGE=? -->
 most effective method of preventing intraoperative hypothermia

<!-- PAGE=? -->
 cannot effectively treat severe hypothermia

<!-- PAGE=? -->
 because of its low specific heat, air has little heat content to give to the cold trauma patient

<!-- PAGE=? -->
0

<!-- PAGE=? -->
@

<!-- PAGE=? -->
|

<!-- PAGE=? -->
Hours

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Fluid at 33*C

<!-- PAGE=? -->
8

<!-- PAGE=? -->
'(G)

<!-- PAGE=? -->
Blankote

<!-- PAGE=? -->
Mattress

<!-- PAGE=? -->
Three

<!-- PAGE=? -->
One

<!-- PAGE=? -->
and

<!-- PAGE=? -->
Fluld

<!-- PAGE=? -->
 Warm iv fluids is not effective at warming patients

<!-- PAGE=? -->
o heat loss from cold intravenous fluids can be significant when large amounts of crystalloid solution or blood are administered

<!-- PAGE=? -->
o Each liter of intravenous fluid at ambient temperature that is infused into adult patients, or each unit of blood at 4°C, decreases the mean core body temperature about 0.25°C

<!-- PAGE=? -->
 less than 10% of metabolic heat production is lost through the respiratory tract

<!-- PAGE=? -->
o even active airway heating and humidification minimally influence core temperature

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
 Convective warming with forced dry air at 43°C can prevent a temperature drop in most trauma patients but cannot effectively treat severe hypothermia

<!-- PAGE=? -->
 Airway rewarming can reduce heat loss caused by latent heat of vaporization, but this technique also transfers very little heat

<!-- PAGE=? -->
 Administration of warm iv fluids is the most effective way to prevent and treat hypothermia in the trauma patient

<!-- PAGE=? -->
o fluids must be administered at a relatively rapid rate

<!-- PAGE=? -->
o For each liter of fluid given at 40°C to a patient with a body temperature of 33°C, 7 kcal of heat energy is gained

<!-- PAGE=? -->
 The most effective method of warming, is continuous arteriovenous rewarming

<!-- PAGE=? -->
Hypovolemia: Yes. These guys get a cold dieresis (the temperature at which this occurs varies between resources) which may not necessarily manifest when vasoconstricted but as they get rewarmed can be a major problem. I can't find any information on how long this takes to occur but urine output in the hypothermic patient cannot be used as an indicator of volume status.

<!-- PAGE=? -->
Hypokalemia: These patients are frequently hypokalemic (likely shifting intracellular due to the catecholamines). However, there are multiple reports of significant hyperkalemia on rewarming (as the intracellular potassium shifts back out, exacerbated by frequent acidosis). Likely, while cold, potassium free solutions should be administered. Hyperkalemia while hypothermic is a poor prognostic sign. So while, they are hypokalemic, we should not treat it.

<!-- PAGE=? -->
Bypass: My ancient JAMA article below seems to indicate that temps below 30 or unstable arrthythmias refractory to treatment are indication for bypass. Internal warming also seems to be indicated with a temp less than 30.

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
 Severe hypothermia - body temperature < 30°C

<!-- PAGE=? -->
o victim may appear clinically dead during the initial assessment

<!-- PAGE=? -->
o hypothermia may exert a protective effect on the brain and organs in cardiac arrest

<!-- PAGE=? -->
o Victims should be transported as soon as possible to a center where monitored rewarming is possible

<!-- PAGE=? -->
 When the victim is extremely cold but has maintained a perfusing rhythm, the rescuer should focus on interventions that prevent further heat loss and begin to rewarm the victim

<!-- PAGE=? -->
o Prevent additional evaporative heat loss

<!-- PAGE=? -->
o Do not delay urgent procedures

<!-- PAGE=? -->
 perform them gently while closely monitoring cardiac rhythm

<!-- PAGE=? -->
 patients are prone to develop ventricular fibrillation (VF)

<!-- PAGE=? -->
 For patients with moderate to severe hypothermia, therapy is determined by the presence or absence of a perfusing rhythm

<!-- PAGE=? -->
 Hypothermia with a perfusing rhythm

<!-- PAGE=? -->
o Mild >34°C

<!-- PAGE=? -->
 passive rewarming

<!-- PAGE=? -->
o Moderate 30°C to 34°C

<!-- PAGE=? -->
 active external rewarming

<!-- PAGE=? -->
o Severe <30°C

<!-- PAGE=? -->
 active internal rewarming

<!-- PAGE=? -->
 consider extracorporeal membrane oxygenation

<!-- PAGE=? -->
 Patients in cardiac arrest

<!-- PAGE=? -->
o CPR with some modifications and active internal rewarming

<!-- PAGE=? -->
o Moderate 30°C to 34°C

<!-- PAGE=? -->
 start CPR, attempt defibrillation, establish IV access, give IV medications spaced at longer intervals, provide active internal rewarming

<!-- PAGE=? -->
o Severe <30°C

<!-- PAGE=? -->
 start CPR, attempt defibrillation once , withhold medications until temperature >30°C (cardioactive medications can accumulate to toxic levels in the peripheral circulation if given repeatedly), provide active internal rewarming

<!-- PAGE=? -->
 peritoneal lavage, esophageal rewarming tubes, cardiopulmonary bypass, extracorporeal circulation, etc

<!-- PAGE=? -->
 Sinus bradycardia may be physiologic in severe hypothermia and cardiac pacing is usually not indicated

<!-- PAGE=? -->
 During rewarming, patients who have been hypothermic for >45 to 60 minutes are likely to require volume administration because the vascular space expands with vasodilation

<!-- PAGE=? -->
 Routine administration of steroids, barbiturates, and antibiotics has not been documented to increase survival rates or decrease postresuscitation damage

<!-- PAGE=? -->
 In hospital, physicians should use their clinical judgment to decide when resuscitative efforts should cease in a victim of hypothermic arrest.

<!-- PAGE=? -->
Hypocalcemia

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 myocardial contractility varies directly with levels of blood ionized calcium

<!-- PAGE=? -->
 delays ventricular repolarization,

<!-- PAGE=? -->
o increasing the QTC interval

<!-- PAGE=? -->
 distal paresthesias

<!-- PAGE=? -->
 muscle spasm

<!-- PAGE=? -->
 Possible prolonged NdMB

<!-- PAGE=? -->
 laryngeal spasm

<!-- PAGE=? -->
 hypocalcemic seizures

<!-- PAGE=? -->
Table 9-23. HYPOCALCEMIA: CLINICAL MANIFESTATIONS

<!-- PAGE=? -->
Cardiovascular

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
Dysrhythmias

<!-- PAGE=? -->
Apnea

<!-- PAGE=? -->
Digitalis insensitivity

<!-- PAGE=? -->
Laryngeal spasm

<!-- PAGE=? -->
ECG changes - prolonged QT

<!-- PAGE=? -->
Bronchospasm

<!-- PAGE=? -->
Heart failure

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
Psychiatric

<!-- PAGE=? -->
Anxiety

<!-- PAGE=? -->
Neuromuscular

<!-- PAGE=? -->
Dementia

<!-- PAGE=? -->
Tetany

<!-- PAGE=? -->
Depression

<!-- PAGE=? -->
Muscle spasm

<!-- PAGE=? -->
Psychosis

<!-- PAGE=? -->
Papilledema

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Weakness

<!-- PAGE=? -->
Fatigue

<!-- PAGE=? -->
Hypernatremia

<!-- PAGE=? -->
Table 46-7 -- Major causes of hypernatremia

<!-- PAGE=? -->
Hyponatremia

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Symptoms of severe hyponatremia (Na <120) include

<!-- PAGE=? -->
o loss of appetite

<!-- PAGE=? -->
o nausea and vomiting

<!-- PAGE=? -->
o cramps

<!-- PAGE=? -->
o weakness

<!-- PAGE=? -->
o altered level of consciouness

<!-- PAGE=? -->
o coma

<!-- PAGE=? -->
o seizures

<!-- PAGE=? -->
 At least 4% of postoperative patients develop plasma Na <130

<!-- PAGE=? -->
 Hyponatremia may be associated with normal, high, or low serum osmolality

<!-- PAGE=? -->
o Ur, Glucose, hyperlipidemia, hyperproteinemia, mannitol, alcohols can all inc. osmolality inspite of hyponatremia

<!-- PAGE=? -->
o low osmolaltity is ALWAYS associated with hyponatremia

<!-- PAGE=? -->
 The majority of hyponatremic, hospitalized patients have normal or increased quantities of total body sodium

<!-- PAGE=? -->
 Inappropriately rapid correction may result in abrupt brain dehydration or permanent neurological sequelae

<!-- PAGE=? -->
o central pontine myelinolysis or the osmotic demyelination syndrome

<!-- PAGE=? -->
o cerebral hemorrhage

<!-- PAGE=? -->
o The symptoms vary from mild to severe

<!-- PAGE=? -->
 Dysarthria

<!-- PAGE=? -->
 Dysphagia

<!-- PAGE=? -->
 paraparesis or quadriparesis

<!-- PAGE=? -->
 behavioral disturbances

<!-- PAGE=? -->
 Lethargy

<!-- PAGE=? -->
 Coma

<!-- PAGE=? -->
 seizures

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Hyponatremia can occur in patients who are hypotonic, normotonic, or hypertonic

<!-- PAGE=? -->
 Factitious hyponatremia can be seen in hyperlipidemia (i.e., chylomicronemia) or hyperproteinemia

<!-- PAGE=? -->
 Hyperosmolality resulting from nonsodium molecules (e.g., hyperglycemia, mannitol overdose)

<!-- PAGE=? -->
 Significant decreases in total-body sodium most commonly occur from diuretic administration

<!-- PAGE=? -->
o normotonic hyponatremia

<!-- PAGE=? -->
 Transurethral prostate (TURP) syndrome is a recognized cause of hyponatremia

<!-- PAGE=? -->
o intravascular absorption of irrigation solution, which typically contains glycine

<!-- PAGE=? -->
o TURP syndrome is a cause of true hypotonic hyponatremia

<!-- PAGE=? -->
 SIADH is associated with a number of processes true hypotonic hyponatremia

<!-- PAGE=? -->
o pulmonary and cranial disorders

<!-- PAGE=? -->
o neoplasms - particularly oat cell carcinoma

<!-- PAGE=? -->
o Sympathetic activation - postoperative pain

<!-- PAGE=? -->
o Various drugs - oral hypoglycemics, TCAs, diuretics

<!-- PAGE=? -->
 Hyponatremia also occurs in mixed disorders - nonosmotic ADH release reduces the rate of urinary sodium excretion and blunts urinary diluting capacity

<!-- PAGE=? -->
o advanced volume contraction

<!-- PAGE=? -->
o intractable heart failure

<!-- PAGE=? -->
o advanced hepatic cirrhosis with ascites

<!-- PAGE=? -->
 signs and symptoms

<!-- PAGE=? -->
o Nausea & vomiting

<!-- PAGE=? -->
o visual disturbances

<!-- PAGE=? -->
o depressed level of consciousness

<!-- PAGE=? -->
o agitation, confusion, coma

<!-- PAGE=? -->
o seizures

<!-- PAGE=? -->
o muscle cramps

<!-- PAGE=? -->
o weakness

<!-- PAGE=? -->
o myoclonus

<!-- PAGE=? -->
 Cerebral edema occurs at or below a serum level of 123 mEq/L

<!-- PAGE=? -->
 Cardiac symptoms occur at 100 mEq/L

<!-- PAGE=? -->
 Hyponatremia associated with increased intravascular volume can result in pulmonary edema, hypertension, and heart failure

<!-- PAGE=? -->
 Water restriction is the mainstay of treatment

<!-- PAGE=? -->
o Hypertonic saline should be used only in cases of severe hyponatremia with neurologic symptoms

<!-- PAGE=? -->
 Sodium Deficit

<!-- PAGE=? -->
o Dose (mEq) = (Weight (kg) × (140 - [Na+]) (mEq/L)) × 0.6

<!-- PAGE=? -->
o Correct at 0.6 to 1 mmol/L/hour until the sodium concentration is 125 mEq/L then slow correction

<!-- PAGE=? -->
o One half the deficit can be administered over the first 8 hours and the next half over 1 to 3 days if symptoms remit

<!-- PAGE=? -->
 Potential complications of hypertonic saline include cerebral edema and central pontine myelinolysis

<!-- PAGE=? -->
o Sodium concentration should be monitored every 1 to 2 hours during rapid correction

<!-- PAGE=? -->
 Menstruant female patients are at greater risk for developing significant neurologic sequelae after hyponatremia

<!-- PAGE=? -->
 The most likely cause of postoperative hyponatremia is the SIADH secretion ( Table 46-5 )

<!-- PAGE=? -->
Table 46-5 -- Major causes of hyponatremia

<!-- PAGE=? -->
Table 46-4 -- Types of hyponatremia and their causes

<!-- PAGE=? -->
Serum sodium

<!-- PAGE=? -->
135 mEqIL

<!-- PAGE=? -->
280

<!-- PAGE=? -->
295

<!-- PAGE=? -->
295

<!-- PAGE=? -->
msom/kg

<!-- PAGE=? -->
Plasma

<!-- PAGE=? -->
msom/kg

<!-- PAGE=? -->
Hypertonic hyponatremia

<!-- PAGE=? -->
paraproteinemia

<!-- PAGE=? -->
osmolality

<!-- PAGE=? -->
hyperglycemia

<!-- PAGE=? -->
hypertriglyceridemia

<!-- PAGE=? -->
mannitol therapy

<!-- PAGE=? -->
glycerol therapy

<!-- PAGE=? -->
< 280 msOsmlkg

<!-- PAGE=? -->
Hypotonic hyponatremia

<!-- PAGE=? -->
primary polydipsia

<!-- PAGE=? -->
100

<!-- PAGE=? -->
100

<!-- PAGE=? -->
excessive tap water in

<!-- PAGE=? -->
mosm/kg

<!-- PAGE=? -->
mosmlkg

<!-- PAGE=? -->
Impaired renal

<!-- PAGE=? -->
infant feedings

<!-- PAGE=? -->
Urine osmolality

<!-- PAGE=? -->
concentrating ability

<!-- PAGE=? -->
tap water enemas

<!-- PAGE=? -->
in infants

<!-- PAGE=? -->
excess waler ingestion

<!-- PAGE=? -->
during swimming

<!-- PAGE=? -->
ECFV

<!-- PAGE=? -->
Decreased

<!-- PAGE=? -->
Incrcascd

<!-- PAGE=? -->
ECFV

<!-- PAGE=? -->
ECFV

<!-- PAGE=? -->
Urinary sodium

<!-- PAGE=? -->
Urinary sodium

<!-- PAGE=? -->
10 mEq/L

<!-- PAGE=? -->
20 mEqIL

<!-- PAGE=? -->
10 mEqL

<!-- PAGE=? -->
Extrarenal solute loss

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
Edematous disorders

<!-- PAGE=? -->
diuretics

<!-- PAGE=? -->
skin

<!-- PAGE=? -->
CHF

<!-- PAGE=? -->
osmotic diuresis

<!-- PAGE=? -->
GIT

<!-- PAGE=? -->
Cirrhosis

<!-- PAGE=? -->
Addisons disease

<!-- PAGE=? -->
Nephrotic syndrome

<!-- PAGE=? -->
RTA with bicarbonaturia

<!-- PAGE=? -->
Normal ECFV

<!-- PAGE=? -->
salt losing nephritis

<!-- PAGE=? -->
SIADH

<!-- PAGE=? -->
Reset osmostat

<!-- PAGE=? -->
Endocrinopathies

<!-- PAGE=? -->
Potassium depletion

<!-- PAGE=? -->
drugs

<!-- PAGE=? -->
hypothyroidism

<!-- PAGE=? -->
diuretuc use

<!-- PAGE=? -->
tumors

<!-- PAGE=? -->
glucocorticoid deliciency

<!-- PAGE=? -->
Hyponalremia: Treatment

<!-- PAGE=? -->
Treat

<!-- PAGE=? -->
disease

<!-- PAGE=? -->
Remove

<!-- PAGE=? -->
drugs

<!-- PAGE=? -->
or

<!-- PAGE=? -->
2 280 mOsm Kg

<!-- PAGE=? -->
Glucose

<!-- PAGE=? -->
Serum Osmolalily Low

<!-- PAGE=? -->
280 mOsm Kg

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
Low Total Body Sodlum

<!-- PAGE=? -->
Normal Tolal Body Sodlum

<!-- PAGE=? -->
Rostrict wator

<!-- PAGE=? -->
(Saline)

<!-- PAGE=? -->
Locp diurolic plus

<!-- PAGE=? -->
Increase cardiac oulou:

<!-- PAGE=? -->
Eliminale excessive sodium

<!-- PAGE=? -->
urinary sodium replacement

<!-- PAGE=? -->
losses

<!-- PAGE=? -->
Treat adrenal insufficiency

<!-- PAGE=? -->
Lithium

<!-- PAGE=? -->
(Dopamine)

<!-- PAGE=? -->
Hernodialysis

<!-- PAGE=? -->
Thyroid hormone replacement

<!-- PAGE=? -->
Urea

<!-- PAGE=? -->
DDx of hypotonic hyponatremia (OSM<280)

<!-- PAGE=? -->
Hypovolemic

<!-- PAGE=? -->
Gastrointestinal losses, vomiting, Diarrhea

<!-- PAGE=? -->
Skin losses

<!-- PAGE=? -->
Third-space losses

<!-- PAGE=? -->
Lung losses

<!-- PAGE=? -->
Renal (Diuretics, renal damage, urinary obstruction)

<!-- PAGE=? -->
Adrenal insufficiency

<!-- PAGE=? -->
Isovolemic

<!-- PAGE=? -->
SIADH

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
Water intoxication

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Dysfunctional osmostat

<!-- PAGE=? -->
Hypervolemic

<!-- PAGE=? -->
Congestive heart failure

<!-- PAGE=? -->
Nephrosis

<!-- PAGE=? -->
Liver dysfunction

<!-- PAGE=? -->
TURP syndrome

<!-- PAGE=? -->
*

<!-- PAGE=? -->
Serum osmolality less than 280 mOsm/L.

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
 The cornerstone of SIADH management is free-water restriction and elimination of precipitating causes

<!-- PAGE=? -->
 Furosemide, combined with quantitative replacement of urinary sodium losses with 0.9% or 3.0% saline, can rapidly increase plasma [Na + ], in part by increasing free-water clearance

<!-- PAGE=? -->
 Aggressive therapy with hypertonic (3%) saline can be accomplished at a rate of 1-2 ml/kg/hr increase plasma [Na + ] by 1-2 mEq/L/hr

<!-- PAGE=? -->
o Treatment should be interrupted or slowed when symptoms improve

<!-- PAGE=? -->
o Frequent determinations of [Na + ] are important to prevent correction at a rate of >10 mEq/L over 24 hours (18 meq/L in 48hrs)

<!-- PAGE=? -->
o Maximum rate of correction should be 8 to 10 meq/L per 24hrs in asymptomatic disease

<!-- PAGE=? -->
Treatment Sodium deficit  = TBW x (desired Na - actual Na)

<!-- PAGE=? -->
Water restriction

<!-- PAGE=? -->
 Water restriction to below the level of output is the primary therapy for hyponatremia in edematous states

<!-- PAGE=? -->
 Restriction to 50 to 60 percent of daily fluid requirements may be required to achieve the goal of inducing a negative water balance

<!-- PAGE=? -->
Sodium chloride administration

<!-- PAGE=? -->
 Hypertonic saline is generally recommended only for symptomatic patients

<!-- PAGE=? -->
True volume depletion

<!-- PAGE=? -->
 Sodium and water will initially be retained

<!-- PAGE=? -->
o The degree to which one liter of a given solution will initially raise the plasma sodium concentration (PNa) can be estimated from the following formula

<!-- PAGE=? -->
 Increase in PNa = (Infusate [Na] - PNa) ÷ (TBW + 1)

<!-- PAGE=? -->
o slowly raises the plasma sodium by approximately 1 meq/L for every liter of fluid infused

<!-- PAGE=? -->
SIADH

<!-- PAGE=? -->
 oral vasopressin antagonists

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
 Central pontine myelinolysis (CPM)

<!-- PAGE=? -->
o most serious complication

<!-- PAGE=? -->
o from overly rapid correction of hyponatremia

<!-- PAGE=? -->
o Increased risk in:

<!-- PAGE=? -->
 cerebral disease

<!-- PAGE=? -->
 alcoholism

<!-- PAGE=? -->
 liver disease

<!-- PAGE=? -->
 malnutrition

<!-- PAGE=? -->
 hypokalemia

<!-- PAGE=? -->
 large burns

<!-- PAGE=? -->
 premenopausal patients undergoing surgery

<!-- PAGE=? -->
 long-standing, severe hyponatremia that is corrected too rapidly.

<!-- PAGE=? -->
o risk is minimal if hyponatremia develops over less than 48 hours, even with rapid correction.

<!-- PAGE=? -->
o onset of CPM may be delayed, manifesting 1-2 days after correction, despite initial clinical improvement

<!-- PAGE=? -->
o Signs & symptoms

<!-- PAGE=? -->


<!-- PAGE=? -->
Dysarthria

<!-- PAGE=? -->
 Dysphagia

<!-- PAGE=? -->
 paraparesis or quadriparesis

<!-- PAGE=? -->
 behavioral disturbances

<!-- PAGE=? -->
 Lethargy

<!-- PAGE=? -->
 Coma

<!-- PAGE=? -->
 seizures

<!-- PAGE=? -->
Hypertrophic Cardiomyopathy

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Hemodynamic Goals

<!-- PAGE=? -->
o Full Preload

<!-- PAGE=? -->
o Inc. Afterload

<!-- PAGE=? -->
 Stents LVOT open

<!-- PAGE=? -->
o Dec. contractility

<!-- PAGE=? -->
 Reduce LVOT obstruction

<!-- PAGE=? -->
 metoprolol

<!-- PAGE=? -->
o Maintain normal HR

<!-- PAGE=? -->
o Maintain NSR

<!-- PAGE=? -->
 Hypertrophic ventrical with diastolic dysfunction

<!-- PAGE=? -->
o Avoid inotropes post CPB

<!-- PAGE=? -->
 May precipitate obstruction

<!-- PAGE=? -->
 Some degree of subvalvular obstruction is present in 20-30% of patients

<!-- PAGE=? -->
o LVOT is narrowed during systole by apposition of the hypertrophic interventricular septum to the anterior leaflet of the mitral valve

<!-- PAGE=? -->
 Rapid blood ejection creates a Venturi effect, pulling the mitral valve leaflet even closer to the septum (SAM, systolic anterior motion)

<!-- PAGE=? -->
o once volume is repleted, the stimulus for ADH release is removed, thereby allowing the excess water to be excreted. At this time, the plasma sodium concentration may return rapidly toward normal

<!-- PAGE=? -->
o dDAVP may be required to slow the rate of water excretion

<!-- PAGE=? -->
 timing and duration of septal-leaflet contact determine the severity and clinical significance of the obstruction

<!-- PAGE=? -->
 Early prolonged contact can generate pressure gradients of 100 mm Hg

<!-- PAGE=? -->
 Later contact is of little importance because the SV has already been ejected

<!-- PAGE=? -->
Hypoxic drive

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Inhaled anesthetics, including nitrous oxide, produce dose-dependent attenuation of the ventilatory response to hypoxia

<!-- PAGE=? -->
 In fact, even subanesthetic concentrations of volatile anesthetics (0.1 MAC) elicit anywhere from a 15 to 75% depression of the ventilatory drive to hypoxia

<!-- PAGE=? -->
 Residual effects of volatile anesthetics may impair the ventilatory drive of patients in the recovery room.

<!-- PAGE=? -->
 Preservation of Ventilatory Response (Best to Worst): Desflurane>Sevoflurane>Enflurane>Isoflurane>Halothane

<!-- PAGE=? -->
Sevoflurane

<!-- PAGE=? -->
Enflurane

<!-- PAGE=? -->
Desflurane

<!-- PAGE=? -->
Isoflurane

<!-- PAGE=? -->
Halothane

<!-- PAGE=? -->
50

<!-- PAGE=? -->
100

<!-- PAGE=? -->
125

<!-- PAGE=? -->
-response to acute hypoxia

<!-- PAGE=? -->
at 0.1 MAC (% of control response)

<!-- PAGE=? -->
Elsevier Science 2005

<!-- PAGE=? -->
Hypoxic Pulmonary Vasoconstriction (HPV)

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 locally mediated phenomenon

<!-- PAGE=? -->
 The SNS may play a role in augmenting the HPV, especially during hypoxemia

<!-- PAGE=? -->
 HPV occurs when alveolar oxygen tension falls to < 100 mmHg in the normal lung and is maximal when O2 tension is ~30 mmHg

<!-- PAGE=? -->
o Diverts blood away from hypoxic areas

<!-- PAGE=? -->
o Minimizes V/Q mismatching

<!-- PAGE=? -->
 Potentiate

<!-- PAGE=? -->
o prostaglandin inhibitors (ibuprophen, cycooxygenase ibnhibitor)

<!-- PAGE=? -->
o almitrine (respiratory stimulant)

<!-- PAGE=? -->
o Acidosis (hypercarbia)

<!-- PAGE=? -->
 Small effect at normal alveolar oxygen tensions but can be dramatic during alveolar hypoxia

<!-- PAGE=? -->
 Possibly d/t reduced levels of NO

<!-- PAGE=? -->
o HFO ventilation

<!-- PAGE=? -->
o Possible

<!-- PAGE=? -->
 Phenyl

<!-- PAGE=? -->
I

<!-- PAGE=? -->
IABP (Intra-aortic balloon pump)

<!-- PAGE=? -->
Barash, Essential Kaplan

<!-- PAGE=? -->
 designed to augment myocardial perfusion

<!-- PAGE=? -->
o increasing coronary blood flow during diastole

<!-- PAGE=? -->
o unloading the left ventricle during systole

<!-- PAGE=? -->
 The gas used for inflation is carbon dioxide (because of its great solubility in blood) or helium (because of its inertial properties and rapid diffusion coefficients)

<!-- PAGE=? -->
 results include

<!-- PAGE=? -->
o improvements in

<!-- PAGE=? -->
 cardiac output

<!-- PAGE=? -->
 ejection fraction

<!-- PAGE=? -->
 coronary blood flow

<!-- PAGE=? -->
 MAP

<!-- PAGE=? -->
o decreases in

<!-- PAGE=? -->
 aortic and ventricular systolic pressures

<!-- PAGE=? -->
 LVEDP

<!-- PAGE=? -->
 PCWP

<!-- PAGE=? -->
 LAP

<!-- PAGE=? -->
 HR

<!-- PAGE=? -->
 frequency of PACs

<!-- PAGE=? -->
 atrial arrhythmias

<!-- PAGE=? -->
 indications

<!-- PAGE=? -->
o myocardial ischemia

<!-- PAGE=? -->
 intractable to maximal medical therapy

<!-- PAGE=? -->
o left ventricular dysfunction

<!-- PAGE=? -->
 inadequately managed with inotropic therapy

<!-- PAGE=? -->
 Actions

<!-- PAGE=? -->
o favorably influence the determinants of myocardial oxygen supply and demand and augment left ventricular output and forward flow

<!-- PAGE=? -->
 increasing diastolic blood pressure

<!-- PAGE=? -->
 Inhibit

<!-- PAGE=? -->
o Direct

<!-- PAGE=? -->
 Alkalemia (hypocapnea & metabolic)

<!-- PAGE=? -->
 Vasodilators (NTG, B2-agonists [salbutamol], CCBs)

<!-- PAGE=? -->
 Dopamine is equivocal

<!-- PAGE=? -->
 Pulmonary infection

<!-- PAGE=? -->
 Inhalational agents

<!-- PAGE=? -->
o Indirect

<!-- PAGE=? -->
 PA Pressure (very high or very low - MS, volume overload, PE, vasoconstrictors

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
o Mixed venous PO2 (high or very low)

<!-- PAGE=? -->
o large hypoxic lung segment

<!-- PAGE=? -->
 Dose dependant

<!-- PAGE=? -->
o PEEP

<!-- PAGE=? -->
o Glucagon

<!-- PAGE=? -->
 Intravenous anesthetics have little to no effect on HPV

<!-- PAGE=? -->
 augmented coronary and systemic perfusion

<!-- PAGE=? -->
 decreasing systolic blood pressure

<!-- PAGE=? -->
 decreasing afterload

<!-- PAGE=? -->
 decreasing left ventricular systolic

<!-- PAGE=? -->
 work

<!-- PAGE=? -->
 tension

<!-- PAGE=? -->
 myocardial oxygen consumption

<!-- PAGE=? -->
o may also have favorable effects on right ventricular function

<!-- PAGE=? -->
 mechanisms are complex

<!-- PAGE=? -->
 probably include accentuation of right ventricular myocardial blood flow

<!-- PAGE=? -->
 decreased RV afterload

<!-- PAGE=? -->
 unloading of the left ventricle  - dec. left atrial and pulmonary vascular pressures

<!-- PAGE=? -->
 improvements in right ventricular mechanical function secondary to changes in left ventricular performance and ventricular interdependence

<!-- PAGE=? -->
 Inappropriate timing

<!-- PAGE=? -->
o Early Inflation (prior to aortic valve closure)

<!-- PAGE=? -->
 aortic insufficiency and LV strain

<!-- PAGE=? -->
o late inflation

<!-- PAGE=? -->
 diminished perfusion pressure to the coronary arteries

<!-- PAGE=? -->
o Early deflation

<!-- PAGE=? -->
 inappropriate loss of afterload reduction

<!-- PAGE=? -->
o late deflation

<!-- PAGE=? -->
 increase LV work by causing increased afterload

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Aortic insufficiency

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Vascular disease

<!-- PAGE=? -->
 arterial dissection

<!-- PAGE=? -->
 severe arteriosclerosis - relative

<!-- PAGE=? -->
o disease process not compatible with survival

<!-- PAGE=? -->
o inability to insert

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o primarily related to ischemia distal to the site of balloon insertion

<!-- PAGE=? -->
o Most common complications

<!-- PAGE=? -->
 Direct trauma to the vessel

<!-- PAGE=? -->
 arterial obstruction

<!-- PAGE=? -->
 thrombosis

<!-- PAGE=? -->
o aortic perforation and balloon rupture occur rarely

<!-- PAGE=? -->
 gas emboli

<!-- PAGE=? -->
o Platelet destruction and thrombocytopenia

<!-- PAGE=? -->
ICP

<!-- PAGE=? -->
Physiologic responses to increased ICP

<!-- PAGE=? -->
 shift of cerebral CSF to spinal arachnoid space

<!-- PAGE=? -->
 increased CSF absorption through the arachnoid granulations

<!-- PAGE=? -->
 translocation of blood out of the intracranial vault

<!-- PAGE=? -->
 TBI patients who need ICP monitoring: (>50% change of ICP>20)

<!-- PAGE=? -->
o GCS 3-8 with abnormal CT head

<!-- PAGE=? -->
 hematoma, contusions, edema, compressed basal cisterns

<!-- PAGE=? -->
o GCS 3-8 with normal head CT plus 1 of the following

<!-- PAGE=? -->
 Age > 40

<!-- PAGE=? -->
 SBP < 90

<!-- PAGE=? -->
 Posturing

<!-- PAGE=? -->
 Indications for ICP monitoring in TBI (A&A - 2008)

<!-- PAGE=? -->
o Severe head injury

<!-- PAGE=? -->
o Intracerebral hemorrhage

<!-- PAGE=? -->
o Subarachnoid hemorrhage

<!-- PAGE=? -->
o Hydrocephalus

<!-- PAGE=? -->
o Stroke

<!-- PAGE=? -->
o Cerebral edema

<!-- PAGE=? -->
o Central nervous system infections

<!-- PAGE=? -->
o Hepatic encephalopathy

<!-- PAGE=? -->
Volumeccomgensation

<!-- PAGE=? -->
Reaching Exhaustion

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Volume Compensation

<!-- PAGE=? -->
(CSF, Blood)

<!-- PAGE=? -->
Intracranial   Volume

<!-- PAGE=? -->
Miller FIGURE 52-2 The intracranial pressure-volume relationship. That compensation is accomplished largely by displacement of cerebrospinal fluid (CSF) and venous blood from intracranial to extracranial spaces. Once the compensatory latitudes are exhausted, small volume increments result in large increases in intracranial pressure, with the associated hazards of either herniation or decreased cerebral perfusion pressure (CPP) resulting in ischemia.

<!-- PAGE=? -->
INTRAPAAENCHYMAL

<!-- PAGE=? -->
FIBEROPTIC CATHETER

<!-- PAGE=? -->
EPIDURAL

<!-- PAGE=? -->
TRANSDUCER

<!-- PAGE=? -->
VENTAICULOSTOMY

<!-- PAGE=? -->
CATHETER

<!-- PAGE=? -->
SUBDURAL BOLT

<!-- PAGE=? -->
Increased ICP

<!-- PAGE=? -->
 STP: decrease in CBF of 50% and CMRO2 of 68%

<!-- PAGE=? -->
 Propofol: decreases CBF by about 50% (like STP), and in CMRO2 by about 40% (less than STP)

<!-- PAGE=? -->
 Ketamine: causes an increase in CMR and CBF

<!-- PAGE=? -->
 Fentanyl causes a mild-moderate global reduction in CBF and CMR in the normal quiescent brain and, like morphine, causes larger reductions when administered during arousal

<!-- PAGE=? -->
 Benzodiazepines: the extent of CBF and CMR reductions produced is intermediate between narcotics and barbiturates

<!-- PAGE=? -->
60

<!-- PAGE=? -->
40

<!-- PAGE=? -->
20

<!-- PAGE=? -->
40

<!-- PAGE=? -->
Thiopenlal

<!-- PAGE=? -->
10

<!-- PAGE=? -->
55 mgkg

<!-- PAGE=? -->
Propolol

<!-- PAGE=? -->
2 mg kg

<!-- PAGE=? -->
inlusion

<!-- PAGE=? -->
0.2 Mgkg

<!-- PAGE=? -->
infusion

<!-- PAGE=? -->
Horphine

<!-- PAGE=? -->
CBF

<!-- PAGE=? -->
Chao?

<!-- PAGE=? -->
Fenlanyl

<!-- PAGE=? -->
Sulentanil

<!-- PAGE=? -->
10 pgkg

<!-- PAGE=? -->
Diazepam

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
0.15 mg kg

<!-- PAGE=? -->
"60

<!-- PAGE=? -->
-20

<!-- PAGE=? -->
20

<!-- PAGE=? -->
40

<!-- PAGE=? -->
60

<!-- PAGE=? -->
80

<!-- PAGE=? -->
Percent change in CBF ard

<!-- PAGE=? -->
 Hyperventilation

<!-- PAGE=? -->
o Current guidelines suggest maintenance of Paco2 at 35 mm Hg, with hyperventilation to 30 mm Hg only for episodes of elevated ICP that cannot be controlled with

<!-- PAGE=? -->
 Sedatives

<!-- PAGE=? -->
 CSF drainage

<!-- PAGE=? -->
 neuromuscular blockade

<!-- PAGE=? -->
 osmotic agents

<!-- PAGE=? -->
 barbiturate coma

<!-- PAGE=? -->
o May not effectively decrease intracranial pressure in the face of severe head trauma

<!-- PAGE=? -->
o Can attenuate the inc. CBF of volatile anesthetics

<!-- PAGE=? -->
o Effect on ICP will only last 6-18 hrs

<!-- PAGE=? -->
Management of inc. ICP

<!-- PAGE=? -->
Table 28-20. SEVERE HEAD INJURY: TREATMENT OF INTRACRANIAL HYPERTENSION  (Barash)

<!-- PAGE=? -->
 Insert ICP monitor

<!-- PAGE=? -->
 Maintain CPP > 70 mm Hg

<!-- PAGE=? -->
 Intracranial hypertension

<!-- PAGE=? -->
First-tier therapy:

<!-- PAGE=? -->
 Ventricular drainage (if available)

<!-- PAGE=? -->
 Mannitol 0.25-1 g·kg -1 iv (may repeat if serum osmolarity<320 mOsm·l -1 and patient euvolemic)

<!-- PAGE=? -->
 Hyperventilation to PaCO2 30-35 mm Hg

<!-- PAGE=? -->
Second-tier therapy:

<!-- PAGE=? -->
 Hyperventilation to PaCO2 < 30 mm Hg (SjO2, AVDO2, and/or CBF monitoring recommended)

<!-- PAGE=? -->
 High-dose barbiturate therapy

<!-- PAGE=? -->
 Consider hypothermia

<!-- PAGE=? -->
 Consider hypertensive therapy

<!-- PAGE=? -->
 Consider decompressive craniectomy

<!-- PAGE=? -->
ICP = intracranial pressure; CPP = cerebral perfusion pressure;SjO2 = jugular bulb oxyhemoglobin saturation; AVDO2 = arteriovenous difference in oxygen content; CBF = cerebral blood flow.

<!-- PAGE=? -->
Mannitol

<!-- PAGE=? -->
 0.25 to 1.00 g/kg IV decreases ICP by

<!-- PAGE=? -->
o increasing plasma osmolarity, which draws water from tissues, including the brain, along an osmotic gradient

<!-- PAGE=? -->
o decreasing cerebrospinal fluid volume by virtue of decreasing the rate of formation of this fluid

<!-- PAGE=? -->
 onset within 10 to 15 minutes

<!-- PAGE=? -->
 duration about 2 hours

<!-- PAGE=? -->
o larger dose may last longer

<!-- PAGE=? -->
 larger doses and repeated administration can result in metabolic derangements

<!-- PAGE=? -->
 not associated with a high incidence of rebound increases in ICP

<!-- PAGE=? -->
 An intact blood-brain barrier is necessary to prevent entrance of mannitol into the CNS, drawing fluid with it and producing rebound cerebral edema

<!-- PAGE=? -->
o may be prevented by maintaining a mild fluid deficit

<!-- PAGE=? -->
 eventually adapts to sustained increases in plasma osmolarity

<!-- PAGE=? -->
 results in vasodilation of vascular smooth muscle

<!-- PAGE=? -->
o dependent on the dose and rate of administration

<!-- PAGE=? -->
o can transiently increase cerebral blood volume and intracranial pressure while simultaneously decreasing systemic blood pressure

<!-- PAGE=? -->
Furosemide

<!-- PAGE=? -->
 decreases ICP by

<!-- PAGE=? -->
o inducing systemic diuresis

<!-- PAGE=? -->
o decreasing CSF production by interfering with sodium ion transport in glial tissue

<!-- PAGE=? -->
o resolves cerebral edema by improving cellular water transport

<!-- PAGE=? -->
 not associated with changes in cerebral blood flow or plasma osmolarity

<!-- PAGE=? -->
 not as effective as mannitol for decreasing ICP

<!-- PAGE=? -->
 Alterations in the blood-brain barrier do not influence the immediate or subsequent effects of furosemide on ICP

<!-- PAGE=? -->
 A combination of furosemide and mannitol is more effective in decreasing ICP than either drug alone

<!-- PAGE=? -->
Acetazolamide

<!-- PAGE=? -->
 Inhibits the formation of CSF

<!-- PAGE=? -->
Brain Herniation Syndromes

<!-- PAGE=? -->
 Transtentorial/uncal

<!-- PAGE=? -->
o medial aspect of the temporal lobe, pressure on CN III with disruption of parasympathetic pupillary constriction and brainstem

<!-- PAGE=? -->
 Subfalcine

<!-- PAGE=? -->
o cingulate gyrus on medial aspect of frontal lobe, pressure on anterior cerebral artery rather than brainstem

<!-- PAGE=? -->
 Central herniation

<!-- PAGE=? -->
o

<!-- PAGE=? -->
diffuse injury with bilateral upper hemispheric herniation with considerable pressure on brainstem

<!-- PAGE=? -->


<!-- PAGE=? -->
Upward/cerebellar herniation

<!-- PAGE=? -->
o mass in the posterior fossa pushed upward through tentorium with significant upper brainstem pressure

<!-- PAGE=? -->
 Tonsillar

<!-- PAGE=? -->
o cerebellar tonsils forced downward through foramen magnum with pressure on brainstem and upper cervical cord

<!-- PAGE=? -->
 Calvarial herniation

<!-- PAGE=? -->
o through fracture sites

<!-- PAGE=? -->
Jugular venous bulbs:

<!-- PAGE=? -->
 SjvO2

<!-- PAGE=? -->
o < 55% is associated with worsened outcome

<!-- PAGE=? -->
o > 75% may indicate low cerebral metabolic rate of oxygen (CMRO2)

<!-- PAGE=? -->
 no direct correlatio n between this measurement and CBF but trend may be useful

<!-- PAGE=? -->
 AVDO2 = 1.34 x hgb x (SaO2 - SjvO2)

<!-- PAGE=? -->
o Normal 6

<!-- PAGE=? -->
o Increase means insuffient blood flow

<!-- PAGE=? -->
o Decrease indicates hyperemia

<!-- PAGE=? -->
o Global measure so prone to errors

<!-- PAGE=? -->
Immunosuppressants

<!-- PAGE=? -->
Barash, P&P, Miller

<!-- PAGE=? -->
 Toxic side effects

<!-- PAGE=? -->
o CNS

<!-- PAGE=? -->
 exists with virtually all chemotherapies

<!-- PAGE=? -->
o Liver

<!-- PAGE=? -->
 Azathioprine, cyclosporine, tacrolimus, cyclophosphamide

<!-- PAGE=? -->
o Renal

<!-- PAGE=? -->
 cyclosporine, tacrolimus

<!-- PAGE=? -->
o Pulmonary

<!-- PAGE=? -->
 cyclophosphamide, bleomycin

<!-- PAGE=? -->
o Heme

<!-- PAGE=? -->
 All chemotherapeutic agents can cause bone marrow suppression

<!-- PAGE=? -->
 anemia, thrombocytopenia, leucopenia

<!-- PAGE=? -->
Cyclophosphamide

<!-- PAGE=? -->
 depresses the pseudocholinestherase activity for several weeks after discontinuation

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o bone marrow depression

<!-- PAGE=? -->
 thrombocytopenia

<!-- PAGE=? -->
o alopecia

<!-- PAGE=? -->
o hemorrhagic cystitis

<!-- PAGE=? -->
o nausea and vomiting

<!-- PAGE=? -->
 can act as anticholinesterase and prolong neuromuscular blockade

<!-- PAGE=? -->


<!-- PAGE=? -->
Cyclosporine

<!-- PAGE=? -->
 causes renal injury secondary to induced sympathetic hyperreactivity, hypertension, and renal vasoconstriction

<!-- PAGE=? -->
o Preexisting renal dysfunction, hypovolemia, and other nephrotoxic insults exacerbate its nephrotoxic effects

<!-- PAGE=? -->
o Many transplant patients must tolerate a moderately elevated serum creatinine to sustain adequate immunosuppression

<!-- PAGE=? -->
 Tacrolimus (FK-506) is a calcineurin immunosuppressive agent related to cyclosporine

<!-- PAGE=? -->
o somewhat less nephrotoxic than cyclosporine and has largely replaced it in liver transplantation

<!-- PAGE=? -->
o mycophenolate has also been developed in an effort to decrease or eliminate the cyclosporine requirement during induction

<!-- PAGE=? -->
Methotrexate

<!-- PAGE=? -->
 CNS toxicity includes

<!-- PAGE=? -->
o encephalopathic syndromes (confusion, ataxia , tremor)

<!-- PAGE=? -->
o quadriparesis

<!-- PAGE=? -->
o seizures (after both is or intrathecal (IT)

<!-- PAGE=? -->
 IT route is also associated with meningeal irritation

<!-- PAGE=? -->
 bone marrow depression

<!-- PAGE=? -->
 ulcerative stomatitis

<!-- PAGE=? -->
 pulmonary interstitial infiltrates

<!-- PAGE=? -->
 GI toxicity

<!-- PAGE=? -->
 occasionally severe liver dysfunction

<!-- PAGE=? -->
Vinca alkaloids (Vincristine, Vinblastin)

<!-- PAGE=? -->
 Myelosuppression is the most prominent side effect

<!-- PAGE=? -->
o leukopenia, thrombocytopenia, and anemia

<!-- PAGE=? -->
o appears 7 to 10 days after initiation of treatment

<!-- PAGE=? -->
 peripheral neuropathies (axonal degeneration)

<!-- PAGE=? -->
o dose-dependent

<!-- PAGE=? -->
o loss of Achilles tendon reflex is the first sign

<!-- PAGE=? -->
o paresthesisas of hands and feet (75% of patients)

<!-- PAGE=? -->
o muscles pains, weakness, sensory impairment

<!-- PAGE=? -->
o CN, recurrent laryngeal nerve

<!-- PAGE=? -->
o autonomic neuropathy (paralytic ileus, bladder atony, orthostatic hypotension)

<!-- PAGE=? -->
o reversible after discontinuing the drug, although this may require months, and in some patients the resolution may be incomplete

<!-- PAGE=? -->
 SIADH

<!-- PAGE=? -->
 Autonomic dysfunction

<!-- PAGE=? -->
o paralytic ileus  with abdominal pain

<!-- PAGE=? -->
o Urinary retention

<!-- PAGE=? -->
o tenderness of the parotid glands

<!-- PAGE=? -->
o dryness of the mouth

<!-- PAGE=? -->
o sinus tachycardia

<!-- PAGE=? -->
Cisplatin

<!-- PAGE=? -->
 peripheral neuropathies and severe nausea

<!-- PAGE=? -->
Adriamycin (Doxorubicin)

<!-- PAGE=? -->
 used for leukemias, lymphomas, solid tumors (breast)

<!-- PAGE=? -->
 Pulmonary infiltrates

<!-- PAGE=? -->
 GI and hepatic disturbances

<!-- PAGE=? -->
 Renal dysfunction

<!-- PAGE=? -->
 acute, reversible EKG changes (nonspecific ST-T) in 33% cases

<!-- PAGE=? -->
 depressed QRS voltage of >30% is irreversible and predictive of subsequent cardiomyopathy

<!-- PAGE=? -->
 Cardiomyopathy

<!-- PAGE=? -->
o days to years after cessation

<!-- PAGE=? -->
o incidence 2-32%

<!-- PAGE=? -->
o mortality 61%

<!-- PAGE=? -->
o risk factor

<!-- PAGE=? -->
 total dose > 550 mg/m 2

<!-- PAGE=? -->
 irradiation

<!-- PAGE=? -->
o Angiography is the best noninvasive diagnostic test

<!-- PAGE=? -->
 Endomyocardial biopsy is the gold standard

<!-- PAGE=? -->
Bleomycin

<!-- PAGE=? -->
 used for lymphomas, testicular tumors, squamous cell carcinoma

<!-- PAGE=? -->
 pulmonary toxicity

<!-- PAGE=? -->
o pulmonary fibrosis

<!-- PAGE=? -->
 most common - 2-40%

<!-- PAGE=? -->
 10% mortality)

<!-- PAGE=? -->
o pHTN

<!-- PAGE=? -->
o acute hypersensitivity rxn

<!-- PAGE=? -->
o noncardiogenic pulmonary edema.

<!-- PAGE=? -->
o Risk factors

<!-- PAGE=? -->
 dose response curve

<!-- PAGE=? -->
 radiation

<!-- PAGE=? -->
 concurrent cyclophosphaminde

<!-- PAGE=? -->
 increased age

<!-- PAGE=? -->
 high FiO2 has been implicated as a risk factor but not clearly proven

<!-- PAGE=? -->
 it is prudent to keep low FiO2 in patients with hx of Bleomycin

<!-- PAGE=? -->
 Common side effects include

<!-- PAGE=? -->
o mucocutaneous reactions - stomatitis

<!-- PAGE=? -->
o alopecia

<!-- PAGE=? -->
o pruritus

<!-- PAGE=? -->
o erythema

<!-- PAGE=? -->
o hyperpigmentation

<!-- PAGE=? -->
 bleomycin causes minimal myelosuppression

<!-- PAGE=? -->
 Unexplained exacerbations of rheumatoid arthritis have occurred

<!-- PAGE=? -->
 Patients with lymphomas who are receiving bleomycin may develop an acute reaction characterized by

<!-- PAGE=? -->
o Hyperthermia

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
o Hypoventilation

<!-- PAGE=? -->
 The likely mechanism is release of an endogenous pyrogen, presumably from destroyed tumor cells

<!-- PAGE=? -->
Indomethacin

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 NSAID

<!-- PAGE=? -->
 Methylated indole derivative with analgesic, antipyretic, anti-inflammatory effects comparable to salicylates

<!-- PAGE=? -->
 One of the most potent inhibitors of cyclooxygenase enzyme known

<!-- PAGE=? -->
 Treatment of choice for ankylosing spondylitis (and useful in arthritis)

<!-- PAGE=? -->
 May be considered for Reiter's syndrome (now known as Reactive Arthritis that develops usually in response to systemic bacterial infection (most common are Chlamydia, Gonorrhea, Yersinia, Shigella, Salmonella, Campylobacter; sxs include uveitis, urethritis, and arthritis: -can't see, can't pee, and can't climb a tree‖)

<!-- PAGE=? -->
 Single dose for heart failure in neonates with PDA (potent inhibitor of prostaglandins)

<!-- PAGE=? -->
 Absorbed rapidly and completely from GI tract

<!-- PAGE=? -->
 Extensive protein binding (90%)

<!-- PAGE=? -->
 Hepatic metabolism to inactive substances

<!-- PAGE=? -->
 Severe adverse side effects limit usefulness of this drug

<!-- PAGE=? -->
o GI disturbances common

<!-- PAGE=? -->
o Severe frontal H/As common

<!-- PAGE=? -->
o LFTs may become abnormal

<!-- PAGE=? -->
o Exacerbation of pre-existing renal disease

<!-- PAGE=? -->
o Neutropenia, thrombocytopenia, aplastic anemia are rare

<!-- PAGE=? -->
o Inhibits platelet aggregation

<!-- PAGE=? -->
o Allergic reactions do occur and cross-sensitivity to salicylates do occur

<!-- PAGE=? -->
 Probably enhaces effects of ADH by inhibition of synthesis of prostaglandins

<!-- PAGE=? -->
 Indomethacin may attenuate effects of furosemide (which is dependent on prostaglandins to increase renal blood flow

<!-- PAGE=? -->
 Should be used with caution in patients with Parkinson's, epilepsy, and psychiatric disorders (in CPS 2004 p 960)

<!-- PAGE=? -->
 Half-life = 4-5 hours

<!-- PAGE=? -->
 Maximum daily dose is 200mg/day (Miller)

<!-- PAGE=? -->
Induced Hypotension

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 SNP

<!-- PAGE=? -->
o The most widely used drug for IV induction of hypotension

<!-- PAGE=? -->
 rapid onset

<!-- PAGE=? -->
 short half-life

<!-- PAGE=? -->
 dilation of resistance vessels without affecting cardiac output

<!-- PAGE=? -->
 may preferentially increase CBF to the ischemic penumbra

<!-- PAGE=? -->
 Inhalational agents cause

<!-- PAGE=? -->
o myocardial depression

<!-- PAGE=? -->
o autoregulatory loss of vital organ blood flow

<!-- PAGE=? -->
o reduction in CPP as MAP decreases

<!-- PAGE=? -->
o increased ICP

<!-- PAGE=? -->
o increased cerebral edema

<!-- PAGE=? -->
o accumulation of anaerobic metabolites

<!-- PAGE=? -->
 Labetalol

<!-- PAGE=? -->
o limited potency/efficacy

<!-- PAGE=? -->
 Mg does not cause hypotension

<!-- PAGE=? -->
 Hydralazine

<!-- PAGE=? -->
o elimination half-life of 4 hrs, but the effective half-life is close to 100 hours !! (due to avid binding to smooth muscle)

<!-- PAGE=? -->
Induction Drugs

<!-- PAGE=? -->
Induction Characteristics and Dosage Requirements for Intravenous Anesthetic Drugs

<!-- PAGE=? -->
Drug

<!-- PAGE=? -->
Induction Dose

<!-- PAGE=? -->
(mg/kg)

<!-- PAGE=? -->
Onset

<!-- PAGE=? -->
(sec)

<!-- PAGE=? -->
Duration

<!-- PAGE=? -->
(min)

<!-- PAGE=? -->
Excitatory

<!-- PAGE=? -->
Activity

<!-- PAGE=? -->
Pain on

<!-- PAGE=? -->
Injection

<!-- PAGE=? -->
Heart

<!-- PAGE=? -->
Rate

<!-- PAGE=? -->
Blood

<!-- PAGE=? -->
Pressure

<!-- PAGE=? -->
Thiopental

<!-- PAGE=? -->
3-6

<!-- PAGE=? -->
<30

<!-- PAGE=? -->
5-10

<!-- PAGE=? -->
+

<!-- PAGE=? -->
0/+

<!-- PAGE=? -->
+

<!-- PAGE=? -->
-

<!-- PAGE=? -->
Methohexital   1-3

<!-- PAGE=? -->
<30

<!-- PAGE=? -->
5-10

<!-- PAGE=? -->
++

<!-- PAGE=? -->
+

<!-- PAGE=? -->
++

<!-- PAGE=? -->
-

<!-- PAGE=? -->
Propofol

<!-- PAGE=? -->
1.5-2.5

<!-- PAGE=? -->
15-45

<!-- PAGE=? -->
5-10

<!-- PAGE=? -->
+

<!-- PAGE=? -->
++

<!-- PAGE=? -->
0/-

<!-- PAGE=? -->
-

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
0.2-0.4

<!-- PAGE=? -->
30-90

<!-- PAGE=? -->
10-30

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0/-

<!-- PAGE=? -->
Diazepam

<!-- PAGE=? -->
0.3-0.6

<!-- PAGE=? -->
45-90

<!-- PAGE=? -->
15-30

<!-- PAGE=? -->
0

<!-- PAGE=? -->
+++

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0/-

<!-- PAGE=? -->
Lorazepam

<!-- PAGE=? -->
0.03-0.06

<!-- PAGE=? -->
60-120

<!-- PAGE=? -->
60-120

<!-- PAGE=? -->
0

<!-- PAGE=? -->
++

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0/-

<!-- PAGE=? -->
Etomidate

<!-- PAGE=? -->
0.2-0.3

<!-- PAGE=? -->
15-45

<!-- PAGE=? -->
13-12

<!-- PAGE=? -->
+++

<!-- PAGE=? -->
+++

<!-- PAGE=? -->
0

<!-- PAGE=? -->
0

<!-- PAGE=? -->
Ketamine

<!-- PAGE=? -->
1-2

<!-- PAGE=? -->
45-60

<!-- PAGE=? -->
10-20

<!-- PAGE=? -->
+

<!-- PAGE=? -->
0

<!-- PAGE=? -->
++

<!-- PAGE=? -->
++

<!-- PAGE=? -->
0 = no change; + = increase; - = decrease.

<!-- PAGE=? -->
Infared Spectroscopy

<!-- PAGE=? -->
 IR analyzers are capable of measuring

<!-- PAGE=? -->
o CO2

<!-- PAGE=? -->
o nitrous oxide

<!-- PAGE=? -->
o all of the commonly used potent volatile agents

<!-- PAGE=? -->
 O2 and N2 cannot be measured by IR technology

<!-- PAGE=? -->
 IR analyzers are based on the fact that gases that have 2 or more dissimilar atoms in the molecule have specific and unique absorption spectra of IR light

<!-- PAGE=? -->
Infective Endocarditis prophylaxis

<!-- PAGE=? -->
AHA 2007 Guidelines

<!-- PAGE=? -->
TABLE 6 Summary of Major Changes in Updated Document

<!-- PAGE=? -->
We concluded that bacteremia resulting from daily activities is much more likely to cause IE than bacteremia associated with a dental procedure.

<!-- PAGE=? -->
We concluded that only an extremely small number of cases of IE might be prevented by antibiotic prophylaxis even if prophylaxis is 100% effective.

<!-- PAGE=? -->
Antibiotic prophylaxis is not recommended based solely on an increased lifetime risk of acquisition of IE

<!-- PAGE=? -->
Limit recommendations for IE prophylaxis only to those conditions listed in Table 3.

<!-- PAGE=? -->
Antibiotic prophylaxis is no longer recommended for any other form of CHD, except for the conditions listed in Table 3.

<!-- PAGE=? -->
Antibiotic prophylaxis is recommended for all dental procedures that involve manipulation of gingival tissues or periapical region of teeth or perforation of oral mucosa only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from IE (Table 3).

<!-- PAGE=? -->
Antibiotic prophylaxis is recommended for procedures on respiratory tract or infected skin, skin structures; or musculoskeletal tissue only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from IE (Table 3)

<!-- PAGE=? -->
Antibiotic prophylaxis solely to prevent IE is not recommended for GU or GI tract procedures.

<!-- PAGE=? -->
The writing group reaffirms the procedures noted in the 1997 prophylaxis guidelines for which endocarditis prophylaxis is not recommended and extends this to other common procedures, including ear and body piercing; tattooing, and vaginal delivery and hysterectomy .

<!-- PAGE=? -->
TABLE 3. Cardiac Conditions Associated With the Highest Risk of Adverse Outcome From Endocarditis for Which Prophylaxis With Dental Procedures Is Recommended

<!-- PAGE=? -->
Prosthetic cardiac valve

<!-- PAGE=? -->
Previous IE

<!-- PAGE=? -->
Congenital heart disease (CHD)*

<!-- PAGE=? -->
Unrepaired cyanotic CHD, including palliative shunts and conduits

<!-- PAGE=? -->
Completely repaired congenital heart defect with prosthetic material or device; whether placed by surgery or by catheter intervention; during the first 6 months after the proceduret

<!-- PAGE=? -->
Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device (which inhibit endothelialization)

<!-- PAGE=? -->
Cardiac transplantation recipients who develop cardiac valvulopathy

<!-- PAGE=? -->
'Except for the conditions listed above; antibiotic prophylaxis is no longer recommended for any other form of CHD.

<!-- PAGE=? -->
tProphylaxis is recommended because endothelialization of   prosthetic material occurs within 6 months after the procedure.

<!-- PAGE=? -->
TABLE 5. Regimens for a Dental Procedure

<!-- PAGE=? -->
IM indicates intramuscular; WV, intravenous.

<!-- PAGE=? -->
tCephalosporins should not be used in an individual with history of anaphylaxis; angioedema; or urticaria with penicillins or ampicillin.

<!-- PAGE=? -->
"Or other first- or second-generation oral cephalosporin in equivalent adult or pediatric dosage.

<!-- PAGE=? -->
Inhalational Anesthetics

<!-- PAGE=? -->
(From Barash)

<!-- PAGE=? -->
(From P&P)

<!-- PAGE=? -->
change in right atrial or central venous pressure

<!-- PAGE=? -->
Lolluranz

<!-- PAGE=? -->
scvolluanc

<!-- PAGE=? -->
change in systcmic vascular rsistancc

<!-- PAGE=? -->
mninimun alvevlr concentration

<!-- PAGE=? -->
1600

<!-- PAGE=? -->
1400

<!-- PAGE=? -->
1200

<!-- PAGE=? -->
Halothane

<!-- PAGE=? -->
Isollurane

<!-- PAGE=? -->
1000

<!-- PAGE=? -->
800

<!-- PAGE=? -->
600

<!-- PAGE=? -->
400

<!-- PAGE=? -->
0.0

<!-- PAGE=? -->
0.5

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
1.5

<!-- PAGE=? -->
2.0

<!-- PAGE=? -->
25

<!-- PAGE=? -->
MAC

<!-- PAGE=? -->
 Most texts say Halothane and Enflurane have most myocardial depressant effects and Sevoflurane, Isoflurane, and Desflurane have primiary decreased SVR effects causing reductions in MAP

<!-- PAGE=? -->
 (Miller Ch 5)

<!-- PAGE=? -->
o All modern volatile anesthetics cause concentration-related decreases in arterial pressure.  The mechanism by which these agents reduce arterial pressure differs among anesthetics.

<!-- PAGE=? -->
o Decreases in arterial pressure produced by halothane and enflurane can be primarily attributed to reductions in myocardial contractility and cardiac output.

<!-- PAGE=? -->
o In contrast, decreases in arterial pressure associated with isoflurane, desflurane, and sevoflurane anesthesia occur as a result of reductions in LV afterload , whereas myocardial contractility is relatively preserved.

<!-- PAGE=? -->
o Thus, isoflurane, desflurane, and sevoflurane maintain cardiac output because these agents produce less pronounced reductions in myocardial contractility and greater decreases in systemic vascular resistance than does halothane or enflurane in humans.

<!-- PAGE=? -->
Insulin

<!-- PAGE=? -->
 produced by beta cells of the pancreas

<!-- PAGE=? -->
 normal production = 40 -50 U /day

<!-- PAGE=? -->
 t1/2 is a few minutes

<!-- PAGE=? -->
 metabolized by kidney and liver

<!-- PAGE=? -->
o risk of hypoglycaemia with insulin treatment in liver disease (increased duration of action)

<!-- PAGE=? -->
 stimulation of insulin release

<!-- PAGE=? -->
o direct effect of glucose

<!-- PAGE=? -->
o vagal stimulation

<!-- PAGE=? -->
o  -adrenergic stimulation

<!-- PAGE=? -->
 action

<!-- PAGE=? -->
o increased uptake of glucose into cells

<!-- PAGE=? -->
 exception is liver and brain

<!-- PAGE=? -->
o potassium entry in to cells

<!-- PAGE=? -->
o anabolic hormone

<!-- PAGE=? -->
 glycogen formation

<!-- PAGE=? -->
 decreased lipolysis and gluconeogenesis

<!-- PAGE=? -->
 deficiency result in catabolism and negative nitrogen balance

<!-- PAGE=? -->
 Counterregulatory hormones (released with stress)

<!-- PAGE=? -->
o catecholamines,  cortisol,  glucagons, growth hormone act to cause hyperglycemia

<!-- PAGE=? -->
 Metformin causes lactic acidosis

<!-- PAGE=? -->
Intubation Complications

<!-- PAGE=? -->
Miller, Dorsch, Barash

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o High pressure (low volume) cuffed ETTs are associated with more ischemic damage to the tracheal mucosa

<!-- PAGE=? -->
 Tissue ischemia occurs when cuff pressure exceeds capillary-arteriolar blood pressure = 30 mm Hg

<!-- PAGE=? -->
o Pediatric pts are more prone to post-intubation croup

<!-- PAGE=? -->
 Laryngeal edema has a peak incidence between 1 and 4 years

<!-- PAGE=? -->
o Injury during intubation is more likely in

<!-- PAGE=? -->
 Children

<!-- PAGE=? -->
 female patients

<!-- PAGE=? -->
 higher incidence of laryngeal edema as compared to men

<!-- PAGE=? -->
 patients with poor dentition

<!-- PAGE=? -->
 difficult tracheal intubation. [Miller 2192]

<!-- PAGE=? -->
o The longer the duration of intubation the greater the potential for tracheal ischemia

<!-- PAGE=? -->
 Ulcerations (erosions) of the larynx and trachea increase in incidence and severity with the duration of intubation

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Smaller tubes are associated with fewer tracheal complications

<!-- PAGE=? -->
Intercostal Nerve Block

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 The intercostal nerves are the primary rami of T1 through T11

<!-- PAGE=? -->
o T12 is technically a subcostal nerve and supplies branches to the ilioinguinal and iliohypogastric nerves

<!-- PAGE=? -->
 Each intercostal nerve has four branches

<!-- PAGE=? -->
o the gray ramus communicans

<!-- PAGE=? -->
 passes anterior to the sympathetic ganglion

<!-- PAGE=? -->
o the posterior cutaneous branch

<!-- PAGE=? -->
 supplies the skin and muscle in the paravertebral area

<!-- PAGE=? -->
o the lateral cutaneous branch

<!-- PAGE=? -->
 arises just anterior to the midaxillary line

<!-- PAGE=? -->
 sends subcutaneous branches anteriorly and posteriorly

<!-- PAGE=? -->
o the anterior cutaneous branch

<!-- PAGE=? -->
 the termination of the nerve

<!-- PAGE=? -->
 Medial to the posterior angles of the ribs, the intercostal nerves lie between the pleura and the internal intercostal fascia

<!-- PAGE=? -->
 At the posterior angle of the rib, the nerve lies in the costal groove accompanied by the intercostal vein and artery.

<!-- PAGE=? -->
Technique

<!-- PAGE=? -->
 readily blocked at the angle of the rib just lateral to the sacrospinalis muscle group

<!-- PAGE=? -->
 the nerve is blocked at the posterior angles of the rib (6 to 8 cm from the midline) on the inferior surface

<!-- PAGE=? -->
o insert the needle 3 - 5mm past the rib

<!-- PAGE=? -->
 an intercostal block can be performed in a supine patient at the midaxillary line

<!-- PAGE=? -->
o the lateral cutaneous branch of the nerve may be missed

<!-- PAGE=? -->
Side Effects and Complications

<!-- PAGE=? -->
 Pneumothorax

<!-- PAGE=? -->
o Incidence is low

<!-- PAGE=? -->
 Routine postoperative CXR showed a 0.42% incidence of nonsymptomatic pneumothorax

<!-- PAGE=? -->
o treatment is usually limited to observation, administration of oxygen, or needle aspiration

<!-- PAGE=? -->
o Rarely, chest tube drainage is required when these treatments are unsuccessful

<!-- PAGE=? -->
 Systemic local anesthetic toxicity

<!-- PAGE=? -->
o large volumes are rapidly absorption

<!-- PAGE=? -->
o epinephrine has been shown to decrease blood levels

<!-- PAGE=? -->
o Patients should be monitored and observed carefully during the block and for at least 20 to 30 minutes afterward

<!-- PAGE=? -->
 Patients with severe pulmonary disease who rely on their intercostal muscles may exhibit respiratory decompensation after bilateral intercostal blockade

<!-- PAGE=? -->
Intraocular pressure (IOP)

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Normal IOP is approximately 12 to 20 mm Hg, with a diurnal variation of 2 to 3 mm Hg and positional changes of 1 to 6 mm Hg.

<!-- PAGE=? -->
 The most important influences on IOP are

<!-- PAGE=? -->
o aqueous humor dynamics

<!-- PAGE=? -->
o changes in choroidal blood volume (CBV),

<!-- PAGE=? -->
o central venous pressure

<!-- PAGE=? -->
o extraocular muscle ton

<!-- PAGE=? -->
 coughing, straining, the Valsalva maneuver, or vomiting can cause transient, but significant increases in IOP

<!-- PAGE=? -->
 narcotics, tranquilizers, and anesthetics reduce IOP

<!-- PAGE=? -->
o relax extraocular muscle tone

<!-- PAGE=? -->
o depress the CNS (i.e., the diencephalon),

<!-- PAGE=? -->
o improve the outflow of aqueous humor,

<!-- PAGE=? -->
o reduce aqueous production

<!-- PAGE=? -->
o lower venous and arterial blood pressure

<!-- PAGE=? -->
 succinylcholine and ketamine may increase IOP

<!-- PAGE=? -->
o succinylcholine - transient 4-6min incr of 10-20mmHg

<!-- PAGE=? -->
 no proven technique to mitigate

<!-- PAGE=? -->
 likely not clinically significant

<!-- PAGE=? -->
o Ketamine after premed with diazepam and meperidine does not affect IOP and IM may decr IOP in kids

<!-- PAGE=? -->
 Control SNS response to intubation with lido, suf or remi

<!-- PAGE=? -->
 Hypocapnia decreases IOP through vasoconstriction of the choroidal blood vessels and decreases the formation of aqueous humor through reduced carbonic anhydrase activity

<!-- PAGE=? -->
o Hypercapnia inc. IOP

<!-- PAGE=? -->
 SF6 gas bubbles remain present for at least 10 days

<!-- PAGE=? -->
o Other intravitreal gases may remain for as long as 21 to 28 days

<!-- PAGE=? -->
 N2O should be avoided in any patient returning for a general anesthetic within 3 to 4 weeks of undergoing intravitreal gas injection

<!-- PAGE=? -->
Ipratropium

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 synthetic quaternary ammonium congener of atropine

<!-- PAGE=? -->
o combines reversibly with muscarinic cholinergic receptors and thus prevent access of the neurotransmitter acetylcholine

<!-- PAGE=? -->
 competitive antagonist

<!-- PAGE=? -->
 most effective in preventing and treating bronchospasm due to beta-adrenergic antagonists or psychogenic stimuli

<!-- PAGE=? -->
 in asthma, ipratropium has a slower onset (30 to 90 minutes) and is less effective than beta agonists

<!-- PAGE=? -->
o beta agonists may be more effective in asthma because they inhibit the release and the subsequent airway smooth muscle contraction caused by chemical mediators such as histamine and leukotrienes

<!-- PAGE=? -->
o Ipratropium may be administered with beta agonists in the treatment of bronchial asthma, because this drug augments the bronchodilating effects of beta agonists

<!-- PAGE=? -->
 Ipratropium is more effective than beta agonists in producing bronchodilation (blocks M3 receptors) in patients with chronic bronchitis or emphysema, emphasizing the role of cholinergic tone in the latter patients

<!-- PAGE=? -->
 Paradoxical bronchoconstriction may occur immediately after inhalation of ipratropium, reflecting preferential blockade of M2 receptors by this drug

<!-- PAGE=? -->
 Ipratropium has no effect on the heart rate and intraocular pressure

<!-- PAGE=? -->
o minimal systemic absorption (<1% of the inhaled dose) of this quaternary ammonium drug

<!-- PAGE=? -->
 Effects of this drug on mucociliary activity and mucus secretion in the airways are minimal

<!-- PAGE=? -->
 Tolerance to the bronchodilator effect of ipratropium has not been observed

<!-- PAGE=? -->
 administered with beta agonists in the treatment of bronchial asthma, because this drug augments the bronchodilating effects of beta agonists and provides its own sustained effect

<!-- PAGE=? -->
IV regional

<!-- PAGE=? -->
CJA 2002, Cousins

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
o 3mg/kg 0.5% lidocaine

<!-- PAGE=? -->
 Adjuvants

<!-- PAGE=? -->
o many drugs have been tried either added to LA or as singular agents in IVRA

<!-- PAGE=? -->
 opioids, ketamine, muscle relaxants not demonstrated to be of any net benefit

<!-- PAGE=? -->
o NSAIDS useful (e.g. ketorolac 20-60 mg added to LA of choice-prolong tourniquet tolerance time)

<!-- PAGE=? -->
o Clonidine useful (1 μg/kg added to LA of choiceno iv in canada )

<!-- PAGE=? -->
o Ketorolac and clonidine improved post-deflation analgesia

<!-- PAGE=? -->
 Fentanyl may also delay post-operative pain, but there is no consensus

<!-- PAGE=? -->
 Advantages

<!-- PAGE=? -->
o Simple technique with a  high success rate

<!-- PAGE=? -->
o Quick onset

<!-- PAGE=? -->
 Disadvantages

<!-- PAGE=? -->
o Inc. risk of local anesthetic toxicity (compared to brachial plexus blocks)

<!-- PAGE=? -->
 Tourniquet

<!-- PAGE=? -->
o Barash pg 728 tourniquet is inflated to 300 mmHg or 2.5 X SBP

<!-- PAGE=? -->
o Miller pg 1695 the proximal cuff is inflated to approx 150 mmHg above SBP

<!-- PAGE=? -->
o The tourniquet may be safely released after 25 minutes

<!-- PAGE=? -->
o Max of 90 min tourniquet time (30-60 is ideal)

<!-- PAGE=? -->
o use the upper arm rather than forearm for occluding tourniquet

<!-- PAGE=? -->
o feeling for the radial pulse to confirm occlusion

<!-- PAGE=? -->
Interscalene Block

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Complications include:

<!-- PAGE=? -->
o injection in the vertebral artery

<!-- PAGE=? -->
o epidural, subarachnoid, subdural injection

<!-- PAGE=? -->
o pneumothorax (especially in COPD)

<!-- PAGE=? -->
o Stellate ggl block - Horner's syndrome (myosis, ptosis, anhydrosis) - 30-50% of cases

<!-- PAGE=? -->
o Recurrent laryngeal nerve block - 30-50%

<!-- PAGE=? -->
o Phrenic nerve block in up to 100%

<!-- PAGE=? -->
o Severe hypotension and bradycardia (Bezold-Jarish reflex) - reported in sitting pts

<!-- PAGE=? -->
o Nerve damage or neuritis uncommon

<!-- PAGE=? -->
J

<!-- PAGE=? -->
Jaundice (new onset) in pregnancy

<!-- PAGE=? -->
Most common to least common

<!-- PAGE=? -->
Viral Hepatitis

<!-- PAGE=? -->
Intrahepatic Cholestasis of Pregnancy (IHCP)

<!-- PAGE=? -->
 PIH/HEELP

<!-- PAGE=? -->
Hepatic rupture (80% related to preeclampsia)

<!-- PAGE=? -->
Fatty Liver of Pregnancy

<!-- PAGE=? -->
Others to consider are:  drug induced hepatotoxicity, cholelithiasis and bile duct obstruction, Budd-Chiari, chronic liver disease

<!-- PAGE=? -->
TABLE 253-3

<!-- PAGE=? -->
-- ETIOLOGY OF NEW-ONSET

<!-- PAGE=? -->
DURING

<!-- PAGE=? -->
JAUNDICE

<!-- PAGE=? -->
PREGNANCY

<!-- PAGE=? -->
DIAGNOSIS

<!-- PAGE=? -->
PREVALENCE

<!-- PAGE=? -->
WHEN

<!-- PAGE=? -->
SYMPTOMS

<!-- PAGE=? -->
SIGNS

<!-- PAGE=? -->
AST

<!-- PAGE=? -->
Alk Phos

<!-- PAGE=? -->
BILI

<!-- PAGE=? -->
OTHER

<!-- PAGE=? -->
MATERNAL

<!-- PAGE=? -->
OUTCOME

<!-- PAGE=? -->
FETAL

<!-- PAGE=? -->
OUTCOME

<!-- PAGE=? -->
RX

<!-- PAGE=? -->
RECURRE

<!-- PAGE=? -->
NCE RATE

<!-- PAGE=? -->
Viral hepatitis

<!-- PAGE=? -->
(leading

<!-- PAGE=? -->
cause of

<!-- PAGE=? -->
jaundice

<!-- PAGE=? -->
during

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
[50% of

<!-- PAGE=? -->
total])

<!-- PAGE=? -->
Acute hepatitis

<!-- PAGE=? -->
A or C in 1 per

<!-- PAGE=? -->
1000

<!-- PAGE=? -->
pregnancies

<!-- PAGE=? -->
Acute hepatitis

<!-- PAGE=? -->
B in 2 per 1000

<!-- PAGE=? -->
pregnancies

<!-- PAGE=? -->
Any

<!-- PAGE=? -->
trimester

<!-- PAGE=? -->
Usual

<!-- PAGE=? -->
symptoms of

<!-- PAGE=? -->
viral hepatitis

<!-- PAGE=? -->
Usual signs of

<!-- PAGE=? -->
viral hepatitis

<!-- PAGE=? -->
Typical of

<!-- PAGE=? -->
non-

<!-- PAGE=? -->
pregnant

<!-- PAGE=? -->
individuals

<!-- PAGE=? -->
with viral

<!-- PAGE=? -->
hepatitis

<!-- PAGE=? -->
Typical of

<!-- PAGE=? -->
non-pregnant

<!-- PAGE=? -->
individuals

<!-- PAGE=? -->
with viral

<!-- PAGE=? -->
hepatitis

<!-- PAGE=? -->
Typical of non-

<!-- PAGE=? -->
pregnant

<!-- PAGE=? -->
individuals with

<!-- PAGE=? -->
viral hepatitis

<!-- PAGE=? -->
Serologic

<!-- PAGE=? -->
diagnosis is

<!-- PAGE=? -->
typical of non-

<!-- PAGE=? -->
pregnant

<!-- PAGE=? -->
individuals with

<!-- PAGE=? -->
viral hepatitis

<!-- PAGE=? -->
Comparable to non-

<!-- PAGE=? -->
pregnant individuals

<!-- PAGE=? -->
Potential for

<!-- PAGE=? -->
transmission at

<!-- PAGE=? -->
delivery is an

<!-- PAGE=? -->
indication for

<!-- PAGE=? -->
passive (hepatitis

<!-- PAGE=? -->
B immuno-

<!-- PAGE=? -->
globulin) and

<!-- PAGE=? -->
active (hepatitis B

<!-- PAGE=? -->
vaccine)

<!-- PAGE=? -->
immunization;

<!-- PAGE=? -->
utility passive

<!-- PAGE=? -->
immunization for

<!-- PAGE=? -->
hepatitis C not

<!-- PAGE=? -->
established

<!-- PAGE=? -->
Supportive and

<!-- PAGE=? -->
similar to

<!-- PAGE=? -->
general

<!-- PAGE=? -->
guidelines for

<!-- PAGE=? -->
viral hepatitis

<!-- PAGE=? -->
Natural

<!-- PAGE=? -->
history of

<!-- PAGE=? -->
viral

<!-- PAGE=? -->
hepatitides

<!-- PAGE=? -->
is

<!-- PAGE=? -->
unchanged

<!-- PAGE=? -->
by

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
Intrahepatic

<!-- PAGE=? -->
cholestasis of

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
(IHCP)

<!-- PAGE=? -->
(second

<!-- PAGE=? -->
leading

<!-- PAGE=? -->
cause of

<!-- PAGE=? -->
jaundice

<!-- PAGE=? -->
during

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
)

<!-- PAGE=? -->
Varies with

<!-- PAGE=? -->
ethnicity (0.1%

<!-- PAGE=? -->
in United

<!-- PAGE=? -->
States-20% in

<!-- PAGE=? -->
Chile)

<!-- PAGE=? -->
Third

<!-- PAGE=? -->
trimester

<!-- PAGE=? -->
Pruritus of

<!-- PAGE=? -->
entire body,

<!-- PAGE=? -->
usually

<!-- PAGE=? -->
beginning

<!-- PAGE=? -->
with palms

<!-- PAGE=? -->
and [CHsoles

<!-- PAGE=? -->
30% become

<!-- PAGE=? -->
jaundiced

<!-- PAGE=? -->
about 2 weeks

<!-- PAGE=? -->
after onset of

<!-- PAGE=? -->
pruritus

<!-- PAGE=? -->
2-10 ×

<!-- PAGE=? -->
4 ×

<!-- PAGE=? -->
but <6

<!-- PAGE=? -->
mg/dL

<!-- PAGE=? -->
bile acids 30-

<!-- PAGE=? -->
100×

<!-- PAGE=? -->
No increase in

<!-- PAGE=? -->
morbidity

<!-- PAGE=? -->
Prematurity,

<!-- PAGE=? -->
fetal distress, and

<!-- PAGE=? -->
peripartum fetal

<!-- PAGE=? -->
death

<!-- PAGE=? -->
Vitamin K +

<!-- PAGE=? -->
cholestyra-

<!-- PAGE=? -->
mine; limited

<!-- PAGE=? -->
study of

<!-- PAGE=? -->
ursodeoxycholi

<!-- PAGE=? -->
c acid,

<!-- PAGE=? -->
dexameth-

<!-- PAGE=? -->
lasone, and S-

<!-- PAGE=? -->
adenosyl- L-

<!-- PAGE=? -->
methione

<!-- PAGE=? -->
Resolves 2

<!-- PAGE=? -->
d-2 wk after

<!-- PAGE=? -->
delivery;

<!-- PAGE=? -->
recurs in

<!-- PAGE=? -->
most

<!-- PAGE=? -->
subsequent

<!-- PAGE=? -->
pregnancies

<!-- PAGE=? -->
Preeclampsia

<!-- PAGE=? -->
's HELLP

<!-- PAGE=? -->
(hemolysis,

<!-- PAGE=? -->
elevated liver

<!-- PAGE=? -->
functions,

<!-- PAGE=? -->
and low

<!-- PAGE=? -->
platelets)

<!-- PAGE=? -->
syndrome

<!-- PAGE=? -->
4-12% of

<!-- PAGE=? -->
women with

<!-- PAGE=? -->
preeclampsia

<!-- PAGE=? -->
Late

<!-- PAGE=? -->
second-

<!-- PAGE=? -->
third

<!-- PAGE=? -->
trimester

<!-- PAGE=? -->
(usually

<!-- PAGE=? -->
earlier in

<!-- PAGE=? -->
gestation

<!-- PAGE=? -->
than

<!-- PAGE=? -->
AFLP)

<!-- PAGE=? -->
Nausea,

<!-- PAGE=? -->
vomiting,

<!-- PAGE=? -->
right upper

<!-- PAGE=? -->
quadrant

<!-- PAGE=? -->
pain; other

<!-- PAGE=? -->
findings of

<!-- PAGE=? -->
preeclampsia

<!-- PAGE=? -->
Right upper

<!-- PAGE=? -->
quadrant

<!-- PAGE=? -->
tenderness,

<!-- PAGE=? -->
hypertension,

<!-- PAGE=? -->
diffuse edema,

<!-- PAGE=? -->
hyperreflexia

<!-- PAGE=? -->
2-10 ×

<!-- PAGE=? -->
1-2 ×

<!-- PAGE=? -->
but <5

<!-- PAGE=? -->
mg/dL

<!-- PAGE=? -->
Platelets

<!-- PAGE=? -->
<100,000,

<!-- PAGE=? -->
microangiopathic

<!-- PAGE=? -->
hemolytic anemia,

<!-- PAGE=? -->
disseminated

<!-- PAGE=? -->
intravascular

<!-- PAGE=? -->
coagulation

<!-- PAGE=? -->
Maternal mortality

<!-- PAGE=? -->
2%,

<!-- PAGE=? -->
risk of

<!-- PAGE=? -->
hemorrhage and

<!-- PAGE=? -->
need for blood

<!-- PAGE=? -->
products

<!-- PAGE=? -->
Prematurity

<!-- PAGE=? -->
and perinatal

<!-- PAGE=? -->
mortality 5-30%

<!-- PAGE=? -->
Delivery and

<!-- PAGE=? -->
other

<!-- PAGE=? -->
therapeutic

<!-- PAGE=? -->
measures for

<!-- PAGE=? -->
preeclampsia

<!-- PAGE=? -->
May

<!-- PAGE=? -->
transiently

<!-- PAGE=? -->
worsen,

<!-- PAGE=? -->
then

<!-- PAGE=? -->
improve

<!-- PAGE=? -->
over several

<!-- PAGE=? -->
days;

<!-- PAGE=? -->
recurrence

<!-- PAGE=? -->
rate 5%

<!-- PAGE=? -->
Hepatic

<!-- PAGE=? -->
rupture (80%

<!-- PAGE=? -->
is associated

<!-- PAGE=? -->
with

<!-- PAGE=? -->
preeclampsia

<!-- PAGE=? -->
)

<!-- PAGE=? -->
Five per 10,000

<!-- PAGE=? -->
pregnancies

<!-- PAGE=? -->
Third

<!-- PAGE=? -->
trimester

<!-- PAGE=? -->
and

<!-- PAGE=? -->
postpartu

<!-- PAGE=? -->
m

<!-- PAGE=? -->
Acute

<!-- PAGE=? -->
abdominal

<!-- PAGE=? -->
pain, nausea,

<!-- PAGE=? -->
vomiting

<!-- PAGE=? -->
Right upper

<!-- PAGE=? -->
quadrant

<!-- PAGE=? -->
tenderness,

<!-- PAGE=? -->
shock; pre-

<!-- PAGE=? -->
existing findings

<!-- PAGE=? -->
of

<!-- PAGE=? -->
pre[CHeclampsi

<!-- PAGE=? -->
a

<!-- PAGE=? -->
2-100 ×

<!-- PAGE=? -->
1-2 ×

<!-- PAGE=? -->
but <5

<!-- PAGE=? -->
mg/dL

<!-- PAGE=? -->
May see

<!-- PAGE=? -->
subcapsular

<!-- PAGE=? -->
hematoma on

<!-- PAGE=? -->
ultrasonography

<!-- PAGE=? -->
Mortality 60%

<!-- PAGE=? -->
Mortality 60%

<!-- PAGE=? -->
Delivery,

<!-- PAGE=? -->
surgery when

<!-- PAGE=? -->
indicated

<!-- PAGE=? -->
Data

<!-- PAGE=? -->
inadequate

<!-- PAGE=? -->
to predict

<!-- PAGE=? -->
outcome,

<!-- PAGE=? -->
one report

<!-- PAGE=? -->
of

<!-- PAGE=? -->
recurrence

<!-- PAGE=? -->
Acute fatty

<!-- PAGE=? -->
liver of

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
(AFLP)

<!-- PAGE=? -->
One per 13,000

<!-- PAGE=? -->
pregnancies

<!-- PAGE=? -->
Third

<!-- PAGE=? -->
trimester

<!-- PAGE=? -->
Malaise,

<!-- PAGE=? -->
nausea,

<!-- PAGE=? -->
vomiting,

<!-- PAGE=? -->
epigastric

<!-- PAGE=? -->
pain

<!-- PAGE=? -->
Right upper

<!-- PAGE=? -->
quadrant

<!-- PAGE=? -->
tenderness;

<!-- PAGE=? -->
may be findings

<!-- PAGE=? -->
of hepatic

<!-- PAGE=? -->
encephalopathy

<!-- PAGE=? -->
1-5 ×

<!-- PAGE=? -->
,

<!-- PAGE=? -->
usually

<!-- PAGE=? -->
<500 U/L

<!-- PAGE=? -->
2-8 ×

<!-- PAGE=? -->
but <10

<!-- PAGE=? -->
mg/dL

<!-- PAGE=? -->
White blood cell

<!-- PAGE=? -->
count >15,000;

<!-- PAGE=? -->
platelets often

<!-- PAGE=? -->
<100,000;

<!-- PAGE=? -->
hypoglycemia;

<!-- PAGE=? -->
disseminated

<!-- PAGE=? -->
intravascular

<!-- PAGE=? -->
coagulation

<!-- PAGE=? -->
Mortality 10-18%

<!-- PAGE=? -->
Mortality 18-25%

<!-- PAGE=? -->
Delivery and

<!-- PAGE=? -->
supportive care

<!-- PAGE=? -->
Normal liver

<!-- PAGE=? -->
function

<!-- PAGE=? -->
restored

<!-- PAGE=? -->
post

<!-- PAGE=? -->
partum;

<!-- PAGE=? -->
usually

<!-- PAGE=? -->
does not

<!-- PAGE=? -->
recur during

<!-- PAGE=? -->
next

<!-- PAGE=? -->
pregnancy

<!-- PAGE=? -->
Additional considerations are drug-induced hepatitis, cholelithiasis with common duct obstruction, Budd-Chiari syndrome, and chronic liver disease.

<!-- PAGE=? -->
o Cervical plexus block and diaphragm weakness

<!-- PAGE=? -->
o Inadequate anesthesia is most likely to occur in the ulnar distribution

<!-- PAGE=? -->
K

<!-- PAGE=? -->
Ketamine

<!-- PAGE=? -->
Miller, P&P

<!-- PAGE=? -->
 Results in dissociative anesthesia

<!-- PAGE=? -->
 Varying degrees of hypertonus and purposeful movement can occur

<!-- PAGE=? -->
 Ketamine interacts with

<!-- PAGE=? -->
o

<!-- PAGE=? -->
N -methyl-D-aspartate (NMDA) receptors

<!-- PAGE=? -->
 may mediate the general anesthetic effects as well as some analgesic actions of ketamine (noncompetitive antagonist)

<!-- PAGE=? -->
o opioid receptors

<!-- PAGE=? -->
 located in the in the brain and spinal cord

<!-- PAGE=? -->
o monoaminergic receptors

<!-- PAGE=? -->
 antinociceptive action of ketamine may involve descending inhibitory monoaminergic pain pathways

<!-- PAGE=? -->
o muscarinic receptors

<!-- PAGE=? -->
 ketamine antagonizes muscarinic receptors

<!-- PAGE=? -->
 anesthesia is partially antagonized by anticholinesterase drugs

<!-- PAGE=? -->
 ketamine produces anticholinergic symptoms (emergence delirium, bronchodilation, sympathomimetic action)

<!-- PAGE=? -->
o voltage-sensitive calcium channels

<!-- PAGE=? -->
 produces undesirable psychological reactions during awakening from anesthesia -emergence reactions

<!-- PAGE=? -->
o incidences varies widely

<!-- PAGE=? -->
 likely 10 - 30% of adult patients

<!-- PAGE=? -->
o Risk factors

<!-- PAGE=? -->
 Adult age

<!-- PAGE=? -->
 Less likely in pediatrics

<!-- PAGE=? -->
 Large dose

<!-- PAGE=? -->
 Rapid administration

<!-- PAGE=? -->
 Female gender

<!-- PAGE=? -->
 Psychological susceptibility

<!-- PAGE=? -->
 High score in psychoticism

<!-- PAGE=? -->
o one of the three traits used by the psychologist Hans Eysenck in model of personality

<!-- PAGE=? -->
 psychoticism, extraversion and neuroticism

<!-- PAGE=? -->
 frequent dreamers

<!-- PAGE=? -->
 Concurrent drugs

<!-- PAGE=? -->
 Benzodiazepines are protective

<!-- PAGE=? -->
 Playing music during anesthesia is NOT protective

<!-- PAGE=? -->
o Common manifestations include

<!-- PAGE=? -->
 vivid dreaming

<!-- PAGE=? -->
 extracorporeal experiences (sense of floating out of one's body)

<!-- PAGE=? -->
 illusions (misinterpretation of a real, external sensory experience)

<!-- PAGE=? -->
o often associated with

<!-- PAGE=? -->
 excitement

<!-- PAGE=? -->
 confusion

<!-- PAGE=? -->
 euphoria

<!-- PAGE=? -->
 fear

<!-- PAGE=? -->
o occur in the first hour of emergence

<!-- PAGE=? -->
 usually abate within 1 to several hours

<!-- PAGE=? -->
o postulated to occur secondary to ketamine-induced depression of auditory and visual relay nuclei and thus lead to misperception or misinterpretation (or both) of auditory and visual stimuli

<!-- PAGE=? -->
 pharmacokinetics resemble thiopental

<!-- PAGE=? -->
o rapid onset, relatively short duration of action

<!-- PAGE=? -->
o S isomer is more potent

<!-- PAGE=? -->
o not significantly protein bound

<!-- PAGE=? -->
o high lipid solubility

<!-- PAGE=? -->
o high hepatic clearance

<!-- PAGE=? -->
o elimination half-time 2 to3 hrs

<!-- PAGE=? -->
o metabolized by p450

<!-- PAGE=? -->
 primary metabolite is norketamine - 1/3 to 1/5 as potent

<!-- PAGE=? -->
o norketamine is excreted by the kidney

<!-- PAGE=? -->
 Clinical effects

<!-- PAGE=? -->
o Intense analgesia with subanesthetic doses

<!-- PAGE=? -->
o Anesthesia

<!-- PAGE=? -->
 1-2 mg/kg

<!-- PAGE=? -->
 Physiologic effects

<!-- PAGE=? -->
o Inc. CBF CRMO2, and ICP

<!-- PAGE=? -->
 Cerebral vasodilator

<!-- PAGE=? -->
o No effect on seizure threshold

<!-- PAGE=? -->
o Inc. SSEP amplitude

<!-- PAGE=? -->
 AEP, VEP and decreased

<!-- PAGE=? -->
o Bronchodilation

<!-- PAGE=? -->
o NO depression of ventilation

<!-- PAGE=? -->
o No change in A/W tone

<!-- PAGE=? -->
o sympathomimetic effect

<!-- PAGE=? -->
 inc. systemic and pulmonary arterial blood pressure

<!-- PAGE=? -->
 inc. HR, CO, cardiac work

<!-- PAGE=? -->
 inc. MVO2

<!-- PAGE=? -->
 coronary vasodilator - if healthy heart

<!-- PAGE=? -->
o critically ill patients may respond with dec. SBP

<!-- PAGE=? -->
 exhaustion of sympathetic stores

<!-- PAGE=? -->
o no change on hepatic or renal function

<!-- PAGE=? -->
o devoid of histamine release

<!-- PAGE=? -->
o rare allergic reaction

<!-- PAGE=? -->
o inhibits plt aggregation

<!-- PAGE=? -->
Ketorolac

<!-- PAGE=? -->
 Potent analgesic, but only moderate anti-inflammatory activity

<!-- PAGE=? -->
 After IM injection, maximum plasma concentrations are achieved within 45-60 minutes (with 30 mg ketorolac producing analgesia equivalent to 12 mg morphine or 100 mg meperidine

<!-- PAGE=? -->
 No respiratory or cardiovascular depression

<!-- PAGE=? -->
 Inhibits platelet aggregation by reversible inhibition of prostaglandin synthetase

<!-- PAGE=? -->
 Does NOT increase bleeding time (Brarash), although Stoelting says ketorolac DOES increase bleeding time, with little clinical significance

<!-- PAGE=? -->
 May cause renal insufficiency by decreasing synthesis of renal prostaglandins, but less risk than other NSAIDs as long as adequate fluid balance is maintained and renal function does not depend of renal prostaglandins as in CHF, hypovolemia, hepatic cirrhosis (where release of vasoactive substances result in prostaglandins being important for preventing renal arteriolar constriction which may decrease renal blood flow

<!-- PAGE=? -->
 Borderline elevations of liver transaminases may occur

<!-- PAGE=? -->
 Protein binding exceeds 99% and clearance is decreased compared with that of opioids (and further in elderly patients)

<!-- PAGE=? -->
 Ketorolac is metabolized principally by glucoronic acid conjugation

<!-- PAGE=? -->
(Stoelting Ch 11)

<!-- PAGE=? -->
 Most serious side effects are GI related (bleeds, peptic ulcer perforations)

<!-- PAGE=? -->
 More bioavailability with PO dose versus IM dose (IM dose is 3x greater than PO)

<!-- PAGE=? -->
 CPS says duration of treatment should be short - not to exceed 5 days post surgical; 7 days for msk pain (no specific reason given)

<!-- PAGE=? -->
L

<!-- PAGE=? -->
Labetolol

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 one-fifth to one-tenth as potent as phentolamine in its ability to block alpha receptors

<!-- PAGE=? -->
 one-fourth to one-third as potent as propranolol in blocking beta receptors

<!-- PAGE=? -->
 the beta- to alpha-blocking potency ratio is

<!-- PAGE=? -->
o 3:1 for oral

<!-- PAGE=? -->
o 7:1 for IV

<!-- PAGE=? -->
Lactic Acidosis

<!-- PAGE=? -->
 Lactate > 4-5 mmol/L

<!-- PAGE=? -->
 Generally anion-gap metabolic acidosis (unless albulin in low)

<!-- PAGE=? -->
 Not as likely to result in hyperkalemia as other metabolic acidosis

<!-- PAGE=? -->
 Type A: associated with poor tissue perfusion

<!-- PAGE=? -->
 Type B: not associated with poor tissue perfusion but from metformin, malignancy, HIV, inborn errors of metabolism

<!-- PAGE=? -->
 D-Lactic acidosis: after iliojejunal bypass, made by gut bacteria

<!-- PAGE=? -->
 Mostly due to failure to use up lactate not due to increased production

<!-- PAGE=? -->
 Lactate: pyruvate ratio stays the same in severe shock

<!-- PAGE=? -->
 Most common cause of metabolic acidosis in the critically ill

<!-- PAGE=? -->
Laparoscopy

<!-- PAGE=? -->
Intra-abdominal pressure

<!-- PAGE=? -->
Pooling of blood

<!-- PAGE=? -->
Caval

<!-- PAGE=? -->
Venous

<!-- PAGE=? -->
Intrathoracic

<!-- PAGE=? -->
Stimulation of

<!-- PAGE=? -->
Vasc. resistance

<!-- PAGE=? -->
in the legs

<!-- PAGE=? -->
compression

<!-- PAGE=? -->
resistance

<!-- PAGE=? -->
pressure

<!-- PAGE=? -->
peritoneal receptors?

<!-- PAGE=? -->
of intraabd. organs

<!-- PAGE=? -->
Release of neurohumoral

<!-- PAGE=? -->
factor(s) (vasopressin;

<!-- PAGE=? -->
catechol.

<!-- PAGE=? -->
Venous return

<!-- PAGE=? -->
Inotropism??

<!-- PAGE=? -->
Systemic vascular

<!-- PAGE=? -->
resistance

<!-- PAGE=? -->
Cardiac output

<!-- PAGE=? -->
Arterial pressure

<!-- PAGE=? -->
 PaCO2 progressively inc. to reach a plateau after 15 to 30 min

<!-- PAGE=? -->
 Physiologic changes

<!-- PAGE=? -->
o CVS

<!-- PAGE=? -->
 Decreased preload, CO (+/- contractility in ICM)

<!-- PAGE=? -->
 Inc. venous pressure 2' to inc. intrathoracic pressure

<!-- PAGE=? -->
 Increased thoracic pressures (PAP, CVP, PCWP)

<!-- PAGE=? -->
 Increased afterload (SVR, PVR, MAP)

<!-- PAGE=? -->
 No change/increased HR

<!-- PAGE=? -->
 Increased SNS

<!-- PAGE=? -->
o Respiratory

<!-- PAGE=? -->
 Decreased FRC

<!-- PAGE=? -->
 Decreased thoracopulmonary compliance

<!-- PAGE=? -->
 Decreased pulmonary blood flow

<!-- PAGE=? -->
 Increased pulmonary artery pressures

<!-- PAGE=? -->
 Increased end-tidal CO2

<!-- PAGE=? -->
 Increased peak inspiratory and mean airway pressures

<!-- PAGE=? -->
 Altered VQ matching (inc dead space)resulting from higher pressures and alterations in pulmonary blood flow

<!-- PAGE=? -->
 Increased minute Ventilation (SV)

<!-- PAGE=? -->
 CV collapse, etiology

<!-- PAGE=? -->
o Vagotonic response

<!-- PAGE=? -->
o Arrhythmia (hypercarbia)

<!-- PAGE=? -->
o Tension PTX

<!-- PAGE=? -->
o Hemmorhage

<!-- PAGE=? -->
o CO2 embolism

<!-- PAGE=? -->
 More common with hysteroscopy

<!-- PAGE=? -->
 More likely to result in -gas lock‖ in Rt side to the rapid delivery of gas

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
 Tachycardia (>2mls of gas)

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
 Inc. CVP

<!-- PAGE=? -->
 Hypoxemia

<!-- PAGE=? -->
 Pulmonary edmea

<!-- PAGE=? -->
 Transient inc. CO2 followed by dec. CO2

<!-- PAGE=? -->
 Rt heart strain on ECG

<!-- PAGE=? -->
 Millwheel murmur

<!-- PAGE=? -->
 Aspiration of air form the CVC

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
 Cessation of insufflation

<!-- PAGE=? -->
 Release of pneumoperitoneum

<!-- PAGE=? -->
 Head down with left lateral decubitus position

<!-- PAGE=? -->
 Ventilate with 100% O2

<!-- PAGE=? -->
 Hyperventilate

<!-- PAGE=? -->
 Aspiration of air from distal lumen of central line or PA cath

<!-- PAGE=? -->
 Consider CPR

<!-- PAGE=? -->
 Consider  inotropes

<!-- PAGE=? -->
 Hyperbaric oxygen therapy if known PFO or signs of CNS involvement

<!-- PAGE=? -->
o Caval compression

<!-- PAGE=? -->
 PaCO2 and Δa-etco2 increase more in ASA class II and III patients than ASA class I patients

<!-- PAGE=? -->
 Carbon dioxide insufflation into the peritoneal cavity increases arterial CO2 tension, which is managed by increasing minute ventilation

<!-- PAGE=? -->
o The absorption of CO2 from a closed cavity depends on

<!-- PAGE=? -->
 Diffusibility

<!-- PAGE=? -->
 Perfusion of the walls of that cavity

<!-- PAGE=? -->
 Site of CO2 insufflation

<!-- PAGE=? -->
 Extraperitoneal > Intraperitoneal

<!-- PAGE=? -->
 NOT on the rate of insufflation

<!-- PAGE=? -->
Table 57-1 Causes of increased Pacoz during laparoscopy

<!-- PAGE=? -->
1 Absorption of carbon dioxide (COz) from the peritoneal cavity

<!-- PAGE=? -->
2

<!-- PAGE=? -->
mismatch: increased physiologic dead space

<!-- PAGE=? -->
Abdominal distention

<!-- PAGE=? -->
Position of the patient (e.9-, steep tilt)

<!-- PAGE=? -->
Controlled mechanical ventilation

<!-- PAGE=? -->
Reduced cardiac output

<!-- PAGE=? -->
These mechanisms are accentuated in sick patients (e.9

<!-- PAGE=? -->
3. Increased metabolism (e.9 insufficient plane of anesthesia)

<!-- PAGE=? -->
4 Depression of ventilation by anesthetics (e g-, spontaneous breathing)

<!-- PAGE=? -->
5 Accidental events

<!-- PAGE=? -->
COz emphysema (ie subcutaneous or body cavities

<!-- PAGE=? -->
Capnothorax

<!-- PAGE=? -->
COz embolism

<!-- PAGE=? -->
(Selective bronchial intubation)

<!-- PAGE=? -->
 renal function decreases to less than 50% of baseline values

<!-- PAGE=? -->
o urine output - inc. after desufflation

<!-- PAGE=? -->
o renal plasma flow

<!-- PAGE=? -->
o glomerular filtration rate

<!-- PAGE=? -->
 Controversy persists with regard to the effect of CO2 pneumoperitoneum on splanchnic and hepatic blood flow

<!-- PAGE=? -->
o Blood flow is likely reduced  but it is of questionable clinical significance

<!-- PAGE=? -->
 Cerebral blood flow velocity increases during CO2 pneumoperitoneum in response to the increased PaCO2

<!-- PAGE=? -->
o When normocarbia is maintained, there are no harmful changes in intracranial dynamics

<!-- PAGE=? -->
o However, ICP rises during CO2 pneumoperitoneum independently of changes in PaCO2

<!-- PAGE=? -->
 Intraocular pressure is not affected by pneumoperitoneum

<!-- PAGE=? -->
Laryngoscopy

<!-- PAGE=? -->
Lange, CJA (Crosby 2002)

<!-- PAGE=? -->
 Studies have demonstrated neck movement, however, particularly C1 and C2, during mask ventilation and direct laryngoscopy despite attempts at stabilization

<!-- PAGE=? -->
 elevation of the laryngoscope blade to achieve visualization of the larynx created superior rotation of the occiput and Cl in the sagittal plane, and mild inferior rotation of C3-C5

<!-- PAGE=? -->
o C2 maintained near-neutral posture

<!-- PAGE=? -->
 the most significant motion was produced at the atlanto-occipital and atlanto-axial joints (mean 6.8° and 4.7°, respectively)

<!-- PAGE=? -->
 most of the cervical motion is produced at the atlanto-occipital and atlanto-axial joints and that the subaxial cervical segments (C4 and below) are displaced only minimally.

<!-- PAGE=? -->
Latex allergy

<!-- PAGE=? -->
Lange, Barash

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Chronic exposure to latex and a history of atopy increases the risk of sensitization

<!-- PAGE=? -->
 Health care workers

<!-- PAGE=? -->
 ~ 5 - 17%

<!-- PAGE=? -->
 Patients with repeated exposure

<!-- PAGE=? -->
 spina bifida

<!-- PAGE=? -->
 spinal cord injury

<!-- PAGE=? -->
 congenital abnormalities of the genitourinary tract

<!-- PAGE=? -->
 Cross-reactivity:

<!-- PAGE=? -->
o Banana

<!-- PAGE=? -->
o Kiwi

<!-- PAGE=? -->
o Mango

<!-- PAGE=? -->
o Passion fruit

<!-- PAGE=? -->
o Avocado

<!-- PAGE=? -->
o Chestnut

<!-- PAGE=? -->
o tomato, potato, papaya

<!-- PAGE=? -->
Laser types

<!-- PAGE=? -->
Table 67-2 -- Laser media wavelengths

<!-- PAGE=? -->
 Fiberoptic bundles work for visible and near-infrared wavelengths

<!-- PAGE=? -->
o Wavelengths outside this range, require an articulated arm containing mirrors

<!-- PAGE=? -->
 hazards associated with laser include

<!-- PAGE=? -->
o atmospheric contamination

<!-- PAGE=? -->
 interstitial pneumonia, bronchiolitis, reduced mucociliary clearance, inflammation, and emphysema

<!-- PAGE=? -->
 may be mutagenic, teratogenic, or a vector for viral infection

<!-- PAGE=? -->
o perforation of a vessel or structure

<!-- PAGE=? -->
o Embolism

<!-- PAGE=? -->
 Associated Nd:YAG

<!-- PAGE=? -->
 Hysteroscopy, tracheal resection

<!-- PAGE=? -->
o inappropriate energy transfer

<!-- PAGE=? -->
 0.5-1.5% incidence of ETT fire

<!-- PAGE=? -->
 FiO2 <0.4 (or as low as possible)

<!-- PAGE=? -->
 N2O is just as dangerous as high FiO2

<!-- PAGE=? -->
 No single ventilation mode is superior (Jet vs. PPV)

<!-- PAGE=? -->
Endotracheal Tube Fires

<!-- PAGE=? -->
Three strategies are used to reduce the incidence of airway fire

<!-- PAGE=? -->
reduction of the flammability of the endotracheal tube

<!-- PAGE=? -->
removal of flammable materials from the airway (jet Ventilation)

<!-- PAGE=? -->
reduction of the available oxygen content

<!-- PAGE=? -->
Reduction of the flammability of the endotracheal tube

<!-- PAGE=? -->
 PVC strongly absorbs far-infrared light and is very sensitive to CO2 laser energy

<!-- PAGE=? -->
 much more easily ignited by CO2 lasers than red rubber tubes

<!-- PAGE=? -->
 more toxic products of combustion than red rubber

<!-- PAGE=? -->
 In vitro, PVC is transparent and therefore immune to Nd:YAG and visible laser light; however, a thin coating of mucus or blood in vivo can absorb energy and restore the hazard

<!-- PAGE=? -->
 Laser resistant tubes may still combust

<!-- PAGE=? -->
 Three types of tape have been used

<!-- PAGE=? -->
aluminum foil

<!-- PAGE=? -->
copper foil

<!-- PAGE=? -->
plastic tape thinly coated with metal on one side

<!-- PAGE=? -->
Lead foil is similar in appearance but is toxic and should never be used in the airway

<!-- PAGE=? -->
 Provides some protection against CO2

<!-- PAGE=? -->
Not as effective against Nd-YAG

<!-- PAGE=? -->
CO2 laser

<!-- PAGE=? -->
 Long wavelength (10,600nm) - infrared

<!-- PAGE=? -->
 is completely absorbed by water in the first layers

<!-- PAGE=? -->
 intense heat with vaporization of the tissue surface at the target

<!-- PAGE=? -->
o unable to penetrate deeper layers

<!-- PAGE=? -->
 causes little tissue edema due to minimal penetration

<!-- PAGE=? -->
o ~ 200 um

<!-- PAGE=? -->
 produces the most smoke because of vaporisation

<!-- PAGE=? -->
 cause corneal ulceration

<!-- PAGE=? -->
 need any clear glass or plastic lens but contacts not good enough

<!-- PAGE=? -->
 can vaporize HPV (+/- HIV and cancer cells) into plume thus need laser masks, smoke evacuation system

<!-- PAGE=? -->
 used for ENT, H&N, and Gyne.

<!-- PAGE=? -->
Misc.

<!-- PAGE=? -->
Other burns

<!-- PAGE=? -->
Perforation

<!-- PAGE=? -->
(organ or vessel)

<!-- PAGE=? -->
249

<!-- PAGE=? -->
Airway fire

<!-- PAGE=? -->
149

<!-- PAGE=? -->
Gas embolism

<!-- PAGE=? -->
Eye exposure

<!-- PAGE=? -->
1996

<!-- PAGE=? -->
 Cannot use fiberoptic bundle

<!-- PAGE=? -->
Argon Laser

<!-- PAGE=? -->
 visible green and blue light (488 and 514 nm) - visible

<!-- PAGE=? -->
 poorly absorbed by water but selective aborption by Hgb thus good for selective coagultaion of vascular or pigmented lesions

<!-- PAGE=? -->
 May burn retina

<!-- PAGE=? -->
 Amber orange glasses (remember amber for argon)

<!-- PAGE=? -->
 used for ophth (retinal) and skin (hemang, Port-Wine)

<!-- PAGE=? -->
 will penetrate and burn laser-resistant ETT

<!-- PAGE=? -->
Nd-Yag Laser (Neodymium Yttrium-aluminum-garnet)

<!-- PAGE=? -->
 Infrared wavelength (1,064 nm)

<!-- PAGE=? -->
 Less absorbed by water

<!-- PAGE=? -->
 deep tissue penetration with minimal vaporization, more thermal coagulation

<!-- PAGE=? -->
 useful in water or urine

<!-- PAGE=? -->
 may burn retina

<!-- PAGE=? -->
 need green tinted goggles or newly available clear ones

<!-- PAGE=? -->
 can use fiberoptic bundle

<!-- PAGE=? -->
 used for debulking tumors

<!-- PAGE=? -->
 will penetrate and burn laser-resistant ETT

<!-- PAGE=? -->
KTP(potassium titanium phosphate) : Nd-Yag Laser

<!-- PAGE=? -->
 Red glasses needed

<!-- PAGE=? -->
LES Pressure

<!-- PAGE=? -->
Table 37-2. LOWER ESOPHAGEAL SPHINCTER EFFECT OF DRUGS USED IN ANESTHESIA

<!-- PAGE=? -->
Increase

<!-- PAGE=? -->
Decrease

<!-- PAGE=? -->
No Change

<!-- PAGE=? -->
Metoclopramide

<!-- PAGE=? -->
Atropine

<!-- PAGE=? -->
Propranolol

<!-- PAGE=? -->
Domperidone

<!-- PAGE=? -->
Glycopyrrolate

<!-- PAGE=? -->
Oxprenolol

<!-- PAGE=? -->
Prochlorperazine

<!-- PAGE=? -->
Dopamine

<!-- PAGE=? -->
Cimetidine

<!-- PAGE=? -->
Cyclizine

<!-- PAGE=? -->
Sodium nitroprusside

<!-- PAGE=? -->
Ranitidine

<!-- PAGE=? -->
Edrophonium

<!-- PAGE=? -->
Ganglion blockers

<!-- PAGE=? -->
Atracurium

<!-- PAGE=? -->
Neostigmine

<!-- PAGE=? -->
Thiopental

<!-- PAGE=? -->
?Nitrous oxide

<!-- PAGE=? -->
Histamine

<!-- PAGE=? -->
Tricyclic antidepressants

<!-- PAGE=? -->
Suxamethonium

<!-- PAGE=? -->
Halothane

<!-- PAGE=? -->
Pancuronium

<!-- PAGE=? -->
Enflurane

<!-- PAGE=? -->
Metoprolol

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
Antacids

<!-- PAGE=? -->
?Nitrous oxide

<!-- PAGE=? -->
Liability

<!-- PAGE=? -->
CJA 1989

<!-- PAGE=? -->
 Drug error is the most common reason for malpractice claims against Canadian anesthesiologists

<!-- PAGE=? -->
Lithotripsy

<!-- PAGE=? -->
The only absolute contraindications to this procedure are

<!-- PAGE=? -->
 Pregnancy

<!-- PAGE=? -->
o possible fetal damage

<!-- PAGE=? -->
 abnormal coagulation parameters

<!-- PAGE=? -->
o risk of subcapsular renal bleeding or perinephric hematoma

<!-- PAGE=? -->
o ASA and NSAIDs should be discontinued

<!-- PAGE=? -->
 an active urinary tract infection

<!-- PAGE=? -->
o risk of sepsis

<!-- PAGE=? -->
Patients with pacemakers are considered acceptable candidates for lithotripsy provided that

<!-- PAGE=? -->
 preoperative determination of the type of pacemaker and its functional status

<!-- PAGE=? -->
 availability of a magnet or programming device in the operating room along with a person skilled in its use

<!-- PAGE=? -->
 availability of an alternative pacing device

<!-- PAGE=? -->
 positioning of the patient so that the pacemaker is not in the shock wave path

<!-- PAGE=? -->
AICDs should be deactivated preoperatively

<!-- PAGE=? -->
Lithotripsy may be problematic in children or patients of small stature (height <48 inches)

<!-- PAGE=? -->
 inc. risk of pulmonary contusion by shock waves

<!-- PAGE=? -->
 The lungs of small patients can be shielded by foam padding during the treatment in an effort to prevent this complication

<!-- PAGE=? -->
Relative contraindications to SWL include

<!-- PAGE=? -->
 complete urinary tract obstruction distal to the stone

<!-- PAGE=? -->
 calcification or aneurysm of the renal artery or aorta

<!-- PAGE=? -->
o aneurysms measuring >6 cm in diameter should not be treated because the risk of accidental rupture increases exponentially with size

<!-- PAGE=? -->
 orthopedic prosthesis

<!-- PAGE=? -->
 renal insufficiency

<!-- PAGE=? -->
Barash CD Ch. 36 - p 103: Absolute contraindications: distal obstruction to the renal calculi; bleeding disorder or anticoagulation; pregnancy.  Relative contraindications: large, calcified renal or aortic aneurysms, untreated UTI, pacemaker or AICD, morbid obesity.

<!-- PAGE=? -->
Liver Transplantation

<!-- PAGE=? -->
Monitoring and Induction

<!-- PAGE=? -->
 RSI: gastroparesis and increased intraabdominal pressure from ascites

<!-- PAGE=? -->
 Invasive lines:

<!-- PAGE=? -->
o Left radial art line

<!-- PAGE=? -->
o Right femoral art line

<!-- PAGE=? -->
o +/- PAC, TEE

<!-- PAGE=? -->
o two large bore (9F) catheters

<!-- PAGE=? -->
 rapid infuser

<!-- PAGE=? -->
 anesthesiologists may place percutaneous lines for use in venovenous bypass

<!-- PAGE=? -->
 foley

<!-- PAGE=? -->
 ng tube

<!-- PAGE=? -->
 routinely 10 U RBC and 10 U FFP

<!-- PAGE=? -->
 fluid warmers and convective air blankets

<!-- PAGE=? -->
Dissection phase

<!-- PAGE=? -->
 blood loss may be high

<!-- PAGE=? -->
 correct coagulopathies

<!-- PAGE=? -->
Barash 6 th :

<!-- PAGE=? -->
o FFP to keep INR < 1.5

<!-- PAGE=? -->
o Infusions of CaCl2 adjusted to iCa is better than intermittent boluses

<!-- PAGE=? -->
o Platelets are detrimental to graft and patient survival so tolerate lowest level possible

<!-- PAGE=? -->
o Keep fibrinogen > 150 mg/dl with cryo

<!-- PAGE=? -->
o Cell saver

<!-- PAGE=? -->
o Fibrinolytics

<!-- PAGE=? -->
o Consider FVIIa (esp for ICP placement in acute hepatic failure)

<!-- PAGE=? -->
o Many patients have a superimposed hypercoagulable state (autoimmune liver disease with antiphospholipid antibodies)

<!-- PAGE=? -->
 Many centers use thrombeleastography or bedside clotting times

<!-- PAGE=? -->
 Avoid procoagulant drugs

<!-- PAGE=? -->
 maintain intravascular volume for renal protection

<!-- PAGE=? -->
o low CVP may decrease blood loss but this may be  harmful for patients with higher MELD scores

<!-- PAGE=? -->
o may need diuresis

<!-- PAGE=? -->
Anhepatic phase

<!-- PAGE=? -->
 liver functionally excluded from circulation: Vena cava clamped above and below, hepatic artery and portal vein are clamped

<!-- PAGE=? -->
 venous return falls by 50-60% = hypotension

<!-- PAGE=? -->
 venovenous bypass may be used:

<!-- PAGE=? -->
o increases venous return and BP

<!-- PAGE=? -->
o increases renal and gut perfusion pressures

<!-- PAGE=? -->
o decompresses pportal pressures (better surgical field)

<!-- PAGE=? -->
o complications: arm lymphedema, air embolism, vascular injury

<!-- PAGE=? -->
o benefits limited when anhepatic times are short

<!-- PAGE=? -->
 otherwise volume loading and pressors

<!-- PAGE=? -->
 surgical piggyback technique preserves caval flow and obviates need for VVB

<!-- PAGE=? -->
 treat severe acidosis with THAM infusion

<!-- PAGE=? -->
Neohepatic phase

<!-- PAGE=? -->
 starts with reperfusion of the graft

<!-- PAGE=? -->
o removal of caval clamps (usually well tolerated)

<!-- PAGE=? -->
o removal of portal vein clamp - hemodynamic instability

<!-- PAGE=? -->
 hypotension from preservation soln (low SVR)

<!-- PAGE=? -->
 most treacherous time

<!-- PAGE=? -->
 pretreat with 25-50 mEq of NaHCO3 for acid load

<!-- PAGE=? -->
 give 500 mg of CaCl2 with portal reperfusion (K washout)

<!-- PAGE=? -->
 also have lidocaine, atropine and NE available

<!-- PAGE=? -->
 worsened fibrinolysis due to washout of plasminogen activator from graft

<!-- PAGE=? -->
o rebolus of TXA or EACA may be helpful

<!-- PAGE=? -->
 methylene blue 1-1.5 mg/kg bolus reduces hemodynamic instability after reperfusion possibly by scavenging free radicals and NO

<!-- PAGE=? -->
 iNO during transplantation may be useful: decreased hepatocyte apoptosis, earlier recovery of graft function

<!-- PAGE=? -->
 usually within 30 min the base deficit improves with graft metabolism of citrate and lactate, bile is porduced

<!-- PAGE=? -->
 within 60 min CO decreases, SVR increases as graft metabolizes stuff

<!-- PAGE=? -->
 renal function generally improves

<!-- PAGE=? -->
 ECD grafts may take longer

<!-- PAGE=? -->
 Biliary anastomoses are completed and sources of surgical bleeding are corrected

<!-- PAGE=? -->
LMA

<!-- PAGE=? -->
CJA - Brimacombe 1995

<!-- PAGE=? -->
 Advantages over the TT

<!-- PAGE=? -->
o increased speed and ease of placement by inexperienced personnel

<!-- PAGE=? -->
o increased speed of placement by anaesthetists

<!-- PAGE=? -->
o improved haemodynamic stability at induction and during emergence

<!-- PAGE=? -->
o minimal increase in intraocular pressure

<!-- PAGE=? -->
o reduced anaesthetic requirements for airway tolerance

<!-- PAGE=? -->
o lower frequency of coughing during emergence

<!-- PAGE=? -->
o improved oxygen saturation during emergence

<!-- PAGE=? -->
o lower incidence of sore throat in adults

<!-- PAGE=? -->
 Advantages over the FM included

<!-- PAGE=? -->
o easier placement by inexperienced personnel

<!-- PAGE=? -->
o improved oxygen saturation

<!-- PAGE=? -->
o less hand fatigue

<!-- PAGE=? -->
o improved operating conditions during minor paediatric otological surgery

<!-- PAGE=? -->
 Disadvantages over the TT

<!-- PAGE=? -->
o were lower seal pressures

<!-- PAGE=? -->
o higher frequency of gastric insufflation

<!-- PAGE=? -->
 Disadvantage over the FM

<!-- PAGE=? -->
o oesophageal reflux was more likely

<!-- PAGE=? -->
Complications with Use of the Laryngeal Mask Airway

<!-- PAGE=? -->
 Gastroesophageal reflux and aspiration

<!-- PAGE=? -->
 Laryngospasm

<!-- PAGE=? -->
 Coughing

<!-- PAGE=? -->
 Bronchospasm

<!-- PAGE=? -->
 Sore throat

<!-- PAGE=? -->
o 4-12% (less than tracheal intubation)

<!-- PAGE=? -->
 Transient changes in vocal cord function (possibly related to cuff overinflation during prolonged procedures)

<!-- PAGE=? -->
 Nerve injury ( recurrent laryngeal, hypoglossal, lingual )

<!-- PAGE=? -->
o LMA cuff pressure should not exceed 60 cm H2O

<!-- PAGE=? -->
o Nitrous oxide may diffuse into cuff and increase pressure

<!-- PAGE=? -->
Advantages of the LMA in Supraglottic Surgery

<!-- PAGE=? -->
 Improved protection of the airway from blood and surgical debris

<!-- PAGE=? -->
 Reduced cardiovascular responses

<!-- PAGE=? -->
 Reduced coughing on emergence

<!-- PAGE=? -->
 Reduced laryngospasm after airway device removal

<!-- PAGE=? -->
 Improved oxygen saturation after airway device removal

<!-- PAGE=? -->
 Ability to administer oxygen until complete restoration of airway reflexes

<!-- PAGE=? -->
 In inexperienced hands, more rapidly and reliably placed than an endotracheal tube, suggesting a potential role in resuscitation.

<!-- PAGE=? -->
 Trauma to the vocal cords is limited

<!-- PAGE=? -->
 Cricoid makes placement more difficult, but can still ventilate, however, may make ETT passage through more difficult

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
 Increased risk of gastric regurgitation

<!-- PAGE=? -->
 Limited ability to open the mouth or extend the neck (e.g., severe rheumatoid arthritis, ankylosing spondylitis)

<!-- PAGE=? -->
 Low pulmonary compliance or high airway resistance

<!-- PAGE=? -->
 Airway obstruction at or below the level of the larynx

<!-- PAGE=? -->
 Oropharyngeal pathology (e.g., hematoma, abscess, tissue disruption)

<!-- PAGE=? -->
 One-lung ventilation

<!-- PAGE=? -->
 Tracheal intubation causes a more frequent incidence of postoperative airway-related complaints

<!-- PAGE=? -->
o sore throat

<!-- PAGE=? -->
 45% vs 18%

<!-- PAGE=? -->
o croup

<!-- PAGE=? -->
o hoarseness

<!-- PAGE=? -->
LMA size

<!-- PAGE=? -->
Local Anesthetics

<!-- PAGE=? -->
P&P, Barash

<!-- PAGE=? -->
 Amino amides have an amide link between the intermediate chain and the aromatic end

<!-- PAGE=? -->
 Amino esters have an ester link between the intermediate chain and the aromatic end

<!-- PAGE=? -->
o amino amides contain the letter "i" twice, as does the term "amino amides."

<!-- PAGE=? -->
 Classifications

<!-- PAGE=? -->
o Esters

<!-- PAGE=? -->
 Procaine

<!-- PAGE=? -->
 Chlorprocaine

<!-- PAGE=? -->
 Tetracaine

<!-- PAGE=? -->
 Benzocaine

<!-- PAGE=? -->
 Cocaine

<!-- PAGE=? -->
o Amides

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 Bupivicaine

<!-- PAGE=? -->
 Ropivicaine

<!-- PAGE=? -->
 Etidocaine

<!-- PAGE=? -->
 Mepivicaine

<!-- PAGE=? -->
 Prilocaine

<!-- PAGE=? -->
 Esters are hydrolyzed by plasma cholinesterase enzymes

<!-- PAGE=? -->
o principally in the plasma and to a lesser extent in the liver

<!-- PAGE=? -->
o Speed or hydrolysis

<!-- PAGE=? -->
 chloroprocaine > procaine > tetracaine

<!-- PAGE=? -->
o cocaine is an exception

<!-- PAGE=? -->
 ester that is metabolized predominantly by the liver

<!-- PAGE=? -->
 also metabolized by plasma cholinesterases

<!-- PAGE=? -->
 water-soluble metabolites that are excreted in urine for 24 to 36 hours

<!-- PAGE=? -->
 produces sympathetic nervous system stimulation by blocking the presynaptic uptake of norepinephrine and dopamine, thus increasing their postsynaptic concentrations

<!-- PAGE=? -->
 Amide undergo enzymatic degradation in the liver

<!-- PAGE=? -->
o liver esterases

<!-- PAGE=? -->
 Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation

<!-- PAGE=? -->
o Rate of metabolism

<!-- PAGE=? -->
 Prilocaine > lidocaine = mepivacaine > etidocaine = bupivacaine = ropivacaine

<!-- PAGE=? -->
o Articaine is an exception

<!-- PAGE=? -->
 amide that is inactivated by plasma esterases

<!-- PAGE=? -->
 PABA is a major metabolite of ester metabolism  anaphylaxis

<!-- PAGE=? -->
 Prolonged action of esters is seen in patients with decreased plasma cholinesterase activity

<!-- PAGE=? -->
o Neonates

<!-- PAGE=? -->
o elderly

<!-- PAGE=? -->
o liver disease

<!-- PAGE=? -->
o increased BUN

<!-- PAGE=? -->
o parturients

<!-- PAGE=? -->
o certain chemotherapeutic drugs

<!-- PAGE=? -->
o atypical plasma cholinesterase

<!-- PAGE=? -->
 local anesthetics are poorly soluble in water

<!-- PAGE=? -->
o limited renal excretion of unchanged drug

<!-- PAGE=? -->
 < 5%

<!-- PAGE=? -->
o exception is cocaine, of which 10% to 12% of unchanged drug can be recovered in urine

<!-- PAGE=? -->
o Water-soluble metabolites of local anesthetics, such as para-aminobenzoic acid resulting from metabolism of ester local anesthetics, are readily excreted in urine

<!-- PAGE=? -->
 Absorption with regional techniques (most to least)

<!-- PAGE=? -->
o Tracheal

<!-- PAGE=? -->
o Intercostal

<!-- PAGE=? -->
o Caudal

<!-- PAGE=? -->
o Paracervical

<!-- PAGE=? -->
o Epidural

<!-- PAGE=? -->
o Brachial

<!-- PAGE=? -->
o Sciatic

<!-- PAGE=? -->
o Subcutaneous

<!-- PAGE=? -->
 Pharmacodynamics

<!-- PAGE=? -->
o Onset = pKa (low pKa = rapid onset) & lipid solubility (decreased)

<!-- PAGE=? -->
 low pKa = rapid onset

<!-- PAGE=? -->
 Mepivacaine < Etidocaine < Lidocaine < Ropivacaine < Bupivacaine < Tetracaine < Procaine < Chloroprocaine

<!-- PAGE=? -->
 Chloroprocaine is unusual in that it has a fast onset time despite its high pKa

<!-- PAGE=? -->
 Onset is faster d/t inc. dose - low toxicity

<!-- PAGE=? -->
 Inc. Lipid solubility minorly slows the rate onset

<!-- PAGE=? -->
o Potency = lipid solubility (increased)

<!-- PAGE=? -->
 Etidocaine > Tetracaine > Bupivicaine > Prilocaine > Lidocaine > Mepivicaine = Procaine = Chloroprocaine

<!-- PAGE=? -->
o Duration = protein binding (increased) & lipid solubility (increased - hydrophobic = longer action)

<!-- PAGE=? -->
 Bupivacaine > Etidocaine > Tetracaine > Mepivacaine > Lidocaine > Prilocaine > Procaine > Chlorprocaine

<!-- PAGE=? -->
o Isomers may have different pharmacodynamics and toxicity

<!-- PAGE=? -->
 Lipid solubility

<!-- PAGE=? -->
o higher lipid solubility correlates with potency

<!-- PAGE=? -->
o higher lipid solubility usually slows the rate of onset of action

<!-- PAGE=? -->
o higher lipid solubility usually prolongs duration of action

<!-- PAGE=? -->
 pKa

<!-- PAGE=? -->
o non-ionized fraction passes through lipid membranes

<!-- PAGE=? -->
o higher pKa relative to body pH = greater proportion ionized, slower onset of action

<!-- PAGE=? -->
 protein binding:

<!-- PAGE=? -->
o increased protein binding associated with increased duration of action

<!-- PAGE=? -->
o only the unbound form is free form pharmacologic activity

<!-- PAGE=? -->
 Pharmacokinetics

<!-- PAGE=? -->
o Inc. systemic levels at the extremes of age

<!-- PAGE=? -->
 Decreased clearance

<!-- PAGE=? -->
o Pregnancy may decrtease clearance

<!-- PAGE=? -->
o Dec. CO will alter pharmacokinetic parameters

<!-- PAGE=? -->
 Dec. dose should be used

<!-- PAGE=? -->
o Hepatic disease will decrease clearance

<!-- PAGE=? -->
Additives

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
 may prolong block

<!-- PAGE=? -->
 may increase intensity of block

<!-- PAGE=? -->
 may decrease systemic absorption of local anesthetic (antagonizes the inherent vasodilating effects of local anesthetics

<!-- PAGE=? -->
 may interact directly with alpha-2 receptors in the brain an dspinal cord

<!-- PAGE=? -->
Table 21-5: effects of addition of epi to local anesthetics

<!-- PAGE=? -->
DECREASE

<!-- PAGE=? -->
INCREASE BLOOD

<!-- PAGE=? -->
DURATION LEVELS (%) DOSE/CONCENTRATION OF EPINEPHRINE

<!-- PAGE=? -->
++, overall supported; --, overall not supported; +/-, inconsistent.

<!-- PAGE=? -->
Alkalinization:

<!-- PAGE=? -->
 Hasten onset of block

<!-- PAGE=? -->
o decrease time by about 5 minutes by increasing proportion of non-ionized drug

<!-- PAGE=? -->
 cannot be alkalinized beyond pH of 6-8 without precipitation

<!-- PAGE=? -->
 causes generation of CO2

<!-- PAGE=? -->
 pH of LA ranges from 3.9 to 6.5 and is especially acidic if prepackaged with epinephrine.

<!-- PAGE=? -->
 the pKa of commonly used local anesthetics ranges from 7.6 to 8.9

<!-- PAGE=? -->
 <3% of the commercially prepared local anesthetic exists as the lipid-soluble neutral form

<!-- PAGE=? -->
 the neutral form is believed to be the most important for penetration into the neural cytoplasm, whereas the charged form primarily interacts with the local anesthetic receptor within the sodium channel

<!-- PAGE=? -->
 local anesthetics cannot be alkalinized beyond a pH of 6.05-8 before precipitation occurs

<!-- PAGE=? -->
 such pHs will triple the available local anesthetic from 3% to 10%

<!-- PAGE=? -->
 alkalinization may affect activity of local anesthetic by activation of vasoconstrictive effects of epinephrine

<!-- PAGE=? -->
 Addition of bicarb hastens onset of analagesia, but results in more hypotension.

<!-- PAGE=? -->
 Addition of bicarb results in generation of CO2, alkalinized lido has similar onset time to 2-chloroprocaine

<!-- PAGE=? -->
Opioids:

<!-- PAGE=? -->
 addition to spinal provides analgesia by attenuating C fiber nociception

<!-- PAGE=? -->
 independent of supraspnial mechanisms

<!-- PAGE=? -->
 results in synergistic analgesia except for 2-chloroprocaine which attenutates the effect of epidural opioids

<!-- PAGE=? -->
 no increase in efficacy if used peripherally:

<!-- PAGE=? -->
o for nerve blocks

<!-- PAGE=? -->
o for intra-articular administration

<!-- PAGE=? -->
Alpha-2 agonists

<!-- PAGE=? -->
 analgesia via supraspinal and spinal adrenergic receptors

<!-- PAGE=? -->
 clonidine also has direct inhibitory effects on peripheral nerve conduction (A and C fibers)

<!-- PAGE=? -->
 central and peripheral nerve analgesia is syndergistic while systemic (supraspinal) are additive

<!-- PAGE=? -->
ESTERS

<!-- PAGE=? -->
Chloroprocaine

<!-- PAGE=? -->
Procaine

<!-- PAGE=? -->
Tetracaine

<!-- PAGE=? -->
8.7

<!-- PAGE=? -->
8.9

<!-- PAGE=? -->
8.5

<!-- PAGE=? -->
95

<!-- PAGE=? -->
97

<!-- PAGE=? -->
93

<!-- PAGE=? -->
810

<!-- PAGE=? -->
100

<!-- PAGE=? -->
5,822

<!-- PAGE=? -->
N/A

<!-- PAGE=? -->
6

<!-- PAGE=? -->
94

<!-- PAGE=? -->
Local Anesthetics Toxicity

<!-- PAGE=? -->
Barash, P&P, Miller

<!-- PAGE=? -->
 Systemic toxicity (CNS) is proportional to potency and inversely proportional to the rate of hydrolysis

<!-- PAGE=? -->
 CNS toxicity

<!-- PAGE=? -->
o Bup (4.0) > Rop (2.9) > Lido (1.0) > Chloro (0.3)

<!-- PAGE=? -->
 CVS:CNS - high levels required for CVS toxicity

<!-- PAGE=? -->
o Bup (2.0) > Rop (2.2) > Chloro (3.9) > Lido (7.1)

<!-- PAGE=? -->
o Lower ratio required for bupivicaine

<!-- PAGE=? -->
 More CVS toxicity

<!-- PAGE=? -->
 initial symptoms

<!-- PAGE=? -->
o Lightheaded/dizzy > blurry vision/tinnitus/numb tongue > seizure/unconscious > coma/respiratory arrest > cardiovascular depression

<!-- PAGE=? -->
 Rate of systemic absorption:

<!-- PAGE=? -->
o Tracheal > Intercostal nerve blocks > caudal > paracervical > epidural > brachial plexus > femoral and sciatic > subcu

<!-- PAGE=? -->
o Rate of absorption and peak level directly proportional to amount given

<!-- PAGE=? -->
o Independent of drug concentration or speed of injection

<!-- PAGE=? -->
o More potent, lipid soluble ones absorb slower, more potent agents cause more vasoconstriction at low doses

<!-- PAGE=? -->
Central Nervous System Toxicity

<!-- PAGE=? -->
 Local anesthetics readily cross the blood-brain barrier

<!-- PAGE=? -->
 generalized CNS toxicity dose-dependent

<!-- PAGE=? -->
o Low doses → CNS depression

<!-- PAGE=? -->
o high doses → CNS excitation and seizures

<!-- PAGE=? -->
 rate of intravenous administration of local anesthetic will also affect signs of CNS toxicity

<!-- PAGE=? -->
 higher rates of infusion of the same dose will lessen the appearance of CNS depression while leaving excitation intact

<!-- PAGE=? -->
 potency for generalized CNS toxicity parallels action potential blocking potency

<!-- PAGE=? -->
o more potent, more toxicity

<!-- PAGE=? -->
 decreased local anesthetic protein binding and clearance will increase potential CNS toxicity

<!-- PAGE=? -->
 External factors that increase CNS toxicity

<!-- PAGE=? -->
o acidosis and increased PCO2

<!-- PAGE=? -->
 increased cerebral perfusion

<!-- PAGE=? -->
 decreased protein binding of local anesthetic

<!-- PAGE=? -->
 trapping of LA in the neuron

<!-- PAGE=? -->
 External factors that decrease CNS toxicity

<!-- PAGE=? -->
o Converse to above, acidosis will increase the cationic form of the local anesthetic, which will decrease the rate of diffusion into the cell

<!-- PAGE=? -->
o barbiturates and benzodiazepines

<!-- PAGE=? -->
 Addition of vasoconstrictors may reduce or promote CNS toxicity

<!-- PAGE=? -->
o decrease systemic absorption and peak blood levels and increase the safety margin

<!-- PAGE=? -->
o decrease the convulsive threshold lidocaine

<!-- PAGE=? -->
 mechanisms are unclear

<!-- PAGE=? -->
 appear to depend on the development of hypertension from vasoconstriction

<!-- PAGE=? -->
 increased cerebral blood flow

<!-- PAGE=? -->
 disruption of the blood-brain barrier

<!-- PAGE=? -->
 decrease clearance d/t dec. hepatic blood flow

<!-- PAGE=? -->
 toxicity from regional anesthesia is uncommon

<!-- PAGE=? -->
 incidence of seizures with epidural injection approximating 1/10,000

<!-- PAGE=? -->
o all closed claim cases are related to epidurals despite the lower incidence

<!-- PAGE=? -->
 incidence of 7/10,000 with peripheral nerve blocks

<!-- PAGE=? -->
Cardiovascular Toxicity of Local Anesthetics

<!-- PAGE=? -->
 much greater doses of local anesthetics are required to produce cardiovascular toxicity than CNS toxicity

<!-- PAGE=? -->
 potency for cardiovascular toxicity reflects the anesthetic potency

<!-- PAGE=? -->
o bupivacaine > levobupivacaine > ropivacaine

<!-- PAGE=? -->
 the later two are 30 to 40% less toxic than bupivicaine

<!-- PAGE=? -->
 ? reduced affinity for brain and myocardial tissue

<!-- PAGE=? -->
 These agents appear to have a different sequence of cardiovascular toxicity than less potent agents

<!-- PAGE=? -->
o lidocaine leads to hypotension, bradycardia, and hypoxia

<!-- PAGE=? -->
o bupivacaine often result in sudden cardiovascular collapse as a result of resistant ventricular dysrhythmias

<!-- PAGE=? -->
 Manifestations include

<!-- PAGE=? -->
o Prolonged PR interval

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Inc. QRS duration

<!-- PAGE=? -->
o Sinus bradycardia and arrest

<!-- PAGE=? -->
o Negative inotrope

<!-- PAGE=? -->
 bupivicaine > tetreacaine > lidocaine > chloroprocaine

<!-- PAGE=? -->
Cardiovascular Toxicity Mediated at the CNS

<!-- PAGE=? -->
 the central and peripheral nervous systems may be involved in the increased cardiotoxicity with bupivacaine

<!-- PAGE=? -->
 The nucleus tractus solitarii in the medulla is an important region for autonomic control of the cardiovascular system

<!-- PAGE=? -->
o Neural activity is markedly diminished by intravenous doses of bupivacaine immediately prior to development of hypotension

<!-- PAGE=? -->
 direct intracerebral injection of bupivacaine can elicit sudden dysrhythmias and cardiovascular collapse

<!-- PAGE=? -->
 Peripheral effects of bupivacaine on the autonomic and vasomotor systems may also augment its cardiovascular toxicity

<!-- PAGE=? -->
o potent peripheral inhibitory effect on sympathetic reflexes

<!-- PAGE=? -->
o potent direct vasodilating properties

<!-- PAGE=? -->
Cardiovascular Toxicity Mediated at the Heart

<!-- PAGE=? -->
 all local anesthetics block the cardiac conduction system via a dose-dependent block of sodium channels

<!-- PAGE=? -->
 bupivacaine's sodium channel blocking abilities may enhance its cardiotoxicity

<!-- PAGE=? -->
o much stronger binding affinity to resting and inactivated sodium channels

<!-- PAGE=? -->
o Bupivacaine dissociates from sodium channels during cardiac diastole much more slowly than lidocaine

<!-- PAGE=? -->
 duration of diastole at physiologic heart rates (60 to 180 beats/min) does not allow enough time for complete recovery of sodium channels and bupivacaine conduction block accumulates

<!-- PAGE=? -->
 Bupivicaine has Increased potency for direct myocardial depression

<!-- PAGE=? -->
o inhibits myocyte release and utilization of calcium

<!-- PAGE=? -->
o reduces mitochondrial energy metabolism, especially during hypoxia

<!-- PAGE=? -->
 All local anesthetics exert a dose-dependent negative inotropic action on cardiac muscle

<!-- PAGE=? -->
o depression of cardiac contractility is proportional to the conduction-blocking potency

<!-- PAGE=? -->
 bupivacaine and tetracaine are more potent cardiodepressants than lidocaine, which in turn is a more potent cardiodepressant than chloroprocaine

<!-- PAGE=? -->
 ventricular arrhythmias and fatal ventricular fibrillation may occur after the rapid intravenous administration of a large dose of bupivacaine but not lidocaine

<!-- PAGE=? -->
 acidosis and hypoxia markedly potentiate the cardiotoxicity of bupivacaine

<!-- PAGE=? -->
Source: Kotelko DM, Shnider SM, Dailey PA, et al. Bupivacaine-induced cardiac arrhythmias in sheep. Anesthesiology 1984;60:10-18; with permission.

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
 parturient animals or patients may be more sensitive to the cardiotoxic effects of bupivacaine than the nonpregnant animal or patient

<!-- PAGE=? -->
o potentiated by

<!-- PAGE=? -->
 decreased FRC and incr O2 consumtion lead to hypoxemia during hypoventilation and apnea

<!-- PAGE=? -->
 aortocaval compression decreases the efficacy of chest compressions

<!-- PAGE=? -->
 large boluses in the epidural veins may reach the heart quicky through a dilated azygous system

<!-- PAGE=? -->
Treatment of Systemic Toxicity from Local Anesthetics

<!-- PAGE=? -->
 best treatment is avoiding systemic toxicity to begin with

<!-- PAGE=? -->
 Toxic levels can occur by unintentional intravenous or intra-arterial injection or by systemic absorption

<!-- PAGE=? -->
o frequent syringe aspiration for blood

<!-- PAGE=? -->
o use of a small test dose

<!-- PAGE=? -->
o slow injection or fractionation of the dose

<!-- PAGE=? -->
o knowledge of toxic doses

<!-- PAGE=? -->
o heart rate, blood pressure, and the electrocardiogram should be monitored during administration of large doses of local anesthetics

<!-- PAGE=? -->
o Pretreatment with a benzodiazepine may lower the probability of seizure

<!-- PAGE=? -->
 Treatment of systemic toxicity is primarily supportive

<!-- PAGE=? -->
o Stop the injection

<!-- PAGE=? -->
o Maintain oxygenation and ventilation

<!-- PAGE=? -->
 systemic toxicity is enhanced by hypoxemia, hypercarbia, and acidosis

<!-- PAGE=? -->
o CNS toxicity will typically occur prior to cardiovascular events

<!-- PAGE=? -->
o Pharmacologic treatment to terminate seizures

<!-- PAGE=? -->
 thiopental (50 to 100 mg)

<!-- PAGE=? -->
 midazolam (2 to 5 mg)

<!-- PAGE=? -->
 propofol (1 mg/kg)

<!-- PAGE=? -->
 succinylcholine will not terminate seizure activity, and increased cerebral metabolic demands will continue unabated

<!-- PAGE=? -->
o Mild cardiovascular depression - bradycardia and hypotension

<!-- PAGE=? -->
 ephedrine (10 to 30 mg)

<!-- PAGE=? -->
 atropine (0.4 mg)

<!-- PAGE=? -->
o Profound cardiovascular depression and malignant dysrhythmias

<!-- PAGE=? -->
 large and multiple doses of

<!-- PAGE=? -->
 electrical cardioversion

<!-- PAGE=? -->
 epinephrine

<!-- PAGE=? -->
 vasopressin

<!-- PAGE=? -->
 amiodarone

<!-- PAGE=? -->
 calcium channel blockers are not recommended

<!-- PAGE=? -->
 intravenous lipid

<!-- PAGE=? -->
 theoretically remove bupivacaine from sites of action

<!-- PAGE=? -->
 1.5ml/kg bolus of 20% lipid solution followed by 0.25ml/kg/min

<!-- PAGE=? -->
 Bolus may repeated once at 3-5min

<!-- PAGE=? -->
 Max infusion of 0.5ml/kg/min

<!-- PAGE=? -->
 Max dose of 8ml/kg

<!-- PAGE=? -->
TABLE 7-1. Comparative pharmacology of local anesthetics

<!-- PAGE=? -->
Classification

<!-- PAGE=? -->
Potency

<!-- PAGE=? -->
Onset

<!-- PAGE=? -->
Duration

<!-- PAGE=? -->
after

<!-- PAGE=? -->
infiltration

<!-- PAGE=? -->
(mins)

<!-- PAGE=? -->
Maximum dose

<!-- PAGE=? -->
for infiltration

<!-- PAGE=? -->
single (adult,

<!-- PAGE=? -->
mg*)

<!-- PAGE=? -->
Toxic plasma

<!-- PAGE=? -->
concentration

<!-- PAGE=? -->
(µg/ml)

<!-- PAGE=? -->
pK

<!-- PAGE=? -->
Esters

<!-- PAGE=? -->
Procaine

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
45-60

<!-- PAGE=? -->
500

<!-- PAGE=? -->
8.9

<!-- PAGE=? -->
Chloroprocaine

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Rapid

<!-- PAGE=? -->
30-45

<!-- PAGE=? -->
600

<!-- PAGE=? -->
8.7

<!-- PAGE=? -->
Tetracaine

<!-- PAGE=? -->
16

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
60-180

<!-- PAGE=? -->
100 (topical)

<!-- PAGE=? -->
8.5

<!-- PAGE=? -->
Amides

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Rapid

<!-- PAGE=? -->
60-120

<!-- PAGE=? -->
300

<!-- PAGE=? -->
>5

<!-- PAGE=? -->
7.9

<!-- PAGE=? -->
Etidocaine

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
240-480

<!-- PAGE=? -->
300

<!-- PAGE=? -->
2

<!-- PAGE=? -->
7.7

<!-- PAGE=? -->
Prilocaine

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
60-120

<!-- PAGE=? -->
400

<!-- PAGE=? -->
>5

<!-- PAGE=? -->
7.9

<!-- PAGE=? -->
Mepivacaine

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
90-180

<!-- PAGE=? -->
300

<!-- PAGE=? -->
>5

<!-- PAGE=? -->
7.6

<!-- PAGE=? -->
Bupivacaine

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
240-480

<!-- PAGE=? -->
175

<!-- PAGE=? -->
>1.5

<!-- PAGE=? -->
8.1

<!-- PAGE=? -->
Ropivacaine

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Slow

<!-- PAGE=? -->
240-480

<!-- PAGE=? -->
200

<!-- PAGE=? -->
>4

<!-- PAGE=? -->
8.1

<!-- PAGE=? -->
Fraction nonionized

<!-- PAGE=? -->
(%)

<!-- PAGE=? -->
pH

<!-- PAGE=? -->
7.2

<!-- PAGE=? -->
pH

<!-- PAGE=? -->
7.4

<!-- PAGE=? -->
pH 7.6

<!-- PAGE=? -->
Protein

<!-- PAGE=? -->
binding

<!-- PAGE=? -->
(%)

<!-- PAGE=? -->
Lipid

<!-- PAGE=? -->
solubility

<!-- PAGE=? -->
Volume

<!-- PAGE=? -->
distribution

<!-- PAGE=? -->
(liters)

<!-- PAGE=? -->
Clearance

<!-- PAGE=? -->
(liters/min)

<!-- PAGE=? -->
Elimination

<!-- PAGE=? -->
half-time

<!-- PAGE=? -->
(mins)

<!-- PAGE=? -->
Esters

<!-- PAGE=? -->
Procaine

<!-- PAGE=? -->
2

<!-- PAGE=? -->
3

<!-- PAGE=? -->
5

<!-- PAGE=? -->
6

<!-- PAGE=? -->
0.6

<!-- PAGE=? -->
Chloroprocaine

<!-- PAGE=? -->
3

<!-- PAGE=? -->
5

<!-- PAGE=? -->
7

<!-- PAGE=? -->
Tetracaine

<!-- PAGE=? -->
5

<!-- PAGE=? -->
7

<!-- PAGE=? -->
11

<!-- PAGE=? -->
76

<!-- PAGE=? -->
80

<!-- PAGE=? -->
Amides

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
17

<!-- PAGE=? -->
25

<!-- PAGE=? -->
33

<!-- PAGE=? -->
70

<!-- PAGE=? -->
2.9

<!-- PAGE=? -->
91

<!-- PAGE=? -->
0.95

<!-- PAGE=? -->
96

<!-- PAGE=? -->
Etiodocaine

<!-- PAGE=? -->
24

<!-- PAGE=? -->
33

<!-- PAGE=? -->
44

<!-- PAGE=? -->
94

<!-- PAGE=? -->
141

<!-- PAGE=? -->
133

<!-- PAGE=? -->
1.22

<!-- PAGE=? -->
156

<!-- PAGE=? -->
Prilocaine

<!-- PAGE=? -->
17

<!-- PAGE=? -->
24

<!-- PAGE=? -->
33

<!-- PAGE=? -->
55

<!-- PAGE=? -->
0.9

<!-- PAGE=? -->
Mepivacaine

<!-- PAGE=? -->
28

<!-- PAGE=? -->
39

<!-- PAGE=? -->
50

<!-- PAGE=? -->
77

<!-- PAGE=? -->
1

<!-- PAGE=? -->
84

<!-- PAGE=? -->
9.78

<!-- PAGE=? -->
114

<!-- PAGE=? -->
Bupivacaine

<!-- PAGE=? -->
11

<!-- PAGE=? -->
15

<!-- PAGE=? -->
24

<!-- PAGE=? -->
95

<!-- PAGE=? -->
28

<!-- PAGE=? -->
73

<!-- PAGE=? -->
0.47

<!-- PAGE=? -->
210

<!-- PAGE=? -->
Ropivacaine

<!-- PAGE=? -->
8.1

<!-- PAGE=? -->
94

<!-- PAGE=? -->
41

<!-- PAGE=? -->
0.44

<!-- PAGE=? -->
108

<!-- PAGE=? -->
TABLE 7-2. Animals manifesting adverse cardiac changes after administration of bupivacaine or lidocaine

<!-- PAGE=? -->
Cardiac change

<!-- PAGE=? -->
Bupivacaine (% of animals)

<!-- PAGE=? -->
Lidocaine (% of animals)

<!-- PAGE=? -->
Sinus tachycardia

<!-- PAGE=? -->
0

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Supraventricular tachycardia

<!-- PAGE=? -->
60

<!-- PAGE=? -->
9

<!-- PAGE=? -->
Atrioventricular heart block

<!-- PAGE=? -->
60

<!-- PAGE=? -->
0

<!-- PAGE=? -->
Ventricular tachycardia

<!-- PAGE=? -->
80

<!-- PAGE=? -->
0

<!-- PAGE=? -->
Premature ventricular contractions

<!-- PAGE=? -->
100

<!-- PAGE=? -->
0

<!-- PAGE=? -->
Wide QRS complexes

<!-- PAGE=? -->
100

<!-- PAGE=? -->
0

<!-- PAGE=? -->
ST-T wave changes

<!-- PAGE=? -->
60

<!-- PAGE=? -->
40

<!-- PAGE=? -->
Long QT

<!-- PAGE=? -->
P&P, CoExD

<!-- PAGE=? -->
 two types of prolonged QT syndromes - congenital &acquired

<!-- PAGE=? -->
o iatrogenic prolonged QT syndrome is far more common than inherited form

<!-- PAGE=? -->
 Drugs

<!-- PAGE=? -->
 antibiotics

<!-- PAGE=? -->
 antidysrhythmics

<!-- PAGE=? -->
o Lidocaine, procainamide, quinidine all increase QT

<!-- PAGE=? -->
o Lidocaine has been used for intraop ventricular arrhythmia in a patient with long QT

<!-- PAGE=? -->
 antidepressants

<!-- PAGE=? -->
 antiemetics

<!-- PAGE=? -->
 Phenothiazines

<!-- PAGE=? -->
o rarely, antipsychotoic drugs prolong the QTc interval and therefore predispose to the development of VT

<!-- PAGE=? -->
 Volatile Anesthetics

<!-- PAGE=? -->
o Halothane, Enflurane, Isoflurane, Sevoflurane

<!-- PAGE=? -->
 Electrolytes

<!-- PAGE=? -->
 Hypokalemia

<!-- PAGE=? -->
 Hypomagnesimia

<!-- PAGE=? -->
 Other

<!-- PAGE=? -->
 severe malnutrition

<!-- PAGE=? -->
 subarachnoid hemorrhage

<!-- PAGE=? -->
 Syncope is the hallmark of the inherited form

<!-- PAGE=? -->
o events are commonly associated with

<!-- PAGE=? -->
 stress

<!-- PAGE=? -->
 emotion

<!-- PAGE=? -->
 exercise

<!-- PAGE=? -->
 other situations associated with sympathetic stimulation

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o correction of electrolyte abnormalities

<!-- PAGE=? -->
 particularly those of magnesium or potassium

<!-- PAGE=? -->
o drugs associated with QT prolongation should be discontinued

<!-- PAGE=? -->
o β-blocker therapy

<!-- PAGE=? -->
 effective in prevention of ventricular dysrhythmias

<!-- PAGE=? -->
o cardiac pacing

<!-- PAGE=? -->
 TdP is often preceded by bradycardia

<!-- PAGE=? -->
 Pacing can prevent this bradycardia

<!-- PAGE=? -->
 Usually used in combination with B-Blockers

<!-- PAGE=? -->
o ICD implantation

<!-- PAGE=? -->
 Prognosis

<!-- PAGE=? -->
o women have longer QT intervals than men

<!-- PAGE=? -->
 incidence of congenital and acquired prolonged QT syndrome is higher in women

<!-- PAGE=? -->
 the incidence of TdP is also higher in women

<!-- PAGE=? -->
o QTc exceeding 500 milliseconds is the strongest predictor of the risk of syncope or sudden death

<!-- PAGE=? -->
o TdP occurs in 1% to 10% of patients receiving QT-prolonging antidysrhythmic drugs

<!-- PAGE=? -->
 the incidence of TdP is much less in patients receiving noncardiovascular QT-prolonging drugs

<!-- PAGE=? -->
 Anesthetic Management

<!-- PAGE=? -->
o preoperative ECG is useful in the presence of a family history of sudden death or a history of unexplained syncope

<!-- PAGE=? -->
o In patients with a prolonged QTc

<!-- PAGE=? -->
 Isoflurane and sevoflurane have been shown to prolong the QTc in otherwise healthy children and adults

<!-- PAGE=? -->
 there is insufficient information to favor one volatile anesthetic over another

<!-- PAGE=? -->
 Droperidol and other antiemetic drugs also increase the QT interval

<!-- PAGE=? -->
 Avoid abrupt increases in sympathetic stimulation

<!-- PAGE=? -->
 Avoid acute hypokalemia due to iatrogenic hyperventilation

<!-- PAGE=? -->
 Consider β-blockade prior to induction in patients believed to be at particular risk

<!-- PAGE=? -->
 defibrillator should be available because the likelihood of perioperative ventricular fibrillation is increased

<!-- PAGE=? -->
 Left stellate ganglion block causes transient shortening of QT

<!-- PAGE=? -->


<!-- PAGE=? -->
Low Molecular Weight Heparin

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
 Advantages vs. unfractionated

<!-- PAGE=? -->
o higher and more predictable bioavailability after subcutaneous administration

<!-- PAGE=? -->
o a longer biological half-life

<!-- PAGE=? -->
o a smaller impact on platelet function

<!-- PAGE=? -->
 Pharmacodynamics

<!-- PAGE=? -->
o Standard heparin consists of components with molecular weights ranging from 4000-30,000 daltons

<!-- PAGE=? -->
 LMWH contains MW between 4000-5000 daltons

<!-- PAGE=? -->
o LMWH strongly inhibit factor Xa, lesser IIa inhibition

<!-- PAGE=? -->
o Decreased platelet antibody formation as compared to UFH

<!-- PAGE=? -->
 Pharmacokinetics

<!-- PAGE=? -->
o More consistent between patients d/t less protein binding

<!-- PAGE=? -->
 Higher bioavailability and more predictable anticoagulant response

<!-- PAGE=? -->
o Less binding to endothelial cells

<!-- PAGE=? -->
 Longer elimination time

<!-- PAGE=? -->
o cleared principally by the kidneys

<!-- PAGE=? -->
 prolonged clearance in renal failure

<!-- PAGE=? -->
 half-life of LMWHs is largely independent of the dose administered

<!-- PAGE=? -->
Dalteparin

<!-- PAGE=? -->
 Adverse reactions and contraindications

<!-- PAGE=? -->
o Hepatic : AST >3 times upper limit of normal (5% to 9%), ALT >3 times upper limit of normal (4% to 10%)

<!-- PAGE=? -->
o Local : Pain at injection site (up to 12%), injection site hematoma (up to 7%)

<!-- PAGE=? -->
 Metabolism & Excretion

<!-- PAGE=? -->
o Onset of action: 1-2 hours

<!-- PAGE=? -->
o Time to peak, serum: 4 hours

<!-- PAGE=? -->
o Duration: >12 hours

<!-- PAGE=? -->
o Distribution: Vd: 40-60 mL/kg

<!-- PAGE=? -->
o Bioavailability: SubQ: 81% to 93%

<!-- PAGE=? -->
o Half-life elimination (route dependent): 2-5 hours

<!-- PAGE=? -->
o Excretion: Urine (40% of dose; 10% as active fragments)

<!-- PAGE=? -->
Enoxaparin

<!-- PAGE=? -->
 Adverse reactions and contraindications

<!-- PAGE=? -->
o Central nervous system : Fever (5% to 8%), confusion, pain

<!-- PAGE=? -->
o Gastrointestinal : Nausea (3%), diarrhea

<!-- PAGE=? -->
o Hematologic : thrombocytopenia (moderate 1%; severe 0.1% - see note below), hypochromic anemia (2%)

<!-- PAGE=? -->
o Hepatic : ALT/AST increased

<!-- PAGE=? -->
o Local : Injection site hematoma (9%), local reactions (irritation, pain, ecchymosis, erythema)

<!-- PAGE=? -->
 Metabolism & Excretion

<!-- PAGE=? -->
o Onset of action

<!-- PAGE=? -->
 Peak effect - Antifactor Xa and antithrombin (antifactor IIa): 3-5 hours

<!-- PAGE=? -->
o Duration: 40 mg dose

<!-- PAGE=? -->
 Antifactor Xa activity - 12 hours

<!-- PAGE=? -->
o Metabolism

<!-- PAGE=? -->
 Hepatic, to lower molecular weight fragments (little activity)

<!-- PAGE=? -->
o Protein binding

<!-- PAGE=? -->
 Does not bind to heparin binding proteins

<!-- PAGE=? -->
o Half-life elimination, plasma

<!-- PAGE=? -->
 2-4 times longer than standard heparin, independent of dose; based on anti-Xa activity: 4.5-7 hours

<!-- PAGE=? -->
o Excretion: Urine (40% of dose; 10% as active fragments)

<!-- PAGE=? -->
Lumbar Plexus Block

<!-- PAGE=? -->
Blockade of the lumbar portion of the sympathetic chain has both diagnostic and therapeutic utility, most notably in the management of a variety of chronic pain syndromes (i.e CRPS), as well as in peripheral vascular disorders.

<!-- PAGE=? -->
Anatomy

<!-- PAGE=? -->
 The sympathetic supply to the pelvic viscera and lower extremities are contained within the lumbar sympathetic chain

<!-- PAGE=? -->
o In particular, the sympathetic fibers supplying the lower extremities consist of preganglionic fibers from T11-L2 (sometimes even including T10 and L3)

<!-- PAGE=? -->
o Similar to what occurs in the upper limb, they enter the paravertebral sympathetic chain and descend to ganglia located from L3-S3 (L3/4/5, S1/2/3), where they synapse with postganglionic fibers

<!-- PAGE=? -->
o These postganglionic fibers either 1) form a plexus around the iliac and femoral arteries (minority) or 2) join the spinal nerves that form the lumbar and lumbosacral plexi (majority), which give rise to the femoral , sciatic , and obturator nerves

<!-- PAGE=? -->
o Since most of the fibers that ultimately supply the lower limb pass through the L2 and L3 ganglia , blockade of this area can achieve almost complete sympathetic denervation of the lower limb

<!-- PAGE=? -->
o However, like the upper limb, some sympathetic fibers to bypass the sympathetic chain and make their way directly via somatic spinal nerves, so complete denervation may not occur in some people

<!-- PAGE=? -->
 The lumbar sympathetic trunks consist of chains situated on the anterolateral surface of the vertebral column , medial to the origin of the psoas muscle

<!-- PAGE=? -->
o Most often each chain has four ganglia, rather than five (the T12 and L1 ganglia are fused); the two chains on either side often differ as well

<!-- PAGE=? -->
o Surrounding structures

<!-- PAGE=? -->
 Anterior: aorta (slightly left of midline, directly anterior to vertebral body), inferior vena cava (right of midline, anterolateral to vertrebral body)

<!-- PAGE=? -->
 Medial: vertebral body

<!-- PAGE=? -->
 Inferolateral: kidneys , psoas muscle , genitofemoral nerve (sits on anterolateral surface of psoas)

<!-- PAGE=? -->
o Consider analogous structures from stellate ganglion block

<!-- PAGE=? -->
 Aorta/SVC = carotid sheath, vertebral arteries

<!-- PAGE=? -->
 Psoas = longus colli

<!-- PAGE=? -->
 Genitofemoral nerve = RLN/phrenic

<!-- PAGE=? -->
 Lung = kidney

<!-- PAGE=? -->
7 cm

<!-- PAGE=? -->
10 cm

<!-- PAGE=? -->
L?

<!-- PAGE=? -->
Sympathetic

<!-- PAGE=? -->
Inlerior

<!-- PAGE=? -->
Aorba

<!-- PAGE=? -->
Psoas major

<!-- PAGE=? -->
ganglla

<!-- PAGE=? -->
Vena cava

<!-- PAGE=? -->
muscle

<!-- PAGE=? -->
Sympathetic ganglia

<!-- PAGE=? -->
copyright@2006 by The McGraw-Hill Companies,Inc All rights reserved

<!-- PAGE=? -->
non

<!-- PAGE=? -->
B

<!-- PAGE=? -->
Distribution of Anesthesia

<!-- PAGE=? -->
 The sympathetic nerves that supply the pelvic viscera and lower extremities do so via the lumbar sympathetic chain, so adequate blockade will result in a temporary denervation of these areas

<!-- PAGE=? -->
 As noted above, there will be a subset of patients that have additional sympathetic innervation carried directly via somatic nerves

<!-- PAGE=? -->
 The details of the pelvic viscera are not discussed here

<!-- PAGE=? -->
Indications

<!-- PAGE=? -->
 Sympathetically mediated pain in the lower extremities

<!-- PAGE=? -->
o CRPS I and II

<!-- PAGE=? -->
o Herpes zoster, post-herpetic neuralgia

<!-- PAGE=? -->
o Phantom limb pain

<!-- PAGE=? -->
 Vascular insufficiency

<!-- PAGE=? -->
o May be useful for Raynaud's, various vasculitides

<!-- PAGE=? -->
o More importantly, may be useful for pain related to peripheral vascular disease (by far the more common indication when doing these blocks in older patients)

<!-- PAGE=? -->
 Neurolytic agents used for this purpose, rather than local anesthetics, for a permanent sympathectomy

<!-- PAGE=? -->
o Not generally used to increase perfusion in the setting of PVD, since culprit vessels presumably stenosed, and thus cannot dilate further, and if anything, creating a steal phenomenon

<!-- PAGE=? -->
 Adjunctive measure in the management of cancer pain (if there is a neuropathic component)

<!-- PAGE=? -->
 +/- Urogenital pain (renal colic, obscure pelvic pain)

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
 Specific

<!-- PAGE=? -->
o No specific contraindications

<!-- PAGE=? -->
 General

<!-- PAGE=? -->
o Coagulopathy /anticoagulation

<!-- PAGE=? -->
o Infection at site

<!-- PAGE=? -->
o Local anesthetic allergy

<!-- PAGE=? -->
o Uncooperative patient

<!-- PAGE=? -->
o Patient refusal

<!-- PAGE=? -->
o Inadequate technical skill

<!-- PAGE=? -->
o Lack of resuscitative equipment

<!-- PAGE=? -->
Side Effects & Complications

<!-- PAGE=? -->
 Needle-related (things you can poke)

<!-- PAGE=? -->
o Aortic or IVC puncture +/- injection, toxic reaction

<!-- PAGE=? -->
o Kidney injury

<!-- PAGE=? -->
o Retroperitoneal hematoma (especially with vascular puncture)

<!-- PAGE=? -->
o Nerve injury

<!-- PAGE=? -->
o Infection, osteomyelitis, discitis

<!-- PAGE=? -->
 Local Anesthetic related (things you can freeze/block)

<!-- PAGE=? -->
o Intravascular injection (as above)

<!-- PAGE=? -->
o Intrathecal or epidural injection (total spinal; may be unable to detect via aspiration test, because of small CSF volume in these areas)

<!-- PAGE=? -->
o Unintended lumbar plexus block leading to motor blockade

<!-- PAGE=? -->
o Genitofemoral nerve block

<!-- PAGE=? -->
o Allergy/anaphylaxis

<!-- PAGE=? -->
 Neurolytic-related

<!-- PAGE=? -->
o Genitofemoral neuralgia (5-10% of neurolytic sympathectomy; burning pain lasting 2-5 weeks)

<!-- PAGE=? -->
o Ureteral stricture

<!-- PAGE=? -->
o Psoas muscle injury (chemical neuropathy leading to neuralgia, hypesthesia, +/- motor weakness)

<!-- PAGE=? -->
Preparation

<!-- PAGE=? -->
 Setup/Monitors

<!-- PAGE=? -->
o Standard CAS monitors & resuscitative drugs/equipment (should be done in controlled OR setting, or equivalent)

<!-- PAGE=? -->
o Sedation often used, therefore patients must be NPO

<!-- PAGE=? -->
o IV access preferable (for delivery of sedation)

<!-- PAGE=? -->
 Positioning

<!-- PAGE=? -->
o Prone (although lateral techniques are described)

<!-- PAGE=? -->
o 1-2 pillows below the abdomen, +/- chin to chest, in effort to flex the lumbar spine

<!-- PAGE=? -->
 Equipment

<!-- PAGE=? -->
o Fluoroscopy

<!-- PAGE=? -->
o Sterile prep tray with gauze, cleaning solution

<!-- PAGE=? -->
o Sterile gown, setup

<!-- PAGE=? -->
o Lidocaine 1-2%, Bupivicaine 0.25%, +/- Neurolytic agents (6% Phenol)

<!-- PAGE=? -->
o Syringe and 25G needle (+/- spinal needle) for skin infiltration

<!-- PAGE=? -->
o -Special‖ procedural needles (with slight angulation on end), or regular procedural needles with -manual‖ angulation using plastic needle cover (22 G, 15 cm Special Technique needle)

<!-- PAGE=? -->
o 5 cc syringe and extension tubing (for contrast)

<!-- PAGE=? -->
o Multiple 10 cc syringes with -thumbhole‖ for easy intermittent aspiration

<!-- PAGE=? -->
Technique

<!-- PAGE=? -->
 Position patient prone, in a comfortable position, with effort made to extend the lumbar spine as optimally as possible

<!-- PAGE=? -->
 Once prone, confirm with patient which side is the operative side

<!-- PAGE=? -->
 Clean the back, remembering to clean more on the operative side rather than the midline

<!-- PAGE=? -->
 Begin sedation (Fentanyl/Midazolam vs Propofol)

<!-- PAGE=? -->
 Orient using fluoroscopy, identifying the L2 and L3 vertebral levels (L3 if doing only one level); use marker to mark on skin

<!-- PAGE=? -->
 Draw a line corresponding to the lower margin of the pedicles (basically the midpoint of the vertebral body), and extend it 7-8 cm lateral, perpendicular to the spinal column; measure 1 cm inferior, and mark the point (do this for both L2 and L3, if injecting at both levels)

<!-- PAGE=? -->
 Prep the skin as per usual, and infiltrate the skin with Lidocaine

<!-- PAGE=? -->
 Through the skin wheal, advance the needle at a 45 degree angle towards the vertebral body - inject local anesthetic generously in order to pass comfortably through the lumbar fascia (can be quite painful)

<!-- PAGE=? -->
o As the needle passes through the psoas muscle, parasthesias may occur in the distribution of the lumbar plexus, usually over the anterior aspect of the thigh (genitofemoral nerve distribution)

<!-- PAGE=? -->
o Aim for the midpoint of the vertebral body, and gradually walk the needle anteriorly until the needle -slips‖ just anterolaterally to the body

<!-- PAGE=? -->
o Confirm using the lateral view that you are just anterior to the body

<!-- PAGE=? -->
o Aspirate (for blood +/- CSF)

<!-- PAGE=? -->
o Inject radioopaque dye (only 0.5-1 cc needed) via extension tubing

<!-- PAGE=? -->
 If you are in the psoas muscle , the dye should spread in a manner that reflects the distribution and striation of the psoas muscle

<!-- PAGE=? -->
 If you are in the correct plane , you should get a discrete , thin distribution of dye (that honestly sort of looks like a ganglion)

<!-- PAGE=? -->
o +/- Repeat with the second needle at L3 (if doing levels)

<!-- PAGE=? -->
 Once satisfied with the distribution of dye, inject a test dose of Bupivicaine 0.25%

<!-- PAGE=? -->
o Bonica et al suggest injecting 2 cc, and waiting 4-5 minutes before injecting the rest, to look for evidence of a subarachnoid block (but I've never seen anyone wait this long)

<!-- PAGE=? -->
 Injection of local anesthetic (via extension tubing)

<!-- PAGE=? -->
o Some (i.e. Clinton) advocate a single injection of 30 cc of Bupivicaine 0.25% , whereas others advocate two injections of 15 cc (i.e. Jill Osborn)

<!-- PAGE=? -->
o Regardless, inject with intermittent aspiration

<!-- PAGE=? -->
o Re-fluoro after injecting the first bit of local anesthetic, to confirm that the contrast continues to spread appropriately

<!-- PAGE=? -->
 Injection of neurolytics

<!-- PAGE=? -->
o If injecting neurolytics, do 3 levels (L2/3/4), so that one can spread smaller volumes can be injected at each level

<!-- PAGE=? -->
o Even more important to confirm radiologically, with a good dye distribution

<!-- PAGE=? -->
o Clinton uses 10 cc of 6% Phenol (~3.3 cc at each level)

<!-- PAGE=? -->
o For each needle, -chase‖ the neurolytic agent with 1 cc of local anesthetic to avoid seeding the tract with Phenol as you withdraw the needle

<!-- PAGE=? -->
o Beware genitofemoral neuralgia (8-10%, for up to 3-5 weeks)

<!-- PAGE=? -->
o Phenol is appropriate here, since we are doing a -small volume‖ block , and you won't get into toxic ranges

<!-- PAGE=? -->
 Afterwards

<!-- PAGE=? -->
o Place patients block side UP for 20 minutes , so that the injected agents distribute to gravity (which will be medial, and away from genitofemoral nerve)

<!-- PAGE=? -->
o Even more important with using neurolytic agents!

<!-- PAGE=? -->
o Much more difficult than stellate block to assess for success

<!-- PAGE=? -->
o Regardless, can still:

<!-- PAGE=? -->
 Ask patient what pain is relative to before

<!-- PAGE=? -->
 See if any other CRPS-related changes

<!-- PAGE=? -->
 Look for warmth of the foot, venodilation

<!-- PAGE=? -->
Misc Notes & Diagrams

<!-- PAGE=? -->
 Think of two groups that come commonly have this block

<!-- PAGE=? -->
o Young people - CRPS

<!-- PAGE=? -->
o Old people - peripheral vascular disease pain

<!-- PAGE=? -->
 Think of the rationale behind sympathetic blockade as rebooting the computer ‖ - don't know how it works, but it does!

<!-- PAGE=? -->
 Things you want to know after the procedure (as per Clinton)

<!-- PAGE=? -->
o Any complications (as described above)

<!-- PAGE=? -->
o Do you have a sympathetic block ?

<!-- PAGE=? -->
o Do you have an element of pain relief ?

<!-- PAGE=? -->
 Pain relief post-block

<!-- PAGE=? -->
o May not notice it right away, but should be some effect within hours

<!-- PAGE=? -->
o One key is that it should outlast the expected duration of the local anesthetic (i.e. Bupivicaine should only give you 10-12 hrs)

<!-- PAGE=? -->
o Generally get some relief that may peak in 2-3 days, and decrease somewhat, but your new baseline should be better

<!-- PAGE=? -->
o You can then do another block, have even more of a decrease in pain, and your baseline should again be better

<!-- PAGE=? -->
o With subsequent blocks (at least at first) you expect more analgesia, and an improved baseline

<!-- PAGE=? -->
o A series of 3 injections (ideally within a week, but may be 1-2 weeks) serve as a gauge to see if the patient responds to these (effectively confirming your diagnosis of CRPS); if they do, continue on with the blocks, but more spaced out

<!-- PAGE=? -->
 Neurolytic agents

<!-- PAGE=? -->
o Indications

<!-- PAGE=? -->
 Intractable cancer pain

<!-- PAGE=? -->
 Refractory neuralgia

<!-- PAGE=? -->
 Ischemic pain related to peripheral vascular disease

<!-- PAGE=? -->
o Contraindications

<!-- PAGE=? -->
 Not really a contraindication, but these aren't usually used for non-malignant pain (except for the vascular-related ischemia) since the effect is only temporary, so is really only

<!-- PAGE=? -->
appropriate for palliation

<!-- PAGE=? -->
o Side Effects

<!-- PAGE=? -->
 Paralysis (if given intrathecally), so must confirm position before injection

<!-- PAGE=? -->
 Back pain (decreased by combining alcohol with local anesthetic)

<!-- PAGE=? -->
o Types

<!-- PAGE=? -->
 Alcohol

<!-- PAGE=? -->
 Exists as 50-100% preparations

<!-- PAGE=? -->
 Extracts membrane phospholipids and precipitated lipoproteins in axons and Schwann cells, leading to cell death

<!-- PAGE=? -->
 Causes severe pain on injection

<!-- PAGE=? -->
 Causes motor block on peripheral nerves

<!-- PAGE=? -->
 Immediate effect, with the longest, best block (4-6 months)

<!-- PAGE=? -->
 Phenol

<!-- PAGE=? -->
 Exists as 3-8% phenol in water, 5-10% in glycerine (prepared by pharmacy)

<!-- PAGE=? -->
o Phenol in glycerol is hyperbaric

<!-- PAGE=? -->
 Coagulates proteins, leading to cell death

<!-- PAGE=? -->
 High affinity for vascular tissue (high incidence of injury to spinal cord vessels), with potential for cardiac and systemic toxicity (seizures) associated with intravascular injection

<!-- PAGE=? -->
 Biphasic effect

<!-- PAGE=? -->
o Anesthetic action within 10-15 minutes, lasts 24 hrs

<!-- PAGE=? -->
o Neurolytic phases follows (degeneration takes 14 d, regeneration takes 14 weeks)

<!-- PAGE=? -->
 Less profound effect, and shorter duration than alcohol

<!-- PAGE=? -->
 Better for peripheral nerves

<!-- PAGE=? -->
 Misc

<!-- PAGE=? -->
 Celiac plexus block - alcohol is preferred, because of the concern of phenol being absorbed by vascular tissue

<!-- PAGE=? -->
 Lumbar plexus block - phenol is preferred

<!-- PAGE=? -->
 After injecting, the needle should be cleared (chased with saline or LA), prior to withdrawal, to prevent damaging structures upon withdrawal of the needle

<!-- PAGE=? -->
 Clinton's perspective - the lumbar block is a small volume block, so phenol is appropriate (and better, since you avoid pain), but the celiac plexus block is a high volume block, and you are more likely to enter toxic range with large volumes of phenol, so you use alcohol, despite the pain

<!-- PAGE=? -->
2

<!-- PAGE=? -->
2

<!-- PAGE=? -->
References

<!-- PAGE=? -->
 Bonica JJ. Sympathetic Nerve Blocks for Pain Diagnosis and Therapy (from Clinton)

<!-- PAGE=? -->
 Cousins

<!-- PAGE=? -->
 Miller

<!-- PAGE=? -->
Lung compliance and elasticity

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Lung Compliance, Elasticity, and Age

<!-- PAGE=? -->
 At birth, children have approximately 24 million alveoli - inc. to 300 million by age 8

<!-- PAGE=? -->
o further lung growth is primarily the result of increased alveolar size

<!-- PAGE=? -->
 Lung compliance changes with age d/t

<!-- PAGE=? -->
o changing alveolar structure

<!-- PAGE=? -->
o amount of elastin

<!-- PAGE=? -->
o amount of surfactant

<!-- PAGE=? -->
 There is less elastic tissue in the neonatal lung than in the lungs of adults

<!-- PAGE=? -->
o By 18 years of age, elastin extends to the alveolus and is at its maximum

<!-- PAGE=? -->
o The elasticity of the lung then slowly decreases over the next 5 decades

<!-- PAGE=? -->
 At birth, compliance is low:

<!-- PAGE=? -->
o alveolar precursors have thick walls

<!-- PAGE=? -->
o decreased amounts of elastin

<!-- PAGE=? -->
o deficiency of surfactant (e.g., hyaline membrane disease)

<!-- PAGE=? -->
 The improved lung compliance occurring over the first years of life is the result of continued development of alveoli and elastin

<!-- PAGE=? -->
 Lung compliance is integrally related to the amount of elastin; hence, compliance peaks in adolescence. It is lower in the very young and the very old

<!-- PAGE=? -->
 with aging lung compliance increases

<!-- PAGE=? -->
o loss of elastic recoil after reorganization of collagen and elastin in lung parenchyma

<!-- PAGE=? -->
 enlargement of the respiratory bronchioles and alveolar ducts

<!-- PAGE=? -->
 tendency for early collapse of the small airways on exhalation

<!-- PAGE=? -->
o altered surfactant production

<!-- PAGE=? -->
 Increased compliance leads to limited maximal expiratory flow and a decreased ventilatory response to exercise

<!-- PAGE=? -->
 There also is a progressive loss of alveolar surface area secondary to increases in size of the interalveolar pores of Kohn

<!-- PAGE=? -->
 The functional results of these pulmonary changes are

<!-- PAGE=? -->
o increased anatomic dead space

<!-- PAGE=? -->
o decreased diffusing capacity

<!-- PAGE=? -->
o increased closing capacity

<!-- PAGE=? -->
 all of these lead to impaired gas exchange

<!-- PAGE=? -->
 Lung elasticity: decr with age d/t loss of elastin and altered surfactant production

<!-- PAGE=? -->
o Increased compliance

<!-- PAGE=? -->
 Lung elasticity greatest as teenager

<!-- PAGE=? -->
 Chest wall compliance: decr with elderly d/t calcification

<!-- PAGE=? -->
 Chest wall compliance greatest in babies

<!-- PAGE=? -->
Table 84-4   -- Age-Dependent Respiratory Variables: Normal Values *

<!-- PAGE=? -->
Lung Dead space

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Physiologic dead space = anatomic and alveolar dead space

<!-- PAGE=? -->
 Normal Vd = 150 ml ( 2 ml/kg, or weight in pounds)

<!-- PAGE=? -->
o ~ 33% of VT

<!-- PAGE=? -->
o In the healthy patient lying supine, the anatomic and total dead space are approximately equal to each other because alveolar dead space is minimal

<!-- PAGE=? -->
 In the erect posture, the uppermost alveoli may not be perfused (zone 1), and alveolar dead space may increase from a negligible amount to 60 to 80 mL

<!-- PAGE=? -->
 Clinical conditions that modify anatomic dead space include

<!-- PAGE=? -->
o tracheal intubation

<!-- PAGE=? -->
o tracheostomy

<!-- PAGE=? -->
o large lengths of ventilator tubing between the tracheal tube and the ventilator Y-piece

<!-- PAGE=? -->
 Alveolar dead space ventilation arises from ventilation of alveoli where there is little or no perfusion

<!-- PAGE=? -->
o physiologic dead space is primarily influenced by changes in alveolar dead space

<!-- PAGE=? -->
 The most common etiology of acutely increased physiologic dead space is an abrupt decrease in cardiac output

<!-- PAGE=? -->
 The PaCO2 will be greater than or equal to end-tidal PaCO2 (PETCO2) unless the patient inspires carbon dioxide

<!-- PAGE=? -->
o difference between PETCO2 and PaCO2 is due to dead space ventilation

<!-- PAGE=? -->
 During intentional pharmacologic or surgical manipulation of pulmonary blood flow, the difference between PaCO2 and PETCO2 serves as a useful physiologic monitor of the effectiveness of these interventions

<!-- PAGE=? -->
 The most quantitative technique used to measure physiologic dead space utilizes a modification of the Bohr equation

<!-- PAGE=? -->
o estimates the fraction of each breath that does not contribute to gas exchange

<!-- PAGE=? -->
 spontaneously breathing patients, normal VD/Vt is between 0.2 and 0.4

<!-- PAGE=? -->
 with PPV, VD/Vt becomes ~0.5

<!-- PAGE=? -->
o Fowler's Method is used to determine anatomic deadspace

<!-- PAGE=? -->
 Factors that decrease Vd include

<!-- PAGE=? -->
o supine position

<!-- PAGE=? -->
o neck flexion

<!-- PAGE=? -->
o artificial airways

<!-- PAGE=? -->
 Factors that increase Vd include

<!-- PAGE=? -->
o upright position

<!-- PAGE=? -->
o neck extension

<!-- PAGE=? -->
o age

<!-- PAGE=? -->
o PPV

<!-- PAGE=? -->
o Anticholinergics

<!-- PAGE=? -->
o decreased perfusion (pulmonary emboli, hTN)

<!-- PAGE=? -->
o emphysema

<!-- PAGE=? -->
Lung Lavage

<!-- PAGE=? -->
 Physiology of unilateral lung  lavage:

<!-- PAGE=? -->
o Hypoxemia IMPROVES on filling of lung (decreases pulmonary blood flow to the side being filled)

<!-- PAGE=? -->
o Hypoxemia OCCURS on emptying of lung (pulmonary blood flow increases as the pressure in the lung decreases but alveoli are still filled with fluid)

<!-- PAGE=? -->
o Cardiac output DECREASES with lung filling (increased PVR) and INCREASES with lung emptying.

<!-- PAGE=? -->
o Risk of lung contamination, significant desaturation and decreased cardiac output, and need for neuromuscular paralysis, and DLT required (of course).

<!-- PAGE=? -->
Lung Separation

<!-- PAGE=? -->
Table 30-2. INDICATIONS FOR ONE-LUNG VENTILATION

<!-- PAGE=? -->
ABSOLUTE

<!-- PAGE=? -->
Isolation of each lung to prevent contamination of a healthy lung

<!-- PAGE=? -->
Infection (abscess, infected cyst)

<!-- PAGE=? -->
Massive hemorrhage

<!-- PAGE=? -->
Control of distribution of ventilation to only one lung

<!-- PAGE=? -->
Bronchopleural fistula

<!-- PAGE=? -->
Bronchopleural cutaneous fistula

<!-- PAGE=? -->
Unilateral cyst or bullae

<!-- PAGE=? -->
Major bronchial disruption or trauma

<!-- PAGE=? -->
Life threatening hypoxemia from unilateral lung disease

<!-- PAGE=? -->
Unilateral lung lavage

<!-- PAGE=? -->
Video-assisted thoracoscopic surgery (miller lists as relative)

<!-- PAGE=? -->
RELATIVE

<!-- PAGE=? -->
Surgical exposure-high priority

<!-- PAGE=? -->
Thoracic aortic aneurysm

<!-- PAGE=? -->
Pneumonectomy

<!-- PAGE=? -->
Upper lobectomy

<!-- PAGE=? -->
Thoracoscopy under general anesthesia

<!-- PAGE=? -->
Surgical exposure-low priority

<!-- PAGE=? -->
Esophageal surgery

<!-- PAGE=? -->
Middle and lower lobectomy

<!-- PAGE=? -->
Lung Volumes

<!-- PAGE=? -->
Inspiratory

<!-- PAGE=? -->
reserve

<!-- PAGE=? -->
Inspiralory

<!-- PAGE=? -->
volume

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Vilal

<!-- PAGE=? -->
9

<!-- PAGE=? -->
3.0

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Tolal

<!-- PAGE=? -->
2.5

<!-- PAGE=? -->
Tidal

<!-- PAGE=? -->
Expiratory

<!-- PAGE=? -->
Iung

<!-- PAGE=? -->
reserve

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
volume

<!-- PAGE=? -->
Functional

<!-- PAGE=? -->
volume

<!-- PAGE=? -->
1.25

<!-- PAGE=? -->
residual

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Residual volume

<!-- PAGE=? -->
The first gases exhaled from large airways are considered to represent dead space gases (phase I) (see the section on Dead Space). The beginning of alveolar gas exhalation is reflected by an increase in the exhaled nitrogen concentration (phase II ), followed by a plateau (phase III) if ventilation is distributed fairly evenly. If the nitrogen concentration continues to increase during phase III, it can be assumed that alveoli are filling and emptying at different rates. Phase IV reflects higher nitrogen concentrations in alveoli of the lung spaces that continue to empty at low lung volumes that cause airways at lung bases to close.

<!-- PAGE=? -->
Lung Volume (L)

<!-- PAGE=? -->
30

<!-- PAGE=? -->
IV

<!-- PAGE=? -->
1

<!-- PAGE=? -->
2

<!-- PAGE=? -->
DS

<!-- PAGE=? -->
CV

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
Lung Transplant

<!-- PAGE=? -->
Miller, CoExD

<!-- PAGE=? -->
 Lack of cough reflex below tracheal anastamosis

<!-- PAGE=? -->
o need to protect airway

<!-- PAGE=? -->
 Lymphatic disruption

<!-- PAGE=? -->
 poor mucocilliary clearance

<!-- PAGE=? -->
 Non-asthmatic recipients will not get asthma

<!-- PAGE=? -->
o asthmatics will continue to have asthma

<!-- PAGE=? -->
 damage to laryngeal nerves (vagus, recurrent laryngeal, phrenic) can occur during implantation but this usually resolves

<!-- PAGE=? -->
o possible risk of aspiration

<!-- PAGE=? -->
 Lung function should return to normal (including HPV)

<!-- PAGE=? -->
o there may be a lingering impairment in ventilatory response to hypercapnea

<!-- PAGE=? -->
 Chemoreceptors returm to normal in ~ 1 month

<!-- PAGE=? -->
 After double-lung transplant, normal or near-normal spirometric function and gas exchange

<!-- PAGE=? -->
o 9 to 12 months post-transplant, single lung recipients, with a remaining diseased lung, will probably have evidence of persisting obstructive or restrictive ventilatory defects,  as well as some degree of abnormal oxygenation

<!-- PAGE=? -->
 allograft function may be compromised at any time by episodes of acute rejection

<!-- PAGE=? -->
o increasing interval from the time of implantation, by the cumulative effects of chronic rejection (bronchiolitis obliterans)

<!-- PAGE=? -->
 immunosuppressive therapy

<!-- PAGE=? -->
o inc. risk for acute pulmonary infection

<!-- PAGE=? -->
o those presenting for surgery should undergo preoperative assessment of pulmonary status

<!-- PAGE=? -->
 CXR

<!-- PAGE=? -->
 Spirometry

<!-- PAGE=? -->
 ABG

<!-- PAGE=? -->
o serve not only as a baseline for stable patients but also-in conjunction with suggestive symptoms or functional decline-as a basis for suspicion of intercurrent infection or acute rejection

<!-- PAGE=? -->
 Fever, malaise, dyspnea, cough, hypoxemia, leukocytosis, and radiographic infiltrates may accompany either

<!-- PAGE=? -->
o transbronchial biopsy may be required to direct management

<!-- PAGE=? -->
Rejection:

<!-- PAGE=? -->
 Comparison of preoperative PFT, arterial blood gas, and CXR results with prior studies can help diagnose acute infection or rejection:

<!-- PAGE=? -->
 Significant decreases in FEV1, vital capacity, and total lung capacity and an obstructive pattern may indicate acute rejection.

<!-- PAGE=? -->
 Arterial blood gas in the presence of rejection will show an increased A-a gradient from stable baseline gases

<!-- PAGE=? -->
 perihilar infiltration on CXR.

<!-- PAGE=? -->
 However, rejection and infection can be difficult to distinguish clinically. If the patient is suspected of having an active pulmonary process, consultation with pulmonary medicine for a possible diagnostic bronchoscopy should be considered prior to surgery.

<!-- PAGE=? -->
Anesthetic considerations

<!-- PAGE=? -->
 Function of the allograft

<!-- PAGE=? -->
o Rejection

<!-- PAGE=? -->
o Infection

<!-- PAGE=? -->
 Immunosuppressive therapy and end-organ damage

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
o renal dysfunction

<!-- PAGE=? -->
 Disease in the remaining lung

<!-- PAGE=? -->
 Physiologic changes in transplanted lung:

<!-- PAGE=? -->
o decreased cough

<!-- PAGE=? -->
o possible increased bronchoconstriction

<!-- PAGE=? -->
 Increased risk of peri-operative pulmonary complications

<!-- PAGE=? -->
 regional preferred (avoid airway instrumentation )

<!-- PAGE=? -->
M

<!-- PAGE=? -->
MAC

<!-- PAGE=? -->
 change in MAC of  6% per decade

<!-- PAGE=? -->
 22% decrease in MAC from age 40 to age 80

<!-- PAGE=? -->
 27% decrease in MAC from age 1 to 40 years

<!-- PAGE=? -->
 MAC is typically expressed for an intermediate age (40 years)

<!-- PAGE=? -->
 MAC is increased by agents that inc. CNS neurotransmitters

<!-- PAGE=? -->
o Dec. by agents that dec. CNS neurotransmitters

<!-- PAGE=? -->
Table 15-4. FACTORS THAT INCREASE MAC

<!-- PAGE=? -->
Increased central neurotransmitter levels (monoamine oxidase inhibitors, acute dextroamphetamine, cocaine, ephedrine, levodopa)

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
Chronic ethanol abuse (determined in humans)

<!-- PAGE=? -->
Hypernatremia

<!-- PAGE=? -->
Table 15-5. FACTORS THAT DECREASE MAC

<!-- PAGE=? -->
Increasing age

<!-- PAGE=? -->
Metabolic acidosis

<!-- PAGE=? -->
Hypoxia (PaO2, 38 mm Hg)

<!-- PAGE=? -->
Induced hypotension (MAP < 50 mm Hg)

<!-- PAGE=? -->
Decreased central neurotransmitter levels (  -methyldopa, reserpine, chronic dextroamphetamine administration, levodopa)

<!-- PAGE=? -->
Alpha-2 agonists

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Hyponatremia

<!-- PAGE=? -->
Lithium

<!-- PAGE=? -->
Hypo-osmolality

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
Acute ethanol administration*

<!-- PAGE=? -->
Ketamine

<!-- PAGE=? -->
Pancuronium*

<!-- PAGE=? -->
Physostigmine (10 times clinical doses)

<!-- PAGE=? -->
Neostigmine (10 times clinical doses)

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
Opioid agonist-antagonist analgesics

<!-- PAGE=? -->
Barbiturates*

<!-- PAGE=? -->
Chlorpromazine*

<!-- PAGE=? -->
Diazepam*

<!-- PAGE=? -->
Hydroxyzine*

<!-- PAGE=? -->
 -9-Tetrahydrocannabinol

<!-- PAGE=? -->
Verapamil

<!-- PAGE=? -->
Anemia (<4.3 ml/O2·dl -1 blood)

<!-- PAGE=? -->
Determined in humans.

<!-- PAGE=? -->
Magnesium

<!-- PAGE=? -->
 increases the duration and intensity of depolarizing and nondepolarizing muscle relaxants by decreasing the amount of acetylcholine liberated from the motor nerve terminals, diminishing the sensitivity of the endplate to acetylcholine, and depressing the excitability of the skeletal muscle membrane

<!-- PAGE=? -->
 Potential adverse effects

<!-- PAGE=? -->
o toxicity from overdose (respiratory, cardiac)

<!-- PAGE=? -->
o inc. bleeding

<!-- PAGE=? -->
o inc. hypotension with hemorrhage

<!-- PAGE=? -->
o dec. uterine contractility

<!-- PAGE=? -->
o Treatment of magnesium toxicity: stop MgSO4, IV calcium, manage airway

<!-- PAGE=? -->
 Treatment of Eclampsia

<!-- PAGE=? -->
o Seizures are usually short-lived.

<!-- PAGE=? -->
o If necessary, small doses of barbiturate or benzodiazepine (STP, 50 mg, or midazolam, 1-2 mg) and supplemental oxygen by mask.

<!-- PAGE=? -->
o If seizure persists or patient is not breathing, rapid sequence induction with cricoid pressure and intubation should be performed.

<!-- PAGE=? -->
Hypermagnesemia

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
Def : Mg > 1 mmol/L (normal = 0.7-1 mmol/L)

<!-- PAGE=? -->
Etiology:

<!-- PAGE=? -->
 iatrogenic (PIH)

<!-- PAGE=? -->
 excessive intake in the presence of RF (GFR<30 ml/min)

<!-- PAGE=? -->
 adrenal insufficiency, hypothyroidism, Rhabdo, Li

<!-- PAGE=? -->
Symptoms:

<!-- PAGE=? -->
 CNS : hyporeflexia, sedation

<!-- PAGE=? -->
 Resp : resp arrest due to paralysis of resp muscles

<!-- PAGE=? -->
 CVS : Vasodilatation with flushing, bradycardia and myocardial depression leads to hypotension at levels of >10 mmol/dL.

<!-- PAGE=? -->
 Neuromuscular :

<!-- PAGE=? -->
o skeletal muscle weakness due to: Impaired release of Ach and decreases motor end-plate sensitivity to Ach in muscle

<!-- PAGE=? -->
 Loss of DTR is a sign of hypermagnesemia (above 8 meq/L)

<!-- PAGE=? -->
 GI : N/V

<!-- PAGE=? -->
ECG: inconsistent but often include

<!-- PAGE=? -->
 prolongation of the PR and QT interval

<!-- PAGE=? -->
 wide QRS complex .  Marked hyper Mg leads to resp arrest.

<!-- PAGE=? -->
 Increased QRS duration

<!-- PAGE=? -->
 Decrease in P-wave voltage

<!-- PAGE=? -->
 Variable degree of T-wave peaking

<!-- PAGE=? -->
 Complete AV block

<!-- PAGE=? -->
 Asystole

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
 Ca Gluconate 1g

<!-- PAGE=? -->
 Promote diuresis with: Lasix and 0.45 saline/ D5W

<!-- PAGE=? -->
 Diuresis with NS is not indicated due to risk of hypocalcemia which would aggravate symptoms (Lange 623)

<!-- PAGE=? -->
Anesthetic considerations :

<!-- PAGE=? -->
 increased sensitivity to NDMR (reduce dose bu 25-50%)

<!-- PAGE=? -->
 potentiation of Sux is not a consistent observation

<!-- PAGE=? -->
 avoid acidosis and dehydration

<!-- PAGE=? -->
 titrate anesthetic drugs slowly (decreased contractility, vasodilation)

<!-- PAGE=? -->
Hypomagnesemia

<!-- PAGE=? -->
 Most common electrolyte abnormality in hospitalized patients, magnesium deficiency occurs in as many as 25%.  Followed by hypokalaemia (10%) and hyponatraemia

<!-- PAGE=? -->
o Of alcoholic patients admitted to the hospital, 30% are hypomagnesemic.

<!-- PAGE=? -->
 most symptomatic patients have serum [Mg 2+ ] <1.0 mg/dl

<!-- PAGE=? -->
 Signs and Symptoms

<!-- PAGE=? -->
o weakness

<!-- PAGE=? -->
o lethargy

<!-- PAGE=? -->
o muscle spasms

<!-- PAGE=? -->
o paresthesias

<!-- PAGE=? -->
o depression

<!-- PAGE=? -->
 When severe, symptoms include seizures, confusion, and coma

<!-- PAGE=? -->
 Cardiovascular abnormalities include

<!-- PAGE=? -->
o coronary artery spasm

<!-- PAGE=? -->
o cardiac failure

<!-- PAGE=? -->
o dysrhythmias

<!-- PAGE=? -->
o hypotension

<!-- PAGE=? -->
 ECG Changes - similar to hypokalemia

<!-- PAGE=? -->
o Prolonged QT & PR intervals

<!-- PAGE=? -->
o ST depression

<!-- PAGE=? -->
o T-wave inversion

<!-- PAGE=? -->
o Flattening or inversion of precordial P waves

<!-- PAGE=? -->
o Widening of the QRS interval

<!-- PAGE=? -->
o Torsades de pointes

<!-- PAGE=? -->
o Treatment-resistant VF (and other arrhythmias)

<!-- PAGE=? -->
o Worsening of digitalis toxicity

<!-- PAGE=? -->
 the sodium-potassium pump is magnesium-dependent, hypomagnesemia increases myocardial sensitivity to digitalis preparations and may cause hypokalemia as a result of renal potassium wasting

<!-- PAGE=? -->
CJA 2003, 50-7 732

<!-- PAGE=? -->
 Signs and symptoms of hypomagnesemia

<!-- PAGE=? -->
 General signs :

<!-- PAGE=? -->
o Generalized weakness

<!-- PAGE=? -->
o Anorexia

<!-- PAGE=? -->
o Apathy, depression

<!-- PAGE=? -->
 Neuromuscular signs :

<!-- PAGE=? -->
o Chvostek's and Trousseau's signs

<!-- PAGE=? -->
o Muscular fasciculations and cramps

<!-- PAGE=? -->
o Tremor

<!-- PAGE=? -->
o Tetany

<!-- PAGE=? -->
o Generalized convulsions

<!-- PAGE=? -->
o Respiratory muscle weakness or paralysis

<!-- PAGE=? -->
 Cardiovascular signs :

<!-- PAGE=? -->
o Cardiac arrhythmias:

<!-- PAGE=? -->
 torsades de pointes ,

<!-- PAGE=? -->
 ventricular tachycardia

<!-- PAGE=? -->
 Supra- and ventricular arrhythmias

<!-- PAGE=? -->
 Digitalis-associated arrhythmias

<!-- PAGE=? -->
o Hypertension

<!-- PAGE=? -->
o Sudden death

<!-- PAGE=? -->
o Coronary artery vasospasm

<!-- PAGE=? -->
 Progressive changes in the EKG

<!-- PAGE=? -->
o Widening of the QRS complex and peaking of the T wave

<!-- PAGE=? -->
o Prolongation of the PR interval and flattening of the T wave

<!-- PAGE=? -->
 Metabolic abnormalities :

<!-- PAGE=? -->
o Hypokalemia

<!-- PAGE=? -->
o Hypocalcemia

<!-- PAGE=? -->
o Metabolic alkalosis

<!-- PAGE=? -->
Table 46-13 -- Major causes of hypomagnesemia

<!-- PAGE=? -->
Causes

<!-- PAGE=? -->
Mechanisms

<!-- PAGE=? -->
Primary nutritional

<!-- PAGE=? -->
Inadequate intake; total parenteral nutrition; refeeding syndrome

<!-- PAGE=? -->
 Attempts to correct potassium deficits with potassium replacement therapy alone may not be successful without simultaneous magnesium therapy

<!-- PAGE=? -->
 The interrelationships of magnesium and potassium in cardiac tissue have probably the greatest clinical relevance in terms of dysrhythmias, digoxin toxicity, and myocardial infarction

<!-- PAGE=? -->
 Magnesium is important in the regulation of potassium channels

<!-- PAGE=? -->
 Both severe hypomagnesemia and hypermagnesemia suppress PTH secretion and can cause hypocalcemia

<!-- PAGE=? -->
 Of alcoholic patients admitted to the hospital, 30% are hypomagnesemic.

<!-- PAGE=? -->
Malignant Hyperthermia

<!-- PAGE=? -->
 autosomal dominant pattern of inheritance with variable expression

<!-- PAGE=? -->
o can not be considered solely autosomal dominant, because at least 6 different genes are suspected to cause MH

<!-- PAGE=? -->
 not possible to exclude MH on the basis of genetic testing alone

<!-- PAGE=? -->
o incidence is 1:15,000 in pediatric patients and 1:40,000 in adults

<!-- PAGE=? -->
o More common in children than adults, male > female

<!-- PAGE=? -->
 Mutations have been identified on the ryanodine receptor gene (50% cases) as well as the dihydropyridine receptor gene

<!-- PAGE=? -->
o the dihydropyridamole  Ca channel -L-type‖ receptor sits on the cell surface and contacts the ryanodine receptor

<!-- PAGE=? -->
o the ryanodine receptor (RYR1 = skeletal form which MH defect found in, RYR2 = cardiac, RYR3 = brain) is coupled with the SR and regulates Ca influx from the SR to the sarcolemma

<!-- PAGE=? -->
 Three disorders are clearly associated with a risk of MH:

<!-- PAGE=? -->
o Central core disease - a channelopathy that presents in infancy and is characterized by generalized muscle weakness.  It is generally not debilitating.

<!-- PAGE=? -->
o King-Denborough syndrome - a rare myopathy characterized by cryptorchidism, markedly slanted eyes, low set ears, pectus deformity, scoliosis, small stature and hypotonia

<!-- PAGE=? -->
o Evans myopathy

<!-- PAGE=? -->
 Possible association with heat stroke, muscular dystrophy, strabismus, hernia, osteogenesis imperfecta (reported increased risk of hyperthermia), Burkitt's lymphoma, neuroleptic malignant syndrome, and myelomeningocele

<!-- PAGE=? -->
 MH-like events, termed -Anesthesia-induced myodystrophies‖ (AIM), occur in other disorders, but the pathophysiology is likely different from an MH.  These disorders include:

<!-- PAGE=? -->
o Muscular Dystrophy

<!-- PAGE=? -->
o Hypokalemic Periodic Paralysis

<!-- PAGE=? -->
o Hyperkalemic Periodic Paralysis

<!-- PAGE=? -->
o Schwartz-Jampel Syndrome Myotonia

<!-- PAGE=? -->
o Osteogenesis imperfecta

<!-- PAGE=? -->
 Signs during MH crisis or AIM:

<!-- PAGE=? -->
o HEENT = Difficult intubation (muscle rigidity, masseter spasm)

<!-- PAGE=? -->
o CVS = hypertension followed by hypotension

<!-- PAGE=? -->
o RESP = tachypnea if spontaneously breathing, inc. CO2 is most common initial sign.

<!-- PAGE=? -->
o MSK = muscle rigidity (eg. masseter muscle rigidity)

<!-- PAGE=? -->
o RENAL = low u/o, dark urine (ARF / myoglobinuria)

<!-- PAGE=? -->
o SKIN  = Hyperthemia, sweating, mottled appearance (increased sympathetics)

<!-- PAGE=? -->
 triggering agents release massive amounts of intracellular Ca resulting in

<!-- PAGE=? -->
o Hypermetabolic State

<!-- PAGE=? -->
 hypoxemia and hypercarbia

<!-- PAGE=? -->
 hyperthermia is a late sign but may increase at a rate of 1-2  every 5 minutes

<!-- PAGE=? -->
o Contractures

<!-- PAGE=? -->
 Masseter muscle spasm may create a situation of difficult intubation

<!-- PAGE=? -->
 Contractures will not break with NdMR

<!-- PAGE=? -->
 -Jaws of steel‖ or prolonged spasm warrant cancellation of procedure

<!-- PAGE=? -->
 Rhabdomyolysis will occur and potentially lead to acute renal failure

<!-- PAGE=? -->
o Electrolyte and Acid/base disturbances

<!-- PAGE=? -->
 Cellular hypoxia leads to lactic acidosis

<!-- PAGE=? -->
 Cell death results in hyperkalemia

<!-- PAGE=? -->
o Secondary Complications

<!-- PAGE=? -->
 Tachycardia/ischemic demand and irregular rhythm may present early from sympathetic activation

<!-- PAGE=? -->
 Hyperkalemia produces peaked T waves and dysrhythmias

<!-- PAGE=? -->
 Heart failure from metabolic derangements and hypoxemia

<!-- PAGE=? -->
 DIC if temp > 41.5 from release of thromboplastin.

<!-- PAGE=? -->
 Other complications include bowel ischemia, limb compartment syndrome, acute renal failure, cerebral edema from hypo-osmolality & fluid shifts

<!-- PAGE=? -->
 Differential Diagnosis

<!-- PAGE=? -->
o Fever (without rigidity)

<!-- PAGE=? -->
 Sepsis

<!-- PAGE=? -->
 Thyrotoxicosis

<!-- PAGE=? -->
 Pheochromocytoma

<!-- PAGE=? -->
 Iatrogenic causes

<!-- PAGE=? -->
 Anticholinergic syndrome

<!-- PAGE=? -->
 Monitoring malfunction

<!-- PAGE=? -->
o Fever and muscle symptoms

<!-- PAGE=? -->
 NMS

<!-- PAGE=? -->
 Cocaine, amphetamine, ecstasy use

<!-- PAGE=? -->
 Hypoxic encephalopathy

<!-- PAGE=? -->
 Ionic contrast agents in CSF

<!-- PAGE=? -->
 Testing of MH

<!-- PAGE=? -->
o 70% of susceptible patients have increased resting plasma concentrations of CK

<!-- PAGE=? -->
 Not a definitive screen test

<!-- PAGE=? -->
o Skeletal muscle biopsy and caffeine-halothane contracture test is gold standard

<!-- PAGE=? -->
 Sensitivity:  100%

<!-- PAGE=? -->
 Specificity:  80-93%

<!-- PAGE=? -->
o Genetic testing of RYR1 gene

<!-- PAGE=? -->
 because of large number of mutations (30+), currently sensitivity only ~ 25%

<!-- PAGE=? -->
 MH CRISIS

<!-- PAGE=? -->
o Call for help and MH cart

<!-- PAGE=? -->
o Discontinue volatiles

<!-- PAGE=? -->
o Hyperventilate with 100% O2 at FGF 10 L/min, actively cool

<!-- PAGE=? -->
o Dantrolene 2.5 mg/kg IV push q5-10 minutes

<!-- PAGE=? -->
Mannitol

<!-- PAGE=? -->
Mannitol is given as an intravenous infusion in a dose of 0.25-1.0 g/kg. Its action begins within 10-15 minutes and is effective for approximately 2 hours. Larger doses produce a longer duration of action but do not necessarily reduce ICP more effectively. Furthermore, larger doses and repeated administration can result in metabolic derangement.

<!-- PAGE=? -->
Mannitol is effective when the blood-brain barrier is intact. By increasing the osmolality of blood relative to the brain, mannitol pulls water across an intact blood-brain barrier from brain to blood to restore the osmolar balance. When the blood-brain barrier is disrupted, mannitol may enter the brain and increase osmolality. Mannitol could pull water into the brain as the plasma concentration of the agent declines and cause a rebound increase in ICP. This rebound increase in ICP may be prevented by maintaining a mild fluid deficit.

<!-- PAGE=? -->
Mannitol has been shown to cause vasodilation of vascular smooth muscle, which is dependent on dose and administration rate. Mannitol-induced vasodilation affects intracranial and extracranial vessels and can transiently increase cerebral blood volume and ICP while simultaneously decreasing systemic blood pressure. Because

<!-- PAGE=? -->
 a unique muscle relaxant that acts within the muscle cell itself by reducing calcium release from the sarcoplasmic reticulum (and therefore decreases muscle contraction) with an onset of 5-10 minutes and an effective half-life of 6 hours

<!-- PAGE=? -->
 Continue boluses until signs of MH are resolved

<!-- PAGE=? -->
 May require 10 to 30 mg/kg

<!-- PAGE=? -->
 After successful management, continue at 1 mg/kg IV q6h for 24-48 hrs

<!-- PAGE=? -->
 Dissolve each bottle in 60 cc sterile warm H2O (7.5 cc/kg once mixed) - Get a bowl!!

<!-- PAGE=? -->
 Much more soluble at 40°C than 20°C degrees

<!-- PAGE=? -->
 Each bottle has 20 mg dantrolene + 0.3 g mannitol (2.5 mg x 70 kg = 175 mg or 9 bottles)

<!-- PAGE=? -->
 Dantrolene has decreased mortality of MH from 70% to less than 5%.

<!-- PAGE=? -->
 Procainamide has also been used

<!-- PAGE=? -->
o Avoid CCB's in presence of Dantrolene

<!-- PAGE=? -->
 myocardial depression and hyperkalemia in pig model

<!-- PAGE=? -->
o Supportive Treatment

<!-- PAGE=? -->
 Volume resuscitation

<!-- PAGE=? -->
 Temperature monitoring and cooling to target of 38ºC (temp can rise 1 degree C/5 min!)

<!-- PAGE=? -->
 Cool lavage open body cavities, stomach, bladder

<!-- PAGE=? -->
 Surface cooling - ice packs

<!-- PAGE=? -->
 Cold IV fluids

<!-- PAGE=? -->
 Metabolic:

<!-- PAGE=? -->
 Hyperkalemia (hyperventilate, calcium, bicarbonate, insulin / glucose)

<!-- PAGE=? -->
 Bicarbonate 2-4 mEq/kg for metabolic acidosis and for urine alkalinization

<!-- PAGE=? -->
 During treatment, hypokalemia frequently results, but potassium replacement is avoided as K+ can retrigger an MH episode

<!-- PAGE=? -->
 Dysrhythmias

<!-- PAGE=? -->
 Procainamide 3 mg/kg up to 15 mg/kg

<!-- PAGE=? -->
 Lidocaine 1-1.5 mg/kg

<!-- PAGE=? -->
 Calcium channel blockers contraindicated (produce hyperkalemia and myocardial depression)

<!-- PAGE=? -->
 Diuresis with volume, lasix, mannitol

<!-- PAGE=? -->
o Disposition

<!-- PAGE=? -->
 Watch for recrudescence in ICU for at least 24-48 hours - occurs in 25% of cases

<!-- PAGE=? -->
 Continuous core temperature monitoring as well as the usual ICU monitors

<!-- PAGE=? -->
 After successful management, continue at 1 mg/kg IV q6h for 24-48 hrs

<!-- PAGE=? -->
mannitol may initially increase ICP, it should be given slowly (10 minute infusion) and in conjunction with maneuvers that decrease intracranial volume (e.g., steroids or hyperventilation).

<!-- PAGE=? -->
Hypertonic agents such as mannitol should be administered cautiously in patients with preexisting cardiovascular disease. In these patients, the transient increase in intravascular volume may precipitate left ventricular failure. Furosemide may be a better agent to reduce ICP in patients with impaired cardiac reserve. Prolonged use of mannitol may produce dehydration, electrolyte disturbances, hyperosmolality, and impaired renal function.

<!-- PAGE=? -->
Mapleson Circuits

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 consist of several common components

<!-- PAGE=? -->
o facemask

<!-- PAGE=? -->
o spring-loaded pop-off valve

<!-- PAGE=? -->
o reservoir tubing

<!-- PAGE=? -->
o fresh gas inflow tubing

<!-- PAGE=? -->
o reservoir bag

<!-- PAGE=? -->
 three distinct functional groups can be seen

<!-- PAGE=? -->
o A

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
B

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
FGF

<!-- PAGE=? -->
F

<!-- PAGE=? -->
 Magill circuit

<!-- PAGE=? -->
 spring-loaded pop-off valve located near the facemask

<!-- PAGE=? -->
 gas flow enters the opposite end of the circuit near the reservoir bag

<!-- PAGE=? -->
o BC

<!-- PAGE=? -->
 spring-loaded pop-off valve is located near the facemask

<!-- PAGE=? -->
 the fresh gas inlet tubing is located near the patient

<!-- PAGE=? -->
 reservoir tubing and breathing bag serve as a blind limb where fresh gas, dead space gas, and alveolar gas can collect

<!-- PAGE=? -->
o DEF

<!-- PAGE=? -->
 -T-piece‖ group

<!-- PAGE=? -->
 fresh gas enters near the patient

<!-- PAGE=? -->
 excess gas is popped off at the opposite end of the circuit

<!-- PAGE=? -->
 variables that dictate the ultimate carbon dioxide concentration include the following

<!-- PAGE=? -->
o fresh gas inflow rate

<!-- PAGE=? -->
o minute ventilation

<!-- PAGE=? -->
o mode of ventilation (spontaneous or controlled)

<!-- PAGE=? -->
o tidal volume

<!-- PAGE=? -->
o respiratory rate

<!-- PAGE=? -->
o inspiratory-to-expiratory ratio

<!-- PAGE=? -->
o duration of the expiratory pause

<!-- PAGE=? -->
o peak inspiratory flow rate

<!-- PAGE=? -->
o volume of the reservoir tube

<!-- PAGE=? -->
o volume of the breathing bag

<!-- PAGE=? -->
o ventilation by mask vs. ETT

<!-- PAGE=? -->
o CO2 sampling site

<!-- PAGE=? -->
 Spontaneous ventilation

<!-- PAGE=? -->
o Mapleson A has the best efficiency

<!-- PAGE=? -->
 requires a fresh gas inflow rate equal to minute ventilation to prevent rebreathing of carbon dioxide

<!-- PAGE=? -->
o Efficiency

<!-- PAGE=? -->
 A > DFE > CB

<!-- PAGE=? -->
 Controlled ventilation

<!-- PAGE=? -->
o Mapleson DEF has the best efficiency

<!-- PAGE=? -->
 require a fresh gas inflow rate of approximately 2.5 times minute ventilation

<!-- PAGE=? -->
o Efficiency

<!-- PAGE=? -->
 DFE > BC > A

<!-- PAGE=? -->
Bain Circuit

<!-- PAGE=? -->
 modification of the Mapleson D system

<!-- PAGE=? -->
 Fresh gas flows through a narrow inner tube within the outer corrugated tubing

<!-- PAGE=? -->
o Fresh gas actually empties into the circuit at the patient end

<!-- PAGE=? -->
 Exhaled gases are vented through the expiratory valve near the reservoir bag

<!-- PAGE=? -->
 may be used for both spontaneous and controlled ventilation

<!-- PAGE=? -->
o fresh gas inflow rate necessary to prevent rebreathing is 2.5 times minute ventilation

<!-- PAGE=? -->
Overflow

<!-- PAGE=? -->
valve

<!-- PAGE=? -->
Corrugated tubing

<!-- PAGE=? -->
Fresh gas inlet

<!-- PAGE=? -->
Face mask

<!-- PAGE=? -->
Reservoir

<!-- PAGE=? -->
bag

<!-- PAGE=? -->
Masseter rigidity

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Differential diagnosis (4):

<!-- PAGE=? -->
1 Masseter muscle rigidity (Jaws of Steel)

<!-- PAGE=? -->
2 Myotonic dystrophy

<!-- PAGE=? -->
3 MH (with generalized rigidity)

<!-- PAGE=? -->
4 Inadequate sux (dose or interval)

<!-- PAGE=? -->
5 TMJ

<!-- PAGE=? -->
 Occurs in response to Sux

<!-- PAGE=? -->
 rigidity can be overcome with effort and usually abates within 2-3 minutes

<!-- PAGE=? -->
 peripheral nerve stimulator usually reveals flaccid paralysis

<!-- PAGE=? -->
o increased tone of other muscles also may be noted

<!-- PAGE=? -->
 If  trismus is associated with rigidity of other muscles MH is very likely

<!-- PAGE=? -->
o Repeat doses of sux does not relieve the problem

<!-- PAGE=? -->
 Occurs as a spectrum of normal response

<!-- PAGE=? -->
MH

<!-- PAGE=? -->
Norral

<!-- PAGE=? -->
Moderate

<!-- PAGE=? -->
Extreme

<!-- PAGE=? -->
JAW MUSCLE TENSION

<!-- PAGE=? -->
Elsevier Science 2005

<!-- PAGE=? -->
 Tachycardia and dysrhythmias are not infrequent

<!-- PAGE=? -->
 25-50% of patients who develop massetter spasm are MH-susceptible

<!-- PAGE=? -->
 initial signs of MH appear in 20 minutes or more

<!-- PAGE=? -->
o Only in rare cases does frank MH supervene immediately

<!-- PAGE=? -->
 If the anesthetic is discontinued, the patient usually recovers uneventfully

<!-- PAGE=? -->
o However, within 4-12 hours, myoglobinuria occurs and CK elevation is detected

<!-- PAGE=? -->
 Muscle biopsy with caffeine-halothane contracture testing has shown that approximately 50% of patients who experience MMR are also susceptible to MH

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
 if at all possible, discontinue the anesthetic and postpone surgery

<!-- PAGE=? -->
o If end-tidal CO2 monitoring and dantrolene are available and the anesthesiologist is experienced in managing MH, he or she may elect to continue with a nontriggering anesthetic

<!-- PAGE=? -->
 After episodes of MMR, the patient should be observed carefully for a period of 12-24 hours for myoglobinuria and signs of MH

<!-- PAGE=? -->
o Consider administration of 1-2 mg·kg -1 of dantrolene

<!-- PAGE=? -->
 Inform the family

<!-- PAGE=? -->
 CK levels should be checked 6, 12, and 24 hours after the episode

<!-- PAGE=? -->
o If still elevated at 12 hours, additional samples should be drawn until it begins to return to normal

<!-- PAGE=? -->
 If the CK level is greater than 20,000 IU in the perioperative period and a concomitant myopathy is not present, the diagnosis of MH is very likely

<!-- PAGE=? -->
Mediastinoscopy

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Significant (occasionally massive) hemorrhage has been the most frequent major problem encountered during mediastinoscopy.

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o hemorrhage 0.73%

<!-- PAGE=? -->
o pneumothorax 0.66% R>L

<!-- PAGE=? -->
o RLN injury 0.33%

<!-- PAGE=? -->
o innominate artery compression

<!-- PAGE=? -->
 other complications include

<!-- PAGE=? -->
o infection

<!-- PAGE=? -->
o arrythmias d/t autonomic activation with stimulation of the trachea

<!-- PAGE=? -->
o phrenic nerve injury

<!-- PAGE=? -->
o tumor implantation in the wound

<!-- PAGE=? -->
o esophageal injury

<!-- PAGE=? -->
o chylothorax

<!-- PAGE=? -->
o VAE

<!-- PAGE=? -->
MEN (Multiple Endocrine Neoplasm)

<!-- PAGE=? -->
Rare, autosomal dominant mutation in genes regulating cell growth

<!-- PAGE=? -->
MEN-1 (3P's) :

<!-- PAGE=? -->
 Parathyroid gland (all 4) tumours, hypersecreting

<!-- PAGE=? -->
 Pancreatic islet cells (gastrinoma, insulinoma, glucagonoma, VIP), and

<!-- PAGE=? -->
 anterior Pituitary (prolactinoma, somatotropinomas etc.)

<!-- PAGE=? -->
MEN-2A :

<!-- PAGE=? -->
 Hyperparathyroidism (parathyroid hyperplasia)

<!-- PAGE=? -->
 Medullary Thyroid Carcinoma

<!-- PAGE=? -->
 Pheochromocytoma

<!-- PAGE=? -->
MEN-2B :

<!-- PAGE=? -->
 Pheochromocytoma

<!-- PAGE=? -->
 Medullary Thyroid Carcinoma

<!-- PAGE=? -->
 Associated abnormalities include mucosal neuromas, medullated corneal nerve fibres, and marfanoid habitus

<!-- PAGE=? -->
Note:  Most cases of MTC and Pheo are sporadic only 10% are related to MEN 2

<!-- PAGE=? -->
METS

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Meningomyelocele

<!-- PAGE=? -->
Barash, CoExD

<!-- PAGE=? -->
 Considerations

<!-- PAGE=? -->
o Anatomical defect

<!-- PAGE=? -->
 Prevention of damage to site

<!-- PAGE=? -->
 Fluid and electrolyte abnormalities

<!-- PAGE=? -->
 Risk of infection

<!-- PAGE=? -->
o Potential for CNS affects:

<!-- PAGE=? -->
 Arnold chiari with brainstem compression-apneas (caudal displacement of the brainstem and cerebelar vermis / tonsils into the cervical spinal canal with compression)

<!-- PAGE=? -->
 hydrocephalus with inc ICP

<!-- PAGE=? -->
o causes obliteration of the normal exit of the foramen of the 4th ventricle

<!-- PAGE=? -->
o 90% of cases will result in obstructive hydrocephalus

<!-- PAGE=? -->
 Sensitive to opoids - abnormal response to hypoxia and hypercarbia with apneas and bradys

<!-- PAGE=? -->
 Bradycardias

<!-- PAGE=? -->
 arrythmias

<!-- PAGE=? -->
o Neonate

<!-- PAGE=? -->
 hypothermia

<!-- PAGE=? -->
o Assoc congenital deficits

<!-- PAGE=? -->
 Cardiac defects

<!-- PAGE=? -->
 Dislocated hips

<!-- PAGE=? -->
 Club foot

<!-- PAGE=? -->
 Extrophy of bladder

<!-- PAGE=? -->
 Prolapsed uterus

<!-- PAGE=? -->
 Klippel-feil syndrome

<!-- PAGE=? -->
 Short neck & trachea

<!-- PAGE=? -->
 Dec. C-spine ROM

<!-- PAGE=? -->
 Low hairline

<!-- PAGE=? -->
 Scoliosis

<!-- PAGE=? -->
 RLD with pHTN & corpulmonale

<!-- PAGE=? -->
o Latex precautions

<!-- PAGE=? -->
o Surgical considerations

<!-- PAGE=? -->
 May require intraoperative nerve stimulation

<!-- PAGE=? -->
 avoid long acting NMB

<!-- PAGE=? -->
o Positioning for intubation

<!-- PAGE=? -->
 There is no evidence that hyperkalemia will result from succinylcholine administration

<!-- PAGE=? -->
 Symptoms of brain stem dysfunction include

<!-- PAGE=? -->
o Stridor

<!-- PAGE=? -->
o Apnea

<!-- PAGE=? -->
o Bradycardia

<!-- PAGE=? -->
o aspiration pneumonia

<!-- PAGE=? -->
o sleepdisordered breathing patterns

<!-- PAGE=? -->
o vocal cord paralysis

<!-- PAGE=? -->
o incoordination

<!-- PAGE=? -->
o spasticity

<!-- PAGE=? -->
Meperidine

<!-- PAGE=? -->
P&P, Barash

<!-- PAGE=? -->
 synthetic opioid agonist at mu and kappa opioid receptors

<!-- PAGE=? -->
 derived from phenylepiperidine

<!-- PAGE=? -->
 analogues of meperidine include

<!-- PAGE=? -->
o fentanyl, sufentanil, alfentanil, and remifentanil

<!-- PAGE=? -->
 meperidine is similar to atropine, and it possesses a mild atropine-like antispasmodic effect

<!-- PAGE=? -->
 principal pharmacologic effects of meperidine resemble morphine

<!-- PAGE=? -->
 side effects - resemble those described for morphine

<!-- PAGE=? -->
o orthostatic hypotension

<!-- PAGE=? -->
 more frequent and more profound than after comparable doses of morphine

<!-- PAGE=? -->
o rarely causes bradycardia but instead may increase heart rate

<!-- PAGE=? -->
 reflecting its modest atropine-like qualities

<!-- PAGE=? -->
o decreases in myocardial contractility

<!-- PAGE=? -->
 unique among opioids

<!-- PAGE=? -->
 patients with cardiac disease experienced decreases in heart rate, cardiac index, and ratepressure product

<!-- PAGE=? -->
 not reversed by naloxone - likely local anesthetic effect

<!-- PAGE=? -->
o histamine release - dec. PVR

<!-- PAGE=? -->
 equal to morphine

<!-- PAGE=? -->
o Delirium and seizures

<!-- PAGE=? -->
 presumably reflect accumulation of normeperidine

<!-- PAGE=? -->
o readily impairs ventilation

<!-- PAGE=? -->
 may be more of a ventilatory depressant than morphine

<!-- PAGE=? -->
o crosses the placenta

<!-- PAGE=? -->
 concentrations of meperidine in umbilical cord blood at birth may exceed maternal plasma concentrations

<!-- PAGE=? -->
o producea less constipation and urinary retention than morphine

<!-- PAGE=? -->
o biliary tract spasm is less after meperidine injection than after morphine injection

<!-- PAGE=? -->
 greater than that caused by codeine

<!-- PAGE=? -->
o does not cause miosis but rather tends to cause mydriasis

<!-- PAGE=? -->
 modest atropine-like actions (dry mouth)

<!-- PAGE=? -->
 has weak local anesthetic properties

<!-- PAGE=? -->
Metformin

<!-- PAGE=? -->
 should be stopped 48hrs prior to elective surgery

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
 Mechanism of action by facilitating the actions of GABA

<!-- PAGE=? -->
o Bind to a specific site on the GABA-A receptor

<!-- PAGE=? -->
o results in a drug-induced increased affinity of the GABA receptor for the inhibitory neurotransmitter, enhanced opening of chloride gating channels resulting in increased chloride conductance, producing hyperpolarization of the postsynaptic cell membrane and rendering postsynaptic neurons more resistant to excitation

<!-- PAGE=? -->
o benzodiazepine receptor occupancy of 20% produces anxiolysis, whereas 30% to 50% receptor occupancy is associated with sedation, and >60% receptor occupancy is required for unconsciousness

<!-- PAGE=? -->
 extensive hepatic metabolism

<!-- PAGE=? -->
 metabolites have pharmacologic activity but less than of the parent compound.

<!-- PAGE=? -->
 Metabolites are excreted in urine as glucuronide conjugates.

<!-- PAGE=? -->
o Very little unchanged midazolam is excreted by the kidneys.

<!-- PAGE=? -->
 The elimination half-time, Vd, and clearance of midazolam are not altered by renal failure

<!-- PAGE=? -->
 In contrast to diazepam, H2 receptor antagonists do not interfere with the metabolism of midazolam

<!-- PAGE=? -->
 drugs that inhibit cytochrome P-4503A (erythromycin, CCB) may decrease the hepatic clearance of

<!-- PAGE=? -->
midazolam, resulting in unexpected CNS depression

<!-- PAGE=? -->
o the hepatic clearance of midazolam is inhibited by fentanyl as administered during general anesthesia due to shared Cytochrome P-4503A

<!-- PAGE=? -->
 hepatic clearance rate of midazolam is five times greater than that of lorazepam and ten times greater than that of diazepam.

<!-- PAGE=? -->
 age has relatively little influence on elimination half-time.

<!-- PAGE=? -->
 By far the most popular oral premedication at this time is midazolam, in a dose of 0.5-0.75 mg·kg -1 . Midazolam is first and foremost an anxiolytic; the child's eyes are usually open and he is aware of the environment, but nothing seems to disturb him.

<!-- PAGE=? -->
 Peak affect ~ 30 minutes after administration, and last approximately 30 minutes

<!-- PAGE=? -->
Milrinone (amrinone)

<!-- PAGE=? -->
Barash, Hensly

<!-- PAGE=? -->
 A phosphodiesterase inhibitor

<!-- PAGE=? -->
 mild inotropic activity & strong vasodilatory effects

<!-- PAGE=? -->
o inc. RV contractility

<!-- PAGE=? -->
o reduce PVR

<!-- PAGE=? -->
o dose dependant inc. in CO

<!-- PAGE=? -->
o reduced SVR

<!-- PAGE=? -->
o dec. PCWP

<!-- PAGE=? -->
 no change in HR and blood pressure

<!-- PAGE=? -->
 No inc. in MvO2

<!-- PAGE=? -->
 First oral intrope available since digitalis

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o dose-related thrombocytopenia

<!-- PAGE=? -->
o centriloblar hepatic necrosis occurs in dogs given high doses for periods exceeding 3 months

<!-- PAGE=? -->
Milrinone

<!-- PAGE=? -->
HR

<!-- PAGE=? -->
Usually no change; may have slight inc. at increased doses

<!-- PAGE=? -->
CO

<!-- PAGE=? -->
Increased

<!-- PAGE=? -->
BP

<!-- PAGE=? -->
Variable

<!-- PAGE=? -->
SVR and PVR

<!-- PAGE=? -->
Decreased

<!-- PAGE=? -->
Preload

<!-- PAGE=? -->
Decreased

<!-- PAGE=? -->
MVO 2

<!-- PAGE=? -->
Often unchanged

<!-- PAGE=? -->
Mineralocorticoid deficiency

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Most patients present with hypotension , hyperkalemia , and a metabolic acidosis

<!-- PAGE=? -->
o Non-anion gap metabolic acidosis

<!-- PAGE=? -->
 Patients with low renin secretion, hypoaldosteronism, and renal dysfunction respond to ACTH stimulation

<!-- PAGE=? -->
 NSAIDs, which inhibit prostaglandin synthesis, may further inhibit renin release and exacerbate the condition

<!-- PAGE=? -->
 Isolated hypoaldosteronism is treated with fludrocortisone orally in a dose of 0.05-0.1 mg/day

<!-- PAGE=? -->
Minute ventilation

<!-- PAGE=? -->
The mechanically ventilated patient with normal lungs has a dead space to alveolar ventilation ratio (VD/VA) of 1:1 rather than 1:2, as during spontaneous ventilation . If mechanical Vt is 1000 ml, 500 ml contributes to VA and 500 ml contributes to VD.

<!-- PAGE=? -->
At rest, the required VA with normal VCO2 is approximately 60 ml·kg -1 ·min -1 . A 70-kg man would then require a VA of 4200 ml·min -1 .

<!-- PAGE=? -->
During spontaneous breathing, the required VE would be 6300 ml¤min -1 , but during mechanical ventilation VE would have to be 8400 ml·min -1 .

<!-- PAGE=? -->
Using this calculation, if a 70-kg resting patient requires VE much in excess of 8400 ml·min -1 , either VD or VCO2 is increased.

<!-- PAGE=? -->
A rule of thumb for mechanically ventilated patients is that doubling baseline minute ventilation decreases PaCO2 from 40 to 30 mm Hg, and quadrupling minute ventilation decreases PaCO2 from 40 to 20 mm Hg.

<!-- PAGE=? -->
alveolar ventilation for normal VCO2 is approximately 60 ml/kg/min dead space : alveolar ventilation is 1:1 with PPV and 1:2 with spont

<!-- PAGE=? -->
.

<!-- PAGE=? -->
70  x  60  = 4200 cc of alveolar ventilation, which would mean a minute volume of:

<!-- PAGE=? -->
1.5  x  4200 = 6300 for spont and   2  x  4200  = 8400 for PPV .

<!-- PAGE=? -->
Steve: so Ve for spont venti is 60cc/kg, but this alveolar ventilation only; to account for dead space needed to x1.5 = 90cc/kg

<!-- PAGE=? -->
Mixed Venous sat

<!-- PAGE=? -->
Mortality

<!-- PAGE=? -->
 All increase odds of dying within 7 days:

<!-- PAGE=? -->
o No. of anesthetic drugs 1-2/3+

<!-- PAGE=? -->
o 80+/<60

<!-- PAGE=? -->
o Physical status score 3-5/1-2

<!-- PAGE=? -->
o Major/minor

<!-- PAGE=? -->
o Emergency/elective

<!-- PAGE=? -->
o Narcotic alone/inhalation alone

<!-- PAGE=? -->
o 60-79/<60

<!-- PAGE=? -->
*All cases performed with the five most frequently used anesthetic techniques.

<!-- PAGE=? -->
From Cohen et al 46 Copyright 1988, American Medical Association.

<!-- PAGE=? -->
MRI

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 rapidly changing magnetic fields can induce artifacts in the ECG trace

<!-- PAGE=? -->
 potential exists for heat generation within monitoring wires because of an -antenna effect,‖

<!-- PAGE=? -->
o Thermal injury in the area of ECG electrodes has been reported

<!-- PAGE=? -->
 Tattoo ink may contain high concentrations of iron oxide

<!-- PAGE=? -->
o Burns at tattoo sites have been reported

<!-- PAGE=? -->
 MRI does not produce ionizing radiation, is noninvasive, and does not in itself produce biologically deleterious effects

<!-- PAGE=? -->
Mucopolysaccharidosis

<!-- PAGE=? -->
Barash, CoExD

<!-- PAGE=? -->
 mucopolysaccharidoses are genetically determined diseases in which mucopolysaccharides are stored in tissues in abnormal quantities

<!-- PAGE=? -->
o large amounts in the urine

<!-- PAGE=? -->
 death due to pulmonary infections, resp failure from skeletal deformities, or cardiac failure both valular and ischemia

<!-- PAGE=? -->
 result from a deficiency of a specific lysosomal enzyme that is required to break down these compounds

<!-- PAGE=? -->
 Most are inherited as autosomal recessive traits

<!-- PAGE=? -->
 Condition is progressive, and patients have characteristic findings

<!-- PAGE=? -->
o coarse facial features (gargoylism)

<!-- PAGE=? -->
o associated skeletal abnormalities

<!-- PAGE=? -->
 difficult A/W

<!-- PAGE=? -->
 ondontoid hypolasia

<!-- PAGE=? -->
 thick soft tissues

<!-- PAGE=? -->
o tongue, phanynx

<!-- PAGE=? -->
 micrognathia

<!-- PAGE=? -->
 short neck

<!-- PAGE=? -->
 stiff TMJ

<!-- PAGE=? -->
 lumbar lordosis

<!-- PAGE=? -->
 stiff joints

<!-- PAGE=? -->
 chest deformity

<!-- PAGE=? -->
 dwarfing

<!-- PAGE=? -->
 odontoid hypoplasia (Morquio's syndrome)

<!-- PAGE=? -->
 corneal opacities

<!-- PAGE=? -->
 limitation of joint motion

<!-- PAGE=? -->
 heart, liver, and spleen enlargement resulting from mucopolysaccharide accumulation

<!-- PAGE=? -->
 Mental deterioration

<!-- PAGE=? -->
 Hunter and Hurler syndromes are the best known variants

<!-- PAGE=? -->
o X-linked recessive disease

<!-- PAGE=? -->
o Respiratory infection and heart disease, both valvular and ischemic, often lead to death when patients are young

<!-- PAGE=? -->
 thick soft tissues and the copious, thick secretions make perioperative and intraoperative airway management a particular problem

<!-- PAGE=? -->
o Postoperative respiratory obstruction is common

<!-- PAGE=? -->
 Due to accumulation of glycosaminoglycans in the tongue and nasopharyngeal tissues

<!-- PAGE=? -->
 Mucopolysaccharidosis IV (Morquio's syndrome)

<!-- PAGE=? -->
o significant skeletal deformities

<!-- PAGE=? -->
o cardiovascular disorders and respiratory insufficiency from marked chest wall deformity

<!-- PAGE=? -->
o acute, subacute, or chronic myelopathy is extremely common

<!-- PAGE=? -->
 secondary to severe hypoplasia or absence of the odontoid process and the second cervical vertebra

<!-- PAGE=? -->
Muscular Dystrophy (Duchenne's)

<!-- PAGE=? -->
Lange, Barash

<!-- PAGE=? -->
 diagnosis is confirmed by muscle biopsy

<!-- PAGE=? -->
 produced by a genetic abnormality resulting in a lack of production of dystrophin

<!-- PAGE=? -->
o sex-linked recessive trait that is clinically evident in boys

<!-- PAGE=? -->
o Female carriers often also have

<!-- PAGE=? -->
 high plasma CK levels

<!-- PAGE=? -->
 variable degrees of muscle weakness

<!-- PAGE=? -->
 rarely, cardiac involvement

<!-- PAGE=? -->
 Plasma myoglobin concentration may be elevated

<!-- PAGE=? -->
 characterized by painless degeneration and atrophy of skeletal muscle

<!-- PAGE=? -->
 Onset of symptoms between the ages of 2 and 5 years

<!-- PAGE=? -->
o Progressive skeletal muscle weakness

<!-- PAGE=? -->
 Patients usually confined to a wheelchair by 12

<!-- PAGE=? -->
 kyphoscoliosis often requires operative instrumentation for stabilization

<!-- PAGE=? -->
 Death occurs when patients are between 15 and 25 years old

<!-- PAGE=? -->
o usually secondary to congestive heart failure or pneumonia

<!-- PAGE=? -->
 Serum CK levels reflect the progression of the disease

<!-- PAGE=? -->
o Early in life, the creatine kinase level is elevated

<!-- PAGE=? -->
o Later, as significant amounts of skeletal muscle have degenerated, the creatine kinase level decreases

<!-- PAGE=? -->
 smooth muscle and cardiac muscle are also affected

<!-- PAGE=? -->
o Smooth muscle involvement results in

<!-- PAGE=? -->
 intestinal tract hypomotility

<!-- PAGE=? -->
 delayed gastric emptying

<!-- PAGE=? -->
 acute gastroparesis

<!-- PAGE=? -->
o Cardiac involvement includes

<!-- PAGE=? -->
 progressive loss of R-wave amplitude in the lateral precordial leads

<!-- PAGE=? -->
 Progressive loss of myocardial tissue

<!-- PAGE=? -->
 reduced myocardial contractility

<!-- PAGE=? -->
 dilated cardiomyopathy

<!-- PAGE=? -->
 ventricular dysrhythmias

<!-- PAGE=? -->
 mitral regurgitation (papillary muscle dysfunction)

<!-- PAGE=? -->
 right ventricular outflow obstruction

<!-- PAGE=? -->
 Degeneration of respiratory muscles can be measured by pulmonary function testing

<!-- PAGE=? -->
o restrictive disease pattern

<!-- PAGE=? -->
o ineffective cough

<!-- PAGE=? -->
 retention of pulmonary secretions, pneumonia, and death

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o directed at prevention of musculoskeletal deformities

<!-- PAGE=? -->
o ACE inhibitors and/or b-adrenergic blockers may retard the development of congestive heart failure

<!-- PAGE=? -->
Multiple Sclerosis

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 patients should be advised that surgery and anesthesia could produce a relapse despite a well managed anesthetic

<!-- PAGE=? -->
o Pyrexia, metabolic, hormonal changes induced by surgery and anesthesia could produce a neurologic exacerbation independent of the type of anesthesia

<!-- PAGE=? -->
 preoperative neurologic examination to document coexisting neurologic deficits

<!-- PAGE=? -->
 avoid spinal anesthesia - relatively high rate of exacerbation following spinal anesthetic

<!-- PAGE=? -->
o epidural is OK

<!-- PAGE=? -->


<!-- PAGE=? -->
relapse rate, was greater if bupivacaine in concentrations higher than 0.25% was used

<!-- PAGE=? -->
 monitor patient temperature

<!-- PAGE=? -->
o temperature increase of 0.5 degrees C can block impulse conduction in demyelinated fibers

<!-- PAGE=? -->
 succinylcholine could produce an exaggerated release of potassium, although this has not been reported in patients with multiple sclerosis

<!-- PAGE=? -->
 Anticonvulsants such as carbamazepine and phenytoin can produce resistance to nondepolarizing muscle relaxants

<!-- PAGE=? -->
 Autonomic dysfunction caused by multiple sclerosis may exaggerate the hypotensive effects of volatile anesthetics

<!-- PAGE=? -->
 Respiratory muscle weakness and respiratory control dysfunction increase the likelihood of the need for supplemental oxygen and/or mechanical ventilation during the immediate postoperative period

<!-- PAGE=? -->
Myasthenia Gravis

<!-- PAGE=? -->
Barash, Chestnut

<!-- PAGE=? -->
 Risk factors for post-op respiratory insufficiency (4):

<!-- PAGE=? -->
Duration of MG > 6 yrs

<!-- PAGE=? -->
PMHX of respiratory disease

<!-- PAGE=? -->
Pyridostigmine > 750 mg QD

<!-- PAGE=? -->
Pre-op VC < 2.9 L (40 cc/kg)

<!-- PAGE=? -->
 PO to IV anticholinesterase conversion = 30:1

<!-- PAGE=? -->
 myasthenic patients are exquisitely sensitive to NdMR

<!-- PAGE=? -->
o Because of rapid elimination, mivacurium, atracurium, rocuronium, and rapacuronium can be effectively titrated to produce satisfactory muscle relaxation with minimal risk of prolonged postoperative paralysis

<!-- PAGE=? -->
 halogenated inhaled anesthetics depress neuromuscular transmission in myasthenic patients

<!-- PAGE=? -->
 Pregnancy

<!-- PAGE=? -->
o Exacerbation of myasthenia gravis may occur in late pregnancy and the early postpartum period

<!-- PAGE=? -->
 1/3 improve, 1/3 remain unchanged, 1/3 get worse

<!-- PAGE=? -->
o skeletal muscle relaxation produced by regional anesthesia in conjunction with inherent muscle weakness may lead to hypoventilation.

<!-- PAGE=? -->
o 15-20% of infants born to myasthenic mothers may exhibit transient neonatal myasthenia within 1-21 days after birth, anticholinesterase therapy and mechanical ventilation may be necessary

<!-- PAGE=? -->
 Anticholinesterases don not cross the placenta (quaternary ammonium)

<!-- PAGE=? -->
 Treatments

<!-- PAGE=? -->
o Anticholinesterases

<!-- PAGE=? -->
 influence the response to both depolarizing and nondepolarizing neuromuscular blocking drugs

<!-- PAGE=? -->
 untreated myasthenics are usually resistant to the effects of succinylcholine

<!-- PAGE=? -->
 myasthenic patients treated with cholinesterase inhibitors may exhibit resistant, prolonged, or normal responses to succinylcholine

<!-- PAGE=? -->
o steroids

<!-- PAGE=? -->
o immunosuppressants

<!-- PAGE=? -->
o PLEX

<!-- PAGE=? -->
o IVIG

<!-- PAGE=? -->
Myasthenic Syndrome (Lambert-Eaton)

<!-- PAGE=? -->
Autoimmune with circulating antibodies directed against pre-synaptic calcium-channels responsible for release of ACh at the NMJ.

<!-- PAGE=? -->
MG versus LEMS:

<!-- PAGE=? -->
Myofacial Pain Syndrome

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 marked tenderness of discrete points (trigger points ) within affected muscles

<!-- PAGE=? -->
 pain can be referred to areas some distance from the trigger point

<!-- PAGE=? -->
 appearance of tight, ropy bands of muscle

<!-- PAGE=? -->
 Autonomic changes, such as vasoconstriction and skin conductivity changes, may occur some distance from the affected muscle

<!-- PAGE=? -->
 Biopsies of trigger points have been reported to show little or no change or to show degenerative changes , the severity of which corresponds to the intensity of the symptoms.

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o regain muscle length and elasticity

<!-- PAGE=? -->
 gently stretch affected muscles

<!-- PAGE=? -->
 appropriate physical therapeutic maneuvers are often painful and may reinitiate muscle contraction

<!-- PAGE=? -->
 Therapy aimed at reducing muscle pain and sensitivity should be administered prophylacticly

<!-- PAGE=? -->
o Trigger point injections and ultrasound

<!-- PAGE=? -->
 botulinum toxin , which produces a long-lasting block of acetylcholine release from peripheral nerves, has been shown to provide lasting pain relief in myofascia syndrome

<!-- PAGE=? -->
o TENS

<!-- PAGE=? -->
Myotonic dystrophy

<!-- PAGE=? -->
 Sustained contractions of muscles after voluntary or mechanical stimulations

<!-- PAGE=? -->
 Failure to relax after neural blockad and NMR due to increased sodium conductances in the muscle cell membrane and impaired calcium reuptake in SR

<!-- PAGE=? -->
 -myotonic muscular dystrophy‖ most common 1:10 000

<!-- PAGE=? -->
 Involves skeletal, cardiac, and smooth muscle

<!-- PAGE=? -->
 Early manifestations = myotonia

<!-- PAGE=? -->
 Progress to muscle weakness and atrophy

<!-- PAGE=? -->
 Multiorgan dysfunction:

<!-- PAGE=? -->
o Presenile cataracts

<!-- PAGE=? -->
o Frontal baldness

<!-- PAGE=? -->
o Hypersomnolence with sleep apnea

<!-- PAGE=? -->
o Pancreatic/adrenal/thyroid/gonadal insufficiency

<!-- PAGE=? -->
o Decreased vital capacity

<!-- PAGE=? -->
o GI hypomotility - pulmonary aspiration, uterine atony

<!-- PAGE=? -->
o Cardiac - atria arrhythmias, heart block, decreased LV function, cor pulmonale (chronic hypoxemia)

<!-- PAGE=? -->
o Treatment:  Phenytoin, supportive, pacemake

<!-- PAGE=? -->
Myopathy of Critical Illness

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Previous terms for "critical illness myopathy"

<!-- PAGE=? -->
o acute quadriplegic myopathy

<!-- PAGE=? -->
o acute (necrotizing) myopathy of intensive care

<!-- PAGE=? -->
o thick filament myopathy

<!-- PAGE=? -->
o acute corticosteroid myopathy

<!-- PAGE=? -->
o critical care myopathy

<!-- PAGE=? -->
 Most published reports have focused on patients with status asthmaticus

<!-- PAGE=? -->
o Affected individuals have typically been treated with corticosteroids and nondepolarizing neuromuscular blockers

<!-- PAGE=? -->
 myopathy has also been documented in

<!-- PAGE=? -->
o in chronic lung disease without paralysis who received corticosteroids

<!-- PAGE=? -->
o in critically ill patients with sepsis who received neither corticosteroids nor nondepolarizing neuromuscular blockers

<!-- PAGE=? -->
 Animal studies found that the number of cytosolic corticosteroid receptors is increased in immobilized muscles relative to contralateral controls

<!-- PAGE=? -->
 prolonged immobility may be the key risk factor for myopathy in corticosteroid-treated patients

<!-- PAGE=? -->
o selective muscle atrophy is a result of changes in glucocorticoid sensitivity

<!-- PAGE=? -->
 Sepsis, immobility, and the catabolism associated with negative nitrogen balance may also result in myopathy

<!-- PAGE=? -->
 Antibodies to nAChRs have been demonstrated in a rodent model of sepsis

<!-- PAGE=? -->
o This myasthenia-like syndrome is also seen in critically ill patients

<!-- PAGE=? -->
 major feature of CIM

<!-- PAGE=? -->
o flaccid weakness

<!-- PAGE=? -->
 tends to be diffuse

<!-- PAGE=? -->
 often includes the facial muscles and the diaphragm

<!-- PAGE=? -->
 features overlap with those of critical illness polyneuropathy and prolonged neuromuscular blockade

<!-- PAGE=? -->
 Electrophysiologic studies and increases in serum creatine kinase concentrations may differentiate neuropathy from myopathy

<!-- PAGE=? -->
Myxedema Coma (hypothyroidism)

<!-- PAGE=? -->
Table 41-5. MANAGEMENT OF MYXEDEMA

<!-- PAGE=? -->
Tracheal intubation and controlled ventilation as needed

<!-- PAGE=? -->
Levothyroxine 200-300 mcg iv over 5-10 min initially, and 100 mcg iv q24h

<!-- PAGE=? -->
Hydrocortisone, 100 mg iv, then 25 mg iv q6h Fluid and electrolyte therapy as indicated by serum electrolytes Cover to conserve body heat; no warming blankets

<!-- PAGE=? -->
MVP

<!-- PAGE=? -->
 midsystolic click or multiple clicks followed by a midsystolic to late systolic murmur at the apex of the left ventricle over the mitral area

<!-- PAGE=? -->
 The majority of patients are asymptomatic

<!-- PAGE=? -->
 Associated mesenchymal and skeletal abnormalities

<!-- PAGE=? -->
Mitral Valve Prolapse

<!-- PAGE=? -->
o Etiology

<!-- PAGE=? -->
 Inherited CT disorder

<!-- PAGE=? -->
 Myxomatous degeneration (replacement of collagen / elastin by mucopolysaccharides)

<!-- PAGE=? -->
 Associated with: Marfan's, Ehlers-Danlos, pseudoxanthoma elasticum, scoliosis, pectus excavatum, hyperadrenergic state, anxiety d/o

<!-- PAGE=? -->
o Mechanism

<!-- PAGE=? -->
 Structural weakness of valve apparatus

<!-- PAGE=? -->
 Displacement or prolapse of MV into LA during ventricular systole

<!-- PAGE=? -->
 Progressive annular dilatation, cordae elongation and stretching of valve leaflets

<!-- PAGE=? -->
 Development of MR

<!-- PAGE=? -->
 ↑ risk of endocarditis and embolic stroke due to surface abnormalities

<!-- PAGE=? -->
o Manifestations: dysrhythmias, atypical chest pain, SOBOE, MVR, TIAs, CVA

<!-- PAGE=? -->
o Complications: infectious endocarditis, embolic stroke, MVR (acute or chronic), CHF, sudden cardiac death

<!-- PAGE=? -->
o Assessment

<!-- PAGE=? -->
 Atypical chest pain, SOBOE, palpitations, syncope, neurological deficits

<!-- PAGE=? -->
 Mid and late apical non-ejection systolic click, focal neurological signs

<!-- PAGE=? -->
o Investigations: ECG (dysrhythmias, +/- nonspecific ST-T wave changes), ECHO (MVP, MVR)

<!-- PAGE=? -->
o Goals

<!-- PAGE=? -->
 Rate - low normal

<!-- PAGE=? -->
 Rhythm - sinus if possible

<!-- PAGE=? -->
 Preload - high normal

<!-- PAGE=? -->
 Afterload - maintain

<!-- PAGE=? -->
 Contractility - maintain (or slightly decrease)

<!-- PAGE=? -->
 MVP worsened by any conditions that decrease ventricular size (i.e. promote emptying)

<!-- PAGE=? -->
o Beneficial: Fluid, phenylephrine,  blockers

<!-- PAGE=? -->
o Avoid

<!-- PAGE=? -->
 MVP and MR worsened by conditions that decrease LV size

<!-- PAGE=? -->
 ↓ preload, ↓ afterload, ↑ HR, ↑ contractility

<!-- PAGE=? -->
 Anxiety, HTN

<!-- PAGE=? -->
 Atropine, ketamine, ephedrine, dehydration

<!-- PAGE=? -->
 Histamine-releasing drugs, NMB which cause tachycardia (pancuronium)

<!-- PAGE=? -->
o Management: Asymptomatic followed every few years with ECHO

<!-- PAGE=? -->
o Anesthetic Implications

<!-- PAGE=? -->
 Preoperatively -; anxiolysis preoperatively (midazolam or lorazepam)

<!-- PAGE=? -->
 Monitors - routine (unless significant MR)

<!-- PAGE=? -->
 Options

<!-- PAGE=? -->
 Local /  sedation okay

<!-- PAGE=? -->
 Regional

<!-- PAGE=? -->
 Brachial plexus block okay

<!-- PAGE=? -->
 Cautious with epidural & spinals b/c can cause abrupt ↓ preload and SVR

<!-- PAGE=? -->
 GA - avoid agents that cause tachycardia, drop preload or afterload significantly

<!-- PAGE=? -->
N

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
 most widely used opioid antagonist

<!-- PAGE=? -->
o pure antagonist at μ-, κ-, and δ-opioid receptors

<!-- PAGE=? -->
 structurally related to morphine and oxymorphone

<!-- PAGE=? -->
 Dose ~ 1 - 4 ug/kg

<!-- PAGE=? -->
o Infusion of 5 u/k/hr

<!-- PAGE=? -->
 very fast onset of action

<!-- PAGE=? -->
o Peak effects occur within 1-2 minutes

<!-- PAGE=? -->
 duration is dose-dependent

<!-- PAGE=? -->
o generally ~ 30 min to 4 hours

<!-- PAGE=? -->
o presumed to be due to its rapid removal from the brain

<!-- PAGE=? -->
o T ½ is 60-90 min

<!-- PAGE=? -->
 metabolized primarily in the liver by conjugation with glucuronic acid to form naloxone-3-glucuronide

<!-- PAGE=? -->
 Naloxone is absorbed orally, but metabolism during its first pass through the liver renders it only one-fifth as potent as when administered parenterally

<!-- PAGE=? -->
 Side Effects

<!-- PAGE=? -->
o reversal of analgesia

<!-- PAGE=? -->
o N&V appear to be closely related to the dose and speed of injection

<!-- PAGE=? -->
o increased sympathetic nervous system activity

<!-- PAGE=? -->
 abrupt reversal of analgesia and the sudden perception of pain

<!-- PAGE=? -->
 tachycardia, hypertension, pulmonary edema, and cardiac dysrhythmias

<!-- PAGE=? -->
 Naloxone can easily cross the placenta

<!-- PAGE=? -->
o Avoid in an opioid-dependent parturient

<!-- PAGE=? -->
Neck Injury (penetrating)

<!-- PAGE=? -->
FIG. 73-8. Horizontal entry zones of the neck for penetrating injuries to the neck (Modified from Jurkovich GJ. The neck In: Early care of the injured patient. Moore EE, ed. Toronto: BC Becket , 1990:126.)

<!-- PAGE=? -->
Cricoid

<!-- PAGE=? -->
cartilage

<!-- PAGE=? -->
 Zone 1 extends from the clavicle to the cricoid cartilage and includes the thoracic inlet. This region contains the major vascular structures of the subclavian artery and vein, jugular vein, and common carotid artery, as well as the esophagus, thyroid, and trachea.

<!-- PAGE=? -->
 Zone 2 extends from the cricoid to the angle of the mandible and contains the common carotid artery, internal and external carotid arteries, jugular vein, larynx, hypopharynx, and cranial nerves X, XI, and XII.

<!-- PAGE=? -->
 Zone 3 is a small but critical area extending from the angle of the mandible to the skull base. This region contains the internal and external carotid arteries, jugular vein, lateral pharynx, and cranial nerves VII, IX, X, XI, and XII.

<!-- PAGE=? -->
Needle-Stick Injury

<!-- PAGE=? -->
 Seroconversion is :

<!-- PAGE=? -->
o HIV 0.3%

<!-- PAGE=? -->
o HCV 3%

<!-- PAGE=? -->
o HBV 30%

<!-- PAGE=? -->
Factors Independently Associated with Percutaneous Injury Transmission Risk Risk Factor Odds Ratio

<!-- PAGE=? -->
 Deep (intramuscular) Injury 16.1

<!-- PAGE=? -->
 Visible blood on sharp device 5.2

<!-- PAGE=? -->
 Device used to enter artery or vein 5.1

<!-- PAGE=? -->
 Source patient with terminal AIDS 6.4

<!-- PAGE=? -->
 ZDV prophylaxis used 0.2

<!-- PAGE=? -->
 Hollow bore needle

<!-- PAGE=? -->
Negative Pressure Pulmonary Edema

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Follows relief of upper airway obstruction

<!-- PAGE=? -->
 Most of the affected patients have experienced larynospasm or epiglottitis

<!-- PAGE=? -->
 Onset: minutes - 1-2 hrs

<!-- PAGE=? -->
 Signs and symptoms

<!-- PAGE=? -->
o frothy pink secretions

<!-- PAGE=? -->
o dec. SaO2

<!-- PAGE=? -->
o wheezing

<!-- PAGE=? -->
o tachypnea

<!-- PAGE=? -->
o dypnea

<!-- PAGE=? -->
 differential diagnosis

<!-- PAGE=? -->
o aspiration

<!-- PAGE=? -->
o ARDS

<!-- PAGE=? -->
o CHF with volume overload

<!-- PAGE=? -->
o Anaphylaxis

<!-- PAGE=? -->
 negative intrapleural pressure causes an increase in venous return, enhancing pulmonary blood volume

<!-- PAGE=? -->
o Intrapleural pressure can be as much as -30 cm H2O

<!-- PAGE=? -->
o causes disruption of the capillary walls of the pulmonary microvasculature when transmitted to the interstitial peribronchial and perivascular spaces

<!-- PAGE=? -->
 increasing preload in the setting of -leaky capillaries‖ facilitates transudation of fluid into the alveolar space

<!-- PAGE=? -->
 To counterbalance this negative gradient, positive intrapleural and alveolar pressure is generated during exhalation, which decreases pulmonary venous return and blood volume

<!-- PAGE=? -->
o expiratory -grunt‖ mechanism

<!-- PAGE=? -->
 rapid relief of airway obstruction results in decreased airway pressure, an increase in venous return, an increase in pulmonary hydrostatic pressure, hyperemia, and finally pulmonary edema

<!-- PAGE=? -->
 the expiratory grunt in limiting pulmonary venous return is lost when the obstruction is relieved

<!-- PAGE=? -->
o increased volume load on both ventricles

<!-- PAGE=? -->
o overwhelming of the pulmonary lymphatic system to remove acutely large amounts of fluid

<!-- PAGE=? -->
 Treatment is usually supportive, with maintenance of a patent airway, oxygen administration, and diuretic therapy in some cases

<!-- PAGE=? -->
 Endotracheal intubation and mechanical ventilation with positive end-expiratory pressure may be necessary in severe cases.

<!-- PAGE=? -->
 Resolution is usually rapid and may occur within hours of inception

<!-- PAGE=? -->
o Most cases resolve within 24 hours without treatment

<!-- PAGE=? -->
 CXR  changes usually resolve in 12-24 hrs

<!-- PAGE=? -->
Nephron

<!-- PAGE=? -->
 glomerular capillaries

<!-- PAGE=? -->
glomerular filtration pressure = 60 % of MAP

<!-- PAGE=? -->
GFP is directly proportional to efferent arteriolar tone and inversely proportional to the afferent arteriolar tone

<!-- PAGE=? -->
20 % of plasma is filtered

<!-- PAGE=? -->
 proximal convoluted tubule

<!-- PAGE=? -->
75 % of ultrafiltrate is reabsorbed isotonically

<!-- PAGE=? -->
major function is  Na reabsorbtion (powered by Na K ATP-ase)

<!-- PAGE=? -->
isotonic urine at the end of proximal tubule

<!-- PAGE=? -->
 the loop of henle (in 10% of neurons- juxtamedullary neurons-  the loop of Henle runs deep into the medulla)

<!-- PAGE=? -->
descending limb

<!-- PAGE=? -->
freely permeable to water

<!-- PAGE=? -->
ascending limb

<!-- PAGE=? -->
thin ascending (same as descending limb)

<!-- PAGE=? -->
thick ascending

<!-- PAGE=? -->
 Impermeable to water

<!-- PAGE=? -->
 Na 2Cl K transporter, Cl in the tubular fluid is the rate limiting factor

<!-- PAGE=? -->
 Hypotonic urine at the end of thick ascended loop

<!-- PAGE=? -->
 The countercurrent multiplier mechanism is established such that both the tubular and the interstitial become increasingly hypertonic with increasing depth into the medulla

<!-- PAGE=? -->
 the distal convoluted renal tubule

<!-- PAGE=? -->
Na reabsorbtion by Na - Cl carrier (5% of filtered Na)

<!-- PAGE=? -->
 the collecting tubule

<!-- PAGE=? -->
cortical

<!-- PAGE=? -->
principal cells - Aldosteron mediated Na reabsorbion and K secretion.  Aldosteron increases the number of K and Na channels in the luminal membrane

<!-- PAGE=? -->
intercalated cells Aldosteron enhanced H+ secreating ATP-ase.  Also K + H + ATPase pump (secretes H and resorbs K)

<!-- PAGE=? -->
medullary

<!-- PAGE=? -->
= main site of action of ADH

<!-- PAGE=? -->
V2 receptors, activate adenyl cyclase- increased permeability to water

<!-- PAGE=? -->
Intercalated cells predominate

<!-- PAGE=? -->
Role in acidifying the urine

<!-- PAGE=? -->
 the juxaglomerular apparatus

<!-- PAGE=? -->
Nerves, peripheral

<!-- PAGE=? -->
         Types ( from most to least sensitive to LA ):

<!-- PAGE=? -->
     B fibre (preganglionic sympathetic)

<!-- PAGE=? -->
     Aδ & C fibres (pain and temperature, C also postganglionic sympathetic)

<!-- PAGE=? -->
     Aγ fibres (efferent muscle spindle)

<!-- PAGE=? -->
     Aβ fibres (afferent somatosensory)

<!-- PAGE=? -->
     Aα fibres (efferent motor)

<!-- PAGE=? -->
Neuroaxial Anesthesia

<!-- PAGE=? -->
Spinal - Block Height

<!-- PAGE=? -->
 Baricity

<!-- PAGE=? -->
o baricity relative to patient position is probably the most important

<!-- PAGE=? -->
o gravity has no effect on the distribution of truly i sobaric solutions

<!-- PAGE=? -->
o Hyperbaric solutions injected at the height of the lumbar lordosis will tend to flow cephalad to pool in the thoracic kyphosis and caudad to pool in the sacrum

<!-- PAGE=? -->
 hyperbaric solutions tend to produce blocks with an average height in the midthoracic region

<!-- PAGE=? -->
o the time required for a local anesthetic solution to become fixed may be considerable

<!-- PAGE=? -->
 up to 60 min

<!-- PAGE=? -->
o most isobaric solutions are actually slightly hypobaric and may have variable block height related to

<!-- PAGE=? -->
 patient positioning

<!-- PAGE=? -->
 variable CSF density

<!-- PAGE=? -->
 temperature of injected solution

<!-- PAGE=? -->
 Dose

<!-- PAGE=? -->
Table 37-2 Factors that Have Been Suggested as

<!-- PAGE=? -->
Possible Determinants of Spread of Local Anesthetic

<!-- PAGE=? -->
Solutions Within the Subarachnoid Space

<!-- PAGE=? -->
CHARACTERISTICS OF THE LOCAL

<!-- PAGE=? -->
ANESTHETIC SOLUTION

<!-- PAGE=? -->
Baricity

<!-- PAGE=? -->
Local anesthetic dose

<!-- PAGE=? -->
Local anesthetic concentration

<!-- PAGE=? -->
Volume injected

<!-- PAGE=? -->
PATIENT CHARACTERISTICS

<!-- PAGE=? -->
Age

<!-- PAGE=? -->
Weight

<!-- PAGE=? -->
Height

<!-- PAGE=? -->
Gender

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
Patient position

<!-- PAGE=? -->
TECHNIQUE

<!-- PAGE=? -->
Site of injection

<!-- PAGE=? -->
Speed of injection

<!-- PAGE=? -->
Barbotage

<!-- PAGE=? -->
Direction of needle bevel

<!-- PAGE=? -->
Addition of vasoconstrictors

<!-- PAGE=? -->
DIFFUSION

<!-- PAGE=? -->
o Drug dose does appear to play a small role in determining block height with i sobaric solutions

<!-- PAGE=? -->
 Difference b/w 10mg and 15mg but no difference b/w 15mg and 20mg

<!-- PAGE=? -->
 volume and drug concentration do not affects block height when dose is held constant

<!-- PAGE=? -->
o Drug dose and volume appear to be relatively unimportant in predicting the spread of hyperbaric local anesthetic solutions except at extremely low dose

<!-- PAGE=? -->
 Injection Site

<!-- PAGE=? -->
o i mportant effect on block height with isobaric solution

<!-- PAGE=? -->
 block height is reduced by two dermatomes per interspace

<!-- PAGE=? -->
 Patient Characteristics

<!-- PAGE=? -->
o Age, and height are NOT correlated with block height

<!-- PAGE=? -->
o CSF volume and weight are correlated with peak block height

<!-- PAGE=? -->
 these variables account for a relatively small amount of the variability

<!-- PAGE=? -->
o patient age, weight, BMI, and height are either not predictive of clinical characteristics of spinal block, or are of such low predictive power as to be unreliable predictors in any individual patient

<!-- PAGE=? -->
Spinal - Duration

<!-- PAGE=? -->
 the principal determinant of spinal block duration is the local anesthetic drug employed

<!-- PAGE=? -->
 Increasing dose increases the duration of spinal block

<!-- PAGE=? -->
 higher blocks tend to regress faster than lower blocks

<!-- PAGE=? -->
o i sobaric local anesthetic solutions will generally produce longer blocks than hyperbaric solutions using the same dose

<!-- PAGE=? -->
o relatively lower drug concentration in the CSF and spinal nerve roots, less time for l ocal anesthetic concentration to decrease below the minimally effective concentration

<!-- PAGE=? -->
 Adrenergic agonists (epinephrine, phenylephrine, and clonidine) are added to local anesthetics in an effort to prolong the duration of spinal anesthesia

<!-- PAGE=? -->
o effectiveness depends on the local anesthetic with which they are combined

<!-- PAGE=? -->
o more effective at prolonging block in the lumbar and sacral dermatomes than in thoracic dermatomes

<!-- PAGE=? -->
o clonidine also prolongs spinal block when administered orally

<!-- PAGE=? -->
o Tetracaine is the local anesthetic that is most dramatically prolonged by addition of adrenergic agonists

<!-- PAGE=? -->
 Phenylephrine > Epinephrine = Clonidine

<!-- PAGE=? -->
o the effect with Bupivacaine is somewhat less than that seen with tetracaine

<!-- PAGE=? -->
o the effect with lidocaine spinal block is controversial

<!-- PAGE=? -->
 l i k e l y  s omewhat longer

<!-- PAGE=? -->
o The mechanism by which adrenergic agonists prolong spinal block is not clear

<!-- PAGE=? -->
 ? reducing local spinal cord blood flow and thereby slowing the rate of drug elimination

<!-- PAGE=? -->
o Adrenergic agonists are potent analgesic agents in their own right when administered into the subarachnoid space - results from

<!-- PAGE=? -->
 i nhibition of nociceptive afferents - stimulation of α-adrenergic receptors in the spinal cord dorsal horn

<!-- PAGE=? -->
Table 43-2 -- Drug selection for hyperbaric spinal anesthesia

<!-- PAGE=? -->
Epidural

<!-- PAGE=? -->
 Increased margin of therapeutic safety + reduced incidence of side effects + less opioid-induced ventilatory depression compared with SAB

<!-- PAGE=? -->
 space is highly vascularized causing a significant redistribution of drug to the systemic circulation

<!-- PAGE=? -->
 epidural space contains fat, connective tissues, a lymphatic network, and the dorsal and ventral roots of the spinal nerves, all of which can serve as a repository for lipophilic agents

<!-- PAGE=? -->
 Morphine, given either iv or epidurally, produce peak serum levels and decay curves that are nearly identical.

<!-- PAGE=? -->
o the small fraction of morphine (2-10%) that diffuses across the dura to bind spinal opiate receptors produce the duration of analgesia.

<!-- PAGE=? -->
 epidural fentanyl peak serum levels are only approximately 50% of similar im injection

<!-- PAGE=? -->
o however, serum levels of fentanyl 24 hours after a continuous rate infusion are similar to those obtained from a similar iv infusion (redistribution becomes saturated)

<!-- PAGE=? -->
 Epidural morphine (hydrophilic) results cephalad spread

<!-- PAGE=? -->
o Because of this property, epidural morphine may be infused at a lower lumbar level and still provide analgesia for surgical procedures performed on the upper abdomen and thorax

<!-- PAGE=? -->
o results in a higher incidence of some side effects

<!-- PAGE=? -->
 Lipophilic drugs (fentanyl) provide more segmental analgesic effect

<!-- PAGE=? -->
 guideline for the catheter locations

<!-- PAGE=? -->
 catheter placement should be approximately at the dermatomal level that corresponds to a point intersecting the upper 1/3 and lower 2/3 of the surgical incision

<!-- PAGE=? -->
o placement of the epidural catheter at a level lower than desired increases epidural drug dosing to achieve effective analgesia, especially when lipophilic opioids are used, and this may lead to an increase in side effects

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
 Morphine, given either iv or epidurally, produce peak serum levels and decay curves that are nearly identical.

<!-- PAGE=? -->
 most of the epidural dose is absorbed into the systemic circulation, a small fraction of the morphine dose ~3% (2-10%) diffuses across the dura to bind spinal opiate receptors and produce analgesia

<!-- PAGE=? -->
o Onset time 30 minutes, peak effect 60-90 minutes

<!-- PAGE=? -->
o Blood levels peak in 10-15 min, CSF levels peak in 1-4 hrs

<!-- PAGE=? -->
o pain relief from iv administration is 1-2 hours duration

<!-- PAGE=? -->
o pain relief from epidural morphine can provide > 12h (can be given as a bolus q 12 hr)

<!-- PAGE=? -->
o terminal half life in CSF is equivalent to plasma: 2-4 hrs

<!-- PAGE=? -->
 hydrophilic - results in cephalad spread.  Can be infused at a lower lumbar level and still provide analgesia for surgery on the upper abdomen and thorax

<!-- PAGE=? -->
o following lumbar injection, present in cervical CSF over 1-5 hours (cisterna magna by 1-2 hrs, 4 and lateral ventricles by 3-6 hrs, brainstem in 6-12 h) - delayed resp depression

<!-- PAGE=? -->
o persists in CSF for prolonged periods, may depend on reabsorption through arachnoid granulations for elimination

<!-- PAGE=? -->
 intrathecal morphine peaks in effect at 20-60 min and lasts 2-12 hrs

<!-- PAGE=? -->
Fentanyl

<!-- PAGE=? -->
 epidural fentanyl peak serum levels are only approximately 50% of similar im injection

<!-- PAGE=? -->
o lipophilic - more segmental effect

<!-- PAGE=? -->
o onset of action = 4-5 minutes and peak effect = 20 minutes.

<!-- PAGE=? -->
o CSF levels peak in 10 min

<!-- PAGE=? -->
o fentanyl (10 mcg·ml-1) with bupivacaine (1 mg·ml-1)

<!-- PAGE=? -->
o however, serum levels of fentanyl 24 hours after a continuous rate infusion are similar to those obtained from a similar iv infusion.

<!-- PAGE=? -->
th

<!-- PAGE=? -->
o This implies that with the initial bolus of fentanyl, there is redistribution of the drug to lipophilic tissues, which become saturated after continuous administration

<!-- PAGE=? -->
 blood conc peaks at 5-10 min (Suf peaks even faster) - lipid solubility facilitates access to arterial route into the spinal cord.  Enters rapidly and binds to opioid receptors

<!-- PAGE=? -->
 no difference in intraop analgesia or side effects after 25 vs 50 mcg of epidural fentanyl for elective C/S

<!-- PAGE=? -->
 intrathecal fentanyl improves the quality of intraoperative spinal anesthesia

<!-- PAGE=? -->
o decrease visceral pain and the central effects of visceral stimulation

<!-- PAGE=? -->
o no enhancement of motor of sypmathetic blockade

<!-- PAGE=? -->
o Facial-truncal pruritus is commonly observed; however, symptoms typically are mild and do not require treatment

<!-- PAGE=? -->
o no incr N/V

<!-- PAGE=? -->
Hydromorphone

<!-- PAGE=? -->
 Bolus works for 7-12 hours

<!-- PAGE=? -->
 Less pruritis and nausea compared to morphine

<!-- PAGE=? -->
 LA + opiate combo = potentiation may be a result of antinociception at different sites in the spinal cord

<!-- PAGE=? -->
o opioids bind to opiate receptors in the substantia gelatinosa

<!-- PAGE=? -->
o local anesthetics block transmission of afferent impulses at the nerve roots and dorsal root ganglia

<!-- PAGE=? -->
o decrease in the incidence and severity of side effects

<!-- PAGE=? -->
 Clonidine has been the most widely used alpha2 agonist for epidural analgesia, producing dose-dependent analgesia when given as a bolus

<!-- PAGE=? -->
o associated with hypotension and with bradycardia because of inhibition of preganglionic sympathetic fibers.

<!-- PAGE=? -->
o This is most prevalent at lower doses, whereas increased doses normalize blood pressure because of systemic vasoconstriction that overrides the central hypotensive effect.

<!-- PAGE=? -->
o Dexmetotomidine is an alpha2 agonist with a very high alpha2-to-alpha1 selectivity (1600) compared with clonidine (ratio of 200)

<!-- PAGE=? -->
 epinephrine containing solutions significantly increase stroke volume and cardiac output

<!-- PAGE=? -->
o dec. SVR, BP, vasodialtion

<!-- PAGE=? -->
o peripheral resistance falls dramatically resulting in a decrease in arterial pressure greater than that seen with nonepinephrine - containing solutions

<!-- PAGE=? -->
o B2 adrenergic vasodilation produced by low doses of absorbed epinephrine accounts for the greater decrease in peripheral vascular resistance and blood pressure

<!-- PAGE=? -->
Site of Action

<!-- PAGE=? -->
 The site of action of spinal and epidural anesthesia is not precisely known

<!-- PAGE=? -->
 neural blockade can potentially occur at any or all points along the neural pathways extending from the site of drug administration to the interior of the spinal cord

<!-- PAGE=? -->
 neural pathways within the spinal cord are largely intact during spinal anesthesia and that the spinal nerve rootlets were the principal site of neural blockade

<!-- PAGE=? -->
 The site of epidural block is less well localized

<!-- PAGE=? -->
 epidural block likely occurs at both extradural and subdural sites with extradu ral radicular block predominating early and subdural spinal block predominating later

<!-- PAGE=? -->
 human studies demonstrate that SSEPs are maintained during epidural anesthesia, although amplitudes are decreased and latencies are increased

<!-- PAGE=? -->
o This contrasts with spinal block in which SSEPs are completely eliminated

<!-- PAGE=? -->
Differential Nerve Block

<!-- PAGE=? -->
 refers to a phenomenon in which nerve fibers subserving different functions display varying sensitivity to local anesthetic blockade

<!-- PAGE=? -->
o Sympathetic nerve fibers are blocked at the lowest concentration of local anesthetic followed by pain, touch, and motor function

<!-- PAGE=? -->
 partially explained by differences in fiber diameter, smaller-diameter neurons exhibiting greater sensitivity than larger-diameter neurons, however, it is clear not the only, or perhaps not even the most important, factor

<!-- PAGE=? -->
 Differential block occurs with both peripheral nerve blocks and central neuraxial blocks

<!-- PAGE=? -->


<!-- PAGE=? -->
In the peripheral nervous system, differential block is a temporal phenomenon with sympathetic block occurring first followed in time by sensory and motor block

<!-- PAGE=? -->
 In spinal and epidural anesthesia differential block is manifest as a spatial separation in the modalities blocked

<!-- PAGE=? -->
o This spatial separation is believed to result from a gradual decrease in local anesthetic concentration within the CSF as a function of distance from the site of i njection

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 The clinical benefits of epidural and intrathecal opioids include:

<!-- PAGE=? -->
o Excellent analgesia

<!-- PAGE=? -->
o Earlier ambulation

<!-- PAGE=? -->
o Reduced risk of DVT

<!-- PAGE=? -->
o Better postop pulm fxn

<!-- PAGE=? -->
o Earlier extubation

<!-- PAGE=? -->
o Reduced likelihood of resp infections

<!-- PAGE=? -->
o Blunted surgical stress response

<!-- PAGE=? -->
o Reduced MAC

<!-- PAGE=? -->
o Absence of motor, sensory or autonomic blockade

<!-- PAGE=? -->
o Decreased blood loss (hypotension, sympathectomy)

<!-- PAGE=? -->
o May get greater urinary retention

<!-- PAGE=? -->
Side Effects of Epidural Opioids

<!-- PAGE=? -->
Respiratory Depression

<!-- PAGE=? -->
 lipophilic opioids (fent, suf) result in early onset resp depression (typically within 30 min of administration) only (Chestnut 491)

<!-- PAGE=? -->
o monitor for 2 hrs

<!-- PAGE=? -->
 hydrophilic drugs (morph and hydromorph)

<!-- PAGE=? -->
o delayed depression 6-12 hrs post injection

<!-- PAGE=? -->
o monitor hourly for the first 12 hours and q2hrs for the second 12 hours

<!-- PAGE=? -->
 Miller pg 2740 Clinical assessments, such as RR, may not reliably predict a patient's ventilatory status or impending respiratory depression

<!-- PAGE=? -->
 Risk factors for respiratory depression after epidural opioid (miller 1474, table 36-8)

<!-- PAGE=? -->
o Drug factors:

<!-- PAGE=? -->
 Hydrophilic (eg morphine)

<!-- PAGE=? -->
 Large doses

<!-- PAGE=? -->
 Repeated doses

<!-- PAGE=? -->
 Concomitant administration of parenteral opioids or other CNS depressants

<!-- PAGE=? -->
o Patient factors:

<!-- PAGE=? -->
 Elderly or debilitated

<!-- PAGE=? -->
 Coexisting resp disease

<!-- PAGE=? -->
 Thoracic epidural

<!-- PAGE=? -->
 High sensitivity to opioids (no prior exposure)

<!-- PAGE=? -->
 Intrathecal admin

<!-- PAGE=? -->
 Raised intrathoracic pressure (PPV, coughing, vomiting)

<!-- PAGE=? -->
 RF respiratory complications

<!-- PAGE=? -->
o advanced age

<!-- PAGE=? -->
o small body habitus

<!-- PAGE=? -->
o morbid obesity

<!-- PAGE=? -->
o history of sleep apnea

<!-- PAGE=? -->
o general debilitation

<!-- PAGE=? -->
somnolence

<!-- PAGE=? -->
nausea and vomiting

<!-- PAGE=? -->
 due to interaction with chemoreceptor trigger zone in area postrema or at the nucleus tractus solitarius

<!-- PAGE=? -->
 metoclopramide 10 mg

<!-- PAGE=? -->
 ondansetron

<!-- PAGE=? -->
 dexamethasone

<!-- PAGE=? -->
 cyclizine 50 mg

<!-- PAGE=? -->
pruritus

<!-- PAGE=? -->
 most common side effect

<!-- PAGE=? -->
 unrelated to histamine release

<!-- PAGE=? -->
 ondansetron is effective

<!-- PAGE=? -->
 naloxone 40-80 mch

<!-- PAGE=? -->
 dephenhydramine 25 mg

<!-- PAGE=? -->
 nalbuphine 2.5-5 mg IV or 10 mg subcu

<!-- PAGE=? -->
 IV propofol 10 mg

<!-- PAGE=? -->
sensory changes

<!-- PAGE=? -->
 intrathecal sufentanil has caused high cervical sensory block, mental status changes, dysphagia, dyspnea, automatisms

<!-- PAGE=? -->
 patients may feel that they cannot breathe or swallow

<!-- PAGE=? -->
 generally subside in 30-60 min

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
 reported in early studies that evaluated intrthecal opioid administration

<!-- PAGE=? -->
 incidence higher when given with local anesthetic or clonidine

<!-- PAGE=? -->
 probably due to pain relief, decreased maternal levels of catecholamines esp epi

<!-- PAGE=? -->
delayed gastric emptying:

<!-- PAGE=? -->
 negligible after epidural fentanyl but occurs with intrathecal administration

<!-- PAGE=? -->
reactivation of herpes simplex virus infections

<!-- PAGE=? -->
 incidence increases with intrathecal opioids

<!-- PAGE=? -->
Clonidine

<!-- PAGE=? -->
 has been the most widely used alpha2 agonist for epidural analgesia, producing dose-dependent analgesia when given as a bolus

<!-- PAGE=? -->
 associated with hypotension and with bradycardia because of inhibition of preganglionic sympathetic fibers.

<!-- PAGE=? -->
 This is most prevalent at lower doses, whereas increased doses normalize blood pressure because of systemic vasoconstriction that overrides the central hypotensive effect.

<!-- PAGE=? -->
 epidural clonidine has been used as a single agent, but it is more frequently been used in combination with LA or opioids to potentiate analgesia and minimize side effects

<!-- PAGE=? -->
 Dexmetotomidine is an alpha2 agonist with a very high alpha2-to-alpha1 selectivity (1600) compared with clonidine (ratio of 200)

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
 addtion of low dose epi shortens latency and prolongs duration of analgesia of epidural BPV

<!-- PAGE=? -->
 1:800 000 to 1:200 000 (1.25 to 5 mcg/ml)

<!-- PAGE=? -->
 variable effect on the uptake of local anesthetic in parturients

<!-- PAGE=? -->
 systemic absorption of epi may increase maternal heart rate and transiently decrease uterine activity secondary to beta-receptor stimulation

<!-- PAGE=? -->
 addition of epi to lido or BPV for epidural analgesia does not prolong labour, affect intervillous blood flow or neonatal outcome

<!-- PAGE=? -->
 increases intensity of motor blockade

<!-- PAGE=? -->
 see below for hemodynamic consequences (essentially fall in SVR and BP)

<!-- PAGE=? -->


<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
 patient refusal

<!-- PAGE=? -->
 Hypovolemia or shock

<!-- PAGE=? -->
 Inc. ICP - increases the risk of brain herniation

<!-- PAGE=? -->
 Coagulopathy or thrombocytopenia increase the risk of epidural hematoma.

<!-- PAGE=? -->
 Sepsis increases the risk of meningitis

<!-- PAGE=? -->
 Infection at the puncture site increases the risk of meningitis

<!-- PAGE=? -->
 Lack of resuscitative equipment

<!-- PAGE=? -->
 Lack of experienced anesthesiologist

<!-- PAGE=? -->
 No IV Access

<!-- PAGE=? -->
 Allergy

<!-- PAGE=? -->
 Stenotic heart disease (AS, MS)

<!-- PAGE=? -->
 Pre-existing neurologic disease (MS)

<!-- PAGE=? -->
Physiology

<!-- PAGE=? -->
Cardiovascular Physiology

<!-- PAGE=? -->
 hypotension and bradycardia, are arguably the most important and most common physiologic changes during spinal and epidural anesthesia

<!-- PAGE=? -->
Spinal Anesthesia

<!-- PAGE=? -->
 Blockade of sympathetic efferents is the principal mechanism by which spinal anesthesia produces cardiovascular derangements

<!-- PAGE=? -->
o i ncidence of significant hypotension or bradycardia is generally related to the extent of sympathetic blockade, which in turn parallels block height

<!-- PAGE=? -->
o however, the severity of cardiovascular changes do not necessarily correlate to block height

<!-- PAGE=? -->
 risk factors associated with hypotension include

<!-- PAGE=? -->
o age >40 to 50 years

<!-- PAGE=? -->
o concurrent general anesthesia

<!-- PAGE=? -->
o obesity

<!-- PAGE=? -->
o hypovolemia

<!-- PAGE=? -->
o addition of phenylephrine to the local anesthetic

<!-- PAGE=? -->
 Hypotension during spinal anesthesia is the result of both arterial and venodilat ion.

<!-- PAGE=? -->
o Venodilation increases volume in capacitance vessels, thereby decreasing venous return  and decreased preload

<!-- PAGE=? -->
o Arterial dilation during spinal anesthesia results in significant decreases in total peripheral resistance - decreased afterload

<!-- PAGE=? -->
 an intact renin-angiotensin system helps to offset the hypotensive effects of sympathetic blockade

<!-- PAGE=? -->
 Heart rate does not change significantly during spinal anesthesia in most patients

<!-- PAGE=? -->
o clinically significant bradycardia occurs with a reported incidence of 10 to 15%

<!-- PAGE=? -->
o risk factors

<!-- PAGE=? -->
 baseline HR < 50

<!-- PAGE=? -->
 prolonged PR interval

<!-- PAGE=? -->
 i ncreasing block height (>T6)

<!-- PAGE=? -->
 age younger than 50 years

<!-- PAGE=? -->
 ASA 1 status

<!-- PAGE=? -->
 concurrent use of beta-blockers

<!-- PAGE=? -->
o The mechanism is not clear

<!-- PAGE=? -->
 Blockade of the sympathetic cardioaccelerator fibers originating from T1-4 spinal segments

<!-- PAGE=? -->
 Diminished venous return sensed by intracardiac stretch receptors with reflex bradycardia

<!-- PAGE=? -->
o there have been reports of sudden, unexplained, severe bradycardia, asystole, and 2 nd or 3 r d degree heart block

<!-- PAGE=? -->
 Bainbridge Reflex

<!-- PAGE=? -->
 Elicited by stretch receptors located in the RA wall and the cavoatrial junction.

<!-- PAGE=? -->
 ↑ RAP → ↑ Vagal afferent to Medulla → Inhibit parasympathetic activity → ↑HR

<!-- PAGE=? -->
 Reverse Bainbridge:

<!-- PAGE=? -->
 Thus, decrease in RAP → ↓ RA baroreceptor tone → ↓ HR

<!-- PAGE=? -->
Epidural Anesthesia

<!-- PAGE=? -->
 The hemodynamic changes produced by epidural anesthesia are largely dependent on whether or not epinephrine is added to the local anesthetic solution

<!-- PAGE=? -->
o High epidural block with no epinephrine results in decreased stroke volume, cardiac output, total peripheral resistance, and arterial pressure

<!-- PAGE=? -->
o result from venous and arterial dilation induced by sympathetic blockade

<!-- PAGE=? -->
 when epinephrine-containing solutions are used for epidural anesthesia, stroke volume and cardiac output increase significantly , however, peripheral resistance falls dramatically

<!-- PAGE=? -->
o decrease in arterial pressure greater than that seen with nonepinephrinecontaining solutions

<!-- PAGE=? -->
o β2-adrenergic-mediated vasodilatation produced by low doses of absorbed epinephrine accounts for the greater decrease in peripheral vascular resistance and blood pressure

<!-- PAGE=? -->
Treating Hemodynamic Changes

<!-- PAGE=? -->
 Treatment must be aimed at decreased cardiac output and/or decreased peripheral resistance

<!-- PAGE=? -->
 crystalloid administration has often been advocated, however, the effectiveness of this therapy in normovolemic patients is controversial

<!-- PAGE=? -->
o Prehydrating does not reliably prevent hypotension, but it has been shown to decrease the incidence of hypotension during spinal anesthesia in some

<!-- PAGE=? -->
 can only increase stroke volume, which has limited ability to restore blood pressure if heart rate or systemic vascular resistance remains low

<!-- PAGE=? -->
o colloids may actually inc. SVR while crystalloids may decrease it

<!-- PAGE=? -->
 Vasopressors are a more reliable approach to treating hypotension secondary to central neuraxial blockade

<!-- PAGE=? -->
o α- and β-adrenergic activity are superior to pure α-agonists for correcting the cardiovascular derangements produced by spinal and epidural anesthesia

<!-- PAGE=? -->
Renal

<!-- PAGE=? -->
 the decrease in renal blood flow accompanying neuraxial block is of little physiologic i mportance

<!-- PAGE=? -->
o Pure α-adrenergic agonists are also used to correct hypotension by inc SVR, possibly at the expense of CO

<!-- PAGE=? -->
 phenylephrine boluses have been shown to produce transient left ventricular dysfunction during epidural anesthesia with nonepinephrine-containing local anesthetics

<!-- PAGE=? -->
Respiratory Physiology

<!-- PAGE=? -->
 Spinal and epidural blocks to midthoracic levels have little effect on pulmonary function i n patients without pre-existing lung disease

<!-- PAGE=? -->
o l ung volumes, resting minute ventilation, dead space, arterial blood gas tensions, and shunt fraction show little or no change during spinal or epidural anesthesia

<!-- PAGE=? -->
o ventilatory response to hypercapnia is actually increased by spinal and epidural

<!-- PAGE=? -->
 expiratory reserve volume, peak expiratory flow, and maximum minute ventilation may be significantly reduced by high spinal and epidural blocks - results in impariement of active expiration

<!-- PAGE=? -->
o adverse affect on COPD or other patients who rely on their accessory muscles of respiration to maintain a clear airway and/or adequate ventilation

<!-- PAGE=? -->
 Patients may complain of dyspnea despite normal or elevated minute ventilation

<!-- PAGE=? -->
o l i k e l y  r e s ult s from the patient's inability to feel the chest wall  move while breathing

<!-- PAGE=? -->
o A normal speaking voice, as opposed to a faint gasping voice, suggests ventilation i s normal

<!-- PAGE=? -->
 Phrenic nerve unaffected even by midcervical levels of sensory anesthesia

<!-- PAGE=? -->
 The most likely cause of transient respiratory arrest during high spinal anesthesia is i schemia of medullary respiratory neurons secondary to decreases in blood pressure and cardiac output severe enough to impair cerebral blood flow

<!-- PAGE=? -->
 Risk factors for respiratory complications

<!-- PAGE=? -->
o advanced age

<!-- PAGE=? -->
o small body habitus

<!-- PAGE=? -->
o morbid obesity

<!-- PAGE=? -->
o history of sleep apnea

<!-- PAGE=? -->
o general debilitation

<!-- PAGE=? -->
Gastrointestinal Physiology

<!-- PAGE=? -->
 gastrointestinal effects of spinal and epidural anesthesia are largely the result of sympathetic blockade

<!-- PAGE=? -->
o GI sympathetic innervation is from T6-L2

<!-- PAGE=? -->
 Blockade resullts in unopposed parasympathetic activity by way of the vagus nerve

<!-- PAGE=? -->
o Inc. secetions, sphincters relax, bowel constriction

<!-- PAGE=? -->
 The decrease in hepatic blood flow during spinal anesthesia parallels the decrease in mean arterial blood pressure

<!-- PAGE=? -->
 Nausea is a common complication of spinal and epidural anesthesia - etiology is unknown

<!-- PAGE=? -->
o i ncreased incidence with

<!-- PAGE=? -->
 blocks higher than T5

<!-- PAGE=? -->
 hypotension

<!-- PAGE=? -->
 opioid premedication

<!-- PAGE=? -->
 history of motion sickness

<!-- PAGE=? -->
 Frequent cause of urinary retention, which delays discharge of outpatients and necessitates bladder catheterization in inpatients

<!-- PAGE=? -->
Endocrine-Metabolic Physiology

<!-- PAGE=? -->
 Surgery results in increased

<!-- PAGE=? -->
o protein catabolism

<!-- PAGE=? -->
o oxygen consumption

<!-- PAGE=? -->
o circulating catecholamines, growth hormone, renin, angiotensin, thyroidstimulating hormone, β-endorphin, glucose, and free fatty acids

<!-- PAGE=? -->
 spinal and epidural anesthesia have been shown to inhibit this stress response

<!-- PAGE=? -->
o greatest with lower abdominal and lower extremity procedures

<!-- PAGE=? -->
o l east with upper abdominal and thoracic procedures

<!-- PAGE=? -->
o l i k e l y  t h e  r esult of blockade of the afferent sensory information that helps initiate the stress response

<!-- PAGE=? -->
o there is as yet no clear evidence that this results in decreased morbidity or mortality

<!-- PAGE=? -->
Another neurophysiologic aspect of central neuroaxial block is that it produces sedation, potentiates the effect of sedative hypnotic drugs, and markedly decreases minimum alveolar concentration of volatile anesthetics

<!-- PAGE=? -->
 Safety maneuvers:

<!-- PAGE=? -->
o low concentration LA (0.1% bupivacaine) + an opioid analgesic allows subarachnoid catheter migration to be identified earlier by the onset of progressive sensory blockade.

<!-- PAGE=? -->
o Catheter sites should be examined daily, temperature curves monitored, and the patient periodically evaluated for signs of meningismus

<!-- PAGE=? -->
o Epidural catheters should be placed at least 1 hour before iv heparinization

<!-- PAGE=? -->
o epidural catheterization (as well as removal of epidural catheters) be performed at least 10-12 hours after a dose of LMWH. Dosing of LMWH should not occur for at least 2 hours after removal of an epidural catheter to avoid manipulation during the peak anticoagulant effect

<!-- PAGE=? -->
o if INR> 1.5 neurologic checks should be continued for at least 24 hours after epidural catheter removal

<!-- PAGE=? -->
o Respiratory rates and level of sedation should be monitored every hour for the first 24 hours of the epidural infusion and every 4 hours thereafter. Apnea monitors can be used to supplement, but cannot replace, direct patient observation.

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
Backache

<!-- PAGE=? -->
 postoperative backache occurs most commonly with epidural anesthesia

<!-- PAGE=? -->
o Epidural > spinal > GA

<!-- PAGE=? -->
 The etiology of backache is not clear, although needle trauma, local anesthetic irritation, and ligamentous strain secondary to muscle relaxation have been offered as explanations

<!-- PAGE=? -->
Postdural Puncture Headache

<!-- PAGE=? -->
 reported incidence as high as 25% in some studies

<!-- PAGE=? -->
 The risk of PDPH is less with epidural anesthesia - no dural puncture

<!-- PAGE=? -->
o with there is a dural puncture, the incidence is 50%

<!-- PAGE=? -->
 H/A characteristics

<!-- PAGE=? -->
o Positional

<!-- PAGE=? -->
 mild or absent when the patient is supine - severe fronto-occipital headache upon sitting - improves on returning to the supine position

<!-- PAGE=? -->
o cranial nerve symptoms (e.g., diplopia, tinnitus)

<!-- PAGE=? -->
 VI most frequent cranial nerve palsy

<!-- PAGE=? -->
o nausea and vomiting

<!-- PAGE=? -->
 believed to result from the loss of CSF through the meningeal needle hole, resulting in decreased buoyant support for the brain

<!-- PAGE=? -->
o brain sags in the upright position, putting traction on pain-sensitive structures

<!-- PAGE=? -->
o Traction on cranial nerves is believed to cause the cranial nerve palsies that are seen occasionally

<!-- PAGE=? -->
 i ncidence decreases with

<!-- PAGE=? -->
o i ncreasing age

<!-- PAGE=? -->
o small-diameter spinal needles with noncutting tips (pencil-point)

<!-- PAGE=? -->
o i nserting cutting needles with the bevel aligned parallel to the long axis of the meninges

<!-- PAGE=? -->
 collagen fibers of the dura mater are arranged randomly; therefore, as many f i bers will be cut with parallel insertion as with perpendicular insertion

<!-- PAGE=? -->
 more likely, the dura mater is under longitudinal tension - a perpendicular hole will tend to be pulled open, and a hole oriented parallel to this tension will be pulled closed

<!-- PAGE=? -->
 there does not appear to be a gender difference in the incidence of PDPH

<!-- PAGE=? -->
 remaining supine following meningeal puncture does not decrease the incidence

<!-- PAGE=? -->
 use of fluid, instead of air, for LOR is protective

<!-- PAGE=? -->
 PDPH usually resolves spontaneously in a few days to a week for most patients

<!-- PAGE=? -->
o May persist for months

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Bed rest / analgesics / caffeine

<!-- PAGE=? -->
o Epidural blood patch

<!-- PAGE=? -->
Epidural Blood Patch

<!-- PAGE=? -->
 Patients who are unable or unwilling to await spontaneous resolution of PDPH should be offered epidural blood patch

<!-- PAGE=? -->
o Likely forms a clot over the meningeal hole

<!-- PAGE=? -->
 Symptoms are relieved within 1 to 24 hours in 85 to 95% of patients

<!-- PAGE=? -->
o 90% of patients who fail an initial blood patch will respond to a second patch

<!-- PAGE=? -->
 The most common side effects of blood patch are backache and radicular pain

<!-- PAGE=? -->
 transient bradycardia and cranial nerve palsies have also been reported

<!-- PAGE=? -->
 The timing of epidural blood patch is controversial

<!-- PAGE=? -->
o prophylactic blood patch may or may not be effective

<!-- PAGE=? -->
 worth considering in high-risk outpatients for whom a return trip to the hospital for epidural blood patch would be difficult

<!-- PAGE=? -->
 Epidurally administered fibrin glue has been shown to be an effective alternative to blood administration

<!-- PAGE=? -->
Hearing Loss

<!-- PAGE=? -->
 a transient (1 to 3 days) mild decrease in hearing acuity (>10 dB) is common after spinal anesthesia

<!-- PAGE=? -->
 i ncidence is roughly 40%

<!-- PAGE=? -->
 3:1 female-to-male predominance

<!-- PAGE=? -->
 l ower inidence with bupivicane vs. prilocaine spinals

<!-- PAGE=? -->
 The mechanism of hearing loss is unclear

<!-- PAGE=? -->
o marked female predominance, the absence of PDPH, and the difference in i ncidence between prilocaine and bupivacaine suggest that CSF leak is not the cause

<!-- PAGE=? -->
 Occurs most often in women receiving IT prilocaine.

<!-- PAGE=? -->
Systemic Toxicity

<!-- PAGE=? -->
 Systemic toxicity does not occur with spinal anesthesia because the drug doses used are too low

<!-- PAGE=? -->
 Both CNS and cardiovascular toxicity may occur during epidural anesthesia

<!-- PAGE=? -->
o CNS toxicity may result from absorption of LA from the epidural space but more commonly occurs following accidental intravascular injection of local anesthetic

<!-- PAGE=? -->
o CVS toxicity can probably only occur from unintended intravascular injection

<!-- PAGE=? -->
 An adequate IV test dose and incremental injection of local anesthetics are the most i mportant methods to prevent both CNS and cardiovascular toxicity during epidural anesthesia

<!-- PAGE=? -->
Total Spinal Anesthesia

<!-- PAGE=? -->
 Profound hypotension and bradycardia are common secondary to complete sympathetic blockade

<!-- PAGE=? -->
 Respiratory arrest may occur

<!-- PAGE=? -->
o respiratory muscle paralysis

<!-- PAGE=? -->
 high levels usually not enough to block the phrenic nerve

<!-- PAGE=? -->
o dysfunction of the brainstem respiratory control centers 2' to hypoperfusion

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
o oxygen and controlled ventilation

<!-- PAGE=? -->
o Vasopressors

<!-- PAGE=? -->
o Atropine

<!-- PAGE=? -->
o Volume

<!-- PAGE=? -->
Neurologic Injury

<!-- PAGE=? -->
 Serious neurologic injury is a rare

<!-- PAGE=? -->
o occurs in approximately 0.03 to 0.1% of all central neuraxial blocks

<!-- PAGE=? -->
o although in most cases the block has not been proven to be causative

<!-- PAGE=? -->
 Persistent paresthesias and limited motor weakness are the most common injuries

<!-- PAGE=? -->
 paraplegia and diffuse injury to cauda equina roots do occur rarely

<!-- PAGE=? -->
 Injury may result from

<!-- PAGE=? -->
o direct needle trauma to the spinal cord or spinal nerves

<!-- PAGE=? -->
o spinal cord ischemia

<!-- PAGE=? -->
o accidental injection of neurotoxic drugs or chemicals

<!-- PAGE=? -->
o i ntroduction of bacteria

<!-- PAGE=? -->
o epidural hematoma

<!-- PAGE=? -->
 l ocal anesthetics intended for epidural and intrathecal use can themselves be neurotoxic i n concentrations used clinically

<!-- PAGE=? -->
o hyperbaric 5% lidocaine has been implicated as a cause of multiple cases of cauda equina syndrome following subarachnoid injection through small-bore (-microspinal‖) catheters

<!-- PAGE=? -->
o maldistribution of the local anesthetic within the CSF has been implicated

<!-- PAGE=? -->
o l ocal anesthetics can

<!-- PAGE=? -->
 produce excitotoxic damage by depolarizing neurons and increasing i ntracellular calcium concentrations

<!-- PAGE=? -->
 damage neuronal plasma membranes through detergentlike actions

<!-- PAGE=? -->
Transient Neurologic Symptoms

<!-- PAGE=? -->
 moderate pain, dysesthesia, or both, in the legs or buttocks after spinal anesthesia

<!-- PAGE=? -->
o pain usually resolves spontaneously within 72 hours, but a few patients have required up to 6 months

<!-- PAGE=? -->
 mechanism responsible remains unclear

<!-- PAGE=? -->
 All local anesthetics have been shown to cause TNS

<!-- PAGE=? -->
o risk appears to be greatest with lidocaine

<!-- PAGE=? -->
 Other risk factors include

<!-- PAGE=? -->
o addition of phenylephrine

<!-- PAGE=? -->
o l i t h o t omy position

<!-- PAGE=? -->
o l egs flexed at the knee (as for meniscectomy)

<!-- PAGE=? -->
o outpatient status

<!-- PAGE=? -->
 a double-orifice pencil-point needle seems to be protective vs. a single orifice needle

<!-- PAGE=? -->
o other sources suggest type of needle has no effect

<!-- PAGE=? -->
 Some references suggest obesity as a risk factor

<!-- PAGE=? -->
 Variables not associated with TNS include

<!-- PAGE=? -->
o l i d ocaine dose

<!-- PAGE=? -->
o addition of epinephrine

<!-- PAGE=? -->
o dextrose

<!-- PAGE=? -->
o paresthesia

<!-- PAGE=? -->
o hypotension

<!-- PAGE=? -->
o blood-tinged CSF

<!-- PAGE=? -->
o among others

<!-- PAGE=? -->
Spinal Hematoma

<!-- PAGE=? -->
 rare but potentially devastating complication of spinal and epidural anesthesia

<!-- PAGE=? -->
o i ncidence estimated to be <1 in 150,000

<!-- PAGE=? -->
 most common presentation is numbness or lower extremity weakness,

<!-- PAGE=? -->
o cousins reports a high incidence of severe back pain

<!-- PAGE=? -->
 Early detection is critical because a delay of more than 8 hours in decompressing the spine reduces the odds of good recovery

<!-- PAGE=? -->
 Coagulation defects are the principal risk factor for epidural hematoma

<!-- PAGE=? -->
o ASRA recommendations

<!-- PAGE=? -->
 NSAIDs - no increased risk

<!-- PAGE=? -->
 subcutaneous unfractionated heparin  - no increased risk

<!-- PAGE=? -->
 ticlopidine  - discontinue for 2 weeks

<!-- PAGE=? -->
 clopidogrel - discontinue for 1 week

<!-- PAGE=? -->
 abciximab  - discontinue for 24 to 48 hours

<!-- PAGE=? -->
 eptifibatide and tirofiban  - discontinue for 4 to 8 hours

<!-- PAGE=? -->
 LMWH prohylaxis - hold for 12 hrs preop

<!-- PAGE=? -->
 f i r st   dos e 24hrs post op for BID dosing and 6 -8 hrs for OD

<!-- PAGE=? -->
 remove catheters 12hrs after last dose, next dose after 2 hrs

<!-- PAGE=? -->
 LMWH treatment - hold 24 hrs

<!-- PAGE=? -->
 fully anticoagulated or thromblysed - no neuroaxial technique

<!-- PAGE=? -->
o removalof catheters is nearly as great a risk for spinal hematoma as its insertion

<!-- PAGE=? -->
o minidose unfractionated heparin and NSAIDs may in fact increase risk when combined

<!-- PAGE=? -->
Table 4. Patient , Anesthetic, and LMWH Dosing Variables Associated With Spinal Hematoma

<!-- PAGE=? -->
Patient factors

<!-- PAGE=? -->
Female gender

<!-- PAGE=? -->
Increased age

<!-- PAGE=? -->
Anesthetic factors

<!-- PAGE=? -->
Traumatic needlelcatheter placement

<!-- PAGE=? -->
Epidural (compared to spinal) technique

<!-- PAGE=? -->
Indwelling epidural catheter during LMWH administration

<!-- PAGE=? -->
LMWH dosing factors

<!-- PAGE=? -->
Immediate preoperative (or intraoperative) LMWH administration

<!-- PAGE=? -->
Early postoperative LMWH administration

<!-- PAGE=? -->
Concomitant antiplatelet or anticoagulant medications

<!-- PAGE=? -->
Twice daily LMWH administration

<!-- PAGE=? -->
Previous Spinal instrumentation

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 There is an increased risk of several complications

<!-- PAGE=? -->
o Unsuccessful identification of the epidural space

<!-- PAGE=? -->
o multiple attempts before successful identification

<!-- PAGE=? -->
o false loss of resistance

<!-- PAGE=? -->
o unintentional dural puncture

<!-- PAGE=? -->
o failed block or inadequate analgesia

<!-- PAGE=? -->
Subdural block

<!-- PAGE=? -->
Chestnut, cousins

<!-- PAGE=? -->
 perforation of the dura without penetration of the underlying arachnoid membrane

<!-- PAGE=? -->
o incidence up to 1 in 100 with myelogram and spinal anesthesia

<!-- PAGE=? -->
 ~.5% with spinal or epidural anesthesia

<!-- PAGE=? -->
 Features

<!-- PAGE=? -->
o onset is intermediate between epidural and spinal

<!-- PAGE=? -->
o block is

<!-- PAGE=? -->
 patchy

<!-- PAGE=? -->
 asymmetric

<!-- PAGE=? -->
 widespread sensory block with sacral sparing

<!-- PAGE=? -->
o compared with spinal

<!-- PAGE=? -->
 variable motor and sacral sparing

<!-- PAGE=? -->
 Less hypotension

<!-- PAGE=? -->
 No aspiration of CSF

<!-- PAGE=? -->
 Possible SOB, hypotension, and decreased LOC (higher potential spread than epidural)

<!-- PAGE=? -->
 subdural space extends intracranially, so cranial nerves may be affected and intubation may be required

<!-- PAGE=? -->
TABLE 21-4 -- CLINICAL FEATURES OF EPIDURAL, SUBDURAL, AND SPINAL BLOCKS

<!-- PAGE=? -->
Neurogenic Pulmonary Edema

<!-- PAGE=? -->
 characterized by

<!-- PAGE=? -->
o marked pulmonary vascular congestion

<!-- PAGE=? -->
o intra-alveolar hemorrhage

<!-- PAGE=? -->
o protein-rich edema fluid

<!-- PAGE=? -->
 Specific features of this syndrome are

<!-- PAGE=? -->
o rapid onset

<!-- PAGE=? -->
o relationship to hypothalamic lesions

<!-- PAGE=? -->
o ability to prevent or attenuate it by B-blockers and CNS depressants

<!-- PAGE=? -->
 thought to result from massive sympathetic discharge from injured brain secondary to intracranial hypertension

<!-- PAGE=? -->
 Traditional therapy for pulmonary edema of cardiac origin is ineffective

<!-- PAGE=? -->
o outcome is frequently fatal

<!-- PAGE=? -->
 Therapy consists of

<!-- PAGE=? -->
o immediate pharmacologic or surgical relief of intracranial hypertension

<!-- PAGE=? -->
o supportive respiratory care

<!-- PAGE=? -->
o careful fluid management

<!-- PAGE=? -->
Neuropathy post regional

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
 Sensory lesions are more frequently transient than motor lesions

<!-- PAGE=? -->
o symptoms of numbness or tingling only may resolve during the first 5 days

<!-- PAGE=? -->
o The patient should be instructed to avoid postures that might compress or stretch the involved nerve

<!-- PAGE=? -->
o Arrangements should be made for frequent contact with the patient

<!-- PAGE=? -->
o Neurologic consultations is appropriate if the symptoms still persist on postoperative day 5

<!-- PAGE=? -->
 motor lesions should be consulted to a neurologist immediately

<!-- PAGE=? -->
o Electromyographic studies may be needed to assess the location of any acute lesion

<!-- PAGE=? -->
 direct an appropriate treatment plan

<!-- PAGE=? -->
 may demonstrate chronic abnormalities of the nerve or, if applicable, the contralateral nerve

<!-- PAGE=? -->
 Postoperative sensory or motor deficits must also be distinguished from residual (prolonged) local anesthetic effect

<!-- PAGE=? -->
 CT and MRI, are useful in identifying infectious processes and expanding hematomas

<!-- PAGE=? -->
 Neurophysiologic testing, such as nerve conduction studies, evoked potentials, and electromyography, are often useful in establishing a diagnosis and prognosis

<!-- PAGE=? -->
Neurolysis

<!-- PAGE=? -->
 Phenol (carbolic acid) has been used extensively for neurolysis since the 1950s, and because of an apparent lower incidence of neuritis, has to some degree supplanted alcohol

<!-- PAGE=? -->
 Preparations of phenol in water, saline, glycerine, and contrast medium have been used clinically in concentrations ranging from 3% to 15%

<!-- PAGE=? -->
 Aqueous preparations of phenol are used in most clinical settings except for subarachnoid administration, in which case glycerine-based solutions are absolutely indicated

<!-- PAGE=? -->
o Phenol mixed with glycerine is hyberbaric with respect to CSF, a property that is essential for controlling its spread in the subarachnoid space

<!-- PAGE=? -->
 Perineural injection of phenol is less commonly associated with the burning pain observed after alcohol injection

<!-- PAGE=? -->
 Phenol produces a biphasic response characterized by an initial local anesthetic effect, producing subjective warmth and numbness that gives way to chronic denervation

<!-- PAGE=? -->
 The hypalgesia that follows may not be as dense as after alcohol, and quality and extent of analgesia may fade slightly within the first 24 hours of administration

<!-- PAGE=? -->
 Although controlled trials of alcohol versus phenol are lacking, alcohol (50% to 100%) would seem to be the agent of choice based on global experience

<!-- PAGE=? -->
 disadvantage of alcohol include

<!-- PAGE=? -->
o severe though transient pain on injection

<!-- PAGE=? -->
o less miscible with contrast medium than phenol

<!-- PAGE=? -->
 Intoxication is unlikely, except in the case of accidental intravascular injection, but occasionally an acetaldehyde syndrome is encountered, though it is usually (not always) innocuous.

<!-- PAGE=? -->
Phenol (6% to 10%)

<!-- PAGE=? -->
 mixes readily with contrast medium, but must be prepared by a compounding pharmacist

<!-- PAGE=? -->
 The apparently greater affinity of phenol for vascular tissue has been cited as a theoretic disadvantage, since this might be predicted to correlate with higher incidences of injury to the spinal cord's nutrient vessels, but the actual clinical significance is unknown

<!-- PAGE=? -->
 Large volumes of phenol may be associated with systemic and cardiac toxicity, and accidental intravascular injection has been reported to produce seizures

<!-- PAGE=? -->
 Phenol may be best reserved for (lower volume) splanchnic block, especially if high concentrations are used, due to potential systemic toxicity.

<!-- PAGE=? -->
 LA effect immediate

<!-- PAGE=? -->
o No pain on injection

<!-- PAGE=? -->
 Neurolytic effect 3-7d (biphasic response)

<!-- PAGE=? -->
 Duration of effect is 2-3 months

<!-- PAGE=? -->
 Hyperbaric in gycerine

<!-- PAGE=? -->
ETOH

<!-- PAGE=? -->
 Hypobaric

<!-- PAGE=? -->
 Efficacy 12-24h

<!-- PAGE=? -->
 Pain on injection common, neuritis

<!-- PAGE=? -->
Neurophysiology

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Anesthetic agents can have profound effects on CMR, CBF, CSF dynamics, and ICP

<!-- PAGE=? -->
 CMR - O2 consumption

<!-- PAGE=? -->
 CBF

<!-- PAGE=? -->
o 20% of total body O2 consumption

<!-- PAGE=? -->
 60% for neuronal electrical activity

<!-- PAGE=? -->
 40% to maintain cellular integrity

<!-- PAGE=? -->
o Average is 3-3.8 ml/100g/min (50 ml/min in adults)

<!-- PAGE=? -->
o Greatest in cortex grey matter and parallels electrical activity

<!-- PAGE=? -->
o 2° to limited O2 reserve, unconciousness occurs after only 10 sec of interrupted O2 supply

<!-- PAGE=? -->
 Irreversible cellular injury occurs after 3-8 min when ATP stores are exhausted

<!-- PAGE=? -->
o Glucose consumption usually parallels CMRO2

<!-- PAGE=? -->
o Varies with metabolic activity

<!-- PAGE=? -->
o Range from 10-300 ml/100g/min

<!-- PAGE=? -->
o Average is 50mls/100g/min

<!-- PAGE=? -->
 80 in grey matter

<!-- PAGE=? -->
 20 in white matter

<!-- PAGE=? -->
o Total in adults is ~ 750 ml/min

<!-- PAGE=? -->
 15-20% of CO

<!-- PAGE=? -->
o CBF of 20-25 are usually associated with cerebral impairment

<!-- PAGE=? -->
o 15-20 produces isoelectric EEG

<!-- PAGE=? -->
o <10 results in irreversible brain damage

<!-- PAGE=? -->
 Regulation of cerebral blood flow

<!-- PAGE=? -->
o CPP is MAP-ICP or CVP (which ever is greater)

<!-- PAGE=? -->
o CPP is normally 80-100mmHg

<!-- PAGE=? -->
o Moderate ↑ ICP can greatly effect CPP and CBF

<!-- PAGE=? -->
o CPP <50 results in EEG slowing ,25-40 have flat EEG

<!-- PAGE=? -->
o <25 results in irreversible brain damage

<!-- PAGE=? -->
o CPP should be maintained > 60mmHg

<!-- PAGE=? -->
 CPP should be maintained higher in certain pathologic conditions

<!-- PAGE=? -->
 Elderly

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 Known cerebrovascular disease

<!-- PAGE=? -->
 Degenerative disease of the C-spine

<!-- PAGE=? -->
 C-spine stenosis

<!-- PAGE=? -->
o Autoregulation

<!-- PAGE=? -->
 Cerebral vasculature adapts rapidly to changes in CPP (10-60 sec)

<!-- PAGE=? -->
 ↓ CPP - vasodilation

<!-- PAGE=? -->
 ↑ CPP - vasoconstriction

<!-- PAGE=? -->
 CBF remains constant between MAPS of 60 - 160

<!-- PAGE=? -->
 Beyond these limits CBF becomes pressure dependant

<!-- PAGE=? -->
 The cerebral autoregulation curve is shifted to the right in pts with chronic HTN

<!-- PAGE=? -->
 May be restored to normal with long-term antihypertension treatment

<!-- PAGE=? -->
 Myogenic and metabolic mechanisms involoved in cerebral autoregulation

<!-- PAGE=? -->
 Myogenic - intrinsic response of smooth muscle cells to changes in MAP

<!-- PAGE=? -->
 Metabolic - metabolic demand determines arterial tone

<!-- PAGE=? -->
o ↑ demand, tissue metabolites, arteriolar vasodilation, ↑ flow

<!-- PAGE=? -->
 NO, H + , adenosine, prostaglandins

<!-- PAGE=? -->
o Extrinsic factors

<!-- PAGE=? -->
 Respiratory gas tensions are the most important extrinsic influence on CBF

<!-- PAGE=? -->
 CBF is directly proportionate to PaCO2 btw 20-80 mmHg

<!-- PAGE=? -->
 1-2 ml/100g/min per mmHg change

<!-- PAGE=? -->
 The almost immediate affect is thought to be 2° to changes in CSF and cerebral tissue pH

<!-- PAGE=? -->
 HCO3 and H + doesn't affect CBF because  ions do not readily cross the BBB

<!-- PAGE=? -->
 CSF [HCO3 -] compensates in 24-48 hrs so the effects of hypo/hypercapnia become diminished with time

<!-- PAGE=? -->
o With inc. ICP, the benefit of hypocapnea will diminish after 6-18 hours

<!-- PAGE=? -->
 Only marked decreased in PaO2 (<50mmHg) increase CBF

<!-- PAGE=? -->
Figure 21-4 Changes in cerebral blood flow (CBF) caused by independent alterations in PaCO2, PaO2, and mean arterial pressure (MAP).

<!-- PAGE=? -->
100

<!-- PAGE=? -->
75

<!-- PAGE=? -->
0

<!-- PAGE=? -->
50

<!-- PAGE=? -->
8

<!-- PAGE=? -->
25

<!-- PAGE=? -->
PaCO?

<!-- PAGE=? -->
MAP

<!-- PAGE=? -->
50

<!-- PAGE=? -->
100

<!-- PAGE=? -->
150

<!-- PAGE=? -->
200

<!-- PAGE=? -->
 Hypo/hyperthermia affects both CMR and CBF

<!-- PAGE=? -->
 CBF changes 5-7% per °C

<!-- PAGE=? -->
 At 20°C the EEG is isoelectric

<!-- PAGE=? -->
 >42°C  decreased O2 activity suggests cell damage

<!-- PAGE=? -->
 Body sites that reflect brain temperature include

<!-- PAGE=? -->
o Esophagus

<!-- PAGE=? -->
o Tympanic membrane

<!-- PAGE=? -->
o Pulmonary artery

<!-- PAGE=? -->
o Jugular bulb

<!-- PAGE=? -->
Figure 21-3 The effect of temperature reduction on the cerebral metabolic rate of oxygen (CMRO2). Hypothermia reduces both of the components of cerebral metabolic activity identified in Figure 21-1 : that associated with neuronal electrophysiologic activity ("Function") and that associated with maintenance of cellular homeostasis ("Integrity"). This effect is in contrast to anesthetics that alter only the functional component. The ratio of CMR at 37°C to that at 27°C, the Q10 ratio, is shown in the graph. EEG, electroencephalogram. (Adapted from Michenfelder JD: Anesthesia and the Brain: Clinical, Functional, Metabolic, and Vascular Correlates. New York, Churchill Livingstone, 1988.)

<!-- PAGE=? -->
6

<!-- PAGE=? -->
Function: 3.3 mL : 100

<!-- PAGE=? -->
min-1

<!-- PAGE=? -->
100

<!-- PAGE=? -->
min-1

<!-- PAGE=? -->
5

<!-- PAGE=? -->
!

<!-- PAGE=? -->
3

<!-- PAGE=? -->
2590

<!-- PAGE=? -->
Function; 1 4

<!-- PAGE=? -->
1690

<!-- PAGE=? -->
Integrity: 0.9

<!-- PAGE=? -->
2

<!-- PAGE=? -->
Function; 0

<!-- PAGE=? -->
Integrity: 0,4

<!-- PAGE=? -->
0

<!-- PAGE=? -->
40

<!-- PAGE=? -->
35

<!-- PAGE=? -->
30

<!-- PAGE=? -->
25

<!-- PAGE=? -->
20

<!-- PAGE=? -->
15

<!-- PAGE=? -->
Temperature ( C)

<!-- PAGE=? -->
9 !

<!-- PAGE=? -->
5

<!-- PAGE=? -->
8

<!-- PAGE=? -->
 Only very extreme changes in blood viscosity alter CBF

<!-- PAGE=? -->
 Intracranial blood vessels are heavily innervated

<!-- PAGE=? -->
 Sympathetic (vasoconstriction)

<!-- PAGE=? -->
 Parasympathetic (vasodilation)

<!-- PAGE=? -->
 Noncholinergic nonadrenergic fibers (Serotonin, Vasoactive intestinal peptide)

<!-- PAGE=? -->
o Normal physiologic function of this innervation is unclear

<!-- PAGE=? -->
o Likely and important factor in pathologic process such as vasospasm post brain injury

<!-- PAGE=? -->
 Blood brain Barrier

<!-- PAGE=? -->
o cerebral vascular endothelial cells have nearly fused junctions

<!-- PAGE=? -->
o results in a lipid barrier which restricts the movement of ionized and large MW particles

<!-- PAGE=? -->
o determinates of movement are

<!-- PAGE=? -->
 MW

<!-- PAGE=? -->
 Charge

<!-- PAGE=? -->
 Lipid solubility

<!-- PAGE=? -->
 Degree of protein binding

<!-- PAGE=? -->
o Water crosses freely

<!-- PAGE=? -->
o BBB may be disrupted by severe HTN, tumors, trauma, strokes, infections, marked hypercapnia, hypoxia, or sustained seizure activity

<!-- PAGE=? -->
 Under these conditions fluid movement becomes dependant on hydrostatic pressure rather than osmotic gradients

<!-- PAGE=? -->
 CSF

<!-- PAGE=? -->
o Major function is to protect brain from trauma

<!-- PAGE=? -->
o Formed in choroids plexuses in lateral ventricles

<!-- PAGE=? -->
 Active secretion of Na +

<!-- PAGE=? -->
 Limited protein and glucose concentrations

<!-- PAGE=? -->
 Carbonic anhydrase inhibitors, steroids, spironolactone, lasix, isoflurane, and vasoconstrictors ↓ CSF production

<!-- PAGE=? -->
o Total production in adults 21 ml/hr (500ml/day)

<!-- PAGE=? -->
o Total volume 150ml

<!-- PAGE=? -->
o Flow

<!-- PAGE=? -->
 Lateral ventricles

<!-- PAGE=? -->
 Foramen of Monroe

<!-- PAGE=? -->
 Third ventricle

<!-- PAGE=? -->
 Cerebral aqueduct

<!-- PAGE=? -->
 Fourth ventricle

<!-- PAGE=? -->
 Foramen of Magendie and luschka

<!-- PAGE=? -->
 Cerebellomedullary cistern

<!-- PAGE=? -->
 Subarachnoid  space

<!-- PAGE=? -->
o Absorbed in the arachnoid granulations over the cerebral cortex

<!-- PAGE=? -->
 Into the cerebral venous sinuses

<!-- PAGE=? -->
 Absorbsion is directly proportional to ICP and inversely proportional to cerebral venous sinus pressure

<!-- PAGE=? -->
 ICP - supratentorial pressure messured in the lateral ventricles - < 10 mmHg

<!-- PAGE=? -->
o Cranial vault has fixed total volume

<!-- PAGE=? -->
 80% brain, 12% blood, 8% CSF

<!-- PAGE=? -->
 Any ↑ in one component must be offset by an equivalent ↓ in an other component to prevent a rise in ICP

<!-- PAGE=? -->
o Intracranial compliance is determined by the change in ICP for a given change in intracranial volume

<!-- PAGE=? -->
o There is a point however where any change in volume results in precipitous rises in ICP

<!-- PAGE=? -->
 Major compensatory mechanisms

<!-- PAGE=? -->
 Displacement of CSF in to the spinal compartment

<!-- PAGE=? -->
 ↑ CSF absorption (driven by ↑ ICP)

<!-- PAGE=? -->
 ↓ CSF production

<!-- PAGE=? -->
 ↓ total cerebral blood volume (mainly venous)

<!-- PAGE=? -->
 Hypertension may ↓ cerebral blood volume 2° to autoregulated vasoconstriction

<!-- PAGE=? -->
 Hypotension may ↑ cerebral blood volume 2° to autoregulated vasodilation

<!-- PAGE=? -->
 Cerebral blood volume is estimated to ↑ 0.05ml/100g per 1 mmHg increase PaCO2

<!-- PAGE=? -->
 Sustained elevation of ICP can lead to catastrophic herniation of the brain

<!-- PAGE=? -->
 Cingulated gyrus under the falx cerebri

<!-- PAGE=? -->
 Uncinate gyrus through the tentorium cerebelli

<!-- PAGE=? -->
 Cerebellar tonsils through the foramen magnum

<!-- PAGE=? -->
 Any area of brain beneath a skull defect (transcalvarial)

<!-- PAGE=? -->
 Effect of anesthetic agents on cerebral physiology

<!-- PAGE=? -->
o Most general anesthetics reduce CBS electrical activity

<!-- PAGE=? -->
 Carbohydrate metabolism decreases

<!-- PAGE=? -->
 ↑ ATP storage

<!-- PAGE=? -->
o Determination of the effects of specific agents are complicated by:

<!-- PAGE=? -->
 Other drug administration

<!-- PAGE=? -->
 Surgical stimulation

<!-- PAGE=? -->
 Intracranial compliance

<!-- PAGE=? -->
 Blood pressure

<!-- PAGE=? -->
 CO2 tension

<!-- PAGE=? -->
o Volatile anesthetics (table 25-1)

<!-- PAGE=? -->
 Dose-dependant decreases in CMR, isoflurane and enflurane produce the greatest depression (up to 50% reduction)

<!-- PAGE=? -->
 Dilate cerebral vessels and impairs cerebral autoregulation in a dose-dependant manner

<!-- PAGE=? -->
Figure 21-5 Schematic representation of the effect of increasing concentrations of a typical volatile anesthetic on autoregulation of cerebral blood flow. Dose-dependent cerebral vasodilation results in attenuation of autoregulatory capacity. Both the upper and lower thresholds are shifted to the left. MAP, mean arterial pressure.

<!-- PAGE=? -->
1

<!-- PAGE=? -->
High dose

<!-- PAGE=? -->
Moderate dose

<!-- PAGE=? -->
Lose dose

<!-- PAGE=? -->
Awake

<!-- PAGE=? -->
50

<!-- PAGE=? -->
100

<!-- PAGE=? -->
150

<!-- PAGE=? -->
200

<!-- PAGE=? -->
MAP (mmHg)

<!-- PAGE=? -->
 This effect appears to be time-dependant

<!-- PAGE=? -->
 After 2-5 hrs CBF begins to return to normal

<!-- PAGE=? -->
 CBV increases 10-12%

<!-- PAGE=? -->
 Cerebral vasculature response to CO2 is generally intact

<!-- PAGE=? -->
 Hyperventilation can blunt the effect on CBF

<!-- PAGE=? -->
 Less effective with desflurane then other volatiles

<!-- PAGE=? -->
 Do not uncouple the normal CBF/CMR relationship

<!-- PAGE=? -->
 Circulatory steal phenomenon may occur in ischemic areas that are already maximally dilated

<!-- PAGE=? -->
o End result of general dilation in reduced blood flow to the ischemic area

<!-- PAGE=? -->
 Volatiles have various affects on CSF production and absorption

<!-- PAGE=? -->
 Isoflurane is the only volatile that has favorable effects on CSF dynamics as it facilitates absorption

<!-- PAGE=? -->
 The net effect on ICP is the result of changes in CBV, alterations in CSF dynamics, and PaCO2

<!-- PAGE=? -->
 It appears that isoflurane may be the volatile of choice for patients with decreased compliance

<!-- PAGE=? -->
 Animal studies suggest that desflurane may increase ICP more than other volatiles

<!-- PAGE=? -->
 Only Enflurane can cause seizure activity patterns on EEG

<!-- PAGE=? -->
 When combined with intravenous agents, N2O has minimal effect on CBF, CMR, and ICP

<!-- PAGE=? -->
 It may potentiate the deleterious of other volatiles

<!-- PAGE=? -->
o Induction agents

<!-- PAGE=? -->
 Induction agents either have no effect or reduce CMR and CBF (except ketamine)

<!-- PAGE=? -->
 Barbiturates

<!-- PAGE=? -->
 Hypnosis, dec. CMR, dec. CBF (2° to ↑ CVR), anticonvulsant effect

<!-- PAGE=? -->
 Dose-dependant dec. to maximum of 50% reduction

<!-- PAGE=? -->
 CMR depression is slightly more than CBF resulting in some luxury perfusion

<!-- PAGE=? -->
 Because the barbiturate dependant vasoconstriction only occurs in normal areas, blood may be redistributed to ischemic areas (reverse steal phenomenon)

<!-- PAGE=? -->
 Ischemic areas remain maximally dilated because of ischemic vasomotor paralysis

<!-- PAGE=? -->
 May ↑ CSF absorption - ↓ total CSF volume - reduced ICP

<!-- PAGE=? -->
 Other theoretical advantages exist

<!-- PAGE=? -->
Awake EEG

<!-- PAGE=? -->
Energy requirement tor

<!-- PAGE=? -->
electrophysiology activity

<!-- PAGE=? -->
8

<!-- PAGE=? -->
EEG suppresion

<!-- PAGE=? -->
Energy requirement tor cellular homeostasis

<!-- PAGE=? -->
Cumulative barbiturate dose

<!-- PAGE=? -->
Figure 21-1 The interdependency [21] of cerebral electrophysiologic function and cerebral metabolic rate (CMR). Administration of various anesthetics, [21][22][26] including barbiturates, results in a dose-related reduction in the cerebral metabolic rate of oxygen (CMRO2) and cerebral blood flow (CBF). The maximum reduction occurs with the dose that results in electrophysiologic silence. At this point, energy utilization associated with electrophysiologic activity has been reduced to zero, but energy utilization for cellular homeostasis persists unchanged. Additional barbiturate causes no further decrease in CBF or CMRO2. EEG, electroencephalogram.

<!-- PAGE=? -->
Propofol

<!-- PAGE=? -->
 ↓ CBF, CMR, and ICP

<!-- PAGE=? -->
 the ↓ in CBF however may exceed that of CMR

<!-- PAGE=? -->
 significant anticonvulsant activity

<!-- PAGE=? -->
 important to maintain CPP

<!-- PAGE=? -->
 Etomidate

<!-- PAGE=? -->
 ↓ CMR, CBF, and ICP similar to barbiturates

<!-- PAGE=? -->
 ↓ CSF production and ↑ absorption

<!-- PAGE=? -->
 The associated myoclonic movements are not associated with seizure activity

<!-- PAGE=? -->
 Opioids

<!-- PAGE=? -->
 Generally Opioids have minimal effect on CBF, CMR, or ICP unless PaCO2 is allowed to rise 2° to hypoventilation

<!-- PAGE=? -->
 ↑ ICP has been reported likely resulting from hypotension with rebound cerebral vasodilation and ↑ CBF

<!-- PAGE=? -->
 Benzodiazepines

<!-- PAGE=? -->
 ↓ CBF, and CMR to a less degree than barbiturates, Propofol, or Etomidate

<!-- PAGE=? -->
 Significant anticonvulsant activity

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 Only induction agents that dilates cerebral vasculature and ↑ CBF 50-60%

<!-- PAGE=? -->
 Total CMR doesn't change

<!-- PAGE=? -->
 May have some seizure activity

<!-- PAGE=? -->
 Impedes CSF absorption

<!-- PAGE=? -->
 ↑ CBF, and CSF results in ↑ ICP in patients with ↓ intracranial compliance

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 ↓ CMR, CBF, and ICP but to a lesser degree than other agents

<!-- PAGE=? -->
o Neuromuscular blockers

<!-- PAGE=? -->
 Lack direct action on the brain

<!-- PAGE=? -->
 Succinylcholine can ↑ ICP possibly 2° to cerebral activation associated with ↑ muscle spindle activity

<!-- PAGE=? -->
 The ↑ is generally minimal if adequate induction agent and hyperventilation is initiated

<!-- PAGE=? -->
 Moreover this effect is significantly ↓ with a defasciculating dose of nondepolerizing muscle relaxant is given

<!-- PAGE=? -->
 ↑ ICP management

<!-- PAGE=? -->
o Defined as ICP >15 mmHg

<!-- PAGE=? -->
o Specific treatment is directed at the underlying cause

<!-- PAGE=? -->
 Correct metabolic disturbances

<!-- PAGE=? -->
 OR for operative lesions

<!-- PAGE=? -->
 Corticosteroids for vasogenic edema 2° to  tumor

<!-- PAGE=? -->
o General treatment measures include

<!-- PAGE=? -->
 Fluid restriction

<!-- PAGE=? -->
 Maintain high normal serum Na + to limit cerebral edema

<!-- PAGE=? -->
 Osmotic agents (Mannitol 0.25-0.5 g/kg)

<!-- PAGE=? -->
 ↑ serum osmolality drawing free water from cerebral tissue

<!-- PAGE=? -->
 Generally avoided in patients with aneurysms AVMs or hemorrhage until after the cranium is opened due to risk of expanding the hematoma 2° to ↓ normal brain volume

<!-- PAGE=? -->
 Loop diuretics

<!-- PAGE=? -->
 Removal of intracellular water from normal brain tissue

<!-- PAGE=? -->
 May also ↓ CSF formation

<!-- PAGE=? -->
 Moderate hyperventilation (PaCO2 30-35 mmHg)

<!-- PAGE=? -->
 ↓ CBF

<!-- PAGE=? -->
 Sedation and paralysis

<!-- PAGE=? -->
 ↓ CMR, and CBF as described above

<!-- PAGE=? -->
Neurotransmitters

<!-- PAGE=? -->
 Glutamate is the major excitatory amino acid neurotransmitter in the CNS

<!-- PAGE=? -->
 Epinephrine-containing neurons are present in the reticular activating system, where its presumed effect is that of an inhibitory neurotransmitter.

<!-- PAGE=? -->
 Glycine is the principal inhibitory neurotransmitter in the spinal cord, acting to increase chloride ion conductance.

<!-- PAGE=? -->
 GABA is the major inhibitory neurotransmitter in the CNS , being present in diverse areas including the cerebral cortex, basal ganglia, cerebellum, and spinal cord.

<!-- PAGE=? -->
NMS

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 a rare, potentially fatal complication of antipsychotic drug therapy that is presumed to reflect dopamine depletion in the central nervous system

<!-- PAGE=? -->
 three key clinical components

<!-- PAGE=? -->
o Impairment in motor function

<!-- PAGE=? -->
o Deterioration in mental status

<!-- PAGE=? -->
o Hyperpyrexia with autonomic instability

<!-- PAGE=? -->
 Duration averages 7 to 10 days, with gradual recovery that parallels the slow metabolism of the triggering drugs.

<!-- PAGE=? -->
 d/t dopamine blockade in hypothalamus and basal ganglia

<!-- PAGE=? -->
 Mortality rate may be as high as 20%

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
o Motor rigidity

<!-- PAGE=? -->
 Akinesia

<!-- PAGE=? -->
 Bradykinesia

<!-- PAGE=? -->
 Dystonia

<!-- PAGE=? -->
 Mutism

<!-- PAGE=? -->
 Dysarthria

<!-- PAGE=? -->
 involuntary movements

<!-- PAGE=? -->
o extrapyrimadal symptoms

<!-- PAGE=? -->
o Autonomic dysfunction

<!-- PAGE=? -->
 Tachycardia

<!-- PAGE=? -->
 respiratory irregularities

<!-- PAGE=? -->
 cardiac arrhythmias

<!-- PAGE=? -->
 alterations in blood pressure

<!-- PAGE=? -->
o Hyperthermia

<!-- PAGE=? -->
 Diaphoresis

<!-- PAGE=? -->
 dehydration

<!-- PAGE=? -->
o Mental status changes

<!-- PAGE=? -->
 Confusion

<!-- PAGE=? -->
 Delirium

<!-- PAGE=? -->
 Stupor

<!-- PAGE=? -->
o Metabolic

<!-- PAGE=? -->
 Acidosis

<!-- PAGE=? -->
 rhabdomyolysis

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Dantrolene is an effective therapeutic modality in many cases

<!-- PAGE=? -->
Table 4 Levenson' $ clinical criteria for diagnosis of NMS [45]

<!-- PAGE=? -->
All three major, or two major and four minor; criteria suggest a high probability of NMS. if supported hy clinical history (eg, not indicativc of MH)

<!-- PAGE=? -->
Nitric Oxide

<!-- PAGE=? -->
 Chemical messenger in a multitude of biological systems

<!-- PAGE=? -->
 Administered by inhalation to produce selective relaxation of the pulmonary vasculature

<!-- PAGE=? -->
o Synthesis and Transport

<!-- PAGE=? -->
 Synthesized in endothelial cells from L-arginine by a family of enzymes known as NO synthases

<!-- PAGE=? -->
 As a gas, diffuses from producing cells into target cells, activates guanylate cyclase to increase cGMP, which causes vasodilation

<!-- PAGE=? -->
 Neurotransmission is NMDA mediated

<!-- PAGE=? -->
 Half-life of < 5 seconds

<!-- PAGE=? -->
 Binds to and is inactivated by Hb

<!-- PAGE=? -->
o Physiological effects

<!-- PAGE=? -->
 CVS

<!-- PAGE=? -->
 Regulates SVR and PVR under baseline conditions

<!-- PAGE=? -->
 Major factor in autoregulation - cells increase production in response to decreased oxygenation

<!-- PAGE=? -->
 Negative inotropic and chronotropic effects

<!-- PAGE=? -->
 Arteries produce more than veins

<!-- PAGE=? -->
 Inhaled NO decreases PVR in the presence of pulmonary vasoconstriction only

<!-- PAGE=? -->
 Resp

<!-- PAGE=? -->
 Bronchodilation

<!-- PAGE=? -->
 Mediator of ventilation-to-perfusion matching

<!-- PAGE=? -->
 Platelets

<!-- PAGE=? -->
 Inhibits activation, aggregation, and adhesion

<!-- PAGE=? -->
 CNS

<!-- PAGE=? -->
 Neurotransmitter

<!-- PAGE=? -->
 Released in response to stim of excitatory NMDA receptor

<!-- PAGE=? -->
o Possibly antinociceptive

<!-- PAGE=? -->
 Immune

<!-- PAGE=? -->
 Modulates inflammation and host defenses, and macrophage killing of pathogens

<!-- PAGE=? -->
 proinflammatory

<!-- PAGE=? -->
o Pathophysiology

<!-- PAGE=? -->
 Essential HTN - may reflect decrease NO release

<!-- PAGE=? -->
 Septic Shock - may reflect excess NO release

<!-- PAGE=? -->
 NO synthetase inhibitors have been tried and had no impact on survival

<!-- PAGE=? -->
 Vasospasm in SAH - may be due to NO inactivation by Hb

<!-- PAGE=? -->
 Cirrhosis - hyperdynamic state may reflect induction of NO sythase

<!-- PAGE=? -->
 Immune - absence may predispose to infection, excess may be a mechanism of inflammation

<!-- PAGE=? -->
o Clinical Uses

<!-- PAGE=? -->
 Selective pulmonary vasodilation because inhaled NO is rapidly inactivated by Hb once it enters bloodstream

<!-- PAGE=? -->
 Decreases need for ECMO but not mortality in persistent pHTN of the newborn

<!-- PAGE=? -->
 Decreases chronic lung disease and death in RDS

<!-- PAGE=? -->
 Not recommended as standard care for ARDS

<!-- PAGE=? -->
 Useful for -salvage‖ therapy of severe ARDS/hypoxemia

<!-- PAGE=? -->
 Increases blood flow to ventilated areas

<!-- PAGE=? -->
o Toxicity

<!-- PAGE=? -->
 Increases methemoglobin levels

<!-- PAGE=? -->
 Wean slowly because of potential rebound

<!-- PAGE=? -->
 NO is oxidized to nitrogen dioxide (NO2) in presence of high FiO2.  NO2 is a known pulmonary toxin, therefore monitor concentrations of NO2

<!-- PAGE=? -->
 Upper limit for NO2 is 5ppm

<!-- PAGE=? -->
Nitrous Oxide

<!-- PAGE=? -->
P&P, Miller, Barash

<!-- PAGE=? -->
 odourless to sweet smelling

<!-- PAGE=? -->
 nonflammable gas that supports combustion

<!-- PAGE=? -->
 low potency as an inhaled anesthetic

<!-- PAGE=? -->
 low blood solubility = rapid achievement of alveolar and brain partial pressure

<!-- PAGE=? -->
 prominent analgesic effects

<!-- PAGE=? -->
 minimal muscle relaxation

<!-- PAGE=? -->
 meta-analysis suggests increase in PONV

<!-- PAGE=? -->
 for OR staff:

<!-- PAGE=? -->
o mental impairment at 0.16%

<!-- PAGE=? -->
o decreased reaction times at 10%

<!-- PAGE=? -->
 Controversy surrounds nitrous oxide in four areas:

<!-- PAGE=? -->
o PONV

<!-- PAGE=? -->
o Potential toxic effects on cell function via inactivation of vitamin B12

<!-- PAGE=? -->
o Adverse effects related to absorption and expansion into air filled structures and bubbles

<!-- PAGE=? -->
o Effect on embryonic development

<!-- PAGE=? -->
 Effects

<!-- PAGE=? -->
o CNS:

<!-- PAGE=? -->
 may increase motor activity with clonus and opisthotonus and at high concentrations in the hyperbaric chamber

<!-- PAGE=? -->
 abdominal muscle rigidity, catatonic movements

<!-- PAGE=? -->
 case report of tonic-clonic movements in a child

<!-- PAGE=? -->
 increases CBF but at < 1 MAC the magnitude of the change is small

<!-- PAGE=? -->
 dec. CMRO2

<!-- PAGE=? -->
o CVS:

<!-- PAGE=? -->
 either no change or modest increases in SBP

<!-- PAGE=? -->
 depresses carotid sinus but quantifying the effect is difficult

<!-- PAGE=? -->
 direct negative inotropic effect

<!-- PAGE=? -->
 more pronounced with preexisting LV dysfunction

<!-- PAGE=? -->
 Does not substantially modify myocardial relaxation

<!-- PAGE=? -->
 May dec. LV compliance

<!-- PAGE=? -->
 mild sympathomimetic effects - inhibited by opioids

<!-- PAGE=? -->
 inc. plasma catecholamines

<!-- PAGE=? -->
 inc. body temp

<!-- PAGE=? -->
 mydriasis

<!-- PAGE=? -->
 diaphoresis

<!-- PAGE=? -->
 increased RA pressure and increased PVR

<!-- PAGE=? -->
 mild inc. SVR

<!-- PAGE=? -->
 may cause reversible A-V dissociation

<!-- PAGE=? -->
 no direct effects on coronary vessels in vitro

<!-- PAGE=? -->
 decreases recovery of contractile function in stunned myocardium

<!-- PAGE=? -->
 may cause imbalances in myocardial O2 supply and MVO2

<!-- PAGE=? -->
 Toxicity

<!-- PAGE=? -->
o reported to produce hematologic toxicity and neurotoxicity with long-term administration

<!-- PAGE=? -->
o both toxicities result from interaction with Vitamin B12

<!-- PAGE=? -->
o Hematologic

<!-- PAGE=? -->
 mild megaloblastic bone marrow changes are not seen after 6 hours, but are seen after about 12 hours of exposure to 50% N2O, after 24 hours, changes are marked

<!-- PAGE=? -->
 Complete bone marrow failure can be expected after several days of continuous exposure

<!-- PAGE=? -->
 Evidence also suggests that bone marrow changes are preventable by pretreating patients with large doses of folinic acid

<!-- PAGE=? -->
o Neurologic

<!-- PAGE=? -->
 subacute combined degeneration of spinal cord, only develops after several months of daily exposure

<!-- PAGE=? -->
 S/Sx include

<!-- PAGE=? -->
 numbness and paresthesia in extremities

<!-- PAGE=? -->
 loss of balance and unsteady gait

<!-- PAGE=? -->
 impairment of touch

<!-- PAGE=? -->
 muscle weakness

<!-- PAGE=? -->
 treatment with B12 did not alleviate the symptoms or enhance recovery

<!-- PAGE=? -->
o NIOSH recommendations limitation of exposure to Time weighted 8 hours of 25 ppm.

<!-- PAGE=? -->
NMB (neuromuscular blockers)

<!-- PAGE=? -->
 Reduced twitch response requires more than 70% of the receptors to be occupied by a nondepolarizing neuromuscular blocker

<!-- PAGE=? -->
 Twitch is completely eliminated when 90% of the receptors are occupied

<!-- PAGE=? -->
 -o‖ = steroid = pancuronium, vecuronium, rocuronium

<!-- PAGE=? -->
 NO -o‖ benzylisoquinolone = mivacurium

<!-- PAGE=? -->
 Laudanosine, a tertiary amine, is a breakdown product of atracurium & cisatracurium's Hofmann elimination

<!-- PAGE=? -->
 associated with central nervous system excitation, and seizures

<!-- PAGE=? -->
 likely only relevant in extremely high total dose or hepatic failure

<!-- PAGE=? -->
 Laudanosine is metabolized by the liver and excreted in urine and bile

<!-- PAGE=? -->
TABLE 8-2.

<!-- PAGE=? -->
Comparative pharmacology of nondepolarizing neuromuscular-blocking drugs

<!-- PAGE=? -->
Supplemental doses (mg/kg)

<!-- PAGE=? -->
ED95 (mg/kg)

<!-- PAGE=? -->
Onset to maximum

<!-- PAGE=? -->
twitch depression

<!-- PAGE=? -->
(mins)

<!-- PAGE=? -->
Duration to return to

<!-- PAGE=? -->
25%control twitch

<!-- PAGE=? -->
height (mins)

<!-- PAGE=? -->
Intubating dose

<!-- PAGE=? -->
(mg/kg)

<!-- PAGE=? -->
N2O

<!-- PAGE=? -->
Volatile

<!-- PAGE=? -->
Pancuronium

<!-- PAGE=? -->
0.07

<!-- PAGE=? -->
3

<!-- PAGE=? -->
-

<!-- PAGE=? -->
5

<!-- PAGE=? -->
60

<!-- PAGE=? -->
-

<!-- PAGE=? -->
90

<!-- PAGE=? -->
0.1

<!-- PAGE=? -->
0.015

<!-- PAGE=? -->
0.007

<!-- PAGE=? -->
Doxacurium

<!-- PAGE=? -->
0.03

<!-- PAGE=? -->
4

<!-- PAGE=? -->
-

<!-- PAGE=? -->
6

<!-- PAGE=? -->
60

<!-- PAGE=? -->
-

<!-- PAGE=? -->
90

<!-- PAGE=? -->
0.05

<!-- PAGE=? -->
-

<!-- PAGE=? -->
0.08;

<!-- PAGE=? -->
Pipecuronium

<!-- PAGE=? -->
0.05

<!-- PAGE=? -->
-

<!-- PAGE=? -->
0.06

<!-- PAGE=? -->
3

<!-- PAGE=? -->
-

<!-- PAGE=? -->
5

<!-- PAGE=? -->
60

<!-- PAGE=? -->
-

<!-- PAGE=? -->
90

<!-- PAGE=? -->
0.14

<!-- PAGE=? -->
Atracurium

<!-- PAGE=? -->
0.2

<!-- PAGE=? -->
3

<!-- PAGE=? -->
-

<!-- PAGE=? -->
5

<!-- PAGE=? -->
20

<!-- PAGE=? -->
-

<!-- PAGE=? -->
35

<!-- PAGE=? -->
0.4

<!-- PAGE=? -->
-

<!-- PAGE=? -->
0.5

<!-- PAGE=? -->
0.1

<!-- PAGE=? -->
0.07

<!-- PAGE=? -->
Vecuronium

<!-- PAGE=? -->
0.05

<!-- PAGE=? -->
3

<!-- PAGE=? -->
-

<!-- PAGE=? -->
5

<!-- PAGE=? -->
20

<!-- PAGE=? -->
-

<!-- PAGE=? -->
35

<!-- PAGE=? -->
0.08

<!-- PAGE=? -->
-

<!-- PAGE=? -->
0.1

<!-- PAGE=? -->
0.02

<!-- PAGE=? -->
0.015

<!-- PAGE=? -->
Rocuronium

<!-- PAGE=? -->
0.3

<!-- PAGE=? -->
1

<!-- PAGE=? -->
-

<!-- PAGE=? -->
2

<!-- PAGE=? -->
20

<!-- PAGE=? -->
-

<!-- PAGE=? -->
35

<!-- PAGE=? -->
0.6

<!-- PAGE=? -->
-

<!-- PAGE=? -->
1.2

<!-- PAGE=? -->
Cisatracurium

<!-- PAGE=? -->
0.05

<!-- PAGE=? -->
3

<!-- PAGE=? -->
-

<!-- PAGE=? -->
5

<!-- PAGE=? -->
20

<!-- PAGE=? -->
-

<!-- PAGE=? -->
35

<!-- PAGE=? -->
0.1

<!-- PAGE=? -->
NMB Autonomic Effects

<!-- PAGE=? -->
NMB anaphylaxis

<!-- PAGE=? -->
 muscle relaxants account for 69.2% of anaphylactic reactions during an anesthetic

<!-- PAGE=? -->
 IgE antibodies to the two quaternary or tertiary ammonium ions mediate anaphylaxis.

<!-- PAGE=? -->
o Succinylcholine is more likely to cause anaphylaxis than nondepolarizing muscle relaxants

<!-- PAGE=? -->
o Succinylcholine contains a flexible molecule that can crosslink two mast cell IgE receptors and, thus, induce mast cell degranulation

<!-- PAGE=? -->
 NdMB have a rigid backbone between their two ammonium ions (e.g., pancuronium or vecuronium)

<!-- PAGE=? -->
o benzylisoquinolinium > aminosteroid

<!-- PAGE=? -->
 OTC drugs, cosmetics, and food products contain quaternary or tertiary ammonium ions that could sensitize people

<!-- PAGE=? -->
 anaphylaxis may develop on the first exposure to a muscle relaxant in a sensitized patient.

<!-- PAGE=? -->
 Crosssensitivity between muscle relaxants occurs in up to 60% of patients

<!-- PAGE=? -->
 Neostigmine and morphine also contain ammonium ions that may cross-react with muscle relaxants

<!-- PAGE=? -->
NdMB- Drugs that affect duration

<!-- PAGE=? -->
 Potentiate (lengthen)

<!-- PAGE=? -->
o Volatiles

<!-- PAGE=? -->
 desflurane > sevoflurane > isoflurane > halothane > nitrous oxide-barbiturate-opioid or propofol anesthesia

<!-- PAGE=? -->
 Mechanisms

<!-- PAGE=? -->
 inhibit current through the postsynaptic nicotinic receptor at the NMJ

<!-- PAGE=? -->
 central effect on α-motor neurons and interneuron synapses

<!-- PAGE=? -->
 augmentation of the antagonist affinity at the receptor site

<!-- PAGE=? -->
o Antibiotics

<!-- PAGE=? -->
 aminoglycosides (neomycin, streptomycin, gentamycin), clindamycin, lincomycins

<!-- PAGE=? -->
 inhibit the prejunctional release of acetylcholine and also depress postjunctional nAChR sensitivity to acetylcholine

<!-- PAGE=? -->
 tetracyclins - ?less likely

<!-- PAGE=? -->
 only post junctional effect

<!-- PAGE=? -->
o Local anesthetics

<!-- PAGE=? -->
o Lasix

<!-- PAGE=? -->
o Antiarrhytmics (quinidine, CCB)

<!-- PAGE=? -->
o Magnesium

<!-- PAGE=? -->
o Dantrolene

<!-- PAGE=? -->
o Cyclosporine

<!-- PAGE=? -->
o Lithium

<!-- PAGE=? -->
 via potassium channels, inhibits neuromuscular transmission presynaptically and muscular contraction postsynaptically

<!-- PAGE=? -->
o Hypokalemia- An acute decrease in the extracellular concentration of potassium increases the transmembrane potential, causing hyperpolarization of cell membranes

<!-- PAGE=? -->
 resistance to the effects of depolarizing neuromuscular-blocking drugs and increased sensitivity to nondepolarizing neuromuscular-blocking drugs

<!-- PAGE=? -->
o tamoxifen

<!-- PAGE=? -->
o hypothermia

<!-- PAGE=? -->
o nondepolarizer after succinylcholine

<!-- PAGE=? -->
 Attenuate (decrease)

<!-- PAGE=? -->
o Anticonvulsants (phenytoin, carbamzapine - hepatic inducers)

<!-- PAGE=? -->
o Azathioprine

<!-- PAGE=? -->
o Hyperkalemia (opposite to hypoK)

<!-- PAGE=? -->
o Hypercalcemia - triggers acetylcholine release from the motor nerve terminal and enhances excitation-contraction coupling in muscle

<!-- PAGE=? -->
o Post burns

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
stoelting ch . 28

<!-- PAGE=? -->
 penicillins, cephalosporins, tetracyclines, and erythromycin are devoid of effects at the neuromuscular junction

<!-- PAGE=? -->
Succinylcholine

<!-- PAGE=? -->
 Potentiate (lengthen)

<!-- PAGE=? -->
Anticholinesterases, cyclophosphamide - inc. pseudocholenesterase (not edrophonium)

<!-- PAGE=? -->
Mg-controversial

<!-- PAGE=? -->
Lithium

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
Quinine

<!-- PAGE=? -->
 ?CCB

<!-- PAGE=? -->
lasix

<!-- PAGE=? -->
Preg, neonates, elderly  dec pseudochol

<!-- PAGE=? -->
 Attenuate (decrease)

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Obese, children

<!-- PAGE=? -->
Pre-treatment with NdMB

<!-- PAGE=? -->
 dose of sux must be increased after the administration of a defasciculating dose of a NdMB

<!-- PAGE=? -->
Table 9-4. Potentiation (+) and resistance (-) of neuromuscular blocking agents by other drugs.

<!-- PAGE=? -->
 Fasciculations

<!-- PAGE=? -->
Miller, Barash, P&P

<!-- PAGE=? -->
o Prevention

<!-- PAGE=? -->
 Small dose of NdMB

<!-- PAGE=? -->
 0.03mg/kg Rocuronium (1/10 th ED95)

<!-- PAGE=? -->
 0.02mg/kg atracurioum

<!-- PAGE=? -->
 Others are not effective

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 Diazepam

<!-- PAGE=? -->
 Fentanyl

<!-- PAGE=? -->
 Calcium

<!-- PAGE=? -->
 vitamin C

<!-- PAGE=? -->
 magnesium

<!-- PAGE=? -->
 dantrolene

<!-- PAGE=? -->
 Myalgias

<!-- PAGE=? -->
Miller, Barash, P&P

<!-- PAGE=? -->
o Risk Factors

<!-- PAGE=? -->
 Young age

<!-- PAGE=? -->
 ambulatory patients

<!-- PAGE=? -->
 minor surgery

<!-- PAGE=? -->
 women

<!-- PAGE=? -->
o not always correlated with intensity of fasciculations

<!-- PAGE=? -->
o strategies to prevent fasciculations generally lead to decreased myalgia

<!-- PAGE=? -->
 pretreatment with prostaglandin inhibitor (lysine acetylsalicylate)

<!-- PAGE=? -->
 lidocaine 1-1.5 mg/kg in conjunction with precurarization is of value

<!-- PAGE=? -->
 calcium, magnesium, vitamin C, benzos and dantrolene show inconclusive results

<!-- PAGE=? -->
 steroids are NOT protective

<!-- PAGE=? -->
Succinylcholine induced inc. ICP

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 there is a poor correlation between the occurrence of visible muscle fasciciulations and an increase in ICP

<!-- PAGE=? -->
 The inc. in ICP canbe blocked with a full, paralyzing dose of vecuronium or a pretreatment (defasiculating) dose of metocurine

<!-- PAGE=? -->
 The inc. ICP effect appears to result from cerebral activation

<!-- PAGE=? -->
o EEG changes and CBF increases

<!-- PAGE=? -->
o caused by afferent activity from the muscle spindle apparatus

<!-- PAGE=? -->
 deep anesthesia has been shown to prevent raised ICP in dogs, but not humans.

<!-- PAGE=? -->
Succinylcholine induced hyperkalemia

<!-- PAGE=? -->
 Burn injury

<!-- PAGE=? -->
o ~ 10% burn required

<!-- PAGE=? -->
o Onset 24-48 hrs post burn

<!-- PAGE=? -->
o Duration of sensitivity is 1 - 2 yrs

<!-- PAGE=? -->
 Massive trauma

<!-- PAGE=? -->
 Severe intra-abdominal infection

<!-- PAGE=? -->
 Hemorrhagic shock with metabolic acidosis

<!-- PAGE=? -->
 Near drowning

<!-- PAGE=? -->
 Prolonged total body immobilization

<!-- PAGE=? -->
 Closed head injury

<!-- PAGE=? -->
 Spinal cord injury

<!-- PAGE=? -->
 Encephalitis

<!-- PAGE=? -->
 Stroke - with hemiplegia

<!-- PAGE=? -->
 Ruptured cerebral aneurysm

<!-- PAGE=? -->
 Guillain-Barre syndrome

<!-- PAGE=? -->
 Tetanus

<!-- PAGE=? -->
 Severe parkinson's disease

<!-- PAGE=? -->
 Polyneuropathy

<!-- PAGE=? -->
 Myopathies (eg. Duchenne's dystrophy)

<!-- PAGE=? -->
 Myotonic dystrophy

<!-- PAGE=? -->
 Upper motor Neuron Lesions

<!-- PAGE=? -->
o ALS

<!-- PAGE=? -->
o MS - if symptomatic

<!-- PAGE=? -->
 No contraindication in

<!-- PAGE=? -->
o Parkinson's

<!-- PAGE=? -->
o cerebral palsy

<!-- PAGE=? -->
o myelomeningocele

<!-- PAGE=? -->
o cerebral aneurysm surgery

<!-- PAGE=? -->
Diseases That Alter the Response to Muscle Relaxants

<!-- PAGE=? -->
Myasthenia gravis

<!-- PAGE=? -->
 usually resistant to SCh

<!-- PAGE=? -->
 highly sensitive to nondepolarizing muscle relaxants

<!-- PAGE=? -->
Myasthenic syndrome

<!-- PAGE=? -->
 Sensitive to both SCh and NdMB

<!-- PAGE=? -->
Myotonia

<!-- PAGE=? -->
 sustained contracture in response to SCh

<!-- PAGE=? -->
 normal response to nondepolarizing muscle relaxants

<!-- PAGE=? -->
Muscular dystrophy

<!-- PAGE=? -->
 SCh contraindicated

<!-- PAGE=? -->
Neurologic diseases

<!-- PAGE=? -->
 isolated reports of hyperkalemia in response to SCh Hemiplegia/paraplegia

<!-- PAGE=? -->
 hyperkalemia in response to SCh

<!-- PAGE=? -->
 resistant to nondepolarizing muscle relaxants

<!-- PAGE=? -->
Burn injury

<!-- PAGE=? -->
 hyperkalemia in response to SCh

<!-- PAGE=? -->
 resistant to nondepolarizing muscle relaxants

<!-- PAGE=? -->
NMB Evaluation and Monitoring

<!-- PAGE=? -->
Train of four

<!-- PAGE=? -->
 four supramaximal stimuli are given every 0.5 seconds (2 Hz). When used continuously

<!-- PAGE=? -->
 dividing the amplitude of the fourth response by the amplitude of the first response provides the TOF ratio

<!-- PAGE=? -->
o with no blockade - all four twitches are the same: TOF ratio is 1.0

<!-- PAGE=? -->
o partial nondepolarizing block, the ratio decreases  - fade

<!-- PAGE=? -->
 fade is inversely proportional to the degree of blockade

<!-- PAGE=? -->
 Fade in the TOF response after injection of succinylcholine signifies the development of a phase II block

<!-- PAGE=? -->
 the degree of block from NdMB can be read directly from the TOF response

<!-- PAGE=? -->
 70-75% of receptors may be still blocked despite a ratio of 1.0

<!-- PAGE=? -->
Double Burst

<!-- PAGE=? -->
 DBS consists of two short bursts (0.2 msec) of 50-Hz tetanic stimulation separated by 750 msec

<!-- PAGE=? -->
 In nonparalyzed muscle, the response to DBS is two short muscle contractions of equal strength

<!-- PAGE=? -->
 In the partly paralyzed muscle, the second response is weaker than the first (i.e., the response fades) o the TOF ratio correlates closely with the DBS3,3 ratio

<!-- PAGE=? -->
 DBS was developed with the specific aim of allowing manual (tactile) detection of small amounts of residual blockade under clinical conditions

<!-- PAGE=? -->
o DBS 3,3 is superior to tactile evaluation of the response to TOF stimulation

<!-- PAGE=? -->
Post tetanic count (PCT)

<!-- PAGE=? -->
 Injewith intense neuromuscular blockade - no response to TOF and single-twitch stimulation occurs

<!-- PAGE=? -->
 It is possible, to quantify intense neuromuscular blockade by applying tetanic stimulation (50 Hz for 5 seconds) and observing the post-tetanic response to single-twitch stimulation given at 1 Hz starting 3 seconds after the end of tetanic stimulation

<!-- PAGE=? -->
 During very intense blockade, there is no response to either tetanic or post-tetanic stimulation

<!-- PAGE=? -->
 However, before the first response to TOF stimulation reappears, the first response to post-tetanic twitch stimulation occur

<!-- PAGE=? -->
o As the intense block dissipates, more and more responses to post-tetanic twitch stimulation appear

<!-- PAGE=? -->
 THE MAIN APPLICATION OF THE PTC METHOD IS IN EVALUATING THE DEGREE OF NEUROMUSCULAR BLOCKADE WHEN THERE IS NO REACTION TO SINGLE TWITCH OR TOF NERVE STIMULATION, AS MAY BE THE CASE AFTER INJECTION OF A LARGE DOSE OF A NONDEPOLARIZING NEUROMUSCULAR BLOCKING DRUG .

<!-- PAGE=? -->
 To ensure elimination of any bucking or coughing in response to tracheobronchial stimulation, neuromuscular blockade of the peripheral muscles must be so intense that no response to post-tetanic twitch stimulation can be elicited (PTC-0)

<!-- PAGE=? -->
 The response to PTC stimulation depends on

<!-- PAGE=? -->
o degree of neuromuscular blockade (Primarily)

<!-- PAGE=? -->
o frequency and duration of tetanic stimulation

<!-- PAGE=? -->
o length of time between the end of tetanic stimulation and the first post-tetanic stimulus

<!-- PAGE=? -->
o the frequency of the single-twitch stimulation

<!-- PAGE=? -->
o the length of single-twitch stimulation before tetanic stimulation

<!-- PAGE=? -->
 When the PTC method is used, these variables should therefore be kept constant

<!-- PAGE=? -->
 because of possible antagonism of neuromuscular blockade in the hand, tetanic stimulation should not be given more often than every 6 minutes If the hand muscles undergo antagonism of neuromuscular blockade while the rest of the body is still paralyzed, the hand muscles are no longer useful for monitoring

<!-- PAGE=? -->
Tetanic stimulation

<!-- PAGE=? -->
 Tetanic stimulation consists of very rapid (e.g., 30-, 50-, or 100-Hz) delivery of electrical stimuli

<!-- PAGE=? -->
 During normal neuromuscular transmission and a pure depolarizing block, the muscle response to 50-Hz tetanic stimulation for 5 seconds is sustained

<!-- PAGE=? -->
 During a nondepolarizing block and a phase II block after injection of succinylcholine, the response will not be sustained (i.e., fade occurs)

<!-- PAGE=? -->
o Fade is normally considered a presynaptic event

<!-- PAGE=? -->
o Physiology

<!-- PAGE=? -->
 At the start of tetanic stimulation, large amounts of acetylcholine are released from immediately available stores in the nerve terminal. As these stores become depleted, the rate of acetylcholine release decreases until equilibrium between mobilization and synthesis of acetylcholine is achieved. Despite this equilibrium, the muscle response caused by tetanic stimulation of the nerve is maintained because the release of acetylcholine is many times greater than the amount necessary to evoke a response. When the "margin of safety" of the postsynaptic membrane (i.e., the number of free cholinergic receptors) is reduced by a nondepolarizing neuromuscular blocking agent, the decrease in release of acetylcholine during tetanic stimulation produces fade

<!-- PAGE=? -->
 The degree of fade depends primarily on

<!-- PAGE=? -->
o the degree of neuromuscular blockade

<!-- PAGE=? -->
o frequency (Hz)

<!-- PAGE=? -->
o length (seconds) of stimulation

<!-- PAGE=? -->
o how often tetanic stimuli are applied

<!-- PAGE=? -->
 During partial nondepolarizing blockade, tetanic nerve stimulation is followed by a post-tetanic increase in twitch tension - post-tetanic facilitation [PTF] of transmission

<!-- PAGE=? -->
o occurs because the increase in mobilization and synthesis of acetylcholine caused by tetanic stimulation continues for some time after discontinuation of stimulation

<!-- PAGE=? -->
o the degree and duration of PTF depend on the degree of neuromuscular blockade

<!-- PAGE=? -->
o PTF usually disappearing within 60 seconds of tetanic stimulation

<!-- PAGE=? -->
 Disadvantages

<!-- PAGE=? -->
o painful

<!-- PAGE=? -->
o late phase of neuromuscular recovery, tetanic stimulations may produce a lasting antagonism of neuromuscular blockade in the stimulated muscle, such that the response of the tested site may no longer be representative of other muscle groups

<!-- PAGE=? -->
NMB antagonists inhibition

<!-- PAGE=? -->
Stoelting PnP

<!-- PAGE=? -->
 Antagonism of neuromuscular blockade by anticholinesterase drugs may be inhibited

<!-- PAGE=? -->
1 Volatile anesthetic

<!-- PAGE=? -->
2 certain antibiotics

<!-- PAGE=? -->
3 hypothermia

<!-- PAGE=? -->
o mild hypothermia had no effect (P&P 260)

<!-- PAGE=? -->
4 respiratory acidosis associated with a PaCO2 of >50 mm Hg

<!-- PAGE=? -->
5 hypokalemia

<!-- PAGE=? -->
6 metabolic alkalosis

<!-- PAGE=? -->
 Reversal of phase II block associated with prolonged or repeated use of succinylcholine can be reversed with neostigmine or edrophonium

<!-- PAGE=? -->
 Reversal of phase II block that occurs in patients with atypical plasma cholinesterase with an anticholinesterase drug may not be reliable

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Metabolic alkalosis -prevents antagonism

<!-- PAGE=? -->
 Respiratory acidosis and met acidosis-augment NMB, but only resp acidosis prevents adequate antagonism

<!-- PAGE=? -->
 Hypokalemia-resistance to antagonism (and potentiates NMB)

<!-- PAGE=? -->
 CCB-make it difficult to achieve adequate revesral with verapamil edrophonium may be better

<!-- PAGE=? -->
 Hypothermia-

<!-- PAGE=? -->
 Efficacy of neostigmine as an antagonist of vecuronium-induced neuromuscular blockade, is not altered by mild hypothermia, although onset time is 20% longer.

<!-- PAGE=? -->
 Antibiotics-aminoglycocides, tetracycline (may deepen block with reversal)

<!-- PAGE=? -->
Special groups:

<!-- PAGE=? -->
Peds

<!-- PAGE=? -->
 more sensitive to effects but bigger Vd so no loading/ initial dose change

<!-- PAGE=? -->
 faster onset than in adults

<!-- PAGE=? -->
 only use sux in emergencies (undiagnosed myopathies)

<!-- PAGE=? -->
 vecuronium acts like a long-acting drug in neonates

<!-- PAGE=? -->
Elderly

<!-- PAGE=? -->
 no change in the sensitivity of the receptor to NMBs with age

<!-- PAGE=? -->
 prolonged duration due to decreased splanchnic and renal blood flow, decreased GFR, decreased hepatic function (increase dosing interval)

<!-- PAGE=? -->
Obese

<!-- PAGE=? -->
 recover more slowly from dox, vec and roc

<!-- PAGE=? -->
 dose at LBW + 20%

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
 no change in sensitivity except resistance to metocurine occurs

<!-- PAGE=? -->
 panc, dTc, dos, pip are eliminated mostly by kidney (prolonged)

<!-- PAGE=? -->
 repeat doses of atracurium may result in build up of laudanosine

<!-- PAGE=? -->
 vec proloned even tho mostly hepatic metabolism because of active metabolite (80% activity)

<!-- PAGE=? -->
 Roc isn't significantly affected according to miller

<!-- PAGE=? -->
Hepatobiliary disease

<!-- PAGE=? -->
 prolonged action from decreased plasma clearance for dTc, panc, dox, vec, roc, miv

<!-- PAGE=? -->
o not consistent.  Some studies have described prolonged clearance without prolonged duration of action

<!-- PAGE=? -->
 increased Vd = apparent resistance so increase initial dose, increase dosing interval

<!-- PAGE=? -->
 Rocuronium onset and duration of action may be prolonged due to greater Vd

<!-- PAGE=? -->
 butyrylcholinesterase synthesis decreases in severe disease (clearance of miv down 50%, duration of action doubled-tripled)

<!-- PAGE=? -->
Noise Pollution

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 background noise level of 75-90 dB common

<!-- PAGE=? -->
 anesthesiologists have on average greater hearing loss than others

<!-- PAGE=? -->
 noise pollution associated with decreased performance in complex tasks

<!-- PAGE=? -->
o monitoring and vigilance, are particularly sensitive to the adverse influences of noise pollution

<!-- PAGE=? -->
 Self-selected background music contributes to reduced autonomic responses and improved performance during a stressful nonsurgical tasks

<!-- PAGE=? -->
 noise pollution is a health hazard

<!-- PAGE=? -->
NPPV

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o acute exacerbations of chronic obstructive pulmonary disease

<!-- PAGE=? -->
o acute cardiogenic pulmonary edema

<!-- PAGE=? -->
o hypoxemic respiratory failure

<!-- PAGE=? -->
o immunocompromised patients

<!-- PAGE=? -->
o adjunct to weaning in patients with COPD

<!-- PAGE=? -->
 PRO

<!-- PAGE=? -->
o reduction in the length of ICU and total hospital stays

<!-- PAGE=? -->
o increased patient comfort

<!-- PAGE=? -->
o reduced need for sedation

<!-- PAGE=? -->
o avoidance of tracheal intubation and its attendant complications

<!-- PAGE=? -->
o maintenance of airway defenses, speech, and swallowing

<!-- PAGE=? -->
 CONS

<!-- PAGE=? -->
o need for patient cooperation

<!-- PAGE=? -->
o lack of direct access to the airway to provide bronchial hygiene

<!-- PAGE=? -->
o facial skin ulcers caused by mask pressure

<!-- PAGE=? -->
o aerophagia.

<!-- PAGE=? -->
Potential

<!-- PAGE=? -->
Indicators 0f Success

<!-- PAGE=? -->
Younger age

<!-- PAGE=? -->
Lower acuity of illness (APACHE score)

<!-- PAGE=? -->
Able to cooperate

<!-- PAGE=? -->
better neurologic score

<!-- PAGE=? -->
Less air leaking

<!-- PAGE=? -->
intact definition

<!-- PAGE=? -->
Moderate hypercarbia (PaCOZ >45 mrHG ,

<!-- PAGE=? -->
Moderate academia (pH <7.35

<!-- PAGE=? -->
>7.10)

<!-- PAGE=? -->
Improvements in gas exchange and heart respiratory rates within first 2 hours

<!-- PAGE=? -->
Reproduced with permission from International Concensus Conferences in

<!-- PAGE=? -->
Intensive Care Medicine :Noninvasive positive pressure Yentilation in acute

<!-- PAGE=? -->
respiratory failure.Am

<!-- PAGE=? -->
Respir Crit Care Med 2001

<!-- PAGE=? -->
163288.Copyright

<!-- PAGE=? -->
2001

<!-- PAGE=? -->
American Thoracic Society

<!-- PAGE=? -->
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

<!-- PAGE=? -->
Anti-inflammatory, analgesic and antipyretic effects Inhibit COX 1 and 2

<!-- PAGE=? -->
 COX 1: constitutive enzyme that produces prostaglandins (important for gastric porection and hemostasis)

<!-- PAGE=? -->
 COX 2: inducible form that produces prostaglandins that mediate pain, inflammation, fever, carcinogenesis

<!-- PAGE=? -->
 Prostaglandin E2 is the key mediator of both peripheral and central pain sensitization

<!-- PAGE=? -->
o Peripherally: Sensitize nociceptors to other mediators of pain such as histamine and bradykinin

<!-- PAGE=? -->
o Centrally: enhance pain transmission at the level of the dorsal horn:

<!-- PAGE=? -->
 Increase release of substance P and glutamate from 1 st order neurons

<!-- PAGE=? -->
 Increase sensitivity of second order pain neurons

<!-- PAGE=? -->
 Inhibit release of neurotransmitters from descending pain-modulating pathways

<!-- PAGE=? -->
Opioid sparing and reduce opioid side effects Ceiling effect wrt max analgesic effects

<!-- PAGE=? -->
S/E

<!-- PAGE=? -->
 Nephrotoxicity: increased in patiets with hypovolemia, CHF, chronic renal insufficiency

<!-- PAGE=? -->
 Platelet dysfunction

<!-- PAGE=? -->
 Gastric ulceration

<!-- PAGE=? -->
 Fluid retention and hypertension

<!-- PAGE=? -->
 Hepatocellular injury

<!-- PAGE=? -->
 Asthma exacerbation

<!-- PAGE=? -->
 Allergic reactions and urticaria

<!-- PAGE=? -->
 tinnitus

<!-- PAGE=? -->
 Inhibit healing process after lumbar fusion

<!-- PAGE=? -->
 s/e of ketorolac increase at high doses, therapy for > 5 days or in vulnerable patients (elderly) (miller 6 th 2719)

<!-- PAGE=? -->
Barash 6 th 1484-6

<!-- PAGE=? -->
O

<!-- PAGE=? -->
OB Anesthesia

<!-- PAGE=? -->
AFE

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Clinical diagnosis

<!-- PAGE=? -->
o Fetal squamous cells in maternal circulation is not diagnostic

<!-- PAGE=? -->
 Low sensitivity and specificity

<!-- PAGE=? -->
 Differential Diagnosis of AFE:

<!-- PAGE=? -->
o Obstetrical = Hemorrhage, Placental abruption, Uterine rupture, Preeclampsia/Eclampsia. Peripartum cardiomyopathy

<!-- PAGE=? -->
o Nonobstetrical = VTE, VAE, Anaphpylactic Shock, Septic Shock, Acute MI

<!-- PAGE=? -->
o Anesthetic = High NA block/Total spinal, Systemic LA toxicity, Aspiration

<!-- PAGE=? -->
 Differential Diagnosis of CVS collapse in Pregnancy:

<!-- PAGE=? -->
o Hypovolemic = blood loss

<!-- PAGE=? -->
o Obstructive = AFE, VTE, Air Embolism

<!-- PAGE=? -->
o Distributive = Anaphylaxis, high NA Block, SIRS/Sepsis, Transfusion Rxn

<!-- PAGE=? -->
o Cardiogenic = MI, CM of Pregnancy, LA CVS toxicity

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Tumultuous labor, strong contractions, uterine stimulants,

<!-- PAGE=? -->
o uterine rupture

<!-- PAGE=? -->
o sudden fetal expulsion

<!-- PAGE=? -->
o cervical  laceration, chorioamnionitis

<!-- PAGE=? -->
o Increased fetal size, Multiple gestation

<!-- PAGE=? -->
o Advanced age

<!-- PAGE=? -->
o Meconium

<!-- PAGE=? -->
o Fetal death

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
Figure ]. Postulated relative contributions to hyJisn.

<!-- PAGE=? -->
Pulmonary Edema

<!-- PAGE=? -->
Dlslrbullve

<!-- PAGE=? -->
Cardiogenic

<!-- PAGE=? -->
1

<!-- PAGE=? -->
2

<!-- PAGE=? -->
2

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Obstructive

<!-- PAGE=? -->
Laie Pnasp

<!-- PAGE=? -->
Tire

<!-- PAGE=? -->
Time

<!-- PAGE=? -->
Figure 2 Postulated   relative contributions to shock in patients with amniotic fluid embolism.

<!-- PAGE=? -->
o Amniotic fluid access to maternal circulation is essential to its pathogenesis

<!-- PAGE=? -->
o The disruption of integrity of fetal membranes, open uterine or cervical veins and concomitant pressure gradient facilitate movement of amniotic fluid into the maternal circulation

<!-- PAGE=? -->
o Initial phase of AFE results in mechanical blockage of the pulmonary circulation & intense pulmonary vasoconstriction due to chemical mediators (PG, leukotrienes, serotonin)

<!-- PAGE=? -->
 Hypoxemia, pulmonary hypertension & cor pulmonale occur and are thought to be transient (less than 30 min duration)

<!-- PAGE=? -->
 Leftward shift of interventricular septum due to RV dilatation

<!-- PAGE=? -->
 May explain early sudden death & neurological sequelae

<!-- PAGE=? -->
o Secondary phase of severe left ventricular dysfunction

<!-- PAGE=? -->
 Myocardial ischemia in the setting of hypoxemia

<!-- PAGE=? -->
 Decreased coronary blood flow & circulating myocardial depressants

<!-- PAGE=? -->
 All result in

<!-- PAGE=? -->
 hypotension & decreased cardiac output

<!-- PAGE=? -->
 Pulmonary edema

<!-- PAGE=? -->
 Alveolar capillary leak & microvascular embolic insult

<!-- PAGE=? -->
 Coagulopathy - DIC

<!-- PAGE=? -->
 Timing

<!-- PAGE=? -->
o 30% occur during 1 st trimester abortions

<!-- PAGE=? -->
o May occur after abdominal trauma or post delivery

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
Arrest

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
Table  1. Cardinal   signs symptoms   of amniotic fluid embolism syndrome

<!-- PAGE=? -->
Hypoxemia Shock (typically obstructive, cardiogenic, or distributive) Coagulopathy/disseminated intravascular coagulation Altered mental status hypoxic encephalopathy

<!-- PAGE=? -->
Table 2. Other symptoms of amniotic fluid embolism

<!-- PAGE=? -->
Table 3. Differentialdiagnosis of amniotic fluid embolism

<!-- PAGE=? -->
Pulmonary thromboembolism

<!-- PAGE=? -->
Air embolism

<!-- PAGE=? -->
Aspiration of gastric contents

<!-- PAGE=? -->
Hemorrhage

<!-- PAGE=? -->
Anesthetic complications

<!-- PAGE=? -->
Sepsis systemic inflammatory response syndrome

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
Myocardial infarction

<!-- PAGE=? -->
Eclampsia

<!-- PAGE=? -->
Cardiomyopathy

<!-- PAGE=? -->
Transfusion reactions

<!-- PAGE=? -->
Table 2. Normal cardiorespiratory changes of pregnancy and effect on resuscitation

<!-- PAGE=? -->
 DDx of maternal Cardiac arrest

<!-- PAGE=? -->
o Injury or trauma

<!-- PAGE=? -->
 Homicide

<!-- PAGE=? -->
 Suicide

<!-- PAGE=? -->
 MVC

<!-- PAGE=? -->
 Illicit drug use

<!-- PAGE=? -->
o Obstetric complications

<!-- PAGE=? -->
 AFE

<!-- PAGE=? -->
 Hemorrhoge

<!-- PAGE=? -->
 Previa, accrete, abruption, atony, DIC

<!-- PAGE=? -->
 Preeclampsia

<!-- PAGE=? -->
 Peripartum cardiomyopathy

<!-- PAGE=? -->
o Iatrogenic complications

<!-- PAGE=? -->
 Failed intubation

<!-- PAGE=? -->
 Aspiration

<!-- PAGE=? -->
 Anesthetic overdose

<!-- PAGE=? -->
 Hypermagnesemia

<!-- PAGE=? -->
 Give calcium

<!-- PAGE=? -->
 Drug errors

<!-- PAGE=? -->
o Pregnancy related medical conditions

<!-- PAGE=? -->
 PE

<!-- PAGE=? -->
 Blood, air, fat

<!-- PAGE=? -->
 Sepsis

<!-- PAGE=? -->
 Aortic dissection

<!-- PAGE=? -->
 Inc. risk in pregnancy

<!-- PAGE=? -->
o Pre-existing medical conditions

<!-- PAGE=? -->
 Asthma

<!-- PAGE=? -->
 Aneurysm

<!-- PAGE=? -->
 Cerebral thrombosis

<!-- PAGE=? -->
 Cardiac pathology

<!-- PAGE=? -->
 >20 weeks gestation the uterus begins to adversely affect resuscitation

<!-- PAGE=? -->
o Venous obstruction

<!-- PAGE=? -->
 Emergency hysterotomy

<!-- PAGE=? -->
o < 20 wks gestation

<!-- PAGE=? -->
 Resuscitate as per protocol

<!-- PAGE=? -->
 No need to consider urgent hysterotomy

<!-- PAGE=? -->
o 20 - 23 wks

<!-- PAGE=? -->
 Perform emergent hysterotomy to save the life of the mother if persistant cardiac arrest despite ACLS for 5 min

<!-- PAGE=? -->
o >24 wks

<!-- PAGE=? -->
 Consider hysterotomy to save the life of both the mother and the fetus

<!-- PAGE=? -->
 Factors linked to increased fetal survival

<!-- PAGE=? -->
 Short arrest interval

<!-- PAGE=? -->
o < 5 min excellent

<!-- PAGE=? -->
o 5 - 15 good to fair survival

<!-- PAGE=? -->
o >15 poor survival

<!-- PAGE=? -->
 No maternal prearrest hypoxia

<!-- PAGE=? -->
 No fetal distress at the time of arrest

<!-- PAGE=? -->
 Effective maternal resuscitation

<!-- PAGE=? -->
 NICU immediately available

<!-- PAGE=? -->
 Defibrillation

<!-- PAGE=? -->
o Usual doses and pad position

<!-- PAGE=? -->
o No proven adverse effect on the fetus

<!-- PAGE=? -->
 Fetal monitoring is recommended

<!-- PAGE=? -->
 Chestnut suggest fetal bradycardia/asystole may occur

<!-- PAGE=? -->
Primnary a Secondlary ABCD Surveys: Hodifications for Pregnant Women

<!-- PAGE=? -->
ACLS Approach

<!-- PAGE=? -->
Primary ABCD Survey

<!-- PAGE=? -->
Breech

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Classification

<!-- PAGE=? -->
o Frank breech-Lower extremities flexed at the hips and extended at the knees

<!-- PAGE=? -->
 48-73%

<!-- PAGE=? -->
 38% are preterm

<!-- PAGE=? -->
o Complete breech-Lower extremities flexed at both the hips and the knees

<!-- PAGE=? -->
 5-12%

<!-- PAGE=? -->
 12% are preterm

<!-- PAGE=? -->
o Incomplete breech-One or both of the lower extremities extended at the hips

<!-- PAGE=? -->
Modifications to BLS and ACLS Guidelines

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
No modificatons .

<!-- PAGE=? -->
Breathing

<!-- PAGE=? -->
No modificatons_

<!-- PAGE=? -->
Circulation

<!-- PAGE=? -->
the uterus laterall. This maneuver will relieve plessure on te inferior vena cava . gravid pull

<!-- PAGE=? -->
Defibrillation

<!-- PAGE=? -->
No modifications in dose or pad position

<!-- PAGE=? -->
Remove an' fetal or uterine monitors before chock deliver;.

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
Insert an advanced airxay early in resuscitation to reduce the tisk of regurgitation and aspiration

<!-- PAGE=? -->
smaller than the one you would use for a nonpregnant woman of similar size.

<!-- PAGE=? -->
Monitor for excessive bleeding

<!-- PAGE=? -->
Mo modifications to intutaton techniques. 4 provider experienced in intubation chould insert te tacheal tube_

<!-- PAGE=? -->
Breathing

<!-- PAGE=? -->
~Tailor ventil Su lator; IFport

<!-- PAGE=? -->
Circulation

<!-- PAGE=? -->
Follo: standard ACLS reommendations for administaton of all resuscitition medications_

<!-- PAGE=? -->
reach the maternal healt unlees or unl #e fetus is delivered.

<!-- PAGE=? -->
Differential Diagnois and Decisions

<!-- PAGE=? -->
Identify and treat revelsible causes of the anest. Coneider causes related to pregnancy and causes onsidered for all ACLS

<!-- PAGE=? -->
 12-38%

<!-- PAGE=? -->
 50% are preterm

<!-- PAGE=? -->
 Factors associated with breech

<!-- PAGE=? -->
o Uterine distention or relaxation

<!-- PAGE=? -->
 Multiparity

<!-- PAGE=? -->
 Multiple gestation

<!-- PAGE=? -->
 Polyhydramnios

<!-- PAGE=? -->
 Macrosomia

<!-- PAGE=? -->
o Abnormalities of the uterus or pelvis

<!-- PAGE=? -->
 Pelvic tumors

<!-- PAGE=? -->
 Uterine anomalies

<!-- PAGE=? -->
 Pelvic contracture

<!-- PAGE=? -->
o Abnormalities of the fetus

<!-- PAGE=? -->
 Hydrocephalus

<!-- PAGE=? -->
 Anencephaly

<!-- PAGE=? -->
o Obstetric conditions

<!-- PAGE=? -->
 Previous breech delivery

<!-- PAGE=? -->
 Preterm gestation

<!-- PAGE=? -->
 Oligohydramnios

<!-- PAGE=? -->
 Cornual-fundal placenta

<!-- PAGE=? -->
 Placenta previa

<!-- PAGE=? -->
 Complications associated with breech presentation

<!-- PAGE=? -->
Complication

<!-- PAGE=? -->
Incidence

<!-- PAGE=? -->
Intrapartum fetal death

<!-- PAGE=? -->
Increased sixteenfold

<!-- PAGE=? -->
Intrapartum asphyxia

<!-- PAGE=? -->
Increased 3.8-fold

<!-- PAGE=? -->
Umbilical cord prolapse

<!-- PAGE=? -->
Increased fivefold to twentyfold

<!-- PAGE=? -->
Birth trauma

<!-- PAGE=? -->
Increased thirteenfold

<!-- PAGE=? -->
Arrest of aftercoming head

<!-- PAGE=? -->
8.8%

<!-- PAGE=? -->
Spinal cord injuries with deflexion

<!-- PAGE=? -->
21%

<!-- PAGE=? -->
Major congenital anomalies

<!-- PAGE=? -->
6%-18%

<!-- PAGE=? -->
Preterm delivery

<!-- PAGE=? -->
16%-33%

<!-- PAGE=? -->
Hyperextension of head

<!-- PAGE=? -->
5%

<!-- PAGE=? -->
 Risk of umbilical cord prolapsed

<!-- PAGE=? -->
o Incomplete > Complete > Frank

<!-- PAGE=? -->
 Epidurals in breech:

<!-- PAGE=? -->
o Do not increase the incidence of complete breech extraction

<!-- PAGE=? -->
o 2 nd stage can be lenghthened slightly

<!-- PAGE=? -->
 Increased perinatal morbidity and mortality

<!-- PAGE=? -->
o Intrapartum fetal asphyxia and death

<!-- PAGE=? -->
o Umbilical cord prolapse (more common if incomplete breech)

<!-- PAGE=? -->
o Birth trauma

<!-- PAGE=? -->
o Arrest of aftercoming head

<!-- PAGE=? -->
o Spinal cord injuries with deflexion

<!-- PAGE=? -->
o Major congenital anomalies

<!-- PAGE=? -->
o Preterm delivery

<!-- PAGE=? -->
 Anesthesia for Vaginal Breech Delivery

<!-- PAGE=? -->
o Delivery should occur in a room where emergency abdominal delivery can be immediately performed (ie OR)

<!-- PAGE=? -->
o Administer aspiration prophylaxis

<!-- PAGE=? -->
o Epidural or CSE are good choices

<!-- PAGE=? -->
o Be prepared to administer GA at any time and be prepared to top up the epidural for Piper forceps or C/S

<!-- PAGE=? -->
o Give O2 - umbilical cord compression is common

<!-- PAGE=? -->
o Provide analgesia without motor block (most OBs insist on spontaneous delivery to the umbilicus)

<!-- PAGE=? -->
o Complications

<!-- PAGE=? -->
 Fetal head entrapment: most commonly at < 32 weeks GA, the lower extremities, buttocks and abdomen may deliver through a cervix that is incompletely dilated and which then traps the head

<!-- PAGE=? -->
 Duhrssen incisions in the cervix at 2, 6 and 10 o'clock.  Associated with genitourinary trauma, hemorrhage (can occur concealed into the peritoneal cavity)

<!-- PAGE=? -->
 Relaxation of skeletal and smooth muscle may be requested (ie RSI and GA with 2-

<!-- PAGE=? -->
3 MAC of volatile).  Relaxation of uterus and cervix within 2-3 minutes

<!-- PAGE=? -->
o If fetal head entrapment is at the level of the perineum, the head often delivers when sux is given as part of an RSI

<!-- PAGE=? -->
o After delivery, d/c the volatile and work on contracting the uterus to limit PPH

<!-- PAGE=? -->
 Relaxation of the uterus and cervix with nitroglycerine IV or SL

<!-- PAGE=? -->
o NTG 50-100 mcg iv or 400 mcg spray

<!-- PAGE=? -->
o Trials/ evidence is lacking

<!-- PAGE=? -->
o Effect is brief

<!-- PAGE=? -->
o Simultaneously prepare for GA

<!-- PAGE=? -->
 C/S

<!-- PAGE=? -->
Cocaine

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
 Cocaine's pharmacologic effects are mediated through

<!-- PAGE=? -->
o Norepinephrine

<!-- PAGE=? -->
o Dopamine

<!-- PAGE=? -->
 Euphoric effect

<!-- PAGE=? -->
o Serotonin

<!-- PAGE=? -->
 vasoconstriction, hypertension, cardiac abnormalities occur as a result of an accumulation of catecholamines

<!-- PAGE=? -->
o prevention of presynaptic reuptake and deactivation of norepinephrine

<!-- PAGE=? -->
o blockade of catecholamine-binding mechanisms

<!-- PAGE=? -->
o stimulation of the sympathoadrenal axis

<!-- PAGE=? -->
 Half-life of cocaine is 0.5 - 1.5 hrs

<!-- PAGE=? -->
 Maternal Complications

<!-- PAGE=? -->
o CARDIOVASCULAR

<!-- PAGE=? -->
 Myocardial ischemia and infarction

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 tachycardia

<!-- PAGE=? -->
 Malignant arrhythmias

<!-- PAGE=? -->
 Asystole

<!-- PAGE=? -->
 Aortic rupture

<!-- PAGE=? -->
o PULMONARY

<!-- PAGE=? -->
 Aspiration

<!-- PAGE=? -->
 Bronchospasm

<!-- PAGE=? -->
 Pneumothorax

<!-- PAGE=? -->
 Pneumomediastinum

<!-- PAGE=? -->
o CENTRAL NERVOUS SYSTEM

<!-- PAGE=? -->
 Convulsions

<!-- PAGE=? -->
 Cerebrovascular accident

<!-- PAGE=? -->
 Intracerebral hemorrhage

<!-- PAGE=? -->
 Subarachnoid hemorrhage

<!-- PAGE=? -->
o RENAL

<!-- PAGE=? -->
 Renal failure

<!-- PAGE=? -->
o GASTROINTESTINAL

<!-- PAGE=? -->
 Bowel ischemia

<!-- PAGE=? -->
o HEPATIC

<!-- PAGE=? -->
 Hepatic failure

<!-- PAGE=? -->
 Hepatic rupture

<!-- PAGE=? -->
o HEMATOLOGIC

<!-- PAGE=? -->
 Thrombocytopenia

<!-- PAGE=? -->
 Disseminated intravascular coagulation

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
o Hypertension/tachycardia

<!-- PAGE=? -->
o Convulsions

<!-- PAGE=? -->
o Hyperreflexia

<!-- PAGE=? -->
o Tremors

<!-- PAGE=? -->
o Hyperpyrexia

<!-- PAGE=? -->
o Acidosis

<!-- PAGE=? -->
o Emotional lability

<!-- PAGE=? -->
o Dilated pupils

<!-- PAGE=? -->
 DDx of hypertension in Pregnancy

<!-- PAGE=? -->
o Drug abuse

<!-- PAGE=? -->
o Preeclampsia/eclampsia

<!-- PAGE=? -->
o Chronic hypertension

<!-- PAGE=? -->
o Pain/noxious stimulation

<!-- PAGE=? -->
o Hypoxia/hypercarbia

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o Malignant hyperthermia

<!-- PAGE=? -->
o Opioid/alcohol withdrawal

<!-- PAGE=? -->
 Neonatal Effects

<!-- PAGE=? -->
o Increased incidence of spontaneous abortion

<!-- PAGE=? -->
o Increased incidence of preterm labor and premature rupture of membranes

<!-- PAGE=? -->
o Increased incidence of placental abruption

<!-- PAGE=? -->
o Decreased uteroplacental perfusion

<!-- PAGE=? -->
o Increased incidence of fetal distress

<!-- PAGE=? -->
o Fetal tachycardia/hypertension

<!-- PAGE=? -->
o Increased incidence of congenital malformations

<!-- PAGE=? -->
o Neonatal central nervous system irritability

<!-- PAGE=? -->
o Perinatal cerebral infarction

<!-- PAGE=? -->
o Intrauterine fetal death

<!-- PAGE=? -->
o Neonatal myocardial infarction

<!-- PAGE=? -->
Anesthetic Management

<!-- PAGE=? -->


<!-- PAGE=? -->
life-threatening events are more common during general anesthesia than during regional anesthesia

<!-- PAGE=? -->
o severe hypertension

<!-- PAGE=? -->
 Hydralazine may restore maternal MAP toward baseline, but it results in profound maternal tachycardia and fails to restore UBF

<!-- PAGE=? -->
 Beta-blockers should be avoided

<!-- PAGE=? -->
o arrhythmias

<!-- PAGE=? -->
o myocardial ischemia

<!-- PAGE=? -->
 Regional anesthesia is not without risk

<!-- PAGE=? -->
o risk of platelet abnormalities

<!-- PAGE=? -->
o increased risk for hypotension

<!-- PAGE=? -->
o ephedrine may not be an effective vasopressor

<!-- PAGE=? -->
 depleted catecholamine stores

<!-- PAGE=? -->
 phenylephrine should be used

<!-- PAGE=? -->
o often complain of pain despite an adequate level of spinal or epidural anesthesia during cesarean section

<!-- PAGE=? -->
 may require opioid supplementation during surgery

<!-- PAGE=? -->
 Possible explanations include

<!-- PAGE=? -->
 an abnormal affect among cocaine addicts

<!-- PAGE=? -->
 anesthesiologist's desire to sedate patients who abuse drugs

<!-- PAGE=? -->
 a central effect of cocaine, which may cause an abnormality of endorphins

<!-- PAGE=? -->
 avoid drugs that

<!-- PAGE=? -->
o sensitize the myocardium to catecholamines (e.g., halothane)

<!-- PAGE=? -->
o release catecholamines or cause tachycardia (e.g., ketamine, atropine).

<!-- PAGE=? -->
 MAC may be decreased in chronic cocaine addicts as a result of the depletion of catecholamines

<!-- PAGE=? -->
o acute use of cocaine may result in increased concentrations of catecholamines, increasing MAC

<!-- PAGE=? -->
 Cocaine use may also alter the response to succinylcholine

<!-- PAGE=? -->
 Cocaine toxicity is often seen many hours after the ingestion of cocaine

<!-- PAGE=? -->
o patients should be considered at risk for cocaine-related complications even if the cocaine use occurred more than 24 hours earlier

<!-- PAGE=? -->
TABLE 52-1 -- THERAPY FOR COCAINE INTOXICATION

<!-- PAGE=? -->
CSE

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Fetal bradycardia due to uterine hyperactivity may occur

<!-- PAGE=? -->
o Possibly d/t the sympatholytic effect of IT lipid soluble opioids

<!-- PAGE=? -->
 There is not an inc. risk of PDPH

<!-- PAGE=? -->
 The epidural catheter will not traverse the dural hole

<!-- PAGE=? -->
 Migration of medication across the dural hole is most likely not clinically significant

<!-- PAGE=? -->
o caudad spread is greater but cephalad spread no different

<!-- PAGE=? -->
DIC

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 The most frequent causes of DIC in pregnancy are:

<!-- PAGE=? -->
o Preeclampsia

<!-- PAGE=? -->
o Abruption

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Retined dead fetus syndrome (may be due to saline abortion)

<!-- PAGE=? -->
o Amniotic fluid embolus

<!-- PAGE=? -->
Dyspnea in Pregnancy

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 DDx

<!-- PAGE=? -->
o Physiologic

<!-- PAGE=? -->
o CVS - Cardiomyopathy, Congenital Heart Disease, Valvular heart diease, ischemia

<!-- PAGE=? -->
o Respiratory - Asthma, Pulmonary Embolism (AFE, DVT), pneumonia

<!-- PAGE=? -->
o Preeclampsia

<!-- PAGE=? -->
o Pre-existing disease

<!-- PAGE=? -->
 Neuromuscular, CF, RLD

<!-- PAGE=? -->
Physiological Dyspnea of Pregnancy

<!-- PAGE=? -->
 During normal and uncomplicated pregnancy, 60-70% feel sensation of -air hunger‖

<!-- PAGE=? -->
o Starts in 1 st or 2 nd trimester - usually stable in 3 rd trimester

<!-- PAGE=? -->
o Explained by increase of abdominal girth

<!-- PAGE=? -->
o Mechanism not clear, likely due to progesterone induced hyperventilation

<!-- PAGE=? -->
Evaluation of Dyspnea

<!-- PAGE=? -->
 Need to distinguish between pathological and physiologic dyspnea

<!-- PAGE=? -->
o Onset, wheezing, crackles

<!-- PAGE=? -->
 Most common pulmonary causes = asthma or pulmonary embolism

<!-- PAGE=? -->
 Peripartum cardiomyopathy

<!-- PAGE=? -->
o often has dyspnea, but rarely presents before 36 weeks and usually is in 4-5 month postpartum

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
 Suspect if previous history of asthma but can have new onset

<!-- PAGE=? -->
 Human chorionic gonadotropin stimulates thyroid and this may augment asthma

<!-- PAGE=? -->
 Objective findings = wheezing, airflow obstruction on PFTs

<!-- PAGE=? -->
o No change in airway mechanics so still will see reversible airway obstruction

<!-- PAGE=? -->
o Metacholine testing not recommended so better to start therapeutic trials

<!-- PAGE=? -->
o Keep in mind that acute asthma blood gas changes are superimposed on resp alkalosis

<!-- PAGE=? -->
 pCO2>35 or pO2<70 represents much more severe compromise

<!-- PAGE=? -->
 severity during pregnancy is related asthma severity prior to pregnancy

<!-- PAGE=? -->
o Trend towards less severe symptoms during last 4 weeks of pregnancy

<!-- PAGE=? -->
o Some gradually improve during pregnancy

<!-- PAGE=? -->
o Those who worsen have worst symptoms between 29 - 36 weeks

<!-- PAGE=? -->
o Asthma symptoms are uncommon during labour and delivery

<!-- PAGE=? -->
o Small but significant increase in complications of pregnancy but can be mediated with good asthma control

<!-- PAGE=? -->
Pulmonary Embolism

<!-- PAGE=? -->
 Pregnancy = risk factor for VTE (1 in 500 - 2000 preg)

<!-- PAGE=? -->
o More common postpartum

<!-- PAGE=? -->
 Risk Factors - Virchow's triad

<!-- PAGE=? -->
o Stasis - pregnancy associated changes in capacitance and compression of large veins by gravid uterus

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Endothelial injury - delivery associated with vascular injury and changes at uteroplacental surface

<!-- PAGE=? -->
increases frequency of VTE postpartum

<!-- PAGE=? -->
 Forceps, vacuum and surgical delivery can exaggerate vascular injury

<!-- PAGE=? -->
o Hypercoagulability

<!-- PAGE=? -->
 Increased factors I, II, VII, IX, X and dec protein S

<!-- PAGE=? -->
 Magnified risk with inherited thrombophilias

<!-- PAGE=? -->
 Clinical diagonosis of DVT and PE is insensitive and nonspecific

<!-- PAGE=? -->
o Sudden onset of dyspnea, pleuritic chest pain, hemoptysis

<!-- PAGE=? -->
o ABGs not sensitive or specific since resp alkalosis is common for PE and pregnancy

<!-- PAGE=? -->
o D-dimer elevations are common in normal pregnancy

<!-- PAGE=? -->
o If clinical suspicion is high CT angiography is best test for workup of PE if negative leg studies

<!-- PAGE=? -->
o V/Q scanning is a useful test and more often diagnostic in pregnant pts than in general population

<!-- PAGE=? -->
Postpartum:

<!-- PAGE=? -->
 still high risk for HD compromise and pulmonary edema for up to 4 days

<!-- PAGE=? -->
o autotransfusion with uterine involution can ppt pulmonary edema

<!-- PAGE=? -->
 this may be offset in C-section b/c of the greater blood loss

<!-- PAGE=? -->
 High dependency unit for @ least 24 hrs with ongoing invasive monitoring then step down unit

<!-- PAGE=? -->
Fetal Heart Rate monitoring

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 neuronal and humoral factors affect the intrinsic FHR

<!-- PAGE=? -->
o Parasympathetic via vaus - dec. FHR

<!-- PAGE=? -->
o Sympathetic activity inc. FHR and cardiac output

<!-- PAGE=? -->
 Baroreceptors respond to increased blood pressure

<!-- PAGE=? -->
 chemoreceptors respond to decreased PaO2 and increased PaCO2

<!-- PAGE=? -->
 Cerebral cortical activity and hypothalamic activity affect the FHR through their effects on integrative centers in the medulla oblongata

<!-- PAGE=? -->
 Several features of the FHR pattern can be assessed

<!-- PAGE=? -->
o Baseline

<!-- PAGE=? -->
 120 to 160 bpm

<!-- PAGE=? -->
 term fetuses have a lower baseline than preterm fetuses

<!-- PAGE=? -->
 bradycardia is the initial fetal response to acute hypoxemia

<!-- PAGE=? -->
 DDx of fetal tachycardia

<!-- PAGE=? -->
 prolonged fetal hypoxia

<!-- PAGE=? -->
 maternal fever

<!-- PAGE=? -->
 chorioamnionitis

<!-- PAGE=? -->
 fetal anemia

<!-- PAGE=? -->
 heart failure

<!-- PAGE=? -->
 Medications

<!-- PAGE=? -->
 Beta-agonists (terbutaline given to treat preterm labor)

<!-- PAGE=? -->
 anticholinergic agent atropine

<!-- PAGE=? -->
o Variability - the degree to which the rate varies both instantaneously and over longer periods

<!-- PAGE=? -->
 includes short- (beat-to-beat) and long-term variability

<!-- PAGE=? -->
 Short-term variability

<!-- PAGE=? -->
o difference between two or three adjacent beats

<!-- PAGE=? -->
o likely results from the influence of parasympathetic tone

<!-- PAGE=? -->
 eliminated by atropine

<!-- PAGE=? -->
 little effect from Beta-blockers

<!-- PAGE=? -->
o Doppler ultrasonography may not always detect short-term variability accurately

<!-- PAGE=? -->
o fetal ECG electrode should be used to obtain the most reliable estimate of short-term variability

<!-- PAGE=? -->
 Long-term variability denotes the rough sine waves that occur 3-6 times per minute, with variation of at least 6 bpm

<!-- PAGE=? -->
o normal FHR variability reflects the presence of normal, intact pathways from the fetal cerebral cortex, midbrain, vagus nerve, and cardiac conduction system

<!-- PAGE=? -->
 severe hypoxemia (decompensation of cerebral blood flow and oxygen delivery) results in a loss of variability

<!-- PAGE=? -->
 variability is absent in an anencephalic fetus

<!-- PAGE=? -->
 the presence of normal variability predicts early neonatal health

<!-- PAGE=? -->
 differential diagnosis of abnormal variability includes

<!-- PAGE=? -->
 Although there is a risk of fetal anomalies associated with radiation exposure, there is a a much higher risk to the fetus if PE is not diagnosed and treated in the mother

<!-- PAGE=? -->
o Absent variability

<!-- PAGE=? -->
 Severe fetal hypoxemia

<!-- PAGE=? -->
 Anencephaly

<!-- PAGE=? -->
o Decreased variability

<!-- PAGE=? -->
 fetal hypoxia

<!-- PAGE=? -->
 fetal sleep state

<!-- PAGE=? -->
 fetal neurologic abnormality

<!-- PAGE=? -->
 atropine

<!-- PAGE=? -->
 dec.CNS activity that results from exposure to drugs

<!-- PAGE=? -->
 opioids

<!-- PAGE=? -->
 BDZ

<!-- PAGE=? -->
 Mg

<!-- PAGE=? -->
 fetal heart block

<!-- PAGE=? -->
o Periodic changes (acceleration or deceleration) and their association with uterine contractions

<!-- PAGE=? -->
 accelerations

<!-- PAGE=? -->
 signal fetal health in the antepartum

<!-- PAGE=? -->
 less significant intrapartum

<!-- PAGE=? -->
o likely precludes the presence of significant fetal metabolic acidosis

<!-- PAGE=? -->
 Early decelerations - not ominous

<!-- PAGE=? -->
 occur simultaneously with uterine contractions

<!-- PAGE=? -->
 are usually are less than 20 bpm below baseline

<!-- PAGE=? -->
 onset and offset coincides with the onset and offset of the uterine contraction

<!-- PAGE=? -->
 In animals, head compression can precipitate early decelerations

<!-- PAGE=? -->
 In humans, early decelerations are believed to result from reflex vagal activity secondary to mild hypoxia

<!-- PAGE=? -->
 Late decelerations

<!-- PAGE=? -->
 begin and end 10 to 30 seconds after the beginning of a uterine contraction

<!-- PAGE=? -->
 smooth and repetitive -occur  with each uterine contraction

<!-- PAGE=? -->
 Animal studies suggest that late decelerations represent a response to hypoxemia

<!-- PAGE=? -->
o delayed onset reflects the time needed for the chemoreceptors to detect decreased oxygen tension and mediate the change in FHR by means of the vagus nerve

<!-- PAGE=? -->
 clinical and animal studies suggest that late decelerations may be an oversensitive test of fetal asphyxia

<!-- PAGE=? -->
 Variable decelerations

<!-- PAGE=? -->
 vary in depth, shape, and/or duration

<!-- PAGE=? -->
 abrupt onset and offset

<!-- PAGE=? -->
 result from baroreceptor- or chemoreceptor-mediated vagal activity

<!-- PAGE=? -->
 umbilical cord occlusion likely results in variable decelerations

<!-- PAGE=? -->
 during the second stage of labor, variable decelerations may result from compression of the fetal head

<!-- PAGE=? -->
o dural stimulation leads to increased vagal discharge

<!-- PAGE=? -->
 The healthy fetus typically can tolerate mild-to-moderate variable decelerations (not below 80 bpm) without decompensation

<!-- PAGE=? -->
 With prolonged, severe variable decelerations (less than 60 bpm) or persistent fetal bradycardia, it is difficult for the fetus to maintain cardiac output and umbilical blood flow

<!-- PAGE=? -->
 the combination of late decelerations and decreased/absent FHR variability is an accurate, ominous signal of fetal distress

<!-- PAGE=? -->
 sinusoidal pattern and the saltatory pattern are two unusual FHR patterns that may indicate fetal compromise

<!-- PAGE=? -->
 sinusoidal FHR pattern is a regular, smooth, wavelike pattern with absent short-term variability

<!-- PAGE=? -->
o may signal fetal anemia

<!-- PAGE=? -->
o Occasionally, maternal administration of an opioid may result in a sinusoidal FHR pattern

<!-- PAGE=? -->
 saltatory pattern includes excessive swings in variability (more than 25 bpm)

<!-- PAGE=? -->
o may signal acute fetal hypoxia

<!-- PAGE=? -->
o weak association between this pattern and low Apgar scores

<!-- PAGE=? -->
 Limitations

<!-- PAGE=? -->
o lacks of specificity - 35% to 50% false-positive rate

<!-- PAGE=? -->
 overly sensitive

<!-- PAGE=? -->
o consistently associated with an increased rate of operative delivery

<!-- PAGE=? -->
o results in a decreased incidence of 1-minute Apgar scores less than 4 and a decreased incidence of neonatal seizures

<!-- PAGE=? -->
 long-term significance is unclear

<!-- PAGE=? -->
o poor positive predictive value for abnormal outcome

<!-- PAGE=? -->
o poor intraobserver and interobserver agreement

<!-- PAGE=? -->
o need for a nurse or physician to assess the FHR tracing continually

<!-- PAGE=? -->
o inconvenience for the patient

<!-- PAGE=? -->
 confinement to bed and application of monitor belts or a scalp electrode)

<!-- PAGE=? -->
o the need to maintain the FHR tracing as a legal document.

<!-- PAGE=? -->
2007 SOGC Guidelines for FHR Interpretation

<!-- PAGE=? -->
Normal Tracing

<!-- PAGE=? -->
Atypical Tracing

<!-- PAGE=? -->
Albnormal

<!-- PAGE=? -->
Tracing

<!-- PAGE=? -->
Previously

<!-- PAGE=? -->
Previously

<!-- PAGE=? -->
Previously

<!-- PAGE=? -->
Reassuring"

<!-- PAGE=? -->
'Non-reassuring"

<!-- PAGE=? -->
Baseline

<!-- PAGE=? -->
110-160 bpm

<!-- PAGE=? -->
Bradycardia 100

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
110 bpm

<!-- PAGE=? -->
100 bpm

<!-- PAGE=? -->
Tachycardia >160 for

<!-- PAGE=? -->
Tachycardia >160 for

<!-- PAGE=? -->
230 min to < 90 min.

<!-- PAGE=? -->
90 min

<!-- PAGE=? -->
baseline

<!-- PAGE=? -->
Erratic baseline

<!-- PAGE=? -->
6-25 bpm

<!-- PAGE=? -->
<5 bpm for

<!-- PAGE=? -->
<5 bpm for > 80 min_

<!-- PAGE=? -->
Variability

<!-- PAGE=? -->
<5 bpm for < 30 min:

<!-- PAGE=? -->
30

<!-- PAGE=? -->
80 min

<!-- PAGE=? -->
225 bpm for >10 min.

<!-- PAGE=? -->
Sinusoidal

<!-- PAGE=? -->
None or occasional

<!-- PAGE=? -->
Repetitive (23)

<!-- PAGE=? -->
Repetitive (23)

<!-- PAGE=? -->
Decelerations

<!-- PAGE=? -->
typical variables or

<!-- PAGE=? -->
uncomplicated

<!-- PAGE=? -->
complicated variables:

<!-- PAGE=? -->
early decelerations

<!-- PAGE=? -->
variable

<!-- PAGE=? -->
deceleration to

<!-- PAGE=? -->
70

<!-- PAGE=? -->
decelerations

<!-- PAGE=? -->
bpm for > 60 secs.

<!-- PAGE=? -->
Occasional late

<!-- PAGE=? -->
loss of variability in

<!-- PAGE=? -->
decelerations

<!-- PAGE=? -->
trough or in baseline

<!-- PAGE=? -->
Single prolonged

<!-- PAGE=? -->
biphasic decelerations

<!-- PAGE=? -->
deceleration > 2 min.

<!-- PAGE=? -->
overshoots

<!-- PAGE=? -->
but <

<!-- PAGE=? -->
3 min:.

<!-- PAGE=? -->
slow return to baseline

<!-- PAGE=? -->
baseline lower after

<!-- PAGE=? -->
deceleration

<!-- PAGE=? -->
baseline tachycardia or

<!-- PAGE=? -->
bradycardia

<!-- PAGE=? -->
Late decelerations

<!-- PAGE=? -->
50% of contractions

<!-- PAGE=? -->
Single prolonged

<!-- PAGE=? -->
deceleration > 3 min.

<!-- PAGE=? -->
but < 10 min

<!-- PAGE=? -->
Accelerations

<!-- PAGE=? -->
Spontaneous

<!-- PAGE=? -->
Absence of

<!-- PAGE=? -->
accelerations present

<!-- PAGE=? -->
acceleration with

<!-- PAGE=? -->
(FHR increases > 15 bpm

<!-- PAGE=? -->
fetal scalp

<!-- PAGE=? -->
lasting > 15 seconds (<32

<!-- PAGE=? -->
stimulation

<!-- PAGE=? -->
weeks gestation increase in

<!-- PAGE=? -->
the FHR > 10 bpm

<!-- PAGE=? -->
lasting

<!-- PAGE=? -->
10 seconds)

<!-- PAGE=? -->
Accelerations present

<!-- PAGE=? -->
with fetal scalp

<!-- PAGE=? -->
stimulation

<!-- PAGE=? -->
ACTION

<!-- PAGE=? -->
EFM may be interrupted

<!-- PAGE=? -->
Further vigilant

<!-- PAGE=? -->
ACTION REQUIRED

<!-- PAGE=? -->
for periods up to 30

<!-- PAGE=? -->
assessment

<!-- PAGE=? -->
required,

<!-- PAGE=? -->
Obtain scalp pH if

<!-- PAGE=? -->
min. if maternal-fetal

<!-- PAGE=? -->
especially when

<!-- PAGE=? -->
appropriatelprepare for

<!-- PAGE=? -->
condition stable andlor

<!-- PAGE=? -->
combined features

<!-- PAGE=? -->
delivery.

<!-- PAGE=? -->
oxytocin infusion rate

<!-- PAGE=? -->
present.

<!-- PAGE=? -->
stable.

<!-- PAGE=? -->
Rising

<!-- PAGE=? -->
Fetal Scalp pH

<!-- PAGE=? -->
 determination is one method that is used to confirm or exclude the presence of fetal acidosis when FHR monitoring suggests the presence of fetal compromise

<!-- PAGE=? -->
o indications include

<!-- PAGE=? -->
 dec. or absent FHR variability

<!-- PAGE=? -->
 persistent late or variable FHR decelerations

<!-- PAGE=? -->
o Relative contraindications include

<!-- PAGE=? -->
 the presence of intact membranes and an unengaged vertex

<!-- PAGE=? -->
 fetal coagulopathy

<!-- PAGE=? -->
 infection

<!-- PAGE=? -->
 chorioamnionitis

<!-- PAGE=? -->
 HIV

<!-- PAGE=? -->
 herpes simplex virus

<!-- PAGE=? -->
 an anticipated need for many samples

<!-- PAGE=? -->
 pH of more than 7.25 is acceptable and indicates that the patient may continue to labor

<!-- PAGE=? -->
 pH of less than 7.20 is considered abnormal, and delivery should be expedited if the value is confirmed by a second pH determination

<!-- PAGE=? -->
 conditions that may give a false-positive result

<!-- PAGE=? -->
o abnormalities of the maternal pH

<!-- PAGE=? -->
o an inadequate sample

<!-- PAGE=? -->
o contamination with amniotic fluid

<!-- PAGE=? -->
o sampling from the caput succedaneum

<!-- PAGE=? -->
Fetal Scalp Stimulation

<!-- PAGE=? -->
 heart rate of a healthy, nonacidotic fetus accelerates in response to scalp stimulation

<!-- PAGE=? -->
o associated with a fetal pH of at least 7.19

<!-- PAGE=? -->
Fetal & Placental pharmacology

<!-- PAGE=? -->
Barash, Chestnut

<!-- PAGE=? -->
 The liver is the first fetal organ perfused by umbilical vein blood, which carries drug to the fetus.

<!-- PAGE=? -->
o Substantial uptake for a variety of drugs

<!-- PAGE=? -->
 Thiopental

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 Halothane

<!-- PAGE=? -->
 drug is progressively diluted as blood in the umbilical vein becomes admixed with fetal venous blood from the

<!-- PAGE=? -->
o gastrointestinal tract

<!-- PAGE=? -->
o lower extremities

<!-- PAGE=? -->
o head and upper extremities

<!-- PAGE=? -->
o lungs

<!-- PAGE=? -->
 Because of this unique pattern of fetal circulation, continuous administration of anesthetic concentrations of nitrous oxide caused newborn depression only if the induction-to-delivery interval exceeded 5-10 minutes

<!-- PAGE=? -->
 rapid redistribution in maternal plasma after administration of thiopental < 4 mg/kg results in fetal arterial concentrations below a level that would result in neonatal depression

<!-- PAGE=? -->
 Other factors include

<!-- PAGE=? -->
o higher relative water content of fetal brain

<!-- PAGE=? -->
o nonhomogeneity of blood flow in the intervillous space

<!-- PAGE=? -->
o progressive dilution by admixture with various componenets of fetal circulation

<!-- PAGE=? -->
 Placenta

<!-- PAGE=? -->
o the driving force for placental drug transfer is the concentration gradient of free drug between the

<!-- PAGE=? -->
maternal and fetal blood

<!-- PAGE=? -->
o The extent of drug transfer is dependent on

<!-- PAGE=? -->
 molecular weight

<!-- PAGE=? -->
 protein binding

<!-- PAGE=? -->
 degree of lipid solubility

<!-- PAGE=? -->
 maternal drug concentration

<!-- PAGE=? -->
 maternal and fetal pH

<!-- PAGE=? -->
o Hemodynamic events

<!-- PAGE=? -->
 Factors decreasing placental blood flow: Aortocaval compression, hypotension, hemorrhage can decrease drug delivery to fetus

<!-- PAGE=? -->
 In labour uterine contractions intermittently decrease placental flow which affects drug uptake in fetus

<!-- PAGE=? -->
 Fetal regional blood flow changes also affect amount of drug taken up by individual organs; during asphyxia more fetal CO perfuses heart, brain placenta

<!-- PAGE=? -->
o Most drugs cross the placenta by simple diffusion, so thiopental and other lipid-soluble drugs with low molecular weights are most readily transferred.

<!-- PAGE=? -->
o Limited transfer with

<!-- PAGE=? -->
 Highly ionized substances

<!-- PAGE=? -->
 poor lipid solubility

<!-- PAGE=? -->
 significant protein binding

<!-- PAGE=? -->
o Fetal pH is slightly lower than maternal pH

<!-- PAGE=? -->
 pH gradient causes the ionized fraction of weak bases, such as opioids and local anesthetics (NH3  NH4+), to be higher in the fetus

<!-- PAGE=? -->
 fetal drug level may be higher than predicted from the maternal total drug level because of (ion trapping)

<!-- PAGE=? -->
 acidotic fetus results in a greater tendency for drug to exist in the ionized form, which cannot diffuse back across the placenta into the maternal plasma

<!-- PAGE=? -->
o causes a larger total amount of drug to accumulate in the fetal plasma and tissues

<!-- PAGE=? -->
o Different total drug concentrations can also result from differences between mother and fetus in the extent of drug binding to plasma proteins

<!-- PAGE=? -->
o regardless of the effects of pH and protein binding, the concentration of free, nonionized drug is the same on both sides of the placenta once equilibrium is reached

<!-- PAGE=? -->
 this is the most important form, because it has the most pharmacologic activity

<!-- PAGE=? -->
o At equilibrium, the concentrations of nonionized drug in the fetal and maternal plasma are equal

<!-- PAGE=? -->
o Transport mechanisms

<!-- PAGE=? -->
 Passive transfer - depends on

<!-- PAGE=? -->
 conc and electrochemical differences across the placenta

<!-- PAGE=? -->
 molecular weight: < 500 D cross easily,

<!-- PAGE=? -->
 lipid solubility: liposoluble drug cross easy ( LA= weak bases)

<!-- PAGE=? -->
 degree of inonization (charged molecules are tranferred within protein channels)

<!-- PAGE=? -->
 facilitated transport

<!-- PAGE=? -->
 active transport

<!-- PAGE=? -->
 other factors that influence placental transport

<!-- PAGE=? -->
 changes in maternal & fetal blood flow

<!-- PAGE=? -->
o any cause of dec. uterine blood flow will affect drug transfer

<!-- PAGE=? -->
 hypotension, contraction etc…

<!-- PAGE=? -->
 placental binding

<!-- PAGE=? -->
 placental metabolism

<!-- PAGE=? -->
 diffusion capacity

<!-- PAGE=? -->
 degree of maternal and fetal plasma binding

<!-- PAGE=? -->
o Drug transfer

<!-- PAGE=? -->
 Inhalation anesthetic agents

<!-- PAGE=? -->
 LA

<!-- PAGE=? -->
 rapid transfer

<!-- PAGE=? -->
o high lipid solubility and low MW

<!-- PAGE=? -->
 Induction agents

<!-- PAGE=? -->
 STP, Propofol, ketamine all cross placenta

<!-- PAGE=? -->
 BZD

<!-- PAGE=? -->
 Diazepam highly lipophyllic - rapidly crosses ([equal] within 1 min)

<!-- PAGE=? -->
 Lorazepam takes 3 hrs after administration to reach F:M=1

<!-- PAGE=? -->
 Midazolam less

<!-- PAGE=? -->
 Opioids:

<!-- PAGE=? -->
 morphine rapidly crosses placenta, high F:M ratio 0.9

<!-- PAGE=? -->
 Fentany more lipophillic but more protein bound

<!-- PAGE=? -->
o F:M ratio 0.37-0.57

<!-- PAGE=? -->
 Sufentanyl F:M 0.8

<!-- PAGE=? -->
o less systemic absorbtion form epidural space

<!-- PAGE=? -->
 small MW ( 234-288 Da), weak bases (lipophilic)

<!-- PAGE=? -->
 bupivacaine F:M 0.2-0.4

<!-- PAGE=? -->
 Lidocaine F:M = 0.5-0.7

<!-- PAGE=? -->
o due to higher protein binding of Bupivacaine

<!-- PAGE=? -->
 NMR

<!-- PAGE=? -->
 are quaternary ammonium salts

<!-- PAGE=? -->
 do not cross placenta

<!-- PAGE=? -->
 fetal blood levels can increase over time with repeat boluses

<!-- PAGE=? -->
 Reversal agents

<!-- PAGE=? -->
 Neostigmine and Edrophonium are ionized at physiologic pH

<!-- PAGE=? -->
 do not cross placenta

<!-- PAGE=? -->
 fetal brady with Neostigmine has be observed (?small amount can cross)

<!-- PAGE=? -->
o Give Neo + Atropine to avoid

<!-- PAGE=? -->
o Glycopyrrolate does not cross placenta

<!-- PAGE=? -->
 Anticholinergics: Atropine crosses placenta F:M= 0.93

<!-- PAGE=? -->
o Metabolism

<!-- PAGE=? -->
 placental drug uptake is limited

<!-- PAGE=? -->
 there is no placental metabolism of the agents commonly used in obstetric anesthesia

<!-- PAGE=? -->
GA Caesarean section

<!-- PAGE=? -->
 Anesthetic maintenance before delivery must balance neonatal vigor with adequate maternal anesthesia

<!-- PAGE=? -->
 High risk procedure for awareness

<!-- PAGE=? -->
o overall rate of recall of 0.9 percent

<!-- PAGE=? -->
o 6.1 percent rate of dreaming

<!-- PAGE=? -->
 FIO2 of at least 50 percent before delivery is recommended

<!-- PAGE=? -->
 Volatile

<!-- PAGE=? -->
o Half MAC volatile in 50% nitrous limits maternal recall without increasing newborn depression

<!-- PAGE=? -->
o time from induction of anesthesia to delivery less than 10 minutes

<!-- PAGE=? -->
o the uterus should contract adequately in response to oxytocin, despite the administration of a low concentration of a volatile halogenated agent

<!-- PAGE=? -->
Mitral Stenosis

<!-- PAGE=? -->
 The most commonly encountered valvular lesion in pregnancy

<!-- PAGE=? -->
 Often do not tolerate CV demands of pregnancy:

<!-- PAGE=? -->
o plasma volume of pregnancy increases risk of pulmonary edema

<!-- PAGE=? -->
o physiological  HR of pregnancy shortens LV filling time and  LAP and PAP

<!-- PAGE=? -->
 ~75% patients will demonstrate clinical deterioration in NYHs status

<!-- PAGE=? -->
 Incidence of cardiac complications related to severity of MS:

<!-- PAGE=? -->
o ~70% severe

<!-- PAGE=? -->
o ~40% moderate

<!-- PAGE=? -->
o ~25% mild

<!-- PAGE=? -->
Anesthetic considerations

<!-- PAGE=? -->
1 Considerations of Pregnancy

<!-- PAGE=? -->
2 Considerations of mitral stenosis

<!-- PAGE=? -->
 risk of endocarditis

<!-- PAGE=? -->
 impaired LV filling

<!-- PAGE=? -->
 increased LAP  pulmonary edema, atrial fibrillation and mural thrombus

<!-- PAGE=? -->
 +/- pul HTN and RV failure

<!-- PAGE=? -->
 medications  anticoagulants, diuretics

<!-- PAGE=? -->
3 Physiologic interaction between MS and pregnancy

<!-- PAGE=? -->
 inability to mount  CO required d/t impaired LV filling

<!-- PAGE=? -->
  SVR and  HR not tolerated

<!-- PAGE=? -->
  preload following delivery poorly tolerated

<!-- PAGE=? -->
 hypovolemia poorly tolerated d/t required  filling pressures

<!-- PAGE=? -->
4 Increased maternal and fetal morbidity and mortality

<!-- PAGE=? -->
Neuroaxial

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Complications of Regional Anesthesia

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
 incidence and severity of hypotension depend on

<!-- PAGE=? -->
 the height of the block

<!-- PAGE=? -->
 the position of the parturient

<!-- PAGE=? -->
 whether prophylactic measures were taken including

<!-- PAGE=? -->
o intravenous administration of fluids

<!-- PAGE=? -->
o avoidance of aortocaval compression (left uterine displacement)

<!-- PAGE=? -->
o vigilant monitoring of blood pressure at frequent intervals

<!-- PAGE=? -->
 prophylactic administration of commonly used doses of ephedrine does not appear to be of benefit regarding prevention

<!-- PAGE=? -->
o Accidental Dural Puncture

<!-- PAGE=? -->
 incidence of up to 3%

<!-- PAGE=? -->
 can lead to the development of PDPH in up to 70% of cases

<!-- PAGE=? -->
 traditional management of accidental dural puncture is to reposition the epidural catheter at a different interspace

<!-- PAGE=? -->
 Alternately the epidural catheter be passed into the spinal space to become a continuous spinal technique

<!-- PAGE=? -->
 establishes rapid and effective pain relief

<!-- PAGE=? -->
 possible dec. incidence of PDPH and the need for an epidural blood patch

<!-- PAGE=? -->
 provides excellent labor analgesia and a route toward almost instant onset of blockade for cesarean section

<!-- PAGE=? -->
 spinal headache may be reduced if

<!-- PAGE=? -->
 injection of CSF from the epidural syringe back into the subarachnoid space through the epidural needle

<!-- PAGE=? -->
 insertion of an epidural catheter into the subarachnoid space

<!-- PAGE=? -->
 injection of preservative-free normal saline through the intrathecal catheter before its removal

<!-- PAGE=? -->
 administration of continuous intrathecal labor analgesia

<!-- PAGE=? -->
 leaving the intrathecal catheter in situ for a total of 12 to 20 hours

<!-- PAGE=? -->
o Post-Dural Puncture Headache

<!-- PAGE=? -->
 See below

<!-- PAGE=? -->
o Total Spinal Block

<!-- PAGE=? -->
 Subdural spread of the local anesthetic can cause a high block characterized by

<!-- PAGE=? -->
 high sensory level

<!-- PAGE=? -->
 sacral sparing

<!-- PAGE=? -->
 incomplete or absent motor block

<!-- PAGE=? -->
 Single-shot spinal anesthesia after a failed spinal or patchy epidural may also precipitate total spinal anesthesia

<!-- PAGE=? -->
 possible mechanisms include

<!-- PAGE=? -->
o Expansion of the epidural space may compress the spinal canal and encourage cephalad spread of intrathecal drugs

<!-- PAGE=? -->
o Rapid transfer of local anesthetic across the dural hole

<!-- PAGE=? -->
o sufficient local anesthetic may be present in the nerve roots to decrease the dose requirements of subsequent spinal anesthesia

<!-- PAGE=? -->
o Neurologic Complications

<!-- PAGE=? -->
 rare, and often they are not due to the neuraxial block

<!-- PAGE=? -->
 three groups

<!-- PAGE=? -->
 those relating directly to anesthesia

<!-- PAGE=? -->
 those unrelated to anesthesia

<!-- PAGE=? -->
o Backache

<!-- PAGE=? -->
 Low back pain is common after delivery

<!-- PAGE=? -->
 prospective studies evaluating labor epidural analgesia and postpartum back pain failed to find a significant link between epidural analgesia and back pain

<!-- PAGE=? -->
 rosk factors for backacje include

<!-- PAGE=? -->
 greater weight

<!-- PAGE=? -->
 shorter stature

<!-- PAGE=? -->
 previous history of back pain

<!-- PAGE=? -->
 younger age

<!-- PAGE=? -->
o Central Nervous System Infections

<!-- PAGE=? -->
 the reported incidence of infection after regional anesthesia is extremely low

<!-- PAGE=? -->
 epidural abscess may form spontaneously in up to 1 in 10,000 patients admitted to the hospital

<!-- PAGE=? -->
 Typical signs and symptoms include

<!-- PAGE=? -->
 Fever

<!-- PAGE=? -->
 back pain

<!-- PAGE=? -->
 localized infection at the level of the epidural site 2 to 3 days after the procedure

<!-- PAGE=? -->
 Endogenous spread may occur from a site of infection elsewhere in the body

<!-- PAGE=? -->
o Spinal and Epidural Hematoma

<!-- PAGE=? -->
 The incidence of neurologic injury resulting from hematoma associated with neuraxial anesthesia is very low

<!-- PAGE=? -->
 ~ 1 in 150,000 for epidural

<!-- PAGE=? -->
 ~ 1 in 220,000 for spinal

<!-- PAGE=? -->
 Risk factors include

<!-- PAGE=? -->
 hemostatic abnormality

<!-- PAGE=? -->
 difficult or bloody placement of needles and catheters

<!-- PAGE=? -->
 LMWH

<!-- PAGE=? -->
o Intervascular injection

<!-- PAGE=? -->
 Five strategies reduce the risk of epidural vein cannulation

<!-- PAGE=? -->
 the lateral as opposed to sitting position

<!-- PAGE=? -->
 fluid administered through the epidural needle before catheter insertion

<!-- PAGE=? -->
 single rather than multiorifice catheter

<!-- PAGE=? -->
 wire-embedded polyurethane compared with polyamide epidural catheter

<!-- PAGE=? -->
 catheter insertion depth 6 cm or less

<!-- PAGE=? -->
 The paramedian as opposed to midline needle approach and smaller epidural needle or catheter gauges do not reduce the risk of epidural vein cannulation

<!-- PAGE=? -->
 those in which anesthesia is an incidental but possibly a contributory factor

<!-- PAGE=? -->
 Neurologic examination of postpartum women has revealed transient postpartum sensory dysfunction not related to anesthesia in up to 21% of women who did not report any symptoms

<!-- PAGE=? -->
 Neurologic complications are five times more common after childbirth itself than after regional blockade

<!-- PAGE=? -->
 Most neurologic injuries after delivery may result from

<!-- PAGE=? -->
 Instrumentation

<!-- PAGE=? -->
 nonanatomic positioning during labor

<!-- PAGE=? -->
 compression of sacral nerve roots by the fetal head

<!-- PAGE=? -->
Neuroaxial Opioids

<!-- PAGE=? -->
Chestnut, Miller

<!-- PAGE=? -->
 Spinal opioids do not provide adequate analgesia for 2 nd stage

<!-- PAGE=? -->
 Side effects of large doses Spinal morphine

<!-- PAGE=? -->
o N/V

<!-- PAGE=? -->
o Somnolence

<!-- PAGE=? -->
o respiratory depression

<!-- PAGE=? -->
o pruritus

<!-- PAGE=? -->
 decreases with decreased dose

<!-- PAGE=? -->
 Clonidine

<!-- PAGE=? -->
o increase duration without increasing motor block

<!-- PAGE=? -->
o increase hypotension

<!-- PAGE=? -->
o May cause fetal bradycardia

<!-- PAGE=? -->
 No sympathectomy with spinal opiods

<!-- PAGE=? -->
o decrease BP d/t pain relief

<!-- PAGE=? -->
 Pruritis is a common s.e of IT > epidural opioid

<!-- PAGE=? -->
o if lipid soluble then segmental

<!-- PAGE=? -->
o morphine = facial

<!-- PAGE=? -->
o Unrelated to histamine release

<!-- PAGE=? -->
 d/t disruption of sensory modulation

<!-- PAGE=? -->
 tx with diphenhydramine

<!-- PAGE=? -->
 naloxone .1mg

<!-- PAGE=? -->
 nalbuphine 2.5mg

<!-- PAGE=? -->
 Respiratory depression

<!-- PAGE=? -->
o 2h with lipid soluble, delayed with morphine up to 24 hrs

<!-- PAGE=? -->
o dose dependant

<!-- PAGE=? -->
o delayed respiratory depression is related to cephlad movement of CSF

<!-- PAGE=? -->
o respiratory rate is NOT may not reliably predict impending respiratory depression

<!-- PAGE=? -->
 urinary retention a problem with NA opioids

<!-- PAGE=? -->
 delayed gastric emptying

<!-- PAGE=? -->
o little effect with epidural fentanyl

<!-- PAGE=? -->
o more delay with spinal fentanyl

<!-- PAGE=? -->
 Reported recrudescence of HSV1 with epidural morphine

<!-- PAGE=? -->
o case reports with Spinal fentanyl and meperdine

<!-- PAGE=? -->
 Fetal effects

<!-- PAGE=? -->
o epidural opioid

<!-- PAGE=? -->
 little effect on FHR

<!-- PAGE=? -->
Neuropathy

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Femoral Nerve

<!-- PAGE=? -->
o Diminished or absent patellar reflex

<!-- PAGE=? -->
o nerve supply to the ilio-psoas muscle is spared, so that some hip flexion is still possible

<!-- PAGE=? -->
 may walk satisfactorily on a level surface but may be unable to climb stairs

<!-- PAGE=? -->
 Obturator and femoral nerve injury

<!-- PAGE=? -->
o Risk factors:  transverse lie, abnormal position of the vertex (OP), fetal macrosomia, prolonged labour

<!-- PAGE=? -->
o Mechanism: compression of the lumbar plexus on one or both sides of the pelvis

<!-- PAGE=? -->
o 25% are bilateral, often mistaken as intraspinal injury

<!-- PAGE=? -->
 Obturator nerve injury (ant divisions of L2,3,4)

<!-- PAGE=? -->
 Weakness of hip adduction and rotation

<!-- PAGE=? -->
 Decreased sensation over medial aspect of thigh above knee

<!-- PAGE=? -->
 Femoral nerve injury (post divisions L2,3,4)

<!-- PAGE=? -->
 Unable to climb stairs, but may be able to walk (weak quads)

<!-- PAGE=? -->
 Decreased patellar reflex

<!-- PAGE=? -->
 Common peroneal injury

<!-- PAGE=? -->
o Weak ankle dorsiflexion

<!-- PAGE=? -->
o May be difficult to discern from lumbosacral plexus injury

<!-- PAGE=? -->
 lateral femoral cutaneous nerve

<!-- PAGE=? -->
o Numberness of anterolateral thigh

<!-- PAGE=? -->
o No motor symptoms

<!-- PAGE=? -->
 Post-partum foot drop

<!-- PAGE=? -->
o Fetal brow compression of lumbosacral trunk as it crosses the sacral ala

<!-- PAGE=? -->
o Results in:

<!-- PAGE=? -->
 Weakness of eversion and dorsiflexion

<!-- PAGE=? -->
 Decreased pinprick along lateral surface of lower leg and dorsal surface of foot

<!-- PAGE=? -->
 Foot drop is almost always unilateral (on opposite side to fetal occiput)

<!-- PAGE=? -->
Nitroglycerin

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 For used for rapid onset of profound uterine relaxation

<!-- PAGE=? -->
o uterine hyperstimulation

<!-- PAGE=? -->
o fetal head entrapment

<!-- PAGE=? -->
 more likely to occur in patients who are less than 32 weeks gestation

<!-- PAGE=? -->
 fetal head is larger than the wedge formed by the fetal buttocks and thighs

<!-- PAGE=? -->
o internal version and extraction of the second twin

<!-- PAGE=? -->
o uterine inversion

<!-- PAGE=? -->
o retained placenta

<!-- PAGE=? -->
 may cause resp depression of neonate

<!-- PAGE=? -->
 infusions of opioid plus local did not depress neonate

<!-- PAGE=? -->
 spinal opioids even less

<!-- PAGE=? -->
 fetal brady after Spinal lipid soluble opioid d/t rapid onset analgesia and decrease circulating catecholamines resulting in increased uterine tone

<!-- PAGE=? -->
 decrease B2 stimulation and relaxation

<!-- PAGE=? -->
 FHR should be monitored

<!-- PAGE=? -->
Non-obstetrical Surgery

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 document date of LMP

<!-- PAGE=? -->
o elective surgery should be postponed until after delivery

<!-- PAGE=? -->
o essential surgery should be avoided during 1 st trimester

<!-- PAGE=? -->
 increased risk of aspiration >16-20 weeks  RSI

<!-- PAGE=? -->
 Pre-Term Labour

<!-- PAGE=? -->
o increased risk of abortion and preterm delivery thought to be related to underlying condition or surgery itself (not related to anesthesia)

<!-- PAGE=? -->
 risk doubled in first trimester

<!-- PAGE=? -->
o A study of 778 appendectomies during pregnancy  22% delivered in the week after surgery

<!-- PAGE=? -->
o no anesthetic technique has been shown to prevent PTL

<!-- PAGE=? -->
o prophylactic use of tocolytics may be useful in certain high-risk procedures (e.g. cervical cerclage)

<!-- PAGE=? -->
 Teratogenicity

<!-- PAGE=? -->
o None of the commonly used drugs are proven teratogens

<!-- PAGE=? -->
o N2O is best avoid

<!-- PAGE=? -->
 Apoptosis in rat brains

<!-- PAGE=? -->
 FHR monitoring

<!-- PAGE=? -->
o should be performed  after ~20-24 weeks, however, has not been demonstrated to improve fetal outcome

<!-- PAGE=? -->
o requires skilled interpretation as misinterpretation can lead to unsafe intervention

<!-- PAGE=? -->
o Loss of beat-to-beat variability is normal under anesthesia (opioids, induction agents > volatiles), but fetal bradycardia indicates fetal distress

<!-- PAGE=? -->
 intrauterine retrolental fibroplasias and premature closure of the ductus arteriosus cannot result from high levels of maternal PaO2

<!-- PAGE=? -->
o Fetal PaO2 never exceeds 60mmHg even when maternal PaO2 increases to 600mmHg

<!-- PAGE=? -->
 Procedures

<!-- PAGE=? -->
o Laparoscopy

<!-- PAGE=? -->
 risks: uterine or fetal trauma, fetal acidosis, decreased uteroplacental perfusion from  intra-abdominal pressure

<!-- PAGE=? -->
 Can do laparoscopy up to and through 2 nd trimester

<!-- PAGE=? -->
 open trochar placement

<!-- PAGE=? -->
 maintain intra-abdominal pressures btw 8-12 (certainly < 15 mmHg)

<!-- PAGE=? -->
 EtCO2 to PaCO2 gradient variable and unpredictable with laparoscopy in pregnancy

<!-- PAGE=? -->
 Artial gas monitoring should be considered

<!-- PAGE=? -->
o ECT

<!-- PAGE=? -->
 OB consultation prior to initiation of treatments

<!-- PAGE=? -->
 should have tocodynamometry within hour prior, and following ECT to ensure uterine contractions are not present

<!-- PAGE=? -->
 intubate if patient beyond 1 st trimester

<!-- PAGE=? -->
o Trauma

<!-- PAGE=? -->
 early fetal U/S and FH assessment

<!-- PAGE=? -->
 all diagnostic modalities required should be performed (primacy of mother)

<!-- PAGE=? -->
 indications for emergent caesarian section:

<!-- PAGE=? -->
 stable mother with a viable fetus in distress

<!-- PAGE=? -->
 traumatic uterine rupture

<!-- PAGE=? -->
 gravid uterus precluding intra-operative repair

<!-- PAGE=? -->
 unsalvageable mother with viable fetus

<!-- PAGE=? -->
 if fetus is pre-viable or dead, optimize mother (i.e. do not go for c-section, vaginal delivery can be performed later)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Fetal Bradycardia

<!-- PAGE=? -->
 indicates fetal distress

<!-- PAGE=? -->
 Treatment: improve oxygenation and perfusion (inc BP, inc uterine displacement, tocolysis, alter surgical manipulation, maternal normocarbia, correct hypovolemia, inc maternal FiO2)

<!-- PAGE=? -->
 If sustained, may require delivery

<!-- PAGE=? -->
o Maternal hyperventilation/ hypocapnia- fetal compromise

<!-- PAGE=? -->
 umbilical artery constriction

<!-- PAGE=? -->
 left shift of the maternal oxy-hemoglobin dissociation curve

<!-- PAGE=? -->
 PPV may lead to decreased CO

<!-- PAGE=? -->
 Therefore the goal is to maintain maternal PaCO2 28-32

<!-- PAGE=? -->
o Pre-term labour (see anesthesia management)

<!-- PAGE=? -->
 Consider deepening anesthetic

<!-- PAGE=? -->
 be prepared for immediate delivery

<!-- PAGE=? -->
 tocolytics (B-agonists) can cause pulmonary edema

<!-- PAGE=? -->
o maternal hypotension ddx

<!-- PAGE=? -->
 deep level of GA

<!-- PAGE=? -->
 sympathectomy due to high epid/spinal

<!-- PAGE=? -->
 aortocaval compression

<!-- PAGE=? -->
 hemorrhage

<!-- PAGE=? -->
 hypovolemia

<!-- PAGE=? -->
o conditions where delivery of fetus immediately prior to surgery:

<!-- PAGE=? -->
 positioning: sitting, prone

<!-- PAGE=? -->
 prolonged case

<!-- PAGE=? -->
 deliberate hypotension

<!-- PAGE=? -->
 maternal hyperventilation

<!-- PAGE=? -->
 major intra-operative blood loss

<!-- PAGE=? -->
 NB: all above potentially w/ neuro

<!-- PAGE=? -->
Oxygen delivery

<!-- PAGE=? -->
P&P, Chestnut

<!-- PAGE=? -->
 Oxygen delivery to the fetus depends on

<!-- PAGE=? -->
o placental perfusion

<!-- PAGE=? -->
o maternal arterial oxygen content

<!-- PAGE=? -->
 [Hg] x 1.39 x % saturation

<!-- PAGE=? -->
 hemoglobin concentration is lowered during normal pregnancy

<!-- PAGE=? -->
 PaO2 may be reduced due to inc. pulmonary venous admixture

<!-- PAGE=? -->
 During pregnancy the oxyhemoglobin dissociation curven is right shifted

<!-- PAGE=? -->
o Normal 27mmHg,

<!-- PAGE=? -->
o Pregnancy 30 mmHg

<!-- PAGE=? -->
 occurs as a result of an increase in the 2,3-diphosphoglycerate content of maternal red cells

<!-- PAGE=? -->
o excessive hyperventilation and hypocarbia during labour may reverse this shift, resulting in impaired maternal-fetal oxygen transfer

<!-- PAGE=? -->
 The fetus is adapted to survive at a much lower arterial oxygen tension

<!-- PAGE=? -->
o umbilical vein PaO2 approximately 30 mm Hg

<!-- PAGE=? -->
o These adaptations include

<!-- PAGE=? -->
 a higher oxygen-carrying capacity

<!-- PAGE=? -->
 fetal hemoglobin [Hb-F] being approximately 17 g/100 ml

<!-- PAGE=? -->
 a greater affinity of Hb-F for oxygen

<!-- PAGE=? -->
o Hb-F oxygen dissociation curve being shifted well to the left

<!-- PAGE=? -->
 P50 of 17 mmHg

<!-- PAGE=? -->
 the Bohr effect

<!-- PAGE=? -->
o decreased affinity of hgb for oxygen in the presence of carbon dioxide, acidosis

<!-- PAGE=? -->
o favors Hb-F oxygen uptake within the placenta

<!-- PAGE=? -->
o accounts for 20 to 40% of maternal-fetal oxygen transfer

<!-- PAGE=? -->
o oxygen stores in the fetus are very limited and metabolic acidosis is readily incurred whenever oxygen transfer fails to meet oxygen requirements

<!-- PAGE=? -->
o Increasing maternal O2 tension will increase O2 tension in the umbilical artery and the umbilical vein

<!-- PAGE=? -->
 increasing the FiO2 from .21 to 1.0 will only increase the UV PO2 by 10 mm Hg at 1 atm (to <50 mm Hg)

<!-- PAGE=? -->
 Limited flow exchange

<!-- PAGE=? -->
o high placental O2 consumption

<!-- PAGE=? -->
o uneven distribution of materal and fetal blood flow in the placenta

<!-- PAGE=? -->
 does not result in any decrease in uterine or umbilical blood flow

<!-- PAGE=? -->
 No fetal abnormalities have been demonstrated in humans or animal models by the administration of 100% O2 at 1 atm

<!-- PAGE=? -->
 Hyperbaric O2 has been shown to cause a number of congenital abnormalities in animal models (faust)

<!-- PAGE=? -->
o spina bifida

<!-- PAGE=? -->
o exencephaly

<!-- PAGE=? -->
o limb defects

<!-- PAGE=? -->
o retrolental fibroplasias

<!-- PAGE=? -->
o retinal detachment

<!-- PAGE=? -->
o microphthalmia

<!-- PAGE=? -->
o stillbirth

<!-- PAGE=? -->
 FiO2 should be increased

<!-- PAGE=? -->
 whenever fetal hypoxia is suspected,

<!-- PAGE=? -->
 routine administration should be provided during cesarean section performed under regional blockade

<!-- PAGE=? -->
Fig 11.2 Placental Oxygen Balance

<!-- PAGE=? -->
Uterine vein

<!-- PAGE=? -->
Uterine Flow = 6oomls'min

<!-- PAGE=? -->
pO2

<!-- PAGE=? -->
pO2

<!-- PAGE=? -->
Maternal [Hb] = 120g

<!-- PAGE=? -->
S02

<!-- PAGE=? -->
989

<!-- PAGE=? -->
S02

<!-- PAGE=? -->
7596

<!-- PAGE=? -->
of HbA: 26.6 mmHg

<!-- PAGE=? -->
Coz

<!-- PAGE=? -->
Coz

<!-- PAGE=? -->
12.2 mlso/dl

<!-- PAGE=? -->
Matenal sinuses

<!-- PAGE=? -->
Mean pOgradient = 3OmmHg

<!-- PAGE=? -->
Diffusion distance = 3.5um

<!-- PAGE=? -->
Foetal capillaries

<!-- PAGE=? -->
Umbilical Flow = 300 mls'min

<!-- PAGE=? -->
pO2

<!-- PAGE=? -->
18mmHg

<!-- PAGE=? -->
pO2

<!-- PAGE=? -->
28mmHg

<!-- PAGE=? -->
S02

<!-- PAGE=? -->
4596

<!-- PAGE=? -->
p50 of HbF: 20 mmHg

<!-- PAGE=? -->
S02

<!-- PAGE=? -->
7096

<!-- PAGE=? -->
Coz

<!-- PAGE=? -->
10.3mlsodl

<!-- PAGE=? -->
Coz

<!-- PAGE=? -->
16.0mlsOdl

<!-- PAGE=? -->
p50

<!-- PAGE=? -->
PCEA

<!-- PAGE=? -->
Miller, Chestnut

<!-- PAGE=? -->
 PCEA allows for individualization of postoperative analgesic requirements

<!-- PAGE=? -->
 safe and effective technique

<!-- PAGE=? -->
 Advantages

<!-- PAGE=? -->
o lower drug use

<!-- PAGE=? -->
 less side effects including

<!-- PAGE=? -->
 motor block

<!-- PAGE=? -->
 hypotension

<!-- PAGE=? -->
o greater patient satisfaction

<!-- PAGE=? -->
o superior analgesia

<!-- PAGE=? -->
o reduced demand on staff

<!-- PAGE=? -->
PDPH

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
 CSF production at 0.35 mL/min, total volume ~150 mL

<!-- PAGE=? -->
 If CSF leak > production, causes low CSF pressure

<!-- PAGE=? -->
 Pain may be caused by:

<!-- PAGE=? -->
o Traction/descent of sensitive intracranial structures

<!-- PAGE=? -->
o Vascular: increased CBF in response to low CSF pressure

<!-- PAGE=? -->
 not all postpartum headaches occur as a result of dural puncture

<!-- PAGE=? -->
o headaches occurred in 15% of parturients who did not receive an epidural

<!-- PAGE=? -->
o DDx

<!-- PAGE=? -->
 Primary H/A disorders

<!-- PAGE=? -->
 Nonspecific H/A

<!-- PAGE=? -->
 Tension, Migraine

<!-- PAGE=? -->
 Secondary H/A disorders

<!-- PAGE=? -->
 PDPH

<!-- PAGE=? -->
 Hypertension, Preeclampsia

<!-- PAGE=? -->
 Intracranial Pathology

<!-- PAGE=? -->
o SAH, Subdural

<!-- PAGE=? -->
o Cortical vein thrombosis

<!-- PAGE=? -->
o Posterior reversible leukoencephalopathy

<!-- PAGE=? -->
o Pneumocephalus

<!-- PAGE=? -->
 Infections

<!-- PAGE=? -->
o Meningitis

<!-- PAGE=? -->
 Bacterial, chemical (arachinoiditis)

<!-- PAGE=? -->
o Sinusitis

<!-- PAGE=? -->
 Substance withdrawal / intoxication

<!-- PAGE=? -->
o Caffeine

<!-- PAGE=? -->
 Risk factors for developing PDPH

<!-- PAGE=? -->
o Hx or previous PDPH

<!-- PAGE=? -->
o Age - Younger more frequent

<!-- PAGE=? -->
o Gender - Females > males

<!-- PAGE=? -->
o Vaginal delivery

<!-- PAGE=? -->
o Morbid obesity is protective

<!-- PAGE=? -->
o Air travel soon after dural puncture

<!-- PAGE=? -->
o Technique

<!-- PAGE=? -->
 Needle design

<!-- PAGE=? -->
 Cutting > blunt

<!-- PAGE=? -->
 Larger > smaller

<!-- PAGE=? -->
 Needle bevel - More when dural fibers cut transversely

<!-- PAGE=? -->
o Pregnancy - More when pregnant

<!-- PAGE=? -->
o # of dural punctures - More with multiple punctures

<!-- PAGE=? -->
o paramedian might reduce the incidence

<!-- PAGE=? -->
 NOT risk factors

<!-- PAGE=? -->
o Pregnancy

<!-- PAGE=? -->
o Continuous spinals

<!-- PAGE=? -->
o Timing of ambulation

<!-- PAGE=? -->
 Features

<!-- PAGE=? -->
o 75% of women with PDPH after birth have difficulty with ADLs

<!-- PAGE=? -->
o Typically frontal/occipital, often radiation to the neck, mild to incapacitating

<!-- PAGE=? -->
o Postural component is a key feature

<!-- PAGE=? -->
 worse upright, some relief horizontal

<!-- PAGE=? -->
 same in cerebral sinus thrombosis

<!-- PAGE=? -->
o Timing: onset PPD 1 or 2

<!-- PAGE=? -->
 lasting < 1 wk

<!-- PAGE=? -->
 7% last > 1 week

<!-- PAGE=? -->
 rarely months

<!-- PAGE=? -->
o Other associated Sx

<!-- PAGE=? -->
 nausea 60%, vomiting 24%

<!-- PAGE=? -->
 neck stiffness 43%

<!-- PAGE=? -->
 ocular (photophobia, diplopia, difficulty in accommodation) 13%

<!-- PAGE=? -->
 auditory (hearing loss, hyperacusis, tinnitus) 12%

<!-- PAGE=? -->
 occasional cranial nerve palsy

<!-- PAGE=? -->
 unusual complication of dural puncture

<!-- PAGE=? -->
 incidence after spinal anesthesia varies from 1:300 to 1:8000

<!-- PAGE=? -->
 All cranial nerves can be involved with the exception of cranial nerves I, IX, and X

<!-- PAGE=? -->
o The VI cranial nerve is the most frequently affected because of its long intracranial course

<!-- PAGE=? -->
o attributed to continuous CSF leakage through the dural hole

<!-- PAGE=? -->
 rarely

<!-- PAGE=? -->
 subdural hematoma, due to traction on vessels

<!-- PAGE=? -->
 seizures d/t cerebral vasospasm

<!-- PAGE=? -->
 dural sinus thrombosis

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o VS, temperature

<!-- PAGE=? -->
o Neurologic exam: CNs, motor, sensory, gait/ ataxia

<!-- PAGE=? -->
o Imaging not recommended unless symptoms suggest another diagnosis

<!-- PAGE=? -->
 contrast enhanced MRI

<!-- PAGE=? -->
o ICHD-II diagnostic criteria:

<!-- PAGE=? -->
 Appears within 5 days of dural puncture

<!-- PAGE=? -->
 Occurs within 15 min of sitting or standing and resolves within 15 min of lying down

<!-- PAGE=? -->
 Associated with one of: neck stiffness, tinnitus, hypacusis, photophocia, nausea

<!-- PAGE=? -->
Table 31-3 Chestnut 4 th :

<!-- PAGE=? -->
 Prophylaxis after unintentional dural puncture:

<!-- PAGE=? -->
o bed rest is not effective and is probably not a good idea in this hypercoagulable population

<!-- PAGE=? -->
o hydration is not effetive

<!-- PAGE=? -->
o abdominal binder was useful after 22G spinals in one old study

<!-- PAGE=? -->
o caffeine not useful

<!-- PAGE=? -->
o interthecal catheters probably do not reduce the risk

<!-- PAGE=? -->
o prophylactic epdural blood patches/ saline are not helpful

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Supportive

<!-- PAGE=? -->
 Visit at least once daily to explain symptoms and prognosis, give support, and offer therapeutic options. Partner should attend if possible. Nurses should help the patient as much as possible, especially with breast-feeding, which can be done in the lateral horizontal position.

<!-- PAGE=? -->
 Detailed notes in chart

<!-- PAGE=? -->
 ASA Closed-Claims Study: 3 rd most common cause of litigation (only behind maternal death and newborn brain damage)

<!-- PAGE=? -->
o Conservative

<!-- PAGE=? -->
 Horizontal position : at least partial relief; prone may be better (  abd pressure)

<!-- PAGE=? -->
 No evidence that increasing fluid intake will cause a greater production of CSF

<!-- PAGE=? -->
o Pharmacologic

<!-- PAGE=? -->
 Acetaminophen, NSAIDS

<!-- PAGE=? -->
 caffeine

<!-- PAGE=? -->
 300 mg po bid (2-3 cups of coffee: coffee contains ~1 mg/mL)

<!-- PAGE=? -->
 effects appear to be transient

<!-- PAGE=? -->
 more effective when headaches are the result of smaller rather than larger needles

<!-- PAGE=? -->
 patients may feel anxious and unable to sleep

<!-- PAGE=? -->
 seizures and cardiac arrhythmias have been reported

<!-- PAGE=? -->
 deleterious effects on the newborn have not been shown

<!-- PAGE=? -->
o caffeine is present in breast milk

<!-- PAGE=? -->
 Vasopressin

<!-- PAGE=? -->
 Theophylline

<!-- PAGE=? -->
 cerebral vasoconstrictor

<!-- PAGE=? -->
 Sumatriptan

<!-- PAGE=? -->
 serotonin agonist with cerebral vasoconstriction properties

<!-- PAGE=? -->
 not all studies support its use

<!-- PAGE=? -->
 adrenocorticotropic hormone (ACTH)

<!-- PAGE=? -->
 anecdotally reported as a treatment

<!-- PAGE=? -->
 epidural morphine

<!-- PAGE=? -->
 helps but caution advised: may leak into CSF via dural hole

<!-- PAGE=? -->
o epidural blood patch

<!-- PAGE=? -->
 delay until residual neuroblockade has resolved

<!-- PAGE=? -->
 initially 90-96% successful but permanent cure in only ~60%

<!-- PAGE=? -->
 12-15 ml should be sufficient for most patients

<!-- PAGE=? -->
 15 ml of blood spreads a mean of 9 segments

<!-- PAGE=? -->
 most spreads cephalad

<!-- PAGE=? -->
 remain supine for 2 hrs post

<!-- PAGE=? -->
 blood is largely broken up by 18-24 hours

<!-- PAGE=? -->
 observational studies suggest that failure is more likely if the blood patch is performed within 24 hours of the dural puncture

<!-- PAGE=? -->
 Contraindicated in

<!-- PAGE=? -->
 high grade fever / sepsis

<!-- PAGE=? -->
o may be performed in the setting of low grade fever of known etiology on antibiotics

<!-- PAGE=? -->
 known coagulopathy

<!-- PAGE=? -->
 local cutaneous infection

<!-- PAGE=? -->
 increased ICP due to space occupying lesion

<!-- PAGE=? -->
 patient refusal

<!-- PAGE=? -->
 complete success rates are approximately 75%

<!-- PAGE=? -->
 65% first patch, 80% 2 nd patch

<!-- PAGE=? -->
 possibly dec. effectiveness if resulting from a large-bore needle

<!-- PAGE=? -->
 headache symptoms resolve almost immediately

<!-- PAGE=? -->
 possible mechanisms include

<!-- PAGE=? -->
o increase in CSF pressure

<!-- PAGE=? -->
o cerebral vasoconstriction

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 back pain 35%, mean duration 27 days

<!-- PAGE=? -->
 neck pain

<!-- PAGE=? -->
 radicular pain

<!-- PAGE=? -->
 cauda equine syndrome, paraparesis

<!-- PAGE=? -->
 meningitis, aseptic meningeal irritation

<!-- PAGE=? -->
 abscess

<!-- PAGE=? -->
 the incidence of complications (especially back pain) increases with increased volume, it appears that increased volume also increases the success rate

<!-- PAGE=? -->
 blood inserted into the epidural space will travel one space below the level of insertion of the epidural needle and up to four spaces above the site

<!-- PAGE=? -->
o Other

<!-- PAGE=? -->
 Epidural saline: bolus gives only transient increase in CSF pressure and symptoms, but infusion 10-20 mL/h has been used in failed blood patch

<!-- PAGE=? -->
 Prophylactic epidural dextran (20 mL of dextraN-40)

<!-- PAGE=? -->
 May be useful in the septic patient

<!-- PAGE=? -->
 Fibrin glue: successfully used but not currently for routine use

<!-- PAGE=? -->
 Surgical repair: rare reports for intractable PDPH x years

<!-- PAGE=? -->
o Prophylactic treatments

<!-- PAGE=? -->
 A variety of things have been tried to prevent the development of PDPH after unintentional or intentional dural puncture, as well as to treat PDPH. Basically, none of them are recommended as routine management at this point

<!-- PAGE=? -->
Physiologic Changes

<!-- PAGE=? -->
P&P, Miller

<!-- PAGE=? -->
Coagulation

<!-- PAGE=? -->
 Plasma factor concentration during pregnancy:

<!-- PAGE=? -->
o INCREASED

<!-- PAGE=? -->
 Fibrinogen (I)

<!-- PAGE=? -->
 VII

<!-- PAGE=? -->
 VIII

<!-- PAGE=? -->
 IX

<!-- PAGE=? -->
 X

<!-- PAGE=? -->
 XII

<!-- PAGE=? -->
 Plasminogen

<!-- PAGE=? -->
 FDP

<!-- PAGE=? -->
o DECREASED

<!-- PAGE=? -->
 Factors XI, XIII, and antithrombin III

<!-- PAGE=? -->
o NOCHANGE

<!-- PAGE=? -->
 Factor II and V

<!-- PAGE=? -->
 INR shortened 20%

<!-- PAGE=? -->
 PTT shortened 20%

<!-- PAGE=? -->
 Thromboelastography

<!-- PAGE=? -->
o hypercoagulable

<!-- PAGE=? -->
 Plt  count

<!-- PAGE=? -->
o no change or decreased

<!-- PAGE=? -->
 no change in bleeding time

<!-- PAGE=? -->
Physiology of Labor

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Supine hypotensive syndrome (aortocaval compression):

<!-- PAGE=? -->
o Form 13-16 weeks

<!-- PAGE=? -->
o 20% decline in SV and CO at term, in supine position

<!-- PAGE=? -->
 During labor

<!-- PAGE=? -->
o CO increases

<!-- PAGE=? -->
 10% stage I

<!-- PAGE=? -->
 25% in late stage 1

<!-- PAGE=? -->
 40 % stage 2

<!-- PAGE=? -->
o uterine contractions

<!-- PAGE=? -->
 further increase by 15-25%

<!-- PAGE=? -->
o Causes

<!-- PAGE=? -->
 increased SNS stimulation

<!-- PAGE=? -->
 autotransfusion from placenta

<!-- PAGE=? -->
 Postpartum

<!-- PAGE=? -->
o Immediately CO and CVP increase by 75% predelivery values

<!-- PAGE=? -->
o CO falls to prelabour levels by 48 hrs

<!-- PAGE=? -->
 to prepregnant levels by 12-24 weeks

<!-- PAGE=? -->
Gastric Emptying

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Risk of aspiration

<!-- PAGE=? -->
o Barash - 12 wks

<!-- PAGE=? -->
o Chestnut - 18-20 wks

<!-- PAGE=? -->
o BCWH - 16 wks

<!-- PAGE=? -->
 gastric emptying

<!-- PAGE=? -->
o decreased during labour only and with admin of opioids (NOT infusion of epidural opioids)

<!-- PAGE=? -->
o delayed in the early postpartum

<!-- PAGE=? -->
 Normal after 18 hrs

<!-- PAGE=? -->
 Prepregnant volume and pH

<!-- PAGE=? -->
 Proportion of women with gastric vol > 25ml is incr during labour

<!-- PAGE=? -->
 Proportion of women with gastric pH <2.5 is decr during labour

<!-- PAGE=? -->
o Acid secretion: decr T1 and T2, N T3

<!-- PAGE=? -->
 Decreased LES tone

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Enhanced progesterone production causes

<!-- PAGE=? -->
o decreased gastrointestinal motility

<!-- PAGE=? -->
o slower absorption of food

<!-- PAGE=? -->
o more acidic gastric secretions

<!-- PAGE=? -->
o decreased LES tone

<!-- PAGE=? -->
PPH

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 5Ts - Tone tissue trauma thrombin turn out

<!-- PAGE=? -->
 Predisposing factors

<!-- PAGE=? -->
o Precipitous labor

<!-- PAGE=? -->
o Instrumental delivery

<!-- PAGE=? -->
o GA

<!-- PAGE=? -->
o Prolonged labor

<!-- PAGE=? -->
o Uterine leiomyomas

<!-- PAGE=? -->
o Macrosomia

<!-- PAGE=? -->
o Twins

<!-- PAGE=? -->
o Chorioamnionitis

<!-- PAGE=? -->
o Multiparity

<!-- PAGE=? -->
o Prior C/S

<!-- PAGE=? -->
o Prior hysterotomy or curettage

<!-- PAGE=? -->
o Stimulated labor

<!-- PAGE=? -->
o History of PPH

<!-- PAGE=? -->
o Fetal demise

<!-- PAGE=? -->
o AFE

<!-- PAGE=? -->
o Tocolytic therapy

<!-- PAGE=? -->
 Abruption raises the risk of persistent hemorrhage secondary to atony and coagulopathy

<!-- PAGE=? -->
Uterine Atony

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o multiple gestation

<!-- PAGE=? -->
o macrosomia

<!-- PAGE=? -->
o polyhydramnios

<!-- PAGE=? -->
o high parity

<!-- PAGE=? -->
o prolonged labour

<!-- PAGE=? -->
o precipitous labour

<!-- PAGE=? -->
o augmented labour

<!-- PAGE=? -->
o chorioamnionitis

<!-- PAGE=? -->
o tocolytic agents

<!-- PAGE=? -->
o high concentration volatile agents

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Non-pharmacologic treatment

<!-- PAGE=? -->
 Massage

<!-- PAGE=? -->
 Bimanual compression

<!-- PAGE=? -->
 Embolization

<!-- PAGE=? -->
 Ligation of uterine arteries

<!-- PAGE=? -->
 Hysterectomy

<!-- PAGE=? -->
o Oxytocin - first line tx for uterine atony

<!-- PAGE=? -->
 20-40 units/L NS IV @ 250ml/h post-delivery; no more than 5 units IV bolus

<!-- PAGE=? -->
 endogenous oxytocin secreted by posterior pituitary, receptors are upregulated near term

<!-- PAGE=? -->
 stimulates uterine contraction in the upper segment by intracellular Ca++ release

<!-- PAGE=? -->
 similar chemical structure to ADH

<!-- PAGE=? -->
 do not be administered with hypotonic solutions - hyponatremia

<!-- PAGE=? -->
 side effects

<!-- PAGE=? -->
 vasodilation & hypotension

<!-- PAGE=? -->
 increase PAP

<!-- PAGE=? -->
 nausea & vomiting

<!-- PAGE=? -->
 water intoxication

<!-- PAGE=? -->
 anaphylaxis

<!-- PAGE=? -->
 duration: < 10 minutes (enzymatic hydrolysis by oxytocinase, minimal amounts excreted unchanged by liver & kidneys)

<!-- PAGE=? -->
o Haemabate /carboprost (15 methyl PGF2a)

<!-- PAGE=? -->
 0.25 mg IM or intramyometrial Q15 mins to max 2 mg

<!-- PAGE=? -->
 side effects

<!-- PAGE=? -->
 bronchospasm

<!-- PAGE=? -->
 pHTN

<!-- PAGE=? -->
 desaturation (presumably VQ mismatching)

<!-- PAGE=? -->
 flushing

<!-- PAGE=? -->
 diarrhea

<!-- PAGE=? -->
 nausea & vomiting

<!-- PAGE=? -->
o Ergonovine

<!-- PAGE=? -->
 0.2 mg IM or 0.02 mg IV PRN

<!-- PAGE=? -->
 stimulates uterine contraction in upper and lower segments

<!-- PAGE=? -->
 likely mediated by alpha-adrenergic receptors

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
 significant vasoconstriction & HTN

<!-- PAGE=? -->
 pHTN

<!-- PAGE=? -->
 Nausea and vomiting

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
 PIH

<!-- PAGE=? -->
 IHD

<!-- PAGE=? -->
 PVD

<!-- PAGE=? -->
 onset: 2-5 minutes

<!-- PAGE=? -->
 duration 2-3 hours

<!-- PAGE=? -->
o Misoprostol (PGE1)

<!-- PAGE=? -->
 200 mcg PO + 400 mcg PV or PR

<!-- PAGE=? -->
 safe for use in asthmatics and patients with pHTN

<!-- PAGE=? -->
Placenta Previa & Acreeta

<!-- PAGE=? -->
 Complications with placenta previa

<!-- PAGE=? -->
o Intraop bleeding

<!-- PAGE=? -->
 incision through the placenta

<!-- PAGE=? -->
 the lower uterine segment does not contract as well as the fundus

<!-- PAGE=? -->
 risk of acresta

<!-- PAGE=? -->
 Fetal risks

<!-- PAGE=? -->
o Prematurity

<!-- PAGE=? -->
o IUGR

<!-- PAGE=? -->
o increased incidence of congenital anomaies ( 6.7% vs 3.2%)

<!-- PAGE=? -->
 Accreta

<!-- PAGE=? -->
o Classification based on degree of pen-etration of the myometrium

<!-- PAGE=? -->
 Accrete

<!-- PAGE=? -->
 adherence of the placenta to the myometrium

<!-- PAGE=? -->
 increta

<!-- PAGE=? -->
 invasion of the myometrium

<!-- PAGE=? -->
 percreta

<!-- PAGE=? -->
 the placenta erodes through the myometrium to involve the serosa of the uterus and even the surrounding structures

<!-- PAGE=? -->
o Risk factors

<!-- PAGE=? -->
 previous uterine surgery or trauma

<!-- PAGE=? -->
 placenta previa

<!-- PAGE=? -->
 inc risk from 0.4% of pregnancies to ~5% of pregnancies with previa

<!-- PAGE=? -->
Preeclampsia

<!-- PAGE=? -->
Chestnut, Miller

<!-- PAGE=? -->
 Preeclampsia new onset of hypertension (SBP ≥ 140 or DBP ≥ 90) and proteinuria (0.3 g or more in 24 hr specimen) after 20 weeks gestation in a previously normotensive woman

<!-- PAGE=? -->
o Relatively normal heart rate

<!-- PAGE=? -->
 DDx between cocaine and Preeclampsia

<!-- PAGE=? -->
 Severe pre-eclampsia:

<!-- PAGE=? -->
o SBP > 160, DBP > 110 on 2 occasions at least 6 hrs apart

<!-- PAGE=? -->
o Proteinuria > 5 g/24 hrs ( +3,+4 on dipstick)

<!-- PAGE=? -->
o Oliguria ( < 400-500cc/24 hrs )

<!-- PAGE=? -->
o Cerebral/visual disturbances

<!-- PAGE=? -->
 HA, blurred vision, altered LOC

<!-- PAGE=? -->
o Pulmonary Edema or cyanosis pending its dx

<!-- PAGE=? -->
o Epigastric/RUQ pain (distension of Glisson's capsule by edema)

<!-- PAGE=? -->
o Hepatic rupture

<!-- PAGE=? -->
o Impaired liver function

<!-- PAGE=? -->
o Thrombocytopenia (Plt adhesion to exposed collagen on endothelial damage)

<!-- PAGE=? -->
o HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets)

<!-- PAGE=? -->
o Evidence of fetal compromise ( IUGR, oligohydramnios)

<!-- PAGE=? -->
2007 SOGC Guidelines

<!-- PAGE=? -->
 Hypertensive disorders of pregnancy should be classified as

<!-- PAGE=? -->
o pre-existing hypertension

<!-- PAGE=? -->
 preeclampsia

<!-- PAGE=? -->
 resistant hypertension

<!-- PAGE=? -->
 new or worsening proteinuria, or one or more of the other adverse conditions

<!-- PAGE=? -->
o gestational hypertension

<!-- PAGE=? -->
 preeclampsia

<!-- PAGE=? -->
 new-onset proteinuria (>0.3g/24h) or one or more of the other adverse conditions

<!-- PAGE=? -->
 Severe preeclampsia should be defined as preeclampsia with

<!-- PAGE=? -->
o onset before 34 weeks' gestation

<!-- PAGE=? -->
o heavy proteinuria or one or more adverse conditions

<!-- PAGE=? -->
 Adverse conditions include

<!-- PAGE=? -->
o maternal symptoms

<!-- PAGE=? -->
 persistent or new/unusual headache

<!-- PAGE=? -->
 visual disturbances

<!-- PAGE=? -->
 persistent abdominal or right upper quadrant pain

<!-- PAGE=? -->
 severe nausea or vomiting

<!-- PAGE=? -->
 chest pain

<!-- PAGE=? -->
 dyspnea

<!-- PAGE=? -->
o maternal signs of end-organ dysfunction

<!-- PAGE=? -->
 eclampsia

<!-- PAGE=? -->
 severe hypertension

<!-- PAGE=? -->
 SBP >160, DBP >110

<!-- PAGE=? -->
 pulmonary edema

<!-- PAGE=? -->
 suspected placental abruption

<!-- PAGE=? -->
 abnormal maternal laboratory testing

<!-- PAGE=? -->
 elevated serum creatinine

<!-- PAGE=? -->
 elevated AST, ALT or LDH with symptoms

<!-- PAGE=? -->
 platelet count <100x109/L or serum albumin < 20 g/L)

<!-- PAGE=? -->
o fetal morbidity

<!-- PAGE=? -->
 oligohydramnios

<!-- PAGE=? -->
 intrauterine growth restriction

<!-- PAGE=? -->
 absent or reversed end-diastolic flow in the umbilical artery by Doppler velocimetry

<!-- PAGE=? -->
 intrauterine fetal death

<!-- PAGE=? -->
 Rick factors

<!-- PAGE=? -->
o Previous preeclampsia in prior pregnancy

<!-- PAGE=? -->
o FHx of preeclampsia

<!-- PAGE=? -->
o Preexisting HTN

<!-- PAGE=? -->
o Inc. BMI prior to pregnancy

<!-- PAGE=? -->
o Multiple gestation

<!-- PAGE=? -->
o Renal disease

<!-- PAGE=? -->
o Pregestational diabetes

<!-- PAGE=? -->
o coagulation abnormalities

<!-- PAGE=? -->
 antiphospholipid syndrome

<!-- PAGE=? -->
 also associated with fetal loss, and maternal thrombosis

<!-- PAGE=? -->
 protein C or S deficiency

<!-- PAGE=? -->
 factor V Leiden mutation

<!-- PAGE=? -->
 hyperhomocysteinemia

<!-- PAGE=? -->
o Chronic autoimmune disease (eg SLE)

<!-- PAGE=? -->
o Advanced maternal age (>35 to 40 years)

<!-- PAGE=? -->
o Prolonged interval between pregnancies

<!-- PAGE=? -->
o Nulliparity/primip/teenage pregnancy

<!-- PAGE=? -->
 Limited sperm exposure, donor insemination, oocyte donation

<!-- PAGE=? -->
 Oral sex  is protective - inc. sperm

<!-- PAGE=? -->
o Partner who fathered a preeclamptic pregnancy in another woman

<!-- PAGE=? -->
o Sickle cell disease/trait

<!-- PAGE=? -->
o Stress, work-related psychosocial strain

<!-- PAGE=? -->
o In utero diethylstilbestrol exposure

<!-- PAGE=? -->
o Multiple pregnancy

<!-- PAGE=? -->
o Structural congenital anomalies

<!-- PAGE=? -->
o Hydrops fetalis

<!-- PAGE=? -->
o Chromosomal anomalies (trisomy 13, triploidy)

<!-- PAGE=? -->
o Hydatidiform mole

<!-- PAGE=? -->
o UTI

<!-- PAGE=? -->
 Smoking is protective

<!-- PAGE=? -->
Pa

<!-- PAGE=? -->
eM

<!-- PAGE=? -->
 Prevention or Preeclampsia

<!-- PAGE=? -->
o Low risk women

<!-- PAGE=? -->
 Recommendations

<!-- PAGE=? -->
 Calcium supplementation

<!-- PAGE=? -->
 Not recommended

<!-- PAGE=? -->
 Prostaglandin precursors

<!-- PAGE=? -->
 Magnesium

<!-- PAGE=? -->
 Zinc

<!-- PAGE=? -->
 Salt restriction

<!-- PAGE=? -->
 Calorie reduction

<!-- PAGE=? -->
 ASA

<!-- PAGE=? -->
 Vit C, E

<!-- PAGE=? -->
 Thiazide diuretics

<!-- PAGE=? -->
 Unclear

<!-- PAGE=? -->
 Heart-healthy diet

<!-- PAGE=? -->
 Stress reduction

<!-- PAGE=? -->
 Iron/folate supplements

<!-- PAGE=? -->
 Pyridoxine

<!-- PAGE=? -->
o Additional items for High risk women (age <18, multiple pregnancy, pre-existing HTN, previous preeclampsia)

<!-- PAGE=? -->
inhibior}

<!-- PAGE=? -->
 Recommendations

<!-- PAGE=? -->
 ASA

<!-- PAGE=? -->
 Possible benefit

<!-- PAGE=? -->
 Avoid interpregnancy weight gain

<!-- PAGE=? -->
 Inc. rest , dec. stress in third trimester

<!-- PAGE=? -->
 Not recommended

<!-- PAGE=? -->
 Prophylactic antihypertensive therapy

<!-- PAGE=? -->
 Unclear

<!-- PAGE=? -->
 Heparin

<!-- PAGE=? -->
 Selenium

<!-- PAGE=? -->
 Garlic

<!-- PAGE=? -->
 multivit

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
o Cardiovascular: hard to delineate (variation in each study) but generally 3 subsets:

<!-- PAGE=? -->
Hyperdynamic circulation, high CI, normal to increased SVR and normal or slightly decreased filling pressures

<!-- PAGE=? -->
Normal CO and lower filling pressures, but increased SVR

<!-- PAGE=? -->
Highly elevated SVR but reduced BV and LV function

<!-- PAGE=? -->
 Other findings

<!-- PAGE=? -->
 dec colloid oncotic pressure

<!-- PAGE=? -->
o Hematologic:

<!-- PAGE=? -->
 Acclerated hypercoagulability, dec ATIII, inc fibrinolysis

<!-- PAGE=? -->
 Thrombocytopenia

<!-- PAGE=? -->
 hemoconcentration

<!-- PAGE=? -->
o Renal:

<!-- PAGE=? -->
 Reduced GFR by 25% (edematous intracapillary cells  ischemia)

<!-- PAGE=? -->
 Nephropathy w/ proteinuria (Cr typically normal), inc uric acid

<!-- PAGE=? -->
 Oliguria (only very rarely  renal failure)

<!-- PAGE=? -->
o Respiratory:

<!-- PAGE=? -->
 Pharyngolaryngeal edema, pulmonary edema

<!-- PAGE=? -->
 Use a smaller ETT

<!-- PAGE=? -->
o Hepatic:

<!-- PAGE=? -->
 Elevated serum transaminase is common

<!-- PAGE=? -->
 RUQ pain capsular pain (edema or rarely hemorrhage in liver)

<!-- PAGE=? -->
 Fibrotic/ischemic changes on bx

<!-- PAGE=? -->
o CNS:

<!-- PAGE=? -->
 H/A, vision dist, hyperreflexia, seizure

<!-- PAGE=? -->
 Etiology seizure unclear  hypertensive encephalopathy w/ loss of CBF autoregulation but sz can occur with only mild inc BP

<!-- PAGE=? -->
 ?vasospasm, microinfarctions, thrombosis, cerebral edema

<!-- PAGE=? -->
 Cerebral hemorrhage and edema are the leading causes of death in pre-eclampsiaeclampsia, together accounting for approximately 50% of deaths

<!-- PAGE=? -->
o Pharmacology

<!-- PAGE=? -->
 Mg potentiates nondepolarizing and depolarizing muscle relaxants

<!-- PAGE=? -->
 Plasma cholinesterase activity is reduced in PIH, resulting in potentiation of succinylcholine independent of magnesium therapy

<!-- PAGE=? -->
o Fetus:

<!-- PAGE=? -->
 Dec uteroplacental BF (diastolic velocity dec, s/d ratio inc)

<!-- PAGE=? -->
 IUGR, oligohydramnios

<!-- PAGE=? -->
 Antihypertensive Treatment (Chestnut)

<!-- PAGE=? -->
o Labetolol

<!-- PAGE=? -->
 combined alpha/beta blocker

<!-- PAGE=? -->
 ratio 1:3 orally and 1:7 IV

<!-- PAGE=? -->
 second line for preeclamptic women

<!-- PAGE=? -->
 Decreases maternal SVR

<!-- PAGE=? -->
 No increase HR

<!-- PAGE=? -->
 No decrease in

<!-- PAGE=? -->
o CI

<!-- PAGE=? -->
o uterine blood flow (UBF)

<!-- PAGE=? -->
o FHR

<!-- PAGE=? -->
 Faster onset than hydralazine

<!-- PAGE=? -->
 Start at 10 mg and then doubled every 10 minutes

<!-- PAGE=? -->
 More variable in effect than hydralazine

<!-- PAGE=? -->
o Nitroprusside

<!-- PAGE=? -->
 smooth muscle vasodilator

<!-- PAGE=? -->
 interacting with sulfhydryl groups on vascular endothelium to release NO

<!-- PAGE=? -->
 Primary effect is arterial but will also reduce venous return

<!-- PAGE=? -->
 Start at 0.5 mcg/kg/min

<!-- PAGE=? -->
 Placental transfer of SNP does occur

<!-- PAGE=? -->
 Theoretical risk of cyanide toxicity

<!-- PAGE=? -->
 Short term use only

<!-- PAGE=? -->
o Hydralazine

<!-- PAGE=? -->
 Most commonly used antihypertensive

<!-- PAGE=? -->
 Preferentially relaxes arterioles by increasing cGMP levels (as did NO) resulting in a decrease in SVR

<!-- PAGE=? -->
 5 mg q 20 minutes to a max of 20 mg

<!-- PAGE=? -->
 If ineffective switch drugs

<!-- PAGE=? -->
 HR, stroke volume and CO all typically increase with hydralazine as a result of baroreceptor activity

<!-- PAGE=? -->
 No effect on uteroplacental blood flow, fetoplacental vascular resistance or renal vascular resistance

<!-- PAGE=? -->
o Nifedipine

<!-- PAGE=? -->
 Ca channel blocker

<!-- PAGE=? -->
 inhibits influx of extracellular Ca into smooth muscle cells

<!-- PAGE=? -->
 Predominantly has effects in arterial and arteriolar smooth muscle

<!-- PAGE=? -->
 Headache, tachycardia and facial flushing may occur

<!-- PAGE=? -->
 Initial dose is 10 mg orally then repeat in 30 minutes and then continue 10-20 mg q3-6h

<!-- PAGE=? -->
 More rapid onset than labetolol

<!-- PAGE=? -->
 exaggerated response in patients receiving magnesium sulphate

<!-- PAGE=? -->
o SOGC Guidelines

<!-- PAGE=? -->
Table 6. Doses of most commonly used agents used for treatment of a BP of 2 160/110 mmHg hypertension

<!-- PAGE=? -->
Table 7 Doses of most commonly used agents used for treatment of a BP of 140-159/90-105 mmHg

<!-- PAGE=? -->
Table 58-10 -- Comparison of properties of hydralazine and labetalol for treatment of hypertension

<!-- PAGE=? -->
 Magnesium sulfate is the agent of choice for seizure control

<!-- PAGE=? -->
 blocks calcium influx via NMDA subtypes of glutamate channels

<!-- PAGE=? -->
 has mild relaxant effects on vascular and uterine smooth muscles

<!-- PAGE=? -->
 potential exaggerated response to nifedipine

<!-- PAGE=? -->
o Magpie Trial

<!-- PAGE=? -->
 reduced seizures by more than 50% and without any serious maternal morbidity

<!-- PAGE=? -->
 secondary effect may be vasodilatation and an increase in cardiac output by reducing SVR.

<!-- PAGE=? -->
o dosing

<!-- PAGE=? -->
 4 g MgSO4 over 10min, then 1 g/hr

<!-- PAGE=? -->
 In renal failure, monitor serum Mg levels - between 2 and 3.5 mmol/L

<!-- PAGE=? -->
o clinical signs of toxicity (respiratory depression, reduced or absent tendon reflexes)

<!-- PAGE=? -->
 5 mEq/L serum levels

<!-- PAGE=? -->
 lengthened PQ and QRS intervals

<!-- PAGE=? -->
 10 mEq/L

<!-- PAGE=? -->
 loss of deep tendon reflexes

<!-- PAGE=? -->
 15 mEq/L

<!-- PAGE=? -->
 AV, SA block

<!-- PAGE=? -->
 respiratory paralysis

<!-- PAGE=? -->
 25 mEq/L

<!-- PAGE=? -->
 cardiac arrest

<!-- PAGE=? -->
o toxicity should be managed with 10 mL of 10% calcium gluconate slow IVP

<!-- PAGE=? -->
HELLP

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Definition: all three for complete, only two for partial HELLP

<!-- PAGE=? -->
o Hemolysis - abnormal peripheral smear and increased bilirubin

<!-- PAGE=? -->
o elevated liver enzymes, AST > 70U/L, LDH > 600

<!-- PAGE=? -->
o low platelets < 100,000/mm3, morbidity increases with Plt < 50,000

<!-- PAGE=? -->
 most patients develop HELLP before delivery, it reaches peak intensity 24-48h post delivery

<!-- PAGE=? -->
o 20% present postpartum (hrs - 6 days)

<!-- PAGE=? -->
 onset from a few hrs to 6days post

<!-- PAGE=? -->
 higher incidence of renal failure and pulm edema

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
o the majority of patients initially complain of malaise and epigastric or RUQ pain

<!-- PAGE=? -->
o Nausea and vomiting occurs in 50% of cases

<!-- PAGE=? -->
o Non-specific viral symptoms also occur

<!-- PAGE=? -->
o 80% have evidence of pereeclampsia before delivery, however HTN and proteinuria may be slight or absent

<!-- PAGE=? -->
 Inc. morbidity with plt < 50 000

<!-- PAGE=? -->
o hemostasis usually normal if no DIC unless < 40 000

<!-- PAGE=? -->
 time course of plt decrease is important

<!-- PAGE=? -->
 steroids may be considered

<!-- PAGE=? -->
 Recovery

<!-- PAGE=? -->
o hemolysis ceases in 48Hrs

<!-- PAGE=? -->
o Plt > 100,000 within 72 hrs from the lowest

<!-- PAGE=? -->
 Complications:

<!-- PAGE=? -->
o subcapsular/intraparenchimal hematoma

<!-- PAGE=? -->
 suspect in RUQ pain, shoulder pain, relapsing hTN

<!-- PAGE=? -->
 the severity of thrombocytopenia correlates with abnormal CT images of liver ( PLT< 20, 000

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
o Pulmonary edema (in 3% of PIH)

<!-- PAGE=? -->
o Placental abruption (in 2% of PIH)

<!-- PAGE=? -->
 Management:

<!-- PAGE=? -->
o Delivery is only definitive tx and should be undertaken immediately

<!-- PAGE=? -->
o May require plts and plasma at time of delivery

<!-- PAGE=? -->
Retained placenta

<!-- PAGE=? -->
 Anesthetic mmgt for retained placenta:

<!-- PAGE=? -->
o Sodium citrate

<!-- PAGE=? -->
o Epidural, spinal, nitrous or small doses ketamine or fentanyl

<!-- PAGE=? -->
o RSI plus high dose vapour

<!-- PAGE=? -->
o Nitroglycerin 50-500ug-relaxes via release of NO, may require placental tissue to be effective, safe in  most situations when uterine relaxation is required

<!-- PAGE=? -->
Spina bifida

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 There is an increased incidence of dystocia in spina bifida

<!-- PAGE=? -->
 Autonomic hyperreflexia is usually a problem only if the lesion is above T8

<!-- PAGE=? -->
 epidural anesthesia is more likely because of the abnormal, discontinuous epidural space

<!-- PAGE=? -->
Thrombophilia

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
o most common inherited causes

<!-- PAGE=? -->
factor V Leiden

<!-- PAGE=? -->
prothrombin mutation

<!-- PAGE=? -->
o other s

<!-- PAGE=? -->
 hyperhomocystinemia

<!-- PAGE=? -->
 deficiencies in AT III, protein C and S

<!-- PAGE=? -->
 antiphospholipid syndrome

<!-- PAGE=? -->
 complications

<!-- PAGE=? -->
o fetal loss

<!-- PAGE=? -->
Thyroid

<!-- PAGE=? -->
 Normal human pregnancy is a euthyroid state, with normal serum concentrations of unbound or free T4 despite increased serum concentrations of TBG and total T4

<!-- PAGE=? -->
 Graves' disease is the predominant cause of hyperthyroidism during pregnancy.

<!-- PAGE=? -->
 Gestational trophoblastic neoplasms frequently are associated with elevated serum hCG concentrations. High concentrations of hCG may possess significant thyroid-stimulating bioactivity because of the structural homology between hCG and TSH

<!-- PAGE=? -->
 Hyperthyroidism is associated with:

<!-- PAGE=? -->
o Hyperemesis gravidarum

<!-- PAGE=? -->
o IUGR/ LBW infants

<!-- PAGE=? -->
o Increased risk of severe pre-eclampsia

<!-- PAGE=? -->
 Radioactive iodine is contraindicated during pregnancy because iodine readily crosses the placenta to the fetus

<!-- PAGE=? -->
 mainstays of therapy for hyperthyroidism during pregnancy are the antithyroid medications propylthiouracil and methimazole; they cross the placenta more easily  fetal hypothyroidism, goiter

<!-- PAGE=? -->
 Regional or GA

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Injuries Unique to Check for in Pregnancy:

<!-- PAGE=? -->
 Premature Contractions

<!-- PAGE=? -->
 Rarely progress  to preterm delivery

<!-- PAGE=? -->
 Tocolysis is not proven in trauma.

<!-- PAGE=? -->
 Abruptio Placentae

<!-- PAGE=? -->
 Different elastic properties in uterus & placenta -shearing‖

<!-- PAGE=? -->
 3 % of minor trauma and upto 50 % in severe trauma

<!-- PAGE=? -->
 Uterine Rupture

<!-- PAGE=? -->
 Rare, 0.6 % of severe abdominal trauma

<!-- PAGE=? -->
 Direct trauma after 12 wks of gestation

<!-- PAGE=? -->
 Prior Surgery (C/S or Myomec.)

<!-- PAGE=? -->
 Maternal-Fetal Hemorrhage

<!-- PAGE=? -->
 Trimesters 1   3%,   T2  12%, T3  45%

<!-- PAGE=? -->
 4-5 X more common in injured pregnant women

<!-- PAGE=? -->
 Causes isoimmunization & fetal death

<!-- PAGE=? -->
 Kleihauer-Betke test - volume of fetal blood

<!-- PAGE=? -->
 To determine amount of Rhogam needed

<!-- PAGE=? -->
o placental abruption

<!-- PAGE=? -->
o fetal growth restriction

<!-- PAGE=? -->
o preeclampsia

<!-- PAGE=? -->
o usual thromboembolic sequelae (PE, stroke)

<!-- PAGE=? -->
TABLE 2 Changes in Normal Pregnancy that Affect Trauma Management * May

<!-- PAGE=? -->
Listed in order from most to least clinically relevant:

<!-- PAGE=? -->
TABLE 1

<!-- PAGE=? -->
Factors Associated with Increased Fetal Mortality After Trauma*

<!-- PAGE=? -->
Maternal hypotension High maternal Injury Severity Scoret Ejection a motor vehicle Maternal pelvic fracture Automobile versus pedestrian accidents Maternal history of alcohol use maternal age Motorcycle crashes Maternal smoking history Uterine rupture from Young

<!-- PAGE=? -->
~Listed in order from those most commonly to least commonly found to contribute to fetal death +A Standard assessment of the level  of traumatic injury, based on codes from the International Classification of Diseases , 9th ed.

<!-- PAGE=? -->
Twins

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Inceased perinatal and maternal morbidity and mortality

<!-- PAGE=? -->
 Many physiologic changes of pregnancy are exaggerated

<!-- PAGE=? -->
o FRC is greatly reduced

<!-- PAGE=? -->
o aortocaval compression is more dramatic

<!-- PAGE=? -->
 Maternal complications

<!-- PAGE=? -->
o preterm premature rupture of membranes

<!-- PAGE=? -->
o preterm labour

<!-- PAGE=? -->
o prolonged labour

<!-- PAGE=? -->
o preeclampsia/eclampsia

<!-- PAGE=? -->
o abruption

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
o Operative delivery

<!-- PAGE=? -->
o Uterine atony

<!-- PAGE=? -->
o Obstetric trauma

<!-- PAGE=? -->
o Antepartum/postpartum hemorrhage

<!-- PAGE=? -->
 Fetal Complications

<!-- PAGE=? -->
o Preterm delivery

<!-- PAGE=? -->
o Congenital anomalies

<!-- PAGE=? -->
o Polyhydramnios

<!-- PAGE=? -->
o Cord entanglement

<!-- PAGE=? -->
o Umbilical cord prolapse

<!-- PAGE=? -->
o Intrauterine growth restriction

<!-- PAGE=? -->
o Twin-twin transfusion

<!-- PAGE=? -->
o Malpresentation

<!-- PAGE=? -->
Obstetric seizure

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
Table 44-4 Differential diagnosis of peripartum seizures

<!-- PAGE=? -->
VBAC

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Previous classical C/S uterine incision contraindicates VBAC

<!-- PAGE=? -->
o Women with a vertical incision within the lower uterine segment that does not extend into the fundus are candidates for VBAC

<!-- PAGE=? -->
 Uterine Rupture

<!-- PAGE=? -->
o Pain is neither sensitive nor specific for uterine rupture

<!-- PAGE=? -->
o risk of uterine rupture increases as the number of cesarean deliveries increases

<!-- PAGE=? -->
 women with one previous cesarean delivery with a low-transverse incision are candidates for VBAC

<!-- PAGE=? -->
 60-80% of VBACs are successful

<!-- PAGE=? -->
 Epidural anesthesia may be used for VBAC.

<!-- PAGE=? -->
 The use of prostaglandins for cervical ripening or induction of labor in most women with a previous cesarean delivery should be discouraged

<!-- PAGE=? -->
 VBAC should be attempted in institutions equipped to respond to emergencies with physicians immediately available to provide emergency care

<!-- PAGE=? -->
Obesity

<!-- PAGE=? -->
CoexD, Miller, Barash, Lange

<!-- PAGE=? -->
 height -100 = IBW (kg)

<!-- PAGE=? -->
 Associated with

<!-- PAGE=? -->
o inc risk of DVT - double

<!-- PAGE=? -->
 Polycythemia

<!-- PAGE=? -->
 Inc. abd pressure

<!-- PAGE=? -->
 immobilization

<!-- PAGE=? -->
o CVS

<!-- PAGE=? -->
 Hypertension

<!-- PAGE=? -->
 dyslipidemia

<!-- PAGE=? -->
 coronary artery disease

<!-- PAGE=? -->
o Obesity-hypoventilation syndrome (pickwikian syndrome)

<!-- PAGE=? -->
 Hypercapnia

<!-- PAGE=? -->
 cyanosis-induced polycythemia

<!-- PAGE=? -->
 RV Failure

<!-- PAGE=? -->
 somnolence

<!-- PAGE=? -->
o gastrointestinal pathophysiology

<!-- PAGE=? -->
 Abnormal liver function tests and fatty liver infiltration

<!-- PAGE=? -->
 Threeforld inc. risk of developing gallbladder and biliary tract disease

<!-- PAGE=? -->
o Inflammation

<!-- PAGE=? -->
o Focal necrosis

<!-- PAGE=? -->
o cirrhosis

<!-- PAGE=? -->
 hiatal hernia

<!-- PAGE=? -->
 gastroesophageal reflux,

<!-- PAGE=? -->
 poor gastric emptying, and

<!-- PAGE=? -->
 hyperacidic gastric fluid

<!-- PAGE=? -->
 increased risk of gastric cancer

<!-- PAGE=? -->
o Renal and Endocrine Systems

<!-- PAGE=? -->
 Impaired glucose tolerance or overt DM II

<!-- PAGE=? -->
 Related to inc. insulin resistance

<!-- PAGE=? -->
 glomerular hyperfiltration

<!-- PAGE=? -->
 increased renal plasma flow (RPF)

<!-- PAGE=? -->
 inc glomerular filtration rate (GFR)

<!-- PAGE=? -->
o decreases after weight loss, which decreases the incidence of overt glomerulopathy

<!-- PAGE=? -->
o degenerative joint and disk disease

<!-- PAGE=? -->
o sleep disorders

<!-- PAGE=? -->
o emotional and altered body image disorders

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
CAS jan 2004 Casati et al

<!-- PAGE=? -->
Gus:

<!-- PAGE=? -->
Table 1. Weight-Based Dosing of Common IV Anesthetics (91-102)

<!-- PAGE=? -->
IBWI Ideal body weight; TBW Total body weight; VI volume of distribution.

<!-- PAGE=? -->
This table is from Oguinnaike, Anesthetic Considerations for Bariatric SurgeryAnA 2002.

<!-- PAGE=? -->
OLV

<!-- PAGE=? -->
Anes Clinics, Lohser

<!-- PAGE=? -->
Predictors of hypoxemia on OLV

<!-- PAGE=? -->
 High percentage of ventilation or perfusion to the operative lung on preoperative V/Q scan

<!-- PAGE=? -->
 Poor PaO2 during two-lung ventilation, particularly in the lateral position intraoperatively

<!-- PAGE=? -->
 Right-sided surgery

<!-- PAGE=? -->
 Good preoperative spirometry (FEV1 or FVC)

<!-- PAGE=? -->
 Surgery in the supine (versus lateral) position

<!-- PAGE=? -->
Summary of ventilatory strategies

<!-- PAGE=? -->
 Tidal volume

<!-- PAGE=? -->
o Protective: 4-6 mL/kg

<!-- PAGE=? -->
 Old strategy was TV 10-12ml/kg

<!-- PAGE=? -->
o Hypoxia or severe hypercapnea: consider 6-10 mL/kg

<!-- PAGE=? -->
 Positive end-expiratory pressure (PEEP):

<!-- PAGE=? -->
o Protective/restrictive/normal: 5-10 cm H2O

<!-- PAGE=? -->
o Obstructive: 3-8 cm H2O (minimize intrinsic PEEP)

<!-- PAGE=? -->
 Respiratory Rate

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Protective: 10-15/min

<!-- PAGE=? -->
o Severe hypercapnea: 6-8/min

<!-- PAGE=? -->
 FiO2

<!-- PAGE=? -->
o Transplant: 21%+

<!-- PAGE=? -->
o Routine: 50% to 80%

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Hypoxia: 100%

<!-- PAGE=? -->
 Inspiratory to Expiratory ratio

<!-- PAGE=? -->
o Restrictive: 1:1 or inverse ratio

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Normal: 1:2

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Obstructive: 1:3-4

<!-- PAGE=? -->
 Pressures

<!-- PAGE=? -->
o Plateau <25 cm H2O

<!-- PAGE=? -->
o Peak <<35-40 cm H2O

<!-- PAGE=? -->
 Minute volume: PaCO2 50-70 mm Hg, potentially higher PaCO2 with severe obstruction/lung transplantation

<!-- PAGE=? -->
 Ventilator mode: PCV for all (? HFJV)

<!-- PAGE=? -->
Hypoxemia during OLV

<!-- PAGE=? -->
 Mild hypoxemia (90% to 95%)

<!-- PAGE=? -->
o Confirm position of lung isolation device

<!-- PAGE=? -->
o Recruit ventilated lung

<!-- PAGE=? -->
o Ensure adequate cardiac output

<!-- PAGE=? -->
o Increase FiO2 toward 1.0

<!-- PAGE=? -->
o CPAP or HFJV to operative lung (after recruitment)

<!-- PAGE=? -->
o Optimize PEEP to nonoperative lung (up or down; toward lower inflection point)

<!-- PAGE=? -->
o Consider reduction in vapor anesthetic and/or total intravenous anesthesia

<!-- PAGE=? -->
o Ensure adequate oxygen carrying capacity (hemoglobin)

<!-- PAGE=? -->
 Severe (<<90%) or refractory hypoxemia

<!-- PAGE=? -->
o Resume two-lung ventilation with 100% O2

<!-- PAGE=? -->
 If not possible, consider Pulmonary artery clamp on operative side during pneumonectomy, transplant

<!-- PAGE=? -->
o Inhaled nitric oxide and/or infusions of almitrine/ phenylephrine

<!-- PAGE=? -->
o Extracorporeal support during lung transplantation

<!-- PAGE=? -->
o cardiopulmonary bypass, extracorporeal membrane oxygenation

<!-- PAGE=? -->
Ondansetron

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 primary adverse effect is headache

<!-- PAGE=? -->
 other side effects include

<!-- PAGE=? -->
o diarrhea

<!-- PAGE=? -->
o constipation

<!-- PAGE=? -->
o sedation

<!-- PAGE=? -->
o transient minor elevations in liver function tests

<!-- PAGE=? -->
 there are no extrapyramidal reactions

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
 3:1 oral:IV conversion for morphine

<!-- PAGE=? -->
 4:1 oral:IV conversion for HM

<!-- PAGE=? -->
 2:1 oral:IV conversion for Demerol

<!-- PAGE=? -->
 2:1 oral:IV conversion for oxycodone

<!-- PAGE=? -->
Opioid Receptors

<!-- PAGE=? -->
TABLE 3-2. Classification of opioid receptors

<!-- PAGE=? -->
Mu1

<!-- PAGE=? -->
Mu2

<!-- PAGE=? -->
Kappa

<!-- PAGE=? -->
Delta

<!-- PAGE=? -->
Effect

<!-- PAGE=? -->
Analgesia:

<!-- PAGE=? -->
supraspinal spinal

<!-- PAGE=? -->
Analgesia:

<!-- PAGE=? -->
spinal

<!-- PAGE=? -->
Analgesia:

<!-- PAGE=? -->
supraspinal

<!-- PAGE=? -->
Analgesia:

<!-- PAGE=? -->
supraspinal spinal

<!-- PAGE=? -->
Euphoria

<!-- PAGE=? -->
Dysphoria,

<!-- PAGE=? -->
sedation

<!-- PAGE=? -->
Depression of

<!-- PAGE=? -->
ventilation

<!-- PAGE=? -->
Depression of

<!-- PAGE=? -->
ventilation

<!-- PAGE=? -->
Low abuse

<!-- PAGE=? -->
potential

<!-- PAGE=? -->
Physical

<!-- PAGE=? -->
dependence

<!-- PAGE=? -->
Low abuse

<!-- PAGE=? -->
potential

<!-- PAGE=? -->
Physical

<!-- PAGE=? -->
dependence

<!-- PAGE=? -->
Miosis

<!-- PAGE=? -->
Miosis

<!-- PAGE=? -->
Constipation

<!-- PAGE=? -->
(marked)

<!-- PAGE=? -->
Constipation

<!-- PAGE=? -->
(minimal)

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Urinary retention

<!-- PAGE=? -->
Diuresis

<!-- PAGE=? -->
Urinary retention

<!-- PAGE=? -->
Agonists

<!-- PAGE=? -->
Endorphins*

<!-- PAGE=? -->
Endorphins*

<!-- PAGE=? -->
Dynorphins

<!-- PAGE=? -->
Enkephalins

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
Synthetic opioids

<!-- PAGE=? -->
Synthetic

<!-- PAGE=? -->
opioids

<!-- PAGE=? -->
Antagonists

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
Naltrexone

<!-- PAGE=? -->
Naltrexone

<!-- PAGE=? -->
Naltrexone

<!-- PAGE=? -->
Naltrexone

<!-- PAGE=? -->
Nalmefene

<!-- PAGE=? -->
Nalmefene

<!-- PAGE=? -->
Nalmefene

<!-- PAGE=? -->
Nalmefene

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
Agonist at mu 1 and 2 CNS:

<!-- PAGE=? -->
 analgesia

<!-- PAGE=? -->
o from interactions in brain, spinal cord, peripheral tissues

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
GU

<!-- PAGE=? -->
 urinary retention (systemic and spinal morphine) can be reversed by anticholinergic (atropine)

<!-- PAGE=? -->
o spinal cord (mu2): presynaptic action on afferent nociceptors to decreases release of substance P and hyperpolarizes postsynaptic neurons in substantia gelatinosa.  Result: decreased afferent transmission of nociceptive impulses

<!-- PAGE=? -->
o supraspinal (Mu1): periaqueuctal gray, locus ceruleus, nucleus raphe magnus in medulla. Descending modulatory systems produce analgesia

<!-- PAGE=? -->
o in inflammation, may activate peripheral receptors to give analgesia

<!-- PAGE=? -->
o in chronic pain, spinal and peripheral receptors may be down regulated (decreased analgesia to morphine)

<!-- PAGE=? -->
 sedation

<!-- PAGE=? -->
o decreases MAC in dose dependent manner with ceiling at 65% MAC

<!-- PAGE=? -->
o spinal and epidural morphine may have a similar effect

<!-- PAGE=? -->
o effect on EEG similar to that of sleep with slow delta waves replacing faster alpha waves

<!-- PAGE=? -->
 changes in affect: euphoria, dysphoria, sleep disturbances (less REM, dreams)

<!-- PAGE=? -->
 may decrease cerebral blood flow and ICP but if ventilation is not controlled ICP will rise with PaCO2

<!-- PAGE=? -->
 respiratory depression

<!-- PAGE=? -->
o dose-dependent

<!-- PAGE=? -->
o decreased responsivity of medullary resp center to CO2 (shift to the R, decreased slope)

<!-- PAGE=? -->
o abnormal respiratory pattern (resembling Cheyne-Stokes)

<!-- PAGE=? -->
o markedly potentiated by normal sleep

<!-- PAGE=? -->
 nausea and vomiting

<!-- PAGE=? -->
o effect is similar regardless of route of administration

<!-- PAGE=? -->
o no difference among opioids at equianalgesic doses (morph, hydromorph, meperidine, fentanyl, sufentanil, alfentanil, remi)

<!-- PAGE=? -->
o stimulate the chemoreceptor trigger zone and increase vestibular sensitivity

<!-- PAGE=? -->
 Inhibited by dopamine antag, serotonin antag, histamine antag, acetylcholine (muscarinic) antagonists

<!-- PAGE=? -->
 pruritis: more common with spinal admin

<!-- PAGE=? -->
o mu receptor effect in the dorsal horn which is NOT histamine mediated

<!-- PAGE=? -->
 miosis

<!-- PAGE=? -->
 affects release of pituitary hormones

<!-- PAGE=? -->
o inhibition of corticotropin releasing factor, gonadotropin releasing hormone mean less ACTH, betaendorphin, FSH and LH

<!-- PAGE=? -->
o possible increase in prolactin and growth hormone

<!-- PAGE=? -->
o inhibition of ADH release

<!-- PAGE=? -->
 decreased cough reflex (codeine most and dextro isomers that are nonanalgesic)

<!-- PAGE=? -->
 muscle rigidity

<!-- PAGE=? -->
o occurs with large doses and likely mediated by mu receptors in supraspinal sites

<!-- PAGE=? -->
o most common with fentanyl

<!-- PAGE=? -->
o effect plateaus 10 min after admin

<!-- PAGE=? -->
o increased by N2O

<!-- PAGE=? -->
o myoclonus

<!-- PAGE=? -->
o tx: naloxone, benzos, thiopental, muscle relaxants

<!-- PAGE=? -->
 decreased gastric secretions and gut motility

<!-- PAGE=? -->
 mediated by mu, kappa, delta receptors in brain, spinal cord, enteric muscle and smooth muscle

<!-- PAGE=? -->
 decreased LES and GERD

<!-- PAGE=? -->
 epidural morphine can delay gastric emptying

<!-- PAGE=? -->
 increased tone in common bile duct and sphincter of Oddi

<!-- PAGE=? -->
o reverse with naloxone or glucagons 2 mg IV

<!-- PAGE=? -->
o may result in increased plasma amylase and lipase

<!-- PAGE=? -->
 dyssynergia between bladder detrusor muscle and urethral sphincter because of failure of sphincter to relax

<!-- PAGE=? -->
Dose dependent histamine release - not mediated by opioid receptors/ not antagonized by naloxone

<!-- PAGE=? -->
Cardiovascular

<!-- PAGE=? -->
 doses used for pain or balanced anesthesia

<!-- PAGE=? -->
o little effect on BP, HR< rhythm

<!-- PAGE=? -->
 higher doses can produce arteriolar and venous dilation, decreased PVR, inhibition of baroreceptor reflexes (postural hypotension)

<!-- PAGE=? -->
 peripheral vasodilation

<!-- PAGE=? -->
o central sympatholytic activity

<!-- PAGE=? -->
o direct action on vascular smooth muscle

<!-- PAGE=? -->
o histamine release

<!-- PAGE=? -->
 does not suppress myocardial contractility

<!-- PAGE=? -->
 dose-dependent bradycardia (stimulation of vagal nuclei in medulla and possible direct effect on SA node and AV node)

<!-- PAGE=? -->
o decreased conductivity imparts decreased vulnerability to VF

<!-- PAGE=? -->
 morphine's ability to reduce systemic inflammation by its action at the mu3-opioid receptor may benefit patients undergoing CPB

<!-- PAGE=? -->
o 40mg given prior to cardioplegia resulted in better recovery of global ventricular function and prevention of post op hypothermia

<!-- PAGE=? -->
immune

<!-- PAGE=? -->
 prolonged exposure produces immuosuppression as does abrupt withdrawal

<!-- PAGE=? -->
 altered development, differentiation, function of bone marrow progenitor cells, macrophages and T cells

<!-- PAGE=? -->
Disposition/ metabolism

<!-- PAGE=? -->
 IM: peak plasma conc at 20 min but hydrophilic and penetrates BBB slowly.  Peak analgesic effect may take 10-40 min

<!-- PAGE=? -->
 Age affects elimination half life:

<!-- PAGE=? -->
o < One week old Neonates 7-8 hours

<!-- PAGE=? -->
o Older infants 3-5 hrs

<!-- PAGE=? -->
o Young adults: 3 hrs

<!-- PAGE=? -->
o 61-80 yo: 4.5 hrs

<!-- PAGE=? -->
 3-glucuronide is predominant metabolite

<!-- PAGE=? -->
 10% excreted unchanged

<!-- PAGE=? -->
 hepatic extraction ratio is 0.7

<!-- PAGE=? -->
 M6G is an active metabolite and seems to be able to penetrate the BBB (can accumulate in renal failure)

<!-- PAGE=? -->
 No change in clearance in patients with cirrhosis or during the anhepatic phase of liver transplantation

<!-- PAGE=? -->
 Glucuronides can accumulate in renal failure leading to ventilatory depression

<!-- PAGE=? -->
 Formation of glucuronides is impaired by MAOI

<!-- PAGE=? -->
 Metabolized to

<!-- PAGE=? -->
o Morphine-3-glucuronide which is pharmacologically inactive

<!-- PAGE=? -->
 Principle product of metabolism

<!-- PAGE=? -->
o morphine-6-glucuronide which produces analgesia and depression of ventilation via its actions at mu receptors.

<!-- PAGE=? -->
 its potency and duration of action are greater than that of morphine

<!-- PAGE=? -->
 it is possible that the majority of analgesic activity attributed to morphine is actually due to morphine-6-glucuronide

<!-- PAGE=? -->
o Normorpine

<!-- PAGE=? -->
 Little op  ioid activity

<!-- PAGE=? -->
 No CNS toxicity

<!-- PAGE=? -->
Meperidine

<!-- PAGE=? -->
 First totally synthetic opioid

<!-- PAGE=? -->
 1/10 th the analgesic potency of morphine

<!-- PAGE=? -->
 local anesthetic properties

<!-- PAGE=? -->
 high doses are associated with CNS excitement and seizures

<!-- PAGE=? -->
 less increase in bile duct pressure compared to morphine and fentanyl and equianalgesic doses

<!-- PAGE=? -->
cardiovascular

<!-- PAGE=? -->
 depresses contractility (not reversible with naloxone and may be altered conductance from the local anesthetic effect)

<!-- PAGE=? -->
 patients with cardiac disease given 1 mg/kg had decreased HR< cardiac index and rate-pressure product

<!-- PAGE=? -->
 causes more hemodynamic instability than morphine or fentanyl, mostly due to histamine release

<!-- PAGE=? -->
 modest atropine like: increases HR and causes mydriasis, dry mouth

<!-- PAGE=? -->
reduces shivering (12.5-50 mg) while equianalgesic doses of morphine and fentanyl do not (not mu receptors, possibly kappa and also alpha2 agonism)

<!-- PAGE=? -->
 clonidine, serotonin antagonists and propofol, and physostigmine can also reduce shivering

<!-- PAGE=? -->
may ppt serotonin syndrome if given to patients on MAOIs, SSRIs

<!-- PAGE=? -->
 autonomic instability, hypertension, tachycardia, diaphoresis, hyperthermia, confusion, agitation, hyperreflexia

<!-- PAGE=? -->
high hepatic extraction ratio - n-demethylated in the liver to form normeperidine and hydrolyzed to meperidinic elimination not prolonged in elderly but it is in neonates and infants moderately lipid soluble acid both metabolites are conjugated and renally eliminated normeperidine:

<!-- PAGE=? -->
 CNS excitation, apprehension, restlessness, tremors, myoclonus, seizures

<!-- PAGE=? -->
 Elimination half life longer than that for the parent compound

<!-- PAGE=? -->
 Total dose should not exceed 1000 mg/24 hrs

<!-- PAGE=? -->
 metabolized mainly in the liver to form normeperidine , the main metabolite, and by hydrolysis to form meperidinic acid

<!-- PAGE=? -->
o Both may then be conjugated and excreted renally

<!-- PAGE=? -->
 Normeperidine is pharmacologically active and potentially toxic

<!-- PAGE=? -->
o Half as potent as parent compound

<!-- PAGE=? -->
o CNS excitiation - apprehension, restleness, myoclonus, and seizues

<!-- PAGE=? -->
Methadone

<!-- PAGE=? -->
 Synthetic mu agonist

<!-- PAGE=? -->
 Long elimination half-life: useful for chronic pain and dependency

<!-- PAGE=? -->
 Side effects similar to morphine

<!-- PAGE=? -->
 Oral bioavailability is 90% reaching peak at 4 hrs

<!-- PAGE=? -->
 In opioid naïve patients, 20 mg as a single dose can provide analgesia for up to 20 hours without resp depression

<!-- PAGE=? -->
 Probably safer to give sustained release morphine or oxycodone

<!-- PAGE=? -->
 Treatment of chronic pain

<!-- PAGE=? -->
o antagonizes NMDA receptors and so is useful in neuropathic pain and minimizes development of tolerance

<!-- PAGE=? -->
o may accumulate if given > 1 per day

<!-- PAGE=? -->
Fentanyl

<!-- PAGE=? -->
 synthetic opioid agonist structurally similar to meperidine

<!-- PAGE=? -->
 100 times more potent than morphine

<!-- PAGE=? -->
 lipid solubility of fentanyl is greater than that of morphine which contributes to its rapid onset of action.

<!-- PAGE=? -->
 Peak plasma concentration IV = 6-7 minutes

<!-- PAGE=? -->
 Elimination half-time is 3-6 hours.

<!-- PAGE=? -->
 The drug's short duration of action is attributed to redistribution to inactive tissues, such as the lungs, fat, and skeletal muscle.

<!-- PAGE=? -->
 Metabolism occurs primarily by hepatic N-demethylation to norfentanyl which is a less potent analgesic.

<!-- PAGE=? -->
 A decreased clearance rate in the elderly may prolong elimination.

<!-- PAGE=? -->
 Fentanyl causes neither myocardial depression nor histamine release

<!-- PAGE=? -->
 Fentanyl can activatate eliptiform activity in patients having surgery for intractable temporal lobe epilepsy

<!-- PAGE=? -->
 Can cause pruritis and have a tussive effect

<!-- PAGE=? -->
o Also suppresses a/w reflexes and cough

<!-- PAGE=? -->
 First synth in 1960

<!-- PAGE=? -->
 50-100x more potent then morphine

<!-- PAGE=? -->
 lipid solubility contributes to its rapid onset of action (peak plasma conc 6-7 min)

<!-- PAGE=? -->
 mu receptor agonist

<!-- PAGE=? -->
 dose dependent analgesia, ventilatory depression, sedation and at high doses, unconsciousness

<!-- PAGE=? -->
 reduces MAC and MAC-BAR (block adrenergic response) in dose dependent fashion via parenteral and epidural routes

<!-- PAGE=? -->
 high dose as sole anesthetic: 50-150 mcg/kg (reliable hemodynamic stability and significant blunting of stress response but need for prolonged post op resp support and awareness is a risk, muscle rigidity can occur)

<!-- PAGE=? -->
 muscle rigidity may make it difficult to ventilate the patient 1500 mcg over 10 min = 50% of patients are rigid

<!-- PAGE=? -->
o increases with age

<!-- PAGE=? -->
o lower doses 7-8 mcg/kg can produce chest wall rigidity without unconsciousness and apnea

<!-- PAGE=? -->
 seizure like movements w/o EEG changes (myoclonus from blockade of inhibitory motor pathways or exaggerations of opioid induced muscle rigidity)

<!-- PAGE=? -->
 can cause epileptiform activity during induction of pts with temporal lobe epilepsy

<!-- PAGE=? -->
 modest increases in ICP in head injury, decreases in MAP, CPP but this doesn't occur if MAP is controlled at a constant level (? Autoregulation)

<!-- PAGE=? -->
 tussive effect

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
 depression develops rapidly (peaks at 5min)

<!-- PAGE=? -->
 increased when given with midaz, blunting of hypoxic ventilatory drive more than hypercarbic ventilatory drive

<!-- PAGE=? -->
airway reflexes:

<!-- PAGE=? -->
 decreases airway reflexes in dose dependent fashion

<!-- PAGE=? -->
 cough is most vulnerable

<!-- PAGE=? -->
 blunt sympathetic response to laryngoscopy

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
 conc dependent negative inotropic effects for morphine, meperidine and fentanyl

<!-- PAGE=? -->
 for fentanyl this occurs at very high plasma levels and hemodynamic stability is the norm for clinically relevant doses

<!-- PAGE=? -->
 7 mcg/kg: slight decrease in HR, no change in MAP

<!-- PAGE=? -->
 higher doses: decreases in HR< MAP, SVR, PVR, pulmonary capillary wedge of 15% then ceiling

<!-- PAGE=? -->
 combo fentanyl + diazepam = significant cardiovascular depression, decreased SV, CO,  SVR, MAP, increased CVP

<!-- PAGE=? -->
 combo fentanyl + N2O - decreased CO, increased SVR, PVR

<!-- PAGE=? -->
 does not cause appreciable myocardial depression

<!-- PAGE=? -->
 does not release histamine

<!-- PAGE=? -->
Endo

<!-- PAGE=? -->
 high dose fentanyl results in increased plasma epi, cortisol, glucose, free fatty acids and growth hormone (stress response)

<!-- PAGE=? -->
 unlike morphine dose not prevent inflammatory effects of CPB

<!-- PAGE=? -->
 no cardioprotection

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
 extreme lipid solubility

<!-- PAGE=? -->
 onset of effects is rapid 10 sec to 1.5 min, duration is brief - wanes by 5 min in rats

<!-- PAGE=? -->
 peak effect lags behind peak plasma by 5 min (have the dose in at least 3 min prior to laryngoscopy)

<!-- PAGE=? -->
 short duration of action is attributed to redistributed to muscle and fat, lungs

<!-- PAGE=? -->
 accumulation in peripheral tissue compartments can be extensive and with prolonged admin, fat can act as a reservoir

<!-- PAGE=? -->
 decreased clearance and elimination with age

<!-- PAGE=? -->
 highly protein bound and binds to red cells

<!-- PAGE=? -->
 decreased pH = greater free (unbound) drug

<!-- PAGE=? -->
 high hepatic extraction ratio that depends on liver blood flow

<!-- PAGE=? -->
 longer elimination half time than morphine but shorter duration because of larger Vd

<!-- PAGE=? -->
o 3-6 hrs

<!-- PAGE=? -->
 adheres to the CPB circuit: sufentanil and alfentanil provide more stable plasma conc during bypass

<!-- PAGE=? -->
 Metabolism occurs primarily by hepatic N-demethylation to norfentanyl which is a less potent analgesic.

<!-- PAGE=? -->
Sufentanil

<!-- PAGE=? -->
 Potency 2000-4000x morphine and 10-15x fentanyl

<!-- PAGE=? -->
 Rapid equilibration between blood and brain and clear plasma concentration-effect relationships

<!-- PAGE=? -->
 Highly selective mu agonist

<!-- PAGE=? -->
 Dose-dependent decreases in MAC with max reduction between 70-90% (ceiling effect)

<!-- PAGE=? -->
 Hemodynamic stability as good as or better than with fentanyl in high doses for cardiac surgery

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
 1 mcg/kg elevates ICP and decreases CPP (MAP dropped in this study)

<!-- PAGE=? -->
 very large doses in dogs decreased cerebral metabolism and blood flow in proportion with ICP unchanged

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
 resp depression at doses associated with clinical analgesia

<!-- PAGE=? -->
o esp in the presence of inhalational anesthetics

<!-- PAGE=? -->
o depresses the slop of ventilatory response to CO2 less than fentanyl but the same as morphine

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
 sympatholytic and direct smooth muscle effect = vasodilation

<!-- PAGE=? -->
 only a modest decrease in MAP is seen with induction doses

<!-- PAGE=? -->
 sufentanil + vecuronium has resulted in sig bradycardia and sinus arrest and decreased MAP

<!-- PAGE=? -->
 even a large dose did not prevent the increases in cortisol, catecholamines, glucose and FFAs associated with CPB

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
 extremely lipophilic

<!-- PAGE=? -->
 similar kinetics to fentanyl but smaller volume of distribution and elimination half life because of higher protein binding, lower ionization at physiologic ph

<!-- PAGE=? -->
 obese patients have larger volume of distribution and longer elimination half life

<!-- PAGE=? -->
Alfentanil

<!-- PAGE=? -->
 10x as potent as morphine, 1/4 th to 1/10 th as potent as fentanyl

<!-- PAGE=? -->
 mu agonist with dose related analgesic effects, decreases MAC

<!-- PAGE=? -->
 in contrast to fentanyl and sufentanil, the duration of even very large doses is short so continuous infusions are required for cardiac surgery

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
-same EEG changes, seizure like movements and muscle rigidity effects as fentanyl

<!-- PAGE=? -->
-increases CSF pressure in patients with brain tumors (fentanyl dose not)

<!-- PAGE=? -->
-MAP and CPP decrease in dose dependent fashion but no changes in ICP when other factors are controlled

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
-recovery of resp function faster than that of fentanyl

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
-HR and MAP unchanged or slightly decreased

<!-- PAGE=? -->
-No negative inotropic effects

<!-- PAGE=? -->
-Profound hypotension can occur in combo with diazepam

<!-- PAGE=? -->
-Bradycardia

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
-a weaker base than other opioids so 90% of unbound plasma alfentanil is nonionized at physiologic ph

<!-- PAGE=? -->
o rapidly crosses the BBB (blood brain equilibration time 1 min compared to 6 min for suf or fentanyl)

<!-- PAGE=? -->
-smaller volume of distribution than fentanyl

<!-- PAGE=? -->
o less lipophilic

<!-- PAGE=? -->
o more protein binding (mostly alpha1 acid glycoprotein)

<!-- PAGE=? -->
o shorter terminal elim half life than fentanyl or sufentanil

<!-- PAGE=? -->
o liver disease prolongs the elimination time but renal disease does not affect it

<!-- PAGE=? -->
o prolonged elimination in elderly and obese

<!-- PAGE=? -->
 Compared to fentanyl, alfentanil has

<!-- PAGE=? -->
o 1/5th the potency

<!-- PAGE=? -->
o 1/3 the duration of action

<!-- PAGE=? -->
o more rapid onset then fentanyl and sufentanil

<!-- PAGE=? -->
 because or low pK so that 90% exists in nonionized form at physiologic pH (this form crosses the BBB)

<!-- PAGE=? -->
 Vd 4-6x smaller (less lipid soluble)

<!-- PAGE=? -->
o metabolism is faster - more available for metabolism

<!-- PAGE=? -->
 Binds to alpha1-acid glycoprotein

<!-- PAGE=? -->
 90% of administered dose has left plasma by 30 min due to distribution to highly perfused tissues

<!-- PAGE=? -->
 three compartment model

<!-- PAGE=? -->
 Like fentanyl, alfentanil is quickly distributed, with rapid and slow distribution half-times of 1.0-3.5 minutes and 9.5-17 minutes, respectively

<!-- PAGE=? -->
o alfentanil has a terminal elimination half-life of 84-90 minutes, which is considerably shorter than those of fentanyl and sufentanil

<!-- PAGE=? -->
o Clearance of alfentanil, 6.4 ml·kg-1·min-1, is half that of fentanyl

<!-- PAGE=? -->
 because alfentanil's volume of distribution is 4 times smaller than fentanyl's, relatively more of the body burden is available to the liver for metabolism

<!-- PAGE=? -->
 elimination is dependent on hepatic plasma flow.

<!-- PAGE=? -->
Remifentanil

<!-- PAGE=? -->
 Ultrashort acting

<!-- PAGE=? -->
 Metabolized by nonspecific plasma and tissue cholinesterases (not butyrylcholinesterase so not affected by those deficient in the enzyme or inhibitors)

<!-- PAGE=? -->
o Clearacne 3L/min (8x that of alfentanil with a smaller Vd)

<!-- PAGE=? -->
o Context sensitive half time nearly independent of infusion duration and is ~4 min

<!-- PAGE=? -->
o Unchanged by renal or hepatic failure

<!-- PAGE=? -->
 Dose dependent analgesia via mu agonism

<!-- PAGE=? -->
 Bolus doses: peak analgesia in 1-3 min, duration 10 min

<!-- PAGE=? -->
 40x as potent as alfentanil

<!-- PAGE=? -->
 dose dependent decrease in MAC

<!-- PAGE=? -->
 at high doses, high incidence of muscle rigidity and purposeless movement

<!-- PAGE=? -->
 blunts responses but does not decrease the value on the BIS monitor

<!-- PAGE=? -->
 pediatric patients need higher doses than adults

<!-- PAGE=? -->
 not a good single agent for induction because of rigidity and unreliability of LOC

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
-no effect on ICP

<!-- PAGE=? -->
-remi depresses MEPs less than other opioids or propofol

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
-dose dependent resp depression

<!-- PAGE=? -->
-blood conc reached with infusions are well tolerated (pt continues to breath) but the same concentration reached with bolus dose often results in apnea

<!-- PAGE=? -->
-peak period of apnea at 5 min

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
-bolus doses cause brief increases in SBP and HR

<!-- PAGE=? -->
-Bolus doses with isoflurane and N2O cause decreases in SBP and HR (not related to histamine)

<!-- PAGE=? -->
-Decreases myocardial blood flow and O2 consumption, HR, CI when given with propofol

<!-- PAGE=? -->
-Rapid injection can result in severe bradycardia and hypotension

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
-post op shivering in 40% (independent of temp)

<!-- PAGE=? -->
-dry mouth, itching, flushing, sweating

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
-unlike other opioids, redistribution plays a very minor role

<!-- PAGE=? -->
-small volume of distribution

<!-- PAGE=? -->
-clearance 4x hepatic blood flow

<!-- PAGE=? -->
-advanced age = greater potency, smaller vol of distribution, decreased clearance

<!-- PAGE=? -->
-base dose on lean body mass since pharmacokinetics are the same in obese and lean people

<!-- PAGE=? -->
-half life in plasma 4 min

<!-- PAGE=? -->
may be associated with acute opioid tolerance:

<!-- PAGE=? -->
-large doses of remi intraop increase dose requirements post op

<!-- PAGE=? -->
-Delayed hyperalgesia is produced by acute exposure to large doses of opioids

<!-- PAGE=? -->
-? Alterations in NDMA receptors?  Ketamine and Mg block opioid tolerance

<!-- PAGE=? -->
Codeine

<!-- PAGE=? -->
 10% demethylated in liver to morphine which produces analgesia

<!-- PAGE=? -->
 demethylated codeine = inactive metabolite and this is excreted by kidneys

<!-- PAGE=? -->
 Effective antitussive

<!-- PAGE=? -->
 Causes histamine release when given IV

<!-- PAGE=? -->
Hydromorphone

<!-- PAGE=? -->
 Derivative of morphine, 5x potency

<!-- PAGE=? -->
 More sedation and less euphoria than morph

<!-- PAGE=? -->
 More rapid elimination and redistribution

<!-- PAGE=? -->
Tramadol

<!-- PAGE=? -->
 Centrally acting analgesic with moderate affinity for mu receptors and weak kappa and delta affinity

<!-- PAGE=? -->
 5-10x less potent analgesic than morphine

<!-- PAGE=? -->
 Enhances spinal descending inhibitory pathways by inhibition of neuronal reuptake of NE and serotonin

<!-- PAGE=? -->
 Only 30% of its effect can be antagonized by naloxone

<!-- PAGE=? -->
 Low risk for respiratory depression and tolerance

<!-- PAGE=? -->
 Less post op shivering

<!-- PAGE=? -->
 Lowers the seizure threshold

<!-- PAGE=? -->
 centrally acting analgesic (racemic mixture) with moderate affinity for mu receptors, weak kappa and delta, and is 5-10 times less potent than morphine

<!-- PAGE=? -->
 Useful in moderate to sever pain

<!-- PAGE=? -->
 Also enhances function of descending spinal inhibitory pathways by inhibition of norepinephine and 5-HT  ondansetron may interfere

<!-- PAGE=? -->
 Naloxone only antagonizes 30% of tramadol

<!-- PAGE=? -->
 Metabolized by hepatic P-450

<!-- PAGE=? -->
 Tramadol slows gastric emptying time although the effect is small compared with other opioids

<!-- PAGE=? -->
 Dose: 3 mg/kg po, IV, IM

<!-- PAGE=? -->
o Pros : Marked decrease in shivering; little respiratory depression

<!-- PAGE=? -->
o Little tolerance development, little sedation, good for chronic pain, good for those unable to take NSAIDs

<!-- PAGE=? -->
o Less GI side effects

<!-- PAGE=? -->
o Cons : interacts with coumadin (controversial), causes seizures in epileptics or those with lower sz threshold (eg. Use of antidepressants); HIGH incidence of nausea and vomiting

<!-- PAGE=? -->
Remifentanil and Alfentanil

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Peak respiratory depression occurred at 5 minutes after each dose of remifentanil and alfentanil

<!-- PAGE=? -->
o maximal respiratory depression effect with seen after 2 ug/kg of remifentanil  and 32 ug/kg of alfentanil

<!-- PAGE=? -->
 duration of respiratory depression

<!-- PAGE=? -->
o 10 minutes after 1.5 ug/kg and 20 minutes after 2 ug/kg remifentanil

<!-- PAGE=? -->
o 30 minutes after 32 ug/kg alfentanil

<!-- PAGE=? -->
 Recovery after 4 hr infusion

<!-- PAGE=? -->
o 8 min (range 5-15) for remifentanil

<!-- PAGE=? -->
o 61 min (range 5-90) for alfentanil

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
TABLE 3-5. Pharmacokinetics of opioid agonists

<!-- PAGE=? -->
pK

<!-- PAGE=? -->
Percent

<!-- PAGE=? -->
nonionized

<!-- PAGE=? -->
(pH 7.4)

<!-- PAGE=? -->
Protein

<!-- PAGE=? -->
binding

<!-- PAGE=? -->
(%)

<!-- PAGE=? -->
Clearance

<!-- PAGE=? -->
(ml/min)

<!-- PAGE=? -->
Volume of

<!-- PAGE=? -->
distribution

<!-- PAGE=? -->
(liters)

<!-- PAGE=? -->
Partition

<!-- PAGE=? -->
coefficient

<!-- PAGE=? -->
Elimination

<!-- PAGE=? -->
half-time

<!-- PAGE=? -->
(hrs)

<!-- PAGE=? -->
Context

<!-- PAGE=? -->
sensitive

<!-- PAGE=? -->
half-time: 4-

<!-- PAGE=? -->
hour

<!-- PAGE=? -->
infusion

<!-- PAGE=? -->
(mins)

<!-- PAGE=? -->
Effect-site

<!-- PAGE=? -->
(blood/brain)

<!-- PAGE=? -->
equilibration

<!-- PAGE=? -->
(mins)

<!-- PAGE=? -->
Morphine

<!-- PAGE=? -->
7.9

<!-- PAGE=? -->
23

<!-- PAGE=? -->
35

<!-- PAGE=? -->
1,050

<!-- PAGE=? -->
224

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1.7-3.3

<!-- PAGE=? -->
Meperidine

<!-- PAGE=? -->
8.5

<!-- PAGE=? -->
7

<!-- PAGE=? -->
70

<!-- PAGE=? -->
1,020

<!-- PAGE=? -->
305

<!-- PAGE=? -->
32

<!-- PAGE=? -->
3-5

<!-- PAGE=? -->
Fentanyl

<!-- PAGE=? -->
8.4

<!-- PAGE=? -->
8.5

<!-- PAGE=? -->
84

<!-- PAGE=? -->
1,530

<!-- PAGE=? -->
335

<!-- PAGE=? -->
955

<!-- PAGE=? -->
3.1-6.6

<!-- PAGE=? -->
260

<!-- PAGE=? -->
6.8

<!-- PAGE=? -->
Sufentanil

<!-- PAGE=? -->
8.0

<!-- PAGE=? -->
20

<!-- PAGE=? -->
93

<!-- PAGE=? -->
900

<!-- PAGE=? -->
123

<!-- PAGE=? -->
1,727

<!-- PAGE=? -->
2.2-4.6

<!-- PAGE=? -->
30

<!-- PAGE=? -->
6.2

<!-- PAGE=? -->
Alfentanil

<!-- PAGE=? -->
6.5

<!-- PAGE=? -->
89

<!-- PAGE=? -->
92

<!-- PAGE=? -->
238

<!-- PAGE=? -->
27

<!-- PAGE=? -->
129

<!-- PAGE=? -->
1.4-1.5

<!-- PAGE=? -->
60

<!-- PAGE=? -->
1.4

<!-- PAGE=? -->
Remifentanil

<!-- PAGE=? -->
7.3

<!-- PAGE=? -->
58

<!-- PAGE=? -->
66-93

<!-- PAGE=? -->
4,000

<!-- PAGE=? -->
30

<!-- PAGE=? -->
0.17-0.33

<!-- PAGE=? -->
4

<!-- PAGE=? -->
1.1

<!-- PAGE=? -->
Pneumonics

<!-- PAGE=? -->
 Onset (Think Onset=Racing/Fast)

<!-- PAGE=? -->
o Alf = Remi > Suf > Fent > Morph -Africans Run Super Fast Marathons‖

<!-- PAGE=? -->
 pKa

<!-- PAGE=? -->
o Alf < Remi < Morph < Suf < Fent < Mep

<!-- PAGE=? -->
 Volume of distribution (Think Shipping/Distribution)

<!-- PAGE=? -->
o Fent > Morph > Suf > Remi > Alf  -Fedex Makes Shipping Really Affordable‖

<!-- PAGE=? -->
 Lipid solubility (Think fat people and lipid solubility)

<!-- PAGE=? -->
o Suf > Fent > Alf > Remi > Mep > Morph -Some Fatties Are Really MEssy MOrons‖

<!-- PAGE=? -->
 Clearance (Think of gassy bowels)

<!-- PAGE=? -->
o Remi > Fent > Morph > Meperidine > Suf > Alf -Rancid Farts Make ME Stay Away‖

<!-- PAGE=? -->
 Protein binding (Think Sex/Binding/Partying)

<!-- PAGE=? -->
o Suf > Alf > Remi > Fent > Morph -Sex And Rock For Me‖

<!-- PAGE=? -->
 Duration (Think how far do opioids go)

<!-- PAGE=? -->
o Morph > Suf > Fent > Alf > Remi -Morphine Sulfate goes FAR‖

<!-- PAGE=? -->
 T 1/2 alpha (Think -Alpha Male‖ but SHORTEST to LONGEST)

<!-- PAGE=? -->
o Remi  < Morphine < Suf <Alf<Fent -Real Men Sacrifice and Feel‖

<!-- PAGE=? -->
 T 1/2 beta (Think metabolism from SHORTEST to LONGEST   )

<!-- PAGE=? -->
o Remi<Alf<Morph<Suf<Fent -Remi Always Metabolized Super Fast‖

<!-- PAGE=? -->
 Context-sensitive half-life:

<!-- PAGE=? -->
o < 8 hrs = Remi < Suf < Alf < Fent  -Remi Sure Abates Fast‖

<!-- PAGE=? -->
o > 8 hrs = Remi < Alf < Suf < Fent

<!-- PAGE=? -->
 %Non-Ionized (think radiation/sunburn)

<!-- PAGE=? -->
o Alf > Remi > Morphine > Suf > Fent > MEperidine -ARMS Fried in Mexico‖

<!-- PAGE=? -->
Opiods in Liver Disease

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Fentanyl

<!-- PAGE=? -->
o almost completely metabolized in the liver

<!-- PAGE=? -->
o should have predictably prolonged elimination in liver disease

<!-- PAGE=? -->
 limited data suggest that fentanyl elimination is not appreciably altered in patients with cirrhosis

<!-- PAGE=? -->
 Alfentanil

<!-- PAGE=? -->
o exclusively metabolized by the liver

<!-- PAGE=? -->
o highly protein bound

<!-- PAGE=? -->
o half-life of alfentanil is almost doubled in patients with cirrhosis

<!-- PAGE=? -->
o higher free fractions of the drug (dec. protein binding)

<!-- PAGE=? -->
 Sufentanil

<!-- PAGE=? -->
o extensively metabolized by the liver

<!-- PAGE=? -->
o highly protein bound

<!-- PAGE=? -->
o Single-dose pharmacokinetics is not significantly altered in patients with cirrhosis

<!-- PAGE=? -->
o continuous infusions and reduced protein binding is as ill defined for sufentanil as for fentanyl

<!-- PAGE=? -->
 Remifentanil

<!-- PAGE=? -->
o hydrolysis by blood and tissue esterases

<!-- PAGE=? -->
o elimination is unaltered in patients with severe liver disease

<!-- PAGE=? -->
 Morphine

<!-- PAGE=? -->
o pharmacokinetics are relatively unchanged by liver failure because of the substantial extrahepatic metabolism of morphine

<!-- PAGE=? -->
 Meperidine

<!-- PAGE=? -->
o pharmacokinetics are altered by liver failure

<!-- PAGE=? -->
o cirrhosis is associated with reduced clearance and a longer terminal half-time of meperidine

<!-- PAGE=? -->
Opioids, neuraxial

<!-- PAGE=? -->
 Bind to mu receptors in the subgstantia gelatinosa

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o N/V

<!-- PAGE=? -->
o Pruritis

<!-- PAGE=? -->
o Resp depression

<!-- PAGE=? -->
o Urinary retention

<!-- PAGE=? -->
o Sedation

<!-- PAGE=? -->
 Benefits (compared to LA alone)

<!-- PAGE=? -->
o Improved analgesia

<!-- PAGE=? -->
o Less regression of sensory block

<!-- PAGE=? -->
o Reduced dose of LA

<!-- PAGE=? -->
Table 18-14. Epidural opioids.

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
Respiratory depression with neuraxial narcotic: Miller

<!-- PAGE=? -->
 Drug factors

<!-- PAGE=? -->
o Hydrophilic

<!-- PAGE=? -->
o Large doses

<!-- PAGE=? -->
o Repeated doses

<!-- PAGE=? -->
o Intrathecal

<!-- PAGE=? -->
o Additional IV opiates (or sedatives)

<!-- PAGE=? -->
 Patient factors

<!-- PAGE=? -->
o ElderlyElderly

<!-- PAGE=? -->
o Poor general condition

<!-- PAGE=? -->
o Lung disease

<!-- PAGE=? -->
o Thoracic epidural

<!-- PAGE=? -->
o Opioid naïve (opiate tolerant/abusing by other sources)

<!-- PAGE=? -->
o Raised intrathoracic pressure (coughing, PPV)

<!-- PAGE=? -->
Pharmacology of Neuraxial Opioids

<!-- PAGE=? -->
 site of action are opioid receptors found in substantia gelatinosa of dorsolateral horn of spinal cord

<!-- PAGE=? -->
 most important property is lipid solubility

<!-- PAGE=? -->
 hydrophilic opioids (e.g. morphine) have high degree of CSF solubility

<!-- PAGE=? -->
o greater degree of cephalad spread

<!-- PAGE=? -->
o longer duration of action

<!-- PAGE=? -->
o higher change of delayed respiratory depression

<!-- PAGE=? -->
 lipophilic opioids (e.g. fentanyl) have low degree of CSF solubility and absorb more readily into substance of spinal cord and epidural fat

<!-- PAGE=? -->
o limit cephalad spread (i.e. stay near dermatome of injection)

<!-- PAGE=? -->
o short duration of action

<!-- PAGE=? -->
o limit chance of delayed respiratory depression

<!-- PAGE=? -->
Mechanisms by which neuraxial opioids cause respiratory depression:

<!-- PAGE=? -->
 Vascular uptake by the epidural or subarachnoid venous plexuses and circulation to brainstem respiratory center

<!-- PAGE=? -->
 Arachnoid penetration and movement into the spinal cord

<!-- PAGE=? -->
 Rostral spread via the aqueous cerebrospinal fluid to the brain stem

<!-- PAGE=? -->
 Rostral spread via direct perimedulary vascular channels

<!-- PAGE=? -->
(Carvalho, 2008)

<!-- PAGE=? -->
Intrathecal Opiods

<!-- PAGE=? -->
 Provide rapid analgesic onset

<!-- PAGE=? -->
o fentanyl/sufentanil - 5-10 min

<!-- PAGE=? -->
o morphine peak effect 20-60 min, duration 2-12 hrs

<!-- PAGE=? -->
 Lack titratability

<!-- PAGE=? -->
 Rostral spread and elimination influenced by lipophilicity

<!-- PAGE=? -->
o highly lipophylic fentanyl/sufentanil are removed from CSF secondary to vascular reabsorption and spinal cord penetration which limits rostral level.

<!-- PAGE=? -->
o Hydrophylic morphine is moved by bulk flow in the cephalad direction

<!-- PAGE=? -->
 influenced by straining/coughing/sneezing but not body position

<!-- PAGE=? -->
o reaches the cisterna magna in 1-2 h

<!-- PAGE=? -->
 fourth and lateral ventricles in 3-6hrs

<!-- PAGE=? -->
o Morphine persists in the CSF with the same terminal elimination half-life as with IV injection (2-4h)

<!-- PAGE=? -->
 Vascular absorption after intrathecal administration is clinically igsignificant

<!-- PAGE=? -->
 Similar side effects as epidural opioids

<!-- PAGE=? -->
o the incidence of respiratory depression of intrathecal opioids is higher (5-7%) as compared to epidural opioids 0.1-2%

<!-- PAGE=? -->
o more recent data shows that the incidence of respiratory depression requiring intervention after single dose intrathecal and epidural opiod is the same (approx 1%) after i.m. and i.v. opioids (ASA 2008; Chaney, 1995).

<!-- PAGE=? -->
 Early respiratory depression (<2-6h) more likely with intrathecal lipophilic fentanyl/sufentanil than with hydrophilic morphine

<!-- PAGE=? -->
Epidural Opioids

<!-- PAGE=? -->
 Epidural morphine is more likely to cause delayed respiratory depression (>6h post injection) than lipophilic narcotics

<!-- PAGE=? -->
o Effect via both IV absorption and diffusion into the spinal cord

<!-- PAGE=? -->
 Morphine

<!-- PAGE=? -->
o peak serum levels and decay curves that are nearly identical to IV administration

<!-- PAGE=? -->
o peak CSF concentration occurs in 1-4 hrs

<!-- PAGE=? -->
o only small percentage (3%) actually crosses dura but then ascends cephlad in CSF for diffuse pain control

<!-- PAGE=? -->
o peaks in 30 - 60 minutes and lasts 12 - 24 hours

<!-- PAGE=? -->
o biphasic respiratory depression:

<!-- PAGE=? -->
 Early from systemic absorption and late from cephlad spread in CSF

<!-- PAGE=? -->
 Fentanyl

<!-- PAGE=? -->
o peak serum levels are only ~50% those of IV injection

<!-- PAGE=? -->
o implies a higher percentages crosses dural into CSF and into spinal cord

<!-- PAGE=? -->
o peaks in 20 minutes and lasts 2.5 hours

<!-- PAGE=? -->
o achieves supraspinal effects via systemic redistribution

<!-- PAGE=? -->
Cerebral

<!-- PAGE=? -->
Azygos Vein

<!-- PAGE=? -->
Venous Sinuses

<!-- PAGE=? -->
Basivertebral

<!-- PAGE=? -->
Venous Plexus

<!-- PAGE=? -->
D

<!-- PAGE=? -->
D

<!-- PAGE=? -->
Do

<!-- PAGE=? -->
Vertebral

<!-- PAGE=? -->
Epidural

<!-- PAGE=? -->
CSF

<!-- PAGE=? -->
Coro

<!-- PAGE=? -->
CSF

<!-- PAGE=? -->
Epidural

<!-- PAGE=? -->
Spinous

<!-- PAGE=? -->
Body

<!-- PAGE=? -->
Space

<!-- PAGE=? -->
Space

<!-- PAGE=? -->
Process

<!-- PAGE=? -->
Figure 29-13. A: Pharmacokinetic model: Epidural injection of a hydrophilic opioid such as morphine. D 0 , un-ionized drug; D  , ionized hydrophilic drug. Major route of clearance is through CSF. Shaded squares are nonspecific lipid binding sites. Role of radicular arteries in drug absorption remains unproven. B: Epidural injection of a lipophilic opioid such as meperidine or fentanyl. Note rapid passage of un-ionized species (D 0 ) via CSF into cord and then clearance by epidural veins, leaving less ionized species (D  ) remaining in CSF to migrate to brain.

<!-- PAGE=? -->
Partial agonists and mixed agonist-antagonists

<!-- PAGE=? -->
 Bind to multiple opioid receptors and have differential effects (agonist, partial agonist, antagonist) at different receptor types

<!-- PAGE=? -->
 Partial agonists have flatter dose response cures and lower maximal effect than a full agonist

<!-- PAGE=? -->
 Act as antagonist when combined with full agonist

<!-- PAGE=? -->
 Uses:

<!-- PAGE=? -->
o postop analgesia

<!-- PAGE=? -->
o intraoperative sedation

<!-- PAGE=? -->
o adjuncts during GA

<!-- PAGE=? -->
o to antagonize some of the effects of full mu agonists

<!-- PAGE=? -->
Nalbuphine

<!-- PAGE=? -->
 Reduces MAC, but only by a small amount

<!-- PAGE=? -->
 When used with diazepam and N2O for surgery, no increases in BP, stress hormones or histamine was seen

<!-- PAGE=? -->
 Sedation is a common side effect, less resp depression than fentanyl

<!-- PAGE=? -->
 Resp depression produced by nalbuphine has a ceiling effect equivalent to that of 0.4 mg/kg of morphine

<!-- PAGE=? -->
 Can antagonize the resp depression of full mu agonists while still providing analgesia (more so than naloxone) since analgesia is mediated by mu and kappa receptors

<!-- PAGE=? -->
 Can also antagonize pruritis from epidural and intrathecal morphine

<!-- PAGE=? -->
 Can ppt withdrawal syndromes in patients with opioid dependence

<!-- PAGE=? -->
Butorphanol

<!-- PAGE=? -->
 Pronounced sedative effect compared to nalbuphine and probably due to kappa agonism

<!-- PAGE=? -->
 Modest decreases in MAC

<!-- PAGE=? -->
 Like nalbuphine can antagonize respiratory depression from fentanyl and morphine without loss of analgesia

<!-- PAGE=? -->
 Does not produce elevation in intrabiliary pressure

<!-- PAGE=? -->
 Treats post op shivering (mechanism unknown)

<!-- PAGE=? -->
 Kappa agonism is anti-pruritic

<!-- PAGE=? -->
 Butorphanol PCA results in less ileus than full mu agonists

<!-- PAGE=? -->
Buprenorphine

<!-- PAGE=? -->
 Highly lipophilic partial mu agonist

<!-- PAGE=? -->
 Slow dissociation from mu receptors leads to prolonged effects that are not easily antagonized by naloxone

<!-- PAGE=? -->
 Bell shaped dose response curve: at very high doses causes progressively LESS analgesia

<!-- PAGE=? -->
 Ceiling to respiratory depression dose response curve

<!-- PAGE=? -->
Opioid antagonists: Naloxone and Naltrexone

<!-- PAGE=? -->
 Effect profile depends on the type and dose of agonist administered and the degree to which physical dependent on the opioid has developed

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
 Pure antagonist at mu, kappa and delta receptors

<!-- PAGE=? -->
 Can antagonist effects of endogenous opioids

<!-- PAGE=? -->
 Sudden complete antagonism of opioid effects in post op patients with naloxone has caused severe hypertension, tachycardia, and ventricular dysrhythmias, acute and sometimes fatal pulmonary edema

<!-- PAGE=? -->
 Mechanism for pulmonary edema probably central catecholamine release and acute pulmonary hypertension

<!-- PAGE=? -->
 Peak effects 1-2 min, generally lasts 1-4 hours

<!-- PAGE=? -->
 Titrate in 20-40 mcg increments

<!-- PAGE=? -->
 For prolonged ventilatory depression: loading dose then 3-10 mcg/hr

<!-- PAGE=? -->
 Can antagonize rigidity (as can GABA agonists like STP, benzos)

<!-- PAGE=? -->
Naltrexone

<!-- PAGE=? -->
 Pure antagonist

<!-- PAGE=? -->
 long acting oral agent

<!-- PAGE=? -->
Optic Neuropathy (Ischemic)

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 incidence of postoperative vision loss after spine surgery in the prone position may be as high as 1%

<!-- PAGE=? -->
 ASA Claims

<!-- PAGE=? -->
o spinal surgery patients at greatest risk for ischemic optic neuropathy and visual compromise

<!-- PAGE=? -->
o predisposing patient-specific factors

<!-- PAGE=? -->
o surgery exceeding 6 hours' duration

<!-- PAGE=? -->
o blood loss of more than a liter

<!-- PAGE=? -->
o Mean blood pressures and hematocrits varied widely

<!-- PAGE=? -->
Anterior Ischemic Optic Neuropathy

<!-- PAGE=? -->
 Pathophysiology of anterior ischemic optic neuropathy is believed to involve temporary hypoperfusion or nonperfusion of the vessels supplying the anterior portion of the optic nerve

<!-- PAGE=? -->
o intra-axonal edema and disturbed autoregulation to the optic nerve head may also play a role

<!-- PAGE=? -->
 risk factors for postoperative anterior ischemic optic neuropathy include

<!-- PAGE=? -->
o Coexisting cardiovascular and endocrine disease

<!-- PAGE=? -->
o Male gender

<!-- PAGE=? -->
o CABG and other thoracovascular operations

<!-- PAGE=? -->
o spinal surgery

<!-- PAGE=? -->
o increased IOP

<!-- PAGE=? -->
 fluid administration and dependant positioning

<!-- PAGE=? -->
o orbital venous pressure

<!-- PAGE=? -->
 massive bleeding, anemia, hypotension, and hemodilution are commonly described intraoperative risk factors, but may not actually corolate with the development of AION

<!-- PAGE=? -->
 emboli may also play a role, but preferentially lodge in the central retinal artery rather than in the short posterior ciliary arteries that supply the anterior optic nerve

<!-- PAGE=? -->
 Presentation

<!-- PAGE=? -->
o painless visual loss (may not be noted until the first postoperative day

<!-- PAGE=? -->
o an afferent pupillary defect

<!-- PAGE=? -->
o altitudinal field defects

<!-- PAGE=? -->
o optic disc edema or pallo

<!-- PAGE=? -->
o MRI or CT initially shows enlargement of the optic nerve. However, optic atrophy is later detected

<!-- PAGE=? -->
 Prognosis varies but is often grim

<!-- PAGE=? -->
 Prevention

<!-- PAGE=? -->
o external pressure on the eyes must be meticulously avoided

<!-- PAGE=? -->
o minimize time in the prone position when the head is notably dependent

<!-- PAGE=? -->
o In patients with pre-existing cardiovascular disease, significant hypertension, or glaucoma, it seems advisable to maintain systemic blood pressure as close to baseline as possible

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o No recognized treatments

<!-- PAGE=? -->
 intravenous acetazolamide, furosemide, mannitol, and steroids

<!-- PAGE=? -->
 Maintaining the head-up position

<!-- PAGE=? -->
 Surgical optic nerve sheath fenestration or decompression is not only ineffective, but may actually be harmful

<!-- PAGE=? -->
Posterior Ischemic Optic Neuropathy

<!-- PAGE=? -->
 posterior optic nerve has a less luxuriant blood supply than the anterior optic nerve

<!-- PAGE=? -->
 relatively few cases have been reported after CABG

<!-- PAGE=? -->
o appears to be less related to coexisting cardiovascular disease

<!-- PAGE=? -->
 male patients predominate

<!-- PAGE=? -->
 commonly associated with surgery involving the neck, nose, sinuses, or spine

<!-- PAGE=? -->
 produced by reduced oxygen delivery to the retrolaminar part of the optic nerve

<!-- PAGE=? -->
o ischemia is likely produced by compression of the pial vessels (supplied by small collaterals from the ophthalmic artery) or embolic phenomena

<!-- PAGE=? -->
 ischemic damage after a hypoxic insult is slow develop so a symptom-free period often precedes the loss of vision

<!-- PAGE=? -->
o onset of symptoms may be delayed several days

<!-- PAGE=? -->
 Manifestations

<!-- PAGE=? -->
o an afferent pupillary defect or nonreactive pupil

<!-- PAGE=? -->
o Disc edema is not a feature

<!-- PAGE=? -->
o CT scan in the early postoperative period may reveal enlargement of the intraorbital portion of the optic nerve

<!-- PAGE=? -->
o Bilateral blindness is more common than with AION

<!-- PAGE=? -->
 possible involvement of the optic chiasm

<!-- PAGE=? -->
 Some cases may show partial improvement spontaneously, but often no improvement is noted

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Steroids may be considered

<!-- PAGE=? -->
 Preventive strategies are as outlined for anterior ischemic optic neuropathy

<!-- PAGE=? -->
Organophosphates

<!-- PAGE=? -->
 insecticides/nerve agents

<!-- PAGE=? -->
o potent inhibitors of acetylcholinesterase

<!-- PAGE=? -->
o inhaled, ingested, absorbed through skin

<!-- PAGE=? -->
 malathion, parathion (both insecticides)

<!-- PAGE=? -->
 tabun, soman (both nerve gases)

<!-- PAGE=? -->
 echothiophate (a topical agent previously used in glaucoma -> prolonged duration of Sux activity

<!-- PAGE=? -->
 inhibition of acetylcholinesterase, resulting in accumulation of ACh at nicotinic and cholinergic sites

<!-- PAGE=? -->
o skeletal muscle weakness - 1-4 d post ingestion, death from apnea

<!-- PAGE=? -->
 Muscarinic effects by organ systems include the following

<!-- PAGE=? -->
o Cardiovascular - Bradycardia, hypotension

<!-- PAGE=? -->
o Respiratory - Rhinorrhea, bronchospasm, bronchorrhea, cough

<!-- PAGE=? -->
o Gastrointestinal - Increased salivation, nausea and vomiting, abdominal pain, diarrhea, and fecal incontinence

<!-- PAGE=? -->
o Genitourinary - Urinary incontinence

<!-- PAGE=? -->
o Ocular - Blurred vision, miosis

<!-- PAGE=? -->
o Glands - Increased lacrimation, increased sweating

<!-- PAGE=? -->
o DDUMBBBELS (diaphoresis and diarrhea; urination; miosis; bradycardia, bronchospasm, bronchorrhea; emesis; lacrimation excess; salivation excess)

<!-- PAGE=? -->
 Nicotinic signs and symptoms include atropine does not reverse nicotinic effects

<!-- PAGE=? -->
o muscle fasciculations, cramping, weakness, and diaphragmatic failure

<!-- PAGE=? -->
o Autonomic nicotinic effects include

<!-- PAGE=? -->
 hypertension, tachycardia, pupillary dilation, and pallor

<!-- PAGE=? -->
o CNS effects include

<!-- PAGE=? -->
 anxiety, restlessness, confusion, ataxia, seizures, insomnia, dysarthria, tremors, and coma

<!-- PAGE=? -->
 effects on NMDA and GABA result in CNS toxicity

<!-- PAGE=? -->
 Treatment:

<!-- PAGE=? -->
o anticholinergics:  atropine 2-6 mg iv q 5 min titrated to secretions (usual dose 15-20 mg - up to more than a gram)

<!-- PAGE=? -->
 endpoint of atropine - control of a/w secretions and improved ventilation

<!-- PAGE=? -->
 preferred to glycopyrrolate for longer duration of action and crosses the BBB

<!-- PAGE=? -->
o oximes:  pralidoxime 600 mg iv; complexes w organophosphate to reactivate acetylcholinesterase

<!-- PAGE=? -->
 slow infusion to avoid laryngospasm, muscle rigidity, and hypertension

<!-- PAGE=? -->
 reverse the actions of OP at the nicotinic receptor and reduce the degree of paralysis

<!-- PAGE=? -->
o benzos:  diazepam 5-10 mg until seizures controlled

<!-- PAGE=? -->
o prophylaxtic pyridostigmine can be taken - min 30 min in advance of exposure

<!-- PAGE=? -->
 long-acting agent that binds with acetylcholinesterase, allowing the enzyme to spontaneously regenerate

<!-- PAGE=? -->
 does not cross the blood-brain barrier

<!-- PAGE=? -->
 Anticholinesterase drugs = cholinergic crisis; manifest as muscarinic & nicotinic sx

<!-- PAGE=? -->
Oxygen

<!-- PAGE=? -->
 Alveolar-arterial gas equation

<!-- PAGE=? -->
o PAO2 = FiO2 x [pB - pH2O] - pCO2/.8

<!-- PAGE=? -->
 Oxygen Content

<!-- PAGE=? -->
o (SaO2  x Hg (g/dl) x 1.34) + (0.003 x PaO2)

<!-- PAGE=? -->
Oxygen Dissociation curve

<!-- PAGE=? -->
Left shift

<!-- PAGE=? -->
Decreased temp

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Decreased 2-3 DPG

<!-- PAGE=? -->
Decreased [H+]

<!-- PAGE=? -->
90

<!-- PAGE=? -->
80

<!-- PAGE=? -->
70

<!-- PAGE=? -->
60

<!-- PAGE=? -->
50

<!-- PAGE=? -->
(reduced affinity)

<!-- PAGE=? -->
Increased temp

<!-- PAGE=? -->
40

<!-- PAGE=? -->
Increased 2-3 DPG

<!-- PAGE=? -->
Increased (H+]

<!-- PAGE=? -->
30

<!-- PAGE=? -->
20

<!-- PAGE=? -->
10

<!-- PAGE=? -->
10

<!-- PAGE=? -->
20

<!-- PAGE=? -->
30

<!-- PAGE=? -->
40

<!-- PAGE=? -->
50

<!-- PAGE=? -->
60

<!-- PAGE=? -->
70

<!-- PAGE=? -->
80

<!-- PAGE=? -->
90

<!-- PAGE=? -->
100

<!-- PAGE=? -->
(mmHg)

<!-- PAGE=? -->
AnaesthesiaUK

<!-- PAGE=? -->
 Bohr effect:

<!-- PAGE=? -->
o increased carbon dioxide in the blood and a decrease in pH results in a reduction of the affinity of hemoglobin for oxygen.

<!-- PAGE=? -->
 Haldane effect

<!-- PAGE=? -->
o Deoxygenation of the blood increases its ability to carry carbon dioxide

<!-- PAGE=? -->
 Conversely, oxygenated blood has a reduced capacity for carbon dioxide

<!-- PAGE=? -->
o partially explains the observation that some patients with emphysema might have an increase in PaCO2 (arterial dissolved carbon dioxide) following administration of supplemental oxygen

<!-- PAGE=? -->
 also related to inc. dead space ventilation relative to alveolar ventilation as a consequence of reduced HPV

<!-- PAGE=? -->
 Normal PaO2 is 100 - age/3 ~ 80 - 90.

<!-- PAGE=? -->
 Pregnant patients are respiratory alkalotics

<!-- PAGE=? -->
o PaCO2 30

<!-- PAGE=? -->
o normal pH

<!-- PAGE=? -->
o high/normal PaO2.

<!-- PAGE=? -->
 Altitude leads to decreased PaO2, SaO2 and PaCO2

<!-- PAGE=? -->
 Peds have a left shifted curve

<!-- PAGE=? -->
o higher SaO2 than expected for PaO2

<!-- PAGE=? -->
o PaO2 75 should give SaO2 of 94% in adults but gives 98% in infant

<!-- PAGE=? -->
 Adults need PaO2 of 100 for SaO2 of 98%

<!-- PAGE=? -->
 fetal hemoglobin  is left shifted

<!-- PAGE=? -->
o P50 = 17, normal 27

<!-- PAGE=? -->
 Sleeping causes increase of PaCO2.

<!-- PAGE=? -->
 When PO2 is less than 60 mm Hg (90% saturation), saturation falls steeply

<!-- PAGE=? -->
 Mixed venous blood has a PO2 (PVO2) of about 40 mm Hg and is approximately 75% saturated

<!-- PAGE=? -->
 A P50 lower than 27 mm Hg describes a left-shifted oxy-Hb curve

<!-- PAGE=? -->
o at any given PO2, Hb has a higher affinity for O2 and is therefore more saturated than normal

<!-- PAGE=? -->
o alkalosis (metabolic and respiratory-the Bohr effect)

<!-- PAGE=? -->
o hypothermia

<!-- PAGE=? -->
o abnormal and fetal Hb

<!-- PAGE=? -->
o carboxyhemoglobin

<!-- PAGE=? -->
o methemoglobin

<!-- PAGE=? -->
o dec RBC 2,3-diphosphoglycerate (2,3-DPG) content

<!-- PAGE=? -->
 may occur with the transfusion of old acid-citrate-dextrose-stored blood; storage of blood in citrate-phosphate-dextrose minimizes changes in 2,3-DPG with time

<!-- PAGE=? -->
 A P50 higher than 27 mm Hg describes a right-shifted oxy-Hb curve

<!-- PAGE=? -->
o at any given PO2, Hb has a low affinity for O2 and is less saturated than normal

<!-- PAGE=? -->
o acidosis (metabolic and respiratory-the Bohr effect)

<!-- PAGE=? -->
o hyperthermia

<!-- PAGE=? -->
o abnormal Hb

<!-- PAGE=? -->
o inc RBC 2,3-DPG content

<!-- PAGE=? -->
o inhaled anesthetics

<!-- PAGE=? -->
o Pregnancy

<!-- PAGE=? -->
 Due to 2,3-DPG effect

<!-- PAGE=? -->
 Abnormalities in acid-base balance result in alteration of 2,3-DPG metabolism to shift the oxy-Hb curve back to its normal position

<!-- PAGE=? -->
o This compensatory change in 2,3-DPG requires between 24 and 48 hours

<!-- PAGE=? -->
o with acute acid-base abnormalities, O2 affinity and the position of the oxy-Hb curve change but with more prolonged acid-base changes, the reciprocal changes in 2,3-DPG levels shift the oxy-Hb curve back toward normal

<!-- PAGE=? -->
 Many inhaled anesthetics have been shown to shift the oxy-Hb dissociation curve to the right

<!-- PAGE=? -->
o Isoflurane shifts P50 to the right by2.6 ± 0.07 mm Hg at  1 MAC

<!-- PAGE=? -->
 high-dose fentanyl, morphine, and meperidine do not alter the position of the curve

<!-- PAGE=? -->
 Methemoglobinemia is left shifted

<!-- PAGE=? -->
 SvO2

<!-- PAGE=? -->
o Shifts in the curve will not effect messured SvO2

<!-- PAGE=? -->
 Will result in a change in mixed venous pO2

<!-- PAGE=? -->
FIGURE 33-9 Hb-O2 saturation curves. Dotted lines indicate common arterial and venous values: SaO2 = 90 percent and S O2 = 70 percent. The middle curve (A0, V0) represents the relationship with pH 7.40, body temperature 37°C. The right-hand curve (A1, V1) would occur if pH were 7.20 or T = 41°C. The left-hand curve (A2, V2) represents the relationship when T = 33°C. Increased levels of any of the four factors shown (temperature, [H + ], erythrocyte 2,3-diphosphoglycerate, PCO2) will decrease HbO2 affinity (rightward shift); decreased levels will raise Hb-O2 affinity (leftward shift). The same arterial and venous Hb-O2 saturation under different conditions can therefore result in a wide range of arterial and venous gas tension values.

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Ao

<!-- PAGE=? -->
A

<!-- PAGE=? -->
80

<!-- PAGE=? -->
60

<!-- PAGE=? -->
Temperature

<!-- PAGE=? -->
Temperature

<!-- PAGE=? -->
1

<!-- PAGE=? -->
40

<!-- PAGE=? -->
2,3 DPG

<!-- PAGE=? -->
1 2,3 DPG

<!-- PAGE=? -->
PCO,

<!-- PAGE=? -->
PCO?

<!-- PAGE=? -->
20

<!-- PAGE=? -->
20

<!-- PAGE=? -->
40

<!-- PAGE=? -->
60

<!-- PAGE=? -->
80

<!-- PAGE=? -->
100

<!-- PAGE=? -->
PO2 (mm Hg)

<!-- PAGE=? -->
Oxygen consumption

<!-- PAGE=? -->
 VO2 = (CaO2 - CvO2) X CO

<!-- PAGE=? -->
Free Radicals

<!-- PAGE=? -->
 Highly reactive negatively charged oxygen molecules

<!-- PAGE=? -->
o Un paired electron

<!-- PAGE=? -->
 Damage lipids of cell membranes

<!-- PAGE=? -->
o Vascular endothelium

<!-- PAGE=? -->
 Superoxide dismutase is an antioxidant enzyme that clears superoxide

<!-- PAGE=? -->
o Catalyzes its dismutation to oxygen and hydrogen peroxide

<!-- PAGE=? -->
 Can cause myocyte injury

<!-- PAGE=? -->
 Oxygen free radicals are formed under normal metabolism, specifically the electron transport chain

<!-- PAGE=? -->
o Other enzymes include

<!-- PAGE=? -->
 Xanthine oxidase

<!-- PAGE=? -->
 P450

<!-- PAGE=? -->
 Monoamine oxidase

<!-- PAGE=? -->
 Nitric oxide synthase

<!-- PAGE=? -->
Toxicity

<!-- PAGE=? -->
Lange, Miller

<!-- PAGE=? -->
 Hypoventilation in CO2 retainers (altered resp drive, inhibition of HPV, increased V/Q mismatch)

<!-- PAGE=? -->
 Absorption Atelectasis

<!-- PAGE=? -->
o breathing high FiO2 can convert lung units that had very low V A/Q ratios into shunt units

<!-- PAGE=? -->
 due to absorption atelectasis

<!-- PAGE=? -->
o results in an increase in R - L shunt

<!-- PAGE=? -->
 increased A-a gradient

<!-- PAGE=? -->
̇

<!-- PAGE=? -->
o increased risk with

<!-- PAGE=? -->
 high FiO2

<!-- PAGE=? -->
 even with FiO2 as low as 0.5

<!-- PAGE=? -->
 low V A/Q ratio

<!-- PAGE=? -->
̇

<!-- PAGE=? -->
 increased exposure time

<!-- PAGE=? -->
 low venous oxygen content (Cv O2)

<!-- PAGE=? -->
 Oxygen toxicity:

<!-- PAGE=? -->
o Correlates to alveolar PAO2,

<!-- PAGE=? -->
 100% O2 should not be administered for more than 12 hours

<!-- PAGE=? -->
 80% O2 - 24 hours

<!-- PAGE=? -->
 60% O2 - 36 hours

<!-- PAGE=? -->
 < 50% FiO2 is considered safe

<!-- PAGE=? -->
o pulmonary toxicity due  to O2 is indistinguishable from ARDS

<!-- PAGE=? -->
 inc. capillary permeability

<!-- PAGE=? -->
 inc. membrane thickness

<!-- PAGE=? -->
 decreased in type I alveolar cells and prolipheration of type II

<!-- PAGE=? -->
o Signs and symptoms

<!-- PAGE=? -->
 Initial

<!-- PAGE=? -->
 retrosternal burning and distress

<!-- PAGE=? -->
 chest tightness

<!-- PAGE=? -->
 cough

<!-- PAGE=? -->
 urge to deep-breathe

<!-- PAGE=? -->
 Progressive

<!-- PAGE=? -->
 Dyspnea

<!-- PAGE=? -->
 Paroxysmal cough

<!-- PAGE=? -->
 Dec. VC

<!-- PAGE=? -->
o recovery of mechanical lung function from this point usually takes ~12-24 hrs

<!-- PAGE=? -->
 may be longer

<!-- PAGE=? -->
̄

<!-- PAGE=? -->
 Continued

<!-- PAGE=? -->
 impairment of pulmonary function

<!-- PAGE=? -->
 deterioration of ABG

<!-- PAGE=? -->
o Pathology

<!-- PAGE=? -->
 similar to tracheobronchitis (exposure for 12 hours to a few days)

<!-- PAGE=? -->
 progresses to involvement of the alveolar septa with pulmonary interstitial edema (exposure for a few days to 1 week)

<!-- PAGE=? -->
 finally, pulmonary fibrosis of the edema (exposure for more than 1 week)

<!-- PAGE=? -->
o mechanism of action is complex

<!-- PAGE=? -->
 interference with metabolism seems to be widespread

<!-- PAGE=? -->
 inactivation of enzymes by O2-derived free radicals

<!-- PAGE=? -->
 Neutrophil recruitment and release of mediators of inflammation

<!-- PAGE=? -->
o In neonates inc. FiO2  is associated with

<!-- PAGE=? -->
 BPD

<!-- PAGE=? -->
 retrolental fibroplasias

<!-- PAGE=? -->
 high risk in prematurity

<!-- PAGE=? -->
o highest risk in those less than 1.0 kg in birth weight and 28 weeks' gestation

<!-- PAGE=? -->
 correlates with arterial PaO2 rather than alveolar

<!-- PAGE=? -->
o PaO2 > 80mmHg for more than 3 hrs constitutes risk in any infant  with a PCA less than 44 weeks

<!-- PAGE=? -->
o hyperbaric O2 therapy

<!-- PAGE=? -->
 toxicity is related to pressure and duration of therapy

<!-- PAGE=? -->
 Prolonged exposure to >0.5 atm is associated with pulmonary toxicity

<!-- PAGE=? -->
 convulsions can occur during exposure to pressures in excess of 2 atm

<!-- PAGE=? -->
Oximetry

<!-- PAGE=? -->
 Patients with sickle cell disease have a rightward shift of the Hb-O2 dissociation curve (i.e., increased P50), and at any given Pa O 2 value, the Sp O 2 is lower than the normal Hb-O2 dissociation curve would predict.

<!-- PAGE=? -->
 At normal oxygenation levels in humans, over a range of hemoglobin levels from 2.3 to 8.7 g/dL, Sp O 2 accurately reflects Sa O 2.However, during hypoxia, Sp O 2 tends to underestimate Sa O 2 to a degree that increases linearly as the hemoglobin concentration falls

<!-- PAGE=? -->
 Below 60% Sa O 2, most units underestimated the actual Sa O 2 (i.e., false low measurement)

<!-- PAGE=? -->
 Ambient light, particularly fluorescent light, can falsely increase the Sp O 2 reading

<!-- PAGE=? -->
 Reduced blood flow to the extremity results in a diminished signal and can cause inability to obtain an Sp O 2 reading or a falsely low reading possibly caused in part by greater fractional tissue consumption of arterial O2, resulting in a lower saturation in the pulsatile blood component that is measured.

<!-- PAGE=? -->
 Vasoconstriction or hypotension can result in loss of Sp O 2 signal. Rx = topical nitroglycerin ointment, digital nerve block, EMLA cream (2.5% lidocaine and 2.5% prilocaine) to the earlobe, covered by an occlusive plastic dressing for 30 minutes

<!-- PAGE=? -->
 when there is peripheral vasoconstriction, and arterial O2 saturation may be changing rapidly (e.g., during difficult airway situations), forehead or ear oximetry may provide a more rapid indicator of desaturation

<!-- PAGE=? -->
P

<!-- PAGE=? -->
P 450

<!-- PAGE=? -->
Pacemakers

<!-- PAGE=? -->
Lange, Hensly, ACLS, Miller

<!-- PAGE=? -->
 Indications for temporary pacemaker

<!-- PAGE=? -->
o Absolute

<!-- PAGE=? -->
 Symptomatic sinus bradycardia or escape rhythm

<!-- PAGE=? -->
 Sick sinus syndrome

<!-- PAGE=? -->
 High AVB (type II 2 nd or 3 rd )

<!-- PAGE=? -->
 Specifically Mobitz II second-degree AV block with a widened QRS or chronic bifascicular block

<!-- PAGE=? -->
 Symptomatic Mobitz I or II second-degree AV block

<!-- PAGE=? -->
 During AMI

<!-- PAGE=? -->
 asystole, 1 st degree AVB with new bifasicular (trifasicular block), alternating BBB, unresponsive bradycardia

<!-- PAGE=? -->
 LQTS (with high risk of torsades)

<!-- PAGE=? -->
o Relative

<!-- PAGE=? -->
 During AMI

<!-- PAGE=? -->
 new or age-indeterminate LBBB or bifasicular block (RBBB with LAFB, LPFB, or 1 st degree AVB); recurrent sinus pauses refractory to atropine; overdrive pacing for incessant VT

<!-- PAGE=? -->
 Heart surgery

<!-- PAGE=? -->
 to overdrive hemodynamically disadvantageous AV junctional and ventricular rhythms; to terminate reentrant SVT or VT; to prevent pause- or bradycardiadependent tachydysrhythmias, transplant

<!-- PAGE=? -->
 insertion of pulmonary artery with LBBB

<!-- PAGE=? -->
 Hypertrophic & dilated cardiomyopathy

<!-- PAGE=? -->
 Threshold for capture

<!-- PAGE=? -->
o Increased by

<!-- PAGE=? -->
 Mild hypoxia

<!-- PAGE=? -->
 Acidosis

<!-- PAGE=? -->
 Hypercarbia

<!-- PAGE=? -->
 Alkalosis

<!-- PAGE=? -->
 hyperNatremia

<!-- PAGE=? -->
 hyperkalemia

<!-- PAGE=? -->
 hypergycemia

<!-- PAGE=? -->
 β-blockers & CCBs

<!-- PAGE=? -->
 Post-prandial state

<!-- PAGE=? -->
 Sleep

<!-- PAGE=? -->
 Drugs: Bretylium, encainide, flecainide, propafenone, sotalol, Quinidine, procainamide

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 Irradiation

<!-- PAGE=? -->
 Myocardial ischemia or infarction

<!-- PAGE=? -->
 Post cardioversion or defib

<!-- PAGE=? -->
 Progression of cardiomyopathy

<!-- PAGE=? -->
o Decreased by

<!-- PAGE=? -->
 Severe hypoxia

<!-- PAGE=? -->
 Hypokalemia

<!-- PAGE=? -->
 β-adrenergic stimulation (exercise)

<!-- PAGE=? -->
 Transesophageal pacing is an atrial mode of pacing

<!-- PAGE=? -->
o Not effective for complete heart block

<!-- PAGE=? -->
AICDs

<!-- PAGE=? -->
PACU

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o nausea and vomiting (9.8%)

<!-- PAGE=? -->
o need for airway support (6.9%)

<!-- PAGE=? -->
o hypotension (2.7%)

<!-- PAGE=? -->
o dysrhythmia (1.4%)

<!-- PAGE=? -->
o hypertension (1.1%)

<!-- PAGE=? -->
o altered mental status (0.6%)

<!-- PAGE=? -->
o rule out myocardial infarction (0.3%)

<!-- PAGE=? -->
o major cardiac events (0.3%)

<!-- PAGE=? -->
 Risk factors for complications

<!-- PAGE=? -->
o Greater ASA status

<!-- PAGE=? -->
o anesthesia duration between 2 and 4 hours

<!-- PAGE=? -->
o emergency procedures

<!-- PAGE=? -->
o abdominal and orthopedic procedures

<!-- PAGE=? -->
Aldrete patient rating score

<!-- PAGE=? -->
ARCCO - Activity, Respiration, Circulation, Consciousness, Oxygenation

<!-- PAGE=? -->
Pain

<!-- PAGE=? -->
Pain Pathways

<!-- PAGE=? -->
 Nociceptors

<!-- PAGE=? -->
o High threshold for activation, and encode the intensity of stimulation by increasing discharge rates

<!-- PAGE=? -->
o Two components

<!-- PAGE=? -->
 First pain -fast , sharp, well-localized sensation via A-delta and tested by pinprick

<!-- PAGE=? -->
 Second pain - duller, slower onset, and poorly localized pain carried via C fibers

<!-- PAGE=? -->
o Both somatic (skin, muscle, tendon, fascia, bone) and visceral (internal organs)

<!-- PAGE=? -->
 Three main sensory fibers

<!-- PAGE=? -->
o A-beta - large diameter , highly myelinated , and conduct quickly ; low activation thresholds and respond to light touch, tactile information

<!-- PAGE=? -->
o A-delta - smaller in diameter, thinly myelinated , an conduct more slowly ; higher thresholds and respond to thermal and mechanical stimuli

<!-- PAGE=? -->
o C - smallest in diameter, unmyelinated , and the slowest for conduction ; highest thresholds and conduct nociceptive or -painful‖ stimuli

<!-- PAGE=? -->
 C-fibers respond to both noxious thermal and mechanical stimuli, but also endogenous chemical mediators (especially in conditions of inflammation)

<!-- PAGE=? -->
 Chemical mediators can sensitize receptors ( primary hyperalgesia )

<!-- PAGE=? -->
 Neuropathy leads to changes in activity, properties, and transmitter content

<!-- PAGE=? -->
o Damaged nerves can have ectopic activity, and increased sensitivity of mechanoreceptors

<!-- PAGE=? -->
o Nerves can cross-excite each other

<!-- PAGE=? -->
o Sympathetic efferents can apparently activate sensory afferents

<!-- PAGE=? -->
 These peripheral fibers are - first-order neurons ‖, and enter the dorsal horn of the spinal cord, where they synapse with - second-order neurons ‖ after ascending or descending 1-3 spinal segments (note: some C-fibers do enter via the ventral root, which is why some patients still feel pain after a rhizotomy)

<!-- PAGE=? -->
 In many instances they communicate with second order neurons via interneurons

<!-- PAGE=? -->
 Pain from the head is carried via the trigeminal (V), facial (VII), glossopharangeal (IX), and vagal nerves (X)

<!-- PAGE=? -->
 The spinal cord gray matter is made up of a series of 10 lamina:

<!-- PAGE=? -->
o The first 6 lamina make up the dorsal horn itself

<!-- PAGE=? -->
o These lamina receive all afferent activity, and are the principle site of modulation of pain by ascending and descending neural pathways

<!-- PAGE=? -->
o Most of the A-delta and C fibers terminate in laminae I-II , while the A-beta ones dominate the higher (deeper) laminae

<!-- PAGE=? -->
o Second-order neurons are either nociceptive-specific (NS) or wide dynamic range (WDR)

<!-- PAGE=? -->
 NS cells synapse with A-delta and C fibers only , and only fire when a high-threshold nociceptive signal is detected

<!-- PAGE=? -->
 WDR cells are more prevalent , and receive input from all three types (A-beta, A-delta, and C) and respond to the full range of stimulation (light touch to noxious pinch, heat, chemical)

<!-- PAGE=? -->
 WDR cells fire differently based on stimulus intensity; NS just plain fire

<!-- PAGE=? -->
 WDR cells also exhibit - wind-up ‖ whereby repetitive stimulation results in an increase of the firing rate, even with the same stimulus intensity

<!-- PAGE=? -->
o Lamina I = primarily noxious stimuli from cutaneous and deep somatic tissue

<!-- PAGE=? -->
o Lamina II = substantia gelatinosa = many interneurons and major player in processing/modulating nociceptive input, and also a major site for action of opioids

<!-- PAGE=? -->
o Lamina III/IV = primarily non-nociceptive

<!-- PAGE=? -->
o Lamina V = home of many WDR's , and visceral afferents ( convergence between somatic and visceral inputs, which can manifest as - referred pain ‖)

<!-- PAGE=? -->
o Glutamatergic and GABAergic interneurons modulate the response of the NS and WDR cells, in addition the astrocytes and microglia

<!-- PAGE=? -->
 After synapsing in the dorsal horn, touch and proprioception are carried ipsilaterally via the dorsal column , whereas most pain fibers cross at the anterior commissure to the contralateral side and ascend via the spinothalamic tract (anteriorly)

<!-- PAGE=? -->
o Spinothalamic tract (ST) fibers send fibers to the thalamus , reticular formation , nucleus raphe magnus , and periaqueductal gray area

<!-- PAGE=? -->
o The lateral ST carries discriminative aspects of pain (location, intensity, duration)

<!-- PAGE=? -->
o The medial ST projects to medial thalamus and autonomic and unpleasant emotional perceptions of pain

<!-- PAGE=? -->
o Other fibers go to the RAS and hypothalamus and likely responsible for the arousal aspect of pain

<!-- PAGE=? -->
o Should be noted that pain fibers also ascend all over the place

<!-- PAGE=? -->
 Spinoreticular tract (arousal and autonomic responses to pain)

<!-- PAGE=? -->
 Spinomesencephalic tract (anti-nociceptive descending pathways, with some projections to the periaqueductal gray area)

<!-- PAGE=? -->
 Spinohypothalamic and spinaotelencephalic tract (hypothalamus, emotional behaviour)

<!-- PAGE=? -->
 Some dorsal horn neurons synapse with anterior horn motor neurons ( reflex muscle activity )

<!-- PAGE=? -->
 Others synapse with sympathetic neurons and result in sympathetically mediated vasoconstriction , and release of catecholamines

<!-- PAGE=? -->
 -Third-order neurons ‖ are located in the thalamus and send fibers to somatosensory areas in the postcentral gyrus of the parietal cortex, where perception and discrete localization of pain takes place

<!-- PAGE=? -->
 Chemical mediators of pain

<!-- PAGE=? -->
o Excitatory

<!-- PAGE=? -->
 Substance P , Calcitonin-gene-related peptide , Glutamate , Aspartate, ATP

<!-- PAGE=? -->
o Inhibitory

<!-- PAGE=? -->
 ACh, Somatostatin, Enkephalins, Beta-Endorphin , Norepinphrine , Adenosine, Serotonin , GABA , Glycine

<!-- PAGE=? -->
Thalamus

<!-- PAGE=? -->
DC

<!-- PAGE=? -->
STT

<!-- PAGE=? -->
Spinal

<!-- PAGE=? -->
Posterior root

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
division

<!-- PAGE=? -->
Anterior root

<!-- PAGE=? -->
Sympathetic

<!-- PAGE=? -->
ganglion

<!-- PAGE=? -->
Viscera

<!-- PAGE=? -->
As, €

<!-- PAGE=? -->
b

<!-- PAGE=? -->
Blood

<!-- PAGE=? -->
vessels

<!-- PAGE=? -->
Aa

<!-- PAGE=? -->
Muscle

<!-- PAGE=? -->
spindle

<!-- PAGE=? -->
Skeletal

<!-- PAGE=? -->
AB

<!-- PAGE=? -->
Tendon

<!-- PAGE=? -->
Receptors in skin

<!-- PAGE=? -->
Ia,

<!-- PAGE=? -->
copyright 02006 bYThe McGraw-Hill companies, Inc All rights reserved

<!-- PAGE=? -->
To dorsal columns

<!-- PAGE=? -->
Mechanoreceptors

<!-- PAGE=? -->
Ab

<!-- PAGE=? -->
Mechanoreceptors

<!-- PAGE=? -->
Nociceptors

<!-- PAGE=? -->
Ad

<!-- PAGE=? -->
Cold recoptors

<!-- PAGE=? -->
Nociceptors

<!-- PAGE=? -->
Thermoreceptors

<!-- PAGE=? -->
c

<!-- PAGE=? -->
Mechanoreceptors

<!-- PAGE=? -->
VII

<!-- PAGE=? -->
VIII

<!-- PAGE=? -->
Copyright @2006 by The McGraw-Hill Companies,Inc

<!-- PAGE=? -->
All rights reserved,

<!-- PAGE=? -->
Dorsal column

<!-- PAGE=? -->
(touch; pressure,

<!-- PAGE=? -->
Gracile

<!-- PAGE=? -->
Cuneate

<!-- PAGE=? -->
vibration, joint

<!-- PAGE=? -->
íasciculus

<!-- PAGE=? -->
fasciculus

<!-- PAGE=? -->
position)

<!-- PAGE=? -->
5

<!-- PAGE=? -->
Laleral

<!-- PAGE=? -->
spinothalamic

<!-- PAGE=? -->
tract

<!-- PAGE=? -->
5

<!-- PAGE=? -->
L

<!-- PAGE=? -->
T

<!-- PAGE=? -->
5

<!-- PAGE=? -->
T

<!-- PAGE=? -->
C

<!-- PAGE=? -->
Vontral spinothalamic tract

<!-- PAGE=? -->
copyright 02006 by The McGraw-Hill Companies,Inc

<!-- PAGE=? -->
Modulation

<!-- PAGE=? -->
 As described above, primary hyperalgesia refers to the sensitization of nociceptors and results in a decrease in threshold, or increase in frequency response, to the same stimulus intensity

<!-- PAGE=? -->
o Can even have spontaneous firing after stimulus (afterdischarges)

<!-- PAGE=? -->
o Commonly occurs with injury, or the application of heat

<!-- PAGE=? -->
o Mediated by histamine , serotonin , and bradykinin

<!-- PAGE=? -->
o produced prostaglandins (PLA2 to arachidonic acid) act on nerve endings, and potentiate the edema from bradykinin

<!-- PAGE=? -->
 NSAIDS, ASA, Tylenol, and steroids act to attenuate this response

<!-- PAGE=? -->
 Secondary hyperalgesia is manifested by the -triple response‖

<!-- PAGE=? -->
o Flushing, local tissue edema, and sensitization around the area of injury to noxious stimuli

<!-- PAGE=? -->
o based mostly around the release of Substance P (blocked by Capsaicin)

<!-- PAGE=? -->
 (this honestly sounds to me like primary hyperalgesia, but I suppose there are some differences  Paul Kliffer has a different take on secondary hyperalgesia - see below)

<!-- PAGE=? -->
 Glutamate is the primary excitatory neurotransmitter in the nervous system, and is greatly involved in the primary afferents synapsing in the dorsal horn

<!-- PAGE=? -->
o Glutamate has an excitatory effect on AMPA and NMDA receptors, which have significant roles in pain ( central modulation )

<!-- PAGE=? -->
 AMPA activation is responsible for setting the initial baseline response to both noxious and tactile stimuli (not sure what this means)

<!-- PAGE=? -->
 NMDA activation has a major role in the concept of wind-up ‖ ( repetitive stimulation resulting an in increase firing rate and duration, even to stimuli of the same intensity )

<!-- PAGE=? -->
 Wind-up and NMDA

<!-- PAGE=? -->
 Normally (i.e. with acute or low-frequency noxious stimuli) the NMDA receptor is not activated , because the ion channel is blocked by Mg ions , and requires a sustained depolarizatio n to displace the Mg and allow the NMDA channel to be activated

<!-- PAGE=? -->
 So prolonged stimulation (and co-release of Substance P and CGRP) leads to prolonged depolarization and removal of the Mg block , allowing wind-up to occur

<!-- PAGE=? -->
 The open NMDA channel allows Ca ions to pass , which results in a multitude of things ultimately leading to central sensitization (elevated responsiveness and activity) and the patient becomes increasingly responsive to painful stimuli

<!-- PAGE=? -->
o Targeting the NMDA receptor with agents like Ketamine , Dextromethorpan , and Memantine has some effect (as you would expect), but the majority cannot achieve complete pain control , mostly because of the narrow therapeutic window and the presence of NMDA receptors elsewhere in the body (i.e. side effects)

<!-- PAGE=? -->
 According to Lange, in addition to wind-up, there is receptor field expansion and hyperexcitability of flexion reflexes - I'm not sure how important these are

<!-- PAGE=? -->
 Inhibition occurs both at the segmental level and supraspinally

<!-- PAGE=? -->
o Segmental

<!-- PAGE=? -->
 The Gate Theory - based on the fact that activation of regular afferent fibers inhibits WDR neurons and ST activity, and that activation of noxious stimuli in one area inhibits WDR neurons at other levels (i.e. pain in one area inhibits pain in other parts ) - and basically states that the activation of nerves that do not transmit pain signals can interfere with signals from pain fibers and inhibit an individual's perception of pain

<!-- PAGE=? -->
 Why rubbing a painful area can improve the sensation of pain

<!-- PAGE=? -->
 Why things like TENS and spinal cord stimulation work

<!-- PAGE=? -->
 Glycine and GABA play a big role here

<!-- PAGE=? -->
o Supraspinal

<!-- PAGE=? -->
 Important structures like the periaqueductal gray area (PAG), the reticular formation , and the nucleus raphe magnus (NRM) send descending inhibitory signals to the dorsal horn

<!-- PAGE=? -->
 PAG stimulation produces widespread analgesia - the pathways mediate their effects on adrenergic , serotinergic , and opiate receptor mechanisms (this is why certain antidepressants work)

<!-- PAGE=? -->
 The NRM and reticular formation act via endogenous opioids , whereas exogenous opioids apparently act in the substantia gelatinosa

<!-- PAGE=? -->
 Preemptive analgesia

<!-- PAGE=? -->
o Centers around the idea that producing an effective analgesic state prior to surgery prevents the peripheral and central hyperalgesia that occurs

<!-- PAGE=? -->
o Has traditionally thought to involve local infiltration , neuraxial blockade , or administration of opiods , NSAIDs or Ketamine

<!-- PAGE=? -->
o Overall, still a touchy subject; seems to be proven somewhat in animals, but not really in humans

<!-- PAGE=? -->
o Ong et al (A&A 2005) did a meta-analysis and found that the most pronounced effect was with epidural analgesia , local anesthetic , and NSAIDs , and the least amount of proof with NMDA antagonists and opioids

<!-- PAGE=? -->
 Epidural analgesia was the only one to improve all variables including post-op pain scores

<!-- PAGE=? -->
o Paul Kilffer's take - preemptive analgesia sounds great, and is probably worth a try, but is probably largely ineffective

<!-- PAGE=? -->
Paul Kliffer's Take Home 4 Concepts

<!-- PAGE=? -->
 Primary hyperalgesia - localized chemical inflammation in the periphery (P = periphery = primary) sensitizes receptors

<!-- PAGE=? -->
 Secondary hyperalgesia - contrasting from Lange, according to Dr. Kliffer this involves the WDR cells, which have a wide receptive area from an anatomical standpoint; stimulation of these WDR cells with nociceptive signals from a discrete area leads to perception of nociception from a much wider area

<!-- PAGE=? -->
 Wind-up - a normal phenomena relating to prolonged nociceptive signals being transmitted in the absence of an equally prolonged stimulus (has to do with the release of neurotransmitters, with details that he didn't think was important); a temporary response that reverses when the inflammation subsides

<!-- PAGE=? -->
 Central sensitization - relates to the NMDA receptor, with an abnormal response that consists of prolonged depolarization permitting the Mg ion to be displaced, becoming more permeable to calcium, increasing NO, increasing receptor numbers (therefore increased sensitivity), a larger receptive field, and increasing excitatory signals to the brain; this is a long-term phenomenon that may or may not be reversible

<!-- PAGE=? -->
Components of major pain pathways:

<!-- PAGE=? -->
 nociception:

<!-- PAGE=? -->
o detection, transduction, and transmission of noxious stimuli

<!-- PAGE=? -->
 nociceptor:

<!-- PAGE=? -->
o a receptor preferentially sensitive to a noxious stimulus or to a stimulus which would become noxious if prolonged

<!-- PAGE=? -->
o free nerve endings

<!-- PAGE=? -->
o adjacent to small blood vessels and mass cells, with which they operate as a functional unit

<!-- PAGE=? -->
o each sensory unit includes

<!-- PAGE=? -->
 end-organ receptor

<!-- PAGE=? -->
 axon

<!-- PAGE=? -->
 dorsal root ganglion

<!-- PAGE=? -->
 axon terminals in the spinal cord

<!-- PAGE=? -->
o in contrast to other special somatosensory receptors, nociceptors exhibit high response thresholds and persistent discharge to suprathreshold stimuli without rapid adaptation and are associated with small receptive fields and small afferent nerve fibre endings

<!-- PAGE=? -->
 A alpha (Aα) fibers

<!-- PAGE=? -->
o heavily myelinated large-diameter

<!-- PAGE=? -->
o incorporated within muscle spindles, Golgi tendon organs, and joints

<!-- PAGE=? -->
o transduce proprioceptive information

<!-- PAGE=? -->
o do not ordinarily participate in signaling pain

<!-- PAGE=? -->
 may be involved with pathologic pain signaling

<!-- PAGE=? -->
 A beta (Aβ) fibers

<!-- PAGE=? -->
o heavily myelinated large-diameter

<!-- PAGE=? -->
o transduce innocuous or low-threshold mechanical stimulation

<!-- PAGE=? -->
 A delta (Aδ) fibers  (lightly myelinated) and the unmyelinated small-diameter C fibers

<!-- PAGE=? -->
o specialized sensory neurons that respond to actual or potential tissue damage

<!-- PAGE=? -->
 nociceptors

<!-- PAGE=? -->
o synapse in the dorsal root ganlia of the spinal cord

<!-- PAGE=? -->
o nociceptive fibers terminate in the superficial dorsal horn

<!-- PAGE=? -->
 marginal zone (lamina I), and the substantia gelatinosa (lamina II)

<!-- PAGE=? -->
 some A-delta fibers project more deeply to lamina V

<!-- PAGE=? -->
o respond to stimulation with slow adaptation and residual firing following the withdrawal of the stimulus

<!-- PAGE=? -->
 Aδ fibers mediate the -first‖ pain or epicritic pain

<!-- PAGE=? -->
o well localized

<!-- PAGE=? -->
 smaller receptive field

<!-- PAGE=? -->
o characterized as sharp or prickling

<!-- PAGE=? -->
o high-threshold mechanoreceptors because they increase their firing rate with increased stimulus intensity

<!-- PAGE=? -->
o demonstrate lessening activity with repeated stimulation, although they can become sensitized and increase the frequency of their discharge

<!-- PAGE=? -->
o travels 1-2 segments up and down (in Lissauer's tract (dorsolateral)) and synapses in posterior horn

<!-- PAGE=? -->
 C fibers mediate the -second‖ pain or protopathic pain

<!-- PAGE=? -->
o temporally follows the epicritic pain

<!-- PAGE=? -->
o 80% of nociceptor primary afferents are nonmyelinated C-fibres

<!-- PAGE=? -->
o poorly localized or diffuse

<!-- PAGE=? -->
 have large receptive fields

<!-- PAGE=? -->
o characterized as burning or dull

<!-- PAGE=? -->
o input that does not fatigue or extinguish with repeated stimulation

<!-- PAGE=? -->
 nociceptors are polymodal

<!-- PAGE=? -->
o transducer noxious stimuli of different modalities

<!-- PAGE=? -->
 thermal, mechanical, or chemical stimuli

<!-- PAGE=? -->
Dorsal root ganglia of spinal cord

<!-- PAGE=? -->
 1st order neuron: (nociceptor)

<!-- PAGE=? -->
o cell body in the DRG of spinal nerve (or trigeminal ganglion for trigeminal nerve)

<!-- PAGE=? -->
o its axon has 2 branches, 1 to periphery (peripheral process) and 1 to CNS (central process) where its synapses with a 2nd-order afferent neuron; have further synaptic connections with the cell bodies of the SNS, ventral motor nuclei, & other regulatory internuncial neurons

<!-- PAGE=? -->
 Aα, Aβ (tactile, pressure, and vibratory sense) enter in dorsal roots - traverse across the top of the dorsal horn of the spinal cord (Lissauer's tract), and ascend ipsilaterally within the dorsal column

<!-- PAGE=? -->
 Aδ and C-fibers (temperature and nociceptive) enter Lissauer's tract and innervate the gray matter of the spinal cord

<!-- PAGE=? -->
o may ascend rostrally or descend caudally through Lissauer's tract before they innervate adjacent spinal levels

<!-- PAGE=? -->
o A-delta and C-fiber input terminates in layers I, II (the substantia gelatinosa), and V

<!-- PAGE=? -->
 The gray matter of the spinal cord is divided into 10 laminae based on histologic appearance

<!-- PAGE=? -->
o The dorsal horn includes laminae I to VI (ventral horn includes VII - X)

<!-- PAGE=? -->
 represents the primary sensory complement of the spinal cord

<!-- PAGE=? -->
o Somatic C-fibers primarily terminate in the laminae I and II (substantia gelatinosa) of the same and/or one to two adjacent spinal segments from which they entered from the periphery

<!-- PAGE=? -->
o visceral C-fibers terminate in the dorsal horn more than five segments rostrally or caudally

<!-- PAGE=? -->
 terminate in laminae I, II, V, X ipsilaterally and also in laminae V and X contralaterally

<!-- PAGE=? -->
 visceral afferents have a wider branching pattern and the nociceptive information they transmit is less localizable to a particular area of the body

<!-- PAGE=? -->
 neurons of the descending pathways and local interneurons also innervate the superficial dorsal horn (laminae I and II)

<!-- PAGE=? -->
o Laminae III and IV contain interneurons and the second-order neurons that make up the dorsal column pathways relaying nonnociceptive sensory and proprioceptive information

<!-- PAGE=? -->
o Laminae IV to VI contain interneurons and a modest portion of nociceptive projection neurons that distribute input to the brainstem and thalamus

<!-- PAGE=? -->
 Somatic nociceptive input is primarily transmitted by second-order lamina I, IV, and V projection neurons as the contralateral spinothalamic tract (STT)

<!-- PAGE=? -->
 Visceral nociceptive input is relayed by second-order neurons whose axons travel within the dorsal column

<!-- PAGE=? -->
o these fibers remain uncrossed until relayed with the crossed medial lemniscal fibers to the thalamus

<!-- PAGE=? -->
 Nociceptive and nonnociceptive sensory information from the head, neck, and dura transmitted via the trigeminal nerve

<!-- PAGE=? -->
 Second order neurons: depending on type of afferent it receives, can be either nociceptive-specific or wide-dynamic range

<!-- PAGE=? -->
o Nociceptive-specific neurons process afferent impulses only from nociceptive afferent fibers

<!-- PAGE=? -->
o Wide-dynamic-range neurons receive input  from A-beta, A delta, and C fibers

<!-- PAGE=? -->
 (located primarily in layers I and V) are an important group of neurons in that they receive input from nociceptive specific and nonspecific afferent fibers

<!-- PAGE=? -->
o Cell body of 2nd-order neuron lies in Dorsal Horn; its axonal projections cross to contralateral side of SC, ascends in the lateral spinothalamic tract to synapse in thalamus; along way sends axonal branches to reticular formation, nucleus raphe magnus, periaquedcutal gray

<!-- PAGE=? -->
 Third-order neurons: synapse with second-order neurons in the thalamus where they send axonal projections into the sensory cortex

<!-- PAGE=? -->
Lissauer

<!-- PAGE=? -->
Tract

<!-- PAGE=? -->
Dorsolateral

<!-- PAGE=? -->
Funiculus

<!-- PAGE=? -->
Marginal Zone

<!-- PAGE=? -->
Substantia

<!-- PAGE=? -->
Gelauosa

<!-- PAGE=? -->
Nucleus Proprius

<!-- PAGE=? -->
Neurobiology of the Spinal Cord

<!-- PAGE=? -->
Dorsal Column Tracts

<!-- PAGE=? -->
 axons of second-order spinal cord projection neurons in addition to the ascending axons of primary afferent neurons relaying touch, pressure, and vibratory sensation

<!-- PAGE=? -->
 In primates and humans, lesions of the dorsolateral quadrant have been reported to produce a hyperalgesia.

<!-- PAGE=? -->
 Dorsal columns are made up of ascending fibers from:

<!-- PAGE=? -->
o large-diameter afferent fibers, sensitive to light touch and vibration, terminate in the dorsal column nuclei after ascending in the dorsal columns

<!-- PAGE=? -->
o nonprimary afferent fibers originating in lamina V that responds to tactile and noxious mechanical and thermal stimulation

<!-- PAGE=? -->
 Role unknown

<!-- PAGE=? -->
 Dorsal column lesions in humans do not alter pain threshold, and stimulation of the dorsal columns in humans often gives rise to sensations of vibration, not of pain.

<!-- PAGE=? -->
Spinothalamic Tract (STT)

<!-- PAGE=? -->
 STT neurons are the primary relay cells providing nociceptive input from the spinal cord to supraspinal levels

<!-- PAGE=? -->
o Also refered to as the Anterolateral Funiculus

<!-- PAGE=? -->
o Originates in laminae I and V

<!-- PAGE=? -->
 axons of STT cross the midline of the spinal cord through the anterior white commissure and ascend primarily in the contralateral lateral and anterolateral tracts

<!-- PAGE=? -->
 terminate primarily in the posterior complex of the thalamus

<!-- PAGE=? -->
o ventral posterior lateral nuclei

<!-- PAGE=? -->
o ventral posterior medial nuclei

<!-- PAGE=? -->
 Spinothalamic and spinoreticular tracts ascend (along with spinomesenthalic, spinohypothalamic, spinotelencephalic, spino cervical tracts)

<!-- PAGE=? -->
 Termination in ventral posterolateral nucleus of thalamus (there to hypothalamus, limbic system, cortex)

<!-- PAGE=? -->
o Projects through internal capsule and corona radiata

<!-- PAGE=? -->
o To primary somatosensory cortex (post central gyrus)

<!-- PAGE=? -->
 There are thought to be two functionally distinct divisions of the STT:

<!-- PAGE=? -->
o the neospinothalamic tract, whose fibers tend to be more lateral, and

<!-- PAGE=? -->
 phylogenetically newer

<!-- PAGE=? -->
 projects to posterior nuclei of thalamus (ventral posterolateral nucleus)

<!-- PAGE=? -->
 discriminative functions (location, intensity, duration of pain)

<!-- PAGE=? -->
o the paleospinothalamic tract, located in the medial portion of the pathway.

<!-- PAGE=? -->
 projects to medial thalamic nuclei,

<!-- PAGE=? -->
 probably associated with autonomic and unpleasant emotional aspects of pain.

<!-- PAGE=? -->
 This older portion of the STT is likely to be important in pain associated with denervation dysesthesia.

<!-- PAGE=? -->
Lateral cervical nucleus

<!-- PAGE=? -->
 The spinocervical tract ascends uncrossed to the lateral cervical nucleus which relays the fibers to the contralateral thalamus; this tract is likely a major alternative pain pathway .

<!-- PAGE=? -->
o Travels in the dorsolateral funiculus

<!-- PAGE=? -->
 Several types of spinocervical neurons have been identified, and they appear to be activated by tactile (hair movement, pressure), noxious thermal (40°-53° C), and noxious mechanical (pinch) stimuli, and close intra-arterial injection of algogenic agents. The spinocervical tract has been well described in cats, but its presence is much reduced in lower primates, and is practically nonexistent in humans

<!-- PAGE=? -->
Spinobulbar Pathways

<!-- PAGE=? -->
 spinal projection pathway traverses brainstem regions containing catecholaminergic neurons

<!-- PAGE=? -->
o locus coeruleus

<!-- PAGE=? -->
o A7 nuclei of the dorsolateral pontine tegmentum (DLPT)

<!-- PAGE=? -->
 modulate nociceptive transmission through the spinal cord via descending inhibitory input

<!-- PAGE=? -->
Descending Inhibitory input

<!-- PAGE=? -->
 project from a number of regions including the periaqueductal gray and locus ceruleus regions, travelling in the dorsolateral funiculus to terminate in the substantia gelatinosa region of the dorsal horn

<!-- PAGE=? -->
 Inhibitory substances include

<!-- PAGE=? -->
o Enkephalins

<!-- PAGE=? -->
o Endorphins

<!-- PAGE=? -->
o Norepinephrine

<!-- PAGE=? -->
o Dopamine

<!-- PAGE=? -->
o Adenosine

<!-- PAGE=? -->
o Acetylcholine

<!-- PAGE=? -->
 Neostigmine produces analgesia

<!-- PAGE=? -->
 Spinal mediated antinocioceptive action of acetylcholine

<!-- PAGE=? -->
Spinohypothalamic, Limbic, and Cortical Connections

<!-- PAGE=? -->
 Pain can provoke fear, anxiety, and depression

<!-- PAGE=? -->
o thought to be mediated by the spinohypothalamic and spinoamygdalar pathways

<!-- PAGE=? -->
Pre-ganglionic sympathetic neurons:

<!-- PAGE=? -->
 Efferent sympathetic signals emanate from cell bodies located in the intermediolateral column of the spinal cord.  These cell bodies receive internuncial projections from the dorsal horn of the gray matter.

<!-- PAGE=? -->
o i.e. the pain pathways seem to interact with pre-ganglionic fibers (see modulating mechanisms, below)

<!-- PAGE=? -->
Modulating Mechanisms

<!-- PAGE=? -->
 can occur either in the periphery or at any point where synaptic transmission occurs

<!-- PAGE=? -->
peripheral modulation :

<!-- PAGE=? -->
 occur either by elimination of (anti-inflammatories) or liberation of allogeneic substances in vicinity of the nociceptor

<!-- PAGE=? -->
o neurotransmitters substance P & glutamate, which directly activate nociceptors

<!-- PAGE=? -->
o potassium and hydrogen ions

<!-- PAGE=? -->
o lactic acid

<!-- PAGE=? -->
o serotonin

<!-- PAGE=? -->
o bradykinin

<!-- PAGE=? -->
o histamine

<!-- PAGE=? -->
o prostaglandins

<!-- PAGE=? -->
o leukotrienes, thromboxanes

<!-- PAGE=? -->
 Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and specific cyclo-oxygenase-2 (COX-2) inhibitors exert an analgesic effect by inhibiting prostaglandin synthesis and reducing prostaglandin E1- and E2mediated sensitization of peripheral nociceptors.

<!-- PAGE=? -->
 trauma may lead to peripheral sensitization

<!-- PAGE=? -->
o primary hyperalgesia

<!-- PAGE=? -->
o secondary hyperalgesia

<!-- PAGE=? -->
 increased pain response evoked by stimuli outside the area of injury

<!-- PAGE=? -->
Somatosensory

<!-- PAGE=? -->
Cortex (51)

<!-- PAGE=? -->
Cingulate

<!-- PAGE=? -->
System

<!-- PAGE=? -->
Cortex

<!-- PAGE=? -->
Thalamus

<!-- PAGE=? -->
(P and

<!-- PAGE=? -->
Nuclei

<!-- PAGE=? -->
Midbrain

<!-- PAGE=? -->
Cand AS

<!-- PAGE=? -->
Brainstem

<!-- PAGE=? -->
(Pons

<!-- PAGE=? -->
& Medulla)

<!-- PAGE=? -->
Nociceptors

<!-- PAGE=? -->
Dorsal

<!-- PAGE=? -->
Spinothalamic

<!-- PAGE=? -->
Root

<!-- PAGE=? -->
Tract

<!-- PAGE=? -->
Ganglion

<!-- PAGE=? -->
Dorsal

<!-- PAGE=? -->
Horn

<!-- PAGE=? -->
Spinal

<!-- PAGE=? -->
Cord

<!-- PAGE=? -->
Painfu

<!-- PAGE=? -->
Substances Released from

<!-- PAGE=? -->
Damaged

<!-- PAGE=? -->
Cells

<!-- PAGE=? -->
Bradykinin

<!-- PAGE=? -->
Cations (protons, potassium ions)

<!-- PAGE=? -->
Free radicals (nitric oxide)

<!-- PAGE=? -->
Histamine

<!-- PAGE=? -->
Prostanoids

<!-- PAGE=? -->
(prostaglandins,

<!-- PAGE=? -->
leukotrienes)

<!-- PAGE=? -->
Purines (adenosine, adenosine triphosphate)

<!-- PAGE=? -->
Serotonin

<!-- PAGE=? -->
Tachykinins (substance P neurokinin A)

<!-- PAGE=? -->
Spinal Modulation

<!-- PAGE=? -->
 Modulation in the spinal cord results from the action of neurotransmitter substances in the dorsal horn or from spinal reflexes, which convey efferent impulses back to the peripheral nociceptive field.

<!-- PAGE=? -->
 excitatory transmitters found in central terminals of first order neurons have been shown to modulate transmission of nociceptive afferent signals

<!-- PAGE=? -->
o L-glutamate and aspartate,

<!-- PAGE=? -->
o vasoactive intestinal peptide,

<!-- PAGE=? -->
o calcitonin gene-related peptide, and

<!-- PAGE=? -->
o neuropeptide Y

<!-- PAGE=? -->
 Substance P, which is found in the synaptic vesicle of unmyelinated C fibers, is also an important neuromodulator that can enhance or aggravate pain.

<!-- PAGE=? -->
 Prostaglandins produced in response to inflammation play a role in inflammation-evoked central sensitization of spinal cord neurons.

<!-- PAGE=? -->
 Inhibitory substances involved in the regulation of afferent impulses in the dorsal horn:

<!-- PAGE=? -->
o Enkephalins

<!-- PAGE=? -->
o b-endorphins

<!-- PAGE=? -->
o norepinephrine

<!-- PAGE=? -->
o dopamine

<!-- PAGE=? -->
o adenosine.

<!-- PAGE=? -->
o Somatostatin, a neuropeptide found in cells that do not contain substance P, may represent another inhibitory neuropeptide involved in afferent modulation.

<!-- PAGE=? -->
 Acetylcholine is also involved in afferent signal processing in the substantia gelatinosa

<!-- PAGE=? -->
o Cholinergic agonists have been demonstrated to produce analgesia, as has neostigmine, which inhibits the breakdown of the endogenous neurotransmitter acetylcholine.

<!-- PAGE=? -->
o Acetylcholine acts at muscarinic (M1 or M3) receptors that appear to mediate spinal antinociception.

<!-- PAGE=? -->
o The analgesic efficacy of modulating the cholinergic system depends on the tonic release of acetylcholine at muscarinic receptors involved in afferent signal processing, because acetylcholine has actions at other spinal sites (inhibition of motor neuron activity, excitation of sympathetic outflow) that produce unwanted side effects.

<!-- PAGE=? -->
 Afferent modulating mechanisms at the spinal level may also involve spinal reflexes in which afferent signals directly evoke somatic or sympathetic efferent impulses.

<!-- PAGE=? -->
 skeletal muscle spasm in an injured area is part of a somatic efferent reflex that is induced as a result of nociceptive afferent signals. Increased skeletal muscle tone initiates more nociceptive signals in a positive feedback loop system from the muscles

<!-- PAGE=? -->
 spinal reflexes may involve the discharge of efferent sympathetic signals evoked from the nociceptive impulse

<!-- PAGE=? -->
o Efferent sympathetic signals emanate from cell bodies located in the intermediolateral column of the spinal cord. These cell bodies receive internuncial projections from the dorsal horn of the gray matter. This sympathetic reflex produces smooth muscle spasm, vasoconstriction, and liberation of norepinephrine in the vicinity of the wound, thereby generating more pain. Release of norepinephrine has been shown to produce or augment pain after injury.

<!-- PAGE=? -->
o Release of norepinephrine has been shown to produce or augment pain after injury.

<!-- PAGE=? -->
 Neuroplasticity

<!-- PAGE=? -->
o includes the concept of central sensitization

<!-- PAGE=? -->
o Central sensitization consists of three changes in the dorsal horn:

<!-- PAGE=? -->
 A reduction in activation threshold

<!-- PAGE=? -->
 An increased responsiveness

<!-- PAGE=? -->
 An expansion of receptive field

<!-- PAGE=? -->
o Sensitization of peripheral nociceptors (by local tissue mediators or injury), the excitability and frequency of neural discharge increase; permitting previously subnoxious stimuli to generate Action Potentials

<!-- PAGE=? -->
 axonal reflexes exaggerate this response by releasing substance P, which results in

<!-- PAGE=? -->
o vasodilation

<!-- PAGE=? -->
o mast cell degranulation

<!-- PAGE=? -->
o enlarging the peripheral receptive field to include adjacent noninjured tissue ( secondary hyperalgesia )

<!-- PAGE=? -->
 Central sensitization

<!-- PAGE=? -->
:

<!-- PAGE=? -->
o composed of secondary hyperalgesia, wind-up, and long-term potentiation

<!-- PAGE=? -->
 Secondary hyperalgesia :

<!-- PAGE=? -->
o secondary hyperalgesia is thought to result from changes at level of dorsal horn

<!-- PAGE=? -->
 Wind-up :

<!-- PAGE=? -->
o the progressive increase in neuronal activity at the level of Dorsal Horn which occurs throughout the duration of  a stimulus of intensity sufficient to activate C fibers

<!-- PAGE=? -->
 nociceptive input does not follow a simple stimulus-response relationship, but occurs as a wind-up of spinal cord neuronal activity

<!-- PAGE=? -->
o dependent on

<!-- PAGE=? -->
 NMDA receptors ( blockade is thought to inhibit windup)

<!-- PAGE=? -->
o temporal summation of the number & duration of APs elicited per stimulus (occurs in the dorsal horn neurons

<!-- PAGE=? -->
o requires a minimum stimulus frequency of 0.5 Hz arising the C fiber

<!-- PAGE=? -->
o once the stimulus frequency reaches a critical threshold, the postsynaptic depolarizing response of these 2nd-order afferent neurons summate to produce bursts of APs instead of a single AP

<!-- PAGE=? -->
 results in the persistence of APs for up to 60 sec after discontinuation of the stimulus

<!-- PAGE=? -->
 results in changes in SC processing that can last for 1-3 hours

<!-- PAGE=? -->
 Long-term potentiation :

<!-- PAGE=? -->
o more permanent changes to second-order neurons which occurs as a result of the wind-up phenomenon

<!-- PAGE=? -->
Supraspinal Modulation

<!-- PAGE=? -->
 Brain stem: descending inhibitory tracts originate from cell bodies located

<!-- PAGE=? -->
o periaqueductal gray matter

<!-- PAGE=? -->
o reticular formation

<!-- PAGE=? -->
o nucleus raphe magnus

<!-- PAGE=? -->
 descend into the dorsolateral fasciculus and synapse in the dorsal horn

<!-- PAGE=? -->
o neurotransmitters act pre-synaptically on the 1 st order neurons, and post-synaptically on the 2 nd order neurons of the spinothalamic tract, or on the internuncial neuron pool

<!-- PAGE=? -->
 2 groups of nerve fibers participate in these inhibitory paths

<!-- PAGE=? -->
o opioids modulate transmission of afferent impulses in the dorsal horn presynaptically at the level of the first order neuron

<!-- PAGE=? -->
o monamine path, originating from locations it he periaqueductal gray and reticular formation

<!-- PAGE=? -->
Cortex

<!-- PAGE=? -->
Descending

<!-- PAGE=? -->
Modulation

<!-- PAGE=? -->
Thalamus

<!-- PAGE=? -->
Periaqueductal

<!-- PAGE=? -->
ENKEPHALN

<!-- PAGE=? -->
GABA

<!-- PAGE=? -->
ROSTRAL

<!-- PAGE=? -->
Locus Ceruleus

<!-- PAGE=? -->
PONS

<!-- PAGE=? -->
Nucleus

<!-- PAGE=? -->
Nucleus Reticularis

<!-- PAGE=? -->
Raphe Magnus

<!-- PAGE=? -->
Gigantocellularis

<!-- PAGE=? -->
SEROTONNGHD

<!-- PAGE=? -->
Nucleus Reticularis

<!-- PAGE=? -->
Paragigantocellularis

<!-- PAGE=? -->
ENKEPHALIN

<!-- PAGE=? -->
MEDULLA

<!-- PAGE=? -->
Anterolateral

<!-- PAGE=? -->
Dorsolateral

<!-- PAGE=? -->
Funiculus

<!-- PAGE=? -->
Funiculus

<!-- PAGE=? -->
SPINAL CORD

<!-- PAGE=? -->
SP

<!-- PAGE=? -->
GABAA

<!-- PAGE=? -->
5-HT,

<!-- PAGE=? -->
NE,

<!-- PAGE=? -->
ENK

<!-- PAGE=? -->
NEUROTENSIN

<!-- PAGE=? -->
DYN

<!-- PAGE=? -->
CCK

<!-- PAGE=? -->
VIP

<!-- PAGE=? -->
CGRP

<!-- PAGE=? -->
SOM

<!-- PAGE=? -->
ADN

<!-- PAGE=? -->
NPY

<!-- PAGE=? -->
sP

<!-- PAGE=? -->
GLU ,

<!-- PAGE=? -->
No

<!-- PAGE=? -->
BOM

<!-- PAGE=? -->
PGE

<!-- PAGE=? -->
PROSTAGLANDINS

<!-- PAGE=? -->
HISTAMINE

<!-- PAGE=? -->
ENZYME INHIBITORS

<!-- PAGE=? -->
SEROTONIN

<!-- PAGE=? -->
(ENK-ASE, ACH-ASE, NO-SYNTHASE

<!-- PAGE=? -->
BRADYKININ

<!-- PAGE=? -->
Gray

<!-- PAGE=? -->
Chemical Mediators of Pain

<!-- PAGE=? -->
 Chemical mediators of pain are numerous

<!-- PAGE=? -->
o intrinsic neurotransmitters include serotonin and substance P

<!-- PAGE=? -->
o extrinsic substances include substances from inflammatory/ immune cells and red blood cells

<!-- PAGE=? -->
 prostaglandins

<!-- PAGE=? -->
 kinins

<!-- PAGE=? -->
 cytokines

<!-- PAGE=? -->
 chemokines

<!-- PAGE=? -->
 ATP

<!-- PAGE=? -->
 The cell bodies of primary afferents, regardless of the structure they innervate, make up the dorsal root ganglia (DRG) located just outside the spinal cord within the bony foramen

<!-- PAGE=? -->
 Glutamate is the primary neurotransmitter in the spinal cord via the AMPA-type glutamate receptor

<!-- PAGE=? -->
o produces a robust, but short-lasting depolarization of the postsynaptic membrane

<!-- PAGE=? -->
o augments the activation of the NMDA-type  glutamate receptor

<!-- PAGE=? -->
o additional neuropeptides include

<!-- PAGE=? -->
 substance P

<!-- PAGE=? -->
 binds to g-linked bradykinin receptors

<!-- PAGE=? -->
 calcitonin gene-related peptide

<!-- PAGE=? -->
 ATP

<!-- PAGE=? -->
 adenosine

<!-- PAGE=? -->
 galanin

<!-- PAGE=? -->
 somatostatin

<!-- PAGE=? -->
Peripheral, Spinal and Supraspinal Mechanisms Involved in Pain Perception and Reaction

<!-- PAGE=? -->
 Transduction

<!-- PAGE=? -->
o activation of peripheral nociceptors. Transduction is inhibited by NSAIDs, antihistamines, and topical local anesthetics

<!-- PAGE=? -->
 Transmission

<!-- PAGE=? -->
o Propagation of action potentials from peripheral nociceptive endings to second-order cells in dorsal horn

<!-- PAGE=? -->
o Nociceptive impulses ascend via the spinothalamic tract to reach supraspinal targets

<!-- PAGE=? -->
o Transmission is blocked by local anesthetics.

<!-- PAGE=? -->
 Central Facilitation

<!-- PAGE=? -->
o Activation of N-methyl-D-aspartic acid (NMDA) receptors is associated with increased sensitivity and firing frequency of dorsal horn neurons.

<!-- PAGE=? -->
o Central facilitation is inhibited by NMDA antagonists such as ketamine

<!-- PAGE=? -->
 Modulation

<!-- PAGE=? -->
o mediated by descending enkephalinergic, adrenergic, and cholinergic nerve fibers, which either inhibit release of nociceptive transmitters from primary afferents or blunt responses of secondorder cells

<!-- PAGE=? -->
o Modulation is enhanced by neuroaxial administration of opioids, clonidine, and neostigmine

<!-- PAGE=? -->
 Spinal Reaction

<!-- PAGE=? -->
o Increased motor and sympathetic outflow results in hypertension, tachycardia, adrenal activation, muscle spasm/splinting

<!-- PAGE=? -->
o Spinal reactions are suppressed by benzodiazepines, beta-adrenergic antagonists, and metaclopramide.

<!-- PAGE=? -->
 Supraspinal Perception

<!-- PAGE=? -->
o Includes the neocortical epicritic component which is responsible for pain localization, and the paleocortical protopathic component, responsible for the severe discomfort and suffering aspects of pain

<!-- PAGE=? -->
o Protopathic perception is blunted by opioid analgesics.

<!-- PAGE=? -->
 Supraspinal Reaction

<!-- PAGE=? -->
o Describes neocortical and paleocortical limbic responses including fear, anxiety, depression, and other pain-related behaviors, and pituitary-hypothalamic responses including release of stress hormones, neuropeptides, and activation of the sympathetic axis

<!-- PAGE=? -->
o Supraspinal reactions are blunted by regional blockade, beta-adrenergic agonists, and anxiolytics.

<!-- PAGE=? -->
Definitions

<!-- PAGE=? -->
Sensitization : When chemical mediators sensitize and/or stimulate the peripheral nociceptors, sensitization is said to occur. This implies that less stimulation will be necessary to trigger an adverse response in the nervous system.

<!-- PAGE=? -->
 When repetitive stimulation of dorsal horn neurons involved in the pain response occurs, the frequency of discharge can be shown with neurophysiologic techniques to increase (sensitization or wind-up)

<!-- PAGE=? -->
 The clinical correlate is that less peripheral stimulation is required to activate a -pain response‖ in the nervous system. Thus, stimuli that are not normally painful, such as lightly stroking the skin, cause patients agony because the nervous system response is augmented by maladaptive changes in the processing of sensory input; the touch hurts and the pain lingers even after the direct stimulation is stopped because of the hyperirritability of the nervous system and the failure of the usual modulatory systems to dampen the reactivity.

<!-- PAGE=? -->
 Central sensitization consists of three changes in the DORSAL horn

<!-- PAGE=? -->
o Reduction in activation threshold

<!-- PAGE=? -->
o Increased responsiveness

<!-- PAGE=? -->
o Expansion of receptive field

<!-- PAGE=? -->
 Allodynia - perception of ordinarily non-noxious stimulus as pain

<!-- PAGE=? -->
 Analgesia - absence of pain perception

<!-- PAGE=? -->
 Anesthesia - absence of all sensation

<!-- PAGE=? -->
 Anesthesia dolorosa - pain in an area that lacks sensation

<!-- PAGE=? -->
 Dysesthesia - unpleasant or abnormal sensation with or without a stimulus

<!-- PAGE=? -->
 Hypalgesia (hypoalgesia) - diminished response to noxious stimulus

<!-- PAGE=? -->
 Hyperalgesia - increased response to noxious stimulus

<!-- PAGE=? -->
 Hyperesthesia - increased response to mild stimulus (encompasses both allodynia and hyperalgesia)

<!-- PAGE=? -->
 Hyperpathia - presence of hyperesthesia, usually associated with overreaction, and persistent sensation after stimulus

<!-- PAGE=? -->
 Hypesthesia (hypoesthesia) - reduced cutaneous sensation (light touch, pressure, temp)

<!-- PAGE=? -->
 Neuralgia - pain in distribution of nerve or group of nerves

<!-- PAGE=? -->
 Paresthesia - abnormal sensation perceived without an apparent stimulus

<!-- PAGE=? -->
 Radiculopathy - functional abnormality in one or more nerve roots

<!-- PAGE=? -->
 Temporal Summation repeated stimulation of same intensity causes augmentation of symptoms

<!-- PAGE=? -->
Gate Control Theory:

<!-- PAGE=? -->
 Melzack and Wall (1965):

<!-- PAGE=? -->
 Basically, the theory proposes that neural mechanisms in the dorsal horns of the spinal cord act as a gate that can increase or decrease the flow of nerve impulses from peripheral fibers to the spinal cord cells that project to the brain

<!-- PAGE=? -->
 the activity of neurons in the spinal cord that receive input from nociceptive fibers may be modified by inputs from other non-nociceptive afferent neurons; i.e. activity of AB afferent inhibits dorsal horn neurons from responding to A-delta, and C-fiber input;

<!-- PAGE=? -->
 thus, pain may be relieved by stimulation of the myelinated afferent fibers; eg. TENS;

<!-- PAGE=? -->
 the dorsal horn acts as a physiological ‗gate', which may be closed by other nociceptive input, thereby decreasing the amount of transmission by C-fibers (pain)

<!-- PAGE=? -->
 Somatic input is therefore subjected to the modulating influence of thegate before it evokes pain perception and response.

<!-- PAGE=? -->
 The theory suggests that large-fiber inputs tend to close the gate whereas small-fiber inputs generally open it, and that the gate is also profoundly influenced by descending influences from the brain.

<!-- PAGE=? -->
 It further proposes that the sensory input is modulated at successive synapses throughout its projection from the spinal cord to the brain areas responsible for pain experience and response. Pain occurs when the number of nerve impulses that arrives at these areas exceeds a critical level.

<!-- PAGE=? -->
Transition from Acute to Persistent Nociception

<!-- PAGE=? -->
 Pain sensation is unique in that it does not rapidly adapt to prolonged stimulation as do the other sensory modalities

<!-- PAGE=? -->
o continued stimulation may produce greater noxious sensation or reduce the stimulus threshold or intensity

<!-- PAGE=? -->
 ie. warm water or light touch of sunburned skin produces a painful sensation that may persist for a few minutes following the stimulation

<!-- PAGE=? -->
 This is termed allodynia

<!-- PAGE=? -->
 Due to central sensitization

<!-- PAGE=? -->
o Hyperalgesia is the finding that a previously noxious stimulus is perceived as more painful

<!-- PAGE=? -->
 increased intensity of noxious stimulation at the site of the injury is the result of the sensitization of the peripheral nociceptors

<!-- PAGE=? -->
o Persistent C fiber activation has been shown to enhance the response to subsequent stimulation and augment the size of the receptive field of the respective dorsal horn neuron

<!-- PAGE=? -->
 afferent input from adjacent dermatomal areas now produces neuronal excitation

<!-- PAGE=? -->
o nonnoxious stimulation becomes increasingly able to activate these neurons.

<!-- PAGE=? -->
o termed wind-up or central sensitization

<!-- PAGE=? -->
 due/to enhanced synaptic transmission and nociceptive processing within the dorsal horn

<!-- PAGE=? -->
 This persistent input will lead to cellular damage and migration of inflammatory cells including macrophages and neutrophils into the peripheral tissue

<!-- PAGE=? -->
o release of histamine, bradykinin, prostaglandins, cytokines, growth factors, protons, and peptides that activate or sensitize receptors on the peripheral nociceptor

<!-- PAGE=? -->
 substance acts on NMDA receptors centrally

<!-- PAGE=? -->
o pathophysiology of allodynia and hyperalgesia observed surrounding the site of injury

<!-- PAGE=? -->
 axonal sprouting and the formation of neuroma may also occur

<!-- PAGE=? -->
 Neuromas of injured primary afferents have altered sensitivity to a number of humoral factors

<!-- PAGE=? -->
o cytokines, prostaglandins, and catecholamines

<!-- PAGE=? -->
 Although acute noxious stimuli are transmitted to the spinal cord via Aδ and C fibers, the presence of allodynia is thought to be mediated by the activation large-diameter Aβ fibers through what has been termed a phenotypi c switch

<!-- PAGE=? -->
o Prior to this peripheral injury, the Aβ fibers do not express substance P

<!-- PAGE=? -->
o following injury these fibers were able to express this neuropeptide

<!-- PAGE=? -->
Dr. Kliffer's Approach to Pain Management (by location of action)

<!-- PAGE=? -->
Periphery

<!-- PAGE=? -->
 Local anesthetics (regional techniques, local infiltration)

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 Steroids

<!-- PAGE=? -->
 Topicals (capsaicin)

<!-- PAGE=? -->
 Neurolytics (alchohol, phenol)

<!-- PAGE=? -->
 Heat & cold

<!-- PAGE=? -->
Spinal Cord

<!-- PAGE=? -->
 Narcotics

<!-- PAGE=? -->
 Local anesthetics (neuraxial techniques)

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 Clonidine

<!-- PAGE=? -->
 Spinal cord stimulation

<!-- PAGE=? -->
 TENS

<!-- PAGE=? -->
 Rhizotomy

<!-- PAGE=? -->
 Cordotomy

<!-- PAGE=? -->
Brain

<!-- PAGE=? -->
 Narcotics

<!-- PAGE=? -->
 Tylenol

<!-- PAGE=? -->
 Gabapentin

<!-- PAGE=? -->
 Antidepressants (TCA's)

<!-- PAGE=? -->
 Lidocaine or Mexilitene

<!-- PAGE=? -->
 Stimulators

<!-- PAGE=? -->
Neuropathic Pain

<!-- PAGE=? -->
 Neuropathic pain generally refers to pain associated with disease or injury of the peripheral or central nervous system

<!-- PAGE=? -->
 Not a single entity, but a heterogenous group of conditions differing in etiology and location

<!-- PAGE=? -->
 Common themes (ones we should be well-versed in)

<!-- PAGE=? -->
o Phantom Limb

<!-- PAGE=? -->
o Diabetic neuropathy

<!-- PAGE=? -->
o Post-traumatic neuralgia

<!-- PAGE=? -->
o Post-herpetic neuralgia

<!-- PAGE=? -->
o Central post-stroke syndrome

<!-- PAGE=? -->
 Another way is to break down by anatomical site

<!-- PAGE=? -->
o Peripheral

<!-- PAGE=? -->
 Neuropatheis (i.e. diabetic )

<!-- PAGE=? -->
 Herpes Zoster & Post-herpetic neuralgia

<!-- PAGE=? -->
 Amputations & trauma

<!-- PAGE=? -->
 Plexopathies

<!-- PAGE=? -->
 Radiculopathies

<!-- PAGE=? -->
 Neoplasms

<!-- PAGE=? -->
 Trigeminal neuralgia

<!-- PAGE=? -->
o Spinal

<!-- PAGE=? -->
 Multiple sclerosis

<!-- PAGE=? -->
 Guillian Barre syndrome

<!-- PAGE=? -->
 Spinal cord injury

<!-- PAGE=? -->
 Arachnoiditis

<!-- PAGE=? -->
 Neoplasm

<!-- PAGE=? -->
 Syringomyelia

<!-- PAGE=? -->
 Spinal stroke

<!-- PAGE=? -->
o Brain

<!-- PAGE=? -->
 Stroke

<!-- PAGE=? -->
 Multiple sclerosis

<!-- PAGE=? -->
 Neoplasm

<!-- PAGE=? -->
 Parkinson's

<!-- PAGE=? -->
 The primary mechanisms involved in neuropathic pain are:

<!-- PAGE=? -->
o Central sensitization - successful activation of NMDA receptors (with prolonged stimuli) that results in a series of intracellular events culminating in increased receptor numbers , increased sensitivity, increased receptive field , and increased information being sent to the brain

<!-- PAGE=? -->
o Decreased inhibitory signals being received

<!-- PAGE=? -->
o A-beta fibers (regular touch) sprout and latch onto cells from Lamina I and II, leading to touch being perceived as pain (allodynia)

<!-- PAGE=? -->
o Sympathetic fibers sprouting onto cells in the dorsal root ganglia (not well understood, but there is some interaction with pain, perhaps sensitization of nociceptors)

<!-- PAGE=? -->
o Inflammation of nerve trunks leads to ectopic nerve activity

<!-- PAGE=? -->
o Altered brain processing leads to recruitment of new brain areas not usually involved in pain

<!-- PAGE=? -->
 Clinical features (not necessary to have all of these)

<!-- PAGE=? -->
o Stimulus-independent (i.e. spontaneous ) pain

<!-- PAGE=? -->
 Continuous or suddenly intermittent

<!-- PAGE=? -->
 Shooting , shock-like , electric , stabbing , cramping , crushing , smarting , burning

<!-- PAGE=? -->
 May simply manifest as a vague, restless discomfort

<!-- PAGE=? -->
o Stimulus-dependent (i.e. evoked ) pain

<!-- PAGE=? -->
 Multiple types (usually mechanical, thermal, or chemical)

<!-- PAGE=? -->
 May persist beyond the duration of the actual stimulus

<!-- PAGE=? -->
o Sensory deficits , parasthesias

<!-- PAGE=? -->
 May involve all modalities, but it is the loss of spinothalamic modalities that are most relevant (cold, warmth, pinprick)

<!-- PAGE=? -->
o Hyperalgesia , allodynia

<!-- PAGE=? -->
o Dysesthesia

<!-- PAGE=? -->
 Abnormal but not unpleasant sensations

<!-- PAGE=? -->
o Referred pain

<!-- PAGE=? -->
 Assessment

<!-- PAGE=? -->
o Characteristics

<!-- PAGE=? -->
o Treatments/Investigations

<!-- PAGE=? -->
o AMPLE history

<!-- PAGE=? -->
o Psychosocial history

<!-- PAGE=? -->
o Want to rule out other causes of pain (especially reversible causes, i.e. infection, hematoma, compartment syndrome, malfunctional analgesia)

<!-- PAGE=? -->
o Targeted physical exam

<!-- PAGE=? -->
 Treatment modalities

<!-- PAGE=? -->
o Intra-op

<!-- PAGE=? -->
 Regional/neuraxial techniques

<!-- PAGE=? -->
 Multimodal analgesia

<!-- PAGE=? -->
 Ketamine 0.1 mg/kg/hr (usually given as 10 mg/hr)

<!-- PAGE=? -->
 NSAIDs , Tylenol

<!-- PAGE=? -->
 Opioids

<!-- PAGE=? -->
 Local infiltration

<!-- PAGE=? -->
o Post-op

<!-- PAGE=? -->
 Ketamine infusions (10 mg/hr) for NMDA antagonism

<!-- PAGE=? -->
 NSAIDs, Tylenol

<!-- PAGE=? -->
 Opioids (i.e. PCA)

<!-- PAGE=? -->
 May help to temporize, especially while waiting for the other modalities to take effect

<!-- PAGE=? -->
 Not classically thought to be helpful, but actually might be, especial\

<!-- PAGE=? -->
 lly in sufficient doses (Paul Kliffer)

<!-- PAGE=? -->
 Will likely need doses that are a fair bit higher, because of central sensitization, but should still be able to get reasonable relief (Paul Kliffer)

<!-- PAGE=? -->
 Gabapentin/Pregabalin (or other anti-convulsants such as Lamotrigine)

<!-- PAGE=? -->
 Start at 100-300 mg PO TID and titrate up, warning and watching for side effects

<!-- PAGE=? -->
 Antidepressants

<!-- PAGE=? -->
 Amytriptyline or Nortriptyline may be helpful, especially if patient is having trouble sleeping

<!-- PAGE=? -->
 +/- SSRI's or SNRI's (Cymbalta), but not first line at all

<!-- PAGE=? -->
 Lidocaine infusion (SC or IV)

<!-- PAGE=? -->
 Nabilone (synthetic cannabinoid, useful since there are apparently cannibis receptors involved in neuropathic pain)

<!-- PAGE=? -->
 Tramadol/Tramacet

<!-- PAGE=? -->
 Topimax/Lamotrigine (sodium channel based anti-convulsants)

<!-- PAGE=? -->
 Sympathetic blockade (to blunt any sympathetic component)

<!-- PAGE=? -->
 Other more invasive strategies

<!-- PAGE=? -->
 Intrathecal narcotics or Clonidine

<!-- PAGE=? -->
 Spinal cord stimulators

<!-- PAGE=? -->
Phantom Limb Pain

<!-- PAGE=? -->
 Nerve injury from an amputation that is followed by changes in the peripheral and central nervous systems that involve induction and maintenance of chronic phantom pain

<!-- PAGE=? -->
 3 distinct components

<!-- PAGE=? -->
o Phantom pain - painful sensations referred to absent limb

<!-- PAGE=? -->
 burning , throbbing , aching pain

<!-- PAGE=? -->
o Phantom sensation - any other sensation in the absent limb ( spasms , fist clenching , itching )

<!-- PAGE=? -->
o Stump pain - pain localized in the stump

<!-- PAGE=? -->
 60-80% of amputees get some variation of this, regardless of age, gender, level or side of amputation; 75% within first few days, but can be delayed months or years

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Pre-amputation pain (retrospective studies)

<!-- PAGE=? -->
o Persistent stump pain

<!-- PAGE=? -->
o Bilateral limb amputations

<!-- PAGE=? -->
o Lower limb amputations

<!-- PAGE=? -->
 Features

<!-- PAGE=? -->
o Intermittent shooting , stabbing , squeezing , throbbing , burning

<!-- PAGE=? -->
o Localize primarily to distal parts of missing limb

<!-- PAGE=? -->
o Stump pain

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Pre-emptive

<!-- PAGE=? -->
 Epidural ( evidence insufficient to recommend routine use )

<!-- PAGE=? -->
 Perineural blocks ( good for post-op pain relief, but not for reducing phantom pain )

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
 Gabapentin / Pregabalin

<!-- PAGE=? -->
 TCA's ( Amytriptyline )

<!-- PAGE=? -->
o Other

<!-- PAGE=? -->
 Acupuncture - case reports of success

<!-- PAGE=? -->
 TENS - apparently some study showed TENS to outer ear reduced phanto pain

<!-- PAGE=? -->
 Spinal cord stimulators - case reports

<!-- PAGE=? -->
Post-Herpetic Neuralgia

<!-- PAGE=? -->
 Presence of pain after a Herpes Zoster infection (reactivation of the VZV virus), occurring 1-3 months after rash is gone - purely neuropathic pain

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
o Virus infects dorsal root ganglion , and remains latent until reactivation, which leads to inflammation

<!-- PAGE=? -->
o Ongoing inflammation results in abnormal conduction and altered information transmission

<!-- PAGE=? -->
o Pathways become more excitable , and impulses and amplified and distorted

<!-- PAGE=? -->
o Pain processing may be altered by the establishment of new pathways/synapses

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Age (most are > 60 yo)

<!-- PAGE=? -->
o Cancer

<!-- PAGE=? -->
o Diabetes

<!-- PAGE=? -->
o Immunosuppression

<!-- PAGE=? -->
o Lymphoproliferative disorders

<!-- PAGE=? -->
 Features

<!-- PAGE=? -->
o Pain (usually unilateral ) of a single thoracic ( T3-L3 most commonly) or ophthalamic dermatome (of the trigeminal nerve )

<!-- PAGE=? -->
o Continuous ( burning , deep aching ) or intermittent ( electric shock-like , lancinating )

<!-- PAGE=? -->
o Allodynia

<!-- PAGE=? -->
o Sensory loss in affected dermatome (altered perception to tactile and thermal sensation)

<!-- PAGE=? -->
o May have associated vesicular rash , hypopigmentation or scarring of skin in affected area, in a dermatomal distribution

<!-- PAGE=? -->
o Pain precedes rash by 48-72 hrs , and lasts 1-2 weeks

<!-- PAGE=? -->
 More common in older adults, and is typically a benign self-limited disorder in younger patients (< 50 yo)

<!-- PAGE=? -->
 Prevention

<!-- PAGE=? -->
o Immunize high risk groups

<!-- PAGE=? -->
o Treat at -acute‖ Herpes Zoster stage (unclear if it will prevent PHN)

<!-- PAGE=? -->
 Antivirals (one of the -cyclovirs)

<!-- PAGE=? -->
 Analgesics

<!-- PAGE=? -->
 Steroids (no studies show benefit)

<!-- PAGE=? -->
 Regional sympathetic blocks (no prospective trial demonstrating role of decreasing PHN, but retrospective results were promising)

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Antivirals

<!-- PAGE=? -->
o Gabapentin/Pregabalin ( arguably 1 st line )

<!-- PAGE=? -->
o TCA's ( Amitryptyline )

<!-- PAGE=? -->
o Sympathetic blocks ( early, within 2 months, can be very effective, PHN resolves in up to 80% )

<!-- PAGE=? -->
o Topical agents (EMA, lidocaine, capsaicin) as adjuvants

<!-- PAGE=? -->
o Opioids (if unresponsive to primary treatments)

<!-- PAGE=? -->
o TENS (helps some, worsens others)

<!-- PAGE=? -->
o Epidural steroids (unsure about this)

<!-- PAGE=? -->
o Spinal cord stimulation

<!-- PAGE=? -->
o Surgery (not recommended)

<!-- PAGE=? -->
 Overall

<!-- PAGE=? -->
o Early antiviral use in acute zoster

<!-- PAGE=? -->
o Early TCA's & Gabapentin/Pregabalin

<!-- PAGE=? -->
o Moderate opioids

<!-- PAGE=? -->
o Sympathetic block early

<!-- PAGE=? -->
o Topical agents as adjuvants

<!-- PAGE=? -->
Myofascial Pain

<!-- PAGE=? -->
 Common regional pain disorder characterized by:

<!-- PAGE=? -->
o Aching muscle pain , muscle spasm , stiffness , or weakness , often in a fixed pattern that does not follow dermatomes

<!-- PAGE=? -->
o Discrete - trigger points ‖ of marked tenderness within muscle or associated connective tissue

<!-- PAGE=? -->
o Tight, ropy bands of muscle over trigger points

<!-- PAGE=? -->
o Autonomic dysfunction characterized by skin changes ( vasoconstriction , piloerection ) overlying the muscle

<!-- PAGE=? -->
o Often develops in patients whose response to stress is an increase in muscle tone

<!-- PAGE=? -->
 Pathophysiology is somewhat unclear; one theory is:

<!-- PAGE=? -->
o Gross trauma or repetitive microtrauma thought to play a role in initiation (Lange)

<!-- PAGE=? -->
o Muscle disruption leads to sarcoplasmic reticulum disruption and release of calcium , resulting in sustained contraction , fatigue, and pain

<!-- PAGE=? -->
o Blood flow is inadequate for the metabolic activity required ( supply/demand mismatch ) and ischemia results, leading to pain

<!-- PAGE=? -->
o ATP becomes depleted , preventing release of myosin from actin, causing the sarcomeres to become rigid , and the muscles to be taut, tight, and ropy

<!-- PAGE=? -->
o All the good stuff ( PG , bradykinin , serotonin ) are released from platelets and mast cells, causing increased firing of muscle nociceptors (PAIN!)

<!-- PAGE=? -->
o Overall:

<!-- PAGE=? -->
 Trauma/injury leads to sustained contraction/pain , and supply/demand mismatch

<!-- PAGE=? -->
 All this sensitizes the nociceptors , which leads to ' trigger points '

<!-- PAGE=? -->
o Paul Kliffer - another theory involves nerve root irritation that leads to unintended contraction; exists in a myotomal (but not necessarily dermatomal) pattern

<!-- PAGE=? -->
 Diagnosis essentially based on:

<!-- PAGE=? -->
o Character of the pain

<!-- PAGE=? -->
o Palpation of discrete trigger points that reproduce it

<!-- PAGE=? -->
 Commonly affected muscles and sites of trigger points and referred pain

<!-- PAGE=? -->
o Scapulocostal syndrome

<!-- PAGE=? -->
 Scapula pain that radiates to occipital region, shoulder , medial arm , or anterior chest wall

<!-- PAGE=? -->
o Masseter muscle

<!-- PAGE=? -->
o Piriformis muscle

<!-- PAGE=? -->
 Overlies sciatic nerve , causing irritation and occasionally hypesthesia resembling radiculopathy

<!-- PAGE=? -->
o Quadratus lumborum

<!-- PAGE=? -->
 Apparently can also mimic low back pain and radiculopathy

<!-- PAGE=? -->
o Gluteus medius

<!-- PAGE=? -->
 Referred pain into posterior thigh/calf , mimicking S1 radiculopathy

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Pain may resolve spontaneously without sequelae, but many continue to have latent trigger points

<!-- PAGE=? -->
o Much of treatment centers around physiotherapy to regain muscle length and elasticity, by gently stretching affected muscles

<!-- PAGE=? -->
o Pain must be overcome before this can happen:

<!-- PAGE=? -->
 Trigger point injections

<!-- PAGE=? -->
 Infiltration of local anesthetic (usually 1-3 cc of 1-2% Lidocaine) or sometimes steroid ( addendum, NEVER steroids , there is no inflammatory component as per Dr. Kliffer ) directly into trigger points; relief confirms diagnosis of myofascial syndrome

<!-- PAGE=? -->
 Botulinum toxin may also be attempted (long-term blockade of ACh release from peripheral nerves) with side effect being weakness in surrounding muscle ( may prevent proper physio )

<!-- PAGE=? -->
 Massage therapy

<!-- PAGE=? -->
 Ultrasound therapy

<!-- PAGE=? -->
 TENS (over trigger points 20-30 min prior to exercise)

<!-- PAGE=? -->
 Topical cooling

<!-- PAGE=? -->
 Vapocoolants (ethyl chloride, fluoromethane spray)

<!-- PAGE=? -->
 Biofeedback of EMG

<!-- PAGE=? -->
 Drugs

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 TCA's

<!-- PAGE=? -->
 Gabapentin

<!-- PAGE=? -->
o Dr. Kliffer's thoughts

<!-- PAGE=? -->
 Must treat the pain to being physio (as above)

<!-- PAGE=? -->
 His primary modalities

<!-- PAGE=? -->
Trigger point injections - it is even the needle itself that causes a little initial contraction but subsequently causes relaxation and relieves the pain, even before LA is injected ; however, the LA helps alleviate the initial soreness that follows injection

<!-- PAGE=? -->
Massage therapy - pressing on trigger points helps relax the muscle

<!-- PAGE=? -->
Topical cooling - somehow helps -stretch‖ out the muscle

<!-- PAGE=? -->
 Using botox may result in muscle relaxation, but prevent you from properly exercising and doing physio (because of the muscle weakness) and may even throw off your biomechanical balance!

<!-- PAGE=? -->
 Ultimately, you must treat the underlying condition leading to myofascial pain, or else it will just return!

<!-- PAGE=? -->
The Rest of the Notes

<!-- PAGE=? -->
Reasons for ineffective analgesia

<!-- PAGE=? -->
The common idea that pain is merely a symptom and not harmful in itself .

<!-- PAGE=? -->
The mistaken impression that analgesia makes accurate diagnosis difficult or impossible

<!-- PAGE=? -->
Fear of the potential for addiction to opioids.

<!-- PAGE=? -->
Concerns about respiratory depression and other opioid-related side effects such as nausea and vomiting.

<!-- PAGE=? -->
Lack of understanding of the pharmacokinetics of various agents.

<!-- PAGE=? -->
Lack of appreciation of variability in analgesic response to opioids.

<!-- PAGE=? -->
Prescriptions for opioids that include the use of inappropriate doses and/or dose intervals.

<!-- PAGE=? -->
Misinterpretation of doctors' orders by nursing staff, including use of lower ranges of opioid doses and delaying opioid administration .

<!-- PAGE=? -->
The mistaken belief that patient weight is the best predictor of opioid requirement.

<!-- PAGE=? -->
The mistaken belief that opioids must not be given more often than four hourly.

<!-- PAGE=? -->
Patients' difficulties in communicating their need for analgesia.

<!-- PAGE=? -->
Principles of postoperative pain management (applicable in all areas of acute pain management)

<!-- PAGE=? -->
Adverse physiological and psychological effects result from unrelieved severe pain .

<!-- PAGE=? -->
Proper assessment and control of pain require patient involvement , frequent assessment and reassessment of pain intensity and charting of analgesia.

<!-- PAGE=? -->
Effective pain relief requires flexibility and tailoring of treatment to an individual rather than rigid application of formulae and prescriptions.

<!-- PAGE=? -->
Pain is best treated early because established, severe pain is more difficult to treat

<!-- PAGE=? -->
While it is not possible or always desirable to completely alleviate all pain in the postoperative period, it should be possible to reduce pain to a tolerable or comfortable level .

<!-- PAGE=? -->
Postoperative analgesia should be planned pre-operatively , with consideration given to the type of surgery, medical condition of the patient, peri-operative use of analgesics and regional anesthetic techniques.

<!-- PAGE=? -->
Postoperative physical therapy requirements for early mobilization should be discussed with the patient and the timing of appropriate and adequate analgesia and early physical therapy requirements considered.

<!-- PAGE=? -->
Ultimate responsibility for pain management should be assigned to those most experienced in its administration and not to the most junior staff members.

<!-- PAGE=? -->
Safe and effective analgesia depends on

<!-- PAGE=? -->
o adequate education of all involved in pain management, including the patient; formal programs, protocols and guidelines covering acute pain management relevant to the institution

<!-- PAGE=? -->
o formal quality assurance programs to regularly evaluate the effectiveness of pain management.

<!-- PAGE=? -->
Summary of pharmacological interventions (Levels of Evidence)

<!-- PAGE=? -->
NSAIDs

<!-- PAGE=? -->
 Oral (alone) (I)

<!-- PAGE=? -->
o Effective for mild to moderate pain.

<!-- PAGE=? -->
o Relatively contraindicated in patients with renal disease and risk of or actual coagulopathy

<!-- PAGE=? -->
.

<!-- PAGE=? -->
o Risk of coagulopathy, gastro-intestinal bleeding and other risk factors should be carefully sought.

<!-- PAGE=? -->
 Oral (adjunct to opioid) (I)

<!-- PAGE=? -->
o Potentiating effect resulting in opioid sparing. Cautions as above.

<!-- PAGE=? -->
 Parenteral (ketorolac) (I)

<!-- PAGE=? -->
o Effective for moderate to severe pain.

<!-- PAGE=? -->
o Useful where opioids are contraindicated or to produce ‗ opioid sparing' , and to minimize respiratory depression, sedation and gastro-intestinal stasis associated with opioid administration.

<!-- PAGE=? -->
o Best used as part of a multi- modal analgesia regimen.

<!-- PAGE=? -->
 Rectal (IV)

<!-- PAGE=? -->
o Similar efficacy to oral preparations.

<!-- PAGE=? -->
Acetaminophen

<!-- PAGE=? -->
 Oral (II) & Rectal (IV)

<!-- PAGE=? -->
o Effective for mild to moderate pain, and as an adjunct to opioids in more severe pain.

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
 Oral (IV)

<!-- PAGE=? -->
o As effective as parenteral in appropriate doses. Use as soon as oral medication tolerated . Route of choice .

<!-- PAGE=? -->
 Intramuscular (I)

<!-- PAGE=? -->
o Has been the standard parenteral route, but injections painful and absorption unreliable .

<!-- PAGE=? -->
o Hence, avoid this route when possible .

<!-- PAGE=? -->
 Subcutaneous (via indwelling subcutaneous needle/cannula) (I)

<!-- PAGE=? -->
o Preferable to intramuscular because of patient comfort and a reduced risk of needlestick injury.

<!-- PAGE=? -->
 Intravenous (I)

<!-- PAGE=? -->
o Parenteral route of choice after major surgery.

<!-- PAGE=? -->
o Suitable for titrated bolus or continuous administration.

<!-- PAGE=? -->
o Significant risk of respiratory depression with inappropriate dosing.

<!-- PAGE=? -->
 PCA (systemic) (I)

<!-- PAGE=? -->
o Intravenous or subcutaneous routes recommended.

<!-- PAGE=? -->
o Good steady level of analgesia.

<!-- PAGE=? -->
o Popular with patients but requires special infusion pumps and staff education.

<!-- PAGE=? -->
 Epidural & intrathecal (I)

<!-- PAGE=? -->
o When suitable, provides good analgesia.

<!-- PAGE=? -->
o Risk of respiratory depression (as with opioids by other routes), but sometimes delayed in onset.

<!-- PAGE=? -->
o Requires careful monitoring.

<!-- PAGE=? -->
o Use of infusion pumps requires additional equipment and staff education. Expensive if infusion pumps are employed.

<!-- PAGE=? -->
Local anesthetics

<!-- PAGE=? -->
 Epidural & intrathecal (I)

<!-- PAGE=? -->
o Indications in particular settings.

<!-- PAGE=? -->
o Effective regional analgesia.

<!-- PAGE=? -->
o May blunt ‗stress response' and aid recovery

<!-- PAGE=? -->
o Opioid sparing.

<!-- PAGE=? -->
o Addition of opioid to local anaesthetic may improve analgesia.

<!-- PAGE=? -->
o Risks of hypotension, weakness, numbness . Requires careful monitoring.

<!-- PAGE=? -->
o Use of infusion pump requires additional equipment and staff education.

<!-- PAGE=? -->
 Peripheral nerve block (I)

<!-- PAGE=? -->
o Plexus block, peripheral nerve block and infiltration.

<!-- PAGE=? -->
o Effective regional analgesia.

<!-- PAGE=? -->
o Opioid sparing.

<!-- PAGE=? -->
' Although evidence for the efficacy of non-pharmacological modalities such as physical therapeutic agents and modalities such as spinal manual therapy, mobilisation, application of superficial heat or cold, massage, exercise, transcutaneous electrical nerve stimulation (TENS) therapy and acupuncture in acute pain management is largely at the expert opinion level , certain patients derive benefit from these techniques '.

<!-- PAGE=? -->
Treatment Categories For Acute and Chronic Pain

<!-- PAGE=? -->
 Biological

<!-- PAGE=? -->
o Disease specific

<!-- PAGE=? -->
 Chemo

<!-- PAGE=? -->
 Radiotherapy

<!-- PAGE=? -->
 Surgery - tumor, disk

<!-- PAGE=? -->
 Immunosuppression (eg. RA)

<!-- PAGE=? -->
o Pharmacological

<!-- PAGE=? -->
 Oral drugs

<!-- PAGE=? -->
 Parental drugs

<!-- PAGE=? -->
 Needles and drugs

<!-- PAGE=? -->
 IT pumps

<!-- PAGE=? -->
o Non-pharmacological

<!-- PAGE=? -->
 Acupuncture

<!-- PAGE=? -->
 Physio

<!-- PAGE=? -->
 Massage

<!-- PAGE=? -->
 Chiropracter

<!-- PAGE=? -->
 Ice/heat

<!-- PAGE=? -->
 Braces/orthotic

<!-- PAGE=? -->
o Neuromodulation

<!-- PAGE=? -->
 TENS

<!-- PAGE=? -->
 Spinal cord stimulation

<!-- PAGE=? -->
 Deep brain stimulation

<!-- PAGE=? -->
 Motor cortex stimulation

<!-- PAGE=? -->
 Transcranial electrical stimulation

<!-- PAGE=? -->
o Neurodestructive

<!-- PAGE=? -->
 Dorsal root entry zone procedure - neuropathic pain from root (common brachial plexus injury) - radiofrequency burn zone where dorsal root enters.  Rarely done.

<!-- PAGE=? -->
 Median branch rhizotomies

<!-- PAGE=? -->
 Celiac plexus alcohol

<!-- PAGE=? -->
 Thalamotomy

<!-- PAGE=? -->
 Trigeminal ganglionectomy

<!-- PAGE=? -->
 Psychological

<!-- PAGE=? -->
o Cognitive treatment

<!-- PAGE=? -->
o Behavioral treatment

<!-- PAGE=? -->
o Education

<!-- PAGE=? -->
o Relaxation

<!-- PAGE=? -->
o Hypnosis

<!-- PAGE=? -->
o Motivation

<!-- PAGE=? -->
o Biofeedback

<!-- PAGE=? -->
 Social

<!-- PAGE=? -->
o Employer interactions

<!-- PAGE=? -->
o Retraining

<!-- PAGE=? -->
o Family interactions

<!-- PAGE=? -->
 Multiple ways of classifying pain

<!-- PAGE=? -->
o Acute vs chronic (beyond the usual course of an acute disease, or after a -reasonable‖ time for healing to occur; 1-6 months but variable)

<!-- PAGE=? -->
o Nociceptive (nerve endings) vs neuropathic (nerve tissue)

<!-- PAGE=? -->
o Etiology (post-op vs cancer vs trauma, etc…)

<!-- PAGE=? -->
o Anatomical (headache vs back, somatic vs visceral)

<!-- PAGE=? -->
Physiologic Sequelae

<!-- PAGE=? -->
Lymphopenia

<!-- PAGE=? -->
Decreased immune function

<!-- PAGE=? -->
Depression of reticuloendothelial system

<!-- PAGE=? -->
Leukocytosis

<!-- PAGE=? -->
Reduced killer T-cell cytotoxicty

<!-- PAGE=? -->
COAGULATION EFFECTS

<!-- PAGE=? -->
Increased platelet adhesiveness

<!-- PAGE=? -->
Increased incidence of thromboembolic phenomena

<!-- PAGE=? -->
Diminished fibrinolysis

<!-- PAGE=? -->
Activation of coagulation cascade

<!-- PAGE=? -->
GASTROINTESTINAL

<!-- PAGE=? -->
Increased sphincter tone

<!-- PAGE=? -->
Ileus

<!-- PAGE=? -->
Decreased smooth muscle tone

<!-- PAGE=? -->
GENITOURINARY

<!-- PAGE=? -->
Increased sphincter tone

<!-- PAGE=? -->
Urinary retention

<!-- PAGE=? -->
Decreased smooth muscle tone

<!-- PAGE=? -->
PAR

<!-- PAGE=? -->
 The most common complications

<!-- PAGE=? -->
o nausea and vomiting (9.8%)

<!-- PAGE=? -->
o need for airway support (6.9%)

<!-- PAGE=? -->
o hypotension (2.7%)

<!-- PAGE=? -->
o dysrhythmia (1.4%)

<!-- PAGE=? -->
o hypertension (1.1%)

<!-- PAGE=? -->
o altered mental status (0.6%)

<!-- PAGE=? -->
o need to rule out myocardial infarction (0.3%)

<!-- PAGE=? -->
o major cardiac events (0.3%)

<!-- PAGE=? -->
Parathyroid Hormone

<!-- PAGE=? -->
 Parathyroid hormone is the principal regulator of calcium homeostasis and is released into the circulation by a negative feedback mechanism

<!-- PAGE=? -->
o Hypocalcemia stimulates the release of PTH, whereas hypercalcemia suppresses both synthesis and release of the hormone

<!-- PAGE=? -->
o PTH increases serum calcium by promoting bone resorption, limiting renal excretion and enhancing gastrointestinal absorption (via effect on vitamin D metabolism)

<!-- PAGE=? -->
o PTH decreases serum phosphate by increasing renal excretion

<!-- PAGE=? -->
 99% of total body calcium in skeleton

<!-- PAGE=? -->
 40% calcium in blood bound to proteins, 60% is ionized or complexed to organic ions (unbound ionized calcium is most NB physiologically)

<!-- PAGE=? -->
 Hyperparathyroidism:

<!-- PAGE=? -->
o Hypercalcemia: serum concentration > 5.5 mEq/L or ionized concentration > 2.5 mEq/L is hallmark of primary hyperparathyroidism

<!-- PAGE=? -->
o Etiology

<!-- PAGE=? -->
 Primary:

<!-- PAGE=? -->
 Due to excess production of parathyroid hormone typically by one gland

<!-- PAGE=? -->
 Benign parathyroid adenoma (90%), hyperplasia (5-10%) or carcinoma

<!-- PAGE=? -->
 Commonly begins in 3 rd to 5 th decade & is 2-3 times more common in females

<!-- PAGE=? -->
 Hyperparathyroidism due to adenoma or hyperplasia is the most common presenting symptom of MEN type 1

<!-- PAGE=? -->
 Secondary:

<!-- PAGE=? -->
 Reflects an appropriate response of the parathyroid gland to secrete PTH to counteract a disease process producing hypocalcemia (i.e. CRF)

<!-- PAGE=? -->
 Treatment is targeted at underlying disease process

<!-- PAGE=? -->
 Rarely results in hypercalcemia

<!-- PAGE=? -->
 Ectopic:

<!-- PAGE=? -->
 Humoral hypercalcemia of malignancy or pseudoparathyroidism

<!-- PAGE=? -->
 Carcinoma of the lung, breast, pancreas, kidney and lymphoproliferative disease

<!-- PAGE=? -->
Parkinson's

<!-- PAGE=? -->
 disorder of the extrapyramidal system and is one of the most common neurodegenerative disease

<!-- PAGE=? -->
 hypothesized that neurodegeneration is induced by genetic, environmental, or infectious disorders

<!-- PAGE=? -->
 Age is the single most consistent risk factor

<!-- PAGE=? -->
 characterized by the progressive depletion of selected neuronal populations, including those dopaminergic neurons of the substantia nigra of the basal ganglia

<!-- PAGE=? -->
o clinical signs occur when approximately 80% of dopaminergic activity is lost

<!-- PAGE=? -->
o Imbalance between the inhibitory actions of dopamine and the excitatory actions of acetylcholine lead to excessive thalamic inhibition

<!-- PAGE=? -->
 Clinical Features

<!-- PAGE=? -->
o classic triad

<!-- PAGE=? -->
 rigidity

<!-- PAGE=? -->
 resting tremor - Pill-rolling tremor

<!-- PAGE=? -->
 bradykinesis

<!-- PAGE=? -->
o Mask like face - dec. blinking

<!-- PAGE=? -->
o Seborrhea

<!-- PAGE=? -->
o oily skin

<!-- PAGE=? -->
o diaphragmatic spasms

<!-- PAGE=? -->
o oculogyric crises

<!-- PAGE=? -->
o Dementia and depression

<!-- PAGE=? -->
o Dysphonia

<!-- PAGE=? -->
o Dysarthria

<!-- PAGE=? -->
o Drooling

<!-- PAGE=? -->
o stooped posture

<!-- PAGE=? -->
o monotone voice

<!-- PAGE=? -->
o shuffling gait/balance problems

<!-- PAGE=? -->
o micrographia

<!-- PAGE=? -->
o akathisia

<!-- PAGE=? -->
o dysphagia

<!-- PAGE=? -->
 No one specific test to confirm the diagnosis Parkinson's disease

<!-- PAGE=? -->
o Diagnosis is clinical

<!-- PAGE=? -->
 Treatment - inc. concentration of dopamine in the basal ganglia and dec. the neuronal effects of acetylcholine

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 Sinement

<!-- PAGE=? -->
PCA

<!-- PAGE=? -->
 Quality of analgesia with PCA has been consistently reported as superior or equal to that with intramuscular opioids

<!-- PAGE=? -->
 opioid use is usually reduced compared with intramuscular control groups

<!-- PAGE=? -->
 satisfaction of patients and nurses is high

<!-- PAGE=? -->
 advantages of PCA

<!-- PAGE=? -->
o high-quality analgesia

<!-- PAGE=? -->
o autonomy

<!-- PAGE=? -->
o elimination of delay in decisions to medicate for pain

<!-- PAGE=? -->
o freedom from painful intramuscular injections

<!-- PAGE=? -->
 Optimal efficacy and safety using PCA requires

<!-- PAGE=? -->
 L-DOPA with Carbadopa  (decarboxylase inhibitor, which prevents peripheral conversion of levodopa to dopamine and optimizes the amount of levodopa available to enter the central nervous system)

<!-- PAGE=? -->
 Most effective treatment (prolongs life)

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
o Dyskinesias

<!-- PAGE=? -->
o Psychiatric disturbance - agitation hallucinations, mania, paranoia

<!-- PAGE=? -->
o Inc myocardial contractility

<!-- PAGE=? -->
o Orthostatic hypotension

<!-- PAGE=? -->
o N/V

<!-- PAGE=? -->
 Selegiline

<!-- PAGE=? -->
 Type B MAOI

<!-- PAGE=? -->
 inhibiting the catabolism of dopamine in the central nervous system

<!-- PAGE=? -->
 selegiline is not associated with tyramine-associated hypertensive crisis

<!-- PAGE=? -->
o type B is not found in GI tract

<!-- PAGE=? -->
o tyramine into the systemic circulation in the setting of pharmacologically inhibited type A monoamine oxidase results in a hyperadrenergic state due to the inherent sympathomimetic activities of tyramine

<!-- PAGE=? -->
 dopamine receptor agonists

<!-- PAGE=? -->
 stimulate striatal receptors without affecting dopamine metabolism

<!-- PAGE=? -->
 bromocriptine, pergolide, pramipexole, and ropinirole

<!-- PAGE=? -->
 Anticholinergic agents such as trihexyphenidyl, benztropine, procyclidine  and orphenadrine are also often prescribed

<!-- PAGE=? -->
o Surgical treatment

<!-- PAGE=? -->
 subthalamic deep brain stimulation

<!-- PAGE=? -->
 fetal mesencephalic tissue implantation

<!-- PAGE=? -->
 Anesthetic management

<!-- PAGE=? -->
o aspiration prophylaxis

<!-- PAGE=? -->
o perioperative respiratory function

<!-- PAGE=? -->
o autonomic nervous system dysfunction is common

<!-- PAGE=? -->
o usual drug regimen should be administered as close to the regular schedule as possible

<!-- PAGE=? -->
 interruption of therapy for more than 6 to 12 hours can result in an abrupt loss of therapeutic effects

<!-- PAGE=? -->
o Avoid drugs that precipitate or exacerbate Parkinson's disease

<!-- PAGE=? -->
 Phenothiazines

<!-- PAGE=? -->
 Droperidol

<!-- PAGE=? -->
 Haldol

<!-- PAGE=? -->
 Butyrophenones

<!-- PAGE=? -->
 Metoclopramide

<!-- PAGE=? -->
o diphenhydramine has been described as effective for drug-induced extrapyramidal symptoms

<!-- PAGE=? -->
PDA

<!-- PAGE=? -->
 Functional closure = 10-15 hrs after birth

<!-- PAGE=? -->
 Anatomic = 4-6 weeks

<!-- PAGE=? -->
 Functional closure = 58% of normal term infants by day 2, 98% by day 4

<!-- PAGE=? -->
Pediatrics

<!-- PAGE=? -->
Apnea

<!-- PAGE=? -->
 Risk Factors for post operative apnea in infants

<!-- PAGE=? -->
o careful planning

<!-- PAGE=? -->
o establishment of appropriate policies and procedures

<!-- PAGE=? -->
o education of physicians and nurses

<!-- PAGE=? -->
o frequent medical assessment of individual patients

<!-- PAGE=? -->
 Opioids best suited for PCA are

<!-- PAGE=? -->
o potent opioids, rapid onset, intermediate duration of action

<!-- PAGE=? -->
Apnea

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 The rate of respiratory depression associated with intravenous PCA is low (<0.5%) and does not appear to be higher than that with systemic or neuraxial opioids

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o background infusion

<!-- PAGE=? -->
o advanced age

<!-- PAGE=? -->
o concomitant administration of sedative or hypnotic agents

<!-- PAGE=? -->
o coexisting pulmonary disease such as OSA

<!-- PAGE=? -->
o Hypovolemia

<!-- PAGE=? -->
o Large incremental doses

<!-- PAGE=? -->
 Overall 0.25% risk of apnea

<!-- PAGE=? -->
o Increases to 2% with background infusion

<!-- PAGE=? -->
 programming error most common mishap among operator errors

<!-- PAGE=? -->
o 1:30,000 to 1:300,000

<!-- PAGE=? -->
 most problems related to PCA use result from user or operator errors

<!-- PAGE=? -->
Background Infusions

<!-- PAGE=? -->
 Advantages

<!-- PAGE=? -->
o more constant opioid serum level

<!-- PAGE=? -->
o improved analgesia, especially during sleep

<!-- PAGE=? -->
o modulation of the final opioid dose by patients

<!-- PAGE=? -->
 Disadvantages

<!-- PAGE=? -->
o difficulty predicting the optimal infusion rate

<!-- PAGE=? -->
o loss of an important safety element because sleeping patients continue to be medicated

<!-- PAGE=? -->
o more human errors in PCA pump programming

<!-- PAGE=? -->
 Recommendations for use of the background continuous-infusion mode are as follows

<!-- PAGE=? -->
o avoid routine use of continuous-infusion mode

<!-- PAGE=? -->
o add the continuous-infusion mode for specific indications

<!-- PAGE=? -->
 pain during sleeping hours

<!-- PAGE=? -->
o base the rate of infusion on established need

<!-- PAGE=? -->
 30-50% of what a patient self-administered with the demand mode

<!-- PAGE=? -->
o decide whether the continuous-infusion mode is needed only at night or around the clock

<!-- PAGE=? -->
o provide regular in-service education to ward nurses on PCA pump-programming procedures

<!-- PAGE=? -->
o Miller

<!-- PAGE=? -->
 Prematurity (Gestational Age) and post conceptual age <52wks at BCCH  (↑ risk with ↓PCA)

<!-- PAGE=? -->
 Hgb < 100 (HCT <30%)

<!-- PAGE=? -->
o Barash

<!-- PAGE=? -->
 Congenital anomalies

<!-- PAGE=? -->
 Hx of apnea & bradycardia

<!-- PAGE=? -->
 Chronic respiratory disease (e.g. BPD)

<!-- PAGE=? -->
 Term + 4 weeks (i.e. at least 42-44 weeks PCA in term infant)

<!-- PAGE=? -->
 Suggest admission and post-operative monitoring for at least 12 apnea free hours if <52-60wks PCA if born premature

<!-- PAGE=? -->
 A combined analysis has determined the following:

<!-- PAGE=? -->
o apnea was strongly and inversely related to both gestational and postconceptual age;

<!-- PAGE=? -->
o an associated risk factor was continuing apnea at home;

<!-- PAGE=? -->
o infants who were small for gestational age seemed to be somewhat protected from apnea

<!-- PAGE=? -->
o anemia was a significant independent risk factor, particularly for infants less than 43 weeks' postconceptual age

<!-- PAGE=? -->
o no relationship exists between apnea and a history of necrotizing enterocolitis, respiratory distress syndrome, bronchopulmonary dysplasia, or intraoperative use of opioid analgesics and muscle relaxants

<!-- PAGE=? -->
 Incidence of postoperative apnea was reported to be lower after spinal anesthesia alone than after general (halothane) anesthesia

<!-- PAGE=? -->
o spinal anesthesia combined with ketamine increases the incidence of apnea more than that with general anesthesia

<!-- PAGE=? -->
 Caffeine seems to be helpful in preventing postoperative apnea

<!-- PAGE=? -->
Anesthetic Uptake

<!-- PAGE=? -->
 Various reasons for the faster uptake of anesthetics in infants have been proposed:

<!-- PAGE=? -->
o the ratio of alveolar ventilation to FRC is 5:1 in the infant and 1.5:1 in the adult;

<!-- PAGE=? -->
o in the neonate, more of the cardiac output goes to the vessel-rich group of organs , which includes the heart and brain;

<!-- PAGE=? -->
o the neonate has a greater cardiac output per kilogram of body mass ;

<!-- PAGE=? -->
 this would cause a decrease in the rate of rise of Fa/Fi by itself, but the distribiton to vesselrich  groups accounts for faster uptake

<!-- PAGE=? -->
o the infant has a lower blood gas partition coefficient for volatile anesthetics

<!-- PAGE=? -->
 reduced solubility

<!-- PAGE=? -->
 An appreciation of the lower MAC in neonates , along with recognition of the more rapid uptake , suggests that care must be taken not to -overpressure‖ the concentration of the volatile drugs to as great a degree or for as long before intubation as would be done with an older infant or adult.

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
 Pediatric Airway Differences

<!-- PAGE=? -->
o Large occiput - Extreme extension can obstruct view, use a shoulder roll

<!-- PAGE=? -->
o Large tongue in relation to oropharynx

<!-- PAGE=? -->
o Larynx is higher in the neck (glottis is at C4 at term and at C3 premature infants)

<!-- PAGE=? -->
o Omega shaped epiglottis

<!-- PAGE=? -->
 Longer and stiffer

<!-- PAGE=? -->
 angled over the laryngeal inlet

<!-- PAGE=? -->
o Slanting vocal cords

<!-- PAGE=? -->
 angled caudally anteriorly

<!-- PAGE=? -->
o The larynx is funnel shaped with the narrowest portion at the cricoid cartilage

<!-- PAGE=? -->
o Obligate nose breathers

<!-- PAGE=? -->
 approximately 8% of premature neonates (31 to 32 weeks' postconceptual age) and 40% of term newborns can convert to oral breathing in the presence of nasal airway obstruction

<!-- PAGE=? -->
 Almost all infants can easily convert to oral breathing by 5 months of age

<!-- PAGE=? -->
o Short neck

<!-- PAGE=? -->
o Short trachea

<!-- PAGE=? -->
 ETT sizing

<!-- PAGE=? -->
o uncuffed

<!-- PAGE=? -->
o 0.5 off for cuffed

<!-- PAGE=? -->
o Premarture

<!-- PAGE=? -->
 2.5 - 3.0 uncuffed

<!-- PAGE=? -->
 ETT Length

<!-- PAGE=? -->
BPD

<!-- PAGE=? -->
Cote, Miller

<!-- PAGE=? -->
 defined as having a need for supplemental oxygen and abnormal chest radiograph findings at 36 weeks post-conceptual age

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o premature infants

<!-- PAGE=? -->
o prolonged ventilation

<!-- PAGE=? -->
 high inspiratory pressures

<!-- PAGE=? -->
 high oxygen concentrations

<!-- PAGE=? -->
 Mixed obstructive restrictive pattern

<!-- PAGE=? -->
o mixture of asthma and interstitial lung disease

<!-- PAGE=? -->
 ABGs show a chronic hypercarbia and varying degrees of hypoxemia

<!-- PAGE=? -->
 CXR

<!-- PAGE=? -->
o large lung volumes

<!-- PAGE=? -->
o fibrosis

<!-- PAGE=? -->
o cystic and atelectatic areas

<!-- PAGE=? -->
 decreased dynamic compliance

<!-- PAGE=? -->
 increased airway resistance

<!-- PAGE=? -->
 increased physiologic dead space

<!-- PAGE=? -->
 increased work of breathing.

<!-- PAGE=? -->
 may be present for years after the initial injury

<!-- PAGE=? -->
o may lead to childhood asthma and recurrent lung infections

<!-- PAGE=? -->
o reduced DLCO

<!-- PAGE=? -->
o reduced exercise tolerance

<!-- PAGE=? -->
o

<!-- PAGE=? -->
 abnormal functional airway growth

<!-- PAGE=? -->
o tracheomalacia

<!-- PAGE=? -->
o bronchomalacia

<!-- PAGE=? -->
 abnormal response to hypoxemia

<!-- PAGE=? -->
 abnormally shaped chest

<!-- PAGE=? -->
 increased PVR

<!-- PAGE=? -->
o cor pulmonale

<!-- PAGE=? -->
o CHF

<!-- PAGE=? -->
 Inc. incidence of SIDS

<!-- PAGE=? -->
o ? need for apnea monitoring

<!-- PAGE=? -->
 Treatment is supportive

<!-- PAGE=? -->
o Oxygen

<!-- PAGE=? -->
o ventilation as necessary

<!-- PAGE=? -->
2 x age (years) + 9 = weight in kilograms

<!-- PAGE=? -->
1 10 ceutimnetel' mark at the Age lips

<!-- PAGE=? -->
o lasix to reduce lung water

<!-- PAGE=? -->
o aggressive nutritional support to overcome the increased WOB

<!-- PAGE=? -->
Croup, Post-extubation

<!-- PAGE=? -->
The reported incidence of perioperative postintubation croup in children ranges from 0.1 to 1%.

<!-- PAGE=? -->
Risk Factors:

<!-- PAGE=? -->
 Too large an ETT (no leak at > 25 cm H2O pressure)

<!-- PAGE=? -->
 Change in patient position during procedure

<!-- PAGE=? -->
 Patient position other than supine

<!-- PAGE=? -->
 Repeated attempts at intubation

<!-- PAGE=? -->
 Traumatic intubation,

<!-- PAGE=? -->
 Patient age between 1 & 4 years,

<!-- PAGE=? -->
 Duration of surgery greater than 1 hour,

<!-- PAGE=? -->
 Coughing on the ETT &

<!-- PAGE=? -->
 Previous history of croup.

<!-- PAGE=? -->
Concurrent URTI has been variously reported both to be a risk factor & to be unrelated.

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 humidified mist

<!-- PAGE=? -->
 nebulized racemic epinephrine - 0.5 ml of 2.25% solution diluted in 3-5 ml of NS over 5-10 minutes

<!-- PAGE=? -->
 dexamethasone administered iv or by nebulizer.

<!-- PAGE=? -->
 The rationale for these treatments is drawn primarily from experience with the treatment of infectious croup in children.

<!-- PAGE=? -->
 It is obvious that these two types of croup are not identical processes & efficacy of any of these interventions for the treatment of postintubation croup has not been proven in a controlled trial.

<!-- PAGE=? -->
 Studies examining the effect of dexamethosone given prior to extuabtion in patients who have had prolonged intubation are contradictory some support the use of dexamethasone to reduce stridor and others do not.

<!-- PAGE=? -->
Cote (p. 251)

<!-- PAGE=? -->
Cyanotic Heart Disease

<!-- PAGE=? -->
INDIVIDUAL LESIONS

<!-- PAGE=? -->
 Abnormalities resulting in R to L shunt, decreased pulmonary blood flow and hypoxemia:

<!-- PAGE=? -->
o Tetralogy of Fallot (TOF)

<!-- PAGE=? -->
o Tricuspid Atresia

<!-- PAGE=? -->
o Ebstein's Anomaly

<!-- PAGE=? -->
o Eisenmenger Syndrome

<!-- PAGE=? -->
 Abnormalities resulting in mixing of pulmonary and systemic circulations

<!-- PAGE=? -->
o Transposition of the Great Arteries (TGA)

<!-- PAGE=? -->
o Truncus Arteriosus

<!-- PAGE=? -->
o Anomalous Pulmonary Venous Return (Partial or Total)

<!-- PAGE=? -->
o Hypoplastic Left Heart Syndrome

<!-- PAGE=? -->
 TOF

<!-- PAGE=? -->
o Most common cyanotic CHD in infancy

<!-- PAGE=? -->
 5-10% of all CHD, 1 in 2000 live births

<!-- PAGE=? -->
o Defect : large VSD, RVOT obstruction, overriding aorta, RVH

<!-- PAGE=? -->
o Other abnormalities : ASD (pentad), right aortic arch, coronary arteries abnormal

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
Artery

<!-- PAGE=? -->
Pulmonary Slanosis

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Atrium

<!-- PAGE=? -->
Ovortidlng Aorta

<!-- PAGE=? -->
Left

<!-- PAGE=? -->
Atrium

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Lelt

<!-- PAGE=? -->
Ventricle

<!-- PAGE=? -->
Ventricle

<!-- PAGE=? -->
1097 HcanPolnt

<!-- PAGE=? -->
o Consequences :

<!-- PAGE=? -->
 R → L shunt which depends on the severity of RVOT obstruction

<!-- PAGE=? -->
 RVOT obstruction is restrictive, VSD is nonrestrictive → the changes in SVR determine the degree the shunting, decreased SVR causes an increase in shunt

<!-- PAGE=? -->
o Clinical presentation / Complications :

<!-- PAGE=? -->
 Hypoxic spells (TET spells) in infancy

<!-- PAGE=? -->
 Sudden hypoxia/acidosis associated with infundibular spasm or decreased SVR

<!-- PAGE=? -->
 Most commonly seen during crying or exercise

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
 B-Blockers (spasm)

<!-- PAGE=? -->
 Fluids

<!-- PAGE=? -->
 phenylephrine (inc SVR)

<!-- PAGE=? -->
 Cyanosis and SOB, decreased exercise tolerance in adults

<!-- PAGE=? -->
 Polycythemia and thrombosis

<!-- PAGE=? -->
 CVA and brain abscess

<!-- PAGE=? -->
 Infective Endocarditis

<!-- PAGE=? -->
o Exam : cyanosis, clubbing, palpate peripheral pulses, systolic thrill (turbulent flow across RVOT), single S2 (no P2), SEM at LSB (RVOT obstruction)

<!-- PAGE=? -->
o Investiagations :

<!-- PAGE=? -->
 CBC - polycythemia

<!-- PAGE=? -->
 ABG - PaO2 < 50, PaCO2 and pH normal

<!-- PAGE=? -->
 EKG : RAD, RVH, RBBB

<!-- PAGE=? -->
 CXR : boot-shaped heart / cardiomegaly, decreased lung markings

<!-- PAGE=? -->
 ECHO : establish dx, associated abnormalities, level and severity of RVOT obstruction, location and size of VSD, size and function of RV, Doppler assessment of shunt

<!-- PAGE=? -->
 Heart catheterization : confirms diagnosis, look for residual lesions, coronary anatomy, intervention for dilatation / stent of pulmonary arteries

<!-- PAGE=? -->
o Treatment :

<!-- PAGE=? -->
 Palliative shunts prior to correction

<!-- PAGE=? -->
 Goal : increase pulmonary blood flow by anastomosing systemic artery to pulmonary arter

<!-- PAGE=? -->
 Waterston: side: side, ascending aorta to RPA

<!-- PAGE=? -->
 Potts: side: side, descending aorta to LPA

<!-- PAGE=? -->
 BT: end: side, subclavian artery to pulmonary artery

<!-- PAGE=? -->
 Complications: pulm htn, LV vol overload, distortion pulm vasculature

<!-- PAGE=? -->
 Corrective surgery

<!-- PAGE=? -->
 Closure of VSD and relief of RVOT obstruction

<!-- PAGE=? -->
 Generally done at a young age

<!-- PAGE=? -->
 Pulmonic regurgitation is a complication of procedure

<!-- PAGE=? -->
o Hemodynamic goals :

<!-- PAGE=? -->
 maintain preload (clear fluids and iv hydration)

<!-- PAGE=? -->
 maintain SVR

<!-- PAGE=? -->
 avoid increased PVR (although main impedance to PBF is RVOT)

<!-- PAGE=? -->
 decrease contractility (to relieve infundibular spasm)

<!-- PAGE=? -->
o SBE prophylaxis as per guidelines

<!-- PAGE=? -->
o Post TOF repair :

<!-- PAGE=? -->
 A fib / flutter

<!-- PAGE=? -->
 Ventricular arrythmias (in 40-50% on Holter)

<!-- PAGE=? -->
 PV regurgitation 2 nd to RVOT repair +/- stenosis, RV dysfunction, TR, aortic regurgitation

<!-- PAGE=? -->
 Aneurysms at the site of repair

<!-- PAGE=? -->
 Residual / recurrent RVOTO

<!-- PAGE=? -->
 RBBB is common, complete heart block is rare, PVCs common in asymptomatic patients, symptomatic VT rare, atrial arrhythmias common and relate to poor hemodynamics, small incidence of late sudden death

<!-- PAGE=? -->
 Aortic regurgitation may occur (usually mild)

<!-- PAGE=? -->
 Indications for intervention : significant RVOT or PA branch stenosis, AI, residual VSD, significant pulmonary regurgitation (with symptoms and RV dilation)

<!-- PAGE=? -->
 Tricuspid Atresia

<!-- PAGE=? -->
o Characterized by small RV, large LV, marked decreased PBF and hypoxemia

<!-- PAGE=? -->
o 1-3% of CHD

<!-- PAGE=? -->
o Associated lesions : ASD (or foramen ovale), PDA or VSD (to allow PBF)

<!-- PAGE=? -->
o Hypoplastic right heart

<!-- PAGE=? -->
o PDA dependent lesion → PGE1 needed

<!-- PAGE=? -->
o Palliation : BT shunt

<!-- PAGE=? -->
o Definitive repair : primary repair or modified Fontan (RA to PA anastomosis), or heart transplant

<!-- PAGE=? -->
o Post-repair goals : maintain low PVR and LAP, high systemic venous pressure

<!-- PAGE=? -->
 Ebstein's Anomaly

<!-- PAGE=? -->
o Apical displacement & dysplasia of TV (congenital downward displacement of the tricuspid valve into the right ventricle)

<!-- PAGE=? -->
o Wide spectrum of pathologic anatomy which determines onset / severity of symptoms

<!-- PAGE=? -->
 Can produce:

<!-- PAGE=? -->
 RV inflow obstruction

<!-- PAGE=? -->
 RV dysfunction

<!-- PAGE=? -->
 TR

<!-- PAGE=? -->
 Altered PBF

<!-- PAGE=? -->
 LV abnormalities

<!-- PAGE=? -->
o Associations:

<!-- PAGE=? -->
 ASD or PFO (75%)

<!-- PAGE=? -->
 WPW

<!-- PAGE=? -->
o Presentation

<!-- PAGE=? -->
 SOB, fatigue (reduced exercise capacity)

<!-- PAGE=? -->
 Cyanosis at rest and / or exercise (R → L shunt at atrial level)

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
Normal

<!-- PAGE=? -->
 CHF (tricuspid stenosis / regurgitation / small RV)

<!-- PAGE=? -->
 Tachyarrhythmias (25%)

<!-- PAGE=? -->
o CXR : marked cardiomegaly, right atrial enlargement

<!-- PAGE=? -->
o ECG : 1 st  degree AV block common, 20% have WPW

<!-- PAGE=? -->
o ECHO : severity of tricuspid valve displacement / dysplasia / regurgitation, RV size, associated lesions, LV function

<!-- PAGE=? -->
o Indications for intervention : decreased exercise tolerance, heart failure, increasing cyanosis, arrhythmia

<!-- PAGE=? -->
o Interventions : surgery for tricuspid valve repair / replacement, RFA for arrhythmias / pre-excitation

<!-- PAGE=? -->
o Endocarditis prophylaxis as per guidelines

<!-- PAGE=? -->
o Post-treatment : usually symptomatic improvement, TVR → often re-operation / thrombotic complications, ongoing arrhythmia problems, risk of sudden death remains, anticoagulants for atrial arrhythmias and prosthetic tricuspid valve

<!-- PAGE=? -->
 Eisengmenger Syndrome

<!-- PAGE=? -->
o Reversal of L-R shunt caused by increased PVR to a level that equals or exceeds SVR

<!-- PAGE=? -->
 Occurs in approx 50% of pts with untreated VSD, 10% of pts with untreated ASD

<!-- PAGE=? -->
 ASD/VSD murmur disappears when Eisenmenger's develops

<!-- PAGE=? -->
o Signs and Symptoms

<!-- PAGE=? -->
 Cyanosis and decreased exercise tolerance

<!-- PAGE=? -->
 Palpitations and development of Afib/flutter

<!-- PAGE=? -->
 Erythrocytosis and thrombosis

<!-- PAGE=? -->
 Hemoptysis or pulmonary hemorrhage

<!-- PAGE=? -->
 Syncope, CVA, sudden death

<!-- PAGE=? -->
o Treatment

<!-- PAGE=? -->
 Irreversible increased PVR contraindicates surgical correction of original defect

<!-- PAGE=? -->
 Treatment of pulmonary htn

<!-- PAGE=? -->
 Phlebotomy for hyperviscosity

<!-- PAGE=? -->
 Combined heart lung transplant, or lung transplant and correction of cardiac defect

<!-- PAGE=? -->
o Anesthetic Management

<!-- PAGE=? -->
 Avoid:

<!-- PAGE=? -->
 Decreasing SVR (may require NE/phenylephine)

<!-- PAGE=? -->
 Increasing PVR (limit PAWP, avoid PEEP, early extubation, avoid hypoxia/hypercarbia/acidosis)

<!-- PAGE=? -->
 Hypovolemia (phlebotomy with isovol replacement may be beneficial)

<!-- PAGE=? -->
 Paradoxical emboli (ensure de-airing of iv's)

<!-- PAGE=? -->
 TGA

<!-- PAGE=? -->
o D-TGA :

<!-- PAGE=? -->
 More common

<!-- PAGE=? -->
 Aorta arises from RV, PA from LV

<!-- PAGE=? -->
Ebstein's Anomaly

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
ASD

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
Artery

<!-- PAGE=? -->
Left

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Ventricle

<!-- PAGE=? -->
Ventricle

<!-- PAGE=? -->
 Parallel circulations requiring mixing for survival: ASD, VSD, PDA

<!-- PAGE=? -->
 Shunt-dependent for survival

<!-- PAGE=? -->
 Atrial septostomy prior to repair otherwise PGE1-dependent

<!-- PAGE=? -->
 Early repairs:

<!-- PAGE=? -->
 Intra-atrial venous switch (baffling)

<!-- PAGE=? -->
 Mustard or Senning

<!-- PAGE=? -->
 Morph RV functions as LV, with early CHF

<!-- PAGE=? -->
 Arrythmias common

<!-- PAGE=? -->
 Recent technique (last 10-15 yrs):

<!-- PAGE=? -->
 Arterial switch

<!-- PAGE=? -->
 Restores normal morphologic & functional pattern

<!-- PAGE=? -->
o L-TGA (-congenitally corrected‖)

<!-- PAGE=? -->
 Atrio-ventricular switch, rare lesion

<!-- PAGE=? -->
 Morphologic RV functions as anatomical LV & vice-versa

<!-- PAGE=? -->
 Can survive long-term undetected

<!-- PAGE=? -->
 Cyanosis with VSD and pulmonary stenosis, PVD if VSD and no pulmonary stenosis, systemic ventricular failure with systemic AV valve regurgitation, referral before systemic ventricular dysfunction

<!-- PAGE=? -->
 Spontaneous CHB (2% per year) and post surgical heart block, endocardial pacing in morphologic LV, atrial arrhythmias common, ventricular arrhythmias with systemic ventricular dysfunction, epicardial pacing if potential for paradoxical embolus

<!-- PAGE=? -->
 Systemic RV → early CHF (= LVF)

<!-- PAGE=? -->
 Associations:

<!-- PAGE=? -->
 AV block

<!-- PAGE=? -->
 VSD

<!-- PAGE=? -->
 Subvalvular PS

<!-- PAGE=? -->
 MR (morphologic TV)

<!-- PAGE=? -->
 CXR : cardiomegaly

<!-- PAGE=? -->
 EKG : rhythm (heart block, atrial / ventricular arrhythmias)

<!-- PAGE=? -->
 ECHO : size & function of systemic ventricle, morphology of left AV valve, associated lesions

<!-- PAGE=? -->
 Indications for intervention : moderate systemic AV valve regurgitation, significant lesions, pacemaker for complete HB with symptoms / profound bradycardia / chronotropic incompetence

<!-- PAGE=? -->
Arterial Switch

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
Pulmonary Artery

<!-- PAGE=? -->
 Interventions : valve replacement, pulmonary artery banding, -double-switch‖ (controversial in adults)

<!-- PAGE=? -->
 Endocarditis prophylaxis in ALL

<!-- PAGE=? -->
 Post-treatment outcome is good if left AV valve replacement before systemic ventricular function deteriorates, atrial arrhythmias common

<!-- PAGE=? -->
 Truncus Arteriosus

<!-- PAGE=? -->
RPA

<!-- PAGE=? -->
LPA

<!-- PAGE=? -->
AO

<!-- PAGE=? -->
AO

<!-- PAGE=? -->
PA

<!-- PAGE=? -->
TA

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
TA

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
MAPCAs

<!-- PAGE=? -->
APA

<!-- PAGE=? -->
LPA

<!-- PAGE=? -->
AO

<!-- PAGE=? -->
AO

<!-- PAGE=? -->
TA

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
TA

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
o There is a single semilunar valve and annulus with a common outflow trunk arising from the ventricles

<!-- PAGE=? -->
o A large and malaligned VSD is also part of the complex

<!-- PAGE=? -->
o There are 4 types of truncus arteriosus

<!-- PAGE=? -->
o May be associated with DiGeorge syndrome

<!-- PAGE=? -->
o Because of the unrestricted VSD and the origin of the pulmonary arteries and the aorta from a single trunk, blood flow to the lungs and the systemic circulation is determined by the relative resistances in these circulations

<!-- PAGE=? -->
o In truncus arteriosus type I, II, and III w/o pulmonary artery stenosis → decreased PVR after birth → increased PBF→ maintains arterial oxygen saturation 75-80% → may reach levels of 85-90% d/t increase in pulmonary to systemic blood flow ratio

<!-- PAGE=? -->
o If  LV volume overload happens rapidly, patient will develop CHF within the first week of life

<!-- PAGE=? -->
o Associations

<!-- PAGE=? -->
 Truncal valve insufficiency / stenosis

<!-- PAGE=? -->
 Pulmonary artery stenosis

<!-- PAGE=? -->
 Aortic arch anomalies

<!-- PAGE=? -->
o Clinical Presentation

<!-- PAGE=? -->
 Mild cyanosis right after birth

<!-- PAGE=? -->
 Cyanosis deceases as pulmonary blood flow increases (type I and II)

<!-- PAGE=? -->
 Signs of HF become significant if the PBF is too great

<!-- PAGE=? -->
 Moderate to severe cyanosis if there is stenosis of pulmonary ostia or pulmonary arteries (type III)

<!-- PAGE=? -->
o CXR : cardiomegaly, pulmonary vascular markings

<!-- PAGE=? -->
o ECG : LVH / RVH

<!-- PAGE=? -->
o ECHO : diagnostic

<!-- PAGE=? -->
o Cardiac catheterization : angiography can reveal the precise origin of pulmonary arteries, severity of obstruction of pulmonary ostia or pulmonary arteries, and coronary anomalies

<!-- PAGE=? -->
o Surgical management :

<!-- PAGE=? -->
 palliative procedure is PA banding

<!-- PAGE=? -->
 surgical repair = close VSD, divide the truncus using the truncal valve as the aortic valve, and place a conduit with or without a valve from the RV to the PA

<!-- PAGE=? -->
 Total Anomalous Pulmonary Venous Return

<!-- PAGE=? -->
Total Anomalous Pulmonary Venous Return

<!-- PAGE=? -->
AlI

<!-- PAGE=? -->
pulmonary

<!-- PAGE=? -->
veins connect

<!-- PAGE=? -->
t0 superior

<!-- PAGE=? -->
vena cava

<!-- PAGE=? -->
PA

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
Mixed blood

<!-- PAGE=? -->
AO

<!-- PAGE=? -->
Pulmona y arlery

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
LA

<!-- PAGE=? -->
Opening

<!-- PAGE=? -->
between

<!-- PAGE=? -->
atria

<!-- PAGE=? -->
four

<!-- PAGE=? -->
o Pulmonary veins connect to the systemic venous system instead of to the left atrium

<!-- PAGE=? -->
o R→L communication via ASD

<!-- PAGE=? -->
o Classified into 4 types: supracardiac (45%), cardiac (25%), infracardiac (25%), and mixed (5%)

<!-- PAGE=? -->
 In the supracardiac type, the common pulmonary vein confluence drains into the right atrium via left innominate vein or into the SVC

<!-- PAGE=? -->
 In the cardiac configuration, the common pulmonary vein connects to the coronary sinus or directly with the right atrium

<!-- PAGE=? -->
 In the infracardiac (subdiaphragmatic) pattern, the common pulmonary vein drains through diaphragm into the portal vein, ductus venosus, hepatic vein, or IVC

<!-- PAGE=? -->
 The mixed type is a combination of the other types

<!-- PAGE=? -->
o Clinical Presentations

<!-- PAGE=? -->
 Differ depending on the degree of pulmonary vein obstruction

<!-- PAGE=? -->
 If obstructed, present with profound cyanosis, severe respiratory distress, and failure to thrive

<!-- PAGE=? -->
 Without pulmonary venous obstruction will have mild cyanosis, CHF, frequent pulmonary infection, and growth retardation

<!-- PAGE=? -->
o EKG : RVH

<!-- PAGE=? -->
o CXR : normal or slightly enlarged heart silhouette and pulmonary edema

<!-- PAGE=? -->
o ECHO : delineates the anatomic connection of the pulmonary veins and the type of TAPVR

<!-- PAGE=? -->
o Surgical management :

<!-- PAGE=? -->
 balloon atrial septostomy may be done if immediate surgery cannot be performed

<!-- PAGE=? -->
 corrective surgery is necessary for all patients with TAPVR (with CPB)

<!-- PAGE=? -->
 Pulmonary Atresia With Intact Ventricular Septum

<!-- PAGE=? -->
o Prevalence is 4.1 per 100, 000 live births

<!-- PAGE=? -->
o In the usual form of pulmonary atresia and intact ventricular septum, the pulmonary valve is atretic with a diaphragm-like membrane; the infundibulum is also atretic in some infants

<!-- PAGE=? -->
o No direct communication b/t RV & PA therefore pulmonary blood flow is entirely PDA dependent and VR must flow from RA to LA via an ASD or PFO

<!-- PAGE=? -->
o PDA closure results in reduced pulmonary blood flow and severe cyanosis

<!-- PAGE=? -->
o

<!-- PAGE=? -->
TR is common d/t high pressure in the RV → high

<!-- PAGE=? -->
RV pressure also decompressed retrograde through the dilated coronary sinus and its microcirculation into LCA or RCA

<!-- PAGE=? -->
 If proximal coronary artery obstruction is present, coronary circulation is perfused by desaturated blood causing myocardial ischemia

<!-- PAGE=? -->
o Clinical Presentations

<!-- PAGE=? -->
 Cyanosis usually apparent within hours of birth d/t PDA closure

<!-- PAGE=? -->
 Severe tachypnea, dyspnea, and hypoxia

<!-- PAGE=? -->
 Tricuspid regurgitation murmur may be audible

<!-- PAGE=? -->
 Progressive hypoxia and metabolic acidosis indicate poor prognosis

<!-- PAGE=? -->
o ECG : commonly shows sinus rhythm with LVH and right atrial enlargement, ST-T abnormalities consistent with subendocardial ischemia frequently seen

<!-- PAGE=? -->
o CXR : enlarged heart and reduced pulmonary vascular markings

<!-- PAGE=? -->
o ECHO : atretic pulmonary valve with no blood flow through it, and a right-to-left interatrial shunt by color Doppler imaging

<!-- PAGE=? -->
o Cardiac catheterization : required in infants with severe hypoplastic right ventricle and anticipated ventriculocoronary artery connections

<!-- PAGE=? -->
o Management :

<!-- PAGE=? -->
 PGE1 to keep PDA open

<!-- PAGE=? -->
 balloon atrial septostomy may be performed to improve the right-to-left atrial shunt if RV sinusoids are confirmed

<!-- PAGE=? -->
 The goals of surgical procedures are to restore ‗‗normal'' biventricular circulation and pulmonary blood flow

<!-- PAGE=? -->
 Initial operation is directed toward establishing pulmonary blood flow with modified BlalockTaussig shunt and promoting normal RV development by relieving RVOTO with a pulmonary valvotomy or transannular path

<!-- PAGE=? -->
 Patients who have severe TR, right ventricle-dependent coronary circulation, or do not have appreciable right ventricular development at follow-up should be tracked to a Fontan procedure or cardiac transplantation

<!-- PAGE=? -->
SURGICAL CIRCULATIONS

<!-- PAGE=? -->
o BT shunt :

<!-- PAGE=? -->
 replaces inherently -twitchy‖ PDA with stable non-restrictive systemic-pulmonary shunt

<!-- PAGE=? -->
 used in lesions with limited pulmonary blood flow (Step 1 of Fontan circulation)

<!-- PAGE=? -->
 Pulmonary blood flow depends on PVR / SVR ratio

<!-- PAGE=? -->
 The high PVR in the neonatal/infant stages, this is useful to limit Qp:Qs

<!-- PAGE=? -->
Atrial

<!-- PAGE=? -->
Patent

<!-- PAGE=? -->
Septal

<!-- PAGE=? -->
Ductus

<!-- PAGE=? -->
Arteriosus

<!-- PAGE=? -->
Absent

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Small

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Ventricle

<!-- PAGE=? -->
 Shunt becomes restrictive as kids grow and they tend to outgrow them by age 3 years (again resulting in decreased PBF)

<!-- PAGE=? -->
o Bi-directional Glenn (around 6 months) :

<!-- PAGE=? -->
 SVC anastomosed with pulmonary trunk which has been detached from pulmonary outflow tract which is closed (Step 2 of Fontan circulation)

<!-- PAGE=? -->
 i.e. SVC flows into PA

<!-- PAGE=? -->
 IVC flows into RA and shunts into LA through ASD (required)

<!-- PAGE=? -->
 Requires adequate preload and pressure gradient with CVP > LAP

<!-- PAGE=? -->
 Kids will outgrow the Glenn as the SVC flow ratio decreases (SVC flow high in infancy secondary to large head) will start to desaturate

<!-- PAGE=? -->
 Glenn is required prior to Fontan, because it gives time for natural improvement of ventricular diastolic function

<!-- PAGE=? -->
 Glenn (plus ligation of BT shunt) reduces the volume load to the ventricle since now it only pumps to the systemic circulation, so whatever is pumped is part of systemic cardiac output, BUT cyanosis is not improved since IVC de-oxygenated blood returns to the RA and is directed (via PFO) to LA, then LV (i.e. right-to-left shunt)

<!-- PAGE=? -->
Modified Blalock-Taussig

<!-- PAGE=? -->
Bl-dlrectlonal Glenn Shunt

<!-- PAGE=? -->
"BT Shunt"

<!-- PAGE=? -->
Temporary surgical procedure as an Intermediate

<!-- PAGE=? -->
procedure tor hearts wlth only one usable ventricle

<!-- PAGE=? -->
Aortic Branch

<!-- PAGE=? -->
(In thls illustration Tricuspid Atresla)

<!-- PAGE=? -->
superior

<!-- PAGE=? -->
vena cava

<!-- PAGE=? -->
shunt

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
removed

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
artery

<!-- PAGE=? -->
(to lungs)

<!-- PAGE=? -->
pulmonary

<!-- PAGE=? -->
artery

<!-- PAGE=? -->
divided

<!-- PAGE=? -->
Ao

<!-- PAGE=? -->
RA.

<!-- PAGE=? -->
This procedure

<!-- PAGE=? -->
LV

<!-- PAGE=? -->
diverts blood from

<!-- PAGE=? -->
an aortic branch

<!-- PAGE=? -->
to the pulmonary

<!-- PAGE=? -->
artery allowing blood

<!-- PAGE=? -->
to flow to the Iungs

<!-- PAGE=? -->
to receive oxygen.

<!-- PAGE=? -->
0 2004

<!-- PAGE=? -->
permitted

<!-- PAGE=? -->
o Fontan (variable, but typically at 3 years of age) :

<!-- PAGE=? -->
 Univentricular circulation

<!-- PAGE=? -->
 Vena cava blood directly feeds the pulmonary arteries and pulmonary venous blood enters the single left ventricle via the LA

<!-- PAGE=? -->
 Repair of TOF or hypoplastic right heart

<!-- PAGE=? -->
 PBF / CO dependence on pressure gradient b/t CVP and LAP

<!-- PAGE=? -->
 Long-term results in PHTN due to elevated pulmonary perfusion pressures

<!-- PAGE=? -->
 Long-term results in hepatic congestion / coagulopathy and protein losing enteropathy

<!-- PAGE=? -->
 Must have normal lungs and normal pulmonary vascular resistance as well as a normal heart with normal LA pressures (i.e. no regurgitant or stenotic lesions)

<!-- PAGE=? -->
 Preload: high

<!-- PAGE=? -->
 Afterload: avoid PPV and high SVR

<!-- PAGE=? -->
 Fenestrations can be made between the IVC and the single atrium - acts as pop-off valve for mixed venous blood to by-pass lungs (if high PVR or diastolic dysfunction) to maintain cardiac output at the expense of some cyanosis; usually put in with Fontan surgery to help in the post-operative period while PVR and diastolic function improve

<!-- PAGE=? -->
 If cyanosis remains significant, the fenestration can be closed.

<!-- PAGE=? -->
Fontan Procedure

<!-- PAGE=? -->
First stage: Bi-directional Glenn:

<!-- PAGE=? -->
4 graf re-routes blcod flow to bypass the right

<!-- PAGE=? -->
atrium. Blood flows

<!-- PAGE=? -->
the superlor vena cava

<!-- PAGE=? -->
Supenor

<!-- PAGE=? -->
dngsto

<!-- PAGE=? -->
to the pulmonary artery and then to the

<!-- PAGE=? -->
vena cava

<!-- PAGE=? -->
lungs

<!-- PAGE=? -->
cick up oxygen.

<!-- PAGE=? -->
Sccond stage: Fontan:

<!-- PAGE=? -->
4 graft and an internal baffie

<!-- PAGE=? -->
(wall) re-route blood flow from

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
the inferior vena cava to the

<!-- PAGE=? -->
artery

<!-- PAGE=? -->
pulmonaly arery

<!-- PAGE=? -->
Right atnum

<!-- PAGE=? -->
Baffle

<!-- PAGE=? -->
Infenor vena cava

<!-- PAGE=? -->
20Û4

<!-- PAGE=? -->
from

<!-- PAGE=? -->
o Norwood : univentricular circulation, repair for hypoplastic left heart, essentially a Fontan circulation with vena cava blood directly feeding the pulmonary arteries and pulmonary venous blood entering the single right ventricle through the RA

<!-- PAGE=? -->
 PBF / CO dependence on preload

<!-- PAGE=? -->
 Long-term results in pHTN due to elevated perfusion pressures

<!-- PAGE=? -->
 Long-term results in hepatic congestion / coagulopathy

<!-- PAGE=? -->
 Long-term results in RVH and RV failure, as RV unable to sustain systemic pressures

<!-- PAGE=? -->
Norwood Procedure

<!-- PAGE=? -->
Tne Dase of the pulmonary artery is

<!-- PAGE=? -->
attacheg to the aorta

<!-- PAGE=? -->
Repair of

<!-- PAGE=? -->
Pulmonary

<!-- PAGE=? -->
aitery base

<!-- PAGE=? -->
Rahwzx

<!-- PAGE=? -->
Modified

<!-- PAGE=? -->
theleit side of the

<!-- PAGE=? -->
Blood traves

<!-- PAGE=? -->
Blalock-Taussig

<!-- PAGE=? -->
through the

<!-- PAGE=? -->
artery to the

<!-- PAGE=? -->
shunt

<!-- PAGE=? -->
aorta ano te

<!-- PAGE=? -->
rest of

<!-- PAGE=? -->
bloco tavels through the nev shunt

<!-- PAGE=? -->
to the pulmonary arery which is

<!-- PAGE=? -->
2ÛÛ4

<!-- PAGE=? -->
HeartCenterOnllne com

<!-- PAGE=? -->
connected to thelungs

<!-- PAGE=? -->
o Mustard / Senning : most patients are now adults as operation replaced by arterial switch in mid 1980s → essentially an intra-atrial baffle diverting blood flow from vena cava to LV which is then pumped to pulmonary circulation while pulmonary vein blood is diverted to RV which is then pumped into the anatomic aorta and to the systemic circulation

<!-- PAGE=? -->
Fetal Hgb

<!-- PAGE=? -->
 low concentration of 2,3-diphosphoglycerate

<!-- PAGE=? -->
o oxyhemoglobin dissociation curve shifted to the left

<!-- PAGE=? -->
 P50 of Hb F is 20 mmHg compared to 27 mmHg for HbA

<!-- PAGE=? -->
o high affinity for oxygen , which facilitates transfer of oxygen from the placenta to the fetus

<!-- PAGE=? -->
o SaO2 of 80% with a umbilical vein PO2 of 28 mm Hg

<!-- PAGE=? -->
 HgF disappears by 4 to 6 months of age

<!-- PAGE=? -->
o 70-90% of Hb present at birth is HbF

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Non-hemorrhagic Volume Depletion

<!-- PAGE=? -->
 Hemodynamic issues with this include: intra-atrial baffle obstruction, significant late morbidity / mortality from arrhythmia / baffle obstruction / RV failure with risk of sudden death

<!-- PAGE=? -->
 Progressive loss of sinus rhythm, slow junctional rhythm may rarely require pacing, tachyarrhythmias (predominantly a-flutter) may be related to high incidence of late sudden death

<!-- PAGE=? -->
 Endocarditis prophylaxis required

<!-- PAGE=? -->
 Low SVR to reduce RV workload but maintain diastolic for coronary perfusion

<!-- PAGE=? -->
Intra-atrial baffle

<!-- PAGE=? -->
(mustard or Senning procedure)

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
Pulmonary Artery

<!-- PAGE=? -->
Baffle

<!-- PAGE=? -->
Anterior Fontanel

<!-- PAGE=? -->
N

<!-- PAGE=? -->
↓

<!-- PAGE=? -->
↓↓

<!-- PAGE=? -->
Skin

<!-- PAGE=? -->
N

<!-- PAGE=? -->
Cool

<!-- PAGE=? -->
Acrocyanosis

<!-- PAGE=? -->
U/O

<!-- PAGE=? -->
Mildly ↓

<!-- PAGE=? -->
↓↓

<!-- PAGE=? -->
Anuria

<!-- PAGE=? -->
Volume Required

<!-- PAGE=? -->
25-50 cc/kg

<!-- PAGE=? -->
50-100 cc/kg

<!-- PAGE=? -->
100-150 cc/kg

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
 A number of medications may be administered rectally for induction/premedication of anesthesia

<!-- PAGE=? -->
o Methohexital

<!-- PAGE=? -->
o Thiopental

<!-- PAGE=? -->
o Ketamine

<!-- PAGE=? -->
o midazolam

<!-- PAGE=? -->
 The main advantage of this approach is that the child falls asleep in the parent's arms or, as is the case with midazolam, separates atraumatically from the parents

<!-- PAGE=? -->
 Midazolam, 0.5 mg/kg administered orally 30 minutes before induction of anesthesia, provides reliable sedation and anxiolysis in children without producing delayed awakening

<!-- PAGE=? -->
 Transmucosal (sublingual) administration of midazolam> is as effective as, and better accepted than, intranasal midazolam as preoperative medication for children

<!-- PAGE=? -->
NEC

<!-- PAGE=? -->
 NEC is a serious condition with mortality approaching 55%

<!-- PAGE=? -->
 Incidence varies from 1.1 - 2.4 per 1000 live births

<!-- PAGE=? -->
 Classically occurring in premies and infants with low birth weight

<!-- PAGE=? -->
o Usually weigh < 2500 g & less than 38 weeks' gestational age at birth

<!-- PAGE=? -->
o Also occurs in full term infants and fed & unfed infants, in single patients or as a nursery epidemic.

<!-- PAGE=? -->
 Occurs after intestinal mucosal injury from ischemia caused by reduced mesenteric blood flow

<!-- PAGE=? -->
 Clinical presentation:

<!-- PAGE=? -->
o Typical infant with NEC is a preterm baby of < 34 weeks' GA & weighing 2000g.

<!-- PAGE=? -->
o Prenatal complications associated with NEC: PROM, placenta previa, maternal sepsis, toxemia of pregnancy,

<!-- PAGE=? -->
o Infants with NEC:

<!-- PAGE=? -->
 Acidotic, hypoxic, hypothermic, shock

<!-- PAGE=? -->
o GI signs appear between 1 st & 10 th days of life in > 90% of babies.

<!-- PAGE=? -->
 Abdominal distension, retained gastric secretions, vomiting, bloody or mucoid diarrhea & occult blood loss in stools.

<!-- PAGE=? -->
 Bowel necrosis & perforation follow  sepsis, thermal instability, lethargy, metabolic acidosis, jaundice, DIC & generalized bleeding.

<!-- PAGE=? -->
 Risk of thrombocytopenia, prolonged INR & PTT.

<!-- PAGE=? -->
o AXR  pathognomonic signs of NEC

<!-- PAGE=? -->
 Dilated, fixed loops of bowel, pneumatosis, gas in the portal venous system & pneumoperitoneum.

<!-- PAGE=? -->
Neonatal Pharmacology

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Total-body water content is significantly higher in premature than term infants and in term infants than 2year-olds

<!-- PAGE=? -->
 These alterations in body composition have several clinical implications for neonates:

<!-- PAGE=? -->
o a drug that is water soluble has a larger volume of distribution and usually requires a larger initial dose to achieve the desired blood level (e.g., most antibiotics, succinylcholine)

<!-- PAGE=? -->
o because neonates have less fat, a drug that depends on redistribution into fat for termination of its action will have a longer clinical effect (e.g., thiopental)

<!-- PAGE=? -->
o a drug that redistributes into muscle may have a longer clinical effect (e.g., fentanyl, for which, however, saturation of muscle tissue has not been demonstrated)

<!-- PAGE=? -->
 In addition to these very basic concepts, other important factors play a role in a neonate's response to medications:

<!-- PAGE=? -->
o delayed excretion because of the larger volume of distribution

<!-- PAGE=? -->
o immature hepatic and renal function and decreased pseudocholinesterase

<!-- PAGE=? -->
o altered drug excretion caused by lower protein binding

<!-- PAGE=? -->
o reduced GFR

<!-- PAGE=? -->
o MetHb reductase levels do not reach adult levels until 3 mos

<!-- PAGE=? -->
 Inc. risk of methemaglobinemia

<!-- PAGE=? -->
Neonatal Physiology

<!-- PAGE=? -->
first 28 day of life or 44 weeks PCA

<!-- PAGE=? -->
in press as: Simon Ford, Jennifer Calvert, Adaptation for life: a review of neonatal physiology, Anaesthesia and Intensive Care Medicine (2008), doi: 0. 0 6/ j.mpaic.2008.0 .009

<!-- PAGE=? -->
Respiratory system

<!-- PAGE=? -->
 Terminal bronchioles are present at 16 weeks

<!-- PAGE=? -->
 Type I and II pneumocytes are distinguishable by 20-22 weeks

<!-- PAGE=? -->
o surfactant presents after 24 weeks - watershed time for pulmonary gas exchange

<!-- PAGE=? -->
 can be increased after 24 weeks by giving β-methasone to the mother

<!-- PAGE=? -->
 Alveolar development continues after birth, increasing five-fold in number to 300 million by 5-6 years of age

<!-- PAGE=? -->
The first breath

<!-- PAGE=? -->
 Fluid is compressed from the fetal lung  - starting to establish lung volume

<!-- PAGE=? -->
 The coordinated first breath is initiated centrally, secondary to arousal from sound, temperature changes and touch at delivery

<!-- PAGE=? -->
 Central chemoreceptors stimulated by hypoxia and hypercarbia further increase respiratory drive

<!-- PAGE=? -->
 The initial breaths generate high negative-inspiratory pressures (70-100 cm H2O) to facilitate lung expansion by overcoming

<!-- PAGE=? -->
o airways resistance

<!-- PAGE=? -->
o inertia of fluid in the airways

<!-- PAGE=? -->
o surface tension of the air/fluid interface in the alveolus

<!-- PAGE=? -->
 surfactant production is stimulated by

<!-- PAGE=? -->
o Alveolar distension

<!-- PAGE=? -->
o cortisol

<!-- PAGE=? -->
o epinephrine

<!-- PAGE=? -->
 Expiration is initially active, with pressures of 18-115 cm H2O generated

<!-- PAGE=? -->
o Forces amniotic fluid from the bronchi

<!-- PAGE=? -->
 Lung expansion and increased alveolar oxygen content reduce pulmonary vascular resistance, increase blood flow and initiate cardiovascular changes

<!-- PAGE=? -->
 Normalization

<!-- PAGE=? -->
o Pulmonary volumes - VT, FRC (10 mins) > PCO2 (1hr) > PO2 (1 hour) > PVR (4 days)

<!-- PAGE=? -->
 volumes first, then gases, then resistance

<!-- PAGE=? -->
Neonatal lung mechanics

<!-- PAGE=? -->
 A marked imbalance exists between chest wall rigidity and elastic recoil of neonatal lungs

<!-- PAGE=? -->
o The chest wall is highly compliant, offering little support to the lungs containing immature elastic fibres facilitating airway collapse

<!-- PAGE=? -->
 Results in a closing capacity that exceeds FRC until the age of 6

<!-- PAGE=? -->
 This is adapted for by the production of PEEP via high-resistance nasal airways and partial closure of the vocal cords

<!-- PAGE=? -->
 Inspiratory reserve volume is limited by a flatter diaphragm and more horizontal ribs

<!-- PAGE=? -->
o Inc. minute volume must be achieved by an inc. in respiratory rate

<!-- PAGE=? -->
 30-50 breathes per minute

<!-- PAGE=? -->
 respiratory fatigue is common in neonates because of the diaphragmatic and intercostal muscles lacking type 1 oxidative muscle fibres

<!-- PAGE=? -->
 Gas exchange across the alveolar membrane is immature in neonates

<!-- PAGE=? -->
o total shunt estimate of 24% of CO at birth, reducing to 10% of CO at 1 week

<!-- PAGE=? -->
 Rapid desaturation is related to

<!-- PAGE=? -->
o Reduced effective FRC (2' to PEEP and low intercostal muscle tone)

<!-- PAGE=? -->
o increased shunt fraction

<!-- PAGE=? -->
o high metabolic rate (6-8 ml of O2/kg/min)

<!-- PAGE=? -->
Control of ventilation

<!-- PAGE=? -->
 generated in the venterolateral medulla, and modulated by central chemoreceptors in response to

<!-- PAGE=? -->
o carbon dioxide

<!-- PAGE=? -->
o pH

<!-- PAGE=? -->
o oxygen content of blood

<!-- PAGE=? -->
 Peripheral chemoreceptors in the aortic and carotid bodies are functional at birth but are initially silent because of high post delivery blood oxygen content

<!-- PAGE=? -->
o Receptor adaptation occurs over 48 hours

<!-- PAGE=? -->
 response to hypoxia is characterized by an initial increase in ventilation followed by a decrease in ventilation; reverting back to a fetal response

<!-- PAGE=? -->
 Ventilatory changes to hypoxia alter with

<!-- PAGE=? -->
o neonatal temperature

<!-- PAGE=? -->
o level of arousal

<!-- PAGE=? -->
o maturity

<!-- PAGE=? -->
 The response to hypercarbia is the same as in adults, but is more rapid because of a lower resting carbon dioxide level

<!-- PAGE=? -->
 All neonates can show a periodic breathing pattern

<!-- PAGE=? -->
o apnoea of less than 5 seconds, often followed by tachypnoea

<!-- PAGE=? -->
o Premature neonates may exhibit apnoeic episodes of more than 15 seconds

<!-- PAGE=? -->
o central respiratory drive improves with maturity but may persist up to 60 weeks postconceptual age

<!-- PAGE=? -->
ABGs

<!-- PAGE=? -->
 Neontates are hypoxic, hypercarbic and acidotic until about 1 hour after birth:

<!-- PAGE=? -->
Table 43-1. NORMAL BLOOD GAS VALUES IN THE NEWBORN

<!-- PAGE=? -->
Cardiac changes

<!-- PAGE=? -->
The fetal circulation

<!-- PAGE=? -->
 Oxygenated placental blood is preferentially delivered to the

<!-- PAGE=? -->
o Brain

<!-- PAGE=? -->
o myocardium

<!-- PAGE=? -->
o upper torso

<!-- PAGE=? -->
 lower oxygen tension blood distributed to the lower body and placenta

<!-- PAGE=? -->
 splitting is achieved via intra- and extracardiac shunts

<!-- PAGE=? -->
o Oxygenated blood from the ductus venosus remains on the posterior wall of the inferior vena cava, allowing it to be directed across the foramen ovale into the left atrium

<!-- PAGE=? -->
o Deoxygenated blood returning from the superior vena cava and myocardium is directed through the right ventricle and the pulmonary artery into the descending aorta via the ductus arteriosus

<!-- PAGE=? -->
 approximately 8-10% of total cardiac output passes through the high-resistance pulmonary circulation

<!-- PAGE=? -->
 The fetal circulation therefore runs in parallel

<!-- PAGE=? -->
o the left ventricle providing 35% and the right providing 65% of cardiac output

<!-- PAGE=? -->
o Fetal cardiac output is therefore measured as a combined

<!-- PAGE=? -->
a Fetal circulation

<!-- PAGE=? -->
b Postnatal circulation

<!-- PAGE=? -->
Lungs

<!-- PAGE=? -->
Falling resistance

<!-- PAGE=? -->
Lungs

<!-- PAGE=? -->
Increased blood flow

<!-- PAGE=? -->
High resistance

<!-- PAGE=? -->
Ductus arteriosus

<!-- PAGE=? -->
Active closure

<!-- PAGE=? -->
Low flow

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
of Ductus arteriosus

<!-- PAGE=? -->
Increased

<!-- PAGE=? -->
pulmonary

<!-- PAGE=? -->
Left

<!-- PAGE=? -->
Foramen

<!-- PAGE=? -->
atrium

<!-- PAGE=? -->
return to left

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
ovale

<!-- PAGE=? -->
Lett atrlum

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Foramen

<!-- PAGE=? -->
atrium closes

<!-- PAGE=? -->
atrium

<!-- PAGE=? -->
1/3

<!-- PAGE=? -->
atrium

<!-- PAGE=? -->
ovale

<!-- PAGE=? -->
foramen ovale

<!-- PAGE=? -->
Left

<!-- PAGE=? -->
ventricle

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
ventricle

<!-- PAGE=? -->
ventricle

<!-- PAGE=? -->
ventricle

<!-- PAGE=? -->
Increased peripheral

<!-- PAGE=? -->
Inferior

<!-- PAGE=? -->
Low peripheral resistance

<!-- PAGE=? -->
Reduced

<!-- PAGE=? -->
resistance

<!-- PAGE=? -->
vena cava

<!-- PAGE=? -->
High flow

<!-- PAGE=? -->
vena cava

<!-- PAGE=? -->
Passive ductus

<!-- PAGE=? -->
Increased blood

<!-- PAGE=? -->
Ductus

<!-- PAGE=? -->
blood flow

<!-- PAGE=? -->
venosus

<!-- PAGE=? -->
venosus

<!-- PAGE=? -->
closure

<!-- PAGE=? -->
pressure

<!-- PAGE=? -->
The red arrows

<!-- PAGE=? -->
Cut cord

<!-- PAGE=? -->
Placenta

<!-- PAGE=? -->
Placenta

<!-- PAGE=? -->
denote oxygenated

<!-- PAGE=? -->
Low resistance

<!-- PAGE=? -->
Low resistance

<!-- PAGE=? -->
blood

<!-- PAGE=? -->
Shunt closure and neonatal circulation

<!-- PAGE=? -->
 Umbilical vessels constrict in response to stretching and increased oxygen content at delivery

<!-- PAGE=? -->
o remove the large low resistance placental vascular bed and increase systemic vascular resistance.

<!-- PAGE=? -->
o Blood flow through the ductus venosus is suddenly reduced, causing passive closure over the following 3-7 days

<!-- PAGE=? -->
 Lung expansion drops pulmonary vascular resistance, causing a marked increase in blood returning to the left atrium

<!-- PAGE=? -->
o Reduced right atrial and increased left atrial pressures

<!-- PAGE=? -->
 functionally closing the foramen ovale within the first few breaths of life

<!-- PAGE=? -->
 it is completely closed in 50% of children by 5 years

<!-- PAGE=? -->
 remains probe patent in 30% of adults

<!-- PAGE=? -->
o dec. PVR and inc. SVR results reverses flow across the ductus arteriosus from left to right

<!-- PAGE=? -->
o the ductus arteriosus is affected by blood oxygen content and circulating prostaglandins

<!-- PAGE=? -->
 prostaglandin E2 produced by the placenta is lost at birth, facilitating ductus arteriosus closure

<!-- PAGE=? -->
 Functional closure of the ductus arteriosus occurs by 60 hours in 93% of term infants

<!-- PAGE=? -->
 Permanent structural closure occurs over the next 4-8 weeks

<!-- PAGE=? -->
 via endothelial destruction and subintimal proliferation

<!-- PAGE=? -->
 Any stimulus such as hypoxia, acidaemia or structural anomaly can increase pulmonary vascular resistance and potentially re-open the ductus arteriosus or foramen ovale

<!-- PAGE=? -->
o right to left shunt, which worsens hypoxia

<!-- PAGE=? -->
o persistent pulmonary hypertension of the newborn

<!-- PAGE=? -->
Neonatal cardiac output

<!-- PAGE=? -->
 Circulating thyroid and catecholamine hormones increase myocardial maturity in late gestation

<!-- PAGE=? -->
 At delivery there is a large surge in circulating catecholamines, which improves myocardial function and allows output to meet the marked metabolic oxygen demand

<!-- PAGE=? -->
o spontaneous thermogenesis

<!-- PAGE=? -->
o feeding

<!-- PAGE=? -->
o breathing

<!-- PAGE=? -->
 At term, the neonatal cardiac output is approximately 200 ml/kg/min

<!-- PAGE=? -->
 the myocardium is stiffer, d/t fewer myofibrils in a disordered pattern

<!-- PAGE=? -->
o the Frank-Starling relationship is on a much flatter section of the curve compared with adults

<!-- PAGE=? -->
 limited increase in stroke volume for a given increase in ventricular filling volume

<!-- PAGE=? -->
 neonatal CO is heart rate dependant

<!-- PAGE=? -->
 There is a dec. baroreceptor response to hypotension

<!-- PAGE=? -->
Ventricular maturation and associated ECG changes

<!-- PAGE=? -->
 The fetal heart is right-side dominant

<!-- PAGE=? -->
o right axis deviation

<!-- PAGE=? -->
o R wave dominance in lead V1

<!-- PAGE=? -->
o S wave dominance in lead V6

<!-- PAGE=? -->
 the classical left ventricular dominance pattern of adulthood is established by 3-6 months

<!-- PAGE=? -->
Haematology

<!-- PAGE=? -->
 contains both adult (HbA) and fetal haemoglobin (HbF)

<!-- PAGE=? -->
o HbA - α2β2

<!-- PAGE=? -->
 Replaces HbF by 6 mon

<!-- PAGE=? -->
o HbF  - α2γ2

<!-- PAGE=? -->
 70-80% at term

<!-- PAGE=? -->
 90% preterm

<!-- PAGE=? -->
 HbF provides a greater affinity for oxygen and helps maintain the molecular structure and function in more acidic environments

<!-- PAGE=? -->
o facilitates oxygen transfer across the placenta from maternal HbA

<!-- PAGE=? -->
o Postdelivery, HbF becomes detrimental as oxygen is not readily given up to the tissues

<!-- PAGE=? -->
 The HbF oxygen dissociation curve is moved to the left after delivery due an increased pH and lower carbon dioxide concentration further limiting oxygen delivery to the peripheries

<!-- PAGE=? -->
 Oxygen delivery to the peripheries is facilitated by an increase in 2,3,diphosphoglycerate levels, shifting the oxygen dissociation curve to the right, thus decreasing the affinity

<!-- PAGE=? -->
 Haematopoiesis occurs in the liver in utero but is restricted to bone marrow from 6 weeks postdelivery

<!-- PAGE=? -->
Fetal and adult ha emoglobin oxygen dissociation curves and perinatal blood gas values

<!-- PAGE=? -->
20

<!-- PAGE=? -->
Fetal

<!-- PAGE=? -->
ml/al

<!-- PAGE=? -->
Adult

<!-- PAGE=? -->
1

<!-- PAGE=? -->
10

<!-- PAGE=? -->
20

<!-- PAGE=? -->
60

<!-- PAGE=? -->
80

<!-- PAGE=? -->
100

<!-- PAGE=? -->
POz (mm Hg)

<!-- PAGE=? -->
Measurement

<!-- PAGE=? -->
Fetus

<!-- PAGE=? -->
Term neonate (1st week)

<!-- PAGE=? -->
pH

<!-- PAGE=? -->
7.25-7.35

<!-- PAGE=? -->
7.36-7.38

<!-- PAGE=? -->
PO, mm Hg (kPa)

<!-- PAGE=? -->
30-35 (4.0-4.6)

<!-- PAGE=? -->
70-85 (9.3-11.3)

<!-- PAGE=? -->
PCO, mm Hg (kPa)

<!-- PAGE=? -->
40-50 (5.3-6.6)

<!-- PAGE=? -->
33-36 (4.4-4.8)

<!-- PAGE=? -->
The P , (the partial pressure of oxygen (PO ) atwhich saturation is 509) of fetal haemoglobin is 27 mm Hg (3.6 kPa) compared with 36 mm Hg (4.8 kPa) for adult haer moglobin. Adult haemoglobin releases twice as much oxygen as fetal haemoglobin because oxygen tension falls from arterial values tovenous values of 40 mm Hg (5.3 kPa) in the neonate. Reproducedwith permission from Rudolph AM. Pediatr Cardiol 1983;4: 17.

<!-- PAGE=? -->
 HbF is lost faster than HbA is synthesized, resulting in neonatal physiological anemia

<!-- PAGE=? -->
Clotting

<!-- PAGE=? -->
 Clotting factors do not cross the placenta

<!-- PAGE=? -->
 factors V, VIII and XIII are at adult concentrations before birth

<!-- PAGE=? -->
 vitamin K-dependent clotting factors (II, VII, IX, X, protein C and S) are initially low because of a lack of vitamin K stores and immature hepatocyte function

<!-- PAGE=? -->
o prolongation in prothrombin time

<!-- PAGE=? -->
o Vitamin K is administered to all newborn babies to protect against haemorrhagic disease of the newborn

<!-- PAGE=? -->
 Platelet counts are in the adult range but function is diminished due to low levels of serotonin and adenine nucleotides

<!-- PAGE=? -->
Thermogregulation

<!-- PAGE=? -->
Heat loss

<!-- PAGE=? -->
 Neonates and in particular premature neonates are at high risk of heat loss and subsequent hypothermia

<!-- PAGE=? -->
o Neonates have a 2.5-3.0-times higher surface area to bodyweight ratio compared with adults

<!-- PAGE=? -->
o limited insulating capacity from subcutaneous fat

<!-- PAGE=? -->
o inability of neonates to generate heat by shivering until 3 months of age

<!-- PAGE=? -->
 Hypothermic preterm babies have a poor outcome in the intensive care setting

<!-- PAGE=? -->
 Heat is lost by

<!-- PAGE=? -->
o radiation (39%)

<!-- PAGE=? -->
 minimized by inc. ambient temperature

<!-- PAGE=? -->
o convection (34%)

<!-- PAGE=? -->
 minimized by warming surrounding air and minimizing air speed across the baby's skin

<!-- PAGE=? -->
o evaporation (24%)

<!-- PAGE=? -->
 reduced by increasing ambient humidity and reducing air speed across the neonate

<!-- PAGE=? -->
o conduction (3%)

<!-- PAGE=? -->
 the ability to sweat is only present after 36 weeks postconceptual age

<!-- PAGE=? -->
Mechanisms of thermogenesis

<!-- PAGE=? -->
 The neonate can produce heat by

<!-- PAGE=? -->
o limb movement

<!-- PAGE=? -->
o stimulation of brown fat (non-shivering thermogenesis)

<!-- PAGE=? -->
 Brown fat makes up about 6% of term body weight

<!-- PAGE=? -->
 interscapular region

<!-- PAGE=? -->
 Mediastinum

<!-- PAGE=? -->
 Axillae

<!-- PAGE=? -->
 vessels of the neck

<!-- PAGE=? -->
 perinephric fat

<!-- PAGE=? -->
 It is highly vascular with sympathetic innervations and high mitochondrial content to facilitate heat generation

<!-- PAGE=? -->
 Norepinephrine is released from sympathetic neurons, activating β3-receptors to stimulate lipases to breakdown triglycerides to glycerol and free fatty acids

<!-- PAGE=? -->
 free fatty acids undergo oxidative phosphorylation in the mitochondria to produce the required energy and heat

<!-- PAGE=? -->
 markedly increases oxygen demand

<!-- PAGE=? -->
 may be impaired in the first 12 hours of life due to maternal sedation

<!-- PAGE=? -->
 peripheral vasoconstriction may be impaired in the preterm neonate, further increasing the risk of hypothermia in this age group

<!-- PAGE=? -->
Thermoneutral environment

<!-- PAGE=? -->
 The thermoneutral environment minimizes neonatal energy requirements in maintaining a normal core temperature of 36.5-37.5°C rectal

<!-- PAGE=? -->
 thermoneutral temperature range varies with age

<!-- PAGE=? -->
o naked term baby at 1 week is 32.0-33.5°C (24.0-27.0°C when the baby is clothed

<!-- PAGE=? -->
o a 30-week gestation baby's range is 34.0-35.0°C naked and 28.0-30.0°C clothed

<!-- PAGE=? -->
 The operating room environment must maintain neonatal thermoneutrality

<!-- PAGE=? -->
Hepatic

<!-- PAGE=? -->
 Most enzymatic pathways are present in the neonate, but are inactive at birth and generally become fully active at 3 months postdelivery

<!-- PAGE=? -->
o the conjugation pathway is fully established at 2 weeks

<!-- PAGE=? -->
Renal

<!-- PAGE=? -->
 A full compliment of 1 million nephrons is present by 34 weeks gestation

<!-- PAGE=? -->
o glomeruli and nephrons are immature at birth, resulting in a reduced glomerular filtration rate (GFR) and limited concentrating ability

<!-- PAGE=? -->
 concentrating ability is limited by a lack of renal medulla osmotic gradient and no medullary tubules

<!-- PAGE=? -->
o The concentrating capacity of the neonatal kidney (600 mOsm/kg) is about half that of the adult (1200-1400 mOsm/kg)

<!-- PAGE=? -->
 GFR is gestational age related

<!-- PAGE=? -->
o reduced with increasing prematurity

<!-- PAGE=? -->
o At 41 weeks postconceptual age the GFR is 1.5 ml/kg/min (20-40 ml/min/1.73 m2)

<!-- PAGE=? -->
 increases to half of adult levels by 3 months

<!-- PAGE=? -->
 Adult levels of GFR 2.0 ml/kg/min (120 ml/min/1.73 m2) are achieved by 2 years of age

<!-- PAGE=? -->
 The limited ability to concentrate urine and the reduced GFR make the neonate susceptible to both dehydration and fluid overload

<!-- PAGE=? -->
 Glycosuria and aminoaciduria are commonly detected because of the capabilities of immature active transport pumps in the proximal tubule

<!-- PAGE=? -->
 Renal immaturity also affects vitamin D formation and calcium homeostasis

<!-- PAGE=? -->
Body fluid composition

<!-- PAGE=? -->
 At term, 75% of neonatal body weight is water

<!-- PAGE=? -->
o 40% in the extracellular compartment

<!-- PAGE=? -->
 Preterm the water content is even higher at 80-85% of body weight

<!-- PAGE=? -->
 For the first 12-24 hours of life, urine output is limited to 0.5 ml/kg/hour by poor renal perfusion, increasing with circulation adaptation

<!-- PAGE=? -->
 Following this initial oliguric phase a period of naturesis ensues

<!-- PAGE=? -->
o Isotonic fluid is lost from extracellular compartments, accounting for the steady 1-2% bodyweight per day weight loss seen in the first 5 days

<!-- PAGE=? -->
o The diuresis reduces the extracelluar water content to 30% of total body water over the neonatal period

<!-- PAGE=? -->
 fluid loss is an important postnatal adaptation to facilitate lung function and reduce the risks of

<!-- PAGE=? -->
o symptomatic patent ductus arteriosus

<!-- PAGE=? -->
o necrotizing enterocolitis

<!-- PAGE=? -->
o BPD

<!-- PAGE=? -->
Fluid requirements

<!-- PAGE=? -->
 Insensible fluid losses (e.g. stool, respiratory and skin evaporation) must be considered when caring for the neonate

<!-- PAGE=? -->
o losses from the stool alone are approximately 5 ml/kg/24 hours

<!-- PAGE=? -->
o a 25-week neonate can lose 15 times as much transdermal fluid as the term neonate

<!-- PAGE=? -->
 After 32-34 weeks transdermal losses fall to 12 ml/kg/day but can vary widely with ambient conditions

<!-- PAGE=? -->
 Fluid therapy must take into account the physiological diuresis that occurs after birth and the maturation of renal solute handling

<!-- PAGE=? -->
o Sodium is not given in the first few days of life until the physiological diuresis is established to avoid fluid retention and overload

<!-- PAGE=? -->
 10% dextrose is used for maintenance fluid, which is gradually increased over the first few days of life to avoid excessive hydration

<!-- PAGE=? -->
 Fluid requirements are initially 60-80 ml/kg/day, increasing to 150 ml/kg/day over the first week

<!-- PAGE=? -->
 Surgery and ventilation all reduce GFR and increase ADH production, therefore fluid intake is often limited to 60% of requirement postoperatively.

<!-- PAGE=? -->
Nutrition

<!-- PAGE=? -->
 the gastrointestinal tract is fully formed by 25 weeks

<!-- PAGE=? -->
 During the last 6 weeks of normal gestation body fat deposition almost doubles to 15% of body weight

<!-- PAGE=? -->
 Glycogen stores increase during the last 9 weeks of gestation to 2-3 times that seen in adults

<!-- PAGE=? -->
Carbohydrates

<!-- PAGE=? -->
 Under the influence of high circulating catecholamines at birth, energy stores are mobilized via glycogenolysis, lipolysis and gluconeogenesis

<!-- PAGE=? -->
o A drop in glucose is seen for the first 2 hours postdelivery

<!-- PAGE=? -->
 Glycogen stores are depleted by approximately 12 hours, after which energy requirements are supported by oxidative fat metabolism until enteral feeding is established

<!-- PAGE=? -->
 Requirement of glucose is .3-.5 gm/kg/hr of glucose in neonates

<!-- PAGE=? -->
o Term: 5-8 mg/kg/min

<!-- PAGE=? -->
o Preterm: 8-10 mg/kg/min

<!-- PAGE=? -->
Nervous system

<!-- PAGE=? -->
 The neural system is precocious in development compared with other organ

<!-- PAGE=? -->
 a full complement of cortical and brainstem cells are present by 1 year

<!-- PAGE=? -->
 The brain increases its size three-fold during the first year

<!-- PAGE=? -->
o cerebral circulation is one-third of cardiac output compared with one-sixth of cardiac output in adults

<!-- PAGE=? -->
 Myelination and organization of the nervous system continue throughout infancy

<!-- PAGE=? -->
 The blood-brain barrier is mature by 6 months

<!-- PAGE=? -->
 Cerebral autoregulation is fully developed at term, maintaining cerebral perfusion down to a MAP of 30 mm Hg

<!-- PAGE=? -->
 the parasympathetic system predominates

<!-- PAGE=? -->
Nocioception

<!-- PAGE=? -->
 Nocioceptive pathways are developed by 24-28 weeks gestation, but still require further maturation through the neonatal period

<!-- PAGE=? -->
Neonatal Sepsis

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Neonates have increased susceptibility to infection

<!-- PAGE=? -->
o developmental immunologic deficiencies

<!-- PAGE=? -->
 Depressed cell-mediated immunity  - more susceptible to viral and fungal infection

<!-- PAGE=? -->
 depressed B-cell function  -  dec. production of immunoglobulins

<!-- PAGE=? -->
 offset by maternal IgG

<!-- PAGE=? -->
o wanes by 2 to 3 months of age which is before infants can adequately produce their own antibodies

<!-- PAGE=? -->
 Perinatal infections are either congenitally or postnatally acquired

<!-- PAGE=? -->
o Congenital infections occur with prenatal exposure

<!-- PAGE=? -->
 TORCH infections: Toxoplasma gondii (T); -other‖ (O), including human immunodeficiency virus (HIV), syphilis, and tuberculosis; rubella (R); cytomegalovirus (C); and herpes simplex virus type 2 (H)

<!-- PAGE=? -->
 Only rarely do these infections cause overwhelming sepsis

<!-- PAGE=? -->
o acquired pathogens are most commonly those that colonize the mother's genital tract

<!-- PAGE=? -->
 group B streptococci

<!-- PAGE=? -->
 most common

<!-- PAGE=? -->
 manifested as severe cardiorespiratory instability and meningitis in 30% of cases

<!-- PAGE=? -->
 By 2 to 3 weeks of age, this organism is more commonly associated with meningitis and less commonly with pulmonary disease

<!-- PAGE=? -->
 E. coli

<!-- PAGE=? -->
 Listeria monocytogenes

<!-- PAGE=? -->
 Herpesvirus

<!-- PAGE=? -->
 Premature infants have a high incidence of acute infections in the newborn period

<!-- PAGE=? -->
Box 84-6

<!-- PAGE=? -->
Common Signs and Symptoms of Neonatal Sepsis

<!-- PAGE=? -->
Temperature instability (hypothermia and hyperthermia)

<!-- PAGE=? -->
Lethargy and poor feeding

<!-- PAGE=? -->
Respiratory distress and apnea

<!-- PAGE=? -->
Hypoglycemia and metabolic acidosis

<!-- PAGE=? -->
Poor cutaneous perfusion, hypotension

<!-- PAGE=? -->
Rashes or petechiae

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
o blood, urine, and CSF  cultures

<!-- PAGE=? -->
 repeated complete sepsis workups are often required

<!-- PAGE=? -->
NRP

<!-- PAGE=? -->
 ventilate at 40-60/min

<!-- PAGE=? -->
 chest compression 1/3 AP diameter of chest : 30 breaths and 90 compression

<!-- PAGE=? -->
o one and two and three and breath (5  in 10sec)

<!-- PAGE=? -->
 Epinephrine

<!-- PAGE=? -->
o given if HR <60 despite + press ventilation and chest compressions

<!-- PAGE=? -->
o 0.1-0.3ml/kg of 1:10 000

<!-- PAGE=? -->
 10-30 mcg/kg

<!-- PAGE=? -->
o ETT

<!-- PAGE=? -->
 0.3-1ml/kg  if given via ETT

<!-- PAGE=? -->
 30-100mcg/kg

<!-- PAGE=? -->
 initial fluid bolus 10ml/kg

<!-- PAGE=? -->
o NS, RL or O neg blood, Albumin

<!-- PAGE=? -->
o over 5-10min

<!-- PAGE=? -->
 Narcan

<!-- PAGE=? -->
o severe resp depression after PPV has restored normal HR and color PLUS hx of maternal narcotic administration within the past 4h

<!-- PAGE=? -->
o recommended concentration 1mg/ml; recommended route ETT or IV preferred but IM or subcutaneous acceptable

<!-- PAGE=? -->
 (but delayed onset of action

<!-- PAGE=? -->
o recommended dose 0.1mg/kg; thus 0.3mg

<!-- PAGE=? -->
o DO NOT give in opioid dependant mothers

<!-- PAGE=? -->
 Will precipitate withdrawal +/- Sz

<!-- PAGE=? -->
 Bicarb

<!-- PAGE=? -->
o After all other steps of resuscitation

<!-- PAGE=? -->
o 2mEq/kg (4ml/kg of 4.2% soln) over > 2 min

<!-- PAGE=? -->
 no ETT use

<!-- PAGE=? -->
 0.5 meq/ml in 4.2% solution

<!-- PAGE=? -->
Opiods

<!-- PAGE=? -->
stewart

<!-- PAGE=? -->
 Neonates, especially preterms metabolize Fentanyl more slowly

<!-- PAGE=? -->


<!-- PAGE=? -->
 As sole anesthetic 12-15 mcg/kg is required to prevent CVS response to sx. Supplemental Fentanyl may not be required for 60-90 min.

<!-- PAGE=? -->
 2-4mcg/kg/hr may supplement N2O for balanced anesthesia if extubations planned

<!-- PAGE=? -->
 larger doses should not be given since they predispose to resp failure

<!-- PAGE=? -->
 infants older than 3 months are less sensitive to fentanly induced resp failure

<!-- PAGE=? -->
 muscle rigidity can occur with the potent analgesics but is rare in infants and children

<!-- PAGE=? -->
o after cultures, treatment with ampicillin and an aminoglycoside, such as gentamicin, is usually begun until specific bacteriologic information becomes available

<!-- PAGE=? -->
o Only about 50% of neonates thought to be septic have positive cultures

<!-- PAGE=? -->
BIRTH

<!-- PAGE=? -->
Routine Care

<!-- PAGE=? -->
Term gestation?

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Amniotic fluid clear?

<!-- PAGE=? -->
Clear airwvay if needed

<!-- PAGE=? -->
Breathing or crying?

<!-- PAGE=? -->
Dry

<!-- PAGE=? -->
Good muscle tone?

<!-- PAGE=? -->
Assess color

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Position; clear airway*

<!-- PAGE=? -->
(as necessary)

<!-- PAGE=? -->
A

<!-- PAGE=? -->
Dry; stimulate; reposition

<!-- PAGE=? -->
Evaluate respirations;

<!-- PAGE=? -->
heart rate; and color

<!-- PAGE=? -->
Consider

<!-- PAGE=? -->
supplementary

<!-- PAGE=? -->
Hn <100

<!-- PAGE=? -->
oxygen

<!-- PAGE=? -->
Provide positive-pressure ventilation*

<!-- PAGE=? -->
B

<!-- PAGE=? -->
Provide positive-pressure ventilation

<!-- PAGE=? -->
Administer chest compressions

<!-- PAGE=? -->
C

<!-- PAGE=? -->
Administer epinephrine

<!-- PAGE=? -->
D

<!-- PAGE=? -->
Tracheal intubation may be considered at several steps

<!-- PAGE=? -->
 The newborn has a lower clearance of morphine, and therefore, a lower dose results in higher plasma values because of a longer elimination half-life. 120 Term infants older than 10 days may clear morphine more rapidly than adults.

<!-- PAGE=? -->
 Cote p148: -Term nenates also have a variable ability to clear fentanyl and may have a longer halflife and lower clearance than odler infants. Older infants (>3months) and children are able to clear a greater amount of drug than adults and therefore have a shorter beta elimination halflife‖

<!-- PAGE=? -->
 Lange 855 :   neonates have decr clearance & incr resp depression

<!-- PAGE=? -->
 Cote 149: Fentanyl in peds: increased vagal tone with bolus administration, also Fentanyl can markedly depress the baroreflex  control of the heart.

<!-- PAGE=? -->
Lange

<!-- PAGE=? -->
 opioids are more potent in neonates than in adults  due to easier entry across BBB, decreasedmetabolic capacity, increased sensitivity of the resp centre.

<!-- PAGE=? -->
 Re morphine in nn : decreased hepatic conjugation, reduced renal clearance

<!-- PAGE=? -->
 Pediatric patients have relatively high rates of biotransformation and elimination as a result of high hepatic flow. Suf, alfenta and possibly Fenta clearances may be higher in children than in adults

<!-- PAGE=? -->
 Children have a high Vd

<!-- PAGE=? -->
 The issue of sensitivity to the respiratory depressant effects of opioids and at what age it decreases has yet to be resolved . It is apparent that altered pharmacokinetics and immaturity of the blood-brain barrier may alter disposition of these drugs in very young children . Morphine is the least lipophilic of the opioid class; a greater proportion of any blood concentration may be able to cross the immature blood-brain barrier of the neonate or young infant compared with adults. Therefore, this medication should be administered with caution in infants younger than 6 months of age .

<!-- PAGE=? -->
PDA

<!-- PAGE=? -->
Park, CoExD

<!-- PAGE=? -->
 Functional closure within 10 to 15 hours after birth

<!-- PAGE=? -->
o constriction of the medial, smooth muscle in the ductus

<!-- PAGE=? -->
 Anatomic closure is completed by 4 to 6 weeks of age

<!-- PAGE=? -->
o permanent changes in the endothelium and subintimal layers of the ductus

<!-- PAGE=? -->
 Factors associated with closure

<!-- PAGE=? -->
o Oxygen

<!-- PAGE=? -->
o prostaglandin E2

<!-- PAGE=? -->
o maturity of the newborn

<!-- PAGE=? -->
 Acetylcholine and bradykinin also constrict the ductus.

<!-- PAGE=? -->
 PA responds to oxygen and acidosis in the opposite manner from the ductus arteriosus

<!-- PAGE=? -->
o Hypoxia and acidosis relax the ductus arteriosus but constrict the pulmonary arterioles

<!-- PAGE=? -->
o Oxygen constricts the ductus but relaxes the pulmonary arterioles

<!-- PAGE=? -->
 The PAs are also constricted by sympathetic stimulation and α-adrenergic stimulation (e.g., epinephrine, norepinephrine)

<!-- PAGE=? -->
o Vagal stimulation, β-adrenergic stimulation (e.g., isoproterenol), and bradykinin dilate the PAs

<!-- PAGE=? -->
Persistent Pulmonary Hypertension

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 may be primary with no recognized etiology

<!-- PAGE=? -->
 may be secondary to

<!-- PAGE=? -->
o meconium aspiration

<!-- PAGE=? -->
o sepsis

<!-- PAGE=? -->
o pneumonia

<!-- PAGE=? -->
o respiratory distress

<!-- PAGE=? -->
o congenital diaphragmatic hernia

<!-- PAGE=? -->
PONV in Children

<!-- PAGE=? -->
 Risk Factors are similar to those in adults with the following differences

<!-- PAGE=? -->
o Vomiting incidence is twice as frequent

<!-- PAGE=? -->
o increases as children age, decreasing after puberty

<!-- PAGE=? -->
o Sex differences are not seen before puberty

<!-- PAGE=? -->
o increases more consistently with specific operations

<!-- PAGE=? -->
 adenotonsillectomy

<!-- PAGE=? -->
 strabismus repair

<!-- PAGE=? -->
 hernia repair

<!-- PAGE=? -->
 orchiopexy

<!-- PAGE=? -->
 penile surgery

<!-- PAGE=? -->
Pyloric Stenosis

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 classic electrolyte pattern in infants with severe vomiting is

<!-- PAGE=? -->
o Dehydration

<!-- PAGE=? -->
o hyponatremic

<!-- PAGE=? -->
o hypokalemic

<!-- PAGE=? -->
o hypochloremic

<!-- PAGE=? -->
o metabolic alkalosis

<!-- PAGE=? -->
o compensatory respiratory acidosis

<!-- PAGE=? -->
Table 20-1. Metabolic Findings in the Newborn Secondary to Pyloric Stenosis

<!-- PAGE=? -->
(<), no change;

<!-- PAGE=? -->
marked

<!-- PAGE=? -->
change.

<!-- PAGE=? -->
Regional

<!-- PAGE=? -->
 Cooperation lacking in paediatric population so regional as a sole technique has limited value

<!-- PAGE=? -->
 Can provide pain control intraoperatively and postoperatively

<!-- PAGE=? -->
o Useful regional techniques in neonates

<!-- PAGE=? -->
 Central neuraxial - caudal, epidural, spinal

<!-- PAGE=? -->
 Peripheral  - infraorbital, brachial plexus, lateral femoral cutaneous nerve, penile block, ilioinguinal block, scalp blocks

<!-- PAGE=? -->
 Basic Rules

<!-- PAGE=? -->
o Calculate the allowable dose of local analgesic agent for the child recognizing pharmacological differences in paeds patients

<!-- PAGE=? -->
o Be prepared for complications of regional with drugs and equipment for to immediately secure airway and ventilate

<!-- PAGE=? -->
 need iv access

<!-- PAGE=? -->
 Dose of intralipid = 1.5mg/kg

<!-- PAGE=? -->
o It is acceptable to perform an epidural and pass a catheter in an asleep paediatric patient

<!-- PAGE=? -->
o Be especially careful of intravascular injections - aspirate frequently

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
 For Epidural/Peripheral Nerve Block

<!-- PAGE=? -->
o Bupivicaine (plain or with epi)

<!-- PAGE=? -->
3mg/kg

<!-- PAGE=? -->
o Ropivicaine

<!-- PAGE=? -->
3mg/kg

<!-- PAGE=? -->
o Lidocaine

<!-- PAGE=? -->
5mg/kg

<!-- PAGE=? -->
 w/1:200 000 epi

<!-- PAGE=? -->
8mg/kg

<!-- PAGE=? -->
o Mepivacaine or prilocaine

<!-- PAGE=? -->
5mg/kg

<!-- PAGE=? -->
 w/1:200 000 epi

<!-- PAGE=? -->
7mg/kg

<!-- PAGE=? -->
 For Spinal Block

<!-- PAGE=? -->
o Tetracaine

<!-- PAGE=? -->
0.4-0.6mg/kg

<!-- PAGE=? -->
o lasts only 90 minutes in infant so need to ensure surgical speed

<!-- PAGE=? -->
TABLE 44-7. Usual Doses of Hyperbaric Local Anesthetics for Spinal Anesthesia in Infants and Children

<!-- PAGE=? -->
LOCAL ANESTHETIC a

<!-- PAGE=? -->
0 - 5 kg

<!-- PAGE=? -->
5 - 15 kg

<!-- PAGE=? -->
>15 kg

<!-- PAGE=? -->
0.5% hyperbaric bupivacaine

<!-- PAGE=? -->
0.5 mg/kg

<!-- PAGE=? -->
(0.1 mL/kg)

<!-- PAGE=? -->
0.4 mg/kg

<!-- PAGE=? -->
(0.08 mL/kg)

<!-- PAGE=? -->
0.3 mg/kg

<!-- PAGE=? -->
(0.06 mL/kg)

<!-- PAGE=? -->
1% hyperbaric tetracaine

<!-- PAGE=? -->
0.5 mg/kg

<!-- PAGE=? -->
(0.05 mL/kg)

<!-- PAGE=? -->
0.4 mg/kg

<!-- PAGE=? -->
(0.04 mL/kg)

<!-- PAGE=? -->
0.3 mg/kg

<!-- PAGE=? -->
(0.03 mL/kg)

<!-- PAGE=? -->
5% hyperbaric lidocaine

<!-- PAGE=? -->
b

<!-- PAGE=? -->
2.5 mg/kg

<!-- PAGE=? -->
(0.05 mL/kg)

<!-- PAGE=? -->
2 mg/kg

<!-- PAGE=? -->
(0.04 mL/kg)

<!-- PAGE=? -->
1.5 mg/kg

<!-- PAGE=? -->
(0.03 mL/kg)

<!-- PAGE=? -->
a Hyperbaric solutions have legal approval for intrathecal injection. Nonhyperbaric and conservative-free solutions are being used increasingly but have no legal approval (which does not necessarily preclude their use). 60

<!-- PAGE=? -->
b The FDA recommends diluting 5% lidocaine with an equal volume of cerebrospinal fluid before injecting the total dose.

<!-- PAGE=? -->
.

<!-- PAGE=? -->
Pharmacokinetics of Locals in Pediatrics

<!-- PAGE=? -->
 The duration of block is much shorter

<!-- PAGE=? -->
 Dose requirements are much higher calculated on a body weight basis to achieve the same segmental

<!-- PAGE=? -->
level of anesthesia

<!-- PAGE=? -->
o possibly due to larger volume of CSF 4ml/kg in infants vs 2ml/kg in adults

<!-- PAGE=? -->
o In infants, dose is about 10 times that of adults and duration is 1/3

<!-- PAGE=? -->
 Rapid absorption - increased CO, increase regional tissue blood flows

<!-- PAGE=? -->
 Larger Vd so longer elimination half life (shorter duration of action)

<!-- PAGE=? -->
 Less protein binding -especially if jaundiced (bilirubin can further decrease binding)

<!-- PAGE=? -->
o Increased plasma free drug

<!-- PAGE=? -->
 Metabolism of local reduced

<!-- PAGE=? -->
o Decreased activity of plasma cholinesterase

<!-- PAGE=? -->
o Hepatic pathways for conjugation of amides is immature in neonates

<!-- PAGE=? -->
 Prilocaine metabolism can cause methemoglobinemia

<!-- PAGE=? -->
 NOTE it is difficult to elicit S&S of toxicity in peds

<!-- PAGE=? -->
 Aspiration  - veins may collapse - false negative response

<!-- PAGE=? -->
 Test dose - CNS toxicity confused with pain or agitation

<!-- PAGE=? -->
 HR response to epinephrine is confused after atropine and baseline high HR

<!-- PAGE=? -->
 Ectopy with higher dose of epinephrine

<!-- PAGE=? -->
 GA suppresses signs of toxicity

<!-- PAGE=? -->
 especially be careful with iv lidocaine in infants with R to L shunt b/c will miss 1st pass absorption within the pulmonary circulation (decrease dose by 50%!)

<!-- PAGE=? -->
Caudal

<!-- PAGE=? -->
 Excellent postoperative analgesia after abdominal, lower limb and perineal surgery

<!-- PAGE=? -->
o Single shot caudal can give analgesia for 6-8 hrs

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
o Triangle between posterior superior iliac spines and coccyx

<!-- PAGE=? -->
o Two sacral cornua are lateral to the hiatus

<!-- PAGE=? -->
 Usually done in lateral decubitus

<!-- PAGE=? -->
o Needle is advanced only 2-3mm past the -pop‖ of the sacrococcygeal membrane

<!-- PAGE=? -->
 Armitage formula: Bupivicaine 0.25% with 1:200K epinephrine

<!-- PAGE=? -->
o 0.5 ml/kg -sacral block

<!-- PAGE=? -->
o 1 ml/kg -high lumbar -low thoracic block

<!-- PAGE=? -->
o 1.25 mL/kg -mid-thoracic block

<!-- PAGE=? -->
 plasma levels for all LA drugs tend to be low after caudal administration

<!-- PAGE=? -->
 Adding epinephrine 1:200,000 provides

<!-- PAGE=? -->
o significant longer duration of action

<!-- PAGE=? -->
o inc. motor block

<!-- PAGE=? -->
o dec. plasma levels

<!-- PAGE=? -->
 Hydrophilic opioids are administered through lumbar or caudal catheters

<!-- PAGE=? -->
o Due to rostral spread a wide range of dermatomes are covered

<!-- PAGE=? -->
 Caudal morphine = 75-100ug/kg to a volume of 0.5ml/kg as single shot

<!-- PAGE=? -->
o Can add clonidine 1-2ug/kg but doesn't seem to really increase duration

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Incorrect positioning

<!-- PAGE=? -->
 Subcutaneous

<!-- PAGE=? -->
 subperiosteal

<!-- PAGE=? -->
 Intraosseous

<!-- PAGE=? -->
 Intravascular

<!-- PAGE=? -->
 Methods for Prevention of Intravascular Injection

<!-- PAGE=? -->
o Slow Injection

<!-- PAGE=? -->
o Repeated Aspiration

<!-- PAGE=? -->
o Constant assessment of patient for clinical signs

<!-- PAGE=? -->
o Epinephrine added to determine if intravascular

<!-- PAGE=? -->
 Peaked T waves (short duration - 30 sec)

<!-- PAGE=? -->
 Increase heart rate

<!-- PAGE=? -->
o Divide doses into aliquots and wait 30 seconds between doses

<!-- PAGE=? -->
 Subdural

<!-- PAGE=? -->
 Subachanoid

<!-- PAGE=? -->
Spinals

<!-- PAGE=? -->
 sitting position is easier as it results in fewer dry taps but lateral is the preferred position because it is safer

<!-- PAGE=? -->
 bloody taps are more common compared to adults

<!-- PAGE=? -->
 requires neck extension to maintain airway

<!-- PAGE=? -->
 the spinal cord is lower than an adults

<!-- PAGE=? -->
o Conus ends at L3

<!-- PAGE=? -->
o Dural space extends to S3-4

<!-- PAGE=? -->
o Adult levels may be achieved by 1 yr old

<!-- PAGE=? -->
 Conus at L1, subarachnoid space at S1

<!-- PAGE=? -->
 Depth =skin to  SA =1.4cm

<!-- PAGE=? -->
 Parasympathetic to heart is blocked with spinal

<!-- PAGE=? -->
o allows HR to compensate for any alterations in SVR

<!-- PAGE=? -->
o This is a greater factor in preservation of hemodynamic stability than relatively small venous capacitance, and relative lack of resting sympathetic peripheral vascular tone

<!-- PAGE=? -->
 Indicated for surgery at or below the umbilicus

<!-- PAGE=? -->
 Can also use for upper abdominal surgery in infants with history of respiratory disease as postoperative apnea of the ex-preterm infant may be less common after spinal

<!-- PAGE=? -->
o Effective in prevention if used as SOLE anaesthetic technique in high risk infants

<!-- PAGE=? -->
 Total spinal may have apnea without a change in blood pressure

<!-- PAGE=? -->
 Contraindications to Spinal

<!-- PAGE=? -->
o Sepsis or infection at site

<!-- PAGE=? -->
o Coagulopathy

<!-- PAGE=? -->
o Lack of parental consent

<!-- PAGE=? -->
TABLE 20-1. Anatomic differences of importance in spinal and epidural anesthesia in children and adults

<!-- PAGE=? -->
Anatomic variable

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
Infant

<!-- PAGE=? -->
Small child

<!-- PAGE=? -->
Older child

<!-- PAGE=? -->
Adult

<!-- PAGE=? -->
Position of lower end of spinal cord

<!-- PAGE=? -->
L3

<!-- PAGE=? -->
Ll at 12 months

<!-- PAGE=? -->
Ll

<!-- PAGE=? -->
Position of lower end of dural sac

<!-- PAGE=? -->
S4

<!-- PAGE=? -->
S2

<!-- PAGE=? -->
S2

<!-- PAGE=? -->
CSF/kg

<!-- PAGE=? -->
4 ml

<!-- PAGE=? -->
4 ml

<!-- PAGE=? -->
3 ml

<!-- PAGE=? -->
2 ml

<!-- PAGE=? -->
2 ml

<!-- PAGE=? -->
Condition of epidural fat

<!-- PAGE=? -->
Loose

<!-- PAGE=? -->
Loose

<!-- PAGE=? -->
Loose

<!-- PAGE=? -->
± Loose

<!-- PAGE=? -->
Firmly packed

<!-- PAGE=? -->
CSF, cerebrospinal fluid.

<!-- PAGE=? -->
 Needle should not be advanced more than 1-2 mm once the sacrococcygeal membrane is perforated (increased chance of dural puncture)

<!-- PAGE=? -->
 Injection of drugs for caudal into subarachnoid space can lead to total spinal block will

<!-- PAGE=? -->
o Unconsciousness, apnea +/- hypotension

<!-- PAGE=? -->
 Control the airway and breathing, and vasopressors/fluid for hypotension

<!-- PAGE=? -->
 Intraneural

<!-- PAGE=? -->
 Rectal

<!-- PAGE=? -->
o Urinary retention - Not uncommon, temporary catheterization may be required

<!-- PAGE=? -->
o Hematoma

<!-- PAGE=? -->
o Absent or patchy block

<!-- PAGE=? -->
Epidurals

<!-- PAGE=? -->
 No significant technical changes in technique, usual considerations apply

<!-- PAGE=? -->
 In kids >10kg, distance from skin to lumbar epidural space in mm is approximately similar to child's weight in kg (20 kg child = 20 mm)

<!-- PAGE=? -->
 Use 19G Tuohy or 21 gauge catheter in kids younger than 5

<!-- PAGE=? -->
 In younger than 5 yo the catheter can be advanced to any level via the caudal route without exiting the dural sleeve of becoming tangeled or knotted

<!-- PAGE=? -->
 .1% bupivicaine with 3ug/cc hydromorphine

<!-- PAGE=? -->
o Run infusion at 0.3 - 0.5mg/kg/hr  or 1 - 1.5ug/kg/hr of hydromorphone

<!-- PAGE=? -->
Ilioinguinal & Iliohypogastic

<!-- PAGE=? -->
 Ilioinguinal and iliohypogastric nerve innervate inguinal area

<!-- PAGE=? -->
 ID ASIS, immediately medial to it insert needle aimed towards umbilicus and fan local into this area

<!-- PAGE=? -->
 Ultrasound useful to identify these nerves

<!-- PAGE=? -->
Renal

<!-- PAGE=? -->
 Characteristics of fetal kidneys :

<!-- PAGE=? -->
o Decreased renal blood flow

<!-- PAGE=? -->
o Decreased glomerular filtration rate ( GFR)

<!-- PAGE=? -->
o Reasons for decreased RBF and decreased GFR :

<!-- PAGE=? -->
 Low SVR

<!-- PAGE=? -->
 High renal vascular resistance

<!-- PAGE=? -->
 Low permeability of glomerular capillaries

<!-- PAGE=? -->
 Small size and number of glomeruli

<!-- PAGE=? -->
 At birth transition changes include increased SVR and decreased renal vascular resistance

<!-- PAGE=? -->
 The other 2 factors change with maturation

<!-- PAGE=? -->
 By 1 month the kidneys are 70% mature

<!-- PAGE=? -->
 The neonatal kidney cannot conserve Na due to immature tubular cells that cannot reabsorb Na under the stimulus of Aldosteron obligate Na loser‖

<!-- PAGE=? -->
 Urine Na = 20-25 mEq/L ( 5-10 mEq/L in adult)

<!-- PAGE=? -->
Respiratory variables

<!-- PAGE=? -->
 The rate of induction and awakening may also be related to the type of anesthetic circuit used .  A nonrebreathing system produces a more rapid rise in alveolar anesthetic concentration.

<!-- PAGE=? -->
 In a circle system must consider the volume of the anesthetic tubing, CO2 absorber, and humidifier in relation to the patient's lung volume. Circuit Vol = 3.5L

<!-- PAGE=? -->
 A nonrebreathing circuit volume = 1.2L; so a change in FI will take shorter to equilibrate

<!-- PAGE=? -->
 A nonrebreathing circuit also allows a more rapid elimination of potent inh agents

<!-- PAGE=? -->
 If very high flows are used a circle system takes on the characteristics of a non-rebreathing system.

<!-- PAGE=? -->
PaO2 = 100 - age/3, so decreased PaO2 in geriatrics  ( lange 498) Normal PaO2 is 90-95 ( normal A-a grd is 5-10 mmHg)

<!-- PAGE=? -->
Summary

<!-- PAGE=? -->
 lung mechanics normalize almost immediately

<!-- PAGE=? -->
 blood gas results take ~ 1 hour to normalize

<!-- PAGE=? -->
 PVR normalizes over 3 months

<!-- PAGE=? -->
Sedation

<!-- PAGE=? -->
Oral midaz .5mg/kg  sedation in 15min and lasts 30-60s (can be given nasal .2mg/kg or rectal .3-1mg/kg) Oral ketamine  (can be given nasal 3-8mg/kg or im or rectal 5mg/kg)

<!-- PAGE=? -->
After 6mo to 1yr may benefit Methohexital 20-30mg/kg

<!-- PAGE=? -->
Transfusion

<!-- PAGE=? -->
 pRBC = 10 - 15 cc/kg

<!-- PAGE=? -->
 PPF = 10 - 15 cc/kg

<!-- PAGE=? -->
 Cryo = 5 - 10 cc/kg (or 0.5 U/kg) - will raise fibrinogen by 0.5 g/L);

<!-- PAGE=? -->
Stridor

<!-- PAGE=? -->
TBW

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 In general, blood volume is approximately:

<!-- PAGE=? -->
o 100 to 120 mL/kg for the premature infant,

<!-- PAGE=? -->
o 90 mL/kg for the full-term infant,

<!-- PAGE=? -->
o 80 mL/kg for the child 3 to 12 months old, and

<!-- PAGE=? -->
o 70 mL/kg for the child older than 1 year.

<!-- PAGE=? -->
TEF

<!-- PAGE=? -->
8%             <1%                    87%                 <1%                   4%

<!-- PAGE=? -->
A) Pure esophageal atresia

<!-- PAGE=? -->
B) EA + proximal fistula

<!-- PAGE=? -->
C) EA + distal fistula

<!-- PAGE=? -->
D) EA + proximal fistula + distal fistula

<!-- PAGE=? -->
E) Pure TEF (aka. H-type)

<!-- PAGE=? -->
F) Esophageal stenosis

<!-- PAGE=? -->
A

<!-- PAGE=? -->
B

<!-- PAGE=? -->
 Incidence = 1 in 4000

<!-- PAGE=? -->
 TEF repair = one of the five most frequent major surgical procedures performed in the first week of life (CDH, omphalocele/gastroschisis, TEF, intestinal obstruction, meningomyelocele)

<!-- PAGE=? -->
 Presentation/Diagnosis

<!-- PAGE=? -->
o Antenatal: inability to swallow amniotic fluid in utero results in polyhydramnios, suspected defects on U/S

<!-- PAGE=? -->
o Inability to pass NG tube to stomach, coiling of NG in blind upper esophageal pouch on CXR

<!-- PAGE=? -->
o Breathing leads to gastric distension (except in pure EA with no fistula)

<!-- PAGE=? -->
o Feeding leads to coughing, choking, cyanosis

<!-- PAGE=? -->
o respiratory distress, diagnosis with barium swallow

<!-- PAGE=? -->
o H type (no esophageal atresia) may present after days-weeks with recurrent pneumonias and refractory bronchospasm

<!-- PAGE=? -->
 Mortality rate from associated congenital heart defect is much higher than that from the surgical correction of the TEF. ~100% survival in term infants without associated defects. Mortality rate in high risk infants (<1800 g or pneumonia) is 20-60%

<!-- PAGE=? -->
 Historical Waterston and Caverly classification:

<!-- PAGE=? -->
o Group A-birth weight > 2500 grams and well

<!-- PAGE=? -->
VATER

<!-- PAGE=? -->
VATERC

<!-- PAGE=? -->
 Vertebral Defects:  hemivertebrae, absent pedicles, fused vertebrae, sacral dysgenesis

<!-- PAGE=? -->
 Anal Malformation:  imperforate anus

<!-- PAGE=? -->
 Tracheoesophageal Fistula

<!-- PAGE=? -->
 Esophageal Atresia

<!-- PAGE=? -->
 Radial (absent digits) and Renal (agenesis) Dysplasia

<!-- PAGE=? -->
 Congenital Heart defects (ASD) and SBE prophylaxis

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
Pentaspan

<!-- PAGE=? -->
CPS

<!-- PAGE=? -->
 hemostatic changes mainly by dilution

<!-- PAGE=? -->
 plasma volume expansion is greater than volume infused

<!-- PAGE=? -->
o 1:1.3

<!-- PAGE=? -->
 Rapidly elminated by kidney

<!-- PAGE=? -->
o a single dose of 500ml results in elimination of 70% within 24hrs, and 80% within 1 week

<!-- PAGE=? -->
 anaphylactoid reactions are more common with albumin infusions then with pentaspan

<!-- PAGE=? -->
 T1/2 is 18-24 hours

<!-- PAGE=? -->
o Group B1-birth weight 1800 to 2500 grams and well

<!-- PAGE=? -->
o Group B2-higher birth weight (>2500 grams), moderate pneumonia and congenital anomaly

<!-- PAGE=? -->
o Group C1-birth weight < 1800 grams

<!-- PAGE=? -->
o Group C2-higher birth weight and severe pneumonia and severe congenital anomaly

<!-- PAGE=? -->
 Group A: immediate correction, group B: staged repair, group C: delay surgery

<!-- PAGE=? -->
 Waterston classification less valuable in predicting outcome in the face of improvements made over the last 25 years in surgical technique, OR/ICU support, treatment of associated anomalies and reflux.

<!-- PAGE=? -->
 Overall survival is now 95%, independent of birth weight. The major cause of death was cardiac (2/3), sleep apnea, renal failure, and unknown causes.

<!-- PAGE=? -->
 The general opinion from a number of papers is that prematurity by itself does not significantly affect outcome and the preexistence of severe congenital anomalies and/or severe pulmonary complications prior to surgery are the principal causes of perioperative morbidity and mortality

<!-- PAGE=? -->
 Newer Montreal classification:

<!-- PAGE=? -->
o high-risk group: life-threatening anomalies, or both a major anomaly and ventilator dependence

<!-- PAGE=? -->
o low-risk group: all other patients

<!-- PAGE=? -->
Peripheral nerves

<!-- PAGE=? -->
Distribution

<!-- PAGE=? -->
Upper Extremity

<!-- PAGE=? -->
 median: pronate (pronator teres) + wrist flex

<!-- PAGE=? -->
o some wrist flexors, thenars (including opponens), lumbricals

<!-- PAGE=? -->
o lumbricals: MCP flexion

<!-- PAGE=? -->
 radial: supination, wrist + elbow extension

<!-- PAGE=? -->
o triceps, wrist and finger extensors and thumb extensors/abductors

<!-- PAGE=? -->
 musculocutaneous: elbow flexion (biceps)

<!-- PAGE=? -->
 ulnar: finger flexion, some wrist flexors, hypothenars, thumb adductor, lumbricals, all interosseus muscles (finger add and ABd)

<!-- PAGE=? -->
o interosseus: finger adduction and abduction

<!-- PAGE=? -->
 RUM thumb: radial = extension, ulnar = adduction, median = ABduction

<!-- PAGE=? -->
 musculocutaneous = C5/6

<!-- PAGE=? -->
 axillary = C5/6

<!-- PAGE=? -->
 radial = C6/7/8

<!-- PAGE=? -->
 median = C6/7/8/T1

<!-- PAGE=? -->
 ulnar = C8/T1

<!-- PAGE=? -->
 medial cutaneous arm = T1(2)

<!-- PAGE=? -->
 medial cutaneous forearm = T1

<!-- PAGE=? -->
The anterior interosseous nerve (volar interosseous nerve) is a branch of the median nerve that supplies the deep muscles on the front of the forearm, except the ulnar half of the flexor digitorum profundus

<!-- PAGE=? -->
Median

<!-- PAGE=? -->
Musculocutaneous

<!-- PAGE=? -->
Radial

<!-- PAGE=? -->
Supra-

<!-- PAGE=? -->
clavicular

<!-- PAGE=? -->
Axillary ,

<!-- PAGE=? -->
Ulnar

<!-- PAGE=? -->
crachial (72)

<!-- PAGE=? -->
Mejial

<!-- PAGE=? -->
crachial cu:

<!-- PAGE=? -->
Lareral

<!-- PAGE=? -->
Lareral

<!-- PAGE=? -->
antecrachial

<!-- PAGE=? -->
Medial

<!-- PAGE=? -->
antecrachial

<!-- PAGE=? -->
brachial

<!-- PAGE=? -->
Radial,

<!-- PAGE=? -->
superficial

<!-- PAGE=? -->
(C6-8)

<!-- PAGE=? -->
Rajial

<!-- PAGE=? -->
suoerficial

<!-- PAGE=? -->
Dorsal

<!-- PAGE=? -->
Palmar

<!-- PAGE=? -->
Jorsal

<!-- PAGE=? -->
7digtal

<!-- PAGE=? -->
Proper palmar digtal

<!-- PAGE=? -->
Palmar

<!-- PAGE=? -->
Mejian (C5-8)

<!-- PAGE=? -->
Forearm Sensation

<!-- PAGE=? -->
 Lateral cutaneous nerve of forearm (purple) Branch of musculocutaneous nerve.

<!-- PAGE=? -->
 Medial cutaneous nerve of forearm (green) - Branch of medial cord.

<!-- PAGE=? -->
 Posterior cutaneous nerve of forearm (pink) - Branch of radial nerve.

<!-- PAGE=? -->
C5,6

<!-- PAGE=? -->
[Musculocutaneous

<!-- PAGE=? -->
C5,6

<!-- PAGE=? -->
Axillary

<!-- PAGE=? -->
Radial

<!-- PAGE=? -->
C6,7,8,T1

<!-- PAGE=? -->
Median

<!-- PAGE=? -->
C8,T1

<!-- PAGE=? -->
Ulnar

<!-- PAGE=? -->
Medial Cutaneous

<!-- PAGE=? -->
of arm

<!-- PAGE=? -->
T1

<!-- PAGE=? -->
Medial Cutaneous

<!-- PAGE=? -->
of forearm

<!-- PAGE=? -->
Superficial Innervatlon

<!-- PAGE=? -->
Muscular Innervation

<!-- PAGE=? -->
Bone Innervation

<!-- PAGE=? -->
Truncal

<!-- PAGE=? -->
Inguinal block: anatomy

<!-- PAGE=? -->
T1o

<!-- PAGE=? -->
T11

<!-- PAGE=? -->
T12

<!-- PAGE=? -->
T12

<!-- PAGE=? -->
Subcostal n.

<!-- PAGE=? -->
Femoralor

<!-- PAGE=? -->
Illoing

<!-- PAGE=? -->
hal n

<!-- PAGE=? -->
Lateral

<!-- PAGE=? -->
lemoral

<!-- PAGE=? -->
cutaneous

<!-- PAGE=? -->
Ilioinguinal n

<!-- PAGE=? -->
L2,3

<!-- PAGE=? -->
Femoral br .

<!-- PAGE=? -->
S2,3

<!-- PAGE=? -->
Genitotemoral

<!-- PAGE=? -->
Femoral n

<!-- PAGE=? -->
Pudendal n.

<!-- PAGE=? -->
Genital br

<!-- PAGE=? -->
Genitotemoral n

<!-- PAGE=? -->
Femoral n.

<!-- PAGE=? -->
Lower Extremity

<!-- PAGE=? -->
 Lumbosacral trunk - L4,5 and S1,2,3,4

<!-- PAGE=? -->
 Lumbar plexus - L1-4 (L5 is included in the lumbarsacral trunk)

<!-- PAGE=? -->
o Iliohypogastric - L1

<!-- PAGE=? -->
o Ilioinguinal - L1

<!-- PAGE=? -->
o Genitofemoral - L1,2

<!-- PAGE=? -->
o Lateral femoral cutaneous - L2,3

<!-- PAGE=? -->
 Sensation to lateral thigh

<!-- PAGE=? -->
o Obturator - L2,3,4

<!-- PAGE=? -->
 does not run through the groove between iliacus & psoas

<!-- PAGE=? -->
 from L2,3

<!-- PAGE=? -->
 has articular branch to hip

<!-- PAGE=? -->
 provides sensory to medial thigh

<!-- PAGE=? -->
o Femoral - L2,3,4

<!-- PAGE=? -->
 runs through the groove between iliacus & psoas

<!-- PAGE=? -->
 roots L2,3,4

<!-- PAGE=? -->
 articular branches to hip

<!-- PAGE=? -->
 sensory to medial thigh

<!-- PAGE=? -->
 Saphenous

<!-- PAGE=? -->
 distal branch of the femoral nerve

<!-- PAGE=? -->
 medial lower leg innervation

<!-- PAGE=? -->
 Sacral plexus

<!-- PAGE=? -->
o Superior gluteal

<!-- PAGE=? -->
o Sciatic (Tibial and Common Peroneal) (L4,L5,S1,2,3)

<!-- PAGE=? -->
o Nerve to Obturator Internis

<!-- PAGE=? -->
o Nerve to pyriformis (S1,2)

<!-- PAGE=? -->
o Posterior cutaneous nerve of the thigh (S2,3,4)

<!-- PAGE=? -->
o Pudendal (S2,3,4)

<!-- PAGE=? -->
o Coccygeal (S4,O1)

<!-- PAGE=? -->
Femoral N

<!-- PAGE=? -->
Saphenous N

<!-- PAGE=? -->
Obturator N

<!-- PAGE=? -->
Lateral Femoral Cutaneous N

<!-- PAGE=? -->
Genito Femoral N

<!-- PAGE=? -->
Iliohypogastric N

<!-- PAGE=? -->
Sciatic N

<!-- PAGE=? -->
Posterior Femoral Cutaneous N

<!-- PAGE=? -->
Tibial N

<!-- PAGE=? -->
Sural N

<!-- PAGE=? -->
Medial Planuar N

<!-- PAGE=? -->
Lateral Plantar N

<!-- PAGE=? -->
Calcaneal N

<!-- PAGE=? -->
Common Peroneal N

<!-- PAGE=? -->
Lareral Cutaneous N

<!-- PAGE=? -->
Superficial Pcroncal N

<!-- PAGE=? -->
Peroneal N

<!-- PAGE=? -->
ANTERIOR VIEW

<!-- PAGE=? -->
POSTERIOR VIEW

<!-- PAGE=? -->
Deep

<!-- PAGE=? -->
Common

<!-- PAGE=? -->
Peroneal

<!-- PAGE=? -->
Nerve

<!-- PAGE=? -->
Dorsi Flexion

<!-- PAGE=? -->
Eversion

<!-- PAGE=? -->
Tibial

<!-- PAGE=? -->
Nerve

<!-- PAGE=? -->
Plantar Flexion

<!-- PAGE=? -->
Flexion of the Tocs

<!-- PAGE=? -->
Inversion

<!-- PAGE=? -->
WWW.nysora.com

<!-- PAGE=? -->
Popliteal Block: Distribution of Anesthesia

<!-- PAGE=? -->
Laloral

<!-- PAGE=? -->
Lateral Sural

<!-- PAGE=? -->
Sural

<!-- PAGE=? -->
Cutaneous

<!-- PAGE=? -->
Deep peroneal nerve

<!-- PAGE=? -->
Cutanoous

<!-- PAGE=? -->
Saphenous

<!-- PAGE=? -->
Saphenous

<!-- PAGE=? -->
Plantar n.

<!-- PAGE=? -->
Supeficial Peroneal

<!-- PAGE=? -->
PT

<!-- PAGE=? -->
Superficial

<!-- PAGE=? -->
Poroncal

<!-- PAGE=? -->
Sural

<!-- PAGE=? -->
Sural n

<!-- PAGE=? -->
surol

<!-- PAGE=? -->
Modial Plantar

<!-- PAGE=? -->
Sural

<!-- PAGE=? -->
Calcaneal n

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
Decp pcroncal

<!-- PAGE=? -->
WWW.nysora.com

<!-- PAGE=? -->
Neuropathy

<!-- PAGE=? -->
Checklist:

<!-- PAGE=? -->
Check for preoperative nerve dysfunction.

<!-- PAGE=? -->
Check tourniquet problems-duration and pressure.

<!-- PAGE=? -->
Check postoperative position, splints, tight bandages; rule out compartment syndrome.

<!-- PAGE=? -->
Check intraoperative surgical factors.

<!-- PAGE=? -->
Risk of neuropraxia is more common in prolonged surgery.

<!-- PAGE=? -->
Table 28-2 -- Distribution of claims for nerve injury

<!-- PAGE=? -->
Upper extremity

<!-- PAGE=? -->
 Ulnar nerve injury is thought to be associated with external nerve compression or stretch

<!-- PAGE=? -->
 three other that may contribute

<!-- PAGE=? -->
o male sex

<!-- PAGE=? -->
o inc. BMI (≥38)

<!-- PAGE=? -->
o prolonged postoperative bed rest

<!-- PAGE=? -->
Lower Extremity

<!-- PAGE=? -->
 motor neuropathies persisting more than 3 months has an incidence of 1 in 3608

<!-- PAGE=? -->
 common peroneal nerve was the most frequent

<!-- PAGE=? -->
o Motor function of the affected nerve recovered in 43% of the patients within 1 year

<!-- PAGE=? -->
 Lithotomy Position Injuries

<!-- PAGE=? -->
o Three risk factors were strongly associated with increased risk of developing a neuropathy in the lithotomy position:

<!-- PAGE=? -->
 prolonged surgery (>3 hours)

<!-- PAGE=? -->
 very thin body habitus

<!-- PAGE=? -->
 recent cigarette smoking

<!-- PAGE=? -->
o Nerves involved include (in dec. frequency)

<!-- PAGE=? -->
 Obturator

<!-- PAGE=? -->
 lateral femoral cutaneous

<!-- PAGE=? -->
 sciatic

<!-- PAGE=? -->
 peroneal nerves

<!-- PAGE=? -->
Evaluation and Treatment

<!-- PAGE=? -->
 early neurology consultation for patients with motor neuropathies;

<!-- PAGE=? -->
o Electromyographic (EMG) studies can be helpful to determine the location of the lesion and may provide information on the potential reversibility of any nerve deficit

<!-- PAGE=? -->
 records electrical activity in muscle tissue and is used to distinguish neuropathy from muscle disease (myopathy)

<!-- PAGE=? -->
 Sensory neuropathies often are transient, and initial reassurance might be all that is necessary

<!-- PAGE=? -->
 Since anesthesiologists often will be unable to provide long-term surveillance of patients who develop sensory deficits, it seems prudent to seek neurology consultation for sensory deficits lasting more than 5 days.

<!-- PAGE=? -->
Prevention

<!-- PAGE=? -->
Table 28-3   -- Consensus Findings of the ASA Task Force on Prevention of Perioperative Peripheral Neuropathies

<!-- PAGE=? -->
Preoperative Assessment

<!-- PAGE=? -->
When judged appropriate, it is helpful to ascertain that patients can comfortably tolerate the anticipated operative position.

<!-- PAGE=? -->
Upper Extremity Positioning

<!-- PAGE=? -->
Arm abduction should be limited to 90 degrees in supine patients; patients who are positioned prone may comfortably tolerate arm abduction greater than 90 degrees.

<!-- PAGE=? -->
Arms should be positioned to decrease pressure on the postcondylar groove of the humerus (i.e., ulnar groove). When arms are tucked at the side, a neutral forearm position is recommended. When arms are abducted on armboards, supination or a neutral forearm position is acceptable.

<!-- PAGE=? -->
Prolonged pressure on the radial nerve in the spiral groove of the humerus should be avoided.

<!-- PAGE=? -->
Extension of the elbow beyond a comfortable range may stretch the median nerve.

<!-- PAGE=? -->
Lower Extremity Positioning

<!-- PAGE=? -->
Lithotomy positions that stretch the hamstring muscle group beyond a comfortable range may stretch the sciatic nerve.

<!-- PAGE=? -->
Prolonged pressure on the peroneal nerve at the fibular head should be avoided.

<!-- PAGE=? -->
Neither extension nor flexion of the hip increases the risk of femoral neuropathy.

<!-- PAGE=? -->
Protective Padding

<!-- PAGE=? -->
Padded armboards may decrease the risk of upper extremity neuropathy.

<!-- PAGE=? -->
The use of chest rolls in laterally positioned patients may decrease the risk of upper extremity neuropathies.

<!-- PAGE=? -->
Padding at the elbow and at the fibular head may decrease the risk of upper and lower extremity neuropathies, respectively.

<!-- PAGE=? -->
Equipment

<!-- PAGE=? -->
Properly functioning automated blood pressure cuffs on the upper arms do not affect the risk of upper extremity neuropathies.

<!-- PAGE=? -->
Shoulder braces in steep head-down positions may increase the risk of brachial plexus neuropathies.

<!-- PAGE=? -->
Postoperative Assessment

<!-- PAGE=? -->
A simple postoperative assessment of extremity nerve function may lead to early recognition of peripheral neuropathies.

<!-- PAGE=? -->
Documentation

<!-- PAGE=? -->
Charting specific positioning actions during the care of patients may result in improvements of care by (1) helping practitioners focus attention on relevant aspects of patient positioning and by (2) providing information that continuous improvement processes can lead to refinements in patient care.

<!-- PAGE=? -->
Positioning

<!-- PAGE=? -->
Lateral Decubitus

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 The down side peroneal nerve is padded to minimize compression damage caused by the weight of the legs

<!-- PAGE=? -->
 pillows are placed between the lower extremities

<!-- PAGE=? -->
 The head is supported so that the cervical and thoracic spines are properly aligned

<!-- PAGE=? -->
 A small pad (axillary roll), thick enough to raise the thorax and prevent excessive compression of the shoulder, is placed just caudad to and out of the down-side axilla

<!-- PAGE=? -->
o ensure adequate perfusion of the down-side hand

<!-- PAGE=? -->
o minimize circumduction of the dependent shoulder, which might stretch its suprascapular nerve

<!-- PAGE=? -->
 Injuries to the dependent eye are unlikely if the head is properly supported

<!-- PAGE=? -->
o Direct pressure on the globe can

<!-- PAGE=? -->
 displace the lens

<!-- PAGE=? -->
 cause retinal ischemia (with hypotension)

<!-- PAGE=? -->
 Careful padding with a pillow or a foam sponge is usually sufficient protection against contusion of the ear

<!-- PAGE=? -->
 Care must be taken to see that the hip tapes or straps lie safely between the iliac crest and the head of the femur rather than over the head of the femur

<!-- PAGE=? -->
o May cause avascular necrosis of the femoral neck

<!-- PAGE=? -->
Potassium physiology

<!-- PAGE=? -->
 Primary intracellular cation (98% in ICF, 2% ECF)

<!-- PAGE=? -->
 Potassium requirements

<!-- PAGE=? -->
o Adult: 1-1.5 mEq/kg/day, infant: 2-3  mEq/kg/day

<!-- PAGE=? -->
o Depends on metabolic rate: increases dramatically with nutrition in previously starved individuals (part of refeeding syndrome)

<!-- PAGE=? -->
 Regulation

<!-- PAGE=? -->
o Na + /K + -ATPase maintains transcellular gradient

<!-- PAGE=? -->
o β2-Adrenergic drugs

<!-- PAGE=? -->
o Insulin

<!-- PAGE=? -->
o pH (acidosis potentiates extracellular shift)

<!-- PAGE=? -->
o aldosterone (increase excretion by secretion of K + at collecting duct)

<!-- PAGE=? -->
Hyperkalemia

<!-- PAGE=? -->
 Potassium >5.5 mEq/L

<!-- PAGE=? -->
 Caused by wide variety of disease states and drugs that ↓ renal potassium excretion

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
 Factitious/pseudohyperkalemia - hemolysis, leukocytosis or thrombocytosis

<!-- PAGE=? -->
 Transcellular potassium shift (ICF  ECF)

<!-- PAGE=? -->
o Succinylcholine

<!-- PAGE=? -->
o Acidosis

<!-- PAGE=? -->
o Insulin deficiency

<!-- PAGE=? -->
o Reperfusion of large vascular bed after period of ischemia (usu >4h)

<!-- PAGE=? -->
o Cell necrosis (e.g. chemotherapy causing tumor lysis, rhabdomyolysis)

<!-- PAGE=? -->
o Malignant hyperthermia

<!-- PAGE=? -->
o Periodic paralysis

<!-- PAGE=? -->
 Increased total body potassium

<!-- PAGE=? -->
o Chronic renal failure (most common cause of chronic hyperkalemia) or acute oliguric renal failure

<!-- PAGE=? -->
o Iatrogenic

<!-- PAGE=? -->
 Overly rapid correction of hypokalemia

<!-- PAGE=? -->
 Blood transfusion

<!-- PAGE=? -->
 Antibiotics containing potassium salts

<!-- PAGE=? -->
o Hypoaldosteronism

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 Amiloride

<!-- PAGE=? -->
 ACE Inhibitors

<!-- PAGE=? -->
 Angiotensin II inhibitors

<!-- PAGE=? -->
 Pentamidine

<!-- PAGE=? -->
 Spironolactone

<!-- PAGE=? -->
 Triamterene

<!-- PAGE=? -->
 Trimethoprim

<!-- PAGE=? -->
 NSAIDs

<!-- PAGE=? -->
 Heparin

<!-- PAGE=? -->
Symptoms

<!-- PAGE=? -->
 Symptoms of hyperkalemia usually manifest at very high levels

<!-- PAGE=? -->
 Can produce muscle weakness (>8 mEq/L), hypotension, paresthesias, and ascending paralysis

<!-- PAGE=? -->
Signs

<!-- PAGE=? -->
 Progressive ECG changes (Miller)

<!-- PAGE=? -->
o narrowed peaked T-waves, shortened QT interval

<!-- PAGE=? -->
o low P-wave amplitude, widened QRS complex, prolonged PR interval, possible 2 nd /3 rd deg. block

<!-- PAGE=? -->
o sine wave ventricular flutter, and eventually asystole

<!-- PAGE=? -->
o ST segments remain sensitive to ischemic changes

<!-- PAGE=? -->
 ECG Findings with increasing serum potassium (from ACLS-AP)

<!-- PAGE=? -->
o 5.5 to <6 = peaking Twaves

<!-- PAGE=? -->
o 6 to <6.5 = increasing PR and QT intervals

<!-- PAGE=? -->
o 6.5 to <7 = flattened P waves and ST segments

<!-- PAGE=? -->
o 7 to < 7.5 = widened QRS complexes, AV conduction delay, loss of P waves

<!-- PAGE=? -->
o 7.5 to < 8 = deepening S waves, merging of S and T waves

<!-- PAGE=? -->
o 8 to 10 = sine-wave shaped complexes begin; idioventricular complexes and rhythms; VT-like appearance

<!-- PAGE=? -->
o 10 = PEA (often with a -sine wave‖ appearance), VF/VT, asystole

<!-- PAGE=? -->
 Terminal event is usually vfib or asystole

<!-- PAGE=? -->
 Supraventricular tachycardia, atrial fibrillation, PVCs, ventricular tachycardia, ventricular fibrillation, or sinus arrest may all occur

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
 Delay elective surgery until hyperkalemia corrected

<!-- PAGE=? -->
 Continuous ECG monitoring with hyperkalemia, or potassium replacement

<!-- PAGE=? -->
 Avoid succinylcholine (normally ↑ K + by 0.5 mEq/L)

<!-- PAGE=? -->
 Avoid IV solutions containing K+

<!-- PAGE=? -->
o Ringer's = 4 mEq/L

<!-- PAGE=? -->
o Normosol/Plasmalyte = 5 mEq/L

<!-- PAGE=? -->
 Avoid resp/metabolic acidosis

<!-- PAGE=? -->
 No effect on MAC or duration of NMB

<!-- PAGE=? -->
 Causes electrical disturbances and poor contractility

<!-- PAGE=? -->
 SVT, Afib, PVCs, VT, VF, asystole can all occur

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 Determined by setting and ECG changes

<!-- PAGE=? -->
 Antagonists , drugs to shift K + intracellularly, drugs to eliminate K +

<!-- PAGE=? -->
 MILD (5 to 6 mEq/L) - eliminate potassium from the body:

<!-- PAGE=? -->
o Diuretics: Furosemide 1 mg/kg slow IV

<!-- PAGE=? -->
o Resins: Kayexalate 15 - 30 g in 50-100 mL of 20% sorbitol, either orally or by retention enema

<!-- PAGE=? -->
o Dialysis: Peritoneal or hemodialysis (usually for more severe cases)

<!-- PAGE=? -->
 MODERATE (6 to 7 mEq/L) - initiate temporary intracellular shift:

<!-- PAGE=? -->
o Hyperventilation

<!-- PAGE=? -->
o Sodium bicarbonate : 50 mEq/L IV or up to 1 mEq/kg over 5 minutes

<!-- PAGE=? -->
o Insulin +/- glucose: 10U regular insulin and 25 g (50mL of D50), and give IV over 15 to 30 minutes

<!-- PAGE=? -->
o Nebulized salbutamol : 5 to 20 mg over 15 minutes

<!-- PAGE=? -->
o Then begin elimination with diuretics, resins, or dialysis (as above)

<!-- PAGE=? -->
 SEVERE (potassium-induced ECG changes/dysrhythmias) - first antagonize:

<!-- PAGE=? -->
o Immediately give 5 to 10 mL of 10% calcium chloride IV (0.5 to 1 g) over 2 to 5 minutes to stabilize heart and antagonize effects of potassium

<!-- PAGE=? -->
o Then initiate rapid shift of potassium intracellularly (as above)

<!-- PAGE=? -->
o Then begin elimination with diuretics, resins, or dialysis (as above)

<!-- PAGE=? -->
Problems

<!-- PAGE=? -->
 Cardiac dysrhythmias, arrest

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
 Potassium <3.5 mEq/L

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
 Four most common causes are:

<!-- PAGE=? -->
o Reduced intake (anorexia, starvation, chronic EtOH)

<!-- PAGE=? -->
o GI losses (vomiting, diarrhea, adenoma)

<!-- PAGE=? -->
o Excessive Renal losses

<!-- PAGE=? -->
 Primary or secondary hyperaldosteronism ( excess mineralocorticoids)

<!-- PAGE=? -->
 Diuretics

<!-- PAGE=? -->
 Chronic metabolic alkalosis

<!-- PAGE=? -->
 RTA

<!-- PAGE=? -->
o Potassium shifts from extracellular to intracellular

<!-- PAGE=? -->
 Acute alkalosis, insulin therapy, stress-related catecholamine activity, and hypokalemic periodic paralysis

<!-- PAGE=? -->
 Surgical stress can decrease potassium by 0.5 mEq/L

<!-- PAGE=? -->
 Medications

<!-- PAGE=? -->
o Exogenous catecholamines (isoproterenol, terbutaline, epinephrine, ritodrine, B2 agonists for tocolytic or respiratory therapy)

<!-- PAGE=? -->
o Penicillin, naficillin, ticarcillin

<!-- PAGE=? -->
o Diuretics (lasix)

<!-- PAGE=? -->
o Insulin

<!-- PAGE=? -->
o Vit B12

<!-- PAGE=? -->
o Lithium overdose

<!-- PAGE=? -->
Symptoms (K+ < 2 to 2.5)

<!-- PAGE=? -->
 Muscular weakness

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
Cardiovascular manifestations

<!-- PAGE=? -->
 autonomic neuropathy

<!-- PAGE=? -->
o orthostatic hypotension

<!-- PAGE=? -->
o dec. sympathetic reserve

<!-- PAGE=? -->
 impaired myocardial contractility

<!-- PAGE=? -->
 electrical conduction abnormalities

<!-- PAGE=? -->
o sinus tachycardia

<!-- PAGE=? -->
o atrial and ventricular arrhythmias

<!-- PAGE=? -->
o disturbances in intraventricular conduction that can progress to ventricular fibrillation

<!-- PAGE=? -->
o enhanced cardiac automaticity and a decreased rate of myocardial repolarization

<!-- PAGE=? -->
 ECG changes

<!-- PAGE=? -->
o widening of the QRS complex

<!-- PAGE=? -->
o prolonged QT

<!-- PAGE=? -->
o ST-segment abnormalities

<!-- PAGE=? -->
 Unreliable for ischemic changes

<!-- PAGE=? -->
o progressive diminution of the T-wave amplitude

<!-- PAGE=? -->
o progressive increase in the U-wave amplitude

<!-- PAGE=? -->
 Other conditions that may increase the amplitude of the U wave include hypercalcemia, digitalis, class 1A and 3 antiarrhythmic drugs, thyrotoxicosis, intracranial hemorrhage, exercise, and the congenital long QT syndrome

<!-- PAGE=? -->
Electrocardiographic features of hypokalacmia

<!-- PAGE=? -->
Broad fal [ waves

<!-- PAGE=? -->
ST depression

<!-- PAGE=? -->
QI interval prolongation

<!-- PAGE=? -->
Ventricular arrhythumnias (premnature ventricular contractions,

<!-- PAGE=? -->
torsades de pointcs; ventricular tachycardia ventricular fibrillation)

<!-- PAGE=? -->
ST depression

<!-- PAGE=? -->
Uuave

<!-- PAGE=? -->
Flat Twave

<!-- PAGE=? -->
hypokalaemia. RighL: Electrocardiogram showing proninent U wave;

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
 No  studies demonstrate increased morbidity or mortality for patients undergoing anesthesia with potassium > 2.6 mEq/L

<!-- PAGE=? -->
 Hypokalaemia  results in

<!-- PAGE=? -->
o resistance to Depolarizing NMB

<!-- PAGE=? -->
 hyperpolarized cell

<!-- PAGE=? -->
o Sensitivity to NdMB

<!-- PAGE=? -->
o diminished ability for neostigmine to antagonise blockade

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
 IV potassium chloride is limited to 0.5 to 1.0 mEq/kg/hour

<!-- PAGE=? -->
 Usual replacement rate is 20 to 40 mEq/hour with constant ECG monitoring

<!-- PAGE=? -->
Problems

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
Pharmacokinetics

<!-- PAGE=? -->
Vd = dose / initial concentration Clearance = k x Vd (k = Cl /Vd) T1/2 = 0.693 / k (T1/2 = 0.693 x Vd / Cl) Steady state ≈ infusion / clearance Elimination ≈ clearance / dose Elimination ≈ k x Vd / dose Actual drug removal = Cl x [drug]

<!-- PAGE=? -->
1 st order kinetics - half life is dose independant -50% eliminated in one half life Zero order kinetics - half life is dose dependant

<!-- PAGE=? -->
First Order Kinetics

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 most drugs follow first-order kinetics

<!-- PAGE=? -->
 A first-order kinetic process is one in which a constant fraction of the drug is removed during a finite period of time

<!-- PAGE=? -->
o fraction is equivalent to the rate constant of the process

<!-- PAGE=? -->
 Rate constants are usually denoted by the letter k, and have units of -inverse time,‖

<!-- PAGE=? -->
 If 10% of the drug is eliminated per minute, then the rate constant is 0.1 min-1

<!-- PAGE=? -->
o Because a constant fraction is removed per unit of time, the absolute amount of drug removed is proportional to the concentration of the drug

<!-- PAGE=? -->
 The rate of change of the concentration at any given time is proportional to the concentration present at that time

<!-- PAGE=? -->
 When the concentration is high, it will fall faster than when it is low

<!-- PAGE=? -->
 First-order kinetics apply not only to elimination, but also to absorption and distribution

<!-- PAGE=? -->
o after five half-times, the process will be almost 97% complete

<!-- PAGE=? -->
 Zero-order kinetics: constant amount of drug is metabolized per unit time

<!-- PAGE=? -->
Clearance:

<!-- PAGE=? -->
 volume that is completely cleared of drug per unit of time

<!-- PAGE=? -->
 the actual rate of drug removal is the clearance times the concentration of the drug

<!-- PAGE=? -->
 NOT changed by infusion rate, dose, plasma concentration

<!-- PAGE=? -->
 directly proportional to Vd

<!-- PAGE=? -->
o Cl = k * Vd

<!-- PAGE=? -->
 related to hepatic metabolism and is dose (in)dependent

<!-- PAGE=? -->
T1/2

<!-- PAGE=? -->
 T1/2 of elimination is determined by Vd and clearance

<!-- PAGE=? -->
o Directly proportional to Vd and inversely proportion to Cl

<!-- PAGE=? -->
 t1/2 = (0.693 * Vd) / Cl

<!-- PAGE=? -->
 the greater the volume of distribution, the longer the elimination half-time

<!-- PAGE=? -->
 the greater the clearance, the shorter the elimination half-time,

<!-- PAGE=? -->
 Knowledge of the elimination half-time for a drug is important for achieving a constant plasma concentration of drug

<!-- PAGE=? -->
Steady State

<!-- PAGE=? -->
 Steady state concentration will depend on infusion and clearance.

<!-- PAGE=? -->
 To maintain an unchanging plasma concentration of drug (steady state), the infusion rate must be equal to the rate of drug clearance by hepatic and renal clearance mechanisms

<!-- PAGE=? -->
Volume of Distribution

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 Vd = amount of drug administered/initial drug plasma concentration

<!-- PAGE=? -->
o If a drug is extensively distributed then the concentration will be lower relative to the amount of drug present-this is a larger volume of distribution

<!-- PAGE=? -->
 Vd quantifies the extent of drug distribution

<!-- PAGE=? -->
o governed by the overall capacity of the tissues versus the capacity of the blood for that drug

<!-- PAGE=? -->
o Overall tissue capacity for drug uptake is a function of the total mass of the tissues into which a drug distributes and the tissue's average affinity for that drug

<!-- PAGE=? -->
 Vd is influenced by physicochemical characteristics of the drug, including

<!-- PAGE=? -->
o lipid solubility

<!-- PAGE=? -->
o binding to plasma proteins

<!-- PAGE=? -->
o molecular size

<!-- PAGE=? -->
 Binding to plasma proteins and poor lipid solubility limit passage of drug to tissues, maintaining a high concentration in the plasma and a small calculated Vd

<!-- PAGE=? -->
 Lipophilic drugs have larger Vds than hydrophilic drugs

<!-- PAGE=? -->
o Vd of barbiturates = 2-2.5L/kg

<!-- PAGE=? -->
o Vd of benzos = 0.7-1.7 L/kg

<!-- PAGE=? -->
o Vd of local anaesthetics = 0.50 (chloroprocaine) to 2.73 (prilocaine)

<!-- PAGE=? -->
o Vd of NdMB is equal to the ECF volume - 0.2-0.4L/kg

<!-- PAGE=? -->
Phase I and II reactions

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
 Phase I reactions include

<!-- PAGE=? -->
o Oxidation

<!-- PAGE=? -->
 reactions that remove electrons from a molecule

<!-- PAGE=? -->
 insertion of a hydroxyl group (OH) - hydroxylation

<!-- PAGE=? -->
o may produce chemically stable, more polar hydroxylated metabolite or unstable compounds that spontaneously split into separate molecules

<!-- PAGE=? -->
 following an initial hydroxylation

<!-- PAGE=? -->
o Dealkylation (removal of a carbon-containing group)

<!-- PAGE=? -->
o deamination (removal of nitrogen-containing groups)

<!-- PAGE=? -->
o dehalogenation

<!-- PAGE=? -->
o dehydrogenation

<!-- PAGE=? -->
o Reduction

<!-- PAGE=? -->
 Reactions that add electrons to a molecul

<!-- PAGE=? -->
 reductive biotransformation is inhibited by oxygen, so it is facilitated when the intracellular oxygen tension is low

<!-- PAGE=? -->
o Hydrolysis

<!-- PAGE=? -->
 insertion of a molecule of water into another molecule

<!-- PAGE=? -->
 usually forms an unstable intermediate compound that subsequently splits apart

<!-- PAGE=? -->
 Phase II reactions

<!-- PAGE=? -->
o Conjugation

<!-- PAGE=? -->
 Forms water-soluble, polar metabolites

<!-- PAGE=? -->
Pheochromocytoma

<!-- PAGE=? -->
 free catecholamine concentration and catecholamine metabolites in the urine is the most common screening test

<!-- PAGE=? -->
o VMA and unconjugated norepinephrine and epinephrine levels are measured in a 24-hour urine collection

<!-- PAGE=? -->
o expressed as a function of the creatinine clearance

<!-- PAGE=? -->
o VMA level is elevated in most cases

<!-- PAGE=? -->
o Urinary metanephrine is not quantified because it is not predictably elevated

<!-- PAGE=? -->
o Free catecholamines represent less than 1% of the originally released hormone, and urinary levels are not always elevated to a significant degree

<!-- PAGE=? -->
o some patients with paroxysmal hypertension have normal values between attacks

<!-- PAGE=? -->
Pre-op guidelines to adequate alpha-blockade (Roizen et al. criteria):

<!-- PAGE=? -->
    No in-hospital BP reading higher than 165/90 mm Hg should be evident for 48 hours before surgery. We often measure arterial BP every minute for 1 hour in a stressful environment (our postanesthesia care unit). If no BP reading is greater than 165/90, this criterion is considered satisfied.

<!-- PAGE=? -->
    Orthostatic hypotension should be present, but BP on standing should not be lower than 80/45 mm Hg.

<!-- PAGE=? -->
    The ECG should be free of ST-T changes that are not permanent.

<!-- PAGE=? -->
    No more than one premature ventricular contraction (PVC) should occur every 5 minutes.

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Alpha-Adrenergic blockade is initiated once the diagnosis of pheochromocytoma is established

<!-- PAGE=? -->
o phenoxybenzamine, a long-acting (24-48 hours), noncompetitive presynaptic (a2) and postsynaptic (a1) blocker, at doses of 10 mg every 8 hours

<!-- PAGE=? -->
 inc. dose until the blood pressure is controlled and paroxysms disappear

<!-- PAGE=? -->
 ~ 80 and 200 mg/day

<!-- PAGE=? -->
 Side effects

<!-- PAGE=? -->
 blunted cardiovascular reflexes

<!-- PAGE=? -->
 postural hypotension

<!-- PAGE=? -->
 nasal stuffiness

<!-- PAGE=? -->
 impaired ejaculation

<!-- PAGE=? -->
o Prazosin, a competitive postsynaptic (a1) blocking agent with a shorter halflife than phenoxybenzamine, has also been used effectively

<!-- PAGE=? -->
o blockade of both a1 and a2 receptors (phenoxybenzamine) might be preferable in patients with severe hypertension

<!-- PAGE=? -->
o most clinicians recommend beginning a blockade therapy at least 10-14 days before Surgery

<!-- PAGE=? -->
o During this time, the contracted intravascular volume and hematocrit return toward normal and the blood pressure is stabilized

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 derived from chromaffin tissue

<!-- PAGE=? -->
 <1% of all cases of HTN

<!-- PAGE=? -->
 usually found in adrenal medulla, but can occur anywhere

<!-- PAGE=? -->
 malignant spread < 15% (generally liver)

<!-- PAGE=? -->
 can be familiar -> MEN Type II a or b -> often bilateral

<!-- PAGE=? -->
 Signs/Symptoms

<!-- PAGE=? -->
o sweating, H/A, hypertension, orthostatic hypotension, tachycardia, glucose intol, polycythemia, wt loss, psycho

<!-- PAGE=? -->
o Often paroxysmal - classic sx's more sensitive than biochemical tests

<!-- PAGE=? -->
Coexisting

<!-- PAGE=? -->
 < 10% malignant

<!-- PAGE=? -->
 typically occur in pts 30-50yo

<!-- PAGE=? -->
 can occur as part of auto dom syndrome: MEN type 2 (a or b)

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o Chemical conf'n of xs catechol's: metabolites of norepi (normetanephrine, metanephine, VMA) or free norepi in urine 24h collection

<!-- PAGE=? -->
o Clonidine will decrease plasma concentrations of catechol's that are released by SNS but NOT by Pheo

<!-- PAGE=? -->
 Signs/Sx's

<!-- PAGE=? -->
o Classic triad: paroxysmal diaphoresis, tachycardia, h/a in hypertensive pt - highly sensitive

<!-- PAGE=? -->
o Can develop dilated cardiomyopathy and CHF

<!-- PAGE=? -->
 Preop

<!-- PAGE=? -->
o Serial measurements of Hct is useful for evaluating intravascular volume expansion and satifactory alpha block (want to see decrease by 5%)

<!-- PAGE=? -->
o Continue preop tx up to OR

<!-- PAGE=? -->
o Risk factors for perioperative complications

<!-- PAGE=? -->
 Large tumor

<!-- PAGE=? -->
 Prolonged surgey

<!-- PAGE=? -->
 High preop levels of catechol's

<!-- PAGE=? -->
 Postop

<!-- PAGE=? -->
o Persistent hypotension refractory to fluids is the principle postop complication

<!-- PAGE=? -->
 Reflects down-regulation of adrenergic receptors

<!-- PAGE=? -->
o Substantial number of pts will remain hypertensive

<!-- PAGE=? -->
o High index of suspicion for hypoglycemia

<!-- PAGE=? -->
o May require corticosteroid replacement if bilateral

<!-- PAGE=? -->
Pheochromocytoma and Pregnancy

<!-- PAGE=? -->
Chestnut

<!-- PAGE=? -->
 Pheo rare during pregnancy

<!-- PAGE=? -->
 Signs and symptoms similar in pregnant pt

<!-- PAGE=? -->
 May be mistaken for PIH

<!-- PAGE=? -->
 Dx prior to labour may reduce mortality from 35% to 0

<!-- PAGE=? -->
 Pregnant and nonpregnant women have similar urine levels of metanephrine and VMA

<!-- PAGE=? -->
 Can localize intraabdominal pheo with U/S, MRI, or CT

<!-- PAGE=? -->
 Medical and Surgical management

<!-- PAGE=? -->
o Definitive tx is surgical resection

<!-- PAGE=? -->
 Preoperative Preparation

<!-- PAGE=? -->
o Alpha-blockade and intravascular volume replacement

<!-- PAGE=? -->
 Phenoxybenzamine 10mg po bid (titrate up to 50)

<!-- PAGE=? -->
 Doxazosin, prazosin, phentolamine similar

<!-- PAGE=? -->
o Beta blockade after alpha if tachycardia or arrhythmias, concern with cardomyopathy

<!-- PAGE=? -->
o -emergency surgery to remove a pheochromocytoma from an unprepared pt should never be contemplated‖

<!-- PAGE=? -->
 Management during Pregnancy

<!-- PAGE=? -->
o Before 24 wks proceed with surgery after pt optimized

<!-- PAGE=? -->
o After 24 wks gravid uterus obstructs surgery, surgical resection can occur at time of C/S

<!-- PAGE=? -->
o Phenoxybenzamine easily crosses the placenta but does not have adverse fetal effects

<!-- PAGE=? -->
o Beta blockers are also safe

<!-- PAGE=? -->
o Nitroprusside 1mcg/kg/min should be safe (fetal cyanide toxicity with much higher doses)

<!-- PAGE=? -->
 Obstetrical Management

<!-- PAGE=? -->
o Increased incidence of fetal death and IUGR

<!-- PAGE=? -->
o Increased risk of abruption

<!-- PAGE=? -->
o Preferred method of delivery is C/S to minimize increased abdominal pressure with labour

<!-- PAGE=? -->
 Anesthetic Management

<!-- PAGE=? -->
o GA, Spinal, Epidural all used

<!-- PAGE=? -->
o Epidural or GA or combined preferred (avoid abrupt hemodynamic changes with SAB)

<!-- PAGE=? -->
Phenylephrine

<!-- PAGE=? -->
 Pure alpha drug

<!-- PAGE=? -->
 Inc. venous & arterial constriction in dose related manner

<!-- PAGE=? -->
 Constriction of capacitance vessels happens before arteriolar constriction.

<!-- PAGE=? -->
 Possible inotropic effect

<!-- PAGE=? -->
 No change CO in normal individuals, may dec. CO in patients with IHD

<!-- PAGE=? -->
 Does not produce dysrhythmias.

<!-- PAGE=? -->
Pneumoperitoneum

<!-- PAGE=? -->
 Peritoneal insufflation to IAPs more than 10 mm Hg induces significant alterations of hemodynamics mainly at the beginning of peritoneal insufflation

<!-- PAGE=? -->
 decreased cardiac output, increased MAP, increased SVR and PVR

<!-- PAGE=? -->
 HR remains unchanged or increases only slightly.

<!-- PAGE=? -->
 The decrease in cardiac output is proportional to the increase in IAP

<!-- PAGE=? -->
 cardiac output decreases 10% to 30% during peritoneal insufflation subsequently increases probably as a result of surgical stress

<!-- PAGE=? -->
 A decrease in venous return is observed after a transient increase in venous return

<!-- PAGE=? -->
 Increased IAP results in caval compression, pooling of blood in the legs and an increase in venous resistance

<!-- PAGE=? -->
 The decline in venous return parallels the decrease in cardiac output

<!-- PAGE=? -->
 reduced in LV end-diastolic volume

<!-- PAGE=? -->
 LVEF does not decrease significantly when IAP increases to 15 mm Hg

<!-- PAGE=? -->
 Cardiac filling pressures rise during peritoneal insufflation because of the increased intrathoracic pressure associated with pneumoperitoneum

<!-- PAGE=? -->
 Right atrial pressure and pulmonary artery occlusion pressure can no longer be considered reliable indices of cardiac filling pressures during pneumoperitoneum

<!-- PAGE=? -->
 The reduction in venous return and cardiac output can be attenuated by increasing circulating volume before the pneumoperitoneum (500cc NS) or slight head-down position before peritoneal insufflation, pneumatic compression device, or by wrapping the legs with elastic bandages

<!-- PAGE=? -->
 increased SVR from mechanical and neurohumoral factors

<!-- PAGE=? -->
 Catecholamines, the renin-angiotensin system, and especially vasopressin are all released during pneumoperitoneum and may contribute to increasing afterload

<!-- PAGE=? -->
 The increase in systemic vascular resistance is affected by patient position  Trendelenburg position attenuates this increase, the head-up position aggravates it

<!-- PAGE=? -->
 increase in SVR can be corrected by administration of vasodilating anesthetic agents, such as isoflurane, or direct vasodilating drugs, such as NTG or nicardipine

<!-- PAGE=? -->
 Use of α2-adrenergic agonists, such as clonidine or dexmedetomidine, and of β-blockers significantly reduces hemodynamic changes and anesthetic requirements.

<!-- PAGE=? -->
 Use of high doses of remifentanil almost completely prevents the hemodynamic changes

<!-- PAGE=? -->
 Urine output, renal plasma flow, and GFR decrease to less than 50%  Urine output significantly increases after desufflation

<!-- PAGE=? -->
 ICP rises during CO2 pneumoperitoneum independently of changes in Paco2

<!-- PAGE=? -->
pneumoperitoneum decr compliance 30-50%

<!-- PAGE=? -->
after pneumoperitoneum is created and kept constant, compliance is not affected by further pt tilting decr FRC

<!-- PAGE=? -->
dead space or shunt not really altered by IAP 14 and 10-20degrees tilt if healthy pt

<!-- PAGE=? -->
PaCO2 increases to plateau at 15-30min

<!-- PAGE=? -->
ETCO-PaCO2 gradients don't change much esp in ASA I

<!-- PAGE=? -->
CO2 has relatively small incr for its high solubility b/c large amts can be stored in blood and compression of vessels limiting absorption

<!-- PAGE=? -->
Pituitary Tumours

<!-- PAGE=? -->
Chromophobe adenomas are NON-SECRETORY

<!-- PAGE=? -->
Pituitary Surgery

<!-- PAGE=? -->
complications include

<!-- PAGE=? -->
 CSF rhinorrhea,

<!-- PAGE=? -->
 hypothalamic injury or stroke,

<!-- PAGE=? -->
 cerebral ischemia, and

<!-- PAGE=? -->
 meningitis.

<!-- PAGE=? -->
 Postop airway obstruction caused by bleeding and secretions in the pharynx

<!-- PAGE=? -->
Placental Abruption

<!-- PAGE=? -->
 RF = chronic HTN, PIH, preeclampsia, cocaine, excessive alcohol intake, smoking, previous history of abruption

<!-- PAGE=? -->
Pollution (Anesthetic Gases)

<!-- PAGE=? -->
Maximum allowable Anesthetic Gases NIOSH Recommendations, 1977

<!-- PAGE=? -->
Anesthetic Gas Maximum TWA Concentration Parts Per Million (PPM) Halogenated agent alone 2 ppm Nitrous oxide 25 ppm

<!-- PAGE=? -->
Combination of halogenated agent plus nitrous oxide:

<!-- PAGE=? -->
Halogenated agent

<!-- PAGE=? -->
0.5 ppm

<!-- PAGE=? -->
Nitrous oxide

<!-- PAGE=? -->
25 ppm

<!-- PAGE=? -->
Dental facilities (nitrous oxide alone)

<!-- PAGE=? -->
50 ppm

<!-- PAGE=? -->
Components

<!-- PAGE=? -->
Porphyria

<!-- PAGE=? -->
 result from defect in heme synthesis

<!-- PAGE=? -->
o used to make hemoglobin (O2 transport), myoglobin (O2 activation) and the cytochromes (electron transport chain)

<!-- PAGE=? -->
 Generally they manifest after puberty-usually auto dom

<!-- PAGE=? -->
Anesthetic Considerations

<!-- PAGE=? -->
Risk of Porphyric Crisis

<!-- PAGE=? -->
Avoidance of pharmacologic and physiologic triggers

<!-- PAGE=? -->
Neurologic dysfunction

<!-- PAGE=? -->
Autonomic

<!-- PAGE=? -->
Hypertension, Tachycardia , Abd pain, Vomiting, diarrhea, orthostatic hypotension

<!-- PAGE=? -->
Cranial

<!-- PAGE=? -->
Bulbar dysfunction ( Aspiration Risk ), respiratory dysfunction

<!-- PAGE=? -->
Peripheral

<!-- PAGE=? -->
Respiratory weakness , peripheral neuropathies, quadraplegia

<!-- PAGE=? -->
Anxiety, confusion, hysteria, seizures , coma

<!-- PAGE=? -->
CRF with severe volume depletion and electrolyte abnormalities

<!-- PAGE=? -->
Hypokalemia, hyponatremia (SIADH), hypomagnesemia

<!-- PAGE=? -->
Anesthetic Goals

<!-- PAGE=? -->
Adequate optimization

<!-- PAGE=? -->
Avoid prolonged fast (dehydration)

<!-- PAGE=? -->
Avoid triggers:

<!-- PAGE=? -->
Barbiturates, etomidate, steroids, diazepam,

<!-- PAGE=? -->
Fasting, progesterone, estrogen, infection, anemia

<!-- PAGE=? -->
Smoking, ETOH, marijuana, ecstasy, amphetamines, cocaine

<!-- PAGE=? -->
Be prepared to treat an acute crisis

<!-- PAGE=? -->
Fluids, glucose, hematin, cimetidine, somatostatin, plasmaphereis

<!-- PAGE=? -->
Manage Sz with midazolam/propofol - avoid diazepam, STP, phenytoin

<!-- PAGE=? -->
Table 3. Features of the Acute Porphyric Attack

<!-- PAGE=? -->
SSx:

<!-- PAGE=? -->
CNS : upper motor neuron lesions, CN palsies, cerebellum and basal ganglia involvment (rare), seizures

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
: postop resp failure from MSK

<!-- PAGE=? -->
weakness common

<!-- PAGE=? -->
Cardiac

<!-- PAGE=? -->
: autonomic NS neuropathy,

<!-- PAGE=? -->
tachycardia, HTN, cardiovascular instability

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
: N/V, abodo pain, diarrhea

<!-- PAGE=? -->
Metab

<!-- PAGE=? -->
: hypoNa, hypoK, hypoMg

<!-- PAGE=? -->
MSK

<!-- PAGE=? -->
: muscular weakness progressing

<!-- PAGE=? -->
to quadriparesis

<!-- PAGE=? -->
Skin

<!-- PAGE=? -->
: cutaneous bullous lesions

<!-- PAGE=? -->
 Acute porphyria- Delay Sx and Treat

<!-- PAGE=? -->
 Stop precipitant

<!-- PAGE=? -->
 Analgesia: opioids

<!-- PAGE=? -->
 Fluid: ensure adequate hydration and carbohydrate load (D5NS)

<!-- PAGE=? -->
o Administration of glucose suppresses ALA synthetase activity and prevents or ablates acute attacks

<!-- PAGE=? -->
 Hematin: 3-4 mg/kg IV over 20 minutes (supplements the intracellular pool of heme and suppresses ALA synthetase activity)

<!-- PAGE=? -->
o Alternative: Heme arginate (better side effect profile)

<!-- PAGE=? -->
 Beta blockers safe for tachycardia and hypertension

<!-- PAGE=? -->
 Seizures: regular anticonvulsants unsafe, use benzodiazepines

<!-- PAGE=? -->
 Psychosis: phenothiazines safe

<!-- PAGE=? -->
 Treat electrolyte disturbances aggressively

<!-- PAGE=? -->
 Somatostatin decreases the rate of ALA synthetase formation and combined with plasmapheresis may reduce pain and induce remission

<!-- PAGE=? -->
 Preoperatively:

<!-- PAGE=? -->
 Avoid prolonged fasting, add glucose to saline solution if required

<!-- PAGE=? -->
 Premedicate to decrease anxiety and stress which could ptt crisis

<!-- PAGE=? -->
 Check lytes: hypo-Na, K, Mg

<!-- PAGE=? -->
 PE: HTN, tachy, neuropathy, CN function, muscular strength, bullous skin lesions

<!-- PAGE=? -->
 No specific prophylaxis of benefit

<!-- PAGE=? -->
 Regional is OK but need good preoperative neuro exam to r/o exacerbation or acute attack

<!-- PAGE=? -->
Drugs - http://porphbook.tripod.com/2.html

<!-- PAGE=? -->
 Unsafe

<!-- PAGE=? -->
o Barbiturates

<!-- PAGE=? -->
o Etomidate - miller says safe

<!-- PAGE=? -->
o NSAIDs

<!-- PAGE=? -->
 Ketorolac

<!-- PAGE=? -->
 Diclofenac

<!-- PAGE=? -->
o ACE inhibitors

<!-- PAGE=? -->
o Ca channel blockers

<!-- PAGE=? -->
o Benzodiazepines - Diazepam, Librium

<!-- PAGE=? -->
o Cephalosporins

<!-- PAGE=? -->
o Sulphonamides

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
o Phenytoin

<!-- PAGE=? -->
 Disputed

<!-- PAGE=? -->
o Lidocaine?

<!-- PAGE=? -->
 In animals has precipitated attacks

<!-- PAGE=? -->
 Has been used for neuraxial in humans and for arrythmias IV (limited experience)

<!-- PAGE=? -->
 Steroids

<!-- PAGE=? -->
o Metoclopramide

<!-- PAGE=? -->
o Other NSAIDS

<!-- PAGE=? -->
 Safe

<!-- PAGE=? -->
o Propofol

<!-- PAGE=? -->
 Certainly safe as induction agent

<!-- PAGE=? -->
 Prolonged infusions can increase porphyrins, thus should probably avoid infusions

<!-- PAGE=? -->
o Ketamine

<!-- PAGE=? -->
 Probably safe and has been used in humans

<!-- PAGE=? -->
 However, does increases ALA synthetase

<!-- PAGE=? -->
 Should only use if clinically warranted

<!-- PAGE=? -->
o Midazolam and ativan probably safe

<!-- PAGE=? -->
o Volatiles / N2O

<!-- PAGE=? -->
o Neuromuscular blockers

<!-- PAGE=? -->
 SCh safe

<!-- PAGE=? -->
 Pancuronium has been listed as unsafe by some authors, however, the majority of NdMR (including pancuronium) are probably safe

<!-- PAGE=? -->
 Should probably avoid extended use of NdMR if possible

<!-- PAGE=? -->
 Weakness

<!-- PAGE=? -->
o Opioids

<!-- PAGE=? -->
o Acetaminophen

<!-- PAGE=? -->
Postherniorrhaphy pain

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Incidence of chronic postherniorrhaphy pain is estimated to be 10-15%

<!-- PAGE=? -->
o sensory disturbances are present that indicate a neuropathic pain state

<!-- PAGE=? -->
 cutaneous hypoesthesia

<!-- PAGE=? -->
 tactile allodynia

<!-- PAGE=? -->
 ilioinguinal nerve

<!-- PAGE=? -->
o provides sensory innervation to the upper medial part of the thigh and the upper part of the scrotum and penis or the labia major and the mons pubis

<!-- PAGE=? -->
 genitofemoral nerve that supplies the spermatic cord

<!-- PAGE=? -->
Post herpetic neuralgia

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 defined as pain persisting well beyond healing of the skin rash

<!-- PAGE=? -->
o 4 weeks to 6 months

<!-- PAGE=? -->
 Most commonly involves the thoracic dermatomes, with the trigeminal dermatone (ophthalmic division V1)  being the 2 nd  most common

<!-- PAGE=? -->


<!-- PAGE=? -->
Overall incidence among patients with herpes zoster infection has been reported to range from 9 to 34%

<!-- PAGE=? -->
o considerably higher in older patients

<!-- PAGE=? -->
 16% in patients under 60

<!-- PAGE=? -->
 47% in patients over 60

<!-- PAGE=? -->
 Antiviral agents have been advocated for management of the acute stage of the disease

<!-- PAGE=? -->
o modestly accelerate the rate of cutaneous healing and to reduce the severity of the acute pain

<!-- PAGE=? -->
o little evidence that it reduces the incidence of postherpetic neuralgia

<!-- PAGE=? -->
 famcyclovir does appear to reduce the incidence and severity if initiated early

<!-- PAGE=? -->
 Mainstays of treatment are

<!-- PAGE=? -->
o Anticonvulsants

<!-- PAGE=? -->
o Opioids

<!-- PAGE=? -->
 rarely provide dramatic relief

<!-- PAGE=? -->
o antidepressants

<!-- PAGE=? -->
 TCAs are first line therapy - best chance of relief with the fewest side-effects

<!-- PAGE=? -->
o The addition of a second drug, such as an anticonvulsant (carbamazepine, valproic acid, phenytoin), may provide some additional benefit

<!-- PAGE=? -->
o Gabapentin has been shown to be significantly more effective than placebo for the management of postherpetic neuralgia

<!-- PAGE=? -->
 local anesthetic blocks are ineffective - At best, they provide very temporary relief

<!-- PAGE=? -->
 No comment in barash 6 th regarding sympathetic blocks but Barash 4 th mentions that if done early they may dec. the incidence of PHN

<!-- PAGE=? -->
 TENS or Topical capsaicin may help in occasional patients, but cause aggravation of pain in patients with severe allodynia

<!-- PAGE=? -->
 steroid injection (Intrathecal, subcutaneous and epidural) have been shown to reduce the acute pain intensity and/or duration

<!-- PAGE=? -->
o No effect on the incidence of PHN

<!-- PAGE=? -->
 NSAIDs are ineffective

<!-- PAGE=? -->
PONV

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 most common anesthesia related reason both children and adults have protracted PACU stays or unexpected admission to hospital

<!-- PAGE=? -->
 most common adverse event in the PACU

<!-- PAGE=? -->
 Risk Factors

<!-- PAGE=? -->
o Previous Hx

<!-- PAGE=? -->
o female gender -  OR = 2.45

<!-- PAGE=? -->
o intraoperative opioids - OR = 4.18

<!-- PAGE=? -->
 effect mediated by direct stimulation of the chemotactic trigger zone

<!-- PAGE=? -->
 high dose morphine also has an antiemetic effect at the vomiting centre

<!-- PAGE=? -->
o Anesthesia

<!-- PAGE=? -->
 Inadequate hydration

<!-- PAGE=? -->
 Gastric distension

<!-- PAGE=? -->
o Procedure

<!-- PAGE=? -->
 laparoscopic

<!-- PAGE=? -->
 strabismus

<!-- PAGE=? -->
 length of procedure

<!-- PAGE=? -->
o Comorbid diseases

<!-- PAGE=? -->
 Menstration

<!-- PAGE=? -->
 Diabetes

<!-- PAGE=? -->
 Anxiety

<!-- PAGE=? -->
 Viral illness

<!-- PAGE=? -->
o Meidactions

<!-- PAGE=? -->
 Volatile

<!-- PAGE=? -->
 N2O - OR = 2.24

<!-- PAGE=? -->
 Neostigmine

<!-- PAGE=? -->
 Protective

<!-- PAGE=? -->
o smoker - OR = 0.53

<!-- PAGE=? -->
o Propofol - OR = 0.40

<!-- PAGE=? -->
o Hydration seems protective

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
o 5-HT3 antagonists are particularly effective

<!-- PAGE=? -->
 in children

<!-- PAGE=? -->
 granisetron > droperidol or meoclopramide

<!-- PAGE=? -->
 in adults

<!-- PAGE=? -->
 granisetrom, metoclopramide or hydroxyzine

<!-- PAGE=? -->
o dexamethasone can enhance treatment of established PONV in the PACU when given with other antiemetics

<!-- PAGE=? -->
o midazolam and propofol have antiemetic properties that outlast their sedative effects

<!-- PAGE=? -->
o Other antiemetics include

<!-- PAGE=? -->
 Atropine

<!-- PAGE=? -->
 Not used due to tachycardia

<!-- PAGE=? -->
 Benedryl

<!-- PAGE=? -->
 H1 antagonist with anti-seritonergic properties

<!-- PAGE=? -->
 Apfel study (NEJM, 350(24): 2441-51, 2004)

<!-- PAGE=? -->
o Risk factors:

<!-- PAGE=? -->
 female

<!-- PAGE=? -->
 nonsmoker

<!-- PAGE=? -->
 history of PONV or motion sickness

<!-- PAGE=? -->
 post op opioid use

<!-- PAGE=? -->
o Ondansetron, dexamethasone and droperidol each reduced the risk of PONV by 26%

<!-- PAGE=? -->
o Propofol reduced the risk by 19%

<!-- PAGE=? -->
o Avoiding nitrous oxide reduced the risk by 12%

<!-- PAGE=? -->
 Apfel et al.  Best Practice and Research Clinical Anesthesiology, 19(3): 485-500, 2005.

<!-- PAGE=? -->
o -metochlopramide is still one of the most frequently used drugs for the prevention and treatment of PONV despite the large body of evidence showing that doses between 10 and 20 mg are of limited efficacy .  Moreover, metoclopramide also failed to reduce vomiting in a dose as large as 50 mg.‖

<!-- PAGE=? -->
o dimenhydrinate appears to be as effective as ondansetron or droperidol but may be associated with sedation

<!-- PAGE=? -->
Antagonist

<!-- PAGE=? -->
Drcporidol

<!-- PAGE=? -->
5-HT,

<!-- PAGE=? -->
Kstarrine

<!-- PAGE=? -->
Muscannlc Dapamine {Dz}

<!-- PAGE=? -->
Nilrogen

<!-- PAGE=? -->
Mustaro

<!-- PAGE=? -->
Receptor

<!-- PAGE=? -->
she

<!-- PAGE=? -->
Digorin

<!-- PAGE=? -->
Glycoside

<!-- PAGE=? -->
Postrema

<!-- PAGE=? -->
Trigger

<!-- PAGE=? -->
Zone

<!-- PAGE=? -->
(CTZ}

<!-- PAGE=? -->
Vustibular

<!-- PAGE=? -->
Pervlcellular

<!-- PAGE=? -->
Retlcular

<!-- PAGE=? -->
Emelic

<!-- PAGE=? -->
Center

<!-- PAGE=? -->
Medleshnum

<!-- PAGE=? -->
Dislension

<!-- PAGE=? -->
Fharynx

<!-- PAGE=? -->
PPV / PEEP

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
Respiratory Effects

<!-- PAGE=? -->
 Two universal pulmonary effects of CPAP/PEEP

<!-- PAGE=? -->
o redistribution of extravascular water

<!-- PAGE=? -->
o increased functional residual capacity (FRC)

<!-- PAGE=? -->
 CPAP/PEEP has been shown to have a favorable effect on the relationship between the closing volume (lung volume at which dependent small-airway closure occurs) and FRC , thereby decreasing the degree of low V/Q that occurs in anesthetized human patients with severe COPD and morbid obesity

<!-- PAGE=? -->
 CPAP/PEEP to the edematous lung decreases intra-alveolar fluid volume and facilitates the movement of water from the less compliant interstitial spaces (between the alveolar epithelium and pulmonary capillary endothelium) where gas exchange occurs to the more compliant interstitial spaces (peribronchial and hilar regions). 83, 84, 85 This redistribution of interstitial water improves oxygenation , lung compliance and V/Q matching.

<!-- PAGE=? -->
 CPAP/PEEP results in an increased FRC by two distinct mechanisms:

<!-- PAGE=? -->
o <10 cm H2O increases the volume of patent alveoli

<!-- PAGE=? -->
o >10 cm H2O alveolar recruitment

<!-- PAGE=? -->
Cardiovascular Effects

<!-- PAGE=? -->
 PPV causes a decrease in cardiac output that can be attributed to at least three mechanisms:

<!-- PAGE=? -->
o decreased venous return

<!-- PAGE=? -->
 the most significant factor causing decreased cardiac output with PPV

<!-- PAGE=? -->
 Increased intrathoracic pressure results in decreased end-diastolic volume and stroke volume of both ventricles .

<!-- PAGE=? -->
 Augmenting preload with additional intravascular fluid will minimize this effect

<!-- PAGE=? -->
o right ventricular dysfunction

<!-- PAGE=? -->
 increases in PVR increase right ventricular afterload

<!-- PAGE=? -->
 most pronounced in patients with pre-existing right ventricular dysfunction

<!-- PAGE=? -->
o alteration of left ventricular distensibility

<!-- PAGE=? -->
 Elevated pulmonary pressures can cause an elevation in RVEDV, resulting in a leftward shift of the intraventricular septum

<!-- PAGE=? -->
 shift limits left ventricular distensibility and causes a decrease in cardiac output

<!-- PAGE=? -->
o effect on RVEDV is two-fold

<!-- PAGE=? -->
 In the normal heart, RVEDV decreases because of decreased filling and increases in RV afterload does not affect RV function or increase RVEDV

<!-- PAGE=? -->
 In RV-dysfunction, elevated RV afterload can increase RVEDV/RVEDP and cause a leftward shift of the intraventricular septum, thus limiting LV distensibility and decreasing cardiac output

<!-- PAGE=? -->
 In some patients with left ventricular dysfunction , positive pressure may actually improve cardiac output

<!-- PAGE=? -->
o patients with elevated filling pressures may have a decrease in end-diastolic volume and improved cardiac performance as the diastolic volume moves to a better position on the Starling curve ( smaller ventricle means less afterload )

<!-- PAGE=? -->
o cardiac function may improve as coronary arterial oxygen content increases with PEEP

<!-- PAGE=? -->
o positive intrathoracic pressure can cause a decrease in ventricular afterload ( decreased transmural pressure ), thereby enhancing cardiac performance

<!-- PAGE=? -->
 PPV can also affect hemodynamic measurements

<!-- PAGE=? -->
o The degree to which intrapulmonary pressures affect central venous, pulmonary artery, and pulmonary capillary pressures is variable and depends in large part on pulmonary compliance.

<!-- PAGE=? -->
o There is evidence that even in the presence of normal compliance, PEEP of greater than 10 cm H2O makes measurement of pulmonary capillary wedge pressure unreliable

<!-- PAGE=? -->
 The increase in mean airway pressure associated with CPAP/PEEP increases the pleural and pericardial pressure , decreasing the cardiac transmural pressure, which may significantly decrease the end-diastolic volume and stroke volume of both ventricles

<!-- PAGE=? -->
 CPAP/PEEP increases right ventricular afterload because of increased pulmonary vascular resistance

<!-- PAGE=? -->
o In the normal heart, this results in a diminished right ventricular end-diastolic volume (RVEDV), whereas the right ventricular ejection fraction (RVEF) remains unchanged . At higher levels of CPAP/PEEP, a greater decrease in RVEDV results, which may reduce RVEF if myocardial contractility is less than optimal.

<!-- PAGE=? -->
 The reduction in pulmonary blood flow is considerably less with spontaneous breathing (CPAP) than with positive-pressure ventilation (PEEP)

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Benefits of PEEP

<!-- PAGE=? -->
o improvement in arterial oxygenation

<!-- PAGE=? -->
o decrease in the work of breathing

<!-- PAGE=? -->
o improvement in ventilation-perfusion inequality

<!-- PAGE=? -->
o With diffuse lung injury

<!-- PAGE=? -->
 improves FRC, compliance, and arterial oxygenation

<!-- PAGE=? -->
 decreases shunting, dead space ventilation, and venous admixture

<!-- PAGE=? -->
 PEEP does NOT decrease the amount of extravascular lung water or prevent the formation of edema fluid in the lungs. Nevertheless, edema fluid is likely to be redistributed to the interstitial lung regions, causing previously flood alveoli to become ventilated

<!-- PAGE=? -->
 Liabilities of PEEP

<!-- PAGE=? -->
o impaired venous return

<!-- PAGE=? -->
o decreased ventricular filling

<!-- PAGE=? -->
o increased pulmonary vascular resistance

<!-- PAGE=? -->
o interference with subendocardial blood flow

<!-- PAGE=? -->
o reduced left ventricular afterload

<!-- PAGE=? -->
o altered configuration and compliance of the right and left ventricles

<!-- PAGE=? -->
o interstitial emphysema, PTX, and pneumomediastinum.

<!-- PAGE=? -->
o changes in ICP, alterations in renal function, and abnormalities in hepatic and gastrointestinal function.

<!-- PAGE=? -->
Phosphate

<!-- PAGE=? -->
Hyperphosphatemia

<!-- PAGE=? -->
Hypophosphatemia

<!-- PAGE=? -->
Preoperative Testing:

<!-- PAGE=? -->
Barash 6 th , Miller 7th

<!-- PAGE=? -->
 Recommended Laboratory Testing

<!-- PAGE=? -->
o Blood Count

<!-- PAGE=? -->
 Neonates

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
 highly invasive procedures that commonly necessitate blood administration, invasive monitoring and postoperative care in a critical care unit

<!-- PAGE=? -->
o total hip, AAA, post fossa craniot for aneurysm

<!-- PAGE=? -->
 Class B - moderately invasive - CEA, TURP, lap chole

<!-- PAGE=? -->
 Malignancy

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
 Tobacco use

<!-- PAGE=? -->
 Anticoagulant use

<!-- PAGE=? -->
 Bleeding disorder

<!-- PAGE=? -->
o Coagulation Studies

<!-- PAGE=? -->
 Chemotherapy

<!-- PAGE=? -->
 Hepatic disease

<!-- PAGE=? -->
 Bleeding disorder

<!-- PAGE=? -->
 Anticoagulants

<!-- PAGE=? -->
o Electrolytes

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
 Diabetes

<!-- PAGE=? -->
 Diuretic, digoxin, or steroid use

<!-- PAGE=? -->
 CNS disease

<!-- PAGE=? -->
 Endocrine disorders

<!-- PAGE=? -->
o Blood Urea Nitrogen/Creatinine

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
 Cardiovascular disease

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
 Diabetes

<!-- PAGE=? -->
 Diuretic or digoxin use

<!-- PAGE=? -->
 CNS disease

<!-- PAGE=? -->
o Blood Glucose

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
 Diabetes

<!-- PAGE=? -->
 Steroid use

<!-- PAGE=? -->
 CNS disease

<!-- PAGE=? -->
o Liver Function Tests

<!-- PAGE=? -->
 Hepatic disease

<!-- PAGE=? -->
 Hepatitis exposure

<!-- PAGE=? -->
 Malnutrition

<!-- PAGE=? -->
o Chest X-Ray

<!-- PAGE=? -->
 Recent upper respiratory infection

<!-- PAGE=? -->
 Physiologic age ≥75 years (some say 60)

<!-- PAGE=? -->
 Thoracic surgery

<!-- PAGE=? -->
 Cardiovascular disease

<!-- PAGE=? -->
 Pulmonary disease

<!-- PAGE=? -->
 Malignancy

<!-- PAGE=? -->
 Radiation Therapy

<!-- PAGE=? -->
 Tobacco ≥20 pack-years

<!-- PAGE=? -->
o ECG

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 AHA has no age recommendation

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
 Class B procedure with at least one clinical risk factor

<!-- PAGE=? -->
 Cardiovascular disease

<!-- PAGE=? -->
 Pulmonary disease

<!-- PAGE=? -->
 Radiation therapy

<!-- PAGE=? -->
 Diabetes

<!-- PAGE=? -->
 Digoxin use

<!-- PAGE=? -->
 CNS disease

<!-- PAGE=? -->
o Pregnancy Test

<!-- PAGE=? -->
 Possible pregnancy

<!-- PAGE=? -->
o Albumin

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
 Malnutrition

<!-- PAGE=? -->
o Type and Screen

<!-- PAGE=? -->
 Physiologic age ≥75 years

<!-- PAGE=? -->
 Class C procedure

<!-- PAGE=? -->
o ABG

<!-- PAGE=? -->
 With the advent of the pulse oximeter, the use of preoperative arterial blood gas sampling has become less important

<!-- PAGE=? -->
 It may still be indicated, to determine a baseline CO2

<!-- PAGE=? -->
 A normal serum bicarbonate will virtually exclude the diagnosis of CO2 retention

<!-- PAGE=? -->
Preoperative evaluation (general)

<!-- PAGE=? -->
 Cardiac risk factors (patient)

<!-- PAGE=? -->
o Major risk factors (4)

<!-- PAGE=? -->
 MI < 1/12 or class III/IV angina

<!-- PAGE=? -->
 Unstable arrhythmia

<!-- PAGE=? -->
 Symptomatic valve disease

<!-- PAGE=? -->
 Symptomatic CHF

<!-- PAGE=? -->
o Moderate risk factors (4)

<!-- PAGE=? -->
 MI < 6/12 or Q waves

<!-- PAGE=? -->
 Stable class I/II angina

<!-- PAGE=? -->
 Stable CHF

<!-- PAGE=? -->
 DM

<!-- PAGE=? -->
o Minor risk factors (6)

<!-- PAGE=? -->
 Advanced age

<!-- PAGE=? -->
 Uncontrolled HTN

<!-- PAGE=? -->
 ECG changes (LVH, LBBB, ST-T)

<!-- PAGE=? -->
 Non NSR (Afib)

<!-- PAGE=? -->
 Low FC

<!-- PAGE=? -->
 CVA

<!-- PAGE=? -->
 Cardiac risk factors (surgical)

<!-- PAGE=? -->
o High risk (4): (cardiac risk > 5 %)

<!-- PAGE=? -->
 Emergent major operations

<!-- PAGE=? -->
 Aortic and other major vascular

<!-- PAGE=? -->
 Peripheral vascular

<!-- PAGE=? -->
 Prolonged surgical procedures with large fluid shifts, blood loss

<!-- PAGE=? -->
o Intermediate risk (5): (< 5 %)

<!-- PAGE=? -->
 Carotid endarterectomy

<!-- PAGE=? -->
 Head and neck

<!-- PAGE=? -->
 Intraperitoneal and intrathoracic

<!-- PAGE=? -->
 Orthopedic

<!-- PAGE=? -->
 Prostate

<!-- PAGE=? -->
o Low risk (4): (< 1 %)

<!-- PAGE=? -->
 Endoscopic procedures

<!-- PAGE=? -->
 Superficial procedure

<!-- PAGE=? -->
 Cataract

<!-- PAGE=? -->
 Breast

<!-- PAGE=? -->
Perioperative Mortality

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Seven day perioperative mortality risk factors (in order)

<!-- PAGE=? -->
o ASA 3-5

<!-- PAGE=? -->
o Emergency surgery

<!-- PAGE=? -->
o Major operation

<!-- PAGE=? -->
o Advanced age

<!-- PAGE=? -->
 >80

<!-- PAGE=? -->
 60-80

<!-- PAGE=? -->
o Male

<!-- PAGE=? -->
o Intermediate Operation

<!-- PAGE=? -->
o Complication in the OR or recovery room

<!-- PAGE=? -->
o Narcotic or inhalational alone

<!-- PAGE=? -->
o Administration of < 2 anesthetic drugs

<!-- PAGE=? -->
 length of procedure was not a risk factor

<!-- PAGE=? -->
Propofol

<!-- PAGE=? -->
Barash, Miller, P&P

<!-- PAGE=? -->
 Independent of the presence of cardiovascular disease, an induction dose of 2 to 2.5 mg/kg produces a 25% to 40% reduction in systolic blood pressure

<!-- PAGE=? -->
 The decrease in arterial pressure is associated with

<!-- PAGE=? -->
o Dec. in cardiac output/cardiac index (≈15%)

<!-- PAGE=? -->
o Dec. SV index (≈20%)

<!-- PAGE=? -->
o Dec. SVR (15% to 25%)

<!-- PAGE=? -->
 The heart rate does not change significantly after an induction dose of propofol

<!-- PAGE=? -->
o Either resets or inhibits the baroreflex, thus reducing the tachycardic response to hypotension

<!-- PAGE=? -->
 Propofol decreases cardiac parasympathetic tone in proportion to the degree of sedation that it produces

<!-- PAGE=? -->
o attenuates the heart rate response to atropine in a dose-dependent manner

<!-- PAGE=? -->
 termination of effect  is affected by

<!-- PAGE=? -->
o decreased hepatic flow

<!-- PAGE=? -->
o redistribution

<!-- PAGE=? -->
o gender  (females have higher Vd and thus more rapid clearance)

<!-- PAGE=? -->
o temperature

<!-- PAGE=? -->
o weight

<!-- PAGE=? -->
o age

<!-- PAGE=? -->
o pre-existing disease and medications

<!-- PAGE=? -->
 Renal function does NOT affect elimination or wakeup from propofol

<!-- PAGE=? -->
o Kidney excrete inactive metabolites

<!-- PAGE=? -->
 Pharmacology:

<!-- PAGE=? -->
o After a single bolus injection, whole blood propofol levels decrease rapidly as a result of both redistribution and elimination

<!-- PAGE=? -->
o recovery from propofol remains rapid even after prolonged infusions

<!-- PAGE=? -->
o required decrease in concentration for awakening after anesthesia or sedation with propofol is generally less than 50%

<!-- PAGE=? -->
o distribution half-life is 2-8 min and the elimination half-life is 1-3 h

<!-- PAGE=? -->
 The context-sensitive half-time of propofol for infusions lasting up to 8 hours is less than 40 minutes

<!-- PAGE=? -->
o the time for the plasma level of the drug to drop 50% after cessation of infusion

<!-- PAGE=? -->
o The rapidity with which the drug level drops is directly related to

<!-- PAGE=? -->
 time of infusion the longer the drug is infused, the longer the half-time

<!-- PAGE=? -->
 extrahepatic metabolism has been demonstrated as clearance exceeds hepatic blood flow

<!-- PAGE=? -->
 time to peak CNS effect is 90 to 100 seconds

<!-- PAGE=? -->
 SBP drop is much slower (double the CNS time )

<!-- PAGE=? -->
o increases with age

<!-- PAGE=? -->
 the elderly show a concentration-dependent increased sensitivity

<!-- PAGE=? -->
 Children have a larger central compartment volume (50%) and more rapid clearance (25%)

<!-- PAGE=? -->
o Require much larger doses

<!-- PAGE=? -->
Propofol Infusion Syndrome

<!-- PAGE=? -->
 a rare, but lethal syndrome associated with infusion of propofol

<!-- PAGE=? -->
o 4 - 5 mg/kg/hr or greater for 48 hours or longer

<!-- PAGE=? -->
 Clinical features

<!-- PAGE=? -->
o cardiomyopathy with acute cardiac failure

<!-- PAGE=? -->
 bradycardia and asytole

<!-- PAGE=? -->
o metabolic acidosis

<!-- PAGE=? -->
o rhabdomyolysis

<!-- PAGE=? -->
o hyperkalemia

<!-- PAGE=? -->
o hepatomegaly

<!-- PAGE=? -->
o lipemia

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
o failure of free fatty acid metabolism

<!-- PAGE=? -->
 inhibition of free fatty acid entry into mitochondria

<!-- PAGE=? -->
 failure of the mitochondrial respiratory chain

<!-- PAGE=? -->
 Early sign may be RBBB with convex ST elevation in V1 - V3

<!-- PAGE=? -->
 Predisposing factors

<!-- PAGE=? -->
o Young age

<!-- PAGE=? -->
o Critical illness

<!-- PAGE=? -->
 CVS or respiratory

<!-- PAGE=? -->
o Exogenous catecholamines

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o supportive

<!-- PAGE=? -->
o Hemodyalisis or hemoperfusion

<!-- PAGE=? -->
Prostaglandins

<!-- PAGE=? -->
 PGE1 (alprostadil)

<!-- PAGE=? -->
o prevents closure of PDA

<!-- PAGE=? -->
o Side effects :

<!-- PAGE=? -->
 Apnea

<!-- PAGE=? -->
 Bronchoconstriction

<!-- PAGE=? -->
 Bradycardia

<!-- PAGE=? -->
 Flushing

<!-- PAGE=? -->
 Hyperthermia

<!-- PAGE=? -->
 Systemic vasodilation

<!-- PAGE=? -->
 Pulmonary vasodilation

<!-- PAGE=? -->
 CNS excitation

<!-- PAGE=? -->
 PGE2

<!-- PAGE=? -->
o fever + pain + inflamation

<!-- PAGE=? -->
 PGI2 (prostacyclin)

<!-- PAGE=? -->
o PHTN Rx

<!-- PAGE=? -->
 PGE F2alpha

<!-- PAGE=? -->
o hemabate (5-Methylprostaglandin 2-alpha)

<!-- PAGE=? -->
o Stimulation of GI and uterine tone

<!-- PAGE=? -->
 PGE D2

<!-- PAGE=? -->
o inhibits platelet  aggregration

<!-- PAGE=? -->
Proteins

<!-- PAGE=? -->
 Albumin

<!-- PAGE=? -->
 basic protein - so binds acidic drugs

<!-- PAGE=? -->
 binds phenytoin, salicylates, and disopyramide (extensively bound to albumin)

<!-- PAGE=? -->
 Decreased in many disease states

<!-- PAGE=? -->
 Alpha1-acid glycoprotein

<!-- PAGE=? -->
 acidic protein so binds basic drugs

<!-- PAGE=? -->
 important binding protein with binding sites for drugs such as quinidine, lidocaine, and propranolol.

<!-- PAGE=? -->
 Increased in acute inflammatory disorders

<!-- PAGE=? -->
Protamine

<!-- PAGE=? -->
Kaplan, P&P, Miller

<!-- PAGE=? -->
 Adverse reactions

<!-- PAGE=? -->
 May precipitously decrease platelets

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
o Rapid administration (type I rxn) histamine mediated

<!-- PAGE=? -->
 Peripheral cardiovascular changes

<!-- PAGE=? -->
 Decreased SVR → dec. venous return → dec. filling pressures

<!-- PAGE=? -->
 Seems to only occur in the presence of heparin

<!-- PAGE=? -->
 Dec. SVR likely 2° to

<!-- PAGE=? -->
o histamine release from mast cells

<!-- PAGE=? -->
 Similar to morphine, vanco, clinda

<!-- PAGE=? -->
o protamine, free or complexed with heparin, acts on endothelial receptors via Nitric Oxide

<!-- PAGE=? -->
 CJA 2006 - occurred with or without heparin

<!-- PAGE=? -->
 Neutralizing dose given over 5 min or longer will rarely cause cardiovascular changes

<!-- PAGE=? -->
 Cardiac inotropy

<!-- PAGE=? -->
 No decrease in CO if preload is maintained

<!-- PAGE=? -->
o Anaphylactoid reaction (type II rxn)

<!-- PAGE=? -->
 thee subsets

<!-- PAGE=? -->
 IIA anaphylaxis

<!-- PAGE=? -->
 IIB - nonimmunologic anaphylacyoid reaction

<!-- PAGE=? -->
 IIC - delayed noncardiogenic pulmonary edema

<!-- PAGE=? -->
o Systemic hypotension

<!-- PAGE=? -->
o Massive capillary leak

<!-- PAGE=? -->
o accumulation of alveolar fluid

<!-- PAGE=? -->
o dec. pulmonary compliance

<!-- PAGE=? -->
o wheezing

<!-- PAGE=? -->
o occur at least 20 minutes following protamine administration

<!-- PAGE=? -->
o Has been attributed to

<!-- PAGE=? -->
 Blood products

<!-- PAGE=? -->
 CPB itself (complement activation, leukocyte aggregation, free radical formation, lung injury)

<!-- PAGE=? -->
 other polycations can directly induce pulmonary vascular damage including

<!-- PAGE=? -->
 protamine

<!-- PAGE=? -->
 hexadimethrine

<!-- PAGE=? -->
 polylysine

<!-- PAGE=? -->
o may be attenuated by verapamil

<!-- PAGE=? -->
o pulmonary vasoconstriction (type III)

<!-- PAGE=? -->
 systemic hypotension

<!-- PAGE=? -->
 dec. LA pressure

<!-- PAGE=? -->
 elevated PAP

<!-- PAGE=? -->
 RV distention and failure

<!-- PAGE=? -->
 Plasma histamine levels do not increase

<!-- PAGE=? -->
 Response may be brief or may require reinstitution of CPB

<!-- PAGE=? -->
 Rechallenging with protamine immediately after can be benign or induce repeat pulmonary vasoconstriction

<!-- PAGE=? -->
 Heparin must precede the protamine

<!-- PAGE=? -->
 Heparin-protamine complexes activate the complement pathway

<!-- PAGE=? -->
 Leukocytes respond by forming free radicals which stimulate the arachidonate pathway

<!-- PAGE=? -->
 An excess of protamine results in larger complexes

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Fish Allergy (vertebrate or fin fish)

<!-- PAGE=? -->
 Patients can respond with anaphylaxis

<!-- PAGE=? -->


<!-- PAGE=? -->
Skin testing is have high sensitivity but low specificity so a negative test is reassuring

<!-- PAGE=? -->
 No link with shell fish

<!-- PAGE=? -->
o NPH insuln

<!-- PAGE=? -->
 Develop antibodies to protamine

<!-- PAGE=? -->
 38-91% have antiprotamine IgG

<!-- PAGE=? -->
 Far fewer hav antiprotamine IgE

<!-- PAGE=? -->
o Other Medical Allergies

<!-- PAGE=? -->
o Unconfirmed risk factors include

<!-- PAGE=? -->
 Prior exposure

<!-- PAGE=? -->
 Multiple exposures at 2 week intervals maximize the chance of an allergic response

<!-- PAGE=? -->
 Signal IV exposure will result in an IgG or IgE response in 28% of patients

<!-- PAGE=? -->
 Still many patients have multiple exposures (heart cath, CPB, vascular surgery and no sequelae

<!-- PAGE=? -->
 Vasectomy

<!-- PAGE=? -->
 No proven inc. risk of rxn

<!-- PAGE=? -->
 Within 1 year 33% of men form IgG antibody to human protamine (weak titres)

<!-- PAGE=? -->
 May cross-react with salmon protamine

<!-- PAGE=? -->
 Case repots of vasectomy related protamine allergy exist - no demonstrated causal relationship

<!-- PAGE=? -->
 Theoretical risk

<!-- PAGE=? -->
 Dec. LV function

<!-- PAGE=? -->
 Hemodynamic instability

<!-- PAGE=? -->
 Prevention

<!-- PAGE=? -->
o Dosing

<!-- PAGE=? -->
 Commonly fixed dose of 1-1.3mg protamine for 100 units of heparin

<!-- PAGE=? -->
 Doesn't account for heparin elimination

<!-- PAGE=? -->
o Activity half-life of 90 min

<!-- PAGE=? -->
 30000 units = 150mg protamine after 90 min

<!-- PAGE=? -->
 Excess protamine results in

<!-- PAGE=? -->
 ↓ plt number and fxn

<!-- PAGE=? -->
 ↓ plt aggregation

<!-- PAGE=? -->
 Free protamine precipitates fibrinogen

<!-- PAGE=? -->
o Slow administration should limit type III reactions

<!-- PAGE=? -->
o Large protamine-heparin complexes would be less likely to form

<!-- PAGE=? -->
o Administer the drug slowly - manufacturer recommends 5mg/min

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Stop the infusion of protamine

<!-- PAGE=? -->
o Stop all cardiovascular depressants

<!-- PAGE=? -->
 Anesthetics

<!-- PAGE=? -->
o Consider heparin boluses (70units/kg) to attempt to decrease heparin-protamine complex size

<!-- PAGE=? -->
 Larger number of smaller complexes

<!-- PAGE=? -->
o Inotropic support selected to not worsen PHTN

<!-- PAGE=? -->
 Inodilators

<!-- PAGE=? -->
 Milrinone

<!-- PAGE=? -->
 Isoproterenol

<!-- PAGE=? -->
 Epinephrine

<!-- PAGE=? -->
o Inhibit histamine release

<!-- PAGE=? -->
 ↑ inotropy

<!-- PAGE=? -->
 ↑ vascular resistance

<!-- PAGE=? -->
o B-blocked patients may be resistant to epinephrine

<!-- PAGE=? -->
 Glucagon 1 mg bolus with possible infusion (1-5mg/hr)

<!-- PAGE=? -->
o Inhaled NO for PHTN (A&A 1999)

<!-- PAGE=? -->
o Methylene blue is NOT recommended

<!-- PAGE=? -->
 inhibitions of NO production

<!-- PAGE=? -->
 May cause PHTN secondary to dec. NO production in lungs

<!-- PAGE=? -->
 Management of Patients at risk

<!-- PAGE=? -->
o prior rxn to protamine

<!-- PAGE=? -->
 skin testing is appropriate

<!-- PAGE=? -->
 intradermal injection 0.01 to 0.02 mL of a 1 µg/mL - test for IgE mediated hypersensitivity

<!-- PAGE=? -->
 positive test - >8mm induration at 10 minutes

<!-- PAGE=? -->
 sensitivity 91%, specificity 78% (22% false positive)

<!-- PAGE=? -->
 neg response provides greater comfort when attempting a rechallenge

<!-- PAGE=? -->
 if poor evidence of sensitivity, proceed as above

<!-- PAGE=? -->
 good evidence, use an alternative to protamine

<!-- PAGE=? -->
 Initial neutralizing dose (~3 mg/kg) by infusion over 10-15 min

<!-- PAGE=? -->
 Additional doses may be given undiluted at a max of 20mg/min

<!-- PAGE=? -->
 Should help type I and type III, type IIA can occur at any delivery rate

<!-- PAGE=? -->
o Antihistamines confer no benefit in general

<!-- PAGE=? -->
 May reduce cutaneous manifestations of anaphylaxis

<!-- PAGE=? -->
 Possible decrease in bronchospasm

<!-- PAGE=? -->
o steroids may diminish the circulatory changes with protamine for nonp specific reasons

<!-- PAGE=? -->
 may reduce bronchospasm

<!-- PAGE=? -->
o fish allergy

<!-- PAGE=? -->
 patients with a strong history of fin fish allergy should receive 1mg protamine in 50 mls of IV fluid over 10 minutes

<!-- PAGE=? -->
 if no response administer the neutralizing dose as described above

<!-- PAGE=? -->
 skin testing may predict this allergy, but the approach would be unchanged since false positive skin tests are common

<!-- PAGE=? -->
 Alternatives

<!-- PAGE=? -->
o Hexadimethrine

<!-- PAGE=? -->
 Synthetic polycation

<!-- PAGE=? -->
 Similar rxn as above

<!-- PAGE=? -->
 With true IgE anaphylaxis, hexadimetrine may not cross-react

<!-- PAGE=? -->
 No longer available due to renal toxicity

<!-- PAGE=? -->
o Platelet factor 4 - not available from Blood bank

<!-- PAGE=? -->
 Potent antiheparin compound

<!-- PAGE=? -->
 Platelet transfusion does not work (BMJ 1984)

<!-- PAGE=? -->
 Recombinant PF4   at a dose of 5mg/kg may neutralize 300U/kg  of heparin (A&A 1995)

<!-- PAGE=? -->
 At risk patients may respond with PHTN

<!-- PAGE=? -->
o Interposed filters (clinics 2004)

<!-- PAGE=? -->
 uses a venovenous circuit with plasma separation

<!-- PAGE=? -->
 separated plasma passes over a poly-L-lysine-agarose surface, which binds and removes heparin, and is then recombined with the blood cells, before returning to the patient's right atrium

<!-- PAGE=? -->
 flow rate of 1400 mL/min

<!-- PAGE=? -->
 returns the ACT and other coagulation parameters to near baseline values in about 30 minutes

<!-- PAGE=? -->
 Clinical effectiveness and safety are yet to be proven

<!-- PAGE=? -->
o Heparinase

<!-- PAGE=? -->
 Enzyme produced by Flavobacterium returns ACT to normal

<!-- PAGE=? -->
 Pt would require a heparin infusion of CPB was to be reinstituted because of the lingering effects of this enzyme

<!-- PAGE=? -->
o Nothing

<!-- PAGE=? -->
 Off-pump CABG

<!-- PAGE=? -->
 No heparin reversal

<!-- PAGE=? -->
Pseudocholinesterase Deficiency

<!-- PAGE=? -->
 Butyrylcholinesterase is synthesized by the liver and is found in plasma and other tissues

<!-- PAGE=? -->
o not in red blood cells

<!-- PAGE=? -->
o Half-life is 8-16 hrs

<!-- PAGE=? -->
 the following are directly related to the function of the pseudocholinesterase enzyme:

<!-- PAGE=? -->
o duration of action of Sux

<!-- PAGE=? -->
o ester linked local anaesthetics

<!-- PAGE=? -->
o toxicity of cocaine

<!-- PAGE=? -->
o toxicity of standard anti-alzheimer drugs

<!-- PAGE=? -->
 >75% decrease of normal enzyme for there to be a clinically evident prolongation of Sux activity

<!-- PAGE=? -->
 Depolarizing neuromuscular block is prolonged by

<!-- PAGE=? -->
o a decreased concentration of the enzyme

<!-- PAGE=? -->
o decreased activity of the enzyme

<!-- PAGE=? -->
 Factors that have been found to lower activity are

<!-- PAGE=? -->
o liver disease

<!-- PAGE=? -->
o advanced age

<!-- PAGE=? -->
o malnutrition

<!-- PAGE=? -->
o pregnancy

<!-- PAGE=? -->
o burns

<!-- PAGE=? -->
o neoplastic disease

<!-- PAGE=? -->
o Medications

<!-- PAGE=? -->
 oral contraceptives. monoamine oxidase inhibitors, echothiophate, cytotoxic drugs, anticholinesterase drugs, tetrahydroaminacrine, hexafluorenium, metoclopramide

<!-- PAGE=? -->
 H2 receptor antagonists have no effect on butyrylcholinesterase activity

<!-- PAGE=? -->
 esmolol inhibits butyrylcholinesterase but causes only minor prolongation of succinylcholine blockade

<!-- PAGE=? -->
 When butyrylcholinesterase activity is reduced to 20% of normal, the duration of apnea after sux inc. from 3 min to 9 min

<!-- PAGE=? -->
Table 24-4 Some Causes of Changes in Cholinesterase Activity

<!-- PAGE=? -->
INHERITED

<!-- PAGE=? -->
Cholinesterase variants that may lead to decreased or increased activity (e.g., silent gene or C5 variant) PHYSIOLOGIC

<!-- PAGE=? -->
Decreases in last trimester of pregnancy

<!-- PAGE=? -->
Reduced activity of the newborn

<!-- PAGE=? -->
ACQUIRED DECREASES

<!-- PAGE=? -->
Liver diseases Carcinoma Debilitating diseases

<!-- PAGE=? -->
Collagen diseases

<!-- PAGE=? -->
Uremia

<!-- PAGE=? -->
Malnutrition

<!-- PAGE=? -->
Myxedema

<!-- PAGE=? -->
ACQUIRED INCREASES

<!-- PAGE=? -->
Obesity

<!-- PAGE=? -->
Alcoholism

<!-- PAGE=? -->
Thyrotoxicosis

<!-- PAGE=? -->
Nephrosis

<!-- PAGE=? -->
Psoriasis

<!-- PAGE=? -->
Electroshock therapy

<!-- PAGE=? -->
DRUGS RELATED TO DISEASES

<!-- PAGE=? -->
Neostigmine

<!-- PAGE=? -->
Pyridostigmine

<!-- PAGE=? -->
Chlorpromazine

<!-- PAGE=? -->
Echothiophate iodide

<!-- PAGE=? -->
Cyclophosphamide

<!-- PAGE=? -->
Monoamine oxidase inhibitors

<!-- PAGE=? -->
Pancuronium

<!-- PAGE=? -->
Contraceptives

<!-- PAGE=? -->
Organophosphorus insecticides

<!-- PAGE=? -->
Hexafluorenium

<!-- PAGE=? -->
OTHER CAUSES OF DECREASED ACTIVITY

<!-- PAGE=? -->
Plasmapheresis

<!-- PAGE=? -->
Extracorporeal circulation

<!-- PAGE=? -->
Tetanus

<!-- PAGE=? -->
Radiation therapy

<!-- PAGE=? -->
Burns

<!-- PAGE=? -->
Atypical Pseudocholinesterase

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
*

<!-- PAGE=? -->
The dibucaine number indicates the percentage of enzyme inhibited.

<!-- PAGE=? -->
 Dibucaine inhibits normal butyrylcholinesterase to a far greater extent than it does the abnormal enzyme

<!-- PAGE=? -->
o dibucaine inhibits the normal enzyme about 80% and the abnormal enzyme about 20%

<!-- PAGE=? -->
 dibucaine number does not

<!-- PAGE=? -->
o measure the concentration of the enzyme in plasma

<!-- PAGE=? -->
o indicate the efficiency of the enzyme in hydrolyzing a substrate such as succinylcholine or mivacurium

<!-- PAGE=? -->
 Both the latter factors are determined by measuring butyrylcholinesterase activity (which may be influenced by genotype

<!-- PAGE=? -->
 Succinylcholine is hydrolyzed by a two-step process

<!-- PAGE=? -->
o first to succinylmonocholine

<!-- PAGE=? -->
o then to succinic acid

<!-- PAGE=? -->
 only about 5% of the injected drug reaches the end-plate region because of a combination of both hydrolysis and diffusion from the plasma

<!-- PAGE=? -->
 Urinary excretion and protein binding play unimportant roles in the disposition of the drug when plasma cholinesterase activity is normal

<!-- PAGE=? -->
o rate of metabolism determines the duration of action of succinylcholine

<!-- PAGE=? -->
o in the absence of the pseudocholinesterase enzyme Sch is metabolized slowly by non-enzymatic means

<!-- PAGE=? -->
 A number of variants exist

<!-- PAGE=? -->
o In one variant, the silent gene, no enzyme is produced

<!-- PAGE=? -->
o In an other, there is a differential inhibition of cholinesterase activity by fluoride

<!-- PAGE=? -->
 fluoride ion inhibits the in vitro hydrolysis of substrate by the abnormal enzyme less than it does in normals

<!-- PAGE=? -->
 Thus the phenotype may be referred to as fluoride-resistant

<!-- PAGE=? -->
 A fluoride number, similar to a dibucaine number, is thereby created

<!-- PAGE=? -->
Pulmonary physiology

<!-- PAGE=? -->
 The inherent tendency for the lungs to collapse (recoil away from the chest wall) is due to elastic fibers that are stretched by lung inflation and therefore attempt to shorten.

<!-- PAGE=? -->
 Even more important, surface tension of the fluid lining the alveoli causes a continual elastic tendency for alveoli to collapse

<!-- PAGE=? -->
 Elastic fibers in the lungs normally account for approximately one-third of the recoil tendency, and surface tension accounts for 2/3 of the recoil

<!-- PAGE=? -->
Distribution of Perfusion & Ventilation

<!-- PAGE=? -->
ZDNE

<!-- PAGE=? -->
ZONF 7

<!-- PAGE=? -->
Fa

<!-- PAGE=? -->
ZONE

<!-- PAGE=? -->
Zone 1

<!-- PAGE=? -->
 Normally there is little or no zone 1 exists.

<!-- PAGE=? -->
 ↑ zone 1 with either ↑ PA (PEEP) or ↓ Pa (hemorrhagic shock)

<!-- PAGE=? -->
Zone 2

<!-- PAGE=? -->
 Ppa becomes positive

<!-- PAGE=? -->
 Blood flow determined by Ppa - PA difference

<!-- PAGE=? -->
 alters with respiratory and cardiac cycle

<!-- PAGE=? -->
Zone 3

<!-- PAGE=? -->
 level where Ppv becomes positive and exceeds PA, thus continuous blood flow

<!-- PAGE=? -->
Chest wall

<!-- PAGE=? -->
Lung

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
 further increase in pulmonary blood flow as descend down zone 3

<!-- PAGE=? -->
Zone 4

<!-- PAGE=? -->
 region of lung where transudation of fluid occurs (e.g. CHF, MR, MS)

<!-- PAGE=? -->
 less PBF than zone 3

<!-- PAGE=? -->
 Ppa > Pinterstitium > Ppv > PA

<!-- PAGE=? -->
Distribution of Ventilation

<!-- PAGE=? -->
 gravity exerts force on lung to assume globular shape, thus more negative force at top of lung, and positive force near base

<!-- PAGE=? -->
o Thus, Ppl increases by 0.25 cm H2O every centimeter down the lung

<!-- PAGE=? -->
 PA is same throughout the lung

<!-- PAGE=? -->
 Thus, Ppl  gradient causes regional differences in transpulmonary pressure

<!-- PAGE=? -->
 Thus, relatively negative pleural  pressure at top of lung results in higher transplulmonary pressure and therefore alveoli to be stented open whereas alveoli at the bottom tend to be smaller due to smaller transpulmonary pressure

<!-- PAGE=? -->
 Preferential ventilation to dependent areas with spontaneous breathing

<!-- PAGE=? -->
Determinants of Pulmonary Blood Flow

<!-- PAGE=? -->
PBF = PAP / PVR

<!-- PAGE=? -->
Gravity

<!-- PAGE=? -->
Hypoxic Pulmonary Vasoconstriction

<!-- PAGE=? -->
Cardiac output

<!-- PAGE=? -->
Lung volumes

<!-- PAGE=? -->
Other: neural and humoral factors

<!-- PAGE=? -->
Hypoxic Pulmonary Vasoconstriction

<!-- PAGE=? -->
aka Von Euler and Liljestrand reflex

<!-- PAGE=? -->
 mechanism to divert blood from poorly ventilated to adequately ventilated segments, thereby improving V/Q ratios

<!-- PAGE=? -->
 Occurs in arterioles of 200 micrometers

<!-- PAGE=? -->
 PA O2 has greater effect on HPV than PVO2

<!-- PAGE=? -->
 likely  due to direct action of alveolar hypoxia on pulmonary smooth muscle cells

<!-- PAGE=? -->
 augmented by respiratory and metabolic acidosis

<!-- PAGE=? -->
 factors which potentiate HPV

<!-- PAGE=? -->
o mechanical factors: atelectasis, hypoventilation

<!-- PAGE=? -->
o metabolic factors: respiratory & metabolic acidosis, hypoxemia

<!-- PAGE=? -->
 factors which inhibit HPV

<!-- PAGE=? -->
o underlying disease: sepsis, mitral stenosis, PE, hypothermia

<!-- PAGE=? -->
o metabolic factors: hypocarbia, metabolic alkalemia

<!-- PAGE=? -->
o drugs

<!-- PAGE=? -->
 inhaled anesthetics

<!-- PAGE=? -->
4000

<!-- PAGE=? -->
3500

<!-- PAGE=? -->
1

<!-- PAGE=? -->
3000

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
2500

<!-- PAGE=? -->
Transpulmonary

<!-- PAGE=? -->
15

<!-- PAGE=? -->
Pressl

<!-- PAGE=? -->
 pulmonary vasodilators  nitroprusside, NTG

<!-- PAGE=? -->
CLOSING CAPACITY AND FRC

<!-- PAGE=? -->
 FRC: the lung volume at the end of a normal exhalation

<!-- PAGE=? -->
o balance point between inward elastic recoil of lung and outward elastic recoil of chest (including diaphragmatic tone)

<!-- PAGE=? -->
o FRC = ERV + RV

<!-- PAGE=? -->
o not determined by propensity of airways to close

<!-- PAGE=? -->
o factors which  FRC

<!-- PAGE=? -->
 Obesity

<!-- PAGE=? -->
 Short stature (FRC is proportional to height)

<!-- PAGE=? -->
 Supine position (vs. upright)

<!-- PAGE=? -->
 Anesthesia (see below)

<!-- PAGE=? -->
 Decreased compliance of lung or chest wall (e.g. restrictive lung disease)

<!-- PAGE=? -->
 Sex: FRC is lower by ~10% in females

<!-- PAGE=? -->
 Age does not alter FRC (in fact, small increase in FRC)

<!-- PAGE=? -->
 Closing Capacity:

<!-- PAGE=? -->
o small airways which lack cartilaginous support relay on radial traction by elastic recoil of surrounding tissue to stent them open

<!-- PAGE=? -->
o volume at which these airways begin to close in dependent parts of the lung is called closing capacity

<!-- PAGE=? -->
o dynamic airway closure

<!-- PAGE=? -->
o CC = CV + RV

<!-- PAGE=? -->
o factors which  CC

<!-- PAGE=? -->
 obesity

<!-- PAGE=? -->
 aging

<!-- PAGE=? -->
 smoking

<!-- PAGE=? -->
 supine position

<!-- PAGE=? -->
 Relationship between CC and FRC

<!-- PAGE=? -->
o shunting and thus hypoxemia, will occur if CC > FRC (either due to  CC or  FRC or both)

<!-- PAGE=? -->
o normally CC < FRC until

<!-- PAGE=? -->
 Age 44 in supine position

<!-- PAGE=? -->
 Age 66 in upright position

<!-- PAGE=? -->
o under anesthesia,  FRC which leads to shunting

<!-- PAGE=? -->
o also note that in children < 5 CC > FRC, thus they are prone to desaturation

<!-- PAGE=? -->
MECHANISMS OF HYPOXEMIA UNDER ANESTHESIA

<!-- PAGE=? -->
  FRC by 15 - 20% (  ERV 25%,  RV by 13%)

<!-- PAGE=? -->
o maximum decrease within a few minutes

<!-- PAGE=? -->
o far more pronounced in above conditions (obesity, pregnancy)

<!-- PAGE=? -->
o further exacerbated by supine position which decreases FRC by 0.5 - 1L and paralysis

<!-- PAGE=? -->
 pushes abdominal contents cephalad but this effect is more pronounced in the dependent portions of the lungs due to lack of muscle tension

<!-- PAGE=? -->
Total lung

<!-- PAGE=? -->
Airway closure begins

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Functional

<!-- PAGE=? -->
Closing

<!-- PAGE=? -->
volume

<!-- PAGE=? -->
residual

<!-- PAGE=? -->
capacity

<!-- PAGE=? -->
Closing capacity

<!-- PAGE=? -->
Residual volume

<!-- PAGE=? -->
Zero lung volume

<!-- PAGE=? -->
100

<!-- PAGE=? -->
Closing

<!-- PAGE=? -->
Capacity

<!-- PAGE=? -->
Ispontaneous

<!-- PAGE=? -->
IPPB

<!-- PAGE=? -->
IPPB

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
PEEP

<!-- PAGE=? -->
Time-

<!-- PAGE=? -->
 Thus, normally when supine, dependent portions of lungs are maximally ventilated (due to shape of PV curve)

<!-- PAGE=? -->
 However, when paralyzed, alveolar ventilation becomes greater to non-dependent portions of lung (similar to OLV)

<!-- PAGE=? -->
 Thus, maximum V/Q mismatch due to preferential ventilation of non-dependent portion exacerbated by paralysis and cephalid movement of abdominal contents combined with maximum perfusion of dependent portion of lung

<!-- PAGE=? -->
o Prolonged immobility and IV fluids can further  FRC with  Zone III and IV

<!-- PAGE=? -->
 Absorption atelectasis due to high FiO2

<!-- PAGE=? -->
 Surgical positioning

<!-- PAGE=? -->
o trendelenburg can result in majority of lung being Zone III / IV

<!-- PAGE=? -->
o dec. FRC only with > 60' position

<!-- PAGE=? -->
o lithotomy causes a small dec. in FRC

<!-- PAGE=? -->
o prone position may inc. FRC

<!-- PAGE=? -->
 Inhibition of HPV

<!-- PAGE=? -->
 Decreased CO

<!-- PAGE=? -->
 Increased VO2 (shivering, sepsis, pain)

<!-- PAGE=? -->
 Underlying disease

<!-- PAGE=? -->
Awake

<!-- PAGE=? -->
Anesthetized

<!-- PAGE=? -->
Nondependent

<!-- PAGE=? -->
Nondependent

<!-- PAGE=? -->
lung

<!-- PAGE=? -->
lung

<!-- PAGE=? -->
Dependent

<!-- PAGE=? -->
Dependent

<!-- PAGE=? -->
lung

<!-- PAGE=? -->
lung

<!-- PAGE=? -->
A

<!-- PAGE=? -->
B

<!-- PAGE=? -->
Solid Line: normal PV relationship

<!-- PAGE=? -->
Dotted line: obstructive lung disease

<!-- PAGE=? -->
Dashed line: restrictive lung disease

<!-- PAGE=? -->
 anesthetized patient in the supine position has an increased airway resistance owing to decreased functional residual capacity, decreased caliber of the airways, endotracheal intubation, and connection of the endotracheal tube to external breathing apparatus and circuitry Transpulmonary pressure

<!-- PAGE=? -->
DEAD SPACE VENTILATION

<!-- PAGE=? -->
 VDPhysiologic = VDAnatomic + VDalveolar

<!-- PAGE=? -->
 VD Anatomic

<!-- PAGE=? -->
o ~2 cc/kg

<!-- PAGE=? -->
 VD Alveolar

<!-- PAGE=? -->
o normally minimal (Thus VDPhysiologic ~ VDAnatomic + VDalveolar )

<!-- PAGE=? -->
o  with  zone I (e.g.  CO, PE etc)

<!-- PAGE=? -->
 Bohr Equation

<!-- PAGE=? -->
o Vd/Vt = (PaCO2 - PETCO2) / PaCO2

<!-- PAGE=? -->
o normally <30% but may increase to 60 - 70% with severe obstructive lung disease

<!-- PAGE=? -->
Progressive Cephalad Displacement

<!-- PAGE=? -->
of the Diaphragm

<!-- PAGE=? -->
Pab

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
Initial

<!-- PAGE=? -->
upright position

<!-- PAGE=? -->
Supine

<!-- PAGE=? -->
position

<!-- PAGE=? -->
Surgical position

<!-- PAGE=? -->
and displacement

<!-- PAGE=? -->
Induction of

<!-- PAGE=? -->
anesthesia

<!-- PAGE=? -->
Paralysis

<!-- PAGE=? -->
This is same mechanisms as when supine (pretend the two lungs represent dependent and non-dependent portion of same lung)

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
FRC;

<!-- PAGE=? -->
 Vt = VD + VA (alveolar ventilation)

<!-- PAGE=? -->
o Spontaneously breathing patient   VD : VA  =  1 :2

<!-- PAGE=? -->
o Mechanically ventilated patient:   VD : VA  =  1:1

<!-- PAGE=? -->
 To maintain normal pCO2, require VA of 60 cc/kg = 4200 mls / min

<!-- PAGE=? -->
o Thus, spontaneously breathing, require Vt of 6300 mls /min

<!-- PAGE=? -->
o Mechanically ventilated patient, require Vt of 8400 mls / min

<!-- PAGE=? -->
Elderly

<!-- PAGE=? -->
 loss of lung elastin

<!-- PAGE=? -->
o increased compliance

<!-- PAGE=? -->
 nonuniform loss of elasin

<!-- PAGE=? -->
o V/Q mismatch

<!-- PAGE=? -->
 breakdown of alveolar septa

<!-- PAGE=? -->
o increase alveolar dead space

<!-- PAGE=? -->
 calcification of thorax

<!-- PAGE=? -->
o decreased thoracic compliance

<!-- PAGE=? -->
 increased work of breathing

<!-- PAGE=? -->
 lung volumes and capacities:

<!-- PAGE=? -->
o modest increase in FRC (increasd RV at the expence of ERV)

<!-- PAGE=? -->
o decreased VC

<!-- PAGE=? -->
o increased closing volume and closing capacity (RV + CV)

<!-- PAGE=? -->
 due to decreased elastic recoil, ultimately surpassing FRC

<!-- PAGE=? -->
 leads to increased V/Q mismatch

<!-- PAGE=? -->
 Mismatch is increased by alveolar destruction

<!-- PAGE=? -->
 overall pulmonary compliance is unchanged

<!-- PAGE=? -->
o inc. lung compliance, dec. chest wall compliance

<!-- PAGE=? -->
 widening of A-a gradient

<!-- PAGE=? -->
VOLUME (L)

<!-- PAGE=? -->
7.0

<!-- PAGE=? -->
7.0

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
6.0

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
VC

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
CC

<!-- PAGE=? -->
3.0

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
3.0

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
20

<!-- PAGE=? -->
20

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
20

<!-- PAGE=? -->
30

<!-- PAGE=? -->
40

<!-- PAGE=? -->
50

<!-- PAGE=? -->
60

<!-- PAGE=? -->
70

<!-- PAGE=? -->
80

<!-- PAGE=? -->
AGE (YEARS)

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
FRC & Postoperative pulmonary function

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 primarily restrictive defect

<!-- PAGE=? -->
o proportional decreases in all lung volumes

<!-- PAGE=? -->
 no change in airway resistance

<!-- PAGE=? -->
 The decrease in FRC, is the yardstick by which the severity of the restrictive defect is gauged

<!-- PAGE=? -->
o generated by

<!-- PAGE=? -->
 abdominal contents that impinge on and prevent normal movement of the diaphragm

<!-- PAGE=? -->
 abnormal respiratory pattern devoid of sighs and characterized by shallow, rapid respirations

<!-- PAGE=? -->
 12 breaths per minute vs. the postoperative patient at 20

<!-- PAGE=? -->
 FRC is defined as the volume of gas in the lung at the end of a normal expiration

<!-- PAGE=? -->
 When expansive chest wall elastic forces are exactly balanced by retractive lung tissue elastic forces; there is no muscle activity and pressures are equal between alveoli and atmosphere

<!-- PAGE=? -->
 Pulmonary vascular resistance increases at volumes above and below FRC

<!-- PAGE=? -->
o PVR increases at volumes above FRC because of compressure of small intra-alveolar vessels

<!-- PAGE=? -->
o PVR increases at volumes below FRC secondary to HPV (of large vessels) due to hypoxic, ateletactic lungs

<!-- PAGE=? -->
 FRC volume = 2L (30cc/kg)

<!-- PAGE=? -->
 The operative site is the single most important determinant of both the degree of pulmonary restriction and the risk of postoperative pulmonary complications

<!-- PAGE=? -->
o Nonlaparoscopic upper abdominal operations cause the most profound restrictive defect,

<!-- PAGE=? -->
 40-50% decrease in FRC

<!-- PAGE=? -->
o Lower abdominal and thoracic

<!-- PAGE=? -->
 FRC decreases by 30%

<!-- PAGE=? -->
o intracranial, peripheral vascular, otolaryngologic

<!-- PAGE=? -->
 FRC reductions to 15-20%

<!-- PAGE=? -->
 There are several strategies by which it is possible to reduce risk of PPC

<!-- PAGE=? -->
o lung-expanding therapies postoperatively

<!-- PAGE=? -->
o choice of analgesia

<!-- PAGE=? -->
o cessation of smoking

<!-- PAGE=? -->
 . After upper abdominal operations, FRC recovers over 3-7 days

<!-- PAGE=? -->
o FRC will recover within 72 hours with use of intermittent CPAP

<!-- PAGE=? -->
 VC generally returns to normal in 1-2 weeks

<!-- PAGE=? -->
 After median sternotomy for cardiac operations, FRC does not return to normal for several weeks, regardless of postoperative pulmonary therapy

<!-- PAGE=? -->
 Total lung capacity (TLC) decreases after abdominal surgery but not after surgery on an extremity

<!-- PAGE=? -->
 Vital capacity is decreased by 25-50% within 1-2 days after surgery and generally returns to normal after 1-2 weeks

<!-- PAGE=? -->
 Residual volume (RV) increases by 13%, whereas expiratory reserve volume decreases by 25% after lower abdominal surgery and 60% after upper abdominal and thoracic surgery

<!-- PAGE=? -->
 Tidal volume (VT) decreases by 20% within 24 hours after surgery and gradually returns to normal after 2 weeks

<!-- PAGE=? -->
 Pulmonary compliance decreases by 33% with similar reductions in functional residual capacity (FRC) secondary to small airway closure

<!-- PAGE=? -->
Stoelting Co-existing

<!-- PAGE=? -->
 VC is decreased about 40% from preop value on the day of upper abdominal surgery and it does not return to near preoperative levels for 10-14 days

<!-- PAGE=? -->
 arterial oxygenation associated with decreases in FRC may not return until 10-14 days after surgery

<!-- PAGE=? -->
FRC decreases during GA due to:

<!-- PAGE=? -->
 Supine position (10-15%)

<!-- PAGE=? -->
 Induction of anesthesia (5-10%, loss of inspiratory tone 15 - 20 % total with supine position)

<!-- PAGE=? -->
o Barash describes a 15-20% dec. in addition to the dec. from supine positioning

<!-- PAGE=? -->
o The reduction in FRC associated with general anesthesia would be expected to increase airway resistance

<!-- PAGE=? -->
 Increases in resistance are not usually observed because of the bronchodilating properties of the volatile inhalational anesthetics

<!-- PAGE=? -->
o The maximum decrease in FRC appears to occur within the first few minutes of anesthesia and does not seem to decrease progressively during anesthesia.

<!-- PAGE=? -->
o During anesthesia, the reduction in FRC is of the same order of magnitude whether ventilation is spontaneous or controlled.

<!-- PAGE=? -->
o In awake patients, FRC is only slightly reduced during controlled ventilation

<!-- PAGE=? -->
o In obese patients, the reduction in FRC is far more pronounced than in normal patients, and the decrease is inversely related to the BMI

<!-- PAGE=? -->
o The reduction in FRC continues into the postoperative period.

<!-- PAGE=? -->
o the reduction in FRC correlates well with the increase in the alveolar-arterial PO2 gradient during anesthesia with spontaneous breathing, during anesthesia with artificial ventilation, and in the postoperative period

<!-- PAGE=? -->
o The reduced FRC may be restored to normal or above normal by the application of PEEP

<!-- PAGE=? -->
 Surgical positioning alters FRC

<!-- PAGE=? -->
o Trendelenburg > 30

<!-- PAGE=? -->
o Lateral - slight decrease

<!-- PAGE=? -->
o Prone increases FRC

<!-- PAGE=? -->
 Paralysis (cephalad shift of dependent diaphragm)

<!-- PAGE=? -->
 Light anesthesia (forced expiration increases airway collapse)

<!-- PAGE=? -->
 Excessive intravascular volume (zone 4 lung: Pa > Pinterstitial > Pv > PA)

<!-- PAGE=? -->
 O2 absorption atelectasis

<!-- PAGE=? -->
 Decreased surfactant production - alveolar II cells decrease surfactant with Halothane / Isoflurane

<!-- PAGE=? -->
 Decreased inspiratory muscle tone at end expiration - expiratory muscles are enhanced which decreases FRC

<!-- PAGE=? -->
of the diaphragm

<!-- PAGE=? -->
Initial upright

<!-- PAGE=? -->
position

<!-- PAGE=? -->
Pab

<!-- PAGE=? -->
FRC

<!-- PAGE=? -->
Supine

<!-- PAGE=? -->
position

<!-- PAGE=? -->
Surgical position

<!-- PAGE=? -->
Induction of

<!-- PAGE=? -->
Ind displacement

<!-- PAGE=? -->
anesthesia

<!-- PAGE=? -->
Pulmonary dead space

<!-- PAGE=? -->
 Physioloic dead space = anatomic +alveolar

<!-- PAGE=? -->
 Physioligic dead space determined by the Bohr equation

<!-- PAGE=? -->
o VDS/VT = (PaCO2 - PECO2)/PaCO2

<!-- PAGE=? -->
 ratio usually <30%

<!-- PAGE=? -->
 can inc. to 60-70% in COPD

<!-- PAGE=? -->
 Ventilation is 2/3 alveolar and 1/3 dead space

<!-- PAGE=? -->
o Ratio 2:1

<!-- PAGE=? -->
 Anatomic dead space is made up by the conducting airways from oronasalpharynx to terminal respiratory bronchioles

<!-- PAGE=? -->
 Alveolar dead space is made up by unperfused alveoli

<!-- PAGE=? -->
 Anatomic dead space = 2ml/kg, in healthy pt lying supine - determined by fowler's method

<!-- PAGE=? -->
o Accounts for the majority of physiologic dead space

<!-- PAGE=? -->
o modified by tracheal intubation, tracheostomy, and large lengths of ventilator tubing between the tracheal tube and the ventilator Y-piece

<!-- PAGE=? -->
 Alveolar dead space from ventilation of alveoli where there is little or no perfusion

<!-- PAGE=? -->
o Examples include Zone 1, pulmonary embolism, dec. CO, ARDS - vasoconstriction, PPV with PEEP d/t the associated dec. in CO

<!-- PAGE=? -->
o physiologic dead space is primarily influenced by changes in alveolar dead space

<!-- PAGE=? -->
 COPD can inc. dead space by destruction of alveolar septa

<!-- PAGE=? -->
alveolar ventilation(VA) = frequency (f) (VT - VD)

<!-- PAGE=? -->
=60ml/kg/min minute ventilation=90ml/min if SV  (60ml/kg + 30ml/kg/min dead space) PPV=120ml/kg/min

<!-- PAGE=? -->
Pulmonary Shunt

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Physiologic pulmonary shunt is normally 2-5% of total CO

<!-- PAGE=? -->
o Also called venous admixture

<!-- PAGE=? -->
 In healthy young to middle-aged, generally anesthetized patients, venous admixture has been found to average 10%

<!-- PAGE=? -->
o didn't vary with spont and PPV

<!-- PAGE=? -->
 physiologic shunt decreases with HPV

<!-- PAGE=? -->
Pulmonary Artery Catheters

<!-- PAGE=? -->
Miller, Barash

<!-- PAGE=? -->
Figure 40-43 Relationship between left atrial pressure (LAP) and

<!-- PAGE=? -->
left ventricular end-diastolic pressure (LVEDP). LVEDP is

<!-- PAGE=? -->
measured at the Z-point on the left ventricular pressure (LVP)

<!-- PAGE=? -->
trace at the time of the electrocardiographic R wave.

<!-- PAGE=? -->
Mean LAP

<!-- PAGE=? -->
(9 mm Hg) underestimates LVEDP (15 mm Hg), but the LAP a

<!-- PAGE=? -->
wave pressure peak closely estimates LVEDP

<!-- PAGE=? -->
. (From Mark JB:

<!-- PAGE=? -->
Atlas of Cardiovascular Monitoring. New York, Churchill

<!-- PAGE=? -->
Livingstone, 1998, Fig. 6-1.)

<!-- PAGE=? -->
80

<!-- PAGE=? -->
40

<!-- PAGE=? -->
(LVEDP}

<!-- PAGE=? -->
LAP

<!-- PAGE=? -->
LAP

<!-- PAGE=? -->
LVP

<!-- PAGE=? -->
 Large A and V waves are present with myocardial ischemia (diastolic dysfunction)

<!-- PAGE=? -->
o Slight elevation in wedge pressure

<!-- PAGE=? -->
Confirmation of Placement in Zone III

<!-- PAGE=? -->
 Lateral CXR

<!-- PAGE=? -->
o Confirm tip is below the Lt atrium

<!-- PAGE=? -->
 Wedge tracing should normal phasic morphology (a and v waves)

<!-- PAGE=? -->
 PCWP should equal PAEDP

<!-- PAGE=? -->
o PCWP > PAEDP indicates that the tip is in either zone I or II

<!-- PAGE=? -->
 Wedge pressure should not vary greatly with ventilation

<!-- PAGE=? -->
Complications of Pulmonary Artery Catheter Monitoring - serious complications caused specifically by pulmonary artery catheterization occur in 0.1% to 0.5% of patients

<!-- PAGE=? -->
 Arrhythmias - most common complication

<!-- PAGE=? -->
 PVC

<!-- PAGE=? -->
 RBBB - 5%

<!-- PAGE=? -->
 complete heart block - <1% with pre-existing LBBB

<!-- PAGE=? -->
 VF - highest risk in pt with ischemia (esp RV)

<!-- PAGE=? -->
 Catheter resistance

<!-- PAGE=? -->
 Mechanical

<!-- PAGE=? -->
 catheter knots

<!-- PAGE=? -->
 Thromboembolism - ↑ with antifibrinolytics

<!-- PAGE=? -->
 Pulmonary infarction

<!-- PAGE=? -->
 Infection, endocarditis - ↑ with >72hr duration, and/or pre-excisting sepsis

<!-- PAGE=? -->
 Endocardial damage, cardiac valve injury

<!-- PAGE=? -->
 Pulmonary artery rupture - 0.02%-0.2% of pts, 50% mortality

<!-- PAGE=? -->
 ↑ risk with

<!-- PAGE=? -->
 patient

<!-- PAGE=? -->
 hypothermia

<!-- PAGE=? -->
 anticoagulation

<!-- PAGE=? -->
 advanced age (>60)

<!-- PAGE=? -->
 pHTN

<!-- PAGE=? -->
 procedure

<!-- PAGE=? -->
 Excessive insertion distance

<!-- PAGE=? -->
o Tip should be within 2 cm of the cardiac silhouette on AP CXR

<!-- PAGE=? -->
 Unnecessary catheter manipulation

<!-- PAGE=? -->
 Unrecognized persistent wedge

<!-- PAGE=? -->
 Prolonged balloon inflation

<!-- PAGE=? -->
 Inflation with liquid

<!-- PAGE=? -->
 hemoptysis is the hallmark

<!-- PAGE=? -->
 may lead to exsanguiation, hypoxemia, occult hTN and resp insufficienty

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
 Cardiopulmonary support

<!-- PAGE=? -->
 Lung isolation

<!-- PAGE=? -->
 PEEP to affected lung to ↓ hemorrhage

<!-- PAGE=? -->
 Reversal of anticoagulation

<!-- PAGE=? -->
 Controversy regarding management of PAC

<!-- PAGE=? -->
 Withdrawal vs. leave insitu to guide antihypertensive treatment

<!-- PAGE=? -->
 Medical tx alone: risk of psudoaneurysm, rebleeding

<!-- PAGE=? -->
 FU angio and embolization

<!-- PAGE=? -->
 Pulmonary artery pseudoaneurysm

<!-- PAGE=? -->
 Complication after rupture

<!-- PAGE=? -->
 Misinterpretation of data

<!-- PAGE=? -->
 Misuse of equipment

<!-- PAGE=? -->
Clinical Findings

<!-- PAGE=? -->
 Myocardial ischemia results in diastolic dysfunction

<!-- PAGE=? -->
o increased left ventricular end-diastolic pressure - increase left atrial and wedge pressure

<!-- PAGE=? -->
o a and v wave components become more prominent as diastolic filling pressure increases

<!-- PAGE=? -->
 most prominent finding

<!-- PAGE=? -->
Interpretation errors

<!-- PAGE=? -->
 LVEDP > PCWP (5) (underestimation):

<!-- PAGE=? -->
o AI or AS

<!-- PAGE=? -->
o Diastolic dysfunction (LVH)

<!-- PAGE=? -->
o Pulmonary valve regurgitation

<!-- PAGE=? -->
o RBBB

<!-- PAGE=? -->
o Post-pneumonectomy

<!-- PAGE=? -->
 PCWP > LVEDP (5) (overestimation):

<!-- PAGE=? -->
o PEEP (zone 1, 2 lung)

<!-- PAGE=? -->
o pHTN (increased PVR)

<!-- PAGE=? -->
o MS or MR

<!-- PAGE=? -->
o VSD

<!-- PAGE=? -->
o Tachycardia

<!-- PAGE=? -->
 Catheter NOT in Zone III (PCWP > LVEDP) (3):

<!-- PAGE=? -->
o PCWP > PAEDP

<!-- PAGE=? -->
o Nonphasic tracing

<!-- PAGE=? -->
o Unable to aspirate blood

<!-- PAGE=? -->
o Above LA on Lat film

<!-- PAGE=? -->
Underestimation of Left Ventricular End-Diastolic Pressure

<!-- PAGE=? -->
Overestimation of Left Ventricular End-Diastolic Pressure

<!-- PAGE=? -->
PADP > PCWP by 0-4 mmHg normally. Factors that make the difference larger are those that increase PVR thus overestimating PCWP.

<!-- PAGE=? -->
acute or chronic parenchymal lung disease

<!-- PAGE=? -->
emboli, alveolar hypoxia

<!-- PAGE=? -->
acidosis

<!-- PAGE=? -->
hypoxemia

<!-- PAGE=? -->
drugs that increase PVR

<!-- PAGE=? -->
increased HR (shortens diastolic runoff into LA)

<!-- PAGE=? -->
PADP < PCWP caused by

<!-- PAGE=? -->
RBBB

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
Not in zone III

<!-- PAGE=? -->
Thermodilution CO

<!-- PAGE=? -->
 cardiac output is inversely proportional to the area under the thermodilution curve

<!-- PAGE=? -->
o smaller AUC, larger CO

<!-- PAGE=? -->
o injectate is washed away quickly

<!-- PAGE=? -->
 Overestimation

<!-- PAGE=? -->
o Smaller injectate-larger reading

<!-- PAGE=? -->
o Intracardiac shunts - Both right-to-left and left-to-right intracardiac shunts

<!-- PAGE=? -->
o Erroneous inc. in injectate temperature

<!-- PAGE=? -->
 an increase of 1°C will cause a 3% overestimation of cardiac output

<!-- PAGE=? -->
 Underestimation

<!-- PAGE=? -->
o significant tricuspid regurgitation

<!-- PAGE=? -->
 may be overestimated, depending on the severity of valvular regurgitation and the magnitude of the cardiac output

<!-- PAGE=? -->
o measurements made in the minutes after bypass are notoriously unreliable and most often lead to marked underestimation of true cardiac output

<!-- PAGE=? -->
 unstable baseline

<!-- PAGE=? -->
 stroke output of the right ventricle varies as much as 50% during the respiratory cycle

<!-- PAGE=? -->
o widely variable measurements of cardiac output are obtained, depending on the point during the respiratory cycle when the measurements are performed

<!-- PAGE=? -->
o accurate measurement of average cardiac output is achieved more reliably by making multiple injections during the different phases of the respiratory cycle and then averaging the result

<!-- PAGE=? -->
Pulmonary assessment, pre-pneumonectomy

<!-- PAGE=? -->
Slinger

<!-- PAGE=? -->
 Predictors of poor outcome (3 legged stool - lung mechanics, parenchymal function, cardiopulmonary interaction)

<!-- PAGE=? -->
o ppoFEV1 < 40% OR

<!-- PAGE=? -->
 RV/TLC > 50%, MVV < 50%, VC < 50%

<!-- PAGE=? -->
o ppoDLCO < 40% OR

<!-- PAGE=? -->
 PaO2 < 60, PaCO2 > 45

<!-- PAGE=? -->
o ppoVO2 < 10 ml/kg.min OR

<!-- PAGE=? -->
 climb < 2 flights

<!-- PAGE=? -->
 6 min walk < 2000 ft

<!-- PAGE=? -->
 exercise drop of SpO2 > 4%

<!-- PAGE=? -->
 Of these, the most valid single test for post-thoracotomy respiratory complications is the predicted postoperative FEV1 (ppoFEV1 %)

<!-- PAGE=? -->
Predictors of poor outcome post-pulmonary resection (Miller):

<!-- PAGE=? -->
Calculating ppoFEV1

<!-- PAGE=? -->
FEV1 of 60% for Left Upper Lobectomy.

<!-- PAGE=? -->
A V/Q scan of the LUQ shows ventilation = 7%, perfusion = 3% of total lung values.

<!-- PAGE=? -->
 ppoFEV1 = preoperative FEV1 x (100 - percentage of functional lung tissue removed)/100

<!-- PAGE=? -->
o = 60% x (100-7)/100 = 55.8%

<!-- PAGE=? -->
 ppoFEV1 = preoperative FEV1 x (42 - 10)/42

<!-- PAGE=? -->
o = 60% x (42-10)/42 = 45.7%

<!-- PAGE=? -->
Pulmonary contusion

<!-- PAGE=? -->
(Barash Ch 48)

<!-- PAGE=? -->
 Pathologically described as intra-alveolar hemorrhage and edema resulting from sudden increase in intraalveolar pressure and rupture of alveolar-capillary interface

<!-- PAGE=? -->
 Cannon be predicted from rib fractures; severe chest-wall injuries may have not lung damage and vice versa

<!-- PAGE=? -->
 Radiologic manifestations lag physiological and clinical findings (4hrs after injury)

<!-- PAGE=? -->
 All patients with suspected blunt chest trauma, serial ABGs ( 5 min RA; use same FIO2) and CXRs should be obtained starting at admission

<!-- PAGE=? -->
 Initial management includes ETT, mechanical ventilation preferable with PEEP and frequent tracheobronchial suctioning

<!-- PAGE=? -->
 Clearing of secretions is paramount  cause bronchial plugging, atelectasis, infection

<!-- PAGE=? -->
Pulmonary hypertension

<!-- PAGE=? -->
 Persistent fetal circulation, etiology (5):

<!-- PAGE=? -->
o Idiopathic

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Hypercarbia

<!-- PAGE=? -->
o Meconium aspiration

<!-- PAGE=? -->
o Respiratory distress (hypoxemia)

<!-- PAGE=? -->
o Congenital diaphragmatic hernia

<!-- PAGE=? -->
 ECG findings PHTN

<!-- PAGE=? -->
o RBBB or incomplete RBBB (rSr′ in lead V1) (RV hypertrophy)

<!-- PAGE=? -->
o Right axis deviation  (RV hypertrophy)

<!-- PAGE=? -->
o Right ventricular hypertrophy

<!-- PAGE=? -->
o P pulmonale (P greater than 2.5 mm in leads II, III, and aVF) RA hypertrophy

<!-- PAGE=? -->
o ‗Strain‖ in RV leads

<!-- PAGE=? -->
o Tall R wave in V1

<!-- PAGE=? -->
o Persistent precordial S waves

<!-- PAGE=? -->
Total Subsegments

<!-- PAGE=? -->
42

<!-- PAGE=? -->
10

<!-- PAGE=? -->
10

<!-- PAGE=? -->
12

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
687147

<!-- PAGE=? -->
10/16/02

<!-- PAGE=? -->
II

<!-- PAGE=? -->
V1

<!-- PAGE=? -->
RA abnormality

<!-- PAGE=? -->
P pulmonale is used when there is tall and peaked P wave in lead II, III and aVF,

<!-- PAGE=? -->
Patient. 80 year old male was admitted with acute exacerbation of his severe COPD. He also has history of coronary artery disease with non Q wave MI and 2 vessels stent placement in 5/02. Echocardiogram did not report of right heart enlargement and the pulmonary artery pressure was estimated to be only slightly elevated. Left atrial size was normal. There was left ventricular inferior wall motion abnormality with over all ejection fraction of about 55%

<!-- PAGE=? -->
P wave abnormalities. There are wide range of variation of P wave abnormalities since several factors may effect the P wave. These include: Anatomic cardiac position to the anterior chest wall; state of autonomic influence; intra and/or interatrial conduction abnormality; atrial pressure and/or volume load; atrial/atria diseases; electrode positioning (precordial lead). The diagnostic sensitivity are poor.

<!-- PAGE=? -->
LA abnormality, RA abnormality, or Intra/inter atrial conduction defect (IACD) are better term than LA enlargement or RA enlargement.

<!-- PAGE=? -->
LA abnormality

<!-- PAGE=? -->
 Prolonged P wave >120 ms (0.12 sec).

<!-- PAGE=? -->
 Notched P wave in lead II ( P mitrale). The 2 peaks should be apart >0.04 sec.

<!-- PAGE=? -->
 Terminal negative P wave in lead V1 area >0.04 (amplitude in mV x duration in second).

<!-- PAGE=? -->
 Left shift of P wave axis on frontal plane (from +45 and +60 to -30 and +45)

<!-- PAGE=? -->
RA abnormality

<!-- PAGE=? -->
 Peaked P wave in lead II (inferior leads) > 2.5 mV. -  Initial positive P wave in lead V1 amplitude >1.5 mV and area >0.06 (amplitude in mV x duration in second).

<!-- PAGE=? -->
 Right shift of P wave axis on frontal plane (from +0 to +75 to more than + 75)

<!-- PAGE=? -->
Comment. 1. V1 does not has criteria of RA abnormality. 2. There are few atrial premature depolarizations. 3. Other abnormality include ECG pattern consistent of severe lung disease patient.

<!-- PAGE=? -->
Pulse Oximetry

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
Pulsus Paradoxus

<!-- PAGE=? -->
 DDx = tamponade, constrictive pericarditis, RV infarct, pulmonary regurgitation, status asthmaticus

<!-- PAGE=? -->
 Physiology:

<!-- PAGE=? -->
 Pulsus paradoxus occurs only when intrapericardial pressure exceeds the diastolic filling pressures of both ventricles.

<!-- PAGE=? -->
 Two factors are involved in the physiology of pulsus paradoxus:

<!-- PAGE=? -->
o intrathoracic pressure change during ventilation

<!-- PAGE=? -->
o the anatomic interrelationship between the ventricles

<!-- PAGE=? -->
 Venous return increases slightly during spontaneous inspiration increasing right ventricular size.

<!-- PAGE=? -->
 Because cardiac size is restricted by the tamponading fluid, the right ventricle can enlarge only at the expense of left ventricular size

<!-- PAGE=? -->
o Left ventricular preload, stroke volume, and systemic pressure thus decrease during inspiration.

<!-- PAGE=? -->
 Positive pressure ventilation may worsen cardiac tamponade by further restricting venous return to the heart

<!-- PAGE=? -->
 Other

<!-- PAGE=? -->
o pulmonary insufficiency can result in an exaggerated decrease in blood pressure during inspiration

<!-- PAGE=? -->
o RV AMI  RV enlarges and will compress LV - more so during inspiration

<!-- PAGE=? -->
PVR

<!-- PAGE=? -->
PVR = 80 x [Mean PAP - PCWP] / CO

<!-- PAGE=? -->
R

<!-- PAGE=? -->
Red Blood cell replacement

<!-- PAGE=? -->
 PRBCs have a hematocrit of 60%

<!-- PAGE=? -->
o the volume to be infused is found by dividing the volume of RBCs desired by the hematocrit (Hct) of the unit of PRBCs

<!-- PAGE=? -->
o PRBCinfused = (Hctdesired × 55 × Weight - Hctobserved × 55 × Weight)/0.60

<!-- PAGE=? -->
Renal drug excretion

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Drugs completely dependent on renal excretion:

<!-- PAGE=? -->
o Digoxin

<!-- PAGE=? -->
o Ionotropes

<!-- PAGE=? -->
o ABx

<!-- PAGE=? -->
 vanco, ceph, penicillin, aminoglycosides

<!-- PAGE=? -->
 Drugs partially dependent on renal excretion

<!-- PAGE=? -->
o Barbiturates

<!-- PAGE=? -->
o Pancuronium

<!-- PAGE=? -->
o Atropine and glycopyrrolate

<!-- PAGE=? -->
o Cholinesterase inhibitors

<!-- PAGE=? -->
 Neostigmine - 50%

<!-- PAGE=? -->
 Edrophonium - 75%

<!-- PAGE=? -->
 Pyridostigmine - 75%

<!-- PAGE=? -->
o Milrinone

<!-- PAGE=? -->
o Hydralazine

<!-- PAGE=? -->
o Sulphonamines

<!-- PAGE=? -->
o Chlopropramide

<!-- PAGE=? -->
o magnesium

<!-- PAGE=? -->
Renal Acid-Base Regulation

<!-- PAGE=? -->
The renal acid-base mechanism works in 3 ways:

<!-- PAGE=? -->
HCO3- is filtered from the plasma and H+ is secreted by cells throughout the tubular system (except the thin loop)

<!-- PAGE=? -->
o two types of cells secreting H+ into the tubules (epithelial cells and intercalated cells)

<!-- PAGE=? -->
o HCO3- and H+ combine in the lumen to neutralize but there is generally more H+ lost (hence the usual urine pH of 6.4)

<!-- PAGE=? -->
o bicarbonate buffering system accounts for >50% of the total buffering capacity of blood

<!-- PAGE=? -->
o bicarbonate buffering system is NOT a powerful buffer because its pH of 6.1 differs greatly from the normal pH of 7.4.

<!-- PAGE=? -->
o ratio of dissolved carbon dioxide to bicarbonate ions is 20:1

<!-- PAGE=? -->
o 99% of carbonic acid in solution almost immediately dissociates into carbon dioxide and water

<!-- PAGE=? -->
when the secretion of H+ exceeds filtered HCO3- it is -mopped up‖ by the phosphate buffering system

<!-- PAGE=? -->
o very powerful buffer in the urine compared to its minimal effect in plasma

<!-- PAGE=? -->
o pKa is 6.8 which makes it maximally active at normal urine pH

<!-- PAGE=? -->
if the HCO3- and phosphate buffer systems are overwhelmed the NH3/NH4+ system will pitch in

<!-- PAGE=? -->
o NH3 is produced by deamination of glutamine in epithelial cell mitochondria constantly and diffuses into the tubules (ammonia production increases in the face of acidemia)

<!-- PAGE=? -->
o in the tubules ammonia combines with H+ to form ammonium (NH4+) which is poorly reabsorbed and therefore -traps‖ the H+ in the tubules thereby getting rid of it.

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 three renal mechanisms that prevent the development of academia

<!-- PAGE=? -->
o reabsorption of filtered bicarbonate

<!-- PAGE=? -->
o acidification of buffers in tubular urine (i.e., excretion of titratable acid)

<!-- PAGE=? -->
o production of ammonia in tubular cells and its excretion as ammonium ion

<!-- PAGE=? -->
 The inability to excrete an acidic urine in the presence of systemic acidosis is indicative of renal insufficiency

<!-- PAGE=? -->
COz + HzO

<!-- PAGE=? -->
Carbonic

<!-- PAGE=? -->
Anhydrase

<!-- PAGE=? -->
HzCO,

<!-- PAGE=? -->
H'

<!-- PAGE=? -->
Na'

<!-- PAGE=? -->
Nat

<!-- PAGE=? -->
Aenal Tubular

<!-- PAGE=? -->
Epilhelial Cell

<!-- PAGE=? -->
Peritubular

<!-- PAGE=? -->
Capillary

<!-- PAGE=? -->
Dlslal

<!-- PAGE=? -->
Renal Tubule

<!-- PAGE=? -->
Renal Failure

<!-- PAGE=? -->
Laboratory Findings

<!-- PAGE=? -->
Manifestations

<!-- PAGE=? -->
Lange End-stage Renal Disease

<!-- PAGE=? -->
Hydrogen ions are actively secreted into renal tubules by epithelial cells lining proximal renal tubules, distal renal tubules, and collecting ducts

<!-- PAGE=? -->
At the same time, sodium ions are reabsorbed in place of the secreted hydrogen ions, and bicarbonate ions formed in the renal tubular epithelial cells enter peritubular capillaries to combine with the sodium ions. As a result, the amount of sodium bicarbonate in the plasma is increased during the secretion of hydrogen ions into renal tubules.

<!-- PAGE=? -->
 Neurological

<!-- PAGE=? -->
o Peripheral neuropathy

<!-- PAGE=? -->
o Autonomic neuropathy

<!-- PAGE=? -->
o Muscle twitching

<!-- PAGE=? -->
o Encephalopathy

<!-- PAGE=? -->
o Asterixis

<!-- PAGE=? -->
o Myoclonus

<!-- PAGE=? -->
o Lethargy

<!-- PAGE=? -->
o Confusion

<!-- PAGE=? -->
o Seizures

<!-- PAGE=? -->
o Coma

<!-- PAGE=? -->
 Cardiovascular

<!-- PAGE=? -->
o Fluid overload

<!-- PAGE=? -->
o Congestive heart failure

<!-- PAGE=? -->
o Hypertension

<!-- PAGE=? -->
o Pericarditis

<!-- PAGE=? -->
o Arrhythmia

<!-- PAGE=? -->
o Conduction blocks

<!-- PAGE=? -->
o Vascular calcification

<!-- PAGE=? -->
o Accelerated atherosclerosis

<!-- PAGE=? -->
o Dysrhythmias (abnormal electrolytes)

<!-- PAGE=? -->
o Capillary fragility

<!-- PAGE=? -->
 Pulmonary

<!-- PAGE=? -->
o Hyperventilation

<!-- PAGE=? -->
o Pulmonary edema

<!-- PAGE=? -->
o Pleural effusion

<!-- PAGE=? -->
 Gastrointestinal

<!-- PAGE=? -->
o Anorexia

<!-- PAGE=? -->
o Nausea and vomiting

<!-- PAGE=? -->
o Delayed gastric emptying

<!-- PAGE=? -->
o Hyperacidity

<!-- PAGE=? -->
o Mucosal ulcerations

<!-- PAGE=? -->
o Hemorrhage

<!-- PAGE=? -->
o Adynamic ileus

<!-- PAGE=? -->
 Metabolic

<!-- PAGE=? -->
o Metabolic acidosis

<!-- PAGE=? -->
o Hyperkalemia

<!-- PAGE=? -->
o Hyponatremia

<!-- PAGE=? -->
o Hypermagnesemia

<!-- PAGE=? -->
o Hyperphosphatemia

<!-- PAGE=? -->
o Hypocalcemia

<!-- PAGE=? -->
o Hyperuricemia

<!-- PAGE=? -->
o Hypoalbuminemia

<!-- PAGE=? -->
 Hematological

<!-- PAGE=? -->
o Anemia

<!-- PAGE=? -->
o Platelet dysfunction

<!-- PAGE=? -->
o Leukocyte dysfunction

<!-- PAGE=? -->
 Impaired cellular immunity

<!-- PAGE=? -->
o Shift in P50 of oxyhemoglobin dissociation curve

<!-- PAGE=? -->
 Endocrine

<!-- PAGE=? -->
o Glucose intolerance

<!-- PAGE=? -->
o Secondary hyperparathyroidism

<!-- PAGE=? -->
o Hypertriglyceridemia

<!-- PAGE=? -->
Causes

<!-- PAGE=? -->
Lange

<!-- PAGE=? -->
 Renal ischemia (ATN)

<!-- PAGE=? -->
 Nephrotoxins (ATN)

<!-- PAGE=? -->
o Endogenous pigments (Hg, Myopglobin)

<!-- PAGE=? -->
o Contrast fye

<!-- PAGE=? -->
o Drugs (antibiotics, NSAIDS, chemotherapeutic agents)

<!-- PAGE=? -->
o Fluoride toxicity (prolonged anesthetic with enflurane, sevoflurane)

<!-- PAGE=? -->
 Intrinsic renal disease

<!-- PAGE=? -->
Table 37-1 --Causes of renal hypoperfusion associated with acute renal failure

<!-- PAGE=? -->
o Pancreatitis

<!-- PAGE=? -->
 Skeletal

<!-- PAGE=? -->
o Osteodystrophy

<!-- PAGE=? -->
o Periarticular calcification

<!-- PAGE=? -->
o Generalized muscle weakness

<!-- PAGE=? -->
o Gout, pseudogout

<!-- PAGE=? -->
 Skin

<!-- PAGE=? -->
o Hyperpigmentation

<!-- PAGE=? -->
o Ecchymosis

<!-- PAGE=? -->
o Pruritus

<!-- PAGE=? -->
Perioperative Renal dysfunction

<!-- PAGE=? -->
Miller ch27 1102

<!-- PAGE=? -->
The most important risk factors for peri-operative renal dysfunction

<!-- PAGE=? -->
 preexisting renal disease

<!-- PAGE=? -->
 preoperative LV dysfunction

<!-- PAGE=? -->
 inc. age

<!-- PAGE=? -->
 Others

<!-- PAGE=? -->
o intraoperative hypovolemia

<!-- PAGE=? -->
o CPB

<!-- PAGE=? -->
o aortic cross-clamping

<!-- PAGE=? -->
o ongoing sepsis

<!-- PAGE=? -->
o previous myocardial revascularization

<!-- PAGE=? -->
o type 1 DM or preoperative glucose levels exceeding 16.6 mmol/L

<!-- PAGE=? -->
Renal Physiology

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 active, energy-dependent reabsorption of sodium begins almost immediately as filtrate enters the proximal tubule

<!-- PAGE=? -->
o ATP drives sodium into tubular cells

<!-- PAGE=? -->
 chloride ion passively follows

<!-- PAGE=? -->
 Glucose, amino acid, and other organic compound reabsorption is strongly coupled to sodium in the proximal tubule

<!-- PAGE=? -->
 the proximal tubule reabsorbs ~65% of the filtered sodium

<!-- PAGE=? -->
 the medullary thick ascending limb (mTAL) of the loop of Henle is metabolically active in their role of reabsorbing sodium and chloride and have a high oxygen consumption compared with the thin portions of the descending and ascending limbs

<!-- PAGE=? -->
 Sodium pumps in the distal tubule and collecting duct are under the control of the adrenal hormone aldosterone

<!-- PAGE=? -->
 Water

<!-- PAGE=? -->
o reabsorption of water is a passive, osmotically driven process that is tied to sodium and other solute reabsorption

<!-- PAGE=? -->
o dependanr on peritubular capillary pressure

<!-- PAGE=? -->
 high capillary pressure opposes water reabsorption in the proximal tubule and tends to increase urine output

<!-- PAGE=? -->
o The proximal tubule reabsorbs ~65% of filtered water in an isosmotic fashion with sodium and chloride

<!-- PAGE=? -->
o The descending limb of the loop of Henle allows water to follow osmotic gradients into the renal interstitium

<!-- PAGE=? -->
o the thin ascending limb and mTAL are relatively impermeable to water and play a key role in the production of concentrated urine

<!-- PAGE=? -->
 approximately 15% of filtered water is reabsorbed by the loop of Henle

<!-- PAGE=? -->
o 20% of the filtrate volume flows into the distal tubule

<!-- PAGE=? -->
o in the collecting duct, water reabsorption is controlled entirely by antidiuretic hormone (ADH) secreted by the pituitary gland

<!-- PAGE=? -->
Renal Vasa Recta

<!-- PAGE=? -->
 (P&P Ch 53)

<!-- PAGE=? -->
 Function of renal medulla is to maintain high osmolarity which is produced by solute transport out of the ascending limb of the loop of Henle

<!-- PAGE=? -->
 This allows tubular flow to be concentrated by osmotic absorption of water from the collecting ducts

<!-- PAGE=? -->
 This function depends on the vasa recta which are peritubular capillaries with a countercurrent arrangement

<!-- PAGE=? -->
 This specialized vascular arrangement minimizes washout of solutes from the medullary interstitium, which is critical to the formation of concentrated urine

<!-- PAGE=? -->
 The vasa recta capillaries descent with the thin loops of Henle into the renal medulla before returning to the renal cortex to empty into the veins

<!-- PAGE=? -->
 Only 1-2% of renal blood flow pases through the vasa recta (sluggish blood flow in medulla compared to cortex)

<!-- PAGE=? -->
 To function properly, the hematocrit of the entering blood is low (10%) or else osmotic removal of water from the descending vasa recta would dramatically increase blood viscosity

<!-- PAGE=? -->
 Autoregulation of the kidney is controlled by afferent arteriole

<!-- PAGE=? -->
 Vasa recta comes from EFFERENT arterioles

<!-- PAGE=? -->
 Situated in medulla

<!-- PAGE=? -->
 JGA regulates aldosterone

<!-- PAGE=? -->
Renin-angiotensin system (RAS)

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 involved in control of blood pressure and blood volume

<!-- PAGE=? -->
 plays a role in sodium homeostasis and renal function, particularly under stress conditions

<!-- PAGE=? -->
 may be initiated by

<!-- PAGE=? -->
o decreases in blood pressure in the renal artery

<!-- PAGE=? -->
o decreases in sodium delivery to the macula densa

<!-- PAGE=? -->
o sympathetic nervous system activation

<!-- PAGE=? -->
 secreted by the juxtaglomerular cells of the kidney, cleaves its substrate, angiotensinogen, to generate angiotensin I, converted to angiotension II by ACE (primarily in the lung)

<!-- PAGE=? -->
 Angiotensin II

<!-- PAGE=? -->
o potent vasopressor

<!-- PAGE=? -->
o stimulates aldosterone secretion through the adrenal cortex

<!-- PAGE=? -->
o has a vagal inhibitory effect

<!-- PAGE=? -->
o causes ganglionic stimulation

<!-- PAGE=? -->
o degraded in the plasma to the carboxyl-terminal heptapeptide angiotensin III or the amino-terminal heptapeptide angiotensin (1-7), both of which appear to be biologically active

<!-- PAGE=? -->
 End result is an increase in blood pressure and sodium retention caused by enhanced aldosterone secretion

<!-- PAGE=? -->
 does not have an active role in maintaining blood pressure in the normal, sodium-replete, intact individual

<!-- PAGE=? -->
Respiratory quotient

<!-- PAGE=? -->
Lange 477

<!-- PAGE=? -->
RQ = CO2 production/O2 consumption, normally = 0.8 reflecting use of fats and CHO CHO = 1 Lipids = 0.7 Proteins = 0.8 VCO2 = 200 ml/min, VO2 = 250 ml/min RQ > 1 = overfeeding RQ < 1 = lipolysis (starvation)

<!-- PAGE=? -->
Resusciatation Drugs: ACLS, PALS and NRP

<!-- PAGE=? -->
Retrobulbar and Peribulbar Blocks

<!-- PAGE=? -->
 practical means to achieve analgesia and profound akinesia of the globe

<!-- PAGE=? -->
 Retrobulbar blocks are accomplished by directing a needle toward the orbital apex with sufficient depth and angulation such that the orbital cone (formed by the four rectus muscles) is penetrated

<!-- PAGE=? -->
 the peribulbar block is executed by directing a needle to less depth and with minimal angulation, parallel to the globe, toward the greater wing of the sphenoid bone

<!-- PAGE=? -->
o Local anesthetic instilled in this extraconal space will eventually penetrate toward the optic nerve and other structures

<!-- PAGE=? -->
o two injections are required; these are placed inferotemporally, and superonasally just below and medial to the supraorbital notch

<!-- PAGE=? -->
o Following careful aspiration, 4 to 5 ml of anesthetic solution is injected in each site

<!-- PAGE=? -->
o Onset is usually slower than with retrobulbar blockade and may be delayed for as long as 15 to 20 minutes

<!-- PAGE=? -->
o theoretically safer because the needle tip is kept at a greater distance from vital intraorbital structures and brain higher failure rate than retrobulbar blocks

<!-- PAGE=? -->
 retrobulbar blocks have a faster onset and require a smaller volume of local anesthetic

<!-- PAGE=? -->
 the large volume of local anesthetic required for the peribulbar blocks results in lid akinesia, negating the need for a separate block of the branches of the facial nerve supplying the orbicularis muscle (eyelid movement)

<!-- PAGE=? -->
 Patients should be instructed to maintain gaze in the neutral position, leaving the optic nerve lax within the orbit in the course of needle insertion

<!-- PAGE=? -->
 Needle penetration should not exceed 31mm (risk of brainstem anesthesia)

<!-- PAGE=? -->
 Elevations in intraocular pressure after a retrobulbar block can be minimized by application of gentle noncontinuous digital pressure or use of an ocular decompression device

<!-- PAGE=? -->
 Complications include

<!-- PAGE=? -->
o Stimulation of oculocardiac reflex arc

<!-- PAGE=? -->
o Superficial hemorrhage → circumorbital hematoma

<!-- PAGE=? -->
o Retrobulbar hemorrhage ± retinal perfusion compromise → loss of vision

<!-- PAGE=? -->
 Signs and symptoms include

<!-- PAGE=? -->
 Pain

<!-- PAGE=? -->
 increasing proptosis

<!-- PAGE=? -->
 subconjunctival or eyelid ecchymoses

<!-- PAGE=? -->
 Consultation with an ophthalmologist / fundoscopic examination / tonometric measurement of IOP / ultrasound to assess presence/location of blood / lateral canthotomy may be warranted

<!-- PAGE=? -->
o Globe penetration ± intraocular injection → retinal detachment, loss of vision

<!-- PAGE=? -->
 intense and immediate ocular pain with sudden loss of vision

<!-- PAGE=? -->
 less likely with peribulbar blocks

<!-- PAGE=? -->
 Risk factors include

<!-- PAGE=? -->
 anteroposterior length > 26 mm by ultrasound

<!-- PAGE=? -->
o commonly noted in high myopes

<!-- PAGE=? -->
 severe enophthalmos

<!-- PAGE=? -->
 previous scleral buckle

<!-- PAGE=? -->
 repeated surgeries

<!-- PAGE=? -->
 posterior staphyloma - abnormal outpouching of the eye

<!-- PAGE=? -->
 repeated injections

<!-- PAGE=? -->
 an uncooperative patient

<!-- PAGE=? -->
o Trauma to optic nerve or orbital cranial nerves → loss of vision

<!-- PAGE=? -->
o Optic nerve sheath injection → orbital epidural anesthesia

<!-- PAGE=? -->
o Extraocular muscle injury, leading to postoperative strabismus, diplopia

<!-- PAGE=? -->
o Intra-arterial injection, producing immediate convulsions

<!-- PAGE=? -->
 Retrograde flow to the internal carotid artery

<!-- PAGE=? -->
o Central retinal artery occlusion

<!-- PAGE=? -->
o Inadvertent brainstem anesthesia

<!-- PAGE=? -->
 Less likely with peribulbar blocks

<!-- PAGE=? -->
 Results from direct spread of LA to the brain along the meningeal sheath surrounding the optic nerve

<!-- PAGE=? -->
 Signs and symptoms

<!-- PAGE=? -->
 violent shivering

<!-- PAGE=? -->
 contralateral amaurosis

<!-- PAGE=? -->
 eventual loss of consciousness

<!-- PAGE=? -->
 apnea

<!-- PAGE=? -->
 hemiplegia, paraplegia, quadriplegia, or hyperreflexia

<!-- PAGE=? -->
 Blockade of cranial nerves VIII to XII results in deafness, vertigo, vagolysis, dysphagia, aphasia, and loss of neck muscle power

<!-- PAGE=? -->
Rheumatoid Arthritis

<!-- PAGE=? -->
 Prevalence 0.3-1.5% in USA

<!-- PAGE=? -->
 Female:Male 2-3:1

<!-- PAGE=? -->
 Pregnancy often alleviates symptoms of RA

<!-- PAGE=? -->
 The most common chronic inflammatory arthritis

<!-- PAGE=? -->
 Characterized by symmetric polyarthopathy

<!-- PAGE=? -->
o Morning stiffness

<!-- PAGE=? -->
o MCPs and PIPs commonly involved in the upper body

<!-- PAGE=? -->
o Knees commonly involved in the lower body

<!-- PAGE=? -->
 Etiology : unknown

<!-- PAGE=? -->
o Activation of cellular immune responses in genetically susceptible hosts?

<!-- PAGE=? -->
o The autoimmune response may be initiated by viral induced activation of B lymphocytes

<!-- PAGE=? -->
 This leads to synovitis

<!-- PAGE=? -->
 Pathologic changes :

<!-- PAGE=? -->
o Cellular hyperplasia of synovium and synovial invasion by lymphocytes, plasma cells, and fibroblasts with ultimate destruction of cartilage and articular surfaces

<!-- PAGE=? -->
 Clinical Manifestations

<!-- PAGE=? -->
o Upper Airway obstruction

<!-- PAGE=? -->
 Direct laryngoscopy and CT demonstrate 54-75% of patients have cricoarytenoid abnormalities

<!-- PAGE=? -->
o Cervical spine instability

<!-- PAGE=? -->
 Since neck positioning required for intubation may be fatal among patients with RA and unrecognized C1-C2 disease, and since subluxation is not always symptomatic, radiographic evaluation of the cervical spine should also be considered for all patients with RA scheduled to undergo surgery requiring manipulation of the neck for either anesthesia or surgery (Uptodate)

<!-- PAGE=? -->
 AAS symptoms = occipital H/A, dysphagia, dysphonia, diplopia (cranial nerve root compression), persistent neck / arm pain (subaxial radicular entrapment), dizziness, upper extremity numbness (long tract compression, vertebral artery insufficiency)

<!-- PAGE=? -->
 Miller recommends awake FOI and positioning of neck while awake

<!-- PAGE=? -->
 Atlanto-axial subluxation

<!-- PAGE=? -->
 Anterior (80%) - avoid flexion

<!-- PAGE=? -->
 Posterior (3-7%) - avoid extension

<!-- PAGE=? -->
 Vertical (10-20%), most dangerous as it may cause compression of medulla - avoid extension

<!-- PAGE=? -->
 Lateral / rotational (2-5%) may cause compression of vertebral arteries, cervical nerves or non-reducible head tilt - avoid rotation

<!-- PAGE=? -->
 Sub-axial subluxation (usually C5-6) - limited movement with neutral stabilization during laryngoscopy

<!-- PAGE=? -->
o CVS

<!-- PAGE=? -->
 Pericarditis → chronic constrictive pericarditis, pericardial effusions (30%),  pericardial tamponade (rare)

<!-- PAGE=? -->
 Myocarditis (rare) & coronary arteritis

<!-- PAGE=? -->
 Heart failure: consider differential

<!-- PAGE=? -->
 Ischemic cardiomyopathy

<!-- PAGE=? -->
 Infiltrative cardiomyopathy (amyloid deposition in longstanding RA)

<!-- PAGE=? -->
 HF is exacerbated by anti-TNF agents, nonselective NSAIDs, COX-2 selective inhibitors, antimalarials, and glucocorticoids

<!-- PAGE=? -->
o Meds

<!-- PAGE=? -->
 Phosphamide - hematologic toxicity, GI toxicity, hemorrhagic cystitis

<!-- PAGE=? -->
 Methotrexate - bone marrow suppression, lung toxicity, cirrhosis

<!-- PAGE=? -->
 TNF inhibitors (infliximab, etanercept) - immunosuppression, SLE

<!-- PAGE=? -->
 Gold - lung, kidney toxicity

<!-- PAGE=? -->
 Steroids - osteoporosis, myelopathy, poor wound healing, immunosuppression, adrenal suppression

<!-- PAGE=? -->
Summary

<!-- PAGE=? -->
 LV systolic and diastolic dysfunction due to RA (LVEF < 40% in 5% of RA patients)

<!-- PAGE=? -->
o Pulmonary

<!-- PAGE=? -->
 Organizing pneumonia

<!-- PAGE=? -->
 Obliterative bronchiolitis (associated with gold, penicillamine, sulfasalazine)

<!-- PAGE=? -->
 Pleural disease common but usually sub-clinical

<!-- PAGE=? -->
o Neurological

<!-- PAGE=? -->
 Mononeuritis Multiplex (vasculitis around nerves)

<!-- PAGE=? -->
 Cerebral necrotizing vasculitis

<!-- PAGE=? -->
 Dural nodules => cord compression

<!-- PAGE=? -->
o Immunologic

<!-- PAGE=? -->
 Increased rate of postoperative infections due to:

<!-- PAGE=? -->
 Immunosuppressant drugs

<!-- PAGE=? -->
 Felty's Syndrome - RA, leukopenia, hepatosplenomegaly

<!-- PAGE=? -->
S

<!-- PAGE=? -->
S2

<!-- PAGE=? -->
S2 Wide Split

<!-- PAGE=? -->
 Pulmonic Stenosis

<!-- PAGE=? -->
 Right Bundle Branch Block

<!-- PAGE=? -->
 Mitral Regurgitation

<!-- PAGE=? -->
S2 Fixed Split

<!-- PAGE=? -->
 Atrial Septal Defect

<!-- PAGE=? -->
 Right Heart Failure

<!-- PAGE=? -->
S2 Paradoxical Split

<!-- PAGE=? -->
 Left Bundle Branch Block

<!-- PAGE=? -->
Sarcoidosis

<!-- PAGE=? -->
CoExD

<!-- PAGE=? -->
 granulomatous disorder invoving many tissues but marked predilection for the thoracic lympth nodes and lungs (hilar lymphadenopathy)

<!-- PAGE=? -->
 Pulmonary fibrosis

<!-- PAGE=? -->
 Pulmonary hypertension

<!-- PAGE=? -->
o Cor pulmonale

<!-- PAGE=? -->
 Hypercalcemia

<!-- PAGE=? -->
 Myocardial sarcoid is rare but may manifest as

<!-- PAGE=? -->
o heart block

<!-- PAGE=? -->
o dysrhythmias

<!-- PAGE=? -->
o Restrictive cardiomyopathy

<!-- PAGE=? -->
 laryngeal sarcoid occurs in 1-5% and may interfere with ETT passage

<!-- PAGE=? -->
 parotid, facial nerve and optic nerve involvement are possible

<!-- PAGE=? -->
 polyneuropathy is a common finding, esp facial nerve palsy from parotid gland involvement

<!-- PAGE=? -->
 hepatic granulomas and splenomegaly are likely

<!-- PAGE=? -->
 Fever of unknown orgin

<!-- PAGE=? -->
SAH

<!-- PAGE=? -->
 Incidence of cerebral aneurysms 1 in 50 (2000 per 100,000)

<!-- PAGE=? -->
 Average incidence of SAH is 10 per 100,000

<!-- PAGE=? -->
 aneurysm rupture is most common cause of SAH

<!-- PAGE=? -->
 Peak incidence of rupture is fifth decade of life

<!-- PAGE=? -->
 Spontaneous SAH most commonly results from aneurysms of the circle of Willis

<!-- PAGE=? -->
o ACOM 30%, PCOM 25%, MCA 25%

<!-- PAGE=? -->
 Other causes of SAH

<!-- PAGE=? -->
o Trauma

<!-- PAGE=? -->
o vertebral and carotid artery dissection

<!-- PAGE=? -->
o dural and spinal AVM

<!-- PAGE=? -->
o mycotic aneurysms

<!-- PAGE=? -->
o sickle cell disease

<!-- PAGE=? -->
o cocaine

<!-- PAGE=? -->
o coagulation disorders

<!-- PAGE=? -->
o pituitary apoplexy

<!-- PAGE=? -->
 Risk factors for rupture

<!-- PAGE=? -->
o Smoking

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
o EtOH

<!-- PAGE=? -->
o cocaine & amphetamine use

<!-- PAGE=? -->
o OCP

<!-- PAGE=? -->
o hypercholesterolaemia (> 6.3 mmol/l)

<!-- PAGE=? -->
o genetic (ADPKD) and familial conditions

<!-- PAGE=? -->
 Morbidity & Mortality

<!-- PAGE=? -->
o 1/3 die pre treatment

<!-- PAGE=? -->
 Causes of death are mainly = primary bleed, rebleeding, vasospasm

<!-- PAGE=? -->
 Rebleeding mortality is approx 80%

<!-- PAGE=? -->
o 1/3 die or become severely disabled during hospitalization

<!-- PAGE=? -->
o 1/3 survive without major disability

<!-- PAGE=? -->
 Complications of cerebral aneurysms include:

<!-- PAGE=? -->
o Intracranial hypertension

<!-- PAGE=? -->
o Rebleed - peak 24 hours, 19% by day 20

<!-- PAGE=? -->
o Vasospasm - 70% angiographically, 30% severe with focal deficits, peak day 6-7

<!-- PAGE=? -->
o Hydrocephalus

<!-- PAGE=? -->
Cerebral Vasospasm:

<!-- PAGE=? -->
 Cause is unknown

<!-- PAGE=? -->
 It is characterized by worsening headache, progressive lethargy and confusion, focal motor and speech impairments and possibly coma/death.

<!-- PAGE=? -->
 Progression can be over hours or days

<!-- PAGE=? -->
 Vasospasm occurs in approx 60-70% of SAH is and is correlated with the amount and location of SA blood

<!-- PAGE=? -->
o only 30% of vasospasm is symptomatic - confirmed with angiography

<!-- PAGE=? -->
o Peak incidence = 6 days post SAH

<!-- PAGE=? -->
o caused by breakdown products of hemoglobin, but most recent research is looking at endothelin as a factor

<!-- PAGE=? -->
 CCB (Nimodipine/Nicardipine) routinely used for prophylaxis and may prevent or reverse ischemic deficits

<!-- PAGE=? -->
 Mainstay remains the -Triple-H Therapy‖ = Hypervolemia, HTN, hemodilution

<!-- PAGE=? -->
o Hypervolemia -crystalloid or colloid for CVP 10-12 or PCWP 12-18

<!-- PAGE=? -->
o HTN to resolution of sx (SBP ~180)

<!-- PAGE=? -->
o Hemodilution to a hematocrit of 33%

<!-- PAGE=? -->
o Reduction of ICP with Mannitol/Ventricular drainage

<!-- PAGE=? -->
Rebleeding:

<!-- PAGE=? -->
 The risk of rebleeding poses one of the greatest dangers if aneurysm clipping is delayed or conservative management is elected

<!-- PAGE=? -->
o rebleeding is the principal cause of death in patients hospitalized after SAH

<!-- PAGE=? -->
 50%of patients treated conservatively experience a rebleed within 6 months of initial hemorrhage, ultimately declining to 2 to 3 percent per year .

<!-- PAGE=? -->
 The greatest risk of rebleeding is within 24 hours of hemorrhage (approximately 4% on day 1) and peaks again between days 14 to 21 .

<!-- PAGE=? -->
 Aneurysm rebleeding is associated with a  50 percent mortality ; of the 50 percent who survive, outcome is often poor

<!-- PAGE=? -->
 Early (0-3 days) aneurysm clipping is favoured in conscious patients

<!-- PAGE=? -->
o ICSTAS Trial showed the best outcomes in early (days 0-3) or late (days 11-14) surgery. Worse results in days 7-10

<!-- PAGE=? -->
o Reduces risk of rebleeding

<!-- PAGE=? -->
o Dec. incidence of medical complications

<!-- PAGE=? -->
 DVT

<!-- PAGE=? -->
 Atelectasis

<!-- PAGE=? -->
 pneumonia

<!-- PAGE=? -->
Hydrocephalus

<!-- PAGE=? -->
 Hydrocephalus occurs in 15% to 25% of SAH

<!-- PAGE=? -->
 40 percent are clinically symptomatic

<!-- PAGE=? -->
 Ventriculostomy may be warranted even in the absence of ventriculomegaly if ICP elevation is suspected.

<!-- PAGE=? -->
 Acute hydrocephalus manifests with impairment of CSF flow through the ventricular system or impedance of CSF absorption at the arachnoid granulations

<!-- PAGE=? -->
 may contribute to the initial poor clinical grade, or its development may manifest as an acute decline in mental status.

<!-- PAGE=? -->
 has been correlated with

<!-- PAGE=? -->
 posterior aneurysms

<!-- PAGE=? -->
 intraventricular hemorrhage

<!-- PAGE=? -->
 thick subarachnoid clot

<!-- PAGE=? -->
 cerebral vasospasm

<!-- PAGE=? -->
 altered LOC on admission

<!-- PAGE=? -->
 hyponatremia

<!-- PAGE=? -->
 advanced age

<!-- PAGE=? -->
 hypertension

<!-- PAGE=? -->
Other Complications

<!-- PAGE=? -->
 DINDS (delayed ischemic neurological deficits) occur in 1/3 of SAH pt and typically present 7-10 days post bleed

<!-- PAGE=? -->
 Hyponatremia post SAH can be from SIADH or cerebral salt wasting syndrome

<!-- PAGE=? -->
o volume status and treatment are different

<!-- PAGE=? -->
o SIADH = normo/hypervolemia  Rx = fluid restriction

<!-- PAGE=? -->
o CSW = hypovolemia and Na wasting  Rx = isotonic fluids

<!-- PAGE=? -->
 Cardiac dysfunction

<!-- PAGE=? -->
o extreme hypertension and autonomic discharge with high catecholamine levels that develops in association with the initial SAH event can result in reversible -stunning‖-like myocardial injury

<!-- PAGE=? -->
 extreme myocardial wall tension

<!-- PAGE=? -->
o Modest elevation in troponin commonly occurs

<!-- PAGE=? -->
o The relationship between ECG changes and myocardial dysfunction is not consistent

<!-- PAGE=? -->
 Myocardial dysfunction (best assessed by ECHO and not by EKG changes) correlates with the severity of the neurologic condition

<!-- PAGE=? -->
o the ECG is not an accurate predictor of myocardial dysfunction

<!-- PAGE=? -->
 usually resolve in 10 days

<!-- PAGE=? -->
 ECG changes include

<!-- PAGE=? -->
 canyon T waves

<!-- PAGE=? -->
 nonspecific T-wave changes

<!-- PAGE=? -->
 QT prolongation

<!-- PAGE=? -->
o Risk for VT, torsades, Vfib

<!-- PAGE=? -->
 ST-segment depression

<!-- PAGE=? -->
 U waves

<!-- PAGE=? -->
o Small positive wave following the t wave

<!-- PAGE=? -->
o cardiac dysfunction associated with SAH does not appear to contribute to morbidity or mortality

<!-- PAGE=? -->
 ECG abnormalities do not herald impending cardiac disease

<!-- PAGE=? -->
 ECG patterns other than those that are typical of myocardial ischemia require no specific interventions or modifications in the approach to the patient

<!-- PAGE=? -->
o ECG changes may indicate a risk for dysrhythmias

<!-- PAGE=? -->
 increased QT interval (>550 ms) has been associated with an increased incidence of malignant ventricular rhythms, including Torsades de pointes

<!-- PAGE=? -->
V2

<!-- PAGE=? -->
V3

<!-- PAGE=? -->
V6

<!-- PAGE=? -->
4]

<!-- PAGE=? -->
25

<!-- PAGE=? -->
Aloo

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
TABLE 3 Cardlac Conditlons Assocated With the Hlghest Rlsk of Adverse Outcome From Endocardltls for Whlch Prophylaxls WIth Dental Procedures Is Recommended

<!-- PAGE=? -->
Prccthetic cardiac valve

<!-- PAGE=? -->
Previcus IE

<!-- PAGE=? -->
enital heart disease (CHD} Conge

<!-- PAGE=? -->
Unrepaired cyanotic CHD, including palliative shunts and conduits

<!-- PAGE=? -->
Completely repaired congenital heart defect with prosthetic material or device; whether placed by surgery or by catheter intervention; the first 6 months after the proceduret during prcsthetic patch or prosthetic device (ihich inhibit endothelialization)

<!-- PAGE=? -->
Cardiac transplanitation recipients who develop cardiac valvulopatliy recommended for any other form of CHD.

<!-- PAGE=? -->
tProphylaxis is recommended because endothelialization of   prosthetic

<!-- PAGE=? -->
PROCEDURES FOR RECOMMENDED PROPHYLAXIS

<!-- PAGE=? -->
 Dental/oral procedures that involve manipulation of gums or teeth or that penetrate the oral mucosa (does NOT include injections through non infected tissue, orthodontic appliances, shedding of deciduous teeth, trauma to lips or oral mucosa)

<!-- PAGE=? -->
 Respiratory tract procedures that involve incision of the respiratory tract mucosa (includes bronchoscopic biopsy, tonsillectomy, adenoidectomy, tonsil abcsess)

<!-- PAGE=? -->
 Surgical procedures involving infected skin, skin structures, or musculoskeletal tissue

<!-- PAGE=? -->
 *ENDOCARDITIS PROPHYLAXIS IS OTHERWISE NOT RECOMMENDED FOR ANY OTHER PROCEDURES (INCLUDING ANY GI TRACT, GU TRACT OR GYN PROCEDURES, SUCH AS UPPER AND LOWER ENDOSCOPY, GI OR GU SURGERY, VAGINAL DELIVERY, C-SECTION, AND HYSTERECTOMY).

<!-- PAGE=? -->
ANTIBIOTIC REGIMENS FOR ENDOCARDITIS PROPHYLAXIS:

<!-- PAGE=? -->
 1 st line = Amoxicillin 2gm PO

<!-- PAGE=? -->
 If allergic amoxil = Keflex 2gm PO or Clindamycin 600mg PO or Azithro/Clarithro 500mg PO

<!-- PAGE=? -->
 If cannot take PO = Ampicillin 2gm IM or IV

<!-- PAGE=? -->
 If cannot take PO and allergic to amoxil = Ancef 1gm IM/IV or Ceftriaxone 1gm IM/IV or Clindamycin 600mg IM/IV

<!-- PAGE=? -->
 *ENDOCARDITIS PROPHYLAXIS IS ONLY RECOMMENDED FOR PATIENTS WITH A LISTED CARDIAC CONDITION WHO ARE UNDERGOING A LISTED PROCEDURE. ANTIBIOTIC SHOULD BE A SINGLE DOSE ALONE 30-60 MINUTES BEFORE PROCEDURE.

<!-- PAGE=? -->
 If dose missed, can be given up to 2hours post procedure

<!-- PAGE=? -->
TABLE 5. Regimens for a Dental Procedure

<!-- PAGE=? -->
IM indicates intramuscular; IV , intravenous

<!-- PAGE=? -->
#Cephalosporins should not be used in an individual with history of anaphylaxis; angioedema; or urticaria with penicillins or ampicillin.

<!-- PAGE=? -->
"Or other first- or second-generation oral cephalosporin in equivalent adult or pediatric dosage

<!-- PAGE=? -->
Scleroderma

<!-- PAGE=? -->
 Autoimmune collagen vascular disease characterized by blood vessel sclerosis (↓ end-organ perfusion) & skin / musculoskeletal / visceral organ fibrosis (e.g. lung / heart / kidney / GI)

<!-- PAGE=? -->
 ↑ frequency / severity among black females

<!-- PAGE=? -->
 Female to male ratio is approximately 3:1

<!-- PAGE=? -->
 Highest incidence in the third to fifth decade

<!-- PAGE=? -->
 Prevalence from 19-75/100,000

<!-- PAGE=? -->
o Highest prevalence currently known is within full-blooded Choctaw tribes of Oklahoma, and may be as high as 469 per 100,000

<!-- PAGE=? -->
 2 major forms of PSS (progressive systemic sclerosis):

<!-- PAGE=? -->
o Limited SS: CREST syndrome

<!-- PAGE=? -->
 Calcinosis

<!-- PAGE=? -->
 Raynaud's

<!-- PAGE=? -->
 Esophageal hypomotility

<!-- PAGE=? -->
 Sclerodactyly

<!-- PAGE=? -->
 Telangectasias

<!-- PAGE=? -->
 Slowly progressive (over years) with long period before onset of visceral abnormalities

<!-- PAGE=? -->
o Diffuse SS

<!-- PAGE=? -->
 Rapid progression of skin involvement (over weeks to months) and earlier onset of visceral abnormalities (2-3 years)

<!-- PAGE=? -->
 Raynaud's Phenomenon is initial presentation in 70%

<!-- PAGE=? -->
o Peripheral vasoconstriction in structurally abnormal vessels, induced by cold / stress / activation of sympathetic outflow

<!-- PAGE=? -->
o Potential ischemic complications

<!-- PAGE=? -->
o Stellate ganglion block may worsen contralateral Raynaud's (but relieves pain from ipsilateral disease)

<!-- PAGE=? -->
o β-blockers relatively contraindicated

<!-- PAGE=? -->
 Skin / MSK

<!-- PAGE=? -->
o Dermal thickening and tightening; cutaneous calcifications

<!-- PAGE=? -->
o Microstomia, restricted neck (and other joint) mobility

<!-- PAGE=? -->
 GI

<!-- PAGE=? -->
o Flexion contractures

<!-- PAGE=? -->
o Ischemic ulcers

<!-- PAGE=? -->
o MSK inflammation & fibrosis → distal weakness, polyarthritis

<!-- PAGE=? -->
o Telangiectasia: nasal and buccal mucosa, tongue, lips, face, tongue

<!-- PAGE=? -->
o Atrophy of esophageal muscularis & mucosal fibrosis cause esophageal dysmotility & ↓ LES tone

<!-- PAGE=? -->
o Chronic reflux esophagitis, dysphagia, UGI bleeding

<!-- PAGE=? -->
o Small intestine atrophy → malabsorption → ↓ vitamin K & coagulopathy; hypomotility

<!-- PAGE=? -->
o Hepatic involvement rare, but can be associated with 1° biliary cirrhosis

<!-- PAGE=? -->
 Respiratory

<!-- PAGE=? -->
o Pulmonary manifestation common

<!-- PAGE=? -->
o Pulmonary vasculature & interstitial fibrosis +/- chronic aspiration pneumonitis

<!-- PAGE=? -->
o RLD characterized  by ↓ lung compliance, ↓ vital capacity and ↓ diffusion capacity

<!-- PAGE=? -->
o Pulmonary HTN & resulting RV failure is leading cause of death

<!-- PAGE=? -->
 Cardiac

<!-- PAGE=? -->
o Myocardial fibrosis in 70-80% but only 25% have clinical symptoms (poor prognosis once symptoms develop)

<!-- PAGE=? -->
o LV diastolic / systolic dysfunction

<!-- PAGE=? -->
o Supraventricular and ventricular arrhythmias

<!-- PAGE=? -->
 Latter strongly associated with mortality & sudden death

<!-- PAGE=? -->
o Ischemia from coronary vessel sclerosis and vasospasm

<!-- PAGE=? -->
o Pericarditis + effusion common but presentation of pericarditis & tamponade rare

<!-- PAGE=? -->
o Systemic HTN & pulmonary HTN effects

<!-- PAGE=? -->
 Renal dysfunction

<!-- PAGE=? -->
o ↓ renal clearance of drugs, secondary HTN +/- hematuria & proteinuria

<!-- PAGE=? -->
o Scleroderma renal crisis ‖

<!-- PAGE=? -->
 Malignant HTN, progressive renal insufficiency, usually with hemolytic anemia

<!-- PAGE=? -->
 ACEi key for prevention / treatment , previously common cause of death

<!-- PAGE=? -->
 NS

<!-- PAGE=? -->
o Peripheral & CN neuropathy from nerve compression by thickened connective tissues

<!-- PAGE=? -->
 Pregnancy is associated with disease progression in 50% cases

<!-- PAGE=? -->
Table 1. Common Features Associated with Progressive Ssstemic Sclerosis (PSS)

<!-- PAGE=? -->
 No disease-modifying treatment to date

<!-- PAGE=? -->
 Treatment aimed at specific organ dysfunction and may include:

<!-- PAGE=? -->
o Vasodilators

<!-- PAGE=? -->
 Prazosin

<!-- PAGE=? -->
 CCBs (nifedipine, felodipine)

<!-- PAGE=? -->
 Prostaglandins

<!-- PAGE=? -->
 Nitrates → useful in pulmonary vasculature, cardiac vasculature & Raynaud's

<!-- PAGE=? -->
 ACEi to prevent renal crisis and for systemic HTN

<!-- PAGE=? -->
o Anti-platelet agents

<!-- PAGE=? -->
o Supplemental O2

<!-- PAGE=? -->
o Generalized Immunosuppression

<!-- PAGE=? -->
 Prednisone

<!-- PAGE=? -->
 Cyclophosphamide

<!-- PAGE=? -->
 Cyclosporine

<!-- PAGE=? -->
o ↓ collagen production

<!-- PAGE=? -->
 Penicillamine

<!-- PAGE=? -->
 Interferon

<!-- PAGE=? -->
Sella Turcica Surgery

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Complications include

<!-- PAGE=? -->
o hemorrhage from the venous sinuses or internal carotid artery

<!-- PAGE=? -->
o arterial spasm or thrombotic occlusion secondary to arterial manipulation

<!-- PAGE=? -->
o venous air embolism if head-up tilt is excessive

<!-- PAGE=? -->
o cranial nerve weakness secondary to trauma or stretching

<!-- PAGE=? -->
 III, IV, V, and VI

<!-- PAGE=? -->
o visual complications secondary to damage of the optic nerve or chiasm

<!-- PAGE=? -->
o Diabetes insipidus is commonly seen during the first 12 hours postoperatively and usually lasts for 2-4 days

<!-- PAGE=? -->
Sepsis

<!-- PAGE=? -->
 Definitions:

<!-- PAGE=? -->
o SIRS (requires 2 or more):

<!-- PAGE=? -->
 Temperature >38, <36

<!-- PAGE=? -->
 HR > 90

<!-- PAGE=? -->
 RR > 20

<!-- PAGE=? -->
 WBC > 12,000, < 4,000, > 10% bands

<!-- PAGE=? -->
o Sepsis:

<!-- PAGE=? -->
 SIRS +

<!-- PAGE=? -->
 Infection

<!-- PAGE=? -->
o Severe sepsis:

<!-- PAGE=? -->


<!-- PAGE=? -->
Sepsis +

<!-- PAGE=? -->
 Organ dysfunction

<!-- PAGE=? -->
 SBP <90 or MAP <70

<!-- PAGE=? -->
 U/O: < 0.5 cc/kg

<!-- PAGE=? -->
 dLOC

<!-- PAGE=? -->
 Acidosis:  pH < 7.3 & lactatic acidosis

<!-- PAGE=? -->
 Platelets: <80,000 or 50% decrease over 3 days

<!-- PAGE=? -->
 Hypoxemia:  PaO2 / FiO2 < 250 with extra-pulmonary infectious source (< 200 if pulmonary source)

<!-- PAGE=? -->
o Septic shock:

<!-- PAGE=? -->
 Severe sepsis +

<!-- PAGE=? -->
 hypotension unresponsive to fluids

<!-- PAGE=? -->
 Coagulation

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
 Intravascular coagulation during sepsis

<!-- PAGE=? -->
o Lab manifestations of DIC include

<!-- PAGE=? -->
 Inc. D-dimer

<!-- PAGE=? -->
 Physiology

<!-- PAGE=? -->
o Early septic shock is characterized by

<!-- PAGE=? -->
 Elevated CO

<!-- PAGE=? -->
 Dec. SVR

<!-- PAGE=? -->
 hypotension

<!-- PAGE=? -->
 hypoxemia

<!-- PAGE=? -->
 relative hypocapnia secondary to hyperventilation

<!-- PAGE=? -->
 Mortality Treatments

<!-- PAGE=? -->
o early goal directed therapy

<!-- PAGE=? -->
o ARDS-net lung protective ventilation strategies

<!-- PAGE=? -->
o early appropriate antibiotics (low door to needle time)

<!-- PAGE=? -->
o regulation of blood sugars (draconian glycemic control measures still being debated but avoidance of hyperglycemia seems to be generally agreed upon as a good thing)

<!-- PAGE=? -->
o APC

<!-- PAGE=? -->
o stress dose steroids (still controversial but those who respond do benefit).

<!-- PAGE=? -->
Serotonin Syndrome

<!-- PAGE=? -->
 SSRIs are the most commonly prescribed class of antidepressants for the treatment of mild to moderate depression, panic and obsessive-compulsive disorders

<!-- PAGE=? -->
o Mechanism of action is through the inhibition of presynaptic reuptake of serotonin

<!-- PAGE=? -->
o Common side effects of SSRIs are insomnia, headaches, nausea & sexual dysfunction

<!-- PAGE=? -->
 Serotonin syndrome is an iatrogenic condition, sharing some clinical features with NMS

<!-- PAGE=? -->
o Serotonin syndrome is the result of over-stimulation of 5-HT1A receptors in central grey nuclei and the medulla and, perhaps, of over-stimulation of 5-HT2 receptors

<!-- PAGE=? -->
 Consider in overdose of SSRI or their use in combination with MAOi, TCAs, or meperidine

<!-- PAGE=? -->
TABLE 22-3 -- Drug and Drug Interactions Associated with Serotonin Syndrome

<!-- PAGE=? -->
SSRIs

<!-- PAGE=? -->
Atypical and cyclic antidepressants

<!-- PAGE=? -->
Lithium

<!-- PAGE=? -->
MAOI

<!-- PAGE=? -->
Anticonvulsants: valproate

<!-- PAGE=? -->
Analgesics: meperidine, fentanyl, tramadol, pentazocine

<!-- PAGE=? -->
Antiemetecs: ondansetron, granisetron, metoclopramide

<!-- PAGE=? -->
Antimigraine drugs: sumatriptan

<!-- PAGE=? -->
Bariatric meds: sibutramine

<!-- PAGE=? -->
Abx: linezolide, ritonavir

<!-- PAGE=? -->
 Dec protein C

<!-- PAGE=? -->
 Thrombocytopenia

<!-- PAGE=? -->
 Inc. PTT

<!-- PAGE=? -->
o There is a reduction in all major physiological anticoagulants

<!-- PAGE=? -->
 Dec. antithrombin III

<!-- PAGE=? -->
 Dec. protein C

<!-- PAGE=? -->
 Dec. tissue factor pathway inhibitor

<!-- PAGE=? -->
 Dec. functional thrombomodlin

<!-- PAGE=? -->
 Converts thrombin from a procoagulant to an activator of protein C

<!-- PAGE=? -->
 Works via the endothelial cell protein C receptor

<!-- PAGE=? -->
o Increase in fibinolysis inhibitors

<!-- PAGE=? -->
 Inc plasminogen activator inhibitor - 1 (PAI-1)

<!-- PAGE=? -->
 Inc. thrombin activator fibrinolysis inhibitor

<!-- PAGE=? -->
OTC and herbal: dextromethorphan, St John's wort, ginseng Drugs of abuse: ecstasy, LSD

<!-- PAGE=? -->
Drug interactions associated with severe serotonin syndrome:

<!-- PAGE=? -->
 Phenylzine and meperidine or SSRIs

<!-- PAGE=? -->
 Tranylcyprmine and imipramine

<!-- PAGE=? -->
 Paroxetine and buspirone

<!-- PAGE=? -->
 Linezolide and citalopram

<!-- PAGE=? -->
 Modobemide and SSRIs

<!-- PAGE=? -->
 Tramadol, venlafaxine and mirtazapine

<!-- PAGE=? -->
Table Mechanisms of common drugs that influence serotonin syndrome

<!-- PAGE=? -->
Four major symptoms:

<!-- PAGE=? -->
 Mental status changes

<!-- PAGE=? -->
o Confusion & restlessness

<!-- PAGE=? -->
o Convulsions, coma & death

<!-- PAGE=? -->
 Neuromuscular symptoms

<!-- PAGE=? -->
o Myoclonus & hyperreflexia

<!-- PAGE=? -->
 Autonomic dysfunction

<!-- PAGE=? -->
o Diaphoresis, tremor & hyperthermia

<!-- PAGE=? -->
o Tachycardia and hypertension is most common but severe cases can develop wild swings in VS/ autonomic dysfunction

<!-- PAGE=? -->
 Gastrointestinal dysfunction

<!-- PAGE=? -->
 Also see:

<!-- PAGE=? -->
o Rhabdomyolysis, ARF, respiratory failure / ARDS (rare complications)

<!-- PAGE=? -->
Distinguishing SSRI syndrome from NMS:

<!-- PAGE=? -->
o Neuromuscular symptoms: in addition to tremor and rigidity that also occur in NMS, features such as shivering, ataxia, myoclonus, hyperreflexia, and ankle clonus may favor the diagnosis of serotonin syndrome

<!-- PAGE=? -->
o Gastrointestinal dysfunction: the presence of nausea, vomiting, and diarrhea is a unique feature not typically seen in NMS

<!-- PAGE=? -->
o Mental status changes and autonomic dysfunction: these are similar to those seen in NMS, although some investigators believe that the degree of temperature elevation is not as high as in NMS

<!-- PAGE=? -->
 Elevations in white blood cells, creatinine kinase levels, and liver enzymes are inconsistently and minimally elevated

<!-- PAGE=? -->
 The course of this condition usually is benign, and most patients recover 1 to 7 days after withdrawal of the offending agent

<!-- PAGE=? -->
 Treatment includes supportive measures and control of autonomic instability, excess muscle activity, and hyperthermia.

<!-- PAGE=? -->
 Cyproheptadine, a 5-HT2A antagonist, can be used to bind serotonin receptors. It is only available for oral use. (4-8mg q4hr, max 32 mg/day).

<!-- PAGE=? -->
 Usually, patients recover without sequelae

<!-- PAGE=? -->
Shivering

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Demerol

<!-- PAGE=? -->
o Clonidine

<!-- PAGE=? -->
o Mg

<!-- PAGE=? -->
o Physostigmine

<!-- PAGE=? -->
o Tramadol

<!-- PAGE=? -->
o ketanserin

<!-- PAGE=? -->
Shunt Lesions:

<!-- PAGE=? -->
Table 51-2   -- Classification of congenital heart defects

<!-- PAGE=? -->
ASD, atrial septal defect; AV canal, atrioventricular canal; CHF, congestive heart failure; PDA, patent ductus arteriosus; p, pulmonary blood flow; s, systemic blood flow; VSD, ventricular septal defect.

<!-- PAGE=? -->
L - R Shunts:

<!-- PAGE=? -->
 ASD, VSD, PDA, AV canal -> Inc Pulm blood flow -> Vol overload & CHF

<!-- PAGE=? -->
 pulmonary blood flow is greatly increased, necessitating an increased CO that often leads to cardiac failure

<!-- PAGE=? -->
 small defects with minimal L-R shunting (Qp/Qs <1.5) are usually asymptomatic

<!-- PAGE=? -->
 Qp/Qs >1.5 should be closed to prevent RV dysfunction and pulmonary hypertension

<!-- PAGE=? -->
o Symptoms include

<!-- PAGE=? -->
o SOBOE, supraventricular arrhythmias, right heart failure, paradoxical emboli, and recurrent pulmonary infections

<!-- PAGE=? -->
 3 pathophysiological problems

<!-- PAGE=? -->
congestion of the pulmonary circulation

<!-- PAGE=? -->
volume overload with resulting increased cardiac work for the LV, which is required to increase SV and HR to ensure adequate systemic perfusion

<!-- PAGE=? -->
excessive pulmonary blood flow, resulting in progressive elevation in PVR

<!-- PAGE=? -->
 Kaplan

<!-- PAGE=? -->
L-R shunt

<!-- PAGE=? -->
 Slower IV induction

<!-- PAGE=? -->
 Fraction of drug is diverted back to pulmonary circulation

<!-- PAGE=? -->
 Faster Inhalational induction

<!-- PAGE=? -->
R - L Shunts

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 TOF, Pulm atresia/VSD, Eisenmenger

<!-- PAGE=? -->
o Dec Pulm blood flow -> Pressure overload, hypoxemia, cyanosis, polycythemia

<!-- PAGE=? -->
 anatomic, absolute shunt arises from the venous return from the pleural, bronchiolar, and thebesian veins;

<!-- PAGE=? -->
o accounts to 2-5% of total cardiac output

<!-- PAGE=? -->
o anatomic shunts of greatest magnitude are usually associated with congenital heart disease causing right to left shunts

<!-- PAGE=? -->
 intrapulmonary shunts can also occur, examples are arterial hypoxemia associated with hepatic failure (hepatopulmonary syndrome) which can occur primarily due to AVMs

<!-- PAGE=? -->
o diseases that may cause absolute shunt include

<!-- PAGE=? -->
 acute lobar atelectasis

<!-- PAGE=? -->
 extensive acute lung injury

<!-- PAGE=? -->
 advanced pulmonary edema

<!-- PAGE=? -->
 consolidated pneumonia

<!-- PAGE=? -->
 pulmonary embolus inc pulmonary artery pressure that results in right-to-left transpulmonary shunting through opened arteriovenous anastomoses and the foramen ovale (possible in 20% of patients)

<!-- PAGE=? -->
o If the embolus contains platelets, serotonin may be released,  - bronchoconstriction and pulmonary edema

<!-- PAGE=? -->
o Finally, the pulmonary embolus can increase PVR (by platelet-induced serotonin release, among other etiologies) and decrease cardiac output

<!-- PAGE=? -->
 Kaplan

<!-- PAGE=? -->
o R-L shunt

<!-- PAGE=? -->
 Faster IV induction

<!-- PAGE=? -->
 Slower inhalational induction

<!-- PAGE=? -->
SIADH

<!-- PAGE=? -->
 normovolemic hypo-osmolar hyponatremia (CSW is hypovolemic)

<!-- PAGE=? -->
 associated with

<!-- PAGE=? -->
o pulmonary & cranial disorders

<!-- PAGE=? -->
o neoplasms - particularly oat cell carcinoma of the lung

<!-- PAGE=? -->
o sympathetic activation (postoperative pain)

<!-- PAGE=? -->
o drugs (oral hypoglycemics, TCA, and diuretics)

<!-- PAGE=? -->
 SIADH usually begins 3-15 days after trauma, lasting no more than 10-15 days with appropriate therapy

<!-- PAGE=? -->
 The presence of hyponatremia plus a urine osmolality higher than maximal dilution confirms the diagnosis

<!-- PAGE=? -->
o urinary sodium concentration usually exceeds 30 mEq/L

<!-- PAGE=? -->
o the fractional excretion of sodium is greater than 1%

<!-- PAGE=? -->
o the serum uric acid is reduced

<!-- PAGE=? -->
 Patients with SIADH exhibit a characteristic response to water restriction

<!-- PAGE=? -->
o 2- to 3-kg weight loss is accompanied by correction of hyponatremia and cessation of salt wasting over 2 to 3 days

<!-- PAGE=? -->
 At least 4% of postoperative patients develop plasma [Na + ] < 130 mEq/L

<!-- PAGE=? -->
 Chlorpropamide is a sulfonylurea and can rarely cause hyponatremia

<!-- PAGE=? -->
o may enhance ADH secretion

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o mild or moderate = restriction of fluid intake to 800 ml/day

<!-- PAGE=? -->
o severe SIADH

<!-- PAGE=? -->
 Fraction of blood is recirculated thru the pulmonary circulation and acquires additional anesthetic

<!-- PAGE=? -->
 More pronounced for the insoluble agents

<!-- PAGE=? -->
demeclocycline ( Demeclocycline interferes with the ability of the renal tubules to concentrate urine and is frequently used in outpatients

<!-- PAGE=? -->
Lithium is generally not used because of the high incidence of toxicity

<!-- PAGE=? -->
 Hyponatremia and mental confusion

<!-- PAGE=? -->
hypertonic saline and furosemide

<!-- PAGE=? -->
 1-2cc/kg/hr until Na >120

<!-- PAGE=? -->
isotonic saline is substituted for hypertonic once the serum sodium is brought into a safe range

<!-- PAGE=? -->
 Too rapid correction of hyponatremia may induce central pontine myelinolysis and cause permanent brain damage

<!-- PAGE=? -->
Serum sodium should not be raised by more than 0.5 mmol/h or 12 mmol/L in 24 hours

<!-- PAGE=? -->
Miller - finding which support the Dx

<!-- PAGE=? -->
    Urinary sodium >20 mEq/L

<!-- PAGE=? -->
    Low serum levels of BUN, creatinine, uric acid, and albumin

<!-- PAGE=? -->
    Serum sodium <130 mEq/L

<!-- PAGE=? -->
    Plasma osmolality <270 mOsm/L

<!-- PAGE=? -->
    Urine hypertonic relative to plasma

<!-- PAGE=? -->
Pharmacologic therapy

<!-- PAGE=? -->
 only for patients who

<!-- PAGE=? -->
o have chronic hyponatremia (serum sodium concentration <125 mEq/L)

<!-- PAGE=? -->
o are unable to comply with water restriction

<!-- PAGE=? -->
o the condition is refractory to water restriction

<!-- PAGE=? -->
 tetracyclines (demeclocycline 300-600 mg PO bid)

<!-- PAGE=? -->
o induces reversible nephrogenic DI

<!-- PAGE=? -->
 osmotic diuretics (urea 0.5-1 g/kg PO qd)

<!-- PAGE=? -->
 loop diuretics (furosemide 40 mg PO qd,)

<!-- PAGE=? -->
 vaspressin receptor antagonists (Conivaptan)

<!-- PAGE=? -->
Sickle Cell Disease

<!-- PAGE=? -->
 SS (sickle cell Disease / anemia) = 70-98% of the hemoglobin is S and the remainder is hemoglobin F

<!-- PAGE=? -->
(fetal)

<!-- PAGE=? -->
o chronic anemia (Hgb 70-80) and chronic hemolysis

<!-- PAGE=? -->
o Infarction of multiple organs

<!-- PAGE=? -->
o Life expectancy 30yrs

<!-- PAGE=? -->
 SA (sickle cell trait) = 10-40% of the hemoglobin is hemoglobin S

<!-- PAGE=? -->
o normal life expectancy and few complications

<!-- PAGE=? -->
o Hemoglobin levels are normal

<!-- PAGE=? -->
o sickling occurs only under extreme physiologic conditions

<!-- PAGE=? -->
 Definitive diagnosis is made with hemoglobin electrophoresis

<!-- PAGE=? -->
 When hemoglobin S deoxygenates, a gel structure is formed that produces structural changes in the RBC

<!-- PAGE=? -->
o The likelihood of sickling is directly related to the amount of hemoglobin S

<!-- PAGE=? -->
 Low oxygen tension and acidosis exaggerate sickle cell formation

<!-- PAGE=? -->
o Sickling begins at oxygen tensions less than 50 mm Hg and becomes most pronounced when the arterial oxygen tension decreases to 20 mm Hg

<!-- PAGE=? -->
 Vascular occlusion may produce stasis with localized hypoxemia and initiate sickling

<!-- PAGE=? -->
Clinical:

<!-- PAGE=? -->
 There are two patterns of pulmonary complications in patients with sickle cell disease

<!-- PAGE=? -->
o sickle cell lung disease

<!-- PAGE=? -->
 characterized by generalized pulmonary fibrosis with hypoxemia and ultimately cor pulmonale, which is a significant cause of mortality in patients with SS disease

<!-- PAGE=? -->
o Acute chest syndrome

<!-- PAGE=? -->
 fever, chest pain, dyspnea, cough, and tachypnea and may suffer acute pHTN and death

<!-- PAGE=? -->
 There are three forms of clinical crises in patients with sickle cell anemia

<!-- PAGE=? -->
o vaso-occlusive (painful) crises

<!-- PAGE=? -->
 Vaso-occlusive crises are characterized by sickling, venous thrombosis, organ infarction, and severe pain. Pain may be secondary to infarction of bone and muscle

<!-- PAGE=? -->
o aplastic crises

<!-- PAGE=? -->
 Aplastic crises produce dramatic decreases in erythropoiesis and hematocrit level

<!-- PAGE=? -->
o splenic sequestration crises

<!-- PAGE=? -->
 Splenic sequestration crises occur in children less than 6 years of age

<!-- PAGE=? -->
 Real Dysfunction

<!-- PAGE=? -->
o Papillary necrosis secondary to medullary ischemia occurs frequently

<!-- PAGE=? -->
o there is an inability to concentrate urine

<!-- PAGE=? -->
 By 6 years in SS, the spleen is virtually nonexistent because of repeated infarctions.

<!-- PAGE=? -->
 Chronic hemolysis produces an elevated serum bilirubin level and results in a high incidence of cholelithiasis in patients with SS disease

<!-- PAGE=? -->
 CVA and ICH and Priapism

<!-- PAGE=? -->
 Surgical diseases that occur with increased frequency in patients with sickle cell anemia include cholelithiasis, peptic ulceration, ischemic colitis, and leg ulcers

<!-- PAGE=? -->
 Laparoscopic surgical techniques have reduced morbidity in SS

<!-- PAGE=? -->
Prevention

<!-- PAGE=? -->
 Maintenance of good systemic oxygenation and hydration to ensure good tissue perfusion is essential.

<!-- PAGE=? -->
 Preoperative transfusion to reduce hemoglobin S levels to 30-40% has been demonstrated to reduce perioperative complications in patients with sickle cell anemia

<!-- PAGE=? -->
 Hydroxyurea has been shown to increase the production of hemoglobin F, which is a potent inhibitor of polymerization of hemoglobin S

<!-- PAGE=? -->
o shown to decrease the frequency and severity of painful crises, the incidence of acute chest syndrome, and the need for transfusion

<!-- PAGE=? -->
 BMT and transplantation of cord blood stem cells have also been efficacious

<!-- PAGE=? -->
Management of Anesthesia.

<!-- PAGE=? -->
 increased risk for perioperative complications including

<!-- PAGE=? -->
o acute chest syndrome

<!-- PAGE=? -->
o sickling crises

<!-- PAGE=? -->
o infection

<!-- PAGE=? -->
o intractable pain

<!-- PAGE=? -->
 Circulatory stasis can be minimized with adequate hydration and anticipation of intraoperative volume loss to avoid acute hypovolemia.

<!-- PAGE=? -->
 Regional anesthesia is often used for these patients - but may produce compensatory vasoconstriction and decreased oxygen delivery to nonblocked areas, making red blood cells in those areas vulnerable to sickling.

<!-- PAGE=? -->
 The use of extremity tourniquets is controversial

<!-- PAGE=? -->
 environmental temperature should be controlled to maintain normothermia

<!-- PAGE=? -->
o Fever increases the rate of gel formation by S hemoglobin. Although hypothermia retards gel formation, the decreased temperature also produces peripheral vasoconstriction.

<!-- PAGE=? -->
 Pain management of the patient with sickle cell disease during a sickling crisis or in the postoperative period can be challenging. A variety of techniques including opioids (morphine), non-narcotic analgesics, and epidural analgesia have been used

<!-- PAGE=? -->
Table 6. Guidelines for Management

<!-- PAGE=? -->
Table 1 . Clinical Features of Sickle Cell Discase

<!-- PAGE=? -->
ACS acute chest syndrome; SCD sickle cell dieease; SS patients homozygous for hemoglobin S; VOC = vasoocclusive crisis .

<!-- PAGE=? -->
Sitting Postion

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 The cerebral and systemic hemodynamic consequence of the seated position are predictable

<!-- PAGE=? -->
o reduction in ICP, cerebral venous pressure and CSF volume, ↓ CBF 20%

<!-- PAGE=? -->
o Cerebral blood flow decreases by approximately 20% with high head elevation.

<!-- PAGE=? -->
 Lower extremity venous pooling is common (up to 1500mL) and may be mitigated by

<!-- PAGE=? -->
o compression bandages /  SCDs

<!-- PAGE=? -->
o G-suit

<!-- PAGE=? -->
o staged positioning over 20 minutes

<!-- PAGE=? -->
 sympathetic tone increases

<!-- PAGE=? -->
 parasympathetic tone decreases,

<!-- PAGE=? -->
 There is a reduction in CVP, PCWP, SVI, CI and MAP (by 10mmHg MAP or 20mmHg SBP)

<!-- PAGE=? -->
o Cardiac output decreases 20-40%,

<!-- PAGE=? -->
o stroke volume falls by as much as 50%.

<!-- PAGE=? -->
o left atrial pressure falls more than right atrial pressure.

<!-- PAGE=? -->
 Conversely, HR & SVR & PVR increase.

<!-- PAGE=? -->
o PVR can double,

<!-- PAGE=? -->
o SVR increases 30-60%

<!-- PAGE=? -->
 the venous capacitance system is essentially unaffected.

<!-- PAGE=? -->
 Oxygen consumption by the tissues is unchanged

<!-- PAGE=? -->
o reduced oxygen supply (reduced cardiac output) causes an increased arteriovenous oxygen content difference.

<!-- PAGE=? -->
 Renal blood flow decreases as much as 30% (as much as 76% in massively obese patients in the sitting position)

<!-- PAGE=? -->
o GFR decreases

<!-- PAGE=? -->
o reduced secretion of antidiuretic hormone

<!-- PAGE=? -->
o renin-angiotensin-aldosterone system is activated, and fluid and sodium are retained

<!-- PAGE=? -->
Smoke inhalation injury

<!-- PAGE=? -->
UptoDate, Lange

<!-- PAGE=? -->
 leading cause of death from fires

<!-- PAGE=? -->
 diagnosis usually made with FOB

<!-- PAGE=? -->
 CXR is a poor predictor of inhalational injury

<!-- PAGE=? -->
o Low sensitivity

<!-- PAGE=? -->
 3 types of injury:

<!-- PAGE=? -->
 thermal injury to airways

<!-- PAGE=? -->
o usually supraglottic and upper airway structures

<!-- PAGE=? -->
o horseness stridor developing over 12-18 hrs

<!-- PAGE=? -->
 direct lung injury from bronchopulmonary toxins

<!-- PAGE=? -->
o deposition of carbonaceous particles into lower airways

<!-- PAGE=? -->
o direct mucosal injury, ARDS 2-3 days after injury

<!-- PAGE=? -->
 exposure to toxic gases

<!-- PAGE=? -->
o CO poisoning > 15 % carboxyHb

<!-- PAGE=? -->
o Cyanide poisonong

<!-- PAGE=? -->
Smoking

<!-- PAGE=? -->
Table 49-8 -- Beneficial effects of smoking cessation and time course

<!-- PAGE=? -->
 the risks of stopping smoking for 1 or 2 days

<!-- PAGE=? -->
o excessive anxiety

<!-- PAGE=? -->
o inc. secretions

<!-- PAGE=? -->
o bronchospasm

<!-- PAGE=? -->
o inc. incidence of DVT

<!-- PAGE=? -->
Sodium Nitroprusside

<!-- PAGE=? -->
Barash, Lange, P&P

<!-- PAGE=? -->
 ferrous iron atom bound with five cyanide molecules and one nitric group

<!-- PAGE=? -->
o ferrous iron reacts with sulfhydryl groups in red blood cells and releases cyanide

<!-- PAGE=? -->
o three possible reactions

<!-- PAGE=? -->
 binding to methemoglobin to form cyanmethemoglobin

<!-- PAGE=? -->
 thiosulfate + cyanide thiocyanate - catalyzed by the enzyme rhodanase in the liver and kidney

<!-- PAGE=? -->
 binding to tissue cytochrome oxidase, which interferes with normal oxygen utilization

<!-- PAGE=? -->
SNP + Oxyhemoglobin (SNP) Methemoglobin (SNP) 5CN Methemoglobin Cyanmethemoglobin Rhodanase; vitamin CN Thiosullate Thiocyanate CN Cytochrome oxidase Cyanide toxicity

<!-- PAGE=? -->
Sounce an GE, Mikhail MS, Murray MJ: Clinica} Anesthesiology , Morg copyright The McGraw-Hill Companies, Inc All rights reserved

<!-- PAGE=? -->
 thiocyanate is excreted in the urine

<!-- PAGE=? -->
o Thiocyanate is cleared slowly by the kidneys (T ½ = 4-7 d)

<!-- PAGE=? -->
o Toxicity is rare, 100x less toxic then cyanide

<!-- PAGE=? -->
 In patients with CRF who are not undergoing dialysis, 3-6 days of SNP are required

<!-- PAGE=? -->
 Nonspecific symptoms:

<!-- PAGE=? -->
 Fatigue, tinnitus, nausea, vomiting

<!-- PAGE=? -->
 Skeletal muscle weakness, hypereflexia, confusion, pshychosis, miosis

<!-- PAGE=? -->
 Seizures, coma

<!-- PAGE=? -->
 Clinical hypothyroidism (thiocyanate can inhibit uptake and binding of iodine in the thyroid)

<!-- PAGE=? -->
o Thiocyanate clearance can be facilitated by dialysis

<!-- PAGE=? -->
 There is no evidence, however, that preexisting hepatic or renal failure increases the likelihood of cyanide toxicity

<!-- PAGE=? -->
 Administration of high doses of sodium nitroprusside can result in cyanide toxicity

<!-- PAGE=? -->
o cyanide molecule binds to cytochrome oxidase, interfering with electron transport and causing cellular hypoxia

<!-- PAGE=? -->
o avoided if dose is < 0.5.mg/kg/h

<!-- PAGE=? -->
 Manifestations

<!-- PAGE=? -->
o increasing tolerance to the drug

<!-- PAGE=? -->
o elevated mixed venous PaO2

<!-- PAGE=? -->
 unable to utilize oxygen

<!-- PAGE=? -->
o metabolic acidosis

<!-- PAGE=? -->
o arrhythmias

<!-- PAGE=? -->
 Methemoglobinemia from excessive doses of sodium nitroprusside or sodium nitrate can be treated with methylene blue (1-2 mg/kg of a 1% solution over 5 min), which reduces methemoglobin to hemoglobin

<!-- PAGE=? -->
 treatment of cyanide toxicity

<!-- PAGE=? -->
o administration of amyl nitrate (by inhalation or directly into the anesthesia circuit)

<!-- PAGE=? -->
o infusion of sodium nitrite

<!-- PAGE=? -->
o sodium thiosulfate

<!-- PAGE=? -->
Spinal cord injury

<!-- PAGE=? -->
Miller, Barash, CoExD

<!-- PAGE=? -->
 Most cord injuries are produced in association with injury to the vertebral column (primary injury)

<!-- PAGE=? -->
o Fracture of one or more of the bony elements

<!-- PAGE=? -->
o Dislocation at one or more joints

<!-- PAGE=? -->
o Tearing of ligament(s)

<!-- PAGE=? -->
o Disruption and/or herniation of the intervertebral disc

<!-- PAGE=? -->
 Secondary, progressive mechanism of cord injury usually follows

<!-- PAGE=? -->
o Begins within minutes and evolves over several hours after injury

<!-- PAGE=? -->
o Possible mechanisms include ischemia, hypoxia, inflammation, edema, excitotoxicity, disturbances of ion homeostasis, and apoptosis

<!-- PAGE=? -->
o Sometimes clinically manifest by neurologic deterioration over the first 8 to 12 hours

<!-- PAGE=? -->
o Spinal cord edema develops within hours of injury, becomes maximal between the third and sixth day after injury, and begins to recede after the ninth day

<!-- PAGE=? -->
 Gradually replaced by a central hemorrhagic necrosis

<!-- PAGE=? -->
 Development of extrajunctional nACh-R on muscles turns whole muscle into NM endplate

<!-- PAGE=? -->
o Can result in massive K+ release and arrest in response to SCh from 24 hrs up to 6 months postinjury

<!-- PAGE=? -->
 Spinal cord syndromes

<!-- PAGE=? -->
o Central cord syndrome - greater loss of motor power in upper than lower extremities often seen after hyperextension injury in pre-existing cervical canal stenosis.  Believed to be 2° to compromised anterior spinal artery supply to central portion of cord where motor fibers run (prognosis is better than other incomplete injuries w/ LE recovering before UE)

<!-- PAGE=? -->
o Anterior cord syndrome - paraplegia and dissociated sensory loss with loss of pain and temperature sensation.  Posterior column function (proprioception, vibration, deep pressure) preserved.  Usually due to infarction in territory supplied by anterior spinal artery.

<!-- PAGE=? -->
o Brown-Sequard syndrome - ipsilateral motor loss (corticospinal tract) and loss of proprioception (posterior column) associated with contralateral dissociated sensory loss beginning one or two levels below the level of injury (spinothalamic tract).  Caused by hemisection of the cord (rarely seen as classic presentation).

<!-- PAGE=? -->
 Chronic Sequelae of Spinal Cord Injuries

<!-- PAGE=? -->
o Impaired alveolar ventilation

<!-- PAGE=? -->
o Autonomic hyperreflexia

<!-- PAGE=? -->
o Chronic pulmonary and urinary tract infections

<!-- PAGE=? -->
o Anemia

<!-- PAGE=? -->
o Renal calculi

<!-- PAGE=? -->
o Osteoporosis and skeletal muscle atrophy

<!-- PAGE=? -->
o Spasticity

<!-- PAGE=? -->
o Decubitus ulcers

<!-- PAGE=? -->
o Depression

<!-- PAGE=? -->
o Chronic pain

<!-- PAGE=? -->
Spinal shock

<!-- PAGE=? -->
 Spinal shock occurs acutely and results in complete cessation of spinal cord functions below the level of the lesion

<!-- PAGE=? -->
o flaccid paralysis

<!-- PAGE=? -->
o loss of visceral and somatic sensation

<!-- PAGE=? -->
o paralytic ileus

<!-- PAGE=? -->
o Vasopressor reflexes

<!-- PAGE=? -->
 may persist from a few days to 3 months

<!-- PAGE=? -->
o some say 1-3 weeks

<!-- PAGE=? -->
 unable to determine extent of injury

<!-- PAGE=? -->
o if bulbarcavernousis reflex is present → cord transaction

<!-- PAGE=? -->
o if bulbarcavernousis reflex is absence → spinal shock

<!-- PAGE=? -->
 Stick finger in bum and pull on foley → anal wink is positive

<!-- PAGE=? -->
 Spinal shock (1-3 weeks) = flacidity and areflexia (has nothing to do w/ HD stability)

<!-- PAGE=? -->
 Neurogenic shock = sympathectomy w/ PNS dominance resulting in:

<!-- PAGE=? -->
o Vasodilation of viscera and extremities - hypotension responsive to pressors

<!-- PAGE=? -->
o Bradycardia and loss of baroreceptor reflex arc to hypotension (responsive to atropine)

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
 Level of the lesion is correlated with degree of respiratory dysfunction

<!-- PAGE=? -->
o Lower thoracic lesions reduce fx of abdominal ms thus decreasing forced expiration

<!-- PAGE=? -->
o Upper thoracic lesions reduce fx in intercostals ms thereby reducing inspiration

<!-- PAGE=? -->
o Cx lesions impair intercostals ms sparing the diaphragm unless the lesion is at C5 or higher

<!-- PAGE=? -->
 decr IRV, ERV, FEV1, VC, IC, TLC

<!-- PAGE=? -->
 incr RV

<!-- PAGE=? -->
 FVC and FRC are reduced (greatest degree noticed with cervical injuries)

<!-- PAGE=? -->
 pattern is that of a restrictive defect , with a normal FEV1 /FVC ratio and with relatively more severe reduction in ERV than in inspiratory capacity

<!-- PAGE=? -->
 The diaphgram contributes 60% to normal VC (C3,4,5)

<!-- PAGE=? -->
o diaphragmatic paralysis is level dependent (C4 or higher = paralysis of diaphragm)

<!-- PAGE=? -->
 can occur days after injury d/t swelling of cord, spread of hematoma or ischemia measure VT q6h to alert need for possible vent

<!-- PAGE=? -->
o Lesions below C6 have variable loss of intercostals and abdominal muscles but intact diaphragm.

<!-- PAGE=? -->
o Lesions at C6 have significant decrease in VC to 30% associated with reduction in ERV

<!-- PAGE=? -->
 VC is higher in the supine position (or with abdominal binder)

<!-- PAGE=? -->
o paralysis decreases abd wall tone so contents no longer push diaphragm into dome

<!-- PAGE=? -->
o better to vent head down

<!-- PAGE=? -->
o RV and FRC decrease

<!-- PAGE=? -->
 Loss of accessory muscle of resp; intercostals helpful insp/exp

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
 sympathetic discharge w/ incr HR and BP immediately followed by parasympathetic reflexes

<!-- PAGE=? -->
o sinus pauses, sick sinus syndrome, nodal escape beats, Afib, PVC, VT and ST changes

<!-- PAGE=? -->
 loss of sympathetic tone below level of injury causes neurogenic shock

<!-- PAGE=? -->
o vasodilation (loss of vascular tone and vasopressor reflex)

<!-- PAGE=? -->
o decreased BP

<!-- PAGE=? -->
o blood pooling with warm extremities

<!-- PAGE=? -->
o decreased HR (unopposed vagal activity if injury T1-T4

<!-- PAGE=? -->
o Treatment - fluid +/- vasopressors

<!-- PAGE=? -->
o lasts hrs to 3-6wks

<!-- PAGE=? -->
 The only intact efferent component of baroreflex pathways in quadriplegic patients is the vagus

<!-- PAGE=? -->
o Bradycardia occurs not only with changes in position, but also with Valsalva maneuvers or increased intrathoracic pressure

<!-- PAGE=? -->
o Severe bradycardia or dysrhythmias may result from unopposed vagal activity during tracheal intubation or suctioning

<!-- PAGE=? -->
 atropine (0.4-0.6 mg) should be given before any instrumentation

<!-- PAGE=? -->
 If bradycardia develops during airway management, treatment includes additional atropine, glycopyrrolate, isoproterenol, or if necessary cardiac pacing

<!-- PAGE=? -->
 This vagal response is particularly accentuated during hypoxemia

<!-- PAGE=? -->
o normal diaphragmatic VT, but subjectively uncomfortable

<!-- PAGE=? -->
o aggravated when the patient is in an upright position

<!-- PAGE=? -->
o difficult to take deep breath/cough

<!-- PAGE=? -->
o paradoxical breathing

<!-- PAGE=? -->
o reduced ability to handle secretions

<!-- PAGE=? -->
 sleep apnea if anterolateral portions of C2-4 levels

<!-- PAGE=? -->
 Pulmonary edema can occur

<!-- PAGE=? -->
o d/t severe catecholamine surge that follows acute trauma to the spinal cord

<!-- PAGE=? -->
 hypertension lasts for only a few minutes but its effects persist

<!-- PAGE=? -->
 pulmonary capillary damage as a result of shifting of a large portion of the blood volume into the pulmonary circulation

<!-- PAGE=? -->
 LV dysfunction

<!-- PAGE=? -->
 Overzealous fluid therapy may lead to acute pulmonary edema when the sympathetic activity returns about 3-5 days after the injury

<!-- PAGE=? -->
o pulmonary embolism or edema can impact already compromised alveolar ventilation

<!-- PAGE=? -->
 resp acidosis d/t hypoventilation

<!-- PAGE=? -->
PULMONARY AND RESPIRATORY MUSCLE FUNCTION IN QUADRIPLEGIC PATIENTS WITH MIDDLE TO LOWER CERVICAL SPINAL CORD INJURY*

<!-- PAGE=? -->
MVV = maximal voluntary ventilation

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
 In as many as 25% of patients with cervical injuries left ventricular dysfunction may contribute to the hypotension

<!-- PAGE=? -->
 Blood pressure in quadriplegic patients may increase 5- to 10-fold in response to the exogenous administration of angiotensin and to catecholamines

<!-- PAGE=? -->
 increased risk aspiration

<!-- PAGE=? -->
o paralytic ileus

<!-- PAGE=? -->
o gastric dilation

<!-- PAGE=? -->
o poor cough

<!-- PAGE=? -->
 increased secretions d/t paralyzed sympathetic nervous system

<!-- PAGE=? -->
Endo

<!-- PAGE=? -->
 increased Ca (mobilized d/t reduced muscle activity)

<!-- PAGE=? -->
o starts 10d

<!-- PAGE=? -->
o peaks 10wks

<!-- PAGE=? -->
 hyperkalemia w/ succinylcholine

<!-- PAGE=? -->
o occurs within the 1 st week to 6 months

<!-- PAGE=? -->
Poikilothermic

<!-- PAGE=? -->
 prone to heat loss d/t inability to vasoconstrict, piloerection

<!-- PAGE=? -->
o don't sense cold (stimulus for wearing more clothes)

<!-- PAGE=? -->
 injury above C7 abolishes sweating

<!-- PAGE=? -->
o hyperthermia and O2 demand

<!-- PAGE=? -->
Spinal shock

<!-- PAGE=? -->
 caused by direct trauma to the spinal cord

<!-- PAGE=? -->
o usually subsides within days to weeks

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Early supportive

<!-- PAGE=? -->
 avoid hypoxemia

<!-- PAGE=? -->
 maintain MAP at normal to high level

<!-- PAGE=? -->
 Immediate immobilization to limit flexion and extension

<!-- PAGE=? -->
o Soft collars are ineffective

<!-- PAGE=? -->
o Hard collars result in 25% dec in flexion and extension

<!-- PAGE=? -->
o Traction provided by halo-thoracic devices are most effective

<!-- PAGE=? -->
 In-line traction as been supplanted by surgical stabilization

<!-- PAGE=? -->
 Steroids are controversial but are likely NOT recommended

<!-- PAGE=? -->
Surgical treatment

<!-- PAGE=? -->
 Patients with unstable spines who are not quadriplegic or paraplegic may become so during positioning for surgery

<!-- PAGE=? -->
o Period of greatest risk is associated with turning the patient prone

<!-- PAGE=? -->
 Unstable cspine # most likely to be associated with worsening following laryngoscopy when the # is high spinal (atlantoaxial, occiptal)

<!-- PAGE=? -->
 Most movement occurs at C1, and C2

<!-- PAGE=? -->
o LMA, DL, Glidescope all equivalent for spinal movement

<!-- PAGE=? -->
o AFOI indicated

<!-- PAGE=? -->
Spirometry

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Vital Capacity

<!-- PAGE=? -->
o the largest volume measured after an individual inspires deeply and maximally to total lung capacity and then exhales to RV

<!-- PAGE=? -->
o lower in supine subjects than in sitting ones

<!-- PAGE=? -->
o vary directly with height and inversely with age

<!-- PAGE=? -->
o performed without concern for effort

<!-- PAGE=? -->
o abnormally low values for VC are said to be restrictive disease

<!-- PAGE=? -->
 FEF25-75 is often referred to as ‗effort independent'

<!-- PAGE=? -->
o flow does not include the initial highly effort-dependent portion of forced expiration

<!-- PAGE=? -->
o it can be decreased by marked reductions in expiratory effort and by a submaximal inspiration

<!-- PAGE=? -->
o FEF25%-75% does not appear to be any more sensitive than FEV1 in detecting mild abnormalities of lung dysfunction

<!-- PAGE=? -->
 maximum voluntary ventilation

<!-- PAGE=? -->
o largest volume that can be breathed per minute by voluntary effort

<!-- PAGE=? -->
o the measurement is significantly affected by changes in airway resistance

<!-- PAGE=? -->
 usually reduced in patients with obstructive airway disease and correlates reasonably well with FEV1

<!-- PAGE=? -->
o effort-dependent

<!-- PAGE=? -->
 Discrepancies between the measured MVV and that predicted by FEV1 often indicate inconsistent or submaximal inspiratory effort

<!-- PAGE=? -->
 flow-volume loops

<!-- PAGE=? -->
o determinants of maximal flow are dependent on lung volume

<!-- PAGE=? -->
 as volume decreases, airways narrow, resistance increases, and flow rates progressively decrease

<!-- PAGE=? -->
o effort dependant

<!-- PAGE=? -->
 at intermediate and low lung volumes, only moderate effort is needed to produce maximal flow

<!-- PAGE=? -->
 at high lung volumes, the expiratory limb is highly effort dependent

<!-- PAGE=? -->
 Peak flow

<!-- PAGE=? -->
o highly effort-dependent

<!-- PAGE=? -->
o markedly affected by obstruction of large airways and is particularly responsive to bronchodilator therapy

<!-- PAGE=? -->
o dependent on expiratory muscle strength

<!-- PAGE=? -->
PFTS

<!-- PAGE=? -->
OBSTRUCTION

<!-- PAGE=? -->
 FEV1/FVC

<!-- PAGE=? -->
o <75% if >40 yrs old

<!-- PAGE=? -->
o <70% if >40 yrs old

<!-- PAGE=? -->
 Severity - based on FEV1

<!-- PAGE=? -->
o Mild 80%

<!-- PAGE=? -->
o Moderate 50-80%

<!-- PAGE=? -->
o Severe 30-50%

<!-- PAGE=? -->
o Very severe <30%

<!-- PAGE=? -->
 Bronchodilator response

<!-- PAGE=? -->
o >12% improvement in FEV1 or FVC

<!-- PAGE=? -->
o PLUS absolute change  >180mls

<!-- PAGE=? -->
RESTRICTION

<!-- PAGE=? -->
 Based on TLC (% pred)

<!-- PAGE=? -->
o Mild 70-80%

<!-- PAGE=? -->
o Moderate 60-70%

<!-- PAGE=? -->
o Moderately severe <60%

<!-- PAGE=? -->
 Based on VC (% pred)

<!-- PAGE=? -->
o Mild 70-80%

<!-- PAGE=? -->
o Moderate 60-70%

<!-- PAGE=? -->
o Moderately severe 50-60%

<!-- PAGE=? -->
o Severe 34-50%

<!-- PAGE=? -->
o Very Severe <34%

<!-- PAGE=? -->
Flow-volume loops

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
fixed (intra- or extrathoracic)

<!-- PAGE=? -->
B

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
Obstructive

<!-- PAGE=? -->
Normal

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
lung disease

<!-- PAGE=? -->
Paw < Patm

<!-- PAGE=? -->
Paw > Patm

<!-- PAGE=? -->
Trachealstenosis

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
variable extrathoracic

<!-- PAGE=? -->
Restrictive

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
TLC

<!-- PAGE=? -->
RV

<!-- PAGE=? -->
Paw > Ppl

<!-- PAGE=? -->
Paw

<!-- PAGE=? -->
Ppl

<!-- PAGE=? -->
1

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
expiration

<!-- PAGE=? -->
inspiration

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
variable intrathoracic

<!-- PAGE=? -->
LUNG VOLUME (L)

<!-- PAGE=? -->
SSEPs

<!-- PAGE=? -->
Barash 6th

<!-- PAGE=? -->
 Inhalation agents including nitrous oxide generally have more depressant effects on evoked potential monitoring than intravenous agents

<!-- PAGE=? -->
o MEP is exquisitely sensitive to the depressant effects of inhalation anesthetics including nitrous oxide

<!-- PAGE=? -->
o Total intravenous anesthesia without nitrous oxide is the ideal anesthetic technique for monitoring of MEP

<!-- PAGE=? -->
 BAEP are less effected by anesthetic technique as compared to VEP and SSEP

<!-- PAGE=? -->
o BAEP can be recorded with any anesthetic technique

<!-- PAGE=? -->
o Indications

<!-- PAGE=? -->
 acoustic neuroma to help preserve function of cranial nerve VIII

<!-- PAGE=? -->
 posterior fossa procedures to monitor brain stem ischemia

<!-- PAGE=? -->
o Most common changes observed are inc. in V latency and I-V inter-wave latency w/ retractor placement (an increase in latency of more than 1 millisecond is significant)

<!-- PAGE=? -->
 if both waves I and V are lost, loss of hearing postoperatively is likely

<!-- PAGE=? -->
 Propofol and thiopental attenuate the amplitude of virtually all modalities of evoked potential but do not obliterate them

<!-- PAGE=? -->
o SSEP and MEP can be monitored even during burst suppression induced by these agents

<!-- PAGE=? -->
 Opioids and benzodiazepines have negligible effects on recording of evoked potentials

<!-- PAGE=? -->
 Monitoring of MEP and cranial nerve EMG in general preclude the use of muscle relaxants

<!-- PAGE=? -->
o short-acting neuromuscular blocking agent for the purpose of tracheal intubation is not contraindicated as its effect usually wears off before monitoring and surgery begins

<!-- PAGE=? -->
 change in -anesthetic depth‖ should be minimized to avoid misinterpretation of the changes in evoked potential recorded during critical times

<!-- PAGE=? -->
 Ketamine and etomidate have been reported to enhance the quality of signals in patients with weak baseline signals

<!-- PAGE=? -->
o the clinical significance and interpretation of signals obtained under these circumstances remain unclear

<!-- PAGE=? -->
Approach to the patient with dyspnea An efficient stepwise method of determining the cause of chronic dyspnea us pulmonary function tests. WNL within normal limits; YC = vital capacity; TLC total lung capacity; DLCO = diffusing capacity; Pimax peak inspiratory pressure ing

<!-- PAGE=? -->
Spirometry

<!-- PAGE=? -->
Lov FEYI/FYC

<!-- PAGE=? -->
Hormal

<!-- PAGE=? -->
Obstruct

<!-- PAGE=? -->
Asthma?

<!-- PAGE=? -->
Restriction

<!-- PAGE=? -->
Bronchodilator

<!-- PAGE=? -->
Hethacholine

<!-- PAGE=? -->
DLCO

<!-- PAGE=? -->
FEYI

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
YNL

<!-- PAGE=? -->
Lox

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
COPD?

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
Normal

<!-- PAGE=? -->
Chest

<!-- PAGE=? -->
Interstitial

<!-- PAGE=? -->
wall

<!-- PAGE=? -->
DLCD

<!-- PAGE=? -->
Pimax

<!-- PAGE=? -->
High

<!-- PAGE=? -->
Low

<!-- PAGE=? -->
XNL

<!-- PAGE=? -->
Emphysema

<!-- PAGE=? -->
Asthma?

<!-- PAGE=? -->
Diaphragm

<!-- PAGE=? -->
Pleural

<!-- PAGE=? -->
weakness

<!-- PAGE=? -->
disease?

<!-- PAGE=? -->
Bronchitis

<!-- PAGE=? -->
cion

<!-- PAGE=? -->
TABLE 46.3 -- Ability of an anesthetic drug to produce a change in sensory and motor evoked potentials that could be mistaken for a surgically induced change

<!-- PAGE=? -->
SSEPs

<!-- PAGE=? -->
BAEPs

<!-- PAGE=? -->
VEPs

<!-- PAGE=? -->
Transcranial MEPs

<!-- PAGE=? -->
Drug

<!-- PAGE=? -->
Lat

<!-- PAGE=? -->
Amp

<!-- PAGE=? -->
Lat

<!-- PAGE=? -->
Amp

<!-- PAGE=? -->
Lat

<!-- PAGE=? -->
Amp

<!-- PAGE=? -->
Lat

<!-- PAGE=? -->
Amp

<!-- PAGE=? -->
Isoflurane

<!-- PAGE=? -->
Yes  *

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Enflurane

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Halothane

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Nitrous oxide   *

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Barbiturates

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Etomidate

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Propofol

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Droperidol

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
-

<!-- PAGE=? -->
-

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Diazepam

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Midazolam

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Yes (p)

<!-- PAGE=? -->
Ketamine

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Opiates

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Dexmedetomidine

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
No

<!-- PAGE=? -->
ND

<!-- PAGE=? -->
ND

<!-- PAGE=? -->
No

<!-- PAGE=? -->
* Potentiates the of the agent it is used with

<!-- PAGE=? -->
Amp, amplitude; BAEPs, brainstem auditory evoked potentials; latency; MEPs, motor evoked potentials; p, prohibitive in clinically useful doses because use of this drug at any dose may render this type of monitoring impossible for a significant period; SSEPs, somatosensory evoked potentials; VEPs, visual evoked potentials.

<!-- PAGE=? -->
 SSEP are recorded after electrical stim of mixed peripheral n., intensity adjusted to produce min motor contraction

<!-- PAGE=? -->
 short latency waveforms recorded

<!-- PAGE=? -->
o Large sensory n  cell body in DLG  ipsilat post column  synapse in dorsal column nuclei at the cervicomedullary junction  cross and travel to contralat thalamus, thru medial leniscus  third order neurons to frontoparietal sensoriomotor cortex

<!-- PAGE=? -->
 Primary cortical response is monitored (least affected by anesthetic drugs)

<!-- PAGE=? -->
 Data suggests that upper limb SSEPs are conducted through dorsal column pathways, LE SSEPs are conducted substantially by the  lateral funiculus  supplied by ant spinal artery with also supplys descending motor tracts (dorsal spinal cerebellar tract) (LE SSEPs are conducted in all quadrants of the spinal cord)

<!-- PAGE=? -->
 Choose anesthetic that does not markedly depress the SSEP and maintain anesthetic depth as constant as possible

<!-- PAGE=? -->
 False neg rare, false positive common, reliability excellent

<!-- PAGE=? -->
 Volatile anesth - all have similar effects:

<!-- PAGE=? -->
o VEP>SSEP>BAEP: dose depend incr in latency and decr in amplitude of cortical but not subcortically recorded signals

<!-- PAGE=? -->
 .5 up to 1 MAC compatible with monitoring cortical SSEPs in neurologically normal patients, neurologically impaired patients have greater sensitivity

<!-- PAGE=? -->
 ET >1.3MAC have a dose related incr probability of obliterating cortical SSEPs even in normal patients

<!-- PAGE=? -->
 Anesth concentration should not be changed during critical periods of intraop monitoring

<!-- PAGE=? -->
o N2O

<!-- PAGE=? -->
 decr amplitude, no change in latency for SSEP

<!-- PAGE=? -->
 Etomidate

<!-- PAGE=? -->
o incr latency and amplitude, has been used to enhance SSEP (cortical, not spinal), no clinically sig effect on BAEP (incr latency and decr amplitude)

<!-- PAGE=? -->
 Droperidol

<!-- PAGE=? -->
o variable effect on amplitude

<!-- PAGE=? -->
 Minimal effect

<!-- PAGE=? -->
o Diazepam

<!-- PAGE=? -->
 incr latency and decr amplitude

<!-- PAGE=? -->
o Midazolam

<!-- PAGE=? -->
 decr amplitude, no change latency

<!-- PAGE=? -->
o Opiods

<!-- PAGE=? -->
 small dose dependent incr in latency and decr in amplitude not clinically significant, avoid large iv boluses at times of postential surgical compromise

<!-- PAGE=? -->
 Physiologic effects

<!-- PAGE=? -->
o Decr MAP

<!-- PAGE=? -->
 SSEP decr amp (esp cortical) with no change in latency (BAEP resistant)

<!-- PAGE=? -->
o Hypothermia

<!-- PAGE=? -->
 incr latency and decr amplituce

<!-- PAGE=? -->
o Hyperthermia

<!-- PAGE=? -->
 decr amplitude and loss at 42C

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
 decr amplitude

<!-- PAGE=? -->
o Anemia

<!-- PAGE=? -->
 incr latency

<!-- PAGE=? -->
Anesthesiology 2003; 99:716-37

<!-- PAGE=? -->
 Nitrous Oxide (60-70%)

<!-- PAGE=? -->
o generally diminishes cortical SSEP amplitude by approximately 50% while leaving cortical latency and subcortical waves unaffected

<!-- PAGE=? -->
o potentiates the depressant effect of volatile anesthetics and most intravenous anesthetics

<!-- PAGE=? -->
 Benzodiazepines

<!-- PAGE=? -->
o mild-to moderate depressant effects on SSEPs

<!-- PAGE=? -->
o Diazepam, 0.1-0.25 mg/kg, produced mild and moderate decreases in cortical amplitude

<!-- PAGE=? -->
 Very long latency peaks (200-400 ms) were abolished

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
o Like etomidate, ketamine increases cortical SSEP amplitude, with the maximum effect occurring within 2-10 min of bolus administration

<!-- PAGE=? -->
o No effect on cortical latency or subcortical waveforms

<!-- PAGE=? -->
 Etomidate

<!-- PAGE=? -->
o dramatically increases cortical SSEP amplitude, up to 400% above preinduction baseline

<!-- PAGE=? -->
o Subcortical amplitude is decreased by up to 50%

<!-- PAGE=? -->
o associated with a high incidence of myoclonic movements

<!-- PAGE=? -->
 Propofol

<!-- PAGE=? -->
o effect on SSEPs is similar to that of the barbiturates

<!-- PAGE=? -->
o 2.5 mg/kg propofol produced no changes in the amplitude of the cortical (N-20) and subcortical (N14) waves after median nerve stimulation

<!-- PAGE=? -->
o Cortical latency and CCT increased by 8 and 20%, respectively

<!-- PAGE=? -->
 Opioids

<!-- PAGE=? -->
o clinically unimportant changes in SSEP latency and amplitude after the administration of opioids

<!-- PAGE=? -->
Table 3. Effect of Intravenous Anesthetics on Somatosensory Evoked Potentials

<!-- PAGE=? -->
All data are from humans.

<!-- PAGE=? -->
In eeveral studies, <10 ugkg fentanylwas added. t In ieolated cases, bolus administration of 1-1.5 mgkg resulted in loss of severe attenuation of the cortical #At times, am plitude depression was severe 76 for median nerve SSEPs (Fig. 3).

<!-- PAGE=? -->
MAC minimum alveolar concentration; NA data not available; N2O nitrous oxide; 1 increase; decrease.

<!-- PAGE=? -->
Table 1. Effect of Inhaled Anesthetics on Somatosensory Evoked Potentials

<!-- PAGE=? -->
NA data not available; negligible less than 5% change in latency; increase; decrease.

<!-- PAGE=? -->
All data are from humans; percent changes are synthesized framn multiple sources and based on reported changes in mean values.

<!-- PAGE=? -->
In a substantial fraction of patients , wave forms were not attainable at this concentration. t Complete loas of waveform observed only with 1.5 minimum #Upto 159 in children 229 $ Fusion to a single early cortical high-amplitude wave with abolition of all laterwave components. Not proven reliable for intraoperative monitoring . Il For example; N-20 for median nerve somatosensory evoked potentials (SSEPs) and P-40 fa posterior tibial nerve SSEPs (Fig. 3).

<!-- PAGE=? -->
STATS

<!-- PAGE=? -->
 power of a study is a description of the ability of the study to detect a true difference

<!-- PAGE=? -->
 beta error as the probability of falsely accepting the null hypothesis ; i.e. concluding that there is NO difference, when a difference does exist - due to under powered study

<!-- PAGE=? -->
 power = 1 - beta

<!-- PAGE=? -->
 alpha error is the probability of falsely rejecting the null hypothesis; i.e. concluding that there IS a difference when there is NOT a difference.  Alpha error is equal to 0.05 (or 5% or 1 out of 20); when p=0.05, there is a 5% probability that the difference was due to chance.

<!-- PAGE=? -->
 sensitivity = fraction of patients with the disease who will test positive for the disease (TP/TP+FN)

<!-- PAGE=? -->
 specificity = the number of people without the disease who will test negative for the disease (TN/TN+FP)

<!-- PAGE=? -->
 positive predictive value = fraction of those who test positive who actually have the disease (TP/TP+FP)

<!-- PAGE=? -->
 negative predictive value = fraction of those who test negative who are acutally negative (TN/TN+FN)

<!-- PAGE=? -->
 decr subjects with: narrower confidence intervals, higher p value and greater than expected tx effect

<!-- PAGE=? -->
Sample size calculation

<!-- PAGE=? -->
Power (greater power  with larger sample size)

<!-- PAGE=? -->
standard deviation/ variability / variance (greater variability in measurement lead to the need for larger size)

<!-- PAGE=? -->
effect

<!-- PAGE=? -->
: the larger the effect the smaller the sample needed alpha error : smaller likelihood of false positive requires larger sample sizes

<!-- PAGE=? -->
beta  ( power = 1-beta)

<!-- PAGE=? -->
magnitude of difference

<!-- PAGE=? -->
Barash chp 3

<!-- PAGE=? -->
Stellate ganglion block

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o Treatment of upper limb CRPS

<!-- PAGE=? -->
 Anatomy:

<!-- PAGE=? -->
o sympathetic preganglionic fibers for head, neck, upper limb leave spinal cord from T1-T6, & converge at Stellate Ganglion (SG)

<!-- PAGE=? -->
o sympathetic chain lies along junction between anterolateral aspect of vertebral bodies & transverse process

<!-- PAGE=? -->
o Three sympathetic ganglia in the neck

<!-- PAGE=? -->
 superior cervical ganglion located at C1-C2

<!-- PAGE=? -->
 Middle Cervical Ganlgion is a small collection of sympathetic nerve cells

<!-- PAGE=? -->
 anterior aspect of the interior thyroid artery, around the level of the cricoid cartilage and the transverse process of the C6 vertebra

<!-- PAGE=? -->
 just anterior to the vertebral artery

<!-- PAGE=? -->
o the vertebral artery moves posteriorly into the foramen intertransversarium at level of C6

<!-- PAGE=? -->
 inferior cervical ganglion is usually fused with the first thoracic ganglion to form a large ganglion called the cervicothoracic ganglion (Stellate Ganglion)

<!-- PAGE=? -->
 anterior to the transverse process of the vertbra prominens (C7)

<!-- PAGE=? -->
 just superior to the neck of the first rib

<!-- PAGE=? -->
 posterior to the origin of the vertebral artery

<!-- PAGE=? -->
 bounded posteriorly by fascia of the prevertebral muscles, anteriorly by carotid sheath (but SG is medial to artery); inferiorly by neck of first rib

<!-- PAGE=? -->


<!-- PAGE=? -->
o the cervicothoracic ganglion is what needs to be blocked

<!-- PAGE=? -->
 because the dome of the pleura rise up to C7, injection is made at the level of C6, and the LA diffuses inferiorly

<!-- PAGE=? -->
 SNS effects of heart

<!-- PAGE=? -->
o Right stellate - supplies anterior epicardial surface, IV septum, and affects HR

<!-- PAGE=? -->
o Left stellate - supplies post/lateral ventricle and has a > effect on contractility

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
o 10ml of LA is deposited ~3 mm superficial to the transverse process of C6 (Chassaignac tubercle)

<!-- PAGE=? -->
 medial to the carotid artery

<!-- PAGE=? -->
o Signs of a success

<!-- PAGE=? -->
 Horner's syndrome

<!-- PAGE=? -->
 vasodilation and increased skin temperature of arm

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o brachial plexus block

<!-- PAGE=? -->
o SAB (or epidural) injection

<!-- PAGE=? -->
o IV injection

<!-- PAGE=? -->
o Hematoma

<!-- PAGE=? -->
o PTX

<!-- PAGE=? -->
o RLN - hoarseness

<!-- PAGE=? -->
o Phrenic - dyspnea

<!-- PAGE=? -->
o Mediastinitis - esophageal puncture

<!-- PAGE=? -->
 Side effects:

<!-- PAGE=? -->
o Horner's syndrome

<!-- PAGE=? -->
 Miosis - constriction

<!-- PAGE=? -->
 Anhydrosis - unilateral

<!-- PAGE=? -->
 Ptosis - ipsilateral

<!-- PAGE=? -->
 Blockage of nose -engorgement/vasodilation

<!-- PAGE=? -->
 Enopthalomos - sunken eyeball

<!-- PAGE=? -->
Steroid Potency

<!-- PAGE=? -->
100mg Solucortef  = Dex 4mg = Prednisone 25mg = Methylpred 20mg

<!-- PAGE=? -->
Table 41-7. GLUCOCORTICOID PREPARATIONS

<!-- PAGE=? -->
Relative Potency*

<!-- PAGE=? -->
Generic Name

<!-- PAGE=? -->
Trade Name

<!-- PAGE=? -->
Anti-inflammatory

<!-- PAGE=? -->
Mineralocorticoid

<!-- PAGE=? -->
Approximate Equivalent Dose

<!-- PAGE=? -->
(mg)

<!-- PAGE=? -->
Short-Acting

<!-- PAGE=? -->
Hydrocortisone (cortisol)

<!-- PAGE=? -->
Cortef

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
1.0

<!-- PAGE=? -->
20.0

<!-- PAGE=? -->
Cortisone

<!-- PAGE=? -->
Cortigen

<!-- PAGE=? -->
0.8

<!-- PAGE=? -->
0.8

<!-- PAGE=? -->
25.0

<!-- PAGE=? -->
Prednisone

<!-- PAGE=? -->
Deltasone

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
0.25 - 0.8

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
Prednisolone

<!-- PAGE=? -->
Hydeltrasol

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
0.25 - 0.8

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
Methylprednisolone

<!-- PAGE=? -->
Medrol

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
± 0.5

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
Intermediate-Acting

<!-- PAGE=? -->
Triamcinolone

<!-- PAGE=? -->
Aristocort

<!-- PAGE=? -->
5.0

<!-- PAGE=? -->
±

<!-- PAGE=? -->
4.0

<!-- PAGE=? -->
Long-Acting

<!-- PAGE=? -->
Dexamethasone

<!-- PAGE=? -->
Decadron

<!-- PAGE=? -->
30.0

<!-- PAGE=? -->
± 0

<!-- PAGE=? -->
0.75

<!-- PAGE=? -->
* Relative milligram comparisons with cortisol. The glucocorticoid and mineralocorticoid properties of cortisol are

<!-- PAGE=? -->
set as 1.0.

<!-- PAGE=? -->
Stress hormones

<!-- PAGE=? -->
Miller Ch 72 p2730

<!-- PAGE=? -->
TABLE 5-1. Neuroendocrine and metabolic responses to surgery

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
Catabolic

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
ACTH, cortisol; ADH, GH, catecholamines; renin; angiotensin-II,

<!-- PAGE=? -->
increase in:

<!-- PAGE=? -->
aldosterone; glucagon; IL-1, TNF, IL-6

<!-- PAGE=? -->
Anabolic

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
Insulin; testosterone

<!-- PAGE=? -->
decrease in:

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
Carbohydrate

<!-- PAGE=? -->
Hyperglycemia, glucose intolerance, insulin resistance

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
Hepatic glycogenolysis (epinephrine; glucagon); gluconeogenesis

<!-- PAGE=? -->
increase in:

<!-- PAGE=? -->
(cortisol, glucagon; GH, epinephrine; free fatty acids)

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
Insulin secretionlaction

<!-- PAGE=? -->
decrease in:

<!-- PAGE=? -->
Protein

<!-- PAGE=? -->
Muscle protein catabolism, increased synthesis of acute-phase

<!-- PAGE=? -->
proteins

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
Cortisol, epinephrine; glucagon; IL-1,IL-6, TNF

<!-- PAGE=? -->
increase in:

<!-- PAGE=? -->
Fat

<!-- PAGE=? -->
Increased lipolysis and oxidation

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
catecholamines, cortisol; glucagon; GH

<!-- PAGE=? -->
increase in:

<!-- PAGE=? -->
Water and

<!-- PAGE=? -->
Retention of H2O and Na

<!-- PAGE=? -->
increased excretion of K'

<!-- PAGE=? -->
decreased

<!-- PAGE=? -->
Electrolyte

<!-- PAGE=? -->
functional extracellular fluid with shifts to intracellular

<!-- PAGE=? -->
compartments

<!-- PAGE=? -->
Flux

<!-- PAGE=? -->
Due to

<!-- PAGE=? -->
Catecholamines; aldosterone; ADH; cortisol, angiotensin-II,

<!-- PAGE=? -->
increase in:

<!-- PAGE=? -->
prostaglandins; and other factors

<!-- PAGE=? -->
ACTH; adrenocorticotropic hormone; ADH, antidiuretic hormone; GH, growth

<!-- PAGE=? -->
hormone; IL, interleukin;

<!-- PAGE=? -->
TNF,tumor necrosis factor.

<!-- PAGE=? -->
also prolactin, thyroxin, PG

<!-- PAGE=? -->
Superventricular tachycardia - SVT

<!-- PAGE=? -->
 Normal EF: calcium channel blockers or beta blockers

<!-- PAGE=? -->
 EF < 40%:, digoxin, diltiazem, amiodarone

<!-- PAGE=? -->
o Avoid beta blockers, verapamil, procainamide, flecanide, propafenone, ibutilide

<!-- PAGE=? -->
 New ACLS guidelines from 2005 say to control the rate with beta blockers or diltiazem, but to use beta blockers with caution if LV dysfunction

<!-- PAGE=? -->
 Magnesium, beta blockers and diltiazem have been shown to be useful for rate control

<!-- PAGE=? -->
 Ibutilide and amiodarone have been shown to be useful for rhythm control

<!-- PAGE=? -->
 Do not administer AV nodal blocking agents to patient with afib and WPW

<!-- PAGE=? -->
SVO2

<!-- PAGE=? -->
 SvO2 = SaO2 - [VO2 / CO x 1.36 x Hgb]

<!-- PAGE=? -->
o VO2 = oxygen consumption

<!-- PAGE=? -->
 Physiologic factors that affect SvO2 include

<!-- PAGE=? -->
o Hg

<!-- PAGE=? -->
o PaO2

<!-- PAGE=? -->
o CO

<!-- PAGE=? -->
o VO2

<!-- PAGE=? -->
 If arterial hemoglobin saturation, oxygen consumption, and hemoglobin concentration remain stable, mixed venous hemoglobin saturation may be used as an indirect indicator of cardiac output .

<!-- PAGE=? -->
 For example, when cardiac output falls, tissue oxygen extraction increases and the mixed venous blood will become more desaturated

<!-- PAGE=? -->
 Normal SvO2 ~ 0.75

<!-- PAGE=? -->
SVR

<!-- PAGE=? -->
SVR = 80*(MAP-CVP)/CO

<!-- PAGE=? -->
Systemic Lupus Erythematosus

<!-- PAGE=? -->
CoExD, Barash, Chestnut

<!-- PAGE=? -->
 Multisystem inflammatory disease of unknown etiology characterized by production of autoantibodies against nuclear, cytoplasmic and cell membrane antigens

<!-- PAGE=? -->
 Diverse antigen-antibody complexes are formed, deposited and followed by secondary inflammatory responses (kidneys, skin, choroids plexus, endothelial surfaces, red and white blood cells and platelets)

<!-- PAGE=? -->
 SLE has a 10:1 female preponderance, occurring most commonly in the 2 nd - 4 th decade

<!-- PAGE=? -->
 Relapsing - Remitting course varying from mild to severe

<!-- PAGE=? -->
 Constitutional symptoms occur in 50 - 100% of patients, fatigue being the most common and often most debilitating

<!-- PAGE=? -->
 Neurologic complications

<!-- PAGE=? -->
o Cognitive deficits, organic brain syndromes, delirium, psychosis, seizures, headaches, depression, anxiety and mania

<!-- PAGE=? -->
o Can be secondary to the SLE disease process itself (vasculitis), secondary to medications, or related to thromboembolic disease in the presence of antiPL Ab's

<!-- PAGE=? -->
o Central and peripheral sensorimotor and autonomic neuropathies

<!-- PAGE=? -->
 Cardiovascular

<!-- PAGE=? -->
o Verrucous endocarditis (non-infectious) usually clinically silent, but produces valvular insufficiency and a source of emboli (mitral and aortic valves). (thickening, vegetations, regurg > stenosis)

<!-- PAGE=? -->
o Accelerated atherosclerosis.

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
o Pericarditis is common and typically asymptomatic but cases of tamponade have been reported

<!-- PAGE=? -->
o Myocarditis and conduction defects

<!-- PAGE=? -->
 Persistant tachycardia and CHF can develop in severe cases

<!-- PAGE=? -->
 Respiratory

<!-- PAGE=? -->
o Laryngeal involvement in as many as 30%

<!-- PAGE=? -->
 Ulceration, cricoarytenoid arthritis, RLN palsy

<!-- PAGE=? -->
o Lupus pnuemonia: diffuse infiltrates, pleural effusion, dry cough, dyspnea, hypoxemia, restrictive pattern on PFTs (interstitial lung disease)

<!-- PAGE=? -->
o Recurrent atelectasis, shrinking lung syndrome

<!-- PAGE=? -->
o alveolar hemorrhage (rare)

<!-- PAGE=? -->
o Pulmonary hypertension (high incidence in pts with Raynaud syndrome)

<!-- PAGE=? -->
o Increased risk of DVT / PE with anti-phospholipid antibodies.

<!-- PAGE=? -->
o In general, PFT's in SLE will show restrictive pattern (sometimes in the absence of significant disease = shrinking lung syndrome)

<!-- PAGE=? -->
 Hematologic

<!-- PAGE=? -->
o Leukopenia, thrombocytopenia and anemia common.

<!-- PAGE=? -->
o Thromboembolism

<!-- PAGE=? -->
 Some patients will have antiphospholipid antibodies predisposing to thromboembolic disease

<!-- PAGE=? -->
 In most instances, prolonged PTT is associated with lupus coagulant, but this is an in vitro effect and patients are paradoxically predisposed to thromboembolic events (as above)

<!-- PAGE=? -->
o Autoantibodies against clotting factors are rare and do cause bleeding diathesis

<!-- PAGE=? -->
o However, may have antibody-mediated factor deficiencies (VIII and prothrombin), thrombocytopenia, or qualitative platelet abnormality resulting in coagulopathy and rarely hemorrhage

<!-- PAGE=? -->
o Cross-matching may take longer due to atypical blood antibodies

<!-- PAGE=? -->
o Functional asplenism can occur

<!-- PAGE=? -->
 Renal disease

<!-- PAGE=? -->
o Approx 50%, most of these being sub clinical.

<!-- PAGE=? -->
o Several forms of glomerulonephritis - proteinuria, hypertension, nephritic syndrome, renal insufficiency

<!-- PAGE=? -->
 GI effects

<!-- PAGE=? -->
o Most commonly a side effect of medications (NSAID and steroid gastritis, ulcers).

<!-- PAGE=? -->
o Liver enzymes may be mildly elevated in 30% of patients

<!-- PAGE=? -->
o SLE vasculitis can result in pancreatitis, peritonitis and colitis, bowel ischemia

<!-- PAGE=? -->
 Musculo-cutaneous

<!-- PAGE=? -->
o Arthritis - joint symptoms in > 90%, often the earliest manifestation, usually migratory and asymmetrical arthritis

<!-- PAGE=? -->
o Avascular necrosis, most often of head or condyle of femur

<!-- PAGE=? -->
o Myopathy, proximal skeletal muscle weakness, increased CK, tendonitis

<!-- PAGE=? -->
o Mucocutaneous - skin lesions - most common is the butterfly malar rash.  Painless oral or nasal ulcers also occur

<!-- PAGE=? -->
o Typical rash - discoid butterfly rash or malar rash, maculopapular rash, exacerbated by sun, alopecia

<!-- PAGE=? -->
 Ophthalmologic

<!-- PAGE=? -->
o keratoconjunctivitis sicca

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Determined by individual disease manifestations

<!-- PAGE=? -->
o No evidence of prophylactic treatment with low dose

<!-- PAGE=? -->
o ASA/NSAIDs can control arthritis and serositis

<!-- PAGE=? -->
o Antimalarials (hydroxychloroquine and quinacrine) are effective for dermatologic manifestations, control arthritis and reduce thromboembolic complications

<!-- PAGE=? -->
o Corticosteroids improve thrombocytopenia and hemolytic anemia.  Also suppress glomerulonephritis and adverse changes in CVS

<!-- PAGE=? -->
 Corticosteroid therapy is a major cause of morbidity in patients with SLE (a prominent cause of death is CAD possibly related to corticosteroid use)

<!-- PAGE=? -->
o Danazol, Vincristine (low dose), cyclophosphamide, splenctomy if thrombocytopenia responds to corticosteroids.  In some patients, low-dose immunosuppressive treatment may be preferable to prolonged intensive treatment with corticosteroids

<!-- PAGE=? -->
o Drugs that can be used during pregnancy:

<!-- PAGE=? -->
 Azathioprine

<!-- PAGE=? -->
 Hydroxychloroquinine

<!-- PAGE=? -->
 Prednisone

<!-- PAGE=? -->
 ASA

<!-- PAGE=? -->
 SLE in Pregnancy exacerbations in maternal disease occur in 30 - 50% of pregnancies usually in 2 nd or 3 rd trimester

<!-- PAGE=? -->
o Pregnancy does not alter the long term course of the disease but 2/3 will flare during pregnancy

<!-- PAGE=? -->
o Exacerbations are treated with steroids

<!-- PAGE=? -->
o Other complications associated with pregnancy and SLE include; increased incidence of PIH, thrombocytopenia, pre-term delivery

<!-- PAGE=? -->
o Renal function may worsen ~30% and may mimic PIH > which require different Rx

<!-- PAGE=? -->
 PIH more likely if:

<!-- PAGE=? -->
 Increased serum uric acid concentratio

<!-- PAGE=? -->
 Proteinuria without active urinary sediment

<!-- PAGE=? -->
 Liver enzyme abnormalities

<!-- PAGE=? -->
o Women with antiphospholipid antibodies need to be given prophylaxis with LMWH or UFH

<!-- PAGE=? -->
o Effects on the fetus:

<!-- PAGE=? -->
 Increased risk of fetal death (20-30%), preterm delivery

<!-- PAGE=? -->
 SA risk 2x baseline

<!-- PAGE=? -->
 Immunosuppressive therapy used in Lupus is associated with increased rate of IUGR, preterm labor, increased rate of abortions but no evidence of teratogenicity

<!-- PAGE=? -->
 Potential for neonatal lupus - anti-Ro Ab crosses placenta causing transient symptoms, but cardiac conduction defect are permanent (congenital heart block)

<!-- PAGE=? -->
Diagnostic Criteria for SLE (need 4+ for research, less for clinical)

<!-- PAGE=? -->
Malar rash

<!-- PAGE=? -->
Discoid rash (erythematous, raised patches with scaling)

<!-- PAGE=? -->
Photosensitivity

<!-- PAGE=? -->
Oral ulceration

<!-- PAGE=? -->
Arthritis

<!-- PAGE=? -->
Serositis (pleuritis or pericarditis)

<!-- PAGE=? -->
Renal disorder (persistent proteinuria or casts)

<!-- PAGE=? -->
Neurologic disorder (sz or psychosis)

<!-- PAGE=? -->
Hematologic disorder (hemolytic anemia, leucopenia, lymphopenia, thrombocytopenia)

<!-- PAGE=? -->
Immunologic disorder (anti-DNA, anti Sm nuclear antibody, anticardiolipin antibodies, lupus anticoagulant, false-positive syphilis test)

<!-- PAGE=? -->
Antinuclear antibody

<!-- PAGE=? -->
T

<!-- PAGE=? -->
Tamponade

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
o tamponade exists when an incr pericardial pressure impairs diastolic filling

<!-- PAGE=? -->
o the pressure is applied equally to heart, but thin walled atria and RV most effected

<!-- PAGE=? -->
o principal hemodynamic feature is decreased CO

<!-- PAGE=? -->
 d/t decreased SV with increased CVP

<!-- PAGE=? -->
o leads to equalization of diastolic press throughout the heart

<!-- PAGE=? -->
 RAP = RVEDP = PAD = LVEDP

<!-- PAGE=? -->
o decreased LV distensibility by RV dialation and septal shift

<!-- PAGE=? -->
o compensation

<!-- PAGE=? -->
 increased HR and contractility to maintain CO

<!-- PAGE=? -->
 increased SVR (incr BP) with venoconstriction (incr venous return)

<!-- PAGE=? -->
 Clinical Features

<!-- PAGE=? -->
o Resp

<!-- PAGE=? -->
 Tachypnea

<!-- PAGE=? -->
 Dyspnea

<!-- PAGE=? -->
 Orthopnea

<!-- PAGE=? -->
o Tachycardia

<!-- PAGE=? -->
TCA

<!-- PAGE=? -->
P&P

<!-- PAGE=? -->
 Tricyclic antidepressant overdose probably represents the most common life-threatening form of drug ingestion

<!-- PAGE=? -->
o Mechanism of action includes

<!-- PAGE=? -->
 Stimulation of catecholamine release and block reuptake

<!-- PAGE=? -->
 Central and peripheral anticholinergic agents

<!-- PAGE=? -->
 inhibit Na and K channels in brain and heart

<!-- PAGE=? -->
 Direct alpha blocking

<!-- PAGE=? -->
 Progression from alert to life-threatening symptoms may be rapid

<!-- PAGE=? -->
 Intractable myocardial depression or ventricular cardiac dysrhythmias are the most frequent terminal event

<!-- PAGE=? -->
 Presenting features of a tricyclic antidepressant overdose include

<!-- PAGE=? -->
 (Three Cs and A - Coma, convulsive, cardiac arrythmias and acidosis)

<!-- PAGE=? -->
o agitation and seizures leading to coma

<!-- PAGE=? -->
o depression of ventilation

<!-- PAGE=? -->
o hypotension

<!-- PAGE=? -->
o hypothermia

<!-- PAGE=? -->
o striking signs of anticholinergic effects

<!-- PAGE=? -->
 mydriasis

<!-- PAGE=? -->
 flushed dry skin

<!-- PAGE=? -->
 urinary retention

<!-- PAGE=? -->
 tachycardia

<!-- PAGE=? -->
 The QRS complex on the ECG may be widened to more than 100 msec

<!-- PAGE=? -->
o the likelihood of seizures and ventricular dysrhythmias is increased when the duration of the QRS complex is greater than 100 msec

<!-- PAGE=? -->
o plasma concentrations of tricyclic antidepressants do not allow prediction of the likely occurrence of seizures or cardiac dysrhythmias

<!-- PAGE=? -->
o Beck's triad

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
 Increased JVP

<!-- PAGE=? -->
 muffled HS

<!-- PAGE=? -->
o Pulsus paradoxus

<!-- PAGE=? -->
o Equalization of diastolic pressures

<!-- PAGE=? -->
 RAP=RVEDP=PAEDP=LAP=LVEDP

<!-- PAGE=? -->
o Electrical alternans

<!-- PAGE=? -->
o CVP abolished y descent; normal or accentuated x descent

<!-- PAGE=? -->
 Labs

<!-- PAGE=? -->
o CXR - increased heart size

<!-- PAGE=? -->
o ECG - decreased voltages in all leads; nonspecific ST or T wave changes; generalized increased ST; electrical alternans

<!-- PAGE=? -->
o Echo - most useful diagnostic (diastolic compression RA/RV, displaced septum); facilitate drainage

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
o Surgical decompression

<!-- PAGE=? -->
o Avoid PPV - impaired venous return - arrest

<!-- PAGE=? -->
 Maintain spontaneous ventilation

<!-- PAGE=? -->
o Anesthetic drugs are that preserve the compensatory mechanisms sustaining forward flow

<!-- PAGE=? -->
 vasodilator (either venous or arteriolar) or myocardial depressant agents should be avoided

<!-- PAGE=? -->
 Maintain HR, afterload, and preload

<!-- PAGE=? -->
 Ketamine, because of its sympathomimetic effects, may be helpful in preserving heart rate and blood pressure response

<!-- PAGE=? -->
 The comatose phase of tricyclic antidepressant overdose lasts 24 to 72 hours

<!-- PAGE=? -->
 risk of life-threatening cardiac dysrhythmias persists for up to 10 days, necessitating continued monitoring of the ECG in these patients

<!-- PAGE=? -->
 Treatment of TCA overdose is directed toward management of central nervous system and cardiac toxicity

<!-- PAGE=? -->
o Coma usually resolves within 24 hours but is frequently severe enough to require active airway support

<!-- PAGE=? -->
o Extrapyramidal effects and organic brain syndrome usually require supportive care only

<!-- PAGE=? -->
 judicious use of physostigmine, 0.5 to 2 mg IV , for obvious anticholinergic psychosis may be indicated

<!-- PAGE=? -->
 only anticholinesterase that crosses the BBB

<!-- PAGE=? -->
o Seizures may precede cardiac arrest and should be treated aggressively with diazepam

<!-- PAGE=? -->
o Phenytoin may be required for sustained effects

<!-- PAGE=? -->
Acidosis associated with seizure activity may abruptly increase unbound tricyclic

<!-- PAGE=? -->
o antidepressants in the circulation and predispose to cardiac dysrhythmias

<!-- PAGE=? -->
o alkalinization of the plasma (pH greater than 7.45) either by intravenous administration of sodium bicarbonate or deliberate hyperventilation of the lungs can temporarily reverse drug-induced cardiotoxicity

<!-- PAGE=? -->
o Lidocaine and phenytoin may be used subsequently to provide sustained suppression of cardiac ventricular dysrhythmias

<!-- PAGE=? -->
o Hypotension may be the result of direct tricyclic antidepressant-induced

<!-- PAGE=? -->
 Vasodilation

<!-- PAGE=? -->
 alpha-blockade

<!-- PAGE=? -->
 myocardial depression

<!-- PAGE=? -->
o may require support with sympathomimetics, inotropes, or both

<!-- PAGE=? -->
o Gastric layage may be useful early in treatment

<!-- PAGE=? -->
 Current ACLS recommends only in first hour haft ingestion

<!-- PAGE=? -->
 most safely performed with a cuffed tracheal tube

<!-- PAGE=? -->
 Activated charcoal significantly absorbs drug throughout the gastrointestinal tract ("intestinal dialysis")

<!-- PAGE=? -->
o avid protein binding of tricyclic antidepressants negates any therapeutic value of hemodialysis or drug-induced diuresis

<!-- PAGE=? -->
Table 19-3 Pharmacologic Treatment of Tricyclic Antidepressant Overdose

<!-- PAGE=? -->
o Seizures

<!-- PAGE=? -->
 Diazepam

<!-- PAGE=? -->
 Sodium bicarbonate

<!-- PAGE=? -->
 Phenytoin

<!-- PAGE=? -->
o Ventricular cardiac dysrhythmias

<!-- PAGE=? -->
 Alkalization (Sodium bicarbonate)

<!-- PAGE=? -->
 Lidocaine

<!-- PAGE=? -->
 Phenytoin

<!-- PAGE=? -->
o Heart block

<!-- PAGE=? -->
 Isoproterenol

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
 Crystalloid or colloid solution

<!-- PAGE=? -->
 Sodium bicarbonate

<!-- PAGE=? -->
 Sympathomimetics

<!-- PAGE=? -->
 Inotropes

<!-- PAGE=? -->
TENS

<!-- PAGE=? -->
 Proposed mechanism

<!-- PAGE=? -->
o hyperstimulation of the nervous system drowns out the pain

<!-- PAGE=? -->
o activation of the descending pain modulation system in the CNS

<!-- PAGE=? -->
o mediation of pain by neurotransmitters such as adenosine and endorphins.

<!-- PAGE=? -->
 highly recommended as an adjunct therapy for patients with neuropathic pain

<!-- PAGE=? -->
 works BEST in patients with

<!-- PAGE=? -->
o musculoskeletal pain

<!-- PAGE=? -->
o peripheral nerve injuries

<!-- PAGE=? -->
o phantom pain

<!-- PAGE=? -->
o stump pain

<!-- PAGE=? -->
o Myofascial pain - TENS applied directly over the trigger points, may produce analgesia during stimulation and often for some time afterward

<!-- PAGE=? -->
o PHN

<!-- PAGE=? -->
 less effective in patients with post-surgery spinal pain

<!-- PAGE=? -->
 TENS is NOT effective in most patients that have no peripheral nociceptive source for their pain

<!-- PAGE=? -->
o central pain states

<!-- PAGE=? -->
o psychosocial-based pain

<!-- PAGE=? -->
o physiologic or psychologic dependence on drugs

<!-- PAGE=? -->
Thermoregulation in Infants

<!-- PAGE=? -->
Thiopental

<!-- PAGE=? -->
 Action likely through an interaction with the inhibitory neurotransmitter GABA in the CNS

<!-- PAGE=? -->
 Activation of the GABA receptor results in inc. transmembrane chloride conductance, resulting in hyperpolarization of the postsynaptic cell membrane and functional inhibition of the postsynaptic neuron

<!-- PAGE=? -->
 barbiturates (and propofol) appear to decrease the rate of dissociation of GABA from its receptor, thereby increasing the duration of the GABA-activated opening of the chloride ion channel

<!-- PAGE=? -->
o Barbiturates can also mimic the action of GABA by directly activating the chloride channels

<!-- PAGE=? -->
IA injection

<!-- PAGE=? -->
 mechanism of damage seems to be precipitation of thiopental crystals in the arterial vessels leading to an inflammatory response and arteritis

<!-- PAGE=? -->
o microembolization eventually results in occlusion of the distal circulation

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
 immediate attempts to dilute the drug

<!-- PAGE=? -->
o best accomplished by injection of saline through the needle or catheter that still remains in the artery

<!-- PAGE=? -->
 prevention of arterial spasm

<!-- PAGE=? -->
o lidocaine 1% - 5-10cc

<!-- PAGE=? -->
o papaverine 40-80mg in 10-20cc NS

<!-- PAGE=? -->
o phenoxybenzamine

<!-- PAGE=? -->
o Stellate ganglion block

<!-- PAGE=? -->
 general measures to sustain adequate blood flow

<!-- PAGE=? -->
o heparinization

<!-- PAGE=? -->
o Urokinase may improve distal blood flow after accidental intraarterial injection of thiopental

<!-- PAGE=? -->
Thoracic surgery complications

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 complications related to thoracic surgery

<!-- PAGE=? -->
o herniation of the heart

<!-- PAGE=? -->
 after pneumonectomy

<!-- PAGE=? -->
o pulmonary torsion

<!-- PAGE=? -->
o respiratory failure

<!-- PAGE=? -->
o reexpansion pulmonary edema

<!-- PAGE=? -->
o RH failure

<!-- PAGE=? -->
o Shunting through PFO

<!-- PAGE=? -->
o Bronchopleural fistula

<!-- PAGE=? -->
o Neural injuries

<!-- PAGE=? -->
o Respiratory insuffic

<!-- PAGE=? -->
o Arrythmias

<!-- PAGE=? -->
o hemorrhage

<!-- PAGE=? -->
 neural injuries related to thoracotomy

<!-- PAGE=? -->
o hilar dissection : damage to phrenic, vagus and RLN

<!-- PAGE=? -->
o parapleagia secondary to

<!-- PAGE=? -->
 dissection of post end of rib

<!-- PAGE=? -->
 damage spinal branches of intercostal art

<!-- PAGE=? -->
 ischemia most likely with dissection of the LLL

<!-- PAGE=? -->
 dissection may create a communication between the epidural space and the pleural cavity and clotted blood can cause compression

<!-- PAGE=? -->
Thyroid

<!-- PAGE=? -->
Thyroid Storm

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Thyroid storm is the name for the clinical diagnosis of a life-threatening illness in a patient whose hyperthyroidism has been severely exacerbated by illness or surgery

<!-- PAGE=? -->
 Occurs either during or immediately after surgery

<!-- PAGE=? -->
 Manifestations include

<!-- PAGE=? -->
o Hyperthermia

<!-- PAGE=? -->
o Tachycardia, dysrhythmias and CHF

<!-- PAGE=? -->
o Agitation and confusion

<!-- PAGE=? -->
o gastrointestinal dysfunction - nausea, vomiting, diarrhea, and jaundice

<!-- PAGE=? -->
 manifestations can be very similarly to malignant hyperthermia, pheochromocytoma, or neuroleptic malignant syndrome

<!-- PAGE=? -->
 Although free T4 levels are often markedly elevated, no laboratory test is diagnostic .

<!-- PAGE=? -->
 Therapy can include

<!-- PAGE=? -->
o blocking the synthesis of thyroid hormones

<!-- PAGE=? -->
 propylthiouracil, 200-400 mg po or via NG q6h (dec. conversion of T4 to T3)

<!-- PAGE=? -->
o blocking the release of preformed hormone with iodine

<!-- PAGE=? -->
 sodium iodide, 250 mg po or iv q6h

<!-- PAGE=? -->
 start after antithyroid agents

<!-- PAGE=? -->
 response in 24 hrs

<!-- PAGE=? -->
 hydrocortisone, 50-100 mg iv q6h

<!-- PAGE=? -->
 impairs the conversion of T4 to T3

<!-- PAGE=? -->
 reduce thyroid hormone secretion

<!-- PAGE=? -->
o meticulous attention to hydration and supportive therapy

<!-- PAGE=? -->
 IV fluids

<!-- PAGE=? -->
 propanolol 10-40 mg po q4-6h or esmolol infusion to treat hyperadrenergic signs

<!-- PAGE=? -->
 extreme caution in the presence of CHF

<!-- PAGE=? -->
 may impair the peripheral conversion of T4 to T3 over 1-2 weeks

<!-- PAGE=? -->
 Cooling blankets and acetaminophen and meperidine (25-50 mg) iv q4-6h may be used to prevent shivering.

<!-- PAGE=? -->
 Using digoxin for heart failure especially in the presence of atrial fibrillation with rapid ventricular response

<!-- PAGE=? -->
o correcting the precipitating cause.

<!-- PAGE=? -->
o In severe cases, attempts may be made to remove thyroid hormone from the peripheral circulation

<!-- PAGE=? -->
 peritoneal dialysis

<!-- PAGE=? -->
 plasmapheresis

<!-- PAGE=? -->
 hemoperfusion

<!-- PAGE=? -->
 cholestyramine resin

<!-- PAGE=? -->
 bind T4 and T3 within the gastrointestinal tract

<!-- PAGE=? -->
 With combined treatment the serum T3 concentration generally returns to normal within 36 to 48 hours

<!-- PAGE=? -->
 Older patients, particularly those who may have an underlying toxic multinodular goiter rather than Graves' disease, may present as so-called masked or -apathetic‖ thyrotoxicosis

<!-- PAGE=? -->
 Thyroid dysfunction, either hyperthyroidism or hypothyroidism, develops in more than 10% of patients treated with the antiarrhythmic agent amiodarone

<!-- PAGE=? -->
Hypothyroid

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o history of RAI therapy

<!-- PAGE=? -->
o external neck irradiation

<!-- PAGE=? -->
o presence of a goiter

<!-- PAGE=? -->
 Pathophysiology

<!-- PAGE=? -->
o generalized reduction in metabolic activity

<!-- PAGE=? -->
 lethargy

<!-- PAGE=? -->
 slow mental functioning

<!-- PAGE=? -->
 cold intolerance

<!-- PAGE=? -->
 slow movements

<!-- PAGE=? -->
o cardiovascular manifestations

<!-- PAGE=? -->
 bradycardia

<!-- PAGE=? -->
 Dec. myocardial contractility

<!-- PAGE=? -->
 Correlates with severity

<!-- PAGE=? -->
 Rarely produces CHF in the absence of coexisting heart disease

<!-- PAGE=? -->
 low voltage on the ECG

<!-- PAGE=? -->
 accumulation of a cholesterol-rich pericardial fluid

<!-- PAGE=? -->
 Angina pectoris is unusual in hypothyroidism and usually appears when thyroid hormone treatment is initiated (catecholamine hypersensitivity)

<!-- PAGE=? -->
o Ventilatory responsiveness to hypoxia and hypercapnia is depressed

<!-- PAGE=? -->
 potentiated by sedatives, opioids, and general anesthesia

<!-- PAGE=? -->
o Other abnormalities

<!-- PAGE=? -->
 anemia

<!-- PAGE=? -->
 Hypothermia

<!-- PAGE=? -->
 sleep apnea

<!-- PAGE=? -->
 impaired renal free water clearance with hyponatremia

<!-- PAGE=? -->
 Basal plasma levels of cortisol are usually normal but the stress response may be blunted and adrenal depression may occur

<!-- PAGE=? -->
 Anesthesia

<!-- PAGE=? -->
o No increase in serious complications with mild or moderate hypothyroidism

<!-- PAGE=? -->
 higher incidence of intraoperative hypotension and postoperative GI and neuropsychiatric complications

<!-- PAGE=? -->
o Euthyroid prior to elective surgery

<!-- PAGE=? -->
 oral thyroxine titrated to achieve TSH in N range over > 6-8 weeks

<!-- PAGE=? -->
 Give normal dose the morning of surgery ( t1/2 1.4-10d)

<!-- PAGE=? -->
o For emergency surgery consider preoperative thyroid replacement (and glucocorticoid):

<!-- PAGE=? -->
 If CAD balance the risk of aggravating symptoms

<!-- PAGE=? -->
 T4 IV loading dose ( levothyroxine 400-500 ug initially then 50-200ug/day)

<!-- PAGE=? -->
 alternately T3 can be used/more rapid onset

<!-- PAGE=? -->
 liothyroxine 0.15 - 0.3 ug/kg IV q6h

<!-- PAGE=? -->
 More potent and less protein bound than T4

<!-- PAGE=? -->
 Hydrocortisone (eg. 100 mg IV then 25 mg IV q6h)

<!-- PAGE=? -->
 Myxedema coma

<!-- PAGE=? -->
o represents a severe form of hypothyroidism

<!-- PAGE=? -->
o characterized by

<!-- PAGE=? -->
 stupor or coma

<!-- PAGE=? -->
 hypoventilation

<!-- PAGE=? -->
 hypothermia

<!-- PAGE=? -->
 hypotension

<!-- PAGE=? -->
 hyponatremia

<!-- PAGE=? -->
o medical emergency with a high mortality rate (50%)

<!-- PAGE=? -->
Table 41-5. MANAGEMENT OF MYXEDEMA

<!-- PAGE=? -->
Tracheal intubation and controlled ventilation as needed Levothyroxine 200-300  g iv over 5-10 min initially, and 100  g iv q24h Hydrocortisone, 100 mg iv, then 25 mg iv q6h Fluid and electrolyte therapy as indicated by serum electrolytes Cover to conserve body heat; no warming blankets

<!-- PAGE=? -->
Torsades de Pointes

<!-- PAGE=? -->
 ventricular tachycardia associated with a prolonged QT interval

<!-- PAGE=? -->
o RATE = 150-200bpm

<!-- PAGE=? -->
o RHYTHM = no atrial component, ventricular component either regular or irregular

<!-- PAGE=? -->
o PR INTERVAl = P buried in QRS

<!-- PAGE=? -->
o QT INTERVAL = QRS complexes wide and phasic variation twisting around a central axis, ST segments & T waves tough to discern

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o Severe bradycardia

<!-- PAGE=? -->
o Electrolyte disturbances

<!-- PAGE=? -->
 Hypokalemia

<!-- PAGE=? -->
 Hypocalcemia

<!-- PAGE=? -->
 Hypomagnesemia

<!-- PAGE=? -->
o Class IA & IC antiarrhythmics

<!-- PAGE=? -->
 Administering standard antidysrhythmics(eg lidocaine, procainamide) may worsen it

<!-- PAGE=? -->
 commonly seen in malnourished individuals and chronic alcoholics

<!-- PAGE=? -->
 Drug interactions

<!-- PAGE=? -->
o erythromycin or moxifloxacin, taken concomitantly with inhibitors like nitroimidazole, Diarrhea, dietary supplements, and various medications like methadone, Lithium, tricyclic antidepressants or phenothiazines may also contribute

<!-- PAGE=? -->
 Treatment includes

<!-- PAGE=? -->
o Repletion of magnesium

<!-- PAGE=? -->
o increasing heart rate pharmacologically or by pacing

<!-- PAGE=? -->
 Factors that are associated with an increased tendency toward torsades de pointes include:

<!-- PAGE=? -->
o Familial long QT syndrome

<!-- PAGE=? -->
o Class IA antiarrhythmics

<!-- PAGE=? -->
o Hypomagnesemia

<!-- PAGE=? -->
o Hypokalemia

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
o Acidosis

<!-- PAGE=? -->
o Heart failure

<!-- PAGE=? -->
o Left ventricular hypertrophy

<!-- PAGE=? -->
o Slow heart rate

<!-- PAGE=? -->
o Female gender

<!-- PAGE=? -->
Total body water

<!-- PAGE=? -->
 2/3 intracellular 1/3 extracellular

<!-- PAGE=? -->
o of extracellular 1/4 =plasma = 5%

<!-- PAGE=? -->
 As below TBW = 60% body weight  = 2/3 ICV + 1/3 ECV

<!-- PAGE=? -->
 Therefore ECV = 20% body weight = ¼ (or 1/5) plasma volume + 4/5 interstitial

<!-- PAGE=? -->
 Therefore plasma volume is 20% of 20% =  4-5% body weight.

<!-- PAGE=? -->
Tourniquet

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Neurologic problems may occur when tourniquets are

<!-- PAGE=? -->
o inflated for long periods (>2 hours)

<!-- PAGE=? -->
o excessive inflation pressures are used

<!-- PAGE=? -->
 A shear force is applied to nerve trunks at the edges of the tourniquet

<!-- PAGE=? -->
 Nerve condiction ceases within 30 minutes of inflation

<!-- PAGE=? -->
o may reflect axonal hypoxia or the direct result of extrinsic pressure on the nerves

<!-- PAGE=? -->
 tourniquets should be deflated every 90 to 120 minutes to minimize the risk of postoperative neurapraxias

<!-- PAGE=? -->
 tourniquet pressure can be kept at 250 mm Hg while maintaining systolic pressures at 90-100 mm Hg

<!-- PAGE=? -->
o provides a pressure gradient of 150 mm Hg between the tourniquet and systolic pressure

<!-- PAGE=? -->
TOF

<!-- PAGE=? -->
 consists of

<!-- PAGE=? -->
o obstruction to right ventricular outflow (pulmonary stenosis)-dynamic and fixed,

<!-- PAGE=? -->
o ventricular septal defect (VSD), -usually nonrestrictive

<!-- PAGE=? -->
o dextroposition of the aorta with septal override, and

<!-- PAGE=? -->
o right ventricular hypertrophy

<!-- PAGE=? -->
 Obstruction to pulmonary arterial blood flow is usually at both the right ventricular infundibulum (subpulmonic area) and the pulmonary valve

<!-- PAGE=? -->
o Small main PA

<!-- PAGE=? -->
o various degrees of branch pulmonary artery stenosis may be present

<!-- PAGE=? -->
 Hypoxic Tet Spells

<!-- PAGE=? -->
o characterized by a paroxysm of

<!-- PAGE=? -->
o hyperpnea (i.e., rapid and deep respiration)

<!-- PAGE=? -->
o irritability and prolonged crying

<!-- PAGE=? -->
o increasing cyanosis

<!-- PAGE=? -->
o decreasing intensity of the heart murmur

<!-- PAGE=? -->
o peak incidence between 2 and 4 months of age

<!-- PAGE=? -->
 usually occur in the morning after crying, feeding, or defecation

<!-- PAGE=? -->
o may lead to

<!-- PAGE=? -->
 limpness

<!-- PAGE=? -->
 convulsion

<!-- PAGE=? -->
 cerebrovascular accident

<!-- PAGE=? -->
 death

<!-- PAGE=? -->
o There appears to be no relationship between the degree of cyanosis at rest and the likelihood of having hypoxic spells

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o knee-chest position.

<!-- PAGE=? -->
o Morphine sulfate, 0.2 mg/kg administered subcutaneously or intramuscularly, suppresses the respiratory center and abolishes hyperpnea

<!-- PAGE=? -->
o Oxygen is usually administered

<!-- PAGE=? -->
 little demonstrable effect on arterial oxygen saturation.

<!-- PAGE=? -->
o Acidosis should be treated with sodium bicarbonate (NaHCO3 ), 1 mEq/kg administered intravenously. The same dose can be repeated in 10 to 15 minutes. NaHCO3 reduces the respiratory center-stimulating effect of acidosis.

<!-- PAGE=? -->
o Vasoconstrictors such as phenylephrine (Neo-Synephrine), 0.02 mg/kg administered intravenously, may be effective.

<!-- PAGE=? -->
o Ketamine, 1 to 3 mg/kg (average of 2 mg/kg) administered intravenously over 60 seconds

<!-- PAGE=? -->
 increases the systemic vascular resistance and sedates the infant

<!-- PAGE=? -->
o Propranolol, 0.01 to 0.25 mg/kg (average 0.05 mg/kg) administered by slow intravenous push, reduces the heart rate and may reverse the spell

<!-- PAGE=? -->
rx of tet spell

<!-- PAGE=? -->
avoid

<!-- PAGE=? -->
Pediatric Anesthesia Handbook p148-49

<!-- PAGE=? -->
TPN

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Sites for emergency intravenous access in order of desirability

<!-- PAGE=? -->
 The subclavian vein is the most common site for early and ongoing central access

<!-- PAGE=? -->
o easily visible

<!-- PAGE=? -->
o seldomly traumatized

<!-- PAGE=? -->
 Femoral vein catheterization carries a high risk of deep venous thrombosis formation

<!-- PAGE=? -->
 Serious chest injury with

<!-- PAGE=? -->
o 1st and 2nd ribs or three contiguous

<!-- PAGE=? -->
o flail chest

<!-- PAGE=? -->
o hemothorax

<!-- PAGE=? -->
 Needle decompression

<!-- PAGE=? -->
o second interspace

<!-- PAGE=? -->
o midclavicular line

<!-- PAGE=? -->
 Chest tube placement

<!-- PAGE=? -->
o 5th interspace

<!-- PAGE=? -->
o just anterior to mid-axillary line

<!-- PAGE=? -->
Classes of Hemorrhagic Shock

<!-- PAGE=? -->
 Resuscitation Goals

<!-- PAGE=? -->
o blood pressure (? 100 SBP)

<!-- PAGE=? -->
o heart rate < 100 bpm for adults

<!-- PAGE=? -->
o urine output 0.5 ml/kg/hr for adults and 1ml/kg/hr for children

<!-- PAGE=? -->
o normalization of level of consciousness

<!-- PAGE=? -->
o normalization of base deficit and/or lactate

<!-- PAGE=? -->
o base deficit

<!-- PAGE=? -->
o blood lactate

<!-- PAGE=? -->
o hct > 25-30%

<!-- PAGE=? -->
Thoracic Trauma

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 The type and severity of trauma to the chest wall (ribs, sternum, and scapula) can predict the likelihood and severity of internal injuries

<!-- PAGE=? -->
o the frequency and severity of visceral injuries increases as the number of fractured ribs increases

<!-- PAGE=? -->
 three or more fractured ribs have

<!-- PAGE=? -->
 a greater likelihood of hepatic and splenic injury

<!-- PAGE=? -->
 a higher mortality rate

<!-- PAGE=? -->
 a higher injury severity score

<!-- PAGE=? -->
 longer ICU and hospital stays

<!-- PAGE=? -->
 lower rib fractures may have underlying spleen or liver injury

<!-- PAGE=? -->
 fracture of the first rib indicates severe underlying trauma

<!-- PAGE=? -->
 aorta

<!-- PAGE=? -->
 subclavian vessels

<!-- PAGE=? -->
 heart

<!-- PAGE=? -->
 abdominal viscera

<!-- PAGE=? -->
 maxillofacial complex

<!-- PAGE=? -->
 brain

<!-- PAGE=? -->
 spinal cord

<!-- PAGE=? -->
o scapular fractures suggest severe injuries in other locations, especially the heart and lungs

<!-- PAGE=? -->
o Sternal fractures are mainly encountered in elderly female motor vehicle occupants wearing seat belts

<!-- PAGE=? -->
 usually not associated with serious trauma to the thoracic or abdominal viscera

<!-- PAGE=? -->
Transdermal Drugs

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
 Only lipid-soluble drugs can penetrate intact skin sufficiently to produce systemic effects

<!-- PAGE=? -->
 Drug -patches‖ produce a stable pharmacologic effect

<!-- PAGE=? -->
 Available drugs include

<!-- PAGE=? -->
o scopolamine (for motion sickness)

<!-- PAGE=? -->
o nitroglycerin

<!-- PAGE=? -->
o fentanyl

<!-- PAGE=? -->
 used for chronic pain

<!-- PAGE=? -->
 Transcutaneous absorption is passive

<!-- PAGE=? -->
o iontophoresis is a process of using an electic current to drive ionized drugs into the skin

<!-- PAGE=? -->
 repulsive electropropulsive force

<!-- PAGE=? -->
 Characteristics favouring transdermal application include

<!-- PAGE=? -->
o combined water & lipid solubility

<!-- PAGE=? -->
o molecular weight < 1000

<!-- PAGE=? -->
o pH 5-9

<!-- PAGE=? -->
o absence of histamine-release

<!-- PAGE=? -->
o QD dosing < 10 mg

<!-- PAGE=? -->
 absorption occurs along sweat ducts and hair follicles which serve as diffusion shunts

<!-- PAGE=? -->
 The rate-limiting step is diffusion across the stratum corneum

<!-- PAGE=? -->
Transsphenoidal Resection

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Complications of transsphenoidal surgery relate to the anatomic landmarks surrounding the sella tursica

<!-- PAGE=? -->
o Cavernous sinuses contain

<!-- PAGE=? -->
 venous structures

<!-- PAGE=? -->
 the internal carotid artery

<!-- PAGE=? -->
o cranial nerves III, IV, V, and VI

<!-- PAGE=? -->
o The optic chiasm, with its associated optic nerves and tracts, lies directly above the sella in front of the pituitary stalk.

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
o Hemorrhage (from venous sinuses or ICA)

<!-- PAGE=? -->
o Vasospasm or thrombotic occlusion of the ICA

<!-- PAGE=? -->
o Venous air embolism

<!-- PAGE=? -->
o Trauma to CN III, IV, V and VI

<!-- PAGE=? -->
o Visual complications (trauma to optic nerve or chiasm)

<!-- PAGE=? -->
o Diabetes insipidus (polyuria, hypernatremia, high serum and low urine osmolality)

<!-- PAGE=? -->
o CSF rhinorrhea

<!-- PAGE=? -->
o Hypothalamic injury or stroke

<!-- PAGE=? -->
o Cerebral ischemia

<!-- PAGE=? -->
o Meningitis

<!-- PAGE=? -->
o Airway obstruction (bleeding and secretions in the pharynx)

<!-- PAGE=? -->
Traumatic Brain Injury

<!-- PAGE=? -->
Barash

<!-- PAGE=? -->
 Factors that aggravate the initial injury include

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
o Hypercarbia

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
o Anemia

<!-- PAGE=? -->
o Hyperglycemia

<!-- PAGE=? -->
 Seizures, infection, and sepsis that may occur hours to days after injury will further aggravate brain damage and must also be prevented or treated promptly

<!-- PAGE=? -->
Table 28-20. SEVERE HEAD INJURY: TREATMENT OF INTRACRANIAL HYPERTENSION

<!-- PAGE=? -->
Insert ICP monitor

<!-- PAGE=? -->
Maintain CPP 50-70 mm Hg

<!-- PAGE=? -->
Intracranial hypertension

<!-- PAGE=? -->
First-tier therapy:

<!-- PAGE=? -->
Ventricular drainage (if available)

<!-- PAGE=? -->
Mannitol 0.25-1 g/kg iv (may repeat if serum osmolarity<320 mOsm/l and patient euvolemic)

<!-- PAGE=? -->
 Onset 10 - 15 min

<!-- PAGE=? -->
Hyperventilation to PaCO2 30-35 mm Hg

<!-- PAGE=? -->
 Good for 4 - 8 hrs

<!-- PAGE=? -->
Second-tier therapy:

<!-- PAGE=? -->
Hyperventilation to PaCO2 < 30 mm Hg (SjO2, AVDO2, and/or CBF monitoring recommended)

<!-- PAGE=? -->
 PaCO2 <25 associated with worse outcomes at 3 -6 months

<!-- PAGE=? -->
High-dose barbiturate therapy

<!-- PAGE=? -->
Consider hypothermia

<!-- PAGE=? -->
Consider hypertensive therapy

<!-- PAGE=? -->
Consider decompressive craniectomy

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 Avoid hypoxemia (paO2<60mm)

<!-- PAGE=? -->
o A single episode of hypoxemia (Pao2 <60 mm Hg) is associated with nearly a doubling of mortality

<!-- PAGE=? -->
 PEEP ok If improves oxygenation and patient adequately fluid resuscitated

<!-- PAGE=? -->
 PaCO2 to 35mmhg to 30 only if inc ICP not attained with sedatives, CSF drainage, NMB, osmotic agents or barbiturate coma

<!-- PAGE=? -->
 Maintain CPP at 50-70 until ICP monitoring

<!-- PAGE=? -->
 Euvolemia and correction of anemia

<!-- PAGE=? -->
 Monitor ICP if :

<!-- PAGE=? -->
o Severe HI and abn CT or

<!-- PAGE=? -->
o normal CT but age <40, motor posturing, or SBP <90

<!-- PAGE=? -->
 Elevate HOB

<!-- PAGE=? -->
 Tx pain with short acting agents

<!-- PAGE=? -->
 NMB only if required

<!-- PAGE=? -->
 Mannitol  decr ICP though osmotic diuresis and cerebral arteriolar vasoconstriction

<!-- PAGE=? -->
 ?hypertonic saline

<!-- PAGE=? -->
 decompressive craniectomy

<!-- PAGE=? -->
 avoid hyperthermia, no benefit in hypothermia unless age <40 and hypothermic on admission ?

<!-- PAGE=? -->
 avoid hyperglycemia

<!-- PAGE=? -->
 undertake life or limb threatening OR at anytime, but delay urgent procedures such as fixation of long bone # until ICP successfully managed

<!-- PAGE=? -->
Critical Pathway for Treatment of Cerebral Perfusion Pressure in Patients with

<!-- PAGE=? -->
Scvere Traumatic Brain Injury

<!-- PAGE=? -->
Initial interventions

<!-- PAGE=? -->
35 mrn Ho

<!-- PAGE=? -->
Pao

<!-- PAGE=? -->
70 mrn Hg or Spo

<!-- PAGE=? -->
949"

<!-- PAGE=? -->
monitorirg

<!-- PAGE=? -->
by

<!-- PAGE=? -->
ICP monitor: Pbro?monor

<!-- PAGE=? -->
'change

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Caretu y remove

<!-- PAGE=? -->
treatment tor ICP

<!-- PAGE=? -->
Ioiracranial

<!-- PAGE=? -->
No

<!-- PAGE=? -->
hyperenslon?

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Consider repeating & crain CT scen

<!-- PAGE=? -->
No

<!-- PAGE=? -->
hcerension?

<!-- PAGE=? -->
220 mm Hu c

<!-- PAGE=? -->
Decompressive

<!-- PAGE=? -->
High-dose

<!-- PAGE=? -->
Hyperventlation 10

<!-- PAGE=? -->
Decompressive

<!-- PAGE=? -->
cranlectomy

<!-- PAGE=? -->
barbilurale

<!-- PAGE=? -->
Paco

<!-- PAGE=? -->
30 mm Hg

<!-- PAGE=? -->
laparotomny

<!-- PAGE=? -->
therapy

<!-- PAGE=? -->
AvjDO , Poro

<!-- PAGE=? -->
andior

<!-- PAGE=? -->
CBF recommendeu

<!-- PAGE=? -->
Tuberculosis

<!-- PAGE=? -->
CoExD

<!-- PAGE=? -->
 Mycobacterium tuberculosis survives most successfully in tissues with high oxygen concentrations

<!-- PAGE=? -->
o increased presentation of TB in the apices of the lungs

<!-- PAGE=? -->
 risk factors for TB infections

<!-- PAGE=? -->
o racial and ethnic minorities

<!-- PAGE=? -->
o foreign-born individuals from areas where TB is endemic (Asia and Africa)

<!-- PAGE=? -->
o intravenous drug abusers

<!-- PAGE=? -->
o HIV infection

<!-- PAGE=? -->
 Almost all M. tuberculosis infections result from aerosol (droplet) inhalation

<!-- PAGE=? -->
o nuclei remain viable for several days

<!-- PAGE=? -->
 It is estimated that 90% of patients infected with M. tuberculosis never become symptomatic and are identified only by conversion of the tuberculin skin test

<!-- PAGE=? -->
o HIV seropositive or immunocompromised are at much higher risk of becoming symptomatic

<!-- PAGE=? -->
 Diagnosis

<!-- PAGE=? -->
o presence of clinical symptoms

<!-- PAGE=? -->
 persistent nonproductive cough

<!-- PAGE=? -->
 anorexia

<!-- PAGE=? -->
 weight loss

<!-- PAGE=? -->
 chest pain

<!-- PAGE=? -->
 hemoptysis

<!-- PAGE=? -->
 night sweats

<!-- PAGE=? -->
o epidemiologic likelihood of infection

<!-- PAGE=? -->
o results of diagnostic tests

<!-- PAGE=? -->
 tuberculin skin (Mantoux) tes

<!-- PAGE=? -->
 skin reaction is read in 48 to 72 hours

<!-- PAGE=? -->
 a positive reading is generally defined as an induration of more than 10 mm

<!-- PAGE=? -->
 For immunocomprimized patients, a reaction of 5 mm or more is considered positive

<!-- PAGE=? -->
 The skin test is nonspecific

<!-- PAGE=? -->
 may be positive if people have received a bacille Calmette-Guérin vaccine

<!-- PAGE=? -->
 have been exposed to TB, or perhaps even other mycobacteria

<!-- PAGE=? -->
 CXR

<!-- PAGE=? -->
 Apical or subapical infiltrates

<!-- PAGE=? -->
 Bilateral upper lobe infiltration with the presence of cavitation

<!-- PAGE=? -->
 Sputum smears and cultures

<!-- PAGE=? -->
 acid-fast bacilli

<!-- PAGE=? -->
 the absence of acid-fast bacilli does not rule out TB, a positive sputum culture containing M. tuberculosis provides a definitive diagnosis

<!-- PAGE=? -->
 Health care workers are at increased risk of occupational acquisition of TB

<!-- PAGE=? -->
o TB is twice as prevalent in physicians as in the general population

<!-- PAGE=? -->
o Anesthesiologists are at increased risk of nosocomial TB by virtue of events surrounding the induction and maintenance of anesthesia that may induce coughing

<!-- PAGE=? -->
o Bronchoscopy is a high-risk procedure

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Anti-TB chemotherapy has decreased mortality by more than 90%

<!-- PAGE=? -->
o vaccination with bacille Calmette-Guérin is not recommended, as it may not confer immunity and confounds the diagnosis of TB

<!-- PAGE=? -->
o toxicity of isoniazid

<!-- PAGE=? -->
 peripheral nervous system

<!-- PAGE=? -->
 toxicity prevented by administration of pyridoxime

<!-- PAGE=? -->
 liver

<!-- PAGE=? -->
 likely related to metabolism by acetylation

<!-- PAGE=? -->
TURP

<!-- PAGE=? -->
 Most common intraoperative problems

<!-- PAGE=? -->
o bleeding requiring transfusion - 2.5% of patients

<!-- PAGE=? -->
o TURP syndrome in 2%

<!-- PAGE=? -->
o cardiac dysrhythmias in 1%

<!-- PAGE=? -->
o extravasation of irrigating fluid in 1%

<!-- PAGE=? -->
 increased risk for perioperative morbidity after TURP

<!-- PAGE=? -->
o large prostate glands (45 g)

<!-- PAGE=? -->
o resection times > than 90 minutes

<!-- PAGE=? -->
o acute urinary retention

<!-- PAGE=? -->
o Advanced age > 80

<!-- PAGE=? -->
 principles govern the absorption of irrigating solution

<!-- PAGE=? -->
o height of the container of irrigating solution above the surgical table

<!-- PAGE=? -->
 hydrostatic pressure driving fluid into prostatic veins and sinuses

<!-- PAGE=? -->
o resection time is proportional to the quantity of fluid that is absorbed

<!-- PAGE=? -->
 ~ 10 to 30 mL of fluid is absorbed per minute of resection time, can be as much as  6 to 8 L in a 2 hr case

<!-- PAGE=? -->
 hepatitis appears more common in rapid acetylators

<!-- PAGE=? -->
 kidneys

<!-- PAGE=? -->
o Rifampicin

<!-- PAGE=? -->
 Thrombocytopenia

<!-- PAGE=? -->
 Leucopenia

<!-- PAGE=? -->
 Anemia

<!-- PAGE=? -->
 renal failure

<!-- PAGE=? -->
 Hepatitis

<!-- PAGE=? -->
o treatment for pulmonary TB is recommended for 6 months

<!-- PAGE=? -->
 Extrapulmonary TB usually requires a longer course

<!-- PAGE=? -->
 Noncompliance with therapy contributes to the emergence of resistant TB strains

<!-- PAGE=? -->
 Management of Anesthesia

<!-- PAGE=? -->
o Elective surgical procedures should be postponed until patients are no longer considered infectious

<!-- PAGE=? -->
 received antituberculous chemotherapy

<!-- PAGE=? -->
 improving clinically

<!-- PAGE=? -->
 and have had three consecutive negative sputum smears

<!-- PAGE=? -->
o If surgery cannot be delayed

<!-- PAGE=? -->
 limit the number of involved personnel

<!-- PAGE=? -->
 high risk procedures (bronchoscopy, tracheal intubation, and suctioning) should be performed in a negative-pressure environment whenever possible

<!-- PAGE=? -->
 Patients should be transported to the operating room wearing a tight-fitting N-95 face mask to prevent casual exposure of others to airborne bacilli

<!-- PAGE=? -->
 Staff should also wear N-95 masks.

<!-- PAGE=? -->
 A high efficiency particulate air filter should be placed in the anesthesia delivery circuit between the Y connector and the patient

<!-- PAGE=? -->
 Bacterial filters should be placed on the exhalation limb of the anesthesia delivery circuit to decrease the discharge of tubercle bacilli into the ambient air

<!-- PAGE=? -->
 Sterilization of anesthesia equipment is with standard methods using a disinfectant that destroys tubercle bacilli

<!-- PAGE=? -->
 Use of a dedicated anesthesia machine and ventilator is recommended

<!-- PAGE=? -->
 SV may be indicated in selected patients

<!-- PAGE=? -->
 Risk of massive hemoptysis with PPV in patients with old pulmonary TB

<!-- PAGE=? -->
 Postoperative care should, if possible, take place in an isolation room, preferably with negative pressure

<!-- PAGE=? -->
 Onset of TURP syndrome may be in 15 mins or delayed 24hrs

<!-- PAGE=? -->
o Hypertension, bradycardia, and mental status changes

<!-- PAGE=? -->
 Manifestations: fluid overload, water intoxication, and solute toxicity

<!-- PAGE=? -->
o Hypervolemia (HTN, bradycardia, CHF, MI, shock)

<!-- PAGE=? -->
o Hypoosmolalit y (pulmonary & cerebral edema  ↑ICP)

<!-- PAGE=? -->
 Hypo-osmolality rather than hyponatremia is the crucial physiologic derangement leading to central nervous system dysfunction during TURP (only H2O crosses BBB)

<!-- PAGE=? -->
o Hyponatremia

<!-- PAGE=? -->
 120 mEq/L: confusion, restlessness

<!-- PAGE=? -->
 115 mEq/L: somnolence, nausea, wide QRS, elevated ST segment

<!-- PAGE=? -->
 110 mEq/L: seizures, coma, Vtach/Vfib

<!-- PAGE=? -->
o Hemolysis (can lead to hyperkalemia and ARF)

<!-- PAGE=? -->
o Toxicity

<!-- PAGE=? -->
 hyper GLYCIN emia (visual changes, CNS changes, seizures, cardiac toxicity)

<!-- PAGE=? -->
 hyperAMMONemia (mental status changes, decreased LOC)

<!-- PAGE=? -->
 hyperGLYCemia (when sorbitol or glucose used)

<!-- PAGE=? -->
 hyperMANNITOLemia (pulmonary edema in cardiac pts d/t volume expansion)

<!-- PAGE=? -->
 Use of near isosmotic solutions (as opposed to distilled water) has eliminated hemolysis and its sequelae as a complication of TURP

<!-- PAGE=? -->
o Reduced incidence of severe CNS problems such as convulsions and coma, associated with extreme hyponatremia

<!-- PAGE=? -->
 the visceral pain sensation from the prostate and bladder neck is transmitted by afferent parasympathetic nerve fibers from S2-3 traveling with the pelvic splanchnic nerves

<!-- PAGE=? -->
 Bladder sensation is supplied by sympathetic nerves of the hypogastric plexus from T11 to L2

<!-- PAGE=? -->
o T10 sensory level is required to eliminate the discomfort caused by bladder distention and other aspects of this procedure

<!-- PAGE=? -->
 Sensory levels above T9 should not be sought because the capsular sign (i.e., pain on perforation of the prostatic capsule) will not be present should perforation occur

<!-- PAGE=? -->
Table 54-12

<!-- PAGE=? -->
TURP syndrome

<!-- PAGE=? -->
signs and symptoms

<!-- PAGE=? -->
Cardiovascular and Respiratory CMS

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
Agitation confusion

<!-- PAGE=? -->
Hyponatremia

<!-- PAGE=? -->
Hypo-osmolality

<!-- PAGE=? -->
Brady tachyarrhythmias

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Hyperglycinemia

<!-- PAGE=? -->
Hemolysis

<!-- PAGE=? -->
[Congestive heart failure

<!-- PAGE=? -->
Coma

<!-- PAGE=? -->
Hyperammonemia

<!-- PAGE=? -->
Pulmonary edema and hypoxemia

<!-- PAGE=? -->
Visual disturbances (blindness)

<!-- PAGE=? -->
Myocardial infarction

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
Glycine:

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 inhibitory neurotransmitter similar to GABA in the spinal cord, brain, retina.

<!-- PAGE=? -->
 most likely cause of visual disturbances, including transient blindness during TURP syndrome

<!-- PAGE=? -->
o likely affects retina physiology independent of cerebral edema

<!-- PAGE=? -->
 usually partial and accompanied by widely dilated pupils, absent light and accommodation reflexes but preserved blink reflex

<!-- PAGE=? -->
 In contrast, cortical blindness is total with loss of blink reflex but preservation of light and accommodation reflexes

<!-- PAGE=? -->
o Vision returns to normal within 24 hour s as serum glycine concentrations approach normal

<!-- PAGE=? -->
o reassurance is probably the best treatment

<!-- PAGE=? -->
 Glycine may lead to encephalopathy and seizures

<!-- PAGE=? -->
o NMDA effect potentiation, an excitatory neurotransmitter

<!-- PAGE=? -->
o Glycine is metabolized to ammonia

<!-- PAGE=? -->
 High levels have not been correlated to CNS symptoms

<!-- PAGE=? -->
 Glycine has been implicated in the myocardial depression and hemodynamic changes associated with TURP syndrome

<!-- PAGE=? -->
Bladder Perforation:

<!-- PAGE=? -->
 Signs and symptoms

<!-- PAGE=? -->
o Bradycardia

<!-- PAGE=? -->
o Hypotension

<!-- PAGE=? -->
o Restlessness

<!-- PAGE=? -->
o Diaphoresis

<!-- PAGE=? -->
o Nausea

<!-- PAGE=? -->
o abdominal pain

<!-- PAGE=? -->
o dyspnea

<!-- PAGE=? -->
o shoulder pain

<!-- PAGE=? -->
o hiccups

<!-- PAGE=? -->
 Extraperitoneal perforation

<!-- PAGE=? -->
o pain in the periumbilical, inguinal, or suprapubic area

<!-- PAGE=? -->
 Intraperitoneal bladder perforation

<!-- PAGE=? -->
o less frequent

<!-- PAGE=? -->
o symptoms related to diaphragmatic irritation

<!-- PAGE=? -->
 pain referred to the upper part of the abdomen, precordial area, shoulder region, or neck

<!-- PAGE=? -->
 The urologist may note the irregular return of irrigating fluid

<!-- PAGE=? -->
 It is of utmost importance to the spinal block level to T10 or below or else this very advantage is lost because the patients would no longer sense the abdominal or back discomfort

<!-- PAGE=? -->
TUR Syndrome (H2O intoxication)

<!-- PAGE=? -->
 general term used to describe a wide range of neurologic and cardiopulmonary symptoms that occur when irrigating fluid is absorbed during TUR procedures

<!-- PAGE=? -->
 The principal components of this syndrome include

<!-- PAGE=? -->
o respiratory distress

<!-- PAGE=? -->
 secondary to volume expansion from rapid intravascular absorption of the irrigating fluid

<!-- PAGE=? -->
o dilution of electrolytes and proteins

<!-- PAGE=? -->
 electrolyte-free irrigating fluid

<!-- PAGE=? -->
o symptoms related to the type of irrigating solution used

<!-- PAGE=? -->
 TURP syndrome seems to occur if hyponatremia is accompanied by hypoosmolality

<!-- PAGE=? -->
o CNS signs and symptoms usually do not manifest themselves if the osmolality remains normal

<!-- PAGE=? -->
o Glycine, urea, mannitol, and sucrose found in irrigating solutions tend to retain near normal osmolality

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o fluid restriction and a loop diuretic such as furosemide

<!-- PAGE=? -->
o Hypertonic saline is rarely if ever necessary and should be considered only in cases of severe hyponatremia

<!-- PAGE=? -->
Transient Bacteremia and Sepsis

<!-- PAGE=? -->
 The prostate harbors many bacteria, which can be a source of intraoperative and postoperative bacteremia via the prostatic venous sinuses

<!-- PAGE=? -->
 This risk is further increased by the presence of an indwelling urinary catheter

<!-- PAGE=? -->
Bleeding

<!-- PAGE=? -->
 Hypertrophied prostate is highly vascular, and operative bleeding is usually significant

<!-- PAGE=? -->
o ~ 2-5 mL/min of resection time

<!-- PAGE=? -->
o ~ 20-50 mL/g  of prostate

<!-- PAGE=? -->
SAB

<!-- PAGE=? -->
 SAB is considered the anesthetic technique of choice for TURP

<!-- PAGE=? -->
 facilitates the early diagnosis of TUR syndrome or extravasation of irrigation fluid

<!-- PAGE=? -->
o T10 level is needed to block the pain from bladder distention by the irrigating fluid

<!-- PAGE=? -->
o Higher block results in loss of the ability to sense the abdominal or back discomfort of a perforated bladder

<!-- PAGE=? -->
 sympathetic block produces increased venous capacitance which may tend to mitigate intraoperative fluid overload

<!-- PAGE=? -->
o circulatory overload can occur when the block regresses

<!-- PAGE=? -->
 SAB vs. GA

<!-- PAGE=? -->
o No difference in ischemia, bleeding, morbidity, mortality, post op cognitive fxn

<!-- PAGE=? -->
 lumbar epidural anesthesia is not ideal because sacral segments are sometimes inadequately blocked

<!-- PAGE=? -->
U

<!-- PAGE=? -->
Ulnar neuropathy

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 acute ulnar deficit with predominant sensory involvement

<!-- PAGE=? -->
 mechanism appears to be acute infarction of the nerve at the elbow

<!-- PAGE=? -->
o EMG suggests axonal degeneration

<!-- PAGE=? -->
 many patients do not notice or complain of ulnar nerve symptoms until more than 48 hours after their surgical procedures

<!-- PAGE=? -->
 Surgery is contraindicated and may be harmful

<!-- PAGE=? -->
 Most patients recover spontaneously

<!-- PAGE=? -->
 Has been reported following the use of automated cycled blood pressure cuffs

<!-- PAGE=? -->
o Compression of the ulnar nerve can be avoided by applying the encircling cuff proximal to the ulnar groove

<!-- PAGE=? -->
 ulnar nerve dysfunction occurs during transient occlusion of the brachial artery

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
o male sex is the most common factor for ulnar neuropathy (5:1)

<!-- PAGE=? -->
o body weight

<!-- PAGE=? -->
 very heavy >>  very thin

<!-- PAGE=? -->
o prolonged hospitalization

<!-- PAGE=? -->
o procedure

<!-- PAGE=? -->
 gallbladder

<!-- PAGE=? -->
 cardiac surgery as high as 60%

<!-- PAGE=? -->
 coma

<!-- PAGE=? -->
 severe burns

<!-- PAGE=? -->
Urinary Composition in Oliguria

<!-- PAGE=? -->
TABLE 53-8. Urinary Composition in Oliguria

<!-- PAGE=? -->
V

<!-- PAGE=? -->
Valvular Heart disease

<!-- PAGE=? -->
Aortic Stenosis

<!-- PAGE=? -->
Mitral stenosis

<!-- PAGE=? -->
 Primary:   almost always secondary to rheumatic fever

<!-- PAGE=? -->
 Congentinal, myxoma, thrombus, valvulitis (SLE, amyloid, carcinoid) or muccopolysaccarride infil

<!-- PAGE=? -->
 Normal MV:  4-6 cm 2 , MV index 4-4.5 cm 2 /m 2

<!-- PAGE=? -->
 LV is relatively underloaded due to the mitral valve obstruction .  This can result in decreased stroke volume and decreased cardiac output

<!-- PAGE=? -->
o inc. LV afterload d/t reflex vasoconstriction

<!-- PAGE=? -->
 Increased LA pressure and volume overload occur (due to narrowed mitral valve orifice).

<!-- PAGE=? -->
 Factors determining valve gradient are given by the following rearrangement of the Gorlin and Gorlin equation:

<!-- PAGE=? -->
LAP - LVEDP = [(cardiac output)/(diastolic time)] 2

<!-- PAGE=? -->
 Therefore whenever cardiac output increases or HR increases (decreased diastolic time), the gradient across the valve increases → inc. LA pressure → CHF and hypotension

<!-- PAGE=? -->
 Conditions which commonly cause this are:

<!-- PAGE=? -->
o Pregnancy

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o Infection

<!-- PAGE=? -->
o Atrial fibrillation (increase rate and no atrial kick)

<!-- PAGE=? -->
 Persistent elevated LAP may result in:

<!-- PAGE=? -->
o Pulmonary edema

<!-- PAGE=? -->
o Pulmonary hypertension

<!-- PAGE=? -->
o RV failure

<!-- PAGE=? -->
 Chronic:

<!-- PAGE=? -->
o Stage 1:  mild mitral stenosis-asymptomatic with physiologic compensation

<!-- PAGE=? -->
 Mean gradient: 1-6

<!-- PAGE=? -->
o Stage 2:  moderate MS-symptomatic impairment

<!-- PAGE=? -->
 MV area: 1-1.5 cm2

<!-- PAGE=? -->
 Mean gradient: 6-12

<!-- PAGE=? -->
o Stage 3:  critical mitral stenosis

<!-- PAGE=? -->
 MV area: < 1 cm 2 , MV area 0.3-0.4 cm 2 is the smallest area compatible with life

<!-- PAGE=? -->
 Mean gradient: >12

<!-- PAGE=? -->
 Severe congestive failure

<!-- PAGE=? -->
 pHTN eventually leads to RV dilation

<!-- PAGE=? -->
 Dilated RV can cause a leftward shift of the intraventricular septum impairing LV ejection

<!-- PAGE=? -->
Aortic regurgitation

<!-- PAGE=? -->
Chronic AR:

<!-- PAGE=? -->
 LVEDV (preload) is compensated for by gradual dilatation of LV (and LVH).  Eventually the LV will fail, and a precipitous rise in LVEDP will follow

<!-- PAGE=? -->
 LVH (and increased myocardial oxygen demand) along with the characteristic low diastolic BP of aortic regurgitation can lead to angina in the absence of CAD

<!-- PAGE=? -->
 Mild AR does not increase myocardial oxygen demand because LVEDP remains relatively normal

<!-- PAGE=? -->
 Symptoms are minimal as long as regurgitant fraction remains less than 40% of stroke volume

<!-- PAGE=? -->
 Overtime, as amount of aortic regurgitation progresses to more than 60% of stroke volume, LV dilation and hypertrophy occur, eventually leading to irreversible LV myocardial tissue damage.

<!-- PAGE=? -->
 The onset of LV dysfunction is followed by an increase in pulmonary arterial pressure and symptoms of dyspnea and CHF.

<!-- PAGE=? -->
 Patients may be asymptomatic for 20 years.  10 year mortality of asymptomatic patients varies from 5 15%.

<!-- PAGE=? -->
 Once symptoms develop (onset of LV dysfunction), progressive deterioration ensues and the expected survival rate is 5 to 10 years

<!-- PAGE=? -->
 Treatment of chronic AR :

<!-- PAGE=? -->
o Afterload reduction (Nifedipine, ACE inhibitors, diuretics)

<!-- PAGE=? -->
o Inotropy (digoxin)

<!-- PAGE=? -->
o Surgical repair of AV prior to LV dysfunction (EF<55% or LV>55mm)

<!-- PAGE=? -->
Acute AR:

<!-- PAGE=? -->
 Previously normal size and normally compliant LV is presented with a large regurgitant volume

<!-- PAGE=? -->
 LVEDV and LVEDP rises concomitantly (no gradual compensation is allowed)

<!-- PAGE=? -->
LV FILLING

<!-- PAGE=? -->
TLA PRESSURE

<!-- PAGE=? -->
1 LA SIZE

<!-- PAGE=? -->
ATRIAL FIBRILLATION

<!-- PAGE=? -->
PULMONARY VENOUS PrESSUrE

<!-- PAGE=? -->
LUMINAL NARROWING

<!-- PAGE=? -->
CARDIAC

<!-- PAGE=? -->
STABLE WITH

<!-- PAGE=? -->
OUTPUT

<!-- PAGE=? -->
REVERSAL OF PULIONARY

<!-- PAGE=? -->
BLOOD FLOW

<!-- PAGE=? -->
SEVERE PULMONARY HYPERTENSION

<!-- PAGE=? -->
1 PULMONARY COMPLIANCE

<!-- PAGE=? -->
PULMONARY VASCULAR RESISTANCE

<!-- PAGE=? -->
WORK OF BREATHING

<!-- PAGE=? -->
RIGHT VENTRICULAR OVERLOAD

<!-- PAGE=? -->
TRICUSPID REGURGITATION

<!-- PAGE=? -->
 Severe CHF is the cardinal clinical sign

<!-- PAGE=? -->
 Myocardial contractility becomes impaired as LVEDP increases→ LV failure and cardiogenic shock

<!-- PAGE=? -->
 Compensatory mechanisms include tachycardia and peripheral vasoconstriction but hypotension and low cardiac output may occasionally ensue.

<!-- PAGE=? -->
 Although beta blockers are often used in treating aortic dissection, these agents should be used very cautiously, if at all, in the setting of acute AR because they will block the compensatory tachycardia.

<!-- PAGE=? -->
 In patients with acute severe AR resulting from infective endocarditis, surgery should not be delayed, especially if there is hypotension, pulmonary edema, or evidence of low output.

<!-- PAGE=? -->
 Treatment of acute AR:

<!-- PAGE=? -->
o Afterload reduction (SNP, milrinone)

<!-- PAGE=? -->
o Inotropy (milrinone, dobutamine)

<!-- PAGE=? -->
o IABP is contraindicated

<!-- PAGE=? -->
o Emergency repair of AV

<!-- PAGE=? -->
 Basically, if severe AR and symptomatic, the only treatment is surgery

<!-- PAGE=? -->
 If asymptomatic with severe AR and normal LV function, other than vasodilator therapy, there is little evidence for long-term medical therapy (digoxin, diuretics, nitrates, or inotropes)

<!-- PAGE=? -->
Mitral regurgitation

<!-- PAGE=? -->
Hensley, Miller, Barash

<!-- PAGE=? -->
 chronic MR - slow development

<!-- PAGE=? -->
o left atrial dilatation (inc compliance)

<!-- PAGE=? -->
 may lead to development of Afib

<!-- PAGE=? -->
o eccentric hypertrophy and dilation of the LV

<!-- PAGE=? -->
 dilation of the LV allows the preservation of a relatively normal LVEDP despite markedly increased LVEDV

<!-- PAGE=? -->
 The increases in oxygen cost is small because there is little pressure development.

<!-- PAGE=? -->
 when dilation and LVH can no longer compensate - forward stroke volume is compromised - CHF

<!-- PAGE=? -->
 CHF occurs with regurgitant fraction >60%

<!-- PAGE=? -->
 An EF of <50% indicates the presence of LV dysfunction.

<!-- PAGE=? -->
o Continued worsening of regurgitation results in

<!-- PAGE=? -->
 inc pulmonary artery pressure

<!-- PAGE=? -->
 pulmonary congestion

<!-- PAGE=? -->
 RV failure

<!-- PAGE=? -->
o Etiology

<!-- PAGE=? -->
 LVH with annular dilatation

<!-- PAGE=? -->
 Mitral valve prolapse (primary, myxomatous valve)

<!-- PAGE=? -->
 Rheumatic fever

<!-- PAGE=? -->
 Previous MI, ongoing ischemia

<!-- PAGE=? -->
o Associated with mitral stenosis

<!-- PAGE=? -->
o Atrial fibrillation occurs in roughly one third of patients with chronic MR, but of little hemodynamic consequence until LV compliance is decreased (late)

<!-- PAGE=? -->
o Mitral valve prolapse is a cause of chronic MR and is associated with:

<!-- PAGE=? -->
 Increased risk of systemic embolization

<!-- PAGE=? -->
 Increased risk of SVT and VT

<!-- PAGE=? -->
o Treatment of chronic MR consists of:

<!-- PAGE=? -->
 Afterload reduction (ACE inhibitors, diuretics)

<!-- PAGE=? -->
 Inotropy (digoxin)

<!-- PAGE=? -->
 If LV dysfunction, ACEI and/or Beta Blockers (carvedilol) have been shown to decrease severity of MR

<!-- PAGE=? -->
 acute MR

<!-- PAGE=? -->
o non-compliant LA causes acute elevations in left atrial and pulmonary vascular pressure

<!-- PAGE=? -->
o no compensate - rapid pressure overload ensues, leading to LV and RV failure, and cardiogenic shock

<!-- PAGE=? -->
 symptoms of pulmonary congestion and pulmonary edema

<!-- PAGE=? -->
 increased pulmonary vascular pressures result in secondary pulmonary vascular changes

<!-- PAGE=? -->
 RVH / RVF

<!-- PAGE=? -->
o Etiology

<!-- PAGE=? -->
 MI or ischemia

<!-- PAGE=? -->
 Endocarditis

<!-- PAGE=? -->
 Trauma

<!-- PAGE=? -->
o Treatment of acute MR consists of

<!-- PAGE=? -->
 Afterload reduction (SNP, milrinone)

<!-- PAGE=? -->
 Inotropy (milrinone, dobutamine)

<!-- PAGE=? -->
 IABP, and possible emergent repair / replacement of mitral valve

<!-- PAGE=? -->
Physical exam findings

<!-- PAGE=? -->
 ASD

<!-- PAGE=? -->
o palpable RV impulse, widely split and fixed S2, soft systolic flow murmur at 2nd IC space (flow across pulmonic valve)

<!-- PAGE=? -->
o CXR - heart enlarged secondary to RA/RV, prominent PA with increased pulmonary vascular markings.

<!-- PAGE=? -->
 HOCM

<!-- PAGE=? -->
o SEM at LLSB, louder with decreased preload, decreases with increased afterload

<!-- PAGE=? -->
o tall A-wave on venous pulsations reflects impaired diastolic relaxation, as does +S3 and/or +S4

<!-- PAGE=? -->
 MVP

<!-- PAGE=? -->
o mid systolic click, mid to late systolic murmur, earlier click and lengthened murmur with decreased preload

<!-- PAGE=? -->
 MR

<!-- PAGE=? -->
o apical holosystolic murmur radiating to axilla, increases with a hand-grip exercise (increased SVR)., widely split S2, +S3.  Characteristic large V waves.

<!-- PAGE=? -->
 PS

<!-- PAGE=? -->
o SEM at 2nd IC space in left parasternal line, soft or absent P2, single or widely split S2, +/- mid systolic click of PV opening

<!-- PAGE=? -->
 The second heart sound is widely split if there is an early A2 or if the P2 is delayed

<!-- PAGE=? -->
o Early A2

<!-- PAGE=? -->
 mitral regurgitation

<!-- PAGE=? -->
 ventricular septal defect

<!-- PAGE=? -->
 shortening of left ventricular systole because of diminished resistance to left ventricular ejection.

<!-- PAGE=? -->
o Delayed P2

<!-- PAGE=? -->
 right bundle branch block

<!-- PAGE=? -->
 delay in the activation of the right ventricle

<!-- PAGE=? -->
 ASD with left to right shunt

<!-- PAGE=? -->
 increase in right ventricular stroke volume which causes a delayed P2, fixed throughout respiratory cycle

<!-- PAGE=? -->
 RVF

<!-- PAGE=? -->
 prolonged right ventricular contraction, fixed throughout respiratory cycle

<!-- PAGE=? -->
 If A.Fib develops, anticoagulation and heart rate control (calcium channel blockers, digoxin, beta blockers, or  rarely, amiodarone)

<!-- PAGE=? -->
 Surgery (prior to symptoms: i.e. prior to LV dysfunction)

<!-- PAGE=? -->
 left bundle branch block (paradoxical or reverse split)

<!-- PAGE=? -->
o split S2 that disappears with inspiration and reappears with expiration

<!-- PAGE=? -->
VAP

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 prevention of ventilator-associated pneumonia

<!-- PAGE=? -->
o elevated HOB

<!-- PAGE=? -->
 most cost effective

<!-- PAGE=? -->
o Sucralfate

<!-- PAGE=? -->
o Aspiration of subglottic secretions

<!-- PAGE=? -->
 Excessive use of gastric pH-altering medications for stress ulcer prophylaxis increase gastric pH and increase the risk of VAP

<!-- PAGE=? -->
Vasopressin

<!-- PAGE=? -->
P&P, Miller, Hensley

<!-- PAGE=? -->
 V1 receptors mediate vasoconstriction in smooth muscles

<!-- PAGE=? -->
o potent nonadrenergic arteriolar vasoconstrictor

<!-- PAGE=? -->
 V2 receptors exert antidiuretic effects

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
o bleeding esophageal varices

<!-- PAGE=? -->
o adult shock refractory VF

<!-- PAGE=? -->
o hemodynamic support in vasodilatory (septic) shock

<!-- PAGE=? -->
o treatment of ADH-sensitive diabetes insipidus

<!-- PAGE=? -->
 has a longer half-life than epinephrine

<!-- PAGE=? -->
o 10-20min

<!-- PAGE=? -->
 Vasoconstriction and increased blood pressure occur only with doses of vasopressin that are much larger than those administered for the treatment of diabetes insipidus

<!-- PAGE=? -->
 Effect is not impaired by acidosis

<!-- PAGE=? -->
o may maintain coronary perfusion pressure

<!-- PAGE=? -->
 Vasopressin, even in small doses, may produce selective vasoconstriction of the coronary arteries, with reductions in coronary blood flow manifesting as angina pectoris

<!-- PAGE=? -->
o These effects may cause dysrhythmias

<!-- PAGE=? -->
 Does not increase myocardiac oxygen consumption (MVO2)

<!-- PAGE=? -->
 Pulmonary artery pressures are also increased by vasopressin

<!-- PAGE=? -->
 produces relatively more vasoconstriction of skin, skeletal muscle, intestine, and adipose tissue than of coronary or renal beds

<!-- PAGE=? -->
 Vasopressin causes cerebrovascular dilation

<!-- PAGE=? -->
 One time dose 40U IV for VF/pulseless VT

<!-- PAGE=? -->
 Large doses of vasopressin stimulate gastrointestinal smooth muscle

<!-- PAGE=? -->
o increased peristalsis may manifest as abdominal pain, nausea, and vomiting

<!-- PAGE=? -->
 Vasopressin may be associated with a decrease in platelet concentration

<!-- PAGE=? -->
 Smooth muscle of the uterus is stimulated by large doses of vasopressin.

<!-- PAGE=? -->
 The circulating plasma concentrations of factor VIII are increased by vasopressin.

<!-- PAGE=? -->
o may be beneficial in the management of moderately severe hemophilia, particularly to reduce bleeding associated with surgery

<!-- PAGE=? -->
o The mechanisms of this effect are not known

<!-- PAGE=? -->
 Allergic reactions ranging from urticaria to anaphylaxis may occasionally follow the administration of vasopressin.

<!-- PAGE=? -->
 Prolonged use of vasopressin may result in antibody formation and a shortened duration of action of the drug

<!-- PAGE=? -->
Venous air embolism

<!-- PAGE=? -->
Barash, Miller

<!-- PAGE=? -->
 MONITORS FOR DETECTION OF VENOUS AIR EMBOLISM

<!-- PAGE=? -->
o Most Sensitive to Least Sensitive

<!-- PAGE=? -->
Transesophageal echocardiography

<!-- PAGE=? -->
Precordial Doppler

<!-- PAGE=? -->
Increase in pulmonary artery pressure

<!-- PAGE=? -->
Decrease in end-tidal CO2

<!-- PAGE=? -->
Increase in end-tidal N2 (specific)

<!-- PAGE=? -->
 Whenever air embolism is suspected

<!-- PAGE=? -->
o Immediately notify the surgeon ediately

<!-- PAGE=? -->
o Flood the surgical field with saline

<!-- PAGE=? -->
o bone wax

<!-- PAGE=? -->
o Nitrous oxide is discontinued

<!-- PAGE=? -->
o 100% FiO2

<!-- PAGE=? -->
o Compress neck veins

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Modest

<!-- PAGE=? -->
Clinically

<!-- PAGE=? -->
Cardio-

<!-- PAGE=? -->
physiol

<!-- PAGE=? -->
physiol

<!-- PAGE=? -->
apparent

<!-- PAGE=? -->
vascular

<!-- PAGE=? -->
changes

<!-- PAGE=? -->
changes

<!-- PAGE=? -->
changes

<!-- PAGE=? -->
collapse

<!-- PAGE=? -->
1

<!-- PAGE=? -->
BP

<!-- PAGE=? -->
PAP

<!-- PAGE=? -->
ECG

<!-- PAGE=? -->
T-echo

<!-- PAGE=? -->
Doppler

<!-- PAGE=? -->
ET-CO2

<!-- PAGE=? -->
CVP

<!-- PAGE=? -->
STETHO

<!-- PAGE=? -->
Decreasing sensitivity

<!-- PAGE=? -->
Elsevier Science 2005

<!-- PAGE=? -->
o Attempt aspiration of air from the right atrial catheter

<!-- PAGE=? -->
o lower the head to heart level when possible

<!-- PAGE=? -->
o vasopressors and volume infusion are administered to treat hypotension

<!-- PAGE=? -->
o avoid PEEP or Valsalva maneuver

<!-- PAGE=? -->
 increase in right atrial pressure may inc. the likelihood of paradoxical embolus

<!-- PAGE=? -->
o Although theoretically repositioning the patient into LLD to prevent RVOT obstruction has been evaluated in animals, it is not practical and should only be considered as a last resort

<!-- PAGE=? -->
o Consider post operative hyperbaric oxygen therapy, especially if paradoxical air embolism.

<!-- PAGE=? -->
 Measures to decrease risk of VAE

<!-- PAGE=? -->
o bone wax

<!-- PAGE=? -->
o avoid N20

<!-- PAGE=? -->
o avoid SV (negative intrathoracic pressure is bad).

<!-- PAGE=? -->
o PPV but avoid PEEP (increases risk of PAE)

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
Volume-targeted ventilation (VTV) vs. pressure-targeted ventilation (PTV)

<!-- PAGE=? -->
Pressure support ventilation

<!-- PAGE=? -->
Miller

<!-- PAGE=? -->
 "spontaneous" mode of breathing

<!-- PAGE=? -->
 The pressure support is maintained until the inspiratory flow decreases to a minimum level or to a percentage of the initial inspiratory flow

<!-- PAGE=? -->
 PSV is a pressure-targeted mode and is very similar to pressure control

<!-- PAGE=? -->
o The difference between these modes is the phase variable that terminates a breath

<!-- PAGE=? -->
 pressure-control mode - breath is terminated after a set time

<!-- PAGE=? -->
 pressure-support mode - breath is terminated by flow

<!-- PAGE=? -->
 patient controls

<!-- PAGE=? -->
o ventilatory timing

<!-- PAGE=? -->
o respiratory rate

<!-- PAGE=? -->
o inspiratory time

<!-- PAGE=? -->
o inspiratory flow rate

<!-- PAGE=? -->
 tidal volume is a function of the respiratory system compliance and resistance

<!-- PAGE=? -->
 airway pressure is held constant throughout the inspiratory period

<!-- PAGE=? -->
o pressure targeted mode

<!-- PAGE=? -->
 causes decreased airway resistance and thereby decreases the work of breathing and delays muscle fatigue

<!-- PAGE=? -->
 becoming widely used mode during the weaning of patients

<!-- PAGE=? -->
 BiPAP is nearly identical to PSV

<!-- PAGE=? -->
Inverse Ratio Ventilation (Pressure Control)

<!-- PAGE=? -->
Barash, Miller, Lange

<!-- PAGE=? -->
 time-triggered, pressure-limited, time-cycled mode of ventilation characterized by a decelerating inspiratory flow pattern, square wave air pressure pattern

<!-- PAGE=? -->
o I:E >1:1 (1.5:1)

<!-- PAGE=? -->
o Achieved by inspiratory pause or decreased inspiratory flow during volume-cycled ventilation

<!-- PAGE=? -->
 recruitment of collapsed alveoli by prolonged inspiratory times, which allow alveolar units with slow time constants to fill.

<!-- PAGE=? -->
 Enhances alveolar recruitment primarily by creating auto-PEEP

<!-- PAGE=? -->
o improves both oxygenation and ventilation

<!-- PAGE=? -->
 Oxygenation is generally proportionate to mean airway pressure

<!-- PAGE=? -->
 Potential hazards include the development of auto-PEEP and consequent high airway pressures - each new breath may begin prior to complete exhalation

<!-- PAGE=? -->
 Does not allow spontaneous breathing (requires heavy sedation or paralysis)

<!-- PAGE=? -->
 improves oxygenation and ventilation in ARDS + severe infant respiratory distress syndrome

<!-- PAGE=? -->
Weaning & Extubation

<!-- PAGE=? -->
Lange, Barash

<!-- PAGE=? -->
 The ease of weaning is generally inversely related to the duration of the mechanical ventilation

<!-- PAGE=? -->
 The process that necessitated mechanical ventilation must be reversed or under control

<!-- PAGE=? -->
 Complicating factors should also be adequately treated

<!-- PAGE=? -->
o Bronchospasm

<!-- PAGE=? -->
o heart failure

<!-- PAGE=? -->
o infection

<!-- PAGE=? -->
o malnutrition

<!-- PAGE=? -->
o metabolic acidosis or alkalosis

<!-- PAGE=? -->
o anemia

<!-- PAGE=? -->
o increased CO2 production due to high carbohydrate loads

<!-- PAGE=? -->
o altered mental status

<!-- PAGE=? -->
o sleep deprivation

<!-- PAGE=? -->
 Underlying lung disease and pulmonary muscle wasting from prolonged disuse are often major factors that complicate weaning.

<!-- PAGE=? -->
 The most useful weaning parameters for extubation are

<!-- PAGE=? -->
o Follows commands

<!-- PAGE=? -->
o Clear oropharynx/hypopharynx

<!-- PAGE=? -->
o Intact gag reflex

<!-- PAGE=? -->
o Sustained head lift for 5 seconds, sustained hand grasp

<!-- PAGE=? -->
o Adequate pain control

<!-- PAGE=? -->
o Minimal end expiratory concentration of inhaled anesthetics

<!-- PAGE=? -->
o ABG tensions

<!-- PAGE=? -->
 High A-a gradient is associated with desaturation

<!-- PAGE=? -->
 <350 for extubation

<!-- PAGE=? -->
o respiratory rate

<!-- PAGE=? -->
o rapid shallow breathing index (RSBI)

<!-- PAGE=? -->
 frequently used to help predict who can be successfully weaned from mechanical ventilation and extubated

<!-- PAGE=? -->
 breathing spontaneously on a T-piece, f/VT

<!-- PAGE=? -->
 RSBI of less than 100 may be successfully extubated

<!-- PAGE=? -->
o Vt >6ml/kg

<!-- PAGE=? -->
o Td/Tv is normally 20-40% under spontaneous ventilation

<!-- PAGE=? -->
 50% with PPV

<!-- PAGE=? -->
 <60% for extubation

<!-- PAGE=? -->
o Negative inspiratory pressure of at least -20cmH2O is criteria for extubation

<!-- PAGE=? -->
o VC > 10ml/kg is criteria for extubation

<!-- PAGE=? -->
 Intact airway reflexes and a cooperative patient are also mandatory

<!-- PAGE=? -->
o Unless pt is trached

<!-- PAGE=? -->
 common techniques to wean a patient include

<!-- PAGE=? -->
o SIMV

<!-- PAGE=? -->
o pressure support

<!-- PAGE=? -->
o CPAP

<!-- PAGE=? -->
o T-Piece

<!-- PAGE=? -->
Vertebrobasilar TIAs

<!-- PAGE=? -->
 Manifestations

<!-- PAGE=? -->
o most common symptom is a motor defect

<!-- PAGE=? -->
 weakness, clumsiness, or paralysis of any combination of extremities up to quadriplegia

<!-- PAGE=? -->
o Sensory phenomena include the following in any combination of extremities

<!-- PAGE=? -->
 Numbness

<!-- PAGE=? -->
 loss of sensation

<!-- PAGE=? -->
 paresthesias

<!-- PAGE=? -->
o unsteady gait

<!-- PAGE=? -->
o disequilibrium

<!-- PAGE=? -->
o vertigo

<!-- PAGE=? -->
o loss of vision

<!-- PAGE=? -->
 varying from complete blindness to partial blindness in homonymous fields

<!-- PAGE=? -->
o Diplopia is another characteristic visual symptom

<!-- PAGE=? -->
von Willebrands

<!-- PAGE=? -->
 Autosomal dominant trait

<!-- PAGE=? -->
 Incidence ~ 1% worldwide

<!-- PAGE=? -->
o 1:100-1:2500 (mild),

<!-- PAGE=? -->
o 1:200,000- 1:250,000 (severe, homozygous form)

<!-- PAGE=? -->
 Functions of von Willebrand factor:

<!-- PAGE=? -->
o Forms a complex with F VIII and decreases the excretion of F VIII (deficiency of vWF leads to decreased levels of F VIIIl)

<!-- PAGE=? -->
o Mediates platelets adhesion (

<!-- PAGE=? -->
 Clinical presentation

<!-- PAGE=? -->
o Bleeding from skin, mm (mimics plt dysfunction)

<!-- PAGE=? -->
o Bleeding in musles, joints (~ hemophilia)

<!-- PAGE=? -->
 Labs

<!-- PAGE=? -->
o Prolonged BT (classically)

<!-- PAGE=? -->
o Low levels of F VIII (may be N, depending on subtype)

<!-- PAGE=? -->
o Low VWF

<!-- PAGE=? -->
o Defective Plt aggregation with ristocetin = most sensitive test

<!-- PAGE=? -->
 Different types based on qualitative and quantitative differences in VWF

<!-- PAGE=? -->
o Type I - decreased levels of VWF (normal structure), 75% of cases; vWF and FVIII levels  = 1040%, BT=N/↑

<!-- PAGE=? -->
o Type IIa

<!-- PAGE=? -->
low/N levels of vWF, abnormal multimer pattern

<!-- PAGE=? -->
o Type IIb - abnormal multimer pattern, platelets enriched plasma has increased sensitivity to ristocetin

<!-- PAGE=? -->
o Type III - undetectable levels of VWF and VIII

<!-- PAGE=? -->
 Ddx hemophilia A: the response to addition of plasma is the rise of F VIII which continues to rise for 48 hrs in the case of vWD

<!-- PAGE=? -->
 Management:

<!-- PAGE=? -->
o DDAVP promotes release of VWF. DDAVP may be contraindicated in type 2B and pseudo vWd because it can cause severe thrombocytopenia due to platelet aggregation in some patients .

<!-- PAGE=? -->
o cryoprecipitate (containf F VIII and VWF). Cryoprecipitate is the preferred form of replacement for active bleeding or for prophylaxis

<!-- PAGE=? -->
 During pregnancy the levels of VWF and FVIII increase

<!-- PAGE=? -->
 Prophylactic Rx is only necessary if F VIII<25%, during labor F VIII should be 50%

<!-- PAGE=? -->
o Type I IIa, SVD start DDAVP 0.3mcg/kg at onset of labor and q12h,

<!-- PAGE=? -->
o If not responsive to DDAVP give cryo or FFP

<!-- PAGE=? -->
 For C/S need F VIII = 80%

<!-- PAGE=? -->
 Check FVIII postpartum ; keep <25% (highest risk of bleeding is postpartum)

<!-- PAGE=? -->
Barash 209, Chestnut 853

<!-- PAGE=? -->
Volatile Anesthesia

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
PHYSICS

<!-- PAGE=? -->
 Vapor pressure

<!-- PAGE=? -->
o Pressure on the walls of a container by a gas

<!-- PAGE=? -->
o Increases with increasing temperature

<!-- PAGE=? -->
o Vapor pressure is independent of atmospheric pressure and is contingent only on temperature and characteristics of the gas

<!-- PAGE=? -->
o Boiling point is the temperature at which vapor pressure equal atmospheric pressure

<!-- PAGE=? -->
o Boiling points of desflurane, isoflurane, halothane, enflurane, sevoflurane are:  22.8, 48.5, 50.2, 56.5, 58.5 respectively

<!-- PAGE=? -->
 Latent heat of vaporization

<!-- PAGE=? -->
o Number of calories required to change 1 g of liquid into vapor without a temperature change

<!-- PAGE=? -->
o This energy must come from the liquid or an external source

<!-- PAGE=? -->
o Temperature of liquid decreases during vaporization and this energy loss can lead to significant decreases in temperature of the remaining liquid

<!-- PAGE=? -->
o Decrease in temperature decreases vaporization

<!-- PAGE=? -->
 Thermal Conductivity

<!-- PAGE=? -->
o measure of the speed with which heat flows through a substance

<!-- PAGE=? -->
o higher the thermal conductivity, the better the substance conducts heat

<!-- PAGE=? -->
o Vaporizers are constructed of metals that have relatively high thermal conductivity, which helps maintain a uniform temperature

<!-- PAGE=? -->
VAPORIZERS temperature-compensated, variable-bypass vaporizers

<!-- PAGE=? -->
 Vapor output depends on

<!-- PAGE=? -->
o vapor pressure of agent (VP)

<!-- PAGE=? -->
o flow rate of carrier gas into vaporizer (CG)

<!-- PAGE=? -->
o barometric pressure (Pb)

<!-- PAGE=? -->
 VO = (CG X VP) / (Pb - VP)

<!-- PAGE=? -->
 Eg Isoflurane which has VP of 240 mmHg at 1 atm with 100 mls/min FGF

<!-- PAGE=? -->
 VO = (100 X 240) / (760 - 240) = 46 mls / min

<!-- PAGE=? -->
 Anesthetic Concentration = VO / Total FGF

<!-- PAGE=? -->
Factors Influencing Vaporizer Output

<!-- PAGE=? -->
Flow Rate

<!-- PAGE=? -->
 vaporizer output can vary with the rate of gas flowing through the vaporizer

<!-- PAGE=? -->
 low flow rates (<250ml/min) - output less than the dial setting

<!-- PAGE=? -->
o Insufficient turbulence is generated at low flow rates in the vaporizing chamber to upwardly advance the vapor molecules

<!-- PAGE=? -->
 high flow rates (15 L/min) - output less than the dial setting

<!-- PAGE=? -->
o incomplete mixing and saturation in the vaporizing chamber

<!-- PAGE=? -->
Temperature

<!-- PAGE=? -->
 the output of contemporary temperature-compensated vaporizers is almost linear over a wide range of temperatures

<!-- PAGE=? -->
 Vaporizers are constructed with metals having relatively high specific heat and high thermal conductivity to minimize heat loss

<!-- PAGE=? -->
Intermittent Backpressure (pumping effect)

<!-- PAGE=? -->
 Intermittent backpressure (PPV, O2 flushing) can cause higher vaporizer output concentration than the dialed setting

<!-- PAGE=? -->
 more pronounced at

<!-- PAGE=? -->
o low flow rates

<!-- PAGE=? -->
o low dial settings

<!-- PAGE=? -->
o low levels of liquid anesthetic in the vaporizing chamber

<!-- PAGE=? -->
 increased by

<!-- PAGE=? -->
o rapid respiratory rates

<!-- PAGE=? -->
o high peak inspired pressures

<!-- PAGE=? -->
o rapid drops in pressure during expiration

<!-- PAGE=? -->
 modern vaporizers are relatively immune

<!-- PAGE=? -->
Carrier Gas Composition

<!-- PAGE=? -->
 When the carrier gas is quickly switched, from O2 to nitrous, there is a rapid transient decrease in vaporizer output followed by a slow increase to a new steady-state value

<!-- PAGE=? -->
o attributed to nitrous oxide's being more soluble than oxygen in halogenated liquid

<!-- PAGE=? -->
o The quantity of gas leaving the vaporizing chamber is transiently diminished until the anesthetic liquid is totally saturated with nitrous oxide

<!-- PAGE=? -->
 The steady-state plateau is achieved more rapidly with increased flow rates, regardless of the ultimate output value

<!-- PAGE=? -->
 Factors that contribute to the characteristic steady-state response include

<!-- PAGE=? -->
o viscosity and density of the carrier gas

<!-- PAGE=? -->
o relative solubilities of the carrier gas in the liquid anesthetic

<!-- PAGE=? -->
Hazards

<!-- PAGE=? -->
Misfilling

<!-- PAGE=? -->
 Vaporizers not equipped with keyed fillers occasionally have been misfiled

<!-- PAGE=? -->
Contamination

<!-- PAGE=? -->
 Contamination of anesthetic vaporizer contents has occurred by filling an isoflurane vaporizer with a contaminated bottle of isoflurane

<!-- PAGE=? -->
Tipping

<!-- PAGE=? -->
 Excessive tipping can cause the liquid agent to enter the bypass chamber and cause output with extremely high concentration of the agent

<!-- PAGE=? -->
o Tec 4 is slightly more immune to tipping than the Vapor 19.1

<!-- PAGE=? -->
 If a vaporizer is tipped, it should not be used until it has been flushed for 20 to 30 minutes at high flow rates with the vaporizer set at a low concentration

<!-- PAGE=? -->
 The Dräger Vapor 2000 series vaporizers have a transport (T) dial setting that helps prevent tipping related problems

<!-- PAGE=? -->
o isolates the vaporizer sump from the bypass chamber

<!-- PAGE=? -->
Overfilling

<!-- PAGE=? -->
 Liquid anesthetic enters the bypass chamber, and up to 10 times the intended vapor concentration can be delivered to the common gas outlet

<!-- PAGE=? -->
Underfilling

<!-- PAGE=? -->
 the combination of low vaporizer fill state (<25% full) in combination with the high vaporizing chamber flow can result in a clinically significant and reproducible fall in vaporizer output

<!-- PAGE=? -->
Leaks

<!-- PAGE=? -->
 vaporizer leaks can cause awareness by the patient during anesthesia

<!-- PAGE=? -->
o loose filler cap is the most common source of vaporizer leaks

<!-- PAGE=? -->
TEC 6 VAPORIZER

<!-- PAGE=? -->
 Desflurane requires own vaporizer for two reasons: low (c/f other volatiles) potency and high volatility (vapor pressure)

<!-- PAGE=? -->
 Vapor pressure of Desflurane at 20degC is 669 mmHg

<!-- PAGE=? -->
o normal flow through a tradiational vaporizer would vaporize much more desflurane

<!-- PAGE=? -->
 E.g. at 1 atmosphere, 100 mls/min:

<!-- PAGE=? -->
 VO = (CG X VP) / (BP - VP)

<!-- PAGE=? -->
 VO = (100 X 669) / (760 - 669) =  735 mls / min

<!-- PAGE=? -->
o This would require huge amount of total bypass flow to dilute Anesthetic concentration to MAC of 6%

<!-- PAGE=? -->
 Anesthetic concentration = 6% = VO / Total FGF

<!-- PAGE=? -->
 Total FGF = VO / 0.06 = .735 / .06 = 12.5 L

<!-- PAGE=? -->
 also, with this degree of vaporization, excessive cooling would occur and would get  VP and inconsistent output (thus Tec6 has external heat source)

<!-- PAGE=? -->
 Thus, vaporizer chamber is heated to 39C which gives a vapor pressure in the sump of 1300 mmHg or approximately 2 atmospheres

<!-- PAGE=? -->
 The following situations close the shut-off valve downstream from the Desflurane sump producing a nooutput situation and immediately activating a -no-output‖ alarm

<!-- PAGE=? -->
o Anesthetic level decreases to below 20 mL

<!-- PAGE=? -->
o Tilting of vaporizer

<!-- PAGE=? -->
o Power failure

<!-- PAGE=? -->
o Disparity between the pressure in the vapor circuit versus the pressure in the fresh gas circuit exceeding a specified tolerance.

<!-- PAGE=? -->
 Fresh gas flow doesn't pass through the vaporizer

<!-- PAGE=? -->
o flow-splitting characteristics of the specific vaporizer

<!-- PAGE=? -->
o dial setting

<!-- PAGE=? -->
Altitude and Anesthesia

<!-- PAGE=? -->
 Anesthetic potency and therefore clinical effect is related to partial pressure of agent rather than volume %

<!-- PAGE=? -->
 Variable bypass vaporizers always provide a constant partial pressure

<!-- PAGE=? -->
o work at ambient pressure, thus which will thus increase volume % at altitude

<!-- PAGE=? -->
o Example: Sevoflurane

<!-- PAGE=? -->
 Sea level (PB 760) at 2% (~ 1MAC)

<!-- PAGE=? -->
 Psevoflurane = .02 X 760 = 15.2 mmHg

<!-- PAGE=? -->
 At 15,000 ft (PB 427)

<!-- PAGE=? -->
 Psevoflurane = 15.2 = Volatile % X 427

<!-- PAGE=? -->
 15.2/427 = vol %

<!-- PAGE=? -->
 Volatile % = 3.5%

<!-- PAGE=? -->
 Tec 6

<!-- PAGE=? -->
o because of design, Tec 6 delivers constant volume % output because it works at absolute pressure

<!-- PAGE=? -->
 need to turn it up at higher altitude

<!-- PAGE=? -->
o important determination of anesthetic potency is partial pressure

<!-- PAGE=? -->
 Sea level, PB = 760

<!-- PAGE=? -->
 Pdesflurane at 1 MAC = .066 X 760 = 50 mmHg

<!-- PAGE=? -->
 At 15,000 ft, PB = 427

<!-- PAGE=? -->
 Tec 6 will still deliver 6.6% = 0.066 X 427 = 28 mmHg

<!-- PAGE=? -->
 In order to provide Pdesflurane of 50 mmHg, we need to increase volume % to 11.7% = 50 / 427

<!-- PAGE=? -->
Uptake and Distribution

<!-- PAGE=? -->
FA/FI

<!-- PAGE=? -->
 a common way to assess anesthetic uptake is to follow the ratio of fractional concentration of alveolar anesthetic to inspired anesthetic ( F A/ F I) over time

<!-- PAGE=? -->
 The faster F A rises relative to F I ,   t h e   f a s t e r   t h e   s p e e d   o f   i n d u c t i o n   s i n c e F A is proportional t o PA ( F A = PA / P barometric) and PA = P bl o o d = P CNS

<!-- PAGE=? -->
o alveolar fraction is directly proportional to the partial pressure of anesthetic in the CNS

<!-- PAGE=? -->
 As fresh gas flows into the circuit, the concentration in the circuit ( F I) will rise according to first-order kinetics:

<!-- PAGE=? -->
o F FGO = fraction concentration of inspired anesthetic leaving the fresh gas outlet (dial setting)

<!-- PAGE=? -->
o T =   t i m e

<!-- PAGE=? -->
o τ = a time constant

<!-- PAGE=? -->
 The time constant is the volume or -capacity‖ of the circuit ( V C) divided by the fresh gas flow

<!-- PAGE=? -->
Rate of Rise of F I

<!-- PAGE=? -->
 Techniques to increase the rate of rise of FI include

<!-- PAGE=? -->
o starting with a higher F FGO

<!-- PAGE=? -->
 Ex: with τ = 4, by first-order kinetics 63% of maximum is reached after one time constant (4min)

<!-- PAGE=? -->
 To attain an F I o f   2 %  a t 4 ,   t he F FGO can be set to 3.2% (2% divided by 0.63)

<!-- PAGE=? -->
o i n c r e as e  t h e  f r es h  g as   flo w

<!-- PAGE=? -->
 dec. τ

<!-- PAGE=? -->
 with high flows (>4 L/min) there is far less mixing because fresh gas pushes -old‖ gas out of t h e  c i r c u i t   c a u s i n g F I t o   i n c r e a s e   a t   a   g r e a t e r   r a t e ;   t h i s   i s   t h e   m o s t   i m p o r t a n t   f a c t o r   i n   r a p i d l y i n c r e as in g F I t o   t h e   d e s i r e d   c o n c e n t r a t i o n

<!-- PAGE=? -->
o dec. the capacity of the circuit (collase the rebreathnig bag)

<!-- PAGE=? -->
 dec. τ

<!-- PAGE=? -->
o The anesthetic circuit, including the CO2 absorbent and plastic tubing, can absorb and decompose t h e  i n ha le d  a n esthetics which will delay the rate of rise in F I

<!-- PAGE=? -->
 Limited clinical significance

<!-- PAGE=? -->
o Mixing with the patients exhaled gases will also dilute the F I, decreasing the rate in Rise

<!-- PAGE=? -->
 Mitigated by high flows pushing the exhaled gas out the pop-off valve

<!-- PAGE=? -->
Rise in FA in the Absence of Uptake

<!-- PAGE=? -->
 Circuit gas enters the lungs where it mixes with alveolar gas

<!-- PAGE=? -->
o with no blood flow, F A would rise according to first-order kinetics

<!-- PAGE=? -->
 t i me constant for alveolar rise in anesthetic concentration equals the FRC (including anatomi c dead space) divided by minute ventilation

<!-- PAGE=? -->
o t wo ways to speed the equilibration of F A with F I ( d e c .   τ )   i n c l u d e

<!-- PAGE=? -->
 i n c r e as e  minute ventilation

<!-- PAGE=? -->
 decrease FRC

<!-- PAGE=? -->
o pediatric inductions by spontaneous breathing so much quicker than adult inductions due to the low FRC relative to a high minute ventilation

<!-- PAGE=? -->
 l o w time constant - more rapid increase in F A/ F I

<!-- PAGE=? -->
Rise in F A in the Presence of Uptake

<!-- PAGE=? -->
 The most important factor in the rate of rise of F A/ F I i s   u p t a k e   o f   a n e s t h e t i c   f r o m   t h e   a l v e o l i   i n t o   t h e bloodstream

<!-- PAGE=? -->
 Anesthetics are s ol uble in tissues, thus uptake of anesthetic from alveoli to blood is again characterized by f i r s t - o r d e r   k i n e t i c s :

<!-- PAGE=? -->
o τ, = -capacity‖ (volume of anesthetic dissolved in the blood at the desired partial pressure) divided by f l o w  ( v o l u m e  o f   an es t he ti c  d e li ve r ed   pe r   un i t  t im e)

<!-- PAGE=? -->
 t h e  c apacity for the more soluble agents is much great than in soluble agents

<!-- PAGE=? -->
 τ = V C/FGF

<!-- PAGE=? -->
 Ex. the bag, tubing, absorbent canister, and piping comprise 8 L, and the fresh gas f l o w  i s   2   L ,   t h e   t i m e   c o n s t a n t   τ   = 8 /2 = 4

<!-- PAGE=? -->
 A characteristic of first-order kinetics is that 95% of maximum is reached after three time constants

<!-- PAGE=? -->
 i n   t h i s   c a s e ,   3   ×   4   =   1 2   m i n u t e s

<!-- PAGE=? -->
 Time constant is greater - slower rate of rise

<!-- PAGE=? -->
 The greater the uptake, the slower the rate of rise of F A/ F I

<!-- PAGE=? -->
 Blood uptake of anesthetic is expressed by the equation:

<!-- PAGE=? -->
 VB is blood uptake

<!-- PAGE=? -->
 δb/g is the blood:gas partition coefficient (solubility)

<!-- PAGE=? -->
 Q i s   c a r d i a c   o u t p u t

<!-- PAGE=? -->
 P A is alveolar partial pressure of anesthetic

<!-- PAGE=? -->
 P v i s   m i xe d   v e n o us   pa r tia l   pr e ss ur e   of   an es t he t ic

<!-- PAGE=? -->
 P B is barometric pressure

<!-- PAGE=? -->
o The greater the value of VB, the greater the uptake from alveoli to blood, and the slower the rise i n   F A / F I

<!-- PAGE=? -->
 A higher uptake will result in decreased rise in FA/Fi and thus more delayed onset of anesthesia P&P

<!-- PAGE=? -->
 Low cardiac output - increases rate of rise PA

<!-- PAGE=? -->
o A decreased CO results in less rapid uptake so the rate of increase in the PA and thus the induction of anesthesia is faster

<!-- PAGE=? -->
 High volume of anesthetic breathing system - reduces rate of rise of PA

<!-- PAGE=? -->
o The volume of the anesthetic breathing system acts as a buffer to slow achievement of the PA

<!-- PAGE=? -->
o High gas inflow rates (5-10 L/min) negate this buffer effect

<!-- PAGE=? -->
 Low blood / gas - increases rate of rise PA

<!-- PAGE=? -->
o A partition coefficient is a distribution ratio describing how the inhaled anesthetic distributes itself between 2 phase at equilibrium

<!-- PAGE=? -->
o It may be thought of as reflecting the relative capacity of each phase to accept anesthetic (is also temperature dependent - temperature   solubility)

<!-- PAGE=? -->
o The rate of increase of the PA toward the PI is inversely related to the solubility of the anesthetic in the blood.

<!-- PAGE=? -->
o Ie. The high blood solubility of methoxyflurane slows the rate at which the PA and Pa increase relative to the PI, and the induction of anesthesia is slow

<!-- PAGE=? -->
 Low FRC - increases rate of rise PA

<!-- PAGE=? -->
o The greater the alveolar ventolation to FRC ratio, the more rapid  is the rate of increase in the PA

<!-- PAGE=? -->
o In neonates this ration is approximately 5:1; in adults it is 1.5:1 (secondary to metabolic rate).

<!-- PAGE=? -->
o Thus, the rate of increase of PA toward Pi and thus inductin is more rapid in neonates than adults

<!-- PAGE=? -->
CONCENTRATION & SECOND GAS EFFECT

<!-- PAGE=? -->
 Concentration Effect: Increasing Fi of an agent results in a more rapid rise in FA/Fi.  This is due to two effects: Concentrating Effect and Augmented Inflow Effect

<!-- PAGE=? -->
o Concentrating Effect: Total lung volume is decreased by amount of gas taken up by the blood. The reduction in volume concentrates the remaining gas within the alveoli.

<!-- PAGE=? -->
 Eg: If 50% of anesthetic is taken up with Fi of 20% and O2 of 80%, FA remaining is 10 / 90 = 11%.  However, if Fi of 80% and half is taken up, remaining is 40 / 60 = 66%.

<!-- PAGE=? -->
 Thus, even though 50% of agent is taken up in both examples, the higher Fi results in a disproportionate increase in FA.

<!-- PAGE=? -->
o Augmented Inflow Effect: Restoring volume taken up by lung by original concentration of agent results in higher percentage of FA of anesthetic.

<!-- PAGE=? -->
 Second Gas Effect: same factors in concentration effect also have effect on second agent if administered concurrently.  Uptake of large volumes of first or primary gas (usually N2O) increase the rate of rise in alveolar concentration of second gas

<!-- PAGE=? -->
o Eg. Lung filled with 80% N2O with another agent at 1%.  Uptake of ½ of N2O results in ↑ FA of second gas to 1.7% (second gas effect).  Restoration of lung volume with same constituents as A results in increased concentration of both N2O and second gas (augmented inflow effect).

<!-- PAGE=? -->
Physiologic Effects

<!-- PAGE=? -->
 Depth of anesthesia - Stages of depth

<!-- PAGE=? -->
o Analgesia (amnesia)

<!-- PAGE=? -->
 Respond to verbal stimulation

<!-- PAGE=? -->
 Intact lid reflex

<!-- PAGE=? -->
 Normal respiratory pattern

<!-- PAGE=? -->
 Intact AW reflexes

<!-- PAGE=? -->
o Excitement (delirium)

<!-- PAGE=? -->
 Uncosciousness

<!-- PAGE=? -->
 Irregular respiratory pattern (hyperventilation)

<!-- PAGE=? -->
 Nonpurposeful movements

<!-- PAGE=? -->
 Hyperreflexia (laryngospasm, vomitting, arrhythmia)

<!-- PAGE=? -->
o Surgical anesthesia

<!-- PAGE=? -->
 No lid response

<!-- PAGE=? -->
 Periodic respiratory pattern

<!-- PAGE=? -->
 Absence of movement with surgical incision (= MAC)

<!-- PAGE=? -->
o Respiratory paralysis (overdose)

<!-- PAGE=? -->
 Cardiorespiratory arrest

<!-- PAGE=? -->
 Cardiovascular Effects

<!-- PAGE=? -->
o  MAP 2' to  SVR

<!-- PAGE=? -->
 halothane relatively preserves SVR

<!-- PAGE=? -->
o Heart rate:

<!-- PAGE=? -->
Toxicity

<!-- PAGE=? -->
 Hepatotoxicity - Hal>Enf>Iso> Des

<!-- PAGE=? -->
 No change with Sevo

<!-- PAGE=? -->
  desflurane, enflurane and isoflurane

<!-- PAGE=? -->
  halothane (impairs baroreceptor function)

<!-- PAGE=? -->
o CVP

<!-- PAGE=? -->
 Halothane, isoflurane, and desflurane inc CVP

<!-- PAGE=? -->
 No change with Sevoflurane

<!-- PAGE=? -->
o Little or no effect on PVR

<!-- PAGE=? -->
o Myocardial contractility

<!-- PAGE=? -->
 CO  by halothane and enflurane

<!-- PAGE=? -->
 CO preserved by desflurane, sevoflurane and isoflurane

<!-- PAGE=? -->
 Reduced in dog model

<!-- PAGE=? -->
o Oxygen consumption is decreased approximately 10 to 15% during general anesthesia

<!-- PAGE=? -->
o distribution of cardiac output is altered by anesthesia

<!-- PAGE=? -->
 Blood flow to liver, kidneys, and gut is decreased

<!-- PAGE=? -->
 blood flow to the brain, muscle, and skin is increased or not changed during general anesthesia

<!-- PAGE=? -->
o Isoflurane, sevoflurane, and desflurane do not sensitize the heart to the arrhythmogenic effects of epinephrine

<!-- PAGE=? -->
 ?halothane, enflurane

<!-- PAGE=? -->
 Renal Effects

<!-- PAGE=? -->
o generally, minimal effects on renal physiology directly

<!-- PAGE=? -->
o dose dependent  RBF,  GFR and  UO and are secondary to cardiovascular effects

<!-- PAGE=? -->
 Hepatic Effects

<!-- PAGE=? -->
o Dec hepatic blood flow:

<!-- PAGE=? -->
 hal>enf>des>>sevo=iso

<!-- PAGE=? -->
 Sevoflurane better preserves hepatic blood flow and oxygen delivery

<!-- PAGE=? -->
General Ventilatory Effects:

<!-- PAGE=? -->
 All volatile anesthetics decrease tidal volume but have lesser effects on decreasing minute ventilation because of an offsetting response to increase respiratory rate

<!-- PAGE=? -->
o Effect is dose dependent

<!-- PAGE=? -->
 higher concentrations of volatile anesthetics, greater decreases in tidal volume and greater increases in respiratory rate

<!-- PAGE=? -->
 Their net effect of a gradual decrease in minute ventilation has been associated with increasing resting PaCO2

<!-- PAGE=? -->
 The relative increases in PaCO2 as an index of respiratory depression with volatile anesthetics evaluated at less than 1.24 MAC are as follows:

<!-- PAGE=? -->
o enflurane > desflurane = isoflurane > sevoflurane = halothane

<!-- PAGE=? -->
 Hypoxic drive

<!-- PAGE=? -->
o Inhaled anesthetics, including nitrous oxide, also produce dose-dependent attenuation of the ventilatory response to hypoxia

<!-- PAGE=? -->
o In fact, even subanesthetic concentrations of volatile anesthetics (0.1 MAC) elicit anywhere from a 15 to 75% depression of the ventilatory drive to hypoxia

<!-- PAGE=? -->
o Residual effects of volatile anesthetics may impair the ventilatory drive of patients in the recovery room.

<!-- PAGE=? -->
o Preservation of Ventilatory Response (Best to Worst):

<!-- PAGE=? -->
 Desflurane>Sevoflurane>Enflurane>Isoflurane>Halothane

<!-- PAGE=? -->
o Hepatic metabolism

<!-- PAGE=? -->
 Methoxyfluorane>halothane>sevofluorane>enflurane>isofluorane>desflurane

<!-- PAGE=? -->
o Sevoflurane is essentially not associated with post-operative hepatic dysfunction

<!-- PAGE=? -->
 not metabolized to a trifluoroacetyl halide

<!-- PAGE=? -->
o Halothane has two distinct types of hepatic injury:

<!-- PAGE=? -->
 20% of adults exposed to halothane show mild elevations of ALT and AST - 1-3 day unprogressive mild hepatitis

<!-- PAGE=? -->
 reductive metabolism of halothane

<!-- PAGE=? -->
o potentiated by dec. hepatic blood flow and oxygen supply

<!-- PAGE=? -->
 does not occur with other volatiles

<!-- PAGE=? -->
 Fulminent hepatitis: Halothane Hepatitis

<!-- PAGE=? -->
o The incidence of liver injury caused by fluorinated volatiles is proportional to the degree of hepatic metabolism:

<!-- PAGE=? -->
 Halothane 20%

<!-- PAGE=? -->
 Enflurane 2.5%

<!-- PAGE=? -->
 Isoflurane 0.2%

<!-- PAGE=? -->
 Desflurane 0.01%

<!-- PAGE=? -->
 Nephrotoxicity

<!-- PAGE=? -->
o metabolism of volatiles can produce inorganic fluoride which is directly nephrotoxic

<!-- PAGE=? -->
o The classic example of fluoride induced nephrotoxicity is with Methoxyflurane due to large amount of inorganic fluoride

<!-- PAGE=? -->
 high output renal insufficiency, characterized by

<!-- PAGE=? -->
 dilute polyuria

<!-- PAGE=? -->
 dehydration

<!-- PAGE=? -->
 serum hypernatremia

<!-- PAGE=? -->
 hyperosmolality

<!-- PAGE=? -->
 elevated BUN and creatinine

<!-- PAGE=? -->
 unresponsive to vasopressin

<!-- PAGE=? -->
o Sevoflurane is defluorinated and also shows relatively high peak serum fluoride levels, however, because of sevo's low blood - gas solubility and rapid elimination, fluoride concentrations fall very quickly and thus renal toxicity due to fluoride is not seen with sevoflurane

<!-- PAGE=? -->
o Desflurane shows no evidence of nephrotoxicity

<!-- PAGE=? -->
o Fluoride production

<!-- PAGE=? -->
 Methoxy>sevo>enflu>iso>halothane>des

<!-- PAGE=? -->
 Interaction with CO2 Absorber

<!-- PAGE=? -->
o Compound A produced during Sevo anesthesia and is worse with Baralyme

<!-- PAGE=? -->
 Risk factors

<!-- PAGE=? -->
 Low fresh gas flow

<!-- PAGE=? -->
 High temperatures

<!-- PAGE=? -->
 High concentrations of sevoflurane

<!-- PAGE=? -->
 Baralyme > soda lime

<!-- PAGE=? -->
o Related to inc temperature

<!-- PAGE=? -->
 Dry absorbents (barash)

<!-- PAGE=? -->
o dehydration of Baralyme increases the concentration of compound A, but dehydration of soda lime decreases the concentration of compound A (Miller)

<!-- PAGE=? -->
 Fresh absorbents (Miller)

<!-- PAGE=? -->
 Theoretical concern but perhaps should avoid in patients with renal dysfunction

<!-- PAGE=? -->
o Carbon Monoxide

<!-- PAGE=? -->
 all inhaled anesthetics produce some CO as a result of their interaction with strong bases in relatively dry CO2 absorbers

<!-- PAGE=? -->
 Risk factors:

<!-- PAGE=? -->
 Choice of anesthetic agent (Des > Enf > Iso >>>Hal =  Sevo)

<!-- PAGE=? -->
 Fi agent

<!-- PAGE=? -->
 Low fresh gas flow

<!-- PAGE=? -->
 Inc. temperature

<!-- PAGE=? -->
 Baralyme

<!-- PAGE=? -->
 Desiccated absorber

<!-- PAGE=? -->
 Reduced animal size per 100g absorbent

<!-- PAGE=? -->
Physiochemical Properties

<!-- PAGE=? -->
Barash, P&P

<!-- PAGE=? -->
 potency of conventional inhaled anesthetics correlates inversely with lipophilicity

<!-- PAGE=? -->
o inc. oil/gas partition coefficient, inc. potency

<!-- PAGE=? -->
 solubility of the inhaled anesthetics in blood and tissues is denoted by the partition coefficient

<!-- PAGE=? -->
o partition coefficient is a distribution ratio describing how the inhaled anesthetic distributes itself between two phases at equilibrium

<!-- PAGE=? -->
o (partial pressures equal in both phases)

<!-- PAGE=? -->
o a blood: gas partition coefficient of 0.5 means that the concentration of inhaled anesthetic in the blood is half that present in the alveolar gases when the partial pressures on the anesthetic in these two phases is identical

<!-- PAGE=? -->
o Partition coefficients are temperature dependent such that the solubility of a gas in a liquid is increased when the temperature of the liquid increases

<!-- PAGE=? -->
Low flows

<!-- PAGE=? -->
 Definition

<!-- PAGE=? -->
o fresh gas flows of less than one half of the minute volume

<!-- PAGE=? -->
 usually less than 2 L/min

<!-- PAGE=? -->
o closed-circuit anesthesia

<!-- PAGE=? -->
 delivery of gases in amounts just sufficient to replace the gases-oxygen and anestheticremoved by the patient

<!-- PAGE=? -->
 Advantages

<!-- PAGE=? -->
o lower cost

<!-- PAGE=? -->
o increased humidification

<!-- PAGE=? -->
o reduced heat loss

<!-- PAGE=? -->
o decreased release of anesthetic to the environment

<!-- PAGE=? -->
o better capacity to assess physiologic variables, such as ventilation

<!-- PAGE=? -->
 Disadvantages

<!-- PAGE=? -->
o more concern about oxygen levels

<!-- PAGE=? -->
 especially if nitrous oxide is used

<!-- PAGE=? -->
 patient also contributes nitrogen from stores in the body

<!-- PAGE=? -->
o possible inc. concentration of carbon monoxide

<!-- PAGE=? -->
o lack of control that low flows and, especially, closed circuits offer

<!-- PAGE=? -->
o possible rebreathing of toxic products from the breakdown of volatile

<!-- PAGE=? -->
 compound A

<!-- PAGE=? -->
MAC factors:

<!-- PAGE=? -->
 Increased MAC required

<!-- PAGE=? -->
o Children.

<!-- PAGE=? -->
o Physiologic derangements [HYPER's] (hyperthermia, hyperNatremia)

<!-- PAGE=? -->
o Increased central neurotransmitter levels (acute amphetamine, cocaine use, MAO-I, ephedrine, ldopa)

<!-- PAGE=? -->
o Chronic ethanol abuse

<!-- PAGE=? -->
 Decreased MAC required

<!-- PAGE=? -->
o Increasing age

<!-- PAGE=? -->
 Dec.  6% per decade

<!-- PAGE=? -->
 Neonates are the exception

<!-- PAGE=? -->
o Physiologic derangements

<!-- PAGE=? -->
 metabolic acidosis

<!-- PAGE=? -->
 hypoxia

<!-- PAGE=? -->
 hypotension (MAP < 50 mm Hg)

<!-- PAGE=? -->
 hypothermia

<!-- PAGE=? -->
 hyponatremia

<!-- PAGE=? -->
 anemia

<!-- PAGE=? -->
o Pregnancy

<!-- PAGE=? -->
o Drugs, acute (lithium, ketamine, opiods, benzos, alpha-2 agonists)

<!-- PAGE=? -->
o Acute ethanol administration

<!-- PAGE=? -->
Neonatal induction

<!-- PAGE=? -->
Barash, Smith

<!-- PAGE=? -->
 Reasons for More Rapid Induction of Anesthesia in Neonates

<!-- PAGE=? -->
o Greater alveolar ventilation relative to the functional residual capacity

<!-- PAGE=? -->
 ratio of alveolar ventilation to FRC is 5:1 in the infant and 1.5:1 in the adult

<!-- PAGE=? -->
o Greater proportion of the cardiac output goes to vessel-rich group of tissues (brain, heart)

<!-- PAGE=? -->
o the neonate has a greater cardiac output per kilogram of body mass (Barash, Smith)

<!-- PAGE=? -->
 In adults, increased CO delays the equilibration of alveolar to inspired anesthetic partial pressures

<!-- PAGE=? -->
 an increased CO in infants actually speeds the equilibration of partial pressures.  This paradoxical effect in neonates may be attributed to the vessel-rich group representing 18% of body weight in infants compared with 8% in adults

<!-- PAGE=? -->
 An increased CO distributed primarily to the VRG in infants speeds the equilibration of anesthetic partial pressures in the VRG

<!-- PAGE=? -->
o Lower MAC requirement

<!-- PAGE=? -->
o lower blood gas partition coefficient for volatile anesthetics

<!-- PAGE=? -->
Relative solubilities in plastics

<!-- PAGE=? -->
 (Least soluble to most soluble)

<!-- PAGE=? -->
o Isoflurane = R, E, V

<!-- PAGE=? -->
o Sevoflurane = R, E, V

<!-- PAGE=? -->
o Desflurane = E, R, V

<!-- PAGE=? -->
o Halothane = E, R, V

<!-- PAGE=? -->
 E = polyethylene

<!-- PAGE=? -->
 R = rubber

<!-- PAGE=? -->
 V = polyvinylchloride

<!-- PAGE=? -->
 All volatiles are the most solube in polyvinylchloride (PVC)

<!-- PAGE=? -->
W

<!-- PAGE=? -->
Waste gases- maximum allowable

<!-- PAGE=? -->
N2O = <25 ppm (one hour ceiling) Halogenated agents = 2ppm or 0.5ppm if N2O used N2O at dentists (N2O alone) = 50 ppm

<!-- PAGE=? -->
WPW

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
 In atrial fib / flutter the following medications may use a paradoxical increase in the ventricular response

<!-- PAGE=? -->
o Adenosine

<!-- PAGE=? -->
o calcium channel blockers

<!-- PAGE=? -->
o digoxin

<!-- PAGE=? -->
o B-blockers

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE**

| Inhalational Anesthetics                          | Magnesium                                          |
|---------------------------------------------------|---------------------------------------------------|
| Insulin                                           | Hypermagnesemia                                   |
| Intubation Complications                           | Hypomagnesemia                                    |
| Intercostal Nerve Block                           | Malignant Hyperthermia                            |
| Intraocular pressure (IOP)                        | Mannitol                                          |
| Ipratropium                                       | Mapleson Circuits                                 |
| IV regional                                       | Masseter rigidity                                  |
| Interscalene Block                                | Mediastinoscopy                                   |
| J                                                 | MEN (Multiple Endocrine Neoplasm)                |
|                                                   | METS                                              |
| Jaundice (new onset) in pregnancy                 | Meningomyelocele                                  |
| K                                                 | Meperidine                                       |
| Ketamine                                          | Metformin                                         |
| Ketorolac                                         | Midazolam                                         |
| L                                                 | Milrinone (amrinone)                             |
| Labetolol                                         | Mineralocorticoid deficiency                      |
| Lactic Acidosis                                   | Minute ventilation sat                             |
| Laparoscopy                                       | Mixed Venous                                      |
| Laryngoscopy                                      | Mortality                                         |
| Latex allergy                                     | MRI                                               |
| Laser types                                       | Mucopolysaccharidosis                             |
| Endotracheal Tube Fires                           | Muscular Dystrophy (Duchenne's)                  |
| CO 2 laser                                        | Multiple Sclerosis                                |
| Argon Laser                                       | Myasthenia Gravis Myasthenic Syndrome (Lambert-Eaton) |
| KTP(potassium titanium phosphate) : Nd-Yag       | Myofacial Pain Syndrome                            |
| Laser LES Pressure                                 | Myotonic dystrophy                                |
| Liability                                         | Myopathy of Critical Illness                      |
| Lithotripsy                                      | Myxedema Coma (hypothyroidism)                   |
|                                                   | MVP                                               |
| Liver Transplantation Monitoring and Induction     | N                                                 |
| Dissection phase                                   | Naloxone                                         |
| Anhepatic phase                                   | Neck Injury (penetrating)                         |
| Neohepatic phase                                  | Needle-Stick Injury                               |
| LMA                                               | Negative Pressure Pulmonary Edema                 |
| LMA size                                          | Nephron                                          |
| Local Anesthetics                                  | Nerves, peripheral                                 |
| Additives Local Anesthetics                        | Neuroaxial Anesthesia Spinal - Block Height      |
| Toxicity                                          | Duration                                          |
| Central Nervous System Toxicity                    | Spinal -                                         |
| Cardiovascular Toxicity of Local Anesthetics      | Toxicity from Local                               |
| Treatment of Systemic Anesthetics                 | Opioids Clonidine                                 |
| Long QT                                           | Epinephrine                                       |
| Low Molecular Weight Heparin                      | Contraindications                                  |
| Lumbar Plexus Block                               | Physiology                                        |
| Lung compliance and elasticity                     | Lung Dead space                                   |
|                                                   | Complications                                     |
| Lung Lavage                                       | Subdural block                                    |
| Lung Separation                                    | Neurogenic Pulmonary Edema                        |
| Lung Volumes                                      | Neuropathy post regional                          |
| Lung Transplant Rejection:                        | Neurolysis Neurophysiology                        |
| Anesthetic considerations                          | Neurotransmitters                                 |
|                                                   | NMS Oxide                                        |
| M                                                 | Nitric                                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```markdown
| Nitrous Oxide                                      | Opioids                                          |
|---------------------------------------------------|--------------------------------------------------|
| NMB (neuromuscular blockers)                       | Opioid Receptors                                 |
| NMB Autonomic Effects                              | Morphine                                         |
| NMB anaphylaxis                                   | Meperidine                                       |
| NdMB- Drugs that affect duration                   | Methadone                                        |
| Succinylcholine                                    | Fentanyl                                         |
| Diseases That Alter the Response to Muscle         | Sufentanil                                       |
| Relaxants                                         | Alfentanil                                       |
| NMB Evaluation and Monitoring                       | Remifentanil                                     |
| NMB antagonists inhibition                          | Codeine                                          |
| Special groups:                                    | Hydromorphone                                    |
| Noise Pollution                                    | Tramadol                                         |
| NPPV                                              | Remifentanil and Alfentanil                      |
| Non-Steroidal Anti-inflammatory Drugs (NSAIDs)     | Pharmacokinetics                                 |
| O                                                 | Pneumonics                                       |
| OB                                                | Opiods in Liver Disease                          |
| Anesthesia AFE                                    | Opioids, neuraxial                              |
| Arrest                                            | Pharmacology of Neuraxial Opioids               |
| Breech                                            | Mechanisms by which neuraxial opioids cause      |
| Cocaine                                           | respiratory depression:                          |
| CSE                                               | Intrathecal Opiods                              |
| DIC                                               | Epidural Opioids                                 |
| Dyspnea in Pregnancy                               | Partial agonists and mixed agonist-antagonists   |
| Fetal Heart Rate monitoring                        | Opioid antagonists: Naloxone and Naltrexone     |
| Fetal Scalp pH                                    | Optic Neuropathy (Ischemic) Organophosphates    |
| Fetal Scalp Stimulation                            | Oxygen                                           |
| Fetal & Placental pharmacology                     | Oxygen consumption                                |
| GA Caesarean section                               | Free Radicals                                    |
| Mitral Stenosis                                   | Toxicity                                         |
| Neuroaxial                                        | Oximetry                                         |
| Neuroaxial Opioids                                | P                                                |
| Neuropathy Nitroglycerin                          | P 450                                            |
| Non-obstetrical Surgery                            | Pacemakers                                       |
| Oxygen delivery                                    | PACU                                             |
| PCEA                                              | Pain                                             |
| PDPH                                              | Components of major pain pathways:               |
| Physiologic Changes                                | Dorsal root ganglia of spinal cord               |
| PPH                                               | Lateral cervical nucleus                          |
| Placenta Previa & Acreeta                         | Pre-ganglionic sympathetic neurons:              |
| Preeclampsia                                      | Modulating Mechanisms                             |
| Retained placenta                                  | Spinal Modulation                                 |
| Spina bifida                                      | Definitions                                      |
| Thrombophilia                                     | Gate Control Theory:                             |
| Thyroid Trauma                                     | Transition from Acute to Persistent               |
|                                                   | Nociception                                      |
| Twins                                             | Physiologic Sequelae                             |
| Obstetric seizure                                  | PAR                                              |
| VBAC                                              | Parathyroid Hormone                              |
| Obesity Pharmacokinetics                           | Parkinson's PCA                                  |
| OLV                                               | Apnea                                            |
|                                                   | Background Infusions                             |
| Predictors of hypoxemia on OLV                     | Summary of ventilatory strategies                 |
| Ondansetron                                       | Apnea                                            |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Serotonin Syndrome                             | Thoracic Trauma                                      |
|------------------------------------------------|-----------------------------------------------------|
| Shivering                                      | Transdermal Drugs                                   |
| Shunt Lesions:                                 | Transsphenoidal Resection                           |
| L - R Shunts:                                  | Traumatic Brain Injury                              |
| R - L Shunts                                   | Tuberculosis                                        |
| SIADH                                          | TURP                                                |
| Sickle Cell Disease                            | Glycine:                                           |
| Sitting Postion                                | Bladder Perforation:                               |
| Smoke inhalation injury                        | TUR Syndrome (H2O intoxication)                    |
| Smoking                                        | U                                                  |
| Sodium Nitroprusside                           | Ulnar                                              |
| Spinal cord injury                             | neuropathy Urinary Composition in Oliguria         |
| Spirometry                                     | V                                                  |
| PFTS                                          |                                                     |
| Flow-volume loops                               | Valvular Heart disease                              |
| SSEPs                                          | Aortic Stenosis                                    |
| STATS                                          | Mitral stenosis                                    |
| Sample size calculation                        | Aortic regurgitation                                |
| Stellate ganglion block                        | Mitral regurgitation                                |
| Steroid Potency                                | Physical exam findings                              |
| Stress hormones                                 | VAP                                                |
| Superventricular tachycardia - SVT            | Vasopressin                                        |
| SVO2                                          | Venous air embolism                                 |
| SVR                                           | Ventilation                                        |
| Systemic Lupus Erythematosus                  | Pressure support ventilation Inverse Ratio Ventilation (Pressure Control) |
| Tamponade                                      | Weaning & Extubation Vertebrobasilar TIAs         |
| TCA                                           | von Willebrands                                     |
| TENS                                          | Volatile                                           |
| Thermoregulation in Infants                    | Anesthesia Uptake and Distribution                  |
| Thiopental                                     | Physiologic                                        |
| IA injection                                   | Effects                                            |
| Thoracic surgery complications                  | General Ventilatory Effects:                        |
| Thyroid                                        | Toxicity                                           |
| Thyroid Storm                                  | Physiochemical Properties                           |
| Hypothyroid                                    | Low flows                                          |
| Torsades de Pointes                            | MAC factors:                                       |
| Total body water                               | Neonatal induction                                  |
|                                                | Relative solubilities in plastics                   |
| Tourniquet                                     |                                                   |
| TOF                                            | W                                                  |
| TPN                                            | Waste gases- maximum allowable                      |
| Trauma                                         | WPW                                                |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 11. Risk Factors for Ischemic Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation**

|          | Non-pregnant | T1 | T2 | T3 |
|----------|--------------|----|----|----|
| PaCO2    | 40           | 30 | 30 | 30 |
| PaO2     | 100          | 107| 105| 103|
| pH       | 7.40        | 7.44| 7.44| 7.44|
| HCO3     | 24           | 21 | 20 | 20 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Location            | pO2 | pCO2 | pH   |
|---------------------|-----|------|------|
| Uterine artery      | 96  | 28   | 7.45 |
| Uterine vein        | 33  | 37   | 7.35 |
| Umbilical artery    | 15  | 44   | 7.33 |
| Umbilical vein      | 28  | 35   | 7.37 |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```markdown
| Subject                                      | Age                  | PO 2 (mm Hg) | PCO 2 (mm Hg) | pH   |
|----------------------------------------------|----------------------|--------------|----------------|------|
| Fetus (term)                                | Before labor         | 20-25        | 40             | 7.37 |
| Fetus (term)                                | End of labor         | 10-20        | 55             | 7.25 |
| Newborn (term)                              | 10 min               | 50           | 48             | 7.20 |
| Newborn (term)                              | 1 hr                 | 70           | 35             | 7.35 |
| Newborn (term)                              | 1 wk                 | 75           | 35             | 7.40 |
| Newborn (preterm, 1500 g)                  | 1 wk                 | 60           | 38             | 7.37 |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Altitude (m/ft)   | P B (mm Hg) | PIO 2 (mm Hg) | PAO 2 (mm Hg) | PACO 2 (mm Hg) | SaO 2 (%) |
|--------------------|-------------|----------------|----------------|----------------|-----------|
| Sea level          | 760         | 159            | 104            | 40             | 97        |
| 3,300/10,000       | 523         | 110 (436)*     | 67             | 36             | 90        |
| 6,600/20,000       | 349         | 73             | 40             | 24             | 70        |
| 9,900/30,000       | 226         | 47             | 21             | 24             | 20        |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 9-5. DIFFERENTIAL DIAGNOSIS OF METABOLIC ACIDOSIS**

| Elevated Anion Gap         | Normal Anion Gap                     |
|----------------------------|--------------------------------------|
| 1. Uremia                  | 1. Renal tubular acidosis            |
| 2. Ketoacidosis            | 2. Diarrhea                          |
| 3. Lactic acidosis         | 3. Carbonic anhydrase inhibition     |
| Toxins                     | 4. Ureteral diversions               |
| 1. Methanol                | 5. Early renal failure                |
| 2. Ethylene glycol         | 6. Hydronephrosis                    |
| 3. Salicylates             | 7. HCl administration                 |
| 4. Paraldehyde             | 8. Saline administration              |
|                            | 9. Adrenal insufficiency              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 25-1. Classification of diuretics**

| Drug        | Route      | Dose                                                                                     |
|-------------|------------|------------------------------------------------------------------------------------------|
| Energy      |            | 200 biphasic 360 mono, 2 J/kg, 2-4 J/kg, 4 J/kg                                         |
| Epinephrine | IV         | 1 mg, 0.01 mg /kg (0.1 ml/kg of 1:10,000), 0.1 mg/kg (0.1 ml/kg of 1:1000) (optional for high dose in pulseless arrest), 0.01 to 0.03 mg/kg, 0.1-0.3 mls/kg of 1:10,000 |
| Epinephrine | Infusion   | 2 - 10 ug/min, 0.1 - 1 ug/kg/min                                                        |
|             | ETT        | 2 - 2.5 mg, 0.1 mg/kg (0.1 ml/kg of 1:1000), Same as IV                                 |
| Bicarb      | IV         | 1-2 mEq/kg of 4.2% sol                                                                   |
| Naloxone    | IV         | 0.1 mg/kg (or 2mg if > 5 yrs or 20kg), 0.1 mg/kg                                        |
|             | ETT,IM     | Same as IV                                                                               |
| Dextrose    | IV         | 0.5 - 1 g/kg (may use 10 - 50%), 0.2 g/kg IV of 10% sol                                |
| Atropine    | IV         | 1mg (0.5 if brady), 0.02 mg/kg with min dose of 0.1 mg                                 |
|             | ETT        | 2 - 3 mg, Same as IV                                                                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Predictor Variable                             | Point Value of Variable                          | Definition                                                                                                           |
|------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| 23 rsk factols for CAD                         |                                                  | Risk factors Family of CAD Hypertersion Hypercholesterolemia Diabetes Current smoker history                       |
| Recent, severe symptoms of angina              | 22 anginal events in last 24 hours              |                                                                                                                     |
| Bevated cardiac markers                         | ST devjaüon 20.5 mm                             | ST depression 20.5 mm is signifcant; bansient ST elevation >0.5 mm for 20 minutes is treated as ST-sgment depression and is high risk; ST elevation 21 mm for more than |
| Prior coronar; artery stenosis                 | 25086                                           |                                                                                                                     |
| Risk of 21 Primary End Pcint in 214 Days       | Risk Status                                     |                                                                                                                     |
|                                                | 1306                                            | Intermediate                                                                                                      |
|                                                | 2086                                            | 5                                                                                                                   |
|                                                | 2696                                            | High                                                                                                               |
|                                                | 6 or                                           | 4196                                                                                                              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```markdown
| Sympathomimetics | CCBs B-Blockers | TCAs | Cardiac Glycosides | Anticholinergics |
|-------------------|------------------|------|--------------------|-------------------|
| Amphetamines      | Bradycardia      | Stimulate catecholamine release and block reuptake | Digoxin            | diphenhydramine   |
| Cocaine           | Impaired conduction | Central and peripheral anticholinergic actions | Digitoxin          | doxylamine        |
| PCP               | Shock            | Alpha blocking effects | Foxglove           |                   |
| Ephedrine         | Cardiac Arrest   | Inhibit K channels in myocardium and Na in brain | oleander           |                   |
| Delerium          | NS bolus         | Dec. LOC | Gastric atony      |                   |
| Mydriasis         | Epinephrine      | Agitation &SZ | N/V                |                   |
| Sweating          | Pacemaker        | Coma | Weakness           |                   |
| Tahcycardia       | Assist device    | Tachycardia | Visual symptoms    |                   |
| SVT               | Calcium infusion  | Bradycardia | Abd pain          |                   |
| VT                | Glucose / insulin inf. | VT | SVT                |                   |
| Impaired conduction | Glucagon       | Impaired conduction | VT                |                   |
| HTN crisis        |                  | Shock | Impaired conduction |                   |
| ACS               |                  | Cardiac Arrest | Shock            |                   |
| Shock             |                  | Acidosis | Cardiac Arrest    |                   |
| Cardiac Arrest    |                  | Urinary retention | Restore potassium and Mg |                   |
|                   |                  | Alkalinization | Restore intravascular volume |                   |
|                   |                  | o Bicarb | Digoxin-specific antibodies |                   |
|                   |                  | o Hyperventilation | Atropine         |                   |
|                   |                  | NS bolus | Low dose defibrillation o 25-50J |                   |
|                   |                  | Mg | Pacemaker          |                   |
|                   |                  | Lidocaine | Lidocaine         |                   |
|                   |                  | Epinephrine | Phenytoin?       |                   |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 17-7 -- Cardiovascular responses to hypercapnia (PaCO2 = 60 to 83 mm Hg) during various types of anesthesia (1 MAC equivalent except for nitrous oxide)***

| Condition                     | Agents/Interventions                                                                                     | Effects/Responses                                                                                     |
|-------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Impaired conduction            | Cholinergics, Carbamates, Nerve Agents, Organophosphates                                               | Bradycardia, VT, Impaired conduction, Shock, Pulmonary edema, Bronchospasm, Cardiac Arrest           |
|                               | Atropine, Decontamination, Pralidoxime, obidoxime                                                      |                                                                                                       |
| Opioids                       | Hypoventilation, bradycardia, hypotension, miosis                                                      | Assist ventilation, Naloxone (Avoid in Demerol induced Sz), ETT, Nalmefene                          |
| Isoniazid                     | Lactic acidosis, +/- Seizures, Tachycardia / bradycardia, Shock, Cardiac Arrest                       | Pyridoxine - 1g/ gram of ingested isoniazid                                                          |
| Sodium channel blockers        | Procainamide, Disopyramide, Lidocaine, Propafenone, Flecainide                                        | Bardycardia, VT, Impaired conduction, Seizures, Shock, Cardiac Arrest                                |
|                               | Bicarb, Pacemakers, Alpha and beta agonists, Lidocaine - not in lidocaine toxicity, Hypertonic saline |                                                                                                       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 12-13. ACTIONS OF ADRENERGIC AGONISTS**

| Receptors                | Sympatho- mimetics | alpha 1 | alpha 2 | Beta 1 | Beta 2 | DA 1 | Dose Dependence (, , or DA) | Comments                             |
|-------------------------|---------------------|---------|---------|--------|--------|------|----------------------------------|--------------------------------------|
| Methoxamine             | + + + +             | ?*      | 0       | 0      | 0      | 0    | Vasoconstriction only             |
| Phenylephrine           | + + + +             | ?       | ±       | 0      | 0      | + +  | Primarily vasoconstriction        |
| Norepinephrine          | + + + +             | + + +   | + + +   | 0      | 0      | + + +| Beta2 effect present but not seen clinically |
| Metaraminol            | + + + +             | ?       | + + +   | 0      | 0      | + + +| Releases NE                        |
| Epinephrine             | + + + +             | + + +   | + + + + | + +    | 0      | + + +|                                      |
| Ephedrine               | + +                 | ?       | + + +   | + +    | 0      | + +  | Direct and indirect                |
| Mephentermine           | 0 to + +            | ?       | + + + + | +?     | 0      | + +  | Cerebral stimulation               |
| Dopamine                | + to + + + + +     | ?       | + + + + | + +    | + + +  | + ++ +|                                      |
| Dobutamine              | 0 to +              | ?       | + + + + | + +    | 0      | + +  | Inotropism greater than            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 3. Cardiac Conditions Associated With the Highest Risk of Adverse Outcome From Endocarditis for Which Prophylaxis With Dental Procedures Is Recommended**

| Drug          | 0   | 0   | +     | + + + + | +   | + + |
|---------------|-----|-----|-------|---------|-----|-----|
| Dopexamine    | 0   | 0   | +     | + + + + | +   | + + |
| Prenalterol   | +   |     | + + + + | + +   |     | +   |
| Isoproterenol | 0   | 0   | + + + + | + + + + | 0   | 0   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 12-16. COMPARISON OF RELATIVE  1 CATECHOLAMINE RESPONSES ON PERIPHERAL RESISTANCE AND CAPACITANCE VESSELS***

| Vasoconstriction          |  1 Arterial (  1a ) |  1 Venous (  1v ) |
|---------------------------|------------------------|----------------------|
| Norepinephrine             | + + + + +              | Norepinephrine        | + + + + +            |
| Metaraminol               | + + + + +              | Phenylephrine        | + + + + +            |
| Phenylephrine             | + + + +                | Metaraminol         | + + + +              |
| Methoxamine               | + + + +                | Dopamine             | + + +                |
| Epinephrine               | 0/+ + + +†            | Epinephrine          | 0/+ + + +†          |
| Dopamine                  | 0/+ + + +‡            | Ephedrine            | + + +                |
| Ephedrine                 | + +                    | Mephentermine        | +?                   |
| Mephentermine             | + +                    | Methoxamine          | 0/+?                 |
| Dobutamine                | +/0                    | Dobutamine           | ?                    |
| Isoproterenol             | 0                      | Isoproterenol        | 0                    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 253-3**

| Muscle                     | Origin                          | Innervation | Function            |
|---------------------------|---------------------------------|-------------|---------------------|
| Cricothyroid              | cricoid cartilage to thyroid lamina | ext branch of SLN | tenses VC           |
| Post cricoarytenoid       | cricoid to arytenoid           | RLN         | ABDuctor of VC      |
| Lat cricoarytenoid        | cricoid to arytenoids          | RLN         | ADDuctor            |
| Thyroarytenoid (vocalis)  | thryroid to arytenoid          | RLN         | relaxes VC          |
| Transverse arythenoid     | between arytenoids              | RLN         | adducts VC          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 1. Drugs Involved in Perioperative Anaphylaxis (5)**

| Substance                     | Incidence of perioperative anaphylaxis (%) | Most commonly associated with perioperative anaphylaxis                     |
|-------------------------------|--------------------------------------------|---------------------------------------------------------------------------|
| Muscle relaxants              | 69.2                                       | Succinylcholine, rocuronium, atracurium                                   |
| Natural rubber latex          | 121                                        | Latex gloves, tourniquets, catheters Foley                                |
| Antibiotics                   | 8                                          | Penicillin and other B-lactams                                            |
| Hypnotics                     | 3.7                                        | Propofol, thiopental                                                      |
| Colloids                      | 27                                         | Dextran, gelatin                                                          |
| Opioids                       | 1.4                                        | Morphine, meperidine                                                      |
| Other substances              | 29                                         | Propacetamol, aprotinin, chymopapain, protamine, bupivacaine            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 10-1 -- Pharmacokinetic variables of commonly used intravenous anesthetics**

| Drug               | Elimination Half-Life (hr) | Clearance (mL/kg/min) | Vd ss (L/kg) |
|--------------------|----------------------------|-----------------------|--------------|
| Dexmedetomidine    | 2-3                        | 10-30                 | 2-3          |
| Diazepam            | 20-50                      | 0.2-0.5               | 0.7-1.7      |
| Droperidol         | 1.7-2.2                    | 14                    | 2.0          |
| Etomidate          | 2.9-5.3                    | 18-25                 | 2.5-4.5      |
| Flumazenil         | 0.7-1.3                    | 5-20                  | 0.6-1.6      |
| Ketamine           | 2.5-2.8                    | 12-17                 | 3.1          |
| Lorazepam          | 11-22                      | 0.8-1.8               | 0.8-1.3      |
| Methohexital       | 2-6                        | 10-15                 | 1.5-3        |
| Midazolam          | 1.7-2.6                    | 6.4-11                | 1.1-1.7      |
| Propofol           | 4-7                        | 20-30                 | 2-10         |
| Thiopental         | 7-17                       | 3-4                   | 1.5-3        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 30-3. Side effects of antiepileptic drugs**

| Drug            | Dose-related                                                                 | Idiosyncratic                                                        |
|-----------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Phenobarbital   | Sedation, Depression, Hyperactivity (children)                              | Agranulocytosis, Allergic dermatitis (rash), Stevens-Johnson syndrome, Arthritic changes, Hepatotoxic effects, Teratogenicity |
| Primidone       | Sedation                                                                     | Rash, Thrombocytopenia, Agranulocytosis, Lupus-like syndrome, Teratogenicity |
| Phenytoin       | Nystagmus, Ataxia, Nausea and vomiting, Gingival hyperplasia, Depression, Megaloblastic anemia, Drowsiness | Agranulocytosis, Aplastic anemia, Allergic dermatitis (rash), Stevens-Johnson syndrome, Hepatotoxic effects, Pancreatitis, Acne, Coarse facies, Hirsutism, Teratogenicity, Dupuytren's contracture |
| Carbamazepine   | Diplopia, Vertigo, Neutropenia, Nausea, Drowsiness, Hyponatremia           | Agranulocytosis, Aplastic anemia, Allergic dermatitis (rash), Stevens-Johnson syndrome, Hepatotoxic effects, Pancreatitis, Teratogenicity |
| Ethosuximide    | Nausea, Anorexia, Vomiting, Agitation, Headache, Drowsiness                 | Agranulocytosis, Aplastic anemia, Allergic dermatitis (rash), Stevens-Johnson syndrome, Lupus-like syndrome |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 8-2.**

| Drug            | Side Effects                                                                                     | Serious Adverse Effects                                   |
|------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Valproic acid    | Tremor, Weight gain, Dyspepsia, Nausea and vomiting, Alopecia, Peripheral edema, Encephalopathy, Teratogenicity | Agranulocytosis, Aplastic anemia, Allergic dermatitis (rash), Stevens-Johnson syndrome, Hepatotoxic effects, Pancreatitis |
| Clonazepam       | Sedation, Vertigo, Hyperactivity (children)                                                     | Allergic dermatitis (rash), Thrombocytopenia             |
| Felbamate        | Insomnia, Anorexia, Nausea, Headache, Irritability                                              | Aplastic anemia, Hepatotoxic effects                       |
| Gabapentin       | Sedation, Ataxia, Vertigo, Gastrointestinal disturbances                                         |                                                          |
| Lamotrigine      | Tremor, Vertigo, Diplopia, Ataxia, Headache, Gastrointestinal disturbances                      | Stevens-Johnson syndrome                                   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 12-11. COMPARISON OF ANTIMUSCARINIC DRUGS  (Barash)**

| Drug            | Duration      | iv     | im     | CNS      | GI Tone | Gastric Acid | Airway Secretions* | Heart Rate   |
|-----------------|---------------|--------|--------|----------|---------|--------------|--------------------|--------------|
| Atropine        | 15-30 min     | 2-4 hr | + +    | - -      | -       | -            | + + +‡            |
| Scopolamine     | 30-60 min     | 4-6 hr | + + +† | -        | -       | - -- -      | - 0‡              |
| Glycopyrrolate  | 2-4 hr       | 6-8 hr | 0      | - - -    | - - -   | - - -        | +0                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 52-11 -- Percent change in cardiovascular variables on initiation of aortic occlusion**

| Cardiovascular Variable                     | Superceliac | Infraceliac | Infrarenal |
|---------------------------------------------|-------------|-------------|-------------|
| Mean arterial blood pressure                 | 54          | 5           | 2           |
| Pulmonary capillary wedge pressure           | 38          | 10          | 0           |
| End-diastolic area                          | 28          | 2           | 9           |
| End-systolic area                           | 69          | 10          | 11          |
| Ejection fraction                           | - 38       | - 10       | - 3        |
| Patients with wall motion abnormalities      | 92          | 33          | 0           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 42-14. Calculation of Apgar Score**

|                | 0                     | 1                     | 2                     |
|----------------|-----------------------|-----------------------|-----------------------|
| Heart rate      | Absent                | <100 beats/min        | >100 beats/min        |
| Respiratory effort | Absent            | Slow and irregular     | Crying                |
| Muscle tone     | Limp                  | Some flexion of extremities | Moving            |
| Reflex irritability | No response       | Grimace               | Crying, cough         |
| Color           | Pale, blue            | Body pink, extremities blue | Pink              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Feature                | ARDS     | Left Heart Failure | Pneumonia | PE      |
|-----------------------|----------|--------------------|-----------|---------|
| Fever, leukocytosis    | Yes      | Possible           | Yes       | Yes     |
| Bilateral Infiltrates  | Yes      | Yes                | Possible  | Unlikely |
| Pleural Effusions      | Unlikely | Yes                | Possible  | Possible |
| Wedge Pressure         | Normal   | High               | Normal    | Normal  |
| Lung lavage Protein     | High     | Low                | High      | High    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 6 Neuraxial Anesthesia in the Patient Receiving Thromboprophylaxis**

| Antiplatelet Medications | Unfractionated Heparin | Low Molecular Weight Heparin | Warfarin | Thrombolytics | Herbal Therapy |
|--------------------------|------------------------|------------------------------|----------|---------------|----------------|
| German Society of Anesthesiology and Intensive Care Medicine | No contraindication | Needle placement h after heparin; heparin h after needle placement discontinuing or catheter removal | Needle placement andor catheter removal 4 h after heparin, heparinize 1 h after neuraxial technique; delay surgery 12 h if | Neuraxial technique 10-12 h after LMWH: next dose h after needle or catheter placement | Discontinue in advance remove catheter prior to initiation of warfarin | Not discussed | Not discussed |
| Spanish Consensus Forum | Discontinue in advance | Not discussed | traumatic Neuraxial technique 4 h after heparin dose; heparinize 30 min after needle placement; delay heparinization 6 h if traumatic | Needle placement 12+ h after LMWH; first postoperative dose 4-12 h; catheters removed 10-12 h after LMWH and 4 prior to next dose; postpone LMWH 24 if traumatic | INR 5 for performance of neuraxial techniques; no INR guidelines for catheter removal | Not discussed | Not discussed |
| American Society of Regional Anesthesia and Pain Medicine | No contraindication with NSAIDs; discontinue ticlopidine 14 d, clopidogrel 7 d, 8-48 h in advance | No contraindication; consider delaying heparin until after block if technical GP difficulty anticipated | Heparinize after neuraxial technique, remove catheter 2-4 h after last heparin dose; no mandatory if traumatic delay | Twice daily dosing: LMWH 24 h after surgery, regardless of technique; remove neuraxial catheter 2 h before first LMWH dose. Single daily dosing: according to European statements | Document normal INR after discontinuation (prior to neuraxial technique); remove catheter when INR (initiation of therapy) | No data on safety interval for performance of neuraxial technique or catheter removal; follow fibrinogen level | No evidence for mandatory discontinuation prior to neuraxial technique; be aware of potential drug interactions |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| class | definition                                                                                      |
|-------|-------------------------------------------------------------------------------------------------|
| 1     | Normal healthy patient                                                                          |
| 2     | Patient with mild systemic disease and no functional limitations                                 |
| 3     | Patient with moderate to severe systemic disease that results in some function limitation        |
| 4     | Patient with severe systemic disease that is a constant threat to life and functionally incapacitating |
| 5     | Moribund patient who is not expected to survive 24 hours with or without surgery               |
| 6     | Brain dead patient whose organs are being harvested                                             |
| E     | If the procedure is an emergency                                                                 |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 12. Stroke Risk in Patients With Nonvalvular AF Not Treated With Anticoagulation According to the CHADSz Index**

| CHADS? Risk Criteria       | Score |
|----------------------------|-------|
| Prior stroke or TIA        | 2     |
| Age >75 y                  |       |
| Hypertension                |       |
| Diabetes mellitus           |       |
| Heart failure               |       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 3 Cardlac Conditlons Assocated With the Hlghest Rlsk of Adverse Outcome From Endocardltls for Whlch Prophylaxls WIth Dental Procedures Is Recommended**

| Patients (N=1733) | Adjusted Stroke Rate (%/y) * (95% CI) | CHADS? Score |
|--------------------|----------------------------------------|---------------|
| 120                | 1.9 (1.2 to 3.0)                      | 0             |
| 463                | 2.8 (2.0 to 3.8)                      |               |
| 523                | 4.0 (3.1 to 5.1)                      | 2             |
| 337                | 5.9 (4.6 to 7.3)                      | 3             |
| 220                | 8.5 (6.3 to 11.1)                     |               |
| 65                 | 12.5 (8.2 to 17.5)                    | 5             |
| 5                  | 18.2 (10.5 to 27.4)                   | 6             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 11. Risk Factors for Ischemic Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation**

| Risk Factors                              | Relative Risk |
|-------------------------------------------|---------------|
| Previous stroke or TIA                    | 2.5           |
| Diabetes mellitus                          | 1.7           |
| History of hypertension                    |               |
| Heart failure                              | 1.4           |
| Advanced age (continuous, per decade)     | 1.4           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 13. Antithrombotic Therapy for Patients With Atrial Fibrillation**

| Risk Category                                          | Recommended Therapy                                                        |
|-------------------------------------------------------|---------------------------------------------------------------------------|
| No risk factors                                       | Aspirin; 81 to 325 mg daily                                              |
| One moderate-risk factor                              | Aspirin; 81 to 325 mg daily, or warfarin (INR 20 to 3.0, target 2.5)    |
| Any high-risk factor or more than moderate-risk factor| Warfarin (INR 2.0 to 3.0, target 2.5)*                                  |
| Less Validated or Weaker Risk Factors                 | Moderate-Risk Factors                                                   | High-Risk Factors                     |
| Female gender                                         | Age greater than or equal to 75 y                                       | Previous stroke; TIA or embolism     |
|                                                       | Hypertension                                                            | Mitral stenosis                      |
| Coronary disease artery                               | Heart failure                                                           | Prosthetic heart valve'              |
| Thyrotoxicosis                                       | LV ejection fraction 35% or less                                        |                                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 14. Risk-Based Approach to Antithrombotic Therapy in Patients With Atrial Fibrillation**

| Patient Features                                                        | Antithrombotic Therapy                               | Class of Recommendation |
|-------------------------------------------------------------------------|-----------------------------------------------------|-------------------------|
| Age less than 60 y, no heart disease (lone AF)                          | Aspirin (81 to 325 mg per day) or no therapy       |                         |
| Age less than 60 y; heart disease but no risk factors                  | Aspirin (81 to 325 mg per day)                     |                         |
|                                                                         | Aspirin (81 to 325 mg per day)                     |                         |
| Age 65 to 74 y with diabetes mellitus or CAD                            | Oral anticoagulation (INR 2.0 to 3.0)              |                         |
| Age 75 y or older; women                                                | Oral anticoagulation (INR 20 to 3.0)               |                         |
| Age 75 y or older, men; no other risk factors                           | Oral anticoagulation (INR 2.0 to 3.0) or aspirin (81 to 325 mg per day) |                         |
| Age 65 or older, heart failure                                           | Oral anticoagulation (INR 20 to 3.0)               |                         |
| LV ejection fraction less than 35% or fractional shortening less than 25%, and hypertension | Oral anticoagulation (INR 2.0 to 3.0)              |                         |
| Rheumatic heart disease (mitral stenosis)                               | Oral anticoagulation (INR 2.0 to 3.0)              |                         |
| Prosthetic heart valves                                                  | Oral anticoagulation (INR 2.0 to 3.0 or higher)    |                         |
| Prior thromboembolism                                                   | Oral anticoagulation (INR 2.0 to 3.0 or higher)    |                         |
| Persistent atrial thrombus on TEE                                       | Oral anticoagulation (INR 2.0 to 3.0 or higher)    | Ila                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 5-1. Neuroendocrine and metabolic responses to surgery**

| Clinical Examination                                   | Technique                                                                                                                                                                                                 | Normal Value          |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Parasympathetic                                       | HR response to a Valsalva maneuver ( Normal response is for the HR to slow with release of valsalva - inc with dysfunction ) The seated subject blows into a mouthpiece (while maintaining a pressure of 40 mmHg) for 15 seconds. The Valsalva ratio is the ratio of the longest R-R interval (which comes shortly after release) to the shortest R-R interval (which occurs during the maneuver) | Ratio of >1.21       |
| HR response to standing                               | HR is measured as the subject moves from a resting supine position to standing. A normal tachycardic response is maximal around the 15th beat after rising. A relative bradycardia follows that is most marked around the 30th beat after standing. The response to standing is expressed as a 30 : 15 ratio and is the ratio of the longest R-R interval around the 30th beat to the shortest R-R interval around the 15th beat | Ratio of >1.04       |
| HR response to deep breathing                         | The subject takes six deep breaths in 1 minute. The maximum and minimum heart rates during each cycle are measured, and the mean of the differences (maximum HR - minimum HR) during three successive breathing cycles is taken as the maximum-minimum HR | Mean difference >15 beats/min |
| Sympathetic                                          | BP response to standing The subject moves from resting supine to standing, and standing SBP is subtracted from supine SBP                                                                                 | Difference <10mmHg    |
| BP response to sustained handgrip                     | The subject maintains a handgrip of 30% of the maximum handgrip squeeze for up to 5 minutes. BP is measured every minute, and the initial DBP is subtracted from the DBP just before release                                                             | Difference >16mmHg    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Effector Organ                     | Adrenergic Response       | Receptor Involved | Cholinergic Response       | Dominant Response (A or C) |
|------------------------------------|---------------------------|-------------------|----------------------------|-----------------------------|
| Heart                              |                           |                   |                            |                             |
| Rate of contraction                | Increase                  | β 1               | Decrease                   | C                           |
| Force of contraction               | Increase                  | β 1               | Decrease                   | C                           |
| Blood vessels                      |                           |                   |                            |                             |
| Arteries (most)                   | Vasoconstriction          | α 1               |                            | A                           |
| Skeletal muscle                    | Vasodilation              | β 2               |                            | A                           |
| Veins                              | Vasoconstriction          | α 2               |                            | A                           |
| Bronchial tree                    | Bronchodilation           | β 2               | Bronchoconstriction        | C                           |
| Splenic capsule                    | Contraction               | α 1               |                            | A                           |
| Uterus                             | Contraction               | α 1               | Variable                   | A                           |
| Vas deferens                       | Contraction               | α 1               |                            | A                           |
| Prostatic capsule                  | Contraction               | α 1               |                            | A                           |
| Gastrointestinal tract             | Relaxation                | α 2               | Contraction                | C                           |
| Eye                                |                           |                   |                            |                             |
| Radial muscle, iris                | Contraction (mydriasis)   | α 1               |                            | A                           |
| Circular muscle, iris              |                           |                   | Contraction (miosis)       | C                           |
| Ciliary muscle                     | Relaxation                | β                 | Contraction (accommodation) | C                           |
| Kidney                             | Renin secretion           | β 1               |                            | A                           |
| Urinary bladder                    |                           |                   |                            |                             |
| Detrusor                           | Relaxation                | β                 | Contraction                | C                           |
| Trigone and sphincter             | Contraction               | α 1               | Relaxation                 | A, C                       |
| Ureter                             | Contraction               | α 1               | Relaxation                 | A                           |
| Insulin release from pancreas      | Decrease                  | α 2               |                            | A                           |
| Fat cells                          | Lipolysis                 | β 1               |                            | A                           |
| Liver glycogenolysis              | Increase                  | α 1               |                            | A                           |
| Hair follicles, smooth muscle      | Contraction (piloerection) | α 1               |                            | A                           |
| Nasal secretion                    |                           |                   | Increase                   | C                           |
| Salivary glands                    | Increase secretion         | α 1               | Increase secretion          | C                           |
| Sweat glands                       | Increase secretion         | α 1               | Increase secretion          | C                           |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 5-1. Comparative pharmacology of benzodiazepines**

| Drug        | Equivalent dose (mg) | Volume distribution (liters/kg) | Protein binding (%) | Clearance (ml/kg/min) | Elimination half-time (hrs) |
|-------------|-----------------------|----------------------------------|---------------------|------------------------|------------------------------|
| Midazolam   | 0.15-0.3              | 1.0-1.5                          | 96-98               | 6-8                    | 1-4                          |
| Diazepam    | 0.3-0.5               | 1.0-1.5                          | 96-98               | 0.2-0.5                | 21-37                        |
| Lorazepam   | 0.05                  | 0.8-1.3                          | 96-98               | 0.7-1.0                | 10-20                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Beta 1 - selective | Intrinsic sympatho mimetic activity | Membrane- stabilizing activity | Protein binding (%) | Clearance | Active metabolites | Elimination half-time (hrs) | Adult oral dose (mg) |
|---------------------|-------------------------------------|-------------------------------|---------------------|-----------|--------------------|-----------------------------|-----------------------|
| Propranolol         | No                                  | 0                             | ++                  | 90-95     | Hepatic            | Yes                         | 2-3                   | 40-80                 |
| Nadolol             | No                                  | 0                             | 0                   | 30        | Renal              | No                          | 20-24                 | 40-320                |
| Pindolol            | No                                  | +                             | ±                   | 40-60     | Hepatic, renal     | No                          | 3-4                   | 5-20                  |
| Timolol             | No                                  | ±                             | 0                   | 10        | Hepatic            | No                          | 3-4                   | 10-30                 |
| Sotalol             | No                                  | 0                             | 0                   | 0         | Renal              | No                          | 8                     | 80-640                |
| Metoprolol          | Yes                                 | 0                             | ±                   | 10        | Hepatic            | No                          | 3-4                   | 50-400                |
| Atenolol            | Yes                                 | 0                             | 0                   | 5         | Renal              | No                          | 6-7                   | 50-200                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug        | Approved | Effect | Side Effect | Dose | Metabolism         | Monitoring | Half-life | Therapeutic Range               |
|-------------|----------|--------|-------------|------|---------------------|------------|-----------|----------------------------------|
| Acebutolol  | Yes      | +      | +           | 25   | Hepatic, renal      | Yes        | 3-4       | 200-800                          |
| Betaxolol   | Yes      | ±      | 0           |      | Hepatic, renal      | -          | 11-22     | 10-20                           |
| Esmolol     | Yes      | 0      | 0           |      | Plasma hydrolysis    | No         | 0.15      | 10-80 IV, 100-300 µg/kg/min IV  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 47-4. Properties of whole blood and packed red cell concentrates stored in CPDA-1**

| Parameter                              | 0     | 35 (Whole Blood) | 35 (Packed Cells) |
|----------------------------------------|-------|------------------|--------------------|
| pH                                     | 7.55  | 6.73             | 6.71               |
| Plasma hemoglobin (mg/dL)             | 0.5   | 46               | 246.0              |
| Plasma potassium (mEq/L)              | 4.2   | 17.2             | 76.0               |
| Plasma sodium (mEq/L)                 | 169   | 153              | 122                |
| Blood dextrose (mg/dL)                | 440   | 282              | 84                 |
| 2,3-Diphosphoglycerate (μM/mL)       | 13.2  | 1                | 1                  |
| Percent survival*                      | -     | 79               | 71                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Test                                      | Sensitivity | Specificity |
|-------------------------------------------|-------------|-------------|
| Stress EKG                                | 68          | 77          |
| Exercise ECHO                             | 76          | 88          |
| Exercise thallium (planar) imaging       | 79          | 73          |
| Dipyridamole-thallium scan (MIBI)       | 88          | 77          |
| DSE (not an option)                      |             | 88          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Effect                          | Verapamil      | Nifedipine     | Nicardipine    | Diltiazem      |
|---------------------------------|----------------|----------------|----------------|----------------|
| Systemic blood pressure         | Decrease       | Decrease       | Decrease       | Decrease       |
| Heart rate                      | Decrease       | Increase to no change | Increase to no change | Decrease       |
| Myocardial depression           | Moderate       | Moderate       | Slight         | Moderate       |
| Sinoatrial node depression      | Moderate       | None           | None           | Slight         |
| Atrioventricular node conduction | Marked depression | None           | None           | Moderate       |
| Coronary artery dilation        | Moderate       | Marked         | Greatest       | Moderate       |
| Peripheral artery dilation      | Moderate       | Marked         | Marked         | Moderate       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Effect                     | Verapamil | Diltiazem | Nifedipine | Lidoflazine |
|---------------------------|-----------|-----------|------------|-------------|
| Negative inotropic        | +         | 0/+       | 0          | 0           |
| Negative chronotropic      | +         | 0/+       | 0          | 0           |
| Negative dromotropic      | + + + +   | + + +     | 0          | 0           |
| Coronary vasodilation     | + +       | + + +     | + + + +    | + + + +     |
| Systemic vasodilation     | + +       | + +       | + + + +    | + + +       |
| Bronchodilation           | 0/+       |           | 0/+        |             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Causes                                                        | PaCO2 to ETCO2 Gradient |
|---------------------------------------------------------------|-------------------------|
| incr dead space (thrombotic/air PE, bronchospasm)            | incr                    |
| hyperventilation                                              | N                       |
| esophageal intubation                                         | incr                    |
| decr CO2 production                                          | N                       |
| decr CO                                                     | incr                    |
| sample contamination (disconnect, cuff leak, sample tube leak)| incr                    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Causes                                                                 | PaCO2 to ETCO2 Gradient |
|------------------------------------------------------------------------|-------------------------|
| rebreathing (CO2 absorber failure, circle system failure, incr circuit dead space) | N                       |
| hypoventilation                                                        | N                       |
| incr CO                                                                | N                       |
| incr CO2 production (incr temp, MH, shivering, sz, HCO3 administration, tourniquet release) | N                       |
| R to L shunt                                                           | incr                   |
| endobronchial intubation                                               | incr                   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Increases in ETCO 2                                   | Decreases in ETCO 2                             |
|------------------------------------------------------|------------------------------------------------|
| ELEMENTS THAT CHANGE CO 2 PRODUCTION                 | ELEMENTS THAT CHANGE CO 2 ELIMINATION          |
| Increases in metabolic rate                           | Decreases in metabolic rate                     |
| Hyperthermia                                         | Hypothermia                                    |
| Sepsis                                               | Hypothyroidism                                 |
| Malignant hyperthermia                               |                                                |
| Hyperthyroidism                                      |                                                |
| Shivering                                            |                                                |
|                                                      | Hypoventilation                                |
|                                                      | Rebreathing                                    |
|                                                      | Hyperventilation                               |
|                                                      | Hypoperfusion (dead space)                     |
|                                                      | Pulmonary embolism                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| MET  | Can you house? | METs | Can you Climb a flight of stairs or walk up a hill? | Walk on level ground at 4 mph (6.4 kph)? | Run a short distance? | Do heavy work around the house like scrubbing floors or lifting or moving heavy furniture? | Participate in moderate METs washing dishes? | Participate in strenuous sports like swimming; singles tennis, football, basketball, or skiing? |
|------|----------------|------|-----------------------------------------------------|------------------------------------------|----------------------|------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------------|
|      |                |      | Greater than 10 METs                                |                                          |                      |                                                                                          |                                                |                                                                                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 2 Active Cardiac Conditions for Which the Patient Should Undergo Evaluation and Treatment Before Noncardiac Surgery (Class |, Level of Evidence: B)**

| Condition                                   | Examples                                                                                                           |
|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Unstable coronary syndromes                 | Unstable or severe angina' (CCS class Recent Mlt                                                                  |
| Decompensated HF (NYHA functional class IV; worsening or new-onset HF) |                                                                                                                    |
| Significant arrhythmias                     | High-grade atrioventricular block                                                                                  |
|                                             | Mobitz Il atrioventricular block                                                                                    |
|                                             | Third-degree atrioventricular heart block                                                                           |
|                                             | Supraventricular arrhythmias (including atrial fibrillation) with uncontrolled ventricular rate (HR greater than 100 bpm at rest) |
|                                             | Symptomatic bradycardia                                                                                            |
|                                             | Newly recognized ventricular tachycardia                                                                            |
| Severe valvular disease                     | Severe aortic stenosis (mean pressure gradient greater than 40 mm Hg; aortic valve area less than 1.0 cm² or symptomatic) |
|                                             | Symptomatic mitral stenosis (progressive dyspnea on exertion; exertional presyncope; or HF)                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Stimulus                                                        | Anatomy                                                                                                           | Response                                                                                                                                                                                                                     | Other                                                                                                                                                                                                                                           |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Increased blood pressure                                         | Carotid-afferent nerve of Hering (glossopharyngeal) Aortic-vagus Cardiovascular centers in medulla             | Inhibition of sympathetic and increase in parasympathetic activity, causing decreased cardiac contractility, heart rate, and vasoconstrictor tone                                                                             | Gain determined by pulse pressure Reduces arterial pressure fluctuation to one third of expected threshold 60 torr, limits 175-300 torr                                                                                                      |
| Forced expiration against closed glottis                        | Same as pressoreceptor reflex                                                                                     | Increased venous pressure in head, upper extremities, with decreased right heart venous return causing decreased blood pressure and cardiac output and reflex increase in heart rate                                           | Glottic opening increases venous return to right heart, resulting in forceful right and then left ventricular contraction, followed by transient bradycardia                                                                                     |
| Inspiratory effort against a closed airway                      | Decreased pleural pressure increasing left ventricular volume through afterload reduction                          | Right ventricular end-diastolic volume and left ventricular end-diastolic pressure increase, while left ventricular end-diastolic volume is unchanged or decreased, and ejection fraction is unchanged                       | Net effect on left ventricular function depends on ventricular interdependence, heart rate, and contractility (position of the heart on diastolic pressure-volume curve) Müller maneuver may cause ventricular akinesis due to increased wall stress, increasing myocardial oxygen demand, or increased left ventricular transmural pressure, decreasing motion in nonfunctional ventricular myocardium |
| Noxious stimuli to the ventricular wall                         | Left ventricular mechanoreceptors with afferent pathway in nonmyelinated vagal C fibers                          | Hypotension, bradycardia, and parasympathetically induced coronary vasodilation                                                                                                                                           | Reperfusion of previously ischemic tissue elicits reflex                                                                                                                                                                                      |
| Serotonin                                                       | Chemoreceptors located between the aorta and pulmonary artery and supplied by the left coronary artery Afferent reflex pathway is intrathoracic vagal branches and the efferent path is via phrenic, vagal, and sympathetic routes | Arterial pressure increases markedly in 4-6 sec owing to increased inotropy and peripheral vasoconstriction                                                                                                              | Reflex may be responsible for hypertension during angina, myocardial infarction, and after coronary bypass grafting and is abolished by vagotomy, atropine, or local anesthesia of the intertruncal space                                   |
| Cerebral ischemia secondary to increased CSF pressure            | Increased cerebrospinal fluid (CSF) pressure compresses cerebral arteries                                         | An increase in arterial pressure sufficient to reperfuse the brain Intense sympathetic activity causes severe peripheral vasoconstriction and HTN with baroreceptor mediated bradycardia                                   |                                                                                                                                                                                                                                                 |
| Increased vagal tone and distention of the right atrium or central veins | Primarily mediated through vagal myelinated afferent fibers; activation of sympathetic afferent fibers may also occur 39 Increased right atrial pressure directly stretches the SA node and enhances its automaticity, increasing the heart rate | Depends upon the pre-existing heart rate With pre-existing tachycardia, there is no effect                                                                                                                                 |                                                                                                                                                                                                                                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category          | Stimulus                                                                 | Anatomy                                                                                                                        | Response                                                                                                         | Other                                                                                                                                                                                                                     |
|-------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Volume loading     | at a slow heart rate causes progressive tachycardia                     | Global atrial distention in response to high pressures causes bradycardia, hypotension, and decreased systemic vascular resistance |                                                                                                                 | Experimental distention of the cavoatrial junctions or other small portions of the atria increases heart rate, but clinical conditions such as heart failure usually do not produce such locally increased atrial pressure 97 |
| CHEMORECEPTOR      | Decreasing oxygen tension or increased hydrogen ion concentrations        | Carotid and aortic bodies chemoreceptors whose nerve fibers pass through the nerve of Hering and the vagus nerve to the medullary vasomotor centers | Increased pulmonary ventilation and blood pressure with decreased heart rate (carotid body chemoreceptors) Stimulation of the aortic bodies causes tachycardia | Normally, the peripheral chemoreceptors are minimally active                                                                                                                                                           |
| OCULOCARDIAC      | Traction on the extraocular muscles (more especially the medial rather than the lateral rectus) or pressure on the globe | Afferent fibers run with the short or long ciliary nerves to the ciliary ganglion and then with the ophthalmic division of the trigeminal nerve to the gasserian ganglion, efferent via vagus | Bradycardia and hypotension as a consequence of this reflex                                                  | Demonstrated in 30-90% of patients undergoing ophthalmic surgery and attenuated by intravenous atropine                                                                                                               |
| CELIAC (VASOVAGAL) |                                                                          | Vagal stimulation via mesenteric traction, rectal distention, traction on gallbladder, respiratory tract receptors              | Bradycardia, apnea, hypotension with narrowed pulse pressure                                                  | Traction on the mesentery or gallbladder, stimulation of vagal nerve fibers in the respiratory tract, or rectal distention stimulates afferent vagal nerve endings to cause bradycardia, apnea, and hypotension (vagovagal reflex) Manipulation around the celiac plexus decreases systolic pressure, narrows pulse pressure, and slightly decreases heart rate |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drugs          | Action   | Heart rate Normal | Heart rate Transplanted | Blood pressure Normal | Blood pressure Transplanted |
|----------------|----------|-------------------|-------------------------|-----------------------|-----------------------------|
| Atropine       | Indircct | Incrcasc          | Nonc                    | Nonc                  | Nonc                        |
| Ephedrinc      | Both     | Incrcasc          | Small increasc          | Incrcasc              | Small incrcasc              |
| Epincphrinc    | Dircct   | Incrcasc          | Incrcasc                | Incrcasc              | Incrcasc                    |
| Phenylcphrine  | Dircct   | Decrcasc          | Nonc                    | Incrcasc              | Incrcasc                    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** ALTERED RESPONSES TO COMMON CARDIOVASCULAR DRUGS AFTER CARDIAC DENERVATION

| Drug         | Action  | HR  | BP  | Physiology                        |
|--------------|---------|-----|-----|-----------------------------------|
| Atropine     | Indirect| -   | -   | No vagolytic effect               |
| Pancuronium  | Indirect| -   | -   | No vagolytic effect               |
| Edrophonium  | Indirect| -   | -   | No vagotonic effect               |
| Neostigmine  | Both    |    | -   | Bradycardia                       |
| Ephedrine    | Both    |    |    | small effect                      |
| Nifedipine   |         |     |     | No depression of nodal conduction  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug            | Type     | Effect 1 | Effect 2 | Notes                                                                                     |
|-----------------|----------|----------|----------|-------------------------------------------------------------------------------------------|
| Verapamil       | Direct   |       |       |                                                                                           |
| Digoxin         | Both     |       | -        | No acute vagotonic effect, inotropic response remains                                      |
| Norepinephrine   | Direct   |       |       | Enhanced ß -stimulatory effect (unmasked by lack of vagal reflex)                        |
| Phenylephrine   | Indirect | -        |       | Diminished vasoconstrictive effects with long-standing heart failure (no vagal mediated dedc. HR) |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Agent                        | CBF | CMRO 2 | Direct Cerebral Vasodilation |
|------------------------------|-----|--------|-------------------------------|
| Halothane                    |    | Yes    |                               |
| Enflurane                    |    | Yes    |                               |
| Isoflurane                   |   | Yes    |                               |
| Desflurane                   |   | Yes    |                               |
| Sevoflurane                  |   | Yes    |                               |
| N 2 O alone                  |     |        | -                             |
| N 2 O with volatile anesthetics|     |        | -                             |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Drug                             | Response 1 | Response 2 | Additional Info |
|----------------------------------|------------|------------|------------------|
| N 2 O with intravenous anesthetics| 0          | 0          | -                |
| Thiopental                       |        |        | No               |
| Etomidate                        |        |        | No               |
| Propofol                         |         |         | No               |
| Midazolam                        |         |         | No               |
| Ketamine                         |            |            | Yes              |
| Fentanyl                         |  /0      |  /0      | No               |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Variable                     | 1 point         | 2 points      | 3 points     |
|------------------------------|------------------|---------------|--------------|
| Total Bilirubin (μmol/L)     | < 34            | 34 - 51      | > 51        |
| Albumin (grams/Litre)        | > 35            | 28-35        | < 28       |
| INR                          | < 1.7           | 1.7-2.3      | > 2.3      |
| Ascites                      | Absent           | Slight-moderate | Tense      |
| Hepatic encephalopathy       | None             | Grade 1 & 2   | Grade 3 & 4 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Grade | Stalus                          |
|-------|---------------------------------|
|       | Alert and crientated            |
|       | Drowsy but orientated           |
| 2     | Drowsy and disoricntated       |
| 3     | Agitated and aggressive         |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Condition                                | INR | PTT | TT | Fibrinogen |
|------------------------------------------|-----|-----|----|------------|
| Advanced liver disease                   | ↑   | ↑   | N or ↑ | N or ↓     |
| DIC                                      | ↑   | ↑   | ↑  | ↓          |
| Vit K deficiency                         | ↑↑  | ↑   | N  | N          |
| Warfarin therapy                         | ↑↑  | ↑   | N  | N          |
| Heparin therapy                          | ↑   | ↑↑  | ↑  | N          |
| Hemophilia FVIII deficiency FIX deficiency | N N | ↑ ↑ | N N | N N        |
| FVII deficiency                          | ↑   | N   | N  | N          |
| FXIII deficiency                         | N   | N   | N  | N          |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Coagulation Test | Measured Aspect                          | Utility                                                                                     |
|------------------|-----------------------------------------|--------------------------------------------------------------------------------------------|
| INR              | Extrinsic pathway, common pathway       | Prolonged in severe factor deficiency, severe hypofibrinogenemia Indirect measure of liver fxn Screening for oral anticoagulants |
| PTT              | Intrinsic pathway, common pathway       | Prolonged in severe factor deficiency, severe hypofibrinogenemia Prolonged in hemophilia Prolonged by heparin Usually prolonged in von Willebrand's disease Prolonged in deficiencies of |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Test                | Pathway            | Result/Interpretation                                                                                     |
|---------------------|--------------------|-----------------------------------------------------------------------------------------------------------|
| Fibrinogen          | Common pathway      | Increased risk of hemorrhage if < 1.0 May be useful preop in the presence of thrombolytic therapy        |
| Bleeding time       | Platelet function   | Marked prolongation (>2x N) ass w/ bleeding Usually minor prolongation w/ ASA Prolonged in von Willebrand's, uremia, myeloproliferative diseases, congenital plt defects |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 16-15 Interpretation of Coagulation Tests**

| PLATELET COUNT | BLEEDING TIME | aPTT | PT | TT | FIBRINOGEN | FDPs | POSSIBLE CAUSE                                         | EXAMPLE                                                                                     |
|----------------|---------------|------|----|----|-------------|------|-------------------------------------------------------|---------------------------------------------------------------------------------------------|
| ↓              | N             | N    | N  | N  | N           | ↓    | Production sequestration ↑ Consumption Immune destruction | Radiation, chemotherapy Splenomegaly Extensive tissue damage H.I.T.                        |
| N              | ↑             | N    | N  | N  | N           | N    | Platelet dysfunction                                   | Drugs: ASA, NSAIDs, Clopidogrel, IIb/IIIa inhibitors; uremia; mild vWD                    |
| N              | ↑             | ↑    | N  | N  | N           | N    | Severe vWF deficiency                                  | vWD                                                                                        |
| N              | N             | ↑    | N  | N  | N           | N    | Factor deficiency Factor inhibition Antiphospholipid antibody | Hemophilia A or B Low-dose heparin, LMWHa Poor collection technique Lupus anticoagulant   |
| N              | N             | N    | ↑  | N  | N           | N    | Factor VII deficiency                                   | Early liver disease Early vitamin K deficiency Early Coumadin therapy                       |
| N              | N             | ↑    | ↑  | ↑  | N           | N    | Multiple factor deficiencies                            | Late vitamin K deficiency Late Coumadin therapy Heparin                                     |
| ↓              | ↑             | ↑    | ↑  | ↑  | ↓           | N    | Dilution of factors and platelets                      | Massive transfusion                                                                         |
| ↓              | ↑             | ↑    | ↑  | ↑  | ↓           | ↑    | Hypercoagulable state ± ↓ production of               | DICc Advanced liver disease                                                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Coagulation factor | Half life      |
|--------------------|----------------|
| Factor II          | 48 60 hours    |
| Factor VII         | 15-6 hours     |
| Factor IX          | 20 24 hours    |
| Factor X           | 24 48 hours    |
| Protcin C         | 1.5 6 hours    |
|                    | 24 48 hours    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Pupil Abnormalities                | Causes                                                                                     |
|-------------------------------------|--------------------------------------------------------------------------------------------|
| Unilateral fixed wide (6-9 mm)      | Acute intracranial mass, Local anticholinergics                                           |
| Bilateral fixed wide (6-9 mm)       | Brain death, End-stage diencephalic herniations, Intoxication with scopolamine, atropine, methyl alcohol, or glutethimide |
| Bilateral pinpoint (< 2mm)          | Acute pontine lesion, Narcotic agents, Nonketotic hyperglycemia, Hypercapnia              |
| Pupil anisocoria (difference 2-3 mm)| Horner's syndrome, Brain stem lesion, Carotid artery dissection                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Blood COHb Level (%) | Symptoms                                                        |
|----------------------|-----------------------------------------------------------------|
| <15-20               | Headache, dizziness, and occasional confusion                   |
| 20-40                | Nausea, vomiting, disorientation, and visual impairment         |
| 40-60                | Agitation, combativeness, hallucinations, coma, and shock       |
| >60                  | Death                                                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Component                        | CSF  | Serum |
|----------------------------------|------|-------|
| Sodium (mEq  l -1 )            | 141  | 140   |
| Potassium (mEq  l -1 )         | 2.9  | 4.6   |
| Calcium (mEq  l -1 )           | 2.5  | 5.0   |
| Magnesium (mEq  l -1 )         | 2.4  | 1.7   |
| Chloride (mEq  l -1 )          | 124  | 101   |
| Bicarbonate (mEq  l -1 )       | 21   | 23    |
| Glucose (mg  100 ml -1 )      | 61   | 92    |
| Protein (mg  100 ml -1 )      | 28   | 7000  |
| pH                               | 7.31 | 7.41  |
| Osmolality (mOsm  kg -1 H 2 O) | 289  | 289   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Percent of body wgt lost | Signs and sx                                                                 | Infants (ml/kg or %body fluid lost) |
|--------------------------|------------------------------------------------------------------------------|--------------------------------------|
| Mild 5%                  | Hx of 12-14h of vomiting and diarrhea Dry mouth Decreased urination Normal vitals | 50 (5%)                              |
| Moderate 10%             | Skin tenting Sunken eyes Weak pulse, +/- hypotension Depressed fontanelles Oliguria Lethargy but rousable | 100 (10%)                            |
| Severe 15%               | CVS instability (mottling, hypotension, incr HR) Anuria Sensorium changes Drowsy to comatose, limp | 150 (15%)                            |
| 20%                      | Coma Shock                                                                   |                                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Type of Butyrylcholinesterase | Genotype         | Incidence * | Dibucaine Number | Response to Succinylcholine or Mivacurium         |
|--------------------------------|------------------|-------------|------------------|---------------------------------------------------|
| Homozygous typical             | UU               | Normal      | 70-80            | Normal                                            |
| Heterozygous atypical          | UA               | 1/480       | 50-60            | Lengthened by about 50%-100%                      |
| Homozygous atypical            | AA               | 1/3200      | 20-30            | Prolonged to 4-8 hr                               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Location                                   | Thiazide diuretics | Loop diuretics | Osmotic diuretics | Potassium-sparing diuretics | Aldosterone antagonists | Carbonic anhydrase |
|--------------------------------------------|---------------------|----------------|-------------------|-----------------------------|-----------------------|---------------------|
| Early proximal convoluted tubule           |                     | +              |                   |                             |                       | +                   |
| Proximal convoluted tubule                 | +                   | +              |                   |                             |                       | +++                 |
| Medullary portion of ascending loop of Henle|                     | +++            | +++               |                             |                       |                     |
| Cortical portion of ascending loop of Henle | +++                 | +              | +                 |                             |                       |                     |
| Distal convoluted tubule                   | +                   | +              | +                 | +++                         |                       | +                   |
| Collecting duct                            |                     |                |                   | +++                         |                       |                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Typical Lab Values in DKA and HHNC

| Lab Value          | DKA       | HONK    |
|--------------------|-----------|---------|
| Glucose (mg/dl)    | >20       | >40     |
| Sodium (mEq)       | low 130s  | 140s    |
| Potassium (mEq)    | 4.5-6.0   | Around 5|
| Bicarbonate (mEq)  | <10       | >15     |
| BUN (mg/dl)        | 9-18      | >18     |
| Serum ketones      | Present    | Absent  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Step | Instruction                                                                                                           |
|------|----------------------------------------------------------------------------------------------------------------------|
| 1    | Be particularly cautious in patients with bronchial wall abnormalities.                                              |
| 2    | Pick an appropriately sized tube.                                                                                   |
| 3    | Be certain that the tube is not malpositioned. * Use fiberoptic bronchoscopy to confirm the position of the double-lumen tube (especially if N 2 O is introduced into the inspired gases). |
| 4    | Avoid overinflation of the endobronchial cuff. *                                                                   |
| 5    | Deflate the endobronchial cuff during turning.                                                                     |
| 6    | Inflate the endobronchial cuff slowly.                                                                              |
| 7    | Inflate the endobronchial cuff with inspired gases.                                                                 |
| 8    | Do not allow the tube to move during turning. *                                                                    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 49-14 -- Limitations to use of the Univent bronchial blocker**

| Limitation                                         | Solution                                                                                                         |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Slow deflation time                                | (a) Deflate the bronchial blocker cuff and compress and evacuate the lung through the main single lumen; (b) apply suction to the bronchial blocker lumen |
| Slow reinflation time                              | (a) Deflate the bronchial blocker cuff and administer a positive-pressure breath through the main single lumen; (b) carefully administer one short high-pressure (20-30 psi) jet ventilation breath |
| Blockage of the bronchial blocker lumen by blood, pus | Suction, stylet, and then suction                                                                               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Limitation                                         | Solution                                                                                     |
|---------------------------------------------------|----------------------------------------------------------------------------------------------|
| High-pressure cuff                                 | Use a just-seal volume of air                                                               |
| Intraoperative leak in the bronchial blocker cuff | Make sure that the bronchial blocker cuff is subcarinal, increase the inflation volume, rearrange the surgical field |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Gas  | Volume (L) | Pressure (psi) | Pin-index | Note                             |
|------|------------|----------------|-----------|----------------------------------|
| O2   | 660        | 1900-2200      | 2-5       | Psi ~ to vol                     |
| N2O  | 1590       | 745            | 3-5       | Psi not ~ to vol Once PSI falls, vol ~400L |
| Air  | 625        | 1800           | 1-5       |                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| coronary artery | ECG leads  |
|----------------|------------|
| LAD            | V3-5      |
| circumflex     | I, aVL    |
| RCA            | II, III, aVF |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| anatomic site | ECG leads       | coronary artery      | associated complications                                   |
|---------------|-----------------|----------------------|-----------------------------------------------------------|
| septal        | V1-2           | LAD (septal)        | infranodal; BBB                                          |
| anterior      | V3-4           | LAD (diagonal)      | LV dysfxn; CHF; BBB; complete heart block; PVC         |
| lateral       | I, aVL, V5-V6  | circumflex           | LV dysfxn; AV nodal block in some                       |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Region        | Leads                     | Artery                     | Findings                                         |
|---------------|---------------------------|----------------------------|--------------------------------------------------|
| inferior      | II, III, aVF              | right (PDA)                | hypotension                                      |
| RV            | V4R                       | prox right                 | hypotension; supranodal and AV nodal blocks; Afib/flutter; PAC |
| posterior     | V1-V4 marked depression   | circumflex or right (PDA)  | LV dysfxn                                       |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 1. Common Physiologic Responses and Side Effects Associated with Electroconvulsive Therapy**

| Yariable                  | Response                                                                                                   |
|--------------------------|-----------------------------------------------------------------------------------------------------------|
| Central nervous system    | Increased blood flow velocity , intracranial pressure, and cerebral metabolism; dizziness, amnesia, confusion, agitation, and headaches |
| Cardiovascular system     | Increased blood pressure; heart and cardiac output; cardiac arrhytlunias fate,                           |
| Musculoskeletal system    | Myoclonic-toxic contractions, bone fractures / dislocations, muscle and joint pain                        |
| Miscellaneous responses    | Increased salivation, nausea and voii dental damage; and oral cavity lacerations                         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 2 Effects of IV Anesthetic and Cardiovascular on the Duration of ECT-Induced Seizure Activity (relative to methohexital or saline; respectively) Drugs**

| Drug                     | Increased                                      | No change                                                                                     | Decreased                                                                                          |
|--------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Anesthetic drugs         | Etomidate (36,4243) Alfentanil (94,951) Remifentanil (96) | Thicpental (39) thiamylal (30) lorazepam (52) midazolam (54) ketamine (51) fentanyl (75) propofol (36,40,44,48) |                                                                                                   |
| Cardiovascular drugs     | Aminophylline (114) Caffeine (115,116)        | Clonidine (84), esmolol (74,861), labetalol (481), dexmedletomidine (83), nifedipine nicardipine (81), trimethaphan (93), nitroprusside (92) nitrog | Diltiazenn (82), lidocaine (9), labetalol (74,75), Esmolol (76,78)                               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 62-4 -- Clinical pharmacology of anesthetic agents in the elderly**

| Drug            | Brain Sensitivity | Pharmacokinetics                     | Dose               |
|-----------------|-------------------|--------------------------------------|--------------------|
| Inhaled agents   | ↑                 | ↓                                    |                    |
| Thiopental       | -                 | ↓ Initial distribution volume         | ↓                  |
| Etomidate        | -                 | ↓ Initial distribution volume         | ↓                  |
|                  |                   | ↓ Clearance                          |                    |
| Propofol         | ↑                 | ↓ Clearance                          | ↓                  |
| Midazolam        | ↑                 | ↓ Clearance                          | ↓                  |
| Morphine         | ↑                 | ↓ Clearance                          | ↓                  |
| Sufentanil       | ↑                 | -                                    | ↓                  |
| Alfentanil       |                   |                                      |                    |
| Fentanyl         |                   |                                      |                    |
| Remifentanil     | ↑                 | ↓ Clearance                          |                    |
|                  |                   | ↓ Central compartment volume          | ↓                  |
| Pancuronium      | NA                | ↓ Clearance *                        | ↓ *                |
| Atracurium       | NA                | -                                    | -                  |
| Cisatracurium    | NA                | -                                    | -                  |
| Vecuronium       | NA                | ↓ Clearance                          | ↓                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| TISSUE/SYSTEM           | ANATOMIC CHANGE                                                             | FUNCTIONAL CHANGE                                                      |
|-------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------|
| Body composition         | Loss of skeletal muscle and other lean tissue components, increased lipid fraction | Prolonged drug effects; decreased metabolism and heat production, decreased resting cardiac output |
| Nervous system           | Loss of neuronal tissue mass, deafferentation, reduced central neurotransmitter activity | Decreased neural plasticity, decreased anesthetic requirement, impaired autonomic homeostasis |
| Cardiovascular system    | Decreased elasticity, reduced b-adrenergic responsiveness                  | Decreased cardiac and arterial compliance, decreased maximal heart rate and cardiac output |
| Pulmonary system         | Increased thoracic stiffness, decreased lung recoil, reduced alveolar surface area | Reduced vital capacity, increased work of breathing, impaired efficiency of gas exchange |
| Renal/hepatic system     | Decreased vascularity and perfusion, loss of tissue mass                   | Decreased drug clearance, inability to withstand salt or water loads   |
| Blood and immune systems  | Thymic involution, resorption of bone marrow                               | Decreased immune competence, loss of hematopoietic reserve            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Current               | Effect                                                                                     |
|----------------------|--------------------------------------------------------------------------------------------|
| 1 mA (0.001 A)      | Threshold of perception                                                                     |
| 5 mA (0.005 A)      | Accepted as maximum harmless current intensity                                               |
| 10-20 mA (0.01-0.02 A) | Let-go current before sustained muscle contraction                                         |
| 50 mA (0.05 A)      | Pain, possible fainting, mechanical injury; heart and respiratory functions continue        |
| 100-300 mA(0.1-0.3 A) | Ventricular fibrillation will start, but respiratory center remains intact                 |
| 6000 mA (6 A)       | Sustained myocardial contraction, followed by normal heart rhythm; temporary respiratory paralysis; burns if current density is high |
| 100 uA (0.1 mA)     | Ventricular fibrillation                                                                    |
| 10 uA (0.01 mA)     | Recommended maximum 60 Hz leakage current                                                   |

A = amperes; mA=milliamperes; uA = microamperes.

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Mechanism                                                        | Effect                                                                                          |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Neural effects                                                   |                                                                                                 |
| "Peripheral" sympathetic block (T10-L2)                          | Blockade of vasoconstrictor fibers to lower limbs: Arteriolar dilatation. Increased venous capacitance and pooling of blood in lower limbs  decreased venous return  CO |
|                                                                  | Reflex increase in vasoconstrictor fiber activity in upper limbs via baroreceptors: Increased vasomotor tone in upper limbs  venous return  CO |
|                                                                  | Reflex increase in cardioaccelerator nerve activity: HR CO                                      |
|                                                                  | Reduced right atrial pressure, due to  venous return a: ?  HR (Note   RA pressure  HR a ; see Fig. 8-21) |
| Adrenal medullary sympathetic block (T6-Ll) (Blockade of splanchnic nerves) | Vasoconstrictor fibers to abdominal viscera: Pooling of blood in gut  decreased venous return   |
|                                                                  | Adrenal medullary catecholamine secretion: Decreased levels of circulating catecholamines  HR  CO |
| "Central" sympathetic block (Tl-T4)                              | Blockade of                                                                                   |
|                                                                  | Cardiac sympathetic outflow from vasomotor center:  HR  CO                                   |
|                                                                  | Cardiac sympathetic reflexes at segmental level                                                |
|                                                                  | Vasoconstrictor fibers to head, neck, and arms: Vasodilatation in upper limbs.                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category                                           | Effects                                                                                      |
|----------------------------------------------------|----------------------------------------------------------------------------------------------|
| Blockade of compensatory lower limb vasoconstriction if T5-L1 is also blocked |                                                                                              |
| Vagal predominance                                 | "Inappropriate bradycardia"; "sudden bradycardia"; vagal arrest (see Fig. 8-21 and Table 8-11) |
| Effects of drug absorption                         |                                                                                              |
| Absorbed local anesthetic                          | Usually no measurable effects on HR, CO, MAP, or TPR even in patients with vascular disease   |
| Moderate blood levels                              | Lidocaine may  CO, which is balanced  TPR, so that MAP is unchanged                       |
| Antiarrhythmic                                    |                                                                                              |
| Maintenance of normal CO                           | Minimal reduction in vascular tone                                                           |
| High blood levels (toxic)                         |  CO  HR                                                                                   |
| Decreased contractility                            |  MAP                                                                                       |
| If convulsions occur hypoxia results in further reduction in CO |                                                                                              |
| Cardiac conducting tissue,? unidirectional blockade | Bupivacaine (very high levels) may  VT, VF, and cardiac arrest                             |
| Vascular dilatation                                |  TPR                                                                                       |
| Absorbed epinephrine                               | CO HR  TPR                                                                                 |
|  -stimulation                                     | MAP may be unchanged or slightly reduced                                                    |
|                                                    | Antagonism of reflex vasoconstriction above level of blockade because of  -effects on muscle vasculature  TPR |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Accelerate                                   | Delay                                         |
|----------------------------------------------|----------------------------------------------|
| Physiologic                                  | Gastric distention                           |
|                                              | Neuroticism (Anxiety)                       |
|                                              | Food                                         |
|                                              | Acid                                         |
|                                              | High osmotic pressure                        |
|                                              | Posture                                      |
| Pathologic                                   | Thyrotoxicosis                              |
|                                              | Shock                                        |
|                                              | Trauma and pain                              |
|                                              | Laparotomy (~24 hrs)                        |
|                                              | Myocardial infarction                        |
|                                              | Pyloric stenosis                            |
|                                              | Crohn's disease                              |
|                                              | Celiac disease                               |
|                                              | Diabetic autonomic neuropathy                |
| Pharmacologic                                | Metoclopramide                               |
|                                              | Neostigmine                                  |
|                                              | Propranolol                                  |
|                                              | Sodium bicarbonate                           |
|                                              | Cigarette smoking                            |
|                                              | Anticholinergics                            |
|                                              | Tricyclic antidepressants                    |
|                                              | Aluminum hydroxide                           |
|                                              | Alcohol                                      |
|                                              | Isoprenaline                                 |
|                                              | Opioid analgesics                            |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                     | Prerenal Azotemia                     | Hepatorenal                           | ATN            |
|-------------------------------|---------------------------------------|---------------------------------------|----------------|
| Urinary sodium                | < 10 mEq/L                           | < 10 mEq/L                           | >30 mEq/L      |
| Urine:Plasma Cr ratio        | >30:1                                | >30:1                                | <20:1          |
| Urinary Osm                   | Exceeds plasma OsM by at least 100 mOsm | Exceeds plasma OsM by at least 100 mOsm | Equal to plasma Osm |
| Urinary sediment              | Normal                                | Unremarkable                          | Casts, cellular debris |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Typical Lab Values in DKA and HHNC

| Lab Value          | DKA        | HONK     |
|--------------------|------------|----------|
| Glucose (mg/dl)    | >20        | >40      |
| Sodium (mEq)       | low 130s   | 140s     |
| Potassium (mEq)    | 4.5-6.0    | Around 5 |
| Bicarbonate (mEq)  | <10        | >15      |
| BUN (mg/dl)        | 9-18       | >18      |
| Serum ketones      | Present     | Absent   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Variable                                   | Calculation                                   | Normal Values               |
|--------------------------------------------|-----------------------------------------------|-----------------------------|
| Cardiac index (CI)                         | CO/BSA                                       | 2.5-4.0 l/min*m2           |
| Stroke volume (SV)                         | CO/HR                                        | 60-90 ml/beat               |
| Stroke index (SI)                          | SV/BSA                                       | 40-60 ml/beat×m2           |
| Mean arterial pressure (MAP)               | Diastolic pressure + one third pulse pressure | 80-120mm Hg                 |
| Systemic vascular resistance (SVR)         | MAP - CVP/CO × 79.9                          | 1200-1500 dyn×cm×s-5       |
| Pulmonary vascular resistance (PVR)        | PAP - PWP/CO × 79.9                          | 100-300 dyn×cm×s-5         |
| Right ventricular stroke work index (RVSWI)| 0.0136(PAP - CVP)SI                          | 5-9 g×m×beat-1×m-2         |
| Left ventricular stroke work index (LVSWI) | 0.0136(MAP - PWP)SI                          | 45-60 g×m×beat-1×m-2       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Inducers                     | Inhibitors                     |
|------------------------------|--------------------------------|
| Phenobarbital                | Cimetidine                     |
| Phenytoin                    | Ketoconazole                   |
| Rifampicin                   | Erythromycin                   |
| Carbamazepine                | Disulfiram                     |
| Ethanol                      | Ritonavir                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 18-1 disease states associated with heparin resistance:**

| State                                                                 | Comment                                                                                                           |
|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Newborn                                                              | Decreased ATIII levels until 6 mo of age                                                                        |
| Venous thromboembolism                                               | May have increased factor VIII level, accelerated clearance of heparin                                           |
| Pulmonary embolism                                                   | Accelerated clearance of heparin                                                                                 |
| Congenital ATIII deficiency Type i Type ii                          | 40-60% of normal ATIII concentration reduced synthesis of normal/ abnormal ATIII molecular defect within the ATIII molecule |
| Acquired ATIII deficiency - preeclampsia - cirrhosis - nephrotic syndrome - DIC - Heparin pretreatment - Estrogen therapy - Cytotoxic drug therapy (L-asparaginase) | < 25% of normal ATIII concentration levels unchanged in normal pregnancy decreased protein synth increased urinary excretion increased consumption of ATIII 85% of normal ATIII conc due to accelerated clearance decreased protein synth |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 15-2 -- Clinically important effects, perioperative concerns, and recommendations for perioperative discontinuation of nine commonly used herbal medicines**

| Herbs (Common Names)                                                                 | Important Pharmacologic Effects                                                                 | Perioperative Concerns                                                                                                           | Preoperative Discontinuation                  |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| Echinacea                                                                             | Activation of cell-mediated immunity                                                             | Allergic reactions                                                                                                            | No data                                      |
| Purple coneflower root                                                                |                                                                                                | Decreased effectiveness of immunosuppressants                                                                                 | Potential for immunosuppression with long-term use |
| Ephedra (ma huang)                                                                   | Increased heart rate and blood pressure through direct and indirect sympathomimetic effects   | Risk of myocardial ischemia and stroke from tachycardia and hypertension                                                      | At least 24 hours before surgery             |
|                                                                                      |                                                                                                | Ventricular arrhythmias with halothane                                                                                       |                                              |
|                                                                                      |                                                                                                | Long-term use depletes endogenous catecholamines and may cause intraoperative hemodynamic instability                          |                                              |
|                                                                                      |                                                                                                | Life-threatening interaction with MAO inhibitors                                                                                |                                              |
| Garlic (ajo)                                                                         | Inhibition of platelet aggregation (may be irreversible)                                       | May increase risk of bleeding, especially when combined with other medications that inhibit platelet aggregation               | At least 7 days before surgery               |
|                                                                                      | Increased fibrinolysis                                                                          |                                                                                                                               |                                              |
|                                                                                      | Equivocal antihypertensive activity                                                             |                                                                                                                               |                                              |
| Ginkgo (duck-foot tree, maidenhair tree, silver apricot)                            | Inhibition of platelet- activating factor                                                       | May increase risk of bleeding, especially when combined with other medications that inhibit platelet aggregation               | At least 36 hours before surgery             |
| Ginseng (American ginseng, Asian ginseng, Chinese ginseng, Korean ginseng)          | Lowers blood glucose                                                                            | Hypoglycemia                                                                                                                  | At least 7 days before surgery               |
|                                                                                      | Inhibition of platelet aggregation (may be irreversible)                                       | May increase risk of bleeding                                                                                                 |                                              |
|                                                                                      | Increased PT/PTT in animals                                                                     | May decrease anticoagulant effect of warfarin                                                                                 |                                              |
|                                                                                      | Many other diverse effects                                                                      |                                                                                                                               |                                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Herbs (Common Names)                                                                 | Important Pharmacologic Effects                                                                 | Perioperative Concerns                                                                                                           | Preoperative Discontinuation                     |
|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Kava (awa, intoxicating pepper, kawa)                                               | Sedation                                                                                        | May increase sedative effect of anesthetics                                                                                   | At least 24 hours before surgery                |
|                                                                                      | Anxiolysis                                                                                     | Ability to increase anesthetic requirements with long-term use unstudied                                                       |                                                 |
| Saw palmetto (dwarf palm, sabal)                                                    | Inhibition of 5-α reductase                                                                    | May increase risk of bleeding                                                                                                 | No data                                         |
|                                                                                      | Inhibition of cyclooxygenase                                                                   |                                                                                                                               |                                                 |
| St. John's wort (amber, goat weed, hardhay, hypericum, Klamath weed)               | Inhibition of neurotransmitter reuptake                                                       | Induction of cytochrome P450 enzymes, affecting cyclosporin, warfarin, steroids, and protease inhibitors and possibly affecting benzodiazepines, calcium channel blockers, and many other drugs | At least 5 days before surgery                  |
|                                                                                      | MAO inhibition is unlikely                                                                      | Decreased serum digoxin levels                                                                                                 |                                                 |
|                                                                                      |                                                                                                | Delayed emergence                                                                                                             |                                                 |
| Valerian (all heal, garden heliotrope, vandal root)                                | Sedation                                                                                        | May increase sedative effect of anesthetics                                                                                   | No data                                         |
|                                                                                      |                                                                                                | Benzodiazepine-like acute withdrawal                                                                                            |                                                 |
|                                                                                      |                                                                                                | May increase anesthetic requirements with long-term use                                                                        |                                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Exposure type      | HIV-Positive Class                          | HIV-Positive Class 2'                     | Source unknown HIV status'                                      | Unknown source'                                               | HIV-Negative          |
|--------------------|--------------------------------------------|-------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|-----------------------|
| Small volume'      | Consider basic 2-drug PEP'                 | Recommend basic 2-drug PEP                | Generally no PEP warranted; however consider basic 2-drug PEP" for | Generally, no PEP warranted; however consider basic 2-drug PEF" in settings where exposure to infected Persons is likely | No PEP warranted      |
| Large volume"      | Kecommend basic 2-drug PEP                 | PEP                                       | Generally. no FEF warranted; however, consider basic 2-drug PEP" for source with HIV | PEF consider basic 2-drug PEF" in settings where exposure to AIv-infected persons is likely | No PEP warranted      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Exposure type                                      | HIV-Positive Class                     | HIV-Positive Class 2"                          | Source unknown HIV status'                      | Unknown source'                                 | HIV-Negative                |
|---------------------------------------------------|----------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------|
| Recommend basic 2-drug PEP                        | expanded 3-drug PEP                   | Generally consider basic risk factors 2-drug   | Generally M PEP consider 2-drug in settings where infected Persons is likely | No PEP warranted            |
| Recommend expanded 3-drug PEP                     | warranted; however, consider basic    | Generally PEP warranted; however consider basic 2-drug PEP' in settings where exposure to HIV-infected persons is likely | No PEP warranted                                |                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Anesthesia      | Heart Rate | Contractility | Cardiac Output | Systemic Vascular Resistance |
|------------------|------------|---------------|----------------|------------------------------|
| Conscious         | ++         | ++            | +++            | -                            |
| Nitrous oxide     | 0          | +             | ++             | --                           |
| Halothane         | 0          | +             | +              | -                            |
| Enflurane         | +          | +             | +              | ---                          |
| Isoflurane        | ++         | ++            | +++            | -                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Major In Vivo Consequences of Mild Perioperative Hypothermia in Humans a

| CONSEQUENCE                                      | INVESTIGATORS      | n  | Δ T core (°C) | NORMOTHERMIC      | HYPOTHERMIC       | P      |
|--------------------------------------------------|--------------------|----|----------------|--------------------|--------------------|--------|
| Inc. Surgical wound infection                     | Kurz et al 107     | 200| 1.9            | 6%                 | 19%                | <.01   |
| Inc. duration of hospitalization                  | Kurz et al 107     | 200| 1.9            | 12.1±4.4 d         | 14.7±6.5 d         | <.01   |
| Inc. intraoperative blood loss                    | Schmied et al 98   | 60 | 1.6            | 1.7 ± 0.3 L        | 2.2 ± 0.5 L        | <.001  |
| Inc. Allogeneic transfusion requirement           | Schmied et al 98   | 60 | 1.6            | 1 unit             | 8 units            | <.05   |
| Inc. Morbid cardiac events                        | Frank et al 112    | 300| 1.3            | 1%                 | 6%                 | <.05   |
| Inc. Postoperative VT                             | Frank et al 112    | 300| 1.3            | 2%                 | 8%                 | <.05   |
| Inc. urinary excretion of nitrogen                | Carli et al 108    | 12 | 1.5            | 982 mmol/d         | 1798 mmol/d        | <.05   |
| Inc. duration of vecuronium                       | Heier et al 113    | 20 | 2.0            | 28 ± 4 min         | 62 ± 8 min         | <.001  |
| Inc. duration of atracurium                       | Leslie et al 114   | 6  | 3.0            | 44 ± 4 min         | 68 ± 7 min         | <.05   |
| Postoperative shivering                           | Just et al 182     | 14 | 2.3            | 141 ± 9 mL•min - 1 •m -2 | 269 ± 60 mL•min - 1 •m -2 | <.001  |
| Inc. duration of                                  | Lenhardt et al 119 | 150| 1.9            | 53 ± 36 min        | 94 ± 65 min        | <.001  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Major In Vivo Consequences of Mild Perioperative Hypothermia in Humans a

| CONSEQUENCE                     | INVESTIGATORS   | n  | Δ T core (°C) | NORMOTHERMIC       | HYPOTHERMIC        | P      |
|----------------------------------|------------------|----|----------------|---------------------|---------------------|--------|
| postanesthetic recovery          |                  |    |                |                     |                     |        |
| Inc. adrenergic activation       | Frank et al 111  | 74 | 1.5            | 330 ± 30 pg/mL      | 480 ± 70 pg/mL      | <.05   |
| Thermal discomfort               | Kurz et al 109   | 74 | 2.6            | 50 ± 10mm VAS       | 18 ± 9mm VAS        | <.001  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Cardiovascular                     | Respiratory         | Psychiatric      | Neuromuscular   |
|------------------------------------|---------------------|------------------|------------------|
| Dysrhythmias                       | Apnea               | Anxiety          | Tetany           |
| Digitalis insensitivity            | Laryngeal spasm     | Dementia         | Depression       |
| ECG changes - prolonged QT         | Bronchospasm        | Psychosis        | Muscle spasm     |
| Heart failure                      |                     |                  | Papilledema      |
| Hypotension                        |                     |                  | Seizures         |
|                                    |                     |                  | Weakness         |
|                                    |                     |                  | Fatigue          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Causes                              | Mechanisms                                                        |
|-------------------------------------|-------------------------------------------------------------------|
| Impaired thirst                     | Coma, essential hypernatremia                                     |
| Solute (osmotic) diuresis          | Mannitol administration, diabetic ketoacidosis, nonketotic hyperosmolar coma |
| Excessive water losses: renal       | Pituitary diabetes insipidus, nephrogenic diabetes insipidus     |
| Excessive water losses: extrarenal  | Sweating                                                          |
| Combined disorders                  | Coma plus hypertonic nasogastric feeding                         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Causes                                                                 | Mechanisms                                                                                          |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Pseudohyponatremia (normal osmolality)                                 | Hyperlipidemia, hyperproteinemia                                                                    |
| Hyponatremia with increased effective osmolality                        | Hyperglycemia, mannitol accumulation                                                                 |
| True hyponatremia with normal effective osmolality                     | Gamma-globulins, lithium, trishydroxymethylaminomethane (THAM)                                     |
| True hyponatremia with edema (sodium excess): low effective osmolality | Congestive heart failure, nephrotic syndrome, cirrhosis of the liver, idiopathic edema, hypoalbuminemia due to malnutrition |
| True hyponatremia (sodium depletion): low effective osmolality         | Renal or extrarenal wasting                                                                          |
| Hyponatremia with normal or expanded effective arterial volume          | Syndrome of inappropriate antidiuretic hormone (SIADH) secretion, water intoxication due to primary polydipsia, water overload in advanced renal failure, vascular or inflammatory renal disease |
| Reduced sodium delivery to the diluting segment                         | Starvation; myxedema?                                                                                |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Hypovolemic Hyponatremia | Hypervolemic Hyponatremia | Euvolemic Hyponatremia |
|--------------------------|---------------------------|-------------------------|
| Hemorrhage               | Congestive heart failure   | Syndrome of inappropriate antidiuretic hormone (SIADH) secretion |
| Burn wound edema         | Nephrotic syndrome        |                         |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Hypovolemic Hyponatremia | Hypervolemic Hyponatremia | Euvolemic Hyponatremia |
|--------------------------|---------------------------|-------------------------|
| Peritonitis              | Cirrhosis                 |                         |
|                          | Transurethral prostate (TURP) syndrome | Pseudohyponatremia     |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Vascular                                      | Miscellaneous                                   | Balloon                                      |
|-----------------------------------------------|------------------------------------------------|---------------------------------------------|
| Arterial injury (perforation, dissection)    | Aortic perforation                             | Perforation (before insertion)              |
| Aortic dissection                             | Aortic dissection                              | Tear (during insertion)                     |
| Femoral artery thrombosis                     | Femoral vein cannulation                       | Incorrect positioning                        |
| Peripheral embolization                       | Pseudoaneurysm of femoral                     | Gas embolization                             |
|                                               | Hemolysis                                      | Inadvertent removal                          |
|                                               | Thrombocytopenia                               |                                             |
|                                               | Infection                                      |                                             |
|                                               | Claudication (after removal)                   |                                             |
|                                               | Hemorrhage                                     |                                             |
|                                               | Paraplegia                                    |                                             |
|                                               | Entrapment                                    |                                             |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Vascular                          | Miscellaneous                     | Balloon                          |
|-----------------------------------|-----------------------------------|----------------------------------|
| vessels Lower extremity ischemia   | Compartment syndrome               | Visceral ischemia                |
| Spinal cord necrosis              | Left internal mammary artery occlusion |                                  |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Indications for ICP monitoring                                      | Risk of raised ICP                                   |
|--------------------------------------------------------------------|-----------------------------------------------------|
| Severe Head Injury (GCS 3-8)                                       |                                                     |
|  Abnormal CT scan                                                 | 50-60%                                              |
|  Normal CT Scan Age > 40 or BP < 90mmHg or abnormal motor posturing | 50-60%                                              |
|  Normal CT scan No risk factors                                   | 13%                                                 |
| Moderate Head Injury (GCS 9-12)                                    |                                                     |
|  If anaesthetised/sedated  Abnormal CT scan                     | approx. 10-20% will deteriorate to severe head injury |
| Mild Head Injury (GCS 13-15)                                       |                                                     |
|  few indications for ICP measurement                               | Only around 3% will deteriorate                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Normal Cerebral Physiologic Values

| Parameter                                      | Value                     |
|------------------------------------------------|---------------------------|
| Cerebral blood flow                            | Global: 45-55 mL/100 g/min |
|                                                | Cortical (mostly gray matter): 75-80 mL/100 g/min |
|                                                | Subcortical (mostly white matter): ~20 mL/100 g/min |
| Cerebral metabolic rate for oxygen             | 3-3.5 mL/100 g/min       |
| Cerebral vascular resistance                    | 1.5-2.1 mmHg · 100 g · min/mL |
| Cerebral venous oxygen tension                  | 32-44 mm Hg              |
| Cerebral venous oxygen saturation               | 55-70%                   |
| Intracranial pressure (supine)                 | 8-12 mm Hg               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Effects of Anesthetics on CBF/CMRO2**

| Anesthetic  | CBF     | CMRO2 | Direct Cerebral Vasodilation |
|-------------|---------|-------|------------------------------|
| Halothane   |     |      | Yes                          |
| Enflurane   |      |      | Yes                          |
| Isoflurane  |       |     | Yes                          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug                                      | Effect 1 | Effect 2 | Approval |
|-------------------------------------------|----------|----------|----------|
| Desflurane                                |        |       | Yes      |
| Sevoflurane                               |        |       | Yes      |
| N 2 O alone                               |        |        | -        |
| N 2 O with volatile anesthetics           |       |        | -        |
| N 2 O with intravenous anesthetics         | 0        | 0        | -        |
| Thiopental                                |      |      | No       |
| Etomidate                                 |      |      | No       |
| Propofol                                  |       |       | No       |
| Midazolam                                 |       |       | No       |
| Ketamine                                  |       |        | Yes      |
| Fentanyl                                  |  /0     |  /0     | No       |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Agent                          | Side Effect/Toxicity                                                                                     |
|--------------------------------|----------------------------------------------------------------------------------------------------------|
| Glucocorticoids               | Adrenal suppression, Glucose intolerance, Cushingoid appearance, Integument fragility, Aseptic necrosis, Peptic ulceration |
| Azathioprine                   | Anemia, Thrombocytopenia, Leukopenia, Pancreatitis, Hepatitis, Decrease nondepolarizing relaxant requirement |
| Cyclosporine, tacrolimus      | Glomerulosclerosis (elevation of blood urea nitrogen, creatinine) more with cyclosp, Hypertension, Hepatotoxicity, Neurotoxicity (Enhanced renal sensitivity to insults, Glucose intolerance with tacrolimus only |
| Antilymphocyte globulin        | Leukopenia, Thrombocytopenia, Systemic symptoms                                                          |
| OKT3                           | Systemic symptoms, Increased susceptibility to cytomegalovirus infections                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug         | Induction Dose (mg/kg) | Onset (sec) | Duration (min) | Excitatory Activity | Pain on Injection | Heart Rate | Blood Pressure |
|--------------|-------------------------|-------------|----------------|---------------------|-------------------|------------|----------------|
| Thiopental   | 3-6                     | <30         | 5-10           | +                   | 0/+               | +          | -              |
| Methohexital | 1-3                     | <30         | 5-10           | ++                  | +                 | ++         | -              |
| Propofol     | 1.5-2.5                 | 15-45       | 5-10           | +                   | ++                | 0/-        | -              |
| Midazolam    | 0.2-0.4                 | 30-90       | 10-30          | 0                   | 0                 | 0          | 0/-            |
| Diazepam     | 0.3-0.6                 | 45-90       | 15-30          | 0                   | +++               | 0          | 0/-            |
| Lorazepam    | 0.03-0.06               | 60-120      | 60-120         | 0                   | ++                | 0          | 0/-            |
| Etomidate    | 0.2-0.3                 | 15-45       | 13-12          | +++                 | +++               | 0          | 0              |
| Ketamine     | 1-2                     | 45-60       | 10-20          | +                   | 0                 | ++         | ++             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 5. Regimens for a Dental Procedure**

| Situation                                             | Agent                                   | Adults          | Children      |
|------------------------------------------------------|-----------------------------------------|------------------|---------------|
| Oral                                                 | Amoxicillin                            | 2 9              | 50 mg/kg      |
| Unable to take oral medication                        | Ampicillin OR                          | 2 g IM or WV     | 50 mg/kg IM or IV |
|                                                      | Cefazolin or ceftriaxone              |                  | 50 mg/kg IM or IV |
| Allergic to penicillins or ampicillin oral          | Cephalexin + OR                        | 2 9              |               |
|                                                      | Clindamycin OR                         | 600 mg           | 20 mg/kg      |
|                                                      | Azithromycin or clarithromycin         | 500 mg           | 15 mg/kg      |
| Allergic to penicillins or ampicillin and unable to take oral medication | Cefazolin or ceftriaxone OR           |                  | 50 mg/kg IM or IV |
|                                                      | Clindamycin                            | 600 mg IM or WV  | 20 mg/kg IM or IV |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 67-2 -- Laser media wavelengths**

| Laser Medium              | Color          | Wavelength (nm) | Typical Application                          |
|--------------------------|----------------|------------------|----------------------------------------------|
| CO 2                     | Far infrared   | 10,600           | General, cutting, superficial, Mirrors       |
| Erbium-YAG              | Infrared       | 2,930            | Dental, arthroscopy                          |
| Holmium-YAG             | Infrared       | 2,060            | Angioplasty                                  |
| Neodymium-YAG           | Near infrared  | 1,064            | General, coagulation, with fiberoptics      |
| Ruby                     | Red            | 694              | Tattoos, nevi                                |
| Krypton                  | Red            | 647              |                                              |
| Helium-neon             | Red            | 632              | Aiming beam                                  |
| Gold (vapor)            | Red            | 632              |                                              |
| Organic dye (liquid)    | Red            | 632              | Phototherapy                                 |
| Organic dye (liquid)    | Yellow         | 585              | Dermatology, ophthalmology                   |
| Copper (vapor)          | Yellow         | 578              |                                              |
| Organic dye (liquid)    | Yellow         | 577              |                                              |
| Krypton                  | Yellow         | 568              | Retina                                       |
| KTP:neodymium-YAG       | Green          | 532              | General, pigmented lesions                   |
| Krypton                  | Green          | 521              |                                              |
| Argon                   | Green          | 514              | Vascular, pigmented lesions                  |
| Copper (vapor)          | Green          | 510              |                                              |
| Organic dye (liquid)    | Green          | 504              |                                              |
| Argon                   | Blue           | 488              | Vascular, pigmented lesions                  |
| Xenon fluoride           | Ultraviolet    | 351              | Cornea, angioplasty                          |
| Xenon chloride           | Ultraviolet    | 308              | Cornea, angioplasty                          |
| Krypton fluoride         | Ultraviolet    | 248              | Cornea, angioplasty                          |
| Krypton chloride         | Ultraviolet    | 222              | Cornea, angioplasty                          |
| Argon fluoride           | Ultraviolet    | 193              | Cornea, angioplasty                          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** GASTRIC EMPTYING RATE ****

| Accelerate                                   | Delay                                         |
|----------------------------------------------|----------------------------------------------|
| Physiologic                                  | Gastric distention                           |
|                                              | Neuroticism                                  |
|                                              | Food                                         |
|                                              | Acid                                         |
|                                              | High osmotic pressure                        |
|                                              | Posture                                      |
|                                              | Pregnancy                                    |
| Pathologic                                   | Thyrotoxicosis                              |
|                                              | Shock                                        |
|                                              | Trauma and pain                              |
|                                              | Myocardial infarction                        |
|                                              | Pyloric stenosis                             |
|                                              | Crohn's disease                              |
|                                              | Celiac disease                               |
|                                              | Diabetic autonomic neuropathy                |
| Pharmacologic                                | Metoclopramide                               |
|                                              | Neostigmine                                  |
|                                              | Propranolol                                  |
|                                              | Sodium bicarbonate                           |
|                                              | Cigaratte smoking                            |
|                                              | Anticholinergics                             |
|                                              | Tricyclic antidepressants                     |
|                                              | Aluminum hydroxide                           |
|                                              | Alcohol                                      |
|                                              | Isoprenaline                                 |
|                                              | Opioid analgesics                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Increase                | Decrease                     | No Change            |
|------------------------|-----------------------------|----------------------|
| Metoclopramide         | Atropine                    | Propranolol          |
| Domperidone            | Glycopyrrolate              | Oxprenolol           |
| Prochlorperazine       | Dopamine                    | Cimetidine           |
| Cyclizine              | Sodium nitroprusside        | Ranitidine           |
| Edrophonium            | Ganglion blockers            | Atracurium           |
| Neostigmine            | Thiopental                  | ?Nitrous oxide       |
| Histamine              | Tricyclic antidepressants    |                      |
| Suxamethonium          | Halothane                   |                      |
| Pancuronium            | Enflurane                   |                      |
| Metoprolol             | Opioids                     |                      |
| Antacids               | ?Nitrous oxide              |                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Phase        | Surgical Procedures                                                                 | Physiologic Changes                                      |
|--------------|-------------------------------------------------------------------------------------|---------------------------------------------------------|
| Preanhepatic | Dissection of porta hepatis Release of hepatic attachments                          | Third space losses (ascites) Hemorrhage (venous collaterals) |
| Anhepatic    | Clamp hepatic aorta, portal vein Venovenous bypass (adults) Clamp IVC Retraction on diaphragm | Obstruction of venous return Oliguria (venous congestion) Atelectasis, decreased compliance |
| Neohepatic   | Anastomosis of IVC Flush hepatic allograft Anastomosis of portal vein, hepatic artery Biliary drainage procedure | Hemorrhage (coagulopathy) Citrate intoxication Hyperkalemia Hypothermia Metabolic acidosis |

IVC = inferior vena cava.

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| LMA Size | Patient Weight (kg) | LMA ID (mm) | Cuff Volume (ml) | Largest ETT Inside LMA (ID, mm) | Largest FOB Inside ETT (mm) | Type of FOB That Will Pass through ETT                     |
|----------|---------------------|--------------|-------------------|----------------------------------|-----------------------------|----------------------------------------------------------|
| <6.5     | 5.25                | 2-5          | 3.5               | 2.7                              | Olympus PF-27M, ENF-P2,BF-N2O; Pentax FB-2 |
| 6.5-20   | 7.0                 | 7-10         | 4.5               | 3.5                              | Olympus ENF-P3, BF-3C20; Pentax FNL-15S |
| 2.5      | 20-30               | 8.4          | 14                | 5.0                              | 4.0                         | Olympus LF-1, LF-2                                     |
|          | 30-70               | 10           | 15-20             | 6.0 cuffed                       | 5.0                         | Olympus BF-2TR, BF-P2OD                                |
| 4        | >70                 | 10           | 25-30             | 6.0 cuffed                       | 5.0                         | Pentax FB-19H, FB-19H3                                  |
| 5        |                     | 11.5         | 35-40             | 7.0 cuffed                       | 6.5                         | Many brands                                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Condition         | VDss (L/kg) | CL (ml/kg/min) | T1/2 (hr) |
|-------------------|-------------|----------------|-----------|
| Normal            | 1.32        | 10             | 1.8       |
| Cardiac failure    | 0.88        | 6.3            | 1.9       |
| Hepatic disease    | 2.31        | 6.0            | 4.9       |
| Renal disease      | 1.2         | 13.7           | 1.3       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** NERVE BLOCK, EPIDURAL, SPINAL ****

| Type       | Drug              | Rating | Dosage     | Concentration              |
|------------|-------------------|--------|------------|----------------------------|
| NERVE BLOCK| Bupivacaine       | +/-    | 10-20      | 1:200,000                  |
| NERVE BLOCK| Lidocaine         | ++     | 20-30      | 1:200,000                  |
| NERVE BLOCK| Mepivacaine       | ++     | 20-30      | 1:200,000                  |
| NERVE BLOCK| Ropivacaine       | --     | 0          | 1:200,000                  |
| EPIDURAL   | Bupivacaine       | +/-    | 10-20      | 1:300,000-1:200,000        |
| EPIDURAL   | Levobupivacaine   | +/-    | 10         | 1:200,000-1:400,000        |
| EPIDURAL   | Chloroprocaine    | ++     |            | 1:200,000                  |
| EPIDURAL   | Lidocaine         | ++     | 20-30      | 1:600,000-1:200,000        |
| EPIDURAL   | Mepivacaine       | ++     | 20-30      | 1:200,000                  |
| EPIDURAL   | Ropivacaine       | --     | 0          | 1:200,000                  |
| SPINAL     | Bupivacaine       | +/-    |            | 0.2 mg                     |
| SPINAL     | Lidocaine         | ++     |            | 0.2 mg                     |
| SPINAL     | Tetracaine        | ++     |            | 0.2 mg                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| LOCAL ANESTHETIC | pK a | %IONIZED (at pH 7.4) | PARTITION COEFFICIENT (LIPID SOLUBILITY) | %PROTEIN BINDING |
|-------------------|------|----------------------|-------------------------------------------|------------------|
| AMIDES            |      |                      |                                           |                  |
| Bupivacainea      | 8.1  | 83                   | 3,420                                     | 95               |
| Etidocaine        | 7.7  | 66                   | 7,317                                     | 94               |
| Lidocaine         | 7.9  | 76                   | 366                                       | 64               |
| Mepivacaine       | 7.6  | 61                   | 130                                       | 77               |
| Prilocaine        | 7.9  | 76                   | 129                                       | 55               |
| Ropivacaine       | 8.1  | 83                   | 775                                       | 94               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Local Anesthetic   | VD SS (l•kg -1 ) | CL (l•kg -1 •hr -1 ) | T 1/2 (hr) |
|---------------------|------------------|----------------------|------------|
| Bupivacaine         | 1.02             | 0.41                 | 3.5        |
| levo -Bupivacaine   | 0.78             | 0.32                 | 2.6        |
| Chloroprocaine      | 0.50             | 2.96                 | 0.11       |
| Etidocaine          | 1.9              | 1.05                 | 2.6        |
| Lidocaine           | 1.3              | 0.85                 | 1.6        |
| Mepivacaine         | 1.2              | 0.67                 | 1.9        |
| Prilocaine          | 2.73             | 2.03                 | 1.6        |
| Procaine            | 0.93             | 5.62                 | 0.14       |
| Ropivacaine         | 0.84             | 0.63                 | 1.9        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| PLASMA CONC. (µg/mL) | EFFECT                                   |
|-----------------------|------------------------------------------|
| 1-5                   | Analgesia                               |
| 5-10                  | Lightheadedness Tinnitus Numbness of tongue |
| 10-15                 | Seizures Unconsciousness                |
| 15-25                 | Coma Respiratory arrest                  |
| >25                   | Cardiovascular depression                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Agent            | Relative potency for CNS toxicity | CVS:CNS |
|------------------|-----------------------------------|---------|
| Bupivicaine      | 4                                 | 2       |
| Ropivacaine      | 2.9                               | 2       |
| Levobupivicaine  | 2.9                               | 2       |
| Etidocaine       | 2                                 | 4.4     |
| Tetracaine       | 2                                 |         |
| Mepivacaine      | 1.4                               | 7.1     |
| Prilocaine       | 1.2                               | 3.1     |
| Lidocaine        | 1                                 | 7.1     |
| Chloroprocaine   | 0.3                               | 3.7     |
| Procaine         | 0.3                               | 3.7     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Cardiac change                     | Bupivacaine (% of animals) | Lidocaine (% of animals) |
|------------------------------------|-----------------------------|---------------------------|
| Sinus tachycardia                  | 0                           | 100                       |
| Supraventricular tachycardia       | 60                          | 9                         |
| Atrioventricular heart block       | 60                          | 0                         |
| Ventricular tachycardia            | 80                          | 0                         |
| Premature ventricular contractions   | 100                         | 0                         |
| Wide QRS complexes                  | 100                         | 0                         |
| ST-T wave changes                   | 60                          | 40                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Classification | Drug           | Potency | Onset | Duration after infiltration (mins) | Maximum dose for infiltration single (adult, mg*) | Toxic plasma concentration (µg/ml) | pK  | Fraction nonionized (%) | pH 7.2 | pH 7.4 | pH 7.6 | Protein binding (%) | Lipid solubility | Volume distribution (liters) | Clearance (liters/min) | Elimination half-time (mins) |
|----------------|----------------|---------|-------|-------------------------------------|--------------------------------------------------|------------------------------------|-----|-------------------------|--------|--------|--------|---------------------|-------------------|------------------------------|------------------------|------------------------------|
| Esters         | Procaine       | 1       | Slow  | 45-60                               | 500                                              |                                    | 8.9 | 2                       | 3      | 5      | 6      | 0.6                 |                   |                              |                        |                              |
|                | Chloroprocaine | 4       | Rapid | 30-45                               | 600                                              |                                    | 8.7 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Tetracaine     | 16      | Slow  | 60-180                              | 100 (topical)                                   |                                    | 8.5 |                         |        |        |        |                     |                   |                              |                        |                              |
| Amides         | Lidocaine      | 1       | Rapid | 60-120                              | 300                                              | >5                                 | 7.9 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Etidocaine     | 4       | Slow  | 240-480                             | 300                                              | 2                                  | 7.7 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Prilocaine     | 1       | Slow  | 60-120                              | 400                                              | >5                                 | 7.9 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Mepivacaine    | 1       | Slow  | 90-180                              | 300                                              | >5                                 | 7.6 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Bupivacaine    | 4       | Slow  | 240-480                             | 175                                              | >1.5                               | 8.1 |                         |        |        |        |                     |                   |                              |                        |                              |
|                | Ropivacaine    | 4       | Slow  | 240-480                             | 200                                              | >4                                 | 8.1 |                         |        |        |        |                     |                   |                              |                        |                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Drug          | Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | Dose 6 | Dose 7 | Dose 8 |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|
| Chloroprocaine| 3      | 5      | 7      |        |        |        |        |        |
| Tetracaine    | 5      | 7      | 11     | 76     | 80     |        |        |        |
| Amides        |        |        |        |        |        |        |        |        |
| Lidocaine     | 17     | 25     | 33     | 70     | 2.9    | 91     | 0.95   | 96     |
| Etiodocaine   | 24     | 33     | 44     | 94     | 141    | 133    | 1.22   | 156    |
| Prilocaine    | 17     | 24     | 33     | 55     | 0.9    |        |        |        |
| Mepivacaine   | 28     | 39     | 50     | 77     | 1      | 84     | 9.78   | 114    |
| Bupivacaine   | 11     | 15     | 24     | 95     | 28     | 73     | 0.47   | 210    |
| Ropivacaine   | 8.1    |        |        | 94     |        | 41     | 0.44   | 108    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Cardiac change                     | Bupivacaine (% of animals) | Lidocaine (% of animals) |
|------------------------------------|-----------------------------|---------------------------|
| Sinus tachycardia                  | 0                           | 100                       |
| Supraventricular tachycardia       | 60                          | 9                         |
| Atrioventricular heart block       | 60                          | 0                         |
| Ventricular tachycardia            | 80                          | 0                         |
| Premature ventricular contractions   | 100                         | 0                         |
| Wide QRS complexes                  | 100                         | 0                         |
| ST-T wave changes                   | 60                          | 40                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 84-4   -- Age-Dependent Respiratory Variables: Normal Values ***

| Variable                                                        | Newborn     | 6 mo       | 12 mo      | 3 yr       | 5 yr       | 12 yr      | Adult      |
|-----------------------------------------------------------------|-------------|------------|------------|------------|------------|------------|------------|
| Respiratory rate (breaths/min)                                  | 50 ± 10    | 30 ± 5     | 24 ± 6     | 24 ± 6     | 23 ± 5     | 18 ± 5     | 12 ± 3     |
| Tidal volume (mL)                                              | 21         | 45         | 78         | 112        | 270        | 480        | 575        |
| Minute ventilation (L/min)                                      | 1.05       | 1.35       | 1.78       | 2.46       | 5.5        | 6.2        | 6.4        |
| Alveolar ventilation (mL/min)                                   | 385        | -          | 1245       | 1760       | 1800       | 3000       | 3100       |
| Dead space-tidal volume ratio                                   | 0.3        | 0.3        | 0.3        | 0.3        | 0.3        | 0.3        | 0.3        |
| Oxygen consumption (mL/kg/min)                                  | 6 ± 1.0    | 5 ± 0.9    | 5.2 ± 0.9  | ±          | 6.0 ± 1.1  | 3.3 ± 0.6  | 3.4 ± 0.6  |
| Vital capacity (mL)                                            | 120        | -          | -          | 870        | 1160       | 3100       | 4000       |
| Functional residual capacity (mL)                               | 80         | -          | -          | 490        | 680        | 1970       | 3000       |
| Total lung capacity (mL)                                       | 160        | -          | -          | 1100       | 1500       | 4000       | 6000       |
| Closing volume as a percentage of vital capacity                | -          | -          | -          | -          | 20         | 8          | 4          |
| Number of alveoli (saccules) × 10 6                            | 30         | 112        | 129        | 257        | 280        | -          | 300        |
| Specific compliance: CL/FRC (mL/cm H 2 O/L)                    | 0.04       | 0.038      | -          | -          | 0.06       | -          | 0.05       |
| Specific conductance of small airways (mL/sec/cm H 2 O/g)     | 0.02       | -          | 3.1        | 1.7        | 0.12       | 8.2        | 13.4       |
| Hematocrit                                                      | 55 ± 7     | 37 ± 3     | 35 ± 2.5   | 40 ± 3     | 40 ± 2     | 42 ± 2     | 43-48      |
| pH a                                                           | 7.30 ± 7.40| -          | 7.35- 7.45 | -          | -          | -          | 7.35- 7.45 |
| PaCO 2 (mm Hg)                                                 | 30-35      | -          | 30-40      | -          | -          | -          | 30-40      |
| PaO 2 (mm Hg)                                                 | 60-90      | -          | 80-100     | -          | -          | -          | 80-100     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Causes                                                        | Mechanisms                                                                                                                                                                                                                     |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gastrointestinal disorders                                     | Specific absorptive defects; malabsorption syndromes; prolonged diarrhea; prolonged nasogastric suction; pancreatitis                                                                                                        |
| Endocrine disorders                                           | Hyperparathyroidism; hypoparathyroidism; hyperthyroidism; primary hyperaldosteronism; Bartter's syndrome; diabetic or alcoholic ketoacidosis; administration of epinephrine; syndrome of inappropriate antidiuretic hormone (SIADH); hungry bone syndrome after parathyroidectomy |
| Chronic alcoholism, alcoholic withdrawal, increased renal excretion | Ethanol ingestion; idiopathic; after renal transplantation; drugs such as cisplatin, aminoglycoside, amphotericin B, diuretics, pentamidine, and theophylline; recovery phase of acute tubular necrosis; colony-stimulating factor therapy |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Activity                                               |
|-------------------------------------------------------|
| Eating, working at a computer, dressing               |
| Walking down stairs or in your house, cooking         |
| Walking 1-2 blocks                                    |
| Raking leaves, gardening                               |
| Climbing 1 flight of stairs, dancing, bicycling       |
| Playing golf, carrying clubs                           |
| Playing singles tennis                                 |
| Rapidly climbing stairs, jogging slowly                |
| Jumping rope slowly, moderate cycling                 |
| Swimming quickly, running or jogging briskly          |
| Skiing cross country, playing full-court basketball   |
| Running rapidly for moderate to long distances         |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug        | Equivalent dose (mg) | Volume distribution (liters/kg) | Protein binding (%) | Clearance (ml/kg/min) | Elimination half-time (hrs) |
|-------------|-----------------------|----------------------------------|---------------------|------------------------|------------------------------|
| Midazolam   | 1                     | 1.2                              | 97                  | 7                      | 2                            |
| Diazepam    | 2                     | 1.2                              | 97                  | 0.4                    | 28                           |
| Lorazepam   | 0.25                  | 1                                | 97                  | 0.8                    | 15                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter      | Effect                                      |
|----------------|---------------------------------------------|
| HR             | Usually no change; may have slight inc. at increased doses |
| CO             | Increased                                   |
| BP             | Variable                                    |
| SVR and PVR    | Decreased                                   |
| Preload        | Decreased                                   |
| MVO 2          | Often unchanged                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| VARIABLE                                                                 | ALL PROCEDURES RELATIVE ODDS OF DYING WITHIN 7 D | 95% CONFIDENCE LIMITS     |
|--------------------------------------------------------------------------|---------------------------------------------------|----------------------------|
| Patient related                                                          |                                                   |                            |
| Age (y)                                                                 |                                                   |                            |
| 60-79/<60                                                               | 2.32                                              | 1.70, 3.17                 |
| 80+/<60                                                                 | 3.29                                              | 2.18, 4.96                 |
| Sex                                                                      |                                                   |                            |
| F/M                                                                      | 0.77                                              | 0.59, 1.00                 |
| Physical status score 3-5/1-2                                           | 10.65                                             | 7.59, 14.85                |
| Surgery related                                                          |                                                   |                            |
| Major/minor                                                             | 3.82                                              | 2.50, 5.93                 |
| Intermediate/minor                                                       | 1.76                                              | 1.24, 2.5                  |
| Length of anesthesia ≤ h/<2 h                                           | 1.08                                              | 0.77, 1.50                 |
| Emergency/elective                                                       | 4.44                                              | 3.38, 5.83                 |
| Other factors                                                            |                                                   |                            |
| Year of operation 1975-1979/1980-1984                                   | 1.75                                              | 1.32/2.31                  |
| Had a complication in the operating or recovery room                     | 1.42                                              | 1.06, 1.89                 |
| Yes/no                                                                  |                                                   |                            |
| Anesthesia related*                                                      |                                                   |                            |
| Experience of anesthetist                                               |                                                   |                            |
| >600 procedures for ≥ 8 y/<600 procedures for <8 y                      | 1.06                                              | 0.82, 1.37                 |
| Inhalation with narcotic/inhalation alone                                | 0.76                                              | 0.51, 1.15                 |
| Narcotic alone/inhalation alone                                          | 1.41                                              | 1.01, 2.00                 |
| Narcotic with inhalation/inhalation alone                                | 0.79                                              | 0.47, 1.32                 |
| Spinal/inhalation alone                                                  | 0.53                                              | 0.29, 0.98                 |
| No. of anesthetic drugs 1-2/3+                                          | 2.94                                              | 2.20, 3.84                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
| Myasthenia Gravis                                      | Lambert-Eaton                                           |
|-------------------------------------------------------|--------------------------------------------------------|
| At the NMJ                                            | Antibodies against post- synaptic ACh receptors       | Antibodies against pre- synaptic calcium-channels responsible for ACh release |
| Activity                                              | Fatigue with activity                                   | Strength improvement with activity                     |
| Reflexes                                             | Normal                                                 | Absent/decreased                                       |
| Treatment                                            | Anticholinesterases                                   | Steroids                                              |
|                                                      | Good                                                  | Good                                                  |
|                                                      | No effect                                             | No effect                                            |
| Muscle Relaxants                                     | Sensitive to NdMRs                                   | Resistant to SCh (or unpredictable)                   |
|                                                      | Sensitive to NdMRs                                   | Sensitive to Succinylcholine                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 43-2 -- Drug selection for hyperbaric spinal anesthesia**

| Local Anesthetic Mixture                     | Dose (mg) * | Duration (min) | To T10 | To T4 | Plain | Epinephrine, 0.2 mg |
|----------------------------------------------|--------------|----------------|--------|-------|-------|---------------------|
| Lidocaine (5% in 7.5% dextrose)            | 50-60       | 75-100         | 60     | 75-100|       |                     |
| Tetracaine (0.5% in 5% dextrose)           | 6-8         | 10-16          | 70-90  | 100-150|      |                     |
| Bupivacaine (0.75% in 8.5% dextrose)       | 8-10        | 12-20          | 90-120 | 100-150|      |                     |
| Ropivacaine (0.5% in dextrose)             | 12-18       | 18-25          | 80-110 | -     |       |                     |
| Levobupivacaine                             | 8-10        | 12-20          | 90-120 | 100-150|      |                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Location of Incision     | Examples of Surgical Procedures                                               | Congruent Epidural Catheter Placement |
|--------------------------|-----------------------------------------------------------------------------|--------------------------------------|
| Thoracic                 | Lung reduction, radical mastectomy, thoracotomy, thymectomy                | T4-8                                 |
| Upper abdominal          | Cholecystectomy, esophagectomy, gastrectomy, hepatic resection, Whipple    | T6-8                                 |
| Middle abdominal         | Cystoprostatectomy, nephrectomy                                            | T7-10                                |
| Lower abdominal          | Abdominal aortic aneurysm repair, colectomy, radical prostatectomy, total abdominal hysterectomy | T8-11                                |
| Lower extremity          | Femoral-popliteal bypass, total-hip or total-knee replacement              | L1-4                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 21-4 -- CLINICAL FEATURES OF EPIDURAL, SUBDURAL, AND SPINAL BLOCKS**

| Epidural                     | Subdural block                                         | Spinal block                                         |
|-----------------------------|-------------------------------------------------------|-----------------------------------------------------|
| Slow                        | Intermediate                                          | Rapid                                               |
| Onset time                  | As expected                                           | Higher than expected; may intracranially, but sacral sparing |
| Spread                      | Higher than expected; intracranially, typically present |                                                     |
| Nature of block             | Segmental                                            | Patchy                                             | Dense                                              |
| Motor block                 | Minimal                                              | Minimal                                            | Dense                                              |
| Hypotension                 | Less than spinal, and dependent on the extent of the block | Intermediate between spinal and epidural, and dependent on the extent of the block | Likely                                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 4 Levenson' $ clinical criteria for diagnosis of NMS [45]**

| Category | Manifestations                                                                                     |
|----------|----------------------------------------------------------------------------------------------------|
| Major    | Fever, rigidity, elevated crcatinine phosphokinase concentration                                   |
| Minor    | Tachycardia, abnormal arterial pressure . taclycardia, altered consciousuess, diaphoresis. leucocytosis |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug            | ED 95 (mg/kg) | Supplemental doses (mg/kg) | Onset to maximum twitch depression (mins) | Duration to return to 25% control twitch height (mins) | Intubating dose (mg/kg) | N2O   | Volatile |
|------------------|----------------|-----------------------------|-------------------------------------------|-------------------------------------------------------|--------------------------|-------|----------|
| Pancuronium      | 0.07           |                             | 3 - 5                                     | 60 - 90                                               | 0.1                      | 0.015 | 0.007    |
| Doxacurium       | 0.03           |                             | 4 - 6                                     | 60 - 90                                               | 0.05 - 0.08             |       |          |
| Pipecuronium     | 0.05 - 0.06    |                             | 3 - 5                                     | 60 - 90                                               | 0.14                     |       |          |
| Atracurium       | 0.2            |                             | 3 - 5                                     | 20 - 35                                               | 0.4 - 0.5               | 0.1   | 0.07     |
| Vecuronium       | 0.05           |                             | 3 - 5                                     | 20 - 35                                               | 0.08 - 0.1              | 0.02  | 0.015    |
| Rocuronium       | 0.3            |                             | 1 - 2                                     | 20 - 35                                               | 0.6 - 1.2               |       |          |
| Cisatracurium    | 0.05           |                             | 3 - 5                                     | 20 - 35                                               | 0.1                      |       |          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug            | Continuous infusion (µg/kg/min) | Volume of distribution (liters/kg) | Clearance (ml/kg/min) | Renal excretion (% unchanged) | Biliary excretion (% unchanged) |
|------------------|----------------------------------|------------------------------------|------------------------|-------------------------------|----------------------------------|
| Mivacurium       | 0.08                             | 2 - 3                              | 12 - 20                | 0.25                          |                                  |
| Pancuronium      |                                  | 0.26                               | 1.8                    | 80                            | 5 - 10                           |
| Doxacurium       |                                  | 0.22                               | 2.7                    | 70                            | 30                               |
| Pipecuronium     |                                  | 0.35                               | 3.0                    | 70                            | 20                               |
| Atracurium       | 6 - 8                            | 0.2                                | 5.5                    | 10                            | NS                               |
| Vecuronium       | 1                                | 0.27                               | 5.2                    | 15 - 25                       | 40 - 75                          |
| Rocuronium       |                                  | 0.3                                | 4.0                    | 10 - 25                       | 50 - 70                          |
| Cisatracurium    |                                  | 1 - 1.5                            | 0.2                    | 4.7 - 5.3                     | NS                               |
| Mivacurium       |                                  | 5 - 6                              |                        | <10                           | NS                               |

| Drug            | Hepatic degradation (%) | Hydrolysis in the plasma | Degradation dependent on body temperature | Degradation dependent on blood pH | Degradation dependent on renal function | Degradation dependent on hepatic function |
|------------------|------------------------|--------------------------|------------------------------------------|-----------------------------------|-----------------------------------------|------------------------------------------|
| Pancuronium      | 10                     | No                       |                                          |                                   |                                         |                                          |
| Doxacurium       | ?                      | No                       |                                          |                                   |                                         |                                          |
| Pipecuronium     | 10                     | No                       |                                          |                                   |                                         |                                          |
| Atracurium       | ?                      | Yes* (Hofmann)          | Yes                                      | No                                | No                                      |                                          |
| Vecuronium       | 20 - 30               | No                       | Yes                                      | No                                | Yes                                     | Yes                                      |
| Rocuronium       | 10 - 20               | No                       | Yes                                      | No                                | Yes                                     | Yes                                      |
| Cisatracurium    | 0                      | No* (Hofmann)           | Yes                                      | No                                | No                                      |                                          |
| Mivacurium       | 0                      | Yes                      | Yes                                      | ?                                 | ?                                       | ?                                        |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug Type                          | Autonomic Ganglia | Cardiac Muscarinic Receptors | Histamine Release |
|------------------------------------|-------------------|------------------------------|-------------------|
| Depolarizing Substance              |                   |                              |                   |
| Succinylcholine                    | Stimulates        | Stimulates                   | Slight            |
| Benzylisoquinolinium Compounds     |                   |                              |                   |
| Mivacurium                         | None              | None                         | Slight            |
| Atracurium                         | None              | None                         | Slight            |
| Cisatracurium                      | None              | None                         | None              |
| Doxacurium                         | None              | None                         | None              |
| d -Tubocurarine                   | Blocks            | None                         | Moderate          |
| Metocurine                         | Blocks weakly     | None                         | Slight            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug Type          | Autonomic Ganglia | Cardiac Muscarinic Receptors | Histamine Release |
|--------------------|-------------------|------------------------------|--------------------|
| Steroidal Compounds |                   |                              |                    |
| Rapacuronium       | ? None            | Blocks moderately            | ? Slight           |
| Vecuronium         | None              | None                         | None               |
| Rocuronium         | None              | Blocks weakly                | None               |
| Pancuronium        | None              | Blocks moderately            | None               |
| Pipecuronium       | None              | None                         | None               |
| Others             |                   |                              |                    |
| Alcuronium         | Blocks weakly     | Blocks weakly                | None               |
| Gallamine          | None              | Blocks strongly              | None               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 9-4. Potentiation (+) and resistance (-) of neuromuscular blocking agents by other drugs.**

| Drug                     | Effect on Depolarizing Blockade | Effect on Nondepolarizing Blockade | Comments                                                                                     |
|--------------------------|---------------------------------|------------------------------------|----------------------------------------------------------------------------------------------|
| Antibiotics              |                                 |                                    | Streptomycins, colistin, polymyxin; tetracycline; lincomycin, clindamycin; bacitracin      |
| Anticonvulsants         |                                 |                                    | Phenytoin; carbamazepine; primidone; sodium valproate                                      |
| Antidysrhythmics        |                                 |                                    | Quinidine; lidocaine; calcium channel blockers, pro- cainamide                             |
| Antihypertensives       |                                 |                                    | Trimethaphan; nitroglycerin (only affects pancuronium)                                     |
| Cholinesterase inhibitors |                                 |                                    | Neostigmine; pyridostigmine; edrophonium                                                    |
| Dantrolene               |                                 |                                    | Used in treatment of malignant hyperthermia (has quater- nary ammonium group)              |
| Furosemide               | <10 ug/kg                       | 1-4 mg/kg                          | Biphasic effect depending on dose                                                             |
| Inhalational anesthetics  |                                 |                                    | See text                                                                                    |
| Ketamine                 |                                 |                                    |                                                                                            |
| Local anesthetics        |                                 |                                    |                                                                                            |
| Lithium carbonate        |                                 |                                    | Prolongs onset and duration of succinylcholine; one case re- ported of prolonged block with nondepolarizer |
| Magnesium sulfate        |                                 |                                    | Used to treat preeclampsia and eclampsia of pregnancy                                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Acceptable Clinical Results to Suggest Normal Function                          | Approximate Percentage of Receptor Occupied When Response Returns to Normal Value | Comments/Disadvantages/Advantages                                                                                     |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Tidal volume                                                                   | At least 5 mL/kg                                                                | 80                                                                                                                    | Insensitive as an indicator of peripheral neuromuscular function                                                      |
| Single twitch                                                                  | Qualitatively as strong as baseline                                             | 75-80                                                                                                                | Uncomfortable, need to know twitch strength before relaxant strength as baseline administration. Insensitive as an indicator of recovery, but useful as a gauge of deep neuromuscular blockade |
| Train-of-four (TOF)                                                           | No palpable fade                                                                 | 70-75                                                                                                                | Still uncomfortable, but more sensitive as an indicator of recovery than single twitch is. Useful as a gauge of depth of block by counting the number of responses perceptible |
| Sustained tetanus at 50 Hz for 5 sec                                          | No palpable fade                                                                 | 70                                                                                                                    | Very uncomfortable, but a reliable indicator of adequate recovery                                                    |
| Vital capacity                                                                 | At least 20 mL/kg                                                               | 70                                                                                                                    | Requires patient cooperation, but is the goal for achievement of full clinical recovery                               |
| Double burst                                                                   | No palpable fade                                                                 | 60-70                                                                                                                | Uncomfortable, but more sensitive than TOF as an indicator of stimulation of peripheral function. No perceptible fade indicates TOF recovery of at least 60% |
| Sustained tetanus at 100 Hz                                                   | No palpable fade                                                                 | 50                                                                                                                    | Very painful, a "stress test" for the neuromuscular junction. It is not always possible to achieve or demonstrate lack of fade at 100 Hz |
| Inspiratory force                                                              | At least -40 cm H2 O                                                           | 50                                                                                                                    | Sometimes difficult to perform without endotracheal intubation, but a reliable gauge of normal diaphragmatic function |
| Head lift                                                                     | Must be performed unaided with patient supine at 180 degrees and for 5 sec     | 50                                                                                                                    | Requires patient cooperation, but remains the standard test of normal clinical function. Must be performed with the patient in a completely supine position |
| Handgrip                                                                      | Sustained at a level qualitatively similar to preinduction baseline             | 50                                                                                                                    | Sustained strong grip, though also requiring patient cooperation. It is another good gauge of normal function         |
| Sustained bite                                                                 | Sustained jaw clench on tongue blade                                            | 50                                                                                                                    | Very reliable with patient cooperation. Corresponds to TOF ratio of 0.85                                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Sign or symptom                     | %  |
|-------------------------------------|----|
| Hypotension                         | 100|
| Fetal distress                      | 100|
| Pulmonary edema or ARDS            | 93 |
| Cardiopulmonary arrest              | 87 |
| Cyanosis                            | 83 |
| Coagulopathy                        | 83 |
| Dyspnea                             | 49 |
| Seizure                             | 48 |
| Atony                               | 23 |
| Bronchospasm                        | 15 |
| Transient hypertension              | 11 |
| Cough                               | 7  |
| Headache                            | 7  |
| Chest pain                          | 2  |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 2. Other symptoms of amniotic fluid embolism**

| Symptom                                                                 |
|-------------------------------------------------------------------------|
| Seizure activity                                                         |
| Confusion                                                                |
| Agitation                                                                |
| Constitutional (fever, chills, headache, nausea, vomiting)             |
| Evidence of fetal distress (late decelerations, bradycardia)            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 2. Normal cardiorespiratory changes of pregnancy and effect on resuscitation**

| Physiologic Parameter            | Change During Pregnancy     | Effect on Resuscitation                                   |
|----------------------------------|-----------------------------|----------------------------------------------------------|
| Cardiac output                   | Increase (by 50%)          | Increased circulation demands during CPR                  |
| Blood volume                     | Increase (by 30-50%)       | Dilutional anemia, decreased oxygen carrying capacity     |
| Systemic vascular resistance      | Decrease (variable)        | Sequestration of blood during CPR                         |
| Minute ventilation                | Increase (by 50%)          | Compensated respiratory alkalosis, decreased buffering capacity |
| Functional residual capacity      | Decrease (by 20%)          | Rapid development of hypoxia                              |
| Oxygen consumption                | Increase (by 20%)          | Rapid development of hypoxia                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Complication                             | Incidence                     |
|-----------------------------------------|-------------------------------|
| Intrapartum fetal death                 | Increased sixteenfold         |
| Intrapartum asphyxia                   | Increased 3.8-fold            |
| Umbilical cord prolapse                 | Increased fivefold to twentyfold |
| Birth trauma                             | Increased thirteenfold        |
| Arrest of aftercoming head              | 8.8%                          |
| Spinal cord injuries with deflexion      | 21%                           |
| Major congenital anomalies               | 6%-18%                        |
| Preterm delivery                         | 16%-33%                       |
| Hyperextension of head                   | 5%                            |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Symptom                                      | Therapy                                         |
|----------------------------------------------|------------------------------------------------|
| Hypertension/tachycardia                     | Nitroglycerin, labetalol, ± benzodiazepine [82] |
| Convulsions                                  | Benzodiazepine/control airway                  |
| Tremors/central nervous system agitation      | Benzodiazepine                                 |
| Angina                                       | Intravenous nitroglycerin ± labetalol [90]    |
| Arrhythmias                                  | Sodium bicarbonate, [86] lidocaine [91]       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category        | Normal Tracing Previously Reassuring | Atypical Tracing Previously 'Non-reassuring' | Abnormal Tracing Previously |
|------------------|--------------------------------------|-----------------------------------------------|-----------------------------|
| Baseline          | 110-160 bpm                         | Bradycardia 100-110 bpm Tachycardia >160 for 230 min to < 90 min. baseline Rising | Bradycardia 100 bpm Tachycardia >160 for 90 min Erratic baseline |
| Variability       | 6-25 bpm                            | <5 bpm for < 30 min:                         | <5 bpm for > 80 min_ 225 bpm for >10 min. Sinusoidal |
| Decelerations     | None or occasional typical variables or early decelerations | Repetitive (23) uncomplicated variable decelerations Occasional late decelerations Single prolonged deceleration > 2 min. but < 3 min:. | Repetitive (23) complicated variables: deceleration to 70 bpm for > 60 secs. loss of variability in trough or in baseline biphasic decelerations overshoots slow return to baseline baseline lower after deceleration baseline tachycardia or bradycardia Late decelerations 50% of contractions Single prolonged deceleration > 3 min. but < 10 min |
| Accelerations      | Spontaneous accelerations present (FHR increases > 15 bpm lasting > 15 seconds (<32 weeks gestation increase in the FHR > 10 bpm lasting 10 seconds) Accelerations present with fetal scalp stimulation | Absence of acceleration with fetal scalp stimulation |
| ACTION            | EFM may be interrupted for periods up to 30 min. if maternal-fetal condition stable and/or oxytocin infusion rate stable. | Further vigilant assessment required, especially when combined features present. | ACTION REQUIRED Obtain scalp pH if appropriate/prepare for delivery. |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                     | Goals                                           | Pregnancy                                   | Labour                                      | Anesthesia                                   | Postpartum                                   |
|-------------------------------|------------------------------------------------|--------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------------------|
| Preload                       | Maintain preload, but avoid overload.          | Maintained, but decreased with caval compression | Increased                                   | Normalized or decreased.                     | Increased.                                   |
| Rate                          | Avoid tachycardia                              | Increased HR                               | Significant increase.                       | Generally attenuates increase in HR         | HR decreases.                                |
| Rhythm                        | Sinus rhythm important.                        | Remains important                          | Remains important.                          | Remains important.                           | Remains important.                           |
| Contractility                 | Maintain contractility                         | Increased                                  | Increased                                   | Possible decrease                            | Increased, then normalizes                  |
| Afterload                     | Maintain SVR                                   | Decrease.                                  | Increased.                                  | Decreased.                                   | Resolving to prepregnant levels.            |
| Pulmonary vascular resistance. | Avoid increased PVR                            | Normal or increased independent of pregnancy. | Increased in the context of mitral stenosis. | May be improved by analgesia and normalization of preload. | Remains increased secondary to stenosis and hypervolemia. |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Properties                  | Lipophilic Opioids         | Hydrophilic Opioids       |
|----------------------------|----------------------------|----------------------------|
| Common agents              | Fentanyl, sufentanil      | Morphine, hydromorphone    |
| Onset of analgesia         | Rapid onset (5-10 min)    | Delayed onset (30-60 min)  |
| Duration of analgesia      | Shorter duration (2-4 hr)  | Longer duration (6-24 hr)   |
| CSF spread                 | Minimal CSF spread         | Extensive CSF spread        |
| Site of action             | Spinal ±systemic          | Primarily spinal            |
| Side effects               |                            |                            |
| Nausea and vomiting        | Lower incidence with lipophilic versus hydrophilic opioids |                            |
| Pruritus                   | Lower incidence with lipophilic versus hydrophilic opioids | Spinal > epidural           |
| Respiratory depression      | Primarily early; minimal delayed | Both early (<6 hr) and delayed (>6 hr) possible |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Symptom           | Incidence |
|-------------------|-----------|
| Nausea            | 60%       |
| Vomiting          | 24%       |
| Neck stiffness    | 43%       |
| Ocular            | 13%       |
| Auditory          | 12%       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                                      | Change    | Amount (%)                                      |
|------------------------------------------------|-----------|-------------------------------------------------|
| Heart rate                                     | Increased | + 20-30                                        |
| Stroke volume                                  | Increased | + 20-50                                        |
| Cardiac output                                 | Increased | + 30-50 (22%-T1, 30-40%-T2, 50%-term)         |
| Myocardial thickness, end-diastolic           | Increased | + 5                                            |
| LVEDV                                         | increased | ?                                               |
| LVESV                                         | no change | --                                              |
| EF                                            | increased | ?                                               |
| Contractility                                  | Variable  | ±10                                            |
| CVP                                           | Unchanged | -                                               |
| Pulmonary capillary wedge pressure             | Unchanged | -                                               |
| Systemic vascular resistance                   | Decreased | - 20                                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Parameter                        | Change            | Amount (% or units)               |
|----------------------------------|-------------------|-----------------------------------|
| Systemic blood pressure           | Slight decrease    | Midtrimester 10-15 mmHg, then rises |
| Pulmonary vascular resistance     | Decreased          | - 30                              |
| Pulmonary artery pressure         | Slight decrease    | -                                 |
| Colloid oncotic pressure         | Decreased          | - 15                              |
| tidal volume                     | increase           | + 40                              |
| respiratory rate                 | increase           | + 20                              |
| minute ventilation                | increase           | + 50                              |
| Alveolar Ventilation             | Increase           | + 70                              |
| Dead Space                       | No Change          |                                   |
| Airway Resistance                | Decrease           | - 36                              |
| Total Pulmonary resistance        | Decrease           | - 50                              |
| ERV                              | decrease           | - 20                              |
| RV                               | decreased          | - 20                              |
| FRC                              | decrease           | - 20                              |
| Closing Volume                   | No Change          |                                   |
| vital capacity                   | No change          | --                                |
| IC                               | Increase           | + 5                               |
| TLC                              | No Change          | 0 - 5 %decrease                   |
| lung compliance (alone)          | No change          | --                                |
| chest wall compliance (alone)    | decrease           | - 45                              |
| total compliance                 | decrease           | - 30-40                           |
| FEV 1                            | No Change          | --                                |
| DLCO                             | decrease           | - 5                               |
| PaCO 2                          | Decrease           | - 10 mmHg                         |
| HCO -                            | Decrease           | - 4 mEq/L                        |
| PO 2                             | Increase           | + 10 mmHg                         |
| O 2 Consumption                  | Increase           | + 20                              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Incidence of Accreta

| No. of prior C/S | %With Accreta |
|------------------|---------------|
| 0                | 5             |
| 1                | 24            |
| 2                | 47            |
| 3                | 40            |
| 4                | 67            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| First trimester markers                                   | Second or third trimester markers                          |
|---------------------------------------------------------|----------------------------------------------------------|
| Demographics                                             | Past history                                              | Current pregnancy                                         |
| Maternal age 240 years                                  | Previous preeclampsia                                    | Anti-phospholipid antibodies                             |
| Pre-existing medical condition(s)                        | Pre-existing hypertension or Pre-existing renal disease   | Or booking proteinuria                                    |
| Pre-existing diabetes mellitus                           | Family history of preeclampsia (mother or sister)       | Multiple pregnancy                                        |
| First ongoing pregnancy                                  | Inter-pregnancy interval 10 years                        | Bocking sBP 2 130 mmHg, or bocking dBP 2 80 mmHg       |
| Ethnicity: Nordic; Black, South Asian or Pacific Island | Lower socioeconomic status                                 | Non-smoking                                              |
| Heritable thrombophilia                                  | Pregnancy triglycerides                                   | Family history of early onset                            |
| Cocaine and methamphetamine use                         | Inter-pregnancy interval < 2 years                       | New partner                                              |
| Gestational trophoblastic disease                        | Excessive weight gain in pregnancy                        | Infection during pregnancy (e.g., UTI, periodontal disease) |
| Abnormal MSSI                                           | Abnormal uterine Doppler                                  | Cardiac output > 7.4 U/min                              |
| Elevated uric acid                                      | Investigational laboratory markers                        |                                                          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Agent        | Dosago                                   | Comments                                                       |
|--------------|------------------------------------------|----------------------------------------------------------------|
| Labotalol    | 1-2 mg'min, max 300 mg (then swtch to cral) | Best avoided in women with asthma or hcart failure. Nconatology bradycardia |
| Nifedipine   | swallowed, every 30 min                 |                                                                |
| Hydralazine  | 0.5 1                                   | increase the risk 0f malemal hypclension May                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 7 Doses of most commonly used agents used for treatment of a BP of 140-159/90-105 mmHg**

| Agont      | Dosago          | Comments                                                   |
|------------|----------------|------------------------------------------------------------|
| Methydopa  |                | There is no evidence to support 0 bading dosc of mcthyldopa. |
| Nifedipine | max 180 mg'd)  |                                                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 58-10 -- Comparison of properties of hydralazine and labetalol for treatment of hypertension**

| Drug               | Hydralazine                | Labetalol                     |
|--------------------|---------------------------|-------------------------------|
| Mode of action     | Vasodilator               | α- and β-blocker (1:3)       |
| Speed of onset     | Gradual                   | Quick                         |
| Dose               | 5-10 mg IV slowly         | 10-20 mg IV slowly            |
| Interval           | Repeat after 20 min       | Titrate to effect             |
| Infusion rate      | 2 mg/hr up to 20 mg/hr    | 20 mg/hr to maximum of 160 mg/hr |
| Effect on heart rate| Compensatory tachycardia | No effect                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 1**

| Affected value or system                     | Change during normal pregnancy                                           |
|----------------------------------------------|-------------------------------------------------------------------------|
| Systolic blood pressure                       | Decreased by an average of 5 to 15 mm Hg                               |
| Diastolic blood pressure                      | Decreased by 5 to 15 mm Hg                                             |
| Electrocardiogram                            | Flat or inverted T waves in leads IlI, Vu, and Vz; Q waves in leads Ill and aVF |
| Blood volume                                 | Increased by 30 to 50 percent                                          |
| White blood cell count                       | May be increased; range: 5,000 to 25,000 per (5 to 25 X 10^9 per L; higher in late pregnancy) mm |
| Fibrinogen D-dimer                          | Increased; range: 264 to 615 mg per dL (2.6 to 6.1 g per L) Frequently positive |
| Respiratory rate                             | Increased by 40 to 50 percent                                          |
| Partial pressure of oxygen                   | Increased; range: 100 to 108 mm Hg                                    |
| Partial pressure of carbon dioxide           | Decreased; range: 27 to 32 mm Hg                                      |
| Bicarbonate                                  | Decreased; range: 19 to 25 mEq per L                                   |
| Base excess                                  | Present; range: 3 to 4 mEq per L                                       |
| Blood urea nitrogen                          | Decreased; range: 3 to 3.5 mg per dL (1.1 to 1.2 mmol per L)          |
| Serum creatinine                             | Decreased; range: 0.6 to 0.7 mg per dL (50 to 60 pmol per L (1.0 mg per dL [90 per L] may be abnormal) umol |
| Alkaline phosphatase                         | Increased because of placental production; range: 60 to 140 IU per L (60 to 140 U per L) |
| Kidneys                                      | Mild hydronephrosis                                                    |
| Gastrointestinal tract                       | Decreased gastric emptying; decreased motility, increased risk of aspiration |
| Musculoskeletal system                       | Widened symphysis pubis and sacroiliac joints, which may lead to misreading of radiologic studies |
| Diaphragm                                    | Higher position in pregnancy; consequently; chest tubes would need to be placed one or two interspaces higher. |
| Peritoneum                                   | Small amounts of intraperitoneal fluid normally present                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Condition                  | Associated Factors                                               |
|---------------------------|-----------------------------------------------------------------|
| Eclampsia                 |                                                                 |
| Cerebrovascular compromise | Cerebral infarction, hemorrhage, SAH, Cerebral venous thrombosis, edema |
| Mass Lesions              | Vascular malformations, tumors, abscess                         |
| Infectious disease        | Meningitis, Viral, Bacterial, Parasitic, HIV                   |
| Epilepsy                  |                                                                 |
| Toxins                    | Central stimulants (e.g. cocaine, theophylline)                |
| Metabolic disorders       | Hyponatremia, hypocalcemia, hypoglycaemia, hyperglycemia       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug                        | Altered pharmacokinetics                                                                 | Clinical implications                                                        |
|-----------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Hypnotics                   |                                                                                          |                                                                           |
| Thiopental                  | TBW                                                                                      | Increased absolute dose; reduced dose per unit body weight; prolonged duration of action |
| Propofol                    | TBW                                                                                      | Increased absolute dose; reduced dose per unit body weight                |
| Midazolam, diazepam        | TBW                                                                                      | Increased absolute dose, same dose per unit body weight; prolonged duration of action, particularly after infusion |
| Neuromuscular blocking drugs |                                                                                          |                                                                           |
| Succinylcholine             | TBW                                                                                      | Increased absolute dose; reduced dose per unit body weight; doses of 120 - 140 mg appear satisfactory |
| Atracurium                  | TBW                                                                                      | Unchanged dose per unit body weight                                       |
| Vecuronium                  | IBW                                                                                      | Give according to estimated lean body weight                              |
| Pancuronium                 |                                                                                          | Unchanged dose per unit body weight                                       |
| Rocuronium                  | IBW                                                                                      |                                                                           |
| Dimethyl tubocurarine      |                                                                                          | Give according to estimated LBW                                           |
| Opioids                     |                                                                                          |                                                                           |
| Fentanyl                    | TBW                                                                                      | Dose per unit body weight unchanged                                       |
| Alfentanil                  |                                                                                          | Adjust dose to LBW                                                       |
| Morphine                    |                                                                                          | No information available                                                  |
| Local anaesthetics          |                                                                                          |                                                                           |
| Lidocaine                   |                                                                                          | I.v. dose: unchanged dose per unit body weight; extradural dose: 75% of dose calculated according to TBW |
| Bupivacaine                 |                                                                                          | High segmental level following subarachnoid blockade                      |
| Inhalational anaesthetics    |                                                                                          |                                                                           |
| Nitrous oxide               |                                                                                          | Increased F I O2 limits practical usefulness; intestinal distension may contribute to perioperative difficulties |
| Halothane                   |                                                                                          | Possible increased risk of halothane hepatitis                            |
| Enflurane                   |                                                                                          | Possibly lower MAC; increased risk of fluoride nephrotoxicity following prolonged administration |
| Sevoflurane                 |                                                                                          | No difference in fluoride concentrations between obese and non-obese patients |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 1. Weight-Based Dosing of Common IV Anesthetics (91-102)**

| Drug                     | Dosing                          | Comments                                                                                                                                                                                                                     |
|--------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Propofol                 | IBW Maintenance: TBW            | Systemic clearance and Vp at steady-state correlates well with TBW (92) High affinity for excess and other well perfused organs. High hepatic extraction and conjugation relates to TBW fat                                   |
| Thiopental               | TBW                             | Increased Vp Increased blood volume, cardiac output, and muscle mass (91). Increased absolute dose Prolonged duration of action (93)                                                                                       |
| Midazolam                | TBW                             | Central Vp increases in line with body weight. Increased absolute dose. Prolonged sedation because larger initial doses are needed to achieve adequate serum concentrations (93, 04)                                          |
| Succinylcholine          | TBW                             | Plasma cholinesterase activity increases in proportion to body weight Increased absolute dose (93)                                                                                                                         |
| Vecuronium               | IBW                             | Recovery may be delayed if given according to TBW because of increased Vp and impaired hepatic clearance (93, 95)                                                                                                         |
| Rocuronium               | IBW                             | Faster onset and longer duration of action. Pharmacokinetics and pharmacodynamics are not altered in obese subjects (96, 97).                                                                                              |
| Atracurium Cisatracurium | TBW                             | Absolute clearance Vpr and elimination half-life do not change: Unchanged dose per unit body weight without prolongation of recovery because of organ-independent elimination (98, 90).                                      |
| Fentanyl                 | TBW                             | Increased Vp and elimination half-time, which correlates positively with                                                                                                                                                   |
| Sufentanil               | TBW Maintenance: IBW            | the degree of (100). Distributes as extensively in excess body mass as in lean tissues. Dose should account for total body mass. obesity                                                                                   |
| Remifentanil             | IBW                             | Systemic clearance and Vo corrected per kilogram of TBW significantly smaller in the obese. Pharmacokinetics are similar in obese and nonobese patients (101). and lean body mass should be considered for (102) Age dosing |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug           | Parenteral | Oral  |
|----------------|------------|-------|
| Morphine       | 10         | 30    |
| Codeine        | 130        | 200   |
| Fentanyl       | 0.1        | -     |
| Hydromorphone   | 1.5-2     | 6-7.5 |
| Levorphanol    | 2          | 4     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug          | Parenteral | Oral    |
|---------------|------------|---------|
| Meperidine    | 75         | 300     |
| Methadone     | 10         | 20      |
| Oxycodone     | 15         | 20-30   |
| Oxymorphone   | 1          | -       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Effect                                   | Mu 1                     | Mu 2                     | Kappa                     | Delta                     |
|------------------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|
| Analgesia                                | supraspinal spinal       | spinal                   | supraspinal               | supraspinal spinal        |
| Euphoria                                 |                          | Dysphoria, sedation      |                           |                           |
|                                          | Depression of ventilation |                          | Depression of ventilation  |                           |
| Low abuse potential                      | Physical dependence      | Low abuse potential      | Physical dependence       |                           |
| Miosis                                   |                          | Miosis                   |                           |                           |
|                                          | Constipation (marked)    |                          | Constipation (minimal)    |                           |
| Bradycardia                              |                          |                          |                           |                           |
| Hypothermia                              |                          |                          |                           |                           |
| Urinary retention                        |                          | Diuresis                | Urinary retention         |                           |
| Agonists                                 | Endorphins*             | Endorphins*             | Dynorphins                | Enkephalins               |
|                                          | Morphine                 | Morphine                 |                           |                           |
|                                          | Synthetic opioids        | Synthetic opioids        |                           |                           |
| Antagonists                              | Naloxone                | Naloxone                | Naloxone                  | Naloxone                  |
|                                          | Naltrexone              | Naltrexone              | Naltrexone                | Naltrexone                |
|                                          | Nalmefene               | Nalmefene               | Nalmefene                 | Nalmefene                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Anesthetic phase                     | Fentanyl                | Sufentanil              | Alfentanil              | Remifentanil                          |
|--------------------------------------|------------------------|------------------------|------------------------|---------------------------------------|
| Premed                               | 25-50 mcg             | 2-5 mcg                | 250-500 mcg            | --                                    |
| Induction With hypnotic With 60-70% N2O High dose opioid | 1.5-5 mcg/kg 8-23 mcg/kg 50 mcg/kg | 0.1-1 mcg/kg 1.3-2.8 mcg/kg 10-30 mcg/kg | 10-50 mcg/kg 120 mcg/kg | 0.5-1 mcg/kg and/or 0.25-0.5 mcg/kg/min 2-5 mcg/kg or 2 mcg/kg/min |
| Maintenance Balanced anesthesia - bolus - infusion high dose opioid | 25-100 mcg 0.033 mcg/kg/min 0.5 mcg/kg/min | 5-20 mcg 0.005-0.015 mcg/kg/min -- | 250-500 mcg 0.5-1.5 mcg/kg/min 2.5-10 mcg/kg/min | 25-50 mcg 0.25-0.5 mcg/kg/min 1-3 mcg/kg/min |
| Transition to PACU mcg/kg/min       |                        |                        |                        | 0.05-0.15 mcg/kg/min                  |
| MAC Bolus infusion                   | 12.5-50 mcg --        | 2.5-10 mcg --         | 125-250 mcg --         | 12.5-25 mcg 0.01-0.2 mcg/kg/min      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| pK         | Percent nonionized (pH 7.4) | Protein binding (%) | Clearance (ml/min) | Volume of distribution (liters) | Partition coefficient | Elimination half-time (hrs) | Context sensitive half-time: 4- hour infusion (mins) | Effect-site (blood/brain) equilibration (mins) |
|------------|------------------------------|---------------------|---------------------|----------------------------------|----------------------|-----------------------------|----------------------------------------------------|-------------------------------------------------|
| Morphine   | 7.9                          | 23                  | 35                  | 1,050                            | 224                  | 1                           | 1.7-3.3                                           |                                                 |
| Meperidine | 8.5                          | 7                   | 70                  | 1,020                            | 305                  | 32                          | 3-5                                                |                                                 |
| Fentanyl   | 8.4                          | 8.5                 | 84                  | 1,530                            | 335                  | 955                         | 3.1-6.6                                          | 260                                             |
| Sufentanil  | 8.0                          | 20                  | 93                  | 900                              | 123                  | 1,727                       | 2.2-4.6                                          | 30                                              |
| Alfentanil  | 6.5                          | 89                  | 92                  | 238                              | 27                   | 129                         | 1.4-1.5                                          | 60                                              |
| Remifentanil| 7.3                          | 58                  | 66-93               | 4,000                            | 30                   |                             | 0.17-0.33                                        | 4                                               | 1.1                                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category                     | Order                                      |
|------------------------------|--------------------------------------------|
| Onset                        | Alf > remi > suf > fent > morph           |
| Duration                     | Morph > suf > fent > alf , remi           |
| Ionization (highest to least)| Meperidine > fentanyl > suf > morph > remi > alfentanil |
| Lipid solubility             | Suf > fent > alfen > remi > meperidine > morph |
| Protein binding              | Suf, alf > fentanyl, remi > meperidine > morph |
| Vol of distribution          | Fent > meperidine > morph > suf > remi > alf |
| Elimination                  | Remi > alf > suf > morph > fent, meperidine |
| Clearance                    | Remi > fent > morph > demerol > suf > alf |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Properties                | Lipophilic Opioids          | Hydrophilic Opioids        |
|---------------------------|-----------------------------|-----------------------------|
| Common agents             | Fentanyl, sufentanil       | Morphine, hydromorphone    |
| Onset of analgesia        | Rapid onset (5-10 min)     | Delayed onset (30-60 min)  |
| Duration of analgesia *   | Shorter duration (2-4 hr)   | Longer duration (6-24 hr)   |
| CSF spread                | Minimal CSF spread          | Extensive CSF spread        |
| Site of action            | Spinal ± systemic           | Primarily spinal            |
| Side effects              |                             |                             |
| Nausea and vomiting       | Lower incidence with lipophilic versus hydrophilic opioids |                             |
| Pruritus                  | Lower incidence with lipophilic versus hydrophilic opioids |                             |
| Respiratory depression     | Primarily early; minimal delayed | Both early (<6 hr) and delayed (>6 hr) possible |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Opioid        | Relative Lipid Solubility | Dose        | Onset (min) | Peak (min) | Duration | Infusion Rate   |
|---------------|---------------------------|-------------|-------------|------------|----------|------------------|
| Morphine      |                           | 2-5 mg      | 15-30       | 60-90      | 4724     | 0.3-0.9 mg/h     |
| Fentanyl      | 600                       | 50-100 pg   | 5-10        | 10-20      |          | 25-50 ug/h       |
| Meperidine    | 30                        | 25-75 mg    | 5-10        | 15-30      | 46       | 5-20 mg/h        |
| Sufentanil    | 1200                      | 20-50ug     | 5-15        |            |          | 10-25 ug/h       |
| Methadone     | 80                        | 1-5 mg      | 10-15       | 15-20      | 6-10     | 0.3-0.5 mg/h     |
| Hydromorphone  |                           | 0.75-15 mg  | 10-15       | 20-30      | 6-18     | 0.1-0.2 mg/h     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Opioid      | Lipid solubility | Parenteral potency | pKa | Mu-rec affinity | Dissoc kinetics | Onset   | Duration  |
|-------------|------------------|--------------------|-----|-----------------|------------------|---------|-----------|
| Morphine    | 1.4              | 1                  | 7.9 | Mod             | Slow             | Delayed | Prolonged |
| Meperidine  | 39               | 0.1                | 8.5 | Mod             | Mod              | Rapid   | Intermed  |
| Methadone   | 116              | 2                  | 9.3 | High            | Slow             | Rapid   | Intermed  |
| Hydromorph  | 25               | 10                 |     | High            | Slow             | Rapid   | Prolonged |
| Alfentanil  | 129              | 25                 | 6.5 | High            | V rapid          | V rapid | Short     |
| Fentanyl    | 816              | 80                 | 8.4 | High            | Rapid            | V rapid | Short     |
| Sufentanil  | 1727             | 800                | 8.0 | V. high         | Mod              | V rapid | short     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Drug            | Mu receptor      | Kappa receptor    |
|-----------------|------------------|-------------------|
| Nalbuphine      | Partial agonist   | Partial agonist    |
| Butorphanol     | Partial agonist   | Partial agonist    |
| Buprenorphine   | Partial agonist   | ---                |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Factor                                      | Effect                                                                                                           |
|---------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Toxic Alterations in Hemoglobin             |                                                                                                                  |
| Carboxyhemoglobin (COHb)                   | overestimates SaO 2                                                                                            |
| Methemoglobin (MetHb)                       | At high levels of MetHb, SpO 2 approaches 85%, independent of actual oxygen saturation (SaO 2 )                |
| Sulfhemoglobin                              | Not reported                                                                                                    |
| Structural Hemoglobinopathies               |                                                                                                                  |
| Hemoglobin F, S, H                         | No significant effect                                                                                            |
| Dyes                                        |                                                                                                                  |
| Fluorescein                                 | No significant effect                                                                                            |
| Indigo carmine                              | Transient decrease                                                                                              |
| Indocyanine green                           | Transient decrease                                                                                              |
| Isosulfan blue (patent blue V)            | No significant effect at low dose; prolonged reduction in SpO 2 at high dose                                   |
| Methylene blue                              | Transient, marked decrease in SpO 2 , lasting up to several minutes possibly secondary effects due to effects on hemodynamics |
| Hemoglobin Concentration                    |                                                                                                                  |
| Anemia                                      | If SaO 2 normal: no effect during hypoxemia: , Hb values less than 14.5 g/dL: progressive underestimation of actual SaO 2 |
| Polycythemia                                | No significant effect                                                                                            |
| Other Factors                               |                                                                                                                  |
| Ambient light                               | can falsely elevate SpO 2 reading .                                                                             |
| Arterial O 2 saturation                     | During hypoxemia, can cause a falsely low reading.                                                             |
| Blood flow                                  | hinder obtaining a reading or cause a falsely low reading.                                                     |
| Jaundice                                    | No effect .                                                                                                     |
| Motion                                      | Movement, especially shivering, may depress SpO 2 reading .                                                    |
| Nail polish                                 | Slight decrease in SpO 2 reading, with greatest effect using blue nail polish, or no change                    |
| Sensor contact                              | "Optical shunting" of light from source to detector directly or by reflection from skin results in falsely low SpO 2 reading. |
| Skin pigmentation                            | Small errors or no significant effect reported. Deep pigmentation can result in reduced signal.                 |
| Tape                                        | Transparent tape between sensor and skin has little effect.                                                    |
| Vasodilatation                              | Slight decrease                                                                                                  |
| tricuspid insufficiency                     | results in falsely low SpO 2 reading                                                                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Inducers       | Inhibitors       |
|----------------|------------------|
| Barbituates    | Cimetidine       |
| Phenytoin      | Grapefruit juice  |
| Macrolides     | Ketoconazole     |
| Steroids       | Erythromycin     |
| Chronic EtOH   | Ritonavir        |
| Smoking        | Disulfuram      |
| INH            |                  |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| First Letter Paced | Second Letter Sensed | Third Letter Response | Fourth Letter Programmable Feature | Fifth Letter Arrhythmia Treatment |
|---------------------|----------------------|-----------------------|------------------------------------|-----------------------------------|
| A = atrium          | A = atrium           | T = triggered         | P = programmable (single)          | O = none                          |
| V = ventricle       | V = ventricle        | I = inhibited         | M = multiprogrammable              | P = Pacing (antitachyarrhythmia) |
| D = dual            | D = dual             | D = dual (T&I)       | O = not programmable                | S = shock                         |
| O = none            | O = none             | O = N/A              | R = rate modulated                 | C = communicating                 |
|                     |                      |                       | D = dual (P & S)                   |                                   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Position I (Shock Chamber) | Position II (Antitachycardia Pacing Chamber) | Position III (Tachycardia Detection) | Position IV (Antibradycardia Pacing Chamber) |
|-----------------------------|----------------------------------------------|-------------------------------------|-----------------------------------------------|
| O = none                    | O = none                                     | E = electrogram                    | O = none                                      |
| A = atrium                  | A = atrium                                   | H = hemodynamic                    | A = atrium                                    |
| V = ventricle               | V = ventricle                                |                                     | V = ventricle                                 |
| D = dual (A + V)           | D = dual (A + V)                            |                                     | D = dual (A + V)                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Postanesthesia Recovery Score (Modified Aldrete Score) Postanesthesia Discharge Scoring System

| Activity                                   | Vital signs (BP and Pulse)                  |
|--------------------------------------------|---------------------------------------------|
| 2 = Moves all extremities voluntarily/on command | 2 = Within 20% of preoperative baseline     |
| 1 = Moves two extremities                  | 1 = 20%-40% of preoperative baseline        |
| 0 = Unable to move extremities             | 0 = >40% of preoperative baseline           |

| Respiration                                | Activity                                    |
|--------------------------------------------|---------------------------------------------|
| 2 = Breathes deeply and coughs freely      | 2 = Steady gait, no dizziness               |
| 1 = Dyspneic, shallow or limited breathing  | 1 = Requires assistance                     |
| 0 = Apneic                                 | 0 = Unable to ambulate                      |

| Circulation                                | Nausea and Vomiting                         |
|--------------------------------------------|---------------------------------------------|
| 2 = BP + 20mm of preanesthetic level      | 2 = Minimal: treat with PO medications      |
| 1 = BP + 20-50mm of preanesthetic level   | 1 = Moderate: treat with IM medications     |
| 0 = BP + 50mm of preanesthetic level      | 0 = Continues: repeated treatment           |

| Consciousness                              | Pain                                        |
|--------------------------------------------|---------------------------------------------|
| 2 = Fully awake                            | Acceptable to patient; control with PO medications |
| 1 = Arousable on calling                   | 2 = Yes                                    |
| 0 = Not responding                         | 1 = No                                     |

| Oxygen Saturation                          | Surgical Bleeding                           |
|--------------------------------------------|---------------------------------------------|
| 2 = SpO 2 >92% on room air                | 2 = Minimal: no dressing change required    |
| 1 = Supplemental O 2 req. to maintain SpO 2 >90% | 1 = Moderate: up to 2 dressing changes     |
| 0 = SpO 2 <92% with O 2 supplementation   | 0 = Severe: more than 3 dressing changes    |

| 10 = Total score                           | 10 = Maximum score                          |
|--------------------------------------------|---------------------------------------------|
| Score >9 required for discharge            | Score >9 required for discharge             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| MODALITY        | RECEPTOR                                               | FIBER TYPE | CONDUCTION VELOCITY AND DIAMETER | RATE OF ADAPTATION | FUNCTION                                   |
|------------------|-------------------------------------------------------|------------|----------------------------------|--------------------|--------------------------------------------|
| Proprioceptive    | Golgi and Ruffini endings, muscle spindle afferents  | Aα         | 70-120 m/s 15-20 microns         | Slow and rapid      | Muscle tension, length and velocity        |
| Mechanosensitive   | Meissner, Ruffini, Pacinian corpuscles and Merkel disc | Aβ         | 40-70 m/s 5- 15 microns          | Rapid (slow- Merkel) | Touch, flutter, motion, pressure, vibration |
| Thermoreceptive    | Free nerve endings                                   | Aδ         | 10-35 m/s 1-5 microns            | Slow                | Innocuous cold                             |
|                   | Free nerve endings                                   | C          | 0.5-1 m/s <1 micron              | Slow                | Innocuous warmth                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Nociceptive            | Type              | Conduction Velocity   | Diameter         | Speed | Pain Type     |
|-----------------------|-------------------|-----------------------|------------------|-------|---------------|
| Free nerve endings     | Aδ                | 10-35 m/s             | 1-5 microns      | Slow  | Sharp pain    |
| Free nerve endings     | C                 | 0.5-1 m/s             |                  | Slow  | Burning pain  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Type      | Size (um)                | Threshold         | Speed (m/s) | Modality                                                                                     | Notes                                                        |
|-----------|--------------------------|--------------------|-------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| A Fibers  | large (20um) myelinated  | low                | 5-120       |                                                                                              |                                                              |
| Aα (alpha)| 12-22                    |                    | 6-120       | Proprioception, motor (skeletal motor)                                                      |                                                              |
| Aβ (beta) | 4-12                     |                    | 50-70       | Touch/ light pressure, muscle spindle reflexes                                               | communicate with WDR neurons                                 |
| Aγ (gamma)| 4-12                     |                    | 35-70       | Infrafusal proprioception                                                                     |                                                              |
| A∂ (delta)| 1-5                      |                    | 5-30 m/s    | Pain (primary nociceptive afferent; respond mostly to thermal/mechanothermal: sharp pricking pain) | Communicate with WDR neurons                                 |
| B         | Medium (1.5-4) myelinated| > A but < C       | 3-30        | e.g preganglionic autonomic sympathetic and visceral afferents                               |                                                              |
| C         | unmyelinated, small (<1.5)|                    | 0.5-2       | Pain (primary nociceptive afferent; autonomic postganglionic; are polymodal (respond to mechanical, heat, chemical, and mechanothermal) | Communicate with WDR neurons                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

|                         | Morphine | Hydromorphone | Oxycodone | Fentanyl | Meperidine | Codeine     |
|-------------------------|----------|---------------|-----------|----------|------------|-------------|
| IV Equivalence to IV Morphine | 1:1      | 5:1           | 1:1       | 100:1    | 1:8        | 1:10        |
| IV Equivalence to 10 mg IV Morphine | 10       | 2             | 10        | 0.1      | 80         | 100         |
| Oral Bioavailability     | 30%      | 60%           | 80%       |          | 30%        | 30%         |
| PO Equivalence to PO Morphine | 1:1      | 10:1          | 2:1 - 3:1 |          | 1:6 - 1:10 |             |
| PO Equivalence to 30 mg PO Morphine | 30       | 3             | 12-15     |          | 250        | 300         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** ADVERSE PHYSIOLOGIC SEQUELAE OF PAIN

| Organ System  | Clinical Effect                                                                                     |
|---------------|-----------------------------------------------------------------------------------------------------|
| RESPIRATORY    | Increased skeletal muscle tension, Hypoxemia                                                        |
|               | Decreased total lung compliance, Hypercapnia, Ventilation-perfusion abnormality, Atelectasis, Pneumonitis |
| ENDOCRINE      | Increased adrenocorticotropic hormone, Protein catabolism                                           |
|               | Increased cortisol, Lipolysis                                                                        |
|               | Increased glucagon, Hyperglycemia                                                                    |
|               | Decreased insulin                                                                                   |
|               | Decreased testosterone, Decreased protein anabolism                                                  |
|               | Increased aldosterone, Salt and water retention                                                      |
|               | Increased antidiuretic hormone                                                                       |
|               | Increased cortisol, Congestive heart failure                                                         |
|               | Increased catecholamines, Vasoconstriction                                                           |
|               | Increased angiotensin II, Increased myocardial contractility                                          |
|               | Increased heart rate                                                                                 |
| CARDIOVASCULAR | Increased myocardial work (mediated by catecholamines, angiotensin II), Dysrhythmias, Angina, Myocardial infarction, Congestive heart failure |
| IMMUNOLOGIC    |                                                                                                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| AMOUNT OF VOLUME DEPLETION (%) | SKIN COLOR | CAPILLARY REFILL TIME (SECONDS) | POSTERIOR TIBIAL PULSE VOLUME | SKIN TEMPERATURE                     |
|---------------------------------|------------|----------------------------------|-------------------------------|--------------------------------------|
| None                            | Pink       | <2                               | ++++                          | Warm                                 |
| 5                               | Pale       | 3-4                              | ++                            | Cold from midcalf and midforearm out |
| 10                              | Gray       | 4-5                              | 0                             | Cold midthigh and upper arm out      |
| 15                              | Mottled    | >5                               | 0                             | Entire extremity cold                |

Symbols: ++++, full; ++, moderately full; 0, markedly diminished or absent

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Finding                                               | Mild                     | Moderate                     | Severe                          |
|------------------------------------------------------|--------------------------|-------------------------------|---------------------------------|
| Percent body weight Mucous membranes Capillary Refill Tears CNS Pulse SBP Respiration | < 5% Slightly Dry N Normal Normal N N N | 5-10% Dry ↓ ↓ Irritable ↑ N or Slightly ↓ Slightly ↑ | >10% Dry ↓↓ Absent Lethargy ↑↑ and Weak ↓↓ ↑ |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Anterior Fontanel Skin U/O | N         | N Mildly ↓ | ↓ Cool ↓↓ | ↓↓ Acrocyanosis Anuria |
|-----------------------------|-----------|------------|-----------|-------------------------|
| Volume                      | 25-50     | 50-100     | 100-150   | cc/kg                   |
| Required                    | cc/kg     | cc/kg      |           |                         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Normal pulmonary function and cardiovascular values

| Measurement                                   | Preterm neonate | Term neonate | 2 year old | Adult  |
|-----------------------------------------------|------------------|--------------|------------|--------|
| Total capacity (ml/kg)                       | 55-70            | 55-70        |            | 27-30  |
| Tidal volume (ml/kg) lung                    | 5-7              | 5-7          |            | 80-85  |
| Functional residual capacity (ml/kg)         | 20-25            |              |            | 30     |
| Vital capacity (ml/kg)                       | 35-40            | 35-40        |            | 60     |
| Respiratory rate (breaths/min)              | 30-50            | 30-50        |            | 12-16  |
| Heart rate (beats/min)                       |                  | 120-160      | 75-115     | 70-90  |
| Systolic blood pressure (mm Hg)              |                  | 60           | 95         | 120    |
| Diastolic blood pressure (mm Hg)             |                  | 35           | 60         | 80     |
| Cardiac output (ml/kg/min)                   |                  | 200          | 100        | 70     |
| Circulating blood volume (ml/kg)             |                  | 90           | 80         | 70     |
| Haemoglobin (g/dl)                           |                  | 16-18        | 10.5-13.5  | 12-17  |
| Neonatal alveolar ventilation (ml/kg/min)    |                  | 100-150      |            | 60     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 43-1. NORMAL BLOOD GAS VALUES IN THE NEWBORN**

| Subject                          | Age          | Po2 (mm Hg) | Pco2 (mm Hg) | pH   |
|----------------------------------|--------------|-------------|--------------|------|
| Fetus (term)                    | Before labor | 25          | 40           | 7.37 |
| Fetus (term)                    | End of labor | 10-20       | 55           | 7.25 |
| Newborn (term)                  | 10 min      | 50          | 48           | 7.20 |
| Newborn (term)                  | 1 h         | 70          | 35           | 7.35 |
| Newborn (term)                  | 1 wk        | 75          | 35           | 7.40 |
| Newborn (preterm 1500 g)        | 1 wk        | 60          | 38           | 7.37 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Measurement               | Fetus           | Term neonate (1st week) |
|---------------------------|------------------|--------------------------|
| pH                        | 7.25-7.35       | 7.36-7.38               |
| PO, mm Hg (kPa)          | 30-35 (4.0-4.6) | 70-85 (9.3-11.3)        |
| PCO, mm Hg (kPa)         | 40-50 (5.3-6.6) | 33-36 (4.4-4.8)         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 20-1. Metabolic Findings in the Newborn Secondary to Pyloric Stenosis**

| SEVERITY OF DEHYDRATION       | pH | PCO₂ | CO₂ | Na | K | CI | HCO₃ |
|-------------------------------|----|------|-----|----|---|----|------|
| Mild                          | 1  | 1    | 1   |    |   |    |      |
| Moderate                      | 1  | 1    | 1   |    |   |    |      |
| Severe circulatory shock      |    |      |     |    |   |    |      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| LOCAL ANESTHETIC                     | 0 - 5 kg               | 5 - 15 kg              | >15 kg                |
|---------------------------------------|------------------------|------------------------|-----------------------|
| 0.5% hyperbaric bupivacaine          | 0.5 mg/kg (0.1 mL/kg)  | 0.4 mg/kg (0.08 mL/kg) | 0.3 mg/kg (0.06 mL/kg)|
| 1% hyperbaric tetracaine             | 0.5 mg/kg (0.05 mL/kg) | 0.4 mg/kg (0.04 mL/kg) | 0.3 mg/kg (0.03 mL/kg)|
| 5% hyperbaric lidocaine b            | 2.5 mg/kg (0.05 mL/kg) | 2 mg/kg (0.04 mL/kg)   | 1.5 mg/kg (0.03 mL/kg)|

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Anatomic variable                        | Neonate | Infant         | Small child | Older child | Adult        |
|------------------------------------------|---------|----------------|-------------|-------------|--------------|
| Position of lower end of spinal cord     | L3      | Ll at 12 months| Ll          |             |              |
| Position of lower end of dural sac       | S4      | S2             | S2          |             |              |
| CSF/kg                                   | 4 ml    | 4 ml          | 3 ml       | 2 ml       | 2 ml        |
| Condition of epidural fat                | Loose   | Loose          | Loose       | ± Loose     | Firmly packed|

CSF, cerebrospinal fluid.

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                                   | Infant        | Adult        |
|---------------------------------------------|---------------|--------------|
| Respiratory frequency                        | 30-50        | 12-16       |
| Tidal volume (ml·kg -1 )                   | 7             | 7            |
| Dead space (ml·kg -1 )                     | 2-2.5        | 2.2          |
| Alveolar ventilation (ml·kg -1 ·min -1 )   | 100-150      | 60           |
| Functional residual capacity (ml·kg -1 )    | 27-30        | 30           |
| Oxygen consumption (ml·kg -1 ·min -1 )     | 7-9          | 3            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Characteristics of Croup and Epiglottitis

| CROUP                                   | EPIGLOTTITIS                          |
|-----------------------------------------|---------------------------------------|
| Etiology                                | Parainfluenza virus                   | Haemophilus influenzae                |
| Age                                     | Infancy 4 months-2 years             | 2-5 years                             |
| Onset                                   | Subacute-exacerbation of preexistent URI | Acute                                 |
| Temperature                             | Low-grade fever                       | High fever                            |
| Course                                  | Usually mild, stridor may worsen at night | Rapid progress of symptoms            |
| Symptomatology                          | Barky cough, stridor                  | Dysphagia, sore throat, respiratory distress, dysphonia |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

|          | Infant | Child |
|----------|--------|-------|
| Fat      | 16%    | 23%   |
| TBW      | 75%    | 70%   |
| ICF      | 40%    | 30%   |
| ECF      | 35%    | 40%   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Measurement                             | Neonate      | Adult      |
|-----------------------------------------|--------------|------------|
| Oxygen consumption (ml/kg/min)         | 7-9          | 3          |
| Tidal volume (ml/kg)                   | 7            | 7          |
| Breathing rate (times/min)             | 30-50        | 12-16      |
| Functional residual capacity (ml/kg)    | 27-30        | 30         |
| Alveolar ventilation (ml/kg/min)       | 100-150      | 60         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| NERVE INJURY SITE                                   | CAUSE                                                                 | COMMENT                                                             |
|-----------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------|
| Upper extremity                                     |                                                                      |                                                                     |
| Brachial plexus                                     | Abduction, external rotation, or extension of shoulder               | Usually resolves within several months                               |
|                                                     | Traction of shoulder                                                |                                                                     |
| Ulnar nerve                                         | Pressure at the elbow                                               | Not uncommon                                                        |
|                                                     | Traction of C8-T1 dermatomes over the 1st rib                      | Postoperative palsy results in numbness of ring and fifth fingers   |
| Radial nerve                                        | Pressure behind the arm                                             | Results in wristdrop                                                |
| Anterior interosseous nerve                         | Pressure at the distal elbow laterally                              | Bandages or external pressure 253                                   |
| Head                                                |                                                                      |                                                                     |
| Supraorbital nerve                                  | Pressure on the supraorbital ridge when lying prone                 | Results in numbness of forehead                                     |
| Lower extremity                                     |                                                                      |                                                                     |
| Lateral femoral cutaneous nerve of the thigh       | Pressure over anterior iliac crest in lateral or prone position or over lateral thigh | Results in numbness of the lateral aspect of the thigh and knee     |
| Femoral nerve                                       | Pressure to the groin of the dependent limb in the lateral decubitus position, pressure from retractors | Results in numbness of the anterior thigh and medial aspect of lower leg, loss of extention of iliopsoas and quadriceps |
| Obturator                                           | Excessive hip flexion and pressure from retractors                  | Impaired hip adduction, medial surface of thigh                     |
| Sciatic                                             | Stretched by hyperflexion of the hip                                 | Impaired knee flexion and all motor                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Nerve                  | Cause                                      | Result                                                                                     |
|-----------------------|--------------------------------------------|--------------------------------------------------------------------------------------------|
| Common peroneal nerve | Pressure below the head of the fibula      | May be due to compartment syndrome, Results in footdrop (loss of eversion and toe extension), dorsal and lateral surface of the foot |
| Tibial                |                                            | Impaired plantar flexion and inversion, platar surface of the foot                        |
| Ankle                 | Pressure from Esmarch bandage              | Pressures beneath Esmarch bandage can be much higher than believed                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 28-2 -- Distribution of claims for nerve injury**

| Nerve                        | Number of Claims | Percent of Total (n = 670) |
|------------------------------|------------------|-----------------------------|
| Ulnar                        | 190              | 28                          |
| Brachial plexus             | 137              | 20                          |
| Lumbosacral nerve root      | 105              | 16                          |
| Spinal cord                  | 84               | 13                          |
| Sciatic                      | 34               | 5                           |
| Median                       | 28               | 4                           |
| Radial                       | 18               | 3                           |
| Femoral                      | 15               | 2                           |
| Other single nerves          | 43               | 6                           |
| Multiple nerves              | 16               | 2                           |
| Total                        | 670              | 100                         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| LOCATION            | HORMONE SECRETED      | CLINICAL PRESENTATION                          | COMMENT                       |
|---------------------|-----------------------|------------------------------------------------|-------------------------------|
| Anterior pituitary   | Prolactin             | Galactorrhea, amenorrhea hypogonadism, infertility | Bromocriptine sensitivity     |
|                     | Adrenocorticotropin   | Cushing disease (hypercortisolism)            | Basophilic adenoma            |
|                     | Growth hormone        | Acromegaly/gigantis m, glucose intolerance     | Eosinophilic adenoma, difficult airway |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Nonsecretory | Mass effect, panhypopituitarism | Chromophobe adenoma, preoperative hormones? |
|--------------|----------------------------------|----------------------------------------------|
| Suprasellar   | Nonsecretory                    | Panhypopituitarism, syndrome of inappropriate antidiuretic hormone, visual (optic chiasm) symptoms |
|              | Craniopharyngioma or suprasellar extension of pituitary lesion |                                              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Nervous system dysfunction                                   | Approximate Involvement % |
|------------------------------------------------------------|---------------------------|
| Autonomic neuropathy                                        |                           |
| Abdominal pain                                             | 95                        |
| Vomiting                                                  | 46                        |
| Tachycardia                                               | 80                        |
| Hypertension                                              |                           |
| Postural Hypotension                                       | 21                        |
| Peripheral neuropathy                                      | 60                        |
| Paresis to paralysis of muscle groups OI extremities      |                           |
| Flaccid quadriplegia                                      |                           |
| Respiratory paralysis                                      |                           |
| Vagal-cranial nerve                                       | 30                        |
| Bulbar involvement                                         |                           |
| Dysphagia                                                 |                           |
| Dysphonia                                                 |                           |
| Respiratory dysfunction                                    |                           |
| Hypothalmic involvement (Syndrome of inappropriate secretion of antidiuretic hormone) | 12                        |
| Pyrexia                                                   |                           |
| Cerebral involvement: mental status changes                |                           |
| Anxiety, confusion, hysteria, depression, psychosis       | 9                         |
| Seizures                                                  | 20                        |
| Coma                                                      | 10                        |
| Laboratory                                                |                           |
| Dark urine                                                |                           |
| Hypochloremia                                            |                           |
| Hyponatremia                                             |                           |
| Hypokalemia                                              |                           |
| Leukocytosis                                             |                           |
| Hypomagnesemia                                           |                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 3. Features of the Acute Porphyric Attack**

| Condition                          | Prevalence          | Symptoms                                                                                     | Triggers                                                                                     |
|------------------------------------|---------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Acute Intermittent Porphyria (AIP) | 1:10,000            | Colicky pain, nausea, vomiting, severe constipation, psychiatric disorders, bulbar paralysis | Induction of ALA synthetase by drugs, infection, menstruation, fasting, other illness       |
| Variegate Porphyria (VP)          | Very common in S.Africa | Bullous photosensitivity                                                                     | Induction of ALA synthetase by drugs, infection, menstruation, fasting, other illness       |
| Plumboporphyria (PP)              |                     |                                                                                              |                                                                                              |
| Hereditary Coproporphyria (HC)    |                     |                                                                                              |                                                                                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Causes                          | Mechanisms                                                                                                           |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Binding to serum proteins        | Including plasma cell dyscrasias                                                                                   |
| Decreased renal excretion        | Renal insufficiency ; hypoparathyroidism ; pseudohypoparathyroidism, types I and II; tumoral calcinosis; pseudoxanthoma elasticum; infantile hypophosphatasia; hyperostosis; hyperthyroidism ; adrenal insufficiency ; bisphosphonate therapy |
| Increased intestinal absorption   | Phosphorus-containing cathartics; medication with vitamin D compounds; granulomatous disease producing vitamin D, including sarcoidosis and tuberculosis |
| Internal redistribution          | Acute metabolic or respiratory acidosis ; reduced insulin level; clonidine administration                           |
| Cellular release                | Rhabdomyolysis ; organ infarction; tumor lysis as in Burkitt's or lymphoblastic lymphomas or metastatic small cell carcinoma |
| Parenteral administration       | Intravenous phosphate salts; lipid (phospholipid) infusion                                                          |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
| Condition                                      |
|------------------------------------------------|
| Chronic alcoholism and alcohol withdrawal      |
| Dietary deficiency and phosphate-binding antacids |
| Severe thermal burns                           |
| Recovery from diabetic ketoacidosis            |
| Hyperalimentation                              |
| Nutritional recovery syndrome                   |
| Respiratory alkalosis                          |
| Therapeutic hyperthermia                       |
| Neuroleptic malignant syndrome                  |
| Recovery from exhaustive exercise               |
| Renal transplantation                          |
| Acute renal failure                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Type of Butyrylcholinesterase | Genotype          | Incidence | Dibucaine Number * | Response to Succinylcholine or Mivacurium          |
|--------------------------------|-------------------|-----------|--------------------|----------------------------------------------------|
| Homozygous typical             | UU                | Normal    | 70 - 80            | Normal                                             |
| Heterozygous atypical          | UA                | 1/480     | 50 - 60            | Lengthened by about 50% - 100%                    |
| Homozygous atypical            | AA                | 1/3200    | 20 - 30            | Prolonged to 4 - 8 hr                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Chest wall**

| Zone | Determinates of Perfusion   |
|------|-----------------------------|
| I    | P A > Ppa > Ppv, V > Q     |
| II   | Ppa > P A > Ppv, V = Q     |
| III  | Ppa > Ppv > P A, V < Q     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| CONDITION                                      | SITE OF DISCREPANCY | CAUSE OF DISCREPANCY                                 |
|------------------------------------------------|----------------------|------------------------------------------------------|
| Decreased left ventricular compliance           | Mean LAP<LVEDP      | Increased end-diastolic a wave                       |
| Aortic regurgitation                           | LAP a wave<LVEDP    | Mitral valve closure prior to end-diastole           |
| Pulmonic regurgitation                         | PADP<LVEDP          | Bidirectional runoff for pulmonary artery flow        |
| Right bundle branch block                      | PADP<LVEDP          | Delayed pulmonic valve opening                        |
| Decreased pulmonary vascular bed (pneumonectomy)| PAWP<LVEDP          | Obstruction of pulmonary blood flow                   |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| CONDITION                          | SITE OF DISCREPANCY         | CAUSE OF DISCREPANCY                                         |
|------------------------------------|-----------------------------|-------------------------------------------------------------|
| Positive end-expiratory pressure    | Mean PAWP>Mean LAP         | Creation of lung zone 1 or 2 or pericardial pressure changes |
| Pulmonary arterial hypertension      | PADP>Mean PAWP             | Increased pulmonary vascular resistance                       |
| Pulmonary veno-occlusive disease    | Mean PAWP>Mean LAP         | Obstruction to flow in large pulmonary veins                 |
| Mitral stenosis                     | Mean LAP>LVEDP             | Obstruction to flow across mitral valve                      |
| Mitral regurgitation                | Mean LAP>LVEDP             | Retrograde systolic v wave raises mean atrial pressure       |
| Ventricular septal defect           | Mean LAP>LVEDP             | Antegrade systolic v wave raises mean atrial pressure        |
| Tachycardia                        | PADP>Mean LAP>LVEDP        | Short diastole creates pulmonary vascular and mitral valve gradients |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Test                                                        | High Risk Patient                          |
|-------------------------------------------------------------|-------------------------------------------|
| Arterial gas                                                | PaCO2>45 or PaO2<50 mmHg                 |
| FEV1                                                       | <2L or ppo <0.8L or 40% of predicted      |
| FEV1/FVC                                                   | <50%                                      |
| Maximal breathing capacity (or max volume ventilation MVV Barash) | <50% predicted                            |
| Maximum VO2 max                                            | <10 ml/kg/min                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** ARTEFACTS IN PULSE OXIMETRY ****

| Category                             | Effect                                                                                                      |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------|
| TOXIC ALTERATIONS IN HEMOGLOBIN     |                                                                                                             |
| Carboxyhemoglobin (COHb)            | Slight reduction in SpO 2 reading (i.e. overestimates fraction of Hb available for O 2 transport)          |
| Cyanmethemoglobin                    | Not reported                                                                                               |
| Methemoglobin (MetHb)               | At high levels of MetHb, SpO 2 approaches 85%, independent of actual SaO 2.                               |
| Sulfhemoglobin                       | Not reported (affects CO-oximetry by producing a falsely high reading of MetHb)                           |
| STRUCTURAL HEMOGLOBINOPATHIES       |                                                                                                             |
| Hemoglobin F                         | No significant effect                                                                                      |
| Hemoglobin H                         | No significant effect (i.e., overestimates fraction of Hb available for O 2 transport)                    |
| Hemoglobin Köln                      | Artifactual reduction in SpO 2 of 8-10%                                                                     |
| Hemoglobin S                         | No significant effect                                                                                      |
| HEMOGLOBIN REPLACEMENT SOLUTIONS     |                                                                                                             |
| Diaspirin cross-linked Hb           | No significant effect                                                                                      |
| Bovine polymerized Hb (oxygen carrier-201) | No significant effect                                                                                  |
| DYES                                 |                                                                                                             |
| Fluorescein                          | No significant effect                                                                                      |
| Indigo carmine                       | Transient decrease                                                                                         |
| Indocyanine green                    | Transient decrease                                                                                         |
| Isosulfan blue (Patent Blue V)      | No significant effect at low dose; prolonged decrease at high dose.                                        |
| Methylene blue                       | Transient, marked decrease in SpO 2, lasting up to several minutes. Possible secondary effects due to effects on hemodynamics (see text) |
| HEMOGLOBIN CONCENTRATION             |                                                                                                             |
| Anemia                               | If SaO 2 normal: no effect. During hypoxemia, at Hb values less than 14.5 g/dL: progressive underestimation of actual SaO 2 |
| Polycythemia                         | No significant effect                                                                                      |
| OTHER                                |                                                                                                             |
| Ambient light interference           | Bright light, particularly if flicker frequency is close to a harmonic of light-emitting diode switching frequency, can falsely elevate SpO 2 reading. |
| Arterial O 2 saturation              | Dependent on manufacturer. During hypoxemia SpO 2 tends to be artifactually low.                           |
| Blood flow                           | Reduced amplitude of pulsations can cause difficulty in obtaining a reading and a falsely low reading.     |
| Henna                                | Red henna: no effect; black henna: may block light sufficiently to preclude measurement.                   |
| Jaundice                             | No effect. Multi-wavelength laboratory oximeters may register a falsely low SaO 2 and a falsely high COHb and MetHb. |
| Motion                               | Movement, especially shivering, may depress SpO 2 reading.                                                |
| Nail polish                          | Slight decrease in SpO 2 reading; greatest effect is with blue nail polish.                               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Factor                                           | Effect                                                   |
|--------------------------------------------------|----------------------------------------------------------|
| Sensor contact                                   | Optical shunting‖ of light from source to detector either directly or by reflection from skin results in falsely low SpO 2 reading. |
| Skin pigmentation                                | Small errors or no significant effect reported. Deep pigmentation can result in reduced signal. |
| Tape                                            | Transparent tape between sensor and skin has little effect. Falsely low SpO 2 has been reported when smeared adhesive is in the optical path. |
| Vasodilatation                                   | Slight decrease                                          |
| Venous pulsation (e.g., tricuspid insufficiency) | Artifactual decrease in SpO 2                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** ALTERATIONS IN PULMONARY VASCULAR RESISTANCE

| Factors                                   | Changes                     |
|-------------------------------------------|-----------------------------|
| ACTIVE CHANGES                            |                             |
| Parasympathetic stimulation               | Unchanged                   |
| Sympathetic stimulation                   | Increased or unchanged      |
| Hypercarbia                               |                             |
| Catecholamines                            | Increased                   |
| Angiotensin                               |                             |
| Serotonin                                 |                             |
| Prostaglandin F                           |                             |
| Hypoxia                                   |                             |
| Acidemia                                  |                             |
| Histamine                                 | Increased or decreased       |
| Acetylcholine                             | Decreased                   |
| Bradykinin                                |                             |
| Prostaglandin E 1                         |                             |
| PASSIVE CHANGES                           |                             |
| Pulmonary hypertension                    | Decreased                   |
| Left atrial hypertension                  |                             |
| Increased pulmonary blood volume           |                             |
| Increased pulmonary interstitial pressure   | Increased                   |
| Increased blood viscosity                  |                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                        | PHYSIOLOGIC OLIGURIA | PRERENAL FAILURE | ACUTE TUBULAR NECROSIS |
|----------------------------------|----------------------|------------------|-------------------------|
| Urinary sodium                   | <10 mEq/L            | <25 mEq/L        | >35 mEq/L               |
| Urinary specific gravity          | >1.024               | >1.015           | 1.010-1.015             |
| Urinary osmolality               | >700 mOsm/kg         | >500 mOsm/kg     | <350 mOsm/kg            |
| Urinary/plasma osmolality        | >2.5:1               | >1.8:1           |  1.1:1                 |
| Urinary/plasma urea              | >100:1               | >20:1            | 3:1, rarely >10:1       |
| Urinary/plasma creatinine        | >60:1                | >30:1, rarely <10:1 | <10:1                 |
| Fractional sodium excretion       | >0.5                 | <1               | >1                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 37-1 --Causes of renal hypoperfusion associated with acute renal failure**

| Causes of Renal Hypoperfusion                                   |
|---------------------------------------------------------------|
| Intravascular Volume Depletion                                  |
| Major trauma, burns, crush syndrome                            |
| Fever                                                          |
| Hemorrhage                                                     |
| Diuretic use                                                  |
| Pancreatitis, vomiting, diarrhea, peritonitis, dehydration, NPO status, bowel preparations |
| Decreased Cardiac Output                                       |
| Congestive heart failure or low output syndrome                |
| Pulmonary hypertension, massive pulmonary embolism             |
| Positive pressure mechanical ventilation                        |
| Increased Renal/Systemic Vascular Resistance Ratio             |
| Renal vasoconstriction                                         |
| α-Adrenergic agonists                                         |
| Hypercalcemia, amphotericin                                   |
| Cyclosporine                                                  |
| System vasodilation                                            |
| Afterload reduction                                            |
| Antihypertensive medications                                   |
| Anaphylactic shock                                            |
| Anesthesia sepsis                                             |
| Renovascular Obstruction                                       |
| Renal artery: atherosclerosis, embolism, thrombosis, dissecting aneurysm, vasculitis |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Condition                                                                                      |
|-----------------------------------------------------------------------------------------------|
| Renal vein: thrombosis, compression                                                           |
| Glomerular and Small-Vessel Obstruction                                                       |
| Glomerulonephritis                                                                            |
| Vasculitis                                                                                    |
| Toxemia of pregnancy                                                                          |
| Hemolytic uremic syndrome                                                                     |
| Disseminated intravascular coagulation                                                        |
| Malignant hypertension                                                                         |
| Radiation injury                                                                               |
| Increased Blood Viscosity                                                                     |
| Macroglobulinemia                                                                             |
| Polycythemia                                                                                  |
| Interference with Renal Autoregulation                                                        |
| Prostaglandin inhibitors in presence of congestive heart failure (CHF), nephritic syndrome, cirrhosis, hypovolemia |
| Angiotensin-converting enzyme inhibition in presence of renal artery stenosis or CHF          |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug         | Route      | Dose                                                                                     |
|--------------|------------|------------------------------------------------------------------------------------------|
| Energy       |            | 200, 300, 360                                                                           |
|              | ACLS       | 2 J/kg, 2-4 J/kg, 4 J/kg                                                                |
| Epinephrine  | IV         | 1 mg                                                                                    |
|              |            | 0.01 mg /kg (0.1 ml/kg of 1:10,000) 0.10 mg/kg (0.1 ml/kg of 1:1000) (optional for high dose in pulseless arrest) |
|              |            | 0.01 to 0.03 mg/kg 0.1-0.3 mls/kg of 1:10,000                                          |
| Epinephrine  | Infusion   | 2 - 10 μg/min                                                                           |
|              |            | 0.1 - 1 μg/kg/min                                                                       |
|              | ETT        | 2 - 2.5 mg 4                                                                            |
|              |            | 0.1 mg/kg (0.1 ml/kg of 1:1000)                                                         |
|              |            | Same as IV                                                                               |
| Bicarb       | IV         |                                                                                          |
|              |            | 1-2 mEq/kg of 4.2% sol 2                                                                |
| Naloxone     | IV         |                                                                                          |
|              |            | 0.1 mg/kg (or 2mg if > 5 yrs or 20kg)                                                  |
|              |            | 0.1 mg/kg 3                                                                             |
|              | ETT,IM     |                                                                                          |
|              |            | Same as IV 5                                                                             |
| Dextrose     | IV         |                                                                                          |
|              |            | 0.5 - 1 g/kg (may use 10 - 50%)                                                         |
|              |            | 0.2 g/kg IV of 10% sol                                                                   |
| Atropine     | IV         | 1mg (0.5 if brady)                                                                      |
|              |            | 0.02 mg/kg with min dose of 0.1 mg                                                      |
|              | ETT        | 2 - 3 mg 4                                                                              |
|              |            | Same as IV                                                                               |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Complications                     | Signs and Symptoms                                                                 | Mechanism                                                                                      |
|-----------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Ocular                            | Perforation of the globe: Ocular pain, intraocular hemorrhage, restlessness       | Direct trauma: myopic eye, posterior staphyloma, repeated injections                         |
|                                   | Retrobulbar hemorrhage: Subjunctival or eyelid ecchymosis, increasing proptosis, pain, 5 increased IOP | Direct trauma (artery or vein)                                                                |
|                                   | Optic nerve damage: Visual loss, optic disc pallor                                 | Direct injury to nerve or blood vessels, vascular occlusion                                   |
| Systemic                         | Intra-arterial injection: Cardiopulmonary arrest, convulsions                     | Retrograde flow to internal carotid and access to midbrain structures                         |
|                                   | Optic nerve sheath injection: Agitation, confusion, ptosis, mydriasis, dysphagia, dizziness, confusion, contralateral ophthalmoplegia, respiratory depression or arrest | Subdural or subarachnoid injection                                                             |
|                                   | Oculocardiac reflex: Bradycardia, other arrhythmias, asystole                    | Trigerninal nerve (afferent arc) to floor of fourth ventricle with efferent arc via vagus nerve |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
****

| System | Effect | History | Physical | Investigations |
|--------|--------|---------|----------|-----------------|
| Airway | Cricoarytenoid arthritis Mucosal Edema TMJ & C-Spine | Dysphonia, globus, dysphagia Stridor Neck pain & stiffness Jaw pain | Mouth opening Neck ROM | Direct laryngoscopy (redness & swelling of the arytenoids) Past anesthetic chart for intubation record |
| Resp   | Pulmonary fibrosis Pleural effusions | Dyspnea, exercise tolerance | Crackles Dullness, ↓ BS | CXR - interstitial pattern PFTs - restrictive defect ABGs |
| CVS    | Pericarditis LV dysfunction Aortitis - AI Dysrhythmias | Dyspnea, orthopnea, exercise tolerance, palpitations | S3, crackles, friction rub, ↓ HS, diastolic murmur | ECG, stress test, MIBI scan, ECHO |
| CNS    | AA subluxation Peripheral nerve compression Mononeuritis multiplex | Neck pain, occipital H/A, brainstem dysfunction, paresthesias in extremities, radiculopathy | Document sensory & motor deficits | X-ray c-spine - flex / ex views Subluxation (3-5 mm) MRI C-spine |
| Renal  | Renal dysfunction | Drug history |  | Cr, urine (RBC, protein) |
| Heme   | Anemia Thrombocytopenia Leukopenia | Fatigue, dyspnea Bleeding, bruising Infections, fever | Pallor Petechiae HSM | CBC |
| MSK    | Arthritis | Joint pain Analgesia required | Restricted ROM Deformities |  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category  | Criteria *                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------|
| Grade I   | Asymptomatic or minimal headache and slight nuchal rigidity                                   |
| Grade II  | Moderate to severe headache, nuchal rigidity, no deficit other than cranial nerve palsy      |
| Grade III | Drowsiness, confusion, or mild focal deficit                                                  |
| Grade IV  | Stupor, moderate to severe hemiparesis, possibly early decerebrate rigidity and vegetative disturbances |
| Grade V   | Deep coma, decerebrate rigidity, moribund appearance                                          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 5. Regimens for a Dental Procedure**

| Situation                                               | Agent                                   | Adults            | Children         |
|--------------------------------------------------------|-----------------------------------------|-------------------|------------------|
| Oral                                                   | Amoxicillin                            |                   | 50 mg/kg         |
| Unable to take oral medication                         | Ampicillin OR                          | 2 g IM or WV      | 50 mg/kg IM or IV|
|                                                        | Cefazolin or ceftriaxone              | 1 g IM or IV      | 50 mg/kg IM or IV|
| Allergic to penicillins or ampicillin ~oral          | Cephalexin + OR                        | 2 g               |                  |
|                                                        | Clindamycin OR                         | 600 mg            | 20 mg/kg         |
|                                                        | Azithromycin or clarithromycin         | 500 mg            | 15 mg/kg         |
| Allergic to penicillins or ampicillin and unable to take oral medication | Cefazolin or ceftriaxone OR | 1 g IM or IV      | 50 mg/kg IM or IV|
|                                                        | Clindamycin                            | 600 mg IM or WV   | 20 mg/kg IM or IV|

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 1. Common Features Associated with Progressive Systemic Sclerosis (PSS)**

| PSS Manifestation                                                                 | Anesthetic Considerations                                                                                      |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Raynaud 's phenomenon                                                              | Peripheral vasoconstriction                                                                                   |
| Dermal thickening, calcifications; contractures                                    | Difficult airway management                                                                                     |
| Skin tightening; microstomia, decreased neck flexibility                          | Oral or nasal bleeding                                                                                         |
| Telangiectasias                                                                    | Aspiration                                                                                                     |
| Esophageal dilatation, decreased LES tone                                          | Decreased Vit K-dependent clotting factors                                                                     |
| Intestinal malabsorption                                                           | Increased positive airway pressure; increased oxygen concentration; extubation delays                            |
| Restrictive pulmonary disease                                                       | Ventricular hypertrophy; diastolic dysfunction, conduction defects, Hypertension, decreased renal clearance      |
| Myocardial fibrosis                                                                 |                                                                                                                |
| Renal disease                                                                      |                                                                                                                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table Mechanisms of common drugs that influence serotonin syndrome**

| 5-HT Synthesis                                   | 5-HT Release                                                                                                           | Inhibit 5-HT Uptake                                                                                                   | Inhibit 5-HT Metabolism                                                                                               | Postsynaptic Receptor Stimulation                               |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| L-tryptophan 5-hydroxytryptophan                 | Amphetamines and derivatives dextramphetamine metamphetamine fenfluramine dexfenfluramine phenteramine MDMA (ecstasy) Cocaine Reserpine Tetrabenazine Levodopa MAOIs phenelzine tranylcypromine isocarboxazide selegiline meclobemide | SSRIs fluoxetine paroxetine sertraline fluvoxamine citalopram Trazadone Nefazadone Venlafaxine TCAs amitriptylline imipramine clomipramine doxepin desipramine Bupropion Dextromethorphan Tramadol Meperidine Sibutramine Cocaine St. John's wort Amphetamine and derivatives | MAOIs phenelzine tranylcypromine isocarboxazide selegiline meclobemide St. John's wort | Buspirone 5HT1 agonists sumatriptan zolmitriptan naratriptan rizatriptan Lithium Carbamazepine |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Condition                     | H                | Condition to Develop                     | Vital Signs                          | Pupils | Mucosa            | Skin                | Bowel Sounds | Neuromuscular Tone                          | Reflexes                                   | Mental Status       |
|-------------------------------|------------------|------------------------------------------|--------------------------------------|--------|-------------------|---------------------|--------------|----------------------------------------------|--------------------------------------------|---------------------|
| Serotonin syndrome             | neric            | <12 hr                                   |                                      |        |                   | Hypertrophic        |              | Increased, Predominantly in lower extremities | Hyporeflexia, clonus (unless masked by increased muscle tone) | Agitation           |
| Anticholinergic "extreme"     | Anticholinergic agent |                                          | yPnea, hyperthermia less            |        | and dry "touch"   |                     |              | Monal                                       | Marma                                      |                     |
| Neuroleptic syndrome           | Dopamine antagonist | ~3 days                                 | hypnea,                              | Nonal  | Sialorrhea, Fall diaphorisis | Nonalor |              | Pleasant in all muscle groups               | Body reflexia                              | Stupor alert        |
| Malignant hyperthermia        | Inhalational anesthesia | 10 min to 24 hr after administration of deline | Hypertension; tachycardia           | high a5 | Appearance diaphoresis | Decreased         |              | Rigor mortis-like rigidity                   | Hyporeflexia                                | Agitation           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 51-2   -- Classification of congenital heart defects**

| Physiologic Classification | Pulmonary Blood Flow | Comments                                      |
|---------------------------|----------------------|-----------------------------------------------|
| Shunts                    |                      |                                               |
| Left-to-right             |                      | Volume-overloaded ventricle                  |
| VSD                       | ↑                    | Develop CHF                                  |
| ASD                       |                      | Pulmonary vascular changes leading to pHTN   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Physiologic Classification          | Pulmonary Blood Flow | Comments                                   |
|-------------------------------------|----------------------|--------------------------------------------|
| PDA                                 |                      |                                            |
| AV canal                            |                      |                                            |
| Right-to-left                       |                      |                                            |
| Tetralogy of Fallot                | ↓                    | Pressure-overloaded ventricle              |
| Pulmonary atresia/VSD              |                      | Cyanotic                                   |
| Eisenmenger complex                 |                      | Hypoxemia                                  |
| Mixing lesions                      |                      |                                            |
| Transposition/VSD                   | Generally            | Variable pressure versus volume loaded      |
| Tricuspid atresia                  | ↓                    | Usually cyanotic                           |
| Anomalous venous return             | but variable p/ s    |                                            |
| Univentricular heart                |                      |                                            |
| Obstructive lesions                 |                      |                                            |
| Interrupted aortic arch             |                      | Ventricular dysfunction                     |
| Critical aortic stenosis            |                      | Pressure-overloaded ventricle              |
| Critical pulmonic stenosis          |                      | Ductal dependence                           |
| Hypoplastic left heart syndrome      |                      |                                            |
| Coarctation of the aorta           |                      |                                            |
| Mitral stenosis                     |                      |                                            |
| Regurgitant lesions                 |                      |                                            |
| Ebstein's anomaly                   |                      | Volume overloaded ventricle                |
| Other secondary causes              |                      | Develop CHF                                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Management Issue                        | Guideline                                                                                                                                                     |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preoperative                            |                                                                                                                                                              |
| History and examination                 | Establish organ damage; risk factors (tables 1 and 2)                                                                                                       |
| Investigations                          | Investigations as indicated by patient and procedure (table 3)                                                                                             |
| Consider prophylatic transfusion        | Transfusion guidelines (table 5) Crossmatch for Rhesus, Kell, and Lewis antigens, alloantibodies                                                            |
| Preoperative fast                       | Standard protocol                                                                                                                                           |
| Intraoperative                          |                                                                                                                                                              |
| Hydration                               | Modify according to renal pathology                                                                                                                         |
| Oxygenation                             | Modify according to organ pathology                                                                                                                         |
| Thermoregulation                        | Normothermia; hypothermia if indicated under deep anesthesia                                                                                                |
| Acid-base balance                       | Standard anesthetic care                                                                                                                                   |
| Transfusion                             | As indicated by hemorrhage and organ pathology                                                                                                              |
| Anesthetic technique                    | As indicated by procedure                                                                                                                                  |
| Postoperative                           |                                                                                                                                                              |
| Basic care                              | Early mobilization; pulmonary toilet; effective analgesia Supplemental oxygen as required                                                                    |
| Pain crisis Acute Chest Syndrome        | Discharge with follow-up care available Pain scoring Early effective analgesia opioids Adjuvant analgesics nonsteroidal antiinflammatory drugs, acetaminophen Consider regional analgesia, incentive spirometry Pulmonary monitoring Psychological support Steroids ~possible benefit Oxygen Bronchodilators, incentive spirometry Effective analgesia Consider broad-spectrum antibiotics |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Complication                     | Features                                                                                      |
|----------------------------------|-----------------------------------------------------------------------------------------------|
| Neurological                     |                                                                                               |
| Pain crisis                      | Occurs in >70% of patients                                                                    |
| Stroke                           | 109 of children; subclinical microvascular occlusion in                                        |
| Proliferative retinopathy       | 509 of SC adults; rare in SS homozygotes                                                      |
| Peripheral neuropathy            | Unusual complication                                                                           |
| Chronic pain syndrome            | A small subset of patients                                                                     |
| Pulmonary                        |                                                                                               |
| Acute Chest Syndrome             | Occurs in 40% of patients; mortality rate of 1.1% for children and 4.8% for adults.          |
| Airway hyperreactivity           | 359 of children                                                                                |
| Restrictive lung disease         | 10-15% of patients                                                                            |
| Genitourinary                   |                                                                                               |
| Hyposthenuria                    | Nocturnal enuresis not a sensitive predictor                                                  |
| Chronic renal insufficiency      | Present in 5-209 of adults                                                                    |
| Urinary tract infection          | Increased incidence; may trigger ACS                                                          |
| Priapism                         | 10-40% of men                                                                                 |
| Pregnancy                        | Probable increased incidence of obstetrical complications, increased incidence of VOC         |
| Gastrointestinal                 |                                                                                               |
| Cholelithiasis                   | Up to 709 of adults                                                                           |
| Liver disease                    | Viral hepatitis from transfusion in up to 109 of adults. Liver failure <2%                   |
| Dyspepsia                       | Mucosal ischemia, rather than increased acid production; is thought to be the cause           |
|                                  | Reflux is not a complication of SCD.                                                          |
| Hematological                    |                                                                                               |
| Hemolytic anemia                 | Typical baseline hemoglobin levels are 6-9 gdl in SS disease, higher in SC disease and Arab phenotype |
| Acute aplastic anemia            | Parvovirus B19 infections trigger acute severe exacerbations of anemia                        |
| Splenic enlargementfibrosis      | Less affected: SC disease; Arab haplotype                                                    |
| Orthopedic                       |                                                                                               |
| Osteonecrosis                    | Up to 509 of adults                                                                           |
| Osteomyelitits                  | Salmonella and Staphlococcus aureus are commonest pathogens.                                 |
| Dactylitis                       | Early onset is a marker of disease severity                                                   |
| Vascular                         |                                                                                               |
| Leg ulcers                       | 209 of SS adults; rare in SC disease                                                          |
| Immunological                    |                                                                                               |
| Immune dysfunction               | Increased susceptibility to infections                                                         |
| Erythrocyte autolalloimmunization| Increased incidence of transfusion                                                             |
| Hemolytic transfusion reactions   | Alloimmunization                                                                              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 49-8 -- Beneficial effects of smoking cessation and time course**

| Time Course | Beneficial Effects                                                                 |
|-------------|------------------------------------------------------------------------------------|
| 12-24 hr    | Dec. CO, shift the oxyhemoglobin dissociation curve to the right, and dec. nicotine levels (dec. tachycardia) |
| 48-72 hr    | COHb levels normalized, ciliary function improves                                   |
| 1-2 wk      | Decreased sputum production                                                          |
| 4-6 wk      | PFTs improve                                                                        |
| 6-8 wk      | Immune function and metabolism normalizes                                           |
| 8-12 wk     | Decreased overall postoperative morbidity and mortality                              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| VARIABLE               | C-4 TO C-7 INJURY | T-3 TO T-12 INJURY |
|------------------------|--------------------|---------------------|
| FVC                    | 52                 | 69                  |
| FEV 1 /FVC             | 85                 | 82                  |
| FRC                    | 86                 | 86                  |
| IC                     | 71                 | --                  |
| ERV                    | 21                 | 64                  |
| TLC                    | 70                 | 82                  |
| RV                     | 141                | 91                  |
| MVV                    | 49                 | 61                  |
| PI max (cmH 2 O)      | 64                 | 79                  |
| PE max (cmH 2 O)      | 41                 | 98                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug                  | SSEPs Lat | SSEPs Amp | BAEPs Lat | BAEPs Amp | VEPs Lat | VEPs Amp | Transcranial MEPs Lat | Transcranial MEPs Amp |
|-----------------------|-----------|------------|-----------|-----------|----------|----------|------------------------|------------------------|
| Isoflurane            | Yes *     | Yes        | No        | No        | Yes      | Yes      | Yes                    | Yes                    |
| Enflurane             | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes                    | Yes                    |
| Halothane             | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes                    | Yes                    |
| Nitrous oxide *       | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes                    | Yes                    |
| Barbiturates          | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes (p)                | Yes (p)                |
| Etomidate             | No        | No         | No        | No        | Yes      | Yes      | No                     | No                     |
| Propofol              | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes                    | Yes                    |
| Droperidol            | No        | No         | No        | No        | -        | -        | Yes                    | Yes                    |
| Diazepam              | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes (p)                | Yes (p)                |
| Midazolam             | Yes       | Yes        | No        | No        | Yes      | Yes      | Yes (p)                | Yes (p)                |
| Ketamine              | No        | No         | No        | No        | Yes      | Yes      | No                     | No                     |
| Opiates               | No        | No         | No        | No        | No       | No       | No                     | No                     |
| Dexmedetomidine       | No        | No         | No        | No        | No       | ND       | ND                     | No                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 3. Effect of Intravenous Anesthetics on Somatosensory Evoked Potentials**

| Drug                                   | Dose                        | Latency      | Amplitude         | Subcortical Waveform                     |
|----------------------------------------|-----------------------------|--------------|-------------------|------------------------------------------|
| 2.5-5.0 mg/kg 75 mg/kg                | <109 1                      | 5-309        | Negligible        | Negligible                               |
| Pentobarbital54,55                    | Up to 20 mg/kg             | 459          | None (latency)    | 20% (amplitude)                         |
| Ketamine44,63,296,237                 | 0.5 mg/kg                  | No effect    | No effect         | No effect 0-309                         |
|                                        | 2-3 +2 mg . kg-1 .h-1      | <109 109     | 40-1809           | None (latency) 50% (amplitude) Negligible |
| Propofol                               | 2.5 mg/kg                  | 1            | No change         | Negligible                               |
|                                        | 2.5 mg/kg; then 10 mg . kg -1 h-1 | 10-15%      | 509               | NA                                       |
| Sufentanil4s                          | 0.5 then 0.25 ug - kg-1 .h-1 |              | 5%                | 25-409                                   |
| Midazolam 63,66.238                   | 0.1-0.3                    | 5%           | 25-409            | Negligible                               |
| Diazepam6                              | 0.1-0.25 mg/kg             | Minimal      |                   | NA                                       |
| Morphine72                             | 0.25                       | 10%          | 1                 | NA                                       |
| Lidocaine 240                          | 1.5 mg/kg; then 3 mg kg-1 .h-1 | 5%          | 1                 | 25-30% | t                               |
| Sufentanilse;                         | 25-100                     | 5-109        | <109              | Variablet 10-309                        |
| Sufentanil + N2O + 0.5% isoflurane/1 ug/kg + infusion | 5-109 | 73509        | No change         |                                          |
| 5 ug/kg Sufentanil (alone)            | ug/kg + Sufentanil propofol | 5-109        | 73409             | No change No change (latency) Amplitude: 40% NA |
| Remifentanil76 (with 0.4 MAC isoflurane) | min kg min 5.0 kg min =1  | NA           | 15-30% 30-40%     | 73409 1 NA                               |
| Clonidine                              | 2-10                       | No effect    | No effect         | 109 Amplitude No effect (latency)      |
| Alfentanil                             | 100 ug/kg + 2 with N2O     | NA           | 509               | NA                                       |
| Dexmedetomidine87                     | 10 ug/kg alone              | No effect    | 409               | ~20% Amplitude                           |
| Low sedative dose                      |                             | NA           | NA                | 109 10% Amplitude                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**Table 1. Effect of Inhaled Anesthetics on Somatosensory Evoked Potentials**

| Anesthetic Drug / Concentration | Latency      | Amplitude   | Subcortical Waveform |
|----------------------------------|--------------|-------------|-----------------------|
| Halothane?4 , 26,34             | 0.5 MAC + 60% NzO | 109 1      | 609                   | Negligible             |
|                                  |              | 109 1      | 709                   | Negligible             |
|                                  | 1.5 MAC + 60% NzO | 10-15%    |                         | Negligible             |
|                                  | 1.5 MAC (alone) | 10-159 1  | 709 1                 | Negligible             |
| Isoflurane23 28,31,365,36       | 0.5 MAC + 60% NzO |            | 50-709                | Negligible             |
|                                  | 0.5 MAC (alone) | 15% 1     | < 309 1               | Negligible             |
|                                  | 1.0 MAC + 60% NzO | 10-159    | 50-75%                | Negligible             |
|                                  | 1.0 MAC (alone) | 159 1     | 509                   | Negligible             |
|                                  | 1.5 MAC + 609 NzO' | >15% 1   | 75%                   | 5% 1 in latency        |
|                                  | 1.6 MAC (alone)' | 15-209 1  | 60-70%                | 5% in latency 209 in amplitude |
| Enflurane24-26                   | 0.5 MAC + 60% NzO | 109 1    | 509                   | Negligible             |
|                                  | 0.2-0.6 MAC (alone) | 109 1   | 209                   | NA                    |
|                                  | 1.0 MAC + 60% NzO' | 209 1    |                         | Negligible             |
|                                  | 1.5 MAC + 60% NzO | Not recordable | Not recordable      | Negligible             |
|                                  | 1.5 MAC (alone)- | >259 1    | 1                     | Negligible             |
| Sevofluranes2,33                |                | 59          |                         | Negligible             |
|                                  | 1.0 MAC + 66% NzO | 109 1    | 459 1                 | Negligible             |
|                                  | 1.5 MAC 66% NzO | <109 1    | 509 1                 | Negligible             |
|                                  | 1.7-2.5 MAC | 10-159 1    | 71009 1 $             | NA                    |
| Desfluraness,39                 | 0.5 MAC      | <5% 1      | <20%                  | Negligible             |
|                                  | 1.0 MAC      | 3-8% 1     | 30-409                | Negligible             |
|                                  |                | 2109 1     | 509                   | Negligible             |
|                                  | with 65% NzOt Any | 2 159 1  |                         | Negligible             |
| Nitrous oxide?e,41,47           | 60-65 %      | No effect   | 50-55% 1              | Negligible             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Data Types   | Definition                                               | Examples                                         |
|--------------|---------------------------------------------------------|--------------------------------------------------|
| INTERVAL     |                                                         |                                                  |
| Discrete     | Data measured with an integer-only scale                | Age, parity                                      |
| Continuous   | Data measured with a constant scale interval             | Blood pressure, temperature                      |
| CATEGORICAL  |                                                         |                                                  |
| Dichotomous  | Binary data                                             | Mortality, gender                                |
| Nominal      | Qualitative data that cannot be ordered or ranked       | Eye color, drug category                         |
| Ordinal      | Data ordered, ranked, or measured without a constant scale interval | ASA physical status score, pain score           |

| Variable Type               | One-Sample Tests                          | Two-Sample Tests                                         | Multiple-Sample Tests                                      |
|-----------------------------|-------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------|
| Dichotomous or nominal      | Binomial distribution                     | Chi-square test                                         | Chi-square test                                           |
| Ordinal                     | Chi-square test                           | Chi-square test, nonparametric tests                    | Chi-square test, nonparametric tests                      |
| Continuous or discrete      | z distribution or t distribution         | Unpaired t test, paired t test, nonparametric tests (nonparametric sign test and Mann-Whitney rank sum test) | Analysis of variance, nonparametric analysis of variance (Kruskal-Wallis one-way analysis of variance) |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Age     | Neutral temp     | Critical temp |
|---------|------------------|---------------|
| Preterm | 34               | 27            |
| Term    | 32 ( to 35)      | 22            |
| Adult   | 28 ( to 32)      | 0             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Body Compartment        | Percentage of Body Weight | Premature | Infant | Adult  |
|-------------------------|--------------------------|-----------|--------|--------|
| Total body water        |                          | 83        | 73     | 60     |
| Extracellular fluid     |                          | 62        | 44     | 15-20  |
| Blood volume            |                          | 6         | 8-10   | 7      |
| Intracellular water     |                          | 24        | 33     | 40     |
| Muscle mass             |                          | 12        | 20     | 50     |
| Fat                     |                          | 3         | 12     | 18     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category                                   | Changes                                                                                      |
|--------------------------------------------|----------------------------------------------------------------------------------------------|
| Neurologic effects                         | Abolition of somatosensory evoked potentials and nerve conduction occurs within 30 minutes. |
|                                            | Application for more than 60 minutes causes tourniquet pain and hypertension.               |
|                                            | Application for more than 2 hours may result in postoperative neurapraxia.                  |
|                                            | Evidence of nerve injury may occur at a skin level underlying the edge of the tourniquet.   |
| Muscle changes                             | Cellular hypoxia develops within 8 minutes.                                                |
|                                            | Cellular creatine declines.                                                                  |
|                                            | Progressive cellular acidosis occurs.                                                       |
|                                            | Endothelial capillary leak develops after 2 hours.                                         |
|                                            | Limb becomes progressively colder.                                                           |
| Systemic effects of tourniquet inflation   | Elevation in arterial and pulmonary artery pressures develops. This is usually slight to moderate if only one limb is occluded. |
| Systemic effects of tourniquet release     | Transient fall in core temperature                                                           |
|                                            | Transient metabolic acidosis                                                                  |
|                                            | Transient fall in central venous oxygen tension (but systemic hypoxemia unusual)             |
|                                            | Release of acid metabolites into central circulation (e.g., thromboxane)                    |
|                                            | Transient fall in pulmonary and systemic arterial pressures                                   |
|                                            | Transient increase in end-tidal CO 2                                                        |
|                                            | Increased oxygen consumption                                                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Intervention                | Effect                                      |
|-----------------------------|---------------------------------------------|
| high FiO2                   | decr PVR; pulm vasodilator                  |
| hydration                   | opens RV outflow tract                      |
| morphine                    | decr PVR; sedation                          |
| ketamine                    | maintains SVR; sedation + analgesia; incr pulm blood flow |
| phenylephrine               | incr SVR                                   |
| propranolol                 | decr HR + infundibular spasm; improves flow across pulm valve |
| halothane                   | decr HR; - inotrope, preserves SVR        |
| STP                         | - inotrope                                 |
| squat/ abd compression      | incr SVR                                   |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Drug/Agent                     | Effect                                   |
|--------------------------------|------------------------------------------|
| atropine                       | incr HR (decr flow across pulm valve)   |
| N2O                            | may incr PVR                            |
| isoflurane                     | decr SVR; incr HR                       |
| epi/ dopamine                  | incr HR; may ppt infundibular spasm     |
| halothane in RV fail          | - inotrope                              |
| NMJ blocker w/ histamine release |                                          |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Complications                                                                 | Etiology                                                                                                           |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Glucose Metabolism                                                            |                                                                                                                   |
| Hyperglycemic glycosuria, osmotic diuresis, nonketotic hyperosmolar dehydration, and coma | Excessive total dose or rate of infusion of dextrose; inadequate endogenous insulin; glucocorticoids; sepsis     |
| Ketoacidosis of diabetes mellitus                                              | Inadequate endogenous insulin response; inadequate exogenous insulin therapy                                      |
| Postinfusion (rebound) hypoglycemia                                           | Persistence of endogenous insulin production secondary to prolonged stimulation of islet cells by high-carbohydrate infusion |
| Respiratory acidosis with hypercarbia                                          | Excessive dextrose administration                                                                                 |
| Amino Acid Metabolism                                                          |                                                                                                                   |
| Hyperchloremic metabolic acidosis                                              | Excessive chloride and monohydrochloride content of crystalline amino acid solutions                              |
| Serum amino acid imbalance                                                     | Unphysiologic amino acid profile of the nutrient solution; different amino acid use with various disorders         |
| Hyperammonemia                                                                | Excessive ammonia in protein hydrolysate solutions: deficiencies of arginine, ornithine, aspartic acid, and/or glutamic acid in crystalline amino acid solutions; primary hepatic disorder |
| Prerenal azotemia                                                             | Excessive total dose or rate of infusion of protein hydrolysate or amino acid solutions                           |
| Lipid Metabolism                                                               |                                                                                                                   |
| Hyperlipidemia                                                                | Excessive total dose or rate of administration of fat emulsion                                                    |
| Hyperamylasemia                                                               | Lipoid pancreatitis                                                                                               |
| Hyperbilirubinemia                                                            | Excessive dose or rate of administration of fat emulsion                                                         |
| Hypoxia                                                                       | Interstitial lipoid pneumonitis with alveolar-capillary block                                                    |
| Serum deficiencies of phospholipid linoleic and arachidonic acids; serum elevations of 5.8.11-eicosatrienoic acid | Inadequate essential fatty acid administration; inadequate vitamin E administration                                 |
| Calcium and Phosphorus Metabolism                                              |                                                                                                                   |
| Hypophosphatemia Decreased erythrocyte 2,3- diphosphoglycerate               | Inadequate phosphorus administration; redistribution of serum phosphorus into cells and/or bone                   |
| Increased affinity of hemoglobin for oxygen                                    | Aberrations of erythrocyte intermediary metabolites                                                                |
| Hypocalcemia                                                                   | Inadequate calcium administration; reciprocal response to phosphorus repletion without simultaneous calcium infusion; hypoalbuminemia |
| Hypercalcemia                                                                  | Excessive calcium administration with or without high doses of albumin; excessive vitamin D administration         |
| Vitamin D deficiency; hypervitaminosis D                                      | Inadequate or excessive vitamin D administration                                                                   |
| Miscellaneous Complications                                                    |                                                                                                                   |
| Hypokalemia                                                                    | Inadequate potassium intake relative to increased requirements for protein anabolism: dieresis                    |
| Hyperkalemia                                                                   | Excessive potassium administration, especially in metabolic acidosis, renal decompensation                         |
| Hypomagnesemia                                                                 | Inadequate magnesium administration relative to increased requirements for protein anabolism and glucose metabolism |
| Hypermagnesemia                                                                | Excessive magnesium administration; renal decompensation                                                           |
| Anemia                                                                         | Iron deficiency; folic acid deficiency; vitamin B 12 deficiency; copper deficiency; other deficiencies            |
| Bleeding                                                                       | Vitamin K deficiency                                                                                              |
| Hypervitaminosis A                                                             | Excessive vitamin A administration                                                                                 |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Complications                                                        | Etiology                                                                                          |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Elevations in SGOT, SGPT, and serum alkaline phosphatase           | Enzyme induction caused by amino acid imbalance; excessive glycogen and/or fat deposition in the liver |
| Cholestatic hepatitis                                                | Decreased water content of bile; amino acid and/or fatty acid imbalance                           |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Vein Type                                   |
|---------------------------------------------|
| Large-bore (16 gauge or greater) antecubital vein |
| Other large-bore peripheral veins           |
| Subclavian vein                             |
| Femoral vein                                |
| Internal jugular vein                       |
| Intraosseous (tibia or distal end of femur) |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Class I                     | Class II                  | Class III                | Class IV                 |
|-----------------------------|--------------------------|--------------------------|--------------------------|
| Blood loss (ml)            | Up to 750                | 750-1500                 | 1500-2000                | > 2000                   |
| Blood loss (% blood volume) | Up to 15%                | 15-30%                   | 30-40%                   | > 40%                    |
| Pulse rate                  | < 100                    | 100-120                  | 120-140                  | > 140                    |
| BP                          | Normal                   | Normal                   | Decreased                | Decreased                |
| Pulse pressure (mmHg)      | Normal or increased       | Decreased                | Decreased                | Decreased                |
| Respiratory rate            | 14-20                    | 20-30                    | 30-40                    | > 35                     |
| UO (ml/hr)                 | > 30                     | 20-30                    | 5-15                     | Negligible               |
| CNS/ mental status          | Slightly anxious         | Mildly anxious           | Anxious, confused        | Confused, lethargic      |
| Fluid replacement            | crystalloid              | crystalloid              | Crystalloid and blood    | Crystalloid and blood    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Parameter                     | PHYSIOLOGIC OLIGURIA | PRERENAL FAILURE | ACUTE TUBULAR NECROSIS |
|-------------------------------|----------------------|------------------|-------------------------|
| Urinary sodium                | <10 mEq/L            | <25 mEq/L        | >35 mEq/L               |
| Urinary specific gravity       | >1.024               | >1.015           | 1.010-1.015             |
| Urinary osmolality            | >700 mOsm/kg         | >500 mOsm/kg     | <350 mOsm/kg            |
| Urinary/plasma osmolality     | >2.5:1               | >1.8:1           | >1.1:1                  |
| Urinary/plasma urea           | >100:1               | >20:1            | 3:1, rarely >10:1       |
| Urinary/plasma creatinine     | >60:1                | >30:1, rarely <10:1 | <10:1                  |
| Fractional sodium excretion    | >0.5                 | <1               | >1                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Variable        | VTV                                         | PTV                                         |
|------------------|---------------------------------------------|---------------------------------------------|
| Trigger          | Patient or Time                            | Patient or Time                            |
| Limit            | Flow                                       | Pressure                                   |
| Cycle            | Volume                                     | Time or Flow                               |
| Tidal Volume     | Constant                                   | Variable                                   |
| Peak Pressure    | Variable                                   | Constant                                   |
| Modes            | 1. Assist/Control (synchronized) intermittent | 1. Assist/Control (synchronized) intermittent |
|                  | 2. Mandatory ventilation                    | 2. Mandatory ventilation                    |
|                  | 3. Pressure support                         |                                             |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Agent           | Sea Level 760 mm Hg | Partial Pressure (mm Hg) | 4000 ft | 8000 ft | 15000 ft |
|------------------|---------------------|--------------------------|---------|---------|----------|
| Halothane        | 0.77%               | 5.9                      | 0.9%    | 1.0%    | 1.4%     |
| Isoflurane       | 1.11%               | 8.4                      | 1.3%    | 1.5%    | 2.0%     |
| Enflurane        | 1.66%               | 12.6                     | 1.9%    | 2.2%    | 2.9%     |
| Desflurane       | 6.30%               | 47.9                     | 7.3%    | 8.5%    | 11.2%    |
| Sevoflurane      | 2.00%               | 15.2                     | 2.3%    | 2.7%    | 3.5%     |
| Diethyl Ether    | 1.92%               | 14.6                     | 2.2%    | 2.6%    | 3.4%     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Increase                     | Decrease                     | Notes                                                                                                                                                                                                                     |
|------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Low  B                      | High  B                     | The lower the blood:gas solubility, the faster the rise in F A / F I 15,29,30,409                                                                                                                                       |
| Low Q                        | High Q                       | The lower the cardiac output, the faster the rise in F A / F I 15,17                                                                                                                                                   |
| High V® A                    | Low V® A                     | The higher the minute ventilation, the faster the rise in F A / F I 17,21,409-411                                                                                                                                      |
| High ( P A - P V )          | Low ( P A - P V )           | At the beginning of induction, P V is zero but rises rapidly (thus [ P A - P V ] falls rapidly) and F A / F I increases rapidly. Later during induction and maintenance, P V rises more slowly so F A / F I rises more slowly. |
| Parameters as described in Eq. (15-16):  B = blood solubility; Q = cardiac output; = minute ventilation; P A , P V = pulmonary arterial and venous blood partial pressure |                              |                                                                                                                                                                                                                           |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
****  
 
| Property                                                        | SEVO  | DES   | ISO   | ENFL  | HALO  | N 2 O   |
|-----------------------------------------------------------------|-------|-------|-------|-------|-------|---------|
| Boiling point (°C)                                             | 59    | 24    | 49    | 57    | 50    | -88     |
| Vapor pressure at 20°C (mm Hg)                                 | 157   | 669   | 238   | 172   | 243   | 38,770  |
| Molecular weight (g)                                           | 200   | 168   | 184   | 184   | 197   | 44      |
| Oil:gas partition coefficient                                    | 47    | 19    | 91    | 97    | 224   | 1.4     |
| Blood:gas partition coefficient                                  | 0.65  | 0.42  | 1.46  | 1.9   | 2.50  | 0.46    |
| Brain:blood solubility                                          | 1.7   | 1.3   | 1.6   | 1.4   | 1.9   | 1.1     |
| Fat:blood solubility                                            | 47.5  | 27.2  | 44.9  | 36    | 51.1  | 2.3     |
| Muscle:blood solubility                                         | 3.1   | 2.0   | 2.9   | 1.7   | 3.4   | 1.2     |
| MAC in O 2 30 - 60 yr, at 37°C P B 760 (%)                     | 1.8   | 6.6   | 1.17  | 1.63  | 0.75  | 104     |
| MAC in 60 - 70% N 2 O (%)                                      | 0.66  | 2.38  | 0.56  | 0.57  | 0.29  |         |
| MAC, >65 yr (%)                                                | 1.45  | 5.17  | 1.0   | 1.55  | 0.64  | -       |
| Preservative                                                   | No    | No    | No    | No    | Thymol| No      |
| Stable in moist CO 2 absorber                                   | No    | Yes   | Yes   | Yes   | No    | Yes     |
| Flammability (%) (in 70% N 2 O/30% O 2 )                       | 10    | 17    | 7     | 5.8   | 4.8   |         |
| Recovered as metabolites (%)                                    | 2 - 5 | 0.02  | 0.2   | 2.4   | 20    |         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| PARAMETER                                   | INFANT      | ADULT      |
|---------------------------------------------|-------------|------------|
| Respiratory frequency (breaths/min)        | 30-50      | 12-16      |
| Tidal volume (mL/kg)                       | 7           | 7          |
| Dead space (mL/kg)                         | 2-2.5      | 2.2        |
| Alveolar ventilation (mL/kg/min)           | 100-150     | 60         |
| Functional residual capacity (mL/kg)       | 27-30      | 30         |
| Oxygen consumption (mL/kg/min)             | 7-9        | 3          |